<SUBMISSION>
<ACCESSION-NUMBER>0001193125-08-162668
<TYPE>10-Q
<PUBLIC-DOCUMENT-COUNT>18
<PERIOD>20080630
<FILING-DATE>20080731
<DATE-OF-FILING-DATE-CHANGE>20080731
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>CRYOLIFE INC
<CIK>0000784199
<ASSIGNED-SIC>3841
<IRS-NUMBER>592417093
<STATE-OF-INCORPORATION>FL
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>10-Q
<ACT>34
<FILE-NUMBER>001-13165
<FILM-NUMBER>08982312
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1655 ROBERTS BOULEVARD N W
<STREET2>STE 142
<CITY>KENNESAW
<STATE>GA
<ZIP>30144
<PHONE>7704193355
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1655 ROBERTS BOULEVARD N W
<STREET2>STE 142
<CITY>KENNESAW
<STATE>GA
<ZIP>30144
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 10-Q </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1">(Mark One) </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B><FONT FACE="WINGDINGS">&#120;</FONT><B></B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">For the Quarterly Period Ended June&nbsp;30, 2008 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">OR </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B><FONT FACE="WINGDINGS">&#168;</FONT><B></B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">For the Period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Commission
File Number 1-13165 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>CRYOLIFE, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Florida</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>59-2417093</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction of incorporation or organization)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer Identification No.)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>1655 Roberts Boulevard, NW </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Kennesaw, Georgia 30144 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices)
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(770)
419-3355 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name, former address and former fiscal year, if
changed since last report) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or
15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">YES&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; NO&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT> <U></U> </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the
definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (check one): </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Large Accelerated filer&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#120;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Non-accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;(Do not check if a smaller
reporting company)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">YES&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp; <FONT FACE="WINGDINGS">&#120;</FONT> </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The number of shares of common stock, par value $0.01 per share, outstanding on July&nbsp;25, 2008 was 28,003,750. </FONT></P> <P
STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Part I &#150; FINANCIAL INFORMATION </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CRYOLIFE, INC. AND
SUBSIDIARIES </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">(IN THOUSANDS, EXCEPT PER SHARE DATA) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preservation services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,711</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,672</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22,551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23,011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">52,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preservation services<BR>(Including write-downs of $307 for the three months and $453 for the six months ended June&nbsp;30,
2007)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,881</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,829</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">General, administrative, and marketing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,358</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,842</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23,177</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,307</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,036</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Change in valuation of derivative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other expense (income), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">21,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">45,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">44,711</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Income before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of preferred stock dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income applicable to common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Income per common share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Weighted average common shares outstanding:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,756</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,661</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28,381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">See accompanying Notes to Summary Consolidated Financial Statements. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CRYOLIFE, INC. AND
SUBSIDIARIES </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">SUMMARY CONSOLIDATED BALANCE SHEETS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">(IN THOUSANDS) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>ASSETS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,719</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Marketable securities, at market</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Restricted marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Trade receivables, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deferred preservation costs, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Inventories</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">67,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">65,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Patents, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,779</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Trademarks and other intangibles, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deferred income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Restricted money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other long-term assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">TOTAL ASSETS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">98,096</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">92,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">LIABILITIES AND SHAREHOLDERS&#146; EQUITY</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,956</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued procurement fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deferred income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,764</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current maturities of notes payable and capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,279</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">21,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,702</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">315</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Notes payable and capital lease obligations, less current maturities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30,057</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Shareholders&#146; Equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Common stock (issued shares of 28,925 in 2008 and 28,526 in 2007)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">123,082</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">120,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Retained deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(46,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(52,981</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accumulated other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Treasury stock at cost (shares of 945 in 2008 and 949 in 2007)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(5,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(5,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total shareholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">71,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">62,627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">98,096</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">92,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">See accompanying Notes to Summary Consolidated Financial Statements. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CRYOLIFE, INC. AND
SUBSIDIARIES </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">SUMMARY CONSOLIDATED STATEMENTS OF CASH FLOWS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">(IN THOUSANDS) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net cash from operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Adjustments to reconcile net income to net cash from operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Loss on sale or disposal of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Write-down of deferred preservation costs and inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Non-cash compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Change in valuation of derivative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other non-cash adjustments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deferred preservation costs and inventories</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(6,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(4,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Prepaid expenses and other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(901</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accounts payable, accrued expenses, and other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net cash provided by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net cash from investing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Capital expenditures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net proceeds from sale of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Restricted money market funds, long-term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchases of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(9,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Sales and maturities of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3,219</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net cash from financing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proceeds from issuance of debt and notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">282</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Principal payments of debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(4,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Principal payments on capital leases</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proceeds from financing of insurance policies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Principal payments on short-term notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proceeds from exercise of stock options and issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Payment of preferred stock dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(486</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchase of treasury stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net cash (used in) provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">(Decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of exchange rate changes on cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents, beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents, end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,719</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">See accompanying Notes to Summary Consolidated Financial Statements. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CRYOLIFE, INC. AND SUBSIDIARIES </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">NOTES TO SUMMARY CONSOLIDATED FINANCIAL STATEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(UNAUDITED) </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 1 &#150; Basis of Presentation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The accompanying
summary consolidated financial statements include the accounts of CryoLife, Inc., and its subsidiaries (&#147;CryoLife&#148;, the &#147;Company&#148;, &#147;we&#148;, or &#147;us&#148;). All significant intercompany accounts and transactions have
been eliminated in consolidation. The accompanying Summary Consolidated Balance Sheet as of December&nbsp;31, 2007 has been derived from audited financial statements and the accompanying unaudited summary consolidated financial statements for the
periods as of and ended June&nbsp;30, 2008 and 2007 and have been prepared in accordance with (i)&nbsp;accounting principles generally accepted in the U.S. for interim financial information and (ii)&nbsp;the instructions to Form 10-Q and Rule 10-01
of Regulation S-X of the U.S. Securities and Exchange Commission (&#147;SEC&#148;). Accordingly, such statements do not include all of the information and disclosures required by accounting principles generally accepted in the U.S. for a complete
presentation of financial statements. In the opinion of management, all adjustments (of normal, recurring nature) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June&nbsp;30,
2008 are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31, 2008. These summary consolidated financial statements should be read in conjunction with the consolidated financial statements and notes
thereto included in CryoLife&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2007. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 2 </B>&#150;<B> Exchange and
Service Agreement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On December&nbsp;19, 2006 the Company announced that it had entered into an exchange and service agreement with
Regeneration Technologies, Inc., (&#147;RTI&#148;) and certain of its affiliates, respecting procurement, processing, and distribution activities for cardiac and vascular tissue processed and distributed by RTI and orthopaedic tissue for the knee
processed and distributed by CryoLife (the &#147;RTI Agreement&#148;). In accordance with the RTI Agreement, CryoLife ceased accepting donated human orthopaedic tissue for processing commencing January&nbsp;1, 2007 and began work to transition
existing arrangements for recovery of human orthopaedic tissue to RTI. Likewise, on January&nbsp;1, 2007 RTI ceased accepting donated human cardiac and vascular tissues for processing and began work to transition its arrangements for recovery of
these tissues to CryoLife. No cash was exchanged in the transaction. CryoLife continued to distribute its existing orthopaedic tissue inventory, and RTI continued to distribute its existing cardiac and vascular tissue inventory, through
June&nbsp;30, 2008. After that date CryoLife became entitled to distribute RTI&#146;s remaining cardiac and vascular tissue inventory, and RTI became entitled to distribute CryoLife&#146;s remaining orthopaedic tissue inventory. CryoLife will pay
RTI a commission with respect to any of CryoLife&#146;s orthopaedic tissue distributed by RTI and will receive a commission from RTI with respect to any RTI cardiac and vascular tissue distributed by CryoLife. Under the RTI Agreement, from
July&nbsp;1, 2008 through December&nbsp;31, 2016, except as set forth above, CryoLife has agreed not to market or solicit orders for certain human orthopaedic tissues and RTI has agreed not to market or solicit orders for human cardiac and vascular
tissues. The agreement also provides for a non-exclusive license of technology from CryoLife to RTI, and contains customary provisions regarding indemnification and confidentiality. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Note 3 &#150; Cash Equivalents and Marketable Securities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company maintains cash equivalents and
investments in several large, well-capitalized financial institutions, and the Company&#146;s policy excludes investment in any securities rated less than &#147;investment-grade&#148; by national rating services. Management determines the
appropriate classification of its marketable securities at the time of purchase and reevaluates such designations quarterly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Debt
securities are classified as held-to-maturity when the Company has the intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost. Trading securities are securities that are acquired principally
for the purpose of generating a profit from short-term fluctuations in price. Trading securities are stated at their fair values, with the realized and unrealized gains and losses, interest, and dividends included in investment </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">income. Debt securities not classified as held-to-maturity or marketable equity securities not classified as trading are classified as available-for-sale.
Available-for-sale securities are stated at their fair values, with the unrealized gains and losses, net of applicable income taxes, reported in a separate component of shareholders&#146; equity. Interest, dividends, realized gains and losses, and
declines in value judged to be other than temporary are included in investment income. The cost of securities sold is based on the specific identification method. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">As of June&nbsp;30, 2008 $5.0 million of the Company&#146;s money market funds were designated as long-term restricted money market funds due to a financial covenant requirement under the Company&#146;s credit
agreement with General Electric Capital Corporation (&#147;GE Capital&#148;) as discussed in Note 6. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of June&nbsp;30, 2008 $563,000 of
marketable securities was designated as held-to-maturity. The held-to-maturity securities were designated as such due to a contractual commitment to hold the securities as pledged collateral relating to one of the Company&#146;s product liability
insurance policies, and, therefore, they were reported as restricted marketable securities on the June&nbsp;30, 2008 Summary Consolidated Balance Sheets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">As of December&nbsp;31, 2007 $3.0 million of marketable securities were designated as available-for-sale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The Company&#146;s cash equivalents include advance funding received under the U.S. Congress 2005 and 2006 Defense Appropriations Conference Reports (the &#147;2005 DOD Grant&#148;) and (the &#147;2006 DOD Grant&#148;), respectively, for
the continued development of protein hydrogel technology for use on the battlefield. The advance funding is accounted for as deferred income on the Summary Consolidated Balance Sheets and is recognized as other revenue as expenses are incurred
related to these grants. As of June&nbsp;30, 2008 $1.8 million of cash equivalents and deferred income was related to the 2006 DOD grant. As of December&nbsp;31, 2007 $1.0 million of cash equivalents and deferred income was related to the 2005 and
2006 DOD grants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following is a summary of cash equivalents and marketable securities (in thousands): </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Cost<BR>Basis</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Unrealized<BR>Holding<BR>Gains</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Estimated<BR>Market<BR>Value</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">June&nbsp;30, 2008 (Unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash equivalents:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,760</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,760</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Restricted money market funds, long-term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,000</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Marketable securities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Restricted government entity sponsored debt securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">563</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">563</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">December&nbsp;31, 2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash equivalents:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,724</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,724</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Marketable securities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Government entity sponsored debt securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,984</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,987</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">There were no gross realized gains or losses on sales of available-for-sale securities for the
three and six months ended June&nbsp;30, 2008 and 2007. Differences between cost and market value listed above, consisting of an unrealized holding gain of $3,000 at December&nbsp;31, 2007, are included as a component of other comprehensive income
on the Company&#146;s Summary Consolidated Balance Sheets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">At June&nbsp;30, 2008 and December&nbsp;31, 2007 all of the Company&#146;s
marketable securities had a maturity date within 90 days. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 4 &#150; Inventories </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Inventories are comprised of the following (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2007</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Raw materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,343</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,956</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Work-in-process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">543</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">650</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,368</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,001</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total inventories</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,254</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,607</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 5 &#150; Income Taxes </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The Company periodically assesses the recoverability of its deferred tax assets in accordance with Statement of Financial Accounting Standards (&#147;SFAS&#148;) No.&nbsp;109 &#147;Accounting for Income Taxes&#148;
(&#147;SFAS 109&#148;), as necessary, when the Company experiences changes that could materially affect its determination of the recoverability of its deferred tax assets. Management provides a valuation allowance when, as a result of this analysis,
management believes it is more likely than not that its deferred tax assets will not be realized. In assessing the recoverability of its deferred tax assets at December&nbsp;31, 2007 the Company reviewed its historical operating results, including
the reasons for its operating losses in prior years and uncertainties regarding projected future operating results. Based on the results of this analysis, at December&nbsp;31, 2007 and June&nbsp;30, 2008 the Company determined that it was more
likely than not that the Company&#146;s deferred tax assets would not be realized. Therefore, as of June&nbsp;30, 2008 and December&nbsp;31, 2007 the Company had a total of $28.2 million in valuation allowances against deferred tax assets and a net
deferred tax liability of $27,000. The Company will reverse the remaining valuation allowance, or a portion thereof, when and if its deferred tax assets meet the SFAS 109 &#147;more likely than not&#148; standard for recognition. Also, the
realizability of the Company&#146;s deferred tax assets could be limited in future periods following a change in control as mandated by Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, which relates to certain specified changes in
control of taxpayers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company adopted the provisions of FIN 48 on January&nbsp;1, 2007. As a result of the adoption of FIN 48, the
Company recorded $1.7 million in liabilities for unrecognized tax benefits plus estimated interest and penalties of $283,000. The aggregate $2.0 million liability was accounted for as a decrease to the January&nbsp;1, 2007 balance of retained
earnings of $762,000 and a reclassification of a portion of the valuation allowances against the Company&#146;s deferred tax assets of $1.2 million to an uncertain tax liability. To the extent these unrecognized tax benefits are ultimately
recognized, it would not affect the annual effective income tax rate due to the existence of the valuation allowance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company
recognizes interest and penalties related to uncertain tax positions in other income and expense on the Company&#146;s Summary Consolidated Statements of Operations. As of June&nbsp;30, 2008 and December&nbsp;31, 2007 the Company had approximately
$390,000 and $347,000, respectively, of accrued interest and penalties related to uncertain tax positions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The tax years 2004-2007 remain
open to examination by the major taxing jurisdictions to which the Company is subject. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 6 &#150; Debt </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On March&nbsp;26, 2008 CryoLife and its subsidiaries entered into a credit agreement with GE Capital as lender (the &#147;GE Credit Agreement&#148;). The
GE Credit Agreement provides for a revolving credit facility in an aggregate amount not to exceed the initial commitment of $15.0 million (including a letter of credit subfacility of up to an aggregate of $1.5 million). The initial commitment may be
reduced or increased from time to time pursuant to the terms of the GE Credit Agreement. While the Company currently expects that its aggregate borrowing capacity under the GE Credit Agreement will equal $15.0 million, there can be no assurance that
the borrowing capacity will remain at this level. The GE Credit Agreement places limitations on the amount that the Company may borrow, and includes various </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">affirmative and negative covenants, including financial covenants such as a requirement that CryoLife (i)&nbsp;not exceed a defined leverage ratio,
(ii)&nbsp;maintain a minimum adjusted earnings before extraordinary gains, interest, taxes, depreciation, and amortization (&#147;Adjusted EBITDA&#148;) as of specified dates, and (iii)&nbsp;not make or commit capital expenditures in excess of a
defined limitation. Further, beginning April&nbsp;15, 2008 as required under the terms of the GE Credit Agreement, the Company is maintaining cash and cash equivalents of at least $5.0 million in accounts in which GE Capital has a first priority
perfected lien. These amounts are recorded as long-term restricted money market funds on the Company&#146;s Summary Consolidated Balance Sheet. The GE Credit Agreement also includes customary conditions on incurring new indebtedness and prohibits
payments of cash dividends on the Company&#146;s common stock. There is no restriction on the payment of stock dividends. Commitment fees are paid based on the unused portion of the facility. The GE Credit Agreement expires on March&nbsp;25, 2011,
at which time the outstanding principal balance will be due. As of June&nbsp;30, 2008 the Company was in compliance with the covenants of the GE Credit Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Amounts borrowed under the GE Credit Agreement are secured by substantially all of the tangible and intangible assets of CryoLife and its subsidiaries and bear interest at either LIBOR plus 3.25% or GE Capital&#146;s
base rate, as defined, plus 2.25%, as applicable. As of June&nbsp;30, 2008 the outstanding balance of the GE Credit Agreement was $315,000, the aggregate interest rate was 7.25%, and the remaining availability was $14.7 million. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On February&nbsp;8, 2005 CryoLife and its subsidiaries entered into a credit agreement with Wells Fargo Foothill, Inc. (&#147;Wells Fargo&#148;) as
lender which provided for a revolving credit facility in an aggregate amount equal to the lesser of $15.0 million (including a letter of credit subfacility of up to an aggregate of $2.0 million) or a borrowing base determined in accordance with the
terms of the credit agreement. The credit agreement with Wells Fargo expired on February&nbsp;8, 2008 in accordance with its terms, at which time the outstanding principal balance of $4.5 million was paid from cash on hand. In the first quarter of
2007 the Company obtained a $500,000 letter of credit under the subfacility of this credit agreement relating to one of the Company&#146;s product liability insurance policies. Upon the February&nbsp;8, 2008 expiration of the credit agreement with
Wells Fargo, the Company remitted to Wells Fargo approximately $500,000 as collateral to cover the remaining term of the letter of credit agreement, which expired on April&nbsp;2, 2008. This remitted amount was refunded to the Company in the second
quarter of 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company routinely enters into agreements to finance insurance premiums for periods not to exceed the terms of the
related insurance policies. In April 2008 the Company entered into such an agreement to finance approximately $1.3 million in insurance premiums. The amount financed accrues interest at a 4.632% annual rate and is payable in equal monthly payments
over a nine month period. As of June&nbsp;30, 2008 the aggregate outstanding balance under this agreement was $872,000. In the second quarter of 2007 the Company entered into two such agreements to finance approximately $1.4 million and $478,000 in
insurance premiums. The amounts financed accrued interest at 7.027% and were payable in equal monthly payments over a nine month and an eight month period, respectively. As of June&nbsp;30, 2008 the aggregate outstanding balance under these
agreements was zero. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 7 &#150; Convertible Preferred Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On March&nbsp;18 and April&nbsp;19, 2005 the Company completed a public offering of 417,000 shares of 6% convertible preferred stock (the &#147;Preferred Stock&#148;) at a price to the public of $50.00 per share. Net
proceeds from the offering, after deducting underwriting discounts and offering-related expenses, totaled approximately $19.1 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Dividends on the Preferred Stock were cumulative from the date of original issue at the annual rate of 6% of the liquidation preference of the Preferred Stock, payable quarterly. Any dividends were required to be declared by the
Company&#146;s board of directors and to come from funds legally available for dividend payments. On March&nbsp;13, 2007 the Company declared a dividend of $0.75 per share on its Preferred Stock. The dividend of approximately $243,000 was paid on
April&nbsp;2, 2007 to shareholders of record on March&nbsp;22, 2007. No dividends were declared during the remainder of 2007. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The
Preferred Stock was convertible at the option of the holder at any time into the Company&#146;s common stock at a conversion rate of approximately 6.2189 shares of common stock for each share of Preferred Stock, based on an initial conversion price
of $8.04. The Company had reserved 4.6&nbsp;million shares of common stock for issuance upon conversion. Through June&nbsp;4, 2007 holders had cumulatively voluntarily converted 139,000 shares of Preferred Stock into 867,000 shares of common stock.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Preferred Stock contained provisions that allowed the Company to convert its Preferred Stock into
common stock if the closing price of the Company&#146;s common stock exceeded $12.06, which is 150% of the conversion price of the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within five trading days prior
to notice of automatic conversion. This condition was satisfied on June&nbsp;4, 2007 and on that day the Company exercised its right to automatically convert the Preferred Stock into common stock. As a result, on June&nbsp;25, 2007 the Company
automatically converted the remaining 278,000 shares of Preferred Stock into 1.7&nbsp;million shares of common stock at the conversion rate of approximately 6.2189 shares of common stock per share of Preferred Stock. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company was required to make additional payments for both the voluntary and automatic conversions of Preferred Stock equal to the aggregate amount of
dividends that would have been payable on the Preferred Stock through and including April&nbsp;1, 2008, less any dividends already paid on the Preferred Stock (the &#147;Dividend Make-Whole Payment&#148;). The Dividend Make-Whole Payment was payable
in cash or, at the Company&#146;s option, in shares of the Company&#146;s common stock, or a combination of cash and shares of common stock. The Dividend Make-Whole Payment is discussed further in Note 8 below. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of June&nbsp;30, 2008 and December&nbsp;31, 2007 there were no outstanding shares of Preferred Stock as a result of the second quarter 2007 automatic
conversion of the Preferred Stock to common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 8 &#150; Derivative </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In accordance with SFAS No.&nbsp;133 &#147;Accounting for Derivative Instruments and Hedging Activities&#148; (&#147;SFAS 133&#148;), the Company was
required to separate and account for the Dividend Make-Whole Payment feature of its Preferred Stock as an embedded derivative (the &#147;Derivative&#148;). As an embedded derivative instrument, the Dividend Make-Whole Payment feature was measured at
fair value and reflected as a current liability on the Company&#146;s Summary Consolidated Balance Sheets. Changes in the fair value of the Derivative were recognized in the line item change in valuation of derivative on the Company&#146;s Summary
Consolidated Statements of Operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company determined the fair value of the Derivative to be $1.0 million on March&nbsp;18, 2005,
the date of issuance. The Company determined the fair value of the Derivative related to the issuance of additional Preferred Stock upon exercise of the underwriter&#146;s over allotment option to be $32,000 on April&nbsp;19, 2005, the date of
issuance. The proceeds from the Preferred Stock recorded on the Summary Consolidated Balance Sheets were reduced by these amounts, which were allocated to the derivative liability. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As discussed in Note 7 above, on June&nbsp;25, 2007 the Company automatically converted the remaining shares of the Preferred Stock into common stock,
thereby, triggering the payment of the remaining Dividend Make-Whole Payment. Through June&nbsp;4, 2007 the Company had issued 132,000 shares of common stock to converting holders in satisfaction of the Dividend Make-Whole Payment. The value of
voluntary conversions during 2007 was $178,000 based on the share prices on the respective dates of conversion. On June&nbsp;25, 2007 the Company issued 69,000 shares of common stock to preferred shareholders to satisfy the Dividend Make-Whole
Payment due to the automatic conversion. The value of the Dividend Make-Whole Payment was $878,000 based on the share price of $12.71 on the date of conversion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The Company recorded other expense of $866,000 for the three months ended June&nbsp;30, 2007 related to the automatic and voluntary conversions of the Preferred Stock to common stock. The Company recorded $821,000 for
the six months ended June&nbsp;30, 2007 related to the first quarter revaluation of the Derivative and the automatic and voluntary conversion of the Preferred Stock to common stock. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">At June&nbsp;30, 2008 and December&nbsp;31, 2007 there was no remaining derivative liability as a result of the second quarter 2007 automatic conversion
of the Preferred Stock to common stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 9 &#150; Comprehensive Income </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The following is a summary of comprehensive income (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,888</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Unrealized loss on investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Translation adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,921</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The tax effect on the change in unrealized loss on investments and the translation adjustment is
zero for each period presented. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Accumulated other comprehensive income consists of the following (in thousands): </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>June&nbsp;30<BR>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Unrealized gain on investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Translation adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total accumulated other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 10 &#150; Income per Common Share </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table sets forth the computation of basic and diluted income per common share (in thousands, except per share data). The net income for the
six months ended June&nbsp;30, 2007 is adjusted by the effect of the Company&#146;s cumulative, convertible Preferred Stock to arrive at net income applicable to common shares in accordance with SFAS No.&nbsp;128 &#147;Earnings Per Share&#148;
(&#147;SFAS 128&#148;). The Company also considers, as applicable, the effect of its Preferred Stock, as discussed in Note 7, the Derivative, as discussed in Note 8, common stock options, as discussed in Note 11, contingently returnable shares, and
contingent stock awards in the calculation of diluted weighted-average shares below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic income per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Numerator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,888</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,291</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,653</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of preferred stock </FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>a</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income applicable to common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,888</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,291</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,653</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Denominator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic weighted-average common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,756</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,661</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic income per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.24</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Diluted income per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Numerator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,888</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,291</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,653</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of preferred stock </FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>a, </SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT
FACE="Times New Roman" SIZE="1"><SUP>b</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net income applicable to common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,888</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,291</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,653</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Denominator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic weighted-average common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,756</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,661</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of dilutive convertible preferred stock </FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>b</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of dilutive stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">545</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">853</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">475</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">735</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of contingently returnable shares </FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>c</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">55</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Effect of contingent stock awards </FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>d</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Adjusted weighted-average common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28,381</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26,333</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28,211</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Diluted income per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.05</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.24</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3px; margin-top:-2px" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"> <P STYLE="line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>a</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="line-height:95%; vertical-align:top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The amount of the accumulated dividend on Preferred Stock reduced the net income applicable to common shares for the six
months ended June&nbsp;30, 2007. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3px; margin-top:-2px" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"> <P STYLE="line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>b</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="line-height:95%; vertical-align:top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The adjustment for the Dividend Make-Whole Payment for conversions during the period would have increased net income
applicable to common shareholders by $866,000 for the three months ended June&nbsp;30, 2007. The common shares that would have been issued to shareholders at the beginning of the period for the conversion of the remaining Preferred Stock and in
payment of the remaining Dividend Make-Whole Payment would have increased the weighted-average shares by 1.8&nbsp;million for the three months ended June&nbsp;30, 2007. These adjustments were excluded from the calculation above, as they were
anti-dilutive pursuant to the provisions of SFAS 128. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">The amount of the accumulated dividend on the Preferred Stock
decreased the net income applicable to common shares by $243,000 for the six months ended June&nbsp;30, 2007. The adjustment for the Dividend Make-Whole Payment for conversions during the period and the adjustment for the quarterly revaluation of
the derivative liability would have instead increased net income applicable to common shareholders by $821,000 for the six months ended June&nbsp;30, 2007. The common shares that would have been issued to shareholders at the beginning of the period
for the conversion of the remaining Preferred Stock and in payment of the remaining Dividend Make-Whole Payment would have increased the weighted-average shares by 2.0&nbsp;million for the six months ended June&nbsp;30, 2007. These adjustments were
excluded from the calculation above, as they were anti-dilutive pursuant to the provisions of SFAS 128. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3px; margin-top:-2px" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"> <P STYLE="line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>c</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="line-height:95%; vertical-align:top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Contingently returnable shares include shares of common stock issued pursuant to stock grants which have not vested and
are returnable to the Company upon forfeiture. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3px; margin-top:-2px" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"> <P STYLE="line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>d</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="line-height:95%; vertical-align:top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Contingent stock awards include shares to be issued pursuant to performance based bonus plans that have been approved by
the compensation committee of the Board of Directors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In future periods basic and diluted earnings per common share are
expected to be affected by the fluctuations in the fair value of the Company&#146;s common stock, the exercise and issuance of additional stock options, contingently returnable shares, and contingent stock awards. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 11 &#150; Stock Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The Company has stock option and stock incentive plans for employees and non-employee Directors that provide for grants of shares and options to purchase shares of Company common stock at exercise prices generally
equal to the fair values of such stock at the dates of grant. The Company also maintains a shareholder approved Employee Stock Purchase Plan (the &#147;ESPP&#148;) for the benefit of its employees. The ESPP allows eligible employees the right to
purchase common stock on a quarterly basis at the lower of 85% of the market price at the beginning or end of each three-month offering period. Pursuant to the adoption of SFAS 123 Revised &#147;Share-Based Payment&#148;
(&#147;SFAS&nbsp;123R&#148;), both the Company&#146;s 15% discount on ESPP stock purchases and the look back portion of ESPP stock purchases are considered components of stock compensation and must be expensed in the Company&#146;s financial
statements. The look back portion of the Company&#146;s ESPP constitutes an option and, as such, the expense is determined by performing a valuation as discussed below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Stock Grants </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company values its stock grants based on the market value, as determined by
the stock incentive plan, on the date of grant. The value of stock grants is expensed over the vesting period of the related grant, and an estimated forfeiture rate is used to reduce the expense recorded. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In February 2008 the Compensation Committee of the Company&#146;s Board of Directors approved the terms of the Company&#146;s 2008 performance-based
bonus plans to recognize the performance of the Company&#146;s executives and managers. A portion of the awards to be issued under these plans will be paid in Company stock pursuant to the Company&#146;s existing stock incentive plans, if the
required performance is achieved. The Company recorded an accrual of $450,000 related to this contingent stock grant during the six months ended June&nbsp;30, 2008. The Company expects to pay out cash and stock related to these bonus plans in the
first quarter of 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">During the first half of 2008 the Compensation Committee of the Company&#146;s Board of Directors authorized grants
of stock from approved stock incentive plans to non-employee Directors and certain Company executives and managers totaling 170,000 shares of common stock, which had an aggregate value of $1.6 million. The grants of stock during the first half of
2008 include 81,000 shares of common stock valued at $786,000 issued as part of the 2007 performance-based bonus plans for certain Company executives and managers. The Company recorded the expense related to the 2007 performance-based bonus plans
during the year ended December&nbsp;31, 2007. The remaining value of the stock granted will be recorded as an expense on the Company&#146;s Summary Consolidated Statements of Operations over the respective vesting periods in accordance with SFAS
123R as discussed below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">During the first half of 2007 the Compensation Committee of the Company&#146;s Board of Directors authorized
grants of stock from approved stock incentive plans to non-employee Directors and certain Company executives totaling 136,000 shares of common stock, which had an aggregate value of $1.4 million. The grants of stock during the first half of 2007
included 68,000 shares of common stock valued at $587,000 issued as part of the 2006 performance-based bonus plan for certain Company executives. The Company recorded the expense related to the 2006 performance-based bonus plan during the year ended
December&nbsp;31, 2006. The remaining value of the stock granted will be recorded as an expense on the Company&#146;s Summary Consolidated Statements of Operations over the respective vesting periods in accordance with SFAS 123R as discussed below.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Stock Options </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Compensation
Committee of the Company&#146;s Board of Directors authorized grants of stock options from approved stock incentive plans to certain Company executives and employees totaling 333,000 and 273,000 shares during the first half of 2008 and 2007,
respectively, with exercise prices equal to the stock prices on the respective grant dates. The value of the stock options granted will be recorded as an expense on the Company&#146;s Summary Consolidated Statements of Operations over the respective
vesting periods in accordance with SFAS 123R as discussed below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Employees purchased common stock totaling 26,000 and 25,000 shares in the
first half of 2008 and 2007, respectively, through the Company&#146;s ESPP. The value of the option portion of the stock purchased was recorded as an expense on the Company&#146;s Summary Consolidated Statements of Operations in each quarterly
period in accordance with SFAS 123R as discussed below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Stock Compensation Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The Company uses the Black-Scholes model to value its stock option grants under SFAS 123R and expenses the related compensation cost using the straight-line method over the vesting period. The fair value of the
Company&#146;s ESPP options is also determined using the Black-Scholes model and is expensed quarterly at the end of the purchase period, as the option is fully vested at that time. The fair value of stock options is determined on the grant date
using assumptions for the expected term, expected volatility, dividend yield, and the risk free interest rate. The term assumption is primarily based on the contractual term of the option and historic data related to exercise and post-vesting
cancellation history experienced by the Company, adjusted based on management&#146;s expectations of future results. The expected term is determined separately for options issued to the Company&#146;s directors and to employees. The Company&#146;s
anticipated volatility level is primarily based on the historic volatility of the Company&#146;s common stock, adjusted to remove the effects of certain periods of unusual volatility not expected to recur, and adjusted based on management&#146;s
expectations of future volatility, for the life of the option or option group. The Company&#146;s model includes a zero dividend yield assumption, as the Company has not historically paid nor does it anticipate paying dividends on its common stock.
The risk free interest rate is based on recent U.S. Treasury note auction results with a similar life to that of the option. The Company&#146;s model does not include a discount for post-vesting restrictions, as the Company has not issued awards
with such restrictions. The period expense is then determined based on the valuation of the options, and at that time an estimated forfeiture rate is used to reduce the expense recorded. The Company&#146;s estimate of pre-vesting forfeitures is
primarily based on the recent historical experience of the Company, and the expense recorded is adjusted to reflect actual forfeitures at each vesting date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The following weighted-average assumptions were used to determine the fair value of options under SFAS 123R: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June&nbsp;30, 2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June 30, 2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Stock<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>ESPP<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Stock<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>ESPP<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Expected stock price volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Expected life of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.25&nbsp;Years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.5&nbsp;Years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.25&nbsp;Years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="7"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June&nbsp;30, 2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June 30, 2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Stock<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>ESPP<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Stock<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>ESPP<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Expected stock price volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Expected life of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.25&nbsp;Years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.5&nbsp;Years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">.25&nbsp;Years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="15"> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">The following table summarizes stock compensation expenses (in thousands):</FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px"></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June 30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June 30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Stock grant expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">444</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">358</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Stock option expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">335</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total stock compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">779</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Included in this total stock compensation expense were expenses related to common stock grants,
options issued prior and subsequent to the adoption of SFAS 123R that continue to vest during the period, and compensation related to the Company&#146;s ESPP. These amounts were recorded as compensation expense and were subject to the Company&#146;s
normal allocation of expenses to inventory and deferred preservation costs. The Company capitalized $30,000 and $24,000 in the three months ended June&nbsp;30, 2008 and 2007, respectively, of the stock compensation </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">expense into its deferred preservation costs and inventory costs. The Company capitalized $49,000 and $44,000 in the six months ended June&nbsp;30, 2008 and
2007, respectively, of the stock compensation expense into its deferred preservation costs and inventory costs. The Company did not recognize a tax benefit, or a related operating cash outflow and financing cash inflow, related to the compensation
expense recorded in the three and six months ended June&nbsp;30, 2008 and 2007, as the Company is maintaining a full valuation allowance on its deferred tax assets. See Note 5 for additional discussions of the Company&#146;s income tax valuation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of June&nbsp;30, 2008 and 2007 the Company had a total of $993,000 and $688,000, respectively, in total unrecognized compensation costs
related to unvested stock grants, before considering the effect of expected forfeitures. This expense is expected to be recognized over each stock grant&#146;s vesting period. As of June&nbsp;30, 2008 the Company has outstanding stock grants that
complete vesting in 2008, 2010, and 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of June&nbsp;30, 2008 and 2007 there was approximately $1.9 million and $2.0 million,
respectively, in total unrecognized compensation costs related to unvested stock options, before considering the effect of expected forfeitures. As of June&nbsp;30, 2008 and 2007 this expense is expected to be recognized over a weighted average
period of 1.6 years and 1.9 years, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 12 &#150; Segment Information </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company has two reportable segments organized according to its services and products: Preservation Services and Implantable Medical Devices.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Preservation Services segment includes external services revenues from the cryopreservation of cardiac and vascular tissues and from
shipments of previously cryopreserved orthopaedic tissues. The Implantable Medical Devices segment includes external revenues from product sales of BioGlue, Hemostase MPH, CardioWrap, and bioprosthetic devices, including the CryoLife-O&#146;Brien
Stentless Aortic Bioprosthesis, and SynerGraft processed bovine vascular grafts. There are no intersegment revenues. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The primary measure
of segment performance, as viewed by the Company&#146;s management, is segment gross margin, or net external revenues less cost of preservation services and products. The Company does not segregate assets by segment; therefore, asset information is
excluded from the segment disclosures below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table summarizes revenues, cost of preservation services and products, and
gross margins for the Company&#146;s operating segments (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June 30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June 30,</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preservation services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,725</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,711</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,149</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,672</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Implantable medical devices</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,280</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,156</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,260</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22,551</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All other </FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>a</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">150</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">144</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">314</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">312</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,155</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23,011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">52,723</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47,535</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cost of Preservation Services and Products:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preservation services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,449</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,976</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,767</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,608</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Implantable medical devices</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,840</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,881</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,832</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,829</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All other </FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>a</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,289</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,857</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18,599</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18,437</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Gross Margin:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preservation services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,276</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,735</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,382</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,064</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Implantable medical devices</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,440</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,275</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">21,428</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18,722</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All other </FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>a</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">150</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">144</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">314</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">312</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,866</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,154</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">34,124</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29,098</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3px; margin-top:-2px" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"> <P STYLE="line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>a</SUP></FONT></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="line-height:95%; vertical-align:top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="1"><SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2">The &#147;All other&#148; designation includes 1) grant revenue
and 2) revenues related to the licensing of the Company&#146;s technology to a third party. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table summarizes net revenues by service or product (in thousands): </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preservation services:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cardiac tissue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,348</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,048</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,586</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,021</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Vascular tissue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,080</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,428</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,939</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,567</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Orthopaedic tissue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">297</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,235</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">624</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,084</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total preservation services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,725</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,711</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,149</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,672</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Products:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">BioGlue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,972</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,930</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,859</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22,093</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other implantable medical devices</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">308</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">226</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">401</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">458</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,280</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,156</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,260</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22,551</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">150</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">144</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">314</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">312</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,155</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23,011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">52,723</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47,535</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 13 &#150; Commitments and Contingencies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Product Liability Claims </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In the normal course of business as a medical device and services
company, the Company has liability and tissue processing complaints filed against it. As of July&nbsp;25, 2008 one liability lawsuit was pending against the Company arising out of the Company&#146;s allograft orthopaedic tissue preservation
services. Management believes this lawsuit is covered by liability insurance. This lawsuit is in the discovery stage. Other parties have made complaints that may result in lawsuits in future periods. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Based on an analysis the Company performed as of June&nbsp;30, 2008 of the pending tissue processing liability lawsuit, the Company accrued a total of
approximately $330,000 for the pending tissue processing liability lawsuit. The $330,000 accrual was included as a component of accrued expenses and other current liabilities on the June&nbsp;30, 2008 Summary Consolidated Balance Sheet. As of
December&nbsp;31, 2007 the Company had accrued a total of approximately $330,000 for the pending tissue processing liability lawsuit. The $330,000 accrual was included as a component of accrued expenses and other current liabilities on the
December&nbsp;31, 2007 Summary Consolidated Balance Sheet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On April&nbsp;1, 2008 the Company bound liability coverage for the 2008/2009
insurance policy year. This policy is a six-year claims-made insurance policy, i.e. claims incurred during the period April&nbsp;1, 2003 through March&nbsp;31, 2009 and reported during the period April&nbsp;1, 2008 through March&nbsp;31, 2009 are
covered by this policy. Claims incurred prior to April&nbsp;1, 2003 that have not been reported are uninsured. Any punitive damage components of claims are also uninsured. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company maintains claims-made insurance policies to mitigate its financial exposure to product and tissue processing liability claims. Claims-made
insurance policies generally cover only those asserted claims and incidents that are reported to the insurance carrier while the policy is in effect. Thus, a claims-made policy does not generally represent a transfer of risk for claims and incidents
that have been incurred but not reported to the insurance carrier during the policy period. The Company periodically evaluates its exposure to unreported product and tissue processing liability claims and records accruals as necessary for the
estimated cost of unreported claims related to services performed and products used. In July 2008 the Company retained an independent actuarial firm to perform estimates of the unreported claims as of June&nbsp;30, 2008. The independent firm
estimated the unreported loss liability using a frequency-severity approach, whereby projected losses were calculated by multiplying the estimated number of claims </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">by the estimated average cost per claim. The estimated claims were calculated based on the reported claim development method and the Bornhuetter-Ferguson
method using a blend of the Company&#146;s historical claim experience and industry data. The estimated cost per claim was calculated using a lognormal claims model blending the Company&#146;s historical average cost per claim with industry claims
data. The independent actuarial firm used a number of assumptions in order to estimate the unreported loss liability including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">A ceiling of $5.0 million was selected for actuarial purposes in determining the liability per claim given the uncertainty in projecting claim losses in excess of
$5.0 million, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The future claim reporting lag time would be a blend of the Company&#146;s experiences and industry data, </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The frequency of unreported claims for accident years 2001 through 2008 would be lower than the Company&#146;s experience in the 2002/2003 policy year, but higher
than the Company&#146;s historical claim frequency prior to the 2002/2003 policy year, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The average cost per claim would be lower than the Company&#146;s experience since the 2002/2003 policy year, but higher than the Company&#146;s historical cost per
claim prior to the 2002/2003 policy year, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The average cost per BioGlue claim would be consistent with the Company&#146;s overall historical exposures until adequate historical data is available on this
product line, and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The number of BioGlue claims per million dollars of BioGlue revenue would be 55% lower than non-BioGlue claims per million dollars of revenue. The 55% factor was
selected based on BioGlue claims experience to date and consultation with the actuary. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company believes that these
assumptions provide a reasonable basis for the calculation of the unreported liability loss, but the accuracy of the actuarial firm&#146;s estimates is limited by the general uncertainty that exists for any estimate of future activity due to
uncertainties surrounding the assumptions used and due to Company specific conditions and the scarcity of industry data directly relevant to the Company&#146;s business activities. Due to these factors, actual results may differ significantly from
the assumptions used and amounts accrued. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Based on the actuarial valuation performed in July 2008 as of June&nbsp;30, 2008, the Company
estimated that its liability for unreported liability claims was $5.0 million. The $5.0 million balance is included as a component of accrued expenses and other current liabilities of $2.5 million and other long-term liabilities of $2.5 million on
the June&nbsp;30, 2008 Summary Consolidated Balance Sheet. Further analysis indicated that the liability could be estimated to be as high as $10.0 million, after including a reasonable margin for statistical fluctuations calculated based on
actuarial simulation techniques. Based on the actuarial valuation, the Company estimated that as of June&nbsp;30, 2008, $1.6 million of the accrual for unreported liability claims would be recoverable under the Company&#146;s insurance policies. The
$1.6 million insurance recoverable is included as a component of other receivables of $800,000 and other long-term assets of $800,000 on the June&nbsp;30, 2008 Summary Consolidated Balance Sheet. These amounts represent management&#146;s estimate of
the probable losses and anticipated recoveries for unreported liability claims related to services performed and products sold prior to June&nbsp;30, 2008. Actual results may differ from this estimate. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of December&nbsp;31, 2007 the Company accrued $6.3 million for unreported liability claims and recorded a receivable of $2.4 million for unreported
liability claims estimated to be recoverable under the Company&#146;s insurance policies. This $6.3 million accrual was included as a component of accrued expenses and other current liabilities of $3.2 million and other long-term liabilities of $3.1
million on the December&nbsp;31, 2007 Summary Consolidated Balance Sheet. The $2.4 million insurance recoverable was included as a component of other current receivables of $1.1 million and other long-term assets of $1.3 million on the
December&nbsp;31, 2007 Summary Consolidated Balance Sheet. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 14 &#150; New Accounting Pronouncements </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company was required to adopt SFAS No.&nbsp;157 &#147;Fair Value Measurements&#148; (&#147;SFAS 157&#148;) for the fiscal year beginning
January&nbsp;1, 2008. SFAS 157 provides a single definition of fair value and a hierarchical framework for measuring it, as well as establishing additional disclosure requirements about the use of fair value to measure assets and liabilities. The
adoption of SFAS 157 did not have a material effect on the Company&#146;s results of operations or financial position. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company was required to adopt SFAS No.&nbsp;159 &#147;The Fair Value Option for Financial Assets and
Liabilities&#148; (&#147;SFAS 159&#148;) for the fiscal year beginning January&nbsp;1, 2008. SFAS 159 provides the option to report certain financial assets and liabilities at fair value, with the intent to mitigate volatility in financial reporting
that can occur when related assets and liabilities are measured differently. The Company does not expect to voluntarily implement the optional fair value measurements portions of SFAS 159 for eligible items. The adoption of SFAS 159 did not have a
material effect on the Company&#146;s results of operations or financial position. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company will be required to adopt SFAS
No.&nbsp;141R &#147;Business Combinations&#148; (&#147;SFAS 141R&#148;) for the fiscal year beginning January&nbsp;1, 2009. FAS 141R establishes principles and requirements for how an acquirer in a business combination recognizes and measures in its
financial statements the identifiable assets acquired, the liabilities assumed, and any controlling interest; recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and determines what
information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. The Company does not expect the adoption of FAS 141R to have a material effect on its consolidated
financial position, results of operations or cash flows. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">PART I - FINANCIAL INFORMATION </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">CryoLife, Inc.
(&#147;CryoLife&#148;, the &#147;Company&#148;, &#147;we&#148;, or &#147;us&#148;) develops and commercializes biomaterials and implantable medical devices, and preserves and distributes human tissues for cardiac and vascular transplant
applications. The Company&#146;s human tissues include the CryoValve<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> SG pulmonary human heart valve, processed using CryoLife&#146;s proprietary SynerGraft<FONT FACE="Times New Roman"
SIZE="1"><SUP>&reg;</SUP></FONT> Technology. The Company&#146;s biomaterials and implantable medical devices include BioGlue<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> Surgical Adhesive (&#147;BioGlue&#148;),
CryoLife-O&#146;Brien<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> Stentless Porcine Aortic Bioprosthesis, and ProPatch<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> Soft Tissue Repair Matrix (&#147;ProPatch&#148;).
Additionally, the Company distributes a microporous polysaccharide hemostatic agent under the private label Hemostase MPH<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> for Medafor, Inc. (&#147;Medafor&#148;) and CardioWrap<FONT
FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>, a bioresorbable thin film sheet used in cardiac reconstruction for MAST BioSurgery, Inc (&#147;MAST&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">In the quarter ended June&nbsp;30, 2008 CryoLife revenues were $27.2 million. This represents the second consecutive quarter that CryoLife exceeded its previous record level of quarterly revenues. The $27.2 million in
revenues included preservation services revenues of $13.7 million and BioGlue revenues of $13.0 million. During the second quarter of 2008 CryoLife continued to focus on physician training to enhance the acceptance of its products with physicians in
the cardiac and vascular surgery specialties. This effort included the appointment of William F. Northrup, III, M.D. to the newly created position of Vice President of Medical Relations and Education. The Company also held a surgeon&#146;s cardiac
allograft symposium in April and announced that it will hold a Ross summit in October 2008, focusing on training and education on the Ross cardiac procedure. The Ross procedure is a cardiac surgery operation where a diseased aortic valve is replaced
with the patient&#146;s own pulmonary valve and a pulmonary allograft, such as CryoLife&#146;s CryoValve or CryoValve SG pulmonary human heart valve, is implanted to replace the patient&#146;s own pulmonary valve. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In the quarter ended June&nbsp;30, 2008 CryoLife announced advances in its product offerings. In April the Company announced that it had signed an
exclusive three-year agreement with Minneapolis-based Medafor to distribute its microporous polysaccharide hemostatic agent under the private label name Hemostase MPH, in May the Company announced the first implant of its combination aortic-mitral
allograft heart valve at the Cleveland Clinic, and in June the Company and its partner BioForm Medical, Inc. (&#147;BioForm&#148;) announced that BioGlue had received CE Mark approval for use in brow lift procedures. See Recent Events below for
further discussion of certain of these items, and see Results of Operations below for further discussion of the Company&#146;s financial results during the quarter ended June&nbsp;30, 2008. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Recent Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Medafor License Agreement </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On April&nbsp;17, 2008 CryoLife signed an exclusive three-year agreement with Medafor. Under terms of the agreement CryoLife will distribute
Medafor&#146;s microporous polysaccharide hemostatic agent for use in cardiac and vascular surgery in the U.S. and for cardiac, vascular, and general surgery, other than orthopaedic and ear, nose and throat surgery, internationally, with the
exception of China and Japan. This product is a plant-based, flowable powder engineered to rapidly dehydrate blood, enhancing clotting on contact. The unique, absorbable powder hemostat, which received CE Mark approval in 2003 and FDA pre-market
approval in September 2006, is distributed by CryoLife under the private label name Hemostase MPH. The Company is not contractually obligated to make minimum purchases under this agreement. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">CryoLife began distributing Hemostase MPH in the U.S. during the second quarter of 2008. Pursuant to the terms of the agreement, Medafor will retain
distribution rights to approximately 41 hospitals until no later than December&nbsp;31, 2008. Medafor also retained the exclusive rights to distribute to U.S. Department of Defense hospitals. Outside of the U.S., CryoLife began distributing
Hemostase MPH in the United Kingdom and Germany during the second quarter of 2008, with distribution in other markets expected to begin later in 2008 and in 2009. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>BioGlue Brow Lift Approval </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On June&nbsp;10, 2008 CryoLife and BioForm announced that they received a CE Mark for the use of BioGlue for periosteal fixation following endoscopic browplasty, commonly called brow lift, a reconstructive plastic
surgery procedure. The CE Mark approval allows the product to be marketed in the European Community (EU). BioGlue will be distributed by BioForm, for use in approved cosmetic and reconstructive plastic surgery in the EU, under the name &#147;BioGlue
Aesthetic&#153; Medical Adhesive.&#148; Under the terms of the agreement, CryoLife is the exclusive supplier of BioGlue to BioForm for all cosmetic and plastic surgery applications, and BioForm is responsible for all clinical trials and regulatory
filings, and for sales and marketing of BioGlue in these applications in 12 EU countries. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Critical Accounting Policies </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">A summary of the Company&#146;s significant accounting policies is included in Part II, Item&nbsp;8, &#147;Note 1 of the Notes to Consolidated Financial
Statements,&#148; contained in the Company&#146;s Form 10-K for the fiscal year ended December&nbsp;31, 2007. Management believes that the consistent application of these policies enables the Company to provide users of the financial statements with
useful and reliable information about the Company&#146;s operating results and financial condition. The summary consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. for interim
financial information, which require the Company to make estimates and assumptions. The following are accounting policies that management believes are most important to the portrayal of the Company&#146;s financial condition and results and may
involve a higher degree of judgment and complexity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Product Liability Claims: </I></B>In the normal course of business as a medical
device and services company, the Company has liability and tissue processing complaints filed against it. As of July&nbsp;25, 2008 one liability lawsuit was pending against the Company arising out of the Company&#146;s allograft orthopaedic tissue
preservation services. Management believes this lawsuit is covered by liability insurance. This lawsuit is in the discovery stage. Other parties have made complaints that may result in lawsuits in future periods. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Based on an analysis the Company performed as of June&nbsp;30, 2008 of the pending tissue processing liability lawsuit, the Company accrued a total of
approximately $330,000 for the pending tissue processing liability lawsuit. The $330,000 accrual was included as a component of accrued expenses and other current liabilities on the June&nbsp;30, 2008 Summary Consolidated Balance Sheet. As of
December&nbsp;31, 2007 the Company had accrued a total of approximately $330,000 for the pending tissue processing liability lawsuit. The $330,000 accrual was included as a component of accrued expenses and other current liabilities on the
December&nbsp;31, 2007 Summary Consolidated Balance Sheet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On April&nbsp;1, 2008 the Company bound liability coverage for the 2008/2009
insurance policy year. This policy is a six-year claims-made insurance policy, i.e. claims incurred during the period April&nbsp;1, 2003 through March&nbsp;31, 2009 and reported during the period April&nbsp;1, 2008 through March&nbsp;31, 2009 are
covered by this policy. Claims incurred prior to April&nbsp;1, 2003 that have not been reported are uninsured. Any punitive damage components of claims are also uninsured. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company maintains claims-made insurance policies to mitigate its financial exposure to product and tissue processing liability claims. Claims-made
insurance policies generally cover only those asserted claims and incidents that are reported to the insurance carrier while the policy is in effect. Thus, a claims-made policy does not generally represent a transfer of risk for claims and incidents
that have been incurred but not reported to the insurance carrier during the policy period. The Company periodically evaluates its exposure to unreported product and tissue processing liability claims and records accruals as necessary for the
estimated cost of unreported claims related to services performed and products used. In July 2008 the Company retained an independent actuarial firm to perform estimates of the unreported claims as of June&nbsp;30, 2008. The independent firm
estimated the unreported loss liability using a frequency-severity approach, whereby projected losses were calculated by multiplying the estimated number of claims by the estimated average cost per claim. The estimated claims were calculated based
on the reported claim </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">development method and the Bornhuetter-Ferguson method using a blend of the Company&#146;s historical claim experience and industry data. The estimated cost
per claim was calculated using a lognormal claims model blending the Company&#146;s historical average cost per claim with industry claims data. The independent actuarial firm used a number of assumptions in order to estimate the unreported loss
liability including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">A ceiling of $5.0 million was selected for actuarial purposes in determining the liability per claim given the uncertainty in projecting claim losses in excess of
$5.0 million, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The future claim reporting lag time would be a blend of the Company&#146;s experiences and industry data, </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The frequency of unreported claims for accident years 2001 through 2008 would be lower than the Company&#146;s experience in the 2002/2003 policy year, but higher
than the Company&#146;s historical claim frequency prior to the 2002/2003 policy year, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The average cost per claim would be lower than the Company&#146;s experience since the 2002/2003 policy year, but higher than the Company&#146;s historical cost per
claim prior to the 2002/2003 policy year, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The average cost per BioGlue claim would be consistent with the Company&#146;s overall historical exposures until adequate historical data is available on this
product line, and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The number of BioGlue claims per million dollars of BioGlue revenue would be 55% lower than non-BioGlue claims per million dollars of revenue. The 55% factor was
selected based on BioGlue claims experience to date and consultation with the actuary. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company believes that these
assumptions provide a reasonable basis for the calculation of the unreported liability loss, but the accuracy of the actuarial firm&#146;s estimates is limited by the general uncertainty that exists for any estimate of future activity due to
uncertainties surrounding the assumptions used and due to Company specific conditions and the scarcity of industry data directly relevant to the Company&#146;s business activities. Due to these factors, actual results may differ significantly from
the assumptions used and amounts accrued. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Based on the actuarial valuation performed in July 2008 as of June&nbsp;30, 2008, the Company
estimated that its liability for unreported liability claims was $5.0 million. The $5.0 million balance is included as a component of accrued expenses and other current liabilities of $2.5 million and other long-term liabilities of $2.5 million on
the June&nbsp;30, 2008 Summary Consolidated Balance Sheet. Further analysis indicated that the liability could be estimated to be as high as $10.0 million, after including a reasonable margin for statistical fluctuations calculated based on
actuarial simulation techniques. Based on the actuarial valuation, the Company estimated that as of June&nbsp;30, 2008, $1.6 million of the accrual for unreported liability claims would be recoverable under the Company&#146;s insurance policies. The
$1.6 million insurance recoverable is included as a component of other receivables of $800,000 and other long-term assets of $800,000 on the June&nbsp;30, 2008 Summary Consolidated Balance Sheet. These amounts represent management&#146;s estimate of
the probable losses and anticipated recoveries for unreported liability claims related to services performed and products sold prior to June&nbsp;30, 2008. Actual results may differ from this estimate. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of December&nbsp;31, 2007 the Company accrued $6.3 million for unreported liability claims and recorded a receivable of $2.4 million for unreported
liability claims estimated to be recoverable under the Company&#146;s insurance policies. This $6.3 million accrual was included as a component of accrued expenses and other current liabilities of $3.2 million and other long-term liabilities of $3.1
million on the December&nbsp;31, 2007 Summary Consolidated Balance Sheet. The $2.4 million insurance recoverable was included as a component of other current receivables of $1.1 million and other long-term assets of $1.3 million on the
December&nbsp;31, 2007 Summary Consolidated Balance Sheet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Deferred Preservation Costs: </I></B>By federal law, human tissues cannot
be bought or sold. Therefore, the tissues the Company preserves and further processes cannot be held as inventory. Tissue is procured from deceased human donors by organ and tissue procurement agencies, which consign the tissue to the Company for
processing, preservation, and distribution. Preservation costs consist primarily of direct labor and materials (including salary and fringe benefits, laboratory expenses, tissue procurement fees, and freight-in charges) and indirect costs (including
allocations of costs from departments that support processing activities and facility allocations). Although the Company cannot own human tissue, the preservation process is a manufacturing process that is accounted for in accordance with ARB
No.&nbsp;43 Chapter 4 &#147;Inventory Pricing&#148; (&#147;ARB 43&#148;). Preservation costs are stated at the lower of cost or market on a first-in, first-out basis and are deferred until revenue is recognized upon shipment of the tissue to the
implanting facilities. Cost of preservation services also includes idle facility expense, excessive spoilage, double freight, and rehandling costs and requires allocation of fixed production overheads to be based on the normal capacity of the
production facilities in accordance with Statement of Financial Accounting Standards (&#147;SFAS&#148;) No.&nbsp;151 &#147;Inventory Costs&#148; (&#147;SFAS&nbsp;151&#148;). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The calculation of deferred preservation costs involves a high degree of judgment and complexity. The
costs included in deferred preservation costs contain several estimates due to the timing differences between the occurrence of the cost and receipt of final bills for services. Costs that contain estimates include tissue procurement fees, which are
estimated based on the Company&#146;s contracts with independent procurement agencies, and freight-in charges, which are estimated based on the Company&#146;s prior experiences with these charges. These costs are adjusted for differences between
estimated and actual fees when invoices for these services are received. Management believes that its estimates approximate the actual costs of these services, but estimates could differ from actual costs. Total deferred preservation costs are then
allocated among the different tissues processed during the period based on specific cost drivers such as the number of donors and the number of tissues processed. At each balance sheet date a portion of the deferred preservation costs relates to
tissues currently in active processing or held in quarantine pending release to implantable status. The Company applies a yield estimate to all tissues in process and in quarantine to estimate the portion of tissues that will ultimately become
implantable. Management determines this estimate of quarantine yields based on its experience in prior periods and reevaluates this estimate periodically. Due to the nature of this estimate and the length of the processing times experienced by the
Company, actual yields could differ from the Company&#146;s estimates. A significant change in quarantine yields could materially impact the amount of deferred preservation costs on the Company&#146;s Summary Consolidated Balance Sheets and the cost
of preservation services, including the lower of cost or market write-down, described below, on the Company&#146;s Summary Consolidated Statements of Operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The Company regularly evaluates its deferred preservation costs to determine if the costs are appropriately recorded at the lower of cost or market value and to determine if there are any impairments to the book value
of the Company&#146;s deferred preservation costs. CryoLife records a charge to cost of preservation services to write-down the amount of deferred preservation costs that are not deemed to be recoverable. These write-downs are permanent impairments
that create a new cost basis, which cannot be restored to its previous levels when tissues are shipped or become available for shipment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The Company recorded a write-down of $234,000 and $341,000 for the three and six months ended June&nbsp;30, 2007 for the value of certain deferred preservation costs that exceeded market value. No write-down for deferred preservation costs
that exceeded market value has been recorded in 2008. The amount of the 2007 write-down was primarily due to excess tissue processing costs incurred in that period that exceeded market value based on then recent average service fees. Actual results
may differ from these estimates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of June&nbsp;30, 2008 deferred preservation costs consisted of $10.2 million for allograft heart valve
tissues, $2.2 million for non-valved cardiac tissues, $19.0 million for vascular tissues and zero for orthopaedic tissues. As of December&nbsp;31, 2007 deferred preservation costs consisted of $7.6 million for allograft heart valve tissues, $2.1
million for non-valved cardiac tissues, $17.1 million for vascular tissues, and $123,000 for orthopaedic tissues. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Deferred Income
Taxes: </I></B>Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and tax return purposes. The Company generated deferred tax assets
primarily as a result of write-downs of deferred preservation costs, accruals for product liability claims, and operating losses. The Company periodically assesses the recoverability of its deferred tax assets in accordance with SFAS No.&nbsp;109
&#147;Accounting for Income Taxes&#148; (&#147;SFAS 109&#148;), as necessary, when the Company experiences changes that could materially affect its determination of the recoverability of its deferred tax assets. Management provides a valuation
allowance when, as a result of this analysis, management believes it is more likely than not that its deferred tax assets will not be realized. In assessing the recoverability of its deferred tax assets at December&nbsp;31, 2007 the Company reviewed
its historical operating results, including the reasons for its operating losses in prior years and uncertainties regarding projected future operating results. Based on the results of this analysis, discussed further below, at December&nbsp;31, 2007
and June&nbsp;30, 2008 the Company determined that it was more likely than not that the Company&#146;s deferred tax assets would not be realized. Therefore, as of June&nbsp;30, 2008 and December&nbsp;31, 2007 the Company had a total of $28.2 million
in valuation allowances against deferred tax assets and a net deferred tax liability of $27,000. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Based on the Company&#146;s results for the year ended December&nbsp;31, 2007 and its projections for
2008, the Company anticipates that it will utilize a portion of its net operating loss carryforwards in the 2008 income tax year to offset its U.S. taxable income, as it did in the 2007 and 2006 tax years. Although CryoLife is beginning to utilize
its net operating loss carryforwards, the Company currently believes that a change in its determination of the recoverability of the related deferred tax asset is not yet warranted, as in accordance with the guidance in SFAS 109, the Company&#146;s
net losses in recent years constitute significant evidence against the recoverability of its deferred tax assets that is difficult to overcome. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Although the Company has concluded that a valuation allowance is still required on its deferred tax assets, if profitable operations continue the Company may reverse all or a portion of its valuation allowance in a future period. If all or
a portion of the valuation allowance is reversed, the Company will record a non-cash gain at that time that is expected to have a material impact on the Company&#146;s results of operations and financial position. In periods following the reversal,
the Company&#146;s effective income tax rate is expected to be significantly higher than the effective income tax rate experienced in periods prior to the reversal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Also, the realizability of the Company&#146;s deferred tax assets could be limited in future periods following a change in control as mandated by Section&nbsp;382 of the Internal Revenue Code of 1986, as amended,
which relates to certain specified changes in control of taxpayers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The tax years 2004-2007 remain open to examination by the major taxing
jurisdictions to which the Company is subject. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Impairments of Long-Lived Assets: </I></B>The Company assesses the potential
impairment of its long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that could trigger an impairment review include the following: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Significant underperformance relative to expected historical or projected future operating results, </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Significant negative industry or economic trends, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Significant decline in the Company&#146;s stock price for a sustained period, or </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Significant decline in the Company&#146;s market capitalization relative to net book value. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">SFAS No.&nbsp;144 &#147;Accounting for the Impairment or Disposal of Long-Lived Assets&#148; (&#147;SFAS 144&#148;), requires the write-down of a
long-lived asset to be held and used if the carrying value of the asset or the asset group to which the asset belongs is not recoverable. The carrying value of the asset or asset group is not recoverable if it exceeds the sum of the undiscounted
future cash flows expected to result from the use and eventual disposition of the asset or asset group. For the year ended December&nbsp;31, 2007 the Company did not experience any factors that indicated an SFAS 144 impairment review was warranted.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">SFAS No.&nbsp;142 &#147;Goodwill and Other Intangible Assets&#148; (&#147;SFAS 142&#148;) requires that goodwill resulting from business
acquisitions and other non-amortizing intangible assets be subject to annual impairment testing. The Company&#146;s non-amortizing intangible assets as of December&nbsp;31, 2007 consist of trademarks and, as a result of the Company&#146;s agreement
with Regeneration Technologies, Inc. (&#147;RTI&#148;) and certain of its affiliates as discussed in Item&nbsp;1, Note 2 of the &#147;Notes to Summary Consolidated Financial Statements&#148;, procurement contracts and access to the procurement of
cardiac and vascular human tissues previously received by RTI. In accordance with SFAS 142, the Company performed an analysis on its non-amortizing intangible assets as of December&nbsp;31, 2007. Based on the results of its analysis, the Company did
not believe that an impairment existed related to its non-amortizing intangible assets as of December&nbsp;31, 2007. Management will continue to evaluate the recoverability of these non-amortizing intangible assets at least on an annual basis in
accordance with SFAS 142. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For the six months ended June&nbsp;30, 2008 the Company did not experience any changes that would materially
affect the Company&#146;s analysis of and recoverability of any of its long-lived assets. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>New Accounting Pronouncements </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company was required to adopt SFAS No.&nbsp;157 &#147;Fair Value Measurements&#148; (&#147;SFAS 157&#148;) for the fiscal year beginning
January&nbsp;1, 2008. SFAS 157 provides a single definition of fair value and a hierarchical framework for measuring it, as well as establishing additional disclosure requirements about the use of fair value to measure assets and liabilities. The
adoption of SFAS 157 did not have a material effect on the Company&#146;s results of operations or financial position. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company was required to adopt SFAS No.&nbsp;159 &#147;The Fair Value Option for Financial Assets and
Liabilities&#148; (&#147;SFAS 159&#148;) for the fiscal year beginning January&nbsp;1, 2008. SFAS 159 provides the option to report certain financial assets and liabilities at fair value, with the intent to mitigate volatility in financial reporting
that can occur when related assets and liabilities are measured differently. The Company does not expect to voluntarily implement the optional fair value measurements portions of SFAS 159 for eligible items. The adoption of SFAS 159 did not have a
material effect on the Company&#146;s results of operations or financial position. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company will be required to adopt SFAS
No.&nbsp;141R &#147;Business Combinations&#148; (&#147;SFAS 141R&#148;) for the fiscal year beginning January&nbsp;1, 2009. FAS 141R establishes principles and requirements for how an acquirer in a business combination recognizes and measures in its
financial statements the identifiable assets acquired, the liabilities assumed, and any controlling interest; recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and determines what
information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. The Company does not expect the adoption of FAS 141R to have a material effect on its consolidated
financial position, results of operations or cash flows. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>(Tables in thousands) </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Revenues </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,155</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23,011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">52,723</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47,535</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Revenues increased 18% for the three months ended June&nbsp;30, 2008 as compared to the three
months ended June&nbsp;30, 2007. Revenues increased 11% for the six months ended June&nbsp;30, 2008 as compared to the six months ended June&nbsp;30, 2007. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The increase in the three and six months ended June&nbsp;30, 2008 was primarily due to an increase in BioGlue revenues and tissue preservation services revenues, as compared to the prior year periods. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">A detailed discussion of the change in preservation services revenues for each of the three major tissue types distributed by the Company and the change
in BioGlue and other implantable medical device revenues is presented below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Cardiac Preservation Services </I></B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,586</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cardiac revenues as a percentage of total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Revenues from cardiac preservation services increased 26% for the three months ended June&nbsp;30,
2008 as compared to the three months ended June&nbsp;30, 2007. This increase was primarily due to volume, consisting of the aggregate impact of favorable tissue mix and a 7% increase in unit shipments of cardiac tissues, which together increased
revenues by 13%, and an increase in average service fees, which increased revenues by 13%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Revenues from cardiac preservation services
increased 26% for the six months ended June&nbsp;30, 2008 as compared to the six months ended June&nbsp;30, 2007. This increase was primarily due to the aggregate impact of favorable tissue mix and a 16% increase in unit shipments of cardiac
tissues, which increased revenues by 15%, and an increase in average service fees, which increased revenues by 11%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The increase in
cardiac volume for the three months ended June&nbsp;30, 2008 was primarily due to the favorable impact of the CryoValve SG pulmonary human heart valve (&#147;CryoValve SG&#148;) both due to the fact that shipments of CryoValve SG command a premium
fee over standard processed pulmonary valves (favorable tissue mix) and due to the net increase in valve shipments when taking into effect shipments of the CryoValve SG and the related reduction in standard processed pulmonary valves. To a lesser
extent the volume increase was due to increased shipments of non-valved cardiac tissues. The increase in cardiac volume for the six months ended June&nbsp;30, 2008 was primarily due to increased shipments of non-valved cardiac tissues and to a
lesser extent the favorable effect of CryoValve SG. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The favorable tissue mix from CryoValve SG was due to the February&nbsp;7, 2008 FDA
clearance of the Company&#146;s 510(k) premarket notification for the CryoValve SG and its subsequent reintroduction in March 2008 coupled with the premium fee charged for the CryoValve SG over the standard processed CryoValve. For the three months
ended June&nbsp;30, 2008, the first full quarter of distributing the CryoValve SG, CryoValve SG revenues accounted for 22% of the Company&#146;s total cardiac preservation service revenues. The increase in shipments of non-valved cardiac tissues was
a result of increased availability of these high demand tissues, which are primarily used in pediatric cardiac reconstructions. The increase in average service fees for the three and six months ended June&nbsp;30, 2008 was primarily due to the fee
increases that went into effect in January 2008 on most standard processed cardiac tissues. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s procurement of cardiac tissues, from which heart valves and non-valved cardiac tissues
are processed, increased 14% for the three months ended June&nbsp;30, 2008 as compared to the three months ended June&nbsp;30, 2007. The Company&#146;s procurement of cardiac tissues increased 14% for the six months ended June&nbsp;30, 2008 as
compared to the six months ended June&nbsp;30, 2007. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company has experienced and could continue to experience an increase in its 2008
cardiac preservation services revenues as a result of continued shipments of the CryoValve SG, which have a premium fee over the standard processed CryoValve. However, there can be no assurance that the CryoValve SG will continue to command premium
fees or that shipments of the CryoValve SG will continue to occur at material levels. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Vascular Preservation Services </I></B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,939</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Vascular revenues as a percentage of total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Revenues from vascular preservation services increased 30% for the three months ended
June&nbsp;30, 2008 as compared to the three months ended June&nbsp;30, 2007. This increase was primarily due to a 26% increase in unit shipments of vascular tissues, which increased revenues by 24%, and an increase in average service fees, which
increased revenues by 6%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Revenues from vascular preservation services increased 21% for the six months ended June&nbsp;30, 2008 as
compared to the six months ended June&nbsp;30, 2007. This increase was primarily due to a 16% increase in unit shipments of vascular tissues, which increased revenues by 16%, and an increase in average service fees, which increased revenues by 5%.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The increase in vascular volume for the three and six months ended June&nbsp;30, 2008 was primarily due to increases in shipments of
saphenous veins, due to the strong demand for these tissues, primarily for use in peripheral vascular reconstruction surgeries to avoid limb amputations. The increase in average service fees for the three and six months ended June&nbsp;30, 2008 was
primarily due to the fee increases that went into effect in January 2008 on most vascular tissues. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s procurement of
vascular tissues increased 1% for the three months ended June&nbsp;30, 2008 as compared to the three months ended June&nbsp;30, 2007. The Company&#146;s procurement of vascular tissues decreased 3% for the six months ended June&nbsp;30, 2008 as
compared to the six months ended June&nbsp;30, 2007. The Company believes that its existing vascular tissues available for shipment and current procurement levels are sufficient to support anticipated future demand for vascular tissues. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Orthopaedic Preservation Services </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">297</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">624</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,084</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Orthopaedic revenues as a percentage of total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Revenues from orthopaedic preservation services decreased 76% for the three months ended
June&nbsp;30, 2008 as compared to the three months ended June&nbsp;30, 2007. This decrease was primarily due to a 76% decrease in unit shipments of orthopaedic tissues, which decreased revenues by 75%. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Revenues from orthopaedic preservation services decreased 80% for the six months ended June&nbsp;30, 2008
as compared to the six months ended June&nbsp;30, 2007. This decrease was primarily due to an 83% decrease in unit shipments of orthopaedic tissues, which decreased revenues by 80%. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The decrease in orthopaedic volume for the three and six months ended June&nbsp;30, 2008 was primarily due to decreases in unit shipments of orthopaedic
tissues, as a result of the limited supply of orthopaedic tissues available for shipment, resulting from the Company&#146;s cessation of procuring and processing these tissues on January&nbsp;1, 2007 and due to declining demand for the
Company&#146;s orthopaedic tissues, as the Company was no longer actively marketing its orthopaedic preservation services during these periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Pursuant to its agreement with RTI, CryoLife ceased marketing its orthopaedic tissue services as of June&nbsp;30, 2008. For a commission, RTI can market and direct CryoLife to ship the Company&#146;s remaining orthopaedic tissues through
December&nbsp;31, 2008. CryoLife expects that RTI&#146;s marketing efforts will generate only nominal amounts of orthopaedic tissue service revenues for the Company in the second half of 2008. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>BioGlue </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,859</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">BioGlue revenues as a percentage of total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Revenues from the sale of BioGlue increased 19% for the three months ended June&nbsp;30, 2008 as
compared to the three months ended June&nbsp;30, 2007. This increase was primarily due to the aggregate impact of favorable product mix and a 7% increase in the number of BioGlue milliliters shipped, which increased revenues by 15%, an increase in
average selling prices, which increased revenues by 3%, and the favorable effect of foreign exchange, which increased revenues by 1%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Revenues from the sale of BioGlue increased 13% for the six months ended June&nbsp;30, 2008 as compared to the six months ended June&nbsp;30, 2007. This increase was primarily due to the aggregate impact of favorable product mix and a 2%
increase in the number of BioGlue milliliters shipped, which increased revenues by 9%, an increase in average selling prices, which increased revenues by 3%, and the favorable effect of foreign exchange, which increased revenues by 1%. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The favorable product mix and volume increase for the three and six months ended June&nbsp;30, 2008 was primarily due to an increase in sales of
BioGlue syringes in domestic and international markets, partially offset by a related decrease in BioGlue cartridge sales, resulting in an increase in the total number of milliliters sold as well as a favorable product mix as the newer syringe
product commands a premium price over the older cartridge product. The increase in average selling prices for the three and six months ended June&nbsp;30, 2008 was primarily due to domestic list price increases that went into effect in January 2008.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Domestic revenues accounted for 70% of total BioGlue revenues for both the three months ended June&nbsp;30, 2008 and 2007. Domestic
revenues accounted for 71% and 72% of total BioGlue revenues for the six months ended June&nbsp;30, 2008 and 2007, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Other Implantable
Medical Devices </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other implantable medical devices revenues as a percentage of total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Revenues from the sale of other implantable medical devices increased 36% and decreased 12% for the three
and six months ended June&nbsp;30, 2008, respectively, as compared to the three and six months ended June&nbsp;30, 2007. Other implantable medical device revenues in 2008 consisted of sales of Hemostase MPH, CardioWrap, and bioprosthetic devices.
Other implantable medical device revenues in 2007 consisted of sales of CardioWrap and bioprosthetic devices. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Other Revenues </I></B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other revenues as a percentage of total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Other revenues for the three months ended June&nbsp;30, 2008 included revenues for research
grants. Other revenues for the three months ended June&nbsp;30, 2007 included revenues for research grants and revenues related to the licensing of the Company&#146;s technology to a third party. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Other revenues for the six months ended June&nbsp;30, 2008 and 2007 included revenues for research grants and revenues related to the licensing of the
Company&#146;s technology to a third party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">In 2005 CryoLife was awarded $930,000
in funding allocated from the U.S. Congress 2005 Defense Appropriations Conference Report (the &#147;2005 DOD Grant&#148;) in connection with the development of BioFoam<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>. In 2007 CryoLife
was awarded $1.9 million in funding allocated from the 2006 Defense Appropriations Conference Report, (the &#147;2006 DOD Grant&#148;) in connection with further development of BioFoam. Grant revenues in 2008 and 2007 are related to funding under
one or both of these grants. The 2007 Defense Appropriations Conference Report (the &#147;2007 DOD Grant&#148;) included $848,000 for the continued development of protein hydrogel technology for use on the battlefield. CryoLife applied for funding
under this bill during 2007. The Company does not currently know if it will be approved to receive funding under the 2007 DOD Grant or when the decision as to that funding will be made. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Through June&nbsp;30, 2008 CryoLife had received cash payments for all funds awarded under the 2005 and 2006 DOD Grants, for a total of $2.9 million. As
of June&nbsp;30, 2008 CryoLife had $1.8 million in unspent cash advances under the grants recorded as cash and deferred revenues on the Company&#146;s Summary Consolidated Balance Sheet. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Costs and Expenses </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Cost of Preservation Services </I></B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cost of preservation services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cost of preservation services as a percentage of preservation services revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Cost of preservation services for the three and six months ended June&nbsp;30, 2008 increased
primarily due to an increase in the volume of tissue shipments. This increase was partially offset by the favorable effect of $234,000 and $341,000 in write-downs recorded in the three and six months ended June&nbsp;30, 2007, respectively, which did
not recur in 2008, related to the Company&#146;s non-valved cardiac tissue costs that exceeded market value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Cost of preservation services
as a percentage of preservation services revenues for the three and six months ended June&nbsp;30, 2008 decreased when compared to the three and six months ended June&nbsp;30, 2007 primarily due to increases in average service fees, and to a lesser
extent the premium related to the Company&#146;s SynerGraft processed tissues and the absence of non-valved tissue write-downs that were experienced in the three and six months ended June&nbsp;30, 2007. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company anticipates that cost of preservation services as a percentage of preservation services
revenues in 2008 may continue to be favorably impacted by shipments of the CryoValve SG, as CryoValve SG currently has and is expected to continue to have a premium fee over the standard processed CryoValve. However, there can be no assurance that
the CryoValve SG will continue to command premium fees or that shipments of the CryoValve SG will continue to occur at material levels. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Cost of
Products </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cost of products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,881</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,829</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cost of products as a percentage of product revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Cost of products for the three and six months ended June&nbsp;30, 2008 was comparable to the three
and six months ended June&nbsp;30, 2007. Cost of products as a percentage of product revenues for the three and six months ended June&nbsp;30, 2008 decreased as compared to the three and six months ended June&nbsp;30, 2007. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">During the three and six months ended June&nbsp;30, 2008 cost of products was favorably impacted due to the effect of changes in product mix, as sales
volume decreased for the higher cost bioprosthetic devices and due to slightly lower per unit BioGlue costs. During the three and six months ended June&nbsp;30, 2008 cost of products was negatively impacted due to increased volume of BioGlue sales
and the write-down of other implantable medical device inventory. These positive and negative impacts largely offset each other during the periods presented. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Cost of products as a percentage of product revenues for the three and six months ended June&nbsp;30, 2008 decreased when compared to the three and six months ended June&nbsp;30, 2007 primarily due to decreases in
BioGlue costs as a percentage of revenues, as a result of an increase in average selling prices and favorable product mix, partially offset by the write-down of other implantable medical device inventory. The increase in average selling prices is
primarily due to price increases that went into effect on the majority of BioGlue products in January 2008. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>General, Administrative, and Marketing
Expenses </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">General, administrative, and marketing expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,358</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,842</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23,177</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">General, administrative, and marketing expenses as a percentage of total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The increase in general, administrative, and marketing expenses for the three and six months ended
June&nbsp;30, 2008 was primarily due to increases in marketing expenses including personnel costs, corporate advertising, and promotional materials to support the Company&#146;s expanding tissue service and product offerings and revenue growth.
Additionally, there were increases in stock compensation expense over the prior year periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">General, administrative, and marketing
expenses included stock based compensation expense of $749,000 and $1.4 million for the three and six months ended June&nbsp;30, 2008 and $549,000 and $923,000 for the three and six months ended June&nbsp;30, 2007. General, administrative, and
marketing expenses included a favorable adjustment to product liability accruals of $610,000 and $530,000 for the three and six months ended June&nbsp;30, 2008 and $490,000 and $505,000 for the three and six months ended June&nbsp;30, 2007. General,
administrative, and marketing expenses for the six months ended June&nbsp;30, 2007 included $686,000 for postemployment benefits. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Research and Development Expenses </I></B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,307</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,036</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Research and development expenses as a percentage of total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Research and development spending for the three and six months ended June&nbsp;30, 2008 and 2007
included research on the Company&#146;s SynerGraft products and tissues, Protein Hydrogel Technologies (&#147;PHT&#148;), and tissue preservation. Research and development spending in 2008 also included research on cold storage and preservation of
internal organs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">SynerGraft products and tissues include the Company&#146;s
allograft and xenograft heart valves, vascular grafts, and ProPatch Soft Tissue Repair Matrix. PHT includes BioGlue, BioFoam, BioDisc<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>, and related products. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company anticipates that research and development expenses for 2008 will exceed 2007, primarily due to increased spending on research related to
BioFoam, BioDisc, cold storage and preservation of internal organs, and SynerGraft products and tissues. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Other Costs and Expenses
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Interest expense was $69,000 for the three months ended June&nbsp;30, 2008, compared to $187,000 for the three months ended
June&nbsp;30, 2007. Interest expense was $139,000 for the six months ended June&nbsp;30, 2008, compared to $340,000 for the six months ended June&nbsp;30, 2007. Interest expense for the three and six months ended June&nbsp;30, 2008 decreased
primarily due to a decrease in line of credit borrowings as a result of the February&nbsp;8, 2008 expiration and payoff of the balance due on the Company&#146;s prior credit agreement with Wells Fargo Foothill, Inc. The Company has maintained lower
balances on its new line of credit with GE Capital entered into in March of 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Interest income was $71,000 for the three months ended
June&nbsp;30, 2008, compared to $105,000 for the three months ended June&nbsp;30, 2007. Interest income was $193,000 for the six months ended June&nbsp;30, 2008, compared to $202,000 for the six months ended June&nbsp;30, 2007. Interest income for
the three and six months ended June&nbsp;30, 2008 and 2007 was primarily due to interest earned on the Company&#146;s cash, cash equivalents, marketable securities and restricted cash and investments. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The change in valuation of the embedded derivative feature of the Company&#146;s preferred stock was zero for the three and six months ended
June&nbsp;30, 2008 as compared to an expense of $866,000 and $821,000 for the three and six months ended June&nbsp;30, 2007. The change in valuation of the Derivative for the three and six months ended June&nbsp;30, 2007 was primarily due to
conversions of the Preferred Stock during the second quarter of 2007 in excess of amounts previously accrued. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s income
tax expense was $260,000 and $375,000 for the three and six months ended June&nbsp;30, 2008, respectively. The Company&#146;s income tax expense was $82,000 and $179,000 for the three and six months ended June&nbsp;30, 2007, respectively. Income tax
expense in the current and prior year periods, was primarily due to estimated alternative minimum tax on the Company&#146;s taxable income in each period that cannot be offset by the Company&#146;s net operating loss carryforwards and estimated
foreign taxes on income of the Company&#146;s wholly owned European subsidiary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Although the Company has concluded that a valuation
allowance is still required on its deferred tax assets, if profitable operations continue the Company may reverse all or a portion of its valuation allowance in a future period. If all or a portion of the valuation allowance is reversed, the Company
will record a non-cash gain at that time that is expected to have a material impact on the Company&#146;s results of operations and financial position. In periods following the reversal, the Company&#146;s effective income tax rate is expected to be
significantly higher than the effective income tax rate experienced in periods prior to the reversal. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Seasonality </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The demand for the Company&#146;s cardiac preservation services has historically been seasonal, with peak demand generally occurring in the second and third quarters. Management believes this trend for cardiac preservation services is
primarily due to the high number of surgeries scheduled during the summer months for school aged patients, who drive the demand for a large percentage of cardiac tissues processed by CryoLife. In recent years the growth rate of CryoLife&#146;s
cardiac business has obscured the seasonal trend, but the Company expects that this seasonal trend will be more apparent in future years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The demand for the Company&#146;s human vascular preservation services does not appear to be seasonal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The demand for BioGlue
appears to be seasonal, with a slight decline in demand generally occurring in the third quarter followed by stronger demand in the fourth quarter. Management believes that this trend for BioGlue may be due to the summer holiday season in Europe and
fewer surgeries being performed on adult patients in the summer months in the U.S. The Company will continue to evaluate the seasonal nature of BioGlue sales. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Net Working Capital </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">At June&nbsp;30, 2008 net working capital (current assets of $67.5 million less current liabilities of $21.3 million) was $46.2 million, with a current
ratio (current assets divided by current liabilities) of 3 to 1, compared to net working capital (current assets of $65.5 million less current liabilities of $24.7 million) of $40.8 million, with a current ratio (current assets divided by current
liabilities) of 3 to 1 at December&nbsp;31, 2007. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Overall Liquidity and Capital Resources </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s primary cash requirements for the six months ended June&nbsp;30, 2008 arose out of the reclassification of cash equivalents to
long-term restricted money market funds as required under the terms of the GE Credit Agreement as discussed below, payment of the balance due under the Company&#146;s prior credit agreement which expired in February 2008, and general working capital
needs, including annual payments of royalties and bonuses accrued in the prior year, capital expenditures for facilities and equipment, and funding of research and development projects. The Company funded its cash requirements primarily through its
operating activities, which generated cash during the period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In March of 2008 CryoLife entered into a credit facility with GE Capital,
which provides for up to $15 million in revolving credit for working capital, acquisitions and other corporate purposes. As of June&nbsp;30, 2008 the outstanding balance under this agreement was $315,000. As of April&nbsp;15, 2008 as required under
the terms of the GE Credit Agreement, the Company is maintaining cash and cash equivalents of at least $5.0 million in accounts in which GE Capital has a first priority perfected lien. As a result these funds would not be available to meet the
Company&#146;s liquidity needs, and as such have been recorded as the long-term asset restricted money market funds on the Company&#146;s Summary Consolidated Balance Sheet. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s cash equivalents include advance funding received under the 2006 DOD Grant for the continued development of protein hydrogel
technology for use on the battlefield. As of June&nbsp;30, 2008 $1.8 million of cash equivalents were recorded on the Company&#146;s Summary Consolidated Balance Sheet related to the 2006 DOD grants. These funds must be used for the specified
purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">CryoLife is actively pursuing three key strategies designed to generate revenue and earnings growth in addition to continuing to
focus on growing its business and leveraging its strengths and expertise in its core marketplaces. These three strategies are: (i)&nbsp;identify and evaluate acquisition opportunities of complementary product lines and companies; (ii)&nbsp;license
Company technology to third parties for non-competing uses; and (iii)&nbsp;analyze and identify underperforming assets for potential sale or disposal. Management&#146;s actions related to this Board directive are ongoing and any material acquisition
of complementary product lines or companies would likely require additional debt or equity financing. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company believes that its anticipated cash from operations, existing cash, cash equivalents,
marketable securities, and borrowing availability will enable the Company to meet its operational liquidity needs for at least the next twelve months. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Product Liability Claims </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As discussed in Critical Accounting Policies above, as of June&nbsp;30, 2008 the Company
had a $330,000 accrual for the pending tissue processing liability lawsuit. The timing and amount of actual future payments with respect to product and tissue processing liability claims is dependent on when and if judgments are rendered, and/or
settlements are reached. Should payments be required, the Company&#146;s portion of these monies would have to be paid from liquid assets. The Company continues to attempt to reach resolution of outstanding claims in order to minimize the potential
cash payout. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As discussed in Critical Accounting Policies above, at June&nbsp;30, 2008 the Company had accrued a total $5.0 million for
the estimated costs of unreported tissue processing and product liability claims related to services performed and products sold prior to June&nbsp;30, 2008 and had recorded a receivable of $1.6 million representing estimated amounts to be
recoverable from the Company&#146;s insurance carriers with respect to such accrued liability. Further analysis indicated that the liability could be estimated to be as high as $10.0 million, after including a reasonable margin for statistical
fluctuations calculated based on actuarial simulation techniques. The $5.0 million accrual does not represent cash set aside. The timing of future payments related to the accrual is dependent on when and if claims are asserted, judgments are
rendered, and/or settlements are reached. Should payments related to the accrual be required, these monies would have to be paid from insurance proceeds and liquid assets. Since the amount accrued is based on actuarial estimates, actual amounts
required could vary significantly from this estimate. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Net Cash from Operating Activities </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Net cash provided by operating activities was $2.8 million for the six months ended June&nbsp;30, 2008 as compared to $1.4 million for the six months
ended June&nbsp;30, 2007. The increase in cash provided by operating activities from the prior year quarter was partially due to an increase in net income generated during the period, partially offset by increases in working capital needs due to the
timing of receipts and payments in the ordinary course of business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The current year cash provided of $2.8 million was primarily due to
net income generated during the period, largely offset by the working capital needs of the Company. The Company uses the indirect method to prepare its cash flow statement, and accordingly, the operating cash flows are based on the Company&#146;s
net income, which is then adjusted to remove non-cash items and for changes in operating assets and liabilities from the prior year end. For the six months ended June&nbsp;30, 2008 the Company&#146;s $6.7 million net income included non-cash items
that generated favorable and unfavorable adjustments to net income. These included favorable adjustments of $2.2 million in depreciation and amortization expense, $1.4 million in non-cash compensation, primarily related to expense for stock options
and stock awards, and $1.1 million in write-downs for impairment of deferred preservation costs and inventory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s working
capital needs, or changes in operating assets and liabilities, also affected cash from operations. For the six months ended June&nbsp;30, 2008 these unfavorable changes included $6.3 million due to the increase in deferred preservation costs and
inventories, $1.8 million due to the increase in accounts receivable, and $918,000 due to the timing difference between making cash payments and the expensing of assets, including the prepayment of insurance policy premiums. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Net Cash from Investing Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Net cash
used in investing activities was $3.2 million for the six months ended June&nbsp;30, 2008, as compared to $1.7 million for the six months ended June&nbsp;30, 2007. The current year cash used was primarily due to $5.0 million in cash equivalents that
was reclassified as long-term restricted money market funds as required under the terms of the GE Credit Agreement as discussed above, $763,000 in capital expenditures and $559,000 in purchases of marketable securities, partially offset by $3.0
million in sales and maturities of marketable securities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Net Cash from Financing Activities </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Net cash used in financing activities was $2.4 million for the six months ended June&nbsp;30, 2008, as compared to net cash provided of $1.7 million for
the six months ended June&nbsp;30, 2007. The current year cash used was primarily due to $4.6 million in principal payments on debt, and $429,000 in principal payments on notes payable, partially offset by $1.3 million in proceeds from the financing
of insurance policies, $1.1 million in proceeds from the exercise of options and the issuance of stock, and $428,000 in proceeds from debt issuance. The principal payments on debt were primarily due to the payoff of the balance due under the
Company&#146;s prior credit agreement which expired in February 2008. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company has no off-balance sheet arrangements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Scheduled Contractual Obligations and Future Payments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Scheduled contractual obligations and the related future
payments as of June&nbsp;30, 2008 are as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Remainder<BR>of 2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2009</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Thereafter</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Operating leases</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18,019</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,254</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,498</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,376</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,336</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,340</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,215</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Compensation payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,035</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,050</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">993</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">992</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchase commitments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,476</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,357</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">119</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Insurance premium obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,445</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,445</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Royalty payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">417</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">417</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">315</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">315</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">114</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">53</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">35</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">510</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">391</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total contractual obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,331</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,890</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,815</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,421</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,654</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,336</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,215</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s operating lease obligations result from the lease of land and buildings that
comprise the Company&#146;s corporate headquarters and manufacturing facilities, leases related to additional office and warehouse space rented by the Company, leases on Company vehicles, and leases on a variety of office equipment. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s compensation payment obligations represent estimated cash payments to be made for its 2008 performance based bonus plans and estimated
payments for post employment benefits for the Company&#146;s Chief Executive Officer (&#147;CEO&#148;). The timing of the post employment benefits is based on the December 2010 expiration date of the CEO&#146;s agreement. Payment of this benefit may
be accelerated by a change in control or by the voluntary retirement of the CEO. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s purchase commitments include
obligations from agreements with suppliers to stock certain custom raw materials needed for the Company&#146;s processing and production and contractual payments for licensing computer software. The Company&#146;s insurance premium obligations
represent installment payments related to payment plans and notes payable from the second quarter 2008 renewal and financing of certain of the Company&#146;s insurance policies. The Company&#146;s royalty payments are primarily related to BioGlue
revenues. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The line of credit obligation results from the Company&#146;s borrowing of funds under the GE Credit Agreement. The timing of
this obligation is based on the agreement&#146;s March&nbsp;25, 2011 expiration date, at which time the outstanding principal balance will be due. The table above does not include interest and fees on the line of credit, as these can vary due to
changes in the level of borrowings and changes in interest rates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s capital lease obligations result from the financing
of certain of the Company&#146;s equipment. The Company&#146;s other obligations contain various items including payments to support research and development activities, litigation settlement obligations, and other items as appropriate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The schedule of contractual obligations above excludes obligations for estimated product liability claims
unless they are due as a result of a pending settlement agreement or other contractual obligation. The schedule does not include additional payments of up to $1.2 million related to licensing of technology from a third party which are contingent
upon the outcome of the Company&#146;s research activities. The schedule of contractual obligations does not include $1.7 million in advance funding received under the 2006 DOD Grant for which a specific timetable of spending has not been
established and for which there are no current agreements or contracts in place. The schedule of contractual obligations above excludes any estimated liability for uncertain tax positions, currently estimated to be $2.2 million, because the Company
cannot make a reasonably reliable estimate of the amount and period of related future payments as no specific assessments have been made by any taxing authorities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">From July&nbsp;1, 2008 through July&nbsp;25, 2008 the Company committed to orders totaling $750,000 under a distribution agreement, which the Company expects to pay during the third quarter of 2008. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Capital Expenditures </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Capital expenditures for
the six months ended June&nbsp;30, 2008 were $763,000 compared to $414,000 for the six months ended June&nbsp;30, 2007. Planned capital expenditures for 2008 are primarily related to routine purchases of tissue processing, manufacturing, computer,
and office equipment needed to support the Company&#146;s business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>FORWARD-LOOKING STATEMENTS </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This Form 10-Q contains forward-looking statements and information made or provided by the Company that are based on the beliefs of its management as
well as estimates and assumptions made by and information currently available to management. The words &#147;could,&#148; &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;should,&#148; &#147;pro forma,&#148; &#147;potential,&#148;
&#147;pending,&#148; &#147;intend,&#148; &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;plan,&#148; &#147;future,&#148; and other similar expressions generally identify forward-looking statements,
including, in particular, statements regarding anticipated revenues, cost savings, insurance coverage, regulatory activity, available funds and capital resources, and pending litigation. These forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, which are as of their respective dates. Such forward-looking statements reflect the
views of our management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions, including, without limitation, in addition to those identified in the text surrounding such statements,
those identified under &#147;Risks and Uncertainties&#148; and elsewhere in this filing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">All statements, other than statements of
historical facts, included herein that address activities, events, or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s ability to increase, and methods for increasing, BioGlue and preserved tissue market penetration; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s continued use of human tissue implant data; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The expected benefits of surgical adhesives and sealants; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s plans to apply for further federal funding for the development of BioFoam; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The anticipated competitive advantages and potential impact on revenues of SynerGraft; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expected increases in grant revenues; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expectations regarding, and possible increases in the cost and retention of, future insurance coverage; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Current intentions not to pay cash dividends on our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Current intentions to retain future earnings for capital requirements; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expectations regarding the use of net operating loss carryforwards; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expected decreases in revenues from the distribution of orthopaedic tissue; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expectations regarding the impact of CryoValve SG pulmonary heart valve on cost of preservation services as a percentage of preservation services revenues;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expectations regarding capital expenditures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expected usage of SynerGraft technology; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expected timing regarding availability of CryoValve SG; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Anticipated future demand for vascular tissues; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Management&#146;s beliefs that current vascular procurement levels are sufficient to support future demand; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Commercialization plans regarding ProPatch; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Potential BioGlue product line extensions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The ability of the Company to distribute Hemostase MPH when expected; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The potential benefits of products licensed from Trophic Solutions; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Information regarding the expected SynerGraft post-clearance study; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The ability of BioGlue to minimize post-operative pain following hernia operations; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The expected outcome of lawsuits filed against the Company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s estimated future liability for existing product liability lawsuits and for product liability claims incurred but not yet reported;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s competitive position, including the impact of price increases; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The receipt of governmental grants for BioFoam development; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Future increases in research and development expenses; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Competitive advantages offered by the Company&#146;s patents, trade secrets, trademarks, and technology licensing rights; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expected impact of adoption of new accounting pronouncements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Expected seasonality trends; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Anticipated impact of changes in interest rates and foreign currency exchange rates; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The ability to expand the Company&#146;s service and product offerings; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Those issues most likely to impact the Company&#146;s future financial performance and cash flows; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The anticipated impact of the Company&#146;s strategic plans and its ability to implement them; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The adequacy of the Company&#146;s financial resources; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The potential reversal of the valuation allowance on our deferred tax assets and subsequent changes in our effect income tax rate; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Other statements regarding future plans and strategies, anticipated events, or trends. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends,
current conditions, and expected future developments as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the Company&#146;s expectations and predictions is
subject to a number of risks and uncertainties which could cause actual results to differ materially from the Company&#146;s expectations, including without limitation, in addition to those specified in the text surrounding such statements, the risk
factors set forth below, the risks set forth under &#147;Risk Factors&#148; in Part I, Item&nbsp;1A of the Company&#146;s Form 10-K for the year ended December&nbsp;31, 2007 and other factors, many of which are beyond the control of the Company.
Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if
substantially realized, that they will have the expected consequences to or effects on the Company or its business or operations. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new
information, future events, or otherwise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>RISKS AND UNCERTAINTIES </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The risks and uncertainties which might impact the forward-looking statements and the Company, its ability to continue as a going concern, and the
trading value of its common stock include concerns that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The FDA has previously issued a recall of certain of our products and has the ability to inspect our facilities, suspend our operations, and issue a recall of our
products in the future; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Key growth strategies identified as a result of our strategic review may not generate the anticipated benefits; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">There are limitations on the use of our net operating loss carryforwards; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We are significantly dependent on our revenues from BioGlue and are subject to a variety of risks affecting this product; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We are reliant on one supplier for significant components of BioGlue; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We are dependent on the availability of sufficient quantities of tissue from human donors; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Physicians have been and may continue to be reluctant to implant our preserved tissues or use our other products; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Our products and the tissues we process allegedly have caused and may in the future cause injury to patients, and we have been and may be exposed to product
liability claims and additional regulatory scrutiny as a result; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We may receive a form 483 notice of observations from the FDA and we may be unable to address the concerns raised by the FDA in such form 483;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">SynerGraft processed pulmonary heart valves may not continue to be accepted by the marketplace; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">SynerGraft processed pulmonary heart valves must be shipped and implanted within one year or we will be required to discard them; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We may experience difficulties and delays in the manufacturing of our products or processing of our tissues </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Our SynerGraft post-clearance study may not provide expected results; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Regulatory action outside of the U.S. has affected our business in the past and may also affect our business in the future; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Our failure to adequately comply with government regulations could result in loss of revenues and customers as well as additional compliance expense;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Our existing insurance policies may not be sufficient to cover our actual claims liability; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We may be unable to obtain adequate insurance at a reasonable cost, if at all; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Intense competition may affect our ability to operate profitably; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We may not be successful in obtaining necessary clinical results and regulatory approvals for products and services in development, and our new products and
services may not achieve market acceptance; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Investments in new technologies and acquisitions of products or distribution rights may not be successful; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">If we are not successful in expanding our business activities in international markets, we will not be able to pursue one of our strategies for increasing our
revenues; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We are dependent on our key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Extensive government regulation may adversely affect our ability to develop and sell products and services; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Uncertainties related to patents and protection of proprietary technology may adversely affect the value of our intellectual property and, therefore, our business;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Future health care reimbursement methods and policies may affect the availability, amount, and timing of our revenues; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Rapid technological change could cause our services and products to become obsolete; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Trading prices for our securities have been, and may continue to be, volatile; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Anti-takeover provisions may discourage or make more difficult an attempt to obtain control of CryoLife; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We are not likely to pay common stock dividends in the foreseeable future, and we may not be able to pay cash dividends on our capital stock due to legal
restrictions and lack of liquidity; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We may not be able to effectively leverage our existing sales force to sell Hemostase MPH; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Surgeons may not chose to utilize Hemostase MPH; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Hemostase MPH may not perform as expected or provide all expected benefits; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Other distributors of the Hemostase MPH product may impede our ability to sell to new or existing customers; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We may not be able to maintain the required Adjusted EBITDA levels or other borrowing conditions under its credit facility; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">There is no guarantee that the credit facility will provide us with sufficient resources to pursue strategic opportunities that may arise, and as a result
additional financing activities may be required; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">While we currently expect that our aggregate borrowing capacity under the GE Credit Agreement will equal $15.0 million, there can be no assurance that the borrowing
capacity will remain at this level; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We expect our effective tax rate to significantly increase if we are required to reverse our valuation allowance on our deferred tax assets.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Quantitative and Qualitative Disclosures About Market Risk. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Interest Rate Risk </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s interest income and expense are sensitive to changes in the general level of
U.S. interest rates. In this regard, changes in U.S. interest rates affect the interest earned on the Company&#146;s cash and cash equivalents of $11.7 million and restricted money market funds and investments of $5.6 million and interest paid on
the Company&#146;s variable rate line of credit as of June&nbsp;30, 2008. A 10% adverse change in interest rates as compared to the rates experienced by the Company in the three months ended June&nbsp;30, 2008, affecting the Company&#146;s cash and
cash equivalents, restricted money market funds and investments, and line of credit would not have a material impact on the Company&#146;s financial position, results of operations, or cash flows. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Foreign Currency Exchange Rate Risk </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The
Company has balances, such as cash, accounts receivable, accounts payable, and accruals that are denominated in foreign currencies. These foreign currency transactions are sensitive to changes in exchange rates. In this regard, changes in exchange
rates could cause a change in the U.S. dollar equivalent of cash or funds that the Company will receive in payment for assets or that the Company would have to pay to settle liabilities. As a result the Company could be required to record these
changes as gains or losses on foreign currency translation. A 10% adverse change in foreign currency rates as compared to the rates on June&nbsp;30, 2008 affecting the Company&#146;s balances denominated in foreign currencies would not have a
material impact on the Company&#146;s financial position, results of operations, or cash flows. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Controls and Procedures. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s
management, including the Company&#146;s President and Chief Executive Officer (&#147;CEO&#148;) and the Company&#146;s Executive Vice President, Chief Operating Officer, and Chief Financial Officer (&#147;CFO&#148;), does not expect that its
disclosure controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system
of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a
control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide
absolute assurance that all control issues and instances of fraud, if any, within the Company have been or will be detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can
occur because of simple error or mistake. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Based upon the Company&#146;s most recent disclosure controls evaluation as of June&nbsp;30,
2008, the CEO and CFO have concluded that the Company&#146;s disclosure controls were effective at the reasonable assurance level to satisfy their objectives and to ensure that the information required to be disclosed by the Company in its periodic
reports is accumulated and communicated to management, including the CEO and CFO, as appropriate, to allow timely decisions regarding disclosure and is recorded, processed, summarized, and reported within the time periods specified in the U.S.
Securities and Exchange Commission&#146;s rules and forms. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">During the quarter ended June&nbsp;30, 2008 there were no changes in the
Company&#146;s internal control over financial reporting that materially affected or that are reasonably likely to materially affect the Company&#146;s internal control over financial reporting. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">38 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Part II - OTHER INFORMATION </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Legal Proceedings. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">There have been no material
changes from the legal proceedings previously discussed in the Company&#146;s Form 10-Q for the quarter ended March&nbsp;31, 2008 in response to Part II, Item&nbsp;1 thereof. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;1A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Risk Factors. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s most recent Form
10-K was filed February&nbsp;21, 2008. There have been no material changes from the risk factors previously disclosed in the Company&#146;s Form 10-K in response to Part I, Item&nbsp;1A of Form 10-K. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Unregistered Sales of Equity Securities and Use of Proceeds. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The following table provides information about purchases by the Company during the quarter ended June&nbsp;30, 2008 of equity securities that are registered by the Company pursuant
to Section&nbsp;12 of the Exchange Act: </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Issuer Purchases of Equity Securities </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Common Stock </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:22pt"><FONT FACE="Times New Roman" SIZE="1"><B>Period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Total&nbsp;Number<BR>of Common<BR>Shares<BR>Purchased</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Average&nbsp;Price<BR>Paid per<BR>Common&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Total&nbsp;Number<BR>of&nbsp;Common&nbsp;Shares<BR>Purchased as Part<BR>of Publicly<BR>Announced Plans<BR>or Programs</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Maximum&nbsp;Number<BR>of Common Shares<BR>That May Yet
Be<BR>Purchased&nbsp;Under&nbsp;the<BR>Plans&nbsp;or&nbsp;Programs</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">04/01/08 &#150; 04/30/08</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,510</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10.12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">05/01/08 &#150; 05/31/08</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,343</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11.52</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">06/01/08 &#150; 06/30/08</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,311</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11.16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">23,164</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10.81</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company currently has no stock repurchase program, publicly announced or otherwise. The common
shares shown were tendered to the Company in payment of the exercise price of outstanding options. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Defaults Upon Senior Securities. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">None. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">39 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Submission of Matters to a Vote of Security Holders. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Annual Meeting of Shareholders was held on May&nbsp;1, 2008. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The following table shows the results of voting: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:67pt"><FONT FACE="Times New Roman" SIZE="1"><B>Matter Voted Upon</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Shares<BR>Voted For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Authority<BR>Withheld</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Abstained</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Broker<BR>Non-Votes</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Election of Directors:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Steven G. Anderson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,197,848</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">874,483</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Thomas F. Ackerman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,201,056</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">871,275</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">James S. Benson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,259,828</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">812,503</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Daniel J. Bevevino</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,266,435</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">805,896</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">John M. Cook</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,228,576</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">843,755</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ronald C. Elkins, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,168,536</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">903,795</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ronald D. McCall, Esq.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,213,483</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">858,848</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Harvey Morgan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,251,955</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">820,376</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Adoption of Non-Employee Directors Omnibus Stock Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15,988,205</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,181,384</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">366,648</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,536,096</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ratification of Deloitte &amp; Touche LLP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">24,791,231</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">150,896</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">130,206</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Other information. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">None. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The exhibit index can be found below.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Articles of Incorporation of the Company. (Incorporated herein by reference to Exhibit 3.1 to the Registrant&#146;s Form 10-K for the year ended December&nbsp;31, 2007.)
</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated By-Laws. (Incorporated herein by reference to Exhibit 3.4 to the Registrant&#146;s Current Report on Form 8-K filed August&nbsp;1, 2007.)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of Certificate for the Company&#146;s Common Stock. (Incorporated by reference to Exhibit 4.2 to the Registrant&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31,
1997.)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">10.1*&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Agreement between CryoLife, Inc. and Medafor, Inc. dated April 18, 2008.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">10.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">CryoLife, Inc. 2008 Non-Employee Directors Omnibus Stock Plan.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Registrant has requested confidential treatment for certain portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">40 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">10.3*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of Non-Employee Director Stock Grant Agreement pursuant to the CryoLife, Inc. 2008 Non-Employee Directors Omnibus Stock Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">31.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Certification by Steven G. Anderson pursuant to section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">31.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Certification by D. Ashley Lee pursuant to section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">32*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">41 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">SIGNATURES </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">CRYOLIFE, INC.<BR>(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ STEVEN G. ANDERSON</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ D. ASHLEY LEE</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">STEVEN G. ANDERSON<BR>Chairman, President, and<BR>Chief Executive Officer<BR>(Principal Executive Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">D. ASHLEY LEE<BR>Executive Vice President,<BR>Chief Operating Officer, and<BR></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Chief Financial Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(Principal Financial and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
FACE="Times New Roman" SIZE="2">Accounting Officer)</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">July&nbsp;31, 2008 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">DATE </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">42 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>dex101.htm
<DESCRIPTION>AGREEMENT BETWEEN CRYOLIFE, INC. AND MEDAFOR, INC. DATED APRIL 18, 2008
<TEXT>
<HTML><HEAD>
<TITLE>Agreement between Cryolife, Inc. and Medafor, Inc. dated April 18, 2008</TITLE>
</HEAD>



 <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
  <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold; FONT-FAMILY: 'Times New Roman'">Exhibit 10.1</font></div><br> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">EXECUTION VERSION</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CONFIDENTIAL TREATMENT
REQUESTED</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN REDACTED ARE</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">WITH
THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">EXCLUSIVE DISTRIBUTION AGREEMENT</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">This Exclusive Distribution Agreement (this &#8220;Agreement&#8221;)
is dated this 16th day of April, 2008, but is effective as of May 1, 2008 (the &#8220;Effective Date&#8221;), by and between CryoLife, Inc., 1655 Roberts Blvd., NW, Kennesaw, GA&#160;&#160;30144 (&#8220;CryoLife&#8221;) and Medafor, Inc., 2800
Freeway Blvd., Suite 800, Minneapolis, MN&#160;&#160;55430 (&#8220;Medafor&#8221;).</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; TEXT-DECORATION: underline">Recitals</font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Medafor
is in the business of developing, manufacturing and selling proprietary hemostatic products, including the Product (as defined below).</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CryoLife develops and commercializes biomaterials and preserves and distributes human tissue for vascular
and cardiac transplant applications.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Medafor desires to appoint CryoLife as the exclusive distributor of the Product
throughout the Territory (as defined below) for use in applications in the Field (as defined below), and CryoLife desires to accept such appointment, all in accordance with the terms and conditions of this Agreement.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Agreement</font></font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">In consideration of the mutual covenants contained in this Agreement, CryoLife and Medafor agree as follows:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE I</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">DEFINITIONS AND RULES OF CONSTRUCTION</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">1.1.</font><font
style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Definitions.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Terms Defined in this Article.</font>&#160;&#160;For purposes of this Agreement, the following terms shall have the following meanings:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Affiliates&#8221; </font>as it relates to a Party, shall mean any Person controlling, controlled by or under common
control with a Party.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Annual Minimum&#8221;</font> shall have the meaning ascribed to it in <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Annual Minimum
Dispute Notice&#8221;</font> shall have the meaning ascribed to it in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Applicable Laws&#8221;</font> means all applicable common law, statutes, ordinances, rules, regulations or orders of any Governmental Authority, including Regulatory Laws.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Bellows Applicator&#8221;</font> means the bellows applicator manufactured by Medafor for use with MPH
Product.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"> </div> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Business Day&#8221;</font> means any day other than a Saturday, a Sunday or a day on which banks in New&#160;York are
authorized or obligated by law or executive order to remain closed.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;China&#8221;
</font>means the People&#8217;s Republic of China</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Claim&#8221;
</font>shall have the meaning ascribed to it in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 7.2</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGMP&#8221; </font>shall have the meaning ascribed to it in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4.2</font>.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Commercially Reasonable Efforts&#8221;</font> means, with respect to a Party&#8217;s diligence in satisfying an
obligation under this Agreement, that the Party applies the level of efforts, expertise and resources that it would apply in the ordinary course of business to satisfy a comparable obligation and that such actions be taken in good
faith.&#160;&#160;In determining whether a Party is applying Commercially Reasonable Efforts, the potential benefit to such Party not taking such efforts (e.g. benefit in receipt of payments for products that are sold inappropriately through a
Crossover) shall not be considered. At the reasonable request of the non-offending Party, as that term is used in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.1</font>, Commercially Reasonable Efforts will include ceasing to
provide Products or MPH Product to the offending distributor.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Confidential
Information&#8221; </font>shall have the meaning ascribed to it <font style="DISPLAY: inline; TEXT-DECORATION: underline">in Section 6.1</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Crossover&#8221; </font>shall have the meaning ascribed to in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.1</font>.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CryoLife Applicator&#8221;</font> means any applicator developed by CryoLife for use with the MPH Product.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CryoLife IP&#8221;</font> shall have the meaning ascribed to it in <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 7.1</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CryoLife
Marks&#8221; </font>means the brand names and marks CryoLife designates pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.4</font> for use on Product packaging.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Department of Defense Hospitals&#8221;</font> those hospitals that are run by the U.S. Department of Defense and located
on any United States military facility anywhere in the world.&#160;&#160;Notwithstanding the foregoing, hospitals run by the Veterans Administration shall not be deemed &#8220;Department of Defense Hospitals&#8221;, regardless of their location.
</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Distribute&#8221;</font> shall be the meaning ascribed to it in <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.1</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 72pt"></font><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Effective Date&#8221;</font> means May 1, 2008.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Failure to
Supply&#8221;</font> shall have the meaning ascribed to it in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 10.2</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;FDA&#8221;</font> means the United&#160;States Food and Drug Administration or any successor agency having the administrative authority to grant Marketing Approval in the
United&#160;States.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Field&#8221;</font> means: (i) all applications in cardiac surgery and vascular surgery in the
United States; and (ii) all general surgery applications outside the United States including cardiac and vascular surgeries, but excluding orthopedic and ear, nose, and throat surgeries. For avoidance of doubt, the parties agree that neurosurgery
and topical applications are also excluded from the definition of &#8220;Field&#8221;.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 2 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Field Action&#8221;
</font> means any correction or removal action by CryoLife or Medafor due to safety, efficacy, quality or regulatory compliance concerns, including actions to recover title to or possession of, or to halt distribution of, Products that previously
have been shipped to customers.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Forecast&#8221; </font>shall be the meaning ascribed to it in <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3.1</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Governmental
Authority&#8221;</font> means the United&#160;States and any other country in which the Product is manufactured, marketed, sold, tested, investigated or otherwise regulated, and all states or other political subdivisions thereof and supranational
bodies applicable thereto, including the European Union, and all agencies, commissions, officials, courts or other instrumentalities of the foregoing.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;HemArrest&#8221; </font>means HemArrest, Inc., a Minnesota corporation.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Insolvency
Event&#8221;</font> means that the Party (a) has commenced a voluntary proceeding under any insolvency law, (b) had an involuntary proceeding commenced against it under any insolvency law which has continued undismissed or unstayed for sixty (60)
consecutive days, (c)&#160;had a receiver, trustee or similar official appointed for it or for any substantial part of its property, (d)&#160;made an assignment for the benefit of creditors or (e) had an order for relief entered with respect to it
by a court of competent jurisdiction under any insolvency law.&#160;&#160;For purposes hereof, the term &#8220;insolvency law&#8221; means any applicable bankruptcy, insolvency or other similar law now or hereafter in effect.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Intellectual Property&#8221;</font> means (a)&#160;discoveries, inventions, improvements, concepts and ideas, whether or
not patentable, (b)&#160;works of authorship fixed in a tangible medium of expression, (c)&#160;Trademarks, (d)&#160;trade secrets and know-how and (e)&#160;all proprietary rights relating thereto, including all applications, registrations and
renewals in connection therewith.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Initial Term&#8221; </font>shall have the meaning ascribed to it in <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 10.1</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Inventory
Cost&#8221; </font>shall mean the specific and direct manufacturing or procurement cost to Medafor associated with the manufacturing or procurement of such inventory (but shall not include overhead, markup or carrying costs).</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;ISO&#8221; </font>shall have the meaning ascribed to it in <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4.2</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Losses&#8221;</font> shall have the meaning ascribed to it in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 9.1</font>.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Marketing Approval&#8221;</font> means, with respect to any country or jurisdiction, the act of the applicable
Regulatory Authority that is necessary under applicable Regulatory Laws for the manufacture, marketing, distribution and sale of the Product in that country or jurisdiction, and satisfaction of all applicable regulatory and notification requirements
and, to the extent applicable, the grant of Pricing Approval.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 3 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Medafor IP&#8221;
</font> shall have the meaning set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 7.2</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;MPH
Product&#8221;</font> means Medafor&#8217;s proprietary product for effecting hemostasis at the site of a wound, cut or incision using a patented technology known as MPH<font
style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font> (Microporous Polysaccharide Hemospheres).&#160;&#160;The MPH Product for surgical use is currently referred to as Arista&#174;. MPH Product includes all product
improvements, modifications, additions and refinements thereto made by Medafor during the Term.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#8220;Other
Manufacturing Laws&#8221; </font>shall have the meaning ascribed to it in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4.2</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Party&#8221;</font> means CryoLife or Medafor, as the context requires.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Person&#8221;
</font> means any individual, group or entity, including Governmental Authorities.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Pricing
Approval&#8221;</font> means, with respect to any country or jurisdiction in which Governmental Authorities determine the pricing at which products will be reimbursed, the approval, agreement, determination or decision by the applicable authorities
establishing that pricing.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Product&#8221;</font> means a Product Applicator containing MPH Product per the Specifications.
</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Product Applicator&#8221;</font> means a Bellows Applicator or a CryoLife Applicator.&#160;&#160;The term &#8220;Product
Applicator&#8221; includes all product applicator improvements, modifications, additions and refinements thereto made by Medafor or CryoLife, as applicable, during the Term.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Product Complaint&#8221;</font> means any expression by a Third&#160;Party of dissatisfaction relating to the identity,
durability, reliability, safety, efficacy or performance of any Product, including actual or suspected product tampering, contamination, mislabeling or misformulation.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Product Information&#8221; </font>shall have the meaning ascribed to it in <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.3</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;QSR&#8221;</font>
shall have the meaning ascribed to it in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4.2</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Regulatory
Authority&#8221;</font> means, with respect to any country or jurisdiction, any Governmental Authority involved in granting Marketing Approval or Pricing Approval or in administering Regulatory Laws in that country or jurisdiction, including the FDA
in the United&#160;States.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Regulatory Laws&#8221;</font> means all Applicable Laws governing (i)&#160;the import, export,
testing, investigation, manufacture, marketing or sale of the Product, (ii)&#160;establishing recordkeeping or reporting obligations, (iii)&#160;any Field Action or (iv)&#160;similar regulatory matters.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 4 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Right of Renewal&#8221;</font> shall have the meaning ascribed to it in <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 10.1</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Specifications&#8221;</font> means, collectively, (i)&#160;Medafor&#8217;s design and functionality specifications relating to the Product set forth in <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit&#160;A</font> and (ii)&#160;any specifications for manufacturing, testing, storing, packaging, shipping or labeling (including CryoLife&#8217;s labeling and packaging requirements and
instructions as set forth herein) the Product set forth in any approved application for Marketing Approval and any supplements and amendments thereto.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Term&#8221;</font> shall have the meaning ascribed to it in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 10.1</font></font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Territory&#8221;</font> shall mean the United States, Canada, the United Kingdom and Germany commencing on the Effective
Date.&#160;&#160;Beginning January 1, 2009, the Territory shall expand to mean the entire world except for the countries of Japan and China.&#160;&#160;Notwithstanding the foregoing, in no event shall the Territory include any Department of Defense
Hospitals.&#160;&#160;Although the Territory shall initially include the United States, the parties agree that in the United States the Territory shall exclude those certain enumerated hospitals listed on <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit B</font> in the United States until the times set forth therein.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Third&#160;Party&#8221;</font> means any Person other than a Party or its Affiliates.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Trademarks&#8221; </font>means all trademarks, service marks, trade dress, logos and trade names, together with all translations, adaptations, derivations and combinations thereof (including all
goodwill associated therewith), and all applications, registrations and renewals in connection therewith.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;United
Kingdom&#8221; </font>means the United Kingdom of Great Britain and North Ireland.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;United&#160;States&#8221;</font> means the United&#160;States of America, including its territories, commonwealths and possessions.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 72pt"></font>&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Year</font>&#8221; shall mean the period commencing the Effective Date and ending
June 30, 2009, or any subsequent twelve month period commencing July 1 and ending on the following June 30.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 72pt"></font>&#8220;<font
style="DISPLAY: inline; FONT-WEIGHT: bold">Year 1</font>&#8221; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Year 2</font>&#8221; and <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Year 3&#8221;</font> shall have the meanings
ascribed to them in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section&#160; 2.2</font>.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">1.2.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Rules of Construction.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">When a reference is made in this Agreement to a Recital, an Article, a Section, a Schedule or an Exhibit, such reference is to a Recital, Article or Section of, or a Schedule
or an Exhibit to, this Agreement, unless otherwise indicated.&#160;&#160;All Exhibits and Schedules attached hereto are incorporated in this Agreement by reference.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Whenever the words
&#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be understood to be followed by the words &#8220;without limitation.&#8221;</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 5 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Pronouns, including
&#8220;he,&#8221; &#8220;she&#8221; and &#8220;it,&#8221; when used in reference to any Person, shall be deemed applicable to entities or individuals, male or female, as appropriate in any given case.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(d)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Article, Section and other
headings contained in this Agreement are for reference purposes only and are not intended to describe, interpret, define or limit the scope, extent or intent of any provision of this Agreement.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(e)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Standard variations on
defined terms (such as the plural form of a term defined in the singular form, and the past tense of a term defined in the present tense) shall be deemed to have meanings that correlate to the meanings of the defined terms.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE II</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">DISTRIBUTION</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2.1.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exclusive Distribution Rights.</font></font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor hereby grants to
CryoLife, and CryoLife hereby accepts, the exclusive right to promote, market, sell and distribute (collectively, &#8220;Distribute&#8221;) the Product throughout the Territory for all uses and applications in the Field.&#160;&#160;Medafor shall
not, directly or indirectly, Distribute, or permit Distribution of, Products or the MPH Product anywhere in the Territory for any uses or applications in the Field, either on its own behalf or through any Affiliate or Third&#160;Party. CryoLife
shall not, directly or indirectly, Distribute, or permit Distribution of, the Product anywhere in the Territory for any uses or applications outside of the Field, either on its own behalf or through any Affiliate or Third Party.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Both Parties acknowledge
and agree that, notwithstanding their efforts to the contrary, given the nature of the industry, the distribution of products and that both Parties employ distributors, there may be inadvertent sales &#8220;Crossover&#8221; by either or both
Parties, i.e. inadvertent sales unknown to CryoLife of Product into applications outside of the Field and inadvertent sales unknown to Medafor of MPH Product or Products into applications in the Field. Upon learning of such inadvertent sales, the
non-offending Party shall give the other Party written notice of the facts and circumstances of the inadvertent sale, and the Party receiving such notice will use its Commercially Reasonable Efforts to prevent additional prohibited sales and report
what steps it has taken to prevent a reoccurrence. Such inadvertent sales shall not be considered a material breach of this Section, provided the other Party takes prompt and Commercially Reasonable Efforts to prevent additional prohibited sales and
timely reports what steps it has taken to prevent a reoccurrence to the non-offending Party.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor represents and warrants that attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Schedule 2.1</font> is a list of all agreements that permit
others to Distribute Products in the Field (or if such agreement is oral, a description of such oral arrangement).&#160;&#160;Medafor represents and warrants that:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(i)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">it has delivered to
CryoLife the most current and complete copies of each of the agreements listed on <font style="DISPLAY: inline; TEXT-DECORATION: underline">Schedule 2.1</font> (or if such agreement is oral, that is has summarized all terms of such oral
arrangement);</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 6 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT
WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(ii)
</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">by the Effective Date there shall be no agreement or arrangements to which it is a party or by which
it is bound that would permit others to Distribute Products in the Field in the United States, Canada, the United Kingdom or Germany; provided however that distribution rights that allow for the promotion, sale or distribution of the Product in
Department of Defense Hospitals shall not be deemed a violation of this Section; and provided, further and notwithstanding the foregoing, the distribution by the three distributors disclosed on <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Schedule 2.1</font> that have agreements that do not expire or terminate on the Effective Date shall not be deemed a violation of this Section to the limited extent that they permit promotion, sale
or distribution to those hospitals within the United States that are identified on <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit B</font>;</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(iii)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">by January 1, 2009 there
shall be no agreements or arrangements to which it is a party or by which it is bound that would permit others to Distribute Products in the Field outside of the United States, Canada, the United Kingdom or Germany, Japan or China; or</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(iv)
</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">it will not take any action with respect to any of its agreements with third parties that may expose
CryoLife to any liability.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(d)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor represents and
warrants that other than the existing distributors identified on <font style="DISPLAY: inline; TEXT-DECORATION: underline">Schedule 2.1</font>, it does not currently have any other agents, representatives, or distributors entitled to Distribute
Products for use in the Field within the Territory, and that there is no restriction, covenant, or agreement to which it is a party or by which it is bound that would prevent or delay Medafor from providing to CryoLife the exclusive distribution
rights contained in this Agreement.&#160;&#160;Medafor agrees that it will not, directly or indirectly, undertake any action, omit to take any action, or enter into any agreement that will prevent or delay the enjoyment by CryoLife of the full
benefits of the exclusive distribution relationship provided in this Agreement.&#160;&#160;Medafor agrees to direct all sales inquiries respecting the Product within the Field in the Territory to CryoLife immediately during the Term of this
Agreement.&#160;&#160;Medafor represents and warrants that its termination of agreements that permit others to Distribute Products in the Field in the Territory shall not cause CryoLife any Losses.&#160;&#160;CryoLife agrees to direct all sales
inquires respecting the Product outside the Field immediately to Medafor during the Term of this Agreement.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2.2.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Annual Minimums. </font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">During the Initial Term, CryoLife agrees to order the following minimum Product amounts (the &#8220;Annual Minimum&#8221;) during the periods set forth below:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div align="left">
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td align="left" valign="top" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td align="left" valign="top" width="27%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 1 - (May 1, 2008 &#8211;
June 30, 2009):</font></div> </td>
<td align="left" valign="top" width="57%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$[***]</font></div> </td> </tr>

<tr>
<td align="left" valign="top" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td align="left" valign="top" width="27%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 2 - (July 1, 2009 &#8211;
June 30, 2010):</font></div> </td>
<td align="left" valign="top" width="57%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$[***]</font></div> </td> </tr>

<tr>
<td align="left" valign="top" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td align="left" valign="top" width="27%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 3 - (July 1, 2010 &#8211;
June 30, 2011):</font></div> </td>
<td align="left" valign="top" width="57%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$[***]</font></div> </td> </tr>

<tr>
<td valign="top" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="27%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="57%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td> </tr> </table> </div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">After Year 3, CryoLife
agrees that the minimums for Years 4-6 shall be as set forth below:</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td align="left" valign="top" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td align="left" valign="top" width="27%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 4 - (July 1, 2011 &#8211;
June 30, 2012):</font></div> </td>
<td align="left" valign="top" width="57%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$[***]</font></div> </td> </tr>

<tr>
<td align="left" valign="top" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td align="left" valign="top" width="27%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 5 - (July 1, 2012 &#8211;
June 30, 2013):</font></div> </td>
<td align="left" valign="top" width="57%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$[***]</font></div> </td> </tr>

<tr>
<td align="left" valign="top" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td align="left" valign="top" width="27%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 6 - (July 1, 2013 &#8211;
June 30, 2014):</font></div> </td>
<td align="left" valign="top" width="57%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$[***]</font></div> </td> </tr>
</table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left">
</div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 7 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr
style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The parties expressly acknowledge and agree that CryoLife&#8217;s obligation
to purchase the Annual Minimums set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Sections 2.2(a)</font> and <font style="DISPLAY: inline; TEXT-DECORATION: underline">2.2(b)</font> is based on CryoLife&#8217;s unimpaired ability
to sell the Product under private label, beginning on the Effective Date throughout the United States, Canada, Germany and the United Kingdom (except for those specific hospitals set forth on <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit B</font>); and beginning on January 1, 2009, throughout out the entire Territory.&#160;&#160;In the event that CryoLife is unable to sell such Products under private label as set forth
herein in the Territory, as a result of impairment (unless such impairment is caused directly by CryoLife) then such Annual Minimums shall be equitably adjusted downward as follows:&#160;&#160;CryoLife shall provide written notice to Medafor of the
impairment and its proposed reduction based on such impairment.&#160;&#160;Medafor shall have fifteen (15) days from receipt of such notice to notify CryoLife in writing that it disagrees with CryoLife&#8217;s reduction with such notice also
detailing the proposed number Medafor believes is the appropriate reduction, if any, in the Annual Minimum.&#160;&#160;In the event that Medafor fails to notify CryoLife, the Annual Minimum for the Year in question shall be reduced per
CryoLife&#8217;s notice set forth above.&#160;&#160;In the event that Medafor notifies CryoLife that it disagrees with CryoLife, the parties shall have fifteen (15) days to resolve the dispute, after which, after which, either Party may notify the
other Party that it requests that an arbitrator decide upon the appropriate reduction pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Schedule 2.2</font> attached hereto pursuant to so called &#8220;Baseball&#8221; arbitration
(such notice, the &#8220;Annual Minimum Dispute Notice&#8221;).&#160;&#160;The parties agree that the equitable adjustment downward for purposes of the &#8220;Baseball&#8221; arbitration shall be based on the following factors: CryoLife&#8217;s
projection of sales in such country(ies), the number of medical procedures that the Product could be sold for use in such country(ies), sales of the Product in similarly situated countries, and other similar facts that the parties deem to be
important.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font
style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The parties acknowledge and agree that the Annual Minimums are based on Medafor&#8217;s current sales of the
Product and therefore, Medafor represents and warrants that it has delivered to CryoLife, prior to the execution of this Agreement, Medafor&#8217;s current sales information for the first quarter of 2008 for the Product and that such information is
true, correct and complete.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(d)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">During Year 1, CryoLife
agrees to submit purchase orders for the Products as follows: (i) for the period between the Effective Date and July 31, 2008, CryoLife will submit to Medafor a purchase order for at least $500,000 of Products and such purchase order shall be
submitted upon the execution of this Agreement by the Parties; (ii) for the period between August 1, 2008 and&#160;&#160;October 31, 2008 and by no later than June 15, 2008, CryoLife shall submit to Medafor a purchase order for at least $750,000 of
Products; (iii)&#160;for the remainder of Year 1, CryoLife shall submit monthly purchase orders for $<font style="FONT-WEIGHT: bold">[***]</font> worth of Products with the understanding that each monthly purchase order shall not be deemed effective
unless it is submitted in accordance with <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3.2</font>.&#160;&#160;CryoLife&#8217;s obligations under this subsection shall be equitably adjusted in the event of any reduction in the
Annual Minimum for Year 1.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(e)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">After the conclusion of
Year 1 and during the remainder of the Term, CryoLife will submit purchase orders for at least 15% of the applicable Annual Minimum for the calendar quarter commencing July 1, 25% for the calendar quarter commencing October 1, 25% for the calendar
quarter commencing January 1, and 35% for the calendar quarter commencing April 1.&#160;&#160;Such purchase orders may be submitted at any time prior to and including the first date of the applicable calendar quarter and should be consistent with
the three (3) month portion of the rolling forecast set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3.1</font>.&#160;&#160;CryoLife may submit purchase orders monthly provided that for a purchase order to be effective
it must be submitted in accordance with <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3.2</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 8 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(f)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The foregoing minimum purchases may be reduced by CryoLife in any given period to the extent of any prior purchase by CryoLife in excess of the minimum amounts specified above
for any and all preceding periods. The inability of CryoLife to meet any minimum purchase requirement by reason of Product returns pursuant to Section 2.6, any breach of this Agreement by Medafor resulting in an impairment to CryoLife&#8217;s
ability to sell into any portion of the Territory based on the timelines set forth herein, supply interruption by Medafor, force majeure, or any Product recall shall not cause CryoLife to be in default under this Section.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(g)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">During Year 1, all Product
purchases shall be for Products in 3 gram and 5 gram volumes. Thereafter, Medafor agrees to make additional volume Product and configurations available for purchase, as reasonably requested by CryoLife, at prices and volumes to be mutually
negotiated and agreed to by the Parties.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2.3.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Marketing and Sales Activities.</font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CryoLife shall have sole control and authority over its marketing activities for the Products.&#160;&#160;All business decisions concerning the sales and marketing of Products
within the Field and the Territory, including the price, product packaging and configuration, and other sale and promotional terms thereof, will be within the sole discretion of CryoLife, except that CryoLife shall provide Medafor with a reasonable
opportunity to review and approve all marketing materials relating to the Products for purposes of compliance with Regulatory Laws and to reasonably protect its rights in its trademarks and copyrights, which approval shall not be unreasonably
withheld or delayed.&#160;&#160;CryoLife shall comply with the appropriate quality control instructions of Medafor as to the form and manner in which such Medafor trademarks shall be used In its discretion, CryoLife may conduct clinical trials for
the Products in order to support CryoLife&#8217;s marketing and sales efforts. CryoLife agrees to provide Medafor with written results of such clinical trials for Medafor&#8217;s records and uses in areas outside of the Field.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor agrees to provide
to CryoLife all reasonable technical assistance, including necessary information related to the Product in the Field to CryoLife in order for CryoLife to market the Product and so CryoLife may develop its own technical, scientific and clinical
information files for purposes of obtaining new product committee approvals at target hospitals.&#160;&#160;Medafor agrees to provide reasonable training CryoLife&#8217;s sales force regarding the Products either at Medafor&#8217;s facilities or in
the Field; provided that CryoLife shall be responsible for the costs and expenses of CryoLife personnel incurred in connection with Medafor providing such train-the trainer technical assistance and training and CryoLife shall reimburse Medafor for
its incurred travel expenses.&#160;&#160;Medafor agrees to provide CryoLife with copies of its product handling manuals, sales literature, promotion materials, training materials, videos, demonstration kits and other applicable information for the
Products.&#160;&#160;To the extent possible Medafor shall provide CryoLife in electronic form and format all such marketing materials and information described in this Section (collectively all such information described in this Section is
&#8220;Product Information&#8221;).</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 9 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Portions of the Product Information may be incorporated into CryoLife&#8217;s materials used for the promotion of the Products.&#160;&#160;Medafor represents and warrants that
the Product Information shall be accurate and complete in all material respects, and undertakes to update any such Product Information when any information included therein becomes outdated, inaccurate, or misleading.&#160;&#160;CryoLife shall have
the right to produce, at its expense, promotional material, Products handling manuals, instructions for use, and other written information relating to the Products that is based in whole or in part on the material supplied by Medafor subject to the
limitations set forth above.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(d)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor will cooperate
with CryoLife in the sponsorship and planning of seminars and marketing events for Products.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(e)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor shall furnish without charge to CryoLife, any market surveys and related information prepared by or for Medafor pertaining to the market for the Products in the
Territory.&#160;&#160;CryoLife will treat such information as Medafor IP in accordance with the applicable provisions of <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 7.1</font>.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2.4.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Branding.</font>&#160;&#160;The Products shall be sold under CryoLife&#8217;s brand names as directed by CryoLife; provided however, that CryoLife&#8217;s branding will use the MPH&#174; trademark owned by
Medafor on its external packaging in a manner reasonably acceptable to Medafor and in accordance with all Applicable Laws and in accordance with appropriate quality control instructions of Medafor as to form and manner of
use.&#160;&#160;Notwithstanding the foregoing, the parties have agreed that CryoLife may use the name Hemostase as the private label and to the extent necessary Medafor agrees to consent to the use and filing of the name Hemostase MPH<font
style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font> or Hemostase MPH<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font> trademarks by CryoLife with appropriate Governmental Authorities, if
CryoLife so desires.&#160;&#160;Medafor shall adapt packaging and labeling for the Products as instructed by CryoLife to meet CryoLife&#8217;s usual, normal and reasonable branding standards, which packaging shall be developed by
CryoLife.&#160;&#160;CryoLife, subject to Medafor&#8217;s reasonable acceptance, shall have final approval over all packaging and labeling of the Products.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2.5.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Sample Products.</font>&#160;&#160;Medafor shall provide to CryoLife sterile samples of Product at no charge according to the following commitment:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: 90pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 1- 800 boxes of 5
gram</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: 90pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 2- 400 boxes of 5
gram</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Unless otherwise agreed, samples shall be delivered to CryoLife at the commencement of Year 1 and Year 2 in accordance with forecasts that in the case of Year 1 have already
been delivered to Medafor, and that will be delivered to Medafor in conjunction with the forecasts set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3.1</font> for Year 2. <font
style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>CryoLife may purchase additional sterile samples of boxes of 3 gram or 5 gram product at a fixed price of $125 per box over the Initial Term.&#160;&#160;If requested by Medafor, CryoLife will
make all reasonable efforts to document the no charge use of these samples.&#160;&#160;CryoLife shall use sample units only for demonstrations and marketing purposes and may not resell any samples.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2.6.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Acceptance of Products.</font>&#160;&#160;CryoLife shall have twenty (20) Business Days to inspect and to verify that the Products conform to the applicable firm order and the Specifications from the date
of arrival of such Products at the point of delivery.&#160;&#160;Unless CryoLife rejects any Product within such twenty (20) Business Day period in writing to Medafor specifying the reason for such rejection, the entire shipment shall be deemed
accepted by CryoLife. Any Product rejected in accordance with the preceding sentence&#160;shall, if requested by Medafor be either returned to Medafor or CryoLife shall provide such other evidence of the deficiency of the Products to
Medafor.&#160;&#160;CryoLife will follow Medafor&#8217;s reasonable instructions to return such Products or to otherwise dispose of them, and will not take any action in relation to such Products until it receives such instructions from
Medafor.&#160;&#160;Medafor shall have fifteen (15) Business Days&#160;from CryoLife&#8217;s notice to check, verify, test and respond to any claims by CryoLife that Products are not in conformity with the Specifications, before agreeing to replace
the defective<font style="DISPLAY: inline; TEXT-DECORATION: line-through">&#160;</font>nonconforming product.&#160;&#160;Medafor shall bear all costs of return (including freight and insurance) for defective or non conforming Product and shall
either replace the defective or nonconforming Product without charge (including payment of freight and insurance for delivery of the replacement Product) or, at CryoLife&#8217;s request, refund to CryoLife the entire amount paid in connection with
the rejected Product (including transportation and shipping charges.&#160;&#160;All such replacement product shall be shipped to CryoLife within thirty five (35) calendar days.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Nothing in
this Section, including the exercise of rights hereunder, shall be construed as a waiver of CryoLife&#8217;s indemnification rights, its warranty rights or any other common law or statutory remedies.&#160;&#160;CryoLife agrees to reimburse Medafor
for any freight and insurance costs incurred by Medafor with respect to Product originally rejected by CryoLife, that Medafor determines through verification and/or testing was not defective and conformed to Specifications.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 10 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE III</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">PURCHASING</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">3.1.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Forecasts.</font>&#160;&#160;On a quarterly basis and twenty (20) days before the end of each quarter, CryoLife shall provide
to Medafor twelve&#160;(12) month rolling forecasts of the anticipated quarterly quantities and mix of the Products that CryoLife expects to order (each, a &#8220;Forecast&#8221;), which shall correspond to at least the minimum purchase quantities
in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font> of this Agreement provided that such forecasts shall not be binding unless and until CryoLife delivers a purchase order to Medafor.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">3.2.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Firm Orders.</font> Medafor shall supply to CryoLife the minimum quantities as described in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font> of this agreement against purchase
orders placed by CryoLife. In regard to purchase orders placed above the minimum purchase requirements as per <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font>, Medafor shall fulfill all firm additional orders for the
Product submitted by CryoLife provided that such orders are not more than 50% above the minimums set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font>. CryoLife shall place any firm purchase orders, so that they
have been received by Medafor no less than thirty-five (35) calendar days prior to the requested ship date.&#160;&#160;Firm purchase orders may be submitted via regular mail or facsimile to the following:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor, Inc.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2700 Freeway Blvd., Suite 800</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Minneapolis, MN&#160;&#160;55430</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Attn:&#160;&#160;Carl Orr</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Fax No.:&#160;&#160;763-571-1035</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 11 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT
WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Each firm order shall be deemed accepted upon receipt by Medafor.&#160;&#160;Except as otherwise provided herein, Medafor may not reject any purchase order received from
CryoLife unless such purchase order: (a) has not been forecasted pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3.1</font> and (b) is not consistent with the Annual Minimums to the extent the order exceeds the
forecasted amount.&#160;&#160;If Medafor rejects a purchase order due to a force majeure event or as otherwise provided herein, Medafor must give notice within two (2) Business Days of receipt of such purchase order (and before receipt of payment)
and must advise CryoLife in writing of the reason.&#160;&#160;In the event of such rejection, CryoLife&#8217;s annual minimum requirements as set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font> shall be adjusted
accordingly.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">3.3.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Transfer Pricing.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Subject to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3.3(b)</font> below, the transfer pricing for the Products ordered by CryoLife during the Initial
Term shall be as set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit C</font>.&#160;&#160;Medafor represents and warrants that its current pricing in the Territory to its distributors and for direct sales by Medafor, if
any, has been delivered to CryoLife and that such information delivered to CryoLife is true, correct and complete.&#160;&#160;The parties acknowledge that in the event that CryoLife is unable to obtain appropriate margins, the parties will, in good
faith, negotiate an equitable adjustment to such pricing.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The transfer pricing set
forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit C</font> is for finished Products (i.e. packaged, labeled and sterilized).&#160;&#160;CryoLife shall be responsible for all applicable (i)&#160;sales, use, value-added or
similar taxes imposed by any Governmental Authority, and (ii)&#160;excises, duties, import fees and export fees. CryoLife shall be also responsible for all&#160;reasonable freight and delivery charges and any other costs for shipment of the Products
from Medafor&#8217;s facilities in Minneapolis, Minnesota to CryoLife&#8217;s facilities as specified in the applicable firm order.&#160;&#160;Title to products and all risk of loss shall pass from CryoLife to Medafor upon Medafor&#8217;s delivery
of Products to CryoLife&#8217;s designated shipper at Medafor&#8217;s Minneapolis, Minnesota location.&#160;&#160;Each shipment of Products from Medafor to CryoLife shall contain such quality control certificates reasonably requested by CryoLife
certifying that the Products shipped conform to the specifications.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">3.4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Payment Terms.</font>&#160;&#160;Medafor shall deliver to CryoLife an invoice
for each firm order, which invoice shall contain customary information for CryoLife to verify the invoice, including the quantity of Products delivered.&#160;&#160;Payment terms for undisputed amounts (excluding for the first and second quarters of
2008 which shall be paid immediately upon delivery of the inventory due) shall be <font style="FONT-WEIGHT: bold">[***] (<font style="FONT-WEIGHT: bold">[***]</font>) </font>days from when the Products are shipped in accordance with <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3.</font>5 or, if later, ten (10) days after date that CryoLife receives the applicable invoice.&#160;&#160;All payments hereunder will be made in United&#160;States dollars.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">3.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shipping.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)&#160;Medafor shall at all times use its Commercially Reasonable Efforts to ship Products to CryoLife no later than the ship date set forth in the applicable firm order.
</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)&#160;Medafor shall package, label, store and ship all Products in compliance with Applicable Laws and in accordance with good commercial and industry
practice.&#160;&#160;CryoLife shall select the shipper.&#160;&#160;The Products shall be delivered to CryoLife sterile and ready for end-user sale and use, including all packaging, labeling, and instructions for use.&#160;&#160;Medafor shall package
the Products suitably for export and appropriately to prevent damage during shipment.&#160;&#160;The packing slip shall have the part number, purchase order number and delivery quantity.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 12 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Products shall be shipped F.O.B. Medafor facilities in Minneapolis, Minnesota.&#160;&#160;At
CryoLife&#8217;s expense, Medafor shall ship the Products to CryoLife as directed by CryoLife in the applicable firm purchase order.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE IV</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">MANUFACTURING</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">4.1.</font><font
style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Inventory.</font></font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor shall at all times
maintain a <font style="FONT-WEIGHT: bold"><font style="FONT-WEIGHT: bold">[***] </font>(<font style="FONT-WEIGHT: normal">[***]</font>) <font style="FONT-WEIGHT: bold">[***] </font></font>supply of Products in inventory to support CryoLife&#8217;s
sales efforts based on the higher of (A) the total amount of Products ordered by CryoLife during the preceding <font style="FONT-WEIGHT: bold">[***] </font>on a rolling basis, or (B) the minimum amount of Products CryoLife is required to purchase
pursuant to subsections 2.2(b) and 2.2(c) for the following <font style="FONT-WEIGHT: bold">[***] </font>on a rolling basis.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor will notify CryoLife immediately in writing upon becoming aware of any supply shortage, or other interruption or potential interruption in the supply of any material,
component, or sub-assembly, in each case as it relates to Products.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor shall at all times
ensure that sufficient manufacturing capacity (including appropriate manufacturing, storage and distribution facilities and qualified personnel) is maintained to meet CryoLife&#8217;s forecasted demand plus 50%.&#160;&#160;If at any time Medafor
does not have enough component materials to fulfill, or other supply or manufacturing problems prevent Medafor from fulfilling, on a timely basis, its supply obligations to CryoLife for CryoLife&#8217;s purchase orders for Products, Medafor shall
promptly notify CryoLife of the nature and extent of the impairment to Medafor&#8217;s ability to supply and shall allocate its remaining manufacturing resources to CryoLife&#8217;s purchase orders for the Products first.&#160;&#160;Only after such
action is taken and completed shall Medafor allocate remaining manufacturing resources to other competitive products Medafor produces, so that CryoLife will not be disadvantaged in its ability to obtain Products during such impairment.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(d)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">In the event Medafor is
unable to fulfill CryoLife&#8217;s purchase orders for Products, CryoLife&#8217;s Annual Minimum and calendar quarter purchase requirements for the Year and subsequent Years shall be suspended until Medafor is able to fulfill CryoLife&#8217;s
purchase orders for at least one calendar quarter. Thereafter, CryoLife&#8217;s Annual Minimum and calendar quarter purchase requirements shall be reduced by a reasonable amount to account for the shortage and any resulting interruption of
CryoLife&#8217;s ability to supply its customers.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(e)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">If this Agreement is
terminated by CryoLife (other than for Medafor&#8217;s breach of this Agreement or pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 10.2(c)</font> or <font
style="DISPLAY: inline; TEXT-DECORATION: underline">10.2(e)</font>) then CryoLife shall reimburse Medafor for the total Inventory Cost of up to <font style="FONT-WEIGHT: bold"><font style="FONT-WEIGHT: bold">[***] </font>(<font
style="FONT-WEIGHT: bold">[***]</font>) <font style="FONT-WEIGHT: bold">[***]</font> </font>inventory maintained pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4.1(a)</font> unless CryoLife directs that inventory be
shipped to CryoLife pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 10.3</font> (in which case CryoLife shall pay the amounts for the inventory as set forth herein); provided that inventory already paid for by CryoLife
shall be deducted from this amount.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 13 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> </div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(f)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">If CryoLife requires any changes to any CryoLife-specific components during the Term, outside of a required change by Regulatory Authorities which renders such
CryoLife-specific components unusable for sale by CryoLife, then CryoLife shall reimburse Medafor for the Inventory Cost of the CryoLife-specific components that are rendered unusable due to such change; provided, however, that the total amount of
reimbursement under this <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4.1(f)</font> shall only be paid for inventory that has been kept as part of the <font style="FONT-WEIGHT: bold">[***] (<font style="FONT-WEIGHT: bold">[***]
</font>) <font style="FONT-WEIGHT: bold">[***]</font> </font>inventory set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4.1(a)</font>.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">4.2.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Manufacturing.</font>&#160;&#160;Medafor will manufacture the Products in accordance with the then current&#160;(i) Specifications, (ii) applicable regulations relating to current Good Manufacturing
Practices (&#8220;CGMP&#8221;) and similar protocols required by the United States Food, Drug and Cosmetic Act and similar laws and regulations in foreign jurisdictions within the Territory that regulate the manufacture, distribution, and sale of
the Products for use in the Field, all as may be amended from time to time (&#8220;Other Manufacturing Laws&#8221;), quality system regulations (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">QSR</font>&#8221;) of the United States
Food and Drug Administration, including master device and lot history records, and ISO 13485 requirements (including appropriate certification) (&#8220;ISO&#8221;), MDD requirements, CMDCAS requirements, and (iii) other pertinent rules and
regulations of any Regulatory Authorities within the Territory that have approved the sale of the Products.&#160;&#160;Upon CryoLife&#8217;s request, Medafor shall provide CryoLife with written evidence of compliance with the criteria set forth
herein.&#160;&#160;During the Term, Medafor will maintain, or cause to be maintained, the Product manufacturing facility&#8217;s registration as a certified medical device manufacturing facility with all applicable Regulatory Authorities or cause
such facility to be maintained such that the facility would pass an audit for compliance with CGMP, QSR, Other Manufacturing Laws and ISO.&#160;&#160;Medafor shall maintain ongoing quality assurance and testing policies sufficient to satisfy its
obligations under this Agreement and Medafor&#8217;s standard quality assurance policies.&#160;&#160;Medafor shall maintain throughout the Term and for the specified shelf life of the Product (or for such longer period as may be required by
Applicable Laws) accurate and complete records relating to its manufacture and testing of the Products, including all records required under Applicable Laws.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">4.3.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Change Labeling.&#160;&#160;</font>Medafor shall not make any changes to the Products (including materials, packaging, and directions for use), the Specifications, the raw materials, component suppliers, or
manufacturing process for the Products, which in any case could reasonably be expected to adversely affect the form, fit, function, regulatory status, or efficacy of the Products or patient safety, unless approved by CryoLife in writing in advance,
which approval may not be unreasonably denied.&#160;&#160;Without limiting the foregoing, all such changes (including changes required by law) shall be submitted to CryoLife no later than sixty (60) calendar days prior to Medafor&#8217;s proposed
date of implementation for such change.&#160;&#160;Unless CryoLife notifies Medafor in writing that it disapproves of such change during the thirty (30) calendar day period following the notification of such change or if such a proposed change is
otherwise required by law, regulation, or directive, Medafor shall be authorized to implement such change and shall be responsible for properly communicating and implementing such change, including with respect to any of Medafor&#8217;s
vendors.&#160;&#160;Without limiting the foregoing, the following changes shall be deemed governed by this Section:&#160;&#160;(i) use of any nonconforming material in the manufacture of any of the Products in variance with the Specifications; (ii)
implementation of any deviation that could affect the handling, sterility, safety, or efficacy of any of the Products and be at variance with the Specifications; or (iii) implementation of any corrective action that could affect the safety or
efficacy of the Products.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 14 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">4.4.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Product Warranty.</font>&#160;&#160;Medafor warrants to CryoLife that the Product, when delivered in accordance with the applicable firm order, will (i)&#160;conform to the Specifications, (ii)&#160;have
been manufactured, tested, stored, packaged, labeled and shipped in compliance with Applicable Laws and in accordance with applicable Regulatory Authorities, including all Marketing Approvals and (iii)&#160;be free of defects in design, material,
engineering, fabrication and workmanship in accordance with the Specifications. The foregoing warranty shall be in effect with respect to each Product for the labeled shelf&#160;life of the Product.&#160;&#160;Medafor further warrants to CryoLife
that the Product, when delivered, shall be free and clear of any liens, security interests or encumbrances of any nature whatsoever.&#160;&#160;The above warranty is contingent upon the proper use of the Products and will not apply to Products that
have been removed from their original packaging or altered before resale by CryoLife.&#160;&#160;In addition, this warranty shall not apply to defects or failure due to: (a) the delivery of Product with items not provided by Medafor; (b) any party
other than Medafor or an authorized Medafor representative modifying the Product; or (c) storage of Products in an environment not intended or recommended by Medafor. EXCEPT AS OTHERWISE SET FORTH IN THIS AGREEMENT OR PROVIDED IN ANY
INDEMNIFICATION, EACH PARTY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED INCLUDING ANY WARRANTIES AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE V</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">REGULATORY MATTERS</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5.1.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Compliance with Laws.</font>&#160;&#160;Each Party shall comply in all material respects with all Applicable Laws that pertain to its activities under this Agreement and, except as otherwise provided for
herein, shall bear the entire cost and expense of such compliance.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5.2.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Marketing Approvals.</font>&#160;&#160;Medafor represents and warrants to CryoLife that it has applied for and received FDA approval and a CE marking for the Product under Medafor brand, and that such
approval and CE marking are in good standing and have never been revoked or suspended for any reason. Medafor has no reason to believe that such approval or CE marking will be revoked or suspended for any reason. In addition, Medafor represents and
warrants to CryoLife that as of March 18, 2008<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>it has applied for all approvals necessary in Canada, Germany, the United Kingdom and the United States to allow CryoLife to Distribute
Product under a private label and that it had received all such approvals in Germany, the United Kingdom and the United States.&#160;&#160;All costs and expenses for maintaining the FDA approval and the CE marking for the Product shall be at
Medafor&#8217;s expense.&#160;&#160;At CryoLife&#8217;s request, Medafor shall use its Commercially Reasonable Efforts to obtain and maintain additional Marketing Approvals for the Product (under the CryoLife brand discussed under <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.4</font>) throughout the Territory (and Medafor understands that any delay in receiving such Marketing Approvals shall reduce the Annual Minimums in accordance with <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font>).&#160;&#160;Medafor shall have primary responsibility for all communications, submissions and interactions with the Regulatory Authorities for the purpose of obtaining and
maintaining Marketing Approvals. CryoLife shall provide reasonable personnel assistance to Medafor with respect to such Marketing Approvals.&#160;&#160;Medafor hereby grants to CryoLife the fully paid-up right to use any and all regulatory approvals
and clearances related to the Product owned by or licensed to Medafor and existing as of the date hereof or obtained during the Term.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%"
align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 15 -</font></div> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5.3.</font><font
style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Actions by Regulatory Authorities.</font>&#160;&#160;Medafor shall
be responsible to Regulatory Authorities throughout the Territory as the manufacturer of the Products.&#160;&#160;If either Party receives notice of an actual or threatened inspection, investigation, inquiry, recall, import or export ban, product
seizure, enforcement proceeding or similar action by a Regulatory Authority with respect to the Product or a Party&#8217;s activities in connection with the Product, it will notify the other Party within forty-eight (48) hours after its receipt of
notice of the action and will promptly deliver to the other Party copies of all relevant documents received from the Regulatory Authority.&#160;&#160;Any notice respecting a recall or action that in any way restricts the ability of either Party to
Distribute Products shall be delivered to the other Party promptly upon receipt. The Parties shall cooperate in response to the action, including providing information and documentation as requested by the Regulatory Authority.&#160;&#160;If the
action primarily concerns CryoLife&#8217;s activities, then CryoLife shall have primary responsibility to respond to the Regulatory Authority; otherwise, Medafor shall have primary responsibility to respond.&#160;&#160;In either case, upon request
of the responding Party, the other Party shall provide consulting advice and assistance with the response.&#160;&#160;In addition, each Party shall promptly notify the other and provide to the other a copy or transcription, if available, of any
communication from any Regulatory Authority relating to the Products, the marketing thereof, or any related matter and shall keep the other Party reasonably apprised of regulatory interactions and similar activities with Regulatory Authorities in
connection with the Products.&#160;&#160;In the event of such action by a Regulatory Authority that impedes CryoLife&#8217;s ability to sell the Product, the Annual Minimums shall be adjusted equitably downward to reflect such impediment in
accordance with the impairment adjustment and &#8220;Baseball&#8221; arbitration mechanism set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font>.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5.4.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Regulatory Audit</font>.&#160;&#160;Medafor will permit authorized representatives of any Regulatory Authority to inspect Medafor&#8217;s plant and production facilities (and will secure the same rights
with respect to any third party plant and production facilities) relating to or used in connection with the manufacture of Products and will promptly notify CryoLife when Medafor receives notice of any such inspection.&#160;&#160;Medafor will advise
CryoLife of the findings of any regulatory inspection and will promptly take the necessary steps to correct any compliance deficiencies found by the Regulatory Authority relating to the production of Products.&#160;&#160;Medafor further agrees to
use its reasonable best efforts to provide to CryoLife such documentation or conduct such analyses as CryoLife may reasonably request in connection with any regulatory submission or audit concerning Products.&#160;&#160;CryoLife will permit
authorized representatives of any Regulatory Authority to inspect CryoLife&#8217;s facilities relating to distribution of Products and will promptly notify Medafor when CryoLife receives notice of any such inspection.&#160;&#160;CryoLife will advise
Medafor of the findings of any regulatory inspection and will promptly take the necessary steps to correct any compliance deficiencies found by the Regulatory Authority relating to CryoLife&#8217;s activities with Products.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 16 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5.5.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Inspections.</font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CryoLife shall have the
right to have its representatives present at the plant or plants at which the Products are manufactured during normal business hours to conduct an initial and periodic inspections of such facilities and manufacturing procedures for compliance with
CGMP, QSR, Other Manufacturing Laws and ISO, the Specifications and CryoLife&#8217;s quality assurance requirements and to inspect Medafor&#8217;s inventory of the Products, work-in-process, raw materials to be used for the Products, production
records, design history file, quality manuals, regulatory dossiers, and such other matters as may be pertinent to proper quality assurance of the Products to be delivered hereunder.&#160;&#160;CryoLife agrees to give Medafor a minimum of five
Business Days&#8217; prior notice of any such inspection and each representative of CryoLife may be required by Medafor to sign an appropriate confidentiality agreement.&#160;&#160;Medafor shall promptly use its Commercially Reasonable Efforts to
take such action as is required to correct any deficiencies identified by CryoLife relating to the production of the Products.&#160;&#160;Medafor further agrees to use its best efforts to provide such documentation or conduct such analyses as
CryoLife may reasonably request in connection with any regulatory submission or audit.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">At CryoLife&#8217;s reasonable request, Medafor will perform a quality system assessment of the vendors who provide Medafor with raw components/materials, sub-assemblies or
contract services for any Product.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5.6.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Product Complaints and Reports.</font>&#160;&#160;The Parties shall each collect and record Product Complaints (and any other events required to be recorded under Applicable Laws) in accordance with
Applicable Laws and their standard procedures and policies in effect from time to time.&#160;&#160;Each Party shall provide to the other Party reports of such complaints or events within seventy-two (72) hours after receipt.&#160;&#160;Medafor shall
be responsible for investigating all Product Complaints, shall promptly respond to such complaints and shall copy CryoLife on any response made by Medafor.&#160;&#160;Medafor shall be responsible for submitting to the Regulatory Authorities all
required reports and other materials, including annual reports, distribution reports and safety reports.&#160;&#160;Each Party shall immediately notify the other Party of any information it learns concerning the safety or efficacy of the Product,
regardless of whether formal reporting to any Regulatory Authority is required.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5.7.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Traceability.</font>&#160;&#160;Medafor shall maintain manufacturing and traceability records with respect to the Products,
including records by lot number.&#160;&#160;CryoLife shall maintain distribution records for the Product per 21 C.F.R. 820.160 for the purpose of maintaining traceability to the customer to facilitate recalls or field actions as
necessary.&#160;&#160;Medafor may audit CryoLife&#8217;s distribution records for the Product upon a minimum of five (5) Business Days prior notice of such audit and each representative of Medafor may be required by CryoLife to sign an appropriate
confidentiality agreement.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5.8.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Field Actions.</font>&#160;&#160;If either Party in good faith determines that a removal, correction, recall or other Field Action involving the Product or its labeling is warranted (whether or not required
by a Regulatory Authority), such Party shall immediately notify the other Party in writing and shall advise such other Party of the reasons underlying its determination that a removal, correction, recall or other Field Action is
warranted.&#160;&#160;The Parties shall consult with each other as to any action to be taken in regard to such removal, correction, recall or other Field Action.&#160;&#160;If, after consultations, either Party in good faith believes that such a
removal, correction, recall or Field Action should be undertaken with respect the Product or its labeling, the Parties shall cooperate in carrying out the same.&#160;&#160;Medafor shall be responsible for all of CryoLife&#8217;s reasonable
out-of-pocket costs and expenses, including the cost of the Products and the replacement cost of the Products, quality control testing and notification in the event of removals, corrections, recalls or other Field Actions with respect to any Product
unless such removal, correction, recall or other Field Action was due to an act or omission by CryoLife.&#160;&#160;Medafor shall be responsible for any required reporting to Regulatory Authorities with respect to any removal, correction, recall or
other Field Action involving the Product or its labeling, provided it copies CryoLife on the same.&#160;&#160;In the event of a recall of any Products, Medafor shall promptly correct noted deficiencies relating to its manufacturing, packaging,
labeling, testing and Medafor&#8217;s storage or handling of Products, if applicable, or cause the vendor of any material, component, or sub-assembly incorporated into such Products to do likewise with respect to such material, component, or
sub-assembly and CryoLife shall correct noted deficiencies related to matters for which it is responsible.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 17 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5.9.</font><font
style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Post-Market Clinical Studies</font>.&#160;&#160;Each Party shall
inform the other Party in the event that such Party becomes aware of post-market clinical studies being conducted with the product.&#160;&#160;Each Party shall inform the other Party in the event that they become aware of published literature or
unpublished reports of data from any clinical or non-clinical laboratory studies involving the product.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE VI</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CONFIDENTIALITY</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">6.1.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Confidentiality.</font>&#160;&#160;In the course of their activities pursuant to this Agreement, the Parties anticipate that they may disclose Confidential Information to one another and either Party may,
from time to time, be either the disclosing Party or the recipient of Confidential Information.&#160;&#160;The Parties wish to protect such Confidential Information in accordance with this <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 6.1</font>.&#160;&#160;The provisions of this Section&#160;shall apply to disclosures furnished to or received by a Party and its employees, agents and representatives (which may include
employees, agents and representatives of its Affiliates).&#160;&#160;Each Party shall advise its employees, agents and representatives of the requirements of this Section and shall be responsible to ensure their compliance with such
provisions.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">For purposes hereof,
&#8220;Confidential Information&#8221; with respect to a disclosing Party means all information, in any form or media, concerning the disclosing Party that the disclosing Party furnishes to the recipient, whether furnished before or after the
Effective Date, and all notes, analyses, compilations, studies and other materials, whether prepared by the recipient or others, that contain or reflect such information; provided, however, that Confidential Information does not include information
that (i)&#160;is or hereafter becomes generally available to the public other than as a result of a disclosure by the recipient, (ii)&#160;was already known to the recipient prior to receipt from the disclosing Party, as evidenced by prior written
documents in its possession not subject to an existing confidentiality obligation to the disclosing Party, (iii)&#160;is disclosed to the recipient on a non-confidential basis by a person who is not in default of any confidentiality obligation to
the disclosing Party or (iv)&#160;is developed by or on behalf of the recipient without reliance on confidential information received hereunder.&#160;&#160;The contents of this Agreement shall be deemed to be Confidential Information of each Party.
</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 18 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The recipient of
Confidential Information shall (i)&#160;maintain its confidentiality using efforts and precautions at least as great as those it uses and takes to protect its own confidential information and trade secrets; (ii)&#160;use such Confidential
Information solely in connection with the discharge of its obligations under this Agreement and (iii)&#160;not disclose such Confidential Information to any person other than those of its agents and representatives who need to know such Confidential
Information in order to accomplish the objectives for which it was disclosed.&#160;&#160;Notwithstanding the foregoing, the recipient of Confidential Information may disclose it to the extent necessary to comply with Applicable Laws, stock exchange
rules, or with an order issued by a court or Regulatory Authority with competent jurisdiction; provided that, in connection with such disclosure, the recipient uses commercially reasonable efforts to obtain confidential treatment or an appropriate
protective order, to the extent available, with respect to such Confidential Information.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Upon request of the disclosing Party, the recipient of Confidential Information shall promptly redeliver to the disclosing Party all Confidential Information provided to the
recipient in tangible form, and the recipient shall not retain any copies, extracts or other reproductions, in whole or in part, of such Confidential Information.&#160;&#160;All notes or other work product prepared by the recipient based upon or
incorporating Confidential Information of the disclosing Party shall be destroyed, and such destruction shall be certified in writing to the disclosing Party by an authorized representative of the recipient who supervised such
destruction.&#160;&#160;Notwithstanding the foregoing, in-house legal counsel to the recipient shall be permitted to retain in its files one copy of all Confidential Information to evidence the scope of the Party&#8217;s obligation of
confidentiality.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(d)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The obligations under this
Section shall remain in effect from the Effective Date through the third&#160;anniversary of the expiration or termination of this Agreement.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(e)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">In addition to any other remedies available in law or equity, the disclosing Party shall be entitled to temporary and permanent injunctive relief in the event of a breach (or
threatened breach) under this Section.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(f)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The provisions of this
Section shall supersede and replace any prior agreements between the Parties relating to Confidential Information covered hereby; provided that notwithstanding the foregoing the Parties acknowledge and agree that upon execution of this Agreement by
the Parties that certain Non-Disclosure Agreement, dated December 13, 2007 between the Parties shall be deemed terminated as of the date of execution but those terms set forth therein shall survive in accordance with their terms.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(g)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Notwithstanding the
provisions of this Article VI, the parties acknowledge they may desire (or be required) to make a public announcement, issue a press release or provide similar publicity with respect to this Agreement or the transactions contemplated herein, and
each Party shall notify the other Party of its intent to make such publicity and deliver a draft of such publicity to the other Party.&#160;&#160;Neither Party shall make any public announcement, press release or similar public pronouncement with
respect to this Agreement or the transactions contemplated herein without the consent of the other Party regarding the content, time and manner of such publicity; provided that neither Party shall unreasonably withhold its consent under this section
and nothing in this Article VI shall prevent either Party from timely making any disclosure required by law or by the New York Stock Exchange.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%"
align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 19 -</font></div> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE VII</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">INTELLECTUAL PROPERTY RIGHTS</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">7.1.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Intellectual Property/Information and Ideas.</font>&#160;&#160;CryoLife acknowledges Medafor's exclusive right, title and interest in Medafor's patents and know-how related to the manufacture, regulatory
approval, or distribution of the Bellows Applicator and the MPH Product and to the trademarks, trade names, trade dress and methods of presentation relating to the Bellows Applicator and the MPH Product (including the Medafor
Mark).&#160;&#160;Medafor acknowledges CryoLife&#8217;s exclusive right, title and interest in the CryoLife Marks and all Intellectual Property rights therein or related thereto, including the CryoLife Applicator (the &#8220;CryoLife
IP&#8221;).&#160;&#160;Except as otherwise expressly provided herein, nothing contained herein shall be construed to convey any right, interest or title in or to the Medafor IP to CryoLife, or any right, interest or title in or to the CryoLife IP to
Medafor.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">7.2.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">IP Representations.</font>&#160;&#160;Medafor hereby represents and warrants to, and covenants with, CryoLife as follows:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor, and only Medafor,
owns or holds valid and enforceable rights to exclusively manufacture, Distribute, use or license (to the extent a license is required) any and all Intellectual Property that is necessary (i)&#160;to manufacture and sell the MPH Product, the Bellows
Applicator, and the Products or to permit others to manufacture or sell the MPH Product, the Bellows Applicator, and the Products (except for the CryoLife Applicator, if any, for which CryoLife grants Medafor a royalty free license during the Term
of this Agreement solely for the purposes of Medafor performing its obligations hereunder), (ii)&#160;CryoLife to Distribute the Product as contemplated by this Agreement and (iii)&#160;for Medafor to grant to CryoLife the Distribution rights under
this Agreement (such Intellectual Property rights collectively, the &#8220;Medafor IP&#8221;).</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor owns or licenses all right, title and interest in and to the Medafor IP, subject only to those rights retained by HemArrest pursuant to that certain Second Amended and
Restated Exclusive License and Royalty Agreement, dated November 1, 2004, by and between HemArrest and Medafor, as amended by that certain Addendum, dated February 15, 2005, by and between HemArrest and Medafor, a copy of which has been provided to
CryoLife, as amended by that certain Agreement, dated May 10, 2006, by and among HemArrest, Medafor, Ted P. Adams, Donald L. Sturtevant and James F. Drake.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor has not granted
any license, covenant not to sue or other right that would be inconsistent with or conflict with the grant of the exclusive Distribution rights under this Agreement.&#160;&#160;Medafor also agrees that if in the event HemArrest has or granted or
does grant any license, covenant not to sue or other right that would be inconsistent with or conflict with the grant of the exclusive Distribution rights under this Agreement then it would be considered a material breach of this Agreement by
Medafor and that CryoLife would be entitled to indemnification pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Sections 7.4</font> and <font style="DISPLAY: inline; TEXT-DECORATION: underline">9.1</font>.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 20 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(d)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">No Person has asserted any
claim, suit, proceeding, action or demand (a &#8220;Claim&#8221;) with respect to any of the Medafor IP, which Claim (i)&#160;challenges the validity of Medafor&#8217;s interest in the Medafor IP, (ii)&#160;alleges that Medafor&#8217;s use or
practice of the Medafor IP infringes, misappropriates or violates the rights of any Person or (iii)&#160;seeks to enjoin or restrain Medafor&#8217;s use or practice of the Medafor IP in any manner that would interfere with the transactions
contemplated by this Agreement.&#160;&#160;Medafor has no knowledge that any Person intends to assert such a Claim.&#160;&#160;Medafor also agrees that in the event that if HemArrest has knowledge that a Person intends to assert such a Claim then it
would be considered a material breach of this Agreement by Medafor and that CryoLife would be entitled to indemnification pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Sections 7.4</font> and <font
style="DISPLAY: inline; TEXT-DECORATION: underline">9.1</font>.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(e)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">To Medafor&#8217;s
knowledge no Intellectual Property or contract rights of others will be infringed by (i) the development, manufacture, distribution or sale of the Products by Medafor or CryoLife as contemplated by this Agreement, (ii) the entering into of this
Agreement, or (iii) the performance of this Agreement by either Party.&#160;&#160;Medafor agrees however that if in the event that any Intellectual Property or contract rights of others are infringed by (i) the development, manufacture, distribution
or sale of the Products by Medafor or CryoLife as contemplated by this Agreement, (ii) the entering into of this Agreement, or (iii) the performance of this Agreement by either Party then it would be considered a material breach of this Agreement by
Medafor and that CryoLife would be entitled to indemnification pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Sections 7.4</font> and <font style="DISPLAY: inline; TEXT-DECORATION: underline">9.1.</font></font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(f)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">As of the Effective Date,
it has not granted and during the Term hereof, it will not grant any Person the right of first refusal to purchase all or substantially all of its assets, the assets constituting the Product or the MPH product.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">7.3.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Trademarks.</font>&#160;&#160;CryoLife shall have the right and license to use Medafor&#8217;s Trademarks associated with the Product for Product marketing purposes and as may be necessary in order to
comply with applicable Regulatory Laws.&#160;&#160;CryoLife shall comply with the reasonable quality control instructions of Medafor as to the form and manner in which such Medafor Trademarks shall be used.&#160;&#160;Trademarks developed by
CryoLife for the Product shall be owned exclusively by CryoLife.&#160;&#160;Other than as expressly provided herein, no Party shall acquire or have any right or license to use the name or Trademarks of the other Party without its prior written
consent.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">7.4.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Infringement Notification.</font>&#160;&#160;Each Party shall promptly notify the other Party of any and all infringements of the Medafor IP or of the CryoLife IP of which such Party becomes aware within
the Territory.&#160;&#160;Medafor shall, at its own cost, take any and all actions, legal or equitable, necessary to defend the Medafor IP against such infringements and to eliminate or minimize the consequences of any infringement of the Medafor IP
in the Field in the Territory. At Medafor&#8217;s request and expense, CryoLife will assist Medafor in taking action against any such infringements. In addition, and in addition to any responsibility of Medafor pursuant to <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 9.1</font>, if any Product is held to constitute an infringement or misappropriation of any third party&#8217;s Intellectual Property right or if Medafor and CryoLife concur that any
Products constitutes an infringement or misappropriation, Medafor will at its expense either: (i) procure the right for CryoLife to continue distributing the Products in accordance with this Agreement at no additional cost to CryoLife, (ii) replace
the Product with a non-infringing and non-misappropriating equivalent product conforming to the Specifications at no additional cost to CryoLife, or (iii) modify the Product to make it non-infringing and non-misappropriating while conforming to the
Specifications at no additional cost to CryoLife.&#160;&#160;If Medafor is unable to secure sufficient rights to permit Cryolife to Distribute the Products in the manner contemplated by this Agreement, Medafor shall promptly repurchase all of
CryoLife&#8217;s Product inventory as provided in Section 10.4, and CryoLife shall be released of its obligation to Distribute the Products.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%"
align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 21 -</font></div> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">7.5.</font><font
style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Patent Prosecution</font>.&#160;&#160;At its own cost, Medafor
shall (or shall require HemArrest to) apply for, prosecute, and maintain all patents or rights to license or use the patents included in the Medafor IP in the Territory<font style="DISPLAY: inline; FONT-STYLE: italic">.&#160;&#160;</font>Medafor
shall keep CryoLife reasonably informed as to the status of the prosecution and maintenance of such patents in the Territory and with respect to any actions regarding such patents in the Territory.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE VIII</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">REPRESENTATIONS AND WARRANTIES</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Each Party hereby represents and warrants to the other Party
that:</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">It is a corporation duly
organized, validly existing and, if relevant in its jurisdiction of organization, in good standing under the laws of its jurisdiction of organization and that it is legally qualified to do business in each jurisdiction in which this Agreement may be
performed and where its activities hereunder require such qualification and has the power and authority to own, lease and operate its assets and to conduct the business now being conducted by it.&#160;&#160;It has all requisite power and authority
to enter into this Agreement and to perform its obligations hereunder.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The execution, delivery and performance by it of this Agreement and the consummation by it of the transactions contemplated hereby have been duly authorized and approved by all
necessary corporate or equivalent action on its part.&#160;&#160;This Agreement has been duly executed and delivered by it and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as the
same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws relating to or affecting creditors&#8217; rights generally.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The execution, delivery
and performance by it of this Agreement and the consummation by it of the transactions contemplated hereby do not and will not:&#160;&#160;(i)&#160;violate any Applicable Laws; (ii)&#160;conflict with, or result in the breach of any provision of,
its certificate of incorporation, bylaws or equivalent organizational documents; (iii)&#160;result in the creation of any lien or encumbrance of any nature upon any property being transferred or licensed by it pursuant to this Agreement; or
(iv)&#160;violate, conflict with, result in the breach or termination of, or constitute a default under (or event which, with notice, lapse of time or both, would constitute a default under), any permit, contract or agreement to which it is a party
or by which any of its properties or businesses are bound.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 22 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(d)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">No authorization, consent or approval of, or notice to or filing with, any Governmental Authority is required for the execution, delivery and performance by it of this
Agreement, other than Marketing Approvals that have not been obtained prior to the Effective Date.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(e)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">It is not a party to any litigation relating to, or that could reasonably be expected to affect its ability to perform its obligations under this Agreement.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE IX</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">INDEMNIFICATION AND INSURANCE</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">9.1.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Indemnification by Medafor.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor shall indemnify and hold harmless CryoLife and its respective shareholders, directors, officers, employees and agents from and against any and all liabilities, damages,
losses, penalties, fines, costs and expenses, including reasonable attorneys&#8217; fees (&#8220;Losses&#8221;), paid or incurred by them in connection with any Claim based upon or arising from:&#160;&#160;(i)&#160;any use of the Products, including
Claims for personal injury, death or property damage; (ii)&#160;any allegations of infringement or violation of any Intellectual Property rights of a third party, as a result of the use, manufacture, sale or distribution of the Product (provided
that the provisions of this <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 9.</font>1 shall be read consistent with the provisions of <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 7.4)</font>; (iii)&#160;any
breach by Medafor of any of its representations, warranties or obligations under this Agreement; (iv)&#160;any violation by Medafor of Applicable Laws; or (v)&#160;any negligent acts or omissions or wilful misconduct of Medafor or its Affiliates or
subcontractors or any of their respective employees or agents relating to the activities subject to this Agreement.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CryoLife shall give Medafor prompt written notice of any Claim with respect to which Medafor&#8217;s indemnification obligations may apply, but any delay or failure of such
notice shall not excuse Medafor&#8217;s indemnification obligations except to the extent that Medafor&#8217;s legal position is prejudiced thereby.&#160;&#160;Medafor shall have the right to assume and control the defense and settlement of any such
Claim; except that CryoLife shall have the right to assume and control, at Medafor&#8217;s expense, the defense and settlement of any such Claim if:&#160;&#160;(i)&#160;CryoLife reasonably determines that there is a conflict of interest between
CryoLife and Medafor with respect to such Claim; (ii)&#160;Medafor fails to employ counsel reasonably satisfactory to CryoLife to represent CryoLife within a reasonable time after Medafor&#8217;s receipt of notice of the Claim or (iii)&#160;in the
reasonable opinion of counsel to CryoLife, the Claim could result in CryoLife becoming subject to injunctive or other non-monetary relief that could have a material adverse effect on CryoLife&#8217;s ongoing business.&#160;&#160;The Party not
controlling the defense shall have the right to participate in the Claim at its own expense, but in any event shall cooperate with the controlling Party in the investigation and defense of the Claim.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">If Medafor is entitled to,
and does, assume and control the defense and settlement of any Claim with respect to which its indemnification obligations apply, then Medafor shall not settle such Claim without CryoLife&#8217;s prior written consent (which consent shall not be
unreasonably withheld or delayed), unless (i)&#160;the sole relief provided in such settlement is monetary in nature and shall be paid in full by Medafor and (ii)&#160;such settlement does not include any finding or admission of a violation by
CryoLife of any Applicable Laws or Third&#160;Party&#8217;s rights.&#160;&#160;Whenever CryoLife assumes and controls the defense and settlement of a Claim with respect to which Medafor&#8217;s indemnification obligations applies, Medafor shall not
be liable for any settlement thereof effected by CryoLife unless CryoLife shall have obtained Medafor&#8217;s prior written consent to the proposed settlement (which consent shall not be unreasonably withheld or delayed).</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 23 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">9.2.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Indemnification by CryoLife.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CryoLife shall indemnify and hold harmless Medafor and its Affiliates and their respective shareholders, directors, officers, employees and agents from and against any and all
Losses, paid or incurred by them in connection with any Claim based upon or arising from:&#160;&#160;(i)&#160;any breach by CryoLife of any of its representations, warranties or obligations under this Agreement; (ii)&#160;any violation by CryoLife
of Applicable Laws or (iii)&#160;any negligent acts or omissions or wilful misconduct by CryoLife or its Affiliates or any of their respective employees or agents relating to the activities subject to this Agreement.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor shall give
CryoLife prompt written notice of any Claim with respect to which CryoLife&#8217;s indemnification obligations may apply, but any delay or failure of such notice shall not excuse CryoLife&#8217;s indemnification obligations except to the extent that
CryoLife&#8217;s legal position is prejudiced thereby.&#160;&#160;CryoLife shall have the right to assume and control the defense and settlement of any such Claim; except that Medafor shall have the right to assume and control, at CryoLife&#8217;s
expense, the defense and settlement of any such Claim if:&#160;&#160;(i)&#160;Medafor reasonably determines that there is a conflict of interest between CryoLife and Medafor with respect to such Claim; (ii)&#160;CryoLife fails to employ counsel
reasonably satisfactory to Medafor to represent Medafor within a reasonable time after CryoLife&#8217;s receipt of notice of the Claim or (iii)&#160;in the reasonable opinion of counsel to Medafor, the Claim could result in Medafor becoming subject
to injunctive or other non-monetary relief that could have a material adverse effect on Medafor&#8217;s ongoing business.&#160;&#160;The Party not controlling the defense shall have the right to participate in the Claim at its own expense, but in
any event shall cooperate with the controlling Party in the investigation and defense of the Claim.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 90pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">If CryoLife is entitled to, and does, assume and control the defense and settlement of any Claim with respect to which its indemnification obligations apply, then CryoLife
shall not settle such Claim without Medafor&#8217;s prior written consent (which consent shall not be unreasonably withheld or delayed), unless (i)&#160;the sole relief provided in such settlement is monetary in nature and shall be paid in full by
CryoLife and (ii)&#160;such settlement does not include any finding or admission of a violation by Medafor of any Applicable Laws or Third&#160;Party&#8217;s rights.&#160;&#160;Whenever Medafor assumes and controls the defense and settlement of a
Claim with respect to which CryoLife&#8217;s indemnification obligations applies, CryoLife shall not be liable for any settlement thereof effected by Medafor unless Medafor shall have obtained CryoLife&#8217;s prior written consent to the proposed
settlement (which consent shall not be unreasonably withheld or delayed).</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">9.3.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Combined Obligations.</font>&#160;&#160;To the extent that CryoLife and Medafor have indemnification obligations to one another
in connection with a single Claim, CryoLife and Medafor shall contribute to the aggregate damages arising from such Claim in such proportion as is appropriate to reflect their relative responsibilities for such damages, as well as any other relevant
equitable considerations.&#160;&#160;The amount paid or payable by CryoLife or Medafor for purposes of apportioning the aggregate damages shall be deemed to include all reasonable legal fees and expenses incurred by such Party in connection with
investigating, preparing for or defending against such Claim.&#160;&#160;Such finding of contribution shall be as agreed to in writing by the parties, or as determined by a judicial determination, in final, non-appealable form.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 24 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">9.4.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Limitation of Liability.</font>&#160;&#160;Except as otherwise specifically stated herein, Medafor shall not be liable for any loss or damages claimed to have resulted from the use, operation, or
performance of the Products, regardless of the form of action; and the sole and exclusive remedies for breach of any or all warranties or representations and for Medafor&#8217;s liability of any kind are limited to repair or replacement of the
Product or actual damages for personal injury or to tangible personal property caused by the sole negligence of Medafor.&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">EXCEPT TO THE EXTENT PROVIDED IN THIS ARTICLE IX, NEITHER PARTY
SHALL BE LIABLE TO THE OTHER PARTY FOR, AND EACH PARTY HEREBY WAIVES, SPECIAL, EXEMPLARY, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR ANY DAMAGE RESULTING FROM LOSS OF USE OR PROFITS.</font></font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">9.5.</font><font
style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Insurance Provisions.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;During the Term of
this Agreement and for a period of seven years thereafter, Medafor shall procure and maintain, from a reputable insurer reasonably satisfactory to CryoLife, insurance in the amount of two million U.S. Dollars ($2,000,000) per occurrence or five
million U.S. Dollars ($5,000,000) in the aggregate, including product liability insurance, which is consistent with normal business practices of prudent companies similarly situated.&#160;&#160;Such insurance policy shall at all times name CryoLife
as an additional insured thereunder and Medafor shall provide a certificate of insurance to CryoLife evidencing such coverage.&#160;&#160;It is understood that such insurance shall not be construed to create a limit of Medafor&#8217;s liability with
respect to its indemnification obligations under this Agreement.&#160;&#160;Medafor shall provide CryoLife with written evidence of such insurance upon request.&#160;&#160;Medafor shall provide CryoLife with written notice at least 15 calendar days
prior to the cancellation, non-renewal, or material change in such insurance.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">During the Term of this Agreement and for a period of seven years thereafter, CryoLife shall procure and maintain, from a reputable insurer reasonably satisfactory to Medafor,
insurance in the amount of two million U.S. Dollars ($2,000,000) per occurrence or five million U.S. Dollars ($5,000,000) in the aggregate, including product liability insurance, which is consistent with normal business practices of prudent
companies similarly situated.&#160;&#160;Such insurance policy shall at all times name Medafor as an additional insured thereunder and CryoLife shall provide a certificate of insurance to Medafor evidencing such coverage.&#160;&#160;It is understood
that such insurance shall not be construed to create a limit of CryoLife&#8217;s liability with respect to its indemnification obligations under this Agreement.&#160;&#160;CryoLife shall provide Medafor with written evidence of such insurance upon
request.&#160;&#160;CryoLife shall provide Medafor with written notice at least 15 calendar days prior to the cancellation, non-renewal, or material change in such insurance.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 25 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE X</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">TERM AND TERMINATION</font></div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">10.1.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Term.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">This Agreement shall take effect as of the Effective Date and shall remain in effect until June 30, 2011 (the &#8220;Initial Term&#8221;).&#160;&#160;At CryoLife&#8217;s option
(&#8220;Right of Renewal&#8221;), this Agreement may be renewed for an additional thirty-six (36) months period if CryoLife meets the Annual Minimums during the Initial Term.&#160;&#160;The Initial Term plus any renewal terms, if any, is referred to
herein as the &#8220;Term.&#8221;</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CryoLife may exercise its
Right of Renewal by giving Medafor written notice of its intent to renew at least sixty (60) days prior to the expiration of the Initial Term.&#160;&#160;If CryoLife does not exercise the Right of Renewal or does not qualify for the Right of
Renewal, then, within the last three (3) months of the Initial Term, the Parties shall discuss options for concluding a new agreement to take effect upon the expiration of this Agreement.&#160;&#160;Nothing in the preceding sentence shall require
either Party to enter into or be bound by a new agreement or shall be construed to require a minimum length of time for such discussions.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">If this Agreement is not renewed as provided above or after the expiration of the Term herein, CryoLife shall be free to continue to sell Products it has purchased from Medafor
unless and until Medafor repurchases such Products from CryoLife.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">10.2.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Termination.</font>&#160;&#160;This Agreement may be terminated prior to the expiration of the Term as follows:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">By either Party for reason
of the other Party&#8217;s material breach of a duty or obligation under this Agreement by giving the other Party not less than thirty (30) days prior written notice of termination to the other Party which specifies such default and such other Party
fails to cure the material default during such thirty (30) day period; provided that CryoLife&#8217;s failure to make payments due for invoices set forth hereunder shall only be subject to a ten (10 day cure period; or</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">By either Party forthwith
on written notice of termination to the other Party for the other Party's voluntary or involuntary petition of bankruptcy, or insolvency, or winding up of its operations; or in the event of nationalization, in whole or part, of the other Party; or
</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">By CryoLife upon thirty
(30) days written notice of termination to Medafor after Medafor fails on any two occasions within any twelve (12) month period to timely deliver Product, or material quantities of Products, that conform to the Specifications and for which Medafor
fails to timely deliver replacement Products that meet Specifications, ordered by CryoLife in accordance with the provisions of this Agreement (a &#8220;Failure to Supply&#8221;); or</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'">(d)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">By
Medafor upon thirty (30) days written notice of termination to CryoLife if CryoLife fails to meet at least 80% of the Annual Minimum of any Year (except for Year 1), provided that in determining whether or not CryoLife has met the purchase
requirement for a particular period, any Products ordered by CryoLife in excess of the amount required for that period may be carried backward or forward to supplement the purchases of the preceding or following period, and any Products ordered by
CryoLife in the previous Year in excess of the Annual Minimum for such previous Year may be carried forward to supplement the inadequate inventory purchases of any period of the following Year; and provided further, that within thirty (30) days of
CryoLife&#8217;s receipt of Medafor&#8217;s written notice of termination, CryoLife does not submit purchase orders to make up for the shortfall during the thirty (30) day period; </font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 26 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(e)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">By CryoLife upon notice in
the event of any Product supply interruption pursuant to <font style="DISPLAY: inline; TEXT-DECORATION: underline">Sections 4.1(c)</font> or <font style="DISPLAY: inline; TEXT-DECORATION: underline">(d)</font> or any recall of Products provided
CryoLife delivers thirty (30) days prior written notice of termination to Medafor of such Product supply interruption or recall and Medafor fails to cure the default during such thirty (30) day period; or</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(f)</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">In the event CryoLife
fails to meet the minimum purchase requirements set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font> (as modified by <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 10.2(d))</font>,
Medafor&#8217;s sole and exclusive remedy is shall be to terminate the Agreement as provided subsubsection (d) above.&#160;&#160;CryoLife shall not be liable for any monetary damages that Medafor may incur as a result of any such
failure.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">10.3.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Effect of Termination.</font>&#160;&#160;Notwithstanding anything to the contrary contained herein, upon termination or expiration of this Agreement other than due to an uncured breach of this Agreement by
CryoLife (outside of a failure to meet the minimum purchase requirements set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.</font>2 as modified by <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section
10.2(d)</font>), (i) Medafor shall continue to fill all CryoLife purchase orders made in accordance with the provisions of this Agreement prior to the date of the initial notice of such termination or expiration; (ii) CryoLife shall continue to have
all rights necessary or appropriate to sell Products (including Products delivered pursuant to post-termination orders and any Products ordered by CryoLife prior to termination or expiration) for six (6) months following the date of termination or
expiration, and Medafor shall continue to comply with all of its duties and obligations hereunder necessary or appropriate to facilitate such sales by CryoLife; (iii) Medafor shall continue to comply with all of its duties and obligations hereunder
necessary or appropriate to permit CryoLife to fulfill its obligations to deliver Products pursuant to tenders or sales contracts outstanding at the time of such termination or expiration until such tenders or sales contracts have expired, including
Medafor&#8217;s obligation to fill any related CryoLife purchase orders, (iv) CryoLife shall continue to comply with its obligations under this Agreement; and (v) CryoLife shall make payments of all undisputed portions of invoices within ten (10)
days of receipt of such invoice (provided that if CryoLife has not paid all other undisputed invoices, payment shall be made COD for such instruments).&#160;&#160;Termination of this Agreement shall not affect rights and obligations of either Party
that may have accrued prior to the effective date of termination or any obligation that by its nature or express terms survives termination.&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Sections 1.1</font>, <font
style="DISPLAY: inline; TEXT-DECORATION: underline">1.2</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">2.1(c)</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">2.1(d)</font>, <font
style="DISPLAY: inline; TEXT-DECORATION: underline">2.1(e)</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">2.3</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">2.4</font>,<font
style="DISPLAY: inline; TEXT-DECORATION: underline"> 2.6</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">3.2</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">3.3</font>, <font
style="DISPLAY: inline; TEXT-DECORATION: underline">3.4</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">3.5</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">4.1(e)</font>, <font
style="DISPLAY: inline; TEXT-DECORATION: underline">4.2</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">4.3</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">4.4</font> and Articles V-Article XI shall survive the
termination or expiration of this Agreement.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">10.4.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Inventory Repurchases</font>.&#160;&#160;Upon termination or expiration of this Agreement for any reason other than for CryoLife&#8217;s material breach of its obligations hereunder, Medafor shall, at
CryoLife&#8217;s option, repurchase from CryoLife all Products that are commercially usable at the Transfer Price paid by CryoLife for such Products, and CryoLife shall return to Medafor any advertising or sales materials previously provided by
Medafor, if any. Within thirty (30) calendar days after any such termination of this Agreement, CryoLife shall provide Medafor an inventory of Products in its possession, including samples of Products, and information relating to the transfer prices
CryoLife paid for such Products.&#160;&#160;If Medafor disputes any information provided by CryoLife, it shall deliver a written notice thereof to CryoLife within fifteen (15) calendar days after receiving such information, in which case, the
Parties shall negotiate in good faith to resolve such dispute; provided that in the event that they fail to resolve the dispute within thirty (30) days after Medafor&#8217;s delivery of such notice of dispute, either party may take any judicial
action it deems necessary or appropriate.&#160;&#160;CryoLife shall deliver to Medafor all remaining Products, including samples, promptly after the expiration of the fifteen (15) calendar day period if no dispute is raised by Medafor, or after the
resolution of such dispute.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 27 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">ARTICLE XI</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">MISCELLANEOUS</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.1.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Agency.</font>&#160;&#160;Neither Party is, nor shall be deemed to be, an employee, agent, partner or legal representative of the other Party for any purpose.&#160;&#160;Neither Party shall have the right,
power or authority to enter into any contracts in the name of, or on behalf of, the other Party, nor shall either Party have the right, power or authority to pledge the credit of the other Party in any way or hold itself out as having the authority
to do so.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.2.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Force Majeure.</font>&#160;&#160;If the performance of any obligation under this Agreement is prevented, restricted or interfered with by reason of war, revolution, civil commotion, acts of terrorism,
blockade, embargo, material changes in Applicable Laws, strikes or similar event which is beyond the reasonable control of the Party affected and could not have been avoided with the exercise of due care, then the Party so affected shall, upon
giving prior written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, or interference, provided that the Party so affected shall notify the other Party within ten (10) days of such
occurrence, shall use its Commercially Reasonable Efforts to avoid or remove such causes of nonperformance, and shall continue performance hereunder with reasonable dispatch whenever such causes are removed.&#160;&#160;If such conditions inhibiting
complete performance shall continue in excess of sixty&#160;(60) days, then the Party that is not affected by the force majeure event shall have the option, by delivery of written notice of termination to the affected Party, to terminate this
Agreement.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.3.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Binding Assignment. </font>This Agreement shall be binding on CryoLife, Medafor, and their respective successors and assigns.&#160;&#160;Neither Party may assign its obligations under this Agreement or in
any way transfer its rights or obligations under this Agreement, directly or indirectly, without the prior written consent of the other Party, which consent shall not be unreasonably withheld.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.4.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Set Off</font>.&#160;&#160;The existence of any Claim by a Party against the other Party or any of its affiliates, whether predicated upon this Agreement or otherwise, shall not entitle the claiming Party
to withhold or set-off any payments due to the other Party under this Agreement.&#160;&#160;If any governmental agency prevents performance of any duty of either Party under this Agreement, either Party may immediately suspend this Agreement and
each Party will be excused from further performance of its obligations under this Agreement unless and until governmental approval is obtained</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%"
align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 28 -</font></div> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.5.</font><font
style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Entire Agreement; Amendments.</font>&#160;&#160;Except for that
certain Non-Disclosure Agreement referenced herein, this Agreement constitutes the entire agreement between the Parties hereto concerning its subject matter and supersedes all previous negotiations, agreements and commitments with respect
thereto.&#160;&#160;This Agreement shall not be released, discharged, amended or modified in any manner except by a written instrument signed by duly authorized officers of each of the Parties hereto.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.6.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Partial Illegality.</font>&#160;&#160;If any provision of this Agreement, or the application thereof to any Party or circumstances, shall be declared void, illegal or unenforceable, the remainder of this
Agreement shall be valid and enforceable to the extent permitted by Applicable Laws.&#160;&#160;In such event, the Parties shall use their best efforts to replace the invalid or unenforceable provision by a provision that, to the extent permitted by
Applicable Laws, achieves the purposes intended under the invalid or unenforceable provision.&#160;&#160;Any deviation by either Party from the terms and provisions of this Agreement in order to comply with Applicable Laws shall not be considered a
breach of this Agreement.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.7.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Headings and Captions. </font>&#160;&#160;Headings and captions used herein are for convenience only and shall not be deemed part of the Agreement.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.8.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Waiver of Compliance.</font>&#160;&#160;No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees, except by an instrument in writing expressly
waiving such provision and signed by a duly authorized officer of the waiving Party, which waiver shall be effective only with respect to the specific obligation and instance described therein. A failure to exercise or a delay in exercising a right
or remedy provided by this Agreement or by Applicable Law shall not constitute a wavier of that right or remedy.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.9.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Notices.</font>&#160;&#160;All notices and other communications in connection with this Agreement, other than firm purchase
orders which are governed by <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section&#160;3.2</font>, shall be in writing and shall be sent to the respective Parties at the following addresses, or to such other addresses as may be
designated by the Parties in writing from time to time in accordance with this Section, by registered or certified mail, postage prepaid, or by express courier service or service fee prepaid:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">To Medafor:</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Medafor, Inc.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2700 Freeway Blvd., Suite 800</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Minneapolis, MN&#160;&#160;55430</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Attn:&#160;&#160;Gary J. Shope, CEO</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">To CryoLife:</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CryoLife , Inc.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">1655 Roberts Blvd NW</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Kennesaw, GA&#160;&#160;30144</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Attn:&#160;&#160;General Counsel</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 29 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">All notices shall be deemed given and received (i)&#160;if delivered by hand, immediately, (ii)&#160;if sent by mail, three&#160;(3) Business Days after
posting, or (iii)&#160;if delivered by express courier service, the next Business Day in the jurisdiction of the recipient.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.10.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Counterparts.</font>&#160;&#160;This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an
original and all of which together shall be deemed to be one and the same instrument.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.11.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Further Actions.</font>&#160;&#160;Each Party agrees, subsequent to the execution and delivery of this Agreement and without
any additional consideration, to execute, acknowledge and deliver such further documents and instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.12.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Jointly Prepared.</font>&#160;&#160;This Agreement has been prepared jointly and shall not be strictly construed against either
Party.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.13.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Third Party Rights.</font>&#160;&#160;Except as otherwise expressly provided herein, this Agreement is not intended to confer
any benefits upon, or create any rights in favor of any Person other than the Parties.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">11.14.</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Expenses.</font>&#160;&#160;Except as otherwise expressly provided in this Agreement, each Party shall be responsible for its
own expenses incurred in connection with this Agreement and the transactions contemplated hereby.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK;</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">SIGNATURES APPEAR ON FOLLOWING PAGE]</font></div><br> <div style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div > <div style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> <div style="PAGE-BREAK-AFTER: always"> <div
style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 30 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div >
<div style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> </div><br> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its
respective duly authorized representative as of the Effective Date.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> <div>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td colspan="2" valign="top" width="41%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">MEDAFOR, INC.</font></div> </td>

<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="37%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div> </td>
<td valign="top" width="4%" style="BORDER-BOTTOM: #ffffff solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">By:
</font></div> </td>
<td align="left" nowrap valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;/s/ Gary J. Shope</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Name:&#160;</font></td>
<td align="left" nowrap valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Gary J. Shope</font></td>
<td valign="top" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Title:&#160;</font></td>
<td valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Chief Executive Officer</font></td>
<td valign="top" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="37%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr> </table> </div> <div>&#160;</div> <div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"> <div>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td colspan="2" valign="top" width="41%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CRYOLIFE INC.,</font></div> </div> </td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="37%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div> </td>
<td valign="top" width="4%" style="BORDER-BOTTOM: #ffffff solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">By:
</font></div> </td>
<td align="left" nowrap valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;/s/ David Ashley Lee</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Name:&#160;</font></td>
<td align="left" nowrap valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">David Ashley Lee</font></td>
<td valign="top" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Title:&#160;</font></td>
<td valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Executive Vice President, Chief Operating Officer and Chief Financial Officer</font></td>
<td valign="top" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="37%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr> </table> </div> <div>&#160;</div> </div> </div><br></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div><br> <div style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 31 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"><font
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> <div style="WIDTH: 100%" align="left"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">EXECUTION VERSION</font></div> </div> </div> </div> <div>&#160;</div> <div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT
WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">EXHIBIT A</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; TEXT-DECORATION: underline">Specifications</font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Product Packaging/Labeling:</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">&#216;</font><font style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The Products will be individually contained within moisture impermeable foil pouches that are compatible with gamma irradiation sterilization.&#160;&#160;Foil product pouches
along with product IFU(s) will be inserted into pre-printed dispensing boxes.&#160;&#160;Some product dispensing box may be individually shrink-wrapped prior to shipment for added environmental and shipping protection. All Products shall be boxed in
containers as agreed to as of the date hereof by the Parties.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline;" face="Wingdings">&#216;</font> Each Product foil pouch label, whether pre-printed onto or adhered to the pouch, will include and contain any and
all applicable elements agreed to by the Parties as of the date hereof (including and required by Regulatory Authorities).</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline;" face="Wingdings">&#216;</font> All materials,
including foil pouches, ink, labels, and dispensing box, will be smudge resistant and compatible with manufacturing, sterilization and shipping activities.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Product Sterilization and Stability:</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline;" face="Wingdings">&#216;</font> The Products and associated packaging/labeling materials will be subjected to the Method VD<font
style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: sub">max</font> of radiation sterilization as described in AAMI TIR27, but will meet at least a minimum sterility assurance level of 10<font
style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">-6</font>.&#160;&#160;The Products and all materials used in the Products shall be shipped and stored at room temperature</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">In addition to the
foregoing:</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All Products shall meet the attached &#8220;<font style="FONT-WEIGHT: bold">[***]
</font>Specifications&#8221; attached hereto; and</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Bellows Applicator specifications shall be composed of two components as set forth on the attached
documents labeled &#8220;LAMEPLAST CAP/TIP&#8221; and &#8220;Lamepast 9gm Bellows&#8221;.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div><br> <div style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
> <div style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> <div style="PAGE-BREAK-AFTER: always"> <div
style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div >
<div style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> </div> <div>&#160;</div> <div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT
WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> </div> <div>&#160;</div> <div>&#160;</div> <div>&#160;</div> <div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="81%">
<tr>
<td valign="middle" width="34%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<img src="g30330image6.jpg" ></font></td>
<td valign="top" width="31%"> <div align="center">
<img src="g30330image1.jpg" ></div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center"><font
style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman'">[DIAGRAM OF THE </font></div> <div align="center"><font style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman'">HEMOSTASE MPH MATERIAL]</font></div> <div align="center">&#160;</div> <div
align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">
<img src="g30330image3.jpg" ></div> </td> </tr>
<tr>
<td width="34%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td width="31%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td> </tr>
<tr>
<td align="right" valign="bottom" width="34%"> <div align="right">
<img src="g30330image5.jpg" ></div> </td>
<td width="31%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;
<img src="g30330image4.jpg" ></font></td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"> </div> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS
OF THIS AGREEMENT WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div>
<div>&#160;</div> <div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td width="55%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td align="right" width="35%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<img src="g30330image7.jpg" ></font></td> </tr>
<tr>
<td valign="top" width="55%"> <div><font
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div> <div>&#160;</div> <div><font
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;OD MAX
[***]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160; ID MIN [***]</font></div> <div><font
size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ID MAX
[***]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; OD MIN [***]</font></div> <div>&#160;</div> <div>&#160;</div> <div>&#160;</div> <div><font
size="2">[***]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOTAL SLOPE
[***]</font></div> <div>&#160;</div> <div style="TEXT-ALIGN: center"><font size="2" style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman'">[DIAGRAM OF THE LAMEPLAST CAP]</font></div> <div>&#160;</div> <div>&#160;</div> <div>&#160;</div>
<div>&#160;</div> <div style="TEXT-ALIGN: center"><font size="2">[***]</font></div> </td>
<td width="35%"> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center"><font
style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman'">[DIAGRAM OF <font size="+0" style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman'">THE LAMEPLAST CAP</font>]</font></div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div
align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> </td> </tr>
<tr>
<td align="right" valign="bottom" width="55%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<img src="g30330image10.jpg" >&#160;</font></td>
<td width="35%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;
<img src="g30330image9.jpg" ></font></td> </tr> </table> </div> <div>&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"> </div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> </div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"> </div> <div>&#160;</div> <div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td align="right" width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<img src="g30330image12.jpg" ></font></td> </tr>
<tr>
<td width="50%"> <div style="TEXT-ALIGN: center">&#160;</div> <div style="TEXT-ALIGN: center">&#160;</div> <div style="TEXT-ALIGN: center">&#160;</div> <div style="TEXT-ALIGN: center">&#160;</div> <div style="TEXT-ALIGN: center">&#160;</div> <div
style="TEXT-ALIGN: center">&#160;</div> <div style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***]</font></div> <div style="TEXT-ALIGN: center"><font size="2">[***]</font></div> <div
style="TEXT-ALIGN: center"><font size="2">[***]</font></div> <div style="TEXT-ALIGN: center">&#160;</div> <div style="TEXT-ALIGN: center">&#160;</div> <div style="TEXT-ALIGN: center">&#160;</div> <div style="TEXT-ALIGN: center"><font
size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [***]</font></div> <div style="TEXT-ALIGN: center">&#160;</div>
<div style="TEXT-ALIGN: center"> <div align="center"><font style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman'">[DIAGRAM OF THE LAMEPLAST 9 GM BELLOWS]</font></div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div
align="center">&#160;</div> <div align="center">[***]</div> <div align="center">&#160;</div> <div align="center">&#160;</div> <div align="center">&#160;</div> </div> <div style="TEXT-ALIGN: center">&#160;</div> <div>&#160;</div> </td>
<td width="50%"> <div align="center"><font style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman'">[DIAGRAM OF THE </font></div> <div align="center"><font style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman'">LAMEPLAST 9 GM BELLOWS]</font></div>
</td> </tr>
<tr>
<td align="right" valign="bottom" width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<img src="g30330image15.jpg" ></font></td>
<td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;
<img src="g30330image14.jpg" ></font></td> </tr> </table> </div> <div>&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"> </div> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="center"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT
WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">EXHIBIT B</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Initial Exclusions from the Territory</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; TEXT-DECORATION: underline">Excluded United States Hospitals</font></font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The following United States hospitals shall not be deemed part of the Territory until the earlier of the date set forth across from such hospital, or the
termination of the distributor by Medafor that is distributing to such hospital:</font></div> <div><br>&#160;</div> <div> <div align="left">
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top" width="14%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Distributor</font></font></div> </td>
<td valign="top" width="49%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Name of Hospital</font></font></div> </td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">CryoLife Start Date</font></font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">October 1, 2008</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
</table> </div> <div>&#160;</div> <div>&#160;</div> <div>&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div
style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 2 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div >
<div style="WIDTH: 100%" align="right"> </div> </div> </div> <div>&#160;</div> <div>&#160;</div> <div>&#160;</div> <div align="left">
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="49%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">January 1, 2009</font></div> </td> </tr>
<tr>
<td valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="18%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td> </tr>
<tr>
<td valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="18%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td> </tr>
<tr>
<td valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="18%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div><br>&#160;</div> <div
style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 3 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT
WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (&#8220;[***]&#8221;). THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> </div><br> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit C</font></font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">United States</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Transfer Prices:</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div align="left">
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top" width="33%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Year</font></font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0px solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Transfer Price 3-gram</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Transfer Price for 5-gram</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 1 (May 1, 2008 &#8211; June 30, 2009)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0px solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 2 (July 1, 2009 &#8211; June 30, 2010)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0px solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 3 (July 1, 2010 &#8211; June 30, 2011)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0px solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 0.5pt solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 4 (July 1, 2011 &#8211; June 30, 2012)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0px solid; BORDER-BOTTOM: black 0.5pt solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 0.5pt solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Direct Sales Outside of United States (U.K. and Germany)
</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Transfer Prices:</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div align="left">
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top" width="33%" style="BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Year</font></font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Transfer Price 3-gram</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Transfer Price for 5-gram</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 1 (May 1, 2008 &#8211; June 30, 2009)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 2 (July 1, 2009 &#8211; June 30, 2010)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 3 (July 1, 2010 &#8211; June 30, 2011)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 0.5pt solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 4 (July 1, 2011 &#8211; June 30, 2012)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 0.5pt solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 0.5pt solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Third Party Sales Outside of United States (Canada, EU
(excluding U.K. and Germany) and ROW)</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Transfer Prices:</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div align="left">
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top" width="33%" style="BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Year</font></font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Transfer Price 3-gram</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline">Transfer Price for 5-gram</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 1 (May 1, 2008 &#8211; June 30, 2009)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 2 (July 1, 2009 &#8211; June 30, 2010)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 3 (July 1, 2010 &#8211; June 30, 2011)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="33%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 0.5pt solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Year 4 (July 1, 2011 &#8211; June 30, 2012)</font></div> </td>
<td valign="top" width="20%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 0.5pt solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td>
<td valign="top" width="19%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-BOTTOM: black 0.5pt solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">$<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font></font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">All transfer prices in Years 5 and 6 shall be adjusted as
follows:</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The price shall increase, if at all based on the lesser of the following, (a) <font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font>% or (b) the increase in Federal
Bureau of Labor Statistics, Consumer Price Index (CPI) for all Urban Consumers (or its successor if one is substituted in the future) from the month of April of the year prior to the current year in which the adjustment must be made until the month
of March of the current year</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div><br> <div style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 4 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"><font
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> </div><br> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; TEXT-DECORATION: underline">SCHEDULE 2.1</font></font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[***] &#8211; CONFIDENTIAL PORTIONS OF THIS AGREEMENT
WHICH HAVE BEEN REDACTED ARE MARKED <br> WITH BRACKETS (&#147;[***]&#148;). THE OMITTED MATERIAL HAS BEEN FILED <br> SEPARATELY WITH UNITED STATES SECURITIES AND EXCHANGE COMMISSION.</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Current Distribution Agreements</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(those United States distributors noted with a * will continue after the Effective Date in accordance with <font
style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.1</font>)</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">*[[***] &#8211; Pennsylvania]</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">*[[***] &#8211; Florida]</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">*[[***] &#8211; Ohio]</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br> <div style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 5 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"><font
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> </div><br> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Schedule 2.2</font></font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#8220;Baseball&#8221; Arbitration</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">In the event that
one Party delivers the other Party an Annual Dispute Notice in accordance with <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.2</font> the parties hereby agree that the dispute over the amount of the reduction for the Annual
Minimum reduction shall be settled by &#8220;Baseball&#8221; arbitration as follows:</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr valign="top">
<td align="right" style="WIDTH: 72pt"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(a)&#160;&#160;</font></div> </td>
<td> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">There shall be a single arbitrator selected in accordance with the then current
rules of the American Arbitration Association (such arbitrator, the &#8220;Arbitrator&#8221;)</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr valign="top">
<td align="right" style="WIDTH: 72pt"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(b)&#160;&#160;</font></div> </td>
<td> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Arbitration shall be held in Chicago, Illinois</font></div> </td> </tr> </table>
</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr valign="top">
<td align="right" style="WIDTH: 72pt"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(c)&#160;&#160;</font></div> </td>
<td> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Once the Arbitrator is selected, the Arbitrator shall direct the Parties to attend
a hearing, and this hearing shall take place within twenty (20) calendar days of the appointment of the Arbitrator.</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr valign="top">
<td align="right" style="WIDTH: 72pt"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(d)&#160;&#160;</font></div> </td>
<td> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Each Party shall have a maximum of one (1) hour in which to make oral submissions
to the Arbitrator at the hearing and a maximum of three (3) 8 inch by 11 inch pages, single sided in which to make written submissions to the Arbitrator.</font></div> </td> </tr> </table> </div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr valign="top">
<td align="right" style="WIDTH: 72pt"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(e)&#160;&#160;</font></div> </td>
<td> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Each Party shall submit to the arbitrator and exchange with each other in advance
of the hearing, their last, best offer stating the name of the Party submitting such offer and the sum that constitutes their reduced Annual Minimum number.&#160;&#160;Such offer shall be delivered a minimum of forty-eight (48) hours before such
hearing.</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr valign="top">
<td align="right" style="WIDTH: 72pt"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(f)&#160;&#160;</font></div> </td>
<td> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The Arbitrator shall have five (5) Business Days from the date of the hearing to
make a final and binding award, and the Arbitrator shall, in the making of such award be limited to awarding only one or the other of the two figures submitted in accordance with (e) above.</font></div> </td> </tr> </table> </div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr valign="top">
<td align="right" style="WIDTH: 72pt"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(g)&#160;&#160;</font></div> </td>
<td> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Each Party shall bear its own costs and expenses for this &#8220;Baseball&#8221;
arbitration and the costs of this &#8220;Baseball&#8221; arbitration shall be allocated between the parties.&#160;&#160;No attorneys&#8217; fees may be awarded.</font></div> </td> </tr> </table> </div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br> <div
style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">- 6 -</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> </div><br></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>dex102.htm
<DESCRIPTION>CRYOLIFE, INC. 2008 NON-EMPLOYEE DIRECTORS OMNIBUS STOCK PLAN
<TEXT>
<HTML><HEAD>
<TITLE>Cryolife, Inc. 2008 Non-Employee Directors Omnibus Stock Plan</TITLE>
</HEAD>



 <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
  <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold; FONT-FAMILY: 'Times New Roman'">Exhibit 10.2</font></div><br> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><a name="a017">CRYOLIFE, INC.</A></font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2008</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> NON-EMPLOYEE DIRECTORS </font><font
style="DISPLAY: inline; FONT-WEIGHT: bold">OMNIBUS</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">STOCK </font><font
style="DISPLAY: inline; FONT-WEIGHT: bold">PLAN</font></font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ARTICLE&#160;1</font></font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">General</font>&#160;</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>This 2008 Non-Employee Directors Omnibus Stock Plan (the &#8220;Plan&#8221;) is established to attract, retain and compensate for service
as members of the Board of Directors highly qualified individuals who are not current employees of CryoLife, Inc (the &#8220;Corporation&#8221;) and to enable them to increase their ownership in the Corporation&#8217;s common stock. &#160;The Plan
provides for the grant of Stock Options, Restricted Stock and Restricted Stock Units (all as defined herein, and collectively, &#8220;Awards&#8221;).&#160; Awards may be made pursuant to written agreements at the discretion of the
Board.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;1.1&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Eligibility.</font> All members of the
Corporation&#8217;s Board of Directors who are not current employees of the Corporation or any of its subsidiaries (&#8220;Non-Employee Directors&#8221;) are eligible to participate in this Plan.</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section&#160;1.2&#160;&#160;&#160;&#160;&#160;<font
style="DISPLAY: inline; FONT-STYLE: italic">Shares Available.</font></font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>&#160;(a)&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Number of Shares Available.</font> There are reserved for issuance under
this Plan 300,000&#160;shares of the Corporation&#8217;s Common Stock, $0.01&#160;par value (&#8220;Common Stock&#8221;), which may be authorized but unissued shares, treasury shares, or shares purchased on the open market or privately. For purposes
of applying the limitation in the preceding sentence and subject to the adjustment and replenishment provisions included in Sections&#160;1.2(b) and (c)&#160;below:</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 72pt"></font>(i)&#160;&#160;the maximum number of
shares of Common Stock that may be issued pursuant to Stock Options shall be 300,000; and</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii)&#160;&#160;the maximum number of shares of
Common Stock that may be issued pursuant to Restricted Stock Awards and Restricted Stock Unit Awards shall be 300,000.&#160;</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Recapitalization
Adjustment.</font> In the event of a reorganization, recapitalization, stock split, stock dividend, combination of shares, merger, consolidation, rights offering, or any other change in the corporate structure or shares of the Corporation,
adjustments in the number and kind of shares authorized by this Plan, in the number and kind of shares that may or are required to be issued hereunder pursuant to any type of award hereunder (including without limitation the maximum numbers set
forth in Section&#160;1.2(a) above), in the number and kind of shares covered by outstanding Stock Options under this Plan and in the Stock Option price thereof, and in the number and kind of shares subject to outstanding Restricted Stock Awards
and/or Restricted Stock Unit Awards shall automatically be made if, and in the same manner as, similar adjustments are made to awards issued under the Corporation&#8217;s incentive plans for management of the Corporation then in effect.</font></div>
</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Replenishment.
</font> To the extent any shares of Common Stock covered by a Stock Option,&#160;&#160;Restricted Stock Award or Restricted Stock Unit Award are forfeited by or are not delivered to a Non-Employee Director or his or her beneficiary because the Stock
Option,&#160;Restricted Stock or Restricted Stock Unit is forfeited or canceled, or the shares of Common Stock are not delivered because they are used to satisfy any applicable tax withholding obligation, such shares shall not be deemed to have been
delivered for purposes of determining the maximum number of shares of Common Stock available for delivery with respect to the respective type of award and with respect to all grants under the Plan.</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ARTICLE&#160;2</font></font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Stock </font><font
style="DISPLAY: inline; FONT-WEIGHT: bold">Option Awards</font></font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section&#160;2.1&#160;&#160;&#160;&#160;&#160;<font
style="DISPLAY: inline; FONT-STYLE: italic">Stock</font>&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Options.</font> Awards may be made under this Plan of options to purchase Common Stock (&#8220;Stock Options&#8221;). No Stock Options
granted pursuant to this Plan may be &#8220;Incentive Stock Options&#8221; under Section&#160;422 of the Internal Revenue Code of 1986, as amended. The grant of a Stock Option entitles the recipient to purchase shares of Common Stock at an exercise
price established by the Board of Directors.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> </div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section&#160;2.2&#160;&#160;&#160;&#160;&#160;<font
style="DISPLAY: inline; FONT-STYLE: italic">Exercise Price.</font> The exercise price of each Stock Option granted under this Article&#160;2 shall be established by the Board of Directors or shall be determined by a method established by the Board
of Directors at the time the Stock Option is granted. The exercise price shall not be less than 100% of the Fair Market Value of a share of Common Stock on the date of grant of the Stock Option. For purposes of determining the &#8220;Fair Market
Value&#8221; of a share of Common Stock as of any date, the &#8220;Fair Market Value&#8221; as of that date shall be the last closing price of the Common Stock on the first business day preceding that date on the New York Stock Exchange or, if the
Common Stock is not listed on the New York Stock Exchange, on any other exchange or quotation system on which the Common Stock is listed or quoted. No Stock Option may be &#8220;repriced,&#8221; as such term is used in rules established by the New
York Stock Exchange.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;2.3&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Exercise.</font> Subject to the provisions of this
Plan, a Stock Option shall be exercisable in accordance with such terms and conditions and during such periods as may be established by the Board of Directors; provided, however, that no Stock Option may be exercised more than seven years after its
grant date and no Stock Option granted hereunder may vest in excess of 1/3 of the number of shares subject to the Stock Option per year for the first three years after the grant date.</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="MARGIN-LEFT: 36pt"></font>Section&#160;2.4&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Payment of Option Exercise Price.</font> The payment of the exercise price of a Stock Option granted under this
Article&#160;2 shall be subject to the following:</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;Subject to the
following provisions of this subsection&#160;2.4, the full exercise price for shares of Common Stock purchased upon the exercise of any Stock Option shall be paid at the time of such exercise (except that, in the case of an exercise arrangement
approved by the Board of Directors and described in paragraph&#160;2.4(c), payment may be made as soon as practicable after the exercise).</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 72pt"></font>(b)&#160;&#160;&#160;The exercise price shall be payable in cash or by tendering shares of Common Stock acceptable to the Board of
Directors and valued at Fair Market Value as of the day of exercise, or in any combination thereof, as determined by the Board of Directors.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 72pt"></font>(c)&#160;&#160;&#160;Subject to compliance with applicable law, the Board of Directors may permit a Stock Option recipient to elect to
pay the exercise price upon the exercise of a Stock Option by irrevocably authorizing a third party to sell shares of Common Stock (or a sufficient portion of the shares) acquired upon exercise of the Stock Option and remit to the Corporation a
sufficient portion of the sale proceeds to pay the entire exercise price resulting from such exercise.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;2.5&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Settlement of Award.</font> Shares of
Common Stock delivered pursuant to the exercise of a Stock Option shall be subject to such conditions, restrictions and contingencies as the Board of Directors may establish in any applicable Option grant agreement. The Board of Directors, in its
discretion, may impose such conditions, restrictions and contingencies with respect to shares of Common Stock acquired pursuant to the exercise of a Stock Option as the Board of Directors determines to be desirable.</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="MARGIN-LEFT: 36pt"></font>Section&#160;2.6&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Nontransferability </font><font style="DISPLAY: inline; FONT-STYLE: italic">of Stock Options</font><font
style="DISPLAY: inline; FONT-STYLE: italic">.</font>&#160;Except as set forth below, no Stock Option granted under this Plan is transferable other than by will or the laws of descent and distribution. Except as set forth below, during the
grantee&#8217;s lifetime, a Stock Option may be exercised only by the grantee or the grantee&#8217;s guardian or legal representative.&#160;&#160;Notwithstanding the foregoing, however, the grantee may transfer the Stock Option for no consideration
to or for the benefit of the grantee&#8217;s Immediate Family, defined below (including, without limitation, to a trust for the benefit of the grantee&#8217;s Immediate Family or to a partnership or limited liability company for one or more members
of the grantee&#8217;s Immediate Family or to an IRA for the benefit of one or more members of his Immediate Family), subject to such limits as the Board may establish, and the transferee shall remain subject to all the terms and conditions
applicable to such Stock Option prior to such transfer. The foregoing right to transfer the Stock Option shall apply to the right to consent to amendments to the grant agreement and shall also apply to the right to transfer ancillary rights
associated with the Stock Option. The term &#8220;Immediate Family&#8221; shall mean the grantee&#8217;s spouse, parents, children, stepchildren, adoptive relationships, sisters, brothers and grandchildren (and, for this purpose, shall also include
the grantee).</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">2</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div>
</div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ARTICLE&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">3</font></font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Restricted Stock and Restricted Stock Units</font></font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="MARGIN-LEFT: 36pt"></font>Section&#160;3.1&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Grant of Restricted Stock or Restricted Stock Units.</font> Subject to the terms and provisions of the Plan, the Board
of Directors, at any time and from time to time, may grant shares of Restricted Stock and/or Restricted Stock Units, as such terms are defined below, to participants in such amounts and upon such terms and conditions as the Board shall determine;
provided, however, that no grant of Restricted Stock or of any Restricted Stock Unit shall in any event vest sooner than one year following the date of grant. &#8220;Restricted Stock&#8221; means an award of Common Stock subject to forfeiture based
on the passage of time, the achievement of performance goals, and/or upon the occurrence of other events as determined by the Board in its discretion, granted subject to the terms of this Plan. &#8220;Restricted Stock Unit&#8221; means an award
denominated in units whose value is derived from Common Stock and which is subject to forfeiture based on the passage of time, the achievement of performance goals, and/or upon the occurrence of other events as determined by the Board in its
discretion, granted subject to the terms of this Plan.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;3.2&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font><font
style="DISPLAY: inline; FONT-STYLE: italic">Other Restrictions.</font></font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;The Board shall impose, in an Award Agreement at the time of
grant or any time thereafter, such other conditions and/or restrictions on any shares of Restricted Stock or Restricted Stock Units granted pursuant to this Plan as it may deem advisable including, without limitation, a requirement that participants
pay a stipulated purchase price for each share of Restricted Stock or each Restricted Stock Unit, that specific performance goals be obtained, the imposition of time-based restrictions on vesting following the attainment of the performance goals,
time-based restrictions, restrictions under applicable laws or under the requirements of any stock exchange or market upon which such shares are listed or traded, or holding requirements or sale restrictions placed on the shares by the Corporation
upon vesting of such Restricted Stock or Restricted Stock Units. Except as otherwise provided in this Article&#160;3 or the applicable award agreement, shares of Restricted Stock shall become freely transferable by the participant, subject to
compliance with applicable laws, after all conditions and restrictions applicable to such shares have been satisfied or lapse.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160; Common Stock subject to a Restricted Stock Award may not be sold,
assigned, transferred, pledged or otherwise encumbered prior to the date it is vested, and except as otherwise specified by the Board, Restricted Stock Units may not be transferred.</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>(c)&#160; Each certificate, if any,
issued in respect of Common Stock pursuant to a Restricted Stock Award shall be registered in the name of the Non-Employee Director and deposited with the Corporation until such time as all restrictions have lapsed.</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="MARGIN-LEFT: 36pt"></font>Section&#160;3.3&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Certificate Legend.</font>&#160;If certificated stock is issued, in addition to any other legends placed on the
certificates,&#160;each certificate representing shares of Restricted Stock granted pursuant to the Plan may bear a legend such as the following:</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>&#8220;The sale or other transfer of the shares of stock represented by this certificate, whether voluntary, involuntary, or by operation
of law, is subject to certain restrictions on transfer as set forth in the CryoLife, Inc. 2008 Non-Employee Directors Omnibus Stock Plan, and in the associated Award Agreement. A copy of the Plan and such Award Agreement may be obtained from
CryoLife.&#8221;</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;3.4 &#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Voting Rights.</font>&#160;Except as otherwise
determined by the Board or required by law, participants in whose names shares of Restricted Stock granted hereunder shall be issued, shall be granted the right to exercise full voting rights with respect to those shares during the period of
restriction. A participant shall have no voting rights with respect to any Restricted Stock Units granted hereunder.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">3</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;3.5&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Dividends and Other Distributions.</font>
During the period of restriction, participants holding shares of Restricted Stock or Restricted Stock Units granted hereunder may, if the Board so determines or as otherwise required by law, be credited with dividends paid with respect to the
underlying shares or dividend equivalents while they are so held in a manner determined by the Board in its sole discretion. The Board may apply any restrictions to the dividends or dividend equivalents that the Board deems appropriate. The Board,
in its sole discretion, may determine the form of payment of dividends or dividend equivalents, including cash, unrestricted Common Stock, Restricted Stock, or Restricted Stock Units.</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="MARGIN-LEFT: 36pt"></font>Section&#160;3.6&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Payment in Consideration of Restricted Stock Units.</font> When and if Restricted Stock Units become payable, a participant
having received the grant of such units shall be entitled to receive payment from the Corporation in cash, shares of Common Stock of equivalent value (based on the Fair Market Value thereof), in some combination thereof, or in any other form
determined by the Board in its sole discretion. The Board&#8217;s determination regarding the form of payout shall be set forth or reserved for later determination in the Award Agreement pertaining to the grant of the Restricted Stock
Unit.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ARTICLE&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">4</font></font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Miscellaneous</font></font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;4.1&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Cessation of Service.</font> Except as
set forth below and unless otherwise determined by the Board, upon cessation of service as a Non-Employee Director (for reasons other than death), all Stock Options, whether or not exercisable at the date of cessation of service, Restricted Stock
and Restricted Stock Units shall be forfeited by the grantee; provided, however, that, unless otherwise determined by the Board, if any Non-Employee Director serves out his/her term but does not stand for re-election at the end thereof,or otherwise
retires in good standing, as determined by the Board in its sole discretion, such grantee&#8217;s Options, Restricted Stock and Restricted Stock Units shall remain in effect, vest, become exercisable and expire as if the grantee had remained a
Non-Employee Director of the Corporation.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;4.2&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Death.</font> Upon the death of a
Non-Employee Director, all unvested Stock Options held by him or her will vest immediately and may be exercised by his or her estate, or by the person to whom such right devolves from the Non-Employee Director by reason of his or her death, at any
time within three years after the date of the Non-Employee Director&#8217;s death, but in no event later than the original termination date of the Stock Option. In no event may a Stock Option be exercised after three years following the
holder&#8217;s death. In addition, all Restricted Stock and Restricted Stock Units shall vest upon the Non-Employee Director&#8217;s death.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;4.3&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Administration.</font> This Plan shall be
administered by the Board of Directors of the Corporation. This Plan may be terminated by the Board of Directors as they deem advisable. The Board may delegate its authority hereunder to the Non-Employee Directors, or to any two or more thereof.
</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 17.65pt"></font>Section&#160;4.4&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Amendments.</font>&#160; This Plan may
be amended by the Board of Directors at any time, except that the following actions may not be taken without stockholder approval:</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(i)&#160;any increase in the number of shares that may be issued under this Plan (except by certain adjustments provided for under this Plan);</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="left">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(ii)&#160; any change in the requirements of Section&#160;2.2 regarding the exercise price of Stock Options;&#160;or</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="left">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(iii)&#160;any repricing or cancellation and regrant of any Stock Option or, if applicable, other Award at a lower exercise, base or purchase price, whether in the form of an
amendment, cancellation or replacement grant, or a cash-out of underwater options or any action that provides for Awards that contain a so-called &#8220;reload&#8221; feature under which additional Stock Options or other Awards are granted
automatically to the grantee upon exercise of the original Stock Option or other Award;</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">4</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">(iv)&#160;any other amendment to this Plan that would require approval of the Corporation&#8217;s stockholders under applicable law, regulation or rule or stock exchange
listing requirement.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">No amendment may revoke or alter in a manner unfavorable to the grantees any Stock Options,&#160;Restricted Stock or Restricted Stock Units then outstanding.</font></div>
</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="MARGIN-LEFT: 36pt"></font>Section&#160;4.5&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Term.</font>&#160; No Stock Option, Restricted Stock or Restricted Stock Unit may be issued under this Plan after May 1,
2013, but Stock Options granted prior to that date shall continue to become exercisable and may be exercised according to their terms.&#160;Restricted Stock and Restricted Stock Units granted prior to May 1, 2013 shall continue to vest in accordance
with their terms and dividend equivalents awarded prior to May 1, 2013 may be paid in accordance with the terms thereof.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section 4.6&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Uncertificated Stock.</font>&#160;Nothing contained in the Plan shall
prohibit the issuance of Stock on an uncertificated basis, to the extent allowed by the Corporation&#8217;s Certificate of Incorporation and Bylaws, by applicable law and by the applicable rules of any stock exchange.</font></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="MARGIN-LEFT: 36pt"></font>Section&#160;4.7&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">No Other Rights</font><font style="DISPLAY: inline; FONT-STYLE: italic">.</font>&#160;&#160;Except as provided in this
Plan, no Non-Employee Director shall have any claim or right to be granted or issued a Stock Option,&#160;Restricted Stock Award or Restricted Stock Unit Award under this Plan. Neither this Plan nor any actions hereunder shall be construed as giving
any Director any right to be retained in the service of the Corporation.</font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> </div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="MARGIN-LEFT: 36pt"></font>Section&#160;4.8&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Prior Plan</font><font
style="DISPLAY: inline; FONT-STYLE: italic">.</font>&#160;&#160;This Plan supersedes&#160;the Corporation&#8217;s 2004 Non-Employee Directors Stock Option Plan (the &#8220;2004 Directors Plan&#8221;), which was terminated on May 2, 2007. Options
granted under the 2004 Directors Plan shall continue to be subject to the provisions thereof&#160;and shall continue to become exercisable and may be exercised according to their terms.</font></div> </div><br> <div
style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> <div
style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">5</font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black"
noshade size="2"> </div> </div> <div > <div style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> </div><br></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>dex103.htm
<DESCRIPTION>FORM OF NON-EMPLOYEE DIRECTOR STOCK GRANT AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Form of Non-Employee Director Stock Grant Agreement</TITLE>
</HEAD>



 <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
  <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold; FONT-FAMILY: 'Times New Roman'">Exhibit 10.3</font></div><br> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;Your Name:</font>&#160;&#160;___________________</font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Total No. of
Shares:</font>&#160;&#160;____________</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; TEXT-DECORATION: underline">CRYOLIFE RESTRICTED STOCK AWARD AGREEMENT</font></font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold">CRYOLIFE, INC.</font> (&#8220;CryoLife&#8221;) is pleased to grant you the restricted stock award described below (&#8220;Stock Award&#8221;).&#160;&#160;This grant is made subject to the further terms and
conditions set forth in this Agreement and the terms of the CryoLife, Inc. 2008 Non-Employee Directors Omnibus Stock Plan (the &#8220;Plan&#8221;).</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td align="left" valign="top" width="31%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Grant Date:
</font></div> </td>
<td align="left" valign="top" width="69%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline">__________</font></font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="31%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Total Number
of Shares of Stock Award:</font></div> </td>
<td align="left" valign="top" width="69%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">__________
</font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="31%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Vesting
Date:</font></div> </td>
<td align="left" valign="top" width="69%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline">__________</font></font></div> </td> </tr>
<tr>
<td valign="top" width="31%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="69%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The following documents accompany this Award Agreement:</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; TEXT-DECORATION: underline">Additional Terms and Conditions of Your Restricted Stock Award</font> describes transferability of your award, what happens if you cease to be a member of the CryoLife Board of Directors (the
&#8220;Board of Directors&#8221; or &#8220;Board&#8221;) before all or a portion of your Stock Award vests, where to send notices and other matters.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; TEXT-DECORATION: underline">The Plan</font>
contains the detailed terms that govern your Stock Award.&#160;&#160;If anything in this Agreement or the other attachments is inconsistent with the Plan, the terms of the Plan, as amended from time to time, will control.</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; TEXT-DECORATION: underline">The Plan Prospectus Document</font> covering the Stock Award contains important information, including federal income tax consequences.</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; TEXT-DECORATION: underline">Most Recent Annual Report of CryoLife</font> (not attached if you previously received the Most Recent Annual Report).</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Please sign below to show that you accept this Stock
Award after review of the above documents.&#160;&#160;Keep a copy and return both originals to Suzanne K. Gabbert, CryoLife, Inc., 1655 Roberts Blvd., NW, Kennesaw, GA 30144.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td align="left" valign="top" width="35%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CRYOLIFE,
INC.</font></div> </td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td align="left" valign="top" width="35%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">GRANTEE:
</font></div> </td> </tr>
<tr>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td align="left" valign="top" width="35%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">[Name and Address]</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div> </td> </tr>
<tr>
<td align="left" valign="top" width="35%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">By:&#160;&#160;______________________________________________&#160;&#160;&#160;</font></div> </td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td align="left" valign="top" width="35%"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">______________________________________________</font></div> <div>&#160;</div> </td> </tr>
<tr>
<td align="left" valign="top" width="35%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Name:</font></div> </td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td align="left" valign="top" width="35%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Print Your Name:</font></div>
</td> </tr>
<tr>
<td align="left" valign="top" width="35%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Its:</font></div> </td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td align="left" valign="top" width="35%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Date:</font></div> </td> </tr>
<tr>
<td align="left" valign="top" width="35%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Date:</font></div> </td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td> </tr>
<tr>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> </div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div> <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; TEXT-DECORATION: underline">ADDITIONAL TERMS AND CONDITIONS OF YOUR</font></font></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; TEXT-DECORATION: underline">RESTRICTED STOCK AWARD</font></font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">EFFECT OF TERMINATION OF SERVICE</font><font
style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;You must be a member of the CryoLife Board of Directors on the applicable vesting date to be entitled to the vesting of your Stock Award on such date.&#160;&#160;Notwithstanding the
foregoing, if you cease to be a member of the CryoLife Board of Directors as a result of your death or disability or because you have served out your full term but are not standing for re-election at the end thereof, your Stock Award shall
immediately become fully vested on the date you cease to be a member of the Board.&#160;&#160;If you cease to be a member of the CryoLife Board of Directors for any other reason, and your Stock Award has not vested as of the date of termination of
Board service, your Stock Award shall automatically be forfeited and cancelled as of the date of such termination of Board service.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">STOCK AWARD SHARE CERTIFICATES</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;Certificates representing the shares of Common Stock to be issued
pursuant to the Stock Award shall be issued in your name and shall be held by CryoLife until the Stock Award is vested or forfeited as provided herein.&#160;&#160;Following vesting of your Stock Award, upon your written request, CryoLife shall
promptly deliver to you a certificate or certificates representing the shares as to which the Stock Award has vested, free of the restrictions described in the following section.&#160;&#160;Your rights in your Stock Award are contingent upon your
executing and returning to the Company a form of stock power with respect to the shares subject to your Stock Award.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">RIGHTS WITH RESPECT TO STOCK AWARD PRIOR TO VESTING</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;You may not transfer your Stock Award or the shares
to be issued hereunder prior to vesting.&#160;&#160;Once this Stock Award vests, you may receive transferable certificates representing the vested portion.&#160;&#160;Prior to vesting, you are entitled to all other rights as a shareholder with
respect to the shares underlying the Stock Award, including the right to vote such shares and to receive dividends and other distributions, if any, payable with respect to such shares after the date of grant.</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font
style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">NOTICES</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;All notices delivered pursuant to this Agreement shall be in writing and shall be (i) delivered
by hand, (ii) mailed by United States certified mail, return receipt requested, postage prepaid, (iii) sent by an internationally recognized courier which maintains evidence of delivery and receipt, (iv) sent by fax to (770) 590-3754, or (v) sent by
email to <font style="DISPLAY: inline; TEXT-DECORATION: underline">gabbert.suzanne@cryolife.com</font>.&#160;&#160;All notices or other communications shall be directed to the following addresses (or to such other addresses as such parties may
designate by notice to the other parties):</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">To CryoLife:</font></div> </td>
<td valign="top" width="37%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">CryoLife, Inc.</font></div> </td> </tr>
<tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="18%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="37%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">1655 Roberts Blvd., NW</font></div> </td>
</tr>
<tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="18%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="37%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Kennesaw, GA 30144</font></div> </td>
</tr>
<tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="18%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></td>
<td valign="top" width="37%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">Attention:&#160;&#160;Secretary</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"> </div> </div> <div style="PAGE-BREAK-AFTER: always"> <div
style="WIDTH: 100%; TEXT-ALIGN: center"> </div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div> <div style="WIDTH: 100%" align="right"> </div> </div> </div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div>
<table cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font></td>
<td valign="top" width="18%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">To you:</font></div> </td>
<td valign="top" width="37%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">The address set forth in the Agreement
</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">MISCELLANEOUS</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;Failure by
you or CryoLife at any time or times to require performance by the other of any provisions in your Restricted Stock Award Agreement (&#8220;Agreement&#8221;) will not affect the right to enforce those provisions.&#160;&#160;Any waiver by you or
CryoLife of any condition or of any breach of any term or provision in this Agreement, whether by conduct or otherwise, in any one or more instances, shall apply only to that instance and will not be deemed to waive conditions or breaches in the
future.&#160;&#160;If any court of competent jurisdiction holds that any term or provision of this Agreement is invalid or unenforceable, the remaining terms and provisions will continue in full force and effect, and thus Agreement shall be deemed
to be amended automatically to exclude the offending provision.&#160;&#160;This Agreement may be executed in multiple copies and each executed copy shall be an original of this Agreement.&#160;&#160;This Agreement shall be subject to and governed by
the laws of the State of Georgia.&#160;&#160;No change or modification of this Agreement shall be valid unless it is in writing and signed by the party against which enforcement is sought, except where specifically provided to the contrary
herein.&#160;&#160;This Agreement shall be binding upon, and inure to the benefit of, the permitted successors, assigns, heirs, executors and legal representatives of the parties hereto.&#160;&#160;The headings of each section of this Agreement are
for convenience only.&#160;&#160;This Agreement, together with the Plan, contains the entire Agreement of the parties hereto, and no representation, inducement, promise, or agreement or other similar understanding between the parties not embodied
herein shall be of any force or effect, and no party will be liable or bound in any manner for any warranty, representation, or covenant except as specifically set forth herein or in the Plan.</font></div> <div
style="DISPLAY: block; TEXT-INDENT: 0pt"></div> <div style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <div > <div style="WIDTH: 100%" align="left"><font
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> <div style="PAGE-BREAK-AFTER: always"> <div style="WIDTH: 100%; TEXT-ALIGN: center"><font
style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> <div style="WIDTH: 100%; TEXT-ALIGN: center"> <hr style="COLOR: black" noshade size="2"> </div> </div> <div> <div style="WIDTH: 100%" align="right"><font
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: 'Times New Roman'">&#160; </font></div> </div> </div> </BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>dex311.htm
<DESCRIPTION>SECTION 302 CERTIFICATION OF CEO
<TEXT>
<HTML><HEAD>
<TITLE>Section 302 Certification of CEO</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 31.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B><U>CERTIFICATIONS </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">I, Steven G. Anderson, certify that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">1. I have reviewed this quarterly report on Form 10-Q of CryoLife, Inc.; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">4. The
registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">a) Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">c) Evaluated the effectiveness of the registrant&#146;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most
recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">b) Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrant&#146;s internal control over financial reporting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Date: July&nbsp;31, 2008 </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ STEVEN G. ANDERSON</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Chairman, President, and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">Chief Executive
Officer</FONT></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>dex312.htm
<DESCRIPTION>SECTION 302 CERTIFICATION OF CFO
<TEXT>
<HTML><HEAD>
<TITLE>Section 302 Certification of CFO</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 31.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">I, David Ashley Lee, certify that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">1. I have reviewed this quarterly report on Form 10-Q of CryoLife, Inc.; </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">3. Based on my
knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman"
SIZE="2">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an
annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s
board of directors (or persons performing the equivalent functions): </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">a) All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control
over financial reporting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Date: July&nbsp;31, 2008 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ D. ASHLEY LEE</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Executive Vice President,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Chief Operating Officer,
and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer</FONT></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>dex32.htm
<DESCRIPTION>SECTION 906 CERTIFICATION OF CEO & CFO
<TEXT>
<HTML><HEAD>
<TITLE>Section 906 Certification of CEO &amp; CFO</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 32 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>18 U.S.C. SECTION 1350, </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AS ADOPTED PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In connection with the Quarterly Report of CryoLife Inc. (the &#147;Company&#148;) on Form&nbsp;10-Q for the quarter
ending June&nbsp;30, 2008, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), each of Steven G. Anderson, the Chairman, President, and Chief Executive Officer of the Company, and David Ashley Lee, the
Executive Vice President, Chief Operating Officer, and Chief Financial Officer of the Company, hereby certifies, pursuant to and for purposes of 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002,
that, to his knowledge: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange
Act of 1934; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ STEVEN G. ANDERSON</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ D. ASHLEY LEE</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">STEVEN G. ANDERSON<BR>Chairman, President, and<BR>Chief Executive Officer<BR>July&nbsp;31, 2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">D. ASHLEY LEE<BR>Executive Vice President,<BR></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Chief
Operating Officer, and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">July&nbsp;31,
2008</FONT></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g30330image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`,L!
M30,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[?/AI\-/AQ?_#CX?WU]\/_``3>WU[X)\*W=Y>7?A70KFZN[JYT
M*PFN+FYN)K!YI[B>9WEFFE=Y)9'9W8L23VW_``JGX7?]$V\`_P#A'>'?_E=7
M$_#2P^([_#CX?O8^*O!-M8OX)\*M9V]W\/\`7;VZ@M3H5@;>&YO(?B780W=Q
M%"42:YBL;*.>0-*EI;*XA3MO[.^*/_0X^`?_``VWB+_YZU`'$_$#X:?#BRT*
MPFL_A_X)M)G\;?#2T>6V\*Z%!(]K?_$?PK8WULSQ6",;>]L;FXL[N$DQW-K/
M-;S*\,KH>V_X53\+O^B;>`?_``CO#O\`\KJXGX@6'Q'30K`WGBKP3/"?&WPT
M5$MOA_KMI(+I_B/X52QF:67XEWJO;VU\;>XN[80I)>VL4UG#=V$TZ7UMVW]G
M?%'_`*''P#_X;;Q%_P#/6H`/^%4_"[_HFW@'_P`([P[_`/*ZC_A5/PN_Z)MX
M!_\`".\._P#RNH_L[XH_]#CX!_\`#;>(O_GK4?V=\4?^AQ\`_P#AMO$7_P`]
M:@`_X53\+O\`HFW@'_PCO#O_`,KJ/^%4_"[_`*)MX!_\([P[_P#*ZC^SOBC_
M`-#CX!_\-MXB_P#GK4?V=\4?^AQ\`_\`AMO$7_SUJ`#_`(53\+O^B;>`?_".
M\.__`"NH_P"%4_"[_HFW@'_PCO#O_P`KJ/[.^*/_`$./@'_PVWB+_P">M1_9
MWQ1_Z''P#_X;;Q%_\]:@`_X53\+O^B;>`?\`PCO#O_RNH_X53\+O^B;>`?\`
MPCO#O_RNH_L[XH_]#CX!_P##;>(O_GK4?V=\4?\`H<?`/_AMO$7_`,]:@`_X
M53\+O^B;>`?_``CO#O\`\KJ/^%4_"[_HFW@'_P`([P[_`/*ZC^SOBC_T./@'
M_P`-MXB_^>M1_9WQ1_Z''P#_`.&V\1?_`#UJ`/`OVI=6^''[./[/'Q<^.=A\
M#/AYXWOOAEX-U'Q/9^$I_#LNEP>(+NT:**WTV:^\$_#'XI^,H8IYID\P>$OA
MKX^\3RH#!H/A#Q#JLEII=U^:OPN_X*$V_CW4+/4?$'_!/OPCX)^'&E_!'PK\
M<O'_`(WNM.^.-W%H'@S5O&MS8:WXPT;5=3_85\-_"*U\%0_"#3K[X^>#]!^-
MWQE^`?[3?B/P1<:/I/BK]E_X=>*;G6]+\.?LEK?A'QOXETNZT3Q#K?PQUO1[
MWR?MFEZK\*];OK"Z^S7$5W;^?:W/Q3DAE\FZ@@N(MZ-LGACD7#HI'ENG_LQ^
M%M)\67'CO2_!W[/.G^+[S0]1\,W?B"S^!%Q;:E=^'M6GU2YU/1+N6+XEJMQI
M=_/KFL/=64R/;R_VG?(T92YF5@#X*\4?MP?#G2ENO$>A_LC_``QO_A?:Z=\1
M==A^(/B+Q/H?AZV\0:#H.@:YXE^$M[X7L]&^$/C'3+F?X^Z!I$7B+P"/$OB/
MPGI/]BWUI8-K=[X^U;PKX#\3L\7?MO>"/!%AX4\>ZO\`L8_#_6?A#\6/C5X@
M_9T^"6I^!O%G@_Q=\6/%WQ>\!>+_`!_X7\>Z?XT^'4'PSL?`OPY\'^3\+/'%
MY\/_`!<WQJ\4/XAU6#PSX1\>Z'\)_$GBS3;)/O#7/V5?!'B>]T74/$/P^_9J
MUR^\.:)<>&]`N]5_9YCOI]%\/7>@6GA6YT/3)+CXB2-8Z1+X;L-/T1M/MREK
M_9MA8VHB$5G;+%''^RCX"A\9ZU\18OAS^S)%X\\2?V<==\81_LZ6Z>(]6.E7
M_A75+!K_`%9?B&+VXD@U'P)X(O=\DI>6X\&^%)9S(WAW1S9@'S-\(_VGOA+\
M9?CKX9^'GAC]GKX16GPE\7-\1=%\-?&#6M4T_3=8\5?$'P%)K%U=_#;PW\,Y
MOA*KP>-=&\/>&?$NO_$#PGX]\:^`/&OAJWTS4(?"/A/XE?\`""_&Z?X0?H9_
MPJGX7?\`1-O`/_A'>'?_`)75Y?;_``!TZT\?P_%6U\._`"V^)ELFIQP>/8/@
M/+!XMA&LF^;57CUZ/XD+J(GU`ZIJXN[@7`GF76M;1Y"FLZHMWZA_9WQ1_P"A
MQ\`_^&V\1?\`SUJ`#_A5/PN_Z)MX!_\`".\._P#RNH_X53\+O^B;>`?_``CO
M#O\`\KJ/[.^*/_0X^`?_``VWB+_YZU']G?%'_H<?`/\`X;;Q%_\`/6H`/^%4
M_"[_`*)MX!_\([P[_P#*ZC_A5/PN_P"B;>`?_".\._\`RNH_L[XH_P#0X^`?
M_#;>(O\`YZU']G?%'_H<?`/_`(;;Q%_\]:@`_P"%4_"[_HFW@'_PCO#O_P`K
MJ/\`A5/PN_Z)MX!_\([P[_\`*ZC^SOBC_P!#CX!_\-MXB_\`GK4?V=\4?^AQ
M\`_^&V\1?_/6H`/^%4_"[_HFW@'_`,([P[_\KJ/^%4_"[_HFW@'_`,([P[_\
MKJ/[.^*/_0X^`?\`PVWB+_YZU']G?%'_`*''P#_X;;Q%_P#/6H`/^%4_"[_H
MFW@'_P`([P[_`/*ZC_A5/PN_Z)MX!_\`".\._P#RNH_L[XH_]#CX!_\`#;>(
MO_GK4?V=\4?^AQ\`_P#AMO$7_P`]:@#B?A_\-/AQ>Z%?S7GP_P#!-W,GC;XE
MVB2W/A70IY$M;#XC^*K&QME>6P=A;V5C;6]G:0@B.VM8(;>%4AB1!VW_``JG
MX7?]$V\`_P#A'>'?_E=7$_#^P^([Z%?FS\5>"8(1XV^):NES\/\`7;N0W2?$
M?Q4E],LL7Q+LE2WN;X7%Q:6QA>2RM98;.:[OYH'OKGMO[.^*/_0X^`?_``VW
MB+_YZU`!_P`*I^%W_1-O`/\`X1WAW_Y74?\`"J?A=_T3;P#_`.$=X=_^5U']
MG?%'_H<?`/\`X;;Q%_\`/6H_L[XH_P#0X^`?_#;>(O\`YZU`'$V'PT^'#_$?
MQ58O\/\`P2]C;>"?A_=V]FWA70C:P75[KOQ+AO+F&W-@88KB[AL+&*YF1!)/
M'96B2LZVT(3MO^%4_"[_`*)MX!_\([P[_P#*ZN)L+#XCGXC^*D3Q5X)%\/!/
MP_:XN&^'^NO:RVKZ[\2Q9PPV8^):307$$R7SW-R]]<QW<=S:116EDUE--?\`
M;?V=\4?^AQ\`_P#AMO$7_P`]:@`_X53\+O\`HFW@'_PCO#O_`,KJ/^%4_"[_
M`*)MX!_\([P[_P#*ZC^SOBC_`-#CX!_\-MXB_P#GK4?V=\4?^AQ\`_\`AMO$
M7_SUJ`#_`(53\+O^B;>`?_".\.__`"NH_P"%4_"[_HFW@'_PCO#O_P`KJ/[.
M^*/_`$./@'_PVWB+_P">M1_9WQ1_Z''P#_X;;Q%_\]:@`_X53\+O^B;>`?\`
MPCO#O_RNKXF_;%\*>%O#'_"NO^$:\-:!X>^W?\)=]M_L/1].TG[9]F_X1C[,
M+K[!;6_VC[/]HN/(\W?Y7GS>6%\Q]WVS_9WQ1_Z''P#_`.&V\1?_`#UJ^)OV
MQ;;Q3;_\*Z_X276-`U;?_P`)<++^P_#6H^'OL^W_`(1C[3]J^W^*_$_VSS=U
MOY`B^P_9_+F\S[3YZ?9P#T?XU^#?BE\1/V%-=\"_!36-0\/?%7Q;\#_#&@>"
M=>TOQ#XK\)WNC:QJ>CZ':C5(_$?@/QM\-?'.D16-M)<W-U=>"_B%X(\6+:1S
MQ^'/%6A:P]GJ5O\`EI^S]^S)_P`%'?AWX[\7ZWXR^)_QS\8^(/!?P?\`#TGP
M[M/%GQ)^,.L?#SQ7XW\%Z]X3^(5]\,;/6O$G[=7Q!\!P?#KQ+JVBZ]\$-#\6
M?&3]E[XO_M7:S\*M1L/&?Q._:]U_QC?^)5O_`-I_AI\/]"O?AQ\/[R:_\;)-
M=^"?"MS*EI\2_B/86J23Z%82NMM8V/BJVL;*W#.1#:6=O!:VT86&WABA1$';
M?\*V\._]!'Q]_P"'6^*/_P`V-`'A/@*#XDZ7\'O#^@_%RR\1/\0[;QW\)_$G
MC+7]3U?2M<\-:AXM^(/Q7\,^._$WAKX>:A;:Q>:S)X'^&FL:_=?#OPVFN:+X
M;,.A>'=+ATJRNM.CBNF^M*\+^('P_P!"M-"L)8K_`,;.S^-OAI;$7/Q+^(][
M&([WXC^%;.9EAO/%4\*7"0SN]I=H@NK"Z$-]8S6U];6]Q%VW_"MO#O\`T$?'
MW_AUOBC_`/-C0!WU%<#_`,*V\._]!'Q]_P"'6^*/_P`V-'_"MO#O_01\??\`
MAUOBC_\`-C0!WU%<#_PK;P[_`-!'Q]_X=;XH_P#S8T?\*V\._P#01\??^'6^
M*/\`\V-`'?45P/\`PK;P[_T$?'W_`(=;XH__`#8T?\*V\._]!'Q]_P"'6^*/
M_P`V-`'?45P/_"MO#O\`T$?'W_AUOBC_`/-C1_PK;P[_`-!'Q]_X=;XH_P#S
M8T`=]7EGQSUCQAX=^"?QB\0?#V*\F\?Z%\+/B#K'@>'3M*77-0E\8:7X2U>]
M\,Q6.B/:WR:Q>2:U!9+:Z4]E>+J$Y2T:UN!,8GU?^%;>'?\`H(^/O_#K?%'_
M`.;&O$/$WQ(_9M\&_$>3X1^*/BIXGT7XCIX0O_'<7A2]^)WQF34+[PQIFG:O
MJ^H7FE2)XA>SUB\M=)T#6M4ET32KJ\UW^SM+O;Y=--M`\J@'XQ^.OV@O^"B]
MI\6?V7?!GPO^+?[0_BKX"7$/Q>UKQ]\=O'O[-=AX`^('C_6_!\O[&PT?P-XU
M\+^&/^"=7Q6TWQDD=_\`$;X_6OA+PA\/?AS^Q&OQFT[0-7T+2_VH/`VN_"?5
M/%OB?ZH^#GQJ_:4UK4/@1:?%KXI?M;^#](MM`\'PZ#K=I^R9X<\8/^U!X_C^
M,OQ,^&WQ.A^.5]H7[+^AS_"_X>Q>&=.^%7C[X?76A?#_`/8[UJ3P-XLN_B9J
MVJ:WHVD^-/!_P_\`HCX7_MF_L/?&?XH7?P>^&WQ@^+7B+QO97)LIEDM?VO\`
M0_"#WH\8?&3X?BRL_B5XBTG2?AMJ%X_C?]GCXZ^%8K2P\6W-Q-KGPC^(.GQ1
MO<>%]52V]^^&WC#X`?%Z'P_=?#/XE>*O&EEXJ\(3>//#VH:+\4/C%/IFJ^$[
M;Q#<^%+C5;;4W\21V!\CQ#9W6ESV,ERFI17%O*SV:PH9``?S\?!3XU_\%R?B
M!\-?V1_"WBRZ^)/A#XK?&SX6^+_'GQ7U?Q5X"^'WA*?X<>*F\2_\$_M=\':)
MXK^([_\`!/?6_AY\(;#6?`WQ7_:033_A)JOP`^+'CSPF_A[Q;\/?%GQH\6^.
MOAUJ?Q%\$_7.K>/?^"D'PM^-6H^!?$?Q7^/'Q%^%&MQ?M"ZE\0OBQIG[,OPP
MUY_@OHWAGQ1_P3<7PQJ/P+TCP)\#M&D\2K8Z!\:OVM!\--`^(-G\=?%NN:3X
M.U#7M9TKXP7OPA\1Z;J?V#I7[;/[%.O77ARPT+QK^T[K6I^*_$<OAW0](TCX
M4?\`!0/4]:N;2&>.V/Q#NM&LO`,^J:5\#)9)0]K^T/J]I8_`>\MUEN[/XC3V
ML$TT?J.D_'7]F;7?B#HGPUT7Q9\>-5US7OA%H'QUA\06&D?M@W?PKT?X8>*M
M,\0:SX:UWQE\;X=*?X,>`-2U[2_"VNWFD^$/'/CWP[XTOH[)1;>'I)+VP2Z`
M/C71OCE^WQ9Q^)8/"VB?$CXO_##0O#7@'2O!WQ,\:?!_1_AW\<O&NEZY\4O$
M6@2_&W6O!DW@/X>^#I=<T[2='-G\1/A]IWPY\!_VAX#GTSXT?#[P;X=22Q\$
M>+OVAK\_M;_:M_8WT/0[+Q*?B?\`&'Q%H.I?"7P;\;M.U/P!:?M>?$VVU#X?
M?$;4CH_P\GL6^'6E^*6N_%WCS5$GL/!GPRMTD^)OBFYL]0BT+PA?-IU]]G^G
M/!6B^"/'_A'PYXVT*;XS6.C>*='L=<TRR\:Z_P#M"_#7Q=:V6HP+<6\'B/P!
M\1M2\*^//!VL)&X6^\/>+O#>AZ_IDX>UU+3+2YCDB4`]EHK@?^%;>'?^@CX^
M_P##K?%'_P";&C_A6WAW_H(^/O\`PZWQ1_\`FQH`[ZBN!_X5MX=_Z"/C[_PZ
MWQ1_^;&C_A6WAW_H(^/O_#K?%'_YL:`.^HK@?^%;>'?^@CX^_P##K?%'_P";
M&C_A6WAW_H(^/O\`PZWQ1_\`FQH`[ZBN!_X5MX=_Z"/C[_PZWQ1_^;&C_A6W
MAW_H(^/O_#K?%'_YL:`.^HK@?^%;>'?^@CX^_P##K?%'_P";&C_A6WAW_H(^
M/O\`PZWQ1_\`FQH`/AM_R+NH_P#8_?%;_P!6CXQKX8_:Y^(OQW\%_'/X;I\+
MO'7QFTRS@\"O?^&?A)X)^">B_$7X4?';XEZM\0="\,Q^$?C/X[/P7\;^,OAE
MH.D>'=1EU:W\3>&/BS\&=/\`#,3WOC/QA>^)_"WA[4]'/I/BKQ[\'_@=X8\%
MWWQ$U#XQ-/\`%']H+QE\&O`NE>`=1^._C?6=:\97_BGXHZY8VB^&OAWJ.KZH
ML-OX6\#^(]>\0>(;G3_(CM]*O]6UJ^>[N)9[CD?#O[7W[#?BS_A6W]@?M`:O
MJ'_"W/C/XZ_9^\`>7\4?C*G]N_%CX<_VS_PD_A5/-\1)]EN8/[&/V&6\\B'5
M/[6\/_8'G_MNP\T`^?M=^*W[='Q(^(6OZ-'8_'7]GOX?:A^TS\%/$OP3\6^!
M_AO\'/$-[XR_9TLOB=8?!7XT^!OB7:^//AW\9V\':%KVE7GA[]H#0M>UC3OA
MA\6ET[QOJ&F:;<Z/X9^%7B(ZYW__``1_^(_[6OQ7_8]\-^/?VU-<\7:K\<_$
M]QX;U[Q#I?C32K7PWK'@RXUSX7_#W6=;\$R>#;7]B[]C%?`7_"/>,-0\36TW
M@.XM?VC[SPI=23Z5<?M1?%(11QZ%Z=X+_:H_8]^(_C/X=>!_A[\4_B1XVU3X
MG_$?XC?"'P[J?AOQ/^T#?^%K#XE_"[P9XL^(/B?P9XK\4_VK%H7A/7+GP;X$
M\::[X9L]>O;%_%=EX7UN7P__`&@-.N-GV"?AKX>'74?'W_AUOBC_`/-C0`FG
M?\E1\8_]B#\-O_4B^*U=XQ(5B%+%02%7:&<@9"J69%R3P-S*N3RRC)KPVP^'
M^A/\1_%5F;_QL(8/!/P_N4=?B7\1TNC)=Z[\2XI5FOD\5"^N;=%LH3;6EQ<2
MVME(]W-9PP37]\]SVW_"MO#O_01\??\`AUOBC_\`-C0!^,GBW]G?_@IS^T"W
MA#PYXP^+WB;]G/2/%/[1,/[0_P#PG?PZ^(WC#4?%OP6^'?B;X8?%S3X/V?M4
MT#X;_%+X-:!X@\0?"'7K#X476E6'C2]_:8_9K\1_$S7;_7/B'\*_C?\`#K2[
MOPC+Y=XV_80_X*1WMG>:_H/[67QLM+SQQ^UA\3_BGJWA;1_BI\>[:\^#GPGL
M?'?Q-@\*S?#V;4OVR[G0O&/Q,U?P=XJ\+:OX/^&GBXM^P':K\-/AUX?\6_L,
MF_OOBGK?Q$_:'7]?_9[\*>%]5\;^*?C39>&O!FA>"[GXD:YXOU_]I'Q3H_A?
M1OAW9,RWGCW5=?U'XBVVDZ=X+M&1UNO%-Y=PZ'`582WR%#CAOAU\;_V,OC!J
M?B+1/A+^U;\.?BEK/A#P;H/Q%\6Z1\.OVOKKQMJ?A?X?>*M%L/$OACQWXBL/
M#7Q6U2[T3P;XC\.ZIIFOZ#XGU.*VT36-%U&PU73[ZXL;NWGD`/DJR^#W[7FJ
M^,?'AT'5/C[X&^*%Y'\4=1\8_%7X@_'"Z\8?LS^-;_2-;U?Q-^S+IOP8^#>C
M_%-U\`:3IFLMX0TWXBV'ACX7?!B\\7?#/2O''@KXO>(?B'KVL>'O$M[\E_%#
MX&?\%$_''Q?;XE>+%_:/L-#\:_!'X<7OB+X5_!WXZ_&+PS;^"]4\8?&?XD^,
M/BM\+/"'C'X;_M__``3^$/AGQ]\-_@[KGACX5Q_$3_AF/Q]XJ\7:GH&F>(?A
MQ\8_AY=/!K&E_N&UA\)U+JWQ"U16CO?#>F.&^._CH,FI>,GMH_"&GN#X\!6]
M\5/>6:>&[0D3ZX]U;+I<=R9X@_5?\*V\._\`01\??^'6^*/_`,V-`'E_[*VC
M_$+0OA);Z?\`$.W\?Z?*OBOQI-X)T3XM>*[#QW\5O#OPRF\27[^`M"^(GC/3
M]?\`%J^)O$FG:";>/^U=3\8>,/%$ND-I47C3Q3KOC*'7M1G\5_;A_P":8?\`
M<Z_^ZE7UU_PK;P[_`-!'Q]_X=;XH_P#S8U\3?MB^&M.\/?\`"NOL%SK]Q]L_
MX2X2_P!N>*_%/B?9]G_X1CRS:_\`"2ZQJWV'=Y[^?]B^S_:=L/VGS?L]OY8!
M]L?"LD?"SX;L%+$?#_P>=B[0S$>'=.(4%F5<G&!N95R?F(&37R[^QY'^UY::
MA\5KC]J/2K2WT_XBZY9_&'X9VUIXKTWQ'>?"K2_&<VIVUY^SMX@M[&TM;2RU
M3X6:-I'A)[C4?#NI>-O"WB#Q#KWC"]TGQC=V<-A"WMOPT^&GPXO_`(<?#^^O
MOA_X)O;Z]\$^%;N\O+OPKH5S=7=U<Z%837%S<W$U@\T]Q/,[RS32N\DLCL[L
M6))\#_9+^.G[*O[96B?%C6OA5\,/#5F/@Q\9O&/P,\;Z?KFA_!G6;RQ\9^#%
ML+B\#7/PR\6?$31M.%[IVJZ;J2^'/$.K:)\0/#T=Y'IWCKP7X2UZ.?2(0#ZR
M^)/_`"+NG?\`8_?"G_U:/@ZN^KPOX@?#3X<66A6$UG\/_!-I,_C;X:6CRVWA
M70H)'M;_`.(_A6QOK9GBL$8V][8W-Q9W<))CN;6>:WF5X970]M_PJGX7?]$V
M\`_^$=X=_P#E=0!WU%<#_P`*I^%W_1-O`/\`X1WAW_Y74?\`"J?A=_T3;P#_
M`.$=X=_^5U`'?45P/_"J?A=_T3;P#_X1WAW_`.5U'_"J?A=_T3;P#_X1WAW_
M`.5U`'?45P/_``JGX7?]$V\`_P#A'>'?_E=3Q\)OA<1G_A6_@'\/!WA[^NG"
M@#NZ*X7_`(5+\+O^B;^`?_"-\.__`"OH_P"%2_"[_HF_@'_PC?#O_P`KZ`.Z
MKXM^,/["7P7^.GQ0\4?%+XA7?C&\U'Q5\)_^%3SZ3I>LVNBV>BVMOJT>N:/X
MS\+ZMIVFP^*?#OCSPWJT%IJOASQ#INOPRZ1JME:7]K$LL(!\&^*GQ2U_PS^V
MAXA_9W^'7[-_P'\9^#/A_P#L8S_M5>*(;[PYJ%O\3/&&L7OBSXJ^!?#GP\\`
M1^'O#'B'3H[K4/$7@KPX99[WP_JU[-::GJ<&G6-UJ`L(&\+TC]HS]IR?X3_L
MC^+]4_X)=:9%XV^+?Q8U7X<?';PC_P`(7=6-Y\)]-T;4H/AO_P`)IKFG)X8U
MM/`G@W7/BKJUGK5CXF;Q#\48K3X,Z+?>.[+2O$^EZIJ&L^"`#VKP-_P2-^`?
MP^A\7Q:!\1_C?'+XTAUBWU*\;Q)X4L]0T]=;^+__``4(^-%U-H.HZ-X+TJ_T
MB]@\3_\`!2'XSV&GZA%<O>6&C>#_`(7>1*NLZ/XFUCQ9]`?!O]B'P3^SW\1K
M?Q=\'OB!\1?"?@F%O%,3?!RZNO#OBKP5'I?BN'1-1U#1-.UWQ9X>UGXD:=I[
M?$'3M:^)\DB>-IM1N/%GC3Q/:S7Q\,/HWA_1_BSXJ_'_`..7@M?^"BMY9?L(
M_##PIX4_9#^%FL?%3X-_$SXF^"M8L/AO\;],\$:2?%?BC2]'U[3?#L,GB&_U
M7PCI?B%C)86WAJW\"^+$T70P_P`2M#O-0\7:9^E/P?\`#7PX^)7PE^%WQ%O_
M`(5_#G3;[Q_\.O!/C6]TZT\(Z%+:V%WXJ\-:9KMS96TLVG^=);VLU^\$,DO[
MQXXU9_F)H`^'-*_X(Y_LG>&Q\+X?#6CZ=:Z?\+_B3?\`QAL-.U_X4_`7QM;:
MI\5M=L_!]MXF^)TLOBWX4ZK=Z-\3-7O/!.G:[9?$;P]<:7XX\+:_J?B74?"F
MO:/_`&U-#$]O^"2'P7U?7-#\1>.O'GB/X@:[IW[/'A3]E;5_%>O_``R_9[@^
M(NM_`WPP?&6FWO@/3_BII7PBL?B/X"T7QSX(\<:O\/\`XA6GPV\3>$8_%'AT
M_:)Q!KMQ=ZM/^DO_``J7X7?]$W\`_P#A&^'?_E?3O^%3?"S_`*)MX!/_`')_
MA[^FG"@#\]?''_!*CX,>-_#^K>![SXD?%?\`X5C=:+XHT'1?AEKY^'?Q"\+Z
M+I'C/XB6?Q1\3^&]4O?B/X!\6>+OB/X"UOQ=;->:C\-OBKXG\;^!9H5TVW70
MHUT72S;_`'[\(_AIH'P;^&/@7X5>%;72++PU\/\`PSI?A70K'0/"7@_P'H=E
MI6D6R6EE::1X,^'^A>&/!/AC3;:!$@L]%\,>'](T>P@1(+.RAC4"KG_"IOA;
M_P!$W\!?^$?X=_\`E;7B_P`7O$7[,_P,U/X,Z;\1O!/@S14^.WQATOX%^!]4
M7X?Z'<:-#\0M>\$^//''A^Q\2ZDFGB#P_I_B"#X?:EX:T?4[W%M>^--9\+>&
MT(O-?M"`#ZAHK\M/"/[:_P"QO\2M'T[QS\)_@?JOQ4^#=OJ&OVOQ(^.O@[X=
M?"7_`(5?\&+#0OB'X_\`A:-=\>S^(_&'A[QEKFFWGBWX;>(XKFU^$7@WXH:_
MX.T5M+\3_$C1/!/AS4(]33RKQW_P4K_8Q^%GP]T+X@_$_P#9<^(7P]@\;SZW
M<_#+0O%G@3]FK3;CXD^#]*^$OQY^,]G\1=&\9CXS3?"/PIX.UCP=^SIX_+GX
MJ_$CX>>)O!=Y=^$I?BEX:\`:-XDM=80`_:"BORY^''[7W[./QCL/#-Q\(OV3
M/%_Q3U/4[7POKOC#1?AWH7[*7C)?ACX#\7>"?"WC?2?B1K_C'P_\<K_X9>/_
M``=>6_BNST71_P#A0'CKXR^)?&>J:;KM]\/O#GB[PII4_B4]%XU_:A_9C\-^
M)_%G@OP9^SEK'QF\4^`/C_\`!_\`9^\>Z+\-_!OP&TVY\)ZE\;&?3/"7Q(NY
M?BQ\1?A?::U\+;3QM:ZS\,]=U?PC<>(_$]I\0/"_C#1;'PAJ=MX1\1:CIH!^
MDE%?DOX1_;P_9`\;?"_PI\?-"_9K\=O^SIXL^&'A7XAV?QZO?A1\(;#P)8Z[
MXW^&/AGXL>%/A+?Z+=>.H_B?+X_UGPUXLTC3(];TGX>ZK\'+/QNT_@'4_BO9
M>,(AH[^K>'?VE_V4O&OQ-^&OPT\"?!9O&3_$XW:Z?XSTSP+\*-+\(>'IK#0(
M=>U+2_$R^+/%'ASQ?%XJTHMJ6D:UX"T+PCKWQ`T34O"_CB76/"UCHO@7Q?J^
MB@'Z)45P/_"J?A=_T3;P#_X1WAW_`.5U'_"J?A=_T3;P#_X1WAW_`.5U`'?4
M5P/_``JGX7?]$V\`_P#A'>'?_E=1_P`*I^%W_1-O`/\`X1WAW_Y74`?GA^U=
MXG\.>#=2_8`\2>+O$&B>%O#NG_\`!3CQI%J&O^(]6L-#T6PEU?X4?MPZ%I,=
MYJNISVUC:R:IK>J:;H^G)//&U[JNH6.GVPEN[NWAD^\++]GSX`:;_9G]G?`S
MX/6']B^)+3QEH_V+X:>"K7^R?%]A_P`(C]@\5:9Y&AQ_8?$EE_P@'@3[)KEK
MY6J6W_"$^$?)ND_X1O1_L7SC\5O%?PH_9X_9^\6_&37?@?I_Q+DT?XLGP-I7
MA#PQX<^'\7B?Q!K7Q&_:5@^#/@;1=-U#QE=Z!X<L+:VUKQ?H%JT^KZYING:7
MHMK*5E2*VB@;YU\4_P#!0/\`8J\#Z?\`&.[\7?`;Q/H=Y\"OC'\.?@Y\0=(D
M^#'AO4KRPO/'T-_+?>-+"YT0ZGI.M^`/`DOA/XIVWB_Q5HFHZEI5E+\)O&LE
MO<W-M9QSN`>M_M!Z!\)OAM^T=_P3:\(^"]!^'?@'7_'G[<'Q=^(EYX8\+Z9X
M:\+:QXSN-%_X)Q?MJ>'O%?CJYT72;>QO?$4VD_VOX&T/Q#XGEMKQ[#^T_">F
M:E?1?;='@E_1PL2.<=_;Z<_IQC)[=J_+37_VQOV7=-^(/C3X;Z-^S7XC\0:Y
M\,?VB/V=_P!GWXG7;?##P#X<T?PA+^TQ\2O#_P`'_A[\1HKWQ+?Z8WB?P4WQ
M'\3:9X<NXO#$&J>))!%J^J:?H=WI.A:Q>6?Z'-\)_A:#D?#;P#TY'_"'>'>G
M//\`R#L\>_'-`#-._P"2H^,?^Q!^&W_J1?%:N^KPNP^&GPX?XC^*K%_A_P""
M7L;;P3\/[NWLV\*Z$;6"ZO==^)<-Y<PVYL##%<7<-A8Q7,R())X[*T25G6VA
M"=M_PJGX7?\`1-O`/_A'>'?_`)74`?&?P/\`V"K3X'Z/K>D:-\4=9U/3_$/[
M/,GP:N_#]YHT0\+Z)XMOYKNY\3?$7PC8R:E<ZEH4'C*]N8M6\2^"UU:?0YO$
ML.H>*]..G:_XK\6WFL>.1?\`!+.!?$WQKUV3X\^-GM?C]X>\)^"/&6FSS>)M
M:TKPEX&TC0/@EX4\<:1\(?!7BSQKXD^%7P[U;XS>$_A5J?A3XL>(K3X>7]_X
MLT74O"JW2+/X5O'\1^M^&OVEOV5/B!X`\4>._A=\$I?B9-X4^$7B#XN7W@?P
M]X"^%.B^-Y8/#LB"Y\!FS^(/BCP5H.C^/-0M+C3M:T2#Q3XA\/\`A+6/#>M:
M#XGLO%TGA_7-*U*[\.^&/_!0[]C+XB^,OCEX#U/]G77/AKXE_9Z^$&A_&+XC
MZ-XLTC]E/Q9X@TS3M;^'_@#XAQ>$[GP7\$OCA\7/'WA_Q6;+XD>'_#V@S^-O
M"OA7P3\2O%D&MZ/\(/&?Q%31[N\4`[CP-_P32C\(:IX(UV;XW^(]1U_X=^,?
M@G'H^L)H26L_C#X)?L^>.)=>^&'PJ^*MJVM3Z=XRUGP[X<L/#%GIWQ'M+30=
M7T?Q?8^*O$/AW3-%\-?$?QMX$U?]2Z_/#1_VH_V)/$&N>'/#>C>$O#=]K'C#
M3O@/KO@^U7X<>&+=/%OAO]H35O#FB^$_$?ANZO%M[76=/\+ZCXL\.P_$NUL9
MIM;\"KK>@R:KI.SQ)X:.L?:/_"J?A=_T3;P#_P"$=X=_^5U`'?5\#_MP_P#-
M,/\`N=?_`'4J^NO^%4_"[_HFW@'_`,([P[_\KJ^)OVQ?"GA;PQ_PKK_A&O#6
M@>'OMW_"7?;?[#T?3M)^V?9O^$8^S"Z^P6UO]H^S_:+CR/-W^5Y\WEA?,?<`
M?4?PT^)?PXL/AQ\/[&^^('@FROK+P3X5M+RSN_%6A6UU:75MH5A#<6US;S7Z
M307$$R/%-#*B212(R.H8$#A_@UX0_9?^`I\8/\._'/A^VN/'.LC6==NO$7QB
MNO&5R!#<:C<Z=HFCS>*_%6KMX?\`"VCW&L:O/HWA?1/L&AZ9/JVI3VMC'-?W
M$DGMOPK95^%GPW=F"JOP_P#![,S$!54>'=.+$L<```$DYP!R>E<9\'/VC_A%
M\?9?$*_"O6_$>O6?AX:9<#7=4^&_Q,\&>%/%NC:U;M=:-XO^%OC#QQX/\-^%
M?C'\/]7A5SI?Q&^$VL>-?`E_(K06OB*6=6C``WX@?$OX<7NA6$-G\0/!-W,G
MC;X:7;Q6WBK0IY$M;#XC^%;Z^N62*_=A;V5C;7%Y=S$".VM8)KB9DAB=QVW_
M``M;X7?]%)\`_P#A8^'?_EC1\2?^1=T[_L?OA3_ZM'P=7?4`<#_PM;X7?]%)
M\`_^%CX=_P#EC1_PM;X7?]%)\`_^%CX=_P#EC7?44`<#_P`+6^%W_12?`/\`
MX6/AW_Y8T?\`"UOA=_T4GP#_`.%CX=_^6-=]10!P/_"UOA=_T4GP#_X6/AW_
M`.6-.'Q9^%X_YJ3X!(QP/^$Q\._S_M&N\IX0GKP/U_S_`)Q0!P7_``MKX7?]
M%(\`_P#A9>'?_EA1_P`+:^%W_12/`/\`X67AW_Y85WWE^_Z?_7H\OW_3_P"O
M0!^1/_"S_`FB_P#!8G4/$.H>([&/PMXT_P""=_@/P'X=\8P"YOO!-UXT\/?M
M"?&;QIK'A>\\:V-O<^%=&UNR\,-!J[:?K6L:?/-!>Z;%;I-<ZGIT%S^G'_"V
MOA=_T4CP#_X67AW_`.6%?+7[1'[0_P`6OA[^U3^QA^SK\+_#GPZU.T_:+'QQ
M\0^.]>\>W?B:VN=`\(?`RU^%^L:Q:>$4\/++$_B37M)\;ZK!ILVLV]QIEKJ-
MEI[W436SW*GY%N/V^?V[;;]G'XD?%J7_`()X_$`_$/P/^T1:^`K'X766G^,[
M_P`6>)/@Y]KE\=ZK\0/"WA-]%L;OQ-!8?!Z71]#T[Q#-XA\--K7Q8O\`6-,D
M\!:/K_AN'X6^(@#Z9_X*'_%OX;R?L%_MF:;I_C+0M?U?Q'^S#\</!_A_0?"E
MZOB_Q'KGB;QK\.?$/A+PQHVC^'/"ZZOKFI7FJ^(-:TVP1;/3YDMA<->7KVUA
M;W5U#ZU^S3\1O`&B?LY?`#1=9\<>#](UC2/@G\*M,U;2=4\3Z+8:GIFI6'@3
M0;2^T[4;&[O8KJROK*ZAEMKNTN8HKBVN(I(9HTD1U'C=Y^T5^U_??M47G[/^
MC_LM6^B>!KK]G67QWH_Q[UVY\::Q\(-*^,UQX>FNK3P/KGC33O#VC'4DT[Q>
MUMX?OO#.G^'].OM0\*)<>.;;QGIVNF+X8CUC]@W]HCQ#^UI^R'\"OVC/%OAO
M1/"7B7XJ^$)?$&L^'?#MU?7NAZ3>P:YJVCR6VF76I_Z?-:L--69'N@)LR$,.
M!0![Q_PMKX7?]%(\`_\`A9>'?_EA1_PMKX7=_B1X!_\`"Q\/#_W(FO0<#T'Y
M"DV+Z?J?\:`//_\`A;7PN_Z*1X!_\++P[_\`+"O'/C3X=_9<_:%\,CP;\7/$
MO@;Q5X:5-4\G3%^)JZ&+6\U72;O16UJPO/#WB72M0TWQ)IEC?W@\.^)M.N[3
M7_#-W<2ZAX?U'3;YOM%?4>Q?3]3_`(UQ7C3X@>"?AY'X8E\:^)--\,Q>,O&7
MA[X>^&)M4E:"#6/&OBR>6T\,^&[:;8\2ZEKU[$;'2XIGB6\OY+>QA=KNZMH9
M0#XS@_9J_85L-5&HZ+J7AKPU9W.OZMXD\1^%/"GQR\0>%O`/CS4-7\>:]\37
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ML<:'X8^*_C/Q+\4=>\'^%_@M/\0$\<ZUXW^#?QR\$6DNF_"NZ\06/Q"\6>`O
M^$M^&NCR?%SX?>%=1\+:YIFH_$GX31^-_`!U6TBTNW\1SZA?:?;78!;\2_!K
M]D'Q/XMU;QT_CF+PWXL\1>(IO$?BK6_`'[17C'X=7GB]KK3?"VE76@^+'\#_
M`!!T$>(?",]MX-T)E\+:H+G1;2=-6ET^TM#XD\2#5J>C_`']A3P[K=EXF\/6
MOPJT#Q';ZU9^)M3U[1/'UKI.K>+_`!18?$W3?C%:>*/B#?6'B&WG^(7B2V^(
MNG2^(K?6_&;:WJ-M)K?BBQMKB'3?%&O6=_N+^WO^S2=/T:]?5_B[;:AK6IC2
MSX,O?V7OVH[#XH>'$CLO".I:EX@^('PCO?@W!\4/AEX'\/:=X^\$ZAXN^(?Q
M%\(>%O`G@VP\5Z#>^*O$>CVNJ6DLG6_%K]L3]GOX*67Q#NO&GB_Q!J%U\*+W
MX8Z?\0O#GPR^%WQ9^-WC?PS=?&:^?3/A@EU\/_@KX&^('CBYC\87Z"VTVXT_
MP]>6\<DUK]NEM%N[1IP#YW\-_L<?\$^/"'@[PY\-O#=]I.E?#'PI\./#OPPT
M;X80_M%^.)?APFC>$OAI9?!_PWX@U#P3=?$:?P]K7Q#TGX=Z;IN@P?$C6K"_
M\;2W.F:7XDN];N/%6E:;KEIZ3)\$/V*#\1-.^*-IJ/@G2/%=CXJTGQS=KH7Q
M<OM#\.>)?&GA_1=!\/\`A[Q9XT\(:5XOM?"WC3Q'H&F>%_#T6BZSXGTC5-0T
MZ73$N+:XCGNM0DO.JG_;@_9CMO$>A^&9?B'J7GZ[):6J^(8OAO\`%2?X>>'M
M8U75;70_#GA;Q]\4X/!$GPT^&?C?QIJ]]IUA\/O`OQ$\6^%_&/Q#N-2TM/`^
MA^(!J=@;BCI7[>O[)GB/Q;\*O`_A#XMP>/?$OQM\%_#'XE?#>T^''@[XA?$:
MSUKX;_&1_B'#\-_B+J6M>!?"7B#0_"7@'Q'>_"SQSI?_``FGC'4M`\,Z/K6E
MV6AZ]JFEZOXC\,V6L`'T!_PM;X7?]%)\`_\`A8^'?_EC1_PM;X7?]%)\`_\`
MA8^'?_EC7?44`<#_`,+6^%W_`$4GP#_X6/AW_P"6-'_"UOA=_P!%)\`_^%CX
M=_\`EC7?44`?E+^VYXT\,7O[&OBJUT75[?Q1J^D_M0?!+QY<>&O!J3^-?&%U
MX2\(_P#!0#X;_$7Q#K.C>#/"<6L^*_$,6G>!M'U/Q5]FT'1M2O;K1K.6\L;:
MYC*;_P!$M/\`C+\*=3L+'4K;XC^#8[?4+.VOH(]0\0Z=I-_'#=PI/$E]I6JW
M%EJFF7B)(JW.GZE9VE_93A[:\MH+B.2)?$OB;\=M/_9K_9[\7_%[4?!_B;X@
M+I7Q@O/".F^"_!]QX=M/$7B/Q)\5OVG_`/A4_A33=/O/%NM^'/#5DLGB?QOI
M#WM[K.MZ=96>GI=7,DY,2QO\]^*O^"K/[/O@?3_C'=>+O!_QDT.\^!7QB^'/
MP<^(.DR>"%U&\L+SQ]#?R7WC2PN=$U+5-)UOP!X$E\)_%.V\8>*M$U'4M*LI
M?A-XUDM[FYMK..=P#J/V\?B7X'UCX1_"SPYX>\26?BK6M9_;5_X)^7D%CX.6
MZ\8OIVC^!/VW?@'\4_&OB;Q-+X8@U:#P?X.\*>`?`?BKQ%X@\:>+)=%\*:5!
MIL=I>ZS#J6IZ397_`-J'XK_"\]?B5X!/U\8^'O\`Y8U\8:]_P4=^%^F_$'QI
M\-]'^&GQ@\0:Y\,?VB/V=_V??B==G0-#\.:/X0E_:7^)7A_X/_#WXC17WB7Q
M!IC>)_!3?$?Q-IOAV[B\,6^I^))!%J^J6&AW>DZ%K%Y9_H>RXY'TYH`\(L/B
M7\.$^(_BJ^?X@>"4L;GP3\/[2WO&\5:$+6>ZLM=^)<UY;0W!OQ#+<6D-_8RW
M,*.9(([VT>546YA+]M_PM;X7?]%)\`_^%CX=_P#EC1IW_)4?&/\`V(/PV_\`
M4B^*U=]0!\@>$_AA^QMX'%P_A6?X8:->WWPBTSX$ZGJMKX^LVUG5_A=HKZA)
MHWAK6-7F\02:AJ@TB35]6;2]3O;B;5K%=2O(K:]CAE$2\I)^SW^PI//KLMVG
MPVO[?Q5>^$;_`,8Z5J7Q+_M'0?&LO@&;P%<^"H?&F@7WB>?1_%EAX6N_AMX9
MN]"TW7[+4-/TV<Z\]K;1KXI\2+JGJ=]^V#^SM9_#C6_BS:^/KCQ+X#\._##7
M/C'JNJ^`_!/Q!^(E\GP\\,:O=Z!XCUBR\->`O"GB3Q1JU_H.L:?J&GZQX7TG
M1;[Q9IUQI]^+O0XELKIHO/\`PO\`\%$/V2?%3^.TC^('BWPDWPW^%.K_`!M\
M4GXK_`WX^_!5!\-/#.C>#M<\;Z_X=D^+_P`,/`\?C:[^&=O\1/`.F_%KPUX)
M;Q#XK^$?BGQKX4\%_$O0_"OC#Q!I6AW8!4T#X!_L*^&;?3+31[;X6VUKH/Q/
MT?XQ>%X)/B'%<Q>#?'OA[Q+K_BG0+_P6EQXEE'A'2-$O/$^M:3I/A3P[_9WA
M73?"%TG@>ST6'PA:6>B0?4G_``M;X7?]%)\`_P#A8^'?_EC7)R?M&_!&+7K[
MPO\`\+&\/R^(M-N_A-:7NBVIO+S483\=-2.C_"2]^RVEI-)+H_CG5%GL=(UZ
M)9-%%S9ZA'>ZA:G3K_[/[50!P/\`PM;X7?\`12?`/_A8^'?_`)8U\3?MB^*_
M"WB?_A77_"->)=`\0_8?^$N^V_V'K&G:M]C^T_\`",?9C=?8+FX^S_:/L]QY
M'F[/-\B;RRWEOM_1>O@?]N'_`)IA_P!SK_[J5`'UG\,[6WOOA)\/[*[A2>UO
M?AUX4M;FWD&Y)K>X\,V$4T3@$$K)&[(P!&X$C->?_`+X"W_P%TD>%;;XS_%/
MXC>!-$\.^'?!GPX\%_$%?A]<6'PV\'^%#J4&AZ1I6N^&?`GAKQEXJO;?1KO3
M/#=SXC^(GB7Q?K^IZ/X7T"XU*_N_$LOB7Q%XCT?AI\-/AQ?_``X^']]??#_P
M3>WU[X)\*W=Y>7?A70KFZN[JYT*PFN+FYN)K!YI[B>9WEFFE=Y)9'9W8L23^
M=/\`P2\^/X_;)^%'A#QC\3?!?[)WB_5/&'[.'[-O[1%YKO[/WPX?P_X8^&VO
M?M#>'O$OB34_V;O&^C^(_&GQ:D?XE_""PT?1I-:\11>--(U#Q38^)K+5M5^$
MWPOMWT6'Q(`?J9\2?^1=T[_L?OA3_P"K1\'5WU>%_$#X:?#BRT*PFL_A_P""
M;29_&WPTM'EMO"NA02/:W_Q'\*V-];,\5@C&WO;&YN+.[A),=S:SS6\RO#*Z
M'MO^%4_"[_HFW@'_`,([P[_\KJ`.^HK@?^%4_"[_`*)MX!_\([P[_P#*ZC_A
M5/PN_P"B;>`?_".\._\`RNH`[ZBN!_X53\+O^B;>`?\`PCO#O_RNH_X53\+O
M^B;>`?\`PCO#O_RNH`[ZI=X]#^G^->7ZG\._@]HVFZAK&K>`OAQINE:597>I
M:EJ%YX4\-P6EAI]C!)=7EY=3R:<L<-M:VT4D\\SL$CB1G8A5)K\2KK]M[_A)
M?"NBZJ/`_P"RK^R5K-C\1OB#X@UZ']KKX%>(]-T_QI^SM:^!K[XJ?!BY\,P:
MS\0?@=KG@?Q5\3_"\5]X+U/X@:KIWQ`T/P_\1/AU\3V\/?"[QUH.F:5)>`']
M`N\>A_3_`!HWCT/Z?XU_/I9_M=^/O$-IXU70?!/[%UCXM\4>*=;\*>!_A;J7
MP1U?5OB9^RM+I_QL^%GP:TG6_P!IGPUI?QHM9OBSI&NW'Q`OM4/]A-^S))9:
MS8Z'X3TR3Q-#K-]XHT3C?@W^VWXV^('P9_9@\5?$M_\`@GA^S_K?QJ_94^%W
M[4GB?XM?$[X'^+=)^#5M?^,OA3\*/C)??`3P[H6H?'#2Y+'Q=K/A3XD^(F\/
M^,-4^+VKZQ8:/\(_&/C:P^#7Q!TU];T;P,`?H!^U0NH:7_P4:_X)D^-9O#WB
MV\\(:5X=_;1\':WXGT/P?XH\2:%X<\1?$?P]\!]$\$6/B?5/#VD:I9^&(O$F
MI6E[;V&HZ_-INEA;#4+F>\BM;"\G@_3W>/0_I_C7XU_LY_M0W_QD\9?`_P`,
M^/OV+O"_P;3XS>*M>6"+7?!.F:G<^'=#TCX`ZA\3];^'GBR\M+>.S\'_`!Q^
M'7CF*P\+^+=$U.*\T#Q5X:N%U_P+=WU_:^-=)^'OSS\6/VM?B[8>']8E^"/P
M^_8W^)7Q1\;>(_#.B^#OV?/"WP&T?QC\;/V;-0N_C[\)_@_>^#?C[HWC#]KG
MX`>`_B#XQ\1:;XQ\9WVFOK?Q(_9`TWPOXL\-Q:!8)\4M'L=;\36X!_0)KVO:
M;X:T/6O$>KO=1:5X?TG4=;U22ST[4-6O(].TJRFO[U[72=(M;[5M3N4MH)7@
MT[3+*\U&]E"6UE:W%S+%`_YZ_P#!(;PUXG\%?\$V?V2?#'C3PQXD\&^)]+^&
M]RNJ^&O%NA:IX9\1Z3)=>+/$=[;PZKH.N6MAJVFSRV=U;W207UG;S&">*39M
M=2?LGPS\+?`ESX=T"Y\0_"[P#:Z_<:+I<^N6I\!^$]/^S:O+8P2:E;_8+'4/
M%UE8^3>M-']DM/%?B>VMMODV_B'6HD34;GX/_:;DUK0_VT?V"/@)\,;+X5^!
M/!GQHM?VDO&/Q5:]^"_@;QA?>)M)^!>G?"#7]+\*6,^IV]I-X=M]?MO%7B#2
MM1UC2YEU&UCO8+NU_P!(LH00#]1]X]#^G^-&\>A_3_&OPFG\-?\`!5"']G'X
MD:LG[+W[+-Y^T+H_[0]I/X$\(VVC?":SMO%O[/D-W+\1]3BMO$USKU[X4\-7
MU]I=UIWP$TG1]:TGQ%XGTW4=)UW6[_QOJ\>MZ5\6?#_T;>?"W]L74_VJ+SP>
M/AG^SKX:_9;U+]G62UC^,FB_#?X=7VK^'OV@KOP]-;M>Z7\-M=U_4_%E]%IG
MB^6/7M.O=7U:]\'R^$[5?`VI>%K[7)I/B<`#]3-X]#^G^-?-W[2_[,W@K]J7
MP[X(\+>.];\6:-H_@7QU=?$2PC\)W&AVEQ?^)%^&WQ%\`>&[J]N]7T+6[FSD
M\$:Q\0+7XH^$[W09=&U2Q^(W@/P5>W>H7WARWU[PUK_SI_P3:UJQ_:4_8;_9
MR^.7Q9\"?"W5/B-\1?`\^L>+=1T7X;^%=!TN]U2W\1ZYI1N+/1[6QDM]/BDM
M]/@8V\+NBON(8YK[@_X51\+?^B:^`/\`PC?#O_RNH`^!=)_X)<_!WP=;^-M+
M^&/Q-^,GPP\/?%?P/I7PI^,ND>&-0\`W=U\5/A1H[:O=VG@OQ!XJ\2?#_7?&
M>DWAU?QO\9=9D\>^$/$'AWXB2:K\=OB=JS^*&UU_!6K^#.4^*W_!)+X/?'#P
M-\1/A[\4/B_\:?$6@^+O`/[27PL\&30CX5:7K7P=^'W[6/B?4/%_QKT3P/K5
MI\,OM^KW?B?7$\&7#:I\0Y?&LEJOPT\&"V@B=O$\GB3])?\`A5'PM_Z)KX`_
M\(WP[_\`*ZC_`(51\+?^B:^`/_"-\.__`"NH`^2-&_8"^&GPUUB^U3]FOQ?X
MH_9/LM1F:Q?PC\`?"7P7\-^`=,\'W/AGP+X<OO!_AGP'K?PM\1>$_"]M)<^`
M-+\3V&MZ)I%KKVD^(M1U^:UOSINM7^ESK<?\$^_A!/XV\7_$@>*_BBGCKXC>
M,;GQ=\2/$#>+(KF/QP+7XO\`@#XM>"=$U3P[=:;/X1T^Q^&,7PR\'_#?P/?^
M']`T?Q#;_#S3[G3M=UC7M:U34]=N_K;_`(51\+?^B:^`/_"-\.__`"NH_P"%
M4?"W_HFO@#_PC?#O_P`KJ`/B_3?^"=GP\T.ZURQ\._%;XP^'/A_XZ^('@CXN
M?%;X::'>>`;#0_BA\5OAM!X8L_!?CK7_`!,O@%_B-I%_8Z=\._A)I6KZ5X1\
M9^'_``_XCTGX1>"M(U;2IM+OO'UEXXY;0?\`@EI\"_!OQ"\.?$GP+XV^*W@G
M6-+T3]EW0M>L-!U/P<-)\4P_LHZ[\4/$G@S5(QJ/@J_U3P'X@\;ZI\7_`![#
M\6-7^&.J>#)/'.C^+/&>F7L4+>.O&-WK7WS_`,*G^%A_YIKX`_\`".\.C^6G
M5&WPG^%PY'PV\`X_[$[P[Q_Y3N:`.[HK@?\`A5/PN_Z)MX!_\([P[_\`*ZC_
M`(53\+O^B;>`?_".\.__`"NH`[ZBN!_X53\+O^B;>`?_``CO#O\`\KJ/^%4_
M"[_HFW@'_P`([P[_`/*Z@#X9_;3T?Q#K7[&/BV/PSX8\7^,=1T?]JCX.>,KS
M0/`?A'Q)X]\63^'/`/\`P4+^'OCCQA?Z1X/\'Z5KOBC7VT/PEX>UO7;RQT'1
M]1U)M/TV[EM[25X]M?HSIE_'J.GV6HP?;1;ZC;0W]NFIZ=?:1J,4%Y&MS##?
M:5J-GI^I:9<PQ2I%-I^I6-KJ5I(CV]_!'=QS*/SP^+_BBR^$NE_`32/`OP)^
M#OQ!\6_'G]L#Q=\!K=?'TL7A#1?#NA10_M`?$.]UM]8T?P!X[U*XGTGPW\(Y
M-!\/Z(FBK9O<7VGPRWNGV%FQ'EWA#]HOQ;XA_P"%1_VO_P`$OOB1X8_X3K]H
MOQ?\(?'']H_#?2C_`,*R^&]K_9?_``K[XVZM_P`4K']N\)>*_P#A-O`?]LM#
MY9\)?9?B=_;!A_X5KXG_`+-`/IK]O&VUC6/A'\+/#GA_PQXQ\5:UK/[:G_!/
MR\@L?!O@SQ7XQ?3M'\!_MN_`/XI^-?$WB:7POHNK6_@_P=X4\`^`_%7B+Q!X
MT\62Z+X3TJ#38[.]UB'4M3TFRO\`[2+$]>W^<FOR:\$?M`Z]XF^)GP(\*>,/
MV!]$^"OAGXJ_M,_%S]FW6;OXI:?IVF^+OM7@[]GGXO?M#>`OB'\.]$M_`']D
M>,_`_BK0/@_JVBZ_J<^OZ0FB:UK%C8:0_B*[TOQ)!HWZ4M\)OA<!G_A6_@$_
M]R=X=_\`E=0`S3O^2H^,?^Q!^&W_`*D7Q6KOJ\+L/AI\.'^(_BJQ?X?^"7L;
M;P3\/[NWLV\*Z$;6"ZO==^)<-Y<PVYL##%<7<-A8Q7,R())X[*T25G6VA"=M
M_P`*I^%W_1-O`/\`X1WAW_Y74`?+O@_]@/X)^`_#OC?P]X8OO&FG?\+&_9[/
M[._C.^CUFS*ZQHO]C3>'E\=G1AI:^';/XD2Z,]GI6H^)+/28%UW3="\,V.MV
M6H0^'=+$'&#_`()B?LSIXQ^+7C6VL_$>F:Q^T!K7P_U?X[W_`(>NM'\*^(OB
MQ#\)]<TWQ#\--%\3>//"VBZ+\0(-'\*WVF6]LMIHGBC2O[7T;;HNL/>:?!:Q
M0>E+\7/V,;GP)JGQ)T73?!?B_P`(Z1\,]=^+]U=_#_X,Z[\1=5N/`?AC5+W0
M]?O](\+^!/`OB'Q5K^MZ5K6FZAI-WX+T+1=1\;)J5E<V0\.M<PR1KYWX"_:M
M_8$^(USXTM]$TJ+0D^'WPZ/Q5\5ZE\3?V4OC'\&=!L_!5OX)\)?$76+G3_$?
MQ>^#?@?0/$.O>$O!OCOPAK7CWP5X<U+5_&_P]7Q!I]AXX\.^'M4D>R0`TO"_
M_!.3X!^$_P#A74EE>>.;B[^$'B?X:ZO\+M3N=<LAJO@[PE\)M7L+WP9\)XM2
M@TF&[U[X8V>D:!X.\.7OA_Q/+K-QJ-MX#\$^(;K47\;^&=,\3P??=?)=I\1/
MV--0U`Z5I\OP?O\`5`/@[*-.L/"&EWMZ]G^T!>)I_P`&]4CM;;0I9I=$\?WS
M/:Z+K\:-HRSVM_'?7UHVG7XM_=O^%4_"[_HFW@'_`,([P[_\KJ`.^KX'_;A_
MYIA_W.O_`+J5?77_``JGX7?]$V\`_P#A'>'?_E=7Q-^V+X4\+>&/^%=?\(UX
M:T#P]]N_X2[[;_8>CZ=I/VS[-_PC'V877V"VM_M'V?[1<>1YN_RO/F\L+YC[
M@#ZC^&GBK7;;X<?#^WA^&GC:_A@\$^%88KZTO_APEK>QQ:%8(EW;)??$"ROD
MM[E0)H5O+.TNA&ZBXMH)@\2=58Z_J.EPM;Z;\&O&6G0/*\[P6,_PGM(6GD"B
M29XX/B-&C2R!%$DA4NVU020!BY\*?^27?#;_`+$'P=_ZCNG5\3_\$[_AM\?/
MASHGQY7X_P"J?$;5-?\`%7QM\7>)O#S_`!"\0?%CQ(;+PQ?:SK!TC3O#NH_$
MG]L+]J/1&T6#318/;1?"_P`&_LQ>`X();:WLO@II=U#<7"@'U%\0/%6NSZ%8
M)+\-/&UDH\;?#2837-_\.'C>2V^(_A6XAM%%G\0+N87%_-$EC:,\26J75S"]
M]<V5B+B\@[;_`(3'Q%_T2GQ]_P"#'X7?_/)H^)/_`"+NG?\`8_?"G_U:/@ZN
M^H`X'_A,?$7_`$2GQ]_X,?A=_P#/)H_X3'Q%_P!$I\??^#'X7?\`SR:[ZB@#
M@?\`A,?$7_1*?'W_`(,?A=_\\FC_`(3'Q%_T2GQ]_P"#'X7?_/)KOJ*`.`?Q
M;K\J/')\)O'DD<BLDD;7_P`+71TD!5T=6^)!5E=2596!#`X(()JC=ZY?:@\,
MM_\`!?QA>R6\L,]O)=R_":Y>">W,C6\T+3?$5VBEA:65H9$*O$99"A4NV?3:
M<H!//Y>M`'F,.N7\$]W=6_P7\80W-_+!/?7$,OPFCGO9K5R]K-=RQ_$427$M
MNY+V\DS.\+$M&5)S2RZ[J$\:13?!CQE-%%);2QQ2S?">2..6R(-G(B/\12J2
M6A53;.JJT!`,13`->I``=!2T`>%>(/C/H?@[4O#>D>*O"^H>%=8\9ZJVF>$=
M+\0>,/@IH>I^*];DEL[,Z?X;LM1^*EM=:YJLESJ=A:-:Z9%=W;RZA9P&)GNX
M4DIGXR>$X-,U7Q6?"CPZ/'XKA\':YXD/B[X'1Z8GCC3_`!3!X#MO"NJZR?BH
MMJGBNQ\:M;^#(=#O+D:O;>*6@\.QVL>K%+.OBK]K'PYX>\3_`/!3C_@EG9^)
M-"T;Q!9V7@C]O;6K*UUO2['5K:TUC2/"?[/E]I.K6L%_!<16^IZ7>Q17FG7\
M2)=65U''<6TL4J*XR)O^",?[*+_`KQY\`;;Q-\<-/\.>.?C!9?&Y?%NG^.M'
MM?B+X0\8:7H%UI^CV/@KQ5'X1#^'?".C^*M3U[XD:9X4L[1=(M/%WB/7;*&!
M/!.HW'A%P#[_`-5^->F:#?ZEI6M^&M5T;4]&\*WGCK6--U7QC\%]/O\`2O!&
MG326VH>,M2L[SXJ0W%CX5L;B&:"\\0W4<6D6TT4D4]XCQLH^#/C9/\2OB!^V
MC_P3O_:+^&OP2^('Q+^$'P^\.?M6>&?%_C#P+XC^".N:=I+?&G1?@]H'@S7!
M.GQ=BM]1\.B[\,:[/J^HZ5/?/86FG3.EM<S-%`_O=M_P3R_9UM?VF8?VHDT_
MQ')XEA^#\'P1_P"%:7%YH5Q\$9O"%MX8/@B*]N?AU-X=>VN?$_\`PA+/X*;7
MYM0>Y?P;++X3=#X>D?33Y+_P1=CCA_X)=?L<11(D447PSOHXXXU5(XXT\:^*
M51$10%1$4!550%50```*`/OW_A,O$O\`T2GQ_P#^##X7?_/(K-UGXA>*-(TC
M5=6C^"_Q1UF32]-OM032-&NOA/<:OJKV5K+<KINE07/Q1L[:?4KYHA:V,5Q=
MVL$EU+$DMS!&S2KZK10!^9W_``3'\'_&;]G_`/8-_9H^#OQ5^!OC_P`-_$'P
M-X$GTWQ1H1UOX1WS:9?77B77=5CM9+JR^)L]K)*MGJ%LTHBE<12L\3D/&PK[
MN_X3+Q+_`-$I\?\`_@P^%W_SR*]#HH`\\_X3+Q(.OPI\?C_N(?"W_P">12?\
M)GXC_P"B5>/O_!C\+?\`YY%>AMC:<^GZ]OUK\1/BI\"/V]?C7/H7PUTCQG\7
M?@SI_A_XOZS;>*OBQ<?$_P`5KH'B/P7=_%KXX_$3P_X@\,Z?\"_VF?@Y\4]8
MT32O`Q^%?A0Z?J_BWP,;2]U3PYX<U_P=X_\`!7A[QSX#E`/UX_X3/Q'_`-$J
M\??^#'X6_P#SR*/^$S\1_P#1*O'W_@Q^%O\`\\BOQ=^%_P`*_P#@HAX9@^.V
MD:'_`,-"'Q_X[^(G[:7AG6?B#\<_V@=-\3?#2^\/_$?]LG4=/_9`^*_P0\/R
M>-?B@WP;@^"_[&XN]=U3PS\.?AQ\,_#MUKT_AG2/$WPU\=>.+B[UCP=S?QY_
M9K_;O^(GA1?%3:Q^T)X;^+D?PI^`WPB\:R_#K]I3]H+_`(5KXCUKX>?'CQ]8
M_%3XI^#_`(+_``;_`&V_V0H[2Y^*7@;P=\,?'D7B'PS\1/@O\48_!WBU_"VO
M:Q'->?$7X=:N`?N-_P`)GXC_`.B5>/O_``8_"W_YY%(?&7B(]?A3X^_\&/PN
M_P#GDUL>"[>^L_!WA.SU/[9_:5KX:T&WU'^T6OGO_MT&EVL5U]NDU3Q+XSU-
M[SSUD^U-J/C#Q7?--O:[\2Z[<&35+KI:`.!_X3'Q%_T2GQ]_X,?A=_\`/)H_
MX3'Q%_T2GQ]_X,?A=_\`/)KOJ*`.!_X3'Q%_T2GQ]_X,?A=_\\FC_A,?$7_1
M*?'W_@Q^%W_SR:[ZB@#\NOV@(/B;K4G[(GBOP?\`!7QOXQL_A#^WIXL^)GC&
MRT_Q?\"?#M\OAG5?!_[57PXN!I#?$+XQ>"].U?5M%\3_`!.T&#4-(M=1-Y>6
MMIJ]UX<CUY+:U6]_0!?B#J[^5L^&GC1O/N;BR@VZQ\*6\Z\M/M/VJTBQ\3#Y
MEU:FRO/M%NFZ6'[)<^:B^1+L_/']K3PMX4\::C_P3]\-^-O#6@^,/#6H?\%.
MO&LE[X>\2Z'8>(]%O;C3_A-^W%JFE37FD:G:7ME</INKV5AJEG/-;N;"^L[;
M4(GAFM$FB[#PI_P2_P#@9X*;X2KI?Q0_:3N3\'_VA/%'[1_@S^T?BBFH#_A/
M?&Z:))XWTK7F7PLJZGX&\5KIWC(:CX<OBEM:O\6/B#'H5WI,EYX/7PH`=9^T
M+=?$CQC\=OV"[GP]\$_'-[I'PT_:.^)7Q6\;:S-XO^`NG0:/X;M?V./VH?@U
M;6MKI&I?&>S\4^(]9U+QK\:O"D<-IX6\/ZW;:9I5CK^I^([W0X;33UU3Z[/C
M/Q$1C_A5/C[W_P")C\+N?_,D\5^6^K?L??"']F+X\?\`!/O4/`]UXU\4ZMXO
M_P""@?QL\4V_B#XH:S'XN\2^#K+XA_\`!.S]M[6/%O@GP7K%UH^GZKX=\$:Y
MXB\,Z3XGU;P_)+<37VO6ME-JMW<V^A^';+1?V)?&/?/'^?3^N*`/!K#Q5KH^
M(_BJX'PT\;/-+X)^'\+V*W_PX%U;1P:[\2WBNYG?X@)8FWO6N9H;9;>\GNDD
ML+LWEM:0O8RWO;?\)CXB_P"B4^/O_!C\+O\`YY-&G?\`)4?&/_8@_#;_`-2+
MXK5WU`'Y[_##]DSX>?"*+7/^$-^&7QLM+OQ5\$=.^!_BFXF\4_"5K77--TNR
M&F6_C>XT2'QS!H-I\0[C2H['2-6\2:?IMJ=<TG0_#5CK-M?1^'=*-OY/9?\`
M!.7X#Z?XQ^+/CFS^$7QCL?$?Q[L?AIHGQMUO2=5^!>@>*/B9X4^$L?PPB\%>
M#M=\<:!XGTOQS9>&K.'X9I9:A8Z!XCT=];TKQ5K^EZM/>6EIX83P_D>'?@]^
MW1KGP6^*7@?XM^)_'&JWVN_L6Z[HGP_\2>#?C'KOP\^*EA\=-734=3M_#>L:
M_P##_P`5>')M(\;^$=92QM/"_P`8O"WBK3IM=\)WUAH7B:YAUGP[KWB+QGX9
MX6_98_X*(>`/&G[2L7@[XH?%6X\,_%7P'X5^"_P,M?&'[1?Q>\:0_#G1HW^'
MGA?Q;\7_`!]XY^-7QH_:&FT/XH>`O`WAOQ1JGP;\4_`[X0>#-7^('BWQ[XOU
MC]IE?C)XST_P-XR\-@'U;X3_`&#_`(1^$9?!5S9?#CX]W=]\,?'_`(0\8_#/
M4[WQ?\(6U7P5X:\">+QXG\*_!^UU.#QE#>Z[\)M,L-/\)>%#X=\63Z]?WVE_
M#_P%KVI:O>>/?#%AXN3[_P#^$Q\1?]$I\??^#'X7?_/)K\V/#?A;_@HYJ>O^
M"?$/BO4(["SE\8_LN:!\9O!5CXJTVRT?;\-O%-A!\9/B[\%]4LM5FU"'P1\1
M8M'U6Y\3?"SQDT5_XC\!^*?#%[9IH7C#PMXO\+?$/]9:`.!_X3'Q%_T2GQ]_
MX,?A=_\`/)KXF_;%UC4=6_X5U]O\*:_X8^S_`/"7>5_;ESX6N/MWF_\`",>9
M]E_X1KQ+XAV?9O+3SS>_8]WVB'[,;C;<>1^B]?`_[</_`#3#_N=?_=2H`^A/
MAIX5UVY^''P_N(?B7XVL(9_!/A6:*QM+#X</:V4<NA6#I:6SWWP_O;Y[>V4B
M&%KR\N[HQHIN+F>8O*_SG^RU^U/X*_:Z\5_M)>$_AE\1?BO977[+_P`;O&WP
M$\=3Z[K?[(FI7U]XU^'OC?QM\//$MQ!X(^'NH^//B?X"T<^)/`.O'PZ?CGX%
M^$>M^-?#[Z9XP\%Z'X@\):E;ZV?HSX:?$OX<6'PX^']C??$#P397UEX)\*VE
MY9W?BK0K:ZM+JVT*PAN+:YMYK])H+B"9'BFAE1)(I$9'4,"!3^&+_LZ?!WPW
MJ?A+X=^,/`>@Z!J_Q"^+?Q3U"Q?XAV>K&?QS\<_BMXT^-OQ0UD76LZ_J%Y"O
MB/XE_$'Q;XA3389X]*T5-471]"LM,T.PT[3;4`N?$#PKKL&A6#R_$OQM>J?&
MWPTA$-S8?#A(TDN?B/X5MX;M39_#^TF-Q832I?6BO*]J]U;0I?6U[8FXLY^V
M_P"$.\1?]%6\??\`@N^%W_SMJXGX@?$OX<7NA6$-G\0/!-W,GC;X:7;Q6WBK
M0IY$M;#XC^%;Z^N62*_=A;V5C;7%Y=S$".VM8)KB9DAB=QVW_"UOA=_T4GP#
M_P"%CX=_^6-`!_PAWB+_`**MX^_\%WPN_P#G;4?\(=XB_P"BK>/O_!=\+O\`
MYVU'_"UOA=_T4GP#_P"%CX=_^6-'_"UOA=_T4GP#_P"%CX=_^6-`!_PAWB+_
M`**MX^_\%WPN_P#G;4?\(=XB_P"BK>/O_!=\+O\`YVU'_"UOA=_T4GP#_P"%
MCX=_^6-'_"UOA=_T4GP#_P"%CX=_^6-`!_PAWB+_`**MX^_\%WPN_P#G;4?\
M(=XB_P"BK>/O_!=\+O\`YVU'_"UOA=_T4GP#_P"%CX=_^6-'_"UOA=_T4GP#
M_P"%CX=_^6-`!_PAWB+_`**MX^_\%WPN_P#G;5XA^TUXD\9_`K]F[]H/XWZ/
M\0O&.NZO\&_@A\5_BKI6B:G9_#6#3=8U+X>>`]?\76.EZA/:_#<74-EJ%UI$
M5I=RVQ$\<$LCPD2!37M__"UOA=_T4GP#_P"%CX=_^6-?*/[>7CGP3XH_8;_;
M-\,^&?&/A;Q%XC\1?LH_M$Z%H'A_0O$&DZOK>N:WJ_PA\8:?I.CZ/I6GW=Q?
MZGJNIW]Q;V6GZ?96\]W>W<\-M;0R32HA`/S4U2#]M#XP_M6?\$J?BCK_`(;^
M(,UPOPH^)_B[Q3\8?A'8^$KCX+>"8?V@+/P]XC?P-XOO?%WP,UFXT%)/A'\)
M[C3Y]3B&LW6H?$+Q!H&BVVK?#^+7/#>H>(?2Y/VO?^"AW_#+WQE^+P_91^/D
M?Q8\`?'2W^'OA/X2VOA?P]JWBOQC\/=9U,:U8>/O#/@V3X4:'>>+M*T7P)KO
M@RSU+7)O%?@>+4/$\GCV34-`\$ZIX%'P^UW]!_V0OC7\*=3_`&6?V>9$\>>'
M-.ET_P"#OP^\/ZAIWB2_7PGKFG:SX7\-:=X;US3]1\/^*%TC7-/GLM9TJ^M5
M^V:?`EU'%'>V3W%A<VMU-]%_\+:^%W_12/`/_A9>'?\`Y84`?GIX%^,'[2/C
M7]K_`,>_LK^+O%]S\.M-O/V,?AI^TIX'\2^&[?P5X@\<>#?$'C[Q!K/PY\1>
M%O%=IXL^#NDZ!K%QX/\`&WAO7K_1;I/#VF1:II":1'KFBV5Z^IV,?TI^S'^R
M59_LK?`3X9?L^>!/C-\5M4\)_"[P^?#^C:CX@L_A//K%[#)J%[JEQ<7TEK\,
M+:W,DMYJ%RR)%"BQ1&.++E"[?(GASXC^"M2_X+`_%/Q7:^(;`>$-`_X)Z_"?
MX=ZAXTNVFT_P5)XY;]H'XE>.'\*Z5XQU"&U\,Z_K5OX5\1Z-K%[9:%JNI2V$
M-YY-Z(+NVN[>#],O^%M?"[_HI'@'_P`++P[_`/+"@`_X0OQ%_P!%7\??^"WX
M7?\`SMZ\Q^+WB)_@SX)N/&NO_$7XOZ\K:UX6\*:#X8\(^'/A1JOBKQ=XR\<^
M)=*\'>#/">@6=WX"TS2TU'Q#XHUO2],74]?U?0_"^@P7$^O>+/$'A_PSI>K:
MU8>G?\+:^%W_`$4CP#_X67AW_P"6%>??%&Y_9Y^,G@K5?A_\0?&G@?5?#>KS
MZ3>E;'XCVWAW6M)UKP[K%AXC\,>)O#/B?PYX@TKQ)X4\6^%/$FE:5XD\*>*_
M#>JZ7XA\->(=+T[6M$U&QU*RMKF,`^%O$7_!2#X!_#GXD>#O@9\<_BO\9_V?
M/VBO'J_LMIX1_9U^+<G[*=C\7O%-]^UE^T;XQ_9C\$Z?X'T;PA>>,=#^*#^!
M?'/@G4_$GQ=U3X4^(O'/AWP1\-[W1_&7]M:K:W_V:+O-._;G^`>J16DUI\>_
MBP8+_P`7_&CP':W$WA;X56]J?%?P7D\+23Z5=WD_@6.TTH?$_2?'7@3Q!\&+
M[6)[#3OB'I'CKP.=/N[?4O&/AK3M5WKW]ES]AC5K/Q5#KWBG_A)M2\;Q_L\_
M\)3XJ\4?M-_$/Q'XSU:?]E7]H;QO^U3\!+QO%NL_$R\UZQN/A_\`'7XB^+/&
M.GC3+ZQM[VSOK+P9JD%[X&T/0O#6FV]-_99_X)U:*-4M=%\'?`K1M`USX::C
M\)-:\%Z1XGTC2_`.J>"]7T[3-'U:#4/`UAKMOX7O-=U71]#T+2=3\73Z5)XK
MO[#0=!@N]9F&BZ6;0`\?\0?\%"/AYH7P_P#B1\8?M_[3&I_!?X=>!?BOXK7X
MMVQ_8QTOPAXU\3?`N'Q7%\8OA7X3M?%'BWP]XPM?&7PXU_P7XC\&>*_%'CCP
MMX+^"VF>,-,NM&D^+3-;7<UO];_LZ_$.#]I;X*^`/CGX*^)GCZP\+?$32[G5
M]'M/^$G_`&3/B4(+>UU;4-(D7_A./V?Y/C+\'?$6;C39F-WX%^)OB[3(=WV2
MYOX-4MK_`$^S\)US]C__`()]^(CJD>IW>A2:=J&E^,[&RT&+]H+Q?!X7\)ZK
M\1?#$_@_QUXV\`>%H_B"/#WP_P#B#XKT*[U%-;\;^#M-T7Q#?ZMKGBGQ)->G
MQ)XR\7ZOKOUQX,\5_"+P/X9TOPMI_P`7M)UNTTE+E(=4\9_%F+QKXFN_M-[<
M7SMJGB;Q-K^I:UJCQR7,D-NU]>S&ULX[:QM_+M+:"*,`ZC_A#O$7_15O'W_@
MN^%W_P`[:C_A#O$7_15O'W_@N^%W_P`[:C_A:WPN_P"BD^`?_"Q\._\`RQH_
MX6M\+O\`HI/@'_PL?#O_`,L:`#_A#O$7_15O'W_@N^%W_P`[:C_A#O$7_15O
M'W_@N^%W_P`[:C_A:WPN_P"BD^`?_"Q\._\`RQH_X6M\+O\`HI/@'_PL?#O_
M`,L:`#_A#O$7_15O'W_@N^%W_P`[:C_A#O$7_15O'W_@N^%W_P`[:C_A:WPN
M_P"BD^`?_"Q\._\`RQH_X6M\+O\`HI/@'_PL?#O_`,L:`#_A#O$7_15O'W_@
MN^%W_P`[:C_A#O$7_15O'W_@N^%W_P`[:C_A:WPN_P"BD^`?_"Q\._\`RQH_
MX6M\+O\`HI/@'_PL?#O_`,L:`/@?]H/0O@G;^$?@A/\`'_QQ\?;B:7]L/7K#
MX&VGP>T[Q)-XT@^.L-_\<8[#6+#_`(4CX*'CD6D_@&U^)M_XPCO;B3P,VAWF
MO6VK:6FCO::=%U?AW]M?]E[Q9_PK;^P/VQ-8U#_A;GQG\=?L_>`/+TGP"G]N
M_%CX<_VS_P`)1X53S?A0GV6Y@_L8_89KSR(-4_M;P_\`8'N/[;L/-\4_:H^+
M_P`)_"NM_L!ZSXF^)WP\\.:/I/\`P4H\7:CJNJZ[XU\-Z1INFZ?K_P`'_P!M
MC3]!O]0O]0U."UL[/6[_`%_0K+2+JYEC@U*[UO2+:S>:?4K))OMNR\)?L7Z;
M_9G]G>%?V8+#^Q?$EIXRT?[%HGPIM?[)\7V'_"(_8/%>F>1:Q_8/$EE_P@'@
M3[)KEKY6J6W_``A/A'R;I/\`A&]'^Q`'R<GQA_9#_:&^-O[+M_H_[0?Q>^)'
MC[PS\:/C=X.^!VL>%M.OX/AUX3^.7A_X(_$ZS^(6E^.X-'^'6E_#)O&5Q\$[
M+XO0_#]OBEIVIW;Z,GCJZ^&[V]W-J]S)^B'_``AGB/\`Z*KX^_\`!=\+?_G;
MU^=_Q\\3_LR?#_\`:#_X)S^'_`.N_`GP3J/BK]M[XJ_$;7=$\(:K\/O#=[XC
MFL/^"='[:GA;Q#X\U;3=%FLY]8DLY]8\"^'-9\47D-PUO-JGA+2+V^1[W1[>
M7]$C\6?A=SCXD>`?8_\`"8^'?Y?VC0!PMAX5UT_$?Q5;CXE^-DFB\$_#^9[Y
M;#X<&ZN8Y]=^):16DR/\/WL1;V36TTULUO9P73R7]V+RYNX4L8K+MO\`A#O$
M7_15O'W_`(+OA=_\[:N)L/B7\.$^(_BJ^?X@>"4L;GP3\/[2WO&\5:$+6>ZL
MM=^)<UY;0W!OQ#+<6D-_8RW,*.9(([VT>546YA+]M_PM;X7?]%)\`_\`A8^'
M?_EC0!\Z+^T#\)+GP+JGQ)T7]HWXD>,/"&D?#/7?B_=7?P_^'.F_$75;CP'X
M8U2]T/7[_2/"W@3X&^(?%6OZWI6LZ;J&DW?@O0M%U'QLFI65U9#PZUS#)&OG
M?@+]M/\`9W^(USXTMM$_:)^.^AI\/OATWQ6\5:E\3?V<O&?P9T&S\%6_@GPE
M\1=8N=/\1_%_]F/P-H'B'7O"7@WQWX0UGQ[X)\.:EJWC?X>CQ!I]AXX\.^']
M3=[))?A?^SC^R5\(HM<_X0WXI:?:7?BKX(Z=\#_%-Q-\2?"K6NNZ;I=D-,M_
M&]QHD1@T&T^(=QI4=CI&K>(]/TVU.N:3H?AJQUFVOH_#NE&W\GLOV"_V$]/\
M8_%GQS9_$+1;'Q)\>[+X::)\;=;TGQK\.]`\4?$SPI\)8_AA%X*\':[XXT#3
MM+\<67AJSB^&:66HV.@>(]'?6]+\5Z_I>K3WEI:>&$\/@'U9:?&KX3ZAJ!TK
M3_VI-<O]4`^#L@TZQT_X>7EZ]G^T!>)I_P`'-4CM;;X52S2Z)X_O6>UT77HT
M;1DGM=0COK^T;3K\6WNW_"'>(O\`HJWC[_P7?"[_`.=M7P!X3_8U_8Q\(R^"
MKFR^+`N[[X8^/_"/C'X9ZE>_$_PBVJ^"_#?@3Q>/$_A7X06NIP10WNN_"?3+
M#3_"7A0^'?%D^O7]]I?P_P#`6O:EJ][X\\,6'BY/O_\`X6M\+O\`HI/@'_PL
M?#O_`,L:`#_A#O$7_15O'W_@N^%W_P`[:OB;]L71]1TG_A77V_Q7K_B?[1_P
MEWE?VY;>%K?[#Y7_``C'F?9?^$:\->'M_P!I\Q//%[]LV_9X?LPM]UQY_P!L
M_P#"UOA=_P!%)\`_^%CX=_\`EC7Q-^V+XK\+>)_^%=?\(UXET#Q#]A_X2[[;
M_8>L:=JWV/[3_P`(Q]F-U]@N;C[/]H^SW'D>;L\WR)O++>6^T`^P_!&M67AO
MX(^#_$6I>?\`V=H'PKT#6K_[-$UQ<BRTKPC:7UU]G@4AII_(@E\J)6#22;4!
M!;->(_LV?M-^)OC5KFJ:!X[\">`/ASJNH>"O"?Q9^'FB>$OC#>?%7Q!JWPH\
M::=IE]HVK>/K>3X8>`-!\(^,()-5M+?5M"\!>)?C%X'A^T6SZ3\4=:>2:"V]
M.^&GBK7;;X<?#^WA^&GC:_A@\$^%88KZTO\`X<):WL<6A6")=VR7WQ`LKY+>
MY4":%;RSM+H1NHN+:"8/$F'\._A_\._A%?>)-2^%?[*<7PYU#QC<Q7?BJ]\$
MZ!\#_#%UX@FM[G4+VV_M6?1O'5G+>0VU]J^LZA;VTSO;6^H:SK%_!%'=ZKJ$
MUR`>I?$G_D7=._['[X4_^K1\'5WU>%_$#Q5KL^A6"2_#3QM9*/&WPTF$US?_
M``X>-Y+;XC^%;B&T46?Q`NYA<7\T26-HSQ):I=7,+WUS96(N+R#MO^$Q\1?]
M$I\??^#'X7?_`#R:`.^HK@?^$Q\1?]$I\??^#'X7?_/)H_X3'Q%_T2GQ]_X,
M?A=_\\F@#OJ_G!\*_P#!3W]OC7?C%X7\`ZWX`^"GA+PEXJ_:,UKP9I6O:Y\,
MO`.@>+M2^%FB>([6RNKG3/"?Q`_X*;_#[1[[PE=^'-:\,:AX4_:'L/&.H?%'
MQWXCN/'WA?1/^"=UO_PJ^XU;Q=_0!_PF/B+_`*)3X^_\&/PN_P#GDUFW&KW-
MXUN]W\$_%ET]I)'-:O</\))VM98G:2*6W,OQ$8PR1222/&\95D>1V4AF)(!^
M2'Q%_P""B/[3\6K?!FR\&^`_A[X(MM7^.6@?L]_&`^-?!V@:U<P?$OP-X>U?
M5_VC+;X>W7QC_:__`&*?#5[X`T35+[PCH'@/X@:-XB^)OBO49M-\7W6A?!OX
MF2+'I^B_*OPC_P""I_\`P4&^)_[%/@[]K?4=%_9L\!7FJ_`[XO\`Q@U7X<>)
MO@#X@37M7:R_9K\*?&[X30^'7LO^"@MSHOAOP7]M\6:9J-KXP^)GB+PKK'QN
M^'E[INMWG@?]E^:\:YM_Z'+S7+[44@34/@OXOODMK@7=NEY+\)KE8+L%F%U"
ML_Q%D$5P"[D3(%D!9CNRS$OD\0:C+&\$OP:\92P20-:R0R3_``G>*2U>$V[V
MSQM\1MC0-;DP-"P,;0DP[2AVT`?E+^RS^WI^T#\2_B=X)\)_$WQ=^S5J\FO>
M*/"OPZU/X.^$?!^C>$OCK+=ZQ\,M6^)&O?&G1+[X9_MN?MH_"O4/A_X7FM[/
MPMK7@KP[XF\96.E6NGZ_XHO_`(YIKMM_PK&VLZC^V;^T]X4/B?3_`(B?&;]B
MWX<#3/BG^TN_ACQW\0?@]\4/!?@WQEX(^`GQ,T_P#HWP#T2SU#]J&]2^^-_C
M#3K+Q)XJU;XI67BRZ@\-Z?=:&N@?LO\`CZWT[7[Z/]2++4YM-F6YT[X(>*=/
MN%MC9K/9'X16LRV9E$QM5E@^(<;BV,RK*8`WE&50^TN`:M3^(=3N%A2X^#GC
M.=+>[2_MUFN/A1*L%_'*UPE["K_$9EBNXYW>9+E-LRS.T@<.Q)`/E3XD>+OC
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M"R.K@,2K*P!`!\<R?M!?%_2_^"9WPK_:-T[Q-\-6^-OB3]G/]GOQG?>*OBY:
MZ9IW@6]\9_$30OA^WB?6+_P_IWB[X/>'M0UB^F\0ZO=>$O`H^(GP@\*^)_%\
MVA>$+[XB?#+P]J=SXNT'\]/B!_P4E_;IM?`WBWXI_#WP+\()_A)XC^*_PO\`
MA[\#OB5XC^$OA311KEGXH^&MMX]UV[C\'_&+_@I!^S@/$=U<)#JPO!\:O&7[
M%LWP]F2Q\/:1I?QTUB5);G]NM$EB\->%=%\#:!\"O$^C^#O#F@:9X6T'PM8-
M\);?0M)\-Z-I\&E:3H=CI<?Q%6RM]*T_3;:"QL[*.(6\-K!%`B"-%`T;S7+[
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M\4>'(-;L_P#A2^F_L+_;VH>;-/\`\*9\8^?<1V\4\WG_``G\V>*S;?:132'X
MB[Y([5SN@1RRP,2T05CDK<Z_J-Y#);7?P:\975O*MNDL%S/\)YX9$M)?/M4D
MBE^(S(ZVT_[ZW5E(AE'F1A'YH`_*_P"-_P#P42^,.FS?&?PI\'--^'6CW7A+
MX&:9XH^%_P`??&WPK^*7Q'^`?CKX[^"M'\/_`!-^,7PKTY=,\=_!5/%UIJWP
MC\3K<?#M_"_Q*AUWPYKG@+XM:CXZL)XO"6G^%]?YKP9_P4?^.'B6Y\13ZWJW
M[-G@^]^%WQP_:!^%+_"36/#7CB+XJ?MAP_"+]M']HS]E#3X?V:)+SXL:=9^!
M]?BM?@]X3UK4HI=`_:)75O&_B:_\&:IIWPUT=M"\9ZA^O3>)]8=/+?X0^-WC
MW3/Y;7GPJ9-]R)5N'VGXCE=UPL\ZS-C,HFE#EA(X:-O$.IO-;7+_``<\9O<6
M4ES+9W#7'PH,UG+>AUO)+:4_$8O!)=K(ZW+Q,C3AW$I<,:`/R0N/^"F'QCET
M_P""\^L^&/AG\'7\5V?PI\1^-+_QQX:\4>+M)\7>$OB-JGB6*RN_@+):?$;X
M>KXRUZ^L-(ACUCP7;7GB'XB_#V70_'NIP>`OBA:Z;X$L?B/]G>#?VC/VD_B#
MXG^(=EX'_9M\#^(/!W@;XT:O\)!XOU'X\#PM<7,7AGXH^(?"GBWQ!=>&)?AK
MK5[;IX;\%6FA^)GL[:_OI=;U2^N=(T?>896@^HG\1ZK*MNDGP=\:2):2126B
M/<_"ETM7@*-`]NK?$9A"\+HAB:,*8RB%""HQQ'@CPWH7PXO?$NI^#?@1X[TC
M4O&&JZOK/B74'\0^!-3O]7U#7/&OC3XA:@]S>:O\6+^X6U7Q;\0_&.HZ=IT$
MD6G:+;:Q_8NBV>GZ'I^EZ98@'R%)_P`%#=<^'WQ)/PD_:'^$'AWX7?$"^\-_
M#W7]%\.Z/\7M'\6F[N_'/Q5\%_"]_#%MJ5UX>\.6VOZWIUMXN/Q"D70(;D+X
M:TK5[*:!)=)GU:XT/V7?^"BL?[1?C;6O!FJ_`_Q'\.Y]$T*:_N9XO%>G>/;N
M76T_9_\`V6/VGT\.6NCZ!HMK>7UQ_P`*D_:_^%<$MSIQO?,^(NE^._"6EVNJ
MZ-I/ASQEXN^M-,T72])\;^+OB-9?`_Q^?&?CF/PM%XCUB]\2^!M36:+P7I^J
M:7X;BTK3=4^+-[I/AJ.PL];UA9$\-V&DKJ%QJ=]>ZF+R\N9KANSB\3ZQ`0T/
MPA\;Q,J[%:*\^%495"D$>P%?B."%\NVMH]H(79;P*!MBC"@'SQ??$;]H'XC?
M$I],^!M]X"\(^%],^''PJ\=ZQH?QX^%_Q#L/%;Q>-]2_:.T"[M5TVV\0^$->
M\/:BNM?#[P'(UCKVDOY6DKK-W"SRW5M;W&;I/C7]K#P3\8/@AX-^,^O_``$U
M[PW\5-0O_#LJ?#'P5X[T'5+?5_#GP*UWQQXNO9+SQ3XWUV*&R3X@>&Y;3PK'
M!;32W'A&]F?6EAUA[8:=]%P:E);:]J'BJW^!WB:'Q1J^D:/X?U7Q)$/A%%KV
MIZ#X>O=<U'0-$U'6$^(:ZA>:1H>H>)_$M_H^FW-Q+9:;>^(=<NK.&"?5K^2>
MOJ-Q%J^N>'O$^K?`;Q!J?B3PC_:W_"*>(=0@^#MYKGAC^W[--/UW_A'M6N/B
M!)?Z+_;5A%'8ZM_9MQ;?VC9QI;7GG0HJ``^`9?\`@J/X?U2_L]+\`_!^_P#&
MNH6O@*'Q?XSM8?B'X>TU_!/B"SU;2=$\6_"K5W73-2BMOBAX,U+Q%X;@\0>%
M-8DT*\TL:W9RZU_8\<D+3_3G[,G[2&N?'OQ+\4K#4O#=CX>T[P7;>%%M;:RN
M+G4S8^(9/$7Q-\`^.O#TOB"6.PAU^#2_%OPLU'5-$U)=`\.WESX9\0Z'=:CI
M-G<W7V:W]SC\0:C$9C'\&O&49N)9IYS'/\*$,UQ<M$\\TQ7XC#S)9WMX'FD?
M<\K01-(6,:%<S29QH6I^)=:T?X(>+].U;QCJ5KK'BC4+:Z^%D=WK>I6.D:?H
M-G=7\P^))>5[;2=+LK.%`5BC6)Y503W%S+*`>NT5P/\`PF/B+_HE/C[_`,&/
MPN_^>31_PF/B+_HE/C[_`,&/PN_^>30!\L_%;XZ>._@QH_P%T+X=>"?"?C;Q
M1\??VQ_'/P1B@\:^,-8\$Z!X?TRZD_:&^*6M^(Y=4T+P?XXU"ZOK;2/A9>:;
MI6EIH@M[S4M5M7N[^RM8)9#YOX0_;A^/GB$?"/\`M?\`8(_:'\,'QU^T7XO^
M$/CC^T='O"/AE\-[7^R_^%??&W5A_9$?V[PEXK_X3;P'_;+0E#X2^R_$[^V#
M!_PK7Q/_`&;0^.NA_%SQ?+^R;XE^'WP%^(GQ!MO@S^W3XT^+'CK3]`\3_!+1
M=4M/!E]X-_:I^'.H7>G-XX^,/@ZROKWP]XF^)N@0ZM96^I+<SVMKJ][X?&N+
M;6?V[[[/BSQ$?)_XM5\1/W#ADQJ_PT&XK&\6)B/B9_I"['8E)_,1I`DQ'G1Q
MR*`?#7@C]M;XV^)_B7\"/"GC#]E'Q)\%?#/Q5_:9^+G[-FL7?Q2\0:CIGB[[
M5X._9Y^+W[0W@+XA_#O1+?PE_9'C/P/XJT#X/ZMHNO:G/K^D)HFM:Q8V.D/X
MBN]+\20:/^E!0@9)SZ^OU]_TKX4_:`L_BYXX^-?[#&L>%_@%\2=2\-?"']HS
MQ_\`%CXD>)SXC^!EEIOACPS-^QW^U%\%M(MY+'4/C%:^(]7U?7_''QJ\*6^F
MVOAW0M8MK;3;'7]1UZ]T:.TT]-4^K#XR\1]#\*?'_P#X,?A</_>DT`-T[_DJ
M/C'_`+$'X;?^I%\5J[ZO"[#Q5KH^(_BJX'PT\;/-+X)^'\+V*W_PX%U;1P:[
M\2WBNYG?X@)8FWO6N9H;9;>\GNDDL+LWEM:0O8RWO;?\)CXB_P"B4^/O_!C\
M+O\`YY-`'P-H?_!1N+Q[\+OBAXO^''PEM[GXA_##]F/6/VC=2^%_Q&^(5WX#
M:6*S^VWV@Z/<^)=&^'GC^>+PCXW\/6%QK/A+XE:+X:\1V%W<PW_AF_T'3O%'
MAWQ=I/AWQ3PU_P`%:?$UKK7[4FC?%?\`9MTCPDO[,OPS\':[J>N^#?BYXZUW
MP=K?QB\<+X#T+P;\%Y?'?QB_9N_9Y\"S/\4/B)XSU;PS\*?''PS\2_%RP&C_
M``\\9:S\>]$_9Y\1S>#_``+XL_22'PQX1MM';P_;_LS75OH;^"9_AJ^E0:7\
M%H;!_AW<K*D_@B2VC\?+$_A699Y_,T%U;32UQ<,;;=/,7KQ^#?!$.M6'B.']
ME^6+7M+U"?5M.UB/1_@I'J-EJ=S+!/-?VUVGCT3179GM;:X2=6$D5Q!%<1,D
MT:N`#YFTO_@I/\+_`!!XA^'VD:#X2\07FC?%ZX_9H'PH\97=P=.\.>,XOVA;
MC17O]$\]]-FNO#OQ$^&NAZROB;5OAYXCMM-U?Q+H^GZ[+X>N)7\&_$-/!GZ/
MU\]V'A#P3I27<>F_LOR6,5]XJLO'-Y':Z-\$X([CQIIWB"[\66'BR5$\>*K>
M(K'Q/J%]XAM-9Q_:%MK-Y=:C#<)=S22MZ-_PF/B+_HE/C[_P8_"[_P">30!W
MU?`_[</_`#3#_N=?_=2KZZ_X3'Q%_P!$I\??^#'X7?\`SR:^)OVQ=8U'5O\`
MA77V_P`*:_X8^S_\)=Y7]N7/A:X^W>;_`,(QYGV7_A&O$OB'9]F\M//-[]CW
M?:(?LQN-MQY`!]4Z9:Z[>_LWZ?9>%VNT\37?P1M+7PZ]A=C3[Y-=N/`<<6D-
M97YFMA97:Z@]N;>[-Q;BVF"3>?$$\Q?$/V,_!O[7?@^W\?1?M;_$/PE\2==O
M=/\`A0/"&M>`_`_BCX;>%[*RT_P!:67B;2'\(^+?C[^T/J<OBJT\3)>/XL\8
MP>+=&TWQC?307]GX:L1;R7%W[3\-/B7\.+#X<?#^QOOB!X)LKZR\$^%;2\L[
MOQ5H5M=6EU;:%80W%M<V\U^DT%Q!,CQ30RHDD4B,CJ&!`[;_`(6M\+O^BD^`
M?_"Q\.__`"QH`/B3_P`B[IW_`&/WPI_]6CX.KOJ\+^('Q+^'%[H5A#9_$#P3
M=S)XV^&EV\5MXJT*>1+6P^(_A6^OKEDBOW86]E8VUQ>7<Q`CMK6":XF9(8G<
M=M_PM;X7?]%)\`_^%CX=_P#EC0!WU%16=S:ZC:6U_8W5O>6-[!%=6=Y:317-
MK=VMPBRP7-M<0N\,]O/$R2PS1.\<L;*Z,5()L^7G.3G)R.,8/Y\C//UQZ4`*
MJC`XSGGFG8'H/R%-"D?Q?H?\?_K9YQFN?U[Q9X8\+?9?^$E\2^'_``]]O\_[
M%_;FKZ?I/VO[*8?M'V7^T+F#[1]G^TV_GF+?Y7G0^9L\Q-P!T6!Z#\A1@>@_
M(5Y[_P`+9^%__12/`'_A8>'O_EE1_P`+9^%__12/`'_A8>'O_EE0!Z%@>@_(
M48'H/R%>>_\`"V?A?_T4CP!_X6'A[_Y94?\`"V?A?_T4CP!_X6'A[_Y94`>A
M8'H/R%&!Z#\A7GO_``MGX7_]%(\`?^%AX>_^65'_``MGX7_]%(\`?^%AX>_^
M65`'P/\`%'XR_M.7'_!03Q1\"/A%XJ\-0>#O`/[!,?[1&F?#;6/`^BZPWQ.^
M+OB/XA?&+X;>&M#U7Q?>^(?"^J>'-!AU'P_X0U%TL-=TJ&XEL+BVO=2L;+4+
MNZA\TTCQ)_P6+B^%'[(\FJ?#_P""DWQ3/Q8U70?VK;:2\\)W-I8?#.PU&#X<
M:-XYM]2L_$^C:9XLBUA]3O?C_?\`AKP!H/PXUZ7PQH6F^"(;_P`+^(+6^\.^
M.>NDUJ+1_P#@JS/\8@VCZE\(/&?["O@[X,1?$K3/&WPZE\.>'OB%X6^-OQ:^
M(]_HWB2TN?&5IXFM([CP_J>C1Z??Z?X?U.RN-3UFQLWGA5+^>R_17_A;/PO_
M`.BD>`/_``L/#W_RRH`_+OX[?$K_`(*3_#[P]_P4R^(&J-\.OAG\(?@W\%/%
M?Q6_9#^(EIHG@WQMJ.O7OPT\.7'CG4-(UWP5)XBFU71[75=(\/ZIX5\3W/BY
M]:EUK4-:M_%W@Z/X=P:/_P`(?JOZ9?`KQ7J_C[X(_!SQUXB>WE\0>-?A7\/?
M%NNRVMNEK:R:QXC\(Z1K&IR6ULF4M[=[V\G:&!"5AC*QJ2JBOF#]O'QQX?\`
M&7[%'[6/@7X>ZMX?^(/COXA_L\_%SX;^#O!WAGQEX$CUC6_$WQ%\#ZUX)T2*
M*;Q#XJT'1K:SM=1UZWO]7N[W5K9+/2+6_NHENKB&*TG]4_9^\:>"_!?P%^"7
M@[Q-XZ\`Z7XD\)_"+X;>&O$&F-XX\*73:=KFA>#=%TO5K%KJQUBZLKAK2_M;
MBW,]G<W-K,8_,MYY8F21@#Z>V+Z?J?\`&C8OI^I_QKS[_A;/PO\`^BD>`/\`
MPL/#W_RRH_X6S\+_`/HI'@#_`,+#P]_\LJ`/0=B^GZG_`!HV+Z?J?\:\^_X6
MS\+_`/HI'@#_`,+#P]_\LJ3_`(6S\,/^BE>`?_"P\.__`"QH`^0_VV/VG_&_
M[-OB+X%+X;UOX3Z;X:\<:OXQTWQ?I_C/1-?\7^/]=O8[;P[HGP^TKP%X9\/^
M/?`]]8:'>>-?%.GV_C_XBV^G_$U_!$#^'(=7^'-CX'\1^-?C)\'?SDM?^"CG
M_!0;PAJOPFL?BS\&OA=9:EJG[,WCC]H'Q9X&TWP#X$TGQEXYDM?#?C[5/`/A
M[2[#2_\`@HG\3_$_PTFUW6O!\6DP:;\#/A__`,%%?%>J6-W:ZMXE\/?"F;54
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MA;QAXI\+Z[\//B3HOB*V^)_Q[TRR^(_C/PG;>-/@GK;_`!GTVP\'Z)X1TWP=
MJ5AKL-QX#^-D?BCQEH_BFUFU7X9:%HD6J:A^C4'Q#^#EJL:6WCKX9VZ12331
M+!XF\+PK'+<RB>XEC6.]4))/,!-,Z@-+*HD<LX!HE^(?P<GE@FF\<_#.::W%
MXL$LOB;PK))`NH\:@(7>]+1"^'_'X$91=?\`+??0!^'_`,9?^"J/[36A_`OQ
MW\=/`_@?X=?#>Y^$/A7]KWXG^)O@[\=?@I\7U\9?$OX3>`_V6/BE^U)^RUXR
M\(ZY<?%7X4W_`,/K'Q;IOPSU7X;?$V]UWX;^/K+5O'>A^/D\$'2-(\*:?J'B
M;T;XK_\`!2[XX?#+4-/U#0K']GGXMZKXZ_:0^#WP`T[]F/P]_P`)5X3^./[/
M$?CS]L3X8?LSOXM_:`\::IX[UZRU"S\7Z1\2]'O]!C;X-_";3O!OC76_"6G6
MFK_&'PGK9\30?L!+\3?A+.Q:;X@_#J5F7RV:7Q7X:D+)LGCV$M?DE?*N;F,*
M<@)<3KC;+(&C7XC_``?6:YNE\>?#9;J\:U:[N5\4>%Q/=-8$FR-S,+[S)S:,
M2;4RLQMB28=A)H`\^_9@^-NH?'_X>:]X[U#0+OPN]A\6_C+X!M-#U31-6\.:
MY8:;\-_B7XE\$:?#XDT769[B[L?$B6VB1IKRQ2'3IM36YN-*']F36A/T57`+
M\5/A8HPOQ(\`*"68X\8>'0-S,69L#4>K,2S'J6))R232_P#"UOA=_P!%)\`_
M^%CX=_\`EC0!XQKWQ_\`AY\`?"?@ZX^(!\5RR_%3]HKQ[\)/`VE^"O`GC#XA
MZ]K7C;6_&GQ7\46]C'H'@C1M=UF.RM/#?@[Q-KFJZM)8KIVEZ;I%U<7EQ$H0
M/SOAS_@H5^QWXL_X5M_8'QO\,ZA_PMSXS^.OV?O`'EQ:FG]N_%CX<_VS_P`)
M1X53S;%/LMS!_8Q^PRWGD0ZI_:WA_P"P//\`VW8>;\G_`+57Q=^$_A;6OV`]
M9\3?$_X>>'-'TG_@I/XNU+5-5UWQIX;TC3=,T[7_`(/_`+:]AH5]J%]J&IV]
MK966MWWB#0K+2+JYECAU*[UK2+:R>:;4K-)OMBR\'?L7Z;_9G]G>%OV8+#^Q
M?$EIXRT?[%H?PIM?[)\7V'_"(_8/%6F>1:Q_8?$EE_P@'@3[)KEKY6IVW_"$
M^$?)NE_X1O1OL0!A>#/V]/V7OB1XS^'7@;X>?$&[\;:I\3_B/\1OA#X>U/PY
MX0\87_A:P^)?PN\&>+/B#XF\&>*_%/\`8<>A^$]<N/!W@3QGKWAFSUZ]L7\5
MV/A?6Y?#YOQI]QL^PSC!ST[U^5'Q\\1_LR?#_P#:#_X)S^'_``#KWP)\$ZCX
MJ_;>^*OQ&UW1/"&J?#_PW>^(YK#_`()T?MJ>%O$'CS5M-T6>RGUB2SGUCP+X
M<UGQ1>0W#6\VJ>$](O;Y'O='MY?T2_X6M\+O^BD^`?\`PL?#O_RQH`-._P"2
MH^,?^Q!^&W_J1?%:N^KPNP^)?PX3XC^*KY_B!X)2QN?!/P_M+>\;Q5H0M9[J
MRUWXES7EM#<&_$,MQ:0W]C+<PHYD@CO;1Y51;F$OVW_"UOA=_P!%)\`_^%CX
M=_\`EC0!^5]A_P`%=-%\9_L9?%W]K+X9?!&XU35_A%_P3Z\$?\%`=7^#WQ#^
M(I^'^MMX3\7>"O&GQ/'@6_\`$&C>`?B$FG7M]\-O!C^)?`_BVST#6=!\87.M
MZ5I5W%X76'6=0TI;7_@J]J>A6O[7L_Q._9_L?#[?LKZSIG@2$^#?B-\0M=TK
MQ]\6M9\7:?\`#G0/`$'B[XG?LZ?!'P1%!XO\<7.I#PWXP^'_`(E^+/AW0O!G
MASQ%XD^,DWP?UO1]1\&VWWE'X5_8YA\#7GPQBT/]G"/X<ZA\(M-_9_O_``&E
MG\-D\(7GP*T?2-5\/Z3\&KKPXJC29_A=IFA:[K6C6'@.6T?PQ::7JVI6,&F)
M;7MQ')JPV?[*UOX@T[Q9`/@/#XGTG6M7\2:;XABN/`D>M67B#7KCQ%=:QK<&
MI)*MXFJZC<^,/%D]S?B;[4\OB;Q`_FAM8U`W`!\^Z#_P42^%OBOXB>%O`OAK
M1+W4-/\`B)XN^#VA?"WQQ/JL%MX5^).B_%?X4>&?B[-J'AJ_AL;Z,^*/"/A?
MQ9I.IWO@74)+/4=>\/R7OB3P[J%_8>'/&B>%OT(KY]T>#]EGP^DJ:$?@3HZ3
M>*+/QLZZ=<>!+,?\)?IUJECIWB9!!+'Y>N6%BBV-EJ482[L[(&TMY8K9GC/H
MG_"UOA=_T4GP#_X6/AW_`.6-`'?5\#_MP_\`-,/^YU_]U*OKK_A:WPN_Z*3X
M!_\`"Q\._P#RQKXF_;%\5^%O$_\`PKK_`(1KQ+H'B'[#_P`)=]M_L/6-.U;[
M']I_X1C[,;K[!<W'V?[1]GN/(\W9YOD3>66\M]H!]L_"G_DEWPV_[$'P=_ZC
MNG5L^#O&'ASQ]X=TWQ9X3U$:MX>U;[7_`&?J'V2^L//^PWUUIMU_HNI6MG>Q
M>5>V=S!F>VCW^7YD>^%XY&QOA3_R2[X;?]B#X._]1W3J?\-/A_I7PN\$Z+X$
MT2[U"^TO0O[2^RW6JO;27\O]IZO?ZQ-Y[VEM9V[;+C4)8XO+MH\0I&'WN&D8
M`9\2?^1=T[_L?OA3_P"K1\'5WU<#\2?^1=T[_L?OA3_ZM'P=7?4`2!$;RV**
M2C%T)`)1RKQEE)R58H[ID'.QV7."16192Z3I.FO8Z;ITNG:7X>MXM.M].L-!
MO[6UM;.QMHEMK31=/M;!5NK*VMEC@M8M&@N+=!']E@&Z(QKJ"4AE3RW(*.WF
MCRPBE2@5&!<2;Y`S,NV-T`B?S'1C&LGQ7^U-X3M?B9XM_8YT/Q)X$U[5/#)_
M:7\8KXFMS:QW?]E:3JG[%W[87ABWUJZU;P_J%Z/"Z#6=:T;3]+\1S:CI,UCK
MVLZ%;6%_!KEY8PD`^T#>PA[-"EUF^W>018WS(FV!K@_;)%MS'I^8U*K]O>VW
MSE;5-URZ1'YG_;?\2ZKX0_8U_:S\2:!KFN>%_$.A_LR?'[6]`\3^';_5=$UG
MPWK.B?"7Q=JVG:]IGB/1Y;6]\-ZGI%U9Q7^EZW;W^GW=CJ%O;36%W%?);FO*
MKW_@G;^QYJ>A:I\/M1^!NN7_`(2\2>$?A;X1U7[=\3_B)>V47A_X*WTU_P##
MS1S/=?$Z;7HKJTO5-WX@U*R@EN_'PO/L_P`1-3\3VK3VD&A^P5X"\,_#?]F&
M\^&_A3X8#P-\._#_`,;/VP[7P!X!@\-6/AC0G^&VL?M8_'35_!%EX=\+7S:?
M'I_AG4_!^I:/)H-OJEGI-A>:->V5W;!](N8+R0`Z>W_9B1O$</C=?VE?VN)=
M)F\?Z]XYC\%GXEW@\-_8/$/A&W\$:7\/SIS^%#XI3X>^&)5/C31[2?5CK[>,
MYI?$&O>)M3T=!I4?GWP`TO4OA'\?_C-\(/\`A:7QL^-NE^`_V9OV29[>Z^*/
MC?5?'WB_4/&NN?$#]LG2]7US5?M`TKPOX>\2^*_#W@_P-;:_K.GZ/X0T;6K;
M1O#VL:K@20W\GWB+MXX[41Z7>!9+9Y&B1M.7[$T42.EG,/MZH9I"Q@B-HUS:
M+)&QEN8H3'*XD%I;WEQ=6^G1)=:B;<7U]#!:QS7(MH9DMVO9@Z7-R+:-1;PA
MA,T2SQK&!#YS0@'Y8?'WP%^TOJOQ<^/>JZ9X=_:8\2:OJ/A;5[']DCQE\$OC
MO:_#3X(?#CPQJOP%T_3M;\/?&CX87_QM\):5XY^*3_'C0_%^M:3X]U?X1^-M
M4T?PO\0?A?IWP\\2^%KKPO\`$#6-'\OF\&?\%;_#]U?W.H^,?A[\4M1\'_%C
MP]\:+^_\"Z;JGP,\.?$SX=^`/@[\'M(G_9L\%_#SQQ\9?VC);;6OBAXCU#XN
MKJ7B'Q#\4?`G@]_B#X:T7Q9>WGAO1M5E^W_0?[(W[,WQS^"?[3'[7OQ2\=6O
MPIE\$?M-^/=6\=WUUX;U[6[WQ9)JOAO56\/_``O0Z,W@[PWI%OI?_"I[B"R\
M67WBG6?'_P`0)_&&G_V%IWC*T^#GAKX5?#[P1W7[1OP1\$?'G]ICX,^"OB?X
M.U3Q-\.=:_95_;"\-:_>6,OBG08[&\UOXJ?L0WUEI,/COPG=:1J_A+6=?TO0
M/$!L1I?B'1M:U;2=)\0I8R3VECJGD@'RI>?"W_@H=%#I>F^)_$/Q#\<?#6+P
MMXEO/$5EX!^*>C_#[XZ:IHFM_'CP!K>M?"BS\1IXD\/Z.OCG3?AKI7BBQ^&/
MQ<T?Q=X'\2+X`US4/!-WXT\$_$C2;;XH^,OBOQ%^SU_P4?\`$7QR?5[G2_VL
MO"7[/?AK]EC1?!?PU^'VB?M3_'K7_'VI>(9/&?[75CXW.N_$[PY_P45^'$6A
M?&74?AQJ_P`"[G3?B!\=_`?[7?BVYCF\#0>"OB9\"/BKX6\4^,]'_:Z]_8F_
M9-TJXN?%VH_#0RRZ5\2+OXYW5Q>^*_B)K%HOC"W\#S^!KNXDT&?Q)?:=?>%S
MX(,^CO\`#DZ5<^!K@N^ICPM+X@D_M)NE_8ETK5/#W[&7[(^@:_IFHZ'KNA_L
MQ?`31];T76+&ZTS5M'U?3/A5X4LM2TO5=.O8H+S3]1T^\@FM+ZRNX8;FTN89
M8+B*.6-T`!\=^`/@?\0_'6N?!WP3\2[_`/:X^''@#0+?]H+7?ANEY\:OB'=_
M%/P]X0\*?$#]F5OACX5_:`^-G@_Q]X\B\<ZOXH@TSXB:IX?M?B?\2/&'CG7_
M``)>*NO:G=>/_#?BJ\TGTGXD_LYWWPMU+X->*/`'Q(_:L\=:V_QR^$N@:KI>
MM_%GXJ?$CP_%X6U;XT:AXY\<>)O$VC137FF:786'A;5M;\(7FOZTMEX:T[P%
M;:;X7G43W*R:C^C&]?7]#_A1O7U_0_X4`?FQX\^`/Q3M/BM\0/B+H7AGQ3XJ
M\$WWQ^\$^*=8^'OAOXHKH&O_`!*^#LWP(OM#\5^&?"@UGQKX;\.:(MC^T1J/
MA?XG:[X<\0>)?`NF^*]'\#Z_IKW>I66M6_A[Q%-IOP>^(OB*Q^!WPL^*/B'X
M\^"K+6_!W[3MV=9^'/Q*^(5[XG^&\FH?&;X;>-O@?X-\8?&?PX;^VB\8^$O@
MFNO_``RN/$WB/7=6M=;GLO&6B:!XS\77.M0:[KGZ0[U]?T/^%&]?7]#_`(4`
M?G/\:OV9[KP-I7A/QG\.OB)^U1XL\0Q?M&_L[2R^%9?C-\6?&WA^#POXS_;?
M^!GC3XFZCJ'A6UU*Z2;PUX4\!V7B;3+J?65N?#OACX6CQ(FNJ=._M'4UTO\`
M@H%\%_VC_CK;_LE>#/V>O'VM?#/2K+]K"R\4_M!>+=)\5?%7PQ86WP0\/_LX
M_M'W,&G>)H/@;^T+^S!\6O%&B:W\<'^"NCV_A[P=\6+2%/$=[X?\1>-O"_C;
MX;>'_&?A75?T#<@XP?7^E-))ZF@#\!?CI^SM^WS\1O!'C?PG\)[S]H;P/\:?
M%.J>'1\7_B1X_P#VI/BII_[/GCK6+'XY_"C5-&U7X#^%_@3^U3\./BY\%?`%
MM\,/#?C>Q\1:5\$=;_9IU2Z\(^);G3/'NC_$WX@7]U=:9]5?%']GS]I+7]'_
M`&:/$?@7QS\>XOB7\-/V5/BQX;U[4;KX]^*/`6FZO\6=7\*_#/1/"MW\2_AM
MHOQ#\0_!CX@_$-K:\^)X\)^)?B)X6^,&D>$/%_\`9_B?4=>O[W2=)\0/^I]%
M`'XO>&_@C^T5I'CC1/BWX`\'?M@V'A#X8Z=\4]2^$'P.^/7[:WQ1\2:QK'Q!
MU_X?7NY?C0(/VE_B7X;^)'PUUKXC76D1>!M+^+&N_%&\^&":9XLU'P5H_A?P
ME<^#M&'LG[-%O^VW\._B+\+/`G[1FB>.?B5I/AOPA\9OA[K_`,8_"OB[PEKG
MP_\`%NI:GXF^$'Q!^&7Q&\5:;JFN>#/%BWFE>%M3\;?"B;5#\-X-5/B7P9XF
MN;+1X?#/B/1M7UG]/:*`/@+Q-\`?AU\;OVQ?BK<_%+P'J6LZ#I7P"_8?\4^$
M]6D?Q9X7MYO%GP^^-G[:?B8:4OB+0;O17UB+0K[5/"NJ^*?`EUJ=[I5U#J.@
M?\)9H-YINHV45UYA^UE^P[^SAX-_9,^/>I^!/A/J>H>./"W[.G[56B?#:"/7
MOB5X^UF^\5_'+0=4U>_LDT'4M>\1-XLUO6OB(GA^[\)MJ6FZK>>"[^&RMO`[
M^&]-C>VK]3**`)OD_P!G]*:VS';/;'_UOZ_A4=%`!1110!X.WQ/^'/P9^$WB
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M(^!?!'_"/`'N?B+]HSX`>$M4TW0_$GQG^&FCZSJ_Q)\+_!S3M)N_&F@+J5S\
M5/&VS_A$/A\+%+U[F+Q9XD:2--&T6>**]OY)(X[>)Y)$5O:=@]3^G^%?EE^U
M[^S?\$/A1X3UCXP?#SX>Z5X7^(_QL_;C_P""7MY\4/$UE>:S--XJN]'_`."D
M'[,3V5U-I]]J=UI&F7);4)A?3Z)I^F2ZJEOID6JM>QZ-I"6/ZF>9[?K_`/6H
M`\]T[CXI>,1W'@'X;?\`J1?%?_"K_P`0O&VD?#7P#XX^(VOQ7\^@^`/!_B7Q
MMK5OI<,-QJ<VD>%-%O==U*+3K>YN;.WGOY+.PF2SAN+NUAEN&C2:Z@1FE6AI
MW_)4?&/_`&(/PV_]2+XK5M^,?">A>/?"/BKP+XILVU#PSXS\.:YX3\1V"7-U
M8O?:%XBTRZT?5[-+RRFM[VT:YT^\N(5N;2>"Z@,@EMYHY41U`/F+X-?ML?"3
MXY_LG^'/VQ/!>G>+O^%8^)!JD=OI5RO@W4O$L%[H7Q%U'X6ZQ;P:AX3\9^)O
MASXGTZ#Q7I-\^D>,O`?Q`\6_#_QIX;6Q\8^`/%WBOPIK6AZQJ7D$_P#P5'_9
MLT#1_#/COXFP>+?@M\#_`(C6&B^*O@_^TC\7-4^$?A3X"?%KX6ZYJ'@?2;3X
MQ:!X]3XK:BO@KP!+J?Q+\`VVFQ_&G3?A;XV\56_BK3=9\$^#?$WA]+[5K3Z"
MM_V0O@M;_#KPW\+5M_B&_A'PWXZ'Q&D@?XP_%;^U/%OBEM3DU>XD^(NNIXQC
MU?XCZ-=WCQBX\,^-;S6_#?V:STVSATJ"UTO3H;7*\'_L1_LZ>!O%6A^+]!\*
M^)'U/P?/_P`6\LM:^)7Q)\2^'/A7I3^((?%%UX4^$_A7Q#XKU/PY\-/!-_KE
MEHMQ?^#?!>EZ+X<N;'PKX(T&33O^$=\!^"])T``\!\(?\%8_V3/B+X;\:>(O
MAW>^._B`_@KQ98^$9=#\%^'M)\1ZOXKNM8_9TL/VH?#VL_#V?3?$D_A_QYX9
M\0_#/6?#PT_7O#.NZA8V^O>)?#]GK+Z7INJ0:N>UTG_@H7\-];ET^\T[X4_&
MC4/!MI??#OPS\3OB/H$?P>\8^"_@E\2/B]H_PY\0_"WX7>/Y?!'QC\2^(O$'
MB;QOX>^+WPP\1V7B+X->'?BO\+M#\,>.O#?BGQ?\0_#GAO4H-7/6V_\`P3[_
M`&3;.+7OL/PSN].U+Q!\5M5^-UQXETSQW\0]+\8:7\4=;^!7AK]FW4_%7A7Q
MAIWBJU\2^#YKKX.>#O"_A>73O"VJ:1H[W6C67B5M/;Q3&VLLFG_\$_\`]ES2
M[C27L_!GB>+2]/O?#6M:KX4;XJ?%-_`GCKQ;X-N);WPIX^^)G@5_&)\)?$CX
MA:!J366JZ?XX\9Z/K/B5-6\.^"-2EU*6]^'G@*;PT`;_`.SC^VC\#OVJ=6N]
M'^$.H^(M0N]/^!GP+^/^I1Z]X=NO#<^D>$OV@?$GQQ\(^$/#VMZ5JDD.MZ!\
M0-"U_P#9[^(>G^.O"&M:587_`(8GBTB.5[F2_D2S\W_;A_YIA_W.O_NI5]#_
M``N_9M^"?P7\3Z]XT^&G@/3/"WBSQ5\-O@Y\)/%'B"TN-0GU+Q)X$^`-GXQL
M/A)I>N2WEY<+J5YX1L?'OBFR@UVY237M0L]0@M-7U*_MM+TF&Q^>/VX?^:8?
M]SK_`.ZE0!]"?#3PKKMS\./A_<0_$OQM80S^"?"LT5C:6'PX>ULHY="L'2TM
MGOOA_>WSV]LI$,+7EY=W1C13<7,\Q>5^V_X0[Q%_T5;Q]_X+OA=_\[:CX4_\
MDN^&W_8@^#O_`%'=.KR[X5>"?B=9_&KX]_$_X@Z;X3T+3/&=K\._!7@/2/#'
MB[5_%TMWX6^&NH?$F[LO%NNOJ?A#PA%X>UCQ+:^/;*._\*V,>O6^BZAI%]%%
MXFURSEL;Z4`V_B!X5UV#0K!Y?B7XVO5/C;X:0B&YL/APD:27/Q'\*V\-VIL_
MA_:3&XL)I4OK17E>U>ZMH4OK:]L3<6<_F_[5]Q\2/A?^RS^TM\3/!7QF\=Z5
MXR^'7[/_`,9/'?A+5)="^$6HQZ;XF\(_#KQ'K^@W\FGZC\+[K3[Y+/5=/M+E
M[._MKFSNEC,-U!-`[QM[]\2?^1=T[_L?OA3_`.K1\'5XS^V=H&F>*_V</B%X
M6UWX=>%/BOX?U]?#UCXA\`^-?A]XF^*F@Z_H4?B?1[[4X_\`A`_"<]CJWB#7
M+6ULWO/"5M)K/AO2X_%]MH<^L^*?#6EQ76MV(!Q<?P`_:^'BS^T)/V]O$;>#
M/^$Z\0ZO_P`(R/V=?@7_`&V/A]<^$8=)\+>"3XI&A+;MKVD^,!/XRUOQP/#:
M0ZW8R1^$;/PEHD4;:_)SGP(T7]HC1_C5\1O@Q\7OVJ?&7Q9O/`W[/'[,_CF7
MQ/8?##X(?#NQO_&GQ"\??M4^%_&&K:;X=TCX>ZI=:3INL:7\)O!D\>AZCXE\
M2+I6H0ZG)I^HI:W_`-FB\`%]XKOK^:U\1?LI_#WX7V&L:0OB&]\8ZY\#_&WQ
M#F\6>)["Z5M-\):18>"O%&D^(O">I_$0:KKVJ:?K]_J-T_AJXT+7+/Q3X?\`
M$>H^/;%X/`/%M]^T!/XB\=?$35OV,O@9I&LSZ7HW@*TU+Q-^SA\3];U`>`?!
M_P"TK\%_AY\,K&[N?"7Q3U/2;KP=X#^$_P`6OBSXTTN6Q@\-ZS=:[X8\4ZZ?
M`?PX\'^&;RY\:@'[?GP7XB[?%?Q]^.G?"X?^\V-)_P`(7XC_`.BK>/3_`-P[
MX7?U^&PK\Q7^-O[0O@&31K;X??LS^$_A?-KGC^/5=?GA^'/Q2UKPQXPT'Q`/
MC?!:RV7_``BU]X+^P^.[RW^&_@;29++QII=Q#X3NM8CNXK"ZT7QCX+NU]@/Q
MC_:=NO`GA+6/#_AK1?'`U+QUXCTGQ=J&F_"GXT>$F\0^'/\`A0OCGXFP7GA+
M1-6^*.H>*_A[)X>^*FBZ1\.+S4KR\\8Z5XI>^3PYX3L-'\076GV%F`>E>._C
M+%\/W\>7FJ>(OC[J'A3X60(GQ.\=:/I'[/,OASP+KDWA71/&EOX9U>SU'3=,
M\7:CJDWAWQ/X5OFU'PSX7U[PI9KXBL1J7B2R%EKC:3Y=_P`-M?`5]<OO#-M^
MT#\3]0\2V.G_`-M?\(YI/AOX5:QXBO?#R_M#0?LSRZ_IWA_3/`=WK-[IZ?$*
M]TF\CAAL3JE]X8UK3-0TS3KW499M(MZ'CK6+B_\`AT_Q.\1?#WX,>._'%I\>
M/V9/@GX4^)OB;X'^+/#WAOQ#X-^,?QR^$7PH\2ZI9?#OQCXUO?&%MJ?@G1_B
MGXQTC0=7?QO=:<_B"U>Y@)L'U[PW+IP_"3]K_P#L[5Y$^$G_``3TL=;GG^)_
MQ>T[&D?%*YT^?]I,^+H+GX/>+-7EB\.VEVSW_AO3-+U;XJ?$&W27QCIGBZVM
M+7PE8:_86,.KT`85U^W-\*%\-^*?&NC_`!*^,?BGP3X=\2_&;P'IGBKP[>_L
MF7%E\0?B3\"+OQ-:>//AS\-M*O[_`$[Q1XN\4V[>$]6>V>TT"+P[;E/LNNZ_
MHFH6NIV>G])-^UEH6D^`_''Q(\57'[5?A3PSX)\"^-O'2+<^!?@-XI\0^,(O
MASI.F:IXU\+>#?"'PXTWQMXKU'QIHTFK6FCP:!J.C:0WB+6&DMO"MSKD,?VE
M][X"?#SP?X^UG]I7PO\`%/X-_`5-:^'/Q57X6WH\`>`&T;P_K.E_$+]G7X(?
M&7Q9)J=EK&IZR-4UVX\0?&SQ?X>O?%D$.BW>N^'X+-KC2].FN+^"7Z?T/X'?
M!_PW-J%QHGPV\'6$^JPZ?;ZC+'H=E*]Y#I=QIEY9I,UQ%*6"WNBZ/?3'AKR^
MTG3;V\,]U8VLT0!\'R?MY_#34_$7Q'\._#GQ'^T_\7O^%87>MZ=XA\0>`O!/
MP$M?"5[J6@^&O!?BF\MO#?B3X@:=X$TOQ!:O9>.++3K?7M.GD\,-XET7Q/X7
MFUN#7M&ET^7T#1?VJO"/B[51H'@'Q?\`M`^/=?M]"O\`Q3K6C^']"_9[LKGP
M[X;T&YTVR\6ZOJMSXJT[PWIDO_"(7NN^&[76-(T:_P!6\0WS^(;"3PSH_B"W
MM-;FTGZGM_@#\$+.XL;FR^$WP^L9--TZ[TFR6Q\*:-96\&F7UI%87=B+6UM(
M;5[::TAB@,4D+JJIF,*Q9C=U3X)?!_6H;.#5/AEX'NX=/6SCLT?PWI2"&#3T
MN([6U!BMD+V<<5W<Q-92%[2:*>2.>&1&VT`?'FK_`+66B:'X!U[XA7]S^U"-
M/L=7\/Z=X4T>T\,_LW7_`(@^)FF^)?C3H7P(TWQ/X+MK%;C3K/1AXU\2Z+<7
M-EX_U/P/XI@T"]_M$^&VN(+FQAYWX@_MN^"?AI:?"G4?$VK?M.+IOQXU6*W^
M"-W9>'OV9II/BIH$GAF[\5CQ=X7TF62WUZWL9-.;P[:Z=X0\1:5H/Q6\0ZWX
MV\*Z%X8^'>M:K/J]KHWW5H?P9^$WAI=830?ASX-TN/7_`!!IGBK68K3P_IJ1
MZAXBT7Q*WC/1=7FC-NT8O-%\7O)XIT>2-4&E^(9)-9L%M]0EDN&J+\"O@PMW
MJ-\?A9X"DO-6U"ZU74+B?PMH]S)/J5]I^OZ5>W@-Q:2"&:[T[Q7XHL[EK<1"
M>#Q'KJ2AO[6O_/`/CI=8_;3\:?%;XV^&OA3\1_AU)X+^#_QL;X<:@?'^D66E
M^*&T"\_9,^"?QC\/W%E=^'O`^M:3KVN:I\5?BQ-HVJ3SZ?X2T[0/A]IZW%M;
M^(?$<.-1P?&&J_M^?"W2_`WBCXC_`!-^##^'=4\2_L@>`/%=MX(T*?6-7'Q`
M^-'[1O@3X-_%[3]`DU_P9X;M(/"&C>'/'UCK?PU\6ZA'>:Q<ZSIE[;>*?`T=
ME/;$_H!X7^'7ACP?K_Q+\2Z%#J%OJGQ;\9:=X^\:O-JM_<V]WXFTOX=>!OA5
M:WEA:S7#PZ3#_P`(9\.O"=E+8Z<L%E+>Z?+J[0_VG>WEU/0\>_"GPE\2=,TK
M1_%9U^ZTS2/B+X"^*5O9VOB?Q!913^*_AGXNT?QWX-:Y^S7Z.^C:5XN\/:'K
MI\/Q-!H]U>:7:BZLYH!+#*`?&G[2W[1&M?"#1/VD?#GA#QS\1KOXI_!S]DOX
MI?M'>&]5\2Z#\&[SX8ZGK'@SPWKNI:1X+U)-.TG1O&.I:VEUIVGZUX@T&PL]
M&6/PA?6UXGBC3KC4K"1NDB\'_P#!0MO%RPR_$[X()X$/C[Q%"=2^QW(\6K\+
MK?P7"?"VIMHB_#671E^(&J_$5IX=;T%/$$OAS1/`Z1WMEXEUKQ`YTU??/B-^
MS5\#_BMI?C[3?&?PZ\/7\_Q+\%>)?A_XL\0VME'IWBVZ\.>+O!=Y\/-<CLO%
M-D(M;TK4[OP9>OX?&M:=>V^JQZ=;V%LMWY.G6*6_KMKHUK:1V$:7.L2_V=;S
M6T#W6O:S=23).NV1[]I[]QJ5QU:&YOQ<3VK'-K)`%4*`?#_P`U7]J35?B?XX
M^$G[0OQ.\-Q>+O!?P)_9Y^)FH-\&]"T)?#UOXJ^*GC+]H_PEXKTNRUGQIX,F
MU+7O#MNOP5T/5/#=U/X:\+:I:#6]4L=5@U%H+6Z3T?XM_$:;X.Z]X(T+7/%/
MQRUX^/?[4M-'U/PSI?[/\FG6_B"#5_"'AKPSX7U%=?T7P_J::QX_\5^.-`\,
M^%KBRTV^\/VFHS3W?C37/"&A0'6&]JTSX6^%-)^)GC#XN6W]N-XU\<^%_!G@
MK7+N?Q'K<NF#PSX!O?&FI^%]+L="^VC2+)+#5/B)XRU+[5'9F]DN]<N&-R(X
MK6*#HO$'@_PIXKC>'Q/X<T7Q#%)I^J:28]:TZUU-!IFMPVUOK%A$M[%,(K35
M(;.U2^@B"1W(@C,JL5S0!^='CGXN_M+^*_B3H?PD_9\\4?\`"/?$>Y^$G[0_
MB/Q'X1_:)TCX?HGAOXF_"[7OV11X+\.Z_P"*OA%H_BS2;#P]K'@;]I27QCJU
M[X4M/B+->Q?\(YIL%YX>U2VUZP;TA/!G_!0^35HT?XJ_`NST%OBFUE+<KI5Y
MJ6M1?!0^#I%3Q%'IY^'VE6$_Q-C^(;1,WA%M6MO"\O@9))!XRA\12+:Q?25A
M\!_A=HWBCP=XOT#PXOAS5O`O@WXE^`?#B^';_4-#L;?P[\7?$'P\\4>/8Y[/
M3;FUBN]2UC7OA9X,U%-;N-^L65QI]T;6]B74]16X]1O-/2]TV]TP7>HVJ7=I
M+9_;+*_N8-1MA)!]G%Q9WQD>>"[A4"6*?+-YX\YQ([N6`/F;]FC5?'_QE_9P
M_9_^+_B?XF>)[#Q+\5O@E\*?B3XAL=!T?X=6NAV6N>.?`F@^*-6M-%MM0\":
MI?V^DV]_JEQ#IT%]J>I7D-FD,=S?W<RO<2<5X\^.]OX&^-UO^S\FK_M&^+_B
M)J?@7PYXW\/1>%?#W[/B:%XCE\3ZC\2X++P=I^O>*M.\+6%CXL@T+X/_`!%\
M8WJ^(GT/PRGAWPZT,'B6Y\2ZEI'AV_\`IOP)\+O"'PU\#^"/ASX.@UC2_"/P
M[\$^%OA[X4TP>)_$<HT_PMX,L=/TW0+22:356EO+NVL=,M+6?5+IIM3OK9)+
M2\NY[6>6!Y]9^&/P_P#$=G>67B+PEHOB!-2TKPWHFIW6N6HU?5M3TSP=>ZIJ
M7A:WU/6]1-SK&H/X>U/6];U/2;F\OI[JRU/6-5U&&=+W4KV>8`^0?@O^TYX:
M^.WQ6^*/P=\%^*_V@8?%OP<O8]'\?2:MH?[/0TK1/$,'_")PZ_X>N[C1M.UJ
M\L=2\.ZAXHN]*>;5+#3](\7W?@KQ[-\,]4\=:9X:GU";S3PYK7_!0GXGZ#XU
M\3_"GXA?!"?2M+\8_M7_``^\-0_$"QNO#M^WC+X.?M2>/?@S\-K37%\._#WQ
M=!+X9N_A_P"!KKQ!X^\46,EMJMSXMN+:R\-^"K+2;B5[#]"M!^%_PY\+/++X
M7\#^%O#5Q/:+8RWGA_0]/T6^>U33O#ND1Q_;]-@M;Q3%IGA#PI8PRK.)8;?P
MUH4<3H-*L?(B^'7PS\*_"S1M4T#P?'JMMIFK>-OB'\0;N#4M=UC6B/$OQ2\>
M>)_B3XRGMY-4O+I[>TU#Q?XPU_4H+")EM;%+J*UMHX[:SLXH0#XOO]3_`&QO
M`WQH^$7A?XB_%/P#<?#;XO\`QVO/AGX;E\%^&M/E\:OX5L?V5/C%\8K[5-:N
M-<\*VNB>'?$5A\3/A+/H]O:V6G^+]+UGP)K%M.]QH?B&&98_M,^#/$8!/_"U
MO'IQ_P!0[X7_`/SM:C\5_#+POXT\4_#;Q?KZZO/JOPF\2:WXO\%QVVNZK9:=
M9^)->\%>*OAY>ZM>Z?:745OJD\/A#QOXKTBP6^6:"RCUNZF@B6XBM9;?MFM(
MFO8;\R7GGPV]W:I&+^_6R:*]>QDF:;35N1IUQ<(VG6XM+N>UEN[".2_BL9K>
M+5-36[`/EJY^$W@_XD?#/7_!/Q:\21>*?`'BCQ[XZT?5O!/Q`\*_!CQ/X,\2
MWMA\5_$-WIZ:EH'C7X;:QIFK7]SK>E6VOPV<T$T,&MQI<:/9V$5I96UKZYIO
M@N;2[#3-*TCXJ>*=.TNS4:%HVFZ;IGPCM+"U31X9K8:-IEG:?#6.WA72[;3K
MB`:=:QJ+*&PFB$,26KK'\`?M9^$_"WCC4O\`@G]X8\:>&_#_`(N\-W__``4Y
M\;RWWA_Q1HVG:_HE[-I?PC_;DU?3)KO2=5MKNPN9=/U6PL=3L)9H':TU&SL[
MVW:.YMX94[+PC_P2Y^!_@L?"@:3\4/VD)Q\&OV@?$_[2/@W^T_BI!>Y\=^./
M[!_X3?2M;SX8C_MCP3XK^Q>,/[1\,W/[JT_X6M\1/[#NM(\_PE_PB(!]1^-O
M@]X.\>W'@S3/B/XM'C2[\.^,]+^(7P\T_P`;>$_@9XCN-"^(7@.22^T3QQX,
MM-=^%EY)IGC/P9--+>:7XET..#6_#LDLEQ:7MFSLY[__`(0[Q%_T5;Q]_P""
M[X7?_.VK\O=:_8X^$G[+_P`>_P#@G_>^"+KQEXJUCQ7_`,%!?C?XF@\0_$W7
M;;QEXC\'V?Q`_P""=W[;^K^+_!7@C7)=*LM1T'P-KOB/PQI7BC4]"\^Z?4M=
MM;&XU&]N[;1/#EIHO[$4`>!V'A773\1_%5N/B7XV2:+P3\/YGOEL/AP;JYCG
MUWXEI%:3(_P_>Q%O9-;336S6]G!=/)?W8O+F[A2QBLNV_P"$.\1?]%6\??\`
M@N^%W_SMJ73P!\4O&0'3_A`?AMT_[&'XK?RZ5D_'.Q\::I\$_C%IOPW?48OB
M)J/PL^(-CX"DT?44TC5H_&EWX2U>W\+/I>K2W5E'I>HIKDEBUEJ,E[:)97(B
MN7NH%B,J`&K_`,(=XB_Z*MX^_P#!=\+O_G;4?\(=XB_Z*MX^_P#!=\+O_G;5
M^<'P2\/_`+8GP_\`V"OAQ\*_&VC?'#XB?'R^\<ZIX5D\=WGC#PW9>.?"W@K4
M/BSJOB/P_P"*O'VL>+_V@/B#XPM_"OA?P3+:>!K!9_C-^T#\9;[PCIN@:C\1
MO%/C3QKJ7BW5#X7X6^$?_!1XZE\/3X0U[XI?#?XN16VBR?M2?%+X[>/M4^.O
M[,'Q(^-%IXO\`VC>._@1^S?H/[4/A[Q+X1^!3^$/#OQ8OX_AEX*\:_LVZ9:Z
M3\1_AM'XS\%?$GXA:)XF/@L`_9/_`(0[Q%_T5;Q]_P""[X7?_.VH_P"$.\1?
M]%6\??\`@N^%W_SMJ_#GP=\(_P#@K'!X0^*ND?%3Q?\`$#Q5H^M?'^XMH/\`
MA7_CW2/!/Q#T_P"#T'_!/[P7H&K>+_@J\OQ;OM5L-#\6?M4:I\2X=.^&7COX
MSZ1XT\'^+=(\'>*_#7CZPT[?X\'ING_#G]N2\UGPOJ.K>#OVB]%^(D%W^S^O
MPCUGP]^U"[_`_P"%GP6L_#/PP7]HWX?_`+1OAKQ+\8O%4?QF^-OB#7_"GQD;
M2/B'XE^%WQF\0Z?:?%7X4:)X!^+7A[4?"_Q`^)FB`'Z\_P#"'>(O^BK>/O\`
MP7?"[_YVU?$W[8NCZCI/_"NOM_BO7_$_VC_A+O*_MRV\+6_V'RO^$8\S[+_P
MC7AKP]O^T^8GGB]^V;?L\/V86^ZX\^I^Q!X$_;=\&^//%*_M4^,]0\;^"+;]
MD/\`8I\'^!->U/7=$N-9UKXT>&=:_:BU;]HK7/&_AGP^(-%TOXF-I_B_X)>%
M_&7BSPY:P^$_B-!X1T'Q'H::9*FI>%_#?5?MP_\`-,/^YU_]U*@#Z$^&GQ`T
M*R^''P_LYK#QL\UIX)\*VTKVGPT^(]_:O)!H5A$[6U]8^%;FQO;<LA,-W9W$
M]K<QE9K>:6%T<]M_PLGP[_T#O'W_`(:GXH__`#'5A^$-?L_"?P)\+^*=1BN9
M].\-?"71-?OH+)(I+R6ST;P=;:C=16D<\]M!)<R06SI`DUQ;Q-*462>)"76W
M\&_BQH'QQ^''A?XJ^$M*\2Z;X/\`&NEV6O\`A*X\4Z7%HU_KWAS4[.VOM*\1
MVFF"]N[N#2-6M[@3:5-J$=E/J-HJ:I9V\VCWNEZC?`'-?$#X@:%=Z%8116'C
M9&3QM\-+DFY^&GQ'LHS'9?$?PK>3*LUYX5@A>X>&!TM+1'-U?W1AL;&&YOKF
MWMY>V_X63X=_Z!WC[_PU/Q1_^8ZCXD_\B[IW_8_?"G_U:/@ZN8_:*^(FM_"'
MX$_%SXI^&]/T_5=;^'GP_P#$_C'3['5HKN?2II?#VEW&I2-JD=A=65Y_9L$-
MO+<7[P7EJT5I%-*;F%$:50#I_P#A9/AW_H'>/O\`PU/Q1_\`F.H_X63X=_Z!
MWC[_`,-3\4?_`)CJ_$#XA?\`!3;]J^^^/O[5?ASX&^&O@%K_`.S;^SI^RSJ7
MQND^.VH>'QXN\)6VL^)?%/[77@+X=:MX@\46/[4_@#4=?\-67C+]F:"PU+PU
M\-_AEXGLO%5M-\1SXC^,/P&OO!WA:R^(/MS?\%+O%G@WP[H\6OZ)X,^-K^#O
MCEJ_A+XN?'GX&>&_$L'P*UW]G#X?^"_A;KOQD_:E\$6.G>,OC$W@#PE\+_%_
MQ;A^'/BK1?'OQ.U^QTWQ3\(OC59P>+M5/ANV,H!^J/\`PLGP[_T#O'W_`(:G
MXH__`#'4?\+)\._]`[Q]_P"&I^*/_P`QU?SU:E_P5#_;IT>Y\56FH:I^RD8?
M"=O_`,%#9+[Q/!\#&TKPQ;Q_LG?M'_M7?LV?#K5->T[Q[_P4J\!_$M--U.__
M`&:[;XB>,D^$'PZ^/EU>V/BJ\\(ZVOP1T+18/C!JGVOXK_;/_:*7]F?4?''P
M^\5?LX^*/'?@K]O']DC]D&\^-VG?#3Q;XL_9U^.WA7]H;XW_`+,?P5\9?%#X
M/>"?#G[2,?B/PH_P\\1_M'ZKX7U#1]:^-/Q`BT[XF_`SX@^";N\U"TU*R\2:
M0`?H/\0IOAO\3_#]IX9\6Z-\2KC2K'QE\.?'MHMA\.OB[I=S#XF^%/Q#\+_%
M+P5>BZL?"<,S0Z?XR\':#?75D[-9:I:VTVF:A#<6%W<V\O;_`/"R?#O_`$#O
M'W_AJ?BC_P#,=7P/\$_VQOB1X^^)>J:-J_B#X%>)]-UOP?\`%;Q9)\'_``#H
M_B>R^-?[*5U\,[K2]*L?"G[26KW/Q"\8:/XEU3QCJDNLV<MXO@;X#R^&]?TX
M>%_#^B?$VS@U7QGIWS!HO_!5;XTW'PB\`>.-?^"WAW2+WQM?Z\K^-H;+Q'=?
M"#1_!FG^/?!_PZ\2?%'Q+KLNO6S>#-$_9^/B74_BS\;O#&NZO)J&K_!CPW=>
M(_`.O3WJ>*;7P0`?JYX,;X;^`]4^(VM:!I/Q._M3XK>/&^(_C2\U'X>_%[4I
M-0\3CP=X/\`6TEJMWX4DBTS3[#P?X"\)Z'8Z98);V4%OI*3>4UW<7=Q/W?\`
MPLGP[_T#O'W_`(:GXH__`#'5^:$'[?\`K/A&#Q!H/B?XU?LC_&/5_#/A#X4^
M)8_B5\)!J7@WP'XR@U'X^^(/AW\==5TGPKJ_QF^*,^B:=\'_`(?:#J/B'Q7!
M:_$KQO:>!;K1=5U_Q?XD&DQWFAZ/XEX$_P""F?QP\5>-/'FJWFK_`+-,7A'3
M?BG\;/A=\,?@/:>&_%L?QU^*'A+PM\</VC?"?PP_:;\'^.[CXURZ-XM^$NI?
M!GX/^&?BUK^A:'\%$T[Q%X/U/Q-X_P#"WQ?L-"M=&T*]`/V<_P"%D^'?^@=X
M^_\`#4_%'_YCJ/\`A9/AW_H'>/O_``U/Q1_^8ZOS"\+?%_XR_M7_`/!(C]H[
MQ[\5=)\/Z[\4_'7[,_[2NE'PW\,?!G@?3[/49+_X4^)HM`T'1O"'PD_:U_;G
MTJ_U2_BO[6UMK.+XU7WBC6)KBV75/`7@S5+D^'8?LNW_`&'?V6SXKC\?0_#>
M=]=D\>>(/BDDA\<?$4:.?%WBOP5!\/\`4+Q?#!\5KX;CT:'P=#'IFC>$%TA/
M"/A^Y,FNZ+H-AXDDDU=@#W+_`(63X=_Z!WC[_P`-3\4?_F.H_P"%D^'?^@=X
M^_\`#4_%'_YCJ^3?V:O@?X"^!'[2GQM\#_"?P5J'A3X9^&OV8_V/?!VCSW`\
M3ZI;7FM>'O'O[8NH7VER^-O%,^I:IXRUS0?"OB7P.FHW>H:]KFKZ?H^H^&[/
M4;M(C8Q#[VV+Z?J?\:`/._\`A9/AW_H'>/O_``U/Q1_^8ZC_`(63X=_Z!WC[
M_P`-3\4?_F.KT38OI^I_QHV+Z?J?\:`/._\`A9/AW_H'>/O_``U/Q1_^8ZC_
M`(63X=_Z!WC[_P`-3\4?_F.KT38OI^I_QHV+Z?J?\:`/._\`A9/AW_H'>/O_
M``U/Q1_^8ZC_`(63X=_Z!WC[_P`-3\4?_F.K(^._Q6T[X&?"#X@_%?4-*U3Q
M%_PAOAR\U'2?"FA6_P!M\1>-O%-PT>F^#?`7ABRW(;_Q3X\\67VB^#_#&G^9
M']OU_6].M#+'YV]?@O\`9K_;E\<_&?XT?"KX:>,7^&7@K5=<^#NN2?$OX2V_
MACQJGQ=\,_'KP)KWB#1?'L&I6?BGQ5X<\4_#?X7WD&A)K_PLN/&7P<U./Q]X
M<OWN]0\?>$M;7PQX;\<`'Z%_\+)\._\`0.\??^&I^*/_`,QU'_"R?#O_`$#O
M'W_AJ?BC_P#,=7\^M_\`\%0?^"@VC>)/V1-(\3_"WX+>%=*_:53]HWXFQ:KJ
M'P_^'J7^I?!GX.>-_P!E?PWX<B\/Z+XE_P""F'@FWT^TU^P_:`UJ8?$+1]>^
M*7Q]UW^P](U#1O\`@GI93MKGAVP^JOA'^TM^TI\>_P!A/P_\3OV@]/M/@_\`
M$;4?VR_V2/AW+'\/DU#X(^*Y_`>O_M:?LR>&_$=AXS\#^%?V@?VA)_A9?^)H
M_%/C3P>OA[3/VB_B-!\2/A!<^$_B+J<O@X?%74OA)X)`/U@_X63X=_Z!WC[_
M`,-3\4?_`)CJ/^%D^'?^@=X^_P##4_%'_P"8ZOFQ/V+[LZ9J6FW'[7?[:,[:
MEX(^)G@_^T5^,NF6FIV&H?$CQ+)XA@\=:;<6G@J&.V\8_#6W:+PQ\+;AX9M$
MT'PU"+?6]$\3ZG))JS:W[*;7]IXK_:]\(W/C?Q?X\TOX??M)^'/"/A_4O&?C
M#5_&6HV%HO[(?[*GB'7M/M[W5;Z\73+>X\=>(?%^O7VA:4NGZ-IWB'6];^PZ
M5IXFDMT`/??^%D^'?^@=X^_\-3\4?_F.H_X63X=_Z!WC[_PU/Q1_^8ZO1-B^
MGZG_`!KS+XM?%'PW\(/AU\0OB-KWVO4++X>>$M1\5ZCH>BP2ZGXBU06UK=2Z
M3H>B:/9QW%_J.O>*-0M5T/PUI=I;3WNLZU<VVG6$%Q=3)$P!9_X63X=_Z!WC
M[_PU/Q1_^8ZC_A9/AW_H'>/O_#4_%'_YCJ_)WPU_P4Q^,6H>'R/$?P(_L+Q?
MX5\#^`-*^,FEIX?\<2W_`,)/CAXH^+_BWX>1Q>)O`VI?V5XTM_@[XW\.>']"
M\9^#O$]]#I_B+POHWQ"^'VN^/-(MO#>L^)=4\$?0O["7[5WQ'_:(DU>Q\?\`
MBGX$^/YY/`'A;XG#4/@1HWB#PXOPGE\9>(O%>F6OP2^*^BZY\2_BT)O'VAZ9
MH%M?Q>+8?$7A"7Q<5\022_"?P-;:18R:T`>GZQX0^#7QC\-^$[3XE>'/BEJ$
M_P`-/CQXV^+O@/4?"6F?M!>"]6\->-[+Q;\3-'TS6+7Q)\,8?#NK&3_A&O&?
MB'0=;\.W^ISZ9=6NKZIH7B;1II$N;.'Z/_X65X?_`.@?X_\`_#5?%+_YCZ^9
M_P!HGQSXK^&'[#'[8?Q+\":O+X?\<?#SX3?MF^.?!NO06]E=S:)XK\)#XM:_
MX>U>&TU*VO-/NI=-U?3[.]CM[^TNK*9X1%=6T\#/$WA2?"/_`(*0WV@^/8/A
MW^U7X`NO"7C7]F_P!X:^#7BSXI^%K#5/BGX&^+Z3^'[WQ+\4?&$?@[X>^&O!
MGB9-<T?Q+X[ABT>PT_3(K.\\%?#5#YQ\1>*-0T``^P?&.E?"'Q]XZ^$7Q'\5
M^'/BIJ7BOX%>(?%/BSX7S0>&/V@]*T/0O$_C+P)XB^&6N:_J/@_1]-T_P?XN
MU;_A!/%_BOPWHM]XST'Q#<>%[+Q+KTOAA]'O-7O[F?TS_A97A_\`Z!_C_P#\
M-5\4O_F/K\L?VO+;_@HM\.?V>_VIOC-J7[17P[\$^%/AM^P+XR^)-C:?"3P[
M:3>._#7[4?P>^&L_C[5+WPYJWCCP!J&C:Q\)O&'B;1]9T[4QKMC:^(/^$1@L
M=,T[1M&U;6I]<\.?LAL'J?T_PH`\&L/B!H2?$?Q5>&P\;&&?P3\/[9$7X:?$
M=[H26FN_$N65IK%/"IOK:W=;V$6UW<6\5K>R)=PV<T\UA?);=M_PLGP[_P!`
M[Q]_X:GXH_\`S'5Y%\;_`(T>%_V<=!_:,^/?C>TU34?"'P;_`&?]"^)/B6QT
M2Y\,V6L7NB^$+CXPZYJ%IIM[XU\1^#_!UE>W%M9O%;WOBSQ9X8\-VDCK<:YX
M@TC3(KK4+?RKXE?\%#_@3\,/V&M)_P""@.KVVOZK\$M;TSX1ZAIEMI7B3X-6
M>IS/\:_B7X+^$W@Z.X\=^*OBSX:_9_TO18/&'CS1?[?^(NK_`!KL/A+I'AN+
M4?&;_$";PE:KK,P!]9?\+)\._P#0.\??^&I^*/\`\QU'_"R?#O\`T#O'W_AJ
M?BC_`/,=7Q7:?\%*?A'JFC1^,-`^%_QU\5?#?28/`FG_`!,^)/A#P]\/_%?A
MWX/_`!#^*7AWX>>*OAI\)?&6B>'_`(F:C\0O$WC7QMH'Q9^&NL:5JWP;\$_%
M/X9V6@^-_#7BGQ!\0=%\)ZSI^NW'DA_X+(?LY6'CSP!\//%'P^^*/A#7_'GP
M9\$?&\6.I^.OV1-<\1Z'X9\?^-?$O@70]-MOAEX$_:E\8?&/XJZI!J?ABZO=
M9U7]GOX<?&/P)H^EWVG27OC..^>\T^R`/TO_`.%D^'?^@=X^_P##4_%'_P"8
MZC_A9/AW_H'>/O\`PU/Q1_\`F.K\T/B+_P`%H/V1?AS\6/B7\(;FS\>^)=;^
M&?[-?B_]J>ZU[PWJOP.C\*>+OAGX37XB3Q2^!]1\4_&OPSJ.LQ^(;'X6^+=1
ML_'%YI.E_!WPK;-X5C^)WQ-\`WWC_P`!V?B1_P`*_P#@LG^R]\5O%3>$--\.
M^-M/U%?AQH_Q%BFTGXA_LE?&:"^7Q'*]MX;\-Z1;?LT?M.?'#5]>G\0ZB]AX
M>T3XA:)I>H?`S4?'&K6/PWM_BT_Q&CO_``G8`'Z6?\+)\._]`[Q]_P"&I^*/
M_P`QU?$W[8OB73O$/_"NOL%MK]O]C_X2XR_VYX4\4^&-_P!H_P"$8\L6O_"2
MZ/I/V[;Y#^?]B^T?9MT/VGROM%OYGG?Q-_X*Y?!?X+^(_A=X(^+?P?\`BQ\.
M?B%\2;7XHW=U\/\`Q=\4?V'-)\4^"!\);;PE=>(=,U""?]L0Z9\4/$]]%XQT
M]='\$?LWZI\<?&WVBPUJRUKP[HUYIS6\G%>*_P!JCP!^V1\&/@O\</AKI.MZ
M-X7UF_\`B%IL%IK6O?"WQ?FXL(_!$TLNF>-O@A\1OB[\(/&.G&*]@C;6/A_\
M2O%VD6NI1ZCX?U"^L_$FB:YH^F@'Z?>!-&T[Q'\%/!OA[5X#<Z3KOPM\/:-J
MELLLT#7&G:IX3L[&]@6>WDBGA,MM/+&)8)(YHRV^.1'56&C\,OA;X(^#OA:W
M\$?#K1V\.>$;&8S:7X=BU#4;S2=$5[:U@EL]"M+^[NHM%TV62V;4)=+TQ;73
MFU:^U/5!;"^U*^FG_+O2?VC/C+H>EZ=HNE^,?LNF:/8V.E:=;'P]X5G^SV&G
MVT%I:0>=<Z'-<3>5;PQQ^;/++-)MW2R.Y+'1_P"&G_CG_P!#Q_Y;7@__`.9^
M@#]-OB3_`,B[IW_8_?"G_P!6CX.KF/VB=9^(GAWX$_%S7_A+;:A>_$O0_A_X
MGU?P1::3HT?B/5;CQ!INEW%Y8PZ7X>EM-077M2DDAVV&BQV%_<:K=F&QM;&\
MN9XK:7\X=2_:+^,FKVT=IJ/C'[1;PW^DZI''_P`(]X5AVWVAZI9ZUI<^Z#0X
MG/V74]/M+GRF8PS^3Y-Q'-;R2Q/?_P"&G_CG_P!#Q_Y;7@__`.9^@#Y:\??%
M;_@I%XV^-'[5_B/X2ZQ\0?`O['OPX_9#U#Q3\,XIO@1H6C^*O%/C'QEXD_;"
M\&Z*GPU^&/C[]D+QCXL^)_C#P#'\,OA/XNM-`UWQ_P"%-&\,>&-6T>[\2_!/
MX\:/\>O"NK^#/<K3]H;]L/PCX-T.Q^'WPU^*?QX\`?#SXQZUJVK_`!>\8_!C
M2?`7Q-^+G[&7PZ\&?"__`(6!?Z[\*[7X?_!*ST_XTZ]\3O&OQ9T3X9^%_A'\
M);>;XG>&_@=IWB;PIX"33/B7I<S=G_PT_P#'/_H>/_+:\'__`#/T?\-/_'/_
M`*'C_P`MKP?_`/,_0!\]?LY:S^WMK?[5OPG\*?&CXB?%OQ/\+H_B9^W-:>(#
M\4_AG\'_`(9KXG\"^!OVK_VJ?A1\$;&2+P=_P3C\06GBG3->^!/PR^$GQ)M9
M(_V@/V2[SQ+_`,+`?QW8>*?B_P"'O&GAOX?:5^DWQ[/QBU;XR_"_X'_!#XLV
M7P17Q=^SC^TUXRM=6;X:>#/B'H6F^-OAY\2_V1]"\%>(;_PMKMO87FHP>&=)
M^)OCL6FA:/XJ\+6.H:AK%M=ZU)?_`-DZ<EM\O?\`#3_QS_Z'C_RVO!__`,S]
M<[=_'+XFW_BK0O'%YKFFW/C#PSH?B7PSX?\`$DOA#P8VL:1X>\97OAC4O%>B
MV-[_`,(]YT&F^(-0\%>$;W5;16\F\NO#>C3S(TFGV[(`?;L'P1_:;CUZ;53^
MUM;6^GWWQ5C\1:G8Z7^SU\,[+5;[X20^"7\.6_PWD\07<^I%O%=IXG9/&UK\
M2;K2KN&**&/P<W@F323)?R=M^R/XLUWXD?LG_LQ_$+QI=6VK^+?'W[/OP;\<
M>+-432]*TJ+5/%'C#X;^'M=\1ZHNE:-9:?HVG?VGJNJ7]T]EI6GV.G6XN7M[
M.TM[8)"OP%?_`+2/QHU2POM,O_&2W-AJ-K<V%[;MX;\)*L]I=P-;W,+/'H*2
M*LL,CH2CJX#$JRL`11\-?'SXJ>#?#F@>$/"GB#3O#OA;PKHNE>&_#?A_1_!_
M@JPTG0M`T.Q@TS1]'TNQM_#J06>G:9IUK;65E:0(D-O;010QJJ(H`!^P":#H
M49M3'HNDH;*VEL[(IIUFIM+.=66>UM2L(^SVTRNZRP1;(I%=E=6#$%\>BZ/%
M<)=Q:3ID=U'9+IT=S'86J7$>GH`$L$F6(2+9*``MJK"!0`!'Z?DM_P`-/_'/
M_H>/_+:\'_\`S/T?\-/_`!S_`.AX_P#+:\'_`/S/T`?K#_PC/AO[%%II\/Z'
M_9T%S]L@L/[*L/L4-WAU^UQ6OV?R([G;)(//2,2XD<;\,V;-WH^D:A!#:W^E
MZ=>VUNR-;V]W96US!`T0"QM#%-$\<31J`$,:J4`PN`*_)7_AI_XY_P#0\?\`
MEM>#_P#YGZ/^&G_CG_T/'_EM>#__`)GZ`/UQ>QLI+J&]DM+:2\MHY8;>[D@C
M>Y@BGV&:*&=D,L4<WEIYJ(ZI)L4.&VC"-IU@TEE,UC9M+IPD&GRM;0F2P$L/
MV>463E"UJ);?]Q((#&'A_=ME/EK\C_\`AI_XY_\`0\?^6UX/_P#F?H_X:?\`
MCG_T/'_EM>#_`/YGZ`/UR6QLDDBE6SM5E@B6""1;>(20P(24AB<+NCB4DE8T
M*HN>%%6J_(/_`(:?^.?_`$/'_EM>#_\`YGZ/^&G_`(Y_]#Q_Y;7@_P#^9^@#
M]?**_(/_`(:?^.?_`$/'_EM>#_\`YGZ/^&G_`(Y_]#Q_Y;7@_P#^9^@#]6_%
MFO:1X3\,>(?%FO0ZE/HOA71-3\3:K'HOA[7?%NMO8>'[.;5[K^QO"WA;3-:\
M3^)-76&S=M+T'PWHVK:_JU^+>QT73;W4I[:VEN0064DBZG%:1)=7%NH-S)9_
M9[XP2K"_DSF:**[CXB@\RWG".C0QI)&KQ!5_)C_AI_XY_P#0\?\`EM>#_P#Y
MGZ/^&G_CG_T/'_EM>#__`)GZ`/UCN='TB]^Q?;-+TVZ_LUEDT[[38VT_V"1/
M+V/9>;$_V5U\J+:T'EE?*CP1L7!>Z3I.I6<^FZAIFG7^GW9A:YL;VRMKJSN6
MMS"\!N+:>.2"8PFVMFA,D;&,P0F,@Q1[?R<_X:?^.?\`T/'_`);7@_\`^9^C
M_AI_XY_]#Q_Y;7@__P"9^@#]:DL;*.#[+'9VJ6W[G_1TMXE@_P!'2*.W_<J@
MC_<1P0)#\O[I(8E3:L:!8K;2=+LA=I::;I]JM_(\M^MO96\"WTT@8227:QQ*
M+F20,XD:8.S!F#$ACG\FO^&G_CG_`-#Q_P"6UX/_`/F?H_X:?^.?_0\?^6UX
M/_\`F?H`_6"]T/1=2,QU'2-+OS<I;QW!O=/M+HSQVKR/;),9XI#,EN\TKP*^
MX0M+*T84NQ-U+6V1/+2WMTCW0OY:PQJF^W$2V[[0H7=`L$"PMC,0AB"%1&FW
M\DO^&G_CG_T/'_EM>#__`)GZ/^&G_CG_`-#Q_P"6UX/_`/F?H`_6X6]N'GD$
M$(DN0BW#B)`]PB(8T$[;0TH5"402%@$)48!(J&RT[3]-2:/3K"SL([BXDNYX
M[*U@M4GNI0BRW,RP)&LEQ(L:+),X:1PB!F(48_)?_AI_XY_]#Q_Y;7@__P"9
M^C_AI_XY_P#0\?\`EM>#_P#YGZ`/MCQW\)T^/7[,'[0/P,EUU_"\7QG\/?M0
M_">3Q-'IJZR_AU/B+KWQ+\'OKJ:0U]IBZJ^D+K!U!=-;4M/%\;<6IOK19?M$
M?M'PTT+Q/X3^'_@_PQXRU_0O%7B?P_X?TW1M8\1>&/"^H>"M!U>YTVV2T6]T
MWPKJOBWQYJ&AP2P0Q%K*Z\8:ZZS"5Q?%'6*/\K]._:,^,NCVTUKIWC'[/!-?
MZOJDD?\`PCWA6;=?ZYJE[K6J3[I]#E<?:M3U"\N?*5A#!YWDVT<-O'%$FA_P
MT_\`'/\`Z'C_`,MKP?\`_,_0!]Z_M8_!K7/VD/V9/CU^SWX>\9Z3\.[_`..7
MPH\<?"*X\;ZUX/O/'UGX;T/XBZ#>^$?%&HP^$['QCX`FU35H_#6KZM'H+/XJ
ML+/3M=DT[5=0M-:L+&YT+4OH/S/;]?\`ZU?D/_PT_P#'/_H>/_+:\'__`#/T
M?\-/_'/_`*'C_P`MKP?_`/,_0!]_>._AWX6^+NH?&7X8>.+6]O?!_C[X.^#?
M"GB2UTW6-5\/ZC-I&M:M\6[*]%AK>AW>GZQI%ZL4K/:ZCIE]:WMG.L<]O-'(
MBL.+;]BW]GFZ^%=W\%-;\)Z[XJ^&6H?$?X??%S4?"OB_X@>/_%%CJ'Q(^&WQ
MBT#]H'1?%EXVM>);R>:^USXU>'+'XC_$"W,@TWXD^([G6I?'=EXAM->UBUO?
MB6']HSXRPZI>ZU'XQVZGJ%AIVEWES_PCWA4^=8:/<ZO=:=!Y+:&;>/[//KFJ
M2>;%$DTWVK;/)*D%LL.A_P`-/_'/_H>/_+:\'_\`S/T`?6^L_L+_`+.'B#4;
M6^U?P[XVN[6.W\%KJWAQ?C#\7;7PAXPU3X;:=#I7PY\6^/?"=GXWM]`\<^/?
M`ME8:$/#'C[Q38:IXQT^[\'?#W4QK<FJ?#;P!>^&L3PW_P`$^_V;?">I'4M%
MT[XF1&\N]#U7Q+87?QN^+VI:3X[\0^'?B;XH^,>E^*?'^F:CXTNK7QCXFB^)
M'C'Q!XFDUK7$N[N6YNX;5W^P6&GVMM\Q_P##3_QS_P"AX_\`+:\'_P#S/T?\
M-/\`QS_Z'C_RVO!__P`S]`'N_B#_`()A_L6^(?&/CSQS+\*]0T+6?B7X>N?#
MWB^T\(?$/XC>#_#6H">Y^.%]#KUOX3\-^*=,\-Z;XMTV_P#VDOCEJ&D>*--T
MNUUC3+_XC:Y=VMU'-%ICV'J5E^Q=\`+<>)IM1T#Q7XFUCQK87NE^,?%/BSXE
M_$;Q#XO\3Z?>:5X<TF&WU?Q5J'BB37)I-$C\'^%M0\*7\-]!J?@[7=`TS7_"
MU[H^L0?;6^-O^&G_`(Y_]#Q_Y;7@_P#^9^C_`(:?^.?_`$/'_EM>#_\`YGZ`
M/I3_`(=Y?LU"6\NH[/XK1:EKEK\0+#QIK`^//QGDUKXC:=\4+?P?9^--.^(^
MK3^.)M0\::?JEEX"\+6:6>N3W4%G;Z=*MFD+ZAJ3WGF/[4?P\\(_"_P_\,/"
MO@;2WT/PVFI?$?5+/1$OM1OM/TN?6+KPK?ZC;Z1#J%U=G2]-GU&:ZOTTJR>'
M3;6YO+IK.UMXY3&/.?\`AI_XY_\`0\?^6UX/_P#F?K@?''Q0\<_$C^R_^$TU
MS^V?[&^V_P!F_P#$LT?3OLW]H_9/MG_()T^Q\[SOL-K_`,?'F^7Y7[K9ODW@
#'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g30330image10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image10.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`&X!
MS@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[4_P!H7]J/0/@)K'P\\#:=\-_B7\=?C-\6H_%U]\-O@7\&W^&,
M/Q&\6^'?AVGAV7XC>+K:]^,GQ,^#_P`-M(\+>`XO%WA0>(M5\2_$+1%^V^)O
M#VC:3%JNNZWI>EW?DWB;_@H/\.-,^`WP^^.7@[X2_'?XIW7Q)^-.G_L[Z'\%
MO#'A[X?^"OC/IWQFN/$&O^%=8\"^*=)^.OQ+^$'@7PSJ/A3Q#X8UK3/$%WJ_
MQ`M]*W6L=WHE_K6G7EE>7'3?M6?`'PW^T#K?PXC\&?&NX^!'[6WP;3Q!\2_@
M%\1?"]YHNL>+O#>D:C)I'ACQ]9>*OA=J]VEE\3_@7XZ230O"OQ,\+:Y9KI4]
MV?#&KZ'KGA7XAZ!X*\4:+^<?QV^*OQ4_:J_9_P#V;/#WC?5-3_9W^/OP[_X*
MH?#+]GKXD^-?@E_PB7B6QT3XA?#C5?%5M<_$'X,S?&;P#\0O"&I^'?%&CWFD
M:]I.G>//`?BP>&YM6U'PCKUK?Z[X=O+P@'ZG?!_]H+XB?$34/$<7Q,_8\_:+
M_98T#P[H$VO-XU^/7C#]CC5/"^J"VGC6[TRR;]G?]K'X^Z]87EI9-/JUS>^)
M=!T#P]%IUG<EM<^V>19S^$:'_P`%#X?B5#;^*OV=?V.?VQOVFO@G>6Z7NF_M
M$?##0/V>_!WPJ\1Z:-1U.QNM=\`:?^T/^T9\#?BW\5O"\=OI;ZWHWC#X4?"W
MQQX3\>Z!?:/JOPSUOQK!K&F_:?"_VVOV;/C9X4_80_;%LM>_:H_:K_;'T_Q#
M\(&@\1?"_P")'@;]E&*^U'X9:1X@TG6OC5X>\":5^RW^RK^S_P"+_$GBOQ]\
M'[/QKX+LO#^I:OXCAU>75H-/TC28=5NHK@_J9\+/&OPZ^(_PU\!^//A#X@\-
M>*OA;XN\):!K_P`/?$7@V]L=1\*:QX.U+3;>X\/WOA^\TQY+";2I=->W^QFT
M<PI"%C4+L*@`^`OC-_P5(^'7PI_9Q\0?M8>&OV<OVIOC=\$/AWH/Q(UKXXZY
M\/?#_P`$_`?BO]GZ[^$[0KXX\+?%;X6?M-_';]GSXJ0^+M*)O671/`_@SQO)
M<0Z;-=12FUU'P_/K/N?@/]L"3Q#XL^#O@'XE?LV_M`?L[^.?CGK?Q/TSP'X7
M^+-]^SEXANY])^%?@7P]X[U;Q=JFJ?`#]H7XX>'--\/ZY:Z]-H7AVU?6Y/%<
MFO:!K/\`;GAC0M#DT+7-;^9_^"P_C#PEXQ_X)&_\%,9O"/BGPYXIB\/?LP?M
M"^$]?E\.:WIFN1Z'XJT+P;J4&N>&=8?3+JZ73/$&C321PZKHUZ8-1TZ5TCN[
M:%V`/H7QU#G]MC_@F:(V5)#I7[68C9T,B*Y^!WA_8SQJ\3.JM@LBR1E@"H="
M=P`/0/&_[<&AV'C_`,:_"WX%?`']H?\`:_\`'?POU;3M"^*NG_L^Z1\)=(\*
M_#C6M2TV754\/Z]\6_VD/C#^SY\%M6\8Z=:"PD\1?#SP5\1O%?Q%\)QZYH-U
MXH\)Z/8ZK;73>A_`#]K#X8_M"ZMXV\%Z-I_COX<_%_X80^';GXH?`OXQ>$;S
MP%\6/`ECXNM[RX\+:Y>:+<2WVB>*O!GB3^S=7L]`^)'PX\1>-OAMK>LZ#XE\
M/Z5XOO->\,>(M-TOY3_X(YS6FG_L'_#+X?ZVUI!\=_A9KOQ"\$_M;Z8VGOI'
MB"']K./QUK^N?'OQ#XGTVXTW1[QKWXB^/-9U3XF:-KLNEVEEXN\)^,/#WBS0
M1+X>UG2I7M_$J\T'Q/\`\%9/V6M.^'\<NH>/OA/^RK^TMJ'[0^J:'J$1L_"?
MPD^*/B3X/VOP8\*?$>SMK^%_[3\??$CP5XG\3?"JWU2RO)8]/^'7Q3OM*BMH
M;G4;J0`^IOV0OVM_@9^W+^SW\._VF_V=?%B>+OA?\2-+:]TV>:.*TUW0=5M)
M6M-=\(>+M(CN+IM"\7>&-3BGTK7M(DGG6"Z@\^RNK[3;FQO[K7_9S_:-\$?M
M.^#_`!GXV\!:5XJTC2O`WQP^/'P"U:W\7V.D6&H7'C']GGXM>+?@WXTU+3HM
M&US7[:;PUJGB?P;JE_X7O+F[M-4O=!GL+K5M&T34);C2[7^>O_@FI\+?&?[)
M/_!.?]@W]OS]FKPOXB\4^'=>_8[^#3_MT?LQ^!=-;4+WXX>$]`\%Z7;6'[1?
MPL\*6,#S:C^U+\(O#UB;"[TW2D75?C_\+K*'X=WZZGXP\(_"=]-_13_@B3X\
M\(?%/]D/XH_$[X>Z]9>*O`/Q'_;\_P""CGCSP/XGTWSCIWB/PAXO_;7^-GB'
MPUKU@;B*"?[%K&BZC9:A:^?##-Y%Q'YD4;[D`!Z/XX_X*?>#_`_CC]J?16_9
M9_:S\5_"_P#8L\2+X:_:0_:(\%Z/^SYKGPQ\`W$/P;\#_'?5M1M?!!_:)M/V
MF?&FD^'_`(>_$/PW?:S<>!/V?O$MQ#<R:C':VEY:Z5?7L/Z3Z3JNG:[I6F:Y
MH]Y#J&DZSI]EJNEW]NQ:WOM.U&VCN[&\@8@%H;FVFBFB8@$HZD@9Q7\Y.B?L
M;^/OVO/C7_P6U\&:#^V'\<?@-X3\0_MB^!O"OB'X6>#]%^"%Y\'/B'%_PP;^
MQM?ZG%\5;[5_A--^T1+X<\6Z5<?\(;XWT7X6_M$_"BVU+P:DEI9-IVHW>K:E
MJ?WI^SS^W5\7_'O[+O[+'Q2\)?\`!/SX\?&*T^*W[/W@'QUJ>J_LN^./V-[/
MX.>%M:O([_1KWPAX3D_:5_:U_9[^(&HZ+#%HEMXD\+:G9^"=1\.W7@?Q-X5^
MS^)]0UJ/7M/T@`V_''_!3[P?X'\<?M3Z*W[+/[6?BOX7_L6>)%\-?M(?M$>"
M]'_9\USX8^`;B'X-^!_COJVHVO@@_M$VG[3/C32?#_P]^(?AN^UFX\"?L_>)
M;B&YDU&.UM+RUTJ^O8?TGTG5=.UW2M,US1[R'4-)UG3[+5=+O[=BUO?:=J-M
M'=V-Y`Q`+0W-M-%-$Q`)1U)`SBOYR=$_8W\??M>?&O\`X+:^#-!_;#^./P&\
M)^(?VQ?`WA7Q#\+/!^B_!"\^#GQ#B_X8-_8VO]3B^*M]J_PFF_:(E\.>+=*N
M/^$-\;Z+\+?VB?A1;:EX-22TLFT[4;O5M2U/]DOV#OC=<_M(?L:?LT?'*\\,
M>&?!MY\2O@]X+\0W7AKP1>3ZCX%TRY?2H;2=/`E_=0P75[X%N9;5[WP9=7,0
MGG\,7.E23-)(S2,`?6E%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`'SE\>?V3?@1^TI>>#M:^*GA77SXQ^'8UN/P!\3OAM\3/B
ME\"_C)X&L_$ZZ<GBK2?!_P`:/@;XT^'/Q7\,Z!XMCT?2(O%WA[1?&5EH?BJ'
M2M-B\0:?J4=A:)%\I?M/?#7_`()[?!+X$?#']GWXJ>%_B%X/\`6WQ`OOB;\)
M?AW^R[#^UK<_'J[^(WAG4]3\;>*_BCX0B_8M>^_:?UG7-/UGQ;JWC'XG?$6Q
MN+UI=1\27OB3XA:Y-<ZO+?7'Z=5\*?M;_LX?%3QGXV^%7[4G[,'B#P;H7[5G
M[/GAWXA^$/!NC?%-=:E^$/Q=^%7Q5O\`P+K'Q.^"WC^X\/\`G:[X+/BK5?AC
MX$U?PE\5O#VFZ]J_P\\3>'K._NO"?C7PW>Z_X3U8`?\`LU^#OV2_A7\-M2_:
M8^$OQV^+7B?X0>*O!3ZYJ/Q)^/7[<W[5G[07PWT?PEHTT][J6LF/]JGX[?$?
MPS\-[O19[6[M?%&I0V'AC7M)>ROM%\23VWV*ZL8?S\UK4O\`@CNFO:YXN-Y^
MU#^SQ\/-9O\`4->\4>-O`4W_``51_8G_`&!_%M[JFK:CKOB'Q5XG\9_#QO@I
M^P=XU7Q9J.K:Q>>,?%>LZMK$'C>W;5H_$^IZUI]A>Q6T'BKXP_"[]JS3_P#@
MF?8ZQ\)+[X'_``8\:_\`!0'XN^$_VHOV>?$'ACPU_9.A?M>?!+P/\>_%VA_"
M;XN3^']/O/!GB6W'[5O@B/X@:-XNL;B70?BE\0?#OP\\2VM_?77B&SAF_>74
MM-T[6=.O](U>PLM5TG5;*ZTW5-+U*U@OM.U+3KZ"2UO;"_LKJ.6VO+*\MI9;
M>ZM;B*2"X@DDBEC>-V4@'S1K7[+O[*&L?LH>+/V89/AIX"T7]DKQI\-?$7A?
MQ/X$\$W4_@+P9J7PZ\5Z;<S^)[F/7_`FI>']4LEU^QO+S5M5\7Z7KEIK>H7-
MW<Z[/K4E_<2WS]'X,L?@!^T;I_[/'[47@6ZTKXB:1H_A#4/&/[/WQ(T36M>3
M2CX1^+OA+3[&_P!5LK"&^LK'5(O$'A<6,!A\3Z5>7ND.K^5!IFJ)<D?G5_P5
M8\5:]'\)/A'_`,$]OV<?A;XK\:>*OVJ+F3PKXQ^%'P!U#X3>"/'?A3]ASX9R
M^'A^TMJG@./XE_$_X'?#OPPFK^%=;\-_`SPW=W?Q!\)KHNH_%2UU3PY_:&I^
M'X=(N.4_X)8^,=6^`GQ:^/G_``3^\8?`+XK?LL^"K75-=_:B_8>^%/QFU?X%
MZEJUG^SIX\URQA^+?PQ\&W/P#^._Q^\$R^'?@3\>-8U232-$A\6V>I>%_AS\
M6?AKI,WA_3M/M;&6Y`/LVX_9U_8Q_;6MM-_::\+67C.TUCQW90Z5+\</@%\6
MOVC?V0OBIX\T3P%J7B/PMI_AWQUXZ^!'CCX'_%'QEX9\+ZF?$-KHGAKQYJ&J
M:#I\S-J&D:<@:SO#\\_L^_M@?\$X/@EX?\7Z%^S)\+/VH[OP[<?$7QMI/COQ
M]\)/^"<'_!2?XTV7Q'^*/PX\0ZC\*?'>L>*?CWX<_9@\>_\`"Z_%OAOQ#X(O
M_`>K^.-4\?\`C74/.\+'0_[=FM])A@@]R_X)6_\`)A?P(_[J?_ZN7XAU\`?\
M$OO!7[?.K_LG76H?!7]I;]D#X?\`PRN/VL_^"B7_``C7A'XH_L/_`!G^,'CO
M2/*_X*%_M1P:S_;OQ%\)_P#!0CX'>'_$7V_Q!%JNIZ9_9_PN\+_V3H][I^A7
M7]MWNF7/B+5@#]E?AMX!^!O['_[/7A;X>^"8-)^$7[/7[/\`\-[?2M$C\2^)
M]7DT3X??#;P5I#2B77/%WC[6=2UH:;H.CVDD^H:QXJURZNX;>"6XU*^9DD<?
M-O[)O[27[#&I>)-3^!/[-,.M?#G4_%NJ_$#XVZ-X0\4?`'X^?`#PU\5+CQ?X
MHOO$GQ&^)'P0U/XT_#3X?^#_`(R:%JWB/5;OQ7KVN?!'4_%WAQ8M=@\4O+%I
M>OV>HWWU[\6_A'\/?CK\/];^%OQ5\/\`_"5^`?$L^A3Z_P"''U76]&M]77PY
MXBTGQ3IMG?W7A[4M)U&XTI]8T33VU;1WO#I/B'3%N]`\066IZ#J6I:9=_G+\
M2KZ;]MK]MO\`9R\-?">#?\(?^"=WQW\4?&OXW_')$F73-;^.DGP-^*GP0\-_
MLO?#6\^SBV\1W^G:5\;M<\<_'CQ!97LVC^"?^$8\*?#N6'4/%GBG5O\`A!P#
MVSQK_P`$T?V1O'WQ'^*/Q2U_0/C9:Z_\;O$^C>,OC)X=\(_M?_MA?#WX2_%3
MQ#H7A+PKX"L[SXA?`?P#\>/#/P0\7VUUX*\$>%?"NNZ5KWP]OM(\3Z#H\&F>
M);#5K66ZCG^XM%T71O#>C:3X=\.Z3IF@>']`TRPT70M"T6PM=+T;1=&TNUBL
M=,TG2=,L8H++3M,TZR@@L["PLX(;6SM88K>WBCAC1!Y+^T'\%/\`AH#X<2?#
MK_A;?QM^"7F>*_`GBK_A._V??'O_``K;XCI_P@OC'1?&'_"-Q^)_[*UK;X4\
M8_V-_P`(OX[T?["?^$A\'ZMK6B?:;/[=]JB]MH`_(SP;^S;_`,$YOVO/C5^U
M/XC\*V7[4,7Q&;XD^%+O]JKP%=_&#_@I'^S!\-?'WC%?`_A_PEX5UKQ5\`->
M\>?"'X)?&+P;XL^'/P\\.Z/#XBT;X>^,?AK\2/!^C62W>H>)-(OB][^L&BZ+
MHWAO1M)\.^'=)TS0/#^@:98:+H6A:+86NEZ-HNC:7:Q6.F:3I.F6,4%EIVF:
M=9006=A86<$-K9VL,5O;Q1PQH@^"OV<_^3]/^"C_`/W9_P#^J:UROT(H`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`**_&+]B/X1?M9_M*?L8?LB?M%^.O^"J/[;VE>-OC[^S!\`OC5XQTOPG\+_^
M"8ECX5TWQ5\5/A3X3\=>(=/\-6.L?\$Z==U>S\/V>KZ[=V^C6NJ:YK.HV^G1
MVT-]JNHW*2WDWT__`,,;_M%?])8/V_O_``W/_!+/_P"EJ4`??U%?`/\`PQO^
MT5_TE@_;^_\`#<_\$L__`*6I7B/C_P`$:O\`"OQUX9^&OQ$_X+5_MM^#_&_C
M+3GU;PSH6M_#W_@E[:R:O8I=S6"RV]Z?^"9;::DMQJ$#Z?8VMQ>PW>H7YBLK
M&"XNIX(I`#];**_#JV\?_#2]\%Z)\0;/_@OA^UG=^%?$>J:IH^C7EMX._P""
M74^H7M]H>B:!XGUH#P]%_P`$R7\1P6FD>%_%GA/Q/JFI7.DPZ=8>&O%7ACQ!
M=7<6C^(='O;W7U/Q%X+TG4O$6DWG_!>+]KE[[PMX+T?XB:O'8>#_`/@EMJT7
M_"$^(-*\+Z[HWB+2[O2O^"9E[9^(+'4-"\;>$M<@_P"$?GU.<Z+XATK5GA73
M[N.X(!^UU%?B9-XE\(0VFAWH_P""Z?[:-W;^)M8TGP_H!TSX:?\`!,[5YM5U
MS6]&UGQ#8Z19VNE_\$OKRZDU!='\.Z]>ZA:>2)M'71M3AUA+&XLKB&/H?"T6
MG>,_"W@CQMX<_P""X?[:5]X7^)/Q5'P.\!:O-\//^"8>F0^+/BV?MX/@'1(=
M5_X)C6-U>^((Y-*U.":VC@*0W.G7UK+*EQ:7$48!^R5%?C8R:7%XV\0_#JY_
MX+D_ME6'C7PIXHL_!GB+0=3\"_\`!+S2[G2O$E_>IIEKI]Q/J/\`P3*M;(I)
MJL]GI#7\5S)IL.KZGH^E3WD>H:SI5M>=-K?@K4O#7PE\(_'?Q%_P6S_;0T'X
M/>/9_AY;^#?B%K'@G_@EGIOASQ)-\6M9T7P_\-4TJ[O/^":$+7)\:ZOXBT.S
M\/D1A;XZG:SQG[-)YP`/UMHK\DM:\%ZEX>\3>*O!FL?\%LOVT[+Q9X'\0^"_
M"OC#PZW@?_@EK-K'AK7OB+X?NO%/@:PUFPM_^"9\UQ8?\)1X?L;W5-(NIT2R
MNK>SNMMP)+>6-*WPG\+3_''PAK_C[X5_\%N_VS/%O@_PK90:IXGUVW\%_P#!
M+/3;7P[H]WHY\06.NZXFM_\`!-#3;G2O#^H:$LNL:;KU]!!H^HZ9;W5[97T]
MO:W,D0!^NU%?B#IWC?X<ZMX9U#Q=IO\`P7O_`&L+S1--O_#.FR-#X3_X):G5
M;V[\:VNKW_@L:'X=/_!,P>(O$=OXQT_P_P"(=0\)WOA_2M3LO$FG^'M?O]%N
M+ZTT35)K3IXY-`FTJWUV#_@NQ^UO<Z/=_#7Q%\8;;4K7PQ_P2LNK.?X;>$/$
MD/@[Q;XJCGM_^":<J-9^%?%=Q%X=\2VP/]HZ#K+-I^JV=I<QR1H`?LO17XC/
MXM\%1R>,8V_X+K_MGEO`&I?$'1_%;)\-/^"9\L>FZI\)_%D'@/XEV,,T?_!+
MYXM5N?`OC2XA\+>)X]'?4&TG77.FW?EW*/&NA8ZQX8U2X\#VFE?\%T/VSM6N
M_B*OBD^$K32OAS_P3(U.[O6\#ZU:>'/&<6HVUC_P3"N)_#EQX3U^_LM&\1VW
MB6/2+C1=2NH;/48[>>14(!^U-%?AW+X\^':#P4UM_P`%Y/VP]83XC>$?AIX\
M\$2^&OA]_P`$R/%,'B3P?\9+GQ=9_"S7]/G\-_\`!,'5838^/+SP#XVM/#;3
M/%)J%UX4U^WCC\[3+M(O3/"/AF3Q[JGPMT3P;_P7`_;&\1:O\;?@_<?M`?"7
M3--\(_\`!*Z:]^('P6M/^$:-Q\2?#-L?^"::RZCX7B'C#PRQOXU&4UBU=49/
M-:,`_7BBOS1^'O[._P`5?BQX#\&?%#X;_P#!87]NKQE\/OB)X6T'QMX'\7:'
MX`_X)9W6C>)_"7BC3+;6O#VOZ3=?\.TU%SINKZ5>VM_93A0)K:>.0`!J[#_A
MC?\`:*_Z2P?M_?\`AN?^"6?_`-+4H`^_J^4/CK^R?I_QB\=>&OBUX0^.'QX_
M9M^,?A?PGJG@&V^)OP'UWX?M?:SX$UC5+76[KPIXM^'_`,:_AM\:/@KXPM+3
M5K9[_P`/:OXE^%^I^*O!USJ&LR^#O$&@/K>K&\^KZ*`/D5?V&OV;[S]FS5?V
M4_%/@[4/'7PK\1ZKJ7BOQ9<>+/%'B*X^(/B?XD:QXR?XCZE\7K[XE:3J.D>-
M-+^+C?$9U\?:3\1/"^L>'_$OA/Q;;:;J_@V]\/2Z/HZV'EVK?L!ZUXJTS4_!
M'CW]N_\`;Q\<?!C6-.N]%U'X-7WQ"^"7A&QN]#OK=[.]TB[^./PN_9^\`_M=
MWUO=VD][;7-U?_M'76JW$5]*)]1D:UTUK#]"Z*`/ESX9?LA?"3X3_''Q9\?/
M#'_"22^*M=^#?PO_`&??"GA_5-1T^?P5\(/@W\*IM7U'3/`OPHT6STBQN]!T
MWQ1XAUB7Q1XYN]9U3Q%JWB/6M/T+=J%KI6@:/I=GU/Q3_9U\$?%CXG?L_?&'
M5=2\5>&_B#^S=XR\3^*O`NO>$-2T_3)M7TKQQX*UCP+XW^'/C2._TG5H]?\`
MAOXNT[4].UC6/#R"PN1XK\'^"/$VG:I8:MX8L)U]ZHH`_/WX!?L*>*_V<[GP
MEH_@?]NS]L#4_A#X-\0:YK.F?`/Q3X>_8>OOAS<:=X@U_6/$M]X3O_$VE?L7
M:)\<I?#Z:IK=Y);W-M\8K7Q5'"D$+^)941_-X?X<_P#!.#QC\%M!U;P5\$?^
M"CG[='PG^'-_\0_BW\2],^'F@>&/^">'B?0O#&N_&SXJ^,_C/XZM-%UKXG_L
M">/O'MSI-SX]\?>)M0TV#Q)XQ\07FG6=Y#ID5^UG9VT<?Z=44`>6?&SX9W_Q
MC^%GC;X8:=\4_B=\%KCQKH=YH#_$OX-7_A+2/B;X7M=0C,%Y>>#]8\;>#O'F
M@Z-J\EL\L%OJ\GAF\O\`33+]LTJ>QU*&UO8/C_\`9I_8#\5?LMZ;\-/!W@;]
MO+]KO7?A%\,!%;Z;\%/$_@3_`()\:?X$\0::LES<7>G^*-8^'7["7@#XI7<F
ML:A=W&L:]X@TKXCZ-XOUS6KBZU?4_$=U?WU_<77Z)T4`>*?M`?!4?'[X=GX>
M-\6/C7\%@WBWP'XL/C?]G_QZ_P`-OB)CP)XRT7Q@?#`\41Z9JSIX2\9C1?\`
MA%?'FCI:*_B#P;JVM:(MW9&^%W#[7110!XYX*^"'A3P)\7/C9\9M(U#Q#<^*
M/CQ_PK?_`(2^PU*[TV;0--_X5?X9N_"N@?\`"-VMKI-GJ-G]LTZ\EFUC^T]4
MUC[1>K')9?V?`&MV]CHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`^`?^"3_P#RBS_X)J?]F`_L;_\`K.OPYK[^
MKX!_X)/_`/*+/_@FI_V8#^QO_P"LZ_#FN`_:]_;W^*?[(WQ'O(=<_9X\)>.?
M@/ILG[,(OO'?A#XM?%/Q#\=)(_VB?VK?A-^RU>KX>_9F\#_LK>.;[QKJW@S4
M?B5?>+M'\*^#/B;KWB_XDIX?T_PEX>T"R\0^*+>/2P#]/:^,/C+^Q9X!^.7Q
MXT7XX>.+E=2NO"7P?U/X=^"=`N8]=;3?#_BZ\\32^(M.^(UW867B?3=`\3WO
MAZ5X9-!TOQ%H-^=%U>V@U[1=3TS5(XIX_E;PS_P5$\2?$OX\?##X7_"O]F;Q
MKJ/@/QMXVU/PWXG\=?$7P+^W#X!\:^"-#T_XC:A\/X]>\0?"O1OV`_'\/PON
M[DZ/JFL1VG[6'C_]EKPS/:QV\NF>-]3T>+7==T'>^)G_``5$TGX9^#_VU?$N
MH_!?5+JY_9)^`OQ_^,^BQ'QO;6OA[XKZQ\#/%7[7^A+\,Y?$"^%KN^\!^(?&
M>B_LD:[XMTW4)/#GBRPLM,UC6;81ZE>>$(4\4`'FGP`_X)8?%[]D+P]H`_9B
M_:L\*Z%X]TRPU#PSK?BOXQ?`37/C'8^+/"'B?0OA./$R:S:2?'GPCXL'BK0O
M%OPXNW^$NKVWCJ'PYX&^%=YX,^#NN^#?'.@_##PCJ<&YI'_!'GX6Z1X'^.7A
MJ;XA:YK_`(G^+?ASX=^$]$\?:Q9:S::MX%T;PSX(^%GA7QS<Z;HOASQCHGA2
MV\0_$74?AS=:P_B'PCH7@K4O"NG:U9>$]%F;0?#]E!-H?";_`(*)_M(?'C7?
M%?@+X5_L?>#)/B/:^*?B,W@F#XH?%[]ISX*_"_5_A5\+O%-AX0\0>/?$OQ5^
M(G_!/G2;34M9U76?$'ABS\*Z-^S/X;_:H^'NHS7^J-J_QA\/V.DVU_J_F_C3
M_@LBO@GX@W'@C5O@]\)[#4_#?PGU/QEXW^&6L?M56%I^T[_PG'A3XB?M!?"C
MXD:+\+/@/I/P;\0:=\6/A'\+/&G[/?B*;Q]\<++XH>'8=&\':C'XJ3P'<_8O
M[*O`#)F_X([>,]&T_P"$L/@W]H3X=76H?";XG>%O%]O/\4?@-XR\5V'B_P`.
M>&OAY\3OAG(?%</P]_:*^#^MWGQ1\1:5\0(/%7B;XBQ>(H]-UWXAVFM^)-3\
M$W5IXBDT>Q]5^('_``2?E^)?@GP1X)UK]J#XA>&K+X4S?'SQ9\,V^'_A#PAI
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M_"NC:W:2KXNT[P_=:-+IJ:H`=!XT_P""1VG?$&Y_;(O/%OQ<TK7Y?VRO`VO^
M'O%%IX@^&EQX@TCX=^*IO&/ASQIX9\8?#;3]1\?%_#7V?5=&CN_%^D:;=6:>
M*=9\+_"[Q+:WN@:[X)NKWQ%]4?MC_L,>'_VR]`^&_P`,?%7Q'\3_``Y^"?@B
MR\:RZQX'^'&D^&[?5?%&MZWX0'P]\**^J^*=,\4>&+#PIX6\&>(/B'8S>'Y?
M`NHW]UJOB#P[KVA>(/"VH^$;>2_\?^)?_!0?XN?"SX<>)OVB_$'[+&BW?[+Q
MT#Q]J/PW\;:1^T#:7'Q;\2WWACPOXPU_P9=^-_A#=?"FR\-^!?!/Q5OO"UEH
MGAG7O#GQA^)WBW0G\6:%J?C?X=>&K"V\1/H?L#?MT^'?^$W_`&AO"\/PZ\1W
M=E\!/V9?@!\?9%@U72X/&?BCQ9\<?BG^UO\`"*;X(2^%]333O#_A;Q;X/\9?
MLLMH5SX@U3Q[/X:O]9\<217]SX=T/PG+XCUT`^4]2_X)*:EXE^)?A_XX^+?V
MDM1O_C1#XH^%&J?$#Q=HGPV@T72_BOX:^'G[.O@[X-:IX8\;Z#>>-==GOCJ?
MCSP98_&;PGK%OK5KJ/@'5]1\2>%],DOM%\7^*Y-9[?X,?\$TO$NE_!#XG_"G
M]I3X[Z+\5M:^(G[(_P`-OV);/Q-\'_A+<?`_2?"_P4^$^D^/-/\`"-\GAKQ/
M\2_C==>(_B)+>?$'5M5U[7/$'B*Z\+WTEI9Z;8>"=*T>YUJQU7V.\_:3_:_\
M,V-GX;\<_L??#+2_C#\1?&.G>%/@-H?AC]K-_$_PD\4_:?"/C;QSKDGQ;^)F
MH?L^>%?'_P`*-2\">&_A_K5[XQM?"/P)^-.@RRZMX2T_P'XJ\=ZGJFLV?AOD
M?#G_``4'UZS\7^./A=\8OV?[WX>_$GX7>%O'4OQ#O/"GQ(L/B1\'='^)7AKP
MQX-\>^#?`NG_`!&F\)>"/%EQH7QA\!>/?#^M_#WQ]X@^%'A2TC\01WOPX\9:
M%X4^(NI^`?#7CH`NZY^RI^V#XD3PUXYUC]K?X/R?'CX3^)[Z_P#@KXKL/V2;
MK3_A9IWA75/#/BSP=K>@_%3X9']H.[\3>.=6\0Z)XDL;N]\0>"_BM\*8]%US
M0(G\):/H/A_7O%'A[6?FCXP_\$;;;XV^&-<F\7?M%:I8_&3Q%X=\:37_`,8/
M#7PST72)[3Q_\3?B=>^-OB7-HGA)_$-Y8Z7\)_&W@W5=4^$^L?#;^U;K6;GP
MY<P^*;WX@7OQ$LK?Q8.HU'_@JGXC^#'[,'Q;_:9_;!^#OP-^"NE^!OB5X!^%
M?@'PQX%_:^M?&8^)GBKQ?X9T'QKJ>GS>-?CM\"_V4/!G@R]T3P?X@37=.LKK
M5=<F\3)X?\56%H;+4++0;;Q+Z1X8_P""GWA+Q1\;?VD?A;I_PNU6]\%_!&*%
M_"/QNT?Q=I^J^`?B)<:M^RM^S)^U#X,L-=@_L:TUGX<2_$;3?VBKGPEX&U5[
M3Q?X3U#5/``M-6\2Z)XR^(_PY\`Z\`>,:A_P1^6R\.^*&\#?&S1?#_Q&\2>.
M/V[?B!<>+M=^%^N^)=#O=;_:]_:IL/VE?!<&L^$H/BYH+2Z9\';?3XO`NJ0:
M#KGAVZ^)$+RZ[]M\&712UC<__!*CXHWOQ\\,_M(Z]^T1\*/$7Q*\3:E\1M=_
M:)>__9Y^(=GX>\3ZYX^\*_`+P3;7WP$T/1_VI].7X,Q>%_"W[/?A33K#3O'=
MW\=],U74+_7/$FN65]KVK7]Y<<L?^"L?[2GBKXZ?#WX(_"?]BCX?ZY<_%[XU
M:_\`!7X<>+_BC\:_VOOA#X$N]6\(_`GXT_'CQ+JVN_%G_AV+XW_9[O\`R=$^
M!WB?0M,\+?!WXW_&?QHVL:AIZ^*/#_A!=*\9IX5^P?'7[>^J>!?@QX'^)<_P
M"\1:YXUUWQ3\6?A[XL^$&D>//"\.O:'\1O@P?%VF^*_"?A3Q7KEOH_@OQ>FL
M>)_!U[I'@SQ%KFK^`=!U73]2T?7=?O?"L4NH6>F@'R_^SY_P1KT7]G7QVOBG
MPG\<KF[\/MX7_8ATB/P3/\/8+/2-#UO]E!_VA-6\=:IX5DMO%I;2=(^.?CG]
MH#Q%\1[W0KN+5+CPCXPOO%=T-;\267B.RLO#S/@'_P`$?-?^")_9H\5?\-:>
M*];^)G[,'P[_`&8?@EX/N]-^&WA_P]\-];^"GP%^#47P>\3^#?$7A*XUOQ!X
MYGO_`(@0^+_CAXNLK[3?BOIGAKPWXE^(?AN[U'P9XLD\!13Z]]/_`+0'[>6L
M?#3]F_\`;&_:$^$WPFT'XI0_LC?"!?C?>^%O&_Q*\1_!N7QIX0T/X<:I\4OB
M%HEQ=+\'/B-K_@/XB>%=`\/Z_H=GX,\1^#I9;KQU8Q^%O%^H_#\_VIJ.D>!>
M,?\`@K=-\.?$_P`-/A/XV_9P\50?&OQ%^T;KO[/GQ%L]$C^/9_9W\*W'ASX%
M_$WXOZEXC^&7[6GCK]EGX>_"#XZ:L=5\`67A6V^%OAVY\/\`Q-71]8U[QSJG
MAO2K'X=^,-'L@#[;_8-_9W^('[)/[(_P(_9B^(OQ,\(_%W4?@'\-_"'PB\.^
M._!WPWU?X566K^!?AYX=TOPEX,;5_"FL_$CXIS_\)2FA:1:GQ+K%IXF@TO6=
M6>XO=,\/^'K.2+2X/KNOE;]DO]H;Q9^T7X*\8:[XZ^%=K\&O%_@OX@ZIX&UW
MP!'\0K+Q]JV@3P:)X?\`$MEIWC%/^$<\&Z[X.\=66D>)M.M_%?A/6/#"Z.FH
M)_PD/PP\:?%OX/>(/A_\6_&_U30`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`?`/_!)__E%G_P`$U/\`LP']C?\`]9U^'->?_M2_%'X%+\:M1\+_
M`!<_91^/_P`1O"GPNL?V;/B5\4?VD_"&M?#FU^#GP3M/`OQUMOC[\&M?\=Z$
MG[1/@_XYZCI?PZ^+/P<T3XD^,-3\#_`OQWX:L/#VG*OCN]O_``(OB[3;3T#_
M`()/_P#*+/\`X)J?]F`_L;_^LZ_#FLSXT_LW_"+XP_'3XH)XA_;!^)7A&QUG
MX0_#N;]I?]D?PIXM_9NL/`WCOX,:5J7Q&L_#VN_%R'Q%\&_$/[1_A#X>^.E'
MCWPGKFH^$/C'\._"7C;1O#7B#PY*+BWM/%<%X`?,T7Q0_9(U'Q#\2?VIO$GP
M)_;2^"GBSX-7&I?$?PK;Z+\?/%?AB#]K+[7\7=6\&^'+?PI\'?V;_P!KS7_`
MOQA/Q`^-*6_@KX=?"3]I_P`(^&-0U3Q!XZT[1+;P)IVD>(]<6/K?B7XF_P""
M=&I:?XR^&7BCX1ZO\3_!G[:OBWX&_!KQY%I]Q>>+/"?Q"\)?M2:]\3/C-\-O
MB9J,=[\0H[WPM\)[_P")7QJ^(%E<>,=(T_0=?TKQGXLTS1]*TF?0;'P?<6&Q
M\'O^"4O_``3SNO"^M^)_!7AKPI\:?@5^TCX^\/\`[4WB_P`*ZS:_"/XJ?`O]
MHKQEKGAOQQ-X=^*'BV>+P/?1_%OPGK6G?$JP\;^%=!U+Q+KGPIT_Q1X5\"_%
M#P/X9TCQ@_B'Q-XHEN?^"87[('CQ_C)X3\"_%'XH>&GT[]GG7?V%M:\*_"#X
MJ>%M)M?V;O"NO>+3^TK\.M*\#>$]+\,W^F?"+XM_!GP]\7_#L_P/U#4-)_M7
MPY\%M?\`A_:7VE>(O#TWA[49@#@-+^.?_!/']JCP/\/?!]AH7QQ\.Z+H7PQ\
M8?'/X'^,_A_\0OB[\$?&5_X2O/`GA/XO^)]'^&W[1?P*^+_A?QKI.K>/?`WC
M73O$[?#*_P#B?X>E^(WAOPSXHU(:%K?AKX8^(;SP[TGA?X&_\$__`(SS:!8^
M%_V5/BC-X*\0_#O4_P!F(?&+PBOQ$\/^%G\('2OB3X=\<_!#Q3XN\!?$FU\?
MWOAZ76O'7Q"TSXIZ]JNEZA\-=?\`B_;6VJ^,O'.L?$SP5X4U;0_<?`?['G[*
M?BK0/C)H'P^^(.I^,M#U>'5?@?XVB\&?$'PIJ!^&7BOP-:>#-"O/#VGW_@[2
MX;SP=\1/`%UX*\/27.BZS=37FC:EY]KK>BO9W0T]:FI_L#_`KP[JGPQ\2_$#
MXB:WJ_PJ^`GQ7LOCG\,?`_Q3T[X*ZMH'PV^,=UKDVJ-XO\+_`!2\1?#9?BQX
M/77?'6LS>);C1O#_`,1M'MKC7M3?PK8R6_PVO&^'4@!Y/:']B?Q?^U]KGP`3
M]F[XP:Y\08_CU:?M&>)/'UQ=:QJGPD\/_&[P!X;L;GPOXD33F^+=UK-CX:+V
M']K7&E>%OAK+\$?"7Q5N_#_B;XMVO@SXJ?&CX5:M\3_&OB7^U'_P3J\7^/?V
MJ_@C^V;\'O%'[*_@O4OB3\7?V8OBW\6/VHOCE\"?A!\#?BAXT^+/[*/PPO\`
MX@>&_!OBGP-^UQK&MZ+=_$G]E'QA\(?$.GW<GAKP!KOE>*X[BT71_BSHOQ*M
MO#7WY#^PUX"M_P!HVU_:/B^*'QL;4(?B-JOQ;F^%=[XD\'ZO\)7^(VH?#6[^
M$UMXIT;3=:\!:CXW\`7=AX(U36]+OK3X7^//`^F>/5U>0?%>Q^($&D>&;?0N
MZ\)_LH?#OP=\;OB'\>],UGQI/XP^)?Q:U3XRZ[IM_J.AR^&K3Q/J_P"SA\`O
MV7[FPTFSM_#EKJD&@IX!_9T\$ZO!:WFL7^H+XPU3Q5J$FJ2Z+?:1X?T,`_'?
M]EKXR_\`!,7]N[XO^-_#WA+]G[XQZ;J_B;]GO6_COK/@#XD?M/\`PXN]*\->
M'_C_`/"SPQJWCRX\(?L'>`/VY/B)\4O@A\5_%'@_]H2_T'Q5\4_"/[*'P]@U
M/6-8\36VF_%K4Y_$WAF^\6_6.F?'G]G#XD6'C+XL?#_]A'X\?&3XD?MC_"S1
M_#?QT^'WA;P[\";WQ#XO^`?PUF\8>&O"&N_$3Q-XL_:"T#]G'Q5X)N=.^*OC
M*U\*)X"^*_C'Q=XTLM5\1^&+/1=8UWP+XB\.>$_1?V3/V-/A?^R)X9;X(_#S
M]L[XZ^*_@[X)\%>#OV9[;X#>,/%_[-5EIW@;QE8?!_X8Z3H.HP>.OA?\"OAO
M^T1HGQOUKX<:7X=\:6NG7?Q@%@L'C^7Q;X:\$Z7IMWX)DT'F-"_91^"_A%]>
MTOP/_P`%!/C9X(^->G^,U3XK_%;PY\1/V38OBAXEG^-_CR3PYX4\`_$KP'J/
MP#U'X+:=+XJ\?>&-7\,_#_6-.^#'ACXKZW\0V^(.J:9XWU7XI^,OB1K_`(B`
M/ESQEXW_`.":/PL_9.^,OQOF^'/[0_B7P#I'QA^#/P[UWQ-X_P#VJO%_@/XX
M>#O&^L^`?`?COP#8?#C]H_\`;"_;"^$^N_LK:%\*K#XYW'AL^&[#X]?`>W^'
M_C.[^)7A?PSX;&H:]*OBKUF+Q9^QK\,_A+\'(/#W[)OQD^)OPJ_:J^`NJ^//
MB+XWL/B]\(?CU'X1^%/C#Q)\.;O6O''Q_P#B]XI_:]\6Z_\`'/Q)JOB;XD>&
MKB'XH?`SQ?\`M.^,-5&C'5/#GC#4-#TSPS?WF%K?P9_8K^%WBSXW_#GPQ_P5
M@\2?L[ZG\+H/AS\9OBG\([;XY_L&ZOKW[/GC#P-X+^#_`(7LOVC/'C_M`_`3
MXH_%K1M>\:>!?"'ABV\8ZM\<_%/B7X<>(!\0]:\7V_A>R\5Z]X<\2Z3ZV/B!
M_P`$I/BUXU^`_P`3/BC^UY^Q=^U-\5_V;?@;XM\??#OXE_%7XI_L<^-/%FD^
M#M,O?#6M^/OVJ[%/"VC^']`\"W^G7OPG-_XA^*'PKT+X>^`/#BV7B**+3]'L
MM/MX-(`/+/V>_P!L[]F#QKIG@#XA_!W]BS]JY_BGXH\%>"?CO\`?@[=7/P<U
M;XA_$WX._M+_``UCM?"'[0'A:>[_`&J-;^!W@'PUXF\`_`N;PS)=_''XE_"?
MXC>"#I]WX:U3POX9O_BK':>.N*L/B)^P)\';7XE0:-^PU^T/9>&?CQ>^&_#G
M[6HU*Z\'RZ7\%/$_C+Q%X`_9)^'W@7XF>!_B'^TQ;^(]&EU/5/A3\,?!G@&7
M]E[P=\0/`>@>'-(\*?$/1M>T3P?JL/C&^S/@?^RY_P`$J?V,_P!FCX97/[/7
M_!0;PG^SQX`\>^+],7X,_M4^'OVA?V/(=<^)'Q6M_`.D?#GXC:CI?Q+\:_#O
M7_AI^T+XP^,#>%[7Q5\2_"GQ#T#XJ^'K3QO907_P]\(_#[3]`\/:-HGOGASX
M-_\`!*Q/C9J_@CQ9\>_V>OC=^V'\/_A[XQOM7O\`XQ_%7]G;XB_M7?#:/Q+:
M>(O'WQ$^--A9WNFQ^-?A/KFM>%/'=I=ZWK'A;0?"/@+2/AMH_@/2M'\-:'X*
MT'2;2@#\]OAY\2_^";W[5Q\)?$SP)^SK_P`%`M1\-Z3\2]2\<3>*O@C_`,%3
M-&U+X=?LT>*9?"^B_#2;XDKI'[)'_!7?Q1X8^%7B#QAH'[16N>#?$'A+X-:'
M<_&.YTWQ/XSU#XF_#O3/#WB[2M;\6?:?P?\`VA?V-/B3\/?@]\,-?_9`_:$^
M!&FV/QP^/7P=_9Z^''Q0UKX977B3XE?&WX4_&?7/@O\`M*V7AOQ!\%?VG?BU
M9^*_&7A[XCS?%+Q9X]U/XF^-+;Q'XT\+>!_C%^T!I<GB[P1X5\1^/TT/B+^Q
MA^Q'\+[_`.#7[1G[9'[;U_XR\7_L8^(_##_!W]H3]J[Q?^Q%X#3X'6/BL>&$
MT+P,7\-_`#X0?"6.Q\<:?X<FM-$U?QGX2U3XD32:]>^(/!7C33/%>@^`?$/@
MWWCX0:I_P3_TCQGX#^!WPY_;"^$OC'XI?#7]H7XW?MKZ/\,K/]H+X*^(?B5/
MXB_;>\0?&WQU>S:QX+T*2+Q%+\+]7F_;BNY/A+):Z187U_I.L_"-YO%?BQ]1
MEO/%H!SO[0OC/]F/P])^US\*/$O[)7QO^(WP2^+?A[4/!?\`P4!^,/PQ@\,:
M3\)/`^A^/_A5::7XG3XA"[^-?P^^,]]<?\*=\9V'B'QWXE_9B^&WCW5/"&A:
MXOBSQ;J^B:W!=WUI4^`?B/\`8I_X*-/\0;33?A+J<D?[+?[67BSQZT>L?'/X
M3>(M1M_C]?\`A3XJ_![Q#XXN?#?[.7[3?Q2\7^`_M_@_Q;\0='A^'/[0>@_#
M#6((->BU>#X86FKZ1;WVB:6J^#?V0OVLO'GQ6E^%/[?L]_X+UKQ=HW@S]K']
MG3]GWX]?LZ^*_AE\2/&[PZ9\/H/!GQ@6;P;X_P#B_P#"[Q%XKTS0M*^'OB;P
MM\)/B=\%[[X@6=A_8?BG3]>O+K4/M?VWX)O/A!\%?`$/A6#XD^'+7PSX(UW5
MO"]]JWBOQCX8@FTWQ+>-=^,[[P[KE^C:5I]GKMMI^J-J@TF:WM+^'1#;WLUN
MT!-U(`+\#/V=?A'^S?X?UCPM\(-`UG0-$UW6EUR]M]=\>?$'XA7,$EOI>GZ%
MI&BZ/J?Q'\4^+=5\.^"_"V@:3I?AWP1\/O#][IG@7P)X=T^S\/\`@WP[H6CV
M\5DOMM8T'B/P]=:U<^&K77=&N?$5EHVE^([S0(-4L9M:M/#VMW>J6&BZ[<Z5
M'.U]!HVKWVAZU9:7JDL"6-_=Z/JEM:3RS:?=I#LT`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`'P#_P2?_Y19_\`!-3_`+,!_8W_`/6=?AS7)_'#
M]CGXG>//V@_$_P`9/!&L?#NPL_BIIGPH^`_Q8B\0ZCXF@U74/V3-.F\1:]\8
MO#FDVVG>']1L;CX@:]K]UINF>"A<WVG:+8:-J_BB_P!3U6.5WT/6NL_X)/\`
M_*+/_@FI_P!F`_L;_P#K.OPYKQ[X[?L=?$+Q3^VUJW[9OA[P+\&O$,WPA^#/
MPYE^&UNOPA\+R?M2_$OQUX`D^.^N-\(?AU^U+KWQB\.:?\$_AAXMU'Q=X6TC
MQ_X8\3_"_5M#\8V^KW+?\)EH<,>H7.F@'Q-\./\`@E?^W_\`"OXDZ7=>$?VQ
M_BKI/PI\#?LT^!/@3\-_AIX<_;1\5^#_`-G_`$GP_P##WX0^"OAM8?#X?LHZ
M;^Q3>R>$KS6+CPOJ>HV_[47P_P#VH?#_`,8/!.IZ[9>(-%\%ZG!H5WX1\2\W
MJO\`P3$_X*&6?PH^.&E>`/%7A_P;XS^,OQ)^+GCSP_X=T;_@KG_P4DT'4?A/
MXL\3?!#]GWX1_##XO>+/VO-'^!R?M"?M;^(/`\/P=U*RMO@_\<O#EA\/=!\*
MW7AK1]"\1S6NBVNGV&?\:O\`@G1_P4.D^&GA3X9^(]+_`&0_VZWTW]J:_P#V
MNM5USXQ?!?4]5^'VC:I\2/@]\<_#OQS\&>$/@Q\:/VIM;NYOB)IOC_6/#_Q!
M_9U\4K\6/!?PRT?X@_%2]\/2>%/@=\*_`%C<6'WW\*?V!+7X.^"?V\H_@Y\)
M?!OPS^*7[0MAX2M-#^*-NG@WX=?%+XQ/:_L[_#72_%E]\3?BW\([?4O&6A>*
M_&7QB'Q4O_%/Q`675O$.E?$'Q;XK^+OA^VU[4]4@U36@#Q'X<?\`!.C]LGX1
MOX=TKPG\8X;S0&^.O[2OQ3CFA_;%_:R\$6GPCU'XR?MM_M%_M`V7Q)F^'VA^
M%]7\,?MAZYXL^#'Q/^%O@GQY\$OC_J?A'X9^'?B%X%\7>,M#\4>+-;^(?BCQ
M;K'U-\"_V6OC[X/_`&%/!W[)WQ+\6:U\0/BUX7^%WP'3XA?'SXI?'SXG?&^;
MXM_'2&ZT'Q;\?=;TOQ+\2(->^)&G_#ZV\5:7>0_#N+7+?16:SU$:+8^`O!6@
M:%83ZI^<WQB_8)^*WQ.\`^,-)_93_P"":O[//[*>@S:E\/W\8?LY?M7:3\`_
MB/\`L\?M0_$[PUX^\.>*K7XQ_%+X0_L[?%_Q3X4U_0?`_AS1/$_AZW^('B;Q
M-H7QZ^*VL?$'3;WQYX(M=-^%7A@:A]C_`!F_9*_:V^+O[+W[*G[-/P6\>Z+^
MS5#\/_#>@?$_X@?$#XG>`;/QW-HGQ+^%0T#4_@C\)-'^&'P@_:-T"WT&S\&?
M$V^MOB[H&KZ'\8?'_@7P'>_`/X;^"+^V^,7A3Q)X@T^<`X_4_P!@']KGPI\/
M/#>B>$_C'\0OC+>ZUIOPZU_XZ^"?B/\`\%-?V^O@N/'7Q3TJV^*T7C+4_AW^
MT9X%T7XJ?&#X%>`H]0\6^`]6TSX>?"7P]X0\$>,X/!%OH'BKPCI-NO\`:5Y^
MLWPOM_B/I7@YM$\9>$_"N@7OAJQ\/Z)X-MM*^-'C[XR3Z[I.G^`/"9N[SQK\
M0/B%\./"/C!]=@\>R>+_``TVJZE!XZUCQ3X7T+P]\3=>URW\5^-M=\`>#O@'
M]G?P1\>/!_[0W[2?QT\2?LD:GX)\0_$OX.>&?%GB&XB^)WP=UJ/XE_%[2=!T
M7^POA?X)\6^'/&MEKVNV&E65E?Z!J%S^T/X&TRP^"_BJ2^TCX)?&#X@_!WQO
M?VG@RG^S]^R!^TGH/PZ_:V^`O[5GCGX>_'KP5^U[X6^(/C'7/$7ASPMXL\->
M&/!_CGXRZ!J?@KXN?"/4O"OQ-^,OQKU76O"%_I5[HNI>%K[P?:>"OAN+*T\5
M:;'\*?`LL]E;^)`#S/P9_P`$L_B)H_B*ZU?XD?':\^.>F?'+Q]X&^.W[3?A_
MQRGA?PUIGA+X]^!/'M_X_P!$\2_LPWWPV^$_A'QSI6G:#J?C?Q59^`O$?Q5\
M>^*_BU\-]&^%G[.6B^$?B'8V/PWT1?#GTU\+?V,_$VA?%GP'\6OBEK/A'QIX
ML\$_$?\`:$\7/XAT.Z\4^'5\06OQ,CT*T\":IK7@BV6'PGJ7B/0K:V\1WTEM
MJYU73O`^L^)-7N_A]=6_]L7Q3\KE_8>_;L^)MUI?B3Q[\+;WX=>*?CSX%C_:
M1^./B70_B?\`!C6_&/PC_;+\"W?B3]G?X=Z!!:ZS=^//!GCWQ`/V0OBEH0A\
M61Q^)OA38:[^S-;0ZCIE]+XSTCP]>^CW/["OQ4\'_%#]IS7?VEOV8/'/_!5G
MX,^-/VC=6\8^%O#7Q+UO]BX^/OB+/JO['?[!WPZT3XX>*?@OXCO/V9/V0/$,
M_A+Q/\'OB9\$]&N-8T+X6?$+X:^'?AYI?B_PAX0\=ZE\4O%'CS70#U;X[?\`
M!.C]JCXC?&K]ISQ]!\6?"_CWX3?$[QCI'Q0^"'P(O_B=XB_9TC^%'Q)T+P#\
M#_`.M>)G^.'P=^!'BCX\6NN_%;PUX)\;>&1XDT/QXH^`K)H'CSP+X<\;^+M=
MB3X;1ZI_P3`^-/Q%^$?Q=M?%7Q<\3_#3QUKW@OQY#\%_@ZG[1WB7]KOX2_#W
MXP^+?V<_%W[.UG\;/''[2?[2'[.6F?M@?%OQEIGA3Q_XQTNSTSQAXJO?AAIO
MAW4-*LE^%NI:MX;TO61XI\2?V5?VD]=_9C^-'[*OQ!_9+^.7Q2T#X@_$/X`_
M&2PUSX<^*?V`_C+H.C_#[P5\0O@]-:_LU:3:_MW?%"70OB;\1?@MX`\,#PS!
MXH^.OP,OOA?X^T'X?/XA_P"$MN/&VM:/HL_Z"^/?@AX^TG_@FYX1^'WP,^$/
MC-?BY\$?"GP4^)OP9^!GBK5/V:_@;XVU/XC_`+.GC_P5\8/!7PE\3:M^S7!I
M/[*/P]D\9ZQX$M?`/BQ/A?;VOP730O$&L:6EK+X1O+ZTF`/(?A9^R%^VC\`[
M[4?B/8W'[.?[6WQO^*'AW4/AQ\=O%W[0_CS5?A1:Z_:V?B+7)K/XW^#(/A!^
MRGXA\/>&K[XE>%;CPIHGQ;_9>T[P)I'@VZB^'?PYBLOC[JNJ>&-;\4>-^!L/
M^"?/[4]Y\,;S]DC6;+]E_0/@*GC7X;>/=(_:*\)>.?B%/\9M%NO`'PJ^&?A*
M\\)^!?V:K_X(:?X)^&>A>*=4\$ZOX$O-3M_VH_&<]A\"_$^O^$DT:^U'79+C
M2?!?"/\`P31^.4WCC_A6GQ9^`OPY^(?[.7P[UVQU7P+J7B?Q!\/_`!E_PM.Y
M_::_9M^+OB7]MO5OB/\`#;Q!MT?1)=1_;$N/"=]_9MG'K=AXP@\866N0PQZ3
MX1N)]/\`0_`G_!-K]H'X?>$;71O@[XK\5?LY^%M#\>_LI:EH'[.'PWT7]E#2
M?V?9M4\'_`GX.Z#\1?C+K::?\+K_`.,6G^*/"'Q3TWQ7K%WI7@+XT>#=)\7:
MOX1M=;A\'^)E\1:IJ'BT`^B],_9Q_;CT_P"(^E?M5WW@G]D3Q%\=O"\^K^!M
M`^`%]\<OB]:_!1_AUJO@+X:>%6^)T'QYF_9DUCQCX6^/%EJW@77#HBV7[.>N
MZ%HOPR^(OCKX6GQ'J=SXBO/'PT?BG^P=\6_C%X?\1:3?ZW\'?@_=>/\`X8_!
M#P?KS?!*TUW0],\`:]X3^,_QW^)7C[6/A_INI^')K?4[^PT[XN:;<>'/$>KI
MHTGCSQWIVN>(O$/AKP+9ZI%I\7RLG[(WQ+TJ?PWXI^!W_!.N]_9S\7_"/4/A
M5X]^-^H:;\7_`(`W&N_MU>)/A%\=/@9\7!X;\.ZSH'Q0N_\`A:?BO71\,]>U
M/PM\>?VR9_@IXZTOQ'_9GAK45T+POX^\<:WH?U5^SA^QU97?[2'A_P#:Y^+G
M[)7PY\`_%7Q-X$_:=EU/Q!XJT;X*^,OC)X`?XL_'R;Q!X&^'_B7X@>#KWQ2]
MYKZ_![7/$.E^)H_!/BSQ9X#T4ZYXK\%Z7XQ\1:/>KJ.O@&5X@_8M^.W[0.N_
M"]/VAOA/^QI\/?!GP-A\$>#O"VB?`_Q3\1O%-UX^\&>&/C7\$OB:-1,^O_!W
MX83_``)TCPY;_!JRUOP!\&O#.H?%7_A&_B(_A3Q!8_'*PN/`UKJ>K]SXR_8P
M^-_BKX)?%+X<ZI\0/`?B?QCXS_:`\3?$S3O&&IIK'AZ+4_"=Y\(XOAKH,OBJ
MRTG0-3M[3QW-):VE[XJ7P]8IX7O+LZAJNA6VB6MU:>%M-_+76O\`@D5\:_#?
M[*G[;/PS_9X\(77[,&H?$OX7_P#!5S2=`^#/[/VB_L9>%/`_[4LGQI_:L_:=
MUK]E;X1_%K4/%?PZ\7:CX5\$^(?V;-7^"O@?1=5\!>.?@;XM^&?PWU#3?`5W
M\0O`.I>!=+L/!7Z'_P#!-_\`93OOV?\`XV?MB^-=>^`OQ:^%WB7XM_%CXC>)
M]0\>^,_`?_!-71/`/Q.TW7?C?\5/&'AW4_A[XX_9,T]/VN?&ENV@>)=-U.[_
M`.&T=8U/Q#IB:E!;Z2EGJXU^W0`^K_@'^S3XE^"?QE\:^(K?6/"TOPAF^!GP
M5^$OPJ\(:5;ZC9ZS\/K/X>>)/BQX@U?PCY+P?V--X$TB;Q_:VOPV_LR73&T'
MPPEOX'_X1NQTWPEI>K:Y]FT44`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`'P#_P2?\`^46?_!-3_LP']C?_`-9U^'-?*G[>7[:'QD_9Z^/GB'P%
MI'CU_`OP_P#`'P7^'_[?'B;6;3P':>,=2U?]EC]FOQ?\0+;]NWX?6_G>`M?L
M])^T:?<?LWVD.M17>K?$(:3\6/&<W@*W\/:GX8TW68_JO_@D_P#\HL_^":G_
M`&8#^QO_`.LZ_#FI?CE^V?XK^$GQIT;X7Z-\&-+\5>&5\9?!?P[XW^(^O?%-
MO`>E>&=/^,ESXFTO1DL$N/AYX@\-S^-+[7M$LM%\$^'_`!YXU^&7@[QSJ]^W
MAB+XEZ)X]U#P'X-\?@'X8>#O^"@G[=OCWXH?'?PY=_&+XX?#G4M+^'FD^+M/
MT[Q!\//V+='^#'PV\(>//^">W[.?[0K^$OAU?:MX`UKXS?$S]N;X.?'3]H+P
MGJ_B[0&E^*W[,.@?L]:O;7?BRTU7Q?<Z3+=^IK\6OVW/"7PD^(_Q6U3_`(*2
M_'W6;GPEHG_!:FVM;'XC>"?^"?'@?X=6,G[!?[5?C']F7X'>*?$_BSP_^P8-
M6\-0V7A:VL/B%\1=>E36_#TWC;1X]9/@U_`*:K\-=7^\OVK/^"J<O[,_QN^+
MGPEC\`_`'Q<GPM^%?C?XA3Z7JW[6C>"?C>D7@_\`9R\9_M!CQ]XU^"2_`?Q4
M/`G[+,\WA*'X3:Q^T@_C_P`0+H/Q-\1:)H8^&NJ/<J'Z3X0?\%!_C5^TAIAT
MW]F[X"?LZ?&3QQX3L[/Q-\4-<\-_MJWMU^S7-X"U_4_$.C>"?$/[/?Q]T/\`
M9C\1:S\>;WQKK'@WQ[H6DIJ/P?\`A3X*T[Q!\._&^C^(_B#HMQIVDMKH!\K?
M"/\`;(_:<TOX!?%?QQ??M%_#']I_PKHGPD\%?\([\:/@9X]^$7[5=OX7^*?B
MSXI_'S18?%-Q\9?@I^S#^RE\*?B-\/I['PEX2^'&OZ=IW[+/A2\^$'C#2H9O
M%&J^--"O?&OCSPQZ3^VK\:?VV?!7Q?\`VIM>^!GBSXT:'\,_@/\`LP^+?'=Y
MJ4VF?L6R_LO>$-2L_P!GSXO^,X-7\1'QGH6K?MBZK\:HO'&D^!]2\*0>'M/\
M0?L_)I$`M_&^G3*^M6<M?XM?\%O/`?PU^$?Q'\?67[-WQQU;Q=X`\-_%/Q7_
M`,(IK_@#XT^&?AK=Z?\`#3]B;QA^V+)H^H_M4:7\#?&/[,MEXUO7\*'X7ZCX
M.\/_`!-\7ZMI6H7-UXFTX>(X--&AWLD'_!6_XLZQX1^.=]X<_9(\+'QS\*=>
M^(5WX7\,>._C7\:OA7X<\>?"WX>>&?BSXPO/')\5^.?V*=-UP7FM:-\$?B#8
M^';SX8^`OC)\#/$?BJTLO#OAG]H376LO'%]X'`/S7T#_`(*+_M<Z?\:_#W@;
M1OVTO^%^:+8?!;X0_$2T^(_P3^*_[`W[3G['=YJ7B;XP_MB6WQ=\/_M!?M*>
M'/V)/V-/%M_\3M8^"OP"%I^R;\)?V9_AA8>)+CXO>`O%"_%^#QAX(74;^?Z_
M\3?MU?M9>'K/]E?P+_PM:&?QU\.?$UA^S]^V%KK>`?ALFH_$?XP>-?A)\4OB
MK\,?$.IZ4FAS:5\-M;U3X3?!*P^-GB+P;X.TC1M+_LW]I#X?_P!FI9:!86EC
M/]#'_@I9^U9/\5/''P<T_P#8O^%DGB[PIJ7P:\$:=K&I_'3]LC1?A+K?Q1^*
M5M\";G5-!/[0-W_P2W?X!#PUX73XP:N+*3PU\3/%_P`9/$"^#[>YOO@/X6LM
M6\1W7@+]*/V>?C%XC^+?A_QE9?$'P+IGPR^+GPF\>W/PP^+O@/P_XU;XD^%=
M`\8KX2\'_$/2Y?!_Q"E\*^!+WQAX5\2?#SXA>!O%^B:MJW@7P3KL=IXA73/$
M'A/0=;T_4-.@`/P>\#?\%$?B-+I7@&"#]O72_BGK.F^._C#\.KR;3_`'P0DM
M/C9XS?X9>"/&MA'\-M3T_P"%_@31OCYX(^#][XGU.#Q/-\$3\,OB[^RQ?BS\
M,_M9?"CXR1?#3XM>,%]PM/VQOB+=>)M%O]5_;:E\,_M-R^./!_A?1_\`@FU-
M\/O@9>2>.?A!?^-=*\.1?&S^P(?`%S^TO?Q?$+X<W%W\9[;X^>%OBCIG[-_P
MOMK^'0/&?P]^T_#_`,=Z==_O?10!^6OP&_:7_:-\1OX$\->.K"#Q9\3;+]@Z
MY^-NKV'ASP9_PB_@/XT?$2_C^&][X+\7>"+JZFU6[T./79=8\0^%O$'@!?%]
MS+X/\2)J$=U%J/AV;P+XP\0_!7CS]K7X^ZMX8M?#?[)__!0\?M-?&;XEW?PA
M\,?$OPLO@O\`9\^'R_L?^.OB%^T#\`OAU;V"^(-*_9?^*UW^ST-:_P"$^\0?
M#\?#3]K3X1_M.?&*P&M?\)_H^B:\OPU\1Z1JO]']%`'Y`_%G]H[X_P#[)WB?
M]FOQ!\<?B%)J7PS^&O[,7BC5/VPM(MQX+^(%]XS^*'BSQ#\./AY\)O%&D>/_
M``S\`/@/<ZSKD?Q1EN?"EA;^`_A+\&_#WBFT^(&JZG=?""RNM*\,:5H_QIX.
M_P""N'[57P"^*OPC_91^/?[/.E?M&?$;7O&W[0S?$[XNV'[3'[)7[/OC\Z/I
M_P"TQ^T!H/PW\(?LZ?LF^,]>\'>.OVJ+OX??"?P?X(TSQ(GPK9O%MU9?V=>O
M9^-/'VMK9:[_`$DT4`?S;^'/^"TGCN?XF_M`^)-0U[]@FZ^&7AOPU^RUX.\(
MQS_M_:/8_LJ?"3QWXI;]L+QG\1=1^/'[8,'[)9\0?#;X[>./#_@WX7?#NW_9
MPU/X:^-M'T+Q/X+TQM"\<6E[XX\12OQ_P8_X+:?&74K+XK?&/XC^$/V?]$\"
M>.O&/PEO/@OX/^*_[6VC?"?X:>$_"NH?L$?L7_M,:U\&_A!\5+?]DF]\1?M"
M_M0_$[Q%^U#=ZY\./AYX@71;;Q_IFD:]I7AZ^^'VE_#_`/M/XA_T\44`?"/P
MS_:@^(WQ1^`'QF^(OBSP-X+^!WB_3C^TM<?!/POI?Q7@^*/C#Q/\-_@EK6J>
M"--^+?BG0=5^''@6V\(ZKJ'BJS@N]4\!Z?'\2-#\*V.K>$[;6O'-[K&OW6@:
M7\=0?\%1OC#X/^'U_P".OB5\"_@?X?\``$@\9>%?AO\`%_QQ^UG?>!]`\0>*
M?A3\3_AU\(/'GC;]H])?V8SX;_9F^$XUKQI?^)YO&?AK7_CC<:1HV@WGV_PA
M807-G,/VB&CZ0NKR>(%TO3EUZ73HM'EUL6-L-7DTBWN9KV#2Y-2$7VQ].AO+
MFXNXK%IC;1W-Q-.D2RRR.VC0!\\_LT?'_P`-?M"_#+PYXOT_QM^SSXJ\3WV@
MV&O>)+']FCX_6'[27PRTNSUK4]?L/#]_X<^*,'@SX;:AXHT'6T\.ZHMAKE_\
M//"D5UJ>E:_I=E;7@T.XO9?H:BB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`^`?^"3_P#RBS_X)J?]F`_L;_\`K.OPYKV'XH?L<?L[?&/X@Z3\
M5/'_`('U34/'^CRZ*(?$>A_$7XG^";C4M)T&?[9;>#_$UKX'\9^'-.\8?#K4
M=0BTW5?$_P`,_%=GK7P]\9ZSX=\(ZSXN\,ZYJO@WPI>:-X]_P2?_`.46?_!-
M3_LP']C?_P!9U^'-??U`'E'BSX'?"SQSX<^+_A'Q9X3AUKPW\>[&?3/BUI-Q
MJFN1V_C#3[GP?IO@*XM)VMM3@FTJ&?PEI.GZ/*N@RZ5O2!KMB;^>XNI?"=>_
MX)_?LLZ]H'A+PRGA#Q_X2TCP++XAA\*1_"[]H+]HGX.WVD>%_%&I?VOJWPL3
M6?A1\5O!FLW7P*^VK`=+_9^OM0NO@CH%K9Z=I^@>`-,T_3;"UMOLVB@#Y+\8
M?L+?LH^.O@]KWP`\0_"#2V^#GB.'Q):ZEX!T3Q#XS\)Z+'9>+?@AK'[.&N:=
MI!\*>(]$O?#NER_!37M4\"V&F>'KO2]/T.TGBU;0[;3O$-E8ZO;8N@?\$_/V
M5/#O_";_`&;P1XTU<?$%?%MMX@7QG\=OC_\`$!;31_&^@_$+PUX@\*^#U\=_
M%#Q&OPZ\#MI'Q6^(L>C>`OAZ/"_@SPM?>+M7UCPOH6C:Q+'?Q?9U%`'Q+XW_
M`.">O[-'Q!\2>//%6OK^T+8ZC\2+WPIJ_B2P\%?MI?MG?#7PI:>(O!#>`V\,
M>,/!?@7X<_'[PKX)^&GCK3D^&OA"V?QW\./#_A3QAJ%E::M8:GK=[9>*?%=O
MK?MWP<_9Y^%OP$TQ-)^&5AXNTZT:'4!J,GB7XI_%3XC:CXEU35M6EUO5_%_C
M36/B1XT\6ZOXZ^(FKWTNW5OB9XROM=^(6J:=!9:-?^)KC1]/L;"V]LHH`***
8*`"BBB@`HHHH`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g30330image12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image12.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`#@!
M3`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/Z%/^"9?_!,O_@F[X]_X)N_\$^O'7CK_@GU^Q#XT\;>-?V(?V4/
M%GC'QCXL_90^`_B/Q5XL\5>(_@/X"UCQ#XF\2^(=8\!7FKZ[X@UW5[V[U36=
M9U2\NM1U34;JYOKZYGN9Y96^WO\`AT__`,$L_P#I&I^P#_XAO^SK_P#.YKXA
M_P""9?@+_@I%>?\`!-W_`()]7G@7]J_]B'PYX)NOV(?V4+GP=X>\6?\`!/KX
M\>-/%6A>%9_@/X"E\/:-XE\8Z/\`\%-/`6D>+/$&EZ0UI8ZSXFTOP+X*T[7M
M1@N=4L?"?ARVNHM'L_M[_A7/_!4S_H\C]@'_`,5J?M%?_38*`#_AT_\`\$L_
M^D:G[`/_`(AO^SK_`/.YKXA_X)E_\$R_^";OCW_@F[_P3Z\=>.O^"?7[$/C3
MQMXU_8A_90\6>,?&/BS]E#X#^(_%7BSQ5XC^`_@+6/$/B;Q+XAUCP%>:OKOB
M#7=7O;O5-9UG5+RZU'5-1NKF^OKF>YGEE;[>_P"%<_\`!4S_`*/(_8!_\5J?
MM%?_`$V"OB'_`()E^`O^"D5Y_P`$W?\`@GU>>!?VK_V(?#G@FZ_8A_90N?!W
MA[Q9_P`$^OCQXT\5:%X5G^`_@*7P]HWB7QCH_P#P4T\!:1XL\0:7I#6ECK/B
M;2_`O@K3M>U&"YU2Q\)^'+:ZBT>S`/M[_AT__P`$L_\`I&I^P#_XAO\`LZ__
M`#N:/^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S_H\C]@'_`,5J?M%?
M_38*/^%<_P#!4S_H\C]@'_Q6I^T5_P#38*`#_AT__P`$L_\`I&I^P#_XAO\`
MLZ__`#N:/^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S_H\C]@'_`,5J
M?M%?_38*/^%<_P#!4S_H\C]@'_Q6I^T5_P#38*`#_AT__P`$L_\`I&I^P#_X
MAO\`LZ__`#N:/^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S_H\C]@'_
M`,5J?M%?_38*/^%<_P#!4S_H\C]@'_Q6I^T5_P#38*`#_AT__P`$L_\`I&I^
MP#_XAO\`LZ__`#N:/^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S_H\C
M]@'_`,5J?M%?_38*/^%<_P#!4S_H\C]@'_Q6I^T5_P#38*`#_AT__P`$L_\`
MI&I^P#_XAO\`LZ__`#N:/^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S
M_H\C]@'_`,5J?M%?_38*/^%<_P#!4S_H\C]@'_Q6I^T5_P#38*`/EO\`;$_9
M3_X(X_L4_!34/CI\3O\`@F!^PIK'A;3_`!-X4\*O::;^S7^P/\.L:CXPUB'1
M=-GU#QS^T9JOP-^#GAG38;F=7NM0\8_$[PY`^([+3CJ.K7=CIMU\U_!I/^"$
MOQK^).N_#O1?^"6W['_A-/#EY\-K/6O$GC[]E3_@G[X?NO#8^*OPWO/B3X2O
M/B+\&(/%&I_M0?!2PNHH=/\`!?VGXZ?`;X8K>>/_`!!HGA_1AJL4UYJ%E]Y_
M$_\`9?\`^"A7QF\.0^$?B9^U'_P3V\6^&H=5M=9.BZA_P39_:32QN+ZS@N[>
MW:[BM?\`@K/!]JA2*]N`;><O`S.LAC,D43IXO=_\$Y_VT=7\.?$_P7XI_:O_
M`&,?''@7XP?V7+X[\"^._P!B#]LOQAX/U+4M(N=`O[77[/0=>_X+"7MEI'B.
M75/#&B:Q?:_I:6FJ7VKVC:C=74MU<7,DP!X_H_@;_@B;K6J6-K!_P25_9GL-
M%O/#?@SQ-+XKU[]AS]CCP[I>GVWCKQ[X6^'>E6-YH>MM8>/I+_2]9\8:'=>,
M3I_@R^T[P+8:AI4/C#4-$UKQ+X2T?Q!I6WPQ_P""*^FW/A2'XH_\$D_V:?@7
M:_$36=!C^&6J?%/]A/\`9&CLO'O@+Q'I-UJME\8K6/P);>.M2\$?#O3/LT=I
MXSM_BUI_P[^(OPW%]8ZU\1_`'A/PI.WB&/TWQ+_P3A_;"\8>-!XZ\2?M-?L.
MZIJZ:S!XD@TV;]A3]LF/PC:^(X/$]IXL7Q#9>"8/^"PT7A*QUR;4;.&SO-5M
M-'AO;[0`/#M[-<:+%;V,,O@__@G3^V7X*UG0=>T[]J;]BO6-2\(:G97W@B3Q
MI^Q%^VIX\M_`NFZ;HGB;P_IO@_P59>,O^"QFMVGA;P%8Z7XNUJWC\%:-!:>'
M)E_L=;S3[J/PUX:32`"Q\"_V3O\`@CW^T%X[^*?@CP3_`,$JOV/;&+X47T6F
M:MXL\2_L8_LAZ?X?\0W_`/:FJZ+=+X8TVPT[5?'<NFVFJZ'K&FP^)=>\%Z!X
M4UW4M'U_3/"NNZ_J/A?Q1::+]0_\.G_^"6?_`$C4_8!_\0W_`&=?_G<U\T_!
M+_@G[^V=^SKK>H:W\'_VE?V#?"37>B2^&M/T8?L!_M=ZSX4\(^&[G58]<O?#
MO@'PEKW_``5_U/PYX"T&_P!7AM=1O-&\(Z9H^FSW=I!.;82!VD^EO^%<_P#!
M4S_H\C]@'_Q6I^T5_P#38*`#_AT__P`$L_\`I&I^P#_XAO\`LZ__`#N:/^'3
M_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S_H\C]@'_`,5J?M%?_38*/^%<
M_P#!4S_H\C]@'_Q6I^T5_P#38*`#_AT__P`$L_\`I&I^P#_XAO\`LZ__`#N:
M/^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S_H\C]@'_`,5J?M%?_38*
M/^%<_P#!4S_H\C]@'_Q6I^T5_P#38*`#_AT__P`$L_\`I&I^P#_XAO\`LZ__
M`#N:/^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S_H\C]@'_`,5J?M%?
M_38*/^%<_P#!4S_H\C]@'_Q6I^T5_P#38*`#_AT__P`$L_\`I&I^P#_XAO\`
MLZ__`#N:/^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S_H\C]@'_`,5J
M?M%?_38*/^%<_P#!4S_H\C]@'_Q6I^T5_P#38*`#_AT__P`$L_\`I&I^P#_X
MAO\`LZ__`#N:/^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_A7/_!4S_H\C]@'_
M`,5J?M%?_38*/^%<_P#!4S_H\C]@'_Q6I^T5_P#38*`/B'_@F7_P3+_X)N^/
M?^";O_!/KQUXZ_X)]?L0^-/&WC7]B']E#Q9XQ\8^+/V4/@/XC\5>+/%7B/X#
M^`M8\0^)O$OB'6/`5YJ^N^(-=U>]N]4UG6=4O+K4=4U&ZN;Z^N9[F>65OM[_
M`(=/_P#!+/\`Z1J?L`_^(;_LZ_\`SN:^(?\`@F7X"_X*17G_``3=_P""?5YX
M%_:O_8A\.>";K]B']E"Y\'>'O%G_``3Z^/'C3Q5H7A6?X#^`I?#VC>)?&.C_
M`/!33P%I'BSQ!I>D-:6.L^)M+\"^"M.U[48+G5+'PGX<MKJ+1[/[>_X5S_P5
M,_Z/(_8!_P#%:G[17_TV"@`_X=/_`/!+/_I&I^P#_P"(;_LZ_P#SN:/^'3__
M``2S_P"D:G[`/_B&_P"SK_\`.YH_X5S_`,%3/^CR/V`?_%:G[17_`--@H_X5
MS_P5,_Z/(_8!_P#%:G[17_TV"@#XA_90_P""9?\`P3=\1_'C_@IIH_B#_@GS
M^Q#KVD>`OVWO`7A/P+I>L_LH?`;5-.\%^%;S_@FY_P`$^O'5YX:\)V-]X!GM
MO#GA^Z\;>-/&/C&YT;1XK/3I_%7BSQ+XAEMFU?7=4O+K[>_X=/\`_!+/_I&I
M^P#_`.(;_LZ__.YKXA_90\`_\%(I_CQ_P4TB\/\`[5_[$.EZO9_MO>`K;QU?
M:S_P3Y^/.O:=XC\5-_P3<_X)]7EGK/A/2['_`(*:>'+GP7X?@\$W7@[P]<^&
MM8UCQ[J-UXJT+Q+XQB\66>D>+-+\"^"_M[_A7/\`P5,_Z/(_8!_\5J?M%?\`
MTV"@`_X=/_\`!+/_`*1J?L`_^(;_`+.O_P`[FC_AT_\`\$L_^D:G[`/_`(AO
M^SK_`/.YH_X5S_P5,_Z/(_8!_P#%:G[17_TV"C_A7/\`P5,_Z/(_8!_\5J?M
M%?\`TV"@`_X=/_\`!+/_`*1J?L`_^(;_`+.O_P`[FC_AT_\`\$L_^D:G[`/_
M`(AO^SK_`/.YH_X5S_P5,_Z/(_8!_P#%:G[17_TV"C_A7/\`P5,_Z/(_8!_\
M5J?M%?\`TV"@`_X=/_\`!+/_`*1J?L`_^(;_`+.O_P`[FO\`.J_X.Y_V>_@'
M^S7_`,%(O@GX%_9S^!_P?^`7@G5OV(?AOXLU7P=\%?AKX,^%7A;4O%5]\>/V
ME-'OO$M_X>\"Z-H.D7OB"\TC0=#TNZUFYLY-1N-.T;2K&:Y>VTZSBA_T5?\`
MA7/_``5,_P"CR/V`?_%:G[17_P!-@K_.J_X.Y]&^/F@_\%(O@G9_M&?$KX/_
M`!5\;2?L0_#>YTKQ#\%?@?XS^`7A:R\*O\>/VE(K'1K_`,'>.OVA/VE-7U+Q
M!;ZO#KE]=>);;QUI.G7FG:CI6EP^$[&YT:\UC7@#^VOX9?"G]H3XT?\`!"7_
M`()O>`/V9?$5QX6^)VH_L=_L!7\>L)X^^,OPUL5\/Z+\!_A[JVM6.M>*_P!G
MWXW?LZ_&.ST;5H[2'2[R+P/\7_"E]*UY"=0.JZ)'J>C7]'X#?`W_`(*0_"\?
M&SQK!XZ^,WQ0^*.F^+O!\GPYT?\`:(\:^*;3P_\`%'PQ%IGBSX;SW7C>YM?V
MK_BW^SQX?NH=*\7Z9\9]9T']GO\`9#_9=M;;Q?X$L/#NLZK\31-;ZDNU_P`$
MR_\`@GU\!_&G_!-W_@GUXQUCQ[^V]9ZOXL_8A_90\2ZI:>$_^"FG_!2+P%X5
MM=1UWX#^`M4OK7PUX%\"_M7^'/!/@OP_!<W4L6C>$_!WA[0O"OAS3EMM'\/:
M-I>D6=I8P?9</_!.[]EVYU?4/#]O\7/V[+C7M(L-+U35=$A_X*W_`/!4*75]
M,TS7)M4MM%U'4--C_;-:\LK'6+C0]:@TN[N88K?4)M'U2*TDF?3[M80#[-^%
MMEJ>A^#M+\'ZJ/'%[<^`;33/`_\`PE_Q`OM*U/Q!\1T\/:'I5J_Q"EU#3==U
MRXNU\37#3SW-QKITK7)M5BU)[O1[:!K2>Z^1?^"3_P#RBS_X)J?]F`_L;_\`
MK.OPYH_X=J?LZ_\`11OV_O\`Q;!_P5,_^C(KXA_X)E_\$^O@/XT_X)N_\$^O
M&.L>/?VWK/5_%G[$/[*'B75+3PG_`,%-/^"D7@+PK:ZCKOP'\!:I?6OAKP+X
M%_:O\.>"?!?A^"YNI8M&\)^#O#VA>%?#FG+;:/X>T;2](L[2Q@`/W<HKX!_X
M=J?LZ_\`11OV_O\`Q;!_P5,_^C(H_P"':G[.O_11OV_O_%L'_!4S_P"C(H`^
M_J*^`?\`AVI^SK_T4;]O[_Q;!_P5,_\`HR*/^':G[.O_`$4;]O[_`,6P?\%3
M/_HR*`/OZBO@'_AVI^SK_P!%&_;^_P#%L'_!4S_Z,BC_`(=J?LZ_]%&_;^_\
M6P?\%3/_`*,B@#[^HKX!_P"':G[.O_11OV_O_%L'_!4S_P"C(H_X=J?LZ_\`
M11OV_O\`Q;!_P5,_^C(H`^_J^9OVP_$'Q`\+_L[>/-8^&'B'QKX0\7I>>`]/
MA\7_``Y\&:1\0?'?A'P_KGQ&\(Z)XV\5^$_!OB#P1\2M"UW7/#?@G4?$.M6%
MMK'P_P#&6F136*W=[X<U6WMY+.7QK_AVI^SK_P!%&_;^_P#%L'_!4S_Z,BLS
M6/\`@G=^R[X>TZYUC7_BY^W7H>D6?D_:]4UC_@K?_P`%0M,TZU^T3Q6L'VF^
MO?VS8+6#S[F>"VA\V5/,GFBA3=)(BL`?EAXM^/G_``4PN?VDM?\``GA_XO\`
MQ^\/?LV^%/V;=`O/AI\:=:_9^TW0O'/QF\4^(_$'[5'AG5_B;XR^&^C_`/!,
M3XZZ?K7Q!\+P>"?A7J=WI6B>)_V3O!?@#1F\+?'*3]G_`/:%\%_$-?@?>_7Y
M^/G[3^IZ3XT\1:AXJ_:P^'OQ$T[X,66M?`WX'R_LD:%XE\)_$BRU_P#9S\'^
M-H_'?QC\::+\%?$2Z!\9M`^,4/Q'\&ZIX2TGXF_![PSX2O\`3]'\/:]\$?%,
M>M>"]>\:]C\1/V<_^"<'P@\&VGQ#^+/[9O[1GPN^']_I>BZW8^.?B)_P6Z_X
M*'^"?!U[HOB6X2S\.ZO:>)O$O[<^F:+<:9K]W)':Z+?PWKVFJW#I!8RSRLJG
MK],_8R_8=UK2$U_1OVEOVN]6T*31O&'B*/6],_X+*_\`!2>_TB3P]\/=77P]
MX^UU-2M/VVI;-M&\#Z^Z:'XPU19C9>&M7==-UJ>RO2("`?F[X(\7_P#!<;Q[
M\2_#_P`%;7QWK7@#5-$\!_`_Q;K/Q"^)7A+X>2>#].\57_C#]M#1/BAX>^(/
MQ/TO_@G[H/@W]H"UL[#X?_L^>,+[X9?!CX=?L?:YXB\#^*O"WAK1?VA?A!K_
M`(DNOB=XE]D\)?$O]O[PSXP\5_"[XQ?&[]K.S^">G^#OA]?ZI^U;I7[*OP<\
M5?'#PYXEUK]H#_@HWX*O-,\*^'_`O[+,_P`*M2^V>#_@_P#LF7/B74)?V<OB
M/!X/\/\`BW2-=U+1_#]G\7-*\<:3]6^-_P!DG]@CX9Z]\./"WQ(_:I_:J^'W
MB?XQ:M/H'PB\.>./^"T7_!1_PIKWQ3UVUCL9;G1?AQI&O?MOV&H>.-6MHM3T
MV2?3?#-OJEY#'J-B\D*K=VYD\Z\,_"C_`()7>-O`OQ"^*'@W]OGXR^+?AI\)
M'N(OBM\1/#/_``78_;YU[P+\,I;18&NX_B%XMTK]O*[T#P6]JMU;-<)XDU#3
M6A6X@,@431E@"Q^SE^T/_P`%#/$WC3Q78_&'X0Z[!\/D_:^^&GPL\%>)H/A?
M<^"=>M?@A<_LH_`_XCZS\1_'OAWQ$8KF3PQX^^('CCQ?I]YK'A6%]2^#_P`6
MM!UKX1^)X6MM+U)/"O['U^4`_9:_X)[M\.I/B^O[7'[3K?"6+X?1?%J7XHC_
M`(+6?\%&&^'4?PJN(YYH/B8_C8?MQ?\`"-)\/IH;:XEA\9MJ8\.21V\\BZDR
MQ2%:GA7]FK_@G1XZ^)=Y\%O!'[8O[27C'XQZ=X+T[XD7_P`)O"O_``6V_P""
MB/B'XEV/P[UBWT&\TCQ[>>!-(_;EO/%-MX+U2T\4^&;K3O%,VE)H=[;^(]!G
MMKZ6+5]/:X`/UJHKX!_X=J?LZ_\`11OV_O\`Q;!_P5,_^C(H_P"':G[.O_11
MOV_O_%L'_!4S_P"C(H`^_J*^`?\`AVI^SK_T4;]O[_Q;!_P5,_\`HR*/^':G
M[.O_`$4;]O[_`,6P?\%3/_HR*`/OZBO@'_AVI^SK_P!%&_;^_P#%L'_!4S_Z
M,BC_`(=J?LZ_]%&_;^_\6P?\%3/_`*,B@#[^HKX!_P"':G[.O_11OV_O_%L'
M_!4S_P"C(H_X=J?LZ_\`11OV_O\`Q;!_P5,_^C(H`^_J*^`?^':G[.O_`$4;
M]O[_`,6P?\%3/_HR*/\`AVI^SK_T4;]O[_Q;!_P5,_\`HR*`#_@D_P#\HL_^
M":G_`&8#^QO_`.LZ_#FO,_C1\5?VAO!G[6&I-X)\9_&[Q!H&D:I^S]ING?L[
M6WP2T35/@#XB^$WB/Q#'+^TA\7M0^,NE?`74_B%I?Q,^&7P\A\6>)/!OAQ/C
M[8>&_$_BGPUX6^'"?#F_U[QYIM]+^2OP2_8P\(W_`/P3\_X(7OX0_:$_;^^$
MFI_M(>'OV-?#/Q0U'X5_\%&?VXO#MC/X5UC]@KXC?%W6?"G@_P`"7WQZUGX6
M_#GPU?\`BSP)X>AM=&\`>`_#EGX7\.VS>'?!,?AG3!!!!](^$O\`@DA^V#9_
M\*I_X3']L+XW:O\`V'^T!XG\1_%K^S/^"EW_``5@M/\`A.?V<]?_`+!_L+X>
M:)G]I.#^P/&WP^_MOQM_9OB&W^SCQ=_P@?PZ_M_4;/\`X3;QI_PC@!<^.'QT
M_P""I=S\!OB%X]T;1_C_`/!+XX?#;P=^V!\2_!GPK\#?!WX)?$[PU\5/#?B3
M]E+XL_&/]E7PMXS27X8_&C4F\>_"OXV^![3X)?\`")_#KXA>%/$WC:2WT;4O
M'NDWFJ?%3PMHFC?K-^P_JWQ9UO\`9F^'FI?''Q5K/C7XG3S^,5\1^)=?U*VU
MC5-12'QQXCAT83ZE9?L>_L%6ETMGH2:;80F#]ECX;"&*U2VDN/&TT,GCWQ-^
M,>G?\$XOB]\*/B]^R5H_Q]_;"_;,\5Z9\7?VSOC!\,IO#/PR_P""E/\`P4BT
MWPYXJ^!]S^QK^T]\;_!5KXWN?$'[1D?BW1?'/@?XA?!_P];Z9<>`?$NDZ?J&
MA6MZ_BN]\6/XA&G>&_U0/_!-/]G8=?B-^W\/^\L'_!4S_P"C(H`3]C?_`).*
M_P""L'_9_P!\.?\`UUG_`,$U*^T?'VM>(_#G@7QGXA\(>$[SQYXLT+PKXAUC
MPQX'T^^TC2[[QCXATW2;N\T7PO9ZGKVH:3HFG7.OZC#;:7!>ZOJFG:9:27:S
MWU[;6T<DR?BA^RA_P3Y^`VO?'C_@III=]X]_;>@MO!?[;W@+PUH\NC?\%-/^
M"D7AS4;S3KK_`()N?\$^O&,MSXLUCP_^U?I>K^/?$"ZOXLU2SMO%GCJ^\1^*
MK/PK:^&O`MGK,'@GP7X.\/:%]O?\.U/V=?\`HHW[?W_BV#_@J9_]&10!\<>'
M?V7/^"DOBSXC_L\GXN?'S4-!MOV=X_C%K_BWQ?X"^(7QCO/#W[0][XD\0?!;
MQMX.T"X\/>#_`(T?L_\`@Z&XMI+KXJ?"ZQ_X7W\$/CYX9\+>`="GE\-Z/H7C
M#6M)\>IX[\+OV$O^"E/P^O\`]C2ZOOVJ_B9XC'@;3[;QG\:+^[^*7[46L7%E
MXJ\31>"WD^'MUX?^,/[<WQP\+?$W0(]8\,W^D_&76/C1I'Q[L=.\$_$/XAZU
M^R9X6^`7C+2?A_)X=_1>_P#^"=O[+VEW&D6>I_%O]NS3KOQ!J3Z-H-K?_P#!
M6[_@J%:7&MZQ'I>I:Y)I6D07'[9D<NI:DFBZ+K&L/8V2S72Z7I.I:@T0M+"Z
MFB\*\??!#_@F+\*=1L=(^*7[<OQW^&VK:IX*U?XE:;I?C[_@N7_P4#\':CJ/
MPYT"2ZAUWQ_8V7B+]NW3KF[\%:)+97D6K^*K>*30M-DM+I+R_@:"4(`8WA+X
M;?MM^%M(NO&?PJT#]H&W\=>!-.\,>*?&/@#]J']I9?'OA3]H;X\NC^!_'MQX
M%O[7XC_$;3?A[\')?`FM>*_&%CX-T3P]\)OAC+\0K+X6:SX/^$'@_6M(\626
M_P`Y:C^RM^V5H_QX^)L7Q&\3_MN?&7X*WOQ!^$VG7D_PL_:,_:$^$_C/Q?\`
M#;PK\#/"&F:[K_@WQIX2_P""CO@/P'X.DU_XTV<^O^)/"GPO_9F^`WB^X5/$
M"Z[\3?&'AJ_N?#FN_=VE_L5_L2:YH>D>)M%_:0_:_P!8\-^(/!NH?$;0/$.E
M_P#!9'_@I5J&AZW\/M)736U7QWI&K6G[;,UAJ?@W3%UG2&U#Q/97$VB62ZKI
MIN;Z(7UL9>NM/^"=G[+]_<W%E8?%K]NV]O+2VL+V[M+3_@K=_P`%0[FYM;/5
M5N'TN[N((?VS'EAMM26TNFL)Y%2*\6VN&MWD$,FT`^K?V?\`3_B7I?P=\"V'
MQ?N;NX^(%OIER-8&J7^F:MKMI92:I?R^&M*\4:SHCRZ)K?C'1O"TFBZ3XQUS
M1;BZTC6O%-CJ^J:7>7EC=V]S-_FU_P#!ZG_RE,^`?_9@/PL_]:*_:IK^_C_A
MVI^SK_T4;]O[_P`6P?\`!4S_`.C(K_.I_P"#NCX'^#/@%_P4B^"?@[P+K7Q>
MUW2-2_8A^&_B6XN_C7^T)\>_VD_%4>HWGQX_:4TN6VT_QS^T9\2_BIXWTGP^
MEKHUG):>$]*\0V?A6QU&;5=8L=&M]7UW7+[40#_16_X)/_\`*+/_`()J?]F`
M_L;_`/K.OPYKK?AW^R5K'@/]J/XA_M3R?&/Q)K_B3XMKKV@>/O`][HNCP^"&
M\!Z<F@V?P<T7PN(XW\3Z)J?PQTSPTHEFN_$>K^&==U_Q]\7?%-CX4\-ZMX[N
M9+;\]/\`@F7_`,$R_P#@F[X]_P"";O\`P3Z\=>.O^"?7[$/C3QMXU_8A_90\
M6>,?&/BS]E#X#^(_%7BSQ5XC^`_@+6/$/B;Q+XAUCP%>:OKOB#7=7O;O5-9U
MG5+RZU'5-1NKF^OKF>YGEE;W+2OV)_\`@BMK7QR\2_LX6'_!/C]A)OB]X2\-
MVWBO6-`NOV!/A?INAOI5Q;Z%>RP:)\0=2^"EI\.?%'B#2M/\4>%]4\1^$O#'
MBS6/%7A;2/%'AK5O$FBZ5INOZ1=7@!^M5?`/_!)__E%G_P`$U/\`LP']C?\`
M]9U^'-'_``Z?_P""6?\`TC4_8!_\0W_9U_\`G<U\0_\`!,O_`()E_P#!-WQ[
M_P`$W?\`@GUXZ\=?\$^OV(?&GC;QK^Q#^RAXL\8^,?%G[*'P'\1^*O%GBKQ'
M\!_`6L>(?$WB7Q#K'@*\U?7?$&NZO>W>J:SK.J7EUJ.J:C=7-]?7,]S/+*P!
M^[E%?`/_``Z?_P""6?\`TC4_8!_\0W_9U_\`G<T?\.G_`/@EG_TC4_8!_P#$
M-_V=?_G<T`??U%?`/_#I_P#X)9_](U/V`?\`Q#?]G7_YW-'_``Z?_P""6?\`
MTC4_8!_\0W_9U_\`G<T`??U%?`/_``Z>_P""6?\`TC4_8!_\0W_9V_\`G<U^
M:GQ__8%_9[3]HSXR_![]E_\`X)C_`/!*?Q!?_#_]CWX7?%?P=X$^('[#/P$M
M;GQ=\5?B[\7_`(S_``ZM;_5OB.MGHNG^%O!G@31OAC:^)-0TE?"'B'5/$2/J
M=A97$%[+IT)`/Z*:*_GEU#_@G;H%Q??$F31/^"&__!*C3]/;]G+P'XF^$]OX
M@^`W[+,]Q'^T?+;^'[OXB?#7QN^D>'YE/ARUD\5ZAI7AWQ+I$K:3<7?PL\1S
MW.I1V/B;PG=ZUVO[-7_!/S]CWQ;\?_B_\+_C]_P3`_X)E>&)M!_9H_8[^.>E
M>`_"O[$W[/$NJ?#/Q/\`&_Q!^U%X*^(WP_\`$'C:#1/$6C_$)=)UG]G[3M6T
MS7M%LM&L+-M>U+1;=_$%GI]GXBU$`_>6O,OC)\/'^*WPW\1^`8]670WU[^R-
MNJ/9'45M?[+U[2]:.;-;JR,WGC3C;C%S%Y9F$WSA/+?Y2_X=-_\`!+/_`*1J
M_L`_^(;_`+.W_P`[JE_X=-_\$LL?\HU?V`L^O_#&_P"SK_\`.Y/]:`/D_P`#
M_P#!(`?#[X)_`3X,:'^T)J<^C_!C]E_P7\`I;6_\"02>';WQ5X>^!'Q`^$'B
MSXF^%=*_X2A]8\)0?$G7/&Z?$#7_``-=>)O$ND:7K6GZA)HU]#?^)M<U*YTM
M*_X).Z]I>K?%/Q</VG?$#^*_&GC#]M*/PGI]OX!TFV\`>'O@W^VE\:?VD_CE
MXQ^'FO:!=:QJGB/6?$>D^,OVD+C4+_QOX=\9>#+'QI>?"7X1R^(/!YMO"5C9
MV_T]_P`.F_\`@EE_TC5_8"_\0X_9U_\`G<5XC\7?V'O^",_P.U[X*>'OB+_P
M3K_8,TBZ^/GQ6@^#/@*[C_8G_9]NM+3QM>^"O&GC?38?$>H1?#CR/#^E:K!X
M)N_#FG:K?$6MSXQU[PIX=4K=:];,H!VWQ6_8$\3_`!U^*/[&OQC^)7QAALO$
MW[*7P^^+_@O5O"7P\T[XC>"_AU\8&^*/Q._9>\7Q6OCC1])^+=KJ&O>`](\,
M?LYSZ=??#7QG?^,O"/B#Q]XC\+_$/4+#9\.=/\,:U\@?!/\`X(]?%OX+_LWV
MW[.%C^TUIVOZ')\$?@5\&-;\3ZU=_M8:KXJ>']GW4=!UOPGK?PY\1>(?VN->
M\5?`#3M9U329\^`/@3XD\`^!/AC#<K>?!?1/`6OF[UFZM>`OA?\`\$(_BRWP
MSMOA-_P3M_8:^).I_&?1/V@-4^$^F^&_V,OV5;8^.]4_9W\7>+?!7B/P=I>L
M^)/#N@>&-.\7>,M7^'OQ&G^'>G>)->T.RUG2/ASX]U?6M2\.6/A/6I;3X9D_
M:6_X(%6_@NP\<:C_`,$?/V8?#MCJ7P'^!'[1%IHOCKX,?\$:OAIXLC^'W[2&
MM_#'3/A9?:KX:^)/[47A'4_#NDZCI?Q>\$^)-:^(_B6'2/@KX9M[Z?PAKOQ/
MLOBG;CX?R`'ZU:C_`,$V?%=SKD?Q!A^/M]JOCZ?X:Z3\%-5TCXCVGQ%^*7@6
M[^#FA^"M%FT[PHGB;Q7\69?VD+WQE9_';P[IWQCTGXQ^*OC[XH\>^'KW4_$L
M>CS6_B?4[3Q?IO9?LC_L'>/_`-F_]HCXV_'7QC\?-5^+MU\;=(^&QUZU:^^,
MG@O2AXJ\#_LW_LO_``!U37YO@YIOQNU']F2;5_$5S^SK<^,$\?Q?!"W^,&E:
M;XPA^'`^(M[X/T!8-3^4/"?PD_X(9>*_^%00K_P39_8OT#4_C>_C$>!]&U[]
MA_\`9C2_:+P/X'T#QUK-UK4FD^%=7TW1[2>U\3Z#X>TB>YU`IJOB[5++0+3S
M)[JWDEZ;XH?L[?\`!%#X0?!?X:?';QE_P3)_8[3P9\7/"-WXH\"V&B?L(?LZ
M^(?%^N:E'\'_`!%\;=)^'VF^%]'\$W>HZS\2/%OA'PIKUCX.\*:`NKS^(O%-
MDGA^QN&NKVP:Y`/VYHK\+=#^#?\`P0F\3:C\,=/\/?\`!//]AS7%^,^L?$?2
M?A;J.B_L/_LZ:UIOC:+X6^'--USQ-K.C7&D>!KZ1]'GU/5;3P+H$UQ!;W>O_
M`!!=/"VG64MS<64MT^U^!?\`P1/M/AU^S?\`$KQ[_P`$P?V-_A7I'[47Q4N_
M@]\/=.\8?L7?LCZQ?Z1XNL_A]\6?B=+)X[U/X9:7\0_"'AC08?"/P7\;7FJ:
MVWBB]L_#-Q;06GBXZ!-#JPTH`_<^BOP'N/A3_P`$<#<376D_\$=OV==>\$67
MB;PQ\,M3^*$'[$O[$'A_P)IGQW^(4_@G3OA1\`Y9O'&J^$_$U]X[^*VO_$KX
M>>$_"'BO1O#&J?!&T\7^,M%\,>,OBYX3UC[?:6+/`_PK_P""./CSX3?LI_&2
MP_X(Y_LZZ3X5_:[^$.I_'+P#;:_^Q;^PK9ZKX7^'UKX(L?B1H]QXV^RZ]?Z-
M/XD\6>"-3L?$VA>"/AUK/Q"\96NB'5M6\4Z%X;TWPIXRN_#H!^_=%?RJ_#'X
M^_\`!OI\4-0\$65A_P`$J_V2]`@\8>&/B/XQFU35_P!G3_@EKK5C8>'_`(8^
M$K_QOX@N_!,7P]^,GCC5/VH+B/0-.N8M4TS]BG3?VFM4\`>*;76?A_\`%FS^
M'OQ!\)^-/"WAOUW]H3_AS!^RMIWA\_'_`/X(L?L__"GQ1XLT'X@>+?#7A'Q_
M^RY_P2[\"V^I>#_AW\4/@=\*=3\47OQ<\:_&7P[^SGX5L-4US]H3X>:GI-AX
MV^-/AKQ#%I5Q?V6OZ+H7BM=+\,ZJ`?TFT5_,M:Z__P`$4_$?Q<\??`KX:?\`
M!%S]G+XM_%CP-K_@[PO;_#_P/^S[_P`$CK3QWXOUGQEX-TSQ_;G2/AYX[_:%
M\%?$3PIH&D^%-1FU&^\;_%SPG\-/`FJW.E7VC>#_`!-XHUNXT73M6_3/X;?\
M$X?^"2'Q5\$Z%X]\*?\`!-C]@XZ-KL5X$MM4_8J_9[TW5]+U+2M2O-$U_0=:
MTZ?X<F33]<\.Z]INI:%K5D6D6UU33KN!)IDC660`_3:BO@'_`(=/_P#!+/\`
MZ1J?L`_^(;_LZ_\`SN:/^'3_`/P2S_Z1J?L`_P#B&_[.O_SN:`/FG]BWX$^)
M?C1_P2__`."*FO>#_'>A^!/$GP`_9^_8?^..FS>)?`]_X^T3Q*EG^Q7=_"_5
M/"E[I6E^.OA]?Z:^HZ+\4M2O;#Q#;ZW=KI&J:98RW.A:U9O<63_LA#-=M;0M
M/;VT=VRQ&X@ANY)[>)BR^>(;J2RMY9Q&A<Q,]G;&=E5&6`.73^43X/?\$\?V
M(/%/_!/K_@A3/#^R+^R9H'C']I'1_P!B[2_C5\3[;]D;]E?Q7\2/']EJO[!?
MQ'^,?BD^(?$?Q/\`@OX^&J:EXU\=>"-%U+Q=K]_8W7B+5]^ILVKPW6HW%V?I
M7PA_P1.MK#_A4?\`PF'[*O\`P1ZUC_A'/VBO%_B[XK_V=^PC\%[;_A.OV>/%
M/]E_V-\.=*W?`R'^Q_%OP\_X2;QW_8VJ+Y=CXD_X0'X8_P!JW.F?\)5XH_X1
M0`_9OXT?![QC\3/BM^RYX^T;Q-X9TGPW^SA\4?&?Q?O_``KJ6A:I=ZW\0O$G
MB3X!_&']G_1-)L_%]KK<-AX$T/P]HWQL\4>*M5EF\%^.[_Q5J>FZ!HUHW@^U
M@U'4]2^BX'N9((6NX88+DQH9X;>=[J".4@%TAN9;:SDGC!X61[6W9Q@F%#Q7
M\U5G_P`$F_@C\+OC3^Q[:?'_`/96_P"";OBJR^)O[:'QK^&@\+?"W]A/]E_1
MO"/B[X(:M^QE^T_\;/"%I\18-9^!%OK\'CCP'\0?@_X>@T"?PEKMIIO]BVM]
M-KEWXBG\1"Q\.?J^?^"3?_!+0`X_X)J_L`>O/[&_[.O\_P#A7/'\O6@"/]C?
M_DXK_@K!_P!G_?#G_P!=9_\`!-2OOZOPC_90_P""9?\`P3=\1_'C_@IIH_B#
M_@GS^Q#KVD>`OVWO`7A/P+I>L_LH?`;5-.\%^%;S_@FY_P`$^O'5YX:\)V-]
MX!GMO#GA^Z\;>-/&/C&YT;1XK/3I_%7BSQ+XAEMFU?7=4O+K[>_X=/\`_!+/
M_I&I^P#_`.(;_LZ__.YH`]0_:?\`V6=)_:<UW]F#4=;\47OAO3OV<_V@M6^/
M7V?2[6X&MZ]J5Q^S1^T;\!/#\&@>(;75=.F\%Z_X3\0_';2OB?HOBA+373#J
M7@&VTC^R%.L#5M*^4OB)_P`$R;KXE>'?@?X<UW]H'Q1$WPH_9Z^-WP#U[Q;H
M6B77@KQ]XN/QJ_:6_8T_:`U#XB:%XI\!>*O"]Q\,_&&C0?LGWFAZ=<>#H;6:
MPU_Q_:^+/#NH>'/^$-M='UCG?A-^Q_\`\$1?CAX#\8_$KX;?L`_L):MX0\`Z
MCK6F>++W6?\`@G]\-O!&J:7)H>D6WB":_3PQXZ^!_AOQ3J.@:KX=OK#Q)X2\
M4:5HM]X;\<^&]1T[Q#X+U77]&U"ROI^%;X%?\$$$\1MX9D_89_85AG=+:/3_
M`!!<?\$ZO!]O\/O$&MS65WJ=UX(\(_%*?]G^/X:^,OB=H6E:=JNL>+OA3X4\
M6:S\2O!>C:/K.K^+?"FBZ;H^IW5H`>DW_P#P2^U.Y>WUJR_:&\0Z;XHT'X+^
M(OV=_#D"^&SK'A"_^%OCGP9XXTKXD7OCJV\5>(?$?C_Q'\2?B3\1_B%JOQC\
M;^-;/XCZ._BKQ=X6^&T/BK3_`!"G@NSOI_L']GC]EG3OV=O%_P`2-8\/^-=8
MUSPEXQ\*?"+PEX1\#:I8VR6/PMT/X66'B^W'AOPGJ:3RZA/X-O=0\7WVI^'_
M``]JS7LG@>"67PMH.ICP78>%O#OAKXC;]E3_`((4)XQ^)7P\;]BC_@G(/'GP
MAT30O$OQ%\'#]BSX('Q+X=\.>)?&.N?#_1/$+:*/A*=0U30K_P`:>&M;\/+J
M^B0:EI\.H6#)<W,,4UO)-PUW\%?^""6G^&_!/B_4/V!_V-=.\.^.])NO$UEJ
M.H?\$P[&P'A'P39S:E!-\2?C#:7?[-<-[\!OA0TND:F+;XK_`!NMOA]\-[Q;
M.:2S\43QA68`_<*O\PG_`(/4_P#E*9\`_P#LP'X6?^M%?M4U_<IX"_8C_P""
M)'Q1N]-L?AW^P[_P3;\8W.K:E\6=%L5T+]D/]GB]1];^!7C/3_A[\7-"GG3X
M:>19:[X$\8ZI9Z)K6BWLMOJ@F>:YM+2YL;.\NH/X#O\`@[G_`&>_@'^S7_P4
MB^"?@7]G/X'_``?^`7@G5OV(?AOXLU7P=\%?AKX,^%7A;4O%5]\>/VE-'OO$
MM_X>\"Z-H.D7OB"\TC0=#TNZUFYLY-1N-.T;2K&:Y>VTZSBA`/[=_P#@F7_P
M4T_X)N^`O^";O_!/KP+XZ_X*"_L0^"_&W@K]B']E#PGXQ\'>+/VK_@/X<\5>
M$_%7ASX#^`M'\0^&?$OA[6/'MGJ^A>(-"U>RN]+UG1M4L[74=+U&UN;&^MH+
MF"6)=O2OVC?^",^D?MA^)_VU+;_@I]^PNGQ/\5>&+/PIJ5M;_M5_L;64=SI-
MCX8T;PK:Z3J?C.SU6'XI:WX3LK;1H];TOX?ZMX[NO`6F^,;[4/&$'AL^(&LK
MZQ**`/L/_A[!_P`$L_\`I)7^P#_XF1^SK_\`/&KXA_X)E_\`!33_`()N^`O^
M";O_``3Z\"^.O^"@O[$/@OQMX*_8A_90\)^,?!WBS]J_X#^'/%7A/Q5X<^`_
M@+1_$/AGQ+X>UCQ[9ZOH7B#0M7LKO2]9T;5+.UU'2]1M;FQOK:"Y@EB4HH`^
MWO\`A[!_P2S_`.DE?[`/_B9'[.O_`,\:C_A[!_P2S_Z25_L`_P#B9'[.O_SQ
MJ**`#_A[!_P2S_Z25_L`_P#B9'[.O_SQJ/\`A[!_P2S_`.DE?[`/_B9'[.O_
M`,\:BB@!1_P5A_X)9@Y_X>5_L`_^)D?L[?\`SQJ^3;7_`(*"?\$_]*_;C\3_
M`+0%G_P4E_X)C7WPH\<?LQ?##X,ZN;K]O#X*Z?\`$/P_XM^&/Q,^-WCJWO--
M\)Q7NH^&_$/ASQ!9?%BRLIK^Z\?^'-3T:ZT>Z:/1=8BN8FC**`/K3_A[)_P2
MT_Z25?L`?^)C_L[?_/'KYA\$?\%#O^">NE?M??M%?'3Q!_P4F_X)GVW@'Q_\
M#/V6?@]\/+?1OVZO@CJ_B^]G^"OB[]J/QSXRU_QIHU]JVA:+X4AN]2_:&T_0
M?#.G:'XH\</J5CX9O-=U6\T&XU*#0;4HH`^GA_P5D_X):_\`22K]@#'_`&>1
M^SM^G_%QS_+-!_X*R?\`!+0?\Y*OV`/P_;'_`&=CV_[*-^'&?RHHH`#_`,%9
M/^"6G_22K]@#_P`3'_9V_P#GC?E7B_QH_;@_X(M?M":)#X=^+G_!0/\`8#\4
MZ/;66OV5G;)^W'\%=!FL#XDTMM'U#4=,U'PY\6M)U/2]>M[-V.B^(M.O+37/
M#UW_`,3#0M0TZ^`N***`/+/#?QT_X("^$/%$OC?P[^V1_P`$X-,\:#Q[;?$?
M2_%D/[:'P+;Q'X6U^W\9^(?B!+8>"=8D^*SWW@CPAJ?BWQCXVU77_`OA2;2/
M!_B-_''C2#7]$U*V\5:Y#?<SX8^)W_!`?PAX6T3X?Z)^WK^Q(OPST#P9\&/`
M=A\+]4_X*)?#O7_AU+H'[/WA[P)X1^%+:IX2U[XVZEI>MZSX=\+?#7PAX>N?
M$&L17VM:_I6G7%MXAOM4_M35&O"B@#HU^.?_``0.DU.77=4_;=_X)]^)O$1_
MX0:2R\2^,?VZ?@]XP\1Z'?\`P\\47/C+P_K7AG7/$OQ?U34_#'B&[\1W$=_X
ML\0:!<Z=K'CI=.T2R\:7NO6&A:/;6/6Z)^UE_P`$2-(^&?PJ^$E]_P`%#/V&
M?&7@KX)^,/!/COX96OQ$_;V^#_C_`%7POXH^&UPEQX!U&TU_Q9\7-4UJ9?"#
M10)H-M=WLUM8PP11QQ%5P2B@#C;/XT?\&_5A!I]O9?M@_P#!-VWBT-='_P"$
M3V_MH?`YI/`=QHOQ9\7_`!PAU'X=SR_%B2?X?ZQJ/Q.\<:[XD\2:QX/DT75/
M%971-+\37>K:1X:\/6&F=-H?[4'_``0VT/1_A?HI_;__`&%_$$'P?^*?C;XU
M^#;WQG_P4`^%WC;69?B=\1OAK\5OA!XU\4^+]:\5_&C5]4\?S^(/AU\;/B3X
M;O+#QO=:_I*P:]#>6]A#J.BZ%=Z:44`<MX.^-G_!!+X?:UX9U3P3^W=^PQX8
MTOPGJOA+Q%I?@#2/^"A?P\M?A/<>*_A_IT&C^`/&6O?"=?CB?AYXF\8>!])T
M_0-/\+>)?$/AS4]7TF+P9\.YX+K[9\-?`%UX:U8_VB/^"%5O\/O@+\)[;_@H
M!^Q';?#7]FGP#X=^&/PC\$6__!1'X?1^'-(\'>#_``QHWA#PC9^(-._X7D8?
M'6I>%M&\/Z0N@^(_&X\0>(]-OK:74K;55O;_`%&:[**`-KQ9^U9_P1'\;ZK9
M:CXC_P""B'[$-[91?"J'X(ZSX43]O_X2VW@;QM\*[:VUZTMO!GQ"\%V_Q@C\
M.^.=*MX?$^NB,>)=/U&<MJ4[/,YV[>4T+X\_\$+]$^(7PY^+%U_P4<_9/\9?
M$GX2Z7XKT+P!XR^)G_!3_0_B?K7A_0_&FL?"G7?$.D12>/\`]H;Q%!=65YJG
MP2^&M[B]@N)TNM"O;P3&^\3>*KG6RB@#+?XS_P#!#1-0U'4-+_X*9?LQ^''O
M_&.F_$*"S\,?\%0O"WA_2]#\<Z7X3L/`L/BOPUI>F?'BWL=`UNX\(Z?'H%_>
M:9!;O?V%SJ*7(D?4;QYOJGP1_P`%*_\`@D7\./">A>!_!?\`P46_X)_:+X8\
M-V*:?I.GC]M+X":A,D0=YI[F^U35?BA?:OK&JZA=RW&H:OK>L7]_K.M:I=7F
MJZO?WNHWEU<RE%`'5?\`#V#_`()9_P#22O\`8!_\3(_9U_\`GC4?\/8/^"6?
M_22O]@'_`,3(_9U_^>-110!^1G[+'[7W[`'BW_@G5_P1XT*\_P""H/[`WP-^
M+'[)OP@_8W^(GB'PM\3_`([?!77=0M_$OA#]CW4_@OXW^%_C+P/-\>?A?XE\
M)>)+*+XC:]!<S7VI"_\`"WB;0HK;5_#6HHEYIU?KK_P]C_X):\?\;*_V`O7C
M]L?]G7I^/Q&Q[?\`ZL@HH`^?/BY^WU_P31^)_P`5_P!E?Q[;_P#!6#_@G7X?
M\-?LX_%?QQ\7=6\+3?M+?`'6==\?:[XB_9\^,7P!\/:;IWBY/COH^G^"])T&
MP^-GBCQ)K2W7@WQG>>);S3M!TZQN_"T-OJ%SJ?T&?^"L7_!+0\'_`(*5_L`G
MK_S>/^SKC_U8P^OY<<444`?#_P"RA_P4T_X)N^'/CQ_P4TUCQ!_P4&_8AT'2
M/'O[;W@+Q9X%U36?VK_@-I>G>-/"MG_P3<_X)]>!;SQ+X3OK[Q]!;>(_#]KX
MV\%^,?!USK.CRWFG0>*O"?B7P]+<KJ^A:I9VOV]_P]@_X)9_])*_V`?_`!,C
M]G7_`.>-110!^>7P;^)G_!'?X`?!?XN?!KX0?\%??V0O`%I\8M976-?\3>%O
MVGOV!-'U&SEEA:TUN>'P_:Z4/!&L^)/&ME-=P_$'XA^*O#.O_$KQE/<QWVJ>
M,#=:7H<FEX^J^)?^")NM^&+CX5ZM_P`%9/V2M3_9Y_X2CXD>/--_9TU+]L#]
MBF]^%]GXZ^,D/BF/XL:[JIF)\7^-=,\>7?Q%^+6MZUX*\>>*?$O@>3Q#\6?&
M.J?\(^1IW@"V\$%%`&1X7T[_`(-]/`GB'XGZU\//^"@O["/PQTSXB:=\&--T
M?P5\*?VO?V1_A?X)^%%K\$OBK\=_B]HUK\+]`\!ZWX?AT+2O&7B#]H?QYI7Q
M*\.W\FK^&O&/AL:?IUWH\%P^K7^J[-AXX_X)`:5H^NZ5I?\`P6B_9STF;XC^
M`KSX2_'74]'_`&Q?V%](N_C+\)I/'/Q!\=Z5\/+V#3]/M]/^%VB^%KWXN_%_
M1_"=Q\#;3X9ZIH&C_%7QG<V=Z/%)\,^)O#110![9\-?VDO\`@BS\*_B5X8^*
M_A?_`(*;?L8IXM\,Z1\9]%E:Y_;D_9R.D^)X/C7\1+'XBZOJ/BS1X/',%CJ_
MB/PU=V%OX=\+^*%BMM?C\*)%HFM:AK-M9:<++^&'_@[G_:$^`?[2G_!2+X)^
M.OV<_CA\'_C[X)TG]B'X;^$]5\8_!7XE>#/BKX6TWQ58_'C]I36+[PU?^(?`
ENLZ]I%EX@L](U[0]4NM&N;R/4;?3M9TJ^FMDMM1LY9BB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g30330image14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image14.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`)$!
MX0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/Z%/^"9?_!,O_@F[X]_X)N_\$^O'7CK_@GU^Q#XT\;>-?V(?V4/
M%GC'QCXL_90^`_B/Q5XL\5>(_@/X"UCQ#XF\2^(=8\!7FKZ[X@UW5[V[U36=
M9U2\NM1U34;JYOKZYGN9Y96^WO\`AT__`,$L_P#I&I^P#_XAO^SK_P#.YKX@
M^$GPL/Q?_P""&?\`P3)\*W/[-_\`PUQH%C^S#_P3,\6^,?V>?L?P4U/_`(61
MX-\(>`/@QK_B/3?[(_:(\;_#KX/:Q]AT^RDU?^R_&7C#2+2\_L_R[-KG4OL=
MK-Y%K/["'[2WB/Q+\$M4^&?[/D?[/GPI\'_$_P")GQ0^#OP4OO'?PP%K^R+9
M>$_AQ:^-O@/X*\0:-\.?B)K'A74=$UK]J_X?Z;XYU'X:_!?Q1XG^'G@CP_\`
M%`>!=/U^3P;X5OKE0#]//^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_AT__P`$
ML_\`I&I^P#_XAO\`LZ__`#N:_)+]HW_@G]\8/C79WWC_`.*7[)_Q<\=S_'3X
M_P#P]_:?^+?PY^&6D?\`!,3XQ?$KPCXLE^"_[17PGTWP?K?A_P#X*":_X_\`
MV4?$5[\$?A[_`,,^?"G7?$_A>WU2?4H;*QUWX8:OJ*KXQO;#Z(^*W[&/[0%Q
M\'/"WP[_`.%/Z[\<_A=<^-OVH?'7C;X3ZM\5/A;'\2-`M/B=XI^*>?"?@[_A
M:DGB;X&>,/#7C7P=XQTS6/!GP8\:W>E_!W2_%5E=?"'QU=>%_@;X\N9?A"`?
M<O\`PZ?_`."6?_2-3]@'_P`0W_9U_P#G<T?\.G_^"6?_`$C4_8!_\0W_`&=?
M_G<U\`1?LB?%I/#W@C4_CS^PWIG[3WP7TCP/\/="\:_L3:9KGP.U>TUOQCH_
MP]\%^'/!/C?3?`WQ]^/DWP%\1Z9\#9-"\6Z&/A7\1?C/JN@>%_\`A.K/Q+\)
M_&/C'4/A9X5'B'"^(/["?[7.O?LQ?MV^"_A]X(3P=JOQX_8+\:_LZ_!KX!Z]
M\9K'7?!>@:7\3_$W[=D>G?"&\\3S:CJVFZ1XC^#7A_XS_!_7M&UN*RG\!:):
M7&J_`SP#XPNO`%@?%6A`'Z.?\.G_`/@EG_TC4_8!_P#$-_V=?_G<T?\`#I__
M`()9_P#2-3]@'_Q#?]G7_P"=S7G/[+OPY^./P-\._ML:IX8_9B/@WQ5XB\;>
M)/'WPJ\->)_B+\-)[7XU?%35[#Q#J&IZS>>*OA]XGN=,O_A_J7B2X\/6.F?&
M7XG^`?A9^TEXD\)E]'^+G@/Q'J_PZ\,>+_&OYN_&#_@G%^WY:?!7P#\#]6T[
M]D_]O#_A7O[4=U^T^?&/QO\`@+:GP)J5M\3_`(,?';2?CI8Z-\#_`(D_M2:Q
M--^T&_QGUB?XR_#_`,97?Q3\&?"\?%K]H"&&QL/A?\.?".K_`/"%@'ZT?\.G
M_P#@EG_TC4_8!_\`$-_V=?\`YW-'_#I__@EG_P!(U/V`?_$-_P!G7_YW-?)?
M[#G[&.J?`W]M_P"-WQ;\3?!'X]:=KGB7P7-X:T[]H/QYX/\`^"95_P""/'?A
MF#0_@SINGV%Y\6_AE%JG_!2+6/B->OX.>?7]!^)_BB[^!:ZCHNOS:;:F&S^&
MDP\Z_P"">W[$G[5W[.O[+'[$'PY\<^&=0T_5?"&O_LT:I\=?AOXA^*'A[Q5#
M\*]9^$?[/7@WX?:GXF^'%QINO^)?#::1J.H:)=>&O''@SPAXE'A_4-;TC1_B
M+X/\/C7/$OQ+\0^.`#[Y_P"'3_\`P2S_`.D:G[`/_B&_[.O_`,[FC_AT_P#\
M$L_^D:G[`/\`XAO^SK_\[FOE[XE_LH?M,ZA<_MS^)O`N@W1UCXG_``N^+O@G
MX=^$[_XBZ3IG@[XK:;\3-8^*":GI.IZ5%K=]HVC>++*PUCPEXC\">+?%6D:3
M>Z-JD-UX/?Q/X8\)^-/B,TF2O[+.M)\1O'SZM_P3V/B7]H+6IOCA?:7_`,%!
M3\4?@O8&;X=^,]%\=P_#_P"$X\8_\+$'[4ET/#_A_7/#/PP7]G_5OAC:_LS0
MKI`\1?\`"?+'8V<T@!];_P##I_\`X)9_](U/V`?_`!#?]G7_`.=S1_PZ?_X)
M9_\`2-3]@'_Q#?\`9U_^=S7XL?M$_P#!+G]H;Q)\0=+N?BQX8_:@_;F^'8^%
MO["FGS^(H_!O_!&SQO\`%CP_XB^$?A?_`(*8:3XR^&NB_#3]JWX5?#+]E&_^
M'OPIU+X\?"W5+/Q;XC^%^O?%[4K[XN:Q_P`(Q\3?%NF>&M1T_P`!_L%_P3S^
M#7CGX-2?M#Z=XD^`FK?`W0?$_P`2K3Q3HQU_Q/\`"77]7\?>(M4MM2N/&WBI
M)?@EXAN/"?B'0/M<VDV?AKXE^-?A]\(?CGXNTM(_#7Q4\&:F/A[X7\<^+0#I
M?^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FOB'_@H+_P3+_X)N^"_@/X"UCP=_P3
MY_8A\)ZO>?MO?\$R_"=YJGAK]E#X#:%J-UX5\>_\%(_V4/`OCKPU<WVE^`;6
MYG\/^-/!/B/Q!X.\6:-+*VG>(_"NO:SX>UBVO-(U2^LY_P!W*_.+_@JOXET[
MP7^R9X>\8ZQ;>(+S2/"?[;W_``2X\2ZK:>$_"?BKQ[XJNM.T+_@IW^R!JM];
M>&O`O@71O$?C;QIX@GMK66+1O"?@[P]KOBKQ'J+6VC^'M&U35[VTL9P#?_X=
M/_\`!+/_`*1J?L`_^(;_`+.O_P`[FC_AT_\`\$L_^D:G[`/_`(AO^SK_`/.Y
MH_X>5_LZ_P#1.?V_O_%3_P#P5,_^@WH_X>5_LZ_]$Y_;^_\`%3__``5,_P#H
M-Z`#_AT__P`$L_\`I&I^P#_XAO\`LZ__`#N:/^'3_P#P2S_Z1J?L`_\`B&_[
M.O\`\[FC_AY7^SK_`-$Y_;^_\5/_`/!4S_Z#>C_AY7^SK_T3G]O[_P`5/_\`
M!4S_`.@WH`^(?^"FG_!,O_@F[X"_X)N_\%!?'7@7_@GU^Q#X+\;>"OV(?VK_
M`!9X.\8^$_V4/@/X<\5>$_%7ASX#^/=8\/>)O#7B'1_`5GJ^A>(-"U>RM-4T
M;6=+O+74=+U&UMKZQN8+F"*5?M[_`(=/_P#!+/\`Z1J?L`_^(;_LZ_\`SN:^
M(?\`@II_P4%^`_C3_@F[_P`%!?!VC^`OVWK/5_%G[$/[5_AK2[OQ9_P3+_X*
M1>`O"MKJ.N_`?Q[I=C=>)?'7CK]E#PYX)\%^'X+FZBEUGQ9XQ\0Z%X5\.:<M
MUK'B'6=+TBSN[Z#[>_X>5_LZ_P#1.?V_O_%3_P#P5,_^@WH`\=^,O["G_!&_
MX":=X+UKXE_\$Y/V#M'T/QOX_P!*^'5EK4'[$_[/E_INB:OJ^C^(-<@U;Q1/
M;_#DMH?A.QL/#>HSZ]XGN(VTKPU9JVM>()M,\/6>JZOI_B]I\#_^"%M[XBUS
MPK#_`,$\?V&AKOA[X3_%+XS:I92_L1?LXPI!X0^$7CGQ9\/_`!-#]MD\#+8+
MKU]K'@7Q=?\`AW1Y+F.;5_#N@:IKR/#86=Q)'],^+?V[/V2O'-SX0NO%/PD_
M;]U63P)XJ'C3PTK_`/!*C_@JO!#9^(E\.>(_"8O+B"V_8^AAU&'^PO%>N6;6
M&HI=:?(;M9Y+9YK>WDC^088/^"35GX0\2^"=)_9(_;K\/Z1XG7QE:S7WAK_@
MF)_P6`\.>+/#VB>/OAMK?PD\3^$_`7CK1?V6K'QI\./!-WX%\2^(M.L?!?@/
M7_#OA?1-2UW5_$NB:3I_B74+G5Y`#Y\_:%^)G_!O#^SUIOP]O=1_X)S?L3>-
M[CXG:-\'-?\`#4.E?LJ_L$_"CP[:Z;\<O`GQI^)'@H>*_BS^U+KW[/GP-\$Z
MM'X3^`_C.ZUOPUXN^*.C>)]/U+5?`6@1:-=Z]X_\+:;J7ZVP?\$I/^"6,\,,
MZ?\`!-3]@(+-%'*H_P"&.OV<9,+(@<`O#\/)87X(^>*62,]8Y'4JQ^(?$NH_
M\$PO$/BOPIX[LOV??^"CW@7QQX)^*'CGXS>&O%WPO_X)T?\`!9/X:Z]8?$CX
MC>$/$?P^\6>(WO/!W[,&D"\>]\">+O$?@ZQTZ]CN-*T/PYJLVE:'8Z=:Q6R0
M?<2?\%*/V=(T2-?AU_P4`*HJHI?_`()1?\%3Y6(4!07DD_8Y>21B!\SR,TCG
MYG9F))`/B+]J_P#X)E_\$W?#GQX_X)EZ/X?_`."?/[$.@Z1X]_;>\>^$_'6E
MZ-^RA\!M+T[QIX5L_P#@FY_P4%\=6?AKQ98V/@&"V\1^'[7QMX+\'>,;;1M8
MBO-.@\5>$_#7B&*V75]"TN\M?M[_`(=/_P#!+/\`Z1J?L`_^(;_LZ_\`SN:^
M(?VK_P#@H-\!M>^/'_!,O5+'P%^V]!;>"_VWO'OB76(M9_X)E_\`!2+PYJ-Y
MIUU_P3<_X*"^#HK;PGH_B#]E#2]7\>^(%U?Q9I=Y<^$_`MCXC\56?A6U\2^.
MKS1H/!/@OQCXAT+[>_X>5_LZ_P#1.?V_O_%3_P#P5,_^@WH`^1?V@OV8/^"1
M7[./BFUTKQA_P2&_96U[P/I7PY\3?&#XN_&?PK^QU^P\OPT_9^^%GA*Y\C6O
M'GQ5A\87_A#XD7F@6B1WM]>-\*?AW\3[_1])TO4M8U^RTG3+;[6_)^-?@M_P
M1J\.>)_%G@OP9_P21_97^,_BKX?_`!^^#_[/WCW1?AQ^QO\`L/:;<^$]2^-A
M?3/"7Q(NY?BQJ/POM-:^%MIXVM=9^&>NZOX1N/$?B>T^('A?QAHMAX0U.V\(
M^(M1TWV;XK_M'_L.?&OQ+I?B?XA?"O\`X*3ZE+8>'KCPAJ>@Z9_P3>_X+!>&
M_!_C3PC=:O:ZY<^$_B)X0\._LJZ7X?\`'_A>ZU&S3^T/#WBRPU71]5T^XU#1
M-6LK[0]4U+3KOF='^*__``3;\.ZW9>)O#W[,W[<^@>([?6K/Q-J>O:)_P2L_
MX*R:3JWB_P`46'Q-TWXQ6GBGX@WUA^R1;S_$+Q);_$73I?$5OKGC-M;U&VDU
MOQ38VUQ#IOBC7K._`.)_8'^"7_!%/_@HK\$IOC[\$/\`@F%^PUI7@;_A(H_#
M]G!XB_9Q_P"">GC+Q!*USX2\*>,[2XUW3/@!XF^-L7PVUE]'\8:8FI_#+XN7
MGP_^-/A.]CGM_&WPS\-+-IDNH_;G_#I__@EG_P!(U/V`?_$-_P!G7_YW->'?
ML[_M2_L8?LM_"KPK\%/A)\.?^"E]K\-_`NB>'_"W@C0/&'_!-_\`X+`?$1O"
M'A'PGX<T?PGX8\(^'M3\<_LIZ]JNG>&M!T'0M/LM-TF*]^SPE)KAA)<W,\K^
MX_\`#RO]G7_HG/[?W_BI_P#X*F?_`$&]`'Q#_P`$^O\`@F7_`,$W?&GP'\>Z
MQXQ_X)\_L0^+-7L_VWO^"FGA.SU3Q+^RA\!M=U&U\*^`O^"D?[5_@7P+X:MK
M[5/`-U<P>'_!?@GPYX?\'>$]&BE73O#GA70=&\/:/;6>D:78V<'V]_PZ?_X)
M9_\`2-3]@'_Q#?\`9U_^=S6!_P`$J/$NG>-/V3/$/C'1[;Q!9Z1XL_;>_P""
MH_B72K3Q9X3\5>`O%5KIVN_\%._VO]5L;;Q+X%\=:-X<\;>"_$$%M=11:SX3
M\8^'M"\5>'-16YT?Q#HVEZO97=C!^CM`'P#_`,.G_P#@EG_TC4_8!_\`$-_V
M=?\`YW-'_#I__@EG_P!(U/V`?_$-_P!G7_YW-??U%`'P#_PZ?_X)9_\`2-3]
M@'_Q#?\`9U_^=S1_PZ?_`."6?_2-3]@'_P`0W_9U_P#G<U]_44`?`/\`PZ?_
M`."6?_2-3]@'_P`0W_9U_P#G<T?\.G_^"6?_`$C5_8!_\0X_9U_^=S7W]7YJ
M?\%8/B=\7O@G^QYXV^+7P9^).L?#GQ1X1U?P=#)<Z5I?A;4QJ^G^)O%^B>%[
MNRN#XDT#6Y+'R(=8:]M[S2)-,OHKB!"UV\6ZWEY,?BX8#!XC&5(5*D,-2G6G
M"GR^T<(+FER\\H1VUNY)?A?W^%>'\1Q9Q%DO#>$Q.%PF*SS,L+EF&Q&-=:.&
MI5\76A0HNM*A1KU8P<YJ+<:4[-KFM%.2ZW_AT_\`\$L^G_#M7]@'/I_PQQ^S
MK_\`.YH_X=/_`/!+(]/^":O[`!_[LX_9U_\`G<U\E?';7OVM_A)^US^QM\.=
M"_:I\1:A#^U18_%G1/'%GK?@3X?W7A'PC?>"?#F@ZZ=5^''AZRT'3KS37M4U
MR6#PW%XJUOQA<03:=ILWBR^\8PR:M;ZEJ>%_CW\9_P!FKXM?M_>#_B#\5/$W
MQV\&?`GX#>&/CQ\/)/'%EX8M?%.GSW'AKQ7J&L>'+[4O"6@>&-/O;?4]6T/;
M;A--M;:QLELDM8;:0ZC-<^6L_I1KU*-7"8FC[+$_5:LY^P<85'@ECXM\E:4G
M%X=W;4;*;C&[U:^WEX49C/+<+F.!S[(\Q>/R1Y]@<)A?[4AB,3@Z?%$>$<0H
MO$Y=0HQJTLVD^2$ZD76P\)U8V?)"?U#_`,.G_P#@EEG'_#M7]@#/I_PQQ^SK
MG_U7-<?\0/\`@F'_`,$R/"'@SQ%XFT3_`()5_L*^-=5T32[B_LO"NB?LA_LM
M6&JZY-;IO%G97GB7P;HVAP2L,LTNH:E:PK&DA0RS>7#+XM\/_$?[<GC;P?\`
MLO?&KP/>_$3Q'JOBG4/`?B[XX6/BW6O@1IOP<\6?"OQEHPU'Q);>`-%T+7]2
M\4^']0\/K?:;-X$O#;6>IWMG93'Q;=:EJ%W=1W'0?"SXH?%;]LGQI^VA<V?Q
M5\3_``Q\"_`WQ[XA^!?PLT+P9;:);W">)O!VD,?%GC[QE-K&DZPWBMM3U^6W
M70M"N?L7AVRT"VDL[[1K_4;JYU&6I9U"<8TX8?%4ZV(C)X;GIQ@JB^K/$.<9
M3?LW[-1<)J\N6KRQ:<9*1C1\.*]"M6Q=?-\BQF6Y/6HK.Y4,57K?5YK.L-DZ
MP=:CA8+&0>,JXB->A.U!U,%&O5A.%>A.DN1_8S_8U_X)6?M>_L]^$?CW9_\`
M!*G]@KP1:^,-1\86=IX=O/V3?V;]<NK.#POXOUSPK%<7&H0?"K3H7FOTT8:@
M]O';M'9M<FT6ZOE@%W-]0M_P2A_X):1*2W_!-;]@)\D`?\8;?LZKC@G'R_#C
M')&.>F1GW_+']E[Q=\5O!7_!*']D+7/A]\=_`7[.O@VW_:.U3_A?_CSQ=J-M
MI_B6^^!2?%KXDS>./`_P>@N_"/C5M1^,/C$Q:=H_@71M-T63Q!J&I2?8-$E2
M_N$D'VE^Q)\7?BI\7OC5^WQ\%]7^(/QUL/AY\/6_9X\0_!>]^+7AWPOH/QP\
M`Z;\8_A_XEUSQ!;3IJ_ARYNVL3JOAZ'5?">G?$GPY=>)M%TZ_-EK]B9P8S]'
MP_EV,S'AK!YU6Q%)MY?AL5BFXS4KU:^#PDK.G25+VOM<93G[*#TI)R=G*$9>
M#XD93E_#WB!QED.4T?89;E'$N<Y=E]#VM6JZ6#P6.KT</!U:TZE:IRTJ<4YU
M9RG)IN3;O?X_\<_"7_@GQ;QZ]XU^!O\`P0J_8O\`VE/@WX/_`&B[W]G'Q?XB
M^%G[,O[/NJ?%&RUSP_-:Z5XT\=Z!\);']GG5;3Q%\-_"?BJ:[\)WVM'XA:5J
MS7^F7>LOH=OX2\OQ`?T[B_X)0?\`!+:1=W_#M?\`8!7!P0?V-?V=<'`!&/\`
MBW(/((SV!S@@$`?D9^R)\<KS]A[_`()9?M*?M9W?C#Q[XV_X0+XQ_M(Z!X8^
M&6I0^"YO!M]\0/$WQ^D\%^#O$.HC3_"^A^*%>3Q3JNFWOBJ2/Q:--CT2?7WT
MK0EO%TJT@^GOVOOB9^TI^P_^R=\)_P!N'3OV@OB'\7=2\":Q\&M3_:2^&_BU
M?A[_`,*^^+G@?XE7NA^'/%EEX+TS1/`.E-\.M<T_Q'XBT>X\":QX:NX+;3M-
MCFMO$EGXJ>>2:?[+'\,\^-I9?@(4*2>9XG*<)B:D\2IYEBZ5.A/V<XU'.G2G
M#VM*+G"-*BYUU=6A*<?B(S=DY)NZ3:32Y4W%+HGLVW>[LMM4C[<'_!)__@EK
MSN_X)K?L!-_W9O\`LZC'_F.3CG],#DY8X'B3_@F/_P`$E/!^AZOXF\4_\$[/
M^"=OA[P]H%E<ZGK>N:S^R/\`LVZ9I.E:;9Q/-=ZAJ&HWOP\@L[.SM8$>6XN+
MF:*&%$=W<(NX_%?BS6?VSOCS^W]\8_V=?A3^V]XY^#OPKU7]CSP9^T#X(N/^
M%5_";7O$'@76?'GB_5-(T/P]I8_X1K1I+K0K*[L[2[UNZ\0WVH^.+G18)?#.
MG^*M*NK^?Q)%ZO\`\%/H/%&F?LR?`OX/>-_'NB>*=#U_Q[\--)_:"\6^+?B;
M\&_@!JWQ6\(>`-/CUCQC'I%UXZ\6>!_"^F^)_'/B'3-+UB33/#%Y]FT.(WJP
MV\&G+$A^3S[`SR/"4:BQ6&Q>,KX>A7IX.A'%N='ZS3I2PZKSGAH05Y54JGLI
M57!1E)Z)7^DX3RBAQ#Q#EN4XG%1P.$Q.)Y<9BY2HP=#"482KXJI3]O6HT9UE
M0A-X>G4JTXU:KIT^9<RO^<7Q$\>_\$D=$UE[WX;?\$3?V3/''PC>[\:Z1HWQ
MNU_]C_\`9X^'_P`/O&>M^#?!OBGQE+:>!;V]^#&NS^(;34+3PEJ<"WDJ:9+:
M1K]MEL6C,,=Q[O\`LQ^%_P#@CY\;_$_A_P"'/Q5_X)%_L;_LS_$CQIH6E^(_
MAWI/Q+_8U_9N3PK\4=*UB""\LV^&_C6?X7Z5;>)[PV5W87(L?[+T^YN4O8X]
M.COKBWU*&Q^!)OA=\4OVR/BGXI\&>#_BS\"?"WAKPAI?C>Z^%7@^']JO]FSQ
MIHL7PIM?A7XY^'W@#PEK/P\^#WQ9\>7'@_6/@S!X\N]%TCQAX5\(V>@^-/"F
MI:C?_$::R\7V-CJ&N>;Z6/%5[\/?B-\(?B)\6_A5XF;PO#X-O_@+KA_;-_83
M3Q1X9^-_@'3?#?AU_BCXJFC_`&@]4USPA$="\(:1\-M#^&?@V\E\-^%/`MM9
MG4X_$?CW2(_%=YS8OAK.L#E4LW_MS"8S$4Z4,34RF-.A"+ISLW1@X1]O&:2;
MBW.I*#:592L[?LM'">%6<8RGPO1X>GDU>HJ>$_UD_MK'8G&X>I*:A2QU:GB,
M7')L3&//&6/HT,+A%4I4Y?4WA:CL?U`I_P`$G_\`@EJ55_\`AVO^P$<@':?V
M-OV=`,,,\$?#CMG]![U)_P`.G_\`@EG_`-(U/V`?_$-_V=?_`)W-?5OP0\1:
MWXO^#GPL\5>)9=*G\0>(_AYX,US6Y]"U32=;T2?5=5\-Z9?ZC-H^M:#=W^AZ
MOI4MY<32:?JFC7UYI6H6C0W>G75Q9RPS/ZC64)\\(3M;FC&5FK-<R3LTNJ3U
M_,_`L31>&Q&(P\I0G*A6J47.F^:$G2FX.<)67-&7+>+MJFF?`/\`PZ?_`."6
M?_2-3]@'_P`0W_9U_P#G<T?\.G_^"6?_`$C4_8!_\0W_`&=?_G<U]_451@?`
M/_#I_P#X)9_](U/V`?\`Q#?]G7_YW-'_``Z?_P""6?\`TC4_8!_\0W_9U_\`
MG<U]_44`?`/_``Z?_P""6?\`TC4_8!_\0W_9U_\`G<T?\.G_`/@EG_TC4_8!
M_P#$-_V=?_G<U]_44`?X!]%%%`'^QU\`)/B/9_\`!"C_`()_ZO\`"GXT>/O@
M-XRT;]AS]@*YL_'?PYT+X/>(]>-GJ'PD^$&@:EHTVF?'#X6?&#P2^G:A9ZS+
M+-,/"2ZQ#=6EF]CJMI%]KANS6?VG?'6@?'&7PQ=_MO:G9_M&:%\<M#^%OA[_
M`()OZUX"^`=WJ_Q/^"MO\5+'P+:?'#4=%T3X;6G[1E]=?%'X9_:?C2_[0'@3
MXB>&_P!F?X7KJBZ%XG^&=I)\/_&^DSQ?`/XK?'+X-_\`!##_`()S^+OV;O#.
MF^,/C-??L?\`_!-KP3X/\/:IX-T/X@PW[^/_``-\#/!NK_9O!_B;]HK]DWPW
MK6I6VAZUJ5UID&O?M#?#+2HKZ&"YN]9ND@_LC4<7X%_\%-_B[_PL_P#:)\,?
MM"S>'-5C_9>^%5IXI^.OPF^'?[('QH^'WQ0^$WB=OA[X-UGP[93?$RU_:,_:
M9^`GQJ\9?&GX@77C/P)X`^`?P!\4>//$>A>(M.A\.Z=\4/BS_8MUXDUT`\(M
M_P#@HQXI^+_B+_@G`WPP_P""A_[,VE0^+_A?\,H/VC/"Y_:K_9)^&.L_%;]H
MI;_X.GXD_!;2?!GB/]C?]J/7OB)\9K5/%[:=K'[.'PN^('[(WC73+KQKX?TJ
M+QOX:O/$_AS6_"V+^S9^WS^W1\1_V.))?A9I_P"T'\>_VL_']Q\-K3P+X*^/
M'@W]ACP_\?O!E]I/A#2/'GQ^^('BKX9_#;Q_^S'\%-$_9PU#1M=^'EM\"+_X
MD>,/!_Q6\0:;\6_#OC$Q>,=)U/PA::Q]S_";]NGX_P#[3'PY^`/@WP!I?PQ_
M9O\`VG_B1<?&32/BQ/\`M"_!OX]:IX(^%7C'X$/\/-0U7X?:3\"O'6M_LE?'
M7Q'XT^,7@7XH^$_C!\(-`\<ZS\)-=;X%IXE^*NK:+>QZ`OA;5/*?C?\`MT_M
MH?`6]\6>.-2\8?L=?%OX8^$6_8'M9/!_P=^#_P`6=:\1Z_>?M+_MX>%_V.?B
MHOA_XOR?M+W6A7FJ:9INA_$GQ3X3\-+\&FN/!OC?Q/X8^'_B'6?B!#\+]=\2
M?%8`]3U3]MKXO:YHGBKX@>&FDTGX<^)_C7^QE\-O!MNG@N.]\;?!WQ1\1?$'
MP#;XO_#[XG3RVVK:1-IVNV7C7QQX$;5M3T30M0^&_P`0]`OM#'B+6-1\;^";
M3P1\XZU^V/XLC^"7QX\=>&/^"FFCZU^T=IOP"\3^,OBI^S1KWA+]G?P9H'[#
MWC2"\\-1/<ZSK,?P(\8_$/\`9DT?P#>ZIJ6B:CKG[;5A^T;IWC.RMYO%7A;P
MCJ5OH]UI=[]$>(OVQ?VM_AKX>\/>)-9U[]BOXW7GQQ^$.O\`Q2^"/@SX7CXE
M>!T\'W>CW'@AK&P\<>/9_'GQC;XK?"35#XM7PSJGQ_\`!_PY^&C^&/%-_P"$
M8H/@]XJ'B1=/LI/VA/\`@IYXB^$_AOXD77@+X.^)?BG\2-#^(7PK\$^$?@;X
M,^&_Q;^*?Q2MKK_A&CXY_:%T?QKX<_9^\._&+78M6\`>']&\0^&/#WBC2=`3
MX5CXCZ[\,K+Q5X[T[P)XR@\>1`'SU^S)^W+X_@\:_#/2?&7[=G[._P"T,=<^
M"/Q*UTZ;8?M%?L_?$3X3>(KSPKXX\;WD_P`4M?\`VC?A1^Q/^R?=3>"-&L;;
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M:I>@'T_1110`4444`%%%%`!7P#_P4K_Y-U^'/_9_W_!)_P#]>F?L;U]_5^</
M_!5?6=1\.?LF>'O$.C^$_$'CW5]"_;>_X)<:SI?@7PG<^%;/Q5XTU'2_^"G?
M[(%]8^$_#5YXZ\2^"_!-KX@\17,$6CZ-<^,/&/A/PK!J-Y;2^(?$N@Z0MWJE
MJ`>4?M$_MR?&3X-?&']H#3=!\2_L\>(O#'PHL--T#PQ^SS=^$/%:_M%>)=8U
M;X'VGQ=NOC,OC:T^-(TC4/A9X)>:^A\6^"K?X%Z7<GPQX?\`$.OP_&&QU*PA
M\/WG$_`;_@I1\;-='[//AOXU?"RQM_$OC#7=2LOVAM>\._#_`%/PO_PH;1?%
M7B63X5_`V_\`B3\/?"7QD_:9\/\`PEU3X@?&C3_%V@?V?XC_`&@?%FCR>!O`
M>L^-5\2Z9>W_`/PC&C_3Q_:S^.S7<U^W_!(W]N]K^YM38W%ZWCO_`()5F[N+
M)BI:SFN3_P`%)_.FM240FW=VB)124^48L']K[]H`M.Y_X)+?M[%[GR_M#GX@
M?\$KRT_DC$/G,?\`@I3F7RAQ'O)V#A<"@#X4TC_@JI^T_KO_``BVCVG[.'A'
M3?$VNK;76G7'B$?$'1O!WC)OA9\2?!/[*O[4^@6.MW5FEYX%N?!/[8/Q!\,^
M'?A]XCUC3?%5GXO^$&IZ=XVTG0_$4\VK#0/U@_9N^/%Y\>[+XN:A=^$=8\$_
M\*X^,VN?"J+0O$FE7NB^)K>;P]X/\#:SJT>OV-U)<6LE]9>(/$NL:3;ZOX>O
M=3\)>)-*T[3O$OA+6=<\.ZOINL7WA9_:_P#V@B`#_P`$F/V^,"1I0/\`A8/_
M``2PP)6N%NGD`_X>4X$C7*K<,X^8SJLQ/F`,)1^V-^T0"Q'_``2=_;\!8[F(
M^(O_``2R!9@JJ&8C_@I4,G:JKDY.U5&<`"@!?^"L'_*+/_@I7_V8#^V1_P"L
MZ_$:OOZOPC_X*:?M7_'CQ'_P3=_X*"^'M8_X)E_MO>`M(UW]B']J_1M4\=>+
M/'O_``3=O/"O@K3M4^`_CVQOO%GB6S\"_P#!07QIXVNO#_ARVGEUC6;;P=X.
M\6>*I].L[F+P]X9U[5VM-+NOM[_ALC]HK_I$_P#M_?\`AQO^"6?_`-,KH`Y#
MX]?&C]LKP?\`M&_&/PY\,/AIJOC#X&^%_@#^Q[KGAO4-%\%-<Z_'\5_BO\??
MVG/#'Q=U30M=U4Q>'_'.A^`?AU\-OA3<_$_P%ITDWC#P;X<\<Z/X\T=5FO;7
M2O$7R!\4O%W_``4[TW]J3XK:'\-_B)\:[_X.:/\`MFMI6A3>(/AG\&=)\"^%
M?V;U_9C_`&+_`!R=1TV_TK]CGQQXW^,_@'2OCI\?_C7X5U?2='\:^#/B'KNC
M_":YTC3?V@O">N_"_P"(LOB[[N_X;(_:*_Z1/_M_?^'&_P""6?\`],KH_P"&
MR/VBO^D3_P"W]_X<;_@EG_\`3*Z`/!M`_:+_`&^_$WC"XLH/@GJGA'2_&G[0
M^D^*?@T_CCP:$\-:S^RP?"'Q.L;GP=XYUGPY+J_B7X8^--8O?A_X&\<ZAKGC
M_P`/Z#XF^'_B'XXZ;X6D\*^-]$\`ZC8:Y]]_LQ^-?B3\1/@OX<\8_%OPEXA\
M!^.]7UWXBC4O!WBS1[#0_$OAW2M.^)7B_2O"6F:W8:1>:EHYU&#PA8Z"+C4-
M%U/5=%UER=8TC5=3TV_M;^X^??\`ALC]HK_I$_\`M_?^'&_X)9__`$RNC_AL
MC]HK_I$_^W]_X<;_`()9_P#TRN@`_;(_Y.*_X)/_`/9_WQ&_]=9_\%*Z^_J_
M"/\`:O\`VK_CSJGQX_X)EWU]_P`$R_VWO#ESX<_;>\>ZSH^CZSX^_P"";L^H
M^/=1G_X)N?\`!07P]+X3\)R^'_\`@H-KVD6?B"STC7=4\=7-SXZU3P7X5;PK
MX+\2V=GXENO&UUX.\'>+/M[_`(;(_:*_Z1/_`+?W_AQO^"6?_P!,KH`/`W[5
MWBC7/VHOB_\`!6]UGX7^,_#?A>\3P[I-I\'O#OC3QIXT^$/BU2D]EIGQOO=/
MU[4[34(->\/75EXEUK4+7PG\-?#OPQU&ZTCX>W/B?X@>(M<N[_PS\X?";_@H
MK\3;[Q?\$M!^(NA^$?'R^._V9M/\>>-?#OP#^'/B?4/B#I7Q=MM"\$Z]=W.E
M>`?^%L>/_B?#\/O&MMXON)/#-K'\,/$_P_\`!MEX>U&+Q9^U%J7CN6U^&\OO
M]M^UC\=;*ZNKZS_X)&?MW6E]?$M>WEMXY_X)5075XQ8N6N[B+_@I,DUP2Y+D
MRNY+$MU.:L1_M>?'V*59XO\`@DK^WM',MM'9K-'X_P#^"5R2K:1,7BM5D7_@
MI0'%M&[.T<`81(S%E4$DT`?(_P`,/^"COQH\=W_P(TZ7QO\`L<S:C\2_B)X3
MAU#1;4^--!UKQ5H/COP_\,_%>K_!GP=%K_Q+>P\)_$S]G/0_B+J-M\7?BCXA
MO_%,/BSQAX7\"?#_`$G]G?P!XU^/FD:'\-?V^K\ZY/VJ/C9--;W,O_!(3]NB
M6XM+J:^M)Y/&G_!*=YK6]GN!>3WEM*W_``4E,D-U-=@74UQ&RRR7`$[NT@W5
MK?\`#9'[17_2)_\`;^_\.-_P2S_^F5T`'_!-3_DW7XC?]G_?\%8/_7IG[9%?
M?U?SC_L<_P#!2_\`X45\-H?AAX^_8W_:"TCQI\9?V[/^"H<WPL\/ZU^T-_P2
MK\!Z]\0_$=]_P4F_:=USQ7X#\">%?BG_`,%'_`7C#QQXN^&&M^++;P#X[7PA
MX>UWP[_PEEC<7/@[Q%XP\%ZIX5\8>(OJKP__`,%D/!GBSQG<?#CPK^R1\;O$
MWQ#M/B)J'P@N_`?A_P#:W_X(RZSXSM?BSI-IK=_JOPON/"^F_P#!5.YUR'XB
M:98^&?$E[J'@J2Q3Q+96GA_6[FYTR.'2K]K<`_8ZBOQDU;_@M%\.]!BOI]<_
M98^,.BPZ7\3--^"NIS:M^V%_P1>TZ+3OC'K.FSZSH_PFOI+S_@JM"EI\3-5T
MBVN=5TWP'<&/Q3?:;;SWUKI4MK%)*M7Q7_P6P^%W@/4/'FD^./V8_BOX,U3X
M66NF7WQ.TWQ7^V5_P18\.ZA\.;+6M<M/#.C7GCRRU?\`X*LV=QX/M=6\27^G
M^'],N/$$>GQ7^N7MII-J\M_<PV[@'[2T5^3?_#U:0^,/"?P\'["_[3!\?^/-
M*\1:YX&\#?\`#2__``1\_P"$P\9Z)X0O;G3?%FL>$_#/_#T?^VO$6E>%]1LK
MS3_$6H:/8WEIHE[:7-KJ4UM/!+&GI>D_MV_&;7FC30_^"7_[<>M22Z)HGB:)
M-)^+G_!*346D\-^)CJ(\-^((UL_^"F4Q?1/$!TC5AHFJJ#8:J=+U$6-Q<&RN
M?*`/T9K\NO\`@K%<_!SQ%^SE_P`*8^,G[06@_L\:)\5M>T?[/XIUGX=>(_B1
M-J(\$:SI7BV;3]+TSP]K>ABPNA=6.FF>_O[B>'[%)<00VOVB5+BW]'_X;(_:
M*_Z1/_M_?^'&_P""6?\`],KK@?'7QT\?_%"'3[;XC_\`!&#]LSQY;Z5)//ID
M'C#Q#_P29\20Z=-<*B7$UC%K/_!1Z]CM)9TCC262!8Y)$149F"J!PYCAIXS`
MXG"P5)NO3=*2KJJZ4H3:52,U1J4:MI4W*-X5(--[Z-'TO!V=4.'>)<FSW$/,
M(0RG&TL?">62P,,=2Q&&O5PM7#RS+!YA@5.EB8TJC6(P>(IRC&2Y.9J2^(/C
M%^UI^Q[\6?C?^RM\<9_V\_A?HFL_LR+XYFM](7]GCXLWVG^+]2^(6C:7HFMS
MS2_\)E:76AV4.GZ/:OI5HG]JSVUY)<7%U?:A"R6T-.]_:<_8*\1?'?\`:&^*
M/CK]M[X=^(/`_P"T7\*;+X.^*/AO9?`WXJ:/J=CX/T[3=9TR!K7QK-K>L02Z
MK-%K^H1W]V?",5I-YD$=O8V4L1>;ZC_M'1NG_#A?]I$@]!]A_P""/1P`.G/_
M``4-/N<^AQ2C4M$'_.!/]HT_73_^"/!_G_P4-KQJ>38J4Y5,0\OG*I7CB:CA
M#'+FKQPT<&I-2QLD[89>Q<6N5Q5W&[N?J,O$CA.CA:&#P-#C:AA\)E5?),-"
M>.X/;H99B,Z_UBJX:G4I<)TZL.;.;XY5E/V\*EH4ZL:2]F_S_P#@1^T?^S=\
M([;0/@KXB_X*<>%O&/[)G@K6]+U?PMX)N/@QXWM?B;J>G:)XAMO%6B^!/$?C
M9?#TEJ?!UIK5M:QZK%8Z6\VOZ!;R>%88=!\/WC6-M?\`#_[3_P"R)\$_C;\9
M_'?[.7_!0'X6>'/AW^TAXAO_`!=\4?`_Q)^#'Q:\877AKQ9J$NHW>I>(/AS?
M:''X4@BNM6N-7U%YK/Q'%>V-DBVBS1:O;VMM;6OW@=0T(\G_`(((?M$GV.E_
M\$=C^?\`QL,Y'H/KZT?;_#__`$@+_:%_'2/^".A/Y_\`#PO-=F'R/"4Z=&G4
MYVL/-RH2A6Q;J48^SE1]E2G4Q$Y0HJE.=.-*_)RMZ:J^>,\5<!B<7F6+CALW
M4LXH1HYKAYT.$X8/,JD<7A\>\=C<'A^&J.&K9E/'86ABYX^5/ZW.K2@G6]G>
M#_'RW\9_LF^$_P!GW]E+P-X%_P""F/PBTWXJ_LB_&Z;XV?#K4?$7[/WQ9UCX
M<:E?:[=^)+CQ3X>\4Z5`D>M:Q%N\37']C>([.[T:_L[:WEM+:RTR_P!537-(
M^I?A%^V?^RI\*OVF/V@OVAKS_@J#\*_$X_:#\(_"F#Q5X<O?V7/B/86L/C;X
M6>$_%WA30;C3FT[4+:XTOX>6$/B*+44\,MJ&I^,M7DLM/MM1^)$<.GZA/XF^
MW#>>&^__``0'_:`;IUT3_@CB>GU_X*$Y_E49G\+-U_X(!?'QL_WM`_X(W'/U
M_P"-A&3]<\^N*^XRW-:.6Y50R6E"K]0P^$>"IP=/!U:JPLL11Q7LEB,1AJ]?
MECB*,*L5[2T)J\;6C;\^XBSS*N)LYS'/\PI9M5S/-<97Q^-JNMEU&%7%5YNI
M5J^PPF`P]&,ISE)RY*<%*5Y2NVV_SN^"GQQ_X)D>#?V1?C)^QE\?/^"@/PP^
M.'PQ^,FN?$SQ'J5]HG[//Q9^&'B'0]:^)'B./QC_`&CIDM_K'Q-TYYO"7BT-
MXB\)W,FGI+9ZK;:7+/)>C3)%N\*/]K']C7XB_`_P'^R/^U%_P4<^!'Q2_9J^
M'.J?#9;F?P]\`/CGX8^+'QF\'?";4M+UCP1X*^(VH7;ZSX6\.VR:AX?T&+QG
MK?AW2M3U7QIIMA+:6[>%-2O+O59OTL9O")Z_\&_OQW;Z^'O^"-Q_G_P4'II'
M@TCG_@WY^.9^OAG_`((TGTY_Y2"]>.H/3CI7M0XFP;JSK5UF\ZU3&?V@ZE*M
MEE)TL;*,83Q.&MEC6'JSBHJ3HJ*DZ=*4E*5*DX_,5%E^GL:>*BDDE[2K"3LN
M5V=H0NKK5/7=7L['SM\$/VL?V-OB!_P4FF^.GPW_`&^O@_XP\1?&CX=>$_V;
M?"_P&T[]F[XOZ/JMUH>A^+;[Q5X;BLOB3J?CB/1HO%$MYJ%W97>I7G@^ST*>
MS%N8='TYT>1_T=_X*"_L]>-OV@O@;:?\*FDLHOC;\(_'OA'XR_!]]3%@NEW7
MCGP1=SM%H^JIJN=,DLM:T6_UC3#:ZI)'I3WMU9MJK_V=%<Y^?]`UO2/">N:7
MXG\*_P#!!']HCPUXDT2[CU#1O$/A[2O^".NC:WI%]"VZ&]TS5=._X*&6U_I]
MW$>8KFUGAGC))1US7O8_;&_:(`V_\.GOV_2OH?B-_P`$LR/7O_P4K_+N.U?-
M<15\%G/LJ>'6/ITHX.EA)/%U<).M%4$HT'2J87"X6"]E&,.656%2;E'FE.6E
MNK(LVQ7#^;X'.,'&A.O@,53Q,*6(I>UP]=1DN>AB:;DO:4*\>:C7IJ4>>E.4
M%*+=U_*K^T;8>"/$WC7Q%K)U[QKX!^/_`(EUWXHZS\>/V=?%7A/5]%US0/%-
M_P#L\_%[^VM0OO&1>7PYXR^'/A.\'A_0_@%I.A1>'4\*>!]<OKG4M&UG5]:N
M/%FJ>[_L]?!=_C?X;O/@C^R;XT\=?%+Q=\:/!?PP\.?M3?&GQ'X>FT'X??#'
MX=V.D>%M2U71]<U+6K13X]^.5AJ2>)?A]H_B3PW::=;ZW\*1'I.J6FNZY'J_
MC73?WT\5_'#QYX[O+._\:?\`!%[]LOQ5?:?!=VEC>>(O$'_!)K6KJSM;^WFM
M+ZVM[C4O^"CUS-#!>6MS<6UW%&ZI<V\\T$ZR12NC;GA?]I?XO^"-*M]#\'?\
M$>_VXO"^BVH<6VD^'_&7_!*71]-M]YW/Y-AIW_!22VM8MQ&YRD*ECR3SSY-?
M&\18W+HY+C,TISRU)TJGLZ#AB:U!-<M.4W4E",FKQG-0E=:PC3?+;]9_XB1P
MC@JD<WR?@_%X?B&G"G4P_P!=S3#8O)Z&-4^>-:6'CEE'%8G#X22ISP.&J8F#
M3A%8S$8R,7[3[Z\$>%=(\#>#O"W@S0(3;:'X4\.Z+X=TBW9@Q@TS1=-MM-L(
MF8!5)BM;6)"P50=I("@XKJ*^`?\`ALC]HK_I$_\`M_?^'&_X)9__`$RNC_AL
MC]HK_I$_^W]_X<;_`()9_P#TRNJBE&,8Q5E&*279)62^Y'XM6JU*]6I6JR<Z
ME:<JE2;>LIS;E.3MU<G>]^K9]_45\`_\-D?M%?\`2)_]O[_PXW_!+/\`^F5T
M?\-D?M%?](G_`-O[_P`.-_P2S_\`IE=49GW]17P#_P`-D?M%?](G_P!O[_PX
MW_!+/_Z971_PV1^T5_TB?_;^_P##C?\`!+/_`.F5T`??U%?`/_#9'[17_2)_
M]O[_`,.-_P`$L_\`Z971_P`-D?M%?](G_P!O[_PXW_!+/_Z970!_B&T444`?
M[77_``3GU?P+X9_X(^_\$]/&GQ)CT@>#?A]_P3R_8]^(>L7VM:;#JEKHD?@;
M]G/X=>*(O$-O:R6]U(-3T&;2TU72KBSA;4;;4+6VFTXK>)"1UFF_&/\`8L^(
M6M_`GQ;J/P7TMO&7QJ^$_C+]HSX;ZKXV^`FF6/BS0[CX>^(/A5X[\7>%/%FK
MZUHOVGX<?'?1/&VG>!_$$_@;Q)J.D>*#XX^$M_?Q.^O?"N>?2/EO]FYOV4W_
M`."(W_!-RP_;3^)WPN^&7[/&H_L9?L!KXS/QK\>>`OA]\*/B!-I/P2^&/B/1
MOAC\0-0^(\]IX;\0^$?%NIZ);IXB\!W-U%;^.]&LK[PQK4&J>%]2U_1M1]G\
M*_!C_@G1HWA"_P##O@3XT_"7PY\&_%W@7]HX_#7X=?#OXJ?!WP9\+_AEX"^'
M_C+X93_M!ZO\!+?P';:%/X3T7]GWXV?#RP\9>*M>TG6K^'X(?%CQ=XBAU>]\
M/1?\(GX?\,`&MK_Q%_9>_:]TVU\/>)_V%M?_`&F_@?\`$#4O`=[\2/'WC'X%
M_`GXE_"7P]X]ATSPQ)X3TCQ]X-\:^,+WXC>/?$7@:S\9VUAJ'BWX9_"OXI^#
M/AM/I_BK3-:\;:!-X<UN"U[W1OB;^RCKUW^SUX(M?@1I"6OQ?\)_![6/AEI]
MU\,/ANNB^%-$^%^LZ_\`%;X)Z=J%K'?S1Z$WPC\9>!YO&7P[M/#]IJ=IX!\:
M)I7B'PE+I^JJ^HVGS9??LJ?\$_\`QQ\4?!G[(6H?M)_#?Q[JGPOUGP5\<E_8
M@\5^(OV6OB-XUTWQM\/]&2QA^-^C^%O$G@36?CY\+-=U^*]AU3Q?XK^&NL^"
MK.6[U#4;OPX_A1?&/C`>):Y^`G[*"?%3X@_"[PK_`,%-?'/A3]H7X13>"=;\
M/^"]&^,G[%^M_%/]C?X=::?$UWH7@?PY\)_&WP,\7V6F^`_$NG_&?['/XE_:
M&\`_%#XA:MHNH>!+;3_B)#;Z9X9:(`]2UWQ[^P'^SCXR_;+TSP3^S'\/K3XB
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M5_AW9>'_``X;&3PA\,;OP]\#-`LK?3]&TO1M"U.3]FS5_P!@/]E/X=>/_@E\
M%?VR_@OX=^#W[)?ASQ/8?$GX66GQ@_9CT[0OV9M#\5^*9M2TC4/BAJ7AK0=!
M\:^!;KPGY&H>%?#WB7XK^*6U;Q!;2:AJ?Q%U/Q[X\4^*X@#Y\\&_$3_@F=^T
M=X:_96^-'P[_`&:_$WP\\8_\%*M"G\'>$?BY\&_#5I^RC^U7X>^&/@BVT;XB
M^;\2/CO\#_B%\+/C_P""_AC=ZIX3^&.@_8/AW\1?$5MXK'C/X>:7>Z-JGP]\
M1:E?6WU%\)_VI/@)X`^!`TKX#:%^TO\`'3_A#_C9X]_9_P#!/PYUOQ?X\^+O
M[0/Q-^(NE76N>/[U]+^*/[6?Q8.I>(/`NM^#9[CXF_#_`.*?Q:^,^B_#27X,
MWGA+4/#GBO3_``9=^#=.D^4F^"W_``2^^#?P%\-_%*R_;]\(_![]G;X@^%/@
MY\*_V?OC'_PT]^S9X>^%/A36?@3\+]3^#]EJ_P"S=\1?$>@S^"D\<>*_"?@O
M3)/B!I>E:GXC\.3^(_A3;>(_#WA#PKJX^(%QXF[BR_9\_P""6?PR\?>&O@=^
MS7\?/@7^Q1\:_'WACP5\3/A-\,?V6?B7^S9\-?'U_<>%_"GQ&DT/]H+P+\$M
M<\/>+="^(VM>(OA9X@\>Z+XR\9^)_AQX_P#"GQ/^'&CV3>/+#Q1;?#OPMJ7A
MD`]7^,?_``5@_9@_9M\!ZMXH_:9@\8?LX>.+#X._$GXLZ-\`_C5JWP;\%_&S
MXCZC\,+O4]/U?X/_``9T2?XNW'@_XV?%K7]0L;&R\#V'PH\<>,?`_C"Y\2>&
M4T;QY.-55HOO;3?BCX$U?XI^,O@KI^N_:/B;\/\`P!\-/BCXN\,_V9K$7]D>
M!/C!XB^+'A/X=:[_`&S/I\7A^_\`^$B\0?`[XHZ?_9FEZK>ZQI'_``B_VO7=
M/TRRUKPY<ZO^6VJ:9_P3T^+W[.7[0'AOQC_P4A\.?&/P=\5O@E\>_P!C'XX_
MM`:S^U-^S?JVMVK>,OA]\3?B;\68Y-=\-Z)IGPC^'GQ.\#_"NU\?_$&+P7H/
M@CP[X!^'WP[\#ZKXF?X667A7PYKMW7<?LZ?LF_"OX*?M^_&GX^6>I_\`!.[3
M_BE^TS\+?&GB'2_#OP%_9:OO@K^U5XL^%EI\:;/QG)\1/&_Q%NOVM/B=H/Q9
MTQ_$7Q*TZQ^/WQ4\(_L[?#B^^-?Q'U/X-Z[X[\3V%GX"^&O@:S`/U0K\J?B3
M_P`%>OV;_A?XK_:\\&Z]X5\=7&K_`+&A^'Z_$5K;X@?LFZ79ZO\`\+%\=>`_
MAYI-PEQXM_::\-'X.Z39:]\1O#UW=>)/VK8_V=_"^K>&8/$'BWP?K7BCPWX:
MUS4[+]*]`\>>!_%=OX:N_"WC+PIXEM/&GA2#QYX.NM`\1:1K-OXL\#W*:3+;
M>,O#4^G7EQ%KOA2XBU[0Y(/$6EM=:1*FM:2Z7C+J-GYWPM\0?^"<OA3XA^-_
M'_CV]_:._:/T'5O$OB2T\:_#:U\/Q_LX?V=^SMXU3XF?!?XN:QXI^$@U_P#9
MSU_4=>O/$_C;X!_#F^UK2?C[J/QN\+PVMCJ%AX?T#0[?4)50`W/AA_P48^`O
MQ5\!2^.=#LO%=NUO/\#$D\/V^I?"KQVM[:?'_P`5>!_!WA/5?"GQ*^$/Q/\`
MB1\!_B3I?AW6?B#X='Q"NOA?\7/&I\'6M[IMQJ$;KXH\$KXHN?L@_MY^%OVN
M]%^'6NVOP(_:`^`=C\:?@SX?_:%^!K_':R^#/E_&+X-^(=/\*ZI#XQ\(WWP1
M^-/QLTK2;G3++QUX+N-<\%?$#4/!7Q$TNW\3:;=3^$39B]N+2?Q9^R)\+K;X
M>ZIJWQH^,/Q6\97GACQU\-OV@/%_QM\8:G\-_"?BR;5_@-8>";P:CXC@^%OP
MT^'GPY7PGK.C?#+2&\=^'+3P!9:!=K'-K&D6.AZ[IGAS5="^<?V2OA_^QE^Q
M]I7PZT0?\%$-0^..F_`3X-M^SC\%[/X]_&O]EZSL_@W\(_!>J?#KX>ZKX3T7
M2?@I\,_@?I.M7UIK7@GX=^%-9\>_$W3_`!M\0HKJSM=&'B^WAUW5;35`#]-/
M!OQ1\"?$#Q%\6/"?A'7?[7\0?`[Q_IOPN^*.G_V9K%A_PB_CO5_A9\-/C5I^
MA?:]4T^RLM:^T?#+XP?#KQ-_:?ARYU?1XO\`A(O[&GU"+Q!I&NZ5IGR!_P`%
M*_\`DW7X<_\`9_W_``2?_P#7IG[&]>?_`+('[&7@CX9?M,_M#_MC^`K/]@W5
M-&_:?\0_$CQ)<^-?@%^Q]XD^&W[0NI:KXB\4^"K6ZL?'/[2FM?M4?%S1?%>C
M-%\,K:Y^+O@SP/\`!;X0>'/B-\?8M6^..J:%X:\?:IXVM?%/0?\`!5>V\57G
M[)GAZS\"ZSX?\.>-KK]M[_@EQ;>#_$/BSPUJ/C3PKH7BJ?\`X*=_L@1>'M9\
M2^#M'\6>`M7\6>']+U=K2^UGPUI?CKP7J.O:=!<Z78^+/#MS=1:Q9@'A'Q2_
MX)R^.?B3^WG\0/VG8M9MO".G^)U^"UOX?^('@W5_AEX;^)WAW1/AE<?#;6[K
M2K7Q3;?L\S_'QD?Q=X)FU:7X=7_[2FI?LO\`C?1I)]+^(O[/?B35-<U/61P&
M@?\`!//]JC2K=KGQ_-^S-\?OBOJOQ?\`C;\1O!OQ\^)(\77^I?LJR?$?]J[]
MH'XOV%]\"_A[XJ\+>.;BP:[^%GQGTS0K^#P7\2?A3XKTR]\&:7\,I?'WB+P+
M;^&_%O@[[6_X5S_P5,_Z/(_8!_\`%:G[17_TV"C_`(5S_P`%3/\`H\C]@'_Q
M6I^T5_\`38*`/`?VX?V,?VO?VC+G]JW5OAE\6O`'AJS^+?[)?QS_`&.OAO\`
M#C7]2\:6&@Q^%_BQ\!/%4%E\5O$'BC1;2]7PIX]LOVBO$6@I?VNF>!/&5Q!\
M*/`=G=:-XJMM9\2ZEX:L_G+Q7_P0H\"RWGCEO"7CR$6]I^S!I'[.GPE.L_![
M]C73K:VL_$?B/XU:C\3)?%'A_P`(?L>>'=#T3P=;V?Q7DN_#OP0^'=OX:_9L
M\4ZS%#J/Q'^"/B/5-*T_4U_0O_A7/_!4S_H\C]@'_P`5J?M%?_38*/\`A7/_
M``5,_P"CR/V`?_%:G[17_P!-@H`^2?VB_@9XD_9B_P""''[>7[/FJV>C3:+\
M,/\`@G-^V3I^C^*=+\16UT/%&J:S\&?C;X@\475EX"T;X?>`/!?P@\'0:AJ4
M$OP_^%/PYTZU^&WPR\)W]A\+?AUX9\'^`_`/AK27_;2OPC_X*:>`O^"D5G_P
M3=_X*"WGCK]J_P#8A\1^";7]B']J^Y\8^'O"?_!/KX\>"_%6N^%8/@/X]E\0
MZ-X:\8ZQ_P`%-/'ND>$_$&J:0MW8Z-XFU3P+XUT[0=1GMM4OO"?B.VM9='O/
MM[_A7/\`P5,_Z/(_8!_\5J?M%?\`TV"@#+^.?[97Q#^#GQF\;^!1\+]/USX>
MZ$W['FEZ+X[TV;7]7U*T\6_M#_&WQ%\/_$^A^./#VFV&/#OAY/".B)>^!_B#
M!?7VCV7B][C2O&VF6-I+H#:_\6?%#]O_`/;<\%_M1_%+X.^&=$^!?C+P9X+_
M`&SU^!.ES6/P7\16&HZ+\+Y/V9?V-/CS:ZU\5O'WBK]LCPAH?A6*7Q'^V1H'
MP[U?XL>%?`GCB7P\_A"TUVQ_9Z\61>.;JR^'WW&?AI_P5'+LY_;#_P""?I=A
M$K.?^":/[1!=EA=Y(`[?\/7R<12.[Q`G".[,F&8DL;X7_P#!4-S(S_M?_P#!
M/IVF61)F;_@F?^T,QE29(HY4E)_X*O9=98[>".16+!T@B5@5C0*`?,Z?\%2_
M'&H?%WX>?#[P[\`]4UG3/BQ^UMJ_PV^&4MW8^*/#>K?$S]ES1?V8_P!JSXOS
M_&SX7WFN:?;^&OB%XCU;Q=^RCKVH>&-*\.ZG<>'M4^&_Q)^%MOJ^I>&O%WB6
M46'Z8_LY?%B;XX_!+X??%B>R33W\;Z1/JJVJZ7K6B%($U2_LK9Y-$\210>(-
M$N)[:TBN+G1]:AAU72[B66QOXH[FWD1?F8?"_P#X*A@V[#]K_P#X)]!K16CM
M6'_!,_\`:&!MD9!&R6[?\/7LPJT86-ECV@H`I!4`5,OPW_X*E+PO[8W[`"@E
MF('_``33_:)`W,Q9C@?\%8.K,2S'J6))R230`O[9'_)Q7_!)_P#[/^^(W_KK
M/_@I77W]7X1_M7^`?^"D4'QX_P""9<7B#]J_]B'5-7O/VWO'MMX%OM&_X)\_
M'G0=.\.>*E_X)N?\%!;R\UGQ9I=]_P`%-/$=SXT\/S^";7QCX>MO#6CZQX"U
M&U\5:[X:\8R^++S2/">J>!?&GV]_PKG_`(*F?]'D?L`_^*U/VBO_`*;!0!YY
M\(?`W[6]K\0_VOI=;T3QI=>#_BIXMUFXT75?BI\:?&_AW5=$L9K?XG:+I&A?
ML[Z-X0^,_P`:?"/@KPMX?\/1?"YM/\3^&?"O[,>MZ_JFLZSXJ\4:-J'CG2)I
M-.X3QOX(_;UU%?V54GTWQR;;P3\,/`D$VK_#3X[3:;KUE\>4A^"D'BSQ=^U-
MX>U6_P##6@?$SP'9^%8/CSHJ^%H+WXW^'-5UO5-/\23^$'\?CX?>*?"/OW_"
MN?\`@J9_T>1^P#_XK4_:*_\`IL%'_"N?^"IG_1Y'[`/_`(K4_:*_^FP4`;_[
M!OASXG^'?A?XN'Q1M/VA='U#5?B-JVK:+X;_`&E/'6C_`!,^(.CZ7<:+H"7E
MXWC32?&_CJVNK;Q?K\6L>.+SPMHMWX?^'OPSUOQ'JOPQ^$OA+1_ACX/\+/>_
M;]?`/_"N?^"IG_1Y'[`/_BM3]HK_`.FP4?\`"N?^"IG_`$>1^P#_`.*U/VBO
M_IL%`'Q'^SS^RSXU_:`^"_Q%D\/^/_`_A7P?XL_:'_X+=_L[?%/2?%GPUO?'
MNK:AX&^+G_!67]HR^UC5/!,X\:>'M`TCQ18:;X3U&QTR;Q7X?\8:%!J&J6&K
M7NAZI;:7<:-JGJW@C_@F1\0/!_BF?4K;]H(6VFW'QI^)/Q#DUU&^/7BOQ]8^
M`_BE\4;WXA^-/A=X*A^)_P"T5X[^#_PH\*^,=*;3?"WBSPI\,/A%X8\`W^O:
M7X6^,-CX0T_XJ?#/X::]X:]F_P""5%MXJL_V3/$-GXZUGP_XC\;6O[;W_!4>
MV\8>(?"?AK4?!?A77?%4'_!3O]K^+Q#K/AKP=K'BSQ[J_A/P_JFKK=WVC>&M
M4\=>--1T'3I[;2[[Q9XBN;676+S]'J`/R3^)7_!-KQ[\9_!7P<^'WQ"^.7A+
M1?#'[/<^C67PVC^"?P[^(WP/UKQ)X4\+_#SQW\/]+\&?%W7?`GQZL9_%GP[\
M4:3XJT[3/B1\*="M_"O@/Q-HEMXHL+73],B\46$7A6'X,?\`!*#PI\*=6_;!
M\9ZC\4-<\7_$+]J'X_:K\7]"U2>X^(EAX%^%7A_5?"GP2\-W?AO2?@]=?%/6
M/A=>^-M0D^$5S-K7QDTSPOX:^(.M^'M?TKP/JVHWWAGP;I%M-^N5%`'Y/:+_
M`,$V_%_AY_B9X5TWXW>%KCX7?&S]HWPS^T]\2+/Q!\(KGQ+\1]-\=>`O'.B^
M,O!_A[X8>*]9^(MUX3\&^`V;P%\-5U70[WX?:_=66LK\7O%/AG4M'\2_%JWU
M;P)[_P#LG?L4Z3^RCJ=BWACQQ>:GX0TO]G?X)?`O0OAXFA6>E^&?!LWPHE\7
MW>LZSX(,5U<7NB>&?&.I>*I-5@\!3RZAIGA"[2[@\.WMMHUU;Z1I_P!Q44`%
M%%%`!17P1^V%\<O@G^SS\6?V0OB'\?OC#\+/@=X`3QU\6=%?QS\8/B#X2^&?
M@]-9U/X-^)SIND/XF\::OHFBKJ>H"VN#8V!O1=7?D3?9XI/*DV_ES\;/V]OB
MYH_Q2T.ZT']MNR^'GQKUK]M;P3\&])_X)X:;\*OA'\6-.\2?L=:U^TMI/P[\
M+_M,6&IZ3X'N?CSIME\9/@/<Z3\<[7]HNZ^)5U^S9X.@\;Q_"27P;_PL+P]/
MK1`/Z/:*_%[X;VW[=?C_`%3X57/B?]NSQ!H&D_M(:Q^T!9RZ7\/_`("?L]V=
MS\'?!/PXU35[CX877PHU3QK\.O&XN_BE?6%K8VGQ4\3?%S3_`(I_#S7K=KFW
M\"?"?X>WZQZ_)\"^+OV^?^"A][X_\.:3:?&_]ESX0:_H7A7X9V/P9^'WQ>^/
M6@_##5?VZM6U7X>>%M0\9_$K2OV:O#O_``3A_:S^.?Q8T*W^*-[XO^']SX&_
M99_:)^$7C+PY?>"]3N=9T'2]$U[P?KVJ@']3=%?S7?LV?MW_`!K\>?&OXPZ7
MXC_;LC\8_';P=_P48^/?[._@#_@G9%\$?A7X=B\1_LN>$?VW/B%\(#\1X]7C
M^'>G?'7XBQ_#GX::7K*)^T]X&\;Z'\`O!Z_"X>!_C#X.\3_%O0_B/XFU_P"1
M/C/^W=\9_P!F_P#X)P7GBKP=^W;_`,,H_'CX)_L=_"^Y_93_`&5_^%&_"GXJ
M?\-*^%(OV4/!'BW6OBY_8/C/P!XH^+/Q!_X1OQ#J7C6X_P"$^^$_BKPW\&?V
M=/\`A6_]N_M*>$O'7A#1_&&E:J`?V&45_.E\7_&OQ&_:(USXZ_#"']NCXVV7
MB/X8_M^_L811V?P5\-?L<7GPW^$'AO6?VU;#P/X*^&Z:1\1?V6_&7QC\$?&/
MPI8V_AGX@>/?#/Q]U+QC!XL\0^'/AW\1OAAK6L_`?Q]XE\`7WU9_P4V^"FK?
M%+QQ\`;32_@]\$/VD=:\<W.L?"7P!\/?C5K_`(JT"^^`7C#5KBVU_4/VT/@]
M<^'?`GCJV@\<_`_PSIUYJFJZG/>_"#Q5;65IHFB?#7XY>$O&?B>S\+>.@#]@
M:*_G3_:7_;'^+/PF\?7NAI_P4#E^%_Q^\-?M$?"_X.^%_P!A"[^#OP?^(&I?
M$W]G^\^)WAWP;/\`'S5-+N/`>H_M#I??$GP9>:KX\F_:"TKQ_IO[-WPZ*_\`
M"%:UX$G\4Z!KFIWGT7\-[;]NOQ_JGPJN?$_[=GB#0-)_:0UC]H"SETOX?_`3
M]GNSN?@[X)^'&J:O<?#"Z^%&J>-?AUXW%W\4KZPM;&T^*GB;XN:?\4_AYKUN
MUS;^!/A/\/;]8]?D`/VAHK\0_P!LGQ3I7Q8_X)C?`[Q)^TIXZ_9<T:P\1?$S
M]FU/BG\1?VN?AAX=\9_LM27FG_$O3--U#Q/\7/A3K7Q+^%'AC4/#6MZG81WI
M\/2_$OPGI=AKM_8?8=06&SMK&?\`/F[_`&M?VG/A-X!^!'PH^$?[0_[+OP0_
M9]\-^"_$>K_"[]I_Q'^TIX%_9N^#?[9'C:X^.GQ=TT?#7]FK2OBS^P5_P4)L
M==^$'AOP-IGP\U;P!\%_A=XC\*^-X_!WC[P[X1^"/Q<^+'A/P)?^*[<`_K"H
MK^:BV^,'QS\)?';Q_P#%+7+SPMX(^+VL^!KA?C!XW\'^$/&WBGP;\(;?Q[\)
M/^"%6C?&CXJ>&?`GQ$\,^$?'MWH'PVT37/$_BS2=,^)/@[1=1\-66EP:G\2_
M"XL-!\2:-+U?B/\`X*`?%GX):7>_%'X4_M,:G_P4._91\.^)?#_P;\._'G3M
M$^`&K2?$[]H#]H[P[X^T+X6_#L^-_P!GGX7?#[X3^.F^%/[0/@SX%_#(^*OA
M=I'@GPOI=I^US>Z/\6QKNO?!_5/$FD`']%E%?SE:G^V!^U-I_P`./B?H'Q0_
M:P3X.:M^P]8:?^S[^U1\=GTC]GKX?Z3\4OC7X@^(TOBG3?B!H?B_XI_`WQ]\
M%O@_X]O?V8?`_@/Q_P"%K+QGX3T3X"2Z[^UM;_#3Q'91>*X/`GBSX?\`[^_#
M'Q'!XP^&OP\\6VTWBFXMO%/@;PGXCM[CQSH]GX>\:SP:WH&GZG#-XPT#3M.T
MC3]#\52QW2OX@T>QTG2[/3-6:[LK;3K*"!+:(`[BBBB@`HHHH`_P#Z***`/]
MHW]B#X=ZW\5_^"+'_!/SP%X=NM*LM8UO]@G]A":TN=:GN[;38UT3X2?!O7[H
M7$]C8ZC=(TEGI=Q';B.SE#W+PI(8HF>:/RCXV?\`!-_]H3XD?%'XN>+/#_C'
MX*V/A;Q!^T-X!N_AWI6O77C>:\@_91^+&@>*]*_;X\'>*8M+\-0R6/Q`^*%[
M\6O'>L>`=#TK7=9\"ZQK?PR^"^N>*]1\,W+^(K2PD^`'PVU3XI_\$*/^"?\`
MX;T'4?C/IFOP_L.?L!:IH]Q\!?BM\9_@[\0VE@^$GP@L]1BM/%7P'\8^"/'E
MQI;:#?:L^K:.NL2:/<6R&]U"QE;3K:XMO'_CGX,_X*2:?\/O'MIX0\7?$/QW
M\.9/B?\`MG^&_A?\'?".C_M/_#']I'^Q[;5?B1IWPH;QU^V;:?M`^,=5N?`/
MB.SM[&#X9^*M%^"/A#7/"-EK?@SQ'H'C37M0\,QWWB4`^U-#_98_:&M_%?A#
MX6ZCX8_9BT[]G_P)^TE>_M.:?\?/#?B'QQ!^TUKWB+_A9FI_$^/P[>?"B?X6
MP^"/#_C+QI-JESX%^,OQWM?C]KES\1/A_JOCK1(/@_X<7QZ?^$8A^*G["OQ.
M\4^)/VEOBKI7Q6U'QEXK\8>)[SQ?^SS\"O&NO^#?!GP"\%>(+CX??"/PCJ&N
M:]XR\'?L\ZU\=M-\0>+C\/=8TC6KC5_%/QD\'Z!H^M1:SX<^'XUJ**UL?S0L
M-!_:FNO$'[-%YXQ\2?ME_!BZL/`WB6[TCX)IX?\`^"Q/[5]IH'CS_A:/CJ&Y
M^#_CC]J3X5?%SX'>`->UKPC!9^'K*V^/O[<_@#X[?"CQWHFJZ5JGPUBU[X7:
M)=ZUXP]B^!WPZ_:"\0?\$Y/$'@KPAXM_:1^-?Q<\3?M$?`I-5@^*&J?\%D_^
M"=?CV#2Y?$7P4;X@^&KOXS?M5_%_]JK]K[P?X(M=&M_$%WXH^*/[/CZ5\&KV
MWN/$.BV'@+3;Q/'NI:@`?3]]^Q5^U7\8?COX=_;(^+7Q=T_X,_&GPI/H_P`-
M_#7[._P1^(VD?$K]GK1_@!?Z;K/ACXC"^^,7CO\`91^&WQ]U3XM^)H/B)\0?
MB/:7?A&S^&'P]NO&7@_]G?0/&WA7QB/@[I'CY\W6OV2OVL?%7P*N?@/K7PB_
M8=\.:3\*/A9X?^'OP7\7_";XI_'7X4^./'_]E^//AMXHU.RL?%O@[X,:=XO_
M`&$?#VO:=\.XQJTOPA\3_M,^*Y/%=YX;\5Z+X@\.:AX`LFU^/P?\0?VJ/@5X
M!^.W[/6G:+\7OB[^UT?"OP^D^`NN^+_!G[37C_\`9JTO4_&/@[X8_#K3M0U[
M]K;Q5\,KWP+KW@_X/_$#7]1\2?%--5UV'X[>-?!7@CQG\2;KX87?B+69[2?R
M!C\>M$^%WPF^&/[?>F?MQQ>$O@WI7Q"^&OC'Q5^PIXU_;$^*WB3XB^+]*N_!
M.K_`[QOXU^,?[*/PV^$?[8/Q8@N_A#KUAHFK^.?!GP\\(^`=:^..@_&=OC=H
M5@L'@B%`#[`U'X-_M7>$?A?^R5J'PL^%?P8\0_%/X(>*O']]XT^&7QN_;V_:
M?^)/AQM"\:>$/B'X7673/VP/B;^R_P#&'X[?%+6+2;Q+H^H+#\1/A)H8M;&6
M]\-V&LPZ5X=T4ZE\>Z/_`,$S/VA--\4>)--O;?X97_A+XC?#+QKI.M^(M'_;
M$_:W\#_"SX;^(?'*?&77+CX5_P##NGPOX"M_V9OVF?@-X9U+XD:7\+_#<WQ=
M^)'A'QO9_!ZPMTTQ="\1>$/"RMW?P0T?XJS?\%"?"FL^-/B'^V!I_AVU^$?@
MNU\,_#?XS?!S]O+6-`UVR?X#6W]K:YX]^-GP1^.NA_\`!*'PG\0;;Q9/K/\`
MPE'A;QW\`/&GQ1O?&VF7/_"/>,=/U+7/`7_"/?*]\OQ;E^%OQFM/@EJ/_!4#
M2_BS?_#CXV0?M1:I\6_#_P#P4N\3>`-!U%?%6K#P1K/[,FB_$37O"/C77/&]
MMJ,[-X;\._\`!-KQ9H-GK?PTBUJV_MC0]5'PCUBU`/IS]I']A?\`:Q_;#@^$
MA^)WPY_8<^#I^&WQ1N8-7M?AEXP^*'C_`%GQM\$[G]CK]M+]G2XMK[QWJ_P)
M^%MS8Q+XD_:?T6[\*?`AO">I>&/`>A6?C_7%^,_BW4]?LO"T>UK'_!.3X_\`
MB;6M<UN?XL^#O`'B`_"CXO?L4>"/B#X!U+7+KXA^!?V$O'GC?]G9]#M?#^J^
M(?!,EE9_M!V/@3X7_$/68-<FM-0\)^'?BGXC\&:O./'-AX?U.XU/YS^&&FZY
MI'@7PUI_Q8\:?\%7_B#J,&GW)_98\6_LZ_#+_@I]\'?[5\1R^*O&$VO+\4OA
MW^UY\6_CG\0=!\=6'BF0Z=:-_P`%0?BAXD_9<U;P!:>`M:^'::+X&U#5=!TS
M1^"L_P"W?X:^(G[0&O>*1^UUK.D?&?X^_M.?LG?#S2/$EI\5=9T3X4:3XN_X
M*$_MK^)O@[^U)X?L/$#W.E^$_A=\.OV=M4\):=8>/K"UTO0[_P"'=O\``;P_
MHVH:GX=T;X>Z+.`?:'P#_92_::_91\:?!KPI\/\`4OAM\??@;X"7XO\`P]F\
M9?&+XFQ?"'XR>#O@_P#%/QK\(_B=9RZ#\/?@?^R6?@KXQU?P-XHTOXG^$O"?
MPYT!/@%X&T?X<:9\+M)TS6K%FU:TT#]3Z_!?X)7'_!3+PQJW[(VH>(?"_C+Q
M!\"_@5^SG\&/V6/CO>>/_B7\1[O]H;XP_%OQ]\*_!</Q#_:/F^&-Q\*-<@^*
M">%_B?)\&H+[XO\`BWXN>"O%WP]M_#'[7MU)X3\5Z3XYMM>L/U'_`&-OBNOQ
M?_9S^%^OW.E_&?2?$>B>#_"7A'QS!\>?@S\</@?\0)O'>A^$/#W_``E=W=^&
MOC_X%\`>-]?M)]5NIL>-K32M2\.>(-074?[,U_4[FSU`P`'YE_\`#NG]H_6O
MVM_V]OCA>G3_``-X-_:(_9S?X2_"F33_`/@I!^V;\9K[6O%OA;XE_M%>+M"?
MXH_!CXL?!>+X5_#'X2?$;3/CMI#'X8?#'6_&>@_LIR>!?%GA/X!V&O>'?CY\
M3;QOV6D^%'PKNTN?MOPR\`73Z@ETNHFZ\(>'[UKW^T/$-IXPU!;R:ZTTRWRW
MOBZPLO%%VUR&-WXBLK37)U;4[>&X3\H?^"<'[3'[8OQG_:&_:C\*_M&^./$'
MB/X;:+X@AU3X%6^L_P#!([]N3]@S3M;\%P?"7]F6.]\4^$_BM^TCXTUWPM9^
M'[/XK:]\:?"US\"/'X\:?'WQ+XJTSQ+\7?#7C_3?@3:^&?AWX8_9V@#P_P#9
MN^'GB?X4_"#1?!7C-]!?Q+;^(_B7X@U(>&-1U#5]#@_X3CXF^,?'%G:6.IZK
MHOAR_O?L5AXCM;.YN)]$T[?>07'E0F`1R/\`./\`P4K_`.3=?AS_`-G_`'_!
M)_\`]>F?L;U]_5^<7_!5?PUIWC3]DSP]X.UBY\06>D>+/VWO^"7'AK5;OPGX
ML\5>`O%5KIVN_P#!3O\`9`TJ^N?#7CKP+K/ASQMX+\006UU++HWBSP=XAT+Q
M5X<U%;;6/#VLZ7J]E:7T`!Y=^UG^QS^UU\5O'?[0?C'X)_&C1?!^C_%GP!X+
M\)VW@?7O&?C+3M.O=0^!FAZC\0O@[<6=[IOAW7[#X;6WC+XV:]XB\"?'2^T3
MPYXGU3Q7\&+_`$RZ=-6O/#=CX0NOGCP=_P`$F?%?P?\`A=:^%]!\&_LZ_M!:
MWXPO[WX@ZYHWQL\*?![P=X.^!_[0VJWVA:E/\;?AS:_"S]E72X_BKXKC_P"$
M>T?1S\6_C!INL?M3:5::3::A!\=_$V8-&L/O?_AVI^SK_P!%&_;^_P#%L'_!
M4S_Z,BC_`(=J?LZ_]%&_;^_\6P?\%3/_`*,B@#.^.'[./[3OQ%^*/P.\9^%/
MB_X3\/Z#\!/".C6HT:>R\3+%\9/%?C^XN?!OQUN_%&G66JPV?A.TT+X5V,+?
M":>YN?B.)?%WC;7Y=6T[0I/#&CZ[JOY_?#7_`((6>#_A_P"'_P!EC2X_&D$T
MW[.OPR^)VO(MG\./V4M`AN/VA_']E\";?R/#I\'_`+)'A7_A77PV9_A/=#Q'
MXJ^"J_"3XP_$5;K4#\7?%WQ&_P"$W\;C6/T2_P"':G[.O_11OV_O_%L'_!4S
M_P"C(H_X=J?LZ_\`11OV_O\`Q;!_P5,_^C(H`_.?Q]^QYXF_81_X(F?\%*/V
M?Y_^$9\0>'O^&'OVZ?&M[XVT&?PGX+L+CQ#J?[->LZ/INC^%_@+\+_A!\+?@
M]\+M"C\/:,!XB7X=Z9H=KXN\?:=XB^+7BK2->^)/Q=\?>*KC]1/VS/@!K_QY
MT#PII]M\/?A-\<_".D#Q;9^+_@#\=[B"/X4^.'\3Z79Z=H7C#6]-U/P'\3/#
M'BG6_AG=6]WJ/AWPEXR\&7OAO59=;OKQM3T/6]*T34HOSU_X*:?\$^O@/X+_
M`.";O_!07QCH_CW]MZ\U?PG^Q#^U?XETNT\6?\%-/^"D7CWPK=:CH7P'\>ZI
M8VOB7P+XZ_:O\1^"?&GA^>YM8HM9\)^,?#VN^%?$>G-=:/XAT;5-(O+NQG^W
MO^':G[.O_11OV_O_`!;!_P`%3/\`Z,B@#Q3Q;_P3L\1_$[XA?L3?%?XH^(/"
MUYXK_8W^%7CI]"TKP3HO@"VT_4/BWJWBWX6>)?"GA_0O&OQ"^#GCGXH?#KX?
MV%CX$E\-:QXU^"GBOX,_$#Q)H]O'I6N03^#M?U?P5''X)_8/^/.G_#MOAY\5
M_B[X>^*\DGQ_\'_&ZX\6Z?-XO\"S7&A_%34#!^V?\%KK0Y[_`,83:M\-/B%:
MW/B_Q+H6EZQXBN+._P!9^)-[I]GI7@"V^'GP_N=-]O\`^':G[.O_`$4;]O[_
M`,6P?\%3/_HR*/\`AVI^SK_T4;]O[_Q;!_P5,_\`HR*`/SS^-_\`P3!_;$^*
M'@S4_A\?CWHVJ_#-_B5^TS\6!\-M:U^UUZP\5W7[5_A?]H"#QU\-O%"_$GX2
M_$CPI<^"?ASXY\8^!/%WPEM]<\*^+O#*+XM^(WA;Q1X`N_!'AWP[X<UVU9?\
M$G/BW9_L^Z]\$K/Q1X#O?`?C#QEXRU?Q-\%_B)!X,U/X<IX?O_V-M2^`W@VU
M\)>&_A%\%O@[\%?AS/IWCK4/^*K\(?#7X#>#_A?XE\.6]GXPM_">C>/DUBY\
M1?H%_P`.U/V=?^BC?M_?^+8/^"IG_P!&11_P[4_9U_Z*-^W]_P"+8/\`@J9_
M]&10!Q/Q]\#>'_AA\1?^",?PW\*>'_#GA/PQX`_;-\0^#/#WA?PAI5EH7A3P
M]HWAG_@DU_P4>T;3=%\-:+IMII^GZ3H6F6EG%9Z3IMC8V=I96,,%O;VMO%&L
M*?II7X1_M7_\$^?@-H/QX_X)EZ78^/?VWI[;QI^V]X]\-:Q+K/\`P4T_X*1>
M(]1L].M?^";G_!07QC%<^$]8\0?M7ZIJ_@+Q`VK^$]+L[GQ9X%OO#GBJ\\*W
M7B7P+>:S/X)\:>,?#VN_;W_#M3]G7_HHW[?W_BV#_@J9_P#1D4`9,_[+7Q._
MX;R\7_M4>';'X2>%Y=:^%.E?"M/BCKFE^'?B#\0[WP!I>N?#WQ%;_#/2-%/P
ML\'>//!&A7.M:=\2-4UA[+]I#6/!=QJ^K>&/$=Q\,M=UM5?PC\SZ]^P#^TVW
MP4\)?#0>(_@!X_\`!'A+]L']LSX^:U^SCXIT;Q!I?P^^*'@GX^?'3]M7QS\&
M]`USXE3:=XIE\+0?"#3OVB/@E\4+#P=9?!_7;3P_\2_@)INA^%_&)M!I'C"S
M]G7]C?\`89?XKR?`9/VF?VMV^.47@<?$Z7X,K_P68_X*3-\5X_AL=93PZ/B%
M)\.Q^VV?%Z>!SX@DCT(>+&T<:"=9D33/[0^VLL!I:E^R1^P1HW@-OBGK'[5/
M[56E?#%-<N?#+_$?4O\`@M%_P4?L?`:>)++Q3=>!KSP^WB^Z_;?B\/+KEIXU
ML;WP?<Z2=1%_!XIL[KP_+;IJUO-:(`>@_L7_`+,?C[X$?$#XP^(/'7AKPO;7
M7BFT\/:.GQ'T/XCZ_P",/%GQJNM%NM4OM3^)OQ@M?$GABUUJ3QYKNL:MJCZ%
M;7?C/Q'H'PP^'"^$?A#X!T_3-`\+7>H:Y^B-?F7X<_8?_8O\8^(O&/A#PC^T
M+^V1XI\6?#R[T[3_`(@>%_#G_!8O_@I?KGB+P-?ZQ9G4-(LO&.BZ9^VM=:EX
M9N]5L%:^TVVUJULIKZS!N;9)807KMO\`AVI^SK_T4;]O[_Q;!_P5,_\`HR*`
M#_@FI_R;K\1O^S_O^"L'_KTS]LBOOZOPC_X)]?\`!/GX#>+/@/X]U35/'O[;
MUK<VO[;W_!33PU%%X:_X*:?\%(O!>G-IW@O_`(*1_M7^#M'N;G1_!W[5^A:1
M>>(+S2-!L;SQ9XLO+&?Q5X]\53ZSXZ\=:SXC\;>(_$'B'5/M[_AVI^SK_P!%
M&_;^_P#%L'_!4S_Z,B@#[^HKX!_X=J?LZ_\`11OV_O\`Q;!_P5,_^C(H_P"'
M:G[.O_11OV_O_%L'_!4S_P"C(H`^_J*^`?\`AVI^SK_T4;]O[_Q;!_P5,_\`
MHR*/^':G[.O_`$4;]O[_`,6P?\%3/_HR*`/OZBO@'_AVI^SK_P!%&_;^_P#%
ML'_!4S_Z,BC_`(=J?LZ_]%&_;^_\6P?\%3/_`*,B@#[^HKX!_P"':G[.O_11
MOV_O_%L'_!4S_P"C(H_X=J?LZ_\`11OV_O\`Q;!_P5,_^C(H`^_J*^`?^':G
M[.O_`$4;]O[_`,6P?\%3/_HR*/\`AVI^SK_T4;]O[_Q;!_P5,_\`HR*`/K_X
M:?"[P)\'_#NI>$_AUH7_``COA_5_'_Q8^*.H:?\`VGK&K_:/'?QQ^*?C+XU?
M%'7?M>NZAJ=[%_PE'Q-^('B[Q-_9D%S%H^B_VO\`V-X<T_2/#]AI>E67?U\`
M_P##M3]G7_HHW[?W_BV#_@J9_P#1D4?\.U/V=?\`HHW[?W_BV#_@J9_]&10!
M]_45\`_\.U/V=?\`HHW[?W_BV#_@J9_]&11_P[4_9U_Z*-^W]_XM@_X*F?\`
MT9%`'J^M?L7?L\>(/BW)\:M4\,>,W\676O:)XNU3PW:?&GXWZ7\%/$'C7PU-
MIUQH/C[Q5^SAI?Q%LOV>?%GQ#TJZT;0[RS\?^)?A?JOC**^T#P_>C7#=:!I$
MUE]3U\`_\.U/V=?^BC?M_?\`BV#_`(*F?_1D4?\`#M3]G7_HHW[?W_BV#_@J
M9_\`1D4`??U%?`/_``[4_9U_Z*-^W]_XM@_X*F?_`$9%'_#M3]G7_HHW[?W_
M`(M@_P""IG_T9%`'W]17P#_P[4_9U_Z*-^W]_P"+8/\`@J9_]&11_P`.U/V=
M?^BC?M_?^+8/^"IG_P!&10!]_45\`_\`#M3]G7_HHW[?W_BV#_@J9_\`1D4?
M\.U/V=?^BC?M_?\`BV#_`(*F?_1D4`??U%?`/_#M3]G7_HHW[?W_`(M@_P""
MIG_T9%'_``[4_9U_Z*-^W]_XM@_X*F?_`$9%`'W]17P#_P`.U/V=?^BC?M_?
M^+8/^"IG_P!&11_P[4_9U_Z*-^W]_P"+8/\`@J9_]&10!_B&T444`?[>7_!)
M_P#Y19_\$U/^S`?V-_\`UG7X<U]_5_/C_P`$_?@E\0_#_P#P3:_X)I^)=?\`
M^"K'[9GP=T/XG_LI?L8>%O`G@S1_`_\`P3?E\'Z'XD\?_`[P,_@SX7^$=2\<
M_P#!/?QMXRN+*%VC\,^$I/&_C/Q/XGU-;?3K76_%'B#Q%>/?:A])6?AV?4[K
M2+#1O^"V?[;7B#4O$/C+XQ?#OP]I7AOX=?\`!,+Q)J_B#QY^S])KEO\`&;P=
MH6DZ%_P3'U#4M9\2_#Z\\-:YIVNZ-IMK=7XU;3Y=)M(+K4I(+64`_7RBOYYI
MOVEOAM!X=T+Q8_\`P5__`."PC>'_`!)X:\#^*=*U"+_@FE\&[C=8_%'XI:E\
M%?A5I&H6L'_!$62]T7QM\5_B9IC^&?A3\.=:MM/^('Q,.H^'-8\"^&=?T#Q7
MX8U75_H+P-]A^(^HZ)HWA#_@MQ^W+?ZWXA^(L?PCTO0[_P"$W_!-;P]KC_$U
M_@?X=_:/?P->Z+XC_P""7>DZII7B2R^#/BSP[XPU33=6M+*?2&U6W\-ZH+/Q
M8LVA1`'[+T5^;/@K]FOXR?$7PEX=\=>#/^"NO[?>M^%/%FDV>N^']7C^&'_!
M,"T34=*U")9[2[6UU'_@F9:7UN)HF#>3=VMO<1DE98D8%1U'_#&_[17_`$E@
M_;^_\-S_`,$L_P#Z6I0!]_45\`_\,;_M%?\`26#]O[_PW/\`P2S_`/I:E'_#
M&_[17_26#]O[_P`-S_P2S_\`I:E`'W]17P#_`,,;_M%?])8/V_O_``W/_!+/
M_P"EJ4?\,;_M%?\`26#]O[_PW/\`P2S_`/I:E`'W]17P#_PQO^T5_P!)8/V_
MO_#<_P#!+/\`^EJ4?\,;_M%?])8/V_O_``W/_!+/_P"EJ4`??U%?`/\`PQO^
MT5_TE@_;^_\`#<_\$L__`*6I1_PQO^T5_P!)8/V_O_#<_P#!+/\`^EJ4`??U
M?`/_``4K_P"3=?AS_P!G_?\`!)__`->F?L;T?\,;_M%?])8/V_O_``W/_!+/
M_P"EJ5\0_P#!07]E#X\Z%\!_`5]JG_!33]M[QI;3_MO?\$R]&BT?Q+X!_P""
M;MKIUGJ/B/\`X*1_LH>'M'\66TO@[_@GSX3U=O$'@+5]4L?'7A.VO-4NO"MY
MXJ\.:-9^.O#7C3P3/X@\':\`>H?&CX1_M^0_M9?'WXM?"+Q#XIG\`>,/`.@_
M"?X*>&S\2/&"^$_"_B[7_!W@;PM>_$[Q;X(U_P".,GP@T7X<>`M=\6^,?B?J
M&I>!_P!G1_VA=8\1_"ZZT5/'7B;PKXD\/^`[WV#QIX;_`&_/$/[(WP]^$/@V
M^T3PC^TY%XA7P7XS^-NK^.4G\.V7AGX8W.L:AHGQ3;5[#PO>Z[XANOC*OAGP
M3I_B'0(_`.DWJQ>.O&MO=0>&TTRSOGZ[_AC?]HK_`*2P?M_?^&Y_X)9__2U*
M/^&-_P!HK_I+!^W]_P"&Y_X)9_\`TM2@#X(\9_L<_P#!0+X[>(/C;\4I?CC\
M2/@%_P`+X\??`ZTT'X*W7Q2_:JN;#X-^#-.\#_!37O'FIW][\`/^"B_PD\/6
MFF:-XK\/>/?!XT+]F%OV;_%?B&_U_P`4:S\0_'?QDT.]TFRC^A_V(O@?^V'^
MS]\7_BQ>_M`_$;XT_'[PAXRUN'PGX!\0Z]XSN_$,\^D:%K.HZ"OQ5^*'ASQ5
M\=-0^&G@'5M1T;PMI'B*PT+]EWX)_!?PY=:=\2+N#Q9X'\8>+M$DUO2?</\`
MAC?]HK_I+!^W]_X;G_@EG_\`2U*/^&-_VBO^DL'[?W_AN?\`@EG_`/2U*`#_
M`(*P?\HL_P#@I7_V8#^V1_ZSK\1J^_J_,+XL?\$YOB?\<?A9\2_@K\4?^"HG
M[?WB?X9?&#X?^,OA=\1?#7_"&?\`!,O1/^$B\"?$#PYJ7A/Q=H7]L^'?^"<F
MD>(-(_M?P_J^H:?_`&GH6JZ9K%A]H^U:9J%E>Q07,7?_`/#&_P"T5_TE@_;^
M_P##<_\`!+/_`.EJ4`)#^PGX7U/_`(*!:I^WCXCUR_A\6:#X%\.^`_AWHOAW
M3OAUI2W6G1^$_%GASQ$?'WC*T^&5K\;_`!!X?!\7:C=:5\([SXTW_P``Y_$=
MIX;^)VI_"6;XL>"/!7C;0/FJU_8Y_;=UC]I'QU^T->?%#X9?#W3%_:<T3]I/
MP;\'M)\1>.OB!HNOW9_9T_9H_96\8^"]=\5S:1\._P#A']/N/AM\"?B=J?@_
M4E\)>)=(M]6_:4UN]U_P,WB3P!HOB.Y^EO\`AC?]HK_I+!^W]_X;G_@EG_\`
M2U*/^&-_VBO^DL'[?W_AN?\`@EG_`/2U*`/BCX'_`/!+'XQ?`WX3ZEX?\%?%
M#PEX8^*OBKXCF^\7^-O#>D^$_"FE7/P>^,N@R>%_VAO"5II'P\^$G@5+WXD^
M'Y-7N/B1X(^+_B:/Q#\3_BK\0?AM\'F^,?Q&OM)TO5H1^LO[.OPVUKX2?"RS
M\"Z_)I4M_9>-OBYKD/\`8DT\VF1:-XT^+GCGQMX<M;=KFRL)(WL_#WB+2[2Z
MMEM4@L[N&>TMGGMH(KB7YQ_X8W_:*_Z2P?M_?^&Y_P""6?\`]+4H_P"&-_VB
MO^DL'[?W_AN?^"6?_P!+4H`/VR/^3BO^"3__`&?]\1O_`%UG_P`%*Z^_J_,+
MQE_P3F^)_P`0/$?PG\6>+O\`@J)^W]J_B#X'?$#4OBC\+M0_X0S_`()EV'_"
M,>.]7^%GQ+^"NH:[]ETS_@G)966M_:/AE\8/B+X:_LSQ%;:OH\7_``D7]LP:
M?%X@TC0M5TSO_P#AC?\`:*_Z2P?M_?\`AN?^"6?_`-+4H`[&Y_9@\;W7[3?B
MSXYVGQDO_!WAOQ)H6EZ9<^'O`MAXHL?%.LRZ._@!M)T_Q5=^*?'OB_X1:AH.
MEKX2\300W&D_!'0_'$MAX_U*PM/&FD+9:C<>*/G2[_X)O^-K'PCX0LO"?[3N
MO6WB?X??M2_MA?M,>&=&\3^`-#UKX)ZMJ'[7WQ+_`&R_$FNZ1X]^'>E:EX>\
M8^)]1\&^!OVS/$F@Z9J5G\5-"\/ZIXU^'W@OQO-X.L+*.Z\+'UK_`(8W_:*_
MZ2P?M_?^&Y_X)9__`$M2C_AC?]HK_I+!^W]_X;G_`()9_P#TM2@#H_V4_P!E
M+7/V<M?\8/?:]\/-<\*'2-/\(_#&U\+>`M2\'>(O#?@^RU74M?U"+Q9>+XKU
M+P]XI\6^-_%VKZ[\1_B1XUM_#>DZ]XS^(7B?6=2U&Z71;/PYH6B_;=?`/_#&
M_P"T5_TE@_;^_P##<_\`!+/_`.EJ4?\`#&_[17_26#]O[_PW/_!+/_Z6I0!^
M;GP,^!G[3WQ?\5?L_>(?A3\4O&OPP^`GPE_;"_X+X>-OC:WA7Q+XZLK?QM\0
MX?\`@L+K3?!;P-)X1\$_'OX,Z9XE\1ZYX0M/V@$\/ZI\8/"_QV^!OAW38O%%
MGXQ^%-SXH\2^`?$>A;OQ@^"'_!5[XH^#O#/AC4/$>K>$]9@_:+T_]I"^\3?#
M?XU?$73$\/?"OQK\-_B@FO\`[-5A<?"SXV?LN>(_%OB[X->-].T6]\"Z-X_N
MO%_[.OB*_P#%?PWL/'^G_$;0=&\7/H7W-_P2HT;4?#G[)GB'P]K'BSQ!X]U?
M0OVWO^"H^C:IXZ\66WA6S\5>--1TO_@IW^U_8WWBSQ+9^!?#7@OP3:^(/$5S
M!+K&LVW@_P`'>$_"L&HWES%X>\-:#I"VFEVOZ/4`?DU\'/@)^U]X!^`_@7P9
MI?Q#^+^E?$F'_@H'^U=XZUWQ9\6_B]K7Q^U/_AF?_A=G[4#_`+.>E>*;WQ]\
M0O%-YJ7PQUOX+6W[.FDWOP\\,:_HOB'1[+4IM1@MO"'Q/BUSQ!IWD'P]^'__
M``4/F\9VWB'XP>'?C8OQ<;XX>&-:^%GB'X??M%Z:_P"S!\+OV;9_'N@ZK\8?
MAE\9O`-S\1-"TKXV^.M1T?P[\2;#P%XYU[]GS6O$T?A'XE_!?0_!OB/X.:]X
M>^)'B7P3^XE%`&'X8UB[\0^&O#VOZAX<USP=?ZYH>DZQ>^$?$[:(WB7PK=ZG
M86][<^'/$+>&=:\2>&VUS0YIWTS5F\/>(M?T0W]K<'2M:U6P-O?3[E%%`!11
M10`4444`%%%%`!17PGJG[6GQ(\,_M_?#C]C;Q3\%_!MGX"^,GP/^-/QF^&OQ
MET7XS:QK/C&5?@7KOP=\.>*_#_C?X.77P9T70_#$>KZA\8+&X\+ZOH7QI\:R
MW>EZ//<:UHV@WUVNF6N)XJ_;!^,OB[XR?&/X0?LB?LY>$OCZ?V;K[PSH7QT\
M<?$/]H&#X&>$M/\`'WB'PM9>/)/@S\,7TGX4_&C5O'/QAT;P-K_@OQ+JVG>+
M]-^%?PQT^+QOH&FZE\6K#5DUBSTL`_0>BORYTO\`X*:Z'\6/#?[/ND?LR?"#
M5?BA^T/^T-'\8#;?`GXB>.M"^$1^!A_9V\0)X`_:`O/VC_&>EZ;\4I_!FD_"
M7XN7NB?"379?AUX-^+NM:[XPU_39?!'A_P`4>'Q>:U:>^?LZ?M8ZA\5/'7QE
M^!7QD^&D/P)_:.^`%AX,\1_$/P#9^.K7XE^!M?\`AW\1+76I?!'Q>^$GQ'7P
M[X(U7QG\,?$&J>%/&OA=;WQ9\.OAMXTT?Q-X,U_3?$?@71HSI%WJH!]E45^;
M?['G[67[6/[7'A3X0_'G3?V9OV<_!W[*7QJTJ3QOX0\=R_M>_%C6/CHWPOU>
M'4KGP%XIN_@5?_L,^%_!T&N>*[&/0M4O?"TOQ_BM]`TW69I%\1ZS>:<MCJ'Z
M24`%%%%`!1110`4444`%%%%`!1110!_@'T444`?[,_[%_P"S1X-_:?\`^"2G
M_!)SPUXXU[Q9HFE^`_V._P!D+XB:<OA.XT*TN;WQ*O[%8^'_`(;O+J\UG0=;
MN;&?P-K'Q`M?BGX0U'0)=&U?3?B3X"\$:A/J-YX?M==\.:][5X2_X)??L^^"
MO$F@>)]"\1?%B"^\`:EX.UKX1Q_\)H+>#X6ZWH7B'2/%'CC6-)&G:;82>,-0
M^.&K>'M"D^,<OQ/?QS'XGCTQ?L,6CW&H:Q<:ET/_``2?_P"46?\`P34_[,!_
M8W_]9U^'-??U`'XY_&7_`((C?LA?'V\\)?\`"U(+GQCHWASP#^SC\,]2L_$G
MPZ^`WB+Q-XC\#_LW?%Z/XQZ-X/?XFZ_\)M3^)7A?P?\`$K68QX<^+GA;P1XI
M\-Z5XP\(SWFFI%IMW=/J(]*\)_\`!)O]GCPGXZ\0_$B'Q=\7+OQ9=>*/AEXV
M\!3VOB/0O!VC_"+Q5\,_A;^S/\)(=0\#>&?AWX8\'>';K3O&/AO]D3X$S^-O
M"_C33/%GA74;WPM<0:5HVBZ-J4NDQ_J%10!XO\`?@\WP%^&>B_"V#QUXG\?:
M)X6S8>%K[Q98^%++5-$\,06]M;:5X863PEX?\.6FHVNE)!(T6IZG:W>MW<EU
M,;[4;A$MTA\*_;[^(OB/X:?!30-5\._$WXV?"#^W/B]\-?">N^//V<O@U8_M
M`?&O2O#FNZQ)%J<'@'X37WP+_:3_`.$JU/4/)@LKR.S^"WC6^T_1Y]2U2WMM
M.^Q/K-A]NUP_CCP!HWC[_A$/[8N=3MO^$+\<:!X_TO\`LV:UA^T:SX<-W]AM
MM0^U65YYNF2_;)3=0VWV6Z?;'Y-[!AMP!\0_LA_M"^/K_4](^$OQAD^,OBRZ
M\?ZO\6O$?[./Q6^,OPLT[X,_%7XC_`GX2>%/V>AK?B[X]?"@_#_X&7GPP^(M
M[\3_`(P^*O#/A_PW8?!+P?#JW@[P;8>*-7\/^$K[5XM*G\WTK_@L+^S9J?Q1
M\;_#:3X=_M":3I?PH\`?'3XM?&;XP:OX)\'6WP6^#GPJ_9Y_:$_:Z_9D^('C
MSXA^-H?B-<R:;8W'Q._8W\=)X/\`#.EZ1J_Q!\8^'O&O@/7-"\'7<&F?%Z+X
M4?:?Q]_9V@^.$W@CQ!HGQ<^+/P"^)OPWNM=?P5\7/@N_PSG\9:/I7BVUL;'Q
MAX8N-$^-'PR^,?PM\0^'/%-OI6D-J>G^*?AUKDEI?:-H^LZ'<Z1K6F66HP^,
M_#G_`()R_LY?#F+XN6,%OXP\6:)\=OV?=!_9U^+&@^,M;T[4+'QIX=L/BG^U
M'\:/%WCC5KO2]"T;7)/B?\5_B/\`M??&+Q+\2O$ZZNEGJ>I7FC7V@:+X;U"U
MU*\U8`^--%_X+1?LX?M&^'/B!X._9Y\?:'X;^,ND6_AWQ+X)T]?C)^QM\;K_
M`,8^`[?XH?#WPOXI\5:;HO[.7[0O[1S^$+(Z9XPM81HOQGTCX;>-UBU26:S\
M,1W^BZL=(^C=8^._Q0D_X)T_$OXTWGQ`\6Z%\1-+G^,UE!\0O`/@#P]XP\=^
M'M/\.?'OQAX%TK4?!7PXB^'OCG0_%WBW0?"6FVEMX<\/O\,_&T_B36+.SBN?
M"_BC4[Z6TO\`U+2OV*7FTOQ+HOQ-_:L_:R^.>F:Q8:9HOAZP^)GBWX3V.F^!
M/#^D^,?"OC6TTW2='^%GP9^&FC>-]674?!FB6`^(GQJT[XJ_%FWT9];L;+Q_
M:OXH\2W&K>N:9^S=X'TKX(W?P%M]5\5OX0O=:\0Z[+J4U]I#>)5N_$OQ)U+X
MI7\<=XFA1Z6+:+Q!JEQ9VB-H[RQZ.D-O--/>J^H2@'Y.ZK\?_P!H31/A%XUN
MW_:"_;V3X(3?$S]G#PUX$_:?\5_L,Z=X?_;MU+5?&'B;XEV_QR\%^'/V1KK_
M`()]Z*/$?A;PQ8:/\)X?"7B^']C#5M7U:Q\8^/)89+RV\'6_C1OU'_9-UMO%
M'P3T[4$^+7[3GQ>>XU;Q%;I\0/VLOV?XOV:/C9,T=Z\2VVH_"B?]F7]E*'3M
M)THXA\.ZK/\`!33XM;LD2\DU7Q$C&]DZ[X_?!:7XZ^"=/\*V/Q4^)/P4UW0O
M%_AKQOX:^)7PFMOA=>^-O#>O>%[QKJUDT^P^,WPS^+_PYOK:^@ENM.U&V\0>
M`-:5K.[D>Q:QU".UO;?HOA)X#\4_#?P7:>%O&7QJ^)GQ_P!<MKW4+J;XD?%O
M2O@WHWC2_@O+@S6^FW=C\"/A+\$_AXEEI,9%II\EEX"LM1DMU#:I?ZE=;KD@
M'XQ)^T%^UW??LE_"+PKX9^+GQ]^+'QQUS]OC]O+]G_Q!XP^#?@3]D&']KKQ]
M\$/V6?VL?VM_A3X<UWP38?%OX;^"OV%O"OB+0_#_`,+_`(06'Q2\7_$[P5X!
M\$7WA>?Q)!X2:U^,'BOP+IVK;7QZ_P""B_QD^#/_``2\\8?%SPU;6GB[]MG2
M_@7^U9XOT[P9XTT2TTC5?A]=_LMZ5XTU7XI^*?CGH7A;3'\(6OB#X):3HFB^
M'OB&OA".#X1>/_CMJWASPE\,_$(\`_$/PEXCK[LO?V$O!MIX#TGPK\.?C)\<
M_@WXP\-?';]I+]H#P?\`&CX?:C\*[[XE>%O$W[5WQO\`B5\=_C#X5M=-^)/P
MF^(7PD\0_#[5?$/Q2UWP[IOAOQS\+?%D^G>&M*\*WAU.X\=>'[3QJ?.OB[_P
M25_8;^/?P&\2_!'XT?!GPC\5=:\2>!OC!X0C_:+^)/@;X7?$+]ISPKK7QQO/
M%.N^.OB?X#^*WC?P!X@;P3\1AXS\8:OX\\-7OAW0[#POX3\41Z4_A_PI8:+I
M&G:-;@'$^,OBI^TH6^-?[26B?&ZXT3P!^SY\8_"WPXL_V<H/`?PYN_`7Q(\`
M:9#\)S\5-?\`'OC#4O"5_P#%RT^*FIS^*_&K?#/4?`7Q"\&?#WPS!:>%(O%_
M@'QS*=9N)OD3]H3]N+P_\5O@9\)?A)XCT[]HS4?BJ_\`P5>_8I\&7OBO5/V+
M_P!J7PI\$YM,^&O_``61^"]KHUM;_M&S_`70_P!F>XLK/PIX/TG2M+UJR^)T
MD/BC6K6VT6SU'6O%VJBTO_TIC_X)Z_!O2_$&G1^#O%7Q*^'7P2AU7X8^(M<_
M9/\``%UX`\.?LW^*?$_P9TKP'H7PPU>[\,P?#R7QQX3TOPMHOPP\`Z7)\.OA
M?\0_`/PC\4V7AFRB\;_#[Q-Y^H&\\I_;A^%^@?"W]DOX6>$/#]YK%YIFG_\`
M!2?_`()L^+X;C6;BRGOFU+XA?\%>_P!F/QKK4$LMEI^GV[6-KJOC#4[?2XTM
MDN(=.@L8KNYO;F*XN[H`^IM9^.WCE_B]XC\"^"?AIX8U_P`"?"^^\'Z;\9O&
MWB7XG7?@_P`5:)>>.=*L]=T9?AE\.[;X=>*;3XE16&D:EIMWKDVN>._AH))[
MB?1?!R^,_$=A>Z-#\6ZG_P`%44\!:1\*O%GQ>^!+^'_!G[0OA7PC\8_@GJ_P
MZ^*-I\4+R+]G;5O%WP9\.>.OB7\=-_@?P9X2^%'B+X6:%\;-#^(WB+P7X2\:
M_&+0]?\``7AGQUJG@CXA^);_`,)ZOI=O^CWB?X&?!CQMXZ\-?$[QA\*?AYXH
M^(O@Z.UB\+>./$'A#0M6\4Z#'I][-J6F+INN7MC-J%L-)U.YN=3T?9/_`,2C
M4;N[O]-^RW=W<32<YX?_`&7/V;/">JZ[KGAGX!_![0=8\3ZU+XB\1:EI/PY\
M)V-YK6MSQ^+8IM2U*>WTI'N[F0>/_'<CM,65KCQKXLNBOVGQ'K$UX`?!9_X*
M^?!*/Q'XPTF7X?\`Q!.BZ%9?'5?"GB:VCT^:W^(WBSX3_P#"'WGP_P#`/A;2
MY'M]3N/%7[27AKQ'J_C3X(01PW-CKGA7PK?ZAJ=[IEQ>V=F>3^"W_!6ZZ^)_
MC*`:_P#LV>)/#7P9UCXAVG@K0OBQH=_\8M82QT.+X8?$[XC>)?B3XH;QY^S7
M\)OA!KW@WPNWPYBTG7X_V<?CM^TCXD\&6WB&#6?BOH/PS72K_3Z_3#1?V<OV
M?O#6K:IKWA[X(?"?0];UK5/`.MZOJ^D_#[PK8:EJ6M?"O0="\*_#/5[V]M=*
MBN+C5/A_X8\+^&_#O@Z_DD:[\.:%X>T32=)EM+#2K&W@R/AG^RI^S1\&)=/E
M^$?P%^$WPT_LA-.CT>'P-X$\.^&+31HM(\.ZGX0TN+1K+1["TL])BL/"NM:O
MX=M8M.@MHX=%U*]TY%%K<21,`?G3\!?^"I?Q&^.%]<ZLO[-_PU\,?"RQ_:0^
M%_P*O?B,W[36N:[%!HWQ5_9L^!/[1/AGQBVEVG[-UIIT&K:XG[2OPE^'7A30
M=0\36'@K7_&EQXATF[^*^A:S<?"[0_BM^OGAW5GU_0-"UV32-8\/R:UH^F:M
M)H/B&V@LM?T1]2LH+QM(URSMKJ^MK36--:8V>IVUO>W<%O>PSQ175Q&BRMX[
M#^RQ^S/;-I;6O[/WP9M3HOC'1OB%I7V3X:^#[86'CKP[X1\'^`M`\7VRP:1&
ML?B+1/!7P\^'_A;2M7`^VV&A^!/!>G6LT5MX5T)+#U[PQX8\.^"?#7A[P;X0
MT/2O#'A+PEH>D^&/"_AK0K&VTO1/#WAW0;"WTK1-#T;3+..*TT[2M)TRTMK#
M3[&UBBMK2TMX;>"-(HU50#<HHHH`****`"BBB@`HHHH`****`/@'_@FI_P`F
MZ_$;_L_[_@K!_P"O3/VR*^_J^`?^":G_`";K\1O^S_O^"L'_`*],_;(K[^H`
M****`"BBB@`HHHH`****`"BBB@#\FOC;_P`IHO\`@G__`-F,?\%#?_5F_L05
MW/\`P3SO[*U^(/\`P4D\$W-K-IOC+PS_`,%"_B1KWB6SO5O8[S4-'^(OP@^"
M/C+X?>)HDOH(#+H^J>"K[2M(TN[LC<:=))X;O[2WN&FL;F*'[3UOX&_"SQ'\
M:?A_^T-K/A?[;\8?A;X%^(?PU\">+_[;\16_]A>"OBMJ?@?6?'VB_P!@6NKP
M>%]3_M[4OAQX+N?[1UG1-0U;2_[&\G1;_3H-1U6*^\G^,O[$'[-7QX\<-\3/
M'O@SQ18_$&[\.:9X+\0^,_A9\8?C3\"/$GCSP)HUWJM_IGP\^*.K?`WXA_#J
M[^*_PXM;O7=:G3X>?$J7Q5X*9]5U`2:$ZW<X<`_%#_@FUXKT75?^"F/Q0^(:
M:)>Z5X+_`&AU_P""FW_"@?$ETMXNB>,+/X4?MT?#K1/B1?>&+F.%M%N8?'VH
MVT/Q'TLP7?V[5_#UG+K7V=TCOG@^V?B#XP^%FL?\%-_VB/#GC;QCIOPW\&Z'
M_P`$[/@=\$/B5\4M1\6:!X,TZP\>_M/_`+1/Q7T3X/\`PVTWQ)K\JZ7#\3KN
M.TO;WP=HMW%<WUYJ/Q%\*6^C:=J=UX@%G+]U^.OV-/V9/B'\,/AK\'-:^$FA
M:)X!^"CZ5-\$K#X;7_B'X/:[\$;S0O#U[X3T;4O@MXW^$VL>"O'/PCU?2O#&
MI:AH-AK'PZ\1^&M4M-*O;FRAO$@FD1D\&_L9_LR>!OA9\0/@QI7PET36?`/Q
M;O+K5?B];?$#4O$?Q5\3_&#7KW3=,T>X\4?%SXA_$_6O%_Q$^*/B]M+T31+"
M/QAX]\5>(?$\%MHNCQ0:M$NE6'V<`_.O5_@%X4_X)H?$/_@G_P"$?V5/BU\;
M]-\#_$_XT^"?V1M;_9E^,'[07QQ_:,\"^+_A/8?"+XC:[#J_PI\,_&CX@^/)
M?@=XA^">F^!;#Q?]L^#\7@[P"_@;1-3\'^(_"LFGW/AJ?0OVQKY'^#W[#/[-
M7P-\=V?Q0\&^$_&NO_$;2-`U;PEX6\<_&?XY?'C]HWQ7X!\(:_+IDVN>#OAC
MKO[0GQ,^)^H_"WPAK$FBZ0=3\*_#NX\,:!?+IEC'<Z=)';0JGUQ0`4444`%%
M%%`!1110`4444`%%%%`'^`?1110!_KC?L0_#S4_A5_P2]_X)T?$WXL_\%D/V
MD/V7/A_XV_9$_8\T?PII?BK_`(=9>!_AMH&N^,/@)X,U'PO\*O!'B3XT?L'Z
MYXEUA[2S@N-*\):9XG\<^,?'FKZ9HYFU;7/$>JQ:CJMQ]PVWP?\`%%[X4T;Q
MY9_\%N/VL[OP/XCFAM_#WC.VM/\`@D7/X4UZXN)$BMX-&\11?\$Z7TC5)IY9
M8XH8K&\G>621$169P#XI^R/^R=HO[5/_``3,_P""&-SXB\:^,_!VB_LZ?`W]
MD#X_WMO\/O&7Q'^&OB[QBX_X)U>/_@;I_A;2_B9\)_'OP[\=>!K=-4^.%CXJ
MURYTO6;ZP\6^'O"^K?#;Q'H>H>&O&^KM;\%\-O\`@A[9?#7]E']G3]FZP^/V
MFZU-\&8-(7Q])XE^#L6N?"/XYZGX?T+2_"VB>(?&GPCN?B#'>V>I6WA;37\)
MZO%I'Q!M8O&'@R]B\+^+9M73PQX&U3PL`?3W@WX6ZW\1O#FC>,?A[_P7$_:I
M\=^$?$EOX8N_#WBKP;'_`,$A?%'AS7K7QMJM[H/@RYT;7-$_X)V7VF:I;^+M
M<TW4=&\,36-U/'K^JV%[IVE-=WEK/#'ZK_PQO^T5_P!)8/V_O_#<_P#!+/\`
M^EJ5XAX'_P""7UYIWC?P7\5OB%^T#X^\5?$3P-K_`,#]1T&R\.>,?CKX-^$L
M'AWX/?&?XE?$RU\'^(?@['\==4\!?%F2W\,>/;+P-X4^(/QOT;XD_$?P]<^&
M[?QF_B.]U^Z1[+];:`/@'_AC?]HK_I+!^W]_X;G_`()9_P#TM2C_`(8W_:*_
MZ2P?M_?^&Y_X)9__`$M2OOZB@#X!_P"&-_VBO^DL'[?W_AN?^"6?_P!+4H_X
M8W_:*_Z2P?M_?^&Y_P""6?\`]+4K[^KY#\;?MN_!KP!XK\;>#-=\%_M>7^K_
M``_2%]=O/!/_``3[_;U^)?A2_6>]T:P0>"?'GPY_9L\5>!_B6ZSZ[9231_#C
MQ%XJDM[*#6=3G6/3O#OB"ZTP`\]_X8W_`&BO^DL'[?W_`(;G_@EG_P#2U*/^
M&-_VBO\`I+!^W]_X;G_@EG_]+4K[?\)^)=.\:>%?#7C'1[;7[/2/%F@:-XET
MNT\6>$_%7@+Q5:Z=KNG6VJ6-MXE\"^.M&\.>-O!?B""UNHHM9\)^,?#VA>*O
M#FHK<Z/XAT;2]7L[NQ@WZ`/@'_AC?]HK_I+!^W]_X;G_`()9_P#TM2C_`(8W
M_:*_Z2P?M_?^&Y_X)9__`$M2OOZB@#X!_P"&-_VBO^DL'[?W_AN?^"6?_P!+
M4H_X8W_:*_Z2P?M_?^&Y_P""6?\`]+4K[^HH`^`?^&-_VBO^DL'[?W_AN?\`
M@EG_`/2U*^0?VVOV:?C/\/\`X8?!SQ=XL_X*$?M?_''P_I'[?W_!++^T/A=\
M4?!7[`VD^!/%'V__`(*:?LD:9:_V[J'P5_8>^#_Q-M_[$O;VV\1:9_PC7Q%\
M.^;K&D:?!K/]K^'Y=5T+4_V\KX!_X*5_\FZ_#G_L_P"_X)/_`/KTS]C>@#[^
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/@'_@FI_R;K\1O^S_O
M^"L'_KTS]LBOOZOYTOV?/VPOVFOV>_`_Q%\)>'?@9^RMXH\":U^VW_P6#\8>
M#/%7CW]J?]J;P?XRNO"?P_\`^"DW[5.K?$KQ-\0?!?P?_P""9_[27@[X6Z!X
M9US6#H.E:OKWQ<O;#Q3Y_AQ;.XL_%/B-/!NG^L>&_P#@J?\`M7>,/BVWP-\,
M?LE?LVZU\38?B-XI^%NHZ)8_'7_@I_)IF@^)/!]A\/-5UG5O%'B\_P#!"]?!
M?A3X:SZ/\6?ASK7ASXR^)/$.E?"#QEH?BW2]:\'^.==THW%W``?NK17Y/?%#
M]K;_`(*/?"3Q?^S_`.#/$_[%O[#LVH?M&_%S7?@UX+OM+_X*1_':32=$\2^'
MO@!\<?VCK_5/&-UJ'_!+739]-\-GP-\`/&>FPWNDVNN7Y\4:CX;LYM+@T>[U
M;7-&R/AY^WA^U9\7?!\GQ#^$_@?_`()#_$_P!"_B))O'/P\_X+%_$?QKX/B?
MPAIAUKQ8DGB;PW_P3`U+18W\+Z,K:MXB5KT'1=,!O]2%K:@RT`?KQ17Y.^,_
MVT/VR?AQ=^'K#XA_"W_@D[X#OO%OC!/AYX4LO&?_``5Y^*?A>[\3>/Y--@UF
M/P-X>MM<_P""75C-K7C"31[JVU5/#.FI<ZTVFW,%\MD;6:.5NC^*?[47[>WP
M+\#:S\4/C;\!?^"8'P=^&GAQM-C\0_$3XI_\%7_C-\/?`V@OK6JV6A:.FL^+
M?%O_``2QTC0-+;5M<U/3M&TU;[4(#?ZKJ%EIUJ);R[@AD`/T_HK\B?AY^W9^
MU?\`%WQ3XD\#?"CP)_P2)^)WC7P;K5AX;\7^#_AY_P`%B?B3XT\4^%?$6J:9
MXGUO3-`\2>'_``W_`,$P-2U;0]:U'1O!/C/5[#2]4M+6^O-+\)>)[^W@DM-!
MU66TED_;G_:UA^(Q^#LOP_\`^"1L7Q<71QXA;X62?\%AOB6GQ&&@-XJ'@0:X
M?!#?\$OQXF&CMXW(\&C4SIGV(^*B/#PG_M<BSH`_7&BORG^*/[8?[:WP.\/^
M(O%GQJ^$7_!*?X0>%O"$/AJY\6>)?BC_`,%<OBS\/_#_`(7M_&>J7NA^#Y_$
M6L^+/^"6^D:=HD/BS6M,U'2/#4NI7-M'KNJ:?>Z?I;75W:SQ1U_AM^V?^V7\
M9?$WQ!\%?"#X5_\`!)_XK>,OA+?6&E_%7PE\-O\`@KQ\5/'/B;X9ZIJLNJP:
M7IWQ!T'PO_P2ZU35?!E]J4VA:W#86GB.TTVYO)='U6.WCD?3[L0@'ZP45\`_
M\+&_X*F?]&;_`+`/_BRO]HK_`.E/T?\`"QO^"IG_`$9O^P#_`.+*_P!HK_Z4
M_0!]_45\`_\`"QO^"IG_`$9O^P#_`.+*_P!HK_Z4_1_PL;_@J9_T9O\`L`_^
M+*_VBO\`Z4_0!]_45\`_\+&_X*F?]&;_`+`/_BRO]HK_`.E/T?\`"QO^"IG_
M`$9O^P#_`.+*_P!HK_Z4_0!]_45\`_\`"QO^"IG_`$9O^P#_`.+*_P!HK_Z4
M_1_PL;_@J9_T9O\`L`_^+*_VBO\`Z4_0!]_45\`_\+&_X*F?]&;_`+`/_BRO
M]HK_`.E/T?\`"QO^"IG_`$9O^P#_`.+*_P!HK_Z4_0!]_45\`_\`"QO^"IG_
M`$9O^P#_`.+*_P!HK_Z4_1_PL;_@J9_T9O\`L`_^+*_VBO\`Z4_0!]_45^47
MPT_:P_X*1?%3QI^T)X%\/?L4?L0V>K?LU_%_1?@KXZN-9_X*0?'BWT[5?%6N
M_`+X'_M%VFH>$YK'_@EIJ-S?>'X_!/Q]\':7<W>L6>@ZBGBK3?$MC'I4VD66
MEZYK/AGCS_@J5^U9\-O%?Q0\#^)_V5/V7'\4?"'4?#&B^+-,\*_M$?\`!2_Q
M_P#VMKWB_4OASI&E>'?A?>^`O^"''B73OCAXDM-1^+GPVM_%'A[X*W?C_6O!
M!\7Z7+XTL=`@-Q+;@'[H45^3G@']L?\`;R^)C^%;;PC^R[^P9<ZIXRMOB+=:
M+X=US_@H#^UUX.\6I%\)/$^E^#?B0FO>#_&/_!'_`$#Q1X2N?"'BC7-%T35K
M/Q7I&BW:7NKZ8D,$RW]J\OLO_"QO^"IG_1F_[`/_`(LK_:*_^E/T`??U%?`/
M_"QO^"IG_1F_[`/_`(LK_:*_^E/T?\+&_P""IG_1F_[`/_BRO]HK_P"E/T`?
MXAM%%%`'^WE_P2?_`.46?_!-3_LP']C?_P!9U^'-??U?A'_P3+_90^/'B/\`
MX)N_\$^O$.C_`/!33]M[P%I&N_L0_LH:SI?@7PGX"_X)NWGA7P5IVJ?`?P%?
M6/A/PU>>.O\`@GUXT\;77A_PY;3Q:/HUSXQ\8^+/%4^G6=M+XA\3:]J[7>J7
M7V]_PQO^T5_TE@_;^_\`#<_\$L__`*6I0!]_45\`_P##&_[17_26#]O[_P`-
MS_P2S_\`I:E'_#&_[17_`$E@_;^_\-S_`,$L_P#Z6I0!]_45\`_\,;_M%?\`
M26#]O[_PW/\`P2S_`/I:E'_#&_[17_26#]O[_P`-S_P2S_\`I:E`'W]17P#_
M`,,;_M%?])8/V_O_``W/_!+/_P"EJ4?\,;_M%?\`26#]O[_PW/\`P2S_`/I:
ME`'W]17P#_PQO^T5_P!)8/V_O_#<_P#!+/\`^EJ4?\,;_M%?])8/V_O_``W/
M_!+/_P"EJ4`??U%?`/\`PQO^T5_TE@_;^_\`#<_\$L__`*6I1_PQO^T5_P!)
M8/V_O_#<_P#!+/\`^EJ4`??U%?`/_#&_[17_`$E@_;^_\-S_`,$L_P#Z6I1_
MPQO^T5_TE@_;^_\`#<_\$L__`*6I0!]_5\`_\%*_^3=?AS_V?]_P2?\`_7IG
M[&]'_#&_[17_`$E@_;^_\-S_`,$L_P#Z6I7R#^VU^S3\9_A_\,/@YXN\6?\`
M!0C]K_XX^'](_;^_X)9?VA\+OBCX*_8&TGP)XH^W_P#!33]DC3+7^W=0^"O[
M#WP?^)MO_8E[>VWB+3/^$:^(OAWS=8TC3X-9_M?P_+JNA:F`?MY1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`?BS^S5^RGX=_:>_9TUZU\5?$#Q]
MX3T?PU^W=_P68L3I/@H>#+1M4D\<?\%)/VU/"5W?2Z]K7A#6_%>DS6NC:EJF
MFSV?AO7M&TCQ)HVKZKH/B_3=?TB[%K%RW@[X,_L%^(O^"A_A_P"`DO[1]M\5
M/VUOV3Y/B/\`M167PH^)/P9^$WC;Q)X`\#?';X@_#3QG-<^&/B)XO^!]VF@:
MCX9N=,\(>'_#FL?#KQ]8_%WPC\/M=T;2+^_MM!M/"\VG_6/[`/B&+PC^R9\;
M/%<^EZ]KD/AC]M[_`(*]>(9M%\+:+J/B3Q/J\6B_\%._VT-2DTOPYX>TBWN]
M5U[7M02V-II&BZ9:W.H:IJ$UO8V5O-<SQ1M_,A\$OV4O^"R_P=^-7P._X*S^
M/?@1\!M5T3QM^UEX@_:3^-/PQ^'VC?M*ZS_P4JB^!'[::_#KX4>,O@Q\2_AG
M<_#ZX\%7>A?L[?"O0_AUK\/PD\)Z5;>)/!6K?"N2\^T7&N/XK>Z`/Z>_VX]-
M_MGXW_\`!+;1_.^S?VK^W5\5M-^T>7YWV?[=_P`$J/\`@IA:^=Y/F1>;Y7F[
M_+\V/?MV^8F=P\5G_P""6<OQ(\+?#_2/V@/BAX7\47_@K1OV=_AMK-C\.OAI
M-X/\'?$7X'?`OP=\7?`7B'X9_$G1?$_C'QY>^,[3XT>#_CM\3?"7CD:IJ8\/
M:?X5UFST[PYX9T_5[:_\0ZO[]^V1_P`G%?\`!)__`+/^^(W_`*ZS_P""E=??
MU`'Y*>%/^":7CGX4^'-1T7X2_M+ZC;ZOX\^'L7PC^*GCCXE^#=6\>^,-0\$:
M-\8_BM\4_">J^`[V#XA>']-\-^,K31_BO?\`PU\=7GB32O&NF_%/PEX1^&\?
MBFUC;P1!!JOW-X^^#_B[XG?L[>/_`()^,/&^CR:_XS\->-/!T'C?2O"M[9VM
MKH6IZCJMOX-NM2\/7?BC4)=0\0Z;X3?0K/Q??VFMZ9IOB/Q/:ZSKVBZ-X4TG
M4K'PQI'T+10!^)^A_P#!)/Q1H^L^//$%K^T=J]AXD/[7/Q__`&RO@CXA%S\<
MO%.E_"KXI_&/XH?M(?$7PZ;+X1^.?V@_$/P7\,Z;X2L/VBM=\$>.+;X(>!_@
MP?CKH:Z[??$J2]UGQ$]Y86_!_P#P1I^&OP[\.ZJ?#?Q$\4^)O'WACXBGXC?`
M37?BKXL^,'CKP9\+-8'QT^('Q>&J:A\+;CXLVG@/Q/X];PU\2?%?P=C^,`T/
M2OBMIGPP\0^(_!FD^+;/PCKVH^'9_P!I:*`/S.F_8$\9ZM\0_BC\9?$/[0.H
M7WQ%^.VEV_AWXL:-;>"[&#X7-X;\+ZCX(O/A?IW@/0;C5;OQKX;/P^M_!$T5
MK!JWQ`\2:'?ZM\1OBOXGAT/2M;\:7DZ]_P#L7?L<:[^R?XB_:4U+4?B9J/C[
M2_CK\?OC=\;]'T^?Q/\`'&;2O""?&?\`:%^-GQXN/#FE?#KQU\:?'_P8\"2:
M$?B['X:U35_@=\-OA*_Q+O=!/C7XBV6N^)+R"73_`+RHH`*^8/AI^TCK/Q0^
M+WQ`^'&D_LW_`!UT7P+\/_$'BOPE<?M%^(=4_9UC^#OB/Q7X.NK"QU;P_P"'
M-"T7]H#7/V@A=->W=U:V=_XB^!7A[0YGTC4)7U>&WETF?5/I^OSS\/\`_!./
M]G:^\0?'+X@^._A5X.T3XT_&;XG>./$.I_M#_`G6O&'P'_::N_A_K7BG1]>\
M.>$+W]I[X*WWPK_:!TRP@M/#VA:9KOAK1OB,OAW4-*TV'P[>MJ_A\R6<@!V>
MM_MT?#SPY\4/$7@S7/AM\8M-^%OA+Q)J'@#Q'^U/<Z/X$7]GO2OBII6D?VUJ
M/PSN)Q\0V^,AUFTA_P")9+XOB^#DGPE'BH'P2OQ&;QDK:".+TG_@HEX:U'1Y
MI-0_9I_:C\+>._$*^'KWX$_!_P`3Z#\%M/\`B/\`M.>'_%;W)T+Q)\(/L_QR
MO?`VA6365E>:SXET?X\^-_@KXP^'&@VYUKXG^&?!>G2VUQ-Y)XS_`&(/C?XS
MT;QE^R?=WWPQ'[%WBWXC7?Q>_P"%H:I\2_BKXI_:@M=3DUVV^(-G\-]3\'>)
M_!^J:)XJ6U^*]G;^*[OXZ>(OV@[WQ3KWA]'\+Z[\,M0UBYO?&]U8U/X4_P#!
M2:72KOXAZ;X=_8VMOV@_A]\*9_V=_@R;7XX_&/3_``+J_@KQGXH\!:Y\5_C9
MXJUR^_9<\37O@3X@ZQ;?"_P:/A_\&X/A[\8/"7@K68+N^U_XL>/M*EN-!O0#
MZS\-?M=^!O$7@+X=>+)_!?Q)\->,/B-\46^#%G\$/$>G^$(/B_H'Q*TG6[_2
M_'OA[6]/TOQKJW@F\M_AAI.B^)/&_C7Q)X0\=>*O"C^`_#>I>)?".N^*[:YT
M2/5_JVOPS^)?_!/?XY_&'X?>"_#OBKX"?L=V.N0^`?''P^T^\\2?M$_&KXM^
M)/V5O'OC+Q+XH\0:W^VC\`/C*_[+_P`*OB-X[_:7\<7GB6#7?'#&W_9V\6KX
MG\.:3J'A_P#:"L1>ZV=0_<6UADM[6VMY;B6\E@MX89;N<1K/=211JCW$RPI%
M")9V4RR"*..,.Q$:(N%`!/1110`4444`%%%%`'P#^QO_`,G%?\%8/^S_`+X<
M_P#KK/\`X)J5YU\9_P#@DG^RO\:?%W[0/C[7-$L8/&/[3GB+X:>(?C)JFJ_#
M?X*_$&S\<1_"'7OAAK_P]\->*M$^)GPT\7Z5XF\(:!<?#3[.OAS7;>^T_4;?
MQ/J)U=-0GT+P9-X;]%_8W_Y.*_X*P?\`9_WPY_\`76?_``34K[^H`^2/AQ^Q
MYX%^$7B+7_&'PU\3>*?!OB7Q38?`_1M:ET/3_`UOX8M_#_P;M]`TO4_#O@[X
M?2>#YO`GPWT+XN^&_#FF^'OB39_#_P`/>&Y&M[:QU7PA<>%-?TC1]6L/RR_;
MQ_;7A^"7[>7Q4^&GQ1_X*>V_[`OPH^''[`?P/_:#^&?@N[M/V/I+/XQ_%WQ+
M\;/VM?#7C>VO=*^/OP<\=_%OXF60\.?"KX:Z5=^`/@GXW\#Z\EM<2-I.HZ1K
MOB"#64_H$K\B?C#IG[1'PD_X*+?&/X_^$?V)?C-^U?\`"/XL?L$?L[?`BQNO
MA-X[_9$T&SM?B'\,OCG^V!XT\6>%?&^B_M(?M)_!#68]&O?#'QB\$R1ZQH7A
M_P`7Z5=Q:EJ-HZ276G75D0#]`?V7O'7Q-^*'[-GP`^)/QI\%V?PY^+_C[X,_
M#/QE\4/`6G7D=_I_@[Q_XE\&Z/K'BWPW87D5U?)-9Z1KEY?65J1?7K)!"D;W
METZ-/)[K7QI_P3_^`?C?]F7]E+X=_!SXA7'AR/Q!H&L?$_7;7PMX,WOX)^%?
MA/Q_\5_&_P`0/`7P-\$S-;6"W?@[X$^!_$_A[X/^&;ZWTW2+*^T;P59WFG:+
MHUA/:Z7:?9=`'^`?1110!_MY?\$G_P#E%G_P34_[,!_8W_\`6=?AS7._\%#_
M`(S:5\)8_P!G.S\7?MQK_P`$_OA]X^^*7BGP_P",/CBVM_LM^&%NO[+^$OCK
MQ/X=\&/XA_:Y^%OQ:^&.GC6M?TBRNC%:>';3Q/?C3/LFFZK;V[WT4_1?\$G_
M`/E%G_P34_[,!_8W_P#6=?AS7W]0!_/EJ?[:_P`1M1\'Q:_\6?V[O^&2_%FB
M^#K^\_9K\,CX*?"PQ_M_QZ5KGCK2O"'Q6M?`'Q+\#^+OB)\0K'XRZ1X?\+^(
M[+]G;]E_7_AI\7_",&NK<WNLII_BKPHEI^JG[0?Q)^,/AC]G#P5XT\')HG@'
MXO>)OB3^R#X8O--\1Z>/$>@Z%>?%W]HKX+?#_P`=^%]7MDDBN+FP;1?&/B'P
MY<:AIUQ;:M9),VJZ-=6NJ6UG<1_7-%`'\_7B3]MCXBZY\8/VH?#/Q\_;)UW_
M`()Q_L_>"/VBM2\$^!_C%XA\"_`3PW=:+JOAW]CG]@WQCJ?P.LOC!^T?\)O'
M7P*L].MOC/\`%#X^>(8=<\:^$_%7BKXV?;QIGP/\;6O@_P"'\UM%]4?L7>-?
MVCOB9\?]8\3?%+]H7XI:]X%N?V;_`(?>-_#GP:OOAG\$O`'PSU:3Q#\5/C7\
M+M`^,^F::?@K8?M'>$_^%M>`?@IX0^-MG\//&GQJUY/!/B#XM^+_``W>6DFC
M:9X4\/\`A']7:*`/Q<_:;_:]^*OPM_:N^+_P^\"?'*.^CTGX.>#=1N/@[_PK
M_P`(^)6^!'A.X\7?#2+XF?M2ZSX+?PWX6^.OC+2O!'P[\:^,OB'X;\8>%?&?
MQ5_9_P#B9>_"SQO^S[<^'/A=\:O`UWJ'CW"U/]K/Q_9_LW^.]"_89_:ZUS_@
MJ-\;_B%XFTOP)\`_B'X?\&_LI>+[CPGXDN-`UCQ+\2=;U7XA?#34/V2/V.?B
M-H?PK\'Z'=>(T\*7NN?#O5]#\67OA'X=^.O&.KZ[\4/`]BW[@44`?@3^T/\`
M\%.()?@O\=;+PI^U!\'?V;/V@?L/[*&H>%?A]\2/C)\`/AWXU^"]CXE^.7@K
MX/?M/W7B36/B!\-?CWHVB>'/A7XL/Q!^'_Q&^+7B#X)?&GP;\,=:\.ZWJB>&
M=9?1%TN?[,U[XT>,O#__``2W\0?'+_AI'PCJWC/2/V>-<\7R_M3>`OB5\$_C
M7X-@N[2TNWN/BEX=^*-A^SW\%_@)XWT[0K9)-4B\0S?LW^#?`3MI[-JO@1K"
MWO([K]*J*`/YD/CE^WK\3_`?A#P['\"_VU_VAOVPO@1:_'CP7I,G[9/[,?A'
M_@GCXT\8ZQ#KWP._:/\`%_Q!^%WC+QSXA^$_A;]CJ[^%'P$U[X;_``L^(WQF
M^+_@?P5X*U[P#\.O'EYH.O>)DUKP1XMU:3Z_U7]K3]L?Q=\1-9\%:%X=UCPS
M\'?$O[/FO_`+PS^U;X!T'X*^)/AO9_\`!0R3P/=ZI%XI\`:AXD^(/BSQOK'A
M?1?'\&I_"+PYHGC#]FG6/A+J_P`3=$L[*^\?Z_<:G%X)U#]L**`/YL]&_P""
ME/[0OQ+OU\2^!?B9<:?X2^/'P?\`%?[;7P$LQ\-_"=SI6C?LV?#'P_X^_9S\
M9^$M,UJY\&ZB+^WO/CM?_LX?M#V.M>-M<NO&-Y8_&1O"%B+3PCH][X8LOHWQ
M5^V=^UGX-\#?"2.^33->\5^,M:^(M_<^-?#W@"./P@WP0N?B]X6\$W/Q0\1Z
M5?R20P^,/V3?`&N^)_'WQ'\'^&O%-M#\4=%\":=XNTC3]''Q!D^&O@7]OZ*`
M/SL_8P^/%Y\0_B?\??A;I_Q;^+/[2O@GX:KX*U;0/VAO&*_L9ZYX$\1WOC>/
M6M<N_"W@GQK^R#XDTF*6/0=(GT".'P=\6_@7\,OB+H^CQ6'B:[U_X@Z-XRT7
M7!J_\%*_^3=?AS_V?]_P2?\`_7IG[&]?>EI8V5A$T-C9VME`\LD[Q6EO%;1/
M/,S/-,T<*(C2RN2\DC`O(Q+,2>3\%_\`!2O_`)-U^'/_`&?]_P`$G_\`UZ9^
MQO0!]_4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'XA_L3>-?V^=
M)^&'QCT_X*?LT_L@?$#X96_[?W_!4W_A&O%WQ1_;A^,_P?\`'>K^;_P4T_:W
MGUG^W?AUX3_X)[_''0/#WV#Q!+JNF:9_9_Q1\4?VOH]EI^NW7]B7NIW/AW2/
MK[_A8W_!4S_HS?\`8!_\65_M%?\`TI^OCKX&?`WQ7\9OV??!-_X.\&_##Q7K
M'PK_`."M?_!3CXB17OQ4U:[31O"$.F_\%3OVR;74_$^E^%5\%>,++Q;XB@T*
MYUC3]#BAO?`'B71-5O[+5_#WQ#T&.'5K35=_1_V`_C@_P7\2?`R+0/@+\,_&
M7Q)T?PS\/_VC?VV?"GB/Q%K/QZ_:F\/Z-<V#>+?B7\4?".A?#OX6FY^(?Q<\
M/^$-(\+>(Q??%?4]3^&UG\1O&>F_"GQAI&D^#O#]SXE`.G^,GA+_`(*F?%KX
MB_LG^/O^&8/V`?#_`/PR_P#'_P`1_'/^R?\`AXA^T5JO_"<?\)!^RS^TK^S3
M_P`(O]O_`.'6VF_\(S]D_P"&A_\`A-?[;^Q^(/M'_"'_`/".?V1#_P`)!_;V
MB>__`/"QO^"IG_1F_P"P#_XLK_:*_P#I3]?#_P"T+^P1^UA^T-\-O$/PI^*N
MG_!WX@V/B7XH?`OXI>,?&`UOX<:K'XUU?X5?!#2?A!X@B3X0_M)?LL?M,_!:
MU_X2GQ#HL'Q(MX/'7@;XCV&B"Y&FZ9!;>*=,T?QII_WIX<_9X\<:#\3/!/Q&
MM]#T:"[L/`?ACX9>*;B+XHZBOBN[\,>%_C%XC\7Z3!J7BJQ^%^EGQIX6TCPS
MKU]<:;\.+S2O#N@VMQK.I>%+"\T[3HVUN]`,O_A8W_!4S_HS?]@'_P`65_M%
M?_2GZ\@^.'[6'_!2+X!>"]%\=>,?V*/V(=2TG7?B_P#L]_!6TM_#7_!2#X\7
MNHQ^*OVE/C[\-/V=/`NH7,.J?\$M-&MD\/Z5XV^*GA[5/%EW'>3:C8^%;/6;
M[1]*U[5[>QT/4?N[]F[X6S?!3X)>`OA7-9^']-7P78:CI5GIGA6(6_AS3-+;
M7=4O-(TW1K9+'38K2PT_2KJSLX+."QMK>S6'[-;1^1%&S?.'_!2O_DW7X<_]
MG_?\$G__`%Z9^QO0`?\`"QO^"IG_`$9O^P#_`.+*_P!HK_Z4_1_PL;_@J9_T
M9O\`L`_^+*_VBO\`Z4_7A_Q>_P""?OQD^(/[2/BKXMZ%\<FT'X<ZO\4_AOJ]
MA\,GN==72)?A#XPTWX;Z9^V3\/M6TNUD_L2_NOBO<?!CX8>*?`>L7-E+J_@O
MQ+;>.#:ZS;Z%X]\0:+>?*/P8_P""47Q@^%_@^/2M1\._!3QIH,_Q'\5^./C/
M\!_$\WPFT+X6?M8:3XM\+:GX7UWP)\4=1^%'[(_@!M;\+76I:EH'Q-BU3XW^
M%OCU\6O&/C#X7>%/"?Q=^+GC+P/JH'A@`_1[_A8W_!4S_HS?]@'_`,65_M%?
M_2GZ/^%C?\%3/^C-_P!@'_Q97^T5_P#2GZ^!_%7_``2K^/GQ*\(ZOX<\<?$[
MP+IWPYU[0/@7H.N?LA>&/#'P?N?V4O%6@?#_`.+'Q9\8:AX9\6Z/XE_9MU7X
M@6EEX-\->-/#">#]+^&/C'X:>`M8U[1[FTU?P1!X6@L]'G_6S]FGX2W/P1\"
MI\-+;PMX;\&^#?"&F_#OPQX`T#P=XCFO/"-CX>\+_"/X?>&K^#PUX&C\(>%=
M%^%&BV_BO2?$=K9^#_#T_B#3]36!O'<^H:7J?B^^\,:$`>%_\+&_X*F?]&;_
M`+`/_BRO]HK_`.E/T?\`"QO^"IG_`$9O^P#_`.+*_P!HK_Z4_7W]10!\`_\`
M"QO^"IG_`$9O^P#_`.+*_P!HK_Z4_1_PL;_@J9_T9O\`L`_^+*_VBO\`Z4_7
MW]7C?QLT/]H/7O#FEVO[.7Q/^#?PJ\71:W%/K.N?&OX$^-OC_P"'+_PX+"_C
MFTK3/"W@7]HO]FK4M(UN34Y-,NXO$%WXQUNPAL+2^TY_#4UQJ-OJFE@'S+_P
ML;_@J9_T9O\`L`_^+*_VBO\`Z4_1_P`+&_X*F?\`1F_[`/\`XLK_`&BO_I3]
M?2OPRT+]HK2O%7Q$N_C)\4_@MX\\$ZGJWG?";P]\,O@'XY^$OBKP5H?]HZO+
M_9WQ$\8^*?VDOC5I'Q0U;^R)]`L?[9\->!?A#9_VCINKZI_8/V;7++1_#_M-
M`'P#_P`+&_X*F?\`1F_[`/\`XLK_`&BO_I3]'_"QO^"IG_1F_P"P#_XLK_:*
M_P#I3]??U%`'P#_PL;_@J9_T9O\`L`_^+*_VBO\`Z4_7D'[0G[6'_!2+]FOX
M!_'#]HOQU^Q1^Q#JO@CX!?"#XE_&KQCI?A/_`(*0?'B^\5:EX5^%?@O6O'7B
M'3_#5CK'_!+30M(O?$-YI.A7=OHUIJFN:-IUQJ,EM#?:KI]L\MY#^KM?`/\`
MP5@_Y19_\%*_^S`?VR/_`%G7XC4`>3Z?^V!^VSJVM^.?#6E?!_\`X)4:EXC^
M&-QK5G\2M`T__@KA\6KW6_AY=^'-'T?Q#XBM?'.E6W_!+>2_\)7&@Z!XAT#7
M-:@U^#3Y=+T?7-'U.^6"RU.RGG\*\1_\%8_'_@^+49_%OBK_`((9^%X='\8^
M(/AYJTOB+_@N9K6B1:7X_P#"BVK^*?`NHR:G_P`$U[5++QCX92_L6\0>&;DQ
M:UHRWEJVHV5L+B$OZ7\7/^"54GQQ\8_%S5O&OQV\4>%O`_C;2?CHG@CX?_`K
M6OC9^S];^$O&'QJDN[K6?&NO>)OA+\=O"_B;Q=;^(;V^CU/XK_"VXU&R^"_Q
M1\7:5-\2M5^'MAX_\<>.];UGS?3O^"1GCRP^-7PC^*P_:0\0&R^%>H_M*)'H
M$/Q3_;EL1J^B_M#_`!0_9[^(LMI'%IO[:-CX>T?POX7C^`T6DW?[/NF^'HOV
M6/'-QXC35O%/P6N;GP]IB$`9^SM\0/VYO#'B[XR_%[P=\//^"67Q+T'_`(*$
M?'O1_CQ\')?#7_!4WXOW&D>(8O"/['O[/?P/OO#?PT\0Z7_P3+URS^,,8\-_
MLP:O\5;O7O"T-HNGZ'K>HV,VDO8>$KGQ-JWJGB7]N[]J[P9K'Q*\/>,/`W_!
M(CPIK_P8\,67C;XPZ'XE_P""Q7Q(T+6/A1X,U-UBTWQ=\2M,U3_@F!:WO@7P
MQJ$DB1V6O^*(-*TJ[=U2"[D9@#]8S_LHS7&F?\$^[!O'44;?L-^/=-\;W$B^
M&WD7XF?8/V,?VA?V26TR%3KL9\(>;-\=D\>B]<^)=L?A=O#/V0MK(U[2OEGX
MJ?\`!,G7?B]9Z+\//$?QPMM%^"_@?]H+XC_M%^!;;P#X3\9_#;XXOXI^,'C3
MQ+XG\<^'_&OQK\`?%OPU=ZIH5G;_`!)^)H\,:KX2\-^"/&L'BI?@W\0]0\47
M'CSX/#Q%XU`.C\-?M7?MU>,Y_`%KX/\`@?\`\$MO%=U\5_`-W\5_A;;>&O\`
M@K+\8=<G^)7PML#X7%]\2?`$.E_\$L[J3QCX!LCXW\%B[\8^'5U'P[;'Q?X7
M$VHH=?TK[7Z7_P`+&_X*F?\`1F_[`/\`XLK_`&BO_I3]?0EG\"K#1O'7P)\2
MZ+XC\0/HGP,^&/Q!^&>G:=XP\0>+OB/XN\167C%/AC;V&J^(_B9X]\3^(/&W
MB36]-MOAV6UGQ%XQU3Q3XH\6ZAJLFJ:WKDVI"[N[WWJ@#X!_X6-_P5,_Z,W_
M`&`?_%E?[17_`-*?H_X6-_P5,_Z,W_8!_P#%E?[17_TI^OOZB@#_``#Z***`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
EHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g30330image15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image15.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`%4`
MGP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/Z%/^"9?_!,O_@F[X]_X)N_\$^O'7CK_@GU^Q#XT\;>-/V(?V4/
M%GC'QCXL_90^`_B/Q5XL\5>(_@/X"UCQ#XE\2^(=8\!7FKZ[X@UW5[R[U36=
M9U2\NM1U34;JYOKZYGN9Y96^WO\`AT__`,$L_P#I&I^P#_XAO^SK_P#.YH_X
M)/\`_*+/_@FI_P!F`_L;_P#K.OPYK[^H`^`?^'3_`/P2S_Z1J?L`_P#B&_[.
MO_SN:^!_VCO@E_P2,_9S_:`^%OP#U;_@DA^Q'XPU;XH>$KKQ;9ZCX;_9/_9@
M_M'3[*UUR?0;F9/"MU\-TU/5]*T:2./6/%FL6%QY'ACPV+S7+Z%[:R=9/WVK
MSK5OA/X#USQCJ?C[5-$>Z\4ZQ\.KSX3ZCJ']IZM`EQX#U#5)-:N]$^Q6]]#9
M0O-J,TD_]IP6\6K1AO*BODA"H`#^=/\`9MA_X)5_M<^#M#U;]GW_`((=_LA?
M$#QAJ2^*-4U+PY:?L^_L.Z?X6TOPMX3L/`3ZAK-G\2=5\.V6@^(;\^*?'K_"
MZ70-(M)KK1?BI\/_`(J>$O%-QH$/@N75[_DM0^(?_!%I-0^*\.C_`/!'/]CV
M_P!+^%7PKT3XEZQJ.I?LM?LBZ//IDNI>'/AIXAU'P_XXTY/`^IR>!X=$D^(Q
M\,S^+)KC6?"]]XM\*^(-*L+^:V6SU&Y_::Z_X)D_L:OX:T'PMH_P]\:>"+#P
MQ/')H&H?#+X[?'OX6^)]*L7\+>!O!^L^'K3QC\._B9X9\51^$?&.D_#?P==?
M$+P>-8_X1CXA^)=,F\9>-M)UWQ=JNKZW?>O:5^QS^S=H'@GQ[\-_#_PQTW0/
M`OQ+3X?1>+_"^B:IX@TS2+RV^%GA;P=X*\!V>G6=IJT47A^RT'PSX"\*Z8EG
MX?73+>_736N=4CO;R^O[BZ`/P)7Q/_P1]O-.^&=YI?\`P1D_8PED^*/C/PGX
M/T)=3_9B_9=L+''B?X>>//B-%XFAU*S^$VKQZIX5O-&\!7=QX2UK2X;FU\8:
M1K?A[Q!:-8Z;J):+TB'0_P#@C_HWPV^"'Q`^)/\`P2!_8A\!W7QJ^/7C?X/P
M>&$_9F_9.\3W_@OP=\,_B--\(_B+\=?%%QI?PZA$?PS\%_$,Z3HOB&[LK6XN
M-*L_$>A:[J9LM)N;FXM/U/O?^"9?['UQ:>%+32O!GQ$\$?\`""^--,\=>#;S
MX7_M!?M`_"C5_#&J:-HOBOPSI6CZ+K?PV^)WA75[+P/8>%?&FO\`A.U^'L5\
M/`\7A6:R\-KH`T;2=+LK3K=>_P"">O[&7BS23H?C+X`>"?'.EQ:!\1/#>EVO
MCQ-3\<#PUI_Q8\=>)_B5\0;GP?)XLU#6)?"&N^)/&?B[5]7NO$_AJ32_$ENL
M6BZ;8ZK:Z7X=T"RTX`_&3Q==_P#!&GP+X\_:;\+^(?\`@CW^Q_>>&OV3/$%G
M;?&3QGX,_9!_9G\;GPGX.G\5:/X0G\::[X4T/X82>(]'CCO-?L]>L=%N+:2Z
MU;P5H?CSQ597+67@G4XI??/VBO@/_P`$E/V7/V:_AO\`M`?%K_@D+^QEIFM_
M$"Z\$6UQ\&-/_9)_94O_`(@>&#K>BS^-/B(+TKX&CTW6;GX,_#?1?&OCCQG8
M^'9=3NM2MO!FI:/X5CUK5K_1X+_]*KC]@O\`98O'^)TMU\.+N:X^-'@[7_`7
MQ6NSXY^(,5]X]\+^(]5L=;N[#Q)?0>*8KO4)]/U6TN+WPYJ4DW]I^%I=>\6#
MP]=Z:GB[Q(FJ>I?%C]FWX%?'?6_".N?&CX8^%?BH_@73_%.G^&-$\?:<GBKP
M=8'Q@_AY]9U27P/K1O/!^H^(43PSIUMHWB74M$N]?\.V5QK5EH&HZ;:^(=<B
MU``_#[QKH'_!%+P=\>O'/[/;?\$K/V)-1\7^$_$/PLT[0M43]D/]F:V\-?$C
M0/B/\.]"^(>J>)/`6K_\*XN+?61\.K/Q=X(L_&6D9BO+1/'/A+5(I&T_6(I$
MV/AC\.O^"/7B3X1>._BM\6/^"17[&OP87P+^S;X!_:YD\.7/[(O[+/CZ\\2_
M`7XG:-XDU+P;XA\,7_A3P$UM=^);O4?"'B#PWJ?@S4(],U;2]:BTLNT^EZU8
MZDWZ@VO_``3M_8[MK;PA;M\'K?4)?`/BCP/XS\':KKGB_P`?>(/$/A[Q'\.O
M@S;?L^>%-0TSQ+KOBG4=?M?LOP?L[?P7J-O%J2VVOV<8OM>BU+5L7XUO@=^P
M9^RY^SW\/?&?PN\!^`-8UKP=\0_!NF_#?QK:_%[XE?%#X^ZKXB^&>B:5K.AZ
M%\,K[Q)\</&7Q!\1CX;:!H_B+Q!IV@>`;?58?"6BVFMZM%IFCVHU"Z\T`_,B
MX_9B_85TFY\*^$O$O_!`']E7P]\5OB1J%K!\,?`]Q\"/V`+_`$OQ#I\7AO7_
M`!5XOOM?\9:9;7=GX3G^&NFZ%!;>-;*73-62;5O%'A*Q\#7GC>._U6ZT/P7X
M@ZW_`,$7/A5<7ND_$+_@CS^R7X3\2:1\//BYK^NZ'J?[(/[*-S'HGQ/^#GB>
M[T+6?@S?^)="\%:UX1'B#Q;I&EZOXP^'6NQ:[)H_BW0M/-M$+/7[B+1Z_8I_
M^"<7[*<O@W5?!4^@?%JYM;_Q-8^+M,\57O[3?[3-_P#%+P)K.DV?B32]&'PI
M^,-[\7;CXI_"/2M%T7QAXH\/Z3H/PT\8>%M#L/#NNZEH,&GKI-R]H;>N?\$X
M_P!B_P`3_#N?X4^)?@AH_B'P)=^%H?"=[H^N^(/&6KW5_!!\2X_C(GB34=?U
M#Q%<>(]0^(;_`!4B7Q]<?$V]U:?X@W?B<OJEUXEFN)96<`_$6Q\5_P#!('5=
M3^)^EZ7_`,$7_P!C"ZN?`'CC]J#P%I<;_LS_`+*]M)XGU?\`99^/FG_L]>*I
M9O-^%/V?0K;Q1XKOUU7PP[76J;=#02:S_9EZS6<?831?\$CK/XT:1^SYJW_!
M&3]B[0OBQINL?$/PY\6_#FI_LT?LG7,'PSU[P!I?P?\`%*V%MK/AWX:^(-*\
M8KXN^'_QV^&?Q`\,36EUI#+X?\10VOB.'P_K\%WHUO\`LMXA_P""?/[*'B?P
M==^!-1^'FM6^@76I?M':PK:%\3_BKX:URPUC]K+XM0_'/X[:MHWBCP]XUTSQ
M)HNI^+/BC;P>*-+O]*U6SN_`\T,5CX#F\-:;&EFN#IW_``39_9-TC7/AQXFT
MKP]\6M-\2?#.W\6VMEXALOVG/VF;?7O'L/CN3PO+XQ3XYZS'\7!J?[0@\12^
M"_"[:F/CA=>/Q.NB6$.%@MXXE`/Q%^&'CW_@D#\<K[P+IOPB_P""*'[(&M:E
MXE\$?LP>)_%ND^+OV9/V3O`^L?#;7OVGO$_[07A30_!?B#3KGX::K)>:CX5O
M?V=?$VJ:GJNFO+HWB#PQXE\%>)_"5UK.BZ]!=CVKX):?_P`$4?C=XM_9/\):
M5_P2B_8LT"X_:N_92\#_`+3NBZEK'[)/[*ATWP+??$[P3??$CX<_!?Q-)%X(
M$U]\1O%O@7PK\3/$MJF@PZAIMAI_P_N9-4FL_P#A)_"?]K_K?X0_X)[?L@^`
M?%K^.O!OP?LO#WBJ?0/V=?#5_J^G^)O&B3:MI?[*&A^,/#/P&;6HW\126^L:
MIX)\.^.O$.B2:]J45UKGB73&TJS\5ZCK</A_0ET[G_`?_!,K]ASX::/X&TKP
M=\`]`TZ\^&=Q\(9?A_XQO==\8:[\3?!UI\#/"'@?P#\-]!\.?%37_$.I_$;2
M/"6E^#?A[X>\.ZMX.L/$\'A7Q7ILWB6+Q5H^LMXR\6OK0!\^_LO_`+"O_!)G
M]J+]FWX!?M*>&_\`@ES^PKX9\/?'_P"#?PV^,VA>'-<_8]_9KGUK0M(^)?@_
M2/&.FZ1JT]A\/);&74M.L]8AM+V2SEDM7N8I&@D>(JQ_+?\`X..O^">_[`WP
M._X(R?MD?%'X*_L/_L@?!_XF^%_^&>?^$:^(OPN_9I^#'P_\=^'?[;_:J^!W
MAW6?["\7>$_!6D>(-(_M?P_J^JZ%J?\`9^H6_P!OT?4]0TRZ\VRO;F"7^D/]
MFO\`9N^%/[)/P=\(_`3X(V/B[2/A;X"LDTKP9H'C'XE_$CXK7OAK0K:&&UTW
MPUI'B7XJ>*_&7BBS\+:%8VUMIGAKPS%K*Z#X:TFVM])T'3].TZ"&U3\>O^#H
MO_E!5^W+_P!VS?\`K8?[/M`'W]_P2?\`^46?_!-3_LP']C?_`-9U^'-?+'_!
M0?XI?M9_!+XM)XN^`?[0'BV6.]UO]@70_#7[-_B^P^`F@?`O7M:^-_\`P46_
M9X_9M\::3XA^)9_9?^)OQ_\`"&D^//A_XR\1>'M8\5:7XC\:WO@9_$NH>+O!
M_@V\U?1?#^E6_P!3_P#!)_\`Y19_\$U/^S`?V-__`%G7X<UPW[27[1O[3/PH
M^)'QR\9^#_%'[/4/[/G[,7PT^%7Q#\?_``O\:?"?XAZC\:/BS_PF5YX\?7O#
MWPT^-6C?'K0O!W@_Q??V/AG3-%^&'A/5/V>_B)/XQ\>7UCX8FU>P'B2TO-$`
M/AW2/VO/VNM9_;.^#'PO^,?[2'[.W[.,MU\5];T3Q)^SS!^UK\$/#-G\4XK?
MXR:IX8MO`7P7N/C)_P`$X?$7QC_:OU&U\,Z?I-E=^'?`FO\`['/BW3M0\065
MC<>,]7O/$6D^(=`W/CE^VY^USX'^$W_!4/Q9X2\1/J[?`/\`9I_:+U?X/7N@
M_#G0?$/C3X:_&*P^,W_!0[P%\$?%=GH=IX=U2P\<^'+.;X$?"3P7K.A^)?"W
MB6WCNX=*\8>(G/A__A8U_>U_!_\`P5E^+6H_"K]J;QA:0>%?C7XQ\$?$V_\`
M@)\'/"_PO_8V_:]\+S^%_P!HB_\`%WBG3=,^$OB;PY%XC^,7CW]KJV^'OPLT
MN']HOXM>./V6/#.CI:_"'POXMO-#\)_;K_02GIGBS_@K1+;7WA*^T+3_``#X
M5T#_`(0[]G;]JGXOZ+\6+37O"WC?X-_L1^.=9UKX6?M">*?&6D77B/2]3T#X
ME_`3XV>'M>T+Q._B3PYHND:%:>']?\-:KX:N_$MC:W&I`'DVB_&_]JCPII46
MO_ME_M[#]D#]GKXO>-/B_P"(_`_[4)\7_LE:HWA2V\(>,;+1?AM\$TUOXM_\
M$_?AE\"_V?1XQT;4]>U631OC)??M8^./&)\$1:)X&^-%AK*ZU-J?SI\3/^"C
M?[6WA'QK/<1_%GXS6VDZ%^R=KOQ.\'>,;SX2_LQ^!?V1_BAI/@[Q;^U^\?Q,
M\>R?$+PG-^TM9?M!?''X#_!OP-\9_@?\&_A%K$O@[5&@US4[[P-+X'T;Q:+3
M[U^$O_!2;XZ^(?#VI^*_BI\(O`?@CP]IOP)E^('BNZ&HZC::Q\'_`(D:O\-?
MA5XM\'>%_'6BMXBUS2?$O@V?Q=XWU[X?^+O%/A?Q?97_`(<U^+P1<6^C:MX/
MUSQCXX^'_N/@;]MOQQK5K\%/B)XKM/`VD_##XQ?&Z]_9SL=!\._#WX\>//%.
MG>/-)\7ZQ\,I_$?B?XC?#+PY\1/AU\+=-\0_$'16B\,^'/BS8^$/#XT'5]'C
MUKXQZ?XKFE\-H`?'WB7]OC]IOP-K7@&WL[J]^+'B_P""GAWQE^R9\7/A!H7A
MKX;:/<?M*_\`!0WQ+H&L3_!G3+_4I&BNO@Y9:[9^`?!7Q3TZTTS7/#'@K2_A
M1^U0OC'X@2V>B?#F-]$\L_:"_:C_`&XM!_8X\2_%B]^.GQR_9M_:4_9G_9+_
M`&]O^%R?"B_^'O[%6KV/BWXT?LW?LZ:Q\5O@S\6OB!IEIX`_:+T+1]1^(?AW
M6?AS\6]6\'?!CXWR_#33SKZ^#+=[^VTK5OMOZ#>'?VROC#K?[<.M?`Q[CX$1
M?!;PS\2[WX0ZPEK:>+=5^+<'C/5?A=JWQ/\`"5OXDU+0_&&L:;\,I]2TKP]>
MS^"8_'/PVM_!OQILV\;V&E?$OX;>-OAEX5\&?'KQ[1/VW?VU?"?[4'[0GPO\
M1_"KPK^U9X*^'G[4.N_`7P-\/OV6/A;X4^$'QJM?#=K^R+^SK^UI9>-_%_C3
M]J;]O#P]\(O$4>E6G[2FA?#/7+71%\*ZG?W_`(*N/&VC:"+/QM)X4^'@!X'\
M8OVW/BYX/\,_%+Q;X!_;>A\1_M1Z5X4^/]YXT_8#N?A7\'+V']G'1O!?PZ^*
MNNZ/XXN=$L/`=I\>_"*?#>\\->']=N/BE\;/B-XQ^"?QT&G/H7P_\.V!^(OA
M"2R^R+W]IO\`:6M?B]^WEX5.FSQ7'[._[%/[*GC/POH$'PSU;Q%X1L?C=XU^
M(W[>%C\4?B/X-M=)L[3QU\7M`U?X;?#;X%>-K?X6Z'XTUK4X+;2[7X>Z1+X>
M^)6M^+GN_$_^";G[=?[;W[5OA6Q^.GQO\#_"KPK^SKJ_[+O@GXIZ=\0_#GPQ
M\-_#WX4M\3=;^#OP?^(FO0-\9/%/[??Q)^,]GX0L]1\6>.9#IOC#]A+P-IVA
M^&]+@EO_`(N:G>:##)X_],^&O[57[7WQDCT7X6:-XV_9'^$OQR\-Z#XP\8?%
M37_B7\+?B7KVA3VGA_5=$\CP3X5^#NB_M%^')+._TW0-?TW6O%WQ1T#]H[XO
M_#ZS\(^(OA;\2_#%MXIT#XLZ;HWAH`\BB_:LTJW\$ZZW@?\`X*W?\+@^$-U\
M1?!NB_';]KH_#3]F+4U_8KL]7\'?$K6-6TH?%7P'\(=$_9>\#2ZKXJ\-?#_P
MHOA?]I/X9_$/QE\"X_%TVN_%[7==M/&OP^M;!_PT_;%_:!\KXLZSX5^..G_M
M2_LX?#+X7_%B\\&_M`6OPX\*-X[^,>AVNG^#)O!7[17A/5?A1X=T/X2_$#2/
MAO\`$+5?'/PK\>?\(%\--%^&GQ+\,^%Y?BYX';0?^$0N_!GQ.[&3]OG]J7XD
M_LL^-_B;\#/AW\.]:^,EM^T?\&/@EX!\/^%_#-A\8O#?B32/&WP2^!/Q)\5>
M)?"UKX\_::_8Y\+?$/3=2U7X@^,-5^&_B;5OCG\&='U+X<'PCJ]Q9:GK<<VF
M^(NZ^,_[57[8'PX\0?L6^!M+\,Z5_P`+,^+7PLO?%OQB^'$_[&?QL^)^JZ]X
MYT7Q!\%_#^L^#8O''[/7[2GQ6^"_[%^E6;^/O%%W?_$'XQ?%+]H;X76%SIUC
MI6F?$'Q3;Z==:[K0!\WZ+\<_VY?`/[/_`,1-%^%_Q6^.O[<'[6'Q"^*VA>&?
M@UX>\9^!/V)],G^'G@+P3\,_AC\2OBIXYDTCPUH/[#?P[U3PZTWQ$L_!.L77
MCKXEG4+#6/%7PY/A.VNM1CU72?%%+X4?\%#/VC_B3\8_V]?%&D:PE[\`_@Q!
M$NC_``UN_A]IT_Q4^"=WK/[$'[$?Q.26QU#0=*-SXGNOA3\=/B?\6;?XN>#/
M'6C>(-2>R\2:GJFD>*M&TSX1:;\-_'&'^PI_P4[_`&M?VW/AE\,[CPUXC_9@
MT/Q+\;=(\#WGASXX>(OV:OVB?`7P8^'OQ.D^'FN^-/C9^S!H'PY\=?'_`$W7
MOVNO'OPDGA\&/H?QJ^$_QH^&GPB^+?ACQ1XK\0>#K2-_A3K^GZSW_BG_`(*)
M?M=6GC70/!G@W2O@_P"/-9\%ZI>:!\3(OAG^S'^TO\8/AQ\4H/#_`,:==^'W
MQ#^(7AS]HGP=\3;/X6_LC>'?AAX`T#6?&^L>&/V@(?B#=>,OB%X2\<?`OP%X
MOUKQ-H"Z_=@'P%XK_P""A'QK@_:0^%7A?XM?\%;OA7^S!\)/'O[3_B3X8?%.
M#1_VB_\`@G=#\6?@AX#T3]EK]I7XE>$[[Q;\!_CC_P`$Y[Z?X%:'X[^*7PR^
M&6DZ?\2/B9^TM\:(?&,/BW2-)\+>$_"=Y\2-#MO"/Z?^-_VJ/VCU_9>^!/B[
MP!\5=%/C/QMXY^.W@?0OC!KWPGL;CPY\5_#/@2;XAZ)\)?C'K'PUN&\+3?V'
MXZL?#OAGXA7^G>!]>\#Z3XQT_4);WP+KVA^$?$&@W-K\[>#?^"C?[?>D^.OV
M8/AA\>-'^&_PY^*_[1=WJNL^`?A)JG[#GCB[\0_&KPW!;_#2[.F^#O'/[./_
M``4J_;*^%?P*TWP]HFK?$GQ???%;X_>+=/?7M+\,7-A<_!GP/:>&9?%/C'Z5
M_9Y_:V_;G\1:9\,H_BC8_LY_$FX^,W[9?[87[(VB>,/A3\+?&_P:T#X7ZA^R
M#\??C7\/[_Q9XW\(>//VF/C'KWC;3?BE\(OV7?CKX[T<>#M?TJ]\$_$F]^%_
MPSU32_$GA?5?$WQ7T,`9^U9^TE^T3#^R#_P50\>^#?B'XN_9\^+O[(W[/7B#
MXG>"+CPQX5^&WB8>$?B3\+?@'XA^+&KZ+I\WQC^$?BC0OB+\+/'WB/PY;1KX
MAU7P=;ZWK/P\UW[5X9NOAYXFFC?0/G#XW?M9?\%`?@?XC^!G@@^-_"NL?".\
M_;X\<?LW/^T/K?B?P#X@_:(^,FD^$?V3_P!H;X@Q>#?B;\!M!_9!^&?P2^'.
MDS>*OAW#XTN?BE\*_B3)XAO=9\(:#X9M_ASHWA/QSXC@\,?=GQ]_:@_:'\&:
MS^TE\0?AWXF_9IT/X/\`['-UH%O\2/A1\2O"OCC6_C1\;?[3^'W@_P"(\D7@
MCXB:+\6/!GAOX'W_`(D@\7KX#^$=EXB^#GQQ_P"%G>/=)DM(I_#MEJ=NUKZ9
M^PM\9/VG_C;HGQ8\5_M$>"M,\(^'XOB/KNF_!*YT?X;^$?`FG>(_A]IGB#Q)
MI%OJMOJN@_MC_M0^(/'&^'3--:;Q!XV^'_[+VMM/-+L^$D<,['3`#F/^";'Q
MV\4_'3X5?$B^\8?':P_:*UCP7\6]2\*S?$;1O#7@CP_H!FG\(^#_`!-J7AC1
MX_`^G^&Y-.A\*:UX@U/0[WX=?$WP-X0^.OP3U*SO/@Y\8IOB1XL\$R_&CXE_
M#/\`P=%_\H*OVY?^[9O_`%L/]GVOW\K\`_\`@Z+_`.4%7[<O_=LW_K8?[/M`
M'W]_P2?_`.46?_!-3_LP']C?_P!9U^'-<K\5-<_8/O/VPO'.H_%;]EKX>^*_
MVG/V8OV<?"_[1&E?M$>*/@3\)?%/C*Q\!P>(_&^FV/A+X4_%+5!>_$NS\:^#
M]6LY+YO#D4?AW3+=_B/X=?PUJ^IZCK.OVVD]5_P2?_Y19_\`!-3_`+,!_8W_
M`/6=?AS7!?'30_V3/$W[6_@WP#X\\<?'OP[\;=5\9?`?XIK'X5^&?Q.E^#^M
MV7A(^/\`3/AS\(?'_P`<+?X,Z_\`!GP_X:^)&NZ/KNKZM\)]=^*OAGQOX[UC
MPSHL5G%_8U\-+UT`Z3X"_M0?\$YOB#9_#;XF^$]>_9G^$GQ<\<_LU_#S]IQO
MAMXVU3X%^`OVFOAG\$/%7@.]^(6D:W\3/!VF^(+WQ-X,TKPAX=^+/B<>(-2-
M_=^$?#]SXN\8"UU^XL=?U"]U+RVS_;2_X(]?$CP_\:/&'C+XD?L*Z3\*9/'7
MCC]E#5?C%\6/&'[+UA\&_P!I:W\:?#SX6_M(_&#PI\-_B#JOBJ^\-_&3X=7^
MJ_'"UL/BWH5S=%+KXQZ#\0[7Q1X<NKG2X]=U;XB\0?L7_P#!)7X9^)_^&@=/
M\>>//%%QJ'Q!\0?LL:-=?!C]DGX1_M'_`!,\%_M!?`3P1>>"->U'2/B=\(OV
M&?BG^V#X+U[X0^&O@UJ,7B.#4?BM:?L[:?IWA_5M)\9>#K_PIXFU?1->Z'PU
M^S5^Q_\`'SPM^V3I^C?M]?M^:9J\5M\49OVTOVF?&_P.^%7P>TWQ]\,?BG\+
MOAOI'B+PY;_$#XN_\$]/"/[+>M?#0?#/X3^"?'7AGQS^S7X;L?$,_A+5M.^(
M*?$;5_!OC/P[J5Z`?H/\%_VP?^">/Q3MM3ET3Q%^SO\`#RX^)OQH^./[*_A7
M1_'7B7]GWPUX@_:0\0?!GQI=_"'QY9?#_P`/:5XRU?6?B'X1UW5O"YM/#ND:
MG96VO^)O"-OX>\0MX2B\*:YX5U#5.OT;6OV!-1\*C]N#X-^'OV=OC+INFW6G
M:3I/QQ_9_M?A-\1)+O4+6]LOA2H\/>//"U_)HEQJ_ARTOAX.OKRVU^/5M(\.
M6]YX8$RV4/\`9#_FUHWAW_@GAH6A^,/$WA/X[?MS^$]+3QSK9^,WPKM?V6?C
M$WQ+_:+\,_M%?M:?'O\`:D\'^&++X-^*OV*=5_:&\7_!FU^-?Q]^+EE\//BM
M^R9H/ABYNO#2#2?%7Q?\52^%9-5M?M[P+X$_9G^"?[#GP:^&-[\>-?M/V0['
MX>_LA?LZ?`[4O$&A:7X<\96[Z!J_@[X=>!+SQA>CP38:K=?$KXD>,W\/1?%&
M76O`_@_1/!2Z=J=YJGA/P#'I'C;7V`.FE_:%_P""3DVMZ]^U--\<?^"=\OB3
MX*^)[SP-XG_:-E^)?[-DFM_"7QG\1K8Z/J'@_7OB\^M&_P#`?B?QW:>%CI=Y
MX?U#Q#I6J^*+;PX;*>TOHM(,5O\`8_A/PI\']5N4^+7@7PW\-=2N_B%<VOQ'
MC^)GA/1_"]Y<^.+OQ#X$\'^#;+QZGC/1[:27Q+<ZY\,?!O@'PI:^*5U*]EU/
MP)X5\'Z%%?3^']#T6UM?SFT7]FG]G+QAXXT7X-_`O]H[]H/X,_'+]DCP#X"\
M!:5XY\">$?ANFNV7A_PUI_C[3+R\T35?CU^S5\0?@1\6-1O;7XP^(-"^*U]X
M1\.^+8O!.NZUH]EJ,'@/QA=P-??5_@WXR_##P[\*_P!HWQ]<?M+^,/C7X8^`
M>N>/-'^+OBL>&_!?BKQ3\(?$'P1^&/ABW^*'@K2_"/P.^#_A^_\`$7B;3Y]"
MU'XFZIX5'@SQSXMO?'GCW7-`\)6H\&_\('\-_"X!\F>"/'7_``2Z^`'Q`^*W
MQ#^&/[-GP:^$/C;X5^//A]^R#XZ^+GPO_9G^'OA76?\`A#]6M-%\$Z1*OC/P
M'X=@\23_`+-'PZ\3_#/6_@YXVUV_DM?!7PN\0?LX_$*V\1Z?HW@?X1W'B:RG
MOO\`AW%JNM>'/V,=3_8C^$FH:'I_Q=U6/X2?"+4?V=?V?KCX9^(_B+9>,]6/
MQK\?_##P9=SMHMC>?!ZVCLOBM\9/%ESX?\.ZTGAWQCX9O/#I\9>-M:D\,P>8
M^#/AA_P2E_9_^(T$WPVU+3_AI\1/A7\2?`/P:^+^L^!?AQ?6^L?M!?&J_P#A
M_;_M`>"O%'[0GC71OA3=77[0'CIO!NF>-O$EY\8SX@U*SM]>\9_%?PUXC\4Q
M>.KZ^T32O7+'XD_L-_LJ>+M;\/:=\0/C+KWC/X,_&+XL>&=0^%/@;X4_'/\`
M:&^(6E^+?B3\+O@-\:O%NBZ-\/?A+\(?'_Q2\8>`?`'PJ^+7P/U:/QAX<LO$
M'A+P+9>-])\-^+_&!UZ&?2=,`/GO]J7XG?\`!-3P?X]_:4US]HO_`()E>"/&
M=OX,LM&^#?C/X_>/O@A^P3?^#_CE=^!_`OPG^,&F_!V+QC\4OC#HOBK3O#OP
M^\+R>`O$":W^T9HWPF^!WA27X?6]U;^.K5?"^A7+]5\//^"GW[+?A?X:^"O&
M/PV_8Z^)GA[X.>#_`(7^,/!7PM\6?!^^_8"\9?#/29?A[\&_%_QV/[,/PQUO
MX"?M=^-O#,-]?_"WX)WFL:)_PB5PO[/6GZAH>A>$O$7Q/\.>+--DT+2N;^(/
MP"_X)U7>O?M)_P#!0;P3\5/C'HGCKX[W/P9\/?$KXP_LY?""'X]?$O4-<UNT
M^`-U^SM:?#/P/:?LS?'GQOK%]X6O-!\":UI^@^#_``;XCTC4=0\4>(K'XX:+
MXLTGPIH.C?#[V/6/V0OV*O$WP5\8?%+]HG4_&'Q(\6_M?^"/"O[,WB+]JK]I
M'X"?#GX3_M:77A7]HZ;PU\`_!7P@O(=,_9F^">M_"&U\8^(/%/AKPE!\/=<^
M%/A#35\9>((9/$GAX:UJUW)<@'.R_$K]DSQ?X#UKX%:-_P`$I_%WQ)OK>W\)
M>&/C]^R'H_P,_8BU5O@[X.^%WAK3/"GPLD^+MKK/QPL?V<O%7A_P]X+L],\.
M_!_P?\*_B7\6?%J^&M%O/#_@/P8;7P=XAT_0NB\+_MT?LS^$-!UBZ\-?L:_%
MWP)^S'X:\*Z#\,]/^/.F_##]GGPS\$KZUOOA_I?Q'\%?!&/X?:;\7K?X\^!X
M=6F^(\7@?0-$^)GP&\`>`+'XH^(Y_!M_K&E:EX@LI-5^9O"NC_\`!/#X'_"O
MX;:=^R[^U?\`M1?L[>'=._X77\+/#2?LM?`=/%GC'QO\,O@/X^^(&J^(_@?J
MW@&Y_8Q^+NI>)M"^&/B+4?B+>_"+XG0^"4_:$\:Z5J/C+Q?X%^./Q!A\4>+/
M$NN=W\)_@M^Q1\3/!-QXDTC]J/\`:RUO]DG5_B'\(--E_96^,'@1_A?\-[?X
MG7WP[^%VG_!W7?%3?$;]ESX=_MGZI-=Z98_#GXK:5JOQ.^-.M>";OQ9<Z3\1
MM5686>E7&F@'M<\7["G[.%U<_`K]GC_@G9X0\4>.KS5_#?Q.TC]GG]F7]G[]
MECP'J'BFZL;;P%XOO/BW`WC?Q;\&?A'H<7PQO+;X5OKOCGQ[XV\)W5CXO/PU
MT3PG>:]XKN?".GRW;;]MOX%?#_QK<>#?&/[%OQL^`W@[X>?V1^T$WQ4\<?#[
M]F_PMX`\)^-OVD/&?CW0/&OC"W\,Z!\;-6^,FB_$'6?'/B3]H5?BAXZC^$MK
M:^,VT[XJ>,=*\8>.?"WQ,\$>)?BC\Y>`++]D+Q%J$;>#_P!OC]MK1?VBKSQ7
MX;_X0/\`:J\5_"G0_!OQ+\9>`/B/K?P9_9^T3X??!9?B?^Q/I7[+7QW_`&<=
M6\477P5T[6_$G@?X._$O0;;QA=>%_BMXR^(D7BJ.W\<P>QZGX7_8H^+/Q9N_
MV7_&GB_]J;XS>/\`5?AUI/ACQS_PF7P7^/?B_P`!_$#PU^S7\3_BKXA\9KXS
M^.9^`G_"FYKS6O&WCKQ?X.\7>&]'^(.B:=+;7OA#P'\,/#/A<7_A73M1`+/C
MG]H?]D'7OB5\/?C/^UA^P#X^^&?Q.\(7WAK_`(9X^-7[0W[-_P`#_'_CU/#'
MB/XE^"?`,7C;X;>,/AOXQ^,WC[X.Z7X>U_XF>&/%/C#PK\0S\)/BGX0\(7>O
M^-]?^'MAI'A#QK=Z!]<>(?VH_@U\'O`GC+6(/"?B'3?"/PR^*&J_">^TOPCX
M?\,6UL=?M?!$?Q0OM2T'3X-?T[3WT"ZTO4&(NG>RU"XUJ6?S-,$$GV^3\Z/@
M[\0?V*?&?A7XF_M)^*_VR?VXOC%X-_9!T7X@?$6]U3]J;X)_$?X53?`KX>?L
MR?$K3O$_QBTOPUX/U?\`8^^!/C7XNS^"_&WP1E^'?Q!\7^+=(^-G[0`UCP1X
MU^&Q^(*^,AXWT^X^A?A7\+/V1?CYX4^-O[//PLN?VF-+\*>'/C5XR\6>)-0\
M2?!?XY_#/P58>*8K+7?@KK'A#X*_%7XW_!'0OAM\2/A_X0;PWJ6C:%IWPM\2
M^/\`2?"]EINDV^F:K;^#?^$?L7`/MOX:_M"_#WXM>)O^$:\%-KUX[?"?P#\8
M8]3U+19]"ME\/?$+Q'X_\*Z?H6H:3K,ECXN\/>.-`UOX;>([#QIX1\3^&M%U
M3PKJ"Q:-JB1:];:QI6E?CK_P=%_\H*OVY?\`NV;_`-;#_9]K]B/`O[/7@+X=
M?%GQ]\8_#4_B.'Q'\2/!?P_\%>)-)N]76Z\*I!\.[SQ9>Z=KFC:,]H&T37-<
ME\87S^*?[-NX-%UB\M;?6AHMMXAO_$.KZY^._P#P=%_\H*OVY?\`NV;_`-;#
M_9]H`^_O^"3_`/RBS_X)J?\`9@/[&_\`ZSK\.:ZCXH?L7Z#\0OC/XT_:'L_'
M?BW0OBU<?"SPWX(^$;W/BGXK:E\)OAIXV\(P?%%_#7Q5\3_L_:9\6/#/P8^,
MGB;0-7^)$>KZ!=^-_!J^)O#DF@11>'_&&ER7D%SI?+_\$G_^46?_``34_P"S
M`?V-_P#UG7X<U\J?MY?LR?M/?$7X^>(?&_PC^%B?%;X?>'/@O\/_`-IWX?\`
MA^[^)G@;P-INH?MZ_L4>+_B!KO[/GPTN-/\`$"17K_\`"]X_BOX>U";Q]XDG
MN?AS\/-6_9M\&7>L_P!D7FJ17-^`0^.?^"*OP_;PWX?\%?`?]IG]IKX'>$=`
M\=^$OB[]AF^.7[0GQ'\3:W\5?!_PA^(WP9?4];^*6M?'32/BU'\/?B-X*\4^
M!?"?Q=^$_AOQUX;\+:_X$^%^F>&O`3?##5=>U/Q5%]Y6'[)&BVW@?]H7P'_P
ME/\`8FD?'5?!PTP^!O#-CX>7X6/X)^"/PR^$.@OX2T[7+_QCI&H0Z->_#2P\
M6:)IGB#3]0T2&*>V\+:[I?B33+.\N=7_`)]/!W_!*;]KF;XH?'?6?BQ\!/@?
MX@TCXC_#S28;GXC^'_#7POO/C1\7OB#K'_!/;]G/X+_&?X6?$7X@^)?C$9]"
M_89\7_&;4/C)XB\(_L[S^$OB%J]_^T+\/+GXN>-/%VD^#-7\(:KXR]37_@C1
MX(\*_"3XCOX1_8#^`6@_$V^T3_@M3H^A:C\.OA;^R)8_$6;0?V@?VJ_&-W^Q
MEH?AC6O%\$?@A9M0_99UZ3PA\.M%\<WJ^!_AEX)U23X5_$6T\':#<:OX4(!^
MAGQF_P""<GQL_:GT:Y7]I']M'6K3QQHD>G^'_A3\1OV2/AIXI_90\5?#+P:/
M%GA3QOXHN['7;7X\_%+Q=>_%;QQXB^'_`(`_M[QWIWBSPYX.L-$\+#1/"_PG
M\/P>(?%DVN^F_%'_`()O?#3]H+X7_`?X,?'?Q5XJU3X7_!/X?^)M&;P9\&/&
MGQM^`%OXI^)WBCPE%\/;CXHW?C'P?\;=0^+,L-EX`UKXJ>%&\$>+OB1XZTSQ
M99_%_P`8WGQ,U3QYJ`TZYMOA/X1_L+_&?X=?`+XKZ+\$_A#\3OAE;>+_`(2>
M"OAA;?`KXYS?L2_"FXUO3$^*?Q\\2^*]4M_AW_P3];3?V-OA_P#$'P[=^/-"
M\7:!XL\%^&=$N/B5X/U";P=\4M5O/&LL'BCX>^D_MJ_\$Z/B1^T)\7_VIOC=
MX=\._!==2U#]F'Q;\._A7=P_!CPK<?M0_$3Q1K'[/GQ?\`6_PW\._M0:]\7M
M)TGX;?!75O$GC[3U\5_#'Q?\*;K1?%&L0G6+KQQI&F3W$MD`?9GPC_95^.GP
MT\=?%3Q]JG[37A_Q9KWC[X/Z)X)T[58/@-;^%=6N_B=I6AZ=I]O\8?C!%I/Q
M1F\'_%K4_#-SIJZ9X`MM/\%_#KQG8?#JZ?P!\2OB9\6AHO@WQ#X5L?L_?L"_
M##]FJ'XB^'/A]XO^*.L_#SXP>`K3PY\3O"GQ6^)WQ-^-&IZ_XTMHM3TVZ^(F
MB^*?BMXY\7W'@IO$.@:YJ>E>)/`7A;3=.\`3RVWA^_\`#^@^&FTW4[?7OY_]
M`_X)9_M#Z;\:_#WB[X5?L=_\*\^#WA[X+?"'0M+UOXV?"W_@F1X+_;$\"_%3
MP5\8?VQ/BEJ>E?L^W'[!'CGX5?LP?`'X8_$A/$GPQ\!_M9>+=-\+^-O'OQS^
M$/Q'\+^!HO#.HWWA/QYKGA;Z_P#$W[!O[4[6?[*_P]\/_"^9_`/[%'B:P^#_
M`,)Y%\>^!8=.U+X">,?A)\4M=\2:_IEC=^/S>G1/AOJNG?LM_LZ^'=/\5:;:
M^/DU+X=_$#Q'HFE77P[\0Q>*]5`/>M'_`.".[7.C^`-'^*'[15M\5[*R_9T\
M0_!WXVZ/XE^!N@S^%_CO\0]7^+VM_$33?BWK&A:QXX\0R>'-.T3PA\3?C[\)
M5^&":GK^B:EX/^*UI:WNMG2_`^F:%J7JW@7_`()KZ[^S+XS^,WCC]A+XH?!+
M]F%/B?\`%"^\7^'_`(27'[)^G>*OV=/`7@C6O@?^S7\,=9\%:=\*/AO\8?@-
MJ%MKC?$#X">(_C-8>+_`WCCX<Z1>>(/C'XKT_P`=^`_'MYIFG>))?S\\#?L4
M_'S0=*\`Z-X;_P""?^J?#NU\&^._C#HWPQN]0^+?[-MW=^#?`_Q`^&7@C3_B
M!XZ^).F>!?BAIEC\,/&_C?QI8>*;7PQXE_9<U'Q-I?[2E@EYK7[9_P`!O`OB
M;XO>,/%/@WW"T_8[^)$'B;1;+6OV(HO$?[3T7CCP?XFT?_@I'#X]^"FFQ^!O
M@[IGC72M>L_@M_;DOQ+F_:>L)?`7PRLYO@]<_`?PM\.-4_9G^*]S:3>*/$GC
M;2;;XC>,(-%`/8?&G_!,'XFZ]\.OBC\&K/XW_LW>.?A)\6_&'@7XT^-O"7[3
MO[%.I_'N/QG^T'H7Q)\%?$KQYXM\?:9HO[4OPA^'?B7X5_$;6O#OB"_;X.Z9
M\.?#$OA+7/$ME>Z-\0)=!\-6OA6_^O?&_P"RCK'BO]B*Y_91\,^+?A;\%/&-
MG\-=!\-^`?B#\$/@%IG@_P"$OPC^(W@J[TSQ%\.O'WPS_9OUKQUXLTG1/#?@
M#QQH.@>*/#WPVU#XB:Q:Q+I,&ER^)G5C>+X-\!OV;?VCOAV_@3PG>ZC/8Z)X
M,_8.N?@[X$^)?B/QM-XV\>>"?B=KT?PWD?PAXWNK_5-6UOQI)X#U[PSJNJ>'
M_B)!K>LGQ!X;;3]"U^\G\1:`_BWQU\%>//\`@G9X@^-7ABU^%W@K]@T_L?V6
MK7?PA\,?M4_$UO%_[*?Q+;]J33;3]H'X!>(O%OB=O#.MZA\9?"_[1A\*^'?"
M/C#XEGXD?ML_"FR^(&IG0/\`A7Z?"3QCIWQ,\4Z`X!]N>!?^"6ME\/\`XLZS
MX^T?X[ZW/X,%Q\$F^'GPDO/`.CCPS\)+/X6?LL?$3]FKQ?I_@O4['7K/5Y+?
MXNWGB[PQ\3_$[:_)J\FFZ_X+;3=/:6/Q'=:EI\MY_P`$C_V>_$5^OBWQSH7P
MR\6_%RUU+X#VNC?'2Z^"?A6#XS^%OA[\'_@[\/OA#X@^'/@_XF3:G?\`C?PM
MHOQ!LO"7B;5Y1HWB"UL-`D\>ZM9/HVOM'>7VL\_\6?V2OB]\&_$_[-?Q%_9:
M\!Q_$SQ%^QK^S%XH^"'PETBXF^!GP?L?&A^*GB'X<>#O$FB:OX;\"^&_A%\)
M_!6A^'O#/A+1OBO?Z=X$\`>$/!2W?@+2M"\'^#3=+IOABX^-/!W[+W_!7']F
M/XJ_"/X1?LN?$[5?#'[)G@OQM^T-XJN?#M_\#?V7/B]X`^)^L_%[]IC]H#XS
M:AK'[1?Q2^(G[6?PO_:=^&-IJ^G?$'PD/#EU^SG\-/BO?:'>R:CJ7BGPMJ_]
MG2>$=5`/T'\6_L,_M&?$K3=`L_B9^UYX,\0W?P6?PQKO[,-YHG[+\/A:+PO\
M1/`?C/P%XV\$^/\`]H.R@^-^I)\;[RPO?A_9Z'KGAOX7S?LQ^$];\-^(_%,-
MKHVB>('\+^)/"OT#\!/V8O%'PI\0^'/'7CKXJ:?\2/'L?A3XRZ?XZU31?AX?
MA]X>\1^+OC7\9K+XR:YK/A?PY)XU\9W7@[PIX=N[9O"OACPEJ?B#QMK::#'I
M]SK_`(\U_7+?4=4U?\>/#GPN_P""I&D_$W]H'XU-H7[>UOJ'Q`\-?LM?"[4_
M$L&I_P#!&R7]JS5_#/P?;]L+Q9=Z%\!]&FU"7]C^P^!/AWXF_''1]0N-3^/6
ME67[2&K^&/%&IVMEJ&IW6B6EMI''_!CX$?\`!8/X8V7Q6^*7B6+]H"3XR_M!
M^,?A+XL\=ZO\*&_X)=W7Q+UGXA>#?V"/V+_`>A'XOW/Q/TRU^&.F?LO>'_CO
MH_[3?@[XC^%_@5=Q_%NUU/PYH/B_X)Z-_8GCKQ7XW^(`!]M?%3_@C%\&/C1\
M)?C?X`^)M]\,/'OC+Q_X>_;^@^#'Q6\=_L]>%/&?B?\`9F\?_MO_`+3OQ[_:
M6TSXI_#!_$'B>\U72?&'P8U7XS:)HMAJOA3Q%X'UKQ=J'PYTKQ7;ZYX+N;ZT
MTKP_]0_L?_L3_P##+/Q(_:#\<?8_V2[C_A=OCOQ=XT_X2CX,?L?_`/"A_CWK
M7_"6?$KQQ\0_LG[0OQN_X7C\2?\`AH+4-%_X3+^R])UG_A!/AKY$]K?ZK_9W
M_$W_`+/T]GPR\-?M++\%OC5\,_CMXH^(OQ=^+_Q/T[]I'Q?H6H:KX6^#?A;X
M<_#'PIKOB/6_"7P9^!GA/7_AUH7@^SU:-O")TK7+"_\`&E_X\\>-*WB75?B-
MXT\/P7OA'PU%\F0?#?\`X*B^`/A]?ZII7Q.^.'BI];'C+PS_`,*8\#Z9_P`$
M_P"#7_@E\//"'Q/^'6D?#B__`&</$'Q%\%:!X<\0_%CQ5\&;+QW?PR_M-_$G
MXF_#R/6;NS@\2:1X8O[2T%T`?MG7X!_\'1?_`"@J_;E_[MF_];#_`&?:_7;]
MFC5OB3=?#+PYI'Q2\,?M#:=XITG0;"?4_%/[2]Q^R?)\3?$^H:GJ>OM<67B.
MW_8Z\0W_`,&[?7O#MI9Z<E^_A'PYX>\,3Z9JN@'2[O7=9C\4OIOY$_\`!T7_
M`,H*OVY?^[9O_6P_V?:`/O[_`()/_P#*+/\`X)J?]F`_L;_^LZ_#FOF?]L+]
MK+XC?"7]JGPAX%M?VAO^%5>#U\;_`+/J:=X"7PE\-KR\^+4OC74/$VB^)/`&
MD:O\0_!TUIXPU&]273_%%_\`!SP;\3_A?^T#XL\'^%_%GCGX%Z]KX^%/COX<
M>-_IC_@D_P#\HL_^":G_`&8#^QO_`.LZ_#FOOZ@#\)?VV/C9^W/X*^)7[7?B
M[X'>*/V@]-^$_P``O@[X^U75+C0/#O[#VK_!?0'M_P!D/Q#XY\,IX$TWQ]H.
MI_M2^(_VJQ\==:^&NM:':^*;35OV49_AJ^LZ9XD6;Q,O]EMY;\/OVS_'7B?P
M;X3G_:%_;_\`B9^PQ\-KF#5=3^$GQ4^.OAG]@W1/VA?C3\0;'Q-XA\,>*/V:
M_P!H>.'X9>./V;O"7QI^$-_X:2[\5?L]_!KP5\/?CEXGTGQWX8L],UO1_$_P
M_P#B?I</]%E%`'\PG[17_!03_@ICX(_9"^,OQCTVP^$/@K2/"_A7X[W^D?&)
M-;U'2/C'HWC?P;_P2W^(_P"T9H'A^;]D3XC?LO:YX4\,^'M*^-F@:?XN'_":
M_M"^(O'&EQ6,7@SQAX?U33_[8T63(\,_MK?M?^/_``C^U5X<TS]M>TDUWP=K
M?QO\8^&O'?P1UC]DOXS>)?A"GP]^'?[3?C?1_@7XPL]1_9!\->#_`(<>+-+U
M+X"^&XO'?P:^(O@;XR?$SPCX(\:6NI_\-'^*-7\9Z//\/?ZDJ*`/Y?\`QQ^U
MU\:?AY\>/CK\-?B=_P`%:/!OPL\`_#?7_P!F[P#K&J^(OV@_^"=6B_M#?##P
MMXKA_9.7QA\<?&?[-WB[_@FMI6B^!]*\57WQ`\56=U\7_&'QY\4?"FUU#X@6
M.D^&O@/X<FU+P;=^!_V5_87^/=O\7/!GB_0IOCUHG[2%KX1\;:S8?"?X]1'X
M=Z;K7[1OP7@TCPK<V7QGBT;X9:9X9\":SHFF_$#6?&OP:D^(GPW\'^&_AGX]
MUSX8ZAXH\'Z78:7K5K:K]UT4`%%%%`!1110`4444`%%%%`!1110`5^`?_!T7
M_P`H*OVY?^[9O_6P_P!GVOW\K\`_^#HO_E!5^W+_`-VS?^MA_L^T`?S"?LG_
M`/!Y-_PR_P#LL_LU?LT_\.Y/^$X_X9X^`'P;^!G_``FO_#7O_",_\)A_PJ7X
M=>'/`/\`PE'_``CG_#+_`(@_X1__`(2#_A'_`.UO[$_M[6_[*^U_8/[7U+[/
M]LF]_P#^(YG_`*Q>?^;L?_DD444`'_$<S_UB\_\`-V/_`,DBC_B.9_ZQ>?\`
MF['_`.21110`?\1S/_6+S_S=C_\`)(H_XCF?^L7G_F['_P"21110`?\`$<S_
M`-8O/_-V/_R2*/\`B.9_ZQ>?^;L?_DD444`'_$<S_P!8O/\`S=C_`/)(H_XC
MF?\`K%Y_YNQ_^21110`?\1S/_6+S_P`W8_\`R2*/^(YG_K%Y_P";L?\`Y)%%
M%`!_Q',_]8O/_-V/_P`DBC_B.9_ZQ>?^;L?_`))%%%`!_P`1S/\`UB\_\W8_
M_)(H_P"(YG_K%Y_YNQ_^21110`?\1S/_`%B\_P#-V/\`\DBC_B.9_P"L7G_F
M['_Y)%%%`!_Q',_]8O/_`#=C_P#)(KX!_P""HW_!UG_P\G_84^.7[%7_``P;
M_P`*7_X71_PK/_BY?_#47_"Q?^$;_P"%=?&'X??%C_D3?^&=O`G]L?VQ_P`(
8)_8'_(U:5_9_]J_VK_IWV'^S;PHH`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g30330image3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image3.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`$<!
M2`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[6_P!JK]K#X/\`[&OPWT'XL_''4]1T7P+KGQ7^$OP@;6M/MK.Z
MBT77OC%X[T7X?^'];UL7FHZ<+;PMHNIZW#JOBK4;5KV^TOP]9ZCJ-KI>HR6H
MM9/I6OQG_P""OWA#0?C3KW_!,C]F+Q=I.F>(O`WQY_X*.>`E^(WAC5K.._LO
M$?@/X/\`P%_:"^->HZ5/;2%D:"3Q!X%\+RW$KP3)%%$QS!(T4R>A?`O]JZ3]
MGC]B;XZ2_M%:IK7BGXD_\$[I?&7P8^)T@:?Q!X[^+$7P_P!+L+W]G_Q?!::5
MX;T:36?'/[2_PL\0?"?Q';:=H/A\VD_Q&\;ZIX6TL75QILP`!]7_``W_`&Q?
M@O\`%?\`:H_:2_8^\%ZCJFI?%K]E/PC\$O%GQ=D\C2SX9TUOCS9^--5\)^&-
M/O[?6+C5I_%.D:%X/MM?\56-_H>F6.GZ7XT\&/INIZQ=WNL6FA]%^T[^U+\$
MOV//A='\9/V@/&-MX'^'S^._AK\.CKES$TZ1^(OBIXZT'P!X<\R%&$@T^SU/
M7XM7\0WJADT7POIFN:]<J;32[C'XP?L'?`W7_P!E;_@JAJ>C?$;4CJ/QA_;.
M_P"":.G?M#_&W4(SJ=Y:ZI^T-X!_:[\;^(OC-#8:GJEQ=W7_``C7A,?M8>#?
M`'PZTF62V&C?#[P9HFDVMI!9:;;6=CPW[<WQ%_9V_;-_X*)2?L[?M!^#OVA?
MBK^R+^P[\*_&4'Q"\,?!;]CK]J/]JCP9XX_;(_:0^'M_X-L-%\3ZO^SC\%/C
M%IGAS6?V?/V<_&&N:U;Z3XQ;2W?Q1\;])OK/3K^[\*W$FG@']''B_7M2\-^$
MO$?B30O!_B+XBZKHFA:GK&D^!?!MWX0L_%7C2^L;*:[L_#7AF]\?>*O`W@6V
MUO79HX]/TJY\7^-/"OAJ*\N89-9\0Z1IXGOX/S<^'?\`P4Q\3_$G]H'X@?LS
MZ5_P3F_;ITGXH?"'3_@_K_Q?M]=\2?\`!/./1/AKX2^.=SXMA^'WBW6-7TC]
MOK6(_$.E7MOX#\9:CJ&G?#V'QGXITNTT":.Y\.C4-1T2QU3#_P""/7[2&N?&
M+]FK6/@K\1[GQU/\:?V-/&ES^SGXXO\`XH_#3XD?!KXA^/?!&@:?::C\!?C7
MX@^&/Q<\`?#'XA>%Y/B[\';OPOKM[%K_`(+TEI_%EGXM6T%Q:V\<\F/^S!_R
MF8_X*P_]FU_\$P/_`$F_;*H`];M_^"A^N>+/B?\`M`?#7X)_L'_ME?M`Q?LU
M_%Z;X&?$CQ]\.]=_89\*^"C\1[7P!X!^)EWI/A^#X[_MK_!OQWJEI:^$_B7X
M1NI-6E\$66G275]<65M<3SV-VL7<_%#]MO4/@Y\&OAM\4/B#^R/^T[HWC?XL
M?&GPO\!_!?[.<.J_LGZI\9;WQKXTNM8M_"]Q=ZYI?[4MY^SWI^@ZM%HMS?+?
M77QW2ZLK6:V34]/LKUIK.#\ZOV./%G[9VA?M'_\`!7"T_9T^`?[,/Q4\%R_\
M%+M?N-6U_P"-?[7/Q5^`7BBR\4/^QY^QW%>:/I_A#P+^Q)^TII.IZ!!I,6C7
MMMXDN?&^D:C=:C?ZIIDOA6SMM(M-7UOUK_@H7XA_::G^"_[#.O>)OA#\"]*_
M:&A_X*0_LXR:-\+-`_:+\?>(O@UJ%[!=^/TT"VU'X\ZE^R[X4\:Z3;ZI8"*X
MU>[M_P!G/6)-#O7>QM+/7X(EU&4`^M_#O[<R6GC3P!X)_:"_99_:<_9#G^+7
MC33?AM\*?$OQR7]G+Q?X(\<_$75M*U[6=.\$CQ;^RU^T7^TAI/@37-2M/#UU
M;:!_PMF;X?:;XNUR[TSPOX-U#Q#XGOH]''M'PG_:3\"_&/XN_M/_``8\,:5X
MLL?%'[)OQ"\!_#7XBW^O6.CVN@:UKOQ#^#/@#XY:+=^"KK3]=U34=1TFU\)_
M$?0].U2?7=*\.7D'B*UU6TM+"]TV"TU>^_*KX-^./CQ_P5LMO#=C\;OAY\#?
MV6O`O[(G[9?@WQ+\<?@5X7^+WQ+^._[0MW\:_P!F+Q;)X]\"?#WQG/XB^!?[
M-'ASX,^&T\;Z9\+?B_I'C#PVWQSTOXS?#::TL-!N?#>D:Y-K,_O/["?_`"?O
M_P`%J/\`L[#]E_\`]=X?LK4`?;'QE_:I^"'P"^(W[./PI^*/C&W\.>-_VK/B
M5J_PH^#&DRQ,_P#;_BW1/!'B#QU?)=3;E33]/^R:';:!;WDF_P"T>+/%/A'0
MHXC-K<<L/J'Q.\?Z-\*/AK\0OBEXBMM3O?#_`,-?`_BSQ_KMGHL-K<ZS=Z-X
M.T#4/$6IVVDV]]>Z=93ZG/9:=/%80WFH6%K+=/$EQ>VL+//'_)U\</''P7_X
M*/?%;]N_XY>(+;]J.6^^'&G3_LM?\$P?BI\*/^">G[;?[3/@#X:>.OV??'>F
M?$#QE^U%X6\??!?]F3XA_#;6M6\3?M=>`]&\,30:=XPOM0'P_P#@O;:5?_88
M?$5Q;5^S7@G]JZ/]M7_@C]\2?VA+W0)_!7CCQ/\`LC?'G0_C!\-[^*]M-9^%
MGQP\$?#SQGX.^,7PSU[3-4LM,UC2=7\%_$+1=?T6;3M:TO3-5B@M[:6[T^U>
M81@`_2OX8^/]&^*_PU^'OQ2\.VVIV7A_XE>!_"?C_0K/6H;6VUFTT;QCH&G^
M(M,MM6M[&]U&R@U."RU&"*_AL]0O[6*Z25+>]NH52>3J=5U.ST72]2UC4)1#
M8:387FIWTQQB*SL+>2ZN93D@8CAB=^2!QR1UKYX_8O\`^3._V3O^S:?@3_ZJ
M[PK6;^W1\1[;X/?L3_M?_%>[N5M(/AK^S#\>?'37#1R3"-O"WPM\4ZU%B&)7
MEG=IK.-(X(E:6:1EBC5G=00#2_8\_:Q^$7[<G[-/PB_:K^!=_J%[\,OC)X7B
M\2:%;ZV-'B\2^'[J*[NM*U_PCXNL]`UGQ%H^F^,/!_B#3]3\->*=+T_7=7M=
M/US2[ZU@U&\AC2YE=\;OVL/A!^S_`/$W]F/X0?$#4-43QW^UO\4=;^$WPBTC
M2;*VO#<ZYX;\`^)/B'KNL:X]Q?V3:?X8TO2_#T6EW>HVD>I7::_XD\,V*Z<U
MO?W-[8_F/_P2W\!0_L%V_P"SA^Q==B\M?`?Q\_8T^$'QG^%S72WTEIIWQ[^#
MWPK^%_@']JCP;#-%IR:-ITWC.UO?A]\;-,TH76GW>M>(]0^-GB"VTRX6VU2X
MMOC/]L2\;XS?%WX6?\%,KEK^[\$_L[?\%9/V,OV6?V9SNO+&Q'PD\._&GQ%^
MR_\`M0_$JRCN=!LYI!\4_C5\;_'WA9KE+[6O#OBCP;\`OA/KFB7MF^H2S.`?
MT*:7^TGX%U?]JKQM^R%;:5XL3XE>`_@%\-?VB]8UR>QT=?`USX)^*?Q!^*7P
MW\/Z7INI1Z[+K\WBJSUSX1^)+O6;&Z\,V>D6^DWNB3V6N:C>7-_8Z:SQ;^TM
MX$\&?M-?!;]E/5-)\6S_`!#^.OPQ^-?Q8\(ZS86&CR^"].\._`C5?A9I'BZR
M\1ZC<:]:ZY::UJ-S\7?#;^&[;3/#NKV-Y!8ZXVIZCH\EM81:G\3>"?\`E.)^
MTA_VBS_8Y_\`6K/VVZ@^//\`RF<_X)S_`/9EW_!1S_U./V(*`/5M7_X*1?#?
M3#?^,+/X'_M+^*OV;=)\;7_PXU;]KOP3X%\%^+O@E8>,M%\?7/PO\16J^%-$
M^)%W^TSJOA;PSXXLK[1=>^*F@_L]:M\(+%+#4-6_X3^31;"\U&"#]L#_`(*&
M77[&EY:7GC+]BW]K;XE_#G6/'OPD^%OAGXP?";5_V,[KP/XI^(7QL\2>'O!7
M@3POI>B_$C]L#X:?%:RFNO&_B;3/"FH:QXC^&NA>&M/OC<:I+K;>%XAK[_,E
MSK/Q"_X(_P"L:Q=^(;5_B5_P2R\8?$GQCXTU;QI9Q:I=_%?_`()_>)/B]XZU
MCQEXFO\`QM9B?47^)_[(^H^/_%=]J#>)M*M;+QK\`(=7O[CQ);^*_AQ:IJ?A
M#LO^"TL\%U^RK\![FVFBN+:X_P""B/\`P38GM[B"1)H)X)OVS/@Y)%-#+&6C
MEBEC97CD1F1T8,I*D&@#]+_@_P#$'Q;\3/!R>)O&GP-^*7[/6M-J=]8'X>?&
M#5_@GK?C&.UM/)^SZT][\`?C#\<?`!TS4_-?[#$GCE]9C^SS?VEI.G[K?S_E
MGXN?MWR_#W]IO5OV3?AU^R3^U!^TQ\4O#GP-\!_M!>*;CX+:E^RAX>\*^'/`
M?Q(\=_$KX>>%XK[5OVC_`-J;X`7E_K]QK_PI\4-=Z=X?TK6;>ST]]+N9;_S+
MN6"V^^*_"?X@:_\`M.Z#_P`%L?CJ_P"S-\)_@/\`%36;K_@EU^R5'XDM_CK^
MT)\0?@#IFAVJ?M2?MJ'2;S1+OX?_`+,?[2EUXKGN;IKE-1TZ_LO!L=E;P02V
MVJZA)=2168!^F7@_]L#X3^./@!\4_P!H?0K7QJGA_P""<7Q:M?BGX%UOPQ)X
M:^*?@GQ9\$[;4[KQ[X"UWPCX@N]-CL?%=K#I@NM%\_54\.^)M'U;P]XIT#Q#
MJ'A'Q#H^OWG@7@O]OCXS_$/P=X3\?^#_`/@EA^W]J_A+QSX9T+QAX6U;_A._
M^"8.G_VIX<\3:7:ZUHFH_8-4_P""D-EJ=E]MTR]M;G[)J-E:7UMYODW=K;W"
M21)\+?`&?5O"'[*W_!7GX5_':QL_"G[<OB72_P!H#]JK]J/P5HMS%>?#X6OQ
MU^!^K^$/@UXA^!^J#7-8O?$OP@L?AI\%M&^&5KXCUNV\,>+-3\<?#CQGJ7BS
MP3X2U#5+?36^B_V2?B#_`,%,X/V4_P!F6#P[^R-^PIJGA^']GSX,1:%J>M?\
M%%?C_H&LZCHT?PX\-IIE_JVA6/\`P2Y\266BZG>60@N+_2;/Q%K]KIUU)+9V
M^M:I#"E].`?KW;2R3V]O/+;36<LT,4LEG<M;O<6LDB*[VUPUG<75HTT#$Q2M
M:W5S;F16,%Q-$5D;XR\$?M]?L[^*_P!G3XC?M3:]K>K?"SX0?"SXI?&WX0^*
MM7^)=KI6F:A_PE7P*^,/BKX'^(1H^G>'-:\4-K47BOQQX3NK?X>:9832^*?%
M,.J:'9CP[9>(-0.AP_9\1E,49G2..8QH9HXI&FBCE*@R)',\4#RQJ^521H(6
MD4!FBC)*#^/?_@DH?!GB#]L7QIX8_;4_X2,Z=IG[:O\`P4*\4?\`!*[P_P")
METM/V;O$/CG2?VN?CS+^T#XHL(XI)%US]MCPAJ=QKD/AFS\;E+WPU\!KD:W\
M&],2^U#XJ:PX!_0Q\4_V]]"^#O[-7P]_:/\`&G[.'[2]C+\5?BK\(?@WX!^!
M4VC_``8TCXZZSXT^/'Q!T7X:_"VVO])\3_&[0/ASX1@\1>(?$6C27<?C?XF>
M&M3\,6%X6\6:;H=]:7UA;=7\._VGOC;XV\:^'_"WB7_@G/\`ME?"#0M9NY+;
M4?B3\1?''_!/C4_!7A.%+6XN%O\`Q!8?";]NWXH_$6YM)988[&-/"W@'Q+?"
MZN[=Y;**R6ZO+;Y*_P""U%QXHL_V</V;[OP1H^@>(?&EK_P4N_X)KW'A#0/%
M7B34?!OA?7/%$'[8?PJET#1_$GB_2/"OCO5O"N@:GJRVEEK'B33/!'C+4=#T
MZ>XU.R\*^(;FUBTB\^MOASXW_P""@NI^-M`L/BY^S%^QOX(^'-S<S)XI\5?#
MG]NOXV?%/QMHUFMG<O;SZ!X`\3?\$ZO@[H7B6YEU!;.UFM-1^)7A2*"SGN;Y
M+VYGM8M.O`#Q?P__`,%&_$?Q#\2?&C1_@I_P3[_;:^./A_X&?&WXE_L_^*_B
M#X'U[]@KPWX5U3XA?"?5ET?Q=#X9TSXQ?MR_"[XA7VDQ7,D,FG:AJ7@;2&U"
M">,Q6RS++#%ZU<_MIV?B#X467Q8^!/[.W[0?[2UM;^,/&G@+Q_X%^&K?`/X>
M_$CX.^+?AY<W>G>,="^)_AO]J/X\_L\0:3JNB:O92Z;+IF@ZGXCU.[$MCK.G
MV=WX8U33-=N_S2_X)^^+/VW-)US_`(*"Z=\"/@#^RO\`$#X=/_P5,_;79O&/
MQ;_:]^+?P@\:V^J3?$#3EU:$?#7P;^Q!\<-"O+#34$,NG7)^*]C<:TS2P7-I
MH`1+B3]/?V=_V>=8_9_^&/QVN?&/BS3?&?Q-^/'Q3^*G[0?Q3UCP_HUSX>\(
MVWC#QOHVDZ':>'/!FBW^I:QJ5IX:\(>"O"'A#PK9WFJZG=:KXANM&O?%&HI8
MWFMS:99`'(?L2?MUW'[<O@KP1\6?!_[)'[4'P@^"'Q-^&]M\3?AQ\9?C3J?[
M)\7A7QEI.HW6EQ:/H]CX7^$/[4WQ?^+>CZ_K%CJ%UK%I'XL^&OAW1[;3]$U2
M'5=9TW5Y=%TO5^X_:U_;!T+]DQ/@3877P>^,?QT\9_M'?&>'X$_"WX>_!3_A
M4$'B74_&TGPY^(7Q2DEU+5/CA\7O@IX"T;0[?PK\,_$LDU_?>-([AK_^S[.W
ML9S=M)#\S?\`!#?_`)1!_P#!.S_LUGX8_P#IH%9W_!2C_DXC_@CE_P!I*S_Z
MQ+^V-0!Z_<_\%!]+^'UM?:[^U/\`LL?M4?L8_#ZPGT6*\^+GQVT[]G[QC\)-
M(AUEM7A_M;QI\0/V5OVA?VD=!^%?AK2+O3+2RU[Q;\7+CP%X6TJ?Q#X?DGUG
M[)=W=S8^S?M1_M4:!^R_X(^'OB^?X:?$WXV:E\5OBSX#^"_P\\!_!B3X6GQ5
MXG\:_$9-3D\-K;ZG\7OB?\(_AY8:/)'I-R]UJNL>.].@A1X&C6=9"4^CM<T3
M1_$VB:QX;\0Z;9:UH'B#2]0T37-'U*WCN].U;1]6M)K#4]-O[696BN;*_LKB
M>UNK>56CF@EDC=2K$'^7SPQXI^+S_P#!-/\`X)P6GA#0-(\>^-/A-_P5F/P2
M^"VC?%7XA^*_!VC>*_AY\`?VH/VG/@W\%K3Q?\4XO!GQ=\56EJ/AIX'\,:=<
M>-8/`_C2\U/[$FK+I5V+TLH!^U?AW]N9+3QIX`\$_M!?LL_M.?LAS_%KQIIO
MPV^%/B7XY+^SEXO\$>.?B+JVE:]K.G>"1XM_9:_:+_:0TGP)KFI6GAZZMM`_
MX6S-\/M-\7:Y=Z9X7\&ZAXA\3WT>CCUGX1_M2_#KXP?&']H?X!Z;IWBWP?\`
M%G]FCQ+X9TGQSX.\=:=I.E:AKOA/QUH$7B'X?_%WP&=*UW7(?$OPH\<0)K.D
MZ%XF\RPO(/$_A3Q=X6U[1M%U_P`/7^GQ_ES\&_''QX_X*V6WANQ^-WP\^!O[
M+7@7]D3]LOP;XE^./P*\+_%[XE_'?]H6[^-?[,7BV3Q[X$^'OC.?Q%\"_P!F
MCPY\&?#:>-],^%OQ?TCQAX;;XYZ7\9OAM-:6&@W/AO2-<FUF?7_X+*:7\9?V
M>_"_@/\`X*)?LAZQX,\._M0?#/4/"G[*E]8?$2/7I_AO\4_AC^US\4?!?P:\
M):'X]L]`N$NF/PB^/GC7X:?&;PYJT5G?7MGIF@>.O#-K#Y7C2XE@`/TE^#W[
M6'PW^._QJ_:0^"WPVTKQAK4G[+'B7PM\/OBC\3#I^AQ?"QOBOXB\-VWC#5?A
M-X7UI?$4OB+7O''P^\,ZMX7U3XAHGA6V\->'IO%NBZ%'XDO_`!+;^(-%T/Z=
MKYF_8^_9D\+?L@_L]?#_`.!7AC4;SQ)=>';;4M:\=^/M7ALX_$OQ3^*OC+5;
MWQ9\4?BIXMFL;:TAN_$_Q!\<ZQKGB75)O)`A:_CL+<)9V=M%'],T`%%%%`!1
M110!\9?'7]G+Q=\6OVL/V&_C7::AX3B^'_[+.N_M">-/$^EZM-J!\4ZEXP^)
M/P<N_A#X#G\*6,>A7^D26^F:9XN\>3^(+^^UO0=1L$FTR#2EU6'4=5@@^?/V
MD/\`@G;K/QR_;@^!/[0^G^/].T3X%V$G@GQ!^U=\%+Z"]OH_CGXW_9HUO6_'
M/['&M6EE<6NH>'K$_#GXC^,]=\3>,=1V:3KVO6_A#X;:,=0U'1](GTV/M/V[
M?VAOVB?A3\4/V%O@I^SCK/P6\)>)OVN/C_X[^$VO>.OC;\*O'/QET+P=H7@K
M]G7XO?&\:AI'@7P)\<?V?]0U+5M2U#X:6F@&2\\>0V=G9ZK<7OV.ZGMHX9)/
M%/CC_@H7^SKX9U+XC_%"+]FG]KKX?^%S+X@^(.E_L_?"GXH?LO\`Q=\.^`-,
MTG5KOQ'JGP^\#?$/X\_M4>&/C#XJT>2UTW4+?PI??$3X12:YI,NLV>DWT_B#
M3]'TSQ*`;?QT_9F^+7B3]M;]GS]K_P"$VI?#IKGX-?LP_M>?!/6/"GCS5O$N
MA_\`"2^(_C-J'P-\6?":47_ASPQXC8>%-+\7?"6_M_'$LHBU/3-+UFUU/P[I
MVNW]O-IS=E^P5^RWJ'[(_P"SCX>^'/B_Q#IWCCXR^*_$/B[XQ_M&?$C2UU);
M'XD?M"_%G7+GQA\5?%NGKK$CZG'H!UZ_;0?!]K>+;S:=X)T+PWIKVEH;/[/'
M<^(W[;'P:\)?`WX1_&[P-J7_``N:T_:3O/!&@_LM^%?A_>Z?)K/Q_P#%WQ*T
M.Y\3>"M#\'W.ISV>GV5E+X7L-6\9^*_$.LS6FF>"/`OASQ1XIU\PVF@W<)XJ
MRTS_`(*=ZD]EXPO/''["?A"WDL+>[O?V>U^$GQ]\>WMOJ,FGK]HT./\`:\3X
MX_#^T>WM]4D8KXC'[%+F:SL_)'AM)=0%UIP!#XG_`&6/B%HG_!0_X>?MH?![
M6O!VG^%?''P+UO\`9V_;!\$>(]2US3-1\:>&O".JWWCS]G/XD^`XM,\/:[I>
MI>/?AGXOUOQWX-U;3-<NO"=KK/P^^)NH7K^);B_\#^'O#VIW?@Y^S!X^^'O[
M?_[;G[5>M:OX/NOAY^TI\(OV./`/@71M+U#6I_&>DZQ^SS#\?H_&ESXLTZ[\
M/V6AV.F:F?BKX>/A>;1_$6NW5Z+/6?[6L]$-O8C4?1OV8/VGK;]H6W^)?AGQ
M'\/?$GP8^.'P,\9IX`^-GP;\6W=EJU]X4UF_TNW\0>%?$WA?Q5I2QZ-\0/A=
M\1O"]Y:>)_AYX^TB*SCU?3WO]&U[1O"_C?PYXM\(^'_,/^"C7[;`_8!^`GAS
M]H&Z^'^O_%#0V^.GP2^%_B7P7X-TN_UWQ[J>A_%OQUIW@*:;X?Z%IK_:=?\`
M&FG7FM6.H:'X;2"ZD\33VS>';6."^U6UO[,`^?/A7\%_^"@_[,7QH_;@\0?"
M;X,_L:_&;X=?M3?M8ZA^TGX6UGXB_MD?&WX'>-?#=CJ?P+^!GPBE\)^(/!GA
MK]@?X]Z%)=VU[\'[K6H]6T[X@7,-S:ZY;VC6%M+8R2W/NOQ?^"O[2'[2G@G]
ME._^(GACX(_"?XC?!O\`;%^$_P`>_'OA7P7\8O'GQ<\$OX"^&MYXJ2:T\(>/
M]<^`/P<UW7?%^KZ?J^GW4>D:S\-?"NC65X;VQ;Q-<P6T&HWGV!\)/BU\-OCQ
M\,O`_P`9/@_XRT/X@_#'XD^'--\6>"?&7AN\2^T?7M"U6`36MW;3)AXY4)>V
MOK&Y2"_TR_@NM.U&VM;^UN;>+\_OV<O^"B%MKW_!.[P=^VS^TE::#H>L>(O%
MOC_P1!X/^%NDZBDWC/QG:?M'>-?@-\)OAY\./#?B3Q-K&I:OX\^(VIZ3X4T+
M3-+N?$9M[_Q5K-Q<F?1=$WKIH!Z/\1?V5?B1H?[:?PW_`&Q_V;?$OA;PY?\`
MC#2M-^#W[:?PT\:ZGXAT_P`)?&OX,:':ZU>_#SQ_X:70]&\00:;^T)\%?$=\
M;/PGJ]]IMEIWC?X<>(/$?@'Q5K^F6^G>#]3T+PCQI^QO^UUHW_#VK7_@'\0/
M@]X.^(_[>OQ!^$M_\"?&OB#6/%KM\'_#FE?LN?`[]F[Q_P"-_%FEV_P\U>WN
M_'WA-O!'C;QK\-O"6F/K/ASQ7>V_@_3_`!/XL\'PZKK,VA>]V%K_`,%.O&;Z
M;XQ/BK]BCX!Z5+*;JY^`WB+X0?&?]H[Q>^F0ZW?SVMAJG[1OAK]HO]GSPIX8
M\2:SX6.D66L1:-^SU\2M`\"^*CJT^E:[\5M#@L'ONB^&7[0WQ+^+2?&'X"ZI
MHOA+]GG]L[X5^&-%U*\TGQ7INJ?&OX07NF>,8=0M_!/QK\!0Z)XJ^#/B;XK?
M!S6-:T;7-(NM*G\0?"KQSHNOZ%JOA?Q+'X=NTTW4]5`/=/V>/@3\//V8/@5\
M)/V=_A/I/]B?#CX+_#_PQ\.O!^GM++<7"Z-X7TNWTR"[U"[G>6XOM6U)X)-2
MU?4;J66ZU'5+N[OKJ66XN))&^(+_`/8E^*OAOQ]_P49L?AAXD^'UK\"/V[O@
M_J_B*S\(:]J7BVSU[X>?M@Z_\/-4^$GC;Q5!;6FBZWH8^%WQ2\)6?@'Q+XLN
MM/N(_$6E>._#NM7UGX7UF/Q-<W=OYA^SU\7O^"E?Q/\`VN/VIOV?_%WQ\_8:
MC\*?LC>,?V>+'Q/JWAS]A?X^:5XA^*WA[XQ_#73/BIK5EH,^I_\`!1[7]-^&
M6LZ5IMS<^&-+UG4-,^)MB;YH/$=WH$\$,GARX_5OXF>);[P9\-_B#XPTN*TG
MU/PIX(\5^)=.@OXYI;&:^T+0;_5+2*]BMY[6XDM)+BUC2YC@NK:9X6=8IX7*
MR*`?"G[,=M_P49^%_@KX!_!KXB_LW?L46_@3X<^#?AK\-/%WQ#\%_MV_'3Q1
MXM_X1_P=X>T?PQJGBOPY\-=<_P""<7@G1M7UF>UTV34[#PEJ?Q1\/64MQ(FF
MW'C"UC#:D/5/^"B7[/'C[]K7]AO]J/\`9C^%^M>%?#GCKX\?![Q9\+=!U[QM
M>:U8^%M(;QC:#1]0U#6+CP]I.N:Q]GMM)N;^6.WL]*NC>7*P6<XAMIYKB+Y+
M_9)\9?\`!4S]J7]E;]FO]IG_`(:>_8!\"_\`#0WP%^$7QO\`^$)_X=X?M%>)
M_P#A$/\`A:G@'0/''_",?\))_P`/2?#W_"0?V#_;G]E_VU_8.B?VI]E^V_V3
MIWG_`&2'Z"\4?M/_`!0^"O[;/PF^`?QPM/A^?@5^T]\/CHW[/OQ7\.:)JOA;
M4K3]J'X?V6HZ_P#$;X.>/VU[X@^);"]'Q.\"JWCOX(0Z)I&E7UI#X&^('A?6
M;_Q;?QZ;JL8`G[>7[(WCS]H7]GGPSX:_9U\:>&?A-^TO\#O$?AWQU^S'\7?%
M-A=W.D_#OQCINAZE\/M?DU%-&LKO5SHOBKX4>+/'7@O5[+2X@;B#78F8`6T;
MQ\C^T7^P)#XE_P""='AW]B']GZ;P]HMY\*+/]FB;X0ZE\0M<\46FD)KW[-7Q
M<^%WQ4\/ZIXK\2Z58^+?%AO=<O\`X<F76-9%CK^I7VI:K=7.H+??:;J1^V^`
M/[4WC[]I;]JK]HGP]\,[+P'+^Q_^S5*?@CK7Q'FTSQ)?^-_BE^UMIVH0WWQ*
M\/>`=?BUS3_!UC\-?@1HQM/!/CF9O#OBC4_$?Q8UK5-!T_7O#/\`PK;Q!I^N
M?*G[$_QD_P""H7[8'[,/PE_:IL_C;^P1X9L/B;9ZWX@A^#ES^Q=^T,MW%I^A
M>-=?\.?\(Q+\9XO^"@>I0Z;>:O::"5_X31/@CKD&AW%^+[_A`]?BL?[+O@#[
M$^-O[/\`\7[;]H;PW^UW^S9K?@>Z^*6F?!W5?@9\0/A!\7-5UOPO\,?C+X`B
M\33^/O`B2_$;PIX2\>^+?A3XS\!>,[WQ#_9'B[3O`7Q$T>[\.>.O%FGZWX#U
MB^A\.:AHV)\-OV<OB]\0?CE;_M7?M5)\._!'Q9\-_!3X@_L^_"CX9_L_^/O&
MGQ`\(?"CP9\4/%WA?Q1\2/%P^+_C7X??"#7?'7Q"\=S?#CX8K:WJ_!SP%I_P
M\LO"L^CZ6GB>76=2UZXQ-'_X**^"Y?V*_AU^UEK/PW\:W'BKXE>(_P#A47A/
M]GSP.UAXL\?^,_VD8/'_`(B^$MU\%_`FIW4GA_0=7$GQ&\(>)K>V\>Z_<^%?
M".G>!]'O_B/XNO/"WA?3=7N=.Z&PL?\`@IUKJZ9XRN_%W[#7PVAFTZ"\U+]G
MJ?X6?';XLZG;:A-;--+H@_:TL_C=\)M-06=S/'9RZU!^QUJ,,XTR:ZM],9-9
MBAT4`^;?'_[)_P"W_P#%C]F'QM^P%\4/BK\#?'?P7^(WP^\0_!7QI^VEKOB#
MQQ+^U-X@^"7B:YNO"^LZ+J_[/47PNC^%6H_'+4OA%=3Z%=?M`'X^VGAQ_B)<
MGXA3_L^7=K#+X5OOH3]N[]D;Q=^T?^S[\'_@S\(]2\)>'IOAC^TS^QQ\6]_C
MG5->M-./@']G'X[?#SXD>(])M+W2-!\3:A=^);[PKX/O+#PY#>VD%AJ&MRV<
M.KZSI%G+<:E;R?#S]NVWU?X/_M/>)?BQ\(/%'PI^/'[&/A7Q)XB_:#_9]AU:
MW\97B6^B^!M6^('ASQ/\'_'-OINB6/Q4^%7Q8T'1=0F^%OCQ-!\,ZCJ%Y9:Q
MX8\9>#_!'CWPOXL\':'S'P&^*?\`P4"\>:?^SG\9]=TC]DKXD?`W]H71O`WB
MKQ5X,^%B_$#P7XZ_9P\'^-OA]/XNMO$FG_%[Q9X]\;>$OVK["TUJ?1=`N4T;
MX2?LVZBUEJ/]NZ9INKQ1SV=L`?I-7Y7_`!/^!G[:/@K_`(*&>.OVP?V=?AS^
MR_\`%OP1\1?V.O@C^SCJ7ACXT_M+_%?]GWQ5X=\4?"CXS?M`_$J^UVQ7P-^R
M#^TOI'B#0-7TOXO:+86AGU+P_J-MJ&F:IYUF]O\`9)KBKKWQQ_;>^+/[>G[3
MO[+7[/\`\3?V5?@YX!_9Q^"7[*WQ*_MGXQ?LN_%S]H'QAXRUO]HG4?C]9ZE9
M_;O!7[9G[->B^'=*\,1_!>T:RA_L'7;O47U^X\^]M5L(A=?>'P2T+]HO0=$U
MBW_:/^*GP5^*WB2?54F\/ZK\$O@%XZ_9^T33-$%I"CZ?K'A_QW^TG^TQ?ZYJ
MK7ZW%RFL67B;P]:):2PV1T*2:!]0N`#XOL?V,?BMXRTS]M/XR?%[5?AE;_M3
M?M?_`+-=A^SG8:#X'U3Q9J/P=^#/@'PCX2^)\/@3P'I_C77?#FD^+_'R)\0?
MB]XX\4^-/B=<_#?P7>^(+>^TJVTSX9Z!#H$%C>T/@NW_``5,^$/P=^$_PF_X
M9/\`V`?$/_"K_AIX$^'?]O\`_#QO]HK2?[<_X0KPMI7AK^V/[*_X=6:G_9G]
MI_V9]M_L_P#M+4/L7G_9OMUWY?GR4O\`@I_\;_VW/V4_@MX[_:6_9^^)O[*]
MOX"\#GX2:&_PJ^,?[+WQ;^(WB_5==^(?Q=\(?##4=93XK^"?VRO@[HVGZ380
M>-K+6++0#\([Z\,NBW5E/XCD36(;G1_H36OC'\0_V1_@5XO^*/[:_P`6OA/\
M5-2L_%/A_0_!*?L\?`#QC\#[OQ5K7C?4M!\&?#SX2^'/`'Q!_:6_:*U#QI\3
M_'7Q"U:WT+PW<6GCCPSIMY-KFF6-UHVG6^F:EX@N0#[.B,IBC,Z1QS&-#-'%
M(TT4<I4&1(YGB@>6-7RJ2-!"TB@,T49)0?DW\)/^"96C:A^QE\2_V5/VF9]`
MUF]\4_M7_M1_M)>`O'/PLUC5X_$?PIU_XI?M1?$KX^?!+XB^`?%&M>'="U/P
MO\7OAC#XL\/W[7UGIMWI>G^*=.U#2X;WQ-X;EEFU3VZPM?\`@IUXS?3?&)\5
M?L4?`/2I93=7/P&\1?"#XS_M'>+WTR'6[^>UL-4_:-\-?M%_L^>%/#'B36?"
MQTBRUB+1OV>OB5H'@7Q4=6GTK7?BMH<%@]]Z7^SW^TCJOQ+\6>/_`((_%SP+
M'\)/VD?A%IWAG6/'/@6SUY?%?@_Q3X.\6K?P>&/BS\(/&#V&BWOB[X9>(M4T
M;7M$276O#WAKQ;X7\2:'JGAWQ9X<TVXCTV\U<`^*?CI^R[^WW\<?V.O@W\-O
M'FM_LT>/OVG/@#^V!^S+\<M.\777CWXB?#OX=?';P+^RY^T%X3^*6C:KXWO=
M'^!?C/5?A#\3OB=X4\(VUMXLT+PGX%^)/@OPMXQU&^GT#5=4T%+6TB^O?ASX
MW_X*"ZGXVT"P^+G[,7[&_@CX<W-S,GBGQ5\.?VZ_C9\4_&VC6:V=R]O/H'@#
MQ-_P3J^#NA>);F74%L[6:TU'XE>%(H+.>YODO;F>UBTZ\/\`@H%\>OB%^S'^
MR#\9/C?\*;?P9<_$3P79>$8_"L?Q"T/6_$O@N/4?%/Q!\)^#3=>(-`\-^*_`
MVN:Q96-KXAN+T6&G>+_#\]Q/;PQG4H(R^?FGX_?&?]O/]B#X.>/OVIOCS\3O
MV0_VBO@I\'-(M/%GQ9\"?"?]F'XS?LR?$;2_AO::[I"^/?'GA#QMXM_;%_:M
M\/\`BC6_`O@U]>\1:=\,;[P!X<_X3V]LK;1X/B)X4G9'O`#Z%_8E_9N\<_LV
MZ?\`M26GCG5?"FJR?&[]MG]I']I'PHWA.^UB^33_``-\8?$]EK7AG2O$)UC0
MM":T\5V-K;21Z[8Z:NK:/;7!1-/UW4XRTJ_8VM64NHZ-JVGP-&DU_IE_90M*
M66)9;JUE@C:1D21Q&'D!<JCL%!*HQP#\:6'[2_C2^_X**ZE^R3'IGA1OA?;_
M`+$/AG]I>TUY=/UE/',OC37/CGXH^&DVF2ZB^N#0_P#A%%\/:+9WL&G_`/",
M1:RFL2W$\NN26;1Z?#0_:]_:?\??`'XS?\$_?AUX.TCP?J6B?M6_M7:A\"_B
M)=>)M/UJ\U71O"5I^S]\:OBM'J/@N?2_$&C6FG>(V\1?#C0[)[O7+'Q%IAT6
MZU6W72%OI[34;$`U_P#@G%^SAXX_9`_82_93_9@^)6J^%-<\??`SX+^#_ASX
MMU?P-?:OJ?A#4=;\/6(MKVZ\.W^OZ%X9UJ[TJ63FUGU/P_I%VZ<RV,#?+7G_
M`.W_`/L\?M`_&G7_`-B;XD?LYZ5\'/$OC#]E#]K*+]H#6/!OQK^)WC;X0>&O
M&/AIO@'\<_A!<:+IOCKP+\%OCUJFE:Y%JGQ5TK5X1=>`+JPGL-,U")[RWN&M
MA)]O?$T?$4_#CQ[_`,*AN/"=K\5AX.\2'X:W'CS2-3U_P3%X[71[QO"C>+M$
MT7Q+X-U?5?#?]N"Q&M6.F>+/#=_<:<;B.UUK39F2ZB^>_P!@_P#:CC_;)_90
M^#_Q^N]#M?!_C3Q/H-SH?Q=^'EM=O=O\+OCAX&U2^\$_&;X973SG[8)?`WQ)
MT#Q)X?@>^2.ZO-/L[+4BAAO89)`#Q_Q3I7_!3SXV^&]<^'NK6'[)?[%^F>(K
M#^R=2^,/P;^.'Q5_:\^*VE:3J%U;0ZW)\._"_P`1OV5OV4?`W@SQI'H0U2W\
M+>,O%-U\4M%T/7[_`$W7]0^'>OVF@S:#K][XD_L.6-G\(/V&O@9^SVF@^$_A
MW^R!^T5^SU\18=.\8Z]XBO=1N_AI\&K'7['4K.VUK^S?$6J>)O'^L'5(+Z6_
M\27-FNOZK+J>I:WXAM[NX:6?<_9I_:>^)/[17[4'[:7AC2M`\(6?[+G[,OB_
MP-\`O!'C6+3];?QQ\2/VA]+\.R>+_P!H66+6O^$@G\*S?#CX;Q^*?A_\.M.M
MK'P]#KW_``LC2?B9:ZOJ8M]'L+,^6?MO_P#!3/P?^QK^T9^R'\![_P`(:IXP
MC^.7C`7GQP\3:58ZQ?6O[/?P-UG5K+X0^"_BSXI;3+*XMK#2?$?[1_CWX6>!
MX[O5)DM(O#__``G>IF,-HHN[0`]'^(O[*OQ(T/\`;3^&_P"V/^S;XE\+>'+_
M`,8:5IOP>_;3^&GC74_$.G^$OC7\&-#M=:O?AYX_\-+H>C>((--_:$^"OB.^
M-GX3U>^TVRT[QO\`#CQ!XC\`^*M?TRWT[P?J>A=%_P`%#/V;/'7[6?[,MY\&
M/ASJOA/1?%%Q\;OV4/B4E_XVOM8T[0!H7P*_:J^#/QR\76CW6A:%XDU$:MJ/
MA/X=:WIWAR`:4UG=^(KK2[34[_2--GN]7L??OV@O'^L_"CX"?&[XI>';;3+W
MQ!\-?A#\2O'^A6>M0W5SHUWK/@[P9K7B+3+;5K>QO=.O9],GO=.@BOX;/4+"
MZEM7E2WO;69DGC/V??'^L_%?X"?!'XI>(K;3++Q!\2OA#\-?'^NV>BPW5MHU
MIK/C'P9HOB+4[;2;>^O=1O8-,@O=1GBL(;S4+^ZBM4B2XO;J97GD`.@^*VG?
M$;5_A?\`$?2O@]XC\/>#_BUJ?@/Q=I_PO\6^+M%G\1^%?#'Q#O-`U"W\&>(?
M$OAZVN;.XUS0-&\1R:;J.KZ1!=6\NHZ?;7%I'*C3!AP?[+?A_P#:#\*?LZ?!
M;PU^U?X[\(_$_P#:4T3X=^&M-^-OQ"\!:7'HO@[QA\1;73XH_$FN^'M-A\.^
M$+>#3KZ^$DD3VWA#PE:W+;[JU\+>'+>>/1K+S[]D?X_>,?CW_P`-.?\`"8:;
MX9TW_A2W[7GQH^`/A;_A&K/5+/[?X.^'/_"-?V)J6O\`]J:SK/VKQ-=?VS=?
MVK>:=_96ES^7!]DT:QVR>;Y_X6_:H^(6M_%K_@I)X#N]'\&QZ1^QW'\,W^&=
MS;Z?K::EKI\9_LT:%\9=4_X3N:3Q#+:ZF(/%&J7%A8?\(_9^&#%H*0VMP;K4
M%?5)`#[[HK\??V2?&7_!4S]J7]E;]FO]IG_AI[]@'P+_`,-#?`7X1?&__A"?
M^'>'[17B?_A$/^%J>`=`\<?\(Q_PDG_#TGP]_P`)!_8/]N?V7_;7]@Z)_:GV
M7[;_`&3IWG_9(?7_`!1\?OVE_B9^TS\5OV5?V<_%O[.OP^\9?LV_"SX&?$OX
MH^*OC=\+OB#\2XOBE=?&T_$>+2?#WP\\`^!_CI\)]3^&OABS;X;WAU#XGZ]X
ML^*IT_4]67P[;_#S7)-'N-7O@#](Z*\L^">O_%GQ-\+?!VM?'7X?>'OA9\7+
MK373QYX&\)>-5^(GA31]=M+RYLYI/#'C(Z/X=N=;T#58;>'6-)EU'0='U:UL
MM0AL-5T^#4+6Y!*`/SK_`."@'_)[?_!%O_L]'XZ_^L!_M5U^IWB/Q%H?A#P]
MKWBSQ/JEGH?AKPQHVJ>(O$.MZC,MOI^CZ'HMC/J6K:I?W#_+!9Z?86UQ=W4S
M?+%!#(YX4U\K?M6_L=:+^U/K7[/_`(O_`.%T_&GX"_$/]F?XEZ]\5?A5\0?@
MDOP9N]=T_P`2>)OAIXS^$NMV^KZ-\=O@W\</`FLZ3>>"_'OB.S%K=>#_`+3;
M7EQ;ZA:WL%Q:0L/-]0_X)\6?Q(L+KPS^U-^UE^U=^V+\-+Z2R?4O@[\:KS]G
M+P)\*_$$5G)-<-I?CGPM^RA^SA^S7_PL_P`,ZA=&RGU?P7\4;WQIX,U4:7:6
ME]X?FTZXU6SU(`_+/]DNVO\`X:>`?^"%_P`6?B/INM:#\*-6UW]K_P`*>&9-
M<TG4]+L_A[K?[74/BCQC^Q\_B33KJQ5O"%MJ'PKM=1^#/A=M8BTE;#Q!\1_#
M/@M3;7GB"WTV?^E:N'\>?#3P!\3_``'KWPO^(/A#0?%OP]\3:1_86M^$=9T^
M"YT2]TM?*:WM_LFU5MGL)K>VN]+NK,V]WI-]:6=_ID]I>V=M/%\D6_[$?BC3
M&T[0/#_[=O[=&A?"+3-+M=$MO@VOCOX(^);-M(L[#[#!:W'Q]\=?L_\`BS]L
MVXO`4M[R3Q%-^TXWBF>[MU\_79+6XOK:[`/#_@7"/&G_``5__;M^)?@L6UWX
M`\!_LF?L;_LV_$'7=.N+"73[O]H7PUXX_:0^,6L>%;IK.XEEG\2>"OA)\8?A
M?=:TEY%'<Z59^,M$LGP)!&B?\%?O^2,?LE_]I3/^"7__`*VI\(J_17X1?!SX
M9?`;P-IWPV^$?@_2_!'@S3;[6]6CTG33=W$M]KWB?6;[Q'XI\3:]J^IW-]K?
MB;Q9XK\1ZIJ?B+Q7XK\1:EJGB/Q/K^I:AK>NZIJ&J7MS=2\-^T?^S9X%_:@\
M,?#OPIX^U7Q9I&G?#/X^_`?]HO0IO!]]H^GWMWXV_9Y^)_ASXL^"]+U>36M"
M\003^%=4\1^&+"R\46-G;6&KWNBS7EMI.N:)?20ZE;@'YJ_$6P_X=(_&#Q-^
MT'X4L=<?_@FY\??&9UG]ISX?Z)`VHZ'^Q-\8O%>HRR:E^U7X*T&WBDO](^`7
MQ*UJ[AC_`&C?"N@QSZ9X"\4WD'QHTG2;'1[SXCL?SX_9NOH;?_@FO_P1L_:`
M;6([[X"?!S_@I)\1/B)\8-<TF>?5/#MIX#^(GQ3_`&U_@S\.?B)J=SI,-_87
M/@OPQ\8/BW\+?$&IZ_=LF@^'=)<^.;S4;&R\/'4;?^J75](TGQ!I.IZ#KVF:
M=K>AZWIU[I&LZ-J]E;:EI.KZ3J5M+9ZCIFIZ=>136=_IU_9S36E[97<,MM=6
MTLL$\4D4CH?G[X$_LF?`G]G7]GC3_P!E/X=>"=/_`.%!:3'\1-.T[X;^)8+3
MQ'X>MO"WQ+\:>+/&NM^!Y+#4;1[:_P#!]C/XQU/0-(TG5(;YX_#$%CINI76J
M3Q7%[=`'TC7Y9ZW97_C?_@LG\-=;\$72SZ-\`/V`_C+X7^/EW8W+_9K+7?C]
M\:?@?K_P)\&:T+;?#/KDVE?"#XI>,[/2[]DN='T26VU98XH/%%A)?>L1_L-Z
MYX<?3-#^$G[;G[:/P4^$VEI#;P?!/PEXA_9Y\>>$(]-74+FZN-$TSQY^T#^S
MC\:/VA/"NAS:=/%X<T_2?!7QK\-67A#0+#3[?P%%X3O;87[?3'P8^!WPW^`7
MA.;PA\-]'N[*VU+5KOQ)XI\0:]K>L^+?''CWQAJ4=O'K'C;XA^.?$U]JOBKQ
MOXQUE;6V74O$7B/5=0U":&WM;..6&PL[.UMP#X`_8[_Y27_\%A_^QO\`V&/_
M`%D_1Z_0/X]?\D,^-'_9)_B+_P"H?K%<K\-?V;O`WPM^.7[2?Q_\/ZKXKO/&
M/[4FI?"C5/B!INLWVCW'AG1[CX/?#VV^&OAE/!UG9:%I^JZ?#?:%:QW>NKK>
ML^(7N=6+SZ?)IEF5L%]A\7>&K'QGX4\3^#]4ENX-,\5^'M:\-:C/820Q7T-C
MKNFW.EW<ME+<075O'=QV]U(]M)/:W,*3*C2P3(&C8`_#O_@F!^RC\>/$G_!-
MC_@GYXAT;_@IG^V[X`TC7?V*?V7-8TOP)X1\!?\`!-Z]\*^#-.U+X)>"+RR\
M*^&KSQY_P3[\;>-[K0/#]O-'I.D7'C#QEXL\43:?:6\FO>)-;U1KK4KGUG_@
ML9;2_$K]G'X<_L5^`H(_%G[6'[4_Q/\``GAS]FG7]0GN]-UKX/\`C7X5ZSI'
MQ'\0?MC7NJ>#](CG\,V_[-^DZ`WQ`DU+2+30[+6/%MSX9^']HULGC.&PD],^
M$G_!./XF_`KX5_#7X)_"O_@J'^W]X6^&/P@\!>$?AC\._#/_``AO_!,S6_\`
MA'O`_@/0-/\`"_A30_[9\1_\$Y=7\0:M_96A:78V/]I:YJVIZO?>1]IU+4+R
M\EFN)/J'PQ^R=\.]!_:<\4?M=:SK?C3X@?&C7?A)X7^!^@:KXWOO#MWH_P`,
MOAOH6H2Z_K^B?#'1=!\,>'K?PS)\3O%C6OBWXGZA(^HWWB?5]&\.6<<^G>'/
M#.@:#IH!\K?\$@/%WA8_L:^%O@'#X$MOA+\7_P!D'6]5_9L_:4^%8UVY\27N
M@?'/P:+?4O%OC<^(M3N+G7?%FA_')-<L_CCX5\<:Y))JOB_0OB#:ZIJDK:P=
M3BA^*/\`@CK^R[\5/&__``3G_9=\2C]OG]L3P?X%UWP]XVFE^"?@?2_V--!\
M":9I3_%#QW;7'A[0_'#?L@7O[1>D6-P4DN?[9M/CHGC2RNKB632_%-@L=JEO
M^Q.G?LL^`]#_`&K?$?[7OAKQ#X[\,^/?'GPFT7X1?%#P9HVK:,GPM^*5AX0U
MFYU;X?>-?&GAJ]\/7NJO\2?A[;:GKWAKPUXM\/>(_#\USX2UZY\/>*+7Q'8:
M5X730-3]E;]F[P-^R'\`/AQ^SC\-=5\5ZWX(^%^FZII>@:KXXOM'U+Q5>6^K
M>(M8\37+ZQ?:#H7AG2+B9+_6[J&!K+0]/1;2.WCDCDF22XE`/S^_:9^&7PK_
M`&6?BG_P2/O=(\*:9X/_`&8O@'^T!XW^$\4EQJ%J^@_#/QG\;/V?OB/\*?@E
MXN\2:OXIU"XU6^O/$GQ!\02_#<^*+Z^O_$&J^//BWIM]JVI7>I:Q<SW7[!UQ
MGQ$^'7@/XN>!?%GPQ^*'@_PY\0/AWX[T+4/#/C+P5XNTBRU[PUXFT#58&MM0
MTG6=(U&&>SOK*ZA<K)%/$P#!9$*R(CK\>6G[#6OZ#'I/AKP1^W/^W-X(^$&C
M:?::1:_!JT\??!;QMIS:/91FWM].?XX_%SX!_$?]K]/+M$L[5=2MOVDK?7%C
ML(9$U1+JZU6XU$`\5T#Q#X)UC_@JS^U!\1[>]\,Z=\.O@G^Q!\%/@5^T!X^U
M35/#MAX33XJ>*/BQ\0/BGX0^'/BC5;B_6+_A(/`?PR\11^)M4TS7UMCHFA_&
MOPJ\.Z+Q6%;R[Q#X&UK_`()+?$3X/:Y\$?$%WJ/_``3T^.'QV^&G[/\`XR_9
M;\17M_J4?[*OQ&_:%^(\7@_X<?$O]EW698K_`%/2/A-JGQ.\8Z1X:^(/[/NI
MW$WA'PCI&L6'B3X0OX0TWP]J7@[6/TATC]D7]G+1OV>O$'[*R?"W1=8^!'C'
MP_XD\.>./!7BV]USQK/\0+;QDEP/&&K_`!"\6>+M4UKQKX[\8^*[BZN-2\2>
M//%OB+6/&VMZU*VN:CK]QK`6]7R#X??L$>%O".N?#JX\;_M`?M,?M`>!?@GJ
M&@:S\"_A'\=?&/P_\3>!_A5X@\*Z<VE>&O$XUKPS\+_!OQ8^,?BCP[:,)_#W
MB/\`:6^)GQOUKP]K<</BG0[W3O%<,>MJ`?"&D_!SXB?%K_@L/_P42'@']J[X
M_?LP'0/V4/\`@G"=5;X&>'/V6_$#>-QJFM_MK"Q7Q./VEOV:_P!H=;0>'/[.
MO#HO_"%KX1:<Z[JO_"0MKPAT,:-^NOP2^%OCGX4Z%J^D>._VD?C3^TOJ&I:L
M-2L_%/QMT+]G;0==\/V8L[>U_L#2+?\`9Q^`G[/_`(9FTDSPR:B9M>\.ZWKO
MVR[N$&M#3UM+&U^9OB!^P3=^(?VDOB=^U'\*_P!L3]JK]FCX@_&3X??"3X;?
M$G2?@[I?[(?B7PAXDT+X(W7Q#N_A]<_V?^T;^R=\?-8T?5=.E^*7C(7MQH.O
MZ7:ZHE_;B\LI#86;1?3/P2^%OCGX4Z%J^D>._P!I'XT_M+ZAJ6K#4K/Q3\;=
M"_9VT'7?#]F+.WM?[`TBW_9Q^`G[/_AF;23/#)J)FU[P[K>N_;+NX0:T-/6T
ML;4`^#?^"W'_`"C0^/7_`&-_[,G_`*UA\#:O?\%.8[SP]K'_``3U^-&M7%S!
M\&O@/_P4"^&7C+XZ7$<=]-IVA^%/&WPI^-/P/\#>-?$<5G:W42>&/!GQI^*W
MPRUC7=4U18-(\*V`E\9ZC>Z?;>&WO[;[+_:E_9N\#?M<?`[Q=\`/B1JOBO1/
M!WC/4O`NJ:IJ7@B^T?3?$T%Q\/OB%X4^)6C)87FO:%XETJ*&ZUWP?IEIJ:W&
MC73S:3/?06DEE>2V]_:^T^(O#OA_Q?H&M>%/%>AZ1XF\,>)-+O\`0_$/AW7]
M.M-7T/7-%U2VDLM2TG5]*OX;BQU'3=0M)IK6]LKN":VN;>62&:-XW92`;-?E
MGK=E?^-_^"R?PUUOP1=+/HWP`_8#^,OA?X^7=C<O]FLM=^/WQI^!^O\`P)\&
M:T+;?#/KDVE?"#XI>,[/2[]DN='T26VU98XH/%%A)?>L1_L-ZYX<?3-#^$G[
M;G[:/P4^$VEI#;P?!/PEXA_9Y\>>$(]-74+FZN-$TSQY^T#^SC\:/VA/"NAS
M:=/%X<T_2?!7QK\-67A#0+#3[?P%%X3O;87[?3'P8^!WPW^`7A.;PA\-]'N[
M*VU+5KOQ)XI\0:]K>L^+?''CWQAJ4=O'K'C;XA^.?$U]JOBKQOXQUE;6V74O
M$7B/5=0U":&WM;..6&PL[.UMP#XB_P""R=K/??\`!-G]I:RM=2O=&N;RR^%]
MK;ZQIL>G2ZCI4]Q\;/AM##J5A%K%AJNDR7MC(ZW5K'JFEZEISSQ1K>V%Y;&6
MWD^,?`?PP^)WB3]M+Q]^PS_P4C_:S_:(_:"\&^(%T_\`:%_8V\+^)Y?V8/A5
M\'_VEOAC\-O$?@WQ!KV@?$#2OV</V<_@1\2/%/Q<_9Y\=6>D2?$KX9ZQX^UC
MX+_$SX>^*_#?B_5?AK<Z;)J>BZ!^R_[2'P!\'?M0_!?QG\"_'^I>)M(\)>.?
M^$=_M;4?!]YI>G^([?\`X1GQ7H7C"P_LZ[UK1O$&F0^=J?A^R@N_M.D7?F6,
MMU%#]GN'BNH>6_:=_93^''[57A_X?Z=XTU/QAX,\6_"+XH^#_C+\(?BQ\,]4
MTO0/B?\`"_X@^#K[S8]5\):YK.A^)-*2Q\3Z#<:SX&\<^'M:T'6?#WC#P+XD
M\0>&];TNYM;]7@`/S1^,/PJ\=_%;_@M;=Z9X#_:6^-G[,][I?_!+?P;?WWB+
MX(Z#^SCKVL^)+63]K+XB6Z:+K4'[2'P`_:!\/P:9!,ZWT4OAW0M!UDW4:)/J
MTUD9+.3S+]L+X#_%/X5?MB_\$=M:\=_MI_M,?M+:;J'[?NNZ7:>$?C9X5_8X
MT'P]H=\W['W[3MVOB/2KG]G+]DSX`>*YM9C@M9],2#6_$^L>'C8ZC>22:"^I
M)I^H6'[(P?LV^!X/VJ+S]KT:OXM?XEWW[/FD_LVSZ,]]HW_"$?\`"#Z/\1M8
M^)UMJZ:8F@IKJ^+9=?UN[M+B^/B0Z,VD1V]O%H,-XDE_+4^./[,'@'X_>/?V
M9/B+XQU?QAINM_LI?&BZ^.GP[M?#.H:+9Z7K/BV[^&7C_P"%,FG>-(-4\/ZS
M=ZCX<7P[\1]<O4M-#OO#NIC6K72KAM7:Q@N].O@#Z.K^;O\`:._:=U+_`()$
M?M(_MPZ5:V8USPU^W=\/'_:@_87\`WUT;6T\8_\`!0=KOPM\#/BI^SSX8FFA
M&EVUY\6/$_B/X$_&6'2(;*\U"YNM:^-'B^_N[FVMIK>Q_I$KP+XT?LR?!K]H
M'Q5\`/&GQ4\*1^)/$'[,OQ?M_CG\(;M[JXMET'XBV?@_Q7X+LM3NHH&5=2M+
M2P\77FIV^G76ZU3Q#I?A_62C7.C6N`#S+]C3X`^'OV'?V.OAS\+_`!%KMM<7
MWP]\%:KXY^-_Q&U%;.*?QC\4_$<FH_$/XY?%+Q%=V-K;)=WGB7QSJOBGQ'>7
MKPM*MI-#`&:*VB4?AO\``CX3_M:_\%`/AE^VO^U-K7['W[+?Q+^$/_!5;PY/
MX.^'-S\=/VT_BY\#?B?X9_8:\-:'J_@K]GO1+'P5X$_8%^.UEX1F\46-]K/[
M1EKJ5K\3[C6G\3?$RRO[_3M!U+0[6SM?Z#OVJOV</"?[7?P`^)/[-WQ`\4>/
M?"?P^^+FCP>%/B!=?#;5]'T'Q1KO@:XU*RN/%W@;^V=9\/\`B2/3O#_Q"T"W
MO_!'B^XTNRLO$?\`PBFOZS'X:U_PWKLEAKNG^Y:-HVE>'='TGP_H6GVFDZ)H
M6FV.C:-I5A"EM8Z9I6F6L5EIVGV5O&%C@M+*T@AMK:&,!(H8T10%4"@#\4/V
M>_CC\3OB=_P2<_:F^%'[1NH6EW^UW^R!\#_V@OV5_P!JG[+>P7T6L_$[X:_!
MO5?[(^)>G745EI+WWAWXT_#O4_!OQ9\/:G)HNBO=V?BYX9M)TR\L[O3[7]*_
MV+_^3._V3O\`LVGX$_\`JKO"M<KXJ_8H^%7BCXH_M'_%9/$'Q%\-ZK^U=^SY
MI_[//QJ\.>'-?TBW\&>)-,T.Q\4:)X:^)L.B:IX<U:2R^+OAOPKXOUCP=IWB
M9+Z31KOPPFE:=KOAG6'T72KBTX+X+_L3?%+X)Q_"_1-+_P""C7[:_C'X<_"N
MR\):%I/PJ\:>#_\`@GH?"6N^#_!MG8Z7IG@SQ'K?@[]@SP?\3I-&N-(T^WTN
M_P!2T+XA:#XOEM]]Q;^)[74F^W@`Y+_@F\A@N/V_[64JMS;_`/!2K]II[B#>
MC2VXU+3/AOK-@)T5BT+7>DZEI^I0)(%>2RO;6X"^5/&S>,_#G;<?M"_\%UKZ
MWDAN+2.]^"6B336\\,ZP:OIO[`/P\U"^TVX6*1WM[VUL=<TB[EMYUCD6WU&T
ME"E)E)^N?B)^Q+H>O?$CQQ\8?@K\>/C[^R+\3_BO+X;F^,'BC]GR\^#FIZ=\
M5[CPCH3>&?#VK>,?AS^T7\&?V@/A+'XPL?#\6DZ#/\2?#'@'PY\3M6\.^&/"
M7A?6O&>H^&/#&BZ-9^G_``X_9@^&'PK^$OC?X0>%#XLDTWXF77CO6?B-XT\2
M^*M4\8_$KQSXO^)4-S!XN\;^)_&7BE]7O=4\17<=Q'::3%-%_P`(]X7T33="
M\)>%M!T7P9X>T/P[IX!^47_!,#]E'X\>)/\`@FQ_P3\\0Z-_P4S_`&W?`&D:
M[^Q3^RYK&E^!/"/@+_@F]>^%?!FG:E\$O!%Y9>%?#5YX\_X)]^-O&]UH'A^W
MFCTG2+CQAXR\6>*)M/M+>37O$FMZHUUJ5S]J?M,?LE:+^TE>Z;\6OV>_CU=?
M!O\`;7_9\AN?`7@[]HOP9=Z-XCDM]0M[33_$.J_!7]ICX<:-+IWA7XF_"_Q.
M=5TS7O%/PN\1Z=I-]X>N-:T_QM\/9_!GB)='U<<A\)/^"<?Q-^!7PK^&OP3^
M%?\`P5#_`&_O"WPQ^$'@+PC\,?AWX9_X0W_@F9K?_"/>!_`>@:?X7\*:'_;/
MB/\`X)RZOX@U;^RM"TNQL?[2US5M3U>^\C[3J6H7EY+-<2>M>*OV$_#-Y\3?
M%WQB^$WQW_:`_9I^(WQ5M_!MM\>-=^!NH?!Z#3_CT_@C29M!TS6_B#X/^*7P
M:^*/@;1_'=YH+VF@ZI\5?A7X:^&_Q6N-`T7PWH%OXWM-%\-Z)86`!M_L&?M0
MZ]^UO^SQ8?$KQOX(L?AQ\4O"?Q$^,'P*^,W@K1=7F\0^&-$^,?[/WQ/\4_![
MXECP9K]S;65YK/@G4O%7@_4-8\(7NHV5IJI\/ZCI]OJUO'J<%V**]P^!?P-^
M&?[-_P`+/"WP;^$6@2>'?`OA*/4WLK:\U75O$.MZKK'B#6=0\3>*_%GBOQ1X
M@O=3\1^+_&WC7Q7K&M>+?&OC'Q)J>I^(O%GBK6M7\0:[J-[JFHW5S*4`?*/[
M<OQ.^+<GB?\`9O\`V1O@'XU'PL^)_P"UUXP\;Z9KGQDMK2PU+Q-\'/@-\)/"
M0\7_`!G\=_#C2M;TO5O#>H_%6]34O!WPY^'DWB:QO]"\*^(?B#!\0-3T/Q39
M^#IO#&L6(_\`@EA_P3[N;?1;KQ=^RS\+OBGX^T%-#>Q^.OQET=_BY^TM_:GA
MVXM;_2?$;?M*?$*?Q#\<XO$UIJUJNN0:[9^/;74+76[B]U2SEMKN]NI)<O\`
M;P^$WQCF\4?LR_M>?L\^%Y?B3\5OV.O'7C;7-8^"EI>Z1I.M?'?X#_%SP7-X
M&^,_PS\&:YXBOM/\/:-\1K1+?P?\4?AV^N7NFZ3XB\6_#/3/`FJZ[X;TKQ??
MZ_IW*?$C]O+_`()4_&[X>2?";]I_XL_LUII_C^W\.3:W^R3^V=I/ACP9\5=;
MU&WUK3M5\.:#K_[)'[0.EZ7\2-<\2:?XTTNRAT+1U^'.JWDGCK0A:>'EN]>T
M@+``>H>'_P!GG6/V;/V;OVF/`X^./Q9^,'P]N?!WCJ_^$F@_&+6_^$W\3?!O
MP1;?">'1_P#A6]M\4-9-Y\1/B5I,6NZ;J^OZ=X@^)WB#Q+XLL[768=!FUF^M
M]*BO+K\"?V(A_P`$$V_X)E_LM+/%_P`$^)OVQW_8/^$R>*8_V;8/@K<_\%%3
M\:'_`&>]%3QXW@6+X!1R?M<?\-!IK[:Z^L2^#E_X63;ZVNL7&K/&\6JR+]@?
MLF_LA_#W2?B+^WM^W?\`"/\`92^&W[&_P!^(?[)$7[/7[,/PN\(?`30/V=O&
MOCKP!X>T[Q?\1?B+^T!\4?AGIG@OP+KO@[4_B;XPU7P]H'@WPSXXT9/&D'@3
MX=:'J^O6FB/J]MHMIY3^SWX&\8?LI_L%?\$Q/^"H_P`!/#6M^)I_!W_!.']B
M_P"'W[>/P=\(:5:7VK?'/]E#0/@;X3U*W^)NA::DEI>:O\:?V5I]5U?QOX0C
M@FNM2\6_#*[^(?P[MK2_U.]\)06@`[]K2#PU;>`O^#?.W_X*]WGP"U".'QMX
MKB_:_OOVHE^&*?!2[^)R?\$Z_CFLMQ\2T^(UK9?"]=5F^*PT)[9;VSM=+'Q$
M;31X;@BO/['0?I1^QTO_``1%;XO.?^"?R_\`!*UOCVGA36FD/['0_9(/Q>3P
M.;C34\1,Y^"H_P"$S7PH;I]'36B<:1]H;35OCYC6H/@O[?O[2G[/.B_M"_\`
M!$7]ISQ!\<OA+X8_9SU?]HOXZ^,K#XZ^*_B#X6\*_"67PKXZ_P"">_[25IX-
MUZ3Q_P"(=4TSPQ:Z9XHO=?T/3]#N;O4X$U+4=7T[3K7S+V\MX)/N[1O^"E__
M``3O\5:5X\U;P+^W-^R-\2(_AE\.O%_Q:\=:?\,_VC?@_P#$+6_#GPW\!:<=
M5\7^,M1T3PAXQUC5+?P_H%D8Y-2U62U2RM'N+:*>>.2YA5P#X&_X*L^*/VG/
MVC?BA\.OV!OV&_'C_#WXR^!?!O\`PWE\7?'\$<EU9^'M*^"OB"74OV5OA#K"
M6FN:5)M_:!_:/\+::-8TZ[VI<_#KX:>,Y"7M[@J_Z*_LW_&'X._\%$?V-O`'
MQ.UCP+H/BOX;?'OX=OI_Q+^#WQ+\,Z/XAL-(U^-KGPS\5O@U\3?!.NIK.E2Z
MOX&\;:9XD\!^-/"VMPWT=MJ^B7^GWL<IC;=^:7[!G["%A^TSX+\=_P#!0#]J
MW5OVJ_!'Q_\`V[O%Y^-2^#/AG^V'^V)^RV/A7^SO'9IH_P"RU\%_$/@S]GGX
MX_"K2+C7_!'P@BTC7?%J^);37]6TKXC^-O'ME:ZP^GF&,>G_`+(O@;2/^">7
M[</Q/_8ATBZ\7C]G3]KK1_$7[7'[*M]X\\:_$#XH:WIOQNT>>SL_VQOA5J7Q
M+^(VH>*/&'B36/$5U>^$_P!HK3)O&7C3Q!XBU:Y\7?%6^:^GATMX[<`\+_8P
M_P""?W[!MA_P4J_X*<06/[$O[(UE#\$OB'^Q#K?P8AM/V;?@W;Q?"+6KS]G+
M0_&5YJ_PPCA\&(G@'5+OQ?#%XJN;_P`*#2;N?Q)%'KDLKZFBW0^>/A'_`,.8
M_P#AK?\`X*P?\/%_^'8G_"Z/^'A^K_\`"*?\-J_\,J?\+0_X5?\`\,F?LG?V
M1_PCW_"\_P#BJ_\`A`O^$K_X3/\`LW^S?^*>_P"$A_X2?[+_`,3+^U:_4#]C
MO_E)?_P6'_[&_P#88_\`63]'KY=_8X_;;_8Q_9K_`&C_`/@KAX(_:+_:Y_9A
M^`7C35_^"EVO^*M)\(?&OX^?"KX5^*-3\+WG['G['>D6?B33]`\=>+-"U:]T
M"ZU;1-9TRVUBVM)=.GU'2-4LHKA[FPNXH@#R#_@H0O\`P2U7X)?\$H3X(7]@
M-?\`@G4__!4JP;Q:?"H_9V'[%;J/V5?VT4\0MXB.D#_A1C*/&Z6R:R=3R/\`
MA*E@6^/]KK&![-H"_L#-\9/V61_P1QC_`&5D\9']H_PW)^T1<_L!6GPO/P>;
M]G*'PCXO'Q6A_:3O?V?X&^&186,^A+\,+?Q[+_PF4?Q*N?!<G@]8[.75I3Z1
M^W!\7O@S^T+XK_X(Z_$'X*?%#X8_''X8:]_P50TO2[+QO\+?&OA7XE^`]9FT
M[]C7]M[2M;TZU\2^$]3UKP]J,EA>17.G:K:17LS6MS%/9W<<<J21C5_9[=O^
M":?[3UA^Q#K[R6'[%W[3GB/Q%XF_8$\2:EK&G)HGP2^*D\%UXG^(W["R0W,=
MI>6/AR^2'7/BI^S/:&?4XX=`/CKX76,MK:>#?"&F2`'ZU^/?A_X#^*O@[Q#\
M.OBAX)\(_$CX?>+M.ET?Q9X%\>^&]&\8>#O$^D3LC3:7XA\,>(;+4=$UK3IF
MC1I;'4K&YMI&1"\1*@C\"/\`@GE^P3^PQ8_M[_\`!52^LOV+_P!DZSOO@'^V
M5^SG<?`J\M?V=/@_;W7P6N+7]CG]G'X@VL_PEN(O!R3?#F:V\?7]]XWMY?!S
MZ,\/B^]N_$L;+K5Q->O_`$2U^1?_``3\_P"3[/\`@M=_V>)^SW_ZP5^S-0!\
MV?L!?MW?L/\`[/6K_P#!0GX>?'[]LK]E/X'>/X_^"I'[;6M/X&^,'[0_PB^&
M?C%-&U/Q]I_]FZL_AGQIXOT36ETS4/L]Q]AOS9"UN_(F^SRR>4^WLOV0/CW\
M"_VC?^"SO[;7C[]GOXT_";X[^!+;]@+]BOPY<^-?@U\1O!_Q0\)6_B'3OC/^
MU?>:AH,_B/P1K.N:/%K-C9ZGIMU>:7)>+?6MMJ%C//`D5W`\GO7_``2A_P"0
M+_P4&_[2M_MT?^I]I->+7'Q:\!_`7_@KG_P4:^-?Q1UZU\,?#KX4?\$M/V0_
MB!XUUZ\E@AATSPWX5^+7[8VLZK.#<3012W!M;22*SM?-22\O)(+2',TT:D`X
MK_@J7\1/VM_CQ^T'X"_8[_8(\3R^&OB7^RY\.&_X*)?''6HXO-TWQ1J7@:^U
MVQ_9)_93U65K*X58/VC_`(G>&_%6J>+%LICJ>F>"_ATK7%F]CXEMVE_7O]G/
MX_\`@K]J?]G+X7_M#?#U[D>$_BU\/]/\6V-C?V]Q9ZKH5[=VCP:]X5URRO(+
M:[L/$/A#Q#;ZKX7\0Z?<V\,]AK>D7]I+&KPL*_+']B7_`()YZ9\9OA[XC_;)
M_:PUC]J+P=^T_P#MJ^*)OCU\0_#OPE_;1_;&_9IT_P"'_@/6+:.T^`?P5U7P
MC^S?^T5\/O!VJZA\'O@_%X9\-ZCJVI:=?ZR?$MQXFCDU![8P11[7[&GAS1_V
M`/VS/CI_P3HL9?$UM\"/COX/U[]M;]B^[\;^-/%/Q"UDZS-JEGH7[9WPDE\=
M^.=4\1^-_$^K>'/B-K?@SXYQWWC?Q1K7B75X/C?XEN4U#4H-`U&2Q`/CS_@A
MC^V%\?\`X8?LU?L)_`/]NKQQ;^.?#/[5'P(\'>+?V'_VF-0M=2L)?%&I_P!C
MW5]KG['OQ9U2^N-2T]_C'\/=`M+75?A)XEO-8M+[XV?#R'5+6TT8>*/AUXAE
MU/[Y^$O_`"G*_;3_`.T=/[#W_J\/VO*\O_X)E_LX_"K]K'_@@]^PY\#/C)HE
MQJ_@SQ=^RE\)9DN]+U"ZT3Q3X2\3:';VVM>$/'W@7Q-ITD.K>$O'O@;Q)8Z;
MXG\'^*-(N(-1T37=-L[R"0JDD4GE_P#P3<\#?MI>"/\`@JC^VEHW[9NG-XHU
MGP?^QS^RU\*?A;^TM8:;'IVA_M5?#?P-\6OVA]9T'XIWMA8VT.C>'/BG8Z5X
MYTGPG\9_!^FNEO9>/-&O?%NDZ;I'@[QQX1LP`?LS^T]\%O%/[0OPDU'X1^&_
MB]XI^"EAXM\0^#X?B#XL\"PW<'CG6?A58^)M,U'XE?#KPAXITW7?#^K_``XU
MKXG>$;34_`8^)F@7<WB?P+8:_?:_X5A@\2VNDZEI_P"-5Q>?LY_#'_@II^R3
M^S;^P=\&]1_90\?6'CWXQ^,_VL]:F^!GBS]EWX-?M$?!+P[\-O&'AKQ'X3TC
M_A.O"?@/3/VQ?C%K?Q=O/AAX[\*_%GX::7\3I-(\->`O&?B34OBO9Z->W%AX
MB_97]HKXS^*/@1X<\&>.-*^%NK?$OP3)\1_#GA_XR7_AR^U>3Q)\*/A=K=MJ
MMKJ7Q?TOP;H7A#Q7JOQ$L/!GB$>&V\8^&K&3P_=Z7X$O_$_CF#5+U_"'_".:
M[^=G[4'Q@^!7[?UU^S'\*OV.?C3X%^.7Q#^'W[9O[._QOU_XC?`;Q;HOQ(\/
M_`'P=\"?B!I7CGXM3?$;QQX*UF?1O`^K^./AY;:[\%[?P'JFN6?B_P`43?%*
M/3IO#-_X7/B2:T`*/[*GP3^!_P#P4+NOVDOVH/VI/`&B_M!BX_:U^/'P9^!W
M@KXTZ#I'C#P;^S[\/OV3OB?XO^`WANY^$7@[4_[3\/\`@;XA^)?%?A7QQ\3-
M?^+NA6EA\5+^^\:6>@S>*E\/>#O"FG:7\67]E\8_$%WXH_91\=V?Q6_:9_9`
M_P""=W_!0O6?A_\`M._#^>S\2?'7XL_&K]BGXG?L767QH_9S\,>-O"&DZ?J_
MQ%_:0T+X+?$7XT^!_#?C?P+)IOQ$\?\`Q;\&_#W0]<\16'Q%UY?$%AJ'VC^R
MI\;_`(&?\$\[W]I']EO]J7XA:%^SV\7[6?QZ^-/P,\9?&KQ!H_@_PA^T)\._
MVK?BAXL^._A^#X0>+M3.F:!XZ^(/A?Q;XN\:?#'Q%\(]!NK_`.*>G7_@ZPUZ
M?PJ?#_C/PEJ.J^E?L(*?">A_MY_M\_&.SUSX.>"/VK?CWJ7[0^AV'Q5T:;P/
MX@\%_LV_!OX#?"[X(_#WQCX]\/ZJPUSPC>^,?"'P?O\`XK3>'/$]EHWBGPOH
M'BS2-"\3^'=&\3:=J]BH!^9UW\%=-N/B#\=]0^$WPX_:F^$WP\_:#\1?`WX+
M?\$SOV8=3^//[<7['OPW@\6>'OA=JC_M"_%SQ%^Q1X&^,_PCT+X>_LA_#SP]
M:^$M<\2_#?XF?`WP=JGB"[\#>./#)\.BP^*?@"PU3^@;]E3]F?X=?LA?`CP+
M\!/AC;2G0O"%I>W6KZ_?K&WB'QYXX\1ZC=>(?'OQ'\77:9.H>+?'WB[4]7\4
M>(+QV93?ZE);VPAL;>UMX?QS_:!N_C_JW@?P;^WCK<GQ$^%&F_'CX]_!7X6>
M*=;\$:5K+_%O]D/_`()?:OX@O];U76--TJ'PQXJU/P;\0_C5XPLO`'B;]I/Q
MEI^D6&O?";X?>*;=#K>C77P+LO$EKZK^SE^TWX/^$_BW]L3Q[\&/BQ\4/VJO
M^"9_P*_9A\&_&'0/BK8_$_QY^V?JK?';2-;^,FH?&[X8_!7X^>,?B#\4/B#\
M=X[;P'X<\!:OK/A:]\<>(M.^&?BW4;;PSI.KZ9!JU_H'AT`_;ZBO)O@/\9/"
M_P"T/\%OA7\=O!&G^*=)\'_%[P'X8^(GAG3/&_A^Z\*^+[#1/%>DVNL:=:^(
M_#MXTD^DZM#;74:7EIYUQ"LH+6UU=6S0W$OK-`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!7.>+?!WA'Q]X?OO"?COPKX<\:^%=4:R?4_#7BW0],\1^'
M]1?3=0M=6TY[[1M8M;S3KMK#5+&RU*R:XMI#:ZA9VMY`8[BWAD0HH`Z.BBB@
C`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g30330image4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image4.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`)$!
MX0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[?/AI\-/AQ?_#CX?WU]\/_``3>WU[X)\*W=Y>7?A70KFZN[JYT
M*PFN+FYN)K!YI[B>9WEFFE=Y)9'9W9F))[;_`(53\+O^B;>`?_".\.__`"NK
MX!_;B^#7B+X]?\$]/!GPZ\.?!'_AI+_BX/\`P3X\?>+?@+O^%G_%V/A9\'?V
MM?V:OC!\9?!7V3XW>+?`GPEUG^V/A+X$\:P?\(YX^\7:%X=\3_\`(NWEY_Q-
M$AE^#+__`()]_&GXAZGH5GX)_9MA_97^"P\>R>-_@W\'K[QQ\*)5_93N/!LW
MP;^(WPYU!?"OPG\9^)_`GA::V_:)^%]]\4=.^&WP5\3>._`/AR74;6Y@UK.K
M:UX?T\`_?'_A5/PN_P"B;>`?_".\._\`RNH_X53\+O\`HFW@'_PCO#O_`,KJ
M_F[_`&E_V#/VA/VB/%VL?%[XT?LF?%_QEIOQJ\:_`3XR>/OA1\,[;_@F%\:_
MB!\/_%GA+P7^W/\`"RR\'S^%/^"@?B/XA?LHWY^&7PG\0_LN:%XSUSPM;ZJ^
MI^,/$/B'Q#\+M:U=O^$UU*R^G_BM^QC^T!<?!SPM\._^%/Z[\<_A=<^-OVH?
M'7C;X3ZM\5/A;'\2-`M/B=XI^*>?"?@[_A:DGB;X&>,/#7C7P=XQTS6/!GP8
M\:W>E_!W2_%5E=?"'QU=>%_@;X\N9?A"`?M+_P`*I^%W_1-O`/\`X1WAW_Y7
M4?\`"J?A=_T3;P#_`.$=X=_^5U?B!%^R)\6D\/>"-3^//[#>F?M/?!?2/`_P
M]T+QK^Q-IFN?`[5[36_&.C_#WP7X<\$^-]-\#?'WX^3?`7Q'IGP-DT+Q;H8^
M%?Q%^,^JZ!X7_P"$ZL_$OPG\8^,=0^%GA4>(<+X@_L)_M<Z]^S%^W;X+^'W@
MA/!VJ_'C]@OQK^SK\&O@'KWQFL==\%Z!I?Q/\3?MV1Z=\(;SQ/-J.K:;I'B/
MX->'_C/\']>T;6XK*?P%HEI<:K\#/`/C"Z\`6!\5:$`?NY_PJGX7?]$V\`_^
M$=X=_P#E=1_PJGX7?]$V\`_^$=X=_P#E=7YX?LT?#;X^?!+PO^VS>>"_V:(O
M`?C/Q9X[USQG\)M)\8?$'X:WNE_%;XI^(X-<FU;QAJWB+X=>*+FRUGX:1:_>
MZ#+:_%CXC>`/A?\`M.^,/!EK<>'?BA\/_$_B'P!X2\5^-_SQ^,?_``3L_;G7
MX0?"WX!:EX:_9L_;;M_@_P#&7QK\;&^+/QP^#=OKNAZSH?QLTOQG=_$RV^&'
MPG^,7[77B3Q1H?[6'@KX@7WB;Q]\,?&_BSXOZ'\&]*U+XF^&/#WAN_\``7@[
M1-3T;X>@']#O_"J?A=_T3;P#_P"$=X=_^5U'_"J?A=_T3;P#_P"$=X=_^5U?
MCM^SM^Q=XF^'?QO_`&Z_&5Q\"?C5I7CWXQ_#OXP^&M#^,/C;PQ_P383P%\4M
M.\2:AI[^"M,TOXO?">(_\%`/$/C&\L+32)/$.F_M*^*)?A)I.I:?KL7ARWT_
M3M)^'D=IZM\,?V7?VA/`MS\/I1INHWGA[5?VI?"/Q.^(OA'Q#\0]/U>'P%I_
MA#P%9>';+QW\.+6;4]5L=,TCQ##:+HOCCX?:)JUC82ZWIND>/O#GA2U\3>(?
MBAKGC4`_3/\`X53\+O\`HFW@'_PCO#O_`,KJ/^%4_"[_`*)MX!_\([P[_P#*
MZOQ`^.7[#W[6WC'X3?\`!4/0OA_X=2/Q)^TI^S3^T7\%/ACX1U[XB>'].\%_
M$AOC9\9O^"AVJ027@M-6UBS\)>(_#WA[XY_!KQ[HWB+7])L&N+34-5^'=[J&
MD2:EXHO?"6_XN_9'\5ZIJ'Q[TM/^">QUO]I;Q;X*_:NL/^'A#?&+X/Z6?B;H
M'Q*\)?$G2_`7@;_A(E^(0_:/U4:[-XC\(:4O[-7Q'^'7AS]E;X6KIPU/PY\0
MYG^'?@7^U`#]H/\`A5/PN_Z)MX!_\([P[_\`*ZC_`(53\+O^B;>`?_".\.__
M`"NK^>+]J_\`X)K?&OQGKNCP?%+2?VJ_V]O!4.L_#;5V\0)\/O\`@C!XV^*^
MDW>A_"_XE^&I-&MOAU^UO\&?A7^RE)X+\*:KKMM$OB%_AC?_`!D%YXF?^Q/%
MVI>'QJ\>G?J3^P7\(O'7PDUK]IN#Q-\"]0^"VA^,/BV_C'1[K5_%GPW\2W_Q
M&\1ZU_:]YXW\86MW\*_$5UI7B;PW+>3Z5;^%OB?\2?`'PC_:$\8Z.(?#OQB\
M&ZI<_#_P[XZ\6@'VI_PJGX7?]$V\`_\`A'>'?_E=7$_$#X:?#BRT*PFL_A_X
M)M)G\;?#2T>6V\*Z%!(]K?\`Q'\*V-];,\5@C&WO;&YN+.[A),=S:SS6\RO#
M*Z-[I7G/Q4N8[+PG;WDRW#PVGC;X7W,J6EI=7]T\<'Q-\(2NMM8V,-S?7MPR
MH5@M+.WGNKF0K#;PRS.B,`6/^%4_"[_HFW@'_P`([P[_`/*ZC_A5/PN_Z)MX
M!_\`".\._P#RNH_X63X=_P"@=X^_\-3\4?\`YCJ/^%D^'?\`H'>/O_#4_%'_
M`.8Z@`_X53\+O^B;>`?_``CO#O\`\KJ/^%4_"[_HFW@'_P`([P[_`/*ZC_A9
M/AW_`*!WC[_PU/Q1_P#F.H_X63X=_P"@=X^_\-3\4?\`YCJ`.)^)?PT^'%A\
M./B!?6/P_P#!-E?67@GQ5=V=Y:>%="MKJTNK;0K^:WN;:XAL$F@N()D26&:)
MTDBD171E8`CMO^%4_"[_`*)MX!_\([P[_P#*ZN)^)?Q`T*]^''Q`LX;#QLDU
MWX)\56T3W?PT^(]A:I)/H5_$C7-]?>%;:QLK=6<&:[O+B"UMHPTUQ-%"CN.V
M_P"%D^'?^@=X^_\`#4_%'_YCJ`/'?C+X@_9I^`>F>#M<^)O@KP3H6@>,_'6G
M^`+;7AX#\/W&D:%J>HZ%XB\1#6/%5VMBHT+PI8:;X8U.XUWQ+<*VF>'K5?[6
MUR73]"M=3U6P\6/[3'[&4.L:9X>O?`V@Z=KVI_!/XC_'S^RKSX>>#O/T[P-\
M-=7UK2;R#5Y[>:XL-/\`$'BM/"7C_5O`NE3WFSQ'HOPW^(-^EW;#PKJ44?TM
MXRE^%OQ!E\*/XP\*^.=;3P7XF;Q=H%O=?"_XM+9PZX_AKQ)X0>>]LX?"D=MJ
MMK)X?\6Z]8S:9J<5WILXO1+-:RRP0/'\GZK^Q'^P7JWA#5?!<OP`\46&FZEH
M%WX1LM7T'P1\?O#OC?P?X.OO`6M?#&Y\'?#GXAZ'IFG^.OAMX4?P-XF\4Z(F
M@>!?$.@:;`?%'B/5+>WBUG6;[49@#YP_:#_X*L_\$VOV?=,^'M]?^"M%\<S_
M`!-TCX/Z[X;BTC3/V</A3X<M=/\`C?X&^-7Q%\&IXK^+/[4?Q3_9\^!G@G6(
M?"WP&\:7&N^&?%WQ1T;Q1IVJ:GX#\/1Z-=Z_X^\+:;J/ZWP?"[X63P0SI\-O
M`(6:*.51_P`(CX9DPLB!P"\-C+"_!`WQ2R1MUCD=2&/P_P"(_P!BW]BC7O%'
MA+QSI_PP^+G@+QKX&^)_CCXR>&/%GPMLOVE_AIKFG?$;XB>#_$?P]\5^(3=>
M#;?2$NS=^`_%OB/P;8:;>17&DZ%X;U6;2=#L=.M8K9(/N-/B-X<C1(UT[X@,
MJ*J*7^%GQ4E<A0%!>23P@\DC$#YGD9G<DL[,220#B_%7PT^'%MKOPTAM_A_X
M)@AO_&U_:7T4/A70HH[VU3X<?$"^2VNT2P5;FW2^LK.\6&8/&+JTMK@*)H(G
M3MO^%4_"[_HFW@'_`,([P[_\KJXGQ5\0-"GUWX:2I8>-E6R\;7]S,)OAI\1[
M:1XW^''Q`LPMI#<>%8IK^X$UW$[6EBES=):I<WSPBQLKRX@[;_A9/AW_`*!W
MC[_PU/Q1_P#F.H`^6/C/\5O@?\$?B-X7\#:]^S+K'B3P]J7A6]\<^/OBWX2\
M%?!*?X=?!+P?:ZW:>'+7Q%\3+/Q%X[\-_$^]TW4=:NTMA)\*_AM\39-#M(+S
M7?%L?ASP[9W.KQ\!XU_:A_9D\-^)_%G@OP9^SEK'QF\4^`/C_P#!_P#9^\>Z
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M;:XATWQ1KMI?@'$_L#_M/?LG?\%%?@E-\?/@A\(_#6D^!O\`A(H_#]G!XBN?
MV7/&7B"5KGPEX4\9VD^NZ9\`/BW\;8OAMK+Z/XPTM=3^&7Q<O/A_\:?"=['/
M;^-OAGX:6;3)=1^W/^%4_"[_`*)MX!_\([P[_P#*ZO#OV=_`7P8_9;^%7A7X
M*?"33OC?:_#?P+HGA_PMX(T#QAI/[0WQ$;PAX1\)^'-'\)^&/"/A[4_'.E:_
MJNG>&M!T'0M/LM-TF*]-O"4FN&$ES<SRO[C_`,+)\._]`[Q]_P"&I^*/_P`Q
MU`'$_#_X:?#B]T*_FO/A_P"";N9/&WQ+M$EN?"NA3R):V'Q'\56-C;*\M@["
MWLK&VM[.TA!$=M:P0V\*I#$B+VW_``JGX7?]$V\`_P#A'>'?_E=5?X5W,=[X
M3N+R%;A(;OQM\4+F)+NTNK"Z2.?XF^+Y46YL;Z&VOK*X57"SVEY;P75M(&AN
M(8ID=%]&H`X'_A5/PN_Z)MX!_P#".\.__*ZC_A5/PN_Z)MX!_P#".\.__*ZN
M^HH`X'_A5/PN_P"B;>`?_".\._\`RNH_X53\+O\`HFW@'_PCO#O_`,KJ[ZB@
M#@?^%4_"[_HFW@'_`,([P[_\KJD7X4?"P@D_#;P#U_Z$_P`/#T_ZAU=U7PA_
MP4E^(GQ8^$G[(7Q6^)?P>\:1>!_%7@_2[74EU0Z'::S<RVCZC:6EU:V+7LOV
M73;J2"Y=DU"2ROG@9%,*0R'STY<=BX8'!XG&U(3J4\+0J5YPI<KG*%.+G)04
MI1BWRIM)R5]EK9'M\.9'7XES_)N'L+B,/AL3G>98/+,-B,6ZT<-3KXVO##T9
M5G0I5JJI^TG%2<*4VMVDDVOK;_A5'PLR?^+:^`.,<_\`"(>'N<_]P[C^M`^$
M_P`+.G_"MO`!/_8G^'OY#3Z_([XS_$7]K7X*?&S]D*ZM?C[:>)[?]J/5I_AI
MK_@O6O`=A'X!\%7EUH6F7^F^*_"]CI^J6GB6\U'2Y)&ENH-<\37HUN4W"M/I
M%I=1VUEN^$?VA/B_^S%\9?VR_AY\6?B7K_QZ\&?!S]G;2OVD?"^K^(].T/1O
M%EB(K3Q)_;OA$R>'-,T_2I[/4KG15DTZ3^SH#IX"1K'-ON'/BQXDH>V=*KA,
M50C#$K#5:M1X=TZ4Y8+Z_2E+V=:<Y*KA[R]R,N22Y9\KW^_K^$>9++XX_`Y_
MD>9RKY2\WP>#PJS:GB<90H<1QX6QT*3QF68:A&K@\UG&+C6JT_K%!^VPSJQB
MT?JI_P`*G^%?3_A6W@#/I_PA_A[_`.5]8GB/X>?#70]"U?5[3X/>$=>NM-T^
MZOH-%TKPGX+BU/59+:%YEL-/DUG^R=)2[N2GE6[:EJ=A9^:R^?=P1;I%_++2
MO%/[=WB70_@O\?OAC=_$_P`8ZIXQO_!OB7XA_#7Q9_PI#2/@=-\-_%=G!J6M
M67@C^RO$`\>Z5J?A^PN;<>'=6U?5=6U#498S<ZU:/YDFGCT[PO\`$3XG?MD?
M%K]IO0_"/Q?\6_!SX;_LY^)X/A?X9'@.S\.'6_&/CZUT*/4O&.O^,YO%.A>(
MXKOP[I>I20:/H.@:9::7#?6J7]_?ZA<RW5O!8:?V]3J.-*&$Q<,16:6$A.-.
M"Q"EAJF(<Z=2<_9_NJ=.?M$Y*49\D;-5(M\S\,L5AO:XNMGF15LMRV$JF>UZ
M&(Q5>65SI9M@LH6%Q6%H4'C>;&8K&T'@YTZ7)7H+$58S@\+74/?_`-DWQ[\&
M?VK/A4_Q5T?X$^&_!5@?&'C/PI#H?B/PQX,NM:A?P?K]YH$]QJ*Z3:7>FVUQ
M<3V<DDEG::AJ,-L28DU"[51,WTN?A1\+47<_PW\!')`&/!OAWCJ3TT_!!QU[
M?F:_!3]FGQ5\9?`__!.?P?)X'^+/@3X3P7O[8'BOP[\<_B_XHU31_#.L:!\)
M[WXP:Y;_`!'U/X36FN:=K6C77Q5UBVC:S\!Z#-I.MRSZM?0V6FZ1J%\]KL^C
M/V(?C3\7/B?^T'^WE^S+?_&#XUZQX`^&OA[X+^(O@W\0/BQX)T7PK\>/""?%
MKPGKMYK;3V?B#P1H]EJ-A8:KIZ:AX+D\7?#X2G3FMFOK+4[64RW?TO#.6X[-
M^&,/G=>O136!I8O%PE&HIPA.OA,--_NZ4J7/&IBX2]DI<[IQE))^ZI?.>).5
MY=PSQ_Q5P]E<''+LLSS'X#`)U9U;8>A5J1HIU:[5:;<*;:G47-)_%9WMWWQ`
M_:W^%>BW'C;7?A'^Q?K7[0_PQ^$OQND_9_\`C!XR^%GA/P%J6O\`A?X@V$VE
M6OB:/PS\.GM&\2>-]&\#WVLV>F^,M5AET6/3;YIQIL6M6=G?WMG^CMM\+/A;
M<PQS+\-?`L8DCCD$<O@OP\DB!U#!)$.G!D=00KHP#(VY<\#'\[O["7CW6OV1
MOV/_`/@H7^U3K?Q5^(?C;1_@[^U3^V4/^%7:O9?#R'PIXV\:6/B?2++2O%>N
MWFC>`]-\7P>(->UJ2Q75ET?Q)IWAFV@EGDT_PW;".*)?<_VC/BU^UG^R-^R5
M\-/^"B%M\??%?Q@U"./X5^,_C[\"?$VF^"+/X+ZO\/\`XI_V-%J^B_"JVT#P
MU9>*_!&K^$KW6M&M?"?B&^\6>+S=01WESXAM-8-_)'7V>.X7A/&T\NR^6'A/
MZ_++,/BISQL?[1QKH4JBHRA4ISA0J4Y3A&52/LZ$GBJ,4FJ=6I'X&GBGR.I4
MNUR*I*,>7]W%2MS)IIR35W;5VB]D['[;CX3?"WG/PV\`G/3_`(H[P\,?^4[/
M7OZ8'/)-+4/AQ\']+L[K4-1^'WP[LK&R@FN;N[NO"?AN"WM[:WC:6:>>:6Q6
M.&&&)'DDDD941%9V(52:_%[XD_$#]LOXZ?\`!0WQ)^S#\)OVM)?@W\,_&'[$
M6@?M!>$-:TKX3Z%JFK>"[GQ-\3;_`$71X+?3]4UE9-9U9K/2=.@UO6-4U2"1
MM/O-9M=%T[0KFXMKNR]/_P""K.J_$/P?^R#\*?A=J/Q#TZ]?QGXO^'W@+XY>
M/+_QMX%^#>H>-?!NE^'-0NOB)+H,WC7Q3HN@6NM^-+C2Q/\`\(Y%JNHP1V%W
MJ%K<17.FQ3SK\EQ'@Y\/9?1Q=3$8?%8C$86GBH8*A]856G&O:-"-:=2A"FG.
MHY0DH2J.'(Y27+RM_7\%9)_KCQ1E7#ZQ"P-/'XU8:MCJRBXT*$(NMB:T8NI#
MGE3H0G.%-RA[2?)!23>F%XI_X*5_LDKXM;1OA9^S7JOQ3\'6OB/4O"5]\8M-
M^&OAC1/A$WB'3-'U/6)=*T?Q=J-G+-K5Y)%I5PD8MM+BM)X3#?V=W=V,\%Q+
MZM^S7^VU^R;\??%VB?#'Q+\"KCX"_%+Q1H%AXE\(>$?BY\+_``QH<7CK1M1M
MQ=0:AX$UV*&XT_Q%;-;E;BW$@TV^OH#)+86-TEK>FV_"G0Y?%?[57QV@^&7P
MP\<_#;P!X)\)V\]Q\,?AOIWQ_P#@GKWA36/`/AKPUXKBTO0M=^'_`()^*_C*
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M"CX7%5;_`(5OX!/RAL'P=X<&<^N-//X8//8FD_X53\+O^B;>`?\`PCO#O_RN
MKD_V;/&&O^/OV?O@[XS\4RZ7/XE\2_#CP?K&O7&B:GIVM:-<:Q>Z%I\^IW.E
M:OI-YJ&EZEI]Q>O--9WNGWUY9SP/');W4\3)*_M594:L:]&E6BFHU:=.HDU9
MI3BII-/5-)H_`\PP<\NQV-R^M*$JF!Q>(PE24)*4)3P]6=&;C):2BY0;B[M-
M--'`_P#"J?A=_P!$V\`_^$=X=_\`E=1_PJGX7?\`1-O`/_A'>'?_`)75WU%:
MG(<#_P`*I^%W_1-O`/\`X1WAW_Y74?\`"J?A=_T3;P#_`.$=X=_^5U=]10!P
M/_"J?A=_T3;P#_X1WAW_`.5U'_"J?A=_T3;P#_X1WAW_`.5U=]10!^!]%%%`
M'W_^T==_$32?V"=1\1?"KXN^-O@AXZ\+?"/P7XDT3Q]X!T3X4^(M>M)=*TK1
MIY=,;2?C/\-?BQX&N=+UB$O8ZG]I\(3:G':R,^DZEI5Z([M/C"[_`&E?'_A7
MXR0>#=2_;LUVX_:3\,?&CPW\)=$_X)Y>*/A_^SM/XD^,'P:L?B?IW@&#X_:[
MH/A+X5:)\>[O5/BY\-5NOCC=_'WX:>-/!O[+7PMDU@Z#KOPGTI/A]XST-_M'
M]H?XL_%SX)?L/:#X]^`WA_2O%/Q>-G^S'X&\!^']9\,6'C.SU/6?BS\4?A-\
M*#!#X4U?XT?LYZ)K^JK9>-;N;0=,U_X[_"7P]<ZY%IR>(/'?A[1OMU_%\)?`
MS_@IE\;F_:`^.WPQ_:)G\'"V_9G\!:%XH_:`^&7A+]DGXM_#OXD?!W3;O]F[
MP+\5;?QKK'Q?TW]I_P#:<_9P^(FM?$+XJZQXC^%7@S]G;X.^+O'/C+3[Q;(V
M7Q-^(4.B:CJVL`'B.N_\%&/%'Q2LO^"9VH?"?_@H?^S-X<?QW\,8;?\`:6L;
MC]JS]DGX47?Q+_:)\/1?LNS^,_@O::'XM_8V_:SN_%OQETP_$[68=6_9Q^&N
MO_LM>-;:7QGI%H_C;P[)?^&[W0L/]FS]OG]NCXC_`+'$DOPLT_\`:#^/?[6?
MC^X^&UIX%\%?'CP;^PQX?^/W@R^TGPAI'CSX_?$#Q5\,_AMX_P#V8_@IHG[.
M&H:-KOP\MO@1?_$CQAX/^*WB#3?BWX=\8F+QCI.I^$+36/MWX1_MY?M!?M-^
M#/@WX!\">'_AY^S%^TUX_P!8^--GX_F_:2^"G[0E[X.^&\WP>E^'^OZ=X+TO
MX&?$/4OV0/CAXQ^(/Q8^&WQ5\*>.O!>F^(-8^&-HG@[PQ\6?'FFMXOT+P/9V
M7B/A_BG^VO\`MH?![Q1JGB#4O&W['7Q3^&6CZM_P3WT*3PQ\'?@W\6?$'B35
M[S]J7]OOPE^Q?\5)/#WQ9E_:;ET+4=3T?3=(^)/BSPGX5'P?2?PCXW\2^&/A
MYXAUWQ[#\+]=\3?%4`[_`%3]MKXO:YHGBKX@>&FDTGX<^)_C7^QE\-O!MNG@
MN.]\;?!WQ1\1?$'P#;XO_#[XG3RVVK:1-IVNV7C7QQX$;5M3T30M0^&_Q#T"
M^T,>(M8U'QOX)M/!'R_XF_;2\;#X-?&GQ[IO_!271="_:IL?A%XMU[XN_L8Z
MWH/[-^DZ!^PKXNL+*W&HVNM^)T^`WC;XF_`G3/A7K).DZO\`'/\`:W@^/_PH
M^)D$%SXI\"_#:ZT[Q5X.T.U^@=<_;9_:[\">!/AW\5+W6/V+/C/8?M->!M3\
M2_`CX8?"]?B7X<N_AQK&F^'5\7PS?$7XS-X^^*-K\9/@_/&(/AYXL^,_@OX(
M_"6?X>_$3Q/\/K>+X:^.T\81Z7IN[^T)_P`%//$7PG\-_$BZ\!?!WQ+\4_B1
MH?Q"^%?@GPC\#?!GPW^+?Q3^*5M=?\(T?'/[0NC^-?#G[/WAWXQ:[%JW@#P_
MHWB'PQX>\4:3H"?"L?$?7?AE9>*O'>G>!/&4'CR(`^>OV9/VY?'\'C7X9Z3X
MR_;L_9W_`&ACKGP1^)6NG3;#]HK]G[XB?";Q%>>%?''C>\G^*6O_`+1OPH_8
MG_9/NIO!&C6-MHWPV'QV^%7P1UCX&^%O''AKQ'^S;\3OA]:?'>#1/B[\0?Z"
M:^,/!/[87A/7/!W[0WQ=OH]>\8?!_P"&?Q&^&.C_``\U7X&?"3XO?'+QMXS^
M'WQ0_9X_9G^+?A_Q'8_#?X.^&_B7\1O&US=Z]\=;Z:2[\$^"6L]&\"6MGK>N
M6%IIVA>(_$TO8?L4_M,:=^V9^R1^SE^U7I?@[Q!\/;;X^_!_P1\3I?`OB73O
M%5CJ/A+4?$^B6M]K'A^VN_&/@_P%J_BSP_I>K-?6OA/XCVGA32_"OQ2\*QZ-
M\2/`K:CX)\5>'M4O0#Z?HHHH`****`"BBB@`K@?B3_R+NG?]C]\*?_5H^#J[
MZO.?BI-);>$[>XAM+B_F@\;?"^:*QM&M4NKV2+XF^$'2TMGOKFRL4N+EE$,#
M7EY:6JR.K7%S!"'E0`_-GX^?MS?%KX1?&SX[^&=%\0?L]:_H'PVTV72?"WP.
MOM#\46OQ_P!1OH/V9]6^/5]\8Y?$5G\5+G3O$GPRT35[:T\+Z_X/M/A!X3?3
MM$M=<\2GXPR:G:V?A2\\^^$/_!2;XY7'A[]FRT^,_P`)H%\5>.?&.OP?M#ZO
MX;^&VL^'8O@3\.YM<M?A5X#\0_$CP%X,^,G[3FB_!W7O$'QHU:[!M/$_QX\9
M^%)OA)\+?B1XTN_%OA[6[G2/"]E]\ZS^U9\!M`^,"_!KQ#J7@?1?C[J?AO2]
M67X4ZS\5_P!F[3?C!J'A#7];M/#FBZFO@6^^,,/C2[\-ZUXDN;'0=+O1I<FE
MZCK=Q::7:2S7\L,#:'B/]JOX-^$/$'A?POXNU+PMX7\4_$_Q'K?@?P5X=\1_
M%?\`9VT7Q!\0_%WA5[FS\1^$/"VD:G\8;;4?%OB/PW):WEKK>@:3;ZAJ>CO;
MW,%_:6[12JH!^66D?\%7/VC=;N/!'AN']G[PCI/C3Q/`VIV,?B%/'6C^%_&5
MI\(/BGX`_9._:NTO0M6O!#J/A23P#^U]\3O!?AWP3XEUK2-?T[Q+\*M?T;Q9
MIFD>));W4)M#_6?]FCXUZM\=_"/C+Q7JWA;5/!<FA?%/QMX$M?#'B'0=0\.>
M*=$@\)SV5E/IOBK3[Z_U*";7[#49+^RO-6T*\N?"FN1V\&L>%+W5/#][IVKW
M^UXG^,GA[P7;ZA=^,_"EWX3MM$\+>)_B!JMUXG\7?!/0H-'\$^$9-/O_`!GX
MVU&;5?BG:QZ?X5\,37NE7OB?Q)<M#I.BRW>GW&JWMLUQ;._A]G_P4-_9-O42
M:P^,OP;NX[CX1ZG^T(DMG^T=^RM<)/\``;1+B_L-9^."20_'5UE^$>D76C:I
M9:G\2U+>#;"XTJ_M[K6HI+&X2(`^HOBM_P`DN^)/_8@^,?\`U'=1KOJ^6[WX
MW>'?C#\!M?\`'_PRTR;QY\./&OPY\4W_`(9^)/@KQK\'O&O@+6M'N-&U.V.N
MZ/XE\'_$W7K'7-(ADCG,EUH3:HS_`&>:*VBN+A!"?9O^$Q\1?]$I\??^#'X7
M?_/)H`\;^._[8'P6_9R\8^%/`7Q-U/6;'Q-XW^$7Q[^-'A6UL-)^U6FK>%_V
M<S\,(_'NFC59[FSTK3_$M]<_%[P78>$-,U:\L+?Q+J=[+I=M?1:A]DMKSYX_
M:A_X*;_#?]D[5?$<7Q#^"?QCO/"'AWX<_"KXB-\5T\=?L>_#CX57Z_&+QU/X
M"\(>$W\7?M`?M6?!F+POXD_M'3?$6H:C?_$"T\'>!8=/\.7EG9^-+_Q)K'A'
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M/%G@FQ^(O@>&\TN?6/$5CI+_`%!\+/BUX-^,FBZOXD\"7IU7P]I7B74/#EMK
MD,^F7FD>(196FG7\.O\`AO4=)U'4K35/#>K6.J6=YH^IK-"U]:R+.+>.)HVD
M^5[W]DG]G_4M:LO%>H?LM^-;[QQ;>+M&\;7_`,19_%WA-OB/XGUK08/#EMI%
MOXU\?+\8%\6>,_#]A#X-\'"W\+^)M6U/PXDWA'PS>#3!>Z)I]S![O\.O#OA_
MX2Z9KFB_#?\`9_\`%7@[1O$?C#Q-X]U;2-%O/AA;:;-XM\9:@VK^*-7@LO\`
MA9C6]C+K>KRW&J7L%E';VC7]U=7,<"R7$I8`[_QC_P`C%\*?^Q^U'_U5WQ)K
MN9YX+6":YN9HK>VMXI)[BXGD2&"""%#)+--+(5CBBBC5GDD=E1$5F9@H)KQ#
MQ5XJUV77?AH[_#3QM;-;>-K^:&&:_P#APTE_(?AQ\0+<VEH;?X@3PI<)#/+?
M,U]+96IM;*Y1+E[Y[.SN^T;Q?X@965OA/X]=6!5E;4/A:592,%2#\22"&!((
M(P1P:`/R^T#_`(*V^%;W]DW]J+X_^*?ACI/@?XL_LV?!_P"(O[08_9GU[XJI
M:^-O'7P:\*?"/3/C?X2\5V>I:A\/]+U717\:^#]6'AM9CX(UCP>OQ+T/Q-I'
M@CQM\2/A_9Z)\4?$7U!\9OVX?`_[/EG^TUJOQ<M_#'AC3/@1X;'BKP?O^(%I
M!J/Q4TNW^%$_Q*UB&:#Q!H/AW2/`]_H\VF:WI]Z\NN^)]#L_#UG:>,-5U[2X
M[G4-%T?T/2OA;\*M"^&_C+X.Z/\`LCV.F_"?XB67B/3?'WPUM/#7P,B\"^-=
M,\8:(GACQ3I?BGPJOCG^Q=>TW7_#,</AK5=/U.RN;.\\/06VARPMI=O!:1]Q
M?PZ=JL7BV#5/V?M;U.W\?:8-%\=6VHVWP=O[7QCHPTV?1CI/BBVNOB#-!KVF
M-I%U=:6]AJ<=U:OI]Q/9O"UO+)$P!\O?!7]M[Q+\1OB_X&^#OCCX+V7@+5_$
MEA\;/#FO>(O#_P`0M:^('@_2_C3^S]XSF\*?$#P!X<\3S_"GP7H6OZ!?V5M=
M>*O`>H^*-1^'GQ@\7>&[/5M;'P`TO0?"WC;6?"_Z#U\M^#_A)\)/A]XDTGQE
MX%_9"T_PAXMT'PM/X)T;Q-X<\-_`[2-?TWPG=:G<ZS=Z#::M9>.H;Z+3[W5[
MZ]U2^B6?-]J%Y>7EVTUQ=3R2>S?\)CXB_P"B4^/O_!C\+O\`YY-`!\-O^1=U
M'_L?OBM_ZM'QC7?5\<K^TY\,OA%)X-\'?$S5=$\!^*?BY\3_`(K:'\*_#WC7
MXG_`SP7KOQ)\2P?$77KO5/"_@#1/%WQ6T/5_&GB'0WU:RM-6T[PS8ZH\-Q-!
M+;-=6%Y87MW7\/\`[?/[,GBSQG<?#CPI\5/A;XF^(=I\1-0^$%WX#\/_`+07
M[,&L^,[7XLZ3::W?ZK\+[CPOIWQQN=<A^(FF6/AGQ)>:AX)DL5\2V=IX?UNX
MN=,CATJ_>W`/LZBOB+4O^"AO[*.BVU]>:Q\9?@]I-IIGQ1L_@?J5UJ7[1W[+
M%C;:?\:M0L)]4L/A!?3W7QUBBM/BC>Z9:W.HV?P_N&C\67-A;SW<.DO;PR2*
MSQ5_P42_9-\"W/C^R\;_`!I^#7@Z\^$\6CS_`!3M/%7[2/[*WAZY^&D'B+68
M_#GA^;Q_!J_QVLY?!L6N^(9H="T:3Q$FFIJ>LRQZ79&>^D6`@'W!17RU=?M?
M_!JR\4^"/!%YXC\+6?C3XFVWB2\^&_A"Z^,7[.UOXH^(-GX-O9--\7W7@C0)
M?C*FK>*[;PKJ,4MAXDGT&TOXM"O8I+75'M9T:,>BZ/\`&"T\0W;:?H'A'7-<
MOT\.^'/%[V6C^+/@YJ=VOA+QC+K4'A'Q0UM9?%*>9?#OBF?PWXBA\.:V4&F:
MY+H&M1Z9<W3Z7?"``]@K\X/^"HNO_#^7]F'7_A7X^^,/@KX*6GQ?N8/"]KXL
M\;Z;KNKV06SECUJ_@L-/T&)II]0:VLML?VF>WMHE=YC))(L<$GW#_P`)CXB_
MZ)3X^_\`!C\+O_GDUP_CC0_#GQ,M+.P^(O[-^H^.['3KA[O3K/Q=IWP7\1VM
MA=21&%[JTM]8\>WL5O<-"S1--"B2M$S1EBI(K@S/#5,9@<3A:3I*>(I.BW75
M1TG"?NU%-4ITJC3@Y)<E2+4FM=&CZ/A#.,+P]Q+DF>8R&-J4LIQ]#,$LNJ82
MGC(U\)+VV&G0GC\+C<(I4\3"E4:Q&%K0E",H.%Y)K\1?C;^U+^S?\7?%'[(W
MBT?M?_L^Z+??LQ^*;3QC>V;:1\2;RW\7ZG#9VVESV-HZ:1#+HEA+868FBN)$
MU6:WO)]K0W$-MF[N:E^TI^QEXM_:?^,WQ<\=_M9?`W6/A7\;/@E#\"/$W@"'
M2/B%%K:>$K==48WW]M'2A;7%_J)U>^M;RSBM+6WAM;A##=R3VBRW'ZQC]G[X
M!#_FR/PD?K\/OV=C_/Q8:5?V?O@`.O[#_@YNN=WPZ_9S/\_%5>!3X?QDJCJ8
MFK@)RE7I8B:ITL:HSJ4L+]4BVI8V2:^K/V4HVY9)7FG*S/U^KXH\'PPU/"8'
M+N,J%*CEN/RC#N>8\+NI1P68YS'/\1"%2'#-.2G_`&M&.+IU>95*4ERTYQI^
MZ?A]\$?C]\-?A3!IOP:U/_@JA\-=:_9:T+6+=].T1?`?B@?%:Y\$6EVD\7PW
MG\53:.UOIV@ZA9Q_V/JFH68N-633)+F#1'TD2VYL^RL?VF?V7_@[^T;\9/BU
M^S?^W9\!]#\`?M"M9:K\1OA[\0O"GQ%U6/0?&5O;&VN_&/A"XT:SL6GN]0,]
M_?W.F:E<6=G-=7CVK3?9HK$67[(G]G[]GT]?V'/!9_WOAS^SD?SSXJYI/^&?
M?V>><_L+^!CGN?AK^S>3TQU_X2CTXKNPW#N#I0H4ZKJ2^K58U</4CB,9*K0M
M3G25*C4JXF<X4?9U*D'33Y&I-\K:5N7,/%W`X[%YCB_J.916;X)X+-L*\-PE
M2P6:*6+PN.EC,?A<)PY0HXC,'C,%A<3]>G!XJ-2BN6JHRG&7\Y.J:]^S;9_!
M;X'>%_#7_!2SX!1_$?\`9]_:IE_:9\&QZ]\./B,WPX\0WU[X@OM<OM"\<:;8
MP3W^J#[5="XTR\L;.Q;1V>XBM&\V6'4;?Z!^"?[5/P"^%7[7OQY_:F\1_P#!
M2G]G;QBGQY\`>`+#Q3X-M?A=X_\`#5NWC'X<^%M;\->&M)L+U;#5YM&\`:6V
MKK?&[W:QXMU:33K,7=U;Q37JW/[9']GG]G9NO["7@$^N?AC^S:?U/BC_`#^%
M,;]G7]G(YS^P=\/6)X.[X7?LU-D#MSXGQW^GYU]]E.;PRG)Z614(5/[/HX.I
M@(1=/"5:RPM6O0Q,Z/UG$4*V(<'7HQJ*]5N,HJS5HGYIQ/G.4<4YYF'$684<
MUGF>9XN6-Q=15\OH4YXB:M*HL/@\!AZ$')2ES<E*-W>3NVV_PV_9Q^/'[!W@
M;X!_M5_LV?M"_MN_L[?$7X=_M0_$;XT?$O5[SP=X;^*6B:MX;U7XSR6]SJ6F
M6EIK.@W]G=6GAW4+:/4]#U![J.Z6]1%GMY8X_DY.V_:,_96\:_LV?#?]B?\`
M:"_X*+?LW^-/V=_`.O>#(/$'BW1_"WQ:M?BK\6OA;\.->AUOPG\-/$^CWOA]
M/#7AE;B#3=#T77O%&C:SJEY<:5HPBL=-MKZ\GO5_?,_LX?LV'K^P3\.#UZ_"
MK]F<]>N,^)..G:HS^S9^S.V=W[`GPS;//S?"3]F,GCH>?$1Z<?CSWKV8<481
MU9UJL,T]I4Q=/'\U&MEL/98VG3=)8JAS9?)4JCIM*3A93<*<I*4H1:^2JX;+
MVK4*6(A%0Y.6K4C-.#LW&7*H\T;]'MJDK.Y^47PJ_:@_9=^(_P#P5(T#]H+X
M;_MD?LX>(/\`A-_@WI7[*GA3X+Z/H'Q3B\5ZEH%AXXUCQIH.JV&N7>@6>@VW
MB.2XOQ93Z3):IH\=K`J1:B6*3']-?^"AW[+>L_M4_`8:#X+NK"S^*'PZ\6Z'
M\6?A=)JL%M<:3<^-_!\.H'3=(U2.\#61T_6K>_O-+N#>I)8QO<PSWD4EO#*E
M=WH/P&^`/A;6]-\2^%_V&_`_AKQ%HMU'?:/KV@?#3]F[1]:TJ]A),5YINJ:=
MXIMKVQN8\GRY[6:*5,G:P)->^_\`"9^(2,?\*G\?8]/[2^%W_P`\BOFN):^`
MSV%"A3I8V%"&7T\!)8JMA:E90HZTG3J87#89)PO>,IPG-R5Y3:7*O1X:S?,.
M%\YP.>9;*C#&9=CJ>-PW/3=6E.<+.=.M2G)J=&K!2IU:=XJ5.4HIJZ9_&A\2
M+;PAX@^+-QXI2]USX)?'#7O&-Q#\5/V>=5\&ZCX?\17>I1^#?'(U)4\76NG6
M?A/4OA)X&DTS0(?AKX=\.&VO)6O7\0^,5U/58--U6?K_`-GWX(6OQ>TF[^!O
M[-?B.\^-7Q!^-O@GP+H7QN^-FH_#Z+1O!_PH\#-IVAWOBA?%NLZYI"0^+OBW
MH<]QXC\&^'_$7@J:RO-?\.7,Z>([O5=>MK>^TS^L;Q/HGAWQI>6.H^+/V<=2
M\27VEK*NG7FNZ?\`!?5KJP6='BG%G/?^/9Y;;SHY'CE\AT\Q)'1]RLRG5\+&
MT\$:;'H_@[X!:_X6TB$DPZ7X?C^#^C6$)P!F*ST[X@V]NA(`!*1`D`#)"\>-
M7QG$N,RR.28S-Z<\M<(T:LJ>'=+%5L/'EM2E/VLJ=.4DY1G.,6FDG&,6DS]>
MAXE<'X'&2S_*."\5AN(8TX5,)#%YMA\5D^#QT9.4,1[%993QF*P^%G&G6PF%
MJXJ$N>/)BL1B8))]1\+O`&C?"OX:^!OAMX=5UT/P+X3\/^$]*$I!D-AH&EVF
ME6SRL,!I7BM4>5A@-(S-P#7<5PA\:>(B"/\`A5'C[_P9?"[_`.>13/\`A,?$
M7_1*?'W_`(,?A=_\\FM*=.%.$*<(J,(1C",>BC%**7R22/Q;$8BMB\16Q6(F
MZE?$U:E>M4EO.K5FZE23MI>4Y.3MU9WU%<#_`,)CXB_Z)3X^_P#!C\+O_GDT
M?\)CXB_Z)3X^_P#!C\+O_GDU9B=]17`_\)CXB_Z)3X^_\&/PN_\`GDT?\)CX
MB_Z)3X^_\&/PN_\`GDT`=]17`_\`"8^(O^B4^/O_``8_"[_YY-'_``F/B+_H
ME/C[_P`&/PN_^>30!^)M%%%`'Z]V-_\`#[0_V=O#'BOXJGPU!\/_``%\-/!?
MQ+\2:KXNM+*[\/\`AFV^&6CZ-X_M?&EX+^"XM[.?P/J'ANS\7Z=JZQB[T/5-
M$LM9L);>_L+:>+Y@T#XY_L7?%#6O@OXSU/X*6-O\0?C)\//B?\<O"=WX[^!N
M@1>-O"_B7X1ZM\+=.^*OP_\`'/B2>QU"U\$?'[PIXG\&^"=&U/PEJ7B./4M1
MUSX'7"Z3JNJ)\*+>YTOL_CBG[,L_[&WA6Q_;#^)GP[^%W[.]_H7P7C^(FI?%
MOQUX(^'OPQ\66-C>^%=8LOAK\0=:^(,UMX9U/P1\0]2TRT\+>+_!E_<PVWC[
MPUJ&J^"M06\T?7=2T^[\'\`_!C_@F-IO@:[L_@]\7O@3X6^!OQ/\!_M#:[\.
MO!7P:^+'P=\'_!WPIX*\&>)OA3+\?_'7P!M_AZ=*L_"NF?!3XN_#;0O&_C+Q
M5X1U633?A3\7O%?B75_$5SI.JZII%II(!UFN?$#]F+]L2/2O#7B[]A/7?VE/
M@G\2IOA\?'/Q-\=_`_X!_$OX.Z%XSL[6POO!GAKX@^%?&/C34_B3XLUCP!-X
MXN[*\\6^!OA3\1/AW\,-4D\7VNM>._#LFE>(FMNXTWXG_LH:M#\"_#D'P(TE
M=,^)GA7X!:Q\.M-G^&'PW&E>%M$\'?$/_A)_@/IUU9IJ$D&B'X/?$32X/'/@
M2TT*"_M/A]XEM[3Q-X-EM=<A2XC^<6_9:_8%\6?%WP+^RA=_M,?#WQUKOPA\
M2_#S]H33?V)/$OBC]E[Q[XXT+XB_"ZPM%T_XZ:1X9USP-JGQ^^&FK:X\EIK/
MC/7OAYK/@W2M0N]0U9M,_L'2_&_C;3_%,#?`?]DS_A8OQ4^#OAW_`(*7>-/#
MGQ\^&K?#76-%\%:5\9OV-M8^*W[&7P^\*^)+OQIX1\'^%?A5XO\`@GXHL]+\
M$:_/\2-/MKGQ'^T7X!^*OCK6_#]_X*T^T\?):V/AEH`#T/QI\2/^"='[,OC7
M]NSQ1;?L[_#'P]X_^#O[/.K_`+3?[5?BSX=?`7X9Z?XE^,'A;X>>'[_XI^+/
M"M_XGM+/1K[XH_$WX<>'I_AQXY\0^&_&.H10Z#:_'+X+:RFL%_&4LNE>[?L^
M_&KX$_&;XC>*-2NOA%:?`7]K7P[-XU\%^-OAA\68?@,?VF-.T+1=!_9_\4^*
M[EM;^#?Q%^+6B^,?A]+X8^(O[,FJZ]K7@GXC^+/#6D3^(?A;X:\9SZ)XQTVQ
M\.:7\]^)O^"6_P"QOKFE^+/`>MZ]JME^TU\??A/^TGX9^*O[4FFCX(^%?VV/
MC_\`#SXP>$=2^&/QBU+QGXWT#X6:3#XB\*>";SXN^`-2\,Z'H/@33?AA\(/%
M'A_X%:-X=\+:!X5T3P]X0O[/[-Z_\$]?V./#7Q%^!/P-_;)^"OPY^%'[+>D?
M%74OBO\``#3?BU^RQH?A[]GBQ^)'C3P]KD/B;XK7&D>&='^*?@2Y^'&HVFL>
M'/"/B3XE^.(+C5H/'_B*3XK7OQ)\56O@?7?"(!XEX-^(G_!,[]H[PU^RM\:/
MAW^S7XF^'GC'_@I5H4_@[PC\7/@WX:M/V4?VJ_#WPQ\$6VC?$7S?B1\=_@?\
M0OA9\?\`P7\,;O5/"?PQT'[!\._B+XBMO%8\9_#S2[W1M4^'OB+4KZV^HOA/
M^U)\!/`'P(&E?`;0OVE_CI_PA_QL\>_L_P#@GX<ZWXO\>?%W]H'XF_$72KK7
M/']Z^E_%']K/XL'4O$'@76_!L]Q\3?A_\4_BU\9]%^&DOP9O/"6H>'/%>G^#
M+OP;ITGRDWP6_P""7WP;^`OAOXI67[?OA'X/?L[?$'PI\'/A7^S]\8_^&GOV
M;/#WPI\*:S\"?A?J?P?LM7_9N^(OB/09_!2>./%?A/P7IDGQ`TO2M3\1^')_
M$?PIMO$?A[PAX5U<?$"X\3=Q9?L^?\$L_AEX^\-?`[]FOX^?`O\`8H^-?C[P
MQX*^)GPF^&/[+/Q+_9L^&OCZ_N/"_A3XC2:'^T%X%^"6N>'O%NA?$;6O$7PL
M\0>/=%\9>,_$_P`./'_A3XG_``XT>R;QY8>*+;X=^%M2\,@'M?BO_@J9^S'\
M*YX/#G[0DOB#]F'XKW_@O2O%GA[X&?M`Z_\`!SP%\5_'6J:GX[\6?#P^`/A5
MI0^+.J^'/C)XQL]<\*QSO/\`"3Q3XW\$:GI?BGPA=^'?&>MR:RUO:?<6F_%'
MP)J_Q3\9?!73]=^T?$WX?^`/AI\4?%WAG^S-8B_LCP)\8/$7Q8\)_#K7?[9G
MT^+P_?\`_"1>(/@=\4=/_LS2]5O=8TC_`(1?[7KNGZ99:UX<N=7_`#D\!:;^
MPUXV^&WQG\1)_P`%!='_`&A--\1>#/\`A0'QO^.6M?M*?L_>++C3M6^'UY\5
MOC?K<&LZIX%T71/AA\./&>A^'_%?C3Q!K'@G0/"WA+P3X2^'OA>*_P!(^'GA
MO2M&UG4;Q_[.G[*WPC^"O[>GQ7_:(LM;_P""<]A\1_VLOAGXWUCPGI/P%_9?
MN_@K^U#\0?AI8?%NS^(UQX]\2_$VX_:V^)WAWXSV0U#XEZ<W[07Q/\#_`+/'
MP]U'XT>.-4^#?BCQ[XET_2_`7PU\%68!^J]?DU\1O^"Q/[-GPSU#]KC3-;\)
M>-I[K]CCQ7\-/!_Q%;_A:G[&'AJTU74OBC\24^%NB7(U#X@_M7^#+#X.Z7:^
M(Y$O6O/VJKG]GD^)_#+KXC^',7C?3&68_IYI?CGP5KDWAZVT3QAX6UBX\6Z#
MJOBOPK!I?B#2=0F\3>%]"NM!L=;\2>'HK2[F?6M`T>]\4^%[/5=8TU;G3M/N
MO$>@V]W<PS:OIZ7'PAXQ_P""<GA[Q;XT\:_$"W_:=_::\)>*-8UW5?$/PNO?
M#4/[,DT7[.E[XK^-'PY^/GQ#C^$]KXJ_9I\3V_B6U^(OQ$^%/@F\\01?M!Q_
M')]$TS3;C2_A]+X*@U/43<@%71?^"H_[.>M_![6_C';Z7XY?3O#OQ$_91^&V
MJ>&=&OOA'X[U*;5/VPO$G[/GA;X9:]X8\;_#3XL>-?@E\0_!NAZI^TEX%'CS
MQ/\`#;XK^+]/T>WT_7Y=&/B)I?"D?BKV#]FK]L&R_:'N['2-<^`?QX_9P\2>
M(OA]IWQ:\`>'/CNGP4NKKXF?"^_?1H+KQKX+UKX"_&KXZ>$);;P]?>)?"]AX
MJ\.:_P")?#_CCPW-XJ\,7&K>%;;3O$&DWUWQ?BO_`()Y_"GXC^"[OPO\5OB'
M\8_B7K^J?'3X(_M$Z]\3=:U?P!X5\=^(?B+\"+3]GQ/#*ZO!\+?AO\/_``#)
MX1\0ZM^S+\+?%7C+P5:>!;3PUJ?BG36U?3-.T5]-\*Q>&^N_9N_8YLOV?=4T
MCQ!X@^/WQY_:0\2^$?AM#\'/AOK_`,=C\#[*?X8?"W[1X:O=5\&^#='^`/P0
M^!/A9HO$]_X+\%WOBKQ)XGT#Q+XVUY_!WA>UOO$\FG:)864(!]$^#?BCX$^(
M'B+XL>$_".N_VOX@^!WC_3?A=\4=/_LS6+#_`(1?QWJ_PL^&GQJT_0OM>J:?
M966M?:/AE\8/AUXF_M/PY<ZOH\7_``D7]C3ZA%X@TC7=*TQ?B3_R+NG?]C]\
M*?\`U:/@ZOS@_81_X)I:=^QC\9/B7\6;'P5_P3A\.7/Q.\/WFGZQ>?LA_P#!
M/3Q3^RC\0H=1G@^%^EQ:59>.O$/[9/[16D:!\()M)^&&E:EKOP5\#>`_!?A7
MQ!\3&B^+EY=1>-[KQC?>-?T7^*BW3^$[=+&:WMKY_&WPO6SN+NVDO;6"Z;XF
M^$%MYKFSAN[":[MXIBCSVT5]923QJT27=LSB9`#\[/VI?^":][^TW\:==\?:
MK\6+K1O`?BOQ1^Q[XB\2^`Y=;^/5QHNI6/[+/[27PO\`CYJ6@W7PYT#X]^%?
M@%K%_P#$:Q^&Y\%0?$;Q+\'];^)'@2WUQ[W1?$=YIVG0^'YX;#_@G-\4/"=Q
MX]3P'^U//:1?&"2[TGXF^*_%OPGTGQ!\51X2LOCA\7_C#X4A\)>-=*\4>&M.
M?Q%96?QJ\6>%O$]Y\1/"WQ`\.>)M2LO#'C.+PQHTNG^*/#OCC](?[.^*/_0X
M^`?_``VWB+_YZU']G?%'_H<?`/\`X;;Q%_\`/6H`_.K]M?\`X)L:W^U_>_'?
MQ)%^T3XB^'7BGXJ_LX_$[]E+PI9Q>#='\3>`?"7P>^+WP>\??#WQK:Z[X;N=
M0TSQ%XA\0ZAXV^(MU\3;O4O#OC;P)9:Y<_#[X0^'O$6FZI!X#LM4EK^/O^"2
M?P'\7M\3Y;'7OB+977B3X$2_![X77_B3XP_M!>/K_P"%GB+7K/X]:;X[^-$E
MWXM^,^I3>-?CEXLTO]H'QUHZ?';Q$S_'/0=#\4>.="TGXE1:-XWUZQNOT=_L
M[XH_]#CX!_\`#;>(O_GK4?V=\4?^AQ\`_P#AMO$7_P`]:@#YS^'7P.U;]G;]
MFKQ]\*W\6IXU\,>'_`?CV30?$.MCQIK/Q1\07^J_\)IK6O\`BKXM_$3QSX]\
M;ZS\2?'7B4ZEI=YX@\5W0TJZU+Q#'KNIR0K9:IIVE:)]E5X7\2[#XCI\./B`
M]]XJ\$W-BG@GQ4UY;VGP_P!=LKJ>U70K\W$-M>3?$N_AM+B6$.D-S+8WL<$A
M65[2Y5#"_;?V=\4?^AQ\`_\`AMO$7_SUJ`/F?]K'PS^U1KNO>"+_`/9JUD6'
M]B?#3X[/XAT75==@T+PCXS\3:E;?#NR\!>%-<U&)Y-=\.ZO?6Q\:77@KQ_H&
MGWTG@3Q19V6JZW:ZKX;EU?PSXB^*?VS?V3?VN?BOX?TO5?@5XZ^,7A?XKZK\
M"?V?O`.J7-Y^U9^U)X)^$UKXDT'XW>!O$GQ'O/$7@/X%?M0?!&^MM>O_``;I
M>LZ=XI^)7PUUOPQ\3-6\-W6I:);>,M6T^]O-`U/];O[.^*/_`$./@'_PVWB+
M_P">M1_9WQ1_Z''P#_X;;Q%_\]:@#\G]:\"_\%)I9;&ST/6O'=O\/M0^"/@7
MX!VEX?'O@JW^-7A[Q]H7A+PY\0]2_:GU[3=0N/$'@^'4Y_%UKXR^#.IZ6/'G
MQ.U/7WN_!6L:WH&L>'E\5>(;C]`_V8M(_:"TC3?BXO[1EWI>H>*+SXPZA/X4
MU'P[J=U=>$]5\!VGP_\`AUHVG:WX4T2_U#4]1\#:1X@\0:5XFUZ?P#?WM[/X
M5US4]8T]-8\36PM_%>N^N_V=\4?^AQ\`_P#AMO$7_P`]:C^SOBC_`-#CX!_\
M-MXB_P#GK4`'C'_D8OA3_P!C]J/_`*J[XDUI>/='UGQ#X&\::!X<OK/3/$.N
M>$_$>CZ#J6HK?OI^GZSJ>CWEEI=]?KI5W8:HUG:7T\%Q=+IM]97Y@CD%G=VU
MP8YD\W\56'Q'77?AH+CQ5X)EF?QM?K8O#\/]=@CMKH?#CX@.\UW$_P`2[EKV
MW-BEY;K;0S6$B74]M>&[>&TEL;WMO[.^*/\`T./@'_PVWB+_`.>M0!^7OP%_
M83^/7@?]E7Q1^SYXZ\0?!BZ\(77B73O$GP]^%,?AC^WI/`^J:/\`$#P7X]LM
M;UKXNZ=I'@3PIXBU>'Q1X>UWQ9H@\(?LV?#.U\/SZGX:M9/[9\7>'M=^(WC+
MM_%O['/Q^O9_VZ(/"OC+X3VO@3]I;]IG0_C5I7PNUO1==O+/Q[X'TW]EG]C;
MX4Z_\.O&?BN%8K7X96_CSXC?`?XMCQF=(\#?%>RU_P`(_$.'6;Z)M:U36]'M
MOT+_`+.^*/\`T./@'_PVWB+_`.>M1_9WQ1_Z''P#_P"&V\1?_/6H`_.3]DS]
MBOXI_!7]I'3_`(R>)]+^&_AW2K7]GW7_`(/7T'@7QOX@UI-0TC5?&G@?QS\/
M/`J:%<?#_P`&>=H/P!33/%_PZ^'FI:]KFM>&]!\#W2:A\+/AM\)_$WQ:^/US
MXW_5FN!_L[XH_P#0X^`?_#;>(O\`YZU']G?%'_H<?`/_`(;;Q%_\]:@#X`^.
MO[&WB[]I3Q-X:\8^'/B-X+\'Z+:?"/\`X*#_`+*/Q$T#QC\-+SXA2:Y\//VL
M_CU\$=?\2^(?"DD?C7POI6C>,?"=I^SC]B\/CQ+H_B_PY=7OBU-1U71KJWT%
MM*UGSCP1_P`$R/B!X/\`%,^I6W[00MM-N/C3\2?B')KJ-\>O%?CZQ\!_%+XH
MWOQ#\:?"[P5#\3_VBO'?P?\`A1X5\8Z4VF^%O%GA3X8?"+PQX!O]>TOPM\8;
M'PAI_P`5/AG\-->\-?I]\*UND\)W"7TUO<WR>-OB@MY<6EM)96L]TOQ-\7K<
M36UG-=W\UI;RS!W@MI;Z]D@C98GN[ED,S^C4`?DQ\1O^";WCOXR>`OA+\.?B
M'\<?"^C>'?@%J/AVW^&H^"/@#XB_`S4O$?@SP;\-OB%\/-'\#_&'5/`?QVLK
MGQGX%\3V'C6WL/B+\--%_P"$4^'^O^'8O%.D:?HND+XLA?P]!\$_^"4OA3X1
MZK^V1XSO?B7J7B[XC_M5_'75OBEH^OW,?CBT\*?"CPCK'A[X#Z1J'@S0_A=>
M?$S6OAX_BC6M1^"5OJ/BCXL:'X?\*>-_%6CWGA;P;XBO-5\/?#SPW"/UNHH`
M_,;3OV`_&F@KXP\,Z)\7_!+_``_^*_Q,L/BA\38_$/PAO-=^(%MK'A7XO:U\
M5_!5E\,O%1^(]GH_A/3K"XN=#MI$UCPKXFN]$U^U\4>-?"5YHVO>+8F\/=U^
MQQ^P5X<_8[\8^)_$OA?QWJ>N:)X@_9E_9+_9RTKP++I$.G>&_`5A^S#JO[0^
MOS7G@?;?7=UI?A7QIK_[0VOZK8>!9WN;'P$;)](\.ZD?#,VCZ#X<^_Z*`"O-
M/C!\8OAG\`OAUXA^+/QA\7:=X$^'7A0Z0OB#Q3JT=[+8Z:^OZ[I?AC18Y8M.
MM;V]EEU+7]:TK2K6*VM9I)+N^@0*`Q8>EU^8?_!8TD?\$]_BSCD_\+)_90_7
M]KWX#CVH`^J]%_;!_9@U_79O#-A\<?A[#KMM\._#/Q7O-.UC7(?#LVG^!/%^
MAZUXHT35]2?Q`NEPZ;=MX6\/:MXHU7P_?R6_B3P[X9@@\0^(M(TK1[_3[VZR
M(_VWOV2Y/!/P]^(O_"^_A[%X-^*6HVVE>"M7N=5DM&OKV?2M*UV==6TVZMX=
M7\*0:/HVO:#J?B>]\6V&AV7A*RU[0Y_$]QI$>L::;K3UG]CK]G3Q!\8_'/Q_
MU;X9Z;<?%_XD?"S7_@IXU\<QZWXLM=7UWX8>([+P[I^H^%)1::];65C:):>%
M]-&EW.E6=AJ6A3W.O7FBWUC>^)O$=UJOEUU_P3?_`&/_`/A5/P=^#EG\#/!B
M^`_@%\6'^,OPA\+-J7CRQT+P%X]U+QE?>+=7\1:!%IWB^+4$NK6XUO6SX9TR
M^U"]T'0!+8:7I^FVV@V4&FQ@'T/\,_CY\(/C%XE^*W@[X:^.--\5>*/@?XR?
MX?\`Q8T.TMM4M=0\$>,$2:5=%U:'4K"R+2SP6\EU9W5F;JPOK/R[RSNI[6:&
M:3V#!]#^1K\Q/V0EG'_!0K_@K9ODA8#XB_L<!PL+J3*/V0O`F]U8SN%C/&V,
MJ[+@YE?(Q^H5`$&#Z'\C1@^A_(U/2$X(7!R03G!P`,9RV-H.2,`D$\D`A6P`
M045^:_\`P5`@^`LOP?\`!-[\?-;^#T&E>'/'\GBGP5X(_:+2:R^!/Q<\?Z?X
M,\4Z7X=^&OBCQ8^G7MIX'\?ZM<ZX-5^!?B[3FF\=^'?C!HOA+7_`7AWQIJND
MW'A+5_BC]EW]DRT^,W_!0W]MO]J=+#X,^"H/A[^US^SY'9ZIJ_[.=Q??MNP#
M2?\`@F+_`,$]/%$/P[E_:[O_`(MM>^'?@M?Q>*#IWCGX+W/PBU^\UC6)O&6I
M3_$%)?%4EOI8!^_]%?RU?L::)^SSIGP'\;ZEX%^*7_!/[Q?/J=]\&F_;$\(?
ML"_`?3?AK^V_X+^%4GQ/G?XB67[8GQ(^%'[1_P`5?BG\3I4NI)M/^*FH)\*_
MA'KEQIT'Q+U-]+MTO=1T:Q^Q8X_^"9/_``I/Q#-_P3:7]FL>&?\`AH[]@J/X
MAM^QD?#X^`K:W_PVE^STU@OB0?!LCX$O\84TLV1U$W8/Q=C\)OHPU@KX8ETD
M,`?NA17\]?P'_9GOOA?HE_\`'#2_#?[(&F:I\:?V^M2DT[6OA3^R6WPA^/FL
MWVG?MD?%R2T/[0_[0B?&;QL_Q\6.X:,V,J?#3X<MI9,DJI=E@@]<_9;3_@F@
M_BKX+_\`"3'X9C_@IRFG>"YOB\VJR0Q_\%#U^)4$&G3_`!!;XT/X"9?C0/@^
MOB^.Y;Q.-7/_``RDWAT:2MF&^&Q\.*0#]N**_GX^!_Q_^,OBC]N[5OVD?''P
ME^-FG_L8?MA7>H_LK>"/'OC;4_@!J_[.NN^"?!MZ\/[('C?P/H_AO]HSQ?\`
M%VRB^-WC#4?VB9+V]\<?L^>%-*\<VG[0GP>TIM>TU/".E6WC7!\"_`?P?\!_
MA7<VO[&_P3\!_"/X@:Q^T7_P5@MO#VF_`+X=_#[X>>(=<UOP1X@_:4\)?#BP
MT:'2]*T/0;[Q'X6\.Z;IGA;X90^(F_L30([+0]%5K'0+4P1@']$M%?BG\%C_
M`,$\Q\?/A(/^"=C?#$?'Q_&=L?VJ$^![VG_"?'X61>"O'/\`;+?\%`([5O\`
MA*QXL7Q++8#P`_[02CXR'XKM$OAECH@^)P'@/PZOOB_X$\%_\$X/!OQ&7XG?
M$7X!^,O&'B?XL>%/C3X9TS5O%/C/X-'_`(8I_:V?QK\'/%%EX6TC4_$DUC:'
M6H-7_9U\2:;I.M7UY"U[\(KJU@UKPS\/1X\`/Z*J*_-G_@F/J'P$'PC^(_A?
M]G`_!K6_AOX0^*UWIJ?$G]G1_(^"OQ1UR]\%^#=4UGQ7I&@:=>7WA+P=\2EN
M+I=+^.WAGP==W>FGXNV/BKQ/KD]KXT\3>)]&TC])J`"BBB@#\#Z***`/U*\:
M?#G6_BY^Q])\-/#=UI5EKOC/X,>&]$TN[UR>[MM)M[NYT#2622_GL+'4KR*W
M`C;>]O874@)&(FYQ^=?QL_X)O_M"?$CXH_%SQ9X?\8_!6Q\+>(/VAO`-W\.]
M*UZZ\;S7D'[*/Q8T#Q7I7[?'@[Q3%I?AJ&2Q^('Q0O?BUX[UCP#H>E:[K/@7
M6-;^&7P7USQ7J/AFY?Q%:6'V3^T=X`UKXD_L$ZCX;\,W_P`8-.\5+\(_!>K^
M%KCX$_$KXN_"CXEGQ!I.E:-=Z=%H7BKX(>*O!WQ`=)9$=+[1+'6&T_6K4R66
MK6%_9/);M^:'QE\`?\%'O#_PQ\9:)X(\8_$WQ_\`#*U^(G[8_@_X4?"'P]:_
MM6>!?VGGT'3-0^(ND?"27XB_MP7'[1/CSQ-K7@OQ+86=A%\._'%K\&_#/BGP
MY;ZYX.\5:5X\\2ZOX=_M+Q.`?;VA_LL?M#6_BOPA\+=1\,?LQ:=^S_X$_:2O
M?VG-/^/GAOQ#XX@_::U[Q%_PLS4_B?'X=O/A1/\`"V'P1X?\9>-)M4N?`OQE
M^.]K\?M<N?B)\/\`5?'6B0?!_P`.+X]/_",0_%3]A7XG>*?$G[2WQ5TKXK:C
MXR\5^,/$]YXO_9Y^!7C77_!O@SX!>"O$%Q\/OA'X1U#7->\9>#OV>=:^.VF^
M(/%Q^'NL:1K5QJ_BGXR>#]`T?6HM9\.?#\:U%%:V/YH6&@_M377B#]FB\\8^
M)/VR_@Q=6'@;Q+=Z1\$T\/\`_!8G]J^TT#QY_P`+1\=0W/P?\<?M2?"KXN?`
M[P!KVM>$8+/P]96WQ]_;G\`?';X4>.]$U72M4^&L6O?"[1+O6O&'MGP,\#_'
M_4?^":'CSPCX0\:_M+_&/XR^*?C_`/LY:?=)\1M/_P""OO["OQ(BTW5OBC^S
M?8_$[PG)\4OVQ/C/^U!^UOX$\!?\(>WC$^/?CK^SC<:9\,?#7AN^\::KX7^'
M4.OZ!XTFU8`^HHOV./VJ_B?^T3X-_;9^+7Q4T?X3?&GP+JOASP+X9_9L^#OQ
M"TCXG_LWV/P`DM-5\/\`Q&M=8^+OCO\`92^&OQ]UCXI>+H/B!\0?B%'/X2M/
MA?\`#V]\6^$OV>?#WC;PMXP'P>TCQ\_.:_\`LB_M8Z_\!%_9OO/A?^QM!X4^
M#W@'2_"GP9^)7A+XS?'3X:?%CXFW&E>,_`.NW+7/B+P3\#['Q-^Q)J/C+2O!
M]U-XX\>_"+QW^T?XNO\`QC>:=XHT%?#E_I%O,:7PQ^(_[2?[+OAOXJ_`OQ'X
M8^./QK_:0N/A_P"#+_X`6%[X;_;!^._[.MCXC\9:WKOA_P`'>`_$_P"V[XF^
M$>I:'J?AKX4:MXF\'^&OBM\5OB;J.@_&;Q5\/_!>M?'+QKX"74+N_MD\QL1^
MTKX=^$WPG^$__!0JW_;'U'PM\(;GXC>$_BG\1_V(?%O[5OQ+\9_%[Q#>/X$\
M3?L[>.]5^*'[&'PF^!_[57C'PW;>"==\;>!OB/<?#+X4?#K05^-7@S5K[XC^
M#=-^&^I^`K[50#Z\U'X-_M7>$?A?^R5J'PL^%?P8\0_%/X(>*O']]XT^&7QN
M_;V_:?\`B3X<;0O&GA#XA^%UETS]L#XF_LO_`!A^.WQ2UBTF\2Z/J"P_$3X2
M:&+6QEO?#=AK,.E>'=%.I?'NC_\`!,S]H33?%'B33;VW^&5_X2^(WPR\:Z3K
M?B+1_P!L3]K?P/\`"SX;^(?'*?&77+CX5_\`#NGPOX"M_P!F;]IGX#>&=2^)
M&E_"_P`-S?%WXD>$?&]G\'K"W33%T+Q%X0\+*W7?`#2/B;-^W]X2UGQ1\0OV
MSM/\'VOPG\*6O@CX;_';X.?\%!=8TK7M!?X')YNN?$#XV?"_XZZ'_P`$Q/"?
MCVVU^?4O^$@\+?&/X`>-/CY>^+=,D^T>,-/\9:YX4_X1[Y:\9K\89/!'QDM?
M@3?_`/!3K3/C3J&H?M46?[4>J?$W0O\`@I[XC^%>@_#IO%/Q,D^&NO\`[,6A
M>,]:\*RZ_P"/;#Q(OPR3X>>'/^";WB_PQJ^M?"*?Q[!;:YI%TGP\U&W`/L3]
MI/\`8C_:A_;/^#/Q#^'/Q7\"?L<?`G5/$?@CQU\'M,U+X*^,/B'X]\0:I\/_
M`!+^RW^U%\#]/U76?B)XD^!/PRN-#TW2_$WQ\TO4?"OP4M_`7BK1/A[IUGXR
MUV#XI^--0\0V_AJUNW_[!7[3;:[K.M>&?B)\-/`6LZ'IWC;]E_X*^,_!FO\`
MB/3M<^%?[$/BJ\M&\,:MX:\.:E\--9\+:)^T3\)]'\4>+M.\.Z(D6L_#WQ=J
M_P`-/A%K?B/Q-9:+?7'@GP#\T^!]/O\`2?`GP]TWXQ>,?^"K_P`0-)MO"H;]
MG+Q?^S;\,O\`@JC\'[O5_BS/\5?B=-K/_"V_AY^T5\5_CC^T=X?\56%TWA#3
M-/7_`(*4?%/Q3^Q/JGP^L_#6O:`-#\":MXF\/:4?`>?]O/PUXW^.NO>,!^V)
MK.G_`!G^.?[2O[)W@+2/&5G\2-9LOA1IWB[_`(*"?MJ>)OA#^U)I=A>O<^&O
M"?PX^'7[/.J>%-.@\?:!:Z9X5O\`P!;_``)\/^&[_4_"VC?#G1IP#ZT^`_[%
MG[2/['/C'X!^%_@MJ'PN^//P%^#]E\<OAEI%W\:OB':_`GXH^`?@S^T#XU_9
MK^(^N1Z!X5_9_P#V2=1^#/C'4OAGXO\`A1\28/AY\/\`0/#GP$\&OX#\3>`/
M`XUKPT/!M]K^L_KK7X+_``2N/^"F7AC5OV1M0\0^%_&7B#X%_`K]G/X,?LL?
M'>\\?_$OXCW?[0WQA^+?C[X5^"X?B'^T?-\,;CX4:Y!\4$\+_$^3X-07WQ?\
M6_%SP5XN^'MOX8_:]NI/"?BO2?'-MKUA^H_[&WQ77XO_`+.?POU^YTOXSZ3X
MCT3P?X2\(^.8/CS\&?CA\#_B!-X[T/PAX>_X2N[N_#7Q_P#`O@#QOK]I/JMU
M-CQM::5J7ASQ!J"ZC_9FOZG<V>H&``^0_P!CC]C_`..7P*_;:_;N^.OCWP[X
M?M_AM^TW\7_%GQ.^'^LZ-^W_`/M@_&C4=.TZZ\#_`+.WPXTGP_XL_91^*?PQ
M\,?L^>&O$&MQ_!C7O'=M\1_"_C/Q'XJ^"/A77_#7[)7PR;5?@3X+T74K7]7:
M_*+_`()G?'O]JWXW^-/VU8OVE/%'B#Q/X6\'?%_X7VW[.]]K/_!-_P#:I_X)
MZZ=??#/6_@%\/;SQ5K/A/2_VH?$'B/Q)XT\/S_&2U^)'AZY\-:CK'B7XA>!/
M%/A;Q+XQ\0>+)/A3\9O@/X%^'OZNT`%<#\2?^1=T[_L?OA3_`.K1\'5WU><_
M%2VCO?"=O9S-<)#=^-OA?;2O:7=U8721S_$WPA$[6U]8S6U]97"JY:"[L[B"
MZMI`LUO-%,B.H!^??[6_[)/Q?^*7QIT[XH>`/!?P/\::K`/ANO@GXI_$C7->
MTWXP?LLP^$[_`,1IX[O_`-FY(_"_B'2='\:>/M*\1K?'Q#I_B'P#%XENM&3X
M>_%5?%/P^U*RG\,==\&O@)^V)\*+7]J+Q!?_`!5^'/C#QO\`M%V^M?$_PM:W
M]MXHAT'X+?'754U/P_IFAQW%S/J*^-_ACX4\!1_##PII=WIF@_#W4=4M/A$+
M_6/#\GB/QYK?B*'Z*/BO]G`?$W6/@J?CGI(^,GAWPK#XZ\0?"4_M,>)/^%FZ
M%X(N-WD>,=8\!_\`"R!XJTSPK/L?R?$-[I4&D2;&V7C;37<3^'?AQ;:%;>*+
MGQEXBM_#-Y#IES:>(I_C9\0HM"NK?6I;6#1KBVU>3QRNGSPZM/?64.F2Q7#1
MW\MY:QVK2O<Q!P#\@9?^"2GCSQCXB^!T?QA^+D/CC1_V0_#_`,=K+]G_`,::
M2-&TSXA^*M0^).L?!_Q]X/L_'OB'QAX"\?\`Q2^&_A_P[XIT+QOX$\4VWP9^
M..@ZG\5_A/HF@^"?BWJGCCX:_$7XB?">2K\+?^"0-Y\`OBM^S#\2?AUKOA[Q
M1IG[-7PSTK2[3PKKFB?`_P"'NHZ]X_O;SQ;K'B,>$O$_PR_9AT:/X%^!HM9A
M\`IJWASX!Z-\*]&^+VCW'C$_&C0O'FI3;M9_1KQ-\=OV*?!5Q\1+/QE^UG\,
M_"5W\(-;\,>&OBU;>)OVPIM!N/A?XC\;R6<7@S0/B)!JOQ7M)?!.M^+I=0L(
M_#&E>)5TR^U^2^LTTJ"[:YA#]MX'\5_LX?$[Q5XW\"_#;XYZ3\0O&WPSN=/L
M_B1X.\#_`+3'B3Q7XJ^'UYJMLM]I=KXW\/:#\2+_`%?PI<ZE9NEW80:]9V$M
MY;.L]NDD3!R`>D_$>2]E^$'CV74K:WLM1D^&WBB2_L[2[DU"TM+U_#%\UU;6
MM_+9Z?+?6\$YDBANY+"QDN8T29[.V:0PHGQH\&>*/B-\'?BQ\//!'CW5OA5X
MT\>?#3QWX,\(_%#0;>"[UWX;^*/%'A?5=#T#Q[HMK=?Z-<ZMX/U6^M/$.G6]
MQ^XFO-.ACF_=LU<K\2_A_H5E\./B!>0W_C9YK3P3XJN8DN_B7\1[^U>2#0K^
M5%N;&^\57-C>V[,@$UI>6\]K<QEH;B&6%W0]M_PK;P[_`-!'Q]_X=;XH_P#S
M8T`?F'I7["OQ*U3]FK]M7X%)\,_V7_V=/#G[2'PFN/`'A3X9?`VVMM?\+6OC
M3Q!X7\5:7\3/B7XW\2^(?A!X9T;QK>^/M7\1PW#2>-OA#XL\0ZU%IT^H?$O5
M?%D6M1>%O#FAX1_X)Y?$'X3^,O@-I7PU^)NFZC^SG\`/!^M?""+X/>/;*,W7
MQ6^&WQTUCQ-JG[1\GB+_`(072?!OPG^'FCVUWK?@C4_A!\'_`(8_!OP_\._`
M=C\%_#/PN^&T/PC^#^MR>#-)_2S_`(5MX=_Z"/C[_P`.M\4?_FQH_P"%;>'?
M^@CX^_\`#K?%'_YL:`/RKU?_`()_?M(F?P=+X%^/-UX#NI/A?X[^$'Q<\0R^
M.O&_B?7O''AOXY>,7C^)7BZV:_LH8C\7/AYX#\#_``;@^"_Q!U:6YU'05T7Q
M!X,M1H6BZA)JUS\[?LH_\$L/VE/A=XRTGXJ^,_%G@;X=?&R?XA>'_B=XR^('
MPPU?X>ZSIFL^(-%^"/Q?\#V6@ZKJ7AS]F/X'_&OXW^`K?Q)\0;#3-:\)_M,_
M%OXGZ0WAD7&J?!_3O@5J^EZ-:6W[N_\`"MO#O_01\??^'6^*/_S8T?\`"MO#
MO_01\??^'6^*/_S8T`?E+_P3,_X)_>(?V`/!T'A7QS!\*M1\=_$/XH_L\7FL
M^-OAO97`U#Q?)\'_`/@EM\$OV>_&VI^,-5U/PUX?UB_U#Q#^T+\*_CY\3[$7
MLVL/?P_$ZX\9ZI=VWC'QIXNTZT_837+6_O=$UBRTJ>WM=3N]*U"UTZZO$N9;
M2VO[BTGBLY[J.TN+2[DMX;AHY)TM;JVN&B5E@N(92LB^/^*OA_H4&N_#2)+_
M`,;,M[XVO[:8S?$OXCW,B1I\./B!>!K2:X\52S6%P9K2)&N[%[:Z>U>YL7F-
MC>WEO/VW_"MO#O\`T$?'W_AUOBC_`/-C0!^4OP._8$_:(\`_LB?&?]G/Q'XN
M^$`\/>-](UY_`7PV.BWOB.Y\.>-[G1/`\D7C;Q+\:;+2_!&D:SJ&I?$KPWXF
M^(-L=`_9X\*7NF_\)'H=SK>H>)OB)I/B;X@>+?H/XE?LG_%O5?\`AL9_A;X@
M^%'A"Q_:1\2KXMOO#NJ>&-6?_A9.JV7[/?PL^%=E;^.O%>@76EW?A&/4=8^'
MS:/XIUBV\/\`Q&U36_`1L-/2&Q>TBM!]K_\`"MO#O_01\??^'6^*/_S8T?\`
M"MO#O_01\??^'6^*/_S8T`?FK^R+^Q-\8O@7\>O#WQ'\3VWPSTSPUI7@+X\>
M%X8?!?B2YN)-#\"_%;XV+\5_A+^SWIN@CX9^&)Y_!G[+NCR7'PT^&NLP^+]+
M^'\/@:VMWT;X'Z%XWU_Q-XRD_6BN!_X5MX=_Z"/C[_PZWQ1_^;&C_A6WAW_H
M(^/O_#K?%'_YL:`#X;?\B[J/_8_?%;_U:/C&N^KPOX?_``_T*[T*_EEO_&R,
MGC;XEVP%M\2_B/91F.R^(_BJSA9H;/Q5!"]P\,"/=W;H;J_NFFOKZ:YOKFXN
M)>V_X5MX=_Z"/C[_`,.M\4?_`)L:`.^HK@?^%;>'?^@CX^_\.M\4?_FQH_X5
MMX=_Z"/C[_PZWQ1_^;&@#OJ*X'_A6WAW_H(^/O\`PZWQ1_\`FQH_X5MX=_Z"
M/C[_`,.M\4?_`)L:`.^KQ[X]_`GX<?M*_"KQ)\&/BSINI:MX#\577A>_U6ST
M?7M8\,:H+[P9XOT'QWX:O+'7=`O-/U;3[C3/%'AG1=3C>TNXA,;3[-<"6UFG
MADZ/_A6WAW_H(^/O_#K?%'_YL:/^%;>'?^@CX^_\.M\4?_FQH`ZW0-+A\/Z%
MHN@PWNKZE#HFDZ=I$6HZ]J=WK>N:A%IMG#91WNM:UJ$LU_J^K72PB?4=4OII
M;R_O))KNYDDFE=CK;QZ']/\`&O//^%;>'?\`H(^/O_#K?%'_`.;&C_A6WAW_
M`*"/C[_PZWQ1_P#FQH`Y/X7_`+/GPR^$/C[XX?$_PA:>(6\<_M$>,-'\:_%/
M7?$/BWQ'XGEU?5/#F@P>%O#-EI=KK>I7MCX;T'PWX<MK;1-%T/0;;3]/L].M
MK>W$+K!#L]N\P=A_3_&O/?\`A6WAW_H(^/O_``ZWQ1_^;&C_`(5MX=_Z"/C[
M_P`.M\4?_FQH`]!WGT'Z_P"-&\^@_7_&O/O^%;>'?^@CX^_\.M\4?_FQH_X5
MMX=_Z"/C[_PZWQ1_^;&@#OR<G)[TE<#_`,*V\._]!'Q]_P"'6^*/_P`V-'_"
MMO#O_01\??\`AUOBC_\`-C0!WU%<#_PK;P[_`-!'Q]_X=;XH_P#S8T?\*V\.
M_P#01\??^'6^*/\`\V-`'?45P/\`PK;P[_T$?'W_`(=;XH__`#8T?\*V\._]
M!'Q]_P"'6^*/_P`V-`'?45P/_"MO#O\`T$?'W_AUOBC_`/-C1_PK;P[_`-!'
MQ]_X=;XH_P#S8T`=]17`_P#"MO#O_01\??\`AUOBC_\`-C1_PK;P[_T$?'W_
M`(=;XH__`#8T`=]17`_\*V\._P#01\??^'6^*/\`\V-'_"MO#O\`T$?'W_AU
MOBC_`/-C0!WU%<#_`,*V\._]!'Q]_P"'6^*/_P`V-'_"MO#O_01\??\`AUOB
MC_\`-C0!^)M%%%`'[9?"G_DEWPV_[$'P=_ZCNG5WU?+.C:OH_@7X:_!F\\8?
M&_Q)X+M/',?PT\!^$[>ZM?AU'I]WXQ\8:3:V_A;PAIMS??#R_N?M>JW2?V7H
MJ:G?S7%]=FULFO+K4;J$7&39_'7X/:G=:18:-^U3K7B#4O$/C+XQ?#OP]I7A
MO3_A[XDU?7_'G[/TFN6_QF\':%I.A?"G4-1UGQ+\/KSPUKFG:[HVFVMU?KJN
MGRZ5:076I206LH!]>45^76G?\%$OV8=7T33O$>F_&O\`;$N]%U/X>:=\48+^
M+]@W]H_R[;PEKWB_Q/X$\)+J\;_L6+/H/BSQ]XH\(:S8?#3X=ZY%I_Q#^)EM
M)H.L>`?"WB/1/%GA74=9]D\`_M2?`'XF_P!F1^#OVK_%-W>ZO\7HO@#;:/J_
MA/PSX3\0V_QKD^$FE?'27X8:OX;\6_!C0]?T#QEI_P`+]:TOQ#K.BZ[ING76
MA7EVOA?64L/%T<VA1@'W#17CG@X#Q]X=T[Q9X3^,_C[5O#^K?:_[/U#^P_AY
M8?:/L-_=:;=?Z+J7PLL[V+RKVSN8/W]M'O\`+\R/?"\<C=+_`,(=XB_Z*MX^
M_P#!=\+O_G;4`=]17`_\(=XB_P"BK>/O_!=\+O\`YVU'_"'>(O\`HJWC[_P7
M?"[_`.=M0!WU%<#_`,(=XB_Z*MX^_P#!=\+O_G;4?\(=XB_Z*MX^_P#!=\+O
M_G;4`=]17`_\(=XB_P"BK>/O_!=\+O\`YVU'_"'>(O\`HJWC[_P7?"[_`.=M
M0!WU%<#_`,(=XB_Z*MX^_P#!=\+O_G;4?\(=XB_Z*MX^_P#!=\+O_G;4`=]7
M`_$G_D7=._['[X4_^K1\'4?\(=XB_P"BK>/O_!=\+O\`YVU<3\0/"NNP:%8/
M+\2_&UZI\;?#2$0W-A\.$C22Y^(_A6WANU-G\/[28W%A-*E]:*\KVKW5M"E]
M;7MBUQ9S@'QU\9_^"<\GQ9^,WQE^+UM\;?%?AJ3XW:7HW@?7_#0F\8ZGX?\`
M"7@";P=X$^'7CW5OAUX6;X@6GP[\-?''Q9\.=)^)'@.U^,USX#U?7=+\._$2
MRT^]M-;TGP?;:-J_4^+?V`X?'O[,7@7]D'Q5\:O&Y^#O@[Q/J,EU>:%I/A;2
M/'^O_#71Y/$5W\(_AS-K$FD7WA;28_ACJ&H>$+FQU[1O!=E=7/\`PK?PH^G6
MNA78O+N;M/%_[2_P7\!^.?$GP^\5?M&_%32]8\'Z7K&H>*=<7X3C4?AMX?OM
M"\,V_C74/!6K?&'2_@%>_":S^*K>#KJW\5:=\'9O&J_%;6O#LJ:UHW@V_P!.
M/VBMC1?CO\-M6^#^A_'?4/CC\;/A_P##7Q'XE\/>$-)U#XT?!.]^`WB67Q!X
MN\::;\/O"UG=_#KXU?L]^`?B/I<'B'Q5J^F6>C:GJOA.RTK4=/O8/$5I>R^'
M&_M8`'S]9_\`!,GPIKVB7U[\6?B;X[\:?%7QI\2_`_Q`^*'Q&\*_$3X]?##^
MU(/#-IX9E\0^&_A7HGA?XWB7X`Z5X\\1^%['7?&,?PHUCP__`,)CY<-IX_/C
M-EN+JZ]`_9X_87C_`&8_BCX[^(/PZ\<PWVE_$+Q/K5S-X/\`%\'Q!\1:%\,?
M`.J>+=9U^3P#\"M$NOBC_P`(?\*]/U;3QX%@\5'P]X3@T[Q-XC\#Q>+M;T?4
M]6U8G3N?\<_MY?LP?#?7=:\->,OVE_CII>M:'\4+CX.R6=O^S;XZUH:UXYTS
MPYXZ\7>)8_!5UH7[+VIV?Q!\)^`O#/PP^(NM_$_XD>!+CQ'\-_A7I_@CQ1/\
M1O%GA==%O_(]@^#'Q[^%O[0?B3XB^%?A+^T#\5_$FJ?"[Q3XK\&^)[F_^%4/
MA#P[?ZYX$\:^(/AOXV_X0#QAXU^`WAWPE\6=&\(_$+PIXC\#^)?$_P`*];\9
M>&=$\6Z-?^'=2U>VU:!K2@#Z'^*W_)+OB3_V(/C'_P!1W4:[ZO"_B7X5UVV^
M''Q`N)OB7XVOX8/!/BJ:6QN[#X<):WL<6A7[O:7+V/P_LKY+>Y4&&9K.\M+I
M8W8V]S!,$E3Y^\=_M/\`@?X=?M=?!/\`8N\0_$GXT?\`"U?CYX.\4^,O`VIV
M.F?`"Y\,1VOA/2?%^NWMCK%B^B0?$6!9M*\!^)I'\6:;\/\`5?AQH&JCPMX3
M\8^-_#/C+XE?"_P]XT`/9_C#\2?%7A_XG_L[?#WP79>+)KKQO\3+F;QW<Z?\
M/?$6N>%8?A=I7PZ^(U[J[ZWX\3PY?>$/"%Q#XPM/!"V\-_XAT;Q!J$]U96>F
M17EM?W4$OYG3?MC?\%%?"?B;0+/7/V8/$/CCPUI7QP_:-NO$&I^%_`OB2QU+
MQK\%_&OA'X_:W^Q'X6\.6<FC7.FVGB>Q^(G@[PI\)?C5JVHZUH*>$M._X0+X
MH^,M0T/P[\2)X$^Q?B;^TK:^`/BC/\#?#=Q^TM\9?C6NG?\`"26/PM^&&E_L
MNVWB75_`6F#P:/'/Q&T^]^*5Q\,O"J^$/AM+\1/`=EXO?4/$=AK\^J^,/#NB
M^$-!\5ZSJMI82?-6I_\`!6G]B;3&TBS/[6/CB_\`$NI^)/AMH-]\.M*L?@?J
M'Q@\)Z;\7_%WP<\$_#CQMXX^"D'A<_%SP?X,\4ZY\=_AW'9:AKO@FSU."+4I
M_MVD6MQ##;W(!Z_\"O'7[;/BJ;]G[0OB[#J7@;Q+9:MXR\"?M*V]Q\.=`FLM
M1U+X6&/Q9X/\?^!O$FA-K'@[2M+_`&@O".N^&K;QE9V6L^+="\(7[ZUX)\!:
MUIWC3PKK>NW'Z85^9ES^W#\-+?6_%NG)XU_:`O-%\+16UE:>-+/3/V:)?#?C
MCQKKGQ]D_9J\"?#KX?6K+'XN\5>)OB3\6)_#>A>"M6M?"T?P]N9?&OA"SUKQ
MQH>MZG/I%EQ_C#_@HO\`"'X5^'O'FH?&_P`1?M5?!#Q;\,/A'\=/B]X^^&OC
MWX??`N_\1Z!9_L^?#CP+\7O&G@B#QA\/=,\=?!7Q/\0-8^&WQ&\,^*_`VC^#
M/BMXDTGQ;;+XBT[3M>76_!OB[2]#`/TE\8_\C%\*?^Q^U'_U5WQ)KJM=U-=%
MT36-9='E32=*U#4WBC@NKF21;"TFNF2.WL8+J]N'=8MJP6=K<74K$1V\$TK)
M&?'_`!5X5UV+7?AHC_$OQM<M<^-K^&&::P^'"R6$@^''Q`N#=V@M_A_!"]P\
M,$MBRWT5[:BUO;ETMDODL[RTZZ[\,ZQ86MS?7WQ?\;65C96\UW>7EW:?"JVM
M;2UMHVFN+FYN)OAPD,%O!"CRSS2ND<4:,[LJJ6`!^6WP3_X*+?%7XF?LF_&;
MXG:MX3\.6OQD^%6D:OXKCU?P_P##+Q[K7[.&K:38Z!X#\=P^&-/^)N@^/?$_
MP^\4>*(?#GC1O"^HW/@SXT:X-.\3:9J,^O>'_#GBOP_XQ^$7AKW[XE?M>^./
MA5_PV#'KNCZ;K(^$/B18_A;K>A_##XB7/A+PGX2B_9_^%WQ.UC4_CYXDTG7_
M`!%IRKH>O>*?%.JQZS;3_#2W\1^&;73_``GI&CIX@TG4/$VK>[6/C7X3O\.O
M#WQ'TW]JS0'^$OC+6M!\-^%/'ECXH_9\;X=>*O$7CSQ9;>#O#&@^'O%%OX*/
MAK7-:\9^.=8L_"N@Z7IM]=7WB+Q9JEMH>GP7FL7T5K+M7OB+P3IOAGQQXTU#
M]IR+3_!OP^O]<TWXD^++W7O@5:^&?!&J>&8X8O$FG^.->G\#1Z5X:O\`P_";
M>/7+77KJRN-*C,*W\=NI04`?$?[)?[=GQ,^.?QUT#X6^+(_A+=:)>^#?C]!=
MWW@JPOM)U[5O$7P+^-47P]\,_&'0M+OOBCXUU5/@C^TE\/[JS^*WPN`\.ZSX
M1T'P_?:/ITG[0WCKQIJUWX(T']7:^>O">I^`_%FOW6A>!OVD+;Q-XHTKPCX3
M\0WNC>$]6^`^LZ_IO@/Q9!<7_@77+K3]'\!W.HV?A'Q-;1W=[X3U.:&/1=9@
MCN+G1Y[F-)7'H_\`PAWB+_HJWC[_`,%WPN_^=M0!^<_Q@^"G[37Q3_:?_9`\
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M;:RL4N+EE,TZV=G:6JR.RV]M!"$B3T:@#\EOA%\!_P!L7X??`#P;X.T'Q]\5
MK#XIQ?M]?M;>.-3\4?&?XP^(?CU<G]G!_C+^U(?V:],\8:AXU^(?BC4M0^%N
MK_!RW_9QTV^^'OA77=)\0Z-97\VI16'A;XF0Z]K5CYAX(^&_[?,7B[PWJWQ(
MT/X[S?%2W^(?PDU+X<^*?!?[1]O<?LV?#7X&&_\``VH_M%?#CXX^!]6^)>F:
M?\<OB)JM[X;^+]GX)\>ZU\!?$6M_\(O\3?@UHOP]\5?"*_\`#WQ`\4^"_P!N
M**`,/PQK%WXA\->'M?U#PYKG@Z_US0])UB]\(^)VT1O$OA6[U.PM[VY\.>(6
M\,ZUXD\-MKFAS3OIFK-X>\1:_HAO[6X.E:UJM@;>^GW***`"BBB@`HHK\^?V
MG_C_`/'SX*?M6?L$^"?"^H?""^^!O[4?QQ\5_`?Q]X:U_P"'GC.^^+&F:EH_
M[.GQZ^.=AXU\'_$[3OBWHWA#1[!+WX2:3X:O/".M?!WQ7<7EKJ>H:K#XMT^8
M6VGP`'Z#45\&_&WX\?'#Q'^T98_LA?LIZA\(?"_Q-T7X0Z9\>OB_\6/C9X,\
M5?%;P7\,?`7BCQCK?@?X:>'[+X2^!/BG\%O$GC7QE\4=<\&?$5K":;XI>#=%
M\(Z'X%U/6=0;7[J_TC0KWP%_^"B'Q,TCPSXI^#WB#X;>!!^W'HW[7^@_L4>'
MO!%IKGB"Q^#?C#QGXY^'$7Q^\%_&K3M4U6TC\7P_"R+]F>34/BYXQ\.VT6J^
M(=&\0>$?&'PLTC7M?O[+3?%FI`'ZX45^6>I?MG_%;]DCQUXI^'_[?&K_``?\
M0>'[3]EOXR_M5^#?C_\``;X>^._A1X4UO0/V;Y-'O/CU\/?$OPJ^('Q0^-5U
MX6\4^%?#?C?P!K_@?5;/XR^(XOB38W/C"270/!,_AB&SU;#N_P!J;]M;X-^#
M_@[^TM^TAX6^`4?[/7QA^(GP7\'^,OA)\//"GQ'L?C;^RQHG[0/B#1_`/P]\
M0^+/BMJ'Q&\8>`_C[/H_Q'\:^`-&^*EGH7PG^!FE^"="U+Q/XCT+7O'4'AF"
M#70#]:****`"BBB@`HHHH`****`"BBB@`HHHH`****`/P/HHHH`_23Q_^S)X
M*_:D^!G[/_A;QYKGBS1M(\"Q^&/B'81^$[C0[.XO_$B?!3QIX`\-W5[=ZQH6
MMW-G)X(UCQ_:_%'PG>Z#+HVJ6'Q&\!^"KV[U"^\.6^O^&O$'EGA+_@E]^S[X
M*\2:!XGT+Q%\6(+[P!J7@[6OA''_`,)H+>#X6ZWH7B'2/%'CC6-)&G:;82>,
M-0^.&K>'M"D^,<OQ/?QS'XGCTQ?L,6CW&H:Q<:E]P_"G_DEWPV_[$'P=_P"H
M[IU=]0!^3OC7_@CM^RQ\1?$&AZQXYM5\96>G?!#X:?L^ZI;>+_AG\"O%/B+6
M_AK\-_$'B+7V\.1?$G7/A7>_$CPOH7CO_A);_2?B)X:\(^*-#\.^*M(`LKW3
M`L]V;C3\.?\`!(O]FSPS>>)K^T\3_%H2WGC#PI\0_A[;:;XDT3PCHOP=\?>`
M_A5^R_\`"/P7XO\`!/AGP+X9\+^&=7U7PUHG['WP1UW2X?B'H_C72K?Q7IGB
M/4X]-2S\2W>F1?J?10!X[\$/A+/\%O!]UX)'CWQ-X[T>/Q'K^K^&V\4:?X3L
MKKPOHNMZA+JD?A2SE\*>'?#PU/3M,O;J]>UU+7$U+79DN?+O=3N%ABV^Q444
M`2JH(R>3SW]#@?H*_GV_8]\#?M[?M#?L6?L!?&GX9?MA>*+;7O$/C[4OBW^T
MC??%S6G\2ZEXM\*ZKJT?PWO?"O@2.W\&ZA:6UGX8\&P^+/&7A7PMXLDU7P'-
M\1K?1;C7?#NI/>VFO^#?Z!@VT'OW[_D,9[\_GW-?"?\`P35^"/Q;_9F_8U^$
M/[/GQHTCPEIWC'X1Z?J7A07W@OQ7=^+="\2Z4^J76N6GB""ZOO#?AB[TN6XG
MUB\T^31I[*ZD@738[PWT@OA;6H!Y+>_L[_\`!1::]_;O:T_:M\+P67QAM!<_
ML@Q/%=;_`(/ZM<2'19;#QK,G@4R:7HMAX3\*^%?L<GPP32-0GU3QU\1]2O)9
M_'VG^'_BG=>;:%'^TS\&OVP/^"7GPQ^+GQ^\4>.?$?Q"_9V_:L\._M`:)HNM
M3/\`"3QOXN^#ND^`/$7A+Q=I6BZCH>F:T=5TN3XB:EH\>OZW/<^)-7T/2/#P
M\4ZAKNO65_X@U;]D-Y_V?ISG'?Z'_P"M^'PS\6_@=\5/'_[>7['OQRTJP\)6
MOPB_9W^&G[2VG>*=7OO$UZOB[6/%7QRTSP'H.CZ+H?A&#P[-9OI^B0^!$U+4
MM;OO$]IYRZO]DMM-,NGM)=@'W3L7T_G1L7T_4_XTSS&]!_G\:-Y]!_GUY_PH
M`?M7T_4_XU&X`/&>GJ??WZ^]+O/H,\=C[^_7_/I32<D$XZ=O3/<>O]/K0`E<
M#\2?^1=T[_L?OA3_`.K1\'5WU><_%2TM;_PG;V-];6][8WOC;X7VEY9W<,=S
M:W=K<_$WPA#<6US;S*\,]O/"[Q3PRH\<L;LCJRL5(!\C?&K_`()^^$_C3K_B
M*YU'XT?&;PYX!\5ZUKWBOQ!\&]%U#P?<?#;4_&7BCPY;>&M9\4W$&J^$;WQ9
M+>1'3M%\8>'=,E\52>'O#/Q%T'3_`!1I>CI:WWB?0_$6?8?\$S?V<&_9Z^'_
M`.RYX@TDS_!'P!J?C?68/AY\.?#W@K]GGP?X@U3QOH7B+PW>76O^%_V>/#7P
MOT.XCMM+\8>*YYK.ULK2R\1:[K<WB#Q9!KNJ6ME/;_4WCG1/V=OAAX0\1?$/
MXE:1\%OAYX!\'Z5=Z[XM\<>.;#P-X2\(>%M$LD\R]UCQ%XEU^+3]%T32K2/Y
M[K4=3OK6TMT^:69%R:\^'Q`_8A.H_"C1QXV_95.K_'F"6Y^!NECQ)\(SJ/QF
MMH+*749KCX46(O?M7Q%@AT^&:_EE\(1:Q''90RW3LL$;R``\%7_@E5^R1J3?
M#>^\>>!]%^*7B/P7^TU=_M:>-?%7Q!\`?"+7=<^/_P`8!\*OC3\*/#.K?'F9
MOAU#!X\A^'NG_&O5?%/P[F>#3]7\&>,O"'@34M"U:ST_0Y-)O>^_9X_8&^%'
M[+/CCXH^/?@KX@\3>%M8^/'QY^)_[0GQXD_L+X77=]\7O%OQ0^(/QL^(UYI'
MBWQ'+\/!XJ'AWPQJGQBL-&\)1Z1KFFZSI?A?X4?#O1WUJY-Q\0;GQU[W=Z1^
MSG86-OJ=]I?P4LM-NWUJ.UU"[LO`MO8W,GAM[J/Q$EO=S1);S/H+V-ZFM+'(
MS:6]G=+?"`V\H3A?B1XY_8G^#FK>&M`^+WC#]EKX5Z[XS\2Z/X,\'Z+\2/$'
MPF\#ZMXK\8>(1G0/"GAK3?$]WI=YKOB77`"='T+2X;K5-3Q_H5K/B@#V?XK?
M\DN^)/\`V(/C'_U'=1KC?%/[.WPM\9_&#PC\<O$&F:Y=>/O!&GZ?IVBR6_C#
MQ9IWAF:/19O%%UH%QKO@S3]8M?"GB6^\/77C3Q/=Z!>:_I&HS:3>ZJ][9M%>
M6MC/:^<>,OBG^P?\.=<\&^&/B%\1?V2/`GB7XBV&E:K\/O#WC+Q?\'/#&N>.
M]+UV/59M$U+P;I.MZA8W_B>PUF'0]:ETJ\T2WOK?4(]'U5[229-/NS#Z=X&T
M3]G;XG^$/#OQ#^&ND?!;XA^`?&&E6NN^$O''@:P\#>+?"'BG1+U/,LM8\.^)
M=`BU#1=;TJ[C^>UU'3+ZZM+A/FBF=<&@#R[7/V(/@-K^J:UXCNE^+=GXSUSQ
M-XA\2S_$+0_V@OCKH'Q'T]/%>E6^C>(?"6A?$#1OB'9>+M!^'&H6-G8,OPXT
MG6+3P3I^I:1X>UW2M$L=>\+>&-3T>Q??L.?LOW_A;X>>!V^&%M9>#_A1\2?A
M[\6OAYX;T;7_`!1H6D>%?&WPI\:_#;XA?#V\TVTT?6K%%TGPQXK^$?P^O;+P
MU+YOAR6TT!=&O=*NM&O]3L+SW3_A5/PN_P"B;>`?_".\._\`RNH_X53\+O\`
MHFW@'_PCO#O_`,KJ`/FM_P#@GO\`LF-/JK0?#2]T[3]4@\;F'P]HWC_XC:'X
M5\-ZW\0_'I^)WB?QMX%\,Z-XLL=%^'WQ%D\;Q:=KNB?$/P19:!XS\*7&@^&D
M\*:WHL7AW1H[)VJ_\$^?V3O$O@_XC^"/&WPTN?B+I'QB\(>._!'Q9O?B/XV\
M=^._$WQ(T/XC'P8GB)O%_BSQ/XDU/Q)JNK6UG\._`VD>$];;4X]5\!:#X2\.
M:!X(N_#^C:)IEC:_27_"J?A=_P!$V\`_^$=X=_\`E=1_PJGX7?\`1-O`/_A'
M>'?_`)74`'C'_D8OA3_V/VH_^JN^)-0?&'P#<_%7X2?%+X7V?BC4/`]Y\2/A
MSXW\`VGC32M+T/7-4\(7/C#PSJ?AZ#Q1INB^)[#5?#6KZAX?EU%-6L]+\0Z7
MJ6AZA<6D=GJUA=V$UQ;R3_\`"J?A=_T3;P#_`.$=X=_^5U'_``JGX7?]$V\`
M_P#A'>'?_E=0!\8_#_\`8;UKPA\#+;X17/QAOD5O'7AWQQ<Z'HFBWMQ\--/O
M-'_:(M_CS?-HUAX[\1>./B[>:QJYB/AV^UWQ;\9_$CR2K;ZC!8V=A"NA#2^*
M7[$^N?$&W^(TNE_'7Q;X3N?%/[1OPW_:5T'P[I^C:2_P^N/%OPEU_P"`7C3P
M;H7Q*TE/L_C'Q=X=/BSX"Z6FO6GAGQ[X#36O#'B#5-"O()8GG>[^O/\`A5/P
MN_Z)MX!_\([P[_\`*ZC_`(53\+O^B;>`?_".\.__`"NH`^-OV;OV*/%/P-^-
MJ?%O6_BWIGB>RL_@7%\';?PGX<\#ZKX3TK5;Z^UGP5XIU;QCK%CK/CSQOI6D
M:GI'B#PUX@L/#$O@+3O!^K:YX$\6:'X-^,NM?%=/@M\%-5\$_H/7`_\`"J?A
M=_T3;P#_`.$=X=_^5U'_``JGX7?]$V\`_P#A'>'?_E=0`?#;_D7=1_['[XK?
M^K1\8UWU><_"NTM;#PG<6-C;6]E8V7C;XH6EG9VD,=M:VEK;?$WQ?#;VUM;P
MJD,%O!"B100Q(D<4:*B*JJ%'HU`!1110`4444`%%%%`!7Y8_\%`O^3J/^".G
M_9_WC[_UW[^VI7ZG5ROB#P+X(\6ZKX.UWQ5X.\*^)M;^'7B"X\6?#[6?$'A[
M2-9U7P+XJN_#^M^$KKQ+X.U'4;.YN_#'B"Y\*^)?$?AFXUG1)K'49_#^OZWH
MTEPVG:K?VTX!^;GANTC^&7_!8CXS:SXPU"'2M/\`VIOV&OV<]$^#<^HSO!;>
M)_%?[,_Q:_:1O/BUX.T:>>&&TEU[0?#WQP^'7BQ="M[J?4[[1]5UK6;:UDLM
M%UB6R_-;XCZM8^,_VY+']O73M3M1^R[\%?\`@JI\(/A;KWQ1BOH;GP3?:5X;
M_8+^,O[+7B[XE6^N6,EYI<O@WP7^U'\>-.^"/B3Q%<7%GI?AG7_#7C*35+R&
MTTO49;+^B3XO_`WX)_M">$)/A]\?/@]\+?C?X"EOK/5)?!'Q?^'WA+XE^$)=
M3TZ3SK#49/#7C/2-:T9[ZQE_>V=VUDUQ:R?/#(C<UTMKX`\!V7@L?#>R\$^$
M;/X>+HTWAQ?`5KX;T:W\%CP[<0R6]QH0\+162:&-&G@EE@ETL6/V&6&22)X&
M1V4@'X.?\%B?!/B/]L/Q5XB_91^`\2>,OB=X+_X)T?\`!0/Q]XOLM"O;:Z/A
MG5/C7\*_#_PD_9\\$^(39S3W.CZM\<=>F\>3^#;:[M,ZYHWPX\63VRFUMY;F
M+WO]LCX[?#OXX?\`!.[X)^'/A-XBTSQEXD_;/\7_`++OPI^"?AW3+RUD\0^(
M-4U3XG_#O7OB1.N@SW-IJ:S?!3X=>'?'_C[XI:9+!#J'@[2?`7B./7[?3[BP
MN(X_T[^#OP"^!/[._AF3P5^S_P#!7X2_`SP;-=RW\OA+X._#CP=\,O#,M]/)
M+-->R:#X*T;1-*>[FEGGEEN6M#-))-*[N6D<G,\)?LT?LX^`/B7XM^-/@3]G
M_P""7@KXQ^/W$OCOXL^$OA3X$\.?$OQK((VA$GBWQWH^@V?BGQ&XA=X@^L:K
M>L(W9`=K$$`]MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_`^BBB@#]+
MKOX@_#?X(?!CX6^-/C7^U/I'P*\(>(-,\`>%-#U?XF>+O@=\/O"MQXJ\0^'X
MIM!\%Z)KGCWPK:1ZCK>H16=XFB:,VJZAKNI0V%PZ"]D@N)J[FS\<_#[4="\.
M^*-/_:NLK[PSXPU&PT?PEXBL_%7P%NM"\4:OJEK#?:9I?AW5X/!;Z?K>I:C9
M7-O=V%CIEQ<W-Y:W$-Q;Q212QNWBGQ3_`&3]%_:I\#_L)W7B+QKXS\':+^SI
M\3O"_P`?[VW^'WC+XC_#7Q=XQ;_AE+XZ?`W3_"VE_$SX3>/?AWXZ\#VZ:I\<
M+'Q5KEUI>LWUAXM\/>%]6^&WB/0]0\,^-]7:W^)_A/\`\$6[#X4?!#]FKX5:
M5^T#?/K'P.'P:7QGJ]O\/XXO!GQ<N_@W\.?!7PXT+Q5J'P\U#Q?JMMX;\;#1
M_"EUIXUVSUS4&U7PMJ.D^$O&47BRQ\#^!KKP\`?IYX2^(7PU^(&A:?XH\!_M
M;Z5XV\-:M)HD.E>(O"/C#X`^)-!U*;Q+X@U/PGX<BT_5]&\&WNGWDGB#Q5HN
ML^&M$2VN)&U7Q!I.IZ-8"?4;"ZMHO4O^$.\1?]%6\??^"[X7?_.VK\TO!/\`
MP2]DTWQQX*^*_CGXY>,-9^(7@?7/@9J&C:5X(\6?'OP)\%(-"^#7QD^)'Q'@
M\*ZG\##\?=>^'_Q"A'A?QU8>"O!OB7XPZ9\2/%W@*7P[:ZYH>M(RZ78Z-^M=
M`'`_\(=XB_Z*MX^_\%WPN_\`G;4?\(=XB_Z*MX^_\%WPN_\`G;5WU%`'`_\`
M"'>(O^BK>/O_``7?"[_YVU'_``AWB+_HJWC[_P`%WPN_^=M7?5\[_%#]J#X:
M_"'QM;>`/%GAG]HC5M=N_!.J_$"*_P#A?^R%^UE\;_!*:%HUGXGOKNPN?B5\
M%O@IX_\`AS9>-IH/".JII7PSO/%4'Q'UV\N_#&G:)X4U#4/&W@RUUX`]*_X0
M[Q%_T5;Q]_X+OA=_\[:C_A#O$7_15O'W_@N^%W_SMJJ?";XK>&/C1X)T_P`?
M^#]+^).C:%J5SJ-I;V'Q9^#7Q?\`@)XVCETR\EL;E]0^&OQT\#?#GXBZ3;2S
MPN^G7NJ>%;.SU>S,6HZ3/>Z?/!=2>DT`<#_PAWB+_HJWC[_P7?"[_P"=M1_P
MAWB+_HJWC[_P7?"[_P"=M7?44`<#_P`(=XB_Z*MX^_\`!=\+O_G;4?\`"'>(
MO^BK>/O_``7?"[_YVU=]10!P/_"'>(O^BK>/O_!=\+O_`)VU<CXU\-:SI^FZ
M/=W?Q!\7ZY;P^/OA=YFEZI9>`H;&Z\SXE^$HD$\FB^"-(U-?L[NMQ%]FU&WS
M-#&L_GVYE@E]LK@?B3_R+NG?]C]\*?\`U:/@Z@#COCQ\*M:^*GASPLGA7Q'H
M_ACQI\/?B#X;^)W@N^\4^'+KQAX,N/$GAA-0M[6Q\8^%+'Q!X5O]:T>6UU6]
MFLFL/$>DZAH'B2WT'Q983SWF@065U\N^(_V-OBCXJN_$;:G\5/A+:V?QJ\/^
M!M%_:';1/@3J&E:M/)X!\8^)/&&E7?P)U5?BK/<?#F66Y\5:JT$WC<_%.XT/
MQ?(_Q+T>6'Q%J&M6>J?HC10!^'GB3_@C)I_B73-"\,:C\=FU/P!)XB^(5SXW
M^&^M>`+Z\\&ZCX-_:/T+QE/^V!X1\(V-C\0=*E\/R_'WXHZOX4^)\VMZ_+XP
M/AF_T;Q7I$.FZE'XSM]1\,:%M_P28\?6/QS\.?&BY_:L\5^,;VWMO";^,Y=9
MO/C9\/\`QAXU\1>&[[5="D\0^(?%'P.^/WPTL/%&BWOPCT7X.>`[SX2>,_#7
MB/X1>)-5^'VK^)O'_A'QI:^*-,\.^$/VSHH`_$C2?^",_ASPOXP^&/B7PU\6
M]*G\._#CX9?!?X;6OPG\=?"NV\;?"PZ-\)?V4/\`@I;^S?>>'--\.-XRT62S
M^&OC'7O^"C6O?$*\^'5[=ZGI>AZ7X'O_`(;Z#=V/A?Q9HY\!?H_^S/\`!+QI
M\$_#5WHWCGQYHWQ*UBYM+&W/BV'P[X@TGQ/<V]IKOB_5-/T;Q%K6O^-_&%YX
MNL_"6C>(=*\(>&_$>M,?'FMV&A3^(OB1XG\;>,->U'6Q],44`%%%%`!1110`
M4444`%%%%`!1110!P/PV_P"1=U'_`+'[XK?^K1\8UWU?$7B+]IKPY\#)(?#W
MB]=&MAX@UO\`:'\8:1/L^+&LRV_A/X=^/=?U'QOXF\5_\(!\%O'FC>!M`T23
M5;#3X-7\4Z_IUAJ^I:CI&D:7<7&OZK:Z,>8T3_@H)\/_`!+\2=*^$?A_P_XF
MUKQ]J_Q"\<?#)=(TSX0?MDWECH_B'X=MX#'B;6/%WB6#]D)_"_@?X:M!\3O`
M>H>&OC+XRUK0?A#XYT?Q)9:UX(\<>(=)CN[VW`/T$HKR;6/&'Q"T.XT."_\`
M!_@5!KVJ7.E6]P/B3KBVUI+:>']<\2SW%_+-\+X?(LTT_P`/WJ&9%F9;A[</
M&L#37$/D_@']K'X<_%;P3%\2_A=\5_V3OB3\.)O^$F\GX@>`?VH]"\8^"9?^
M$*L7U/QGY7BKP[X)U'0I/^$2TV*74/$VV_/]@V,;W>J_9(%:0`'UC17S!XL_
M:8\(^`M6\,Z%XY^(7[,'@O7/&OBR3P#X-T;Q9^TKIGAS5O%OCJ+3+36I?!7A
MG3M8\"6=YKWBR/1K^QU:3PYI4-WK":9>VE^UF+6XAE?H/BG\;8O@7X&UGXH?
M&W7?V?\`X._#3PXVFQ^(?B)\4_CZOP^\#:"^M:K9:%HZ:SXM\6_#O2-`TMM6
MUS4]-T;35OM0@-_JNH66G6HEO+N"&0`]_HKY)^'G[6_PS^+OBGQ)X&^%'Q<_
M9)^)WC7P;K5AX;\7^#_AY^U/H'C3Q3X4\1:IIGB?6],T'Q)X?\-^"M2U;0]:
MU'1O!/C/5[#2]4M+6^O-+\(^)K^W@DM-!U66TO\`_#4G@8^/+OX6#XF?LK_\
M+.L-+M-;OOAS_P`-.:/_`,)Y9:+?^*I?`ECJ]WX0_P"$&_X2"VTN\\;P3^#;
M2_FT]+2X\50R^'H96U>-[-0#ZGHKYL^)O[0^@_!3PYXJ\7_&3QG^S;\)?"7@
M6S\,:AXV\4_$W]HRS\!^'/!UAXUUN?PSX-OO%6M^*O`&E:9X?L_%OB.VN?#_
M`(8N=7NK.'7M;MY]*TI[N_BDMUS?A?\`M0>"?C?XA\=^$_@O\2?V6OB]XJ^%
MMUIEE\3?#7PO_::TGQ_X@^'5YK;:FFC6GCO1O"G@75M1\(W6KR:)K*:9;^(+
M;3Y;]M(U-;5)3870B`/J6BN!_M'XH_\`0G>`?_#D^(O_`)U-']H_%'_H3O`/
M_AR?$7_SJ:`.^HK@?[1^*/\`T)W@'_PY/B+_`.=31_:/Q1_Z$[P#_P"')\1?
M_.IH`[ZBN!_M'XH_]"=X!_\`#D^(O_G4T?VC\4?^A.\`_P#AR?$7_P`ZF@#O
MJ*X'^T?BC_T)W@'_`,.3XB_^=31_:/Q1_P"A.\`_^')\1?\`SJ:`.^HK@?[1
M^*/_`$)W@'_PY/B+_P"=31_:/Q1_Z$[P#_X<GQ%_\ZF@#OJ*X'^T?BC_`-"=
MX!_\.3XB_P#G4T?VC\4?^A.\`_\`AR?$7_SJ:`.^HKRK3?%?Q'U2]\06-OX*
M\$I+X;U>'1;YIOB-KJQRW5QH.B>(DDM"GPND>2W%EK]G$SS)!(+J*Y01&&.*
M>;Y$\=_\%%OAA\-_%?Q0\$>)]+UY_%'P@U+PQHOBS3/"OPE_;'\?_P!K:]XN
MU+X<Z1I7AWX77O@+]D/Q+I_QP\26FH?%SX;6_BCP]\%KOQ_K7@C_`(2_2Y?&
MECH$!N)8`#]$**^8?!?[1:^/V\+V_AS3O"/]J>,+CQ?::-X<\0:W\5?!OBZ*
MZ\`FQ'C&WU_P;XQ^!&@^*O",_A]M5T=-0C\6:/HCI)K6B1(LDFLZ6MW[!_:/
MQ1_Z$[P#_P"')\1?_.IH`[ZBN!_M'XH_]"=X!_\`#D^(O_G4T?VC\4?^A.\`
M_P#AR?$7_P`ZF@#\3:***`/VR^%/_)+OAM_V(/@[_P!1W3J[ZO"_AIX5UVY^
M''P_N(?B7XVL(9_!/A6:*QM+#X</:V4<NA6#I:6SWWP_O;Y[>V4B&%KR\N[I
MHT4W%S/,7E?MO^$.\1?]%6\??^"[X7?_`#MJ`.^HK@?^$.\1?]%6\??^"[X7
M?_.VH_X0[Q%_T5;Q]_X+OA=_\[:@#OJ*X'_A#O$7_15O'W_@N^%W_P`[:C_A
M#O$7_15O'W_@N^%W_P`[:@#OJ*X'_A#O$7_15O'W_@N^%W_SMJ/^$.\1?]%6
M\??^"[X7?_.VH`[ZBN!_X0[Q%_T5;Q]_X+OA=_\`.VH_X0[Q%_T5;Q]_X+OA
M=_\`.VH`[ZBN!_X0[Q%_T5;Q]_X+OA=_\[:C_A#O$7_15O'W_@N^%W_SMJ`.
M^HK@?^$.\1?]%6\??^"[X7?_`#MJ/^$.\1?]%6\??^"[X7?_`#MJ`.^K@?B3
M_P`B[IW_`&/WPI_]6CX.H_X0[Q%_T5;Q]_X+OA=_\[:N1\:^&M9T_3='N[OX
M@^+]<MX?'WPN\S2]4LO`4-C=>9\2_"42">31?!&D:FOV=W6XB^S:C;YFAC6?
MS[<RP2@'ME%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!\,_$W]E/
MP[^T]X<TBU\5?$#Q]X3T?PSXM_:.L3I/@H>#+1M4D\<>*O'OA*[OI=>UKPAK
M?BO29K71M2U339[/PWKVC:1XDT;5]5T'Q?INOZ1=BUB^$O!'P3_8'UK_`(*%
M>'?V?_\`AH^+XI?MI?LFS_%']J:P^$GQ*^#GPF\<>(/A]X)_:"^)OP\^(=]>
M>%?B)XQ^!MVWA_4]`U6W\-:)H&L?#SXB6GQ9\(?#W7]#T6XNK#P]8^&9;+]=
M="\0Q>$?AIXW\5SZ7KVN0>&->^-_B&;1?"VBZAXD\3ZO%HOQ`\<ZE)I?ASP[
MI%O=:KKVO:@EL;32-%TRUN=0U34)K>QLK>:YGBC;^-#X)?LI?\%E_@[\:O@=
M_P`%9_'OP(^`VJZ)XV_:R\0?M)_&GX8_#[1OVE=9_P""E47P(_;37X=?"CQE
M\&/B7\,[GX?7'@J[T+]G;X5Z'\.M?A^$GA/2K;Q)X*U;X5R7GVBXUQ_%;W0!
M_9W\3=-_MF?P!H_G?9O[5\5>(=-^T^7YWV?[=\(_B?:^=Y/F1>;Y7F^9Y?FQ
M[]NWS$SN'YI67_!+.\\8Z%X.@^.7Q=T?Q#K/AB+]EWP;J-E\-?`^M>"_`GC'
MX._LW>!?C#\/-6\#^,?"7BCQ_P"/X=<U?XZ>$OCW\2/"/Q6\2K/I\.I>!X?A
MWX;M]%%W\.-%UZ;]0?&/_(Q?"G_L?M1_]5=\2:[Z@#\B?#'_``3)\>_#/PUJ
M6@?"W]J+5]-U3QY\/6^$?Q3\>^.O!-]X]\=W?@K1_C7\4_BIX*UOX>W]SX]T
MS0/#7CG3O#?Q8U;X:>-;WQ?X:^(6B_$[1_"?PKO?%FESVWPZ70O$WWU\2_A1
MXN^+?P"^)7P?\7^,=`AU_P`>Z)X[\+P>+M!\*:C9:9INA:UJVKIX->[\.:CX
MLU>[O]:T?PG+H6G^*;Z+Q#96/B+Q)::OKVDZ5X8TS4K/PWI7OE%`'XEZ3_P2
M.\4:9JWCK7K;]I'7-,\2#]K[X\_MG_!'Q'#>?'/Q+IWPK^*?Q=^*W[1GQ+\.
M+9_"3QQ^T%XB^"_AK2/"]C^T-KG@3Q]9_!#P/\&/^%\^'3X@NOB9+>ZQXE>]
ML.C\`?\`!(/P1\*/"'C"Q\%?$[Q3K?C9/&D'B_X/Z]\3O$WQ8\<>%?A]]E_:
M+\7?'V.+5_AW<?%2U\(>)_$D\'BV^^&\_P`2HM+T?XC1>!VD\/6WB6/P\T6A
MQ?LC10!^8>L_\$^?&?B?Q/\`'GXF>(?VA=0N/B/^TQ\.O%7PS^*VGVW@FQ7X
M6VWAYM'\/Z3\+(_`GARYU>X\:Z$OPQB\-R36]CJWQ#U_1-6U3X@?%CQ%!I&B
MZYXWN[N/B/AIX8^'?_!*NX^+'BSXW_%GXG>.])_;%_;`^-.M?"7PC\-_A[^V
MW^T'XD/COXV?$W]J3]L&Y^'O@W]G/X>^)_VB_"_A&;PSX$U/QM)XD\4_`KX(
M_"72O'-M\/;_`,=_%9]3\2WU@]M^N=?FG_P41^$'Q.^,GC;_`()QZ1\,/%OQ
M?^&=UX8_;MU?Q=XK^,7P5\)^`O%GBKX1>%(_V"/VZO#1\5Z@GQ8^%WQD^%FB
M>']<\3^)O#/PUNM:\?>`-6TG^T?'VE:/H\^F^,=8\,WT`!]R_#GXK>$OBC\.
MM,^*>@V_CCPYX2U6WUJ[2/XN?"WXG_`7QAIEKH&J:EI&I7/B;X;?'#P?\//B
M/X0MTN-)O+RRF\5>%-&CU;0FL?$NDM>^'=5TO5;SY[\!?\%!/V0_B-IOCK6]
M&^+J^'M`^'G@3Q-\5]>\2?%3P)\3/@EX8U/X/>#FC7Q/\:_`7B7XR^#/`>A?
M%3X'Z.)[62Y^-'PPU#QA\+C!?Z;<1>+)8-3T^2Y\?^/W[,?[;7C'X`_%#X$^
M"?VQ?"?CGPIXX_9O^./POU3Q%\;_`-G+09_VG_%GC_XD^$?B7I/ASQ)8_&OX
M&?$C]GO]G7P#8>%[OQ1X,TK1+"V_8KUQX=&\'SW'B'4O$>NZ_=:W9?)7QWU#
MXA_MC^%/`$'P?_94^/WAO6OV:OA1X^UCX@>%/BO\)M=^!TVK^-=)N/AB8_V5
M/A7K/Q;MO!?@_P"+<GQ$_P"$0U>T@^(_P\\0^(/V=)[?P]H%Q-\61%JNFW%N
M`?H]X3_;W_92\8>&_B=XIM?B9?\`ABR^#FD>'O$?Q&TGXH_#3XL?!GQKH/A?
MQEJ&IZ1X$\76_P`._BYX%\$^/_$'@[XC:QHVK:-\-/%WAKPUK'AKXD:QIUWI
M7@;5-?U"![8>E_`W]I3X1?M%:9XDU#X9ZMXLCO/!FI6VE>,_!_Q,^%GQ6^!?
MQ.\'7=_:'4-);Q;\)?CCX*^'7Q/\,66NZ<&U+PYJ>N>$;#3/$>F))J&A7>H6
M<;SK^>_B;XQ^'OB/\8_%?[6.I_LM_M0Z_P#!G]G/]G&ZT$>&?&/[(OQ<C^)7
MQ7^.U[\9_`/Q0\&:/\(O@1XE\&K\6/%?B+X':Q\(K;5-,^)]C\/%^']IXA^(
M6B:_\-/B-K<&C>*=5T/P?Q=JFH_M%_L^?M-_$#01^V1X`^,OQ@N?@!X<_:L\
M6?#O]AK]ICX/_%?P#^RMX<\3>,;F/X1_LJ:!^UA^ROX:U3]HJY\#:#XC^)\7
MBFZ\-?#SXE>/=6N?B;\0_%/A_P"''A[4_&'PO^%]J`?M[\-OB7X*^+W@_3?'
M_P`.]8?Q%X-UJYU>#0_$"Z5K6E6.NP:-K%_HDVL:$=;T[39=:\,ZE=:=/=^&
M/%NEQ7?ACQCH,NG^*/">K:UX:U;2M6O>ZKX=_8/\3_%;Q#\./&=CX[_X6GK'
MP_\`"7C>R\,?L_?$+XY?!#2/V;_C#\2?A-:?#_P1>#Q!XZ^"FD>%?AD/!=SH
M_C>_\8>"]-74/@A\`+[4].\,07D/PAT?13H_B;Q9]Q4`%%%%`!1110`4444`
M<#X._P"1B^*W_8_:=_ZJ[X;5^?7QG_X))_LK_&GQ=^T#X^US1+&#QC^TYXB^
M&GB'XR:IJOPW^"OQ!L_'$?PAU[X8:_\`#WPUXJT3XF?#3Q?I7B;PAH%Q\-/L
MZ^'-=M[[3]1M_$^HG5TU"?0O!DWAO]!?!W_(Q?%;_L?M._\`57?#:N^H`^/_
M``)^QE\/_AAXZU'XE?#OQ'XC\%>,-9\*?!/P;JC^&]$^&^F^%QH?PE/A72_$
ML.@>!H_`K>%/!\GQO\"?#_X;?#/XH2^%=+TE[?P5\,/AO:?#IO`>I^#],U1?
M#_VQ?V_X?V1/VJ_V2?@YXBTFUUWP7^T=\(_VM=?M/#?AOPSKOBOXX^/_`(P_
M!?7OV7=,^%/PP^"^BZ9KEGI^J:IXNL_C+X\OO$ECJFBWT-GIGARV\5ZAXC\$
M^$/"GC#6)?TPK\8/^"A/['NL_M7?MX_L#3VR_%'P/:_"S]GC]O\`\0^#_P!I
M;X::5J)O/V<?CW?>+OV%[KX-^*H_$C6-UX2M]>UJW\.^/+.W\`>-6G\/?%WP
M+I_Q(\#Z]H?B+P?>>+=.(!^G?P-N_COJG@QM<_:#TWX>>&?&6O:I>ZMIW@/X
M=IK%_;_#SPQ=LKZ)X-\4^,]3US4;/XA>-=*MMO\`PD_BSPUH?@[PM<:I)/8:
M!H=UIMA!K^L>R5\T_LP_$_XK^/O!VL^'OCU\.=2^'WQL^%NN#P-\1;BQ\.^(
M;'X4_$/4K6QMKRQ^)_P/\3ZO`]GXG^'/C73[B'5[73H=5U'Q%X!U274/`WC-
M(->T62>^^EJ`/P/HHHH`_;+X4_\`)+OAM_V(/@[_`-1W3J^'?^"A_P`9M*^$
ML?[.=GXN_;C7_@G]\/O'WQ2\4^'_`!A\<6UO]EOPPMU_9?PE\=>)_#O@Q_$/
M[7/PM^+7PQT\:UK^D65T8K3P[:>)[\:9]DTW5;>W>^BG^XOA3_R2[X;?]B#X
M._\`4=TZN^H`_`/5_P!LWQIJGA[PCJ'QS_X*!_\`##RP^!(]5^!.N#X,?".V
M3]NG5++XE_%#PIX9\=6WAOXT>`O'>I>-K'XO>#O"7P[\96/[*?[-EU\.?VB[
M"#X@+<:?XJL+'Q?X#73?TM^*7Q,_:!A_9H^"GCCPYIOA?X5_'?QUXK_97M/%
MW@[QGIMUXD\->'M2^(GCSX?6/Q1^&VIO97=MJ5JKV.L>(_!=KXLT^2\O_#-]
M+;>*8-(\0MIAT'4_L^B@#\-/B'^V7K^M:UXGM_C!^V3K_P#P3D^"MK\3?BQH
M4?QE\5>"?@)X7\0:-XM\%>'?@H-+^!.H_$;]HSX;_$OX`>#9],U7Q-XYU1F\
M4^%_$WB/XW136TOP4\<3^'?"NHZC?>W?L7>-?VCOB9\?]8\3?%+]H7XI:]X%
MN?V;_A]XW\.?!J^^&?P2\`?#/5I/$/Q4^-?PNT#XSZ9II^"MA^T=X3_X6UX!
M^"GA#XVV?P\\:?&K7D\$^(/BWXO\-WEI)HVF>%/#_A']7:*`/Q5^/7[7?Q3\
M!_M5?M#_``U\-?M'V<&CZ/\`#KP1J;^`;;X5^%?%-]^R]X&E\3_`?P]X[^/?
MB+PK-H^A?&#5'L-&^(?Q&\>^&_B/J%Q\6?V9_'VG:!/X273_`(8^+OV>/B-9
M?'?+UO\`:S^*EM^SMKGAW]@S]IG6_P#@J9\:_&?Q$_LGX/\`Q+T#PK^RAK\N
MC>'/"NE>&O$WQ=O]<\?>"_$?['_[('Q8\,>"UU#2?!MQ?>#]7\#Z]X&\2?$_
MPKX:\1'QKXQTYK#4/V^HH`_!S]H;_@I=IMW\"?VC8_`7[4OPD_9^^/,6L_LH
M^(OA_P""OB;\5_@;\*_B#\&OA3\1_%O[-O@KXR>(_&;?$SX6?&^T\'^$?`_B
MKQK\2_"'COXP>-?@'\7O#/PU\066M/)X:UB7PS:Z`GUCXB^-7B[P_P#\$PS\
M;+G]I[PA-XF@^%&B:QJ_[6?@+XF_`KXS^#M/M+[Q+I^FZ_\`%;P]\5T_9W^#
MG[/?C#3M!T2ZO]4A\57?[-?@[P!"U@]SJO@,V5I=K<_IE10!_,!\:_V^/C1X
M1TCP;I/P`_;4^-_[5_PHG^(/BS1?!G[8GP2\$?L%:UX<\5>)Y_#_`(<FL-`_
M:7^*GB#X5^%/V8$_9B^#'C77=-TOXU_&G]GK0?AQXMT+2/%VC>#9=4'Q`\)>
M*-5OOL_Q-^V'^V7XF^*7[3?AWP7\/=:\`_"CQ'\&OB]\+?V+?C[K>A?"K6_A
M9XB_;%_9^\'>+=;UC4;/0(_']_\`'#6=$^(/C33?BSX>;2/'WPT\+^`K_P``
M_LR>$?%?PM\;:U??&[4);']L**`/YQ?!/_!1[X]?%/Q>S^#OB5XD3PE\9/A]
MI_[?7P/NQ\(]`B\):5^QKXF^(<7[,W@/X8_\)GKGPWL([SQ+KOB6;PM^T!K>
MC>)7'QAT>;X@0Z')J%KX&T&XT-_=]8_;:_:1\,^'OV>+;Q?KMCI%]XX^#'B/
MXC>//B7I7PU@E\"VWPWU[XT?LP>$H?C1J-O>&]@TO7OV?/A[\1?B;=?$32=+
MUUO"YN]*TSXK^+O"/A[X<>(M,\.>%/W#HH`^"/V(_C#>^/-1^.'PU/Q;^+/[
M1VA_!SQ'X4L=$_:.^)4'[(M]I_Q/3QGI&HZ_/:^%O%7['&H:'X#U.+PO!#81
MW>@>+O@E\%/B!X=TK5_#5YK6D>*[3Q%IWB>Y^N?B3_R+NG?]C]\*?_5H^#J[
M2RL;+3;:*RTZSM;"SA+^3:65O%:VT7F2/+)Y4$"1Q1^9+(\K[4&Z1W=LLQ)X
MOXD_\B[IW_8_?"G_`-6CX.H`[ZBBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`\3\%7OCV'3=8CT7PUX0U#3%\??%'[-=ZIXWUG2+Z;/Q+\6M/Y^G6
MGP^URWM_+N#+%%Y>J77GPI'.YMWE:WAZ[^T?BC_T)W@'_P`.3XB_^=37QU\;
MO@;XK^,VB_!2_P#!W@[X8>*]8^%?[5?B[XB17WQ4U:[31O"$.F_%3QE:ZGXF
MTOPJO@KQA9>+?$,&A7.L6&AQ0WO@#Q+HFJW]EJWA[XAZ#'#JUIJOR]H/[`?Q
MQ3X*>,?@/!H/P&^%_BWXGZ9X*\"_M$?MJ>$/$OB36?CI^U7HN@W=Q+XX^*/Q
M7\%Z'\._A6C_`!(^+6@^'-"\,:[)<?%75=7\!6GQ/\?Z;\-?&6BZ3X$\*7/B
MD`_4?6+3XHZMJ/A2_P#^$8\`V_\`PC&OW.N>5_PL+Q%+]N^T>%O$OAK[+YG_
M``J^/[-L_P"$A^V^?LN-WV/[-Y*_://@W_[1^*/_`$)W@'_PY/B+_P"=37\_
M/Q]_X)E_ML?M#Z+JO@?XPS_!7XB^'=3_`&[?A;^U5XG\0+XG^'^O#QQX6\%?
M\$N-#_8GUO0XO@W^T_\`LD?M0_`G2]1U?X_>%[3XX0:#XV\!_$G0](T;7+G4
MO#NIZ)\4]"T+Q59_IM\:OV8OCA\5=-^&T_A#Q_;_``K\3^!/A[^TEH,=UJ?C
M+Q#\2-*O-=^)6J^#X?!>C^+;>7P_X5;QY\/-3\,Z+KNE^*-(NH=#U;P;::GI
MK^!=3'BCPWH'BRQ`/M#^T?BC_P!"=X!_\.3XB_\`G4UD:WXK^(^@64-]>>"O
M!,L5QJ_A_146V^(VNR2"Z\2:]IOAVQD82_"Z%!;Q7NJ6\MVX<R1VJ3/#%/,J
M02?(?[+/[./[2OPA^,/BWXE?$KXD^#_$GA7XE>$K3P9K/PTT:3Q+<6?PZL_@
M^-(\(_`K4_!FMZFUO8:I_P`))X(M_%/B'XH:8/"/A6XL?&_C-;*VUWQCI/A?
M3M0NOM/XD_\`(NZ=_P!C]\*?_5H^#J`#^T?BC_T)W@'_`,.3XB_^=31_:/Q1
M_P"A.\`_^')\1?\`SJ:_+[]I+]@7]H'XJ?';XC_$/X??%_P_X=^'/C?Q=\#K
MV?X<:M>^*8[#7/"?CE?"OP6_;STSQ5!;QZCIL\GB7]F7X;_#F^^!&FZ98V5O
M8?&71]>O?$VJ6.B>-/$D]S\M_"#_`().?%_X;^"X-%U/PW\#_&V@7'Q.\1>.
M_C1\"?%C?"/2/A7^U3I/BCP_>^'-<\'_`!-O/A7^R+X"'B#P^FIW^@?%C3K_
M`../A?XZ_%CQMXZ^$_@[P?\`%_XR>*/`VKBY\)`'[R_VC\4?^A.\`_\`AR?$
M7_SJ:/[1^*/_`$)W@'_PY/B+_P"=37XU7/\`P3)_:)\<:<+#XE?&#P7;?#W5
MM$^!GA?QI^R?X+\,?"V7]EGQYX&\&_%KXP>)O$W@7QQI/C']GW7_`(D76E^%
M?AW\0=!\+^'=.^'7C7X5?#OQQ=:+>6GB+X9:/X0N(_"=?I/^QU\$=6_9V^#?
MAOX077AOPOX5T/P'X4^%GA+PQI7@KQ/<ZIX0%OX6^#/PZ\.>)[GPYX.;P9X1
MTOX9Z7<>/M+\6O%X;T:37X-?E\[XB:AJ&F:UXTU+PSH0![=_:/Q1_P"A.\`_
M^')\1?\`SJ:/[1^*/_0G>`?_``Y/B+_YU-=]10!P/]H_%'_H3O`/_AR?$7_S
MJ:/[1^*/_0G>`?\`PY/B+_YU-=]7C?QLT/\`:#U[PYI=K^SE\3_@W\*O%T6M
MQ3ZSKGQK^!/C;X_^'+_PX+"_CFTK3/"W@7]HO]FK4M(UN34Y-,NXO$%WXQUN
MPAL+2^TY_#4UQJ-OJFE@'3?VC\4?^A.\`_\`AR?$7_SJ:/[1^*/_`$)W@'_P
MY/B+_P"=37*?#+0OVBM*\5?$2[^,GQ3^"WCSP3J>K>=\)O#WPR^`?CGX2^*O
M!6A_VCJ\O]G?$3QCXI_:2^-6D?%#5O[(GT"Q_MGPUX%^$-G_`&CINKZI_8/V
M;7++1_#_`+30!P/]H_%'_H3O`/\`X<GQ%_\`.IH_M'XH_P#0G>`?_#D^(O\`
MYU-=]10!P/\`:/Q1_P"A.\`_^')\1?\`SJ:R/$'BOXC^&]!UOQ%?>"O!,MEH
M&D:EK5Y%:?$;79+J6UTNRFOKB.V2;X700R7#Q6[K"DL\,;2%0\L:$N/5:X'X
MK?\`)+OB3_V(/C'_`-1W4:`/*O\`AH?0?M7C2Q_X3/\`9L^V_#9/$LGQ%L_^
M&C+/[5X!3P9I>FZYXP?QI;_\(!YOA9/"FBZSI&K^)7UQ+`:%I>JZ;J&J&UM+
MZUFE\,\2?\%)_P!DKP;:7NH>+_VN_P#@GQX5L--\:^)?AKJ5[XD_;G^&FAVF
MG_$;P7%IT_C'P!>W.IZ!:PVOC7PG#K&D3>)?"L[QZ[H46J:=)JEC:K>VQE^9
M?VG?^"18_:B\._M#^$_$GQ[U[P%X>^+?A+]K#1_`>C?">3XO?#/2/`GBO]IO
M0$LKOQ7XOL?`7QV\,2_%?P^_B:ZU7QA\6/@OXBOK3X)?&S7[FYUKQ1X!L]?U
M_P`3:MJ=/PS_`,$H_''A[XV_!GXM?\-#ZQ<VGPEU+]JV)O#S?$']LAH];\/_
M`+3OCS]G?QI+9102_M=R>&]'\.^$8?@,=./P&MO#,O[+/B+4?$UOXJOO@G!K
M_AK3;F4`^_\`X<_&32/%,^DZYX$\;_LX^/;/]H&*^^)OPIF\)?M`VNO6OC_P
MCX8\,>!O#.O>(/A]=Z/X%U&+QYX;T=HM%N]7\1^'/M6F:6?$>EVMY+%]HM+B
M\I>+OVOOA=\/[OXG6'CSXP_LB^";[X)Z-X=\1?&6R\7?M5^'?#5W\)/#_C"_
MCTKPEKOQ.M]9\%V<W@+1O%.J31:;X=U3Q4FE66MW\L=GID]S<.L9ZCP3\`)O
M".F_LM6#^*8K\_LX?#M_`D\JZ.]L/%SM\/-$\"_VG$AU.?\`L10^D-J?V1VU
M4E;A;3[2#$;F3X4^.7_!+/4/COX<T?X7^(/CA'X<^$W@[]J+1OVF_!\G@3PE
MXL^'_P`;FU#4OVO_``%^U=\2O".O_&SX>?%7P=X@M!K$_ASQ/X3\&>._A_8^
M!?'OAG6-5^'WQ.U/7/$7CCX5Q7_C``_1/3?B=K&LZS8^'M'?X*ZMK^I^$[/Q
M[INA:;\:[J_UC4/`VHW0L=/\:6.F6OPUEO;OPG?WI%G9^(H()-'NKHBW@O'E
M.P]9_:/Q1_Z$[P#_`.')\1?_`#J:YB/X1QVWQC\%?%&UUVZ-EX-^#7B_X1PZ
M%J3:EK>J7T?B7Q3\./$-MKM[XKU?5KW5+^ZLXO`36=Z^JIJ&I:M<:E_:5YJS
M7$4PNO9:`.!_M'XH_P#0G>`?_#D^(O\`YU-']H_%'_H3O`/_`(<GQ%_\ZFN^
MHH`_`^BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
LB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g30330image5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image5.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`%4`
MGP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[?/AI\-/AQ?_#CX?WU]\/_``3>WM[X)\*7=Y>7?A30KFZN[JYT
M*PFN+FYN)K!YI[B>9WEFFE=Y)9'9W9F8D]M_PJGX7?\`1-O`/_A'>'?_`)74
M?"G_`))=\-O^Q!\'?^H[IU=]0!P/_"J?A=_T3;P#_P"$=X=_^5U?`_[1W[3W
MP'_9S_:`^%OP#U;]G+0_&&K?%#PE=>+;/4?#>C>"/[1T^RM=<GT&YF3PK=:8
MFIZOI6C21QZQXLUBPN/(\,>&Q>:Y?0O;63K)^FU>=:M\)_`>N>,=3\?:IHCW
M7BG6/AU>?"?4=0_M/5H$N/`>H:I)K5WHGV*WOH;*%YM1FDG_`+3@MXM6C#>5
M%?)"%0`'Y.?`#]OWX2_M4?#/P-XU_9Z_8<N_BCXE\9>%_%/CYO"6C7GP%T[1
MK7P'X77PM`=<T?XB^(-8TCPKXNO-?U_Q4/!&@:=H3RVZ>./"WCK1/$NJ^&[3
MPO/JUSPOCO\`X*L?L@>%)==U#1OV;]*\2>#=*^`?@_\`:#7Q7=6/P^\+KI7@
M[QAX3A\70W?Q#TG5]+-S\.M"TFW-SH&L>+=6FO-"L_%T=IH+RA[^.YC^Z+?_
M`()C?L7Z?X0\*^!]`^&GBCP=X?\`!.K:GJGAC_A`/C7\<OA[K>F6_B&T\*VO
MC+PP/%7@CXCZ!XHN_`?Q#F\&:%K/Q)^']]K%SX+^(7B9-1\4^,-#UGQ#K.K:
MG>^U3?LC?L[R^$/&_P`/XOAII.G^!OB'X=^&_A#Q/X1TF[U;2/#LWA;X1Z;8
MZ/\`#WP]I>D:;?VMCH&C^'=*TVRTZ'3]"ATZVNK.!;>_CNHBRD`_+GQU_P`%
M._V<?!]E\*3!^R"USK'Q;NO@M8Z+IFM:;\/]!@TV?XR_!O\`:?\`C193:GJ%
MKH^OM+INEZ#^RUXKL[;4M+LM0@\02^*?">HV`ATNXOKFS[;4O^"@7P"\'V7P
M\N?B7^R9IW@^?XB?MB>*_P!DNUM;)_A1XD;P];>`?&0^''COXV^(E@AT^[C^
M&WA?X@WWACPQ?KI%EJ^N))XQ\/:I/8VNE2WUU8_37C#_`()=?L9>,]*\(:5/
MX&^(OA1OA]>^`;[P'KGPO_:*_:+^$GC'P6?A?X/^,/P\\!V/A7QQ\,_BKX4\
M8:!I'AWP#\>_BIX)MM&TK6[72[GPIXE30+^TNM,T;0[;3>N\:_\`!.C]B_XD
MP>([;XA_`GPWXZA\3VWQCAO?^$OU'Q)XDFTR\^/OBIO&OQ6U_P`)76L:U>7?
M@;Q9XE\2&._A\7^#)]"\3>'UMK2T\-ZKI%G:P01@'QKXU_X*)?LP^!/B-^U_
MX,U;]F6SOO#_`.Q!J'AJ\^/?CCP_I'P^URS\'?#W4D^'U[XG^(&N:#I]C+K6
MAVWA7PW\01XX@\/ZE#%J_BOP3X&^(^N^'EN3X76SU'U3]HC]KK]GS]EK]E3X
M4?M-_&7]FO3_``Y>?%?4_!-C8?!L:+\.#\1=&B\1Z'JGQ`\6F]BO5L+'4=5^
M%?P@\->-?B5XW\/Z')J6JBR\&:YHNAPZOJ*VAN?H'Q%_P3\_9,\4O^T++K7P
MQN[B7]JSX;>+_A'^T%-%X_\`B3:W'Q-\`^-O#6D^$=9T;7+FU\717$4UMH6D
MFU\.ZMILMCK'A.?6O%FH>&;_`$G4/&'B:ZU7UGXM?LS?`7X\R^##\:?A;X5^
M*-G\/HM?3PCH?CFR;Q'X8TJX\2Z=9Z1J6K'PMJ<MQX>OM?ATRS%EHWB'4=,N
M];\.P7FJ#0+_`$UM7U-KH`^$=7_;<_94T?\`:TU3]D.?X$:6_C6'QM\-?"7A
MOQ&GACP./#7CBR\??!#6?C9JWB7PM*UJ+C4-.^'-A%X*T#QO`B&YTZ]^*'@2
M^C$EGJ\><+X!_MX_LR?%GX":]\?/'W[,S?!C0](_9/\`A;^VSIVC:IX7^'WC
M?4/%/[/WQBT'Q-K'@W5_#\_A*.:%_&`O/".L>'-:\%:G'INH:?K;Z7]FN=1T
MK4X=47ZKTW_@GE^R'I?B3X5^,8/A3)<>+?@KXI\,^-/AOXEU+QU\1=5US0?$
M?A'X`1_LP:+>RZCJ7BRZN=7A'P6M[3POJFG:R]_INO7]C8>+==M-1\7V-IKL
M-CX`_P#!/W]DW]FGX6^)?@Q\,?AG>W7PZ\7^!-&^%7B+0OBC\0?B5\<I=1^$
M_AK2=8T+PQ\)_P"V/C3XO\>ZU9_"WPOH_B'7M-\,_#FPU"U\&^'[36M5BTC1
M;,7]UYH!XY<_&:\TE/"7ASQ)_P`$[=0\/?%OXE:U%IWPS^'%UKW[-M]:^(-,
MM?"NL>,/%VN:[XSTGQ1?:3X4@^'>G:3#IOC&SN+74;J?Q#K_`(>T_P`$#QI8
MWE[JNF_._B?_`(*7?LH>#O$'@3PKXG_9?O/#7B#QKX=^(L%SI_B'PU\,K1/"
M7QH^$_Q@/PC\;?`/7]2TV;6-)N?&CW&D>.O%?@[6?#E_KOA3QEX;\`ZW<:?J
MT#W>CB_^SU_X)P_LI#P+J/P_?P]\6+BPO/%EIXUTSQ7??M,_M+ZC\6?!.OZ;
MI>LZ#I,OPQ^->H?%RZ^+OPMT[1O#OB+7O#6D:'\/?&WAO1=/\.:QJ6A6U@FE
MWD]J^OXD_P"">7['7BWPEH_@77?@KI%WX5T"T\,6^D:4NN^+;?[)=>$?C#9_
M'[1O$#7\&OQZG=^+F^,%DOCO6O&5]>W/BGQ/K-UJI\2ZOJUOK.K07H!^?:_\
M%.OV<'MOC5>I^R1:R0?"#5/VT])BCCMOA_\`;/$]S^Q-\4T^$?C7;%-HD-KH
MR^,O$;->^$S)>ZB(M'"7&M'3[QFL8]7Q'_P4>^`OA3XO^#_@%X@_8\M=%^+E
MUXD^,GA?XH>&;]OA?<V7PSU/X-0_LM:[>Q0:_P"'=/\`$&G^,&\9^`/VO?A%
M\0/!T=N=%9M$O[VR\3_\(SK,"Z>_WEX@_P""??[)OB?P3K'P\U?X:Z@_A;7%
M_:D%]:V'Q&^)^C:@DG[9WQ'E^+7[1=S8:]H_C*PUW3+SQQ\0)G\06%WI^HVU
MQX)<1V/@23PUIL:6:\6/^"8?[(2:E\(]=A\._&&V\3?!>\\>7GAOQA:?M2_M
M0VGC?Q8/BAK/PUUWXB:=\:?&MO\`&"+Q5^T!H7C.]^#_`,,X/$/A[XWZOX_T
M/4M(\&Z)H-QI[Z):KIY`/BSX7_\`!3/X`?&_P#X/\;_"C]C8:[<Z]K7[*?A3
MQ-X4\01_#/PCKW@+QA^U5XN\<>`-"\-ZXFH:;<0W-QX0\7^"FM]7O[%I-,UO
MP]KFC>+_``S=:EH5[:W%SZ_\./V\_P!D?XB_&']DKX+6OP/T/2_$W[6'P;E^
M+FG7%QHOPXNK;X;'5K#QEJWPX\(>-[.V)UF/5OBAI?PK^,5QX4U.STU]!:Y^
M&NJZ;<W\>H:IH]O=?5G@G_@GY^R)\.;G4[SP3\'K#P[=:UK7[-/B36;C3_$G
MC*.;5_$'[(6E:5H7[/FMZLY\1,VIZIX&T;0]'TR>^OS<W/BVRTVRM_&DGB&.
MV@6.CX>_X)T_L9>%KOPGJVB_`[0H/$G@.^^$][X(\9W>L^*]5\>>#X_@G=:7
M>_#[1_#'CK5M>OO%N@^&+*XTM9-=\*:5K-IX<\9_VEX@7QCI>NKXBUL7X!VO
M[/.H?!G]H?X(?##XX:'\'?"/A[2/BAX1TOQ?IVB:MX4\*W&I:9:ZI&9(K2]F
ML]/:UDN(@,2-`QC)^Z2.:@_:+^'W@+0_@WXQU31?!'A#2-3M?^$>^S:CI?AK
M1M/OK?S_`!5H=O-Y%W:64-Q#YUO-+!+Y<B^9#+)$^4=E/H?P#^`/PT_9F^&V
MF?"/X167B?2_`.B7^K7VB:/XI^(/C[XDW&BIK%[)?S:3I&M_$?Q+XKU[3?#=
MC-*T.@^%[/4X?#WANP$>F:!INFZ=#%:IE?M/_P#)#/''_<M?^IAX?H`[[X4_
M\DN^&W_8@^#O_4=TZOS?_:W\=?M3?#'XQ^._$_P0^,FN>(A;:1^PKIO@C]FK
MQ_-\&_!'P'O?$/QQ_;7\+_!CQW<:U\4])_9>^*/[07AH>(O`6F:GHQU:+6_'
M=GX<E\5Z]K.B^"Y-4M?"\GAS](/A3_R2[X;?]B#X._\`4=TZO@;]I+]HW]IG
MX4?$CXY>,_!_BC]GJ']GS]F+X:?"KXA^/_A?XT^$_P`0]1^-'Q9_X3*\\>/K
MWA[X:?&K1OCUH7@[P?XOO['PSIFB_##PGJG[/?Q$G\8^/+ZQ\,3:O8#Q):7F
MB`'R-\)/VL_VF_&?[:/P$^&GQ6_:-^#GPJBU%OC6/&'[/$OQ_P#@EX0NOBCX
MF\.?M8?MK_"NZ\'_``/T/QU^Q!K_`,9/VM])^$GACX->`=#N-4\"_$3]BWQ%
MHWAW3-"^(_Q"TOQ;K'Q'U+PQX?ZJ7]L3]I[2/''QR-YXL.M_#[0_%_@'P'X<
M_LGX=Z%>Z]\//$?B'_@J?^W#^S[;:OJESINB2P7_`(&\1_!#X.^!/A=JVHZS
MIUS=>%?$'A_PUXL%Z+_Q=XW\4V7`>#_^"LOQ:U'X5?M3>,+2#PK\:_&/@CXF
MW_P$^#GA?X7_`+&W[7OA>?PO^T1?^+O%.FZ9\)?$WAR+Q'\8O'O[75M\/?A9
MI</[1?Q:\<?LL>&='2U^$/A?Q;>:'X3^W7^@E/3/%G_!6B6VOO"5]H6G^`?"
MN@?\(=^SM^U3\7]%^+%IKWA;QO\`!O\`8C\<ZSK7PL_:$\4^,M(NO$>EZGH'
MQ+^`GQL\/:]H7B=_$GAS1=(T*T\/Z_X:U7PU=^);&UN-2`/.;#XY_M)^$/!?
MA/5?VNOV_F_9&^'_`,8/%GQQ\>>`?CW,W[,GC.UDTK1-5^&>F_!KX)_\)-X]
M_8H^$7PC^#[:TFK^.+^X^#?C/2/V@?C1\0H["&P^&O[5.K:EI6O0:5YQXW_;
MQ_;$TCQKXVNEUKXS:)K7A7_@GIXU_:`OO".I?#+]G7P#^SOJ_B/PY^RGXQ^(
M6/AO:?$_2Q^T]'^UFOQ>;X;>*KSX.^+_`!=KOP=^'_P,U77X/B180>*[:SU&
M3Z>^$O\`P4F^.OB'P]J?BOXJ?"+P'X(\/:;\"9?B!XKNAJ.HVFL?!_XD:O\`
M#7X5>+?!WA?QUHK>(M<TGQ+X-G\7>-]>^'_B[Q3X7\7V5_X<U^+P1<6^C:MX
M/USQCXX^'_NOPN_;:\<^+[WX$>*/$FG^![#X>_'/XO?$3X$Z7I/AKP+\=O&>
MMZ)XN^%^H^)O!VK^(/$WQ1^'OA7XA?"?P`_B?Q]X2U&V\-^`/BU/\.;6/PW>
M02CXK:OXRTS5?!D0!\QW7[=?[1VA>-/'6BV=U%\3=;\*?LW>*_@3X6^%_A[P
M/X<T+6?B1_P4A^%/Q'^"'P]\8ZUH6L>(-5T;2F^'7B[Q!^TS\*]-TVVU'Q)X
M7^'_`($T?PUX^\5^*_$_]A6NJZMX+;<_'W]J[7)/V;O'^N?''XH_"/QIH_[+
M_P`9+;]I3]FJW\`_LPIX"O\`]I+X%?&']G3X.^)];UX3>"/C=\0O#4>MR_'[
MQ'XMT_0/AM^T]K'@672_#GPBO?#^O>(_#\OC'5/B=]&>'?VROC#K?[<.M?`Q
M[CX$1?!;PS\2[WX0ZPEK:>+=5^+<'C/5?A=JWQ/\)6_B34M#\8:QIOPRGU+2
MO#U[/X)C\<_#:W\&_&FS;QO8:5\2_AMXV^&7A7P9\>O'M$_;=_;5\)_M0?M"
M?"_Q'\*O"O[5G@KX>?M0Z[\!?`WP^_98^%OA3X0?&JU\-VO[(O[.O[6EEXW\
M7^-/VIOV\/#WPB\11Z5:?M*:%\,]<M=$7PKJ=_?^"KCQMHV@BS\;2>%/AX`>
M,^)OVQ_C1;>#OV@];^&W[:]OX_\`VB=/_9\_:L\5_%S]EBZ^%7P>GM_^"=/B
M_P"'/P7^(?BWX9>*+GP[I/@S1?BSIMOH7Q)T+P9X#DT_]IWQM\0-%_:83Q')
M\2_@XGAKP!8W6FK]L7O[2GQL_P"$!_;:U.ZEF\*>+/@5XH^&W@TW$OPUU;Q5
MI'POL]1\`?#>_P#BK\5/"_A;3[.P\3?%WP7X6T_Q%XG^,_A6P^WZAJ7BC0K&
MS\-.VG:A]NT+3OE;_@GY^WS^W)^TS\-[W]H;XT>"_@WX._9\F_9&\-?&'1_B
M38_#CPO\,_@JGQ2U#X(_"7XF:TNI_&WQ=_P4#\?_`!CTOP#I^J>*/'$U[:>-
M/V&_A[I?A[PGI27.H_&2^NO#\5QX]]=^&7[5'[8OQGAT[X9Z'X\_9-^$GQI^
M&?@C6OB!\=O$?Q:^!OQA?P[XF32_B'XX\"7G@7P-\)(/VC_#%Q\/+SP:_@U+
M_P"*?Q,LOV@/VDO`7A?2_%OPL\4>$HOB)X/^+7AC7+4`XBX_:=\.VWP4\.ZA
MX?\`^"M/_"7_`+/FJ_&O5?"GB_\`X*+?\(9^RI>_\()8VWPIN/%5K\/?^%U:
M#\';']AEOMOC-/LW_"W-1^"USX6\%_9/^%&>+K?4?C!K>F>(H>>TK]MK]J"R
M\">+O$>HZQ=>+?"^A?"GX/0Z#X_\.?"RW?Q#KO\`PLC]L+]K'X,?";]IZ[\+
M:=HNH10^`_CG\)?@Q\+_`!3XJCT_P]-X.\%#XE:?\1K*W\$?"_1?%^M:7W&H
M_MZ_M4_$K]G.]^(/[/?PS\$:I\6]<_:!^#7PK\"^%=&\):3\9;+4/#/CG]D'
MX3?M'^*-6T*S\?\`[4W[$_@[X@K_`&OXP\4R>#_%FJ_'+X-Z3J'PTAT+6XO#
MNM>)T3P_XD],^,W[4_[5?@'XM?LE?#'P[X>TNZ\2?$;X<^"/%'Q>\`-^R!\<
MOB7J^M^)-4\9>"O"OCC1V^+OP1^.WCGX&?L9:7X1L=7\2Z\?%'QJ\6?'+P'J
M5UIG_".>&_'GBH:9/X@U4`\3\9_M&_M;_`OPKIVE^`?$_P`9OVQ_'4W[6?QE
M\:_%%O$O@?\`9BCU#X3?L-_L\_%3_A#/B=9:/9>"=-_94T6ZO=2TR3P]I'@^
M1F^*?QNU/Q#K?BSQ1X1\%_$_2O`^J>#=/L^)OVV/C[IFL?M%ZKH7B!_%?PU\
M(V?P_LO"FL^$_`NE^)]8\'7_`,4?VOOVI/A7X,\:/#HFA:@^M?#QO"7PG\&^
M"_$NJ7NCZU#X9BU;3?B;XAU'0O"FC?$/Q=:^*?L*?\%._P!K7]MSX9?#.X\-
M>(_V8-#\2_&W2/`]YX<^.'B+]FK]HGP%\&/A[\3I/AYKOC3XV?LP:!\.?'7Q
M_P!-U[]KKQ[\))X?!CZ'\:OA/\:/AI\(OBWX8\4>*_$'@ZTC?X4Z_I^L]A/_
M`,%'/VO)_C3<_"_PWI7P<\=R?##1M+M_B(GPO_9@_::^)WP]^*%TGQ8^/?@3
MX@_$;1/VI_#GQ/C^"W[*'AGX8>$/A-;^*[WX:_'?3O'7B3Q_\0]"^)'P)^'7
MCK7/%&D6/B$`'A_AC]M#QQJ>I>/(_C5_P5T^%_P$\,M^UG\2/`=MXE\%_M`_
M\$_OB/XB^%2^&;7X]/X(^`?Q)^''C[_@G_\`#U/@OK/BF;PEHS0?#/Q1X_\`
MV@/C9XU3P9?6OA;XS>'KBR\0OXG^[_C=^TA^U)I_P<_8M\0>!_$&A>"_BG\9
M-)^`=_XTL?$?P]?2_#VOZMXM_:=_8H\#^)-.U7PEXHAU+QK\-[#Q=X*^*WQ#
M\/3:.VH2^+_APGC'SKLZGXN\'Z=-'\A>%?\`@HS_`,%`]+\9?LS_``M^-NF?
M##X9?&+]HV36M7^&_P`*]<_85\>:KK/QDT2&S^&UU#9>%?%_[-O_``4S_:]^
M%_P3T;PUI&K_`!&\9:G\3OCUXYT6?Q'H_A>[TR;X1>`+;PW)XN\7?;GP,^/W
M[<6JGX,Z7\4+C]G3XC2_&_Q]X_\`"]KXX^&'P?\`'/P>\._"VP^!WQ'\36OQ
M`7Q5X/\`&O[4'QC\1>-;SXF?#;PMJ5M\.+_PKK.F0>!/'Z17'C+2_$_AFX5(
MP";7/BM\9OC3^R?XZ\:>$OC-\7?V>O&=I^UW<_#O3/$OASP#\%HOB)X7\&1_
MM+Z7\([KP'JGAKXU?![XK^!7ETG0M8N[-M:E\(:EJ=[J6DZ=K%AXGU/3+B:?
M5_FMOVP/VU-&\;VVE>/=6\!^$_AF?B=^V;X<\"^._">HM\7?B!\1O"7P9_X*
M._"/X`Z7J'Q,^$=G^S=\/XOAYK'@#X7^)[WPCX=\.?"CQM\7=1^*<.OZGKVL
MWF@^-=%\/-J'U!\8OVI_VAO"OB#X\_$KP9XF_9BL/@E^RQXXT;P;X_\`@AXN
M\/>-];_:/^+<M_X9\(^(!:>$_'FE_%/PMX5^#GCWQI-XNM]-^`OP]UWX,?&)
MOC3=/X26/Q1X+C\?6\WAOUG]@KXP_M-_''X;^*?'W[2/@S3?!R:OXL>[^$G]
MC?#GPGX`TK7?AG>645SH^L:?<>'OVPOVK=8\8VD[2,(?%'C?0_V;_%=Z@']H
M_`GPNV00#7_X)]_%K4_C5^RM\/\`QSJ_Q?3X_P"H27_C'09_C1;#X8W>D_$G
M_A&O%^M:)'XI\/>)/@MIGA[X4^-/#=_%9)_87B[P;X0\`)JVFQVZ^)OAQ\//
M'%MXH\&:)ZM^T_\`\D,\<?\`<M?^IAX?KWRO`_VG_P#DAGCC_N6O_4P\/T`=
M]\*?^27?#;_L0?!W_J.Z=7YO?M/?%7]@3X>_'/XY?&/XT_L>:-\2OVB_V*_V
M>?AY\>=%^,B_LW_"CQU\7?%/AW7/$7C[2?#/PQ_9K^)7B&:'QAJGQ4\+^*+*
MQM+CP0-:\'6FCZI\:?AO)INK3MXWOI=/_2'X4_\`)+OAM_V(/@[_`-1W3J_/
M#]H3PA^R%XY_:NT/X:?$7QK\==`^+_C&+PEK&IZ?X:^$?CG4?@OXFT'Q!H/B
M?PKX#^''C_XW7'P*\5_!SPP=9\9>`--^)OACP)J?Q8\)?$'6?B9\*O`E_:17
MOAJ2?PQXG`/HO2/B%^P7X6\?>*7T[Q7^R9X+^+WPU^'.B_$?X@V*Z[\&O#GQ
M2^&/PM;3_$.I:+XO\=VT%[;^)_!?@BWT_P"(?BZXL?$&MFP\.PV_C7Q++:7W
MD>)-3DO?&+/]H7_@E1\3O!UIXX\0>-_V&YO`W[16N?%O]F[PCXG\>>)?V<9/
M#'[3EKJWQ"N3\4_A]X$UJ]UK4-'^-'A7Q_\`$;4;C5?$OA33+O6X_%7BK4I+
M[Q%H4FNWC[_BWQE\"?\`@F/X&\:_$+]IJS^)7CW7?%/Q:^(6L?LMW'BKX"_L
MI?#CX^_%SP?^T/\``+[/J'C#5K3XC?!?]BOXG_M56^O?#R_^`3ZUXQL?BG\0
M_$_[->B+X5>PU3P-:^&)K#1Y-3X:?"C]D7XI>#OBEX:\,?MJ_MLVFG?L]>+?
M''Q,_:M^-OQ%^!_@WX0^%_C+HOCCXFR?M0ZU;^*_B?\`%3]A;P-\!/$'PUEU
M!X_'NA^*/V0U\#W5S\+=?T'Q/:^-M0\(>)/"^OWH!]Q_"O\`:C_X)]^/I([#
M2?%?[,W@GQ#\8_%GQS^$'ACP=XE\8_L\Z=XQ^/-G\$?$>I_#OXHGPOX;\/>,
MM<U+QWX3MT\(-)J>BWD)UW2?#-IIO_";>%O#;1II\'9:-%^Q':Z/H?[:'PD\
M%?`CXA0^+;SP3X>\,?'?X':-\,?%LOB:+Q3XB\/_``1T;4_#_P`0O#5PNEZQ
M9:4EW8>%-1U?3=>N+NS\*:)/X<MVNK;2[;1#^;GC&\_X)\^-=1/C]OC7^VYX
M<M-"\4_#6Q\>?`O1/V3/C>OC7]H.6Q^/GQ5_:?\`V>-:M?@YXD_8MUW]IWQK
M\._`'QE\4_$GQ9X'^)'[+\/ASP!XIM-,O-"^*WBSXB>'/#TFFVWZ`O<?L_>%
M/V9/`UUXH^-EM8_LQ^)?$G[)NB?L^ZA8:!IOA9-`TF/6?@QH/P=\(,UKH$]S
MJ4OB_P")FDVVK>)]4U/PYX<M?"/AGQ%?Z?J.G^#-%\%:KXGB`,N]^/7_``2F
MBOKS]KG4?C1_P3WCU+X7^.-?^%U_^T[>_$7]G!+[X=_$GQ9I-C#XH^'=Y\:9
M]8%QX1\<>)=#TK38M?\`",WB73]>UG2=.L4U'3[FSLX!']G:1\/_`(9V^N7_
M`(^T#P3X$@\2^*M8;QGJGC72/#?A^+7/$>OZAX,\*>`6\5W_`(CLK);_`%C6
M+[X>>"/`W@MM=N+RXO;GP9X0\*>'#=/H>@:/9VGYM^`/V?OV;_&7B]/A9^S]
M^T/^T+\*OC)^R-X:^$GPNN?&_ACP7X*LM;ET#X;^'/&G@:[.CZG\?/V;?%_P
M5^,,/BL>)/$'A_XR^,_AQH'BJ/PUX\TTZ#;:W\.?&-KJNF7/UR/CY\%;3X4_
MM*_$6?\`:/?5?`?P)UKXF>'OC/\`$*W_`.$4NG_9[UCX4^#-*;XF:1./#O@>
M*VMKGX?6]O/X]UT^*-&\5W&EZCK&IR7<[^$[;2]`T@`^5_A3J?\`P3(^&UUK
M7QR^#'[,7P8^&6MP_%=OV#O%/Q)\`?LN>"/A_P"+;2T\-#1?".F:!K6O:)X1
MT;Q)<_LWQ^'/!_@C4/#_`(ECFO?A@/A5I_@WQS;-!\-=)MM>TR'0]._X)M_$
MQ?@?^RW/^Q?\%KOP]I?C'XH:O^S[\'O$O[-_P,N?`GA34/@_\0OB5\//B[\3
M_AMX.^SZCX>\'Z7X"\4^";)?%_B[0M+TK4-+G^,/P9TZ\4>)/B;I6BC@?`W@
M[_@EW\#/%GB#PC\-+^U^&J:%\?/A7\`_B9\-/!GPMUC3?`OCS]I/2/!NOW&F
M>)/B#I.F_"B33/'/C3Q[X8^,L'A[XO?'F._N="\9:M8^$?`WC_QT_BKP;:Z'
M8^F:1XH_8L_8\U?X>:7:>/\`XX>)/$/P7M/VE?A'I'@[0/A[\=/VE?B$UM\8
MOB/\'_CG\6O$'C+1_AM\+/B)\5==TCP;K5I\/H3\7]8D?PII6G>);R'QWXLU
M[Q+>'5;(`^7_`-KOXM_\$Q/".O?M'?$S]J;_`()H?#OQMJ'@ZP\,>#-5^,/Q
M7^#G_!/F>R_:*\.>&?C?^S_\`=0TS1OB9\:OC5X=M_#_`(-^#'Q)^*GP3M]8
ME_:FUGX&>&K+2K*RUOX?2^*+3PF6L??_`(;?\%"O@,ND7EY\-_V1OBMI7AOX
M??"#X;Z+\*M7^'\O[%6L^#_']CK?PG^!?Q;\-_L\_`WQ/\+_`-J+Q#X2*>%O
M"?QV^&]I;ZKJ.K>#_P!FVXOHK]_`7Q8\2:!I]EK5YXKXU^#/_!/>#0_VIOVK
M_A9\:?CEX2U_]I'XN?LQ7_Q/^,?[*_P:M?V@_BQK'QB\'^(O@[^U)^SOJ/PT
M\)6G[+7[0_B;QO%:^%=:^'-M_8>D>!/'WPTC\#:QJK^)]!@\=:3K/BC1?H"Z
M_8L_8F\7?"SXE^,/B]I'B/QIK_\`P4"TCX-_#OXQ_'+XP_!KP]\)?VEOBOHV
MJ?#CX0?"KPO\-/B1_8?P,^#WC'X:Z?XVM_AAX?G\2?#;Q!X(\!VGA;XA>*_$
M]EI'A[P#>7NB>']"`/.=7^,/[$&J?".X\&'_`()J^(?''PG;P;H1_:5^%VB_
MLS?LT>*O!O[//A#X%ZYXS^`&C:!\:_"</CJX\&_$F3X+7'P9\7^!_#G@3]FT
M?M%:[X>\#^#;'4_`OA^Y^'6H^$M7U;U=/VL?V;O@R/BIH<7[)7CCX:?"#X?_
M``X^(O@[PQ\3_#O@']G>#X/?'#P_^S=X#\>?%C7O@A\+M-\#_%;4/&5@?#GA
M.7XL:[X(\)_&+X??";P7JZ0_$.\\(:A=VMSJEY>?%^H>(O\`@FSX1^"WP$LO
MA[^U[^U3X!^#?C+X<^)OV;]'\%_LZ?!_Q?J(_:+^$'[/$7[15_JG@/7/A[\.
M_P!DGQ1XM\)67AGPM\)OCZFB_%OX$:%\%/B7X^\!>$'U71?BEXOTB;PMJ]][
MQX-T+]BKXNZ-KOQGU_\`:,_:#UC]GOXF>-?C-X*\)_`KXZ?#!_V??AC\'?B!
MXZ^`WCI_BSJ^F^%_%_[,_P`%OV@?#WV_X"77Q)U+3_$?[0'C7Q7X%TCPIXHU
M:[\$S:?!K6AY`-/1O$/[!_P4\4_%S]G#]FC_`()J6'BCQ9\(OCK:Z1XQ^$G[
M-'[-7[+?@G2+CQ7X8^#G[)O[2<WQKM[SQ1XR^$WPUM['PKHWQV^!%II.H^)O
M$.@_%?Q!\0O!E]9?#;P9XK7P'I^L-ZYJG[;'P7^&/Q$_X07Q;^RS\:?ACX8\
M&Z>?&7A#XJZA\/\`X,1^$9Y?'WP4^-G[0&L-X1\`>%/BGK7[1&@>+]:\/_!_
MXL>'_$'AW6_@=X6\7ZM\0HO[`DTO4!XDLM1OOEKX/>%?V5_&EY#I_P`,_P!M
MS]NGP1^TKK7CNXUOQ7\?_&OP:L/@?\>OVCK'XJZ%\/?AEIU_JO@[XS?L2>"O
M@=\6_A5+X/\`@3\*?A_X/^-GPR^!1L/"EEX#T&3P[\6-)\3>)=?UGQ5ZWK%U
M^Q#^T)\8/&'PAN/$/[5WB_QM\)/ATNJ^,8+7X(?M6GPWJOA+P)\*/VD?V<Y=
M0T?X_3_!`Z7\0O&>H6GQL^+-GIUY\-/BYK7Q,\1?%[P$J>$);CQ3X'\9:/<`
M'2W?QE_9"\:?%KPC\7OVB_V(=;^$O[2/PY\6?#SPO\//'/[0OP"^"7B?XP^"
M_#/Q9N?%6F>#/B9X+^+/PZ\4?%Z/PK\.)KKP]XDM?&LNF^/=+\5?":V6?4OC
M#X1\!:+<2:B?;?%G[9WP-^"'P-\*?$Q?`GQ"L_AU/X^^,7P?\/\`A'X=^`--
MUC7M-U'X!:/\=-4\31:-X#\+:M+=7^EWMC^SWXRMO!6B^#[76/$FMWFI^$],
M@\,VMUJ=[!I7R-^SQXH_8R^)L/C3QYJG[2O[5/Q^\1^!]'^"7Q$\4ZW^UA\%
M/&?PL\4:-\'/%?C3]H?X/_!?PE%\--;_`&6/@#I6I_#[Q%XZ\.?'/2-2U:S^
M'FI_$GQA=:!:ZO\`%+QUKVC0>#[V7U+X)?"C]E#]H[X,>$_A!\*M8_:C/P\_
M9V^*7C7Q]H/BOXF_"[X[?#B[\8ZY\5M(^.^@:C=Z#\3?VD_@WX?@^/WA+[)\
M7_&U[:>.O`&K>-#<W%OX.UGQ%XWU@:H9_%(!]J_!K]H3X?\`QWUOXW:/\/WU
M*^@^!7Q,\+?"[7_$,HTB7PWXLU/QE^SQ\"OVF="\1>`M2TG6-4;6O"-W\//V
MA/!%JNJ:C;Z+=R^(K+Q%;VVF7&BVNDZ[K57]I_\`Y(9XX_[EK_U,/#]6/@O^
MSM\.?@)KOQ[U[X>PZQ:3?M&?&N3X]^/+'4M2&H:=9>.9_A1\*/@[<0^%H6MX
MIM'\.R^&/@[X6O(]%EN+^*QU>ZU@Z;+9:--INC:77_:?_P"2&>./^Y:_]3#P
M_0!WWPI_Y)=\-O\`L0?!W_J.Z=7S/\4/V+]!^(7QG\:?M#V?COQ;H7Q:N/A9
MX;\$?"-[GQ3\5M2^$WPT\;>$8/BB_AKXJ^)_V?M,^+'AGX,?&3Q-H&K_`!(C
MU?0+OQOX-7Q-X<DT"*+P_P",-+DO(+G2_ICX4_\`)+OAM_V(/@[_`-1W3J_(
MS_@H)^R[^UO\1_C!XL^)7[._@3PQXP'@7X4_#OXR?`R/7?&>B^%Y)OVQO!7B
M_P`4?"[7=$N;G4]6MCH>D^,?V4/B1XY\*V_B^;3YK+PU?W=S=C^V+FX&@W(`
M[QS_`,$5?A^WAOP_X*^`_P"TS^TU\#O".@>._"7Q=^PS?'+]H3XC^)M;^*O@
M_P"$/Q&^#+ZGK?Q2UKXZ:1\6H_A[\1O!7BGP+X3^+OPG\-^.O#?A;7_`GPOT
MSPUX";X8:KKVI^*HOO*P_9(T6V\#_M"^`_\`A*?[$TCXZKX.&F'P-X9L?#R_
M"Q_!/P1^&7PAT%_"6G:Y?^,=(U"'1KWX:6'BS1-,\0:?J&B0Q3VWA;7=+\2:
M99WESJ_Y4Z?_`,$]?CEX=_;7_:0\<6?P'^"\'P5\17_[+VE?!SXI>!O#G@'2
M_C?\0O!GPG\`_L*^#/'GA#]HSQQK/Q#L-8U#X5:!_P`*>\8ZE\%_A=I'P_U:
M*+7_``CXQU_7]=T/^TOA[I?CJI\1O^"2/POTOP%<3?#+]A'X%:-XNTG]F/\`
MX*-?#C2;GX5_"7]D?1_B!::I\9_CIX#OO@WX6\$W/Q"L+3X=_P!I>(O@KK'Q
MKT/PW;>.9&^&.AZ-XO\`%O@?XDG2=`\<Z[H6M`'U)\=/^":_QT_:NL+&\_:&
M_;?UW1_B%X*N#IWPB^(W[(WPR\6?LI^)/A[X2NY[+6?$JG6]/_:`^)'C74?B
M!X^\1^&?`!\;>,=#\;>#_#3^#_"=WX1\%_#GP0_B_P`3:[?>U_&#_@G)\*/V
MB?AQ\"/@U\9]<\3?\*>^!WPXUSPW8_#CX(>,OC%^SWI>J^/]:\$6?PQC\?1>
M*?`/Q@'Q,@T;0_AOJ?Q/\$:=\.?$GCOQEHFNZ)\6?%(^(VH^/;VWTV[@^`/#
MW[`?QIT?X5_#C2O@]\-?'OPU\/VGQO\`^"9FI^)_@]\8[C]D;X>:G9?#+]F'
M_@H3X7_:;^(/BJ/X;?L4/8?LB>#/B)X(T72/$>HP1_!71O"]I\3_``9XK-AX
MK/C7XD^&_"EGH?IG[37_``3X^(?Q5\??\%!_C+%X-\":K-\5O`VK>`/ASX=\
M)_"CX07W[2?QE\-ZE^S!\(/`5_X6N_CC\7_B1+\);KX-P>+=-\9Q^#/V=/C9
M\+=.\%6_Q=TK5/B7XO\`&&I^"/&::*@!]C_`7]D_X[_"#7OC;XL\2?M0:'\0
M?%OQ/\"Z1X?T'Q';?`B/P/+:>-M)T[4H[+XI?%7PYI/Q6U#P)\5?&&CW6H6O
MAS1M<T+PC\*O%FK?"?PSX+\!_%3Q=\4]>\*:7\04@^#W_!._X5_`KPW\8/A_
MX%\8?$W6/AK\>_A9/X&^*GA;XN?$?XF?'*]UWQ?<Z;K.@WOQ%TKQ!\6/'GBN
M;PDGB#P[XBU32_%'P[\+V.E?#Z\>UT"[T#1/"YT_5(==_&^\_P"":W[1T=S<
M:C\'OV9O!GPT\*6?[#/QH^$OPRUKQ_\`"']AWP9^V7X<^,VO?#C]J30_#7PN
M\?ZW^Q]\2?A?^RIX1_98\4:Y\5])U[7/`'P.\,7B>)/B/_P@OB'Q7=^'F'C_
M`,::!]0^+_V,_P!J34_&D^M6OPPO]=TSP3X7^$'[.'@73]2^-VD6%GXM^!?[
M*G[9/[(/Q<^#_CC6M0GU[6+_`,(^-_B'X-;]IC6_&7B'3-$U'QDMCX$\-V>O
MVVN>(3\//#;@'>Z3_P`$<4OXO!EK\6OVD'^,>A1_L_>!?A;\;?`/BGX%^"8O
MA=\>?BYI7[4-C^T=\4?VB/$O@C^WKZ+3/$'QETR]\?\`PF\2^`)-3UWP/9>$
MO'&\6>I0:#;:1>>_^$_^"?>N_L[:IXEU;]A?XB?!/]EZT\3>(-<,OPWD_97T
MWQ7\$=$\#:R=!OX-#\*?#3X>_%GX&/X7\7:'XDM/%?B+3O%>B>)K/PQJEYXW
MU+_A,_AOXLGTS2;NV_.%_P!A_P"/]S\,/A]X5\%_L1GX;W7A_P#9._;+^$/@
MQ-2\=_`+1KGX<^'OB?X*_:"T+PA\*]>\,_#?XS:EX5^'/Q`\6:]XJ^$^H3VO
MP3\4_$[]D+XI&\\4^*_B5\+_`-GGQE\&?V:;CP!](7_[)'Q&N_B]XTU31OV0
MW\-?&>?Q5^TKKWC7]ND?%+X;7$?Q^^$GQ'\/_%^S^'?P780^-W^-VO/'<^+/
MAW81_!OXL>`/#'[/WP-7PU)KOPK\<ZOJ'A7PQ#J8!T?BC_@EE\3=5\"_$GX.
M0_'#]F3XC?!/X@^/OAI\;+WP'^U+^P[J7Q^_X2'XW^"_"7P>\'^)_$'Q3MM'
M_:J^$?PW\>_#KQI#\,]9\4V_PTT/X6_#ZX\(^./%&E:II7C6Z\/^#H?"NM_7
M_P`9/V/]3^*O[#MM^R;X>\;?#SX&^-/#_@WX20?#?XE_!CX%Z9X=^&/P<^*W
MP.\2^"_'_P`*O'WPJ_9XUGQOXATSPWX4^'_Q$\!>&?$/@WX97OQ#UB'1--TJ
MPT%O%E]]F_M.3R?X;?LX_M(^'-._:P\,#7D\-ZAXK_90^#7P0_9T^+MWXUO/
M$?BN#7/"/A'X[QV&J^.KEUN_$EIXI^%_B+XDZ#H=QXDN-3\6WGCO3_#^G?$&
M;Q->>*?$'B+0?#WQ==?\$ZK3XY^!O'_PK\/?L1O^P3\%_'OB;X"VGQ3^'C#]
MB_XKCXJ>-?`7Q'L/%OBW]H&/X::Q#^T]^SIXY2UT#3;/0C\0_CKX$OOCE\6Y
M)GOO'?PPT;4O!_@[4Y@#WP?\$CM-M?CAJGQ8TKX]:E9^&K7XF:!XJ^&GPQG^
M'D4^A_"WX?Z-^PC^UE^R/>_#;0+BS\<:;83W'B'XF?M>_$#]H?7?')\/6>LZ
MK'IOA_X2ZI97^EZ)X:\8^'>FU;_@D#^S?XAUR;QYK7AWX8#XS:KXP\0:CXA_
M:!T;X%>`-/\`COJ'P^\2_LGZY^ROJ'PVL_BA?_VUXFM--ATS6AXLLI-2N]<T
M&-[&V\/7/A&[M0=1&=^TA^R;\</%WQU\57/@+1+K6/A+\3?V3_@'^PYXDU+3
M/%>A?#?5/#'PG\;_`!!_:'F_:B^(NECPSXB\+20>,?`G@=_@M)\/K?PCX1\,
MW>D:CXFUU?`&H_/JUIX6^=/!/@3_`(+3>$?BCI&G:3XU;P[\"?!_[#?@OPKX
M#^"D7P:_9.\1?#F3XY:)^S/X8TR_'B_]H^__`&DK'X^^'_CC8?M&P^)8-)MM
M%_9P^(_[*U[\,-,\*0:EK9UOQ!K^M^&@#[2\0_L;?M3^/M:TSXE_$C]K?X5:
M]\:_A39PZ7^SAXC\/_LFZOX6^&WA"SO/'/@+QEXRU#XU?#B7]IK7O$?QD\2>
M/(?AMX5T+6KWP/\`%/X!>'=(M+.:]\'>$_#5]>7<D_O_`.SY^S'?_!/Q'/XN
MUGXBKX\\0ZS\)/"7@/Q7=1^$(O"EKJ_C'3?BE\:OBYXQ\<:=90^(=;31=)\4
M>)_C5JT.C^"S)J4GA72])M+:;Q5XCEN'N(?QG\<^"/\`@L#X4_9T^+^O?L^Z
M9^V98?'+XF?$;X_^-]`NO$][_P`$@[K]I76_B'8?`G]GSX;_`+*NI_M%07=W
M<_L7:;^SK%=?#_Q_HWQ0LOV=X;#X\R66D?"74=/M'N;_`.)%]>_61^"_[<OP
M9\9SR?!_5OB_K>F?%3]JOX_?&+Q9<Z'IO["EMX7E;Q?\2M'LO`EK^TIJ?BSP
MQX1^)^J_`73?@OH&FZ;X;N?@2/%'[5-I>16/A[Q3XJ'ACPYX;T73`#H]6_X)
M!_!'QAX_U#XH?$R#X5_%#Q]I/P5_9M^%/P=\9^.OV?\`PCXF\8?`K6_@'^T-
M^TE\>]7^(/PT\4Z_KNKZUX7U7XD2?'K0?#.HVGA>Z\-7>E/\+M(UZYUWQ$VI
M66D>&OH3]AS]C#_ACK3_`(G:9]E_96F_X3S6](U3_A*/V?OV2O\`AFOXB>,/
M[*E\1/\`VW^T=XQ_X77\6O\`A?WQ&N/[<\]O'G]D?#O9J-SXFOO[`?\`X23R
M-+Y_P]X3_:.\6?L6^.?@Y\7KOX@_$G]I+7/@='J_B[7_`!?HOPC\):!)\1/B
MMI_B#5KOX.>#=9^'&F^#?`&LV/P=F2V\&R>(H[2XM;W2G\.ZEJGC?Q3X@O?$
M%Q8?._CKPA_P5'\)>&?%$^F_%?\`:'^*=KXO^)FG^*=6L_A#H/\`P3ET+X[?
M"OX=W/C/]HB%?AI^S*/C;X/\)_`/58=+T5?V8IO%NL?M/:AX^\1:AX(_X6E?
M>$/%]O\`$:[T?PYI`!^S5>!_M/\`_)#/''_<M?\`J8>'Z[3X7:OXGU'PXFG^
M+/"_Q(T'4_#5OX7T1M=^*-Q\(9O$?Q!EE\`>#_$&K>,'A^"WB+6?"-E<6WB+
M7=:\#^*+6/1_!%HWC_P9XPN_!7A>X^%EUX`\7^*^+_:?_P"2&>./^Y:_]3#P
M_0!WWPI_Y)=\-O\`L0?!W_J.Z=7YF?M)_M1?$?X=_M=?"[X;V?QQ;P)X7UCX
MZ_!?PM:?#>#P5X'U?4?BKI/C*U\*Z?XK\'Z5J/BSPY`WB"ZM+7Q-J/BZ^\&>
M#_B3X(^-5AX>TK7/CCX#MOBGX#_9^^*GP)^)7Z9_"G_DEWPV_P"Q!\'?^H[I
MU=]0!^(G[2'QS_;(\,_$?]O[Q+\/-?\`VAO^%2_`/P;J&B:$?`7A7]CC7O"'
MA_6G_9D^#WQ*TC3/@WH7C70-2^/_`(O_`&L+CQY\0;K5;:V^*VG>(?V4[OP9
MK/A;18UE\7VGB#3+3Q:V_;-^*ES\)?A7K_Q9_;K\4?LGOJ/PSUCQY\"=3^)'
M@C]D;6OBS^UQ\3A\9_BQX<TS]FGXU^'="\`>)/AKJOQP\#^"O"?PK\/?%C]G
MK]CU/AE\8=8^(/Q,US2?!>O>']0\&WVGVW]$E%`'XF^+/VL/VXM-\2ZP=9\.
M_#'P)\,5\>ZQH6C^*=-\=R^(/BLOB"U^&OPR\1:C\.O$7P9US]GFQ\*>&O#?
MAO6]?\5FR\<6OQY\9^*-6DM=/M-2\,V=O>N=%^5O`O[97[4WQ1^%?Q]\/Z;^
MV-(_C#PQXN^-^M:?\4_@E)^RW\6-2^%T/A#1!XIT+X'ZY>:K^R]IGP\\,_$3
MPE+X5O++XD_!_P`;_"KQ[\0/AQX.^(FA0:G\;_B'XDU;0O&GA[^ENB@#^=/Q
M+^U9\1?#'Q8_::\&?%?_`(*E^"O@G\.OA]\<OAQ\+=2\6'X^?L"Q_&/]G[P>
M$N;0^,/B/\%_B+^P!I/AKX*+\6-6L-,L[+QM\5_BW\;O#7C1O$P?X=^!?A5-
MJFAZ?HWZ]_L>_&IOBU\)?#L'B?X@^'?'/Q+TO2-0UG4+^RCT?P_XE\;_``CO
M?BC\5OA]\"OVB-5^'VG/#+X4\-_M'>%OA1JGCSPM=VNE:=X2U>^@\5:?X/#6
M7AR[M-/^L:*`"BBB@`HHHH`****`"BBB@`HHHH`*\#_:?_Y(9XX_[EK_`-3#
MP_7OE>!_M/\`_)#/''_<M?\`J8>'Z`/F3PI^V+_PC'A;PUX:_P"%=?;O^$>T
M#1]#^V_\)=]F^V?V3IUM8?:OLW_",7'V?[1]G\WR//G\K?Y?G2;=[;__``W#
M_P!4P_\`+U__``2HHH`/^&X?^J8?^7K_`/@E1_PW#_U3#_R]?_P2HHH`/^&X
M?^J8?^7K_P#@E1_PW#_U3#_R]?\`\$J**`#_`(;A_P"J8?\`EZ__`()4?\-P
M_P#5,/\`R]?_`,$J**`#_AN'_JF'_EZ__@E1_P`-P_\`5,/_`"]?_P`$J**`
M#_AN'_JF'_EZ_P#X)4?\-P_]4P_\O7_\$J**`#_AN'_JF'_EZ_\`X)4?\-P_
M]4P_\O7_`/!*BB@`_P"&X?\`JF'_`)>O_P""5'_#</\`U3#_`,O7_P#!*BB@
M`_X;A_ZIA_Y>O_X)4?\`#</_`%3#_P`O7_\`!*BB@`_X;A_ZIA_Y>O\`^"5<
M#\4/VJ?^%D>!M<\%_P#""?V-_;/]F?\`$R_X2C^T?LW]G:QI^K?\>?\`PCMC
5YWG?8?L__'U%Y?F^;\^SRW**`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g30330image6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`D(!
MS0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[@OAE\,OAO?_#?X?7U]\/O!%[>WO@CPI=WEY=^%-!N;J[NKG0;
M":XN;FXFL'FGN)YG>6::5WDED=G=F9B3V_\`PJCX6_\`1-?`'_A&^'?_`)74
M?"?_`));\-?^Q`\&_P#J.Z;7?T`<!_PJCX6_]$U\`?\`A&^'?_E=1_PJCX6_
M]$U\`?\`A&^'?_E=7?T4`<!_PJCX6_\`1-?`'_A&^'?_`)74?\*H^%O_`$37
MP!_X1OAW_P"5U=_10!P'_"J/A;_T37P!_P"$;X=_^5U'_"J/A;_T37P!_P"$
M;X=_^5U=_10!P'_"J/A;_P!$U\`?^$;X=_\`E=1_PJCX6_\`1-?`'_A&^'?_
M`)75W]%`'`?\*H^%O_1-?`'_`(1OAW_Y74?\*H^%O_1-?`'_`(1OAW_Y75W]
M%`'YS_M^_M(?LW?\$[?V>M>_:7^*7[,_BGXG^`/"]W;V_B/3O@;\,_A'XC\7
M:19213W5QK=QHWCGQE\.K>XT;2["TO\`5-7NK#4KR73=,T^]O[JWCMH&D/CG
M[0G_``4-_87_`&?-*_84UJ7X*ZS\7=,_X*'_`!%^"_PU_9_O/@_\-/A'JMK!
MJG[04&GW'PEUOX@7OC;QGX"L?"WAKQ?%?7#Z9?07.KWMTFA^))+73;B+0=1>
M#Z__`&P_AEJ?Q?\`"GPU\#1_#&^^*?A*\^+GAJ]^)VA6^H>#;&P/PV73==T?
MQ;!JL7B[Q5X8_M.VU'3=;ELGT[2#J%[<0/<H;=/W?F_STWW_``1V_:Y^#W[,
M7_!-CX*^'5N_VE/%G['/_!7'X!_M):MXL?Q5X`\.7/A_]@O]E+XF_M!3_!OX
M7:/=^,O$_A1M?\:6/@SXJ#Q5I&@/;0V&FZ]XV\5>%[OQ3#IGAW1KJ\`/Z!/#
MWQ6_9`\3_M0>._V.=,\/?#QOV@?AO\&?`'QW\6>"9/!GA5I;#P%\0O$GB;PO
MIDJW5M;W,4NK:1J7AVTE\1Z<-O\`9FG>,?`^H1SW5OXC@>+X?OO^"BWP0T_X
MT?`/]GRZ_P"":/[4,/Q:_:<^&WQ*^+7P6\)W7@3]AK3KKQ5X&^%VGP:OKVHW
MTNJ_M8V,/A&_OM*O-/OM'T#QD^@:](M_#::IINE:E#>V5I\X>,OV(_VXO#'[
M8W["W_!23X>>$[GQC\;8?%WQ4\'_`+:/P9EU#X*>$+S3/V;?CL)-4\0>!H_B
M8WQ",/Q:N?@)XCT[PBOP&L)-2A@U/0_"NGGQ%?\`A>;?IA^L_P!HC]F3X^>.
M?^"P_P"P!^UIX5^&UWJOP)_9X^"G[2GPX^)7BT>*O`%C=V>N?&S1]&T_PU=:
M3X:U+Q=9>)=6TK1YK*=O$L\&E+=V\05M&L=<=@@`//O"/_!4#]F?Q_X^_:*^
M&/@G_@GA^TMXB\<?LL>$/V>O&OQ@\.)\.OV,M&UO3-*_:6^#%]\?O`%AX>T/
MQ/\`M/Z'KOC#Q/IOPPT;Q'K?B_PGX:TS4O$>BS>&=;L+?3=2NK>W2ZJ?#K_@
MK)^PUX[T;0O&FL_LF_%OX7?"O7OVT;[]@%/BS\0?AC^S9/X.TS]I:VURX\,V
M7AG6=,^'GQJ\?_$&Q\-ZUK\"Z7IWC?\`X0>7PO;RW%O<:WJ6D6+O=1^`:/\`
ML8_M0_#/_@K5_P`%!_\`@H2G[*GQ:^*&G_$CQ5^RWXX_9&T;P=^T-\'O`WA7
M7_$_P7_8?^,'[*'CVU^/?A;6OCIH>EV>A:S?_%9]3\`>)+CP)\4?%7AC3K'4
MK_3=%\,7NLZII>K_`!K\`/\`@DC^WW\$7\!_M)VWPV/B_P",'P;_`."G_P`<
M_P!I_5OV1OB/\9_"/B/]GSXW?`OX]:\BZ=\0OA]X;U'X@^+/AC\(?VLO@9:W
M&H^)?`_CV33O#.K6]U>2:?-XL\4I9V%H0#]_/"G[37[-OBW]NWX@_P#!/JU_
M9E\2:9\7/AK\&=&^/7B'QKJO@+X&#X43?#KQ'XCN_"OA^_TS5=-^(>I^.+G4
M=6UFT,,.DS^`+2ZM(9X9]3%A&)C#U7PG_:#_`&.?CU\$_B_\>/@?X(\)_%7P
MA\$OB!\;?AAXQT_PKX,^'\>NR>,O@'XDU;P]XTTW1_[?OM$\/7,.H0:7#XH\
M)W][XAT^RU[PEKGA_68Y[<:I%;I^=OQ#_9E_;5_X>?\`[5O[6WPU^#/BS1O`
M?QW_`&%_A'^R-X.\;6/CWX'P>-_`GB>'XQ)J'Q`^)EGX<O?BO:I+)X%^'^LZ
MQXM\#6TM^LGB+QGHFEZ#J-OI6GWLNIPT_P!G+]AS]JO]B_\`:E_X*'>%OA]X
M!;XH?L<_MD_"#1OB'X?U3PQ=?!KX:IX#_:YL/`^H?#SQ78:!\+Y_'NDO:>#O
MB5X4A\-7WB7Q9.8;P^-=#M(AI"Z*]SKA`/TI_8A^,_[.'[>?[,?PQ_:P^%GP
M%G\$_#CXNZ?J.K^#=)^*G@'X5Z9XRN-(TW6+_0I-1O\`3?`_B7Q_HUA%<:EI
M=_%;6\OB!K_9;&:XL[>.6!I?(M>_;1_8]LOB[^U!\&?!7P$UOXO^)?V,?#_A
M/7_VE[OX8?#;X1ZC:?#-_&WAR[\8:!HQT/Q+XQ\*^/?&FIR^&;5M6U&Z^'G@
MWQ;X?T7>=-UC7+'6K34M-LO!_P#@DW\,_P!M#]D3]C+]A#]BCXB?LOZ]X4U+
MX4P>)O#W[07QAO\`XF?`C6OA[H7A6*7XH^.M(E^'=CX3^)OBGX@>+]7\2^*;
MSP+X,NK?5/`7A>#1=.UOQ%K8OV.CV4EWY!^W9_P37^,W[37CWXE?&[X>_"#0
M_@;^W1H?CX:?^QK^W]^SQ\:(?AMXO\._#>Q/AV2R@_;1\,M9:,?'7A6Q-KK&
M@67A3P_X=^/NH>*?`UKHFBZ@GPZN+G5S(`?0_P`=_P#@HW^R7^S]\?/VB/V?
M?$_[''Q>\2ZY^RS^S4O[7GQF\:^"OAM^S1J/@;P]^SY#>:C::IX]L!K?QK\/
M^.=>_L*'2-2U+5?#FD>![OQ4NG6<L]CHE]*4@=+S_@H]^R+J7[0WA']FSX3_
M`+(GQ)^/'C+XB_L7^!_V^/AOXD^'/A']DW0/`7C[]G;XE>/=,^&?@+5_#VN_
M&GX^?"2^3Q5XK\9ZYH>CZ-X/UO1M'U>\FUG3C'&1,PC\9\2?\$V/&/QX_P""
MM?Q^^.?[2/PJ\4>+/V2/BQ^PE\._V9+_`%+1_C'<?#[2/B#XQ\*^,M2\0>+[
M/XA?#KX8_%_0_$GB3X4^+M&O)M.C\*^+],\1Z)?W=W]DUWPQ#8QG4APO[2/_
M``3\^+'B'_@L#\.?VN/#?[-7Q+\0?LM?!?\`8)^`?P`^'FB_`GXM?"+X6ZI'
M\9OV?/VYO#7[5_@72[CP)K'QS^$^D:O\!8/#7A'3?"E_X?\`%']H:9%J[V%S
M:_#F^?P]HNMV`!]U?#C]M/\`9-^-OQ-U?X-_`;]FGQC\:/B9X"\`?#3Q_P#'
M?POX0^&?P6T1/V;Q\7/#J>)_`_@;XQ>(_B3X_P#`?A&'XH7^G"_&H?#_`.'O
MB#X@^(M"GTC5?[;M;"WM4N)>$\6?\%#OV2O"?Q>^`_P4N/V/_B]?^,?VB?@_
M\<?C7X"5?A)\!?#T%CX7_9YL[Z\^).D^,M-\<_%7PGXJ\)^,-/\`L$EI:^'=
M4\.).]^ZV=[-83PWBVWA?_!/7]C;]K;]A;]J+]N+X[:_\)K#XE^`?^"DOCKP
M5^TSJOA3P=\3O",GQ$_9=^.>MKXLU[XE_";Q_=^.=9\.>&/B!\+]"UOQ]>:3
MX9^(WPOU_7-7CL?#`CL_A?)8:G9&QZ7]M7]D_P#:D^+O_!1S]D']IKP?\'F\
M1_#[X*_LA?M@?"3XB7VA^/?AS;#_`(6+^T!\.K;1/"UCX2L_&7BOP?KFM:#8
M:Y#-::KK6JZ-X?DAMFM[R'3YP\T=N`8EE_P5U_9)U#]D;0?VY;;_`()]?M)R
M_LW^(/AKXO\`BO#XPA\`_L27NL:7X2\(6'CR_DN/$7@G3_VJKOQEX?;Q$/AC
MXZL?"MYJNB6VBZOJ^@3Z2=7MM0N;"WNOIOP9^V_^R1\3_&?PM^%'PG_9L\4_
M%#XW?$?X%>#OVEM<^#/A'P%\`_\`A+/@I\%OB#%IDW@KQ9\;?$WB#XFZ#\)O
M"-_XG@UC3[K0_!.E?$GQ'X_U73YSJEAX6N-+BEO4_*WX$?\`!([]H'X1?\$/
M/CS^R]%\._%\W[:7QS_8YL/V6O$O@?6?C=HWBWX>6^L^"_''[0/BWP3XB\':
MQXB^*&K^"?`W@JY@^/>I0:[I/A.W\,L^HZ;+J;^#;S4+N?4;WV[]@O\`X)V?
MM*_L"?M:>)?VL],^'FH_%?P?^U1^R%^R[\(_CQ\)K3QU\/+3XR?`_P".G[-_
MP^\$_"^#4O"M[XE\9Z=\,?B!\&_$^D>'=3UF62V^)NF>+?#37%AI^E>%=3L[
M:+3+4`_2KXC_`+4?[&'P7_95\4?MB?&_X<V/P:^$?@GQOKWP]\60_$7X7>%M
M'\7:'XD\/_'34/V>[N*;1+5]0MKS3[SQUILU_I&JZ5JE_I^K>#);7Q=8SS:5
M.L@R?VR_VG/@+^Q5X,\;_$GQ9^QY\0_BU\./AC\&M?\`CG\2O'7P8\`?L[7G
MA_P3X,T/4(["*UU%OB?\6?A9J.L>)->5-2O]!T7PCIWB22YTW1-4N;V?3]EG
M'>\S^VU^RY\5/V\]#U']GOXD>';KX>?!*\^"OQ-3Q/KNB0_#/XFZ;XK^(WQ.
M\-:U\/+'1_#EOXG\3>$_$^A>(?AOX!UGQ-)HOBO4/"UEHEYXO\;Q:C97FD2^
M"-*UJ_\`D!?V;?\`@H%\3O\`@@7\0OV&?C?\)UN_VRA^S7XF_9;T66V^(WPR
MU#P[\0+'2M/F\+?#/XC:AXL/C0V6FI>>"K3P['XY35[@^(4\56^M75GI^L6=
MQ;WLP!V_CO\`X*J?LM?"_P`(^`O'?Q$_X)Z?M->$_"GQ2U3]D+3/AQK=]\+_
M`-CV_P!-\8_\-LW'Q!L_@[=Z3?Z'^TOJUC&NGWGPWUR#XB:7J5S8>(O!:ZAX
M:O+S1+C3O$.G7DOK.N?\%#/V+]/\+?M&?$_PY^S;X[^)'P*_9$\7:[X#_:6^
M/GP\^%/P:UOX;_"KQ9X'L=)U/XKZ4]E>>/\`2OB3\1HO@WI^LV]U\2]8^#GP
M^^(V@Z0EKJL6EZIK5QI&HPVWSM^V_P#L7_M2?'#_`()U_P#!-?\`9^^'WPAO
M-0^*?[.WQP_87^(?Q9T&^\;_``NTNV\/:!^S#9:=8>/$MM:O/'4>C:YJ&LM;
M2S^#[?1+Z_BO[<#^V[CP].P@KSSX?_\`!.#]JS]G7]AG_@H__P`$Z_A9X$T#
MQ_X8_;9\>?M.ZU\#?CAXB^('AW0M!^$_@#]K_P`'6'A/Q9HG[0^BSWVH^.9?
M'7P?BOO$<VCZA\)=`^*>A_$TVFBR7=]X%DO+U;(`^VO'_P#P4,_8$^&G[2'[
M-O[/OBGX:>3H?[6/A+X>^*?@K^TY8?#GX8:E^RUKUU\7[3QE>?!SP?J?Q(M/
M$LFNZ!XN^+D7P_\`%:?#:TU7P5;Z1XJETJ9-/UI^".BU+]L[]EK2O$WP7^'M
M[^S!XF@^*_[0WQ?_`&B_@Y\&OA5<>%_V9K+Q7XZU/]E+Q!XB\-?''Q5IVIZA
M\8;3P'9>%/">J>'72VBU?QGIWC'Q!'J^C-H'A#47N+I+'QCPM_P2I^'.L?!;
MQ+_P3]^-7P_\4?$/]F*V_8#_`&./V7="^,]YJ?@:RU:\^(?[..J?M`:I=_$;
MPOIR>*]8\9^"/&6C:K\4/"GBKP1J3>&)-(TO7=-U;2@T_A^QM$USQ#3_`/@E
MW\3/$'[&7[-W[(_[<OPL\._M]:%\+-9_;3\8?$7XOZ+\0K;X:_M11?%3Q3^U
M!<^.?V7_`(T_!/Q7JFI>$8-+\<^(OAIXH\5ZI\7;;5OBYX-BLM=^QIJ>L_$&
M>R.EZV`?M!\);3X-?%[P-9>.M*^"FG>$[>ZUOQGX>N/#OCOX:^&=`\5Z3JW@
M3QIXA\!Z];:KI4,>HPP#^W/#6HR6$T-[<0WVFR6=_%)Y=RJK^9?CW_@HA\%O
MAK\-_P!H3XP^*OV*]OPS^!?[6FL?LHP>)-#M/`'B.[\6:GX#\9^)-"^+GCZ?
MPOH_A^Y\4>&_#'@'PIX7OO&:(-(UV35X94MKZX\.:+8:[XIT?[>_X)U?!G]H
MC]G[]D/X7?"3]J3XL:O\:/BWX1F\:6\WC7Q)K[^,?%B>![WQUXCU+X7>%O&7
MCJ33='?Q[XR\%_#F[\,>%?%/C,Z7:+KVN:3?74+ZA`8M6O\`P?\`X)9Z[H%_
MIO[>WARVUC2+W7-$_P""F?[;5UKV@P:A9W.JZ18Z[\7M8_L>YU?2XY7O+"TU
ME=-U(:9->010ZB+"^%JTWV6X$8!+:_M;_`:;]IOQW^S)<_LB^);+Q-X%_9\M
M_C]<ZC-X%^%OE7ME:>'8O$_BWPJLYU=/!\6L^%[?Q'\,?#T\4?CFZU"3Q=\1
M=,34=&T7P/:P^/M2\F^&'_!0#X*?%3X?_LA?%+0_V-HK/P)^U9^TEJO[,)UK
M5].\%:+<^`/&\>EZKK/AS5IO#>O>&=(\7>(/#FO6?AKQ;9W%Q<^'_"]_I6K^
M&[A8[#4_#VK^&_$FL_M/M4L'*@NJLJL0-P5RI90V,@,40L`<$JI(X%?EE_P4
MOUK1[;Q[_P`$O]!N=6TVWUS5O^"F/P>U'2M&GO[6+5M3T_1?A)\=(-9O]/TZ
M25;R]L])FUG1X=3NK:&6"PEU738[IXGOK42@'Z(?\*H^%O\`T37P!_X1OAW_
M`.5U`^$_PM'_`#37P!_X1WAW_P"5U=_10!P'_"I_A;_T37P!_P"$;X=_^5M'
M_"I_A;_T37P!_P"$;X=_^5U=_10!P'_"J/A;_P!$U\`_^$=X=^G_`$#O3C%'
M_"J/A;_T37P!_P"$;X=_^5U=_10!P'_"J/A;_P!$U\`?^$;X=_\`E=1_PJCX
M6_\`1-?`'_A&^'?_`)75W]%`'`?\*H^%O_1-?`'_`(1OAW_Y74?\*H^%O_1-
M?`'_`(1OAW_Y75W]%`'`?\*H^%O_`$37P!_X1OAW_P"5U'_"J/A;_P!$U\`?
M^$;X=_\`E=7?T4`<!_PJCX6_]$U\`?\`A&^'?_E=1_PJCX6_]$U\`?\`A&^'
M?_E=7?T4`<!_PJCX6_\`1-?`'_A&^'?_`)74?\*H^%O_`$37P!_X1OAW_P"5
MU=_10!P'_"J/A;_T37P!_P"$;X=_^5U'_"J/A;_T37P!_P"$;X=_^5U=_10!
MP'_"J/A;_P!$U\`?^$;X=_\`E=7P?^V'X7\,^&-8\#Q>&O#FA>'XKO3-9DNH
M]"TC3M)CN7BNK%8GN$L(+=9FC5W6-I`Q168*0&.?TOK\[OVW_P#D.?#_`/[!
M6N_^E>GT`?3?PR^'V@WOPW^'UY-?^-TFN_!'A2YE2T^)OQ(L+5))]!L)76VL
M;'Q7;65E;JSD0VEG;P6MM&%AMX8H41%[?_A6OAW_`*"/C_\`\.O\4O\`YLJ/
MA/\`\DM^&O\`V('@W_U'=-KOZ`.`_P"%:^'?^@CX_P#_``Z_Q2_^;*C_`(5K
MX=_Z"/C_`/\`#K_%+_YLJ[^B@#@/^%:^'?\`H(^/_P#PZ_Q2_P#FRH_X5KX=
M_P"@CX__`/#K_%+_`.;*N_HH`X#_`(5KX=_Z"/C_`/\`#K_%+_YLJ\H^+OB/
MX+_`S1O#^N?$?Q+\6K&W\6^++#P+X5T_PQX@_:,^(WB;Q+XNU+2]8UJRT'0/
M!WPWO?%OBW6+^32/#VMZFZ:?HEPEO8Z7>W5R\4,+/7TM6/K,>DQ6\>MZKIHU
M`^&#>:]820Z-<:[JVG74.DZE87-WH-A86=_J\NL3:/J.JZ5##HEK-JM_:ZE>
M:5:Q7`U"2VG`/RRT[_@I;_P36U7P/?\`Q.LOVAOBH_PVTS2?B#K=W\09]'_;
M6L_!*Z9\)KRUT_XH3V_BJ]\-6^A7K_#N^O+:T\;6MG?W%WX8N)5BUF"S96"]
MMH?[<_[`_B#3/#6L6?QN^*EC8>._"/A+QW\-)/$L'[8/@^?XO^%/'VK:!H7@
M75?@G9>+=)T2^^-0\::KXI\.6GA2Q^%-MXPU'Q$VM:=-I%G>6]S',?P4^`WP
M%^,UC_P;8?MK_`SQ)^S1^T%:?M`:OJO[<,?P^^$NN?LW?&.#XLZGJ7Q6^(WC
MJZ\&7O@[P7?^`4\5WD7BGPSJ[+'K&B:?)9IIVIO::C>6R7C0R:7P0_9YTGXC
M_L(_L/?L?_M+>`_^"E>K_$Z*#]G+XL>$?CQX'_9'_:`^#GQ-_P""8&O_``+_
M`&#_`(%_#M=/\,_$2X_9\\':!K5_X?\`CO\`#'5/".A^$_#>G_$KQ3XM\.^,
M;CQ-XCG\2:QX9?QC0!_1-J_[0G[)NC^'M)\2#XG?%'Q!;:W\5IO@7I^B^!=4
M_:A^(WCEOC)9^`M6^*&J_#*[^''@$>)?B#IOC3P_X#T'6_$/BG0-3\,VE_X5
MM])U&T\1PZ7J%G/9IS/[-O[6O[%/[7EQX:A_9V^,?Q+^(MKXV\%^-_B'X&UZ
M.^_:J\+^$/'?@SX:^--`^'/Q"U[P+XU\:V_ASPAXUMO!/CSQ1H/A+Q3#X8UO
M5;O0]=U%-.U&WMYX;E8?)/\`@F/'^U+HWP;^-%Q^VJMS\3M4^'G[0_BMO@C^
MT)J_[/NL_"+XW_M!_"C1/AIX.\(^'_C'\0_@-;Z&WBSPQ\35L3XC^%2W4'AG
M0O$?B[PGX8M;E?#LNE:G;:YXI\'_`.#;SX3^.O@__P`$?_V0/AQ\:OA!\0OA
M!\:OAC'^T=H7B/PC\8/A;XP^&?Q!\+V?CG]J3XK>/+:R73O'GAW0=:32?$^@
MW/@WQ#(VGI+IFHI%HTMP\ES80I;@'[.?\*U\._\`01\?_P#AU_BE_P#-E1_P
MK7P[_P!!'Q__`.'7^*7_`,V5=_10!P'_``K7P[_T$?'_`/X=?XI?_-E1_P`*
MU\._]!'Q_P#^'7^*7_S95W]%`'`?\*U\._\`01\?_P#AU_BE_P#-E1_PK7P[
M_P!!'Q__`.'7^*7_`,V5=_10!P'_``K7P[_T$?'_`/X=?XI?_-E7(>"/!.EZ
MQHM[=ZCK/C^XN(?%_P`0M+CD_P"%I_$R';8:'X^\2Z+I<&R#Q=$A^RZ9I]I;
M>:RF:?R?.N))KB265_;JX#X:_P#(NZC_`-C_`/%C_P!6EXRH`/\`A6OAW_H(
M^/\`_P`.O\4O_FRH_P"%:^'?^@CX_P#_``Z_Q2_^;*N_HH`X#_A6OAW_`*"/
MC_\`\.O\4O\`YLJ/^%:^'?\`H(^/_P#PZ_Q2_P#FRKOZ*`/#?B+;?#'X4>!/
M%OQ+\>>(OB/H_@KP+H6H^)_%FL6OC[XW:^^C^'](MVO-6U>;2O#?B#5]9GLM
M+LHYK_49;/3K@6.GV]S?W(BL[:XFC\Z^'WQ/_9S^*WP)T[]ICX=^/?B;XK^"
M&L>&)/&FB^.-,\2?M&F/7/"4=L+P^(]#T"XNX/%6M:-)9[KNWO\`2]#N[>ZM
M8YKBV>6&&9TTOVXK34]2_8P_:ST?0]"\2^*->U_]G#XU>&M`\-^#O#'B#QGX
MHU[7_$GPZ\1:#H>D:'X7\*Z;K&OZQ?ZCJNHV=K#;:=IUS(HE,\PCMH9IH_R*
M_P""?GQ@\1?"_P#X)6_L:_LG>(?V=OVO=,^,-K^R/KGP\^)NA:_^QM^U3X9L
MOAE?^$_@;XWOYXM<\1^(?@_I?AF\U?5?&5CX9\#^']`T75M6UGQ!JGB:.;1K
M"]LM/U*[LP#[<\"?M_\`_!.?XD^(_P!GCPKX0_:9\17NL_M90:Y<_LVIJ?BG
M]IGPUIOQFA\-W&HVFM/X'UWQ1_8V@ZK]CO=)OK`(-2C>YU".*PM%N+R[LX)^
ME^+G[9_[!/P,^*?C3X(_$[]HCQ'H7Q5^''PCU_X\?$'P5IOC7]HOQ?JW@;X0
M^%-'/B+Q-X\\7-X,N?$-GX=T;P_X=-OXBUC^U[JTO--T#4-(UN[M8M+UG2;N
M]_EN\!_L/?M*_$7_`(),_L:>'O!OP&^/GP^_;H_83_9S\._M*?L_Z/X^^`GQ
M@\!W^C_M%?`S]J_QI\1%^&=UJ7B[P9X?TE_$?CWX6:EK^GZ-X1GUNUDU[4-:
M\-7`AN8DMU;W?_@H5^S/\?#^U7\6_$&D?L]_'3X@^*/B+_P0H_X*-_#[XI>-
M_A3\`/C5\0?`WB']L;]H:Q\4ZOI?PI\.>._#WP]OK'Q-<M-?Z7X`^%MK/J%Y
M?VGP^\->#/#DMRJ:3;0Q@'[I6?\`P4F_X)P:E8_#O5-*^._QFUC2_B]XB\/^
M#_A/JFC>%?VY=7TSXG>,/%?A73/'/AOPA\/M1TWPE=67C+Q9K?@W6M)\4:=X
M9\.SZCKESH>H6FI1V!M9ED/J&E?MC?L):U8W^J6/[0/B<:7H6B#7_&6IWWC+
M]HW2=.^&EC+K^O\`A73[?XOWVJW-E:_!W7->\3^%O$/A[PMX8^*4OA#Q)XMU
MK2;O3/#.DZM>*L+?AMXT^$7Q3L_V7_\`@UX\-Z'^SE^T'%JW[-GQ1_8Y\3_M
M'>']$_9H^-C:E\&AX-_9NM/"GQ)UGXIZ3IOP[:[\(W&G>/&O;37+K7K>UN;W
M4)9]2W7<$SWC^O?MY_LS_&/PM^T#^UU^TW_P3_T']HSX0_M5:_KGP[\`>+/@
M3+\"?$?QA_86_P""H'AJ;X6?#_5#=?%*W@T`^!OA=K%I-X_\;_!_7_C%K'C[
MX?MH4_A#Q%?7MQ#/K6K^)6`/Z/?^%:^'?^@CX_\`_#K_`!2_^;*C_A6OAW_H
M(^/_`/PZ_P`4O_FRKLM.>_ET^QDU2WMK34Y+*U?4;6SN7O+.VOW@1KRWM;N2
M"UDNK:&X,D<%S);6SSQ*LC00LQC6[0!P'_"M?#O_`$$?'_\`X=?XI?\`S94?
M\*U\._\`01\?_P#AU_BE_P#-E7?T4`<!_P`*U\._]!'Q_P#^'7^*7_S95Y]<
M_#'PKHOCO0+?2)/%VG)XIM/$][XC>R^(OQ#@NM9N]*72Y-.N+^\C\4K=SRVS
MZE?LC-/EC=2&3?D8^@*X#7/^2A>`?^P5XW_]%>':`#_A6OAW_H(^/_\`PZ_Q
M2_\`FRJC<_"'P5>7=C?W9\8W5]I;3MIE[<_$SXESW>G-=(D=RUC<R^+FFM&N
M8XT2<V[QF9$19-RJ`/3:*`.`_P"%:^'?^@CX_P#_``Z_Q2_^;*C_`(5KX=_Z
M"/C_`/\`#K_%+_YLJ[^B@#@/^%:^'?\`H(^/_P#PZ_Q2_P#FRH_X5KX=_P"@
MCX__`/#K_%+_`.;*N_HH`X#_`(5KX=_Z"/C_`/\`#K_%+_YLJ^8O$_[07[(G
M@K]I7P!^Q]XO^,_BOPS^T?\`%71=0\1?#7X9:YX^^/FF7OCO1M*TG6=;U*]\
M*Z_=ZI%X2UM;+3O#FO27$-AK\]PEQH^HZ>8?[0M9K5?MROYP/^"O'[,GQH^.
M7Q<\2?&S]F'X<>.-?_:O_8QLO^"?O[1/[,5^_@;QMI'@OXC>*?A9\;OVK7^-
M7P7MOBE<>'!X)U&VUWX4_%72+WQ3X9T_7;V[N[K_`(1RQO;,&.Z2V`/T+^+/
M[>?_``3P^!WCKXU?#7XG_M*^(O#GC7]G+P=X>^('QUT6#Q;^TKXB'PK\%^*[
MKP[9>'_$?C/4O"[ZUI&D:;J=YXL\.6D,LU_OCNM6M8)TBE,B)@:G_P`%$/\`
M@GOHOBR7P'K'Q?\`C]I/CF#X97WQKG\&:G\/OV][#Q9#\&M,3S-2^+<OAVZ\
M$1:Q'\,M/C!DOO'KV8\*VB#=<:K&O(_FF_X*6?LC_M'GXM_\%5M'\%?L\_M)
M?%O4_BO_`,$J/@I\/++QU\.?V;/CKXI\)?&#]IW4?VQ-&^+_`,9=)\`ZSHO@
M+4=)U6XEU'6?$?BRTTC2KZYL]%\,^596DB6.E>7!^T/@7[;'^QM^U/\`#"_^
M'O[4OQJ^.6J?L5_'0Z=\:?B-^Q+\:/AI\0%T3QU\/?#7A/P#^S'HT^H_L_?#
M4^-/$%CXC$VGP>#OA-I&KZ?!HG@/2O&WC*TT_5];\\`'U0O_``4J_P"":W]@
M>#/%4W[0_P`4K'PS\1W\`+\._$&J:5^VII.C>/X_BKJVI:#\-KSP1J6I^'+2
MT\6:;XXUO1]4TCPSJF@2ZAIVK:E8W%E:74EPGEGZ`MOVB/V19_C5XN_9XF^+
MGC[2/C!\/_AJ/C'X[\(^)?$_[2'A1?!GPI*W!7XA^*O$?B6XTGPIX?\`"#26
MEU;+KNJZY:6#7UO-8+,;V-[<?S;?&_\`9^^-?B#_`((6_P#!&KX3:3^SW^TI
M:_'OX3_'K]AD?$'P_P"'OV9?BKJOQB^#?AKX<:\;[XF:]KWAG4/A;KU_X9TK
MPI-_8VL3R>*O#\_AC5[W3;9_L.NQ:=<V\?/_`+=7[!7[8/[37[8/_!5'X:?"
MB^_:=\:ZC^T!_P`$J_@W\,OA+^T#\8/@X_PT\%^.OB#X!_:%T'XL^*?V?XOB
M?X0^!OP?^#&G3>+_``+X<U3P:YUB"Q8_\)C<66LZ_L!^P@']+OPZ_:;_`&+_
M`(K>(_!_A/P1\=?$E_K_`,2M`U3Q7\)+/5OB!\??"<7QN\*Z):V]_J_BCX"Z
MAXNU/0M-^.WAO3;"\L[^]UWX0WGC72K>PN[6]DNUM;B&5^$\%_MR_P#!/OQ[
MXJU'P=H?[1GBBRUC2OCAK7[,NH7/C+Q5^TO\.O#-O^TAX=95UKX`?\)M\06\
M,>"Y?C38F2#?\+H-?D\;2"ZLV@T25;ZT,WY-?M>_`_XX?MUZE_P1$\$_`+X+
M?'/X.:O^QW\>?@U^T#^T7XX^(_PA\<_![2_V?/`WPC\&^$+;Q1\/-%USQOX<
MT;1_BAXR\2ZC!/X2\.^'/@S-\2/#>KSZ$][K5];^#'M]8N?S]\4?LO\`[3/Q
M[_8,_P""S?[%'@/]F;]I#1?C_P#MG?\`!>?XR_'/]G7Q+\0/@!\9/A1X`T+X
M+:M\=?V>/'UA^TK=?%_X@^"O"W@G0O!B^$/AAXWM["73/$D_CG59;NUL/#_A
MK4IM6MXY@#^U+_A6OAW_`*"/C_\`\.O\4O\`YLJ/^%:^'?\`H(^/_P#PZ_Q2
M_P#FRKJM"L;[3-$T;3=2U2?7-1T_2M.L=0UJZBA@N=8O;2TAM[O5+B&W5((9
M[^>.2[EB@188Y)F2-50*!JT`<!_PK7P[_P!!'Q__`.'7^*7_`,V5'_"M?#O_
M`$$?'_\`X=?XI?\`S95W]%`'`?\`"M?#O_01\?\`_AU_BE_\V5'_``K7P[_T
M$?'_`/X=?XI?_-E7?T4`<!_PK7P[_P!!'Q__`.'7^*7_`,V5?!_[8?AS3O#^
ML>!X["?7;A;G3-9>0Z[XH\3>)Y%,=U8JHMY?$NKZM+:*0Q\R.U>%)6"M*KLB
M%?TOK\[OVW_^0Y\/_P#L%:[_`.E>GT`?07A,W?ACX.>$/%?B+XOP>"_"FF?#
M[POJ6H:GKMGX+TO0/#^F?V#IS*U_K>LVD,%M9VB.D1O-0NUW`*TTI=B3@ZG\
M<OA%HFA>'O%&L_MF?";2?#7BX0'PIXBU/QE\&+#0O$XNKFYL[8^'M7NKJ+3]
M:^T7=G>6L']FW%R)KFTN8(\R02JGXM_\%$KGQ!IO[9'_``0+UCXT+;I_P3WT
MCQE\2;OXYW_B%6;X5:5^T?)^S_:V7[(.J?%R6\0Z!I\5G\3;E7^&.I:])'I5
MGXN;4I;F:&\72G;B_P#@O]X>^$&H?`'X-?%CX":A\,;/XH_$O_@IQ_P3L\,^
M,OB3I&GP>+/#&K>*/A_XI\>+X"O_`!Q9^%_$'AF+QGJ/A.S\5/'K5C;^+]%\
M47?A*+1=!N/$.B6-KH%U8@'[GZU\?O@MX<U+5]&\1?MK?!W0=7T#3(M:U[2M
M:\<_!/2]2T31IS"L.K:O8WU[!=:;IDS7%NL5_>10VLC3PA)294W<_9?M5?LV
M:C8ZIJ>G_M^?L^W^FZ'%;SZWJ%E\4O@'=6.CP7<XM;2;5+J#5I(-.AN;DBWM
MY+N2%)ISY4;-(=M?R4_\%"]/^-&A?M8_\%SM/_:"^)7PE^)GQ!_X<,Z$P\1?
M![X/^*_@7X2&C2_%FX&F:6?`WC;X[_M$:V=8MI996O-7'Q!%KJ*7ME';Z#IC
M0M+??8W[(&D?#KXS?\$M/V8/A#^U5XA_9\\>>-?B7\-/^"8GPF^$OA7P)X@M
MYO&L/[`GB*3_`()3^$_B7X6\?:3=:O>ZM9&U^,T^LZ-XXGNH%T:Q\::[91Z%
M;Z6OB"YL9`#^EWQ1X_\`"/@CP9HOQ&\:?M0^"O"'P]\2'1QX=\>>*-6^%F@>
M#->/B&R?4M`&B^*-6^R:)JAUS3D>_P!'%C?3_P!I62/<V7GP*9!1\+_%+X?^
M.#XJ'@O]K'X>^+SX%2ZF\;+X7\0?"3Q`?!T-DK-=R^*AI,EX?#T=HJLUS)J_
MV-8`I,I0`U_#]^T)X,^/>@_\$89_@#^TKHFM6S?\$N?V[/AA^Q=\-O%GB%88
MM-^+-S8?M7^#=1\-_$_P[9W$K2II7@?]G:Y\`>!/`?B2"VM&N/#WCOXA:,"%
MCU**M#Q_/XK7]IW]J:[\41F[_8?TS_@YD\*:G^W4TR37?@BS^'5IX2\&-X`U
M#XW0P)+IX^`]EXWAFN/'DWBX?\()#K-KX3;Q,K>79[`#^XOP+XOT'XH6$>J_
M#3]I/PO\1-+FDU&*'4O`MY\,O%NGRRZ/)8PZO%'>:`FH6\DFES:GIL6HHDA:
MQDU"QCNA$]W;B3=U.:XT30=3\4ZS\<;/2/#&B'4!K/B/4[3P%8:#I!TF]FTW
M5!J>KW5I#I]A_9FHVUQ8:@+NXA-G>P3VESY<\3QK\]_%#XB?LU^!D\5?M/\`
MPXLOAK\1OCEX,^$\?P9\$_\`"!ZYX3.L^.+CXG^,?#$'P=^!EUXEM-0M="MW
M^(/Q<LO"VA?#ZU\4ZS8:9HM[K>O:G8W&EZ1=^)]0'XI_\$W_`(B_$G]GKQ__
M`,%8O^";7[1LWQ'T?QI'H_Q'_;]_9Z/QLU;X>7GCWQQ\'/VE="\03_&:_@D^
M&WC_`.(OA$Z;X3_:"L?$]Y<P:9XGU&:.]\:W]Q>R13K=VMF`?T/>`_$.G?%3
MP_%XM^&'[0^@_$?PK/<SV</B7P%)\./&'AZ:[M0AN;2+6?#T.HZ=)<VXEB,\
M"7)FB$D9D50ZYZFYT7Q+9&V6\^*UW:->W4=E9BYT+P=;F[O94DDBM+82Z:AN
M+J2.&5TMXM\KI%(RH51B/PW_`.#?[]H;X,^$?^"2/_!,7X6ZI\1/"4GQ,^)G
MASQ9X$\&?#ZQ\1:'=^,=6\0:=XI^,/CS6X5\/C48]1AM_#_@GPGXC\4:U<30
M(MII>E2[5FO+BQM+OD?^"\7BW]H;Q3\-[SQ3^R9X:^)7B_Q3_P`$UM>^&O[<
M'BB^^'_B'X:6G@JV^(_PZ\2Z1XU3P'\5K/7/B-X9\=ZM;:3^S98?%GQ1JO@#
MPEX0\=7.NQ?$KX:7M[H8%SH\DX!^XUYXJT73_'FD_"R__:/\-6/Q.U_3[K5M
M"^'%Y=?#2V\>:UI5C!<75[J>D^$)HX_$&I:?9VMI=7-U>V>G36UO!;7$TLB1
MPRLOG.N?M%_`KPQ!<7/B7]N'X*>'K:SUFX\.7=QKGQ`^!VDP6OB"T222[T*Y
MFO[^WC@UFUCBEDN-+E9;Z%(I&D@548C\B/VP?@?X)_X*WR_!'X\_LH?$^T\`
M?M$^&_V./"'[7G[`OQYLM1@@UGX;_$FX^(EIJ>F:9XGBLCJ:OX-\96LD_P`,
M?B_X9U+3];TR`370U/0M4U;PU9V(_.']I'XU_$7XM_LI?\$D/B_^T;\-W_9\
M^+E]_P`'.G[*DGQO^'/B.YAL;;P'XZ\":G\5_"OQ&D2]O)E@7PB=<\/:EKF@
MZK/=3VLGA2_TF^;4;J"5;V<`_KS\*W$WCO0[/Q/X(^.=EXR\-:B';3O$/A6U
M\`^(=#OUC<QR-9ZMI%I>6%T(Y%9',%PX5P5;#`BNB_X1CQE_T4O5?_";\)__
M`"KK\$_^";5K<7__``68_P""O?C']G3^QI?V&=?T+]G&'5=8\!)`WP=\2?MD
M6/@ZRA^)U]\/;_1S_P`(=JGC+3K%=:L_CK>>%6GO/^$SGT2/QM/_`,)`D0/]
M%=`'`?\`",>,O^BEZK_X3?A/_P"5='_",>,O^BEZK_X3?A/_`.5==_10!P'_
M``C'C+_HI>J_^$WX3_\`E71_PC'C+_HI>J_^$WX3_P#E77?T4`<!_P`(QXR_
MZ*7JO_A-^$__`)5UQ'P^\.^+)M!OW@^(.I6B+XW^)L31)X?\,S!YH/B1XKAN
M;HM-IKN'O;B.6\DB4B&&2=H;=$@CC1?=JX#X:_\`(NZC_P!C_P#%C_U:7C*@
M`_X1CQE_T4O5?_";\)__`"KH_P"$8\9?]%+U7_PF_"?_`,JZ[^B@#@/^$8\9
M?]%+U7_PF_"?_P`JZ/\`A&/&7_12]5_\)OPG_P#*NN_HH`X#_A&/&7_12]5_
M\)OPG_\`*NC_`(1CQE_T4O5?_";\)_\`RKKOZ*`.`_X1CQE_T4O5?_";\)__
M`"KH_P"$8\9?]%+U7_PF_"?_`,JZ[^B@#@/^$8\9?]%+U7_PF_"?_P`JZ/\`
MA&/&7_12]5_\)OPG_P#*NN_HH`X#_A&/&7_12]5_\)OPG_\`*NC_`(1CQE_T
M4O5?_";\)_\`RKKOZ*`.`_X1CQE_T4O5?_";\)__`"KH_P"$8\9?]%+U7_PF
M_"?_`,JZ[^B@#@/^$8\9?]%+U7_PF_"?_P`JZXC6/#OBM?'7@B)_B#J<D\FF
M^,6ANCX?\,J]LL<>A><B1+IHAD%P'0,TJ.T?E`Q%=[Y]VK@-<_Y*%X!_[!7C
M?_T5X=H`/^$8\9?]%+U7_P`)OPG_`/*NC_A&/&7_`$4O5?\`PF_"?_RKKOZ*
M`.`_X1CQE_T4O5?_``F_"?\`\JZ/^$8\9?\`12]5_P#";\)__*NN_HH`X#_A
M&/&7_12]5_\`";\)_P#RKH_X1CQE_P!%+U7_`,)OPG_\JZ[^B@#@/^$8\9?]
M%+U7_P`)OPG_`/*NC_A&/&7_`$4O5?\`PF_"?_RKKOZ*`.`_X1CQE_T4O5?_
M``F_"?\`\JZ/^$8\9?\`12]5_P#";\)__*NN_HH`X#_A&/&7_12]5_\`";\)
M_P#RKH_X1CQE_P!%+U7_`,)OPG_\JZ[^B@#@/^$8\9?]%+U7_P`)OPG_`/*N
MC_A&/&7_`$4O5?\`PF_"?_RKKOZ*`.`_X1CQE_T4O5?_``F_"?\`\JZ/^$8\
M9?\`12]5_P#";\)__*NN_HH`X#_A&/&7_12]5_\`";\)_P#RKH_X1CQE_P!%
M+U7_`,)OPG_\JZ[^B@#@/^$8\9?]%+U7_P`)OPG_`/*NC_A&/&7_`$4O5?\`
MPF_"?_RKKOZ*`.`_X1CQE_T4O5?_``F_"?\`\JZ^#_VP],U?3M8\#KJ_B*Y\
M1/+INM-!)=:=I>GFU1;JQ#QHNF6ULLHD)4EI@[*4`4@$@_I?7YW?MO\`_(<^
M'_\`V"M=_P#2O3Z`/LCX:65GJ7PB^'MAJ%I;7]A>?#KPC;7=E>P17-I=6\WA
MO3DE@N;:='AGAD0E9(I49'4E64@D5IZO\-/AQX@LM'TW7OA_X)UO3O#T$MMH
M&GZOX5T+4K+0[6=;=)K?1[2]L)H-,@F2SM%EALHX(Y%M;=75A!'M_G*_X*AZ
MEK&G?M-?\$$=#T;0OB#XMTOXG>/OB=X0^(GPX^&?C.W\":Q\7/#&A_L^:3KN
MA>%-=U+4?'/PXT#5=+\/:Y=77B33+7Q/XKLK+2KIM1O=*)U.\-O>_*OQ1^&/
M[<?[-7Q@_P""''PP^-_Q`MOB[\8?B'^V7^V:EWX(\7_'+Q_J'AV]^!C>$[_Q
MU\$OV?\`XU?'"X\'>-?%WQDMOA!IE^UU:^(O&'@GQTMOXCDFT[2GO=/MX?$5
MP`?UCW7P3^#-[.]S>?"/X8W=S+L\RXNO`7A6>>38BQIOEETEW<I&BHNYCM1%
M484#$'_"B?@A_P!$;^%7_AO/"/\`\IZ_D2TWX%_M`_M6>(O^#@KPUH?CR^^"
M_P"T3^S!^T#^SW\6?V9K+P3\6_&GBKX5_#CQ7X%^#.H_$B^^%-E+J_ASP%I^
ML_!GXOFTO-'^(O@W5_AMIO@_4[[78M;UCPIK-WX:TNZ?ZV\/?%WX^_\`!53_
M`()R_!G]O'X!>*_`W[-W[27[2_B#X4?#_P"$OPL\5^,?&GA'P-\6;;]F[QUX
MT\0_M#_`/5_'W@*]B\8^";;]HKQA\)OC!X?T_P`5:-JEOXBN?@CX0\">$KC4
MO#&H>-/'$+`']+VO?#_P'XIM[2S\3^"?"/B.TT]WDL+77O#>C:O;V4CPPVSR
M6D&H65Q%;.]O;6\#O"J,T,$,1)2)%6#P_P##;X=>$Y;R?PKX!\%>&9]0M6L-
M0F\/^%="T:6^L78.]E>2:=86SW-HSJKM;S,\+,JL4)`-?R9_M6?M/^(_&?\`
MP1E_X+`VM_\`#O\`:%_9,_:T_9@\=?#J7XD?"+QY\8]9^*-Y^S?X^\0>$_V>
MK'PT/V:_CWI_B'4+V_\`A5XO\"17'C;PY-HE_P"'Y]-_X6+XKL+?1+/PKK>E
M3ZQ]3?\`!,CQ5XL_:Y_;6_;W^'G[0^O?$'0?#W[%_AK]D+X?_LV?`;PY\2/&
M_P`-O#'ACP-\1OA%J7C36/C]<Z#X!\1>&)O&?CSXO:[`OB#3_B1XE;6-8\+:
M=/)H/AF_T@7FK"^`/Z)[KX;?#J^T&U\+7O@'P5>>&+&];4K+PY=>%M#N-!L]
M19;E6O[72)K!]/M[UEO;Q6NH;=)RMW<@R$3R[ZNK_"KX7^(-5N]=U[X;^`M;
MUR_0)?:SJ_@_P]J6JWJ+9IIZI=ZC>:=-=W"+81QV*K-,X%FB6P'DJ$'X<?\`
M!5#X@?'S]EO]A>X^$G[%GQ/^-GCKX\^!)?$G[4NF^.6\)?&;]HWQ?J/PZ^"_
MQPL_C#_PJ/QSXT\!:)XXU;1W^)5RS?"?0?$GQ4U#3?#GC+P!X%^)FB:YK5S-
M9:M;'QC]OC]I3PK^T_<?\&^/[1/P?UO4;3X<_M:?ML?!H^(K#3M6NK1/%?PW
M\9?#;Q!XCU;X3_$:VL)K:W\3:-HWB*&73?$GA#7X;S2(_$&DWL=SIXG24$`_
MHLT3X3_"SPSJEKK?AOX:?#_P_K5EY_V+5]$\&^'-*U2T^TV\MI<_9;^PTZWN
MX//M+B>UF\J5/-MYIH9-T4CJUV;X<_#V=_$,D_@3P;,_BWRSXK>;PQHDC>)O
M*G^U1'Q"SV).M>7<_P"DI_:1N=DX$R@28:N&^*'A#P#^T)X6\<?!;5O$FM+9
MZ?K?@-?B!;>"O$6M>&M<LET_6_#/Q&@\(WOB3P]=:?JFD#Q9H5A86NOV.F:I
M9:TW@[Q,DOF6<&MZ==3_`,_/_!/S]GOP3\9?^"@O_!8KX?>--6^(=]X1_9L_
M:^_90N?@MX?G^)WQ"U#0?!.@6WPTLO&_B7P-9>']4\37NAWG@CQ]=V=UIWC+
MPWJFGWVFZM9:G=3&"/48;&\M0#^C70?A7\,/"VI1:SX8^''@+PYJ\$<L4&JZ
M#X/\/:/J4,4\;0SQQ7VGZ=;W4<<T3-%*B2JLD;,CAE;%6O$7PY^'OB^>"Y\6
M>!/!OBBYMS*;>X\1>%]$UN>`SK`DYAEU*QN9(C,EM;I*49?,6"!7W"*,+_$_
M_P`$H?#WQR_:+_X(]>%_B+JOQN\>_LN?'N]^$OB/P;^SU^WMXW^.GQ#\1K\7
MOC3^T9^U)^VQ^S4?!'CO2SK^KW&GQ^!AH7P2\-^&O$DNBW_B_P"'MW<Z+\0?
M"5Y9VFFW-O/^NW[$.I:]\>_B+^T7^PE^V9\%?CC^RQ^T3X.^&/[)'Q+\:_#'
MPI^TE\1?BQ^SG\1OAA\,_CKX\\1:%\9/V>/B?=>-;_QGX1T'XY>+M'OO`_QE
M^'NL7&C:UJGA_P`.Q:-KE_XIU@>-YK$`_H4L[.STZTM[#3[2VL;&TB2WM+.S
M@BM;2V@C4+'#;V\")#!#&H"I'&BH@`"J!BK-?QC?L(_"O6?C/X4_X+P3)^T]
M\2/@'\2?V<O^"H'[67PF_94^/FN_$_XDZSX?_9PTFVO?$7P_^'>AW.CWWB2^
MTD_"OP]-XDMX[G3M2L;C3/#*1VOBVW-EJ/ARPU&S_4;_`()??%OXP>'/VF/$
M/[&G[7GP9^)OP(_:R^&7[+FE^-;B'2?CUXU_:)_92_:,^&ME\0=&\(:C^T=\
M)O$7C;Q'JOB/X?>/-;\<W4MAX[\%^,-/@\7:O%?Z?K.IZGJ-]8:H(`#]\Z**
M*`"BBB@`K@/AK_R+NH_]C_\`%C_U:7C*N_K@/AK_`,B[J/\`V/\`\6/_`%:7
MC*@#OZ***`"BBB@`HHHH`****`"BBB@`HHHH`****`"N`US_`)*%X!_[!7C?
M_P!%>':[^N`US_DH7@'_`+!7C?\`]%>':`._HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`*_.[]M__D.?#_\`[!6N_P#I7I]?HC7Y
MW?MO_P#(<^'_`/V"M=_]*]/H`N7_`.SK\'/C:G[-_P`4?B?^SQX^\<>/_@;X
M2\.7?P=\;6GQ"M-`?P'J5SH%M;ZAXG\!VVE?&GPV/#NL>(+*466JZ[%I&F^(
M]9T*.PT/7I9=.T^TTVT[CXM_L]_"'X[?$7X8?%GXJ_LW?$;Q3\1/@I=W.H_"
M+Q1_PL32M#O?AMJU\LT>I:YX,@\-_'+1[#P_X@UBTG.F:WK^G6D&M:WHT-EH
MNK7]YI-A965O\F_M#?%KXL_`WQ=^QA\3_!'BGQ`OPJ^'W[,OQ/\`BU^TQ\,;
M7=J6D^/?@S\/M8_9;\%>)?$EKI<D%Y-8>)_@KX7^-WC/XTZ=)X6BM-=\;+X#
MC\!7S:E;ZIID6G]CX^^.OQ!\4?\`!0[]G/P;X0\8ZO\`\,[6/PX_:3?6O#OA
M2]L;.S^+GQ9\`>&_@SXQBU&?Q`EU#'K?A7P/I'C[1]!T*UM==TOP]>^,]3^(
MFE>,[?4AX=TQM.`/6O"_[)?P"\$ZU\;O$GA/]F;XJZ!XA_:2@$/QXUW3?C!<
M0:Q\571(((+_`,8ZD/VA#>:KK-GI\+:'I^NR3+K6G>&KO5/#%A?V_A[5]5TR
M\;\._P!D#]F+X5?"+PY\`?!/[%<MC\$?!OBB[\:^#/A/K%S\/?%WP_\`!GBJ
M^.OR7>N>#O"WC#XM:]I'A2]N+SQ5XDU>1O#]KIR-K^NZKXAV#7+VXU!_#_B)
M_P`%%O%Y\#ZK-\//A?H^E_$7PM\=_P#@F5X.\1:/XK\:KJ'AIOAU^WS^TM\+
M?@W%/I_BKPWX8UG3=2\5Z#%XD\5Z'K7_``C\>O>$-.GLX?%'A?QIXTBC@TF[
M^F(/VP[75_BQ>?#+P=\)OB'X_M?"?QLL_@!\4?%O@S0O$FK:+\//'%W\*=#^
M*,VO7NIOX7MO"EY\.=%_X2GPWX+\2:_<^+M(\4:-XIU8/+X&F\/6MSKJ`'/>
M*_V2OV;_`!M\%/$'[.?B3]CS6+SX*>,=<C\3>//A_:ZYX,TC2OB/K\<-K`=6
M^)USHWQBT_5OB7>SKI^DRWDOCS4/$)OKO0_#U[>">\\/:)/87[_]E[]GO5M0
M\":UK/['VI:YXD^&OANW\%>$?%^O:AX`USQO:^!K2Y:\MO`.K^-]6^+=YXM\
M5^`(+HI<1^!?%FLZWX266"T<:/FSM?)\1TG]O^\\6:?^S/X^UCX">-=&\(_&
MOX[?'7X5?#H>'/BYX>DU^X\:_`OX(_MM>,O%FF^/_"]PGA?PQ=:+K.E_LO\`
MB&'P99WWC#5/#S^(_%'@_P`2Z_>^%[SPBLHY7XZ?ME>)/'/POUI/`K^(/A/\
M0/@W^W]_P2K^%WB^?PYXBM=?T/Q9X"_:;_:Q_8XM?$6DV7B+^Q;"#6_#GBOX
M5?&GQ)X+\1#3;0Z=<74-U=^'?$6N:#=Z?JUZ`?9MK\*/`NG>+_''CO2?@-\5
M-$\3_$7X>Z'\*O%5[H'Q)TK0+.?P!X7MKRT\+>']%T31OCC8Z'X2C\*1ZIK<
MWA74/"6FZ'JWAJ^\2>*M2T._T_4/%7B*ZU/Y;MO^":/[#EEX'^&OPRLOV&_$
MUE\.O@SXLU'QY\(?`UG\2%M?"?PM\;:M/+=:EXL^'F@0?M!1Z9X-\17EW<WM
MW-K'AZVTZ_-YJ&IW:SBXU._EN.^_:;^)T_PP_:]_97OM=^(?B7P?\(6^#'[8
M'Q&^+FEVOB#6+/PIJ&G?`W0?A7XET'7M>TFQE82IX5MO%'BV^NEL8HCKEM-!
M9:]!K5IIFDVMGXUJ/[9FM_#_`/:6^*7Q&^)5QXFT?X%V?[!G[//QD\(_#:RU
MBW\2-)XK^+'QT^(/@?0E32K+2+$V'Q"\3SOX-\(ZG86U_P")M$M[EK$Z1XCO
MX)+TQ@'V9\#_`(3?#K]F_1O%F@?!7]G#QIX)T[QWXSNOB)XS,7B;P9KNH^*/
M&]YX>\-^$[CQ+KFM>)_C!K6LZCJ;^&O"'AG11+<W\BQZ?HMC!$B+$=W`?#K]
MEGX(?"7Q)\7/&7PY_9S^+_A/QC\>X(8_C-XNTWXSWI\4_$F[M((+33]>\5>(
MKG]H>XUG4O%VDV,`TW1/&DEZ/%NB:5/?:5I.M66G:EJ%M<Y&J_MM^*M,\9?#
M+X>3?LV_$#3O%'Q<_:7\5_LS^!=4\77FI>`_`GB#5M&_9(^)G[6NA_$;2-8\
M7^#M*\8W_P`.M0T7X6^*OAQXDO8OAXGB'PQX\T#Q+!8^'O%.F6/AZ]\6<7X(
M_;A\>_%;XL_LH>$_"?PZ\/Z!X>^*FO\`[=_@[XPVFL>,+J]USPSX_P#V&_BU
M)^S[XZ\.^#[R#P>-.\3>&[KXCV7B;4]`\27A\)WOB#1](T*6YT[P['J>H6L0
M!A>#_P#@F7^P5X#L/!.B>&O^"?4$'A?X<:MJ6N^!?`^J:QX5\2?#OPOK&LQ:
MS#J^HZ3\.O$OQKU?P-!=:FGB'73?R'P\QNY-8U*:?S)KR=W^L?AM\,/AS\'O
M^$L?X7?LP:QX%O/'+P-XMU;PY+\+M.U_78K'^T%T:QO?$47Q._MTZ5X:BU74
M;;PAH\6H1Z5X.LKR>R\+6>D6C^17Q;\`/VX/BW\8OB!XE\-_"_X-VNJ^%M`_
M9I^(GQD\/>$O''Q?O&^(GBOXF:?^TY\=_@VO@R]\4W?@_P`0:+I.BRZM\')[
M/PS<_P!K7.GZ-I7BFWCNUEM-"LK>+[P_9X^.J?M#>`?`WQ.T'0M.L/!OCCX5
M?#OQY#<Q>(+[4-5T?Q5XSTVYU77?AWJ^DW?A;1'L=3\$6W]F0:Q+?W%EK2:E
MJ,FG:GX5T.>R8S@'@/PX_8V_9C^$UG\8=+\#_L=>(+'1_P!H37[_`,6_'70M
M9\4^&?&'A[XP^+=7U.+6-:\6?$KP_P",OC5K^B^,_%>NZA$)=?\`$OB"QO\`
M7->AENK/5[^]LKR[MYO7_AG\+?AG\&M4\1ZY\+?V5[WP/K?BV+3[/Q!K&@V_
MPDM=5O\`2='FOKC0_#O]HGXD27EIX2\.SZIJDWAKPA936WACPY+JFIOH>DZ>
MVHWIG^H:*`.`_P"$R\1?]$H\?_\`@Q^%O_SRJ/\`A,O$7_1*/'__`(,?A;_\
M\JN_HH`X#_A,O$7_`$2CQ_\`^#'X6_\`SRJ/^$R\1?\`1*/'_P#X,?A;_P#/
M*KOZ*`.`_P"$R\1?]$H\?_\`@Q^%O_SRJXCX?>*]>@T&_2+X9>-[U6\;_$V8
MS6U_\-TC22Y^)'BNXFM&%Y\0;28W%A-*]C=LD3VKW5M,]C<WMDUO>3^[5^=?
MQ,^-WBSPC\6?V/OV>/"MW/X<A_:<_:$_:NLO%_CBUL[2ZU'2?!WP:TGXN_$^
M]\+^&IM2@N],TWQ1XXUS3_#VGMJ=U8ZA<V7@>P\>2Z%!IWB0:/XE\/@'VK_P
MF7B+_HE'C_\`\&/PM_\`GE4?\)EXB_Z)1X__`/!C\+?_`)Y5?*'Q0^)?Q!_9
MC^*'PM\*Z1%XJ^.=A^UE\3F^#?P8\(^+_&FA:!IOPD\;^`OV9OVB/C]K%IJO
MCB;PQJOC+6/!_C?1/@/>+_;/B1?B%XPTCQ/JE_))J-QX>30/#MCJ>%?VV/"?
MB6+]G/Q,OA>ZC^%_[4WQ(\5?"'X3^.]/UJ+599?'/AS0OBGXGTN;Q-X?_LRR
M?1O!OCO0?@]XMNO!OB.TU75]2:[O?"VF>*_#7A6]UFXCTL`^F_\`A,O$7_1*
M/'__`(,?A;_\\JC_`(3+Q%_T2CQ__P"#'X6__/*KY!\)_M[^%/%OPR^*'Q0L
M/!&KS6'PHB^&</C?PIIMQK>L_$OX<:_X^\37.B>(_"GQI^%6G^#V^)WPMU_X
M/Z&=)^('Q+AN/!WB"VC^'^H7'BKP7=>,M)T\W5UWOAW]N/\`9AO=)^#2^._V
MA?V=/AKXK_:,UG5M%^`?A;4?VAOA1>7_`,<$7QU<>!/"FJ_!&:?7-/F^*4'C
M>YF\.WOAVU\+:5?ZG]J\4Z-X?OM.AUZ1].(!]`_\)EXB_P"B4>/_`/P8_"W_
M`.>51_PF7B+_`*)1X_\`_!C\+?\`YY5?BQ\-O^"AFL?`_P"!WPY\3_%CP]\5
M/C;XQA^!W_!1CXSCQ%'X\TC3K77_``I^S?\`MT?"+X*W_AK7-%OI+/3;_P`5
MZ=HGQ@^'3>$/$EW8!-$\/Z1XJT33#&?$%_&WM?[6_P"V;XBT+X2_%*\EN-9^
M!?C+]ES]O_\`X)K?#WXG7OACQ#)XNTK7_@[\<_VK_P!D.3Q*QO[;PO8:A>Z9
MXN^"7QA\3^%/&OA2TT5M1TS7['6=.T;5/$FCG1=?UP`_3S_A,O$7_1*/'_\`
MX,?A;_\`/*H_X3+Q%_T2CQ__`.#'X6__`#RJ^0_&_P"W&?"0U#2]`^$VL?&/
MQL/@YJ_[1WACP/\``O5==^*.J>-O@BVL_P!E_#^_\/:IH?@'_A'V^(GQ4BM-
M;;P=X8O=4M_A]-J.DFQN_B_#9WMMJQ\A_:)_:QUWQF/A9=?`G4_$&A^%_!O_
M``4?_9T_9G^*/B>+5X="O=>U&\\;>#+;XF>"6\+SZ3>WU]X3ME\4OX%\22:A
MJOAK6X_%VEZO:P:!?^'[2VUW4`#]&O\`A,O$7_1*/'__`(,?A;_\\JC_`(3+
MQ%_T2CQ__P"#'X6__/*KQ;]I;]J3P_\`LV'P?%XAT:&5?'-GXMCT#7?$FN_\
M(+X`N/&&@_\`"-P>&/A???$?4M(U#P?X:^(WQ7U'Q(NF?"S1_&FI^%])\77^
MBZ[IMGKRZQ;Z?IFI^5:5^U5\2H?C+^V1X6UKP#X8U#P5^S[\1?V:?AIX*.E>
M.;'1]5U*3XV>'_AQJ^J>,?&5SXLTC0])TC1O#1^)QU;Q!!H^M>(]>'ASP7+8
M>!_"?C3QIJ]AH>K`'U]_PF7B+_HE'C__`,&/PM_^>51_PF7B+_HE'C__`,&/
MPM_^>57Q+I'[?MUXSLO@7:_#SX)ZGKOBWXX_&/\`:^^`NGZ9XB\;6O@WP]X=
M^(_[&7BSXT>"/B+!J>MWGAG4?$CZ!XB\1?`SQ9%X.U-_`MGJ<ECJ&@7/B/0?
M#MS<:G8:5Y1^U/\`M=^//&W[`_Q7^/WP2T3QKX(\%>*_V7/"W[1?P#^/OA;Q
M-X;>35])\4ZGI&I:!H6K:->"VUWPAXLUGPEJFB>)(+..TUG1Y-$UB_L+WQ1H
MVOZ5<:9(`?IC_P`)EXB_Z)1X_P#_``8_"W_YY5'_``F7B+_HE'C_`/\`!C\+
M?_GE5YM\$_CO<?%3QG\?/AOK_@\>"O''[/\`\0?#_@[Q#86GB%?%>CZQI'C7
MX<>$/BCX,\2:7K0T7P^Z37GA_P`7Q:5XAT.XTT/H/BG1-;L['4?$/A\Z'XFU
MKZ(H`X#_`(3+Q%_T2CQ__P"#'X6__/*KB-8\5Z\_CKP3.WPR\;Q2PZ9XQ6.T
MDO\`X;FXNUECT(/);M%\09+14M=BF<75U;2,)H_LR7!$PB]VK@-<_P"2A>`?
M^P5XW_\`17AV@`_X3+Q%_P!$H\?_`/@Q^%O_`,\JC_A,O$7_`$2CQ_\`^#'X
M6_\`SRJ[^B@#@/\`A,O$7_1*/'__`(,?A;_\\JC_`(3+Q%_T2CQ__P"#'X6_
M_/*KOZ*`.`_X3+Q%_P!$H\?_`/@Q^%O_`,\JC_A,O$7_`$2CQ_\`^#'X6_\`
MSRJ[^B@#@/\`A,O$7_1*/'__`(,?A;_\\JC_`(3+Q%_T2CQ__P"#'X6__/*K
MOZ*`.`_X3+Q%_P!$H\?_`/@Q^%O_`,\JC_A,O$7_`$2CQ_\`^#'X6_\`SRJ[
M^B@#@/\`A,O$7_1*/'__`(,?A;_\\JC_`(3+Q%_T2CQ__P"#'X6__/*KOZ*`
M.`_X3+Q%_P!$H\?_`/@Q^%O_`,\JC_A,O$7_`$2CQ_\`^#'X6_\`SRJ[^B@#
M@/\`A,O$7_1*/'__`(,?A;_\\JC_`(3+Q%_T2CQ__P"#'X6__/*KOZ*`.`_X
M3+Q%_P!$H\?_`/@Q^%O_`,\JC_A,O$7_`$2CQ_\`^#'X6_\`SRJ[^B@#@/\`
MA,O$7_1*/'__`(,?A;_\\JC_`(3+Q%_T2CQ__P"#'X6__/*KOZ*`.`_X3+Q%
M_P!$H\?_`/@Q^%O_`,\JO@_]L/5]1U;6/`[W_A?7?##0Z9K*QQ:[/X9N)+L/
M=6):2W/AKQ'X@B58BH6074ELY9U\I)%#LOZ7U^=W[;__`"'/A_\`]@K7?_2O
M3Z`/=_!?P=T#Q0WP%^+FH:SXC36_!7P(G^'6GZ#;S:*_A+4?"GQ(L?A_K'C?
M3M<TF]T.\N=2.O7_`,/O`TDDSZC')IZ>&;:'2&T^+5/$:ZUP-M^P!^SKIVG?
M!SPWHFE>)-"\"_`SX8_$OX/>!OA]IOB!CX6/@+XRVUK9?%;2=?\`M]I?:_KD
M_CBRL-.M]1U.[UW^TM+:R6]\-76AZE>:G>WWTS\)_P#DEOPU_P"Q`\&_^H[I
MM=_0!\1VW_!/G]FV#0O$>@S:=\1M27Q3IO[--EJ>KZS\7_B7J_B);_\`9!\?
MP_%#]GGQ)8:UJ'B:XO-.\3_#SQQ9:3KEGJUG)$^IR:-I]KK,6H60N[>[[FQ_
M8]^"VD?&OQ%\?="B^(>@^.?&+:!J/C72])^+?Q-M_AMXX\8>$O#6C^#O"?Q(
M\;_":3Q5-\-?&/Q)\.^%O#OAW1+#QIXD\+ZGK-Q;^&O"MSJL^HZCX1\+7NC?
M4=%`'P-XB_X)O_LZ^,/A+\//@;XMD^(/B+X8?#;QE\;/&^C^&[_Q5!%_:FJ?
MM$>!/C+\,?BY:>(-4T[1['6+_2?$_@#]HCXY>&([2WO[*31;3XDZE>:%<:;J
MWA[P-J/A7HM7_8(^!^KZ?XHM)-5^*Z7_`(X^)/[-WQ>\9^(KSXF^(_$_B#Q-
M\1OV3?$'@SQ=\$?$^HW?C67Q/;17?ASQ9\./A_K^IP:?9V-EXGG\(:7I?B&V
MU'P]<:QHNJ?:]%`'@7Q&_9R\!?%/XH_#WXK^+KOQ!>:O\-?"WQ!\%Z#X=6XT
M>7P7J'AGXKVVDV'Q(TKQ+H%_H=\/$%MXOTO0-"TN^34+J1=/L]+B.@C2;N]U
M:ZU'QC3?^"='[*MIH7BGPOJ_A3QMXV\.^+_@1;_LRZMH_C_XO_%?QE9I\#--
MUG6-;T#P)I_]M^,;J>Q'A6[UJ<>%/%,,P\;^'?LUG=:5XFMM3CGOY_N2B@#Y
M`TW]BGX6Z2WP/N8/%_QKU36/V?\`XHZM\8_`_BCQS\7/%?Q5\87OC[6/A5XW
M^!TVI>*_%OQ8N?''B'Q!I]I\)?B7\0?!6F^'Y]1BT"PM_%^J:_;Z:OB^'2O$
M6G/\"?L3?!GX?7?@75M&N?'EQXB^&_Q/_:(^+?A'Q+>^+[J#5K#Q5^U9XWUK
MXH?'FWO$T2VT?2M;\-^._B=K^I>/+GPSKFF:CHVF:N]MINCVMAX5T^P\.VWU
MY10!\9_#+]C/X:?L[R-XV^#.F:[K?Q,\.>`?B)X4\*Q>.?B9X@T+P]XFA\8^
M//%?QAB\,^.M0\/^'M;M8]#'Q4\9^+M9LO$<O@+Q?J_@Z#QEK;:/HVK6MAH6
MA6?O7P@^%_AWX2^$;SP_X=\/Z/X:_P"$A\:?$+XF>(],T*XO+S2QXW^*_CC7
M_B+XUGM;V_@M+J]AF\3>)=2\F[>PTM)X%B:#1]'M_*TRT]2HH`****`"BBB@
M`HHHH`*^9M6^"'PW^.O@&RT3XC:-?7I\(?&OXB>/?!/B#0/$7B/P7XS\"^-]
M&^)/Q"L-/\6>"O&W@_5=#\5>%]:72=8UK0+^XT?5K6/6_"^O>(?">O0ZGX8\
M0ZWI%_\`3-?*NJ?M`?#KX(V7P[T#QN_BN7Q!\;OCE\=_AY\+M%\*>!O%_C.]
M\5>-O#?_``O/XRZAX<C?PSHVIV.D7TGP_P#A=XWUFP?7[S2K2^_L2Y@M[EGC
ME,0!8OOV2OAUJGB/X)>,-4\1_$[5O%GP&^)$OQ8\(^)->\<7OB36M3\:3?##
MX@_!F2Y\2W_B*WU:6ZT1?AG\6_BKX:M?"6D'1/"FG2_$/Q)XETW1K/Q>VE^(
M-,Z+P3^S'\(/A[=Z*_A?0KZTT;PG\0O&OQ8\"^$KK6M3U+PM\/\`XC?$=/'$
M7COQ/X*TR_N+B30CXAM_B1XWM4T"WNF\*>'+7Q)J]OX/T'P[%J-ZMQP%Y^W5
M^S?9?#OPW\5W\5ZV?`&O:#X@\47^OR^"_%>G)X'T'P=\0M&^$WC6Y^(=AK&D
MZ;JG@[5/!7Q,UZQ\%>*O"&K64?C?1M7M?$,ESX:&F^#_`!??Z%Y3\</^"DWP
M?^%L?QVT3P=X1^*OQ8^('[//Q'^&?PA^)WAWP_\`#WQ'X?T+P=\0/B\GPSO?
M`]EK_CKQQ:>%O!_]DZEX?^+?@SQ1;ZMI&M:G9ZKI5]]GT6>_U-DLR`>]:!^R
M3\(_#5IJ*Z4?&\6OZGX<^`?@VY\=R^._$DWQ!F\(?LP^*]6\;_!#PWJ/C![T
MZQXBTWPAXF\1>*+_`%!O%4^NWWCJW\5>)-(^(E[XLT75[K3G]7^&WPM\&?"+
MP:?`OP^TS_A'=#E\0>/?%]PMNR2W%UXQ^*'C?Q)\2_B#XIG-Q'+:G5O%7Q`\
M7^)O%NI1QVL>F)JFL74=EIUKIRP6,/C\/[4'P[A^+WCCX3W'B'5;KXA:!#\,
M-,M/A&O@C4M+\3#Q1X]\&_$[XA6&EZ/XJU"^C\(>.;C5O!_PW\4ZM=76A:FO
MA?PG!X.U5-4\2S3W#I9^#ZA^W;X9TSX^_#-=2\8>%M%_9@^)W[(B_'+P]X@\
M3^%/$_@WQP_CGQ)\</@[\*O`&CZFOBR]TN^T@>))?BE8:)%X-USP3X>\1Z-X
MHN!!KUY&4EL].`&ZO_P2\_9XUWPUI7A#5?$?Q?NO#VB^`/CM\+=,L!XPT:!K
M?P)^TQ\5/`/QK^-VA->VWA.'4+C_`(3?XF_"_P`">)7U.YNYM8\/#0(]%\*:
MAH7AZ_U72;[U+Q9^P[\+/&NH?$75=>\5_$V;4OBI\7/V=_CEXRN[;6_#=I]N
M^)?[*NN^!/%/P0UVTMH/"*V6FP>%?$WPO^'>N7>CV-M#H_B2Z\)VEMXDLM5T
MS4_$-AK+?#W[?G[,/C#PKK'BGP;X[D\8OX;USXS>&/$OA7PIIESXA\;:/XD_
M9YM=.OOC/X?A\+Z4;G4/$^M^"K'6M#U&/2O!"^)[_P`9:-KVA^(/A[;^+O#^
MK6&J3^[?&3XU_#[X"^%M%\9_$O4-7TSP_K_Q)^$_PDTRZT?PKXH\6SR>.OC=
M\2O"WPC^&VEW%CX4TC6;VQM=?\?^,_#?A_\`M>]MX-)LKK5+47EY"9HED`/F
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M4\2>'+F#4#I]Y)<Q@'T!\9OV?/AO\?=+O=`^)MIK.M>&-;^'_P`0?A3XL\)0
MZ_J=EX5\:_#GXJ?\(POCSPKXK\/PS_V9JD.M6WA+2K&VUL6\'BKP[83ZW:>%
M]>T6'Q'KRZCPOCO]C7X&?$/Q%\0_%FN:9XOLM?\`B?XF^#/CGQ1?^&_B)XW\
M,D>/O@#JV@ZO\+?'6D6^BZY9VNC^*-!D\*^&-/N;ZR@CAUK0]#MM$UFUOM,O
M-7MM2X;]H+]L'0/!OPB^.FL?"C4;>_\`B+X)^!7[47Q*^&^L^(/!GB7Q!\+?
M$'BK]EV*?1OB+X?U#5-%U#089;CPAXYFTG0-7T2Z\2>&-0\0J^N3>"KO7H?"
M/C&?P_=^'_[;_P`%]2\&W]Y\0?%-QX&\5^!_`_[._B7Q_9^,O"WB'P+!*O[2
M=Y?>$OA1K?AE?$MC91ZMX=^(GQ)\.^,?`OAB]M)Y8F\0^%]8L[IX+:VBO;@`
MUO"W[$GP6\$>(?ACXA\(S>/=&?X2?%[X^_'3PCI<OC74_$6G+\2?VG?$'CWQ
M+\:M9U67Q8NOZQJ-MXOU3XG>.)SI+ZLFF:1<:_=:CHMM8:PL.I1\8O\`P3D_
M9LM/AA\2_@UHT?Q3T7X9?$VQU+0[KP5%\8?B'KGA?P+X2UO7[/Q3KG@?X0^&
MO%^N^)/#OPD\':KK]C;WTNA^`=)T*&QMX;/1-'?3?#NDZ)I&F=?H_P"W9^S=
MXE\'7'C'POXQNO%45CJ'QIT?4_#?AC2;K7O&=IJ_[.LL</QJTBR\-:7]IO\`
MQ7JO@=[BRE73?`P\47WC'3M3TK7/A[!XNT'4K+4Y_L&@#Q3X<_`OPO\`#3X@
M_%SXFZ3K?BK5_%7QPU'PCK'Q`GUZ]TF>QOM5\#^$=,\">'[_`$[3]+T32;;2
M)(/"VC:9IEU!IZQ6=ZUJM_<VSZC-<7<OM=%%`!7`:Y_R4+P#_P!@KQO_`.BO
M#M=_7`:Y_P`E"\`_]@KQO_Z*\.T`=_1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`5^=W[;_\`R'/A_P#]@K7?_2O3Z_1&OSN_;?\`
M^0Y\/_\`L%:[_P"E>GT`?:7PG_Y);\-?^Q`\&_\`J.Z;7?UP'PG_`.26_#7_
M`+$#P;_ZCNFUW]`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%?
MF5^T!X.^(?BOXA?\$]-6^'NC:I=+\+_^"A7[0OQ&\<^)(?".J>+=!\$>"M3_
M`&:/V_\`X(6VO>);33=0T:0V%_\`$;XV?#OPMY,&KVM_;0^(+SQ.Z+X<\+>)
MM3TK]-:\4T;Q[X%^'G@J^UOX@>-/"7@;1I/B+\7K>/5_&/B+1_#.F27%K\0?
MB!J]S`E_K5Y8VC36^DZ7J>J3QK*7BT[3K^]D5;:TN)8P#XM^*7_!-72_'O@#
MQ-\,M!^,VN^$O!OCKP-\=]+\8:+=>#M)\3V!^*/[0'QM\0_M$>._C/X/LIM6
MTFS\(^)_$/Q/\7^)T\567D:S#J_@74;?PIH=[X2O;%/$<MW6?^"=\_B._P#V
M[M1UOXRI)<?MK_%?X"?&8'3OAT;)/AEXP_9S\%_!;P9X$AVW'CO4/^$ST'4(
M/@/X+U+Q58$^%;S4;N^\2Q:5J>A6U_IL>C?:6N?M!_`3PR_C"/Q)\;_A#X>D
M^'FC>"/$?C^/7/B5X,TE_`WA[XF3ZQ:_#?7O&"W^M6[>&=&^(%SX>U^W\$:I
MK0LK'Q7/H>L0Z#/?R:;>K!\F_'+_`(*(?#3P#H_[1%I\*AX>^*/Q$_9:^*7[
M/OPQ^-'A#5O%,W@N#PO>?';Q?\-M%:YM;]-!\0WFM7O@[PQ\3_#GBN^M(]+L
M/#^H37EOX;/B_3-575/[)`.;^)/_``3Z\7>./V@]9_:?T#]HN;X>_%^VU/X1
MZ[\.M;T/X4:7JVG^&-3^&WPV^,/PGU_3O%FC>(?&.HZ?X\\'_$;P?\<?&BZS
MH%O%X0U/1=;T_P`&ZWH7B6VO/#LG]J/^/O\`P3QUCX^^._!?Q"UG]HSQ3H'B
MWX>?#'0_#?@_QGIG@/PW<>-](^*/A7XZ?#G]H7PS\5A=75__`,()=6EEXZ^&
M.AZ3J/PXN?AS)X;U7P%J6O\`A9KJU:]L]4T[[ET7XT_!SQ'X8OO&WA[XL_#/
M7?!FEZWJGAK4_%VB^//"VJ>&-.\2:)+)#K?A^^U^QU6?2K36](FBEBU32KB[
MCO["6.1+NWA=&`Y[5?VE_P!G#0AIQUO]H#X):,-7T7PKXDT@ZK\5O`FG#5/#
MOCJ[-AX(U[3C=Z]"+W1?&5\#9>%=4MO-L?$-V#;Z1/>3#90!\]_%G]C#7?CW
M\(X_A=\;/C0WQ&N=1TGQ:=>\5:G\,/#&G7OA_P`>ZY8^&+#PC\5O@;%HVI6&
MH_!+X@?"!=#U;4/A;XATK7?$6IZ-KOBK5];UF]U^_6WD7UG]I3]GS4?CY\*/
M!WPQTWQXOA&3PE\:OV8?C,/$FN^&[CQS>:M>_LN_'SX9?M#^&]'OK:'Q1X/<
MGQ5XO^%'AW2_$FK&_DG_`+!OM=2QM8-4N['4]-Q/%7[8GP8L-=_:9^'6@?$G
MX8:=\3OV8_AGH/CWQZ/BKXVMOAO\,O"UQXVTWQ/=>#XO'7CVXM-4F\.^&[:Y
MT'3Y?'?B6QT#6[?PEI7B319!!JFLW#Z)%]")\0/`<OBX_#^+QMX1D\>"SO-1
M/@F/Q)HS^+AI^G)I4NH7Y\-K>G619V$>NZ))>71LO(M4UC2GG=%U"T,P!^8G
MCW_@F3XN\70V?]A?M.W?@/4-,_:1_:?_`&B]-UOPY\+91J\-[^TQ8:[8ZKX+
MGN9?B>L4^@Z-!XEUG3M3N(X+:Z\4Z#=MI130I6FU";K_``C_`,$WK;P=JWCO
MQ%IGQ?9==\8?MV>#_P!O73UA^'&FV/ASPQ\0=(^`'@C]G;Q3X&L-`LO$\+W/
M@/5_!WA&XO/"D,FJ0ZUX0U74+.35M4\;PZ7<IK'V;XE^.GP]\#_$.\\)>._B
M?\$?!UBFC>`A8V/B3XJZ)H7Q#D\6_$#Q=JOA'PUI=YX,UB.QA@T;Q=J4>CZ'
MX"U*'6KC4_%OB^?5?#=AHAN+*UFOO._BI^V5\"?`'PT\(_$O1OB?\.?&'AWX
M@_&7X?\`P(\)^)/#OC7PUKWA1_''CKXAZ5\/;Y[K6]+UAM+F@\`27VIZ_P"+
MM.35+2\@M/#VH:7)<:??RQ/&`>,V_P"P?XKT?X8?M&?`GPY^TEXEM/@=\:-,
M_:#A\#_#S6?AYX5U8_"74OVF=5\;^(/B(K>*-.O?#_B+QYX5T'7OB)XIO_AG
MX6U&\T1O"L-U8Z=K6M>+K+1=&CL.4\7_`/!.#4/'.N>+_$NJ?'R]\/>(]4^"
M/[#GPW\">)?`GPXLM*UWX<?$#]@;XM?%OXU?"/XJ6)\5>+O''A_Q'!KWC+XT
M>+;#QUX`U[P[-I&M>#8=+\/0ZK:3KJNKZM]/?#3]JOX4:[X:LH/B+\9?V9]!
M^)VG1:O#XX\*>!/C]X1\;Z'H=]H6KZUI5_)9ZOJ,?A766M%_L.\GO8=6\.:9
M=Z%>6^IZ+?>?<:-=7DOH]]^T'\`]+UG0_#FI?&_X0:=XA\3Z;H&L^&M!OOB5
MX,M-9\0Z1XLCO9O"VJZ'I=QK4=]JVF^)8M-U&70+ZP@N+768["]?3I;E;6<Q
M@'SE\7OV-M<_:`^#]G\*_C7\8HOB#=7.A^+HM?\`%M]\+O#6F:CH_CW7H?#]
MOX1^+GP531]4LM0^"OQ&^#R:3JMS\*_$>CZYKVI:+JOB/4-8UF[\0:C%#/7V
M_I]G_9]A8V`N;N]%E:6UI]LU"<W-_="VA2'[3>W)53<WD^SS;F<JAFF=Y"`6
M(KC+#XK_``NU72-=U_3/B3X!U'0?"^KQ>'_$VMV'C'P[>:1X=UZ>/39H-$UW
M4K?49+/2-7FAUG1Y8M-U":WO)(]6TQTA9;ZU,OCW['W[0M]^U!\%9OBOJ7AO
M0/"EY;?&S]J7X0S:7X5\72^//#=TO[.'[4'QB_9TA\2:)XMF\/\`A:36=,\8
MP?"N+Q?:3'0=/6WAUQ;-%GCMENIP#Z@HHHH`*X#7/^2A>`?^P5XW_P#17AVN
M_K@-<_Y*%X!_[!7C?_T5X=H`[^BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`K\[OVW_\`D.?#_P#[!6N_^E>GU^B-?G=^V_\`\ASX
M?_\`8*UW_P!*]/H`^TOA/_R2WX:_]B!X-_\`4=TVN_K@/A/_`,DM^&O_`&('
M@W_U'=-KOZ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*_/_XR
M?!KXK?&'0?!5C\/4^&$WA_3?'7[5FF>-U\<7NL>'/%>F)XXD^*'@GP[XD^'G
MC/0/!WC#6=.N=&O]9NHO%/A;3Y?!4GC?P]J4NFWWCJST6SU;PKXP_0"N`^&O
M_(NZC_V/_P`6/_5I>,J`/QZ\3_\`!.S]I:]^#GC;X>Z)JWP/G\0?%K_@FC^Q
MC^Q5XQU/6?'OCZVTKP=\0?V1/$G[0&OCQ+X=2T^$-]>^-?"'Q"3]H+5;5[_5
M/^$(UOPM)X3T^X'AWQ&-=N8-'Z_XN?L%?M"^)=<_X*'WW@ZZ^"FK:?\`MI_'
M7]BOXY>&H?%OCGQOX;E\(3_LZ>$/V:?!'CWP;XC@TKX2>,H-1M-6L/V?9]8\
M*^(M/F+ZC<^*X]&UGP[H4&COJ^I_LK10!^-WCO\`8M_:WO/BS\8OC=X)U/X.
M'6;S]OC1/VKOAK\--2^.?QK\#>&O'OPXN?\`@GI\*OV'O%W@;X@_$/X?_"B/
MQ5\(/&]GJ_@76OBAX2\1>$?#GQA\/RQ:Q+X9U_0IUU74-2MN3^,G_!.KXY^)
M_A]^U/X!^$GAG]FGX>:/\;/^"6WC3]B+X;Z-8_$#XD:-HGPZ^)7CK7?C3K4U
MW(L/P<\0Z@?AQX8?XMVQM_$MG<R>*/$^H>&7U*7P+X6_MB*TT;]D/'/CSP?\
M,_"^I>-/'OB'3?"WA?27L(K[6-4F,5M'<ZMJ5GHND6,2HLD]YJ6L:SJ.GZ/I
M&FV<,]_JNK7]EINGVUS>W4$,G6T`?D-^T;^P_P#M!?%3P]_P51T_PA=?!M+_
M`/X*&?L5>'/@7X5C\3>.?&NE6?PV^*UE\'/BS\'M5CU^ZTOX3^(9M<^'UO;_
M`!#L/%&F^+=.L;/Q)?SZ==Z%<^`-+22'7*]T_9S^`_[07PS^(&M:5\3?#W[/
M7B_X8:=\9?C_`/'KX9?%5?$GBWQ-\>/".H_M,>,?&_Q)\:_""U\.:_\`"O2-
M#T71?!?BCXBZUX4\/?%[0OB@E_XM^%&@^'_!^J_![PQ+)<7]I^@M%`'Y'_MC
M_L8?M%?'3]H67XE_#NV^!TO@IK;_`()Z((O'GQ'\<^'O$<\G['__``4,\(_M
ME>.;>?1=#^"OC;25MO%7A#P]=^#?"\O_``D4S-X@NX[C5[;3]+,L@XF']AO]
MJZQUC]H&_@7X!W]G\3O^"M/P=_;U\'V]W\6_B1:-IGPA^'W@G]GOPWKOA'5H
MT^`>H1:=\0+_`%3X):EJVGZ7I;:IX8N&\7E[SQ1:7&GSOJ7[344`?EI\/?V5
M_P!I7P2+5Y=,_9ZO8I?^"@/[1O[3>M6"^-?&/]L?\*O^-FA_%S3M"N?!_P`0
MF^"T?B'P!\6O#=Q\0[&Q\16?A?3K*/Q9X//BGP6?BKIGAGQ'KNDZ]\W_``Y_
MX)E_M'Z=\"K#X$^*O''PG\)^1_P1S^"O_!.,_%#P-XM\=>)M>L?BM\*-)\4Z
M5=>/(?">I_#GP(-1^&FOG6[&ZO+$>.M&\37-I%J&C-!://!K,/[MT4`?D[I'
M[)7[2`O/!?QX'@[]F[P!^TIX9^.'PZ^)OCWPGX9^-'QQ\?\`@7]H71_`WP9^
M.'P$>S^)OQX\?_"^+XBV'V3PK\<I/&/PW\.'X1^,;?X<>*_AIX1TFX\4>---
MOSJOASZQ_8P^"WCWX!?"'Q7X#^(DG@V;6];_`&F?VROC582>!M8UG6M&B\-?
MM+_M;?&K]I'PWI=Q<:YX8\*7<&L^'-(^+%MX8UFWAT^XT]]0T6:\L-1N+:\C
MC@^L:*`"BBB@`K@-<_Y*%X!_[!7C?_T5X=KOZ\Y\32R6_CGP3/%:SWTL&A^/
M9HK*U:V2YO)([;P^Z6MN][<V=FL]PRB*%KN[M;59'4SW$$0>50#T:BO@[PW^
MW[X%\5Z%\`-?T;X._'&:W_:6^-/Q-^`?PNM9K7X06U[=_$/X2>%?C7XT\86F
MM+-\8EM=&TR+P[^SS\7+S3M4N+MX;^3PO';1HMSKOAZ+5/J#X4?&#P7\9=(\
M2ZIX/N+];GP5X[\5?#'QOH.L63:=KWA#Q]X*OELO$/AK6K/?/;_:(!-9:EI^
MHZ;=ZAHFO:!JFC^(M`U34]#U;3M0N`#U&BN$^*/Q)\&_!KX9_$7XO_$;6(_#
MWP]^%/@7Q=\2?'>ORPSW,6A^#?`WA_4/$_BC6);>UCEN;B/3-$TN^O7@MXI9
MY5@*0QO(RJ;7@_Q3J?BA/$)U3P'XQ\!2Z#XDNM!MH/&#^$9'\2V4&G:7J%OX
MK\/3>#O%GBZTE\-ZA_:;V-K_`&M<Z1K\.HZ7JEMJ6@:?Y$$ER`=C116-XA\0
M:%X2T#6_%7BG5]-\/>&O#6D:EK_B'7M8O(-/TC1-$T>SGU#5=6U2_NGBMK+3
MM.L+>XO+V[N)(X+:VAEFE=8T9@`;-%<9H_C*/Q%=^%Y=!T'7=4\(^+/!DWC.
MP^(,3:#:^&;:.67P^VB:!?Z9J6NV/CV/7?$VF:Y<ZWI#6O@N[T"ST_P]K5OX
MCUW0=9E\/Z3KO&?$KXX>&/A9X_\`V>/AYXATCQ-=ZC^TM\4?$WP@\#:OH]KH
M]SH6C^,?#'P.^+O[04T7BZ2\UO3]6L-.U/P'\$?'<>EWVC:1KX.O6VG:=J46
MFV^H1W\8![-116?JU[<:=I6IZA9Z3J&OW=AI][>VNA:3+I4.JZU<VMO+/!I.
MF3:[J>BZ)%J&HRQK9V4FLZSI.E1W,T;:AJ=A:+-=1`&A14,$CS00S2036LDL
M,<CVMPT#3VSR(K-;S-:S7-LTL+$QR-;W%Q`75C#-+&5=O"OB9^T'X<^%OQ3^
M"'PGUKPIXTU35OCWK7BG0O"7B#1$\'_\(MI%YX+\):OXZ\2R>*[K7/&&AZQI
MUIIOA/0M4UDW&G:)JXNDMA962W&IS0V,@![W17Q[XO\`VQ=$\"_#72/BOXF^
M"GQPT_PEXB^-OPV^!7AZ5[3X4?VAKGB#XQ?&CP=\`?A7XKT^R/Q:4M\/_'GQ
M*\>>%['0?$-Q);W#Z!J<'C"\TNT\*2PZQ+0^*7[<7PY^#]W>Z#XQ\!?%2+QO
MI_BG]G+PS=^`;&Q\`3>(EB_:O^,^G?L\_!'Q-:7]Q\1+3P=JOAGQ'\9]2C\"
MZQ=:/XJU#4O!E[$VJ^,-*T/P]=:9K%^`?:-%>1?#GXT>$?B1XF^(_@73[?6?
M#_Q`^$NH>&K'XA>!O$MK96^N>'U\9^'X?$_A+5%N='U#6O#VMZ'XBTF2X.G:
MWX=US6--.IZ5KVA7-S;Z[H&LZ;8^NT`%%>,_'SXW^&/V=OAK>_%/QEI'B;6?
M#FG>)O`'A>\MO"=MI%[J\-W\1_'GAOX<Z%>FVUK6]`M9-/MO$/BK2FU5XKZ2
M\M]/-Q=6UE>/`8&/@G\;_#'QVT?QQK/A?2/$VBQ_#[XM_$WX+Z]9^*;72+6]
M;Q;\*/%%YX2\2W-A_8FMZ]:7.AW&J6,SZ/>/=P75W9[)KFPLW?R0`>S45\C?
MM4>+8O&W[.W[9?PW^$VM:QK_`,9/!_P$^(&EIX>^',VN3>.O#_CWQG\+O$6I
M?#73-/E\,`:K8>+]4G?2=6T>QT^X36;:UOM&U66&VLM5TVYNKO[3=K9_%7X7
M>*?A)X?UWQ;X4\?>+?"UEJ'@OQ%;_#WX\ZOIWA;6==BUR'POK_B)/A9J_P`/
M-7M3I-]H]]=M8:GXZ\-OX9UVV\/:KK4=K='0H;X`^K*_.[]M_P#Y#GP__P"P
M5KO_`*5Z?7W)X!D\32^!/!4OC32H=#\8R>$O#DGBS1+?6V\20:/XE?1[)M>T
MJ#Q&\-N^OQ:?JANK2/6GMX&U5(5OFAB,Y1?AO]M__D.?#_\`[!6N_P#I7I]`
M'VE\)_\`DEOPU_[$#P;_`.H[IM=_7RSX=U32_"'PY^%S^(_C9XI\-2:[X&T&
M[TC0H+#X>7ER;#3]`T>?5Y]-TX_#G5M>GT#PO:WUK/KVMW3WEKX>TIH]3\2:
MK;VOFWQZ_P`&ZQH_Q$T[P_K7@/X^>+_&'AWQ;X'\,?$GPKXJ\.:=\--7\'>)
M_`OC2"6[\*^)/#OB^R^%\WAG6]/UZQA_M+3_`.S-5NIYM+FL]4\D:??V5S<`
M'N]%<!_PAOB+_HJ_C_\`\%WPM_\`G:T?\(;XB_Z*OX__`/!=\+?_`)VM`'?T
M5P'_``AOB+_HJ_C_`/\`!=\+?_G:T?\`"&^(O^BK^/\`_P`%WPM_^=K0!W]%
M<!_PAOB+_HJ_C_\`\%WPM_\`G:T?\(;XB_Z*OX__`/!=\+?_`)VM`'?T5P'_
M``AOB+_HJ_C_`/\`!=\+?_G:T?\`"&^(O^BK^/\`_P`%WPM_^=K0!W]%<!_P
MAOB+_HJ_C_\`\%WPM_\`G:T?\(;XB_Z*OX__`/!=\+?_`)VM`'?T5P'_``AO
MB+_HJ_C_`/\`!=\+?_G:T?\`"&^(O^BK^/\`_P`%WPM_^=K0!W]%<!_PAOB+
M_HJ_C_\`\%WPM_\`G:T?\(;XB_Z*OX__`/!=\+?_`)VM`'?T5P'_``AOB+_H
MJ_C_`/\`!=\+?_G:T?\`"&^(O^BK^/\`_P`%WPM_^=K0!W]?FE^U'\./B1\2
M?A?X9M?A;;ZR_BSPG\5/V@_&6D)=^#?#/Q/^$7B75[;7?B3X<TSX9?'7X8Z]
MK/AW5_$'@#XBR^)Y=,@\2>`/$/AKQM\/O$ECH_BJ/Q/H?A*U\77+?=W_``AO
MB+_HJ_C_`/\`!=\+?_G:UQ'P^\*:]/H-^\7Q-\;V2KXW^)L)AMK#X;O&\EM\
M2/%=O-=L;SX?7<PN+^:)[Z[5)4M4NKF9+&VLK);>S@`/QD^+G[/]_P#&#X^_
MMH_!S2?A7IGAGX]ZW_P2B_X)N1_!G5M',?BO2/V=/VFH_B3_`,%._#_@?XDZ
M?\0M0-EJ=A>_"C7M!\,ZG:?$@+:^(=;\+_#9='LI+S6]0T#PKK?K'AW]GS]I
M'5?VO/BRWQ;\*_'S4;C3_P!IW7_C[^R[^T+X/\5_L_1_`;P[\.-7^&NF^#-%
M\(>.I[O[+^U!IMSX+T^\\1>"_$7P4M(-6^&_Q'N)M+\26<UAI^J>(-;\(?IO
M_P`*.\'>%_&7BWXUPZW/H_Q'USPKIOA_QM\4;#X?_!*W^('B#P7X0?4-3T3P
M]X@\767PC'B?7?#_`(<FO]4O-$T.]OKRRTVXO[V73;2*>\F,LWAOQ#X;\87G
MB.P\,?M&:[K5WX2BCNO$4-B?A+(=+L)=1\0:-%JTS'X;JDNB2ZWX2\7:#'KE
MNTVD/K_A'Q9H2WIU;PQKMG8`'Y":C^SK\5_BC^P_K_A'Q7^QAXX\,_M0>&_A
MY^QQX(^-FK>*O&GPS\1:3^T+XH_9F^,?@OQWXG\2?#6VTCXE:]HGCY]7L6^*
MOB:Q^)GQ$T+X;?$'Q/!XJT'PIJL.H:F^K:#X*]`U[X$ZI_PM_P#;,^)=M^QU
M=^/;O6OC[^Q3KOPL34/#^F>'=9TGX?>&O#OP'T+XQ^(OA_J,?B#PK9ZO#X#U
M7P;K6I>,?AG8>--*\/\`QDTSPO)X;U2S^(/@G7ET3Q'^L^CZ)?\`B#2-+U[1
M?C)XXU+1];TZQU?2=1M;#X6O;7^F:E;17MA>V[_\*T&^"ZM9HIXF(&Z.13@9
MJ+7M+N/"VAZQXF\2?&WQ?H/A[P]I=_K>NZYJ\/PFT_2M'T?2K66^U+5-3O[G
MX<1VUE86%G!-=7=U/)'#!!%)+(RHC$`'SG_P3W\"?$OX8_L^Z[X!^*?ACQ1X
M5US1/VG/VV-3\,V?BJZ\'75S<?"7QQ^V1\=_B%\#Y],3P)JFH>&],T2'X,^*
M_`=CI6@:9;Z-IWAFUM$\.Z5HFG:5I5E;I]PUX5X(U.Q^(MOX@N/"'QL^(FH_
M\(IXHU+P7XEM+OPQX%T+5-`\4:/!97=]HVJZ/K_PETO5;&Y%AJ>EZG:FXLDA
MU#2=3TW5M.ENM,U"TNINV_X0WQ%_T5?Q_P#^"[X6_P#SM:`._HKS>[\,ZQI]
MI=7^H?&'QO8V-C;SW=Y>W=I\*+:TM+2VB::XNKJXF^&Z0V]O;PH\L\TKI%%&
MCR.RHI(I/I&I1ZY;^''^+/Q*&JW6DWNMP(/#?P_:Q;3]/O+"QNF?6%^%1T>&
M[2YU.S$>FS7\>I7,+RW5M:2VMK=S0`'JM%>"^(-<T3PKXS\`?#SQ#\?_`!;I
M7C;XIW'B*T^'WARYT_X9_P!H>*;CPEH-WXG\1QZ<L?PODB_XE.@6-WJ=RUQ)
M`GD0.(FDEVQGN_\`A#?$7_15_'__`(+OA;_\[6@#OZ*X#_A#?$7_`$5?Q_\`
M^"[X6_\`SM:/^$-\1?\`15_'_P#X+OA;_P#.UH`[^BOF?QA\0?!7P^^%'B/X
MW>.?VBO&'@_X8>#OAVGQ7\7>)?$NB>`-%?PI\/7TNZUG_A)O$FA:A\)H/$FA
M6L>G6&H2SVVJ:/:ZA;2Z=J-G<6<5Y87=O#ZS_P`(;XB_Z*OX_P#_``7?"W_Y
MVM`'?UYSXFN8[/QSX)NY5G>*UT/Q[<2I:VMS?7+1P6WA^5UM[*RBN+R\G95(
MAM;2">ZN)"L4$,DKHC3_`/"&^(O^BK^/_P#P7?"W_P"=K7$:QX4UY/'7@F!O
MB;XWEEFTSQBT=W)8?#<7%HL4>A%X[=8OA]':,EUO43FZM;F11#']F>W)F,H!
M^//A/X(_%37/A!_P3>^'VK^`?CUX`U7X6?M[_M??$_XI:[X7\-^)O#_BKX3>
M`OBC\#?^"DG@CX>?$.SUVULKBQN);CQ9^TC\&6M['3CXDBCAU[4$\7Z#+H'A
M[QQ9Z=]A_"OX?_M!6W[%?[1G[-VC:#=_![]K72_`WQR\(Z!\>#%J9\#?&+XT
M>-?#/B#_`(0G]K/1/%L6JZYK7VOQSXDU;0O&_C7PQKNJGQC\./%<6N^"K8ZO
MX=\.>&_$VM_?7_"&^(O^BK^/_P#P7?"W_P"=K1_PAOB+_HJ_C_\`\%WPM_\`
MG:T`?C#^U=^S+\4OB?\`LP_MQ2_#?X(Z_P"#[;XW_P#!*7QU^S^O[-XTO1+S
M4O%G[7NMZ%\0M/\`A\\6GZ1J5]X6N?$GPXU+7H?#>J?&&VG/AOQ'::_X;U^V
M\=:QX<^'\.I:!]4?\%*+'PP?^"?_`(G30O"#6&@0^/\`]EZZTCPG!X<7PI>V
MD5W^U)\'%FTZTT#48=#.@ZC=17EY9/;W*Z7M>\G2YFAAGFE/WM_PAOB+_HJ_
MC_\`\%WPM_\`G:UQ7C_X"^'/BOX<F\'?%/6KKXE>$;B^TS5)_"OC_P`"?!#Q
MEX<GU+1+Z#5-&U&;0_$7PFU'3);[2-3MK;4-,NWM6N+"^MX+NUDBN(HY%`/S
MS'[.OB7P=XR\2KX4_9[NM>_9Z^+7[9UM\0_#7@3P];^'-"MO@;X4U']BUOA=
MXL^)T7P7\4>(/"W@>^T_XC_&(^(+74_`GC+0->T3PUXD\82?'?7/AO?>+I;G
M7O#OQA\//V*?B[\2O@MX?^'_`,>/V>+[Q)\7[3_@AC\!_P!GF35/BUH7AOQ9
M9VG[:G@;P7\1]#UU3X[U"Z\0>'4\>VFH^(M&OK/XBPZTS+;:E+''XA@U&TUC
M3K/^@R+P1KL$44$'Q3\=PP0QI%##%I?PKCBBBC4)'''&GPT")&B`*B*`J*%5
M5```D_X0WQ%_T5?Q_P#^"[X6_P#SM:`/P%^-7P!_:=E^._[+WQ"^`O[/7C/2
M$^'W_!..T^'7C7PFMCX7\(V/BK7M!_;3_83^.WC;]FC4]<BUI/`NFZW\</V?
M_@7^T)X#T_4==UZW\!6.I^+;70?&OB+0YO%"6EUZ_P#M8?!+XP_$WX3_`+.5
MG^R=\"?BC^S!X[U/]I']JWXI:(OB:ZCO+OX*^*OB_P#\$S_VXO@'X,^,'B:S
M^'GC'Q_X<^%&F3?M+?'WX9.WA+P3X@,VEIJ6L?$:[T31&@\>76A?LW_PAOB+
M_HJ_C_\`\%WPM_\`G:T?\(;XB_Z*OX__`/!=\+?_`)VM`'X^^"OV?/B+XD^&
M^N^*]-^''[6G[-OQ*\>>//@WJOB"/XDV7[*7Q*\,>"/%GPB\#?$ZUU36M4_9
MS^!4]E\,?BC\(M6BNM,^%OC*\T6+2OBO\4H-0\#^+O!LWA;5OAIX*\<:;];>
M-?A]\1=4_P""6GBSX3:S\']&\)_%>_\`V(]<^&=K\#OAK+=^*M#\-^/I_@U=
M>$O#G@'P;<W%UJD\MCI&OMIFEZ5>7>M:K;Z+';QW-WXKU&TT^7Q'/]F?\(;X
MB_Z*OX__`/!=\+?_`)VM<)K.LZ;X?\>>"OAEJ_QN^(EGXV^(FG^*M4\':3_P
MBW@B>#6;+P5!IUUXGD76K;X1S:#83:7;ZMITS6FJ:G9W=TETIL8+K;)L`/Q/
M^'W[/7Q$T#5O%/CNT^`'CK1_&\/_``4R_8E^+7@OQ'_PK74[7Q-HWP%TO]BO
M]B+X.?M)Z_HFH_V<+W1-$U+QC\+OC[X<^(&B64UKK'C-(9]1ETC7=,\7^&+[
M6_M?_@HC\!?&?[1'Q9_8M\+>%;CXE>%+#PI\1/B?XH\0_%CP-X7N?$6D_#6^
MO?A+XFT?X<WWC/3;FWDT+Q?X,U_XBG0/#GCWP!J:WFC>)/`VI:]IOC-='\):
MC>ZU;_9VH^)=-TCXB>'_`(6ZG\8?B[8^+?%5O=S>'6N/AQH:>$M8N;'3-1UN
MZT*R^(I^"?\`PKR3Q;%H6CZMKP\&?\)2/%DF@Z7J.MQ:*^EV5S=P^C?\(;XB
M_P"BK^/_`/P7?"W_`.=K0!^6W[1?C/XV_M(_LQZ-\-O&W[-OQD\(?%WP?^VS
M^PUJOC&V\(>&_%4W@OQC\//V>?V^OV=_BW\3OC=\(O&NCW$?B#3?`]W\+/AS
MXI\;^%]$\2R>%?C'97,,/AK3/#NKZ_'I6I:QX_\`M4?L\?$/6?&_C7Q%\(?A
MK\9?$7PI^)WQ5_X):>*_&%]XD?Q_XA^+&IZ]^S!_P45^%/QH^(FL>!]=\5ZK
M>_'#P1\/OAU^SWX8\<:Y?>$-?U/PMX9/CB72=1_9]\+3_$'QS\3=2\3_`+4_
M\(;XB_Z*OX__`/!=\+?_`)VM'_"&^(O^BK^/_P#P7?"W_P"=K0!\C?L@>#/&
M_P`(O%GQP^%GQ.\)^+O%.NZSXRE\>>'OVI-;MI]9_P"&@OAOK-JMKX&TCXBZ
MK+//>>%OBK\&/#UK#\*M>\*:AIN@>%M;T;0-!^(/@JSM)O&WB3PGX3_,/]E/
M]FGXD?$3X<?L\_$[]FG[+\$/'_@:_P#^"GG@SXG?%.YT9=*3Q[H'C;XA?M`>
M"_@5X#U34]*D_M+QKH_A#XP77@#XN^'47^U;+X?:;\*]4T1'\+ZQXAL=(U;]
M\9?!&NSQ2P3_`!3\=S031O%-#+I?PKDBEBD4I)'+&_PT*/&Z$JZ,"KJ65E()
M!X[P#\!?#OPH\.1>#OA;K5W\-?",%]J>J0>%OA_X$^"'@[P[#J>MW\^J:SJ,
M6A^'?A-IVF1WVKZG<W.HZG>):BXO[ZXGN[N26XEDD8`_%.']GKXR:C^R3\1]
M1U3X!_M3>&/CQXHL_P!A?P#\0/!?Q`U?X!^(M&\3:S^SS\?O#7CCQ7XD^'/A
MS]FY?^$<US3]!T%_&MW>_&KQS:Z!X_\`B5X:A\$^&[]-9N?#GA[1-`XF3]G'
M]HOQ5\0/C'I'C;X-?M0>)_V:OCG\1OVT=$M_#WP??X*>`O'/@_7?BW\?Y_'?
M@OXIZE=?M!G1->\&:!\0_AQJ&F-H'Q3^#^K:-\6O@WXK\"6[ZC;:/JVIZ1=:
M3_0O_P`(;XB_Z*OX_P#_``7?"W_YVM'_``AOB+_HJ_C_`/\`!=\+?_G:T`?(
MO[-_P:\2_#;]K?\`;:\9Z_\`#I]/TSXOW_P%\3^$/B@G_"+WL'BFR\-_!#P;
M\/\`Q7H]YJMG/:>)WUR#QGX3U74=1M]1\/:?9W<$ECK6]'U*UA/WS7`?\(;X
MB_Z*OX__`/!=\+?_`)VM'_"&^(O^BK^/_P#P7?"W_P"=K0!W]?G=^V__`,AS
MX?\`_8*UW_TKT^OM+_A#?$7_`$5?Q_\`^"[X6_\`SM:^#_VP](U'2=8\#I?^
M*-=\3M-IFLM'+KL'AFWDM`EU8AH[<>&O#GA^)EE+!I#=1W+AD7RGC4NK`'$_
MM$^#]'\32?L9:KH/QH^)/[*_QX\(_`GXD:S\)_VF]"\*P^+?@[X>T:XM_P!G
M;3?'7P4_:#T3Q/IDWPUU_P`&?&?4;KP#K6C>$_$GB7P%XPUK7/A0M]\+O&FB
M>*-">X'QA_PU?\1OAGXE\'>'/C5!>_#KQ/I?[%?[/VF>#/V9?`OQ-\6_!GX-
M6?[1.I_$[XN_#+2&UCQ.+K3?%OPJ^%MQ\.Q\/_BKXXTWQ]K=[XG^&'PWM]"_
MMC3=>\4V-CHGB;]]?A/_`,DM^&O_`&('@W_U'=-KOZ`/P"^%/Q3^+:?&"S_9
MYD_:?^-7BB+2?$OP`\1?!/X_>#_@W\7/CEX`_:2OK/Q0WC/]K+PU#\1M,\5Z
MO\(?"OAAM<U'Q'\*=6\-_%/6M5B^#GP:N_`NO_#[Q9_PD_ANY\2VG[^T44`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7YN_%3]GSPQ\8OC]\)O`'Q?
M\#:KKW@#Q!\!?^"@NFZU<65SXCT9+-/&O[2?[(WB?P_8P^/O!M[IFJ>$=8\5
M>&=/U2[T^+3/$>BZ_J.D:?X@@MRT>GZQ%;?I%7/^&M<_X2'3KF_^R_8_L_B#
MQ9H?E>?]HW_\(QXIUGPU]J\SR8-OV[^R?MOD;&^R_:/LWG7'E>?(`?+M[^Q)
M^R?I5Q<^+M1^&9EETKXD7?QSNKB]\6?$/6+1?&%OX(G\#7=Q)H,_B6^TZ^\+
MGP09]'?X<G2KGP-<%WU,>%I?$$G]I-^77[/'[/'C#X5?L<Z5J'PM\%>,OB/\
M2/A;_P`$Y?A1X;\2_"7QAI]YX>C\:>*_`?P[\<?'WX;_`+'[::EGIM_J5_XO
M^)/Q:O--^-&IZE/;R0?#>#X>_"RXT2_U3QA\1O$*?OW%J&GSM`L%]9S/<K<O
M;+%<P2-<)9RI!>O`$=C*MK-+'#<M&&$$LB1RE'=0;E`'YZZG\8OVGO%/['/[
M5_C;X6^$1X@^-/@FQ^.>C_LR:E::+#I<WQCC\+^&7G^'?C;1O"NOK+IHU75/
M$,M]H>BZ7J9M_#7B[5_#UIJ0DT[PQXCA:V^'OVZ/$?B?Q)^S5^WE+X>\7^-=
M?_9;\4?LK?!;4?AO-X@UGQW;^+[;]H[7OB+\6-%^*7P_T"^U)[3Q_,Y\)Z5\
M+H/&WPJUJ>3_`(0GQ6]WH46@:;>ZCXKT33?WKHH`_.?]N+XAR^`_@M^S3XC^
M'GQ7\2>&/!?B?]J[]DWPMK'C;PKXNNM8;Q+\)/B)\2-$TCQ"MYXVNI-?U34/
M#FN^%]3DN;OQ-%JWFIIS#6?[9AMX#=)\Y>(O&GQQ\'_#/3_`M_XK_:)UC1?%
MGQU_:LTS]GKXB:%'XQ\3ZKKWPKT/X;>*]3^#>A_$_P`7>%]!U#XI:Y<2^+[[
M5?\`A2&NMKN@R?$GPMX!\)>)O'7Q$\7"]-OX^_4+XR_!'PI\<=/\$:9XNU'Q
M'86_P_\`B;X'^+OAX^';ZQL)1XV^'&M0>(O!]]?/>Z9J0O++2M;MK>_?3&5+
M'46B6VU.&\LFDMG]CH`_F-^,7BKXV?M8_L^?MX>!M2^(?QQ\0?$JX_X(0?L[
M?%_P'\'/!.O>,/AYJU_^US\0_@W^W=IGQ?T:W\`^#(_"^NZQX@U&:^_9HO\`
MQ+\,=3M[ZPAN/%OPPN;_`,/+I_BGPS%>?5?[4O[4GQ"^'7[1OPTMO@=XL^)G
MC;X2S_LW^`O&WQ#\`^'[?Q?XR\;6OPYE_:P_9_A^)'C;PSX1N-.O?BEXC^)5
MM^S3J7Q5\36^F6_]H?$^Z\!:?XF\2>`=,OO$&DZ5#/\`N`UQ;K<16C3PK=30
MSW,-LTJ"XFM[5[>*YGBA+"62&VDO+2.XE56CB>ZMTD96GC#3T`?ST_M??%+Q
MSIN@_LC>.?V7O%'Q0^+/Q-_M?]O/Q_\`L[2_&+PQ/H?C_5W\5?LT?&.;X5Z%
MH/ACQ]H'A#Q+K.CZ/XC\3:'\+?@W-\6]-LM8^)>I:=X4L]:\3^)8/$MKXOUG
MW+3_`(O?$C7?A?=_%+X2_'?QSXH\*^-OCGX?O/"?A/X^?!3]I3]F[P79+HGP
M1^()\?\`P0UOXJ>-+G7_`(]_"CP_J?BSPC9>+#\5-=T+Q;X.\(_&5M.^#>EZ
M1XHM?$NI>`M$_:2B@#XPU/PI\5/CG^P1I?A_PWK?Q8^"GQS\=_LS^%;_`,,:
MMXW\0WOA_P"+OPY^+]U\/M*UG08?BCJ_@N[TMY?$>A^-DM+'XI6.CW%OIVM/
M#XBTN-187NVOF[X5^-/BSXJ^)ESXV^)-O\9?A5\"_P!I;]G7X7_M26-MXP\7
M^-/#M_\`LL^)?A%I0M/C=\/?$VI:GK,.D>!H==N/&?P<\0VG@^>P@TGQ#::3
M\9;O6M+O[#2[N'1_U@HH`_DCT#Q+X^\>?\$V?^"A'Q&^+NL_%3Q5\6_CU_P0
M!_9NT^;6/%=W\0=3L?&OQPU?]DSX^_#7XH^#]/TZX>7P59_%F3]HC4%\'ZQ\
M/M,L=/\`&5G\2?$>J:=;Z!;ZOXLU9-4_9?\`9.^-6K:]^WK^V]\$K'XI:C\1
M?@QHOP@_9`^-?P;NM:\42>,UN?%7Q2M_C7;?'A_!7B>YN;J.X\*6=KH'P)UZ
MZ\&^')D\*?#V[^(&FR:-I'A[2_&VE:?)^HM%`!7G/B:*2X\<^"8(KJ>QEGT/
MQ[#%>VJVSW-G));>'T2ZMTO;:\LVGMV82PK=VEU:M(BB>WGB+Q-Z-7G/B9;E
M_'/@E+*6"WO&T/QZMI/=6TEY;0736WA\037%I%=6,MU!'*4>:WBO;.2>-6B2
MZMV82H`?,_[&/QO\8^//V3/^%X_&GQ'-XBUBT\3?M`R:]>Z'X22(6GAKX1_%
MOXB^`M/M]#\*^$=,N=6U.\D\-^`[;4[FRM8-:UK5_$>H:E'I42VMQI.AV'5:
M/^V?\'M5O-;T*X7Q+X=\:Z%\5?`OP7N_`?BJTT/0/$3?$'XF?#33/B[X#T0W
ME]XA3PG87'B?P)JD5[IMMK/B;3+]]=B?P1)91^.;C3O#=]Y+X3_8S^,/A#]E
M_4_V7?#O[4;^#-'UNX^+4E[\5?AM\+;[PA\8M$'Q:\>>-_B%JEUX"\27_P`5
MO%&A>$]<T?6O&<MIH^MW'A?7Y[;2[%?*@BU>:+5[.MH_[`=O"OQ@A\6>,_AU
MX[T+X]:[\,->^*GPV\1_`'P[>?![Q*?AU\')?A(_AX^`;OQ9>RVOA?4[C3_!
MWQ!TVU3Q"^OZ!XT\,R3_`/"2ZMINIQV&F`'8?%S_`(**_LN_`?PIHOBSXP>,
MI/AW%??"SP'\:O$/AWQ:^AZ!XS\!?#7XAZC<:3HWB'Q3X2U;7;/6[R6RU'3?
M$5KK>@^"K7Q?XDTY_"OB)O[(FCLHGN?7/A?^TIX7^+_Q!^(O@+P7X*^)<MO\
M*O&_B_X:^-_'6K>']*T;P3I7C[P;IO@?6[WPQ'+?^((O%%]<ZIHOQ`T35="U
M.R\+3Z#J%M!J\;:M!>:=):O\\>'_`-@W7_AUXJ^%/B[X2_M1?%KPAJ_A?]G;
MX:?LM_%_4O$NE^%_B;KWQO\`A?\`!_5?&7B#X;ZSJ'B+Q?:W&J^%/BIX0UKX
ME?$R72_'-O-KME<Z?X\UFTU_POKEY::%JFD?0G[/WP'U/X):Q^T'JNH>-+'Q
M>OQW^/'B#XY"VM/"<_A@^%;K7_"7@OP?+X<\Z;Q5XE_MRWM['P/I=U'J1ATB
M5[RZU`M9B"2VAM0"I'^UI\'S9?$'Q#<7^K6?@/X7V/QTN_&GQ(>QM;[P=HUQ
M^S?XLM?!/Q=T2^ET?4-2U[3O$?A[Q#/=6]AH&K:#I^J>)K32=4U/PS;:MIT5
MO=7-N7]I;P]!=ZOHLWPY^,<7BO2/B2?A8_AB7P,(?MGB`_!Z[^.T6J6GC:75
M4^%:^#)?A[8W3-XVOO']EX9LO&B1?"_4M2LOB9=V7A*Y^??&?_!.OX>?$W6?
MC_J_CSQ=JMO-^T7\)/C?\%_B%<?#+0],^&>I^*?#?Q8\9:7XB\%>+?'D]C/K
M.D^.OBY^SGX=T/3_``#\"_B7J&A66L:#X:O_`!1#XB@\3#7((=)[E/V9OC;J
MVF_">;X@?M7:]X^\6_#?XDKXPUF\OOA5X.T+P'X_\,+X(\9>!H_"_B'X;>'K
M^PL6UBR7Q>/'FE>*+C6M1T^Q^*/A[PWXD;PA<^']&T[P=:`''7O_``4O_9S.
MAV'B;PM8?%/Q_H&I?L?>$?V\+75O"7@5ULI/V8/&$3W]IX_6;Q/JGAH2WFFZ
M%!>Z_J/@^#S?&,UG93:;HFA:SXFGL-!O.U\4_MX_!'PIXO\`%/A:YLO'VI67
M@34/V=[;QSXYTOPW:'P)X6TG]J379O"WP?\`%=UK.I:SIMWK'AK6/$PM-'U6
M[\+:7K]]H`U"+6]3TZ#PQ8:[KFD_+?@__@EG?^"/`6F?#K1_C_;7.@Z+_P`$
MQ_#'_!,;3;G5OA*]QK`^'_A'2=2T72/B7>W-E\3M-LKGQ>UAJ)%_I<.FV>CW
M%Q`DT/V56>(];XD_X)T>*O$NB_%_2;GX\Z!;R?%OPM^QEX9NKJ#X-:@5T1/V
M-O%:^+_#]Y;V[_&$F];QMJ'F6^LP2W$"Z79,D=C)/+&9I`#V;7?^"BW[*>@_
M$K_A4\OQ"MM4\937WQMT'3=+\/3:1X@U+5?&/[.^@>(?$_Q:\%6_AK2M7NO&
M5AX@\,Z/X.\:W"3:]X:T?P]JTW@_7K/2-=O;N&T@O+?@=1^U7XU_9F_:X\(W
M'B+P+\//!/A+QUJ'AWPOX]\!V2:_\5?"GQ\^'/P]UWPQXST'6])^(UPO@[2+
M"S-B)=-\1^%+[Q!=ZC;:WH]_IGAY[2VO[CG?"?[%_C;P$_QU\-^$/VD/$-K\
M'?C#XB^-_P`1M)^$6K?#SPMJ>E^`_BA^T7?^+?$_Q9U"#Q5:7ND^+?$7P\U?
MXD>._&'Q0T?P#>ZG9:MHOC#7;F(^/+_PQ:Z;X<LOI_X!?#"?X)?`[X/_``:N
M/$$7BMOA+\,_!'PTB\2PZ,_AX:[9^!?#>G>&+#5)=%?5]=_L^ZO;'3+>>\@3
M5;N'[6\SP-'"T<,0!R$OP4U/Q=\3?A=\7_B#J7AB+QC\);OQ'+X9NO`GA[6O
M#.JZAI/BCPMXM\(:WX4\9:U=^,M=3Q%X'U:/7="\;'P1)IPL=$^('A'PYK$.
MLZY/HEEJ+_1=%%`!1110`4444`%%%%`!1110`5^=W[;_`/R'/A__`-@K7?\`
MTKT^OT1K\[OVW_\`D.?#_P#[!6N_^E>GT`?:7PG_`.26_#7_`+$#P;_ZCNFU
MW]<!\)_^26_#7_L0/!O_`*CNFUW]`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%?$'BGXQ/X0\7_`SX)F:S\/0?M#_`!5_:DT0^-M7MM.N]-M+
MGP#J?C[QA#X(TRUU=CI=[XO\9P1WFIZ?87UMJ,5QX.\&?$!H;$7D-KJ.F_;]
M>,Z%X*\&^/O`^H:#XZ\)>&?&NA)\3OB/JJZ+XLT'2O$>DKJFD?%WQ=?Z5J2Z
M=K%I>68U#3+Z&*\T^\$/VBRNXH[BVDBF17`!^$G[._[4&M?L\?L=_P#!-:RT
M+5/@?I/A_P`0_L>_M&W4?B_Q9X(UG6SX9\?>!-2^$^@>!M-T6^\.>*(+K2_!
MVO\`B7QW9Z9XE\(V=O'>ZI/8>'()?%VAV6GW=P_TCX1_;T_:#\7^)?$_P[TV
M7X=:/J'@3_@K+<_L!ZCXB\0^&)/%&NZO\,KO]D[P]^T9I?B;4;'PKXV\/>%]
M+^)&D:_XHC\':]+I0O\`PMJ-GX?O7L-*TN_O&N++]6=5^`_P.UV/2(=;^#/P
MHUF+P_HNL^&]`BU7X=^$-0CT3P[XBCEA\0:!I"7>CS+INBZ[#/-%K.EV2PV.
MIQS2QWL$ZR.&:?@'\"C<V5Z?@M\)C>:;K6C>)=.NS\.?!YN;#Q'X=T2S\->'
M]?LISHWFVNM:%X<T[3_#^C:K`Z7VF:)8V>E64\%A:P0(`?B1??\`!4KX_P#P
MVT?]FS7?B/\`\*=U/0_CMX1^.=AXF\2W>BZU\-_!_P`)]8_9^_X*&?LD_L5:
MI\5/%GBB?Q+XT32_!7BCPY^TOJ_CG7DO=)DTKP5KGAGPW:R7I\-S>(M3;Z&M
M?C/^T)?_`+1_[)NG^-OBOX)\2Z#(W[=NIW>@?LT^(]+\7>"_BOI7POM?A9-\
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MOLSQC^T%\9/A7\<OAS\,_&^KZ'KO@OQ5X^\`_#V3XJ^$/!VG7F@V?C;Q]K?B
MW7;7X:?$_P`#P>-[[XB_"W7=;\&1>"-)^%'Q*TJR\>?#37-1C\71?$0^"]2U
M[PI<:)]=7'P#^!5Y8^-],N_@M\)KK3?B9JT.O?$C3[GX<^#Y[+X@:[;OYMOK
M/C>TET9H/%>K02?O(=1UZ._O(I/G296YKK;?P%X%L]9M?$5IX+\)6OB"PM;>
MQLM=M_#FCP:S96-I9-IMK9VNIQ6:7MO:VVG,VGV]O%.D,-DS6L:+`3&0#\VO
MVGM,\5#_`(*/_LN:O\./&'@7X9>./^'=/_!2ICX^\<>"SXQT6WTWP[^T'_P2
MVU6QM?$%A:^*?!5Y<Z#87=[?7=YGQ!`;#2KWQ"VFMIVHZ@-7LO+]%_X*"_'W
MXDZOX-\&Z;X<^!/[.'Q7;]E[]B/]IO5_AU^U!X]USP5/XN_X:%U'7G^-W@#P
MQIVD^$/%/B+7E^%UCH%[\/-*U#P\]MK>C?&N^T"'Q9I6J^&KFTT7Q/\`L%K?
MA/PKXEFTNX\1^&O#_B"XT.YEO=%GUO1M.U6;2+R:(P37>ERW]M.^GW,L!,,L
M]HT,KQ$QNY0XJGKG@+P-XGUSPOXG\2^#/"?B'Q+X(N[N_P#!?B'7/#NCZMKG
MA"^OX%M;Z]\+ZM?V=Q?Z!=WMLJV]W<:3<6DUS`JQ3.\8"T`?D7X.^/'QM^'7
MPJ^-WQSUSXM:WXL\*_"O_@I=\3?"'QGL?%ND^"[A_#O[*^F_&Z3X/W=_HMSI
M?AS0F\+Z3\)O"UYX=^)/B#5[D7[W'P]\`^,TM(F\0ZQ#K$,_B?\`;H^+GPD\
M$_%:3XB:EH@\6_`K]K#P-\*?&OB/Q;;Z/X$^'%G\!_VHOBI\+;7]G7XO>/M1
MAT+4;OPWH_ACX0?%26R\9^*]*6+08?C/\+O'=MX@L-,\)/\`9=#_`%P@\#^"
M[9O%CVWA#PO;MX]G:Y\=-!X?TF)O&ERVEPZ&\_BQH[13XCF;1;:VTAI=8-Y(
M=+MX=/+?9(HX5O:GX:\.:U;:U9:SH&B:M9^)-,_L7Q%::GI5C?VVOZ-Y5W!_
M9.M074$L6JZ9Y.H7\/V"^2>U\J^NX_*V7,PD`/R;\1?ME_'KPKJ7PJ^$&O\`
MC[]D*Q\9_&.?]KR3X=_'B#XI:N_P9O+GX'WWPPO_`(,_#'Q+KM_\/[+3KWXS
M>+_!_P`2=7\2_$W0/">FP:3J&B_!+XK3>!+KPE>WUK!X'Y/Q=^VY^U+X7N?B
MUKFI:M\`;C2_@KH7_!-#Q1K/A_P)X7\8>)?#WC`?M:^.&\$?&/2/#?Q(U[Q7
MH&I7OAZT\V\UCX5^,9_A_P"']1\B#PY<^(_"LT:ZWI>K_K+>_![X1ZCX,T7X
M<:A\+/AS?_#SPU-I5SX<\!WO@CPS=>#-`N-"E\_1)]$\+SZ8^AZ5-H\_[[2I
M;&QMWT^7]Y:-"_S5FZ[\!?@9XHO?$>I>)O@Q\)_$6H^,'T63Q;J&N_#KP?JU
M[XID\-RK/X=D\1W6H:/<3ZV^@SJLVBMJ<ETVERJLEB8'`(`/%_VJ3JNH>,/V
M/_!NG^./&7@2T^(?[1WC'PCK6H>"/%>J>$]4U"R'[&'[7/B;3;2:73KJ"#68
M-+\4^&_#WBVQT/6K;5=$D\0>&=%U*]TF\?3+?R_G1O@]XAL?BQ#\`_\`A87_
M``5$U&PU'PW\(K*W_:*/Q%^';?"31+CX26%QXUOM0OO$D=U9>*9O$GQCN[(^
M#/B\TGPZO-,U^ZU"TT3PU;>#+!GUF'].Y-+TN;^S1+I]C)_8]PMUI&^SMY!I
M5TEG<Z<EQIV^-A8W":?>7=@DUMY4JV=U<VJL()Y8WT*`/E7]C/6K[7?@KJMU
M>^)-;\6QV/[0W[8OAS1M<\0^)M7\8ZG-X4\(_M>_'/PKX,L/^$EU[4=6U;5-
M.T3PEHVBZ'HLEUJ-WY&BZ=I]I!+]FMX57VO7/^2A>`?^P5XW_P#17AVNVL[*
MSTZVCL]/M+6QLX=_DVMG;Q6MM%YDC2R>7!`B1)OE=Y'VJ-TCL[99B3Q.N?\`
M)0O`/_8*\;_^BO#M`'?T444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%?G=^V__`,ASX?\`_8*UW_TKT^OT1K\[OVW_`/D.?#__`+!6
MN_\`I7I]`'VE\)_^26_#7_L0/!O_`*CNFUW]>$?#+QS:VGPW^'UHWAOQO.UK
MX(\*6[3VGA'6+FUF:#0;"(RVUS%;F*XMY2I>&>,F.6-ED0E6!KN/^%A6G_0K
M>/\`_P`(K7/_`)'H`[^BN`_X6%:?]"MX_P#_``BM<_\`D>C_`(6%:?\`0K>/
M_P#PBM<_^1Z`._HK@/\`A85I_P!"MX__`/"*US_Y'H_X6%:?]"MX_P#_``BM
M<_\`D>@#OZ*X#_A85I_T*WC_`/\`"*US_P"1Z/\`A85I_P!"MX__`/"*US_Y
M'H`[^BN`_P"%A6G_`$*WC_\`\(K7/_D>C_A85I_T*WC_`/\`"*US_P"1Z`._
MHK@/^%A6G_0K>/\`_P`(K7/_`)'H_P"%A6G_`$*WC_\`\(K7/_D>@#OZ*X#_
M`(6%:?\`0K>/_P#PBM<_^1Z/^%A6G_0K>/\`_P`(K7/_`)'H`[^BN`_X6%:?
M]"MX_P#_``BM<_\`D>C_`(6%:?\`0K>/_P#PBM<_^1Z`._HK@/\`A85I_P!"
MMX__`/"*US_Y'H_X6%:?]"MX_P#_``BM<_\`D>@#OZ_-;X@>&-9^)WQM^&7P
M;M/B]\6_A)I?C;X,_P#!1+59M6^$'CVZ\'>([77?#O[4O[+.FZ/XJTZVFBU3
MPUJ/B3PYH_BWQ3IF@ZIXB\,^(!X>M_%>N/IT%M+J<\DGW5_PL*T_Z%;Q_P#^
M$5KG_P`CUP'@'Q?I<.E7%Q-X2\7W-[;^,OBHUK?0^"]4NI+6WU?XD^)+VXM(
MKM;9G@=]EI%J=HDBE+RS%O<J9K0!`#R/Q;^RS>Z=I>O^)HOVMOVCO#LNF>.-
M6^*ZWWC+XJW=Q\.]#T>V\`77A63X?^)],T6;P%K%Q\%M,BW^.-2L+7Q[X8\8
MKXL@?7HOB3I=M%':0=I^Q#XNU;QM^QA^R;XP\1:SKNO^(?$/[.7P2U#Q'XB\
M62ZS+X@\0>([KX>^&TUW7-6U#Q"HU;6;W6M8^V:A_;UU+=#Q&;J/6K6^U"UU
M*WOKCV*?QWIMS#-;7/A#QU<6]Q%)#/;S^!]9EAGAE0QRPS126K))%(C,DD;J
MR.C%6!!(I(/'FFVT$5O;>$?'4%O;11P06\'@?68H((8D6.*&&)+98XHHHU5(
MXT"HB*%4``"@#XA\?_MY^*_!?QC\>?#&U^!^BZQHW@/]I;]GK]FJ\\5S?%R[
MTO4+_6OVF/`7ASQ-X`\3VGAA?A7J4$>EZ3XE\6:'X>\:64_B1+O3-$.H^*-!
M?Q/?6<'A.^\F\-?\%,]"U7XD>`=+\5_"6^\->*/%5[\8/@M8KIGQF\2:WX.3
MXO?#7_@HGI'_``3\\1>&VT2;P5X<T+5/#M]\3K%O&OAOXM:IX;M/&EMX"@O=
M%LO!]CJ>OW>A7WTCXD_9I_9F\6^+O%?CK7OA3\;+KQ1XW^+?PJ^.GB74+?QA
M^T/I<%[\4?@C86&F?"[Q+;:5I7CNRT?2(?"UCI>F6\7AW1K#3_"^JKIUB^NZ
M+J<EG;NGG%S^P;^Q!?'Q!_:/P!^,&JIXG'Q0DU2#5_''[2^K6L6H?&/X]#]J
M+Q]KNBVFI?$>ZM?#'BF^_:'6#XQ:!XL\-0Z3XF\#>.[+3=<\":MX:N-+T_[,
M`>A>,OVJ/C?X3\6?`WX9R_LX>%;3XE_''XD?'SX=Z/IGB7X_V]CX0TU/A!X-
M\8?$/PCXRD\5>#_A9X_UB7PQ\4_!OABRU.VM-0\&:+XS\'76OVUAK?A*Y-I/
M<.GPT_;?L?BC<?LR7^@_#[9X*_;,^%/C3XG_`+.WBN3Q7/))J(\-^%=#^(.@
M^'OB=HD?A$7'P^NO&/@#6G\0VNH:5=^.K+1KS0=<\.ZP(-7;P_%XAU]&^`/[
M/6AZM\&_$%K\.OCO>^(_@-K?B3Q-\._$WB'QO^T7XK\3'Q)XO\+3^!_$7B'Q
M_P"(_%'CW6-;^,>NZGX.G;PQ)J_QAO\`QWJ$&B16>G6MQ;VMC91V_4>#OA=\
M"OA];Q6G@KX2?$'PU:V%GX_T[P_;Z7I_Q*@A\$Z?\4-6M]=\<:?\.(_[69?A
MI8ZUJUI:7D=G\/QX;MM(DM+5-$CTV*VAC0`^%_#?_!6/Q%K7P9\._&[4/V;]
M'TGPSKO[$G[*'[>TMA'\<+S4=6L/@W^T7/>6GBG0#&OP9M+>Z^(_PWN+-Y=!
MT5)XO#?Q#L'2>_\`%WP\O=VFCTSQA_P4+\8:Y\!_''QK^!_P0U?7?!,?[/?[
M3GQ5\%_%#Q-_PE.E^$M%\3_!/2M9U+P3I?CW2M5\&>'H+W1_B18Z'J^HV$_P
M]\7>,+O3=0TB3PWKD.D1ZA!XB@Z*#]A;]BJV^']K\+;?X&_&V#P'9?LY^!OV
M2K30(_B)^T^J6_[/7PUUJ;7_``+\.H[\?$S^U1;>&]0GFCL?$(OCXN;2I#H-
MSK\^A8TX=?X)_90_9.^'EQ\1SX5^"?Q8MM$^*]IXVM/&G@+5O$'Q[\4?">=_
MB7_:O_"QM5\.?!WQ3XVUGX5>`_$?C_\`MW73XV\5>`_!WAKQ-XJ.N:R==U:_
M.JZA]I`.:TC]M_Q;!9Z#X&TWX/\`B'XQ_%_PG\(_V6_B5\8=*\$76KB.VT7]
MH/6/$ND3:OX;U=?AY9^#+K5_#6@>!O%'Q"UC1/%NJ?##1[VQ2#0/#&LW^I">
M*SKV_P"WSXLM/#OQ`^(WBGX&Z9H/PB^'/[17Q7_9V\4^/=-^(/CGQI+X1O/A
M3XB\8Z%J7Q5^(/ASPE\!=4O/"'P=NI/#&G6^H^,TN];7P;JGB>RN/&=CHG@7
M2M=\?Z?VDW[+?[+EQXJ^&?C=OA+\:XO%OPI\#:+\,/#VO6OC/]HJQU#Q)\-/
M#FH7VJ^'OAW\89++Q];I\?\`P)H.J:IJNHZ-X1^.R_$;P]I=_J^K7=CIT$^I
MW\EQTOAOX&?`'PA8W.G^&_AW\=-*@N_C+XV_:`GE@\8_M"27Y^+/Q&TCQ9H?
MC7Q+'JEQXYFU.WM->T_QQXH^T>%(+N+P=;WVI)J]CX?M=6T_2[ZR`/IOX:^+
M9/'_`,.O`'CR:VT:RE\:^"?"OBV6S\.^*=,\<^'[23Q)H5AK+VVA>-M%CBT;
MQAHT#7ABTSQ3I,4>F>(+)+?5K"-+6[B4=M7S_P""=.^'7PWTGP3X=\!?#WXB
M>$O"WPX^'VD?"WP/X,T/1/'-AX'\-^!?#]MI-CH.C:?X)ANQX3$NAZ=H>FZ5
MH^LS:/+KVF:1#-I%CJ<&FWM]:W'H/_"PK3_H5O'_`/X16N?_`"/0!W]%<!_P
ML*T_Z%;Q_P#^$5KG_P`CT?\`"PK3_H5O'_\`X16N?_(]`'?UP&N?\E"\`_\`
M8*\;_P#HKP[1_P`+"M/^A6\?_P#A%:Y_\CUQ&L^.K63QUX)N1X;\;JMOIOC!
M#%)X1UA+B4SQZ$%>VMV@$DZ1>6WGN@(A#Q[\>8F0#W:BN`_X6%:?]"MX_P#_
M``BM<_\`D>C_`(6%:?\`0K>/_P#PBM<_^1Z`._HK@/\`A85I_P!"MX__`/"*
MUS_Y'H_X6%:?]"MX_P#_``BM<_\`D>@#OZ*X#_A85I_T*WC_`/\`"*US_P"1
MZ/\`A85I_P!"MX__`/"*US_Y'H`[^BN`_P"%A6G_`$*WC_\`\(K7/_D>C_A8
M5I_T*WC_`/\`"*US_P"1Z`._HK@/^%A6G_0K>/\`_P`(K7/_`)'H_P"%A6G_
M`$*WC_\`\(K7/_D>@#OZ*X#_`(6%:?\`0K>/_P#PBM<_^1Z/^%A6G_0K>/\`
M_P`(K7/_`)'H`[^BN`_X6%:?]"MX_P#_``BM<_\`D>C_`(6%:?\`0K>/_P#P
MBM<_^1Z`._HK@/\`A85I_P!"MX__`/"*US_Y'H_X6%:?]"MX_P#_``BM<_\`
MD>@#OZ*X#_A85I_T*WC_`/\`"*US_P"1Z/\`A85I_P!"MX__`/"*US_Y'H`[
M^BN`_P"%A6G_`$*WC_\`\(K7/_D>C_A85I_T*WC_`/\`"*US_P"1Z`._K\[O
MVW_^0Y\/_P#L%:[_`.E>GU]I?\+"M/\`H5O'_P#X16N?_(]?!_[8FN1:_K'@
M>2'2]:TX6VFZTA77M&O-(DE,EU8-NMDO8XS.B[<2-'N",5#8+#(!]+>&_CG\
M+_A]H7P*^'/BSQ%<Z?XX\=?"S2-;\'>&[;PUXKUK4?$NE>&=`T-?$]]HZZ'H
M>I17L/A=+_3;CQ.896;P[9:KI-_K2V-EJNG7%S[QX5\6>%_'/AW1_%_@KQ'H
M7B[PIXALHM2T'Q+X9U:PUW0=:T^?/DWVEZOID]S87]K)M8)/:W$L1*LH8E2!
M^1?Q^F^)\WQU_P"">%M\#O$GP_\`#GQ6LOV5OVHK?PQK'Q0\+^(O%OP\TOQ5
MXK\`_`FU^'6G^-[;POXF\)ZCI-GXQU_P[J=AH]R=8^V:D-#U^/0](U^^TRXL
MH_F[1OBGXS\.^&/`?P.^'NH?M-_LV>#?%_PK^/3:KXNL?@%\3_CW\8/AG_P4
M3\<_'CQ#X\^*MC\1])^$&G>'_"<5[<>-/%GB'Q[\'-5UGPK)^R?\9]'D\:6_
MANPN/`EIX;TQP#^B:O+/&/QK^&'P\^$_C'XY>/?%,7@SX4_#[0?%'BCQMXO\
M4Z9K>A6GAGP[X,DU"/Q-K&K6&I:9;:Q;6&EC2[Z9YVTXK<V<*WUG]ILY[>>7
MXE\->.OC2/VLWTKQ)?\`BOQ!\)-2E^)4MYXFT^3Q/\.7^"TG@SX?Z+I4VB?$
M_P"'_B"/6OAIXQ^&?B7Q'%K_`(F^%WQU\!>*['4D\4-+\/\`7/#'BY/#GB?Q
MCH7Y$^+_`(L_M)_&O_@F7^UC\*?C%9_'_P`=ZU\0_P#@FS^V/I_P/U;P]X.^
M)>N>+_BG^T3+XQ_;0\,>*OA?\0[3P/X7E6+6K?X/6O[+U[\+/!WBBVTNT\:>
M%?&_CC6=`TG5K?P\VI:$`?U1T5^(W[5OQ!^/'A3QQ^U?;^#+W]I5;?Q'8?\`
M!._XE_L^:?X+\._''6@MI<?';4O#'[1MKX<TWP_I%^=&=?"/]EQ?$SX<7D%E
M+;:?JFBWVL>%XKC6+">Z]8^`'Q+^._C[]JC7O#?Q,\6_&#P'XK^&7QQ_:7TS
MQ%\*A^SU\4U^#WQ%_9MU36/&;?LN^,+3XVZYJ"_!.")O`-O\+->FU3P)81?$
MM_BC#\0/AKXEM+BSM?%=]8`'ZPT5^67[3'C/]J-_$O[8'AKX=#Q=X=^)'@_X
M3?"/QA^P6ND0:S_P@'Q1^(DD/B^?Q'X;\6R6UE-X?\2W6I?$/3=+\'_%OPUX
MD>^B\!_!>\\.?$;2H_"+ZEJWB]/`_$WQ?^+6@?';X]:Y!\6/B5>6O@7_`(*T
M_LV?"KX?>'+O7=2/@JU_9@^*'[+W[(MI\<;?_A%;"&RT3Q-\/]"^*.N?'X'Q
M=X@MM;M?AKXZ\%>*SI>M:#K/A_Q<+D`_;*YUO3[/6-*T&9KO^TM9M-5O;!(M
M-U*XM&M]&;3UOVN]4M[.72]-D5M4LQ;0:E>6D^H%YO[.BNOLEW]GUZ_([_@I
M/\:/C#\(_&?@JY^%7Q*\3>"(%_9/_;E\4ZM%I7AC6O&VA6_CGPAX)^'NJ?"+
M6]7\,^&/#WB+7;W7H[P>-H_!MK#INLO>W5MJ]U8^%_$LNB76G-\\^.?VE=4\
M7_!_]J3XB_`KX^?&+0;R;XA?L@Z?\./ASK%C\6K'XD?#S0'^+?@G0/C1K&E0
M?&7PK!=:_P"%_&NCWGB;4;N71=-\11>&?#.B7>IZYK6A)J=QX2\+@'[PZSK6
MGZ!9PWVI-=K;3ZMH.BQFRTW4M5F.H>)=<T[P[I*O:Z3:7MU%:/JNJV:W^I2P
MIINC6+7.L:S=V&CV-]?6U>?Q-HL$^B6_VM[I_$.O:EX9TR33;.^U:U_MK2-.
M\0:IJ=IJ-[IEM=V>BI8P>%];M;B\UJ?3[&/6;6'P^;G^W=0TW3KO\5/&_P`9
M_BCX2\+_`+5/A[PM\5/B&FE_"7_@KI_P3V\#?"S5;CQ'K7BC7M3_`&7OB3K_
M`/P3M\4?M,Z?-XMU]M;U[Q7\+=.NO''[:=EXGUO^U+C3O`GASP'XY\-)JNBZ
M!\*[[3]%\*L?$_[3WP'_`&6OV3O#/P"F^)UK\?Y_VP_^"DWA_P`0?#OXI7OC
MFXTOQWKK?`3_`(*/>*?@I:_$35/B2M[>7/P_U[]I&S_9532_%MGK,?A/7/&G
MC?PO(-4U77_&\,FI`']'U%?AO^UA\2_VAM+_`&<_VD?B5^S=XY^--MX9N?\`
M@EK^T9XUBGUZU\1CXM>!/VY-"TKPE/\`LT>'_"NA>)]&DUWP_P#%7QS/K'Q(
MT+XA_!_2M.MWT;Q%X:^&UC:>"O#.J>*+27Q#]H?LU>-]:N?VI_VN?AQ!XY\1
M^-OAAI?AW]G?XE?#?4/$GB#4/%D,FN?$;P]XW_X6@OA#Q%J$UQ;GPTDVA>!-
M7D\'^&IH?"W@B]\2HNC:/H&G^(K*P8`^^****`"BBB@`KYG^,WQI\%?L<_`7
MQM\9OBL-=O\`PAX5\83WM_;^"M&D\0^(;N;XN?&:+0O"6FZ5HYGL6O;Z76_'
MV@Z?=()XXXR;J99)(HPS_3%?CC_P6X\*S^/_`-A5/$^A?$'Q'X<T[X5_M-?L
MY^*M>T7PW?W%MH_Q,@B^..A?""[^'WCB&&YMX]2\.:)XI\<67C^*PNXKVWA\
M=?#;PI?K;+=Z=;7MH`?5%A_P40_9NF^+/B3X':Y?>/\`P?\`%'P9\#/#W[07
MC'P=XE^&_BM-?\+>!];T#6/$^HV^L:+HMCK6LQ:MX.T;2H#XKN+?3KGPQ!K.
MN:'X2T;Q)K7C"[GT"T\]@_X*P_L:S_!OX`?'7_A+O%4?@3]I'QS9_#CX=W/_
M``ANI7%Q+XQFM+*XU#0I;BQ:[T37=8T>>_BT>70O`6L^,]?U[Q!::YH'@O2?
M%.K>%O%%IHOVWJWPH^#MUXCUCQSKGPW^&UQXL\3:#J/@;Q!XNU7PAX9EU_Q%
MX9\7+X:T;5/"&MZ[=Z>;_5]$\2Q^&O".DWN@ZA<W-EJ\>A>']/EM;A--L(8L
MZ3]GWX"S:'X=\,3_``3^$D_AOPAXGU7QMX3\/W'PX\'SZ)X7\9:YK5]XCUGQ
M9X<TN71WL=$\2:KX@U/4M;U#6],@M=3O-6O[S4)[I[JYFE<`Y7X-_M,^`?C;
M\1OV@_A5X;TCQSH7C3]F?QWI7@'XD:=XT\,R>'HY;_Q%H@\3>&-<\+W#7=TF
MO^%O$WAJ6S\0:'K$8MQ=Z5J%C.UO"\QBC]-T'XG?#SQ3J/BK2/#OC3PYK&I^
M"&D7Q;9V&K6D\V@)#J_B3P[/<Z@JRXBLK;Q-X,\:>%[J_4M96WBGP7XQ\-3W
M$>N>%/$%AIOY^_LB?\I"?^"MW_92?V.O_60O`=<E\4OV==9^&4O[5OCKX&>%
M/%?Q;\56GP<^*?B^_P#`7B%A;:+\6/%-[\1/VA?VK/!/[,&B#3+/3FUK3OB/
M\9?CAX@@^)^K7-WY%M\)X_AM\*TTS6+OQ?\`$#Q/0!^K.CZOIGB#2-+U[1;V
M#4M'UO3K'5])U&U??;7^F:E;17MA>V[X&^"ZM9HIXFP-T<BG`S6C7S!^RW\3
M?BG\3=$^*T_Q,\)OHMAX-^-7BOP+\*_&;:9=:"OQE^%FD:#X2U'1_BE'X<O`
M+C0DN_$>L^*_!GE82SUEO!+>*M(B@T;Q!I\$?T_0`4444`%%%%`!1110`444
M4`%><^)KF.S\<^";N59WBM=#\>W$J6MK<WURT<%MX?E=;>RLHKB\O)V52(;6
MT@GNKB0K%!#)*Z(WHU<!KG_)0O`/_8*\;_\`HKP[0!P>G_M/?`O5?A!KOQ]T
M[Q[;7?P;\,R^)$U_XA1:)XG/A_2HO!EY=Z=XQO[J8Z()UT?PCJ.G:KIOBC7%
M@;1_#VHZ-K=AJ]]9W>BZK#9[6I?'_P"#>BWEAIVM^/\`1=%U#4M=\+^$K6QU
MD7NDW@\<>-K+2-3\(_#J[MM0M+:;3OB;XCTO7]%U31_AIJ"6OCR^TO4K74H?
M#SV4@GK\Z/A]X%\0:/\`\$[OCA^R-JMA>V'QT\60_MQ?##P]X+FTW43J6J3?
M&#XS?&ZU^'WC>TMXK6227X::UI'COPMXGG\?*I\,:)H6HR2:]J6F7NG:G96?
M&?$'PEXU\,?'GQ[\7_V<=9\8R_\`"6?M8?":W_:3_8L^-O@G5KOX7?%VY\'^
M,_A!X3N_VL?V;_'6J:9H.O?#[Q!\-OA_HOA'XA>)O&7A?6_''P$U35?AM<>$
M_&OA;0O']OJWBR,`_3GP+^TK\#?B1/I5OX0^(>E7TNO^*?&7@7PY_:-IK'AN
M/Q/XY^'.J>*-$^(O@GPM-XFTW1X?$WC'X?:QX(\9:7X[\+Z#)J.N^#M0\*>(
M[3Q'8:;/HNHQV_N5?CY^PU\&;'XS?"9[KQSXFED\,?"C_@II_P`%"_V@_!?@
M72-#E\/:K=ZQJG_!07]KKQU\)/$GC'7M1O\`4=1UOP;KWAGQ]H/Q9\"CPUI7
M@RW\2Z-JGA6\N]6\4^#[R[LM<^P/C)\%/BYXN\<7WBJ#QC:?%+X6RV.G0)^S
M/XJUS7OA/X:2YAMH[;6[R7X@_#J&[G\?:3KD,+/??#+XQ>#O&O@[5KF]NK1]
M7\/:3*(H`#UG5/VD/@!H?Q<\-_`/6?C/\,=*^-?C"UN;OPK\++_QKH%KXZ\0
M1VEC=ZK/%I/AR:^34KV\_LG3M4UB'3X('O[K1](UC5K:VET[2-2N;7?TCXR?
M"K73>?V7\0/"]S%9:+>^)VNVU6VMM/O?"NFRVUMJ7BW1M1NV@L-?\(Z9>WEO
MINI>*M#N=0\/Z?JSG2;S4H=2CEM4_/CXA_&']F+6OB_\`_V<?$'@/Q?\-M4^
M&OQ0^%'Q+MOA_HGP+\>ZMI]G\5H-(&A?"'P3:>,/@]X1\5?"'2(/"4FLZ'X@
M\:>+8OB)!X3\+:-H.B>%-2OKO0;[QI_PA_@O[`7@#X@_!_XD_"74_%&BZE+\
M#]*_9*^)5AX(\'_$2"XTSXA?\$N-,'B[X0>*?$_[&GBKQC.;72_B3X!UO2M-
M\$Z?X0\4:]%'XRL='_9NTZ^T#4O&?PHU72=:\.`'[2>"O&W@_P")'A'PKX^\
M`>)]"\9^"?'/A?P_XV\&^*_#6IVFLZ!XH\'^+-,@UKPQXGT+5+&6:TU/0O$&
MDW-OJ6CZG:2RVFH64T=Q;2R1,&KYJ^/'BCQKX>^,W[/+^"/%&MW]B?'6E:3\
M5_AIX9\2>#)M8'P\\;Q:YX5TCQO=_#75/"]WXG\3>&K/QY+H4WBKQ7I/C#P]
M/\/_``SX9UKQ%I=AK=E;>,+"?XG_`&)?A?J?B?\`X)Q?\$TO#=O\`K+5/B;X
M-_8/_9>\'W_Q2\5>,KOX->(/@SKWA?X-^"O"_CCP/%XM\$-+^T+X?\;:+XBT
MK4M-\1^!]#TCPQHM_-9ZOX8\5>,="NC>V=?J+\'O!_CWP+X%T_P[\2_BE>_&
M+Q;;W>I3W?C2]\+Z+X/$ME=7LTNEZ/::)HSW12RT/3S;Z;#?:SJVO>(=4:"3
M4=:UN_O;F1U`/4****`"BBB@`HHHH`****`"BBB@`HHHH`*_.[]M_P#Y#GP_
M_P"P5KO_`*5Z?7Z(U^=W[;__`"'/A_\`]@K7?_2O3Z`/IOX96'Q(?X;_``^>
MQ\5^"+:R?P1X4:SM[OX?:]>W4%JV@V!MX;F\A^)MA#=W$4)1)KF*QLHYY%:5
M+2V5Q"G;_P!G?%+_`*'+P!_X;7Q%_P#/7KY1/[0'CSP'X[_8Z^`GA;X9>$?%
M=K\<O@9XS\4IXQU_XHZSX.N/#-Y\'?#?PUGOM*;PUIWPI\:QZQ;:W:^.[%[3
M5!XCTN6TN+*[@FTN6-H;E_*_@+_P4Y^'GQ3^)WQ!\$_$G3/"WP,T+PG\/_@?
MKOA[Q'XL^(,,X\8>./B;^TE^V=^RWXC\.Z9]N\.^'M/F\)6/Q'_9!NKWX:>/
MK*^O-.^)O@OXC>#/$S67A:;5[71"`?H%_9WQ2_Z'+P!_X;7Q%_\`/7H_L[XI
M?]#EX`_\-KXB_P#GKTV]^*WPWT[Q78^![_QKX?L_%.I:T/#%CI5SJ$4+W7BQ
M_#I\81>#HKERMBWC6?P>&\86W@[[2/$]SX127Q1;Z5)H,4FH+1N?C3\);*^U
MS3M0^(GA/2[GPWHGC#Q+K;:MK-II5I8>&_A[J.GZ-X^\1/J&HR6VGRZ#X'US
M5++0?%^LP7,VF^&M?>;0M9N;+5K2\LX`#0_L[XI?]#EX`_\`#:^(O_GKT?V=
M\4O^AR\`?^&U\1?_`#UZ^3OCC^WM\)/!7[.GQP^.'P0\6_##X\ZM\%/AYX5^
M)NK^$-(^)%EI\<G@WQJ_F>&/$]QJ6DZ7XGNH-`\0:=:ZY=>&M672FT7Q%J'A
MS6M#@UFQNM+UBXTKZ5T+X\_!KQ1I'B77?#7Q+\(>(=-\'>,%^'WB670]7M]6
MN-*\>36NCW]AX+FT^P:XU&7Q5K6G^(O#NH>'=`MK6;5/$FG^(O#U_H%IJ5IK
MNE378!N?V=\4O^AR\`?^&U\1?_/7H_L[XI?]#EX`_P##:^(O_GKUPFO?M2?L
MY>%]$\/>(O$GQM^&F@Z3XMU[QEX4\,S:MXMTBPN==\6_#O1/$WB/Q_X0TS3;
MFYCU.Z\7>"-&\&>++WQ;X6CLSK_AT>'=7@U;3K2YL9X4ZBV^-?PJOM5FT/3?
M'&B:KK2:3XIUNSTG2)9]7U'7].\#7D6F>-W\(V>FP7=QXTN?!FKW-GHGB[3_
M``E'K6H^&M=O].T/6[6RU;4;&RN`#F_B/\*-?^+?@CQ#\.OB%K'P^\0>#_%%
MI'9ZSI?_``@GC;29I4M[NWU"SN;+5]$^,NFZWH^J:;J-I9ZEI.LZ-J6GZMI.
MIV=KJ.FWMK>VT$\<'P_^$GBWX::4=(\.>.[34H2S,;_Q^?C5\6/$15G,AM_^
M$K^*?[0?C+Q/]C60L\=C_;'V.)R6C@1B35OPS^TO\!/&,'AV[\-?%3PEJUAX
MO^#6E?M#>%-4@OVCTCQ+\$-:CTF73?B?H.KW$4.F:MX0GCU_0V?5;"[GBMO[
M8TQ;H0-?6PD]&\)>.?"?CF'5YO"NM6^JMX>U9?#_`(CLA'<V>J^&_$#:-H_B
M$^'_`!)HVH06FK>']>BT3Q!HFIW.BZQ966IVMIJEE)<VL7GH"`9G]G?%+_H<
MO`'_`(;7Q%_\]>C^SOBE_P!#EX`_\-KXB_\`GKUW]%`'`?V=\4O^AR\`?^&U
M\1?_`#UZ/[.^*7_0Y>`/_#:^(O\`YZ]=_10!P']G?%+_`*'+P!_X;7Q%_P#/
M7H_L[XI?]#EX`_\`#:^(O_GKUW]%`'`?V=\4O^AR\`?^&U\1?_/7H_L[XI?]
M#EX`_P##:^(O_GKUW]%`'`?V=\4O^AR\`?\`AM?$7_SUZ\5'PEC^,?PV\0_#
MSXJV/PM^(/PRU_Q[XW/BCP/XL^&5_K6F:Y-H7QAUO78YG2]\?RV$36_B?2+?
M7M!:?2KV70[FVTQC-J-YIPO[CZIK\M/BA\6_C9H7[5_[#/P#^&/CW2O`G@WX
MT>-?VZO&/Q5:]\$Z3XQOO$VD_`OXA>$=?TOPI8W&J7-I-X=M]?M_%?B#2M1U
MC2YEU&UCO8+NU_TBRA!`/TUT'0M'\+Z'HWAGP_IUMI&@>'=)T[0M#TJR3RK/
M3-'TBSAT_3=/M8\GR[:RLK>"V@3)V11(N3CC6K\8+OQG_P`%HX/V;_B7J\/P
MG^"]]^T1H_[0UM/X"\(6^M>"+"U\7?L_074WQ(U&"#Q1<^+=0\*>&+V_TRZT
MWX":3I.M:/XD\3Z7J.E:[K=]XUUB/6]*^+&@?1]Y+_P48U3]JB\\'A?AIX:_
M9;U+]G66UC^,FB:1X<OM7\._M!7?AZ6V:]TOX;:[XPU/Q7?1:9XOFCU[3KW5
M]6O?!\OA.U7P-J7A:^UR>3XG``^R/`WP>^%GPSUSXA>)_A_\/_"?@_Q)\6?$
MY\9_$W7]`T6RT_6?'GBKR#;)KOBK4H(EO-:U""U)MK6:^FF^R6Y,%L(HF*&_
M<Z?\2FN)VM/%O@:"T::5K:&X^'FOW5Q#;EV,,4]S%\3[..YFCCV)+/':6J3.
M&D2VA5A$ORM_P3<^.7Q%_:4_89_9S^.7Q8OM+U?XD_$7P+<:QXLU#2-)@\/Z
M3?:K;^(M<TGS[72;0S6^FPRP:?`6@A,JQL790V<'!^$G_!0#P7\5-2^)-O#X
M%\2:=I_A'05\0^#KBQNEUG5/B(EY^T9\??V:/#_AVUTNXT[1;7P[XS\6^-_@
M/=W?AK0=2U>XM[O2_%=A+>ZKIS:%XE.F@'V#_9WQ2_Z'+P!_X;7Q%_\`/7H_
ML[XI?]#EX`_\-KXB_P#GKUUNCS:K<:1I5QKUA9:5KD^FV,VLZ7IFIS:UINFZ
MK+;1/J-AI^LW&F:+/JUE9WC36]IJ<^C:3-?P1I=2:98/*UK%I4`<!_9WQ2_Z
M'+P!_P"&U\1?_/7H_L[XI?\`0Y>`/_#:^(O_`)Z]=_10!P']G?%+_H<O`'_A
MM?$7_P`]>C^SOBE_T.7@#_PVOB+_`.>O7?T4`<!_9WQ2_P"AR\`?^&U\1?\`
MSUZ/[.^*7_0Y>`/_``VOB+_YZ]=_10!P']G?%+_H<O`'_AM?$7_SUZ/[.^*7
M_0Y>`/\`PVOB+_YZ]=_10!P']G?%+_H<O`'_`(;7Q%_\]>N(UBP^)`\=>"5E
M\5^"'NVTSQB;6>/X?:]';PQK'H7VE;BU;XFRRW+R@PB!X[NT6W*2%X[KS5$/
MNU><^)FN4\<^"7LHH+B\70_'K6D%U<R6=M/=+;>'S!#<7<5K?2VL$DH1)KB*
MRO)((V:5+6X91$X!/_9WQ2_Z'+P!_P"&U\1?_/7H_L[XI?\`0Y>`/_#:^(O_
M`)Z]?%/P7_;RO_BIX4^`<6I_"O0O#?QB_:-^('[1'ACP%\-=)^)VH^)_#^G^
M#/V9?%_B+PG\2/B5XK\?7OPP\*7NFZ1;7>C:/96NDZ5X$UW4)/$?C[P-H_F'
M3KWQ!XA\-=!\0OVJ/CO\.?BY\$?A3K/[.?@A3\=_VE-6^`7@[Q5)\>/$,.BW
M&DZ?^Q[\8?VJH?B)`(?@#>2W"G4_@3\1/A/JW@^=K#5-(U&WT#Q@M_J&C:_!
M96X!];?V=\4O^AR\`?\`AM?$7_SUZ/[.^*7_`$.7@#_PVOB+_P">O7#?`#XW
MP?'/0/'>HMX9N?"VK_#;XO\`Q*^"_B>R&H'7=`O/$GPUU^31-1U3PAXG_L[1
MU\2^'KQ3`#>MI.F7FDZ[%KGA35["TUOP]J<"<)H'[7'A#6?VLO$O[*=WX<US
M1-3M?`5QXM^'WQ"U":S/A'XLZ[X-OM(@^-_@?P>T#22'6_@O9^//A%<^(?M<
MR2ZM=>-]>T_2[+?\-_%L\(![I_9WQ2_Z'+P!_P"&U\1?_/7H_L[XI?\`0Y>`
M/_#:^(O_`)Z]?,$_[4GQ(D^-'[3_`,)M/^%OPLM+#]G/P=\)_&47C7QC\>?$
M/AC3_%EG\6]-\?7>CV^J6-I\!_$*>#I--NO`DUGJ$D.I^*TD75+::S6>:)K.
M7`^&_P"VYJ'Q5^(?B[X9^%/ACH!\<?"3XP>%OA;\>OAIJ7Q52W^,WPITCQ'H
M>D7B_%>?X:VG@2_;Q'\+[K6-9M+?PGXOL?$-IH7B[PL+GQA;:GI\6G:MI&G`
M'TWI6O\`B77=!G\5:)\6O@[K/A>TDUR&Z\2:5X0O]0T&VF\,:CJ&C^)8I]8M
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M:QX+TW1_#?B35--\8WOBDZ5J6G:>D>F>$;CPUX3:_P!>/AH^(=6`.]_L[XI?
M]#EX`_\`#:^(O_GKT?V=\4O^AR\`?^&U\1?_`#UZ[^B@#@/[.^*7_0Y>`/\`
MPVOB+_YZ]']G?%+_`*'+P!_X;7Q%_P#/7KOZ*`.`_L[XI?\`0Y>`/_#:^(O_
M`)Z]']G?%+_H<O`'_AM?$7_SUZ[^B@#@/[.^*7_0Y>`/_#:^(O\`YZ]']G?%
M+_H<O`'_`(;7Q%_\]>N_HH`X#^SOBE_T.7@#_P`-KXB_^>O1_9WQ2_Z'+P!_
MX;7Q%_\`/7KOZ*`.`_L[XI?]#EX`_P##:^(O_GKT?V=\4O\`H<O`'_AM?$7_
M`,]>N_HH`X#^SOBE_P!#EX`_\-KXB_\`GKU\'_MAP>)K?6/`X\2ZOH6K2MIF
MLFU?0O#FH^'XX4%U8^:MQ'?^*/$[7+.Q0QO'+:"-596CE+!D_2^OSN_;?_Y#
MGP__`.P5KO\`Z5Z?0`W6_P!G+Q'\6_BG^PK\6+OPY\*_$_PN^"?P6\?Z+XIT
M7QU>W]WK]_JGQ>\*_"^RLM1\.^')?`FO^'K@^&;?P,TIFU'Q#IEQJ#:Y-:Q?
MV>E@;C4/-?VF/V(?C#\6/%'[:EQ\.Y/A#X=\+_M&_L;_`+*G[+_P[MM3\2>*
M-%G\'ZC^SO\`%+]I_P"(%]KFKZ-H?PWU33K'0=3L/VDSI&A:;H>I7L]B_@*W
MEF$4/B7R_#7W/\,OAMX&OOAO\/KZ\\,Z;<7=YX'\*75U/(DA>>YN="L)IYG(
MD`+RRN[L0`-S$@#-=O\`\*L^'O\`T*>E?]^Y?_CM`'Q6/V+?$^KR^,O#'BCQ
M?IEQX!\4?MK_``L_;ATC4[/4-<E^('@_Q1\/_%_PP^*=W\)[:\FL;6RUOPK>
M?$KX:R6-MXM:[T25O@_XMO\`X97/@51I4?B#5N=U;]FKQ;\*]2_:7^,3>*-&
M\*^!O&/PE_:Q'B/X4^&-:\4:]X+\5^-?B5XZM_&7@+XJ:/X>\6Q"R^#/CRW\
M(:9JVC?&'1_AE/)X;^/7Q'\;R_$'Q)8V_B/POI=WK'WM_P`*L^'O_0IZ5_W[
ME_\`CM'_``JSX>_]"GI7_?N7_P".T`?C/X5_8M^(O[1G["'PXO-.N?!'ACXG
M>+_^":_P+_92T#3-7U[Q58Z#I-K`GA'Q7XVUCX@-!X-NM5@\0Z1JOA[3]%TK
MP<OAZ[N?!VI6_C&PN_$-Q)XAN5TSZ3U?]C7XV:S^T'X[^/T7B3X?^']23]J7
MX&?M+?#OPU:>*/%NJZ5KJ>`?V7-<_95^(7P^^(K'P3HG]GVGB/P;XQ\5:_X2
M\1Z5!XG&@^+K3P?K.H>&]2309+&[_07_`(59\/?^A3TK_OW+_P#':/\`A5GP
M]_Z%/2O^_<O_`,=H`^$M5_8J\;VGQP^#_P`8?"VJ>#I/L'_!0?QE^V_\7=$U
M?Q!XCLK/3X?$?[`OQ"_8/LO!OPQM;?PIK$-[=IHOBW1?BCKUYJ\GA.PUGQCI
M?B<);64GC5M2T'H/A%^Q7KW@=OV8]&\6^-+/7]&_8_\`B]\=?B7\,/%-A<:Q
M'XS\=Z;\6_#'QG\":#X:^)5M=QBS'_"+^#/C;JD?BF^@UC7XOB%XZ\&>$_B"
M+'PC-O\`#UA]F_\`"K/A[_T*>E?]^Y?_`([1_P`*L^'O_0IZ5_W[E_\`CM`'
MY5_"3_@G9\7?`/@WX'>`?$NJ?`OQKX.^!'_!/BQ_X)]1>&M?@\9ZO8_%7PCX
M<\1?""WT_P`=>*YH]+T0^$KGQ?X$^%\T>N>%M&M?$$O@_P`2ZRLNA>+]?@LH
M+]/OO]F#X)>*O@3X<^('AOQ!X\U_QGHGB#XF7?BOX=Z3XJ\7>)OB=XC^&O@:
M;P1X$\.P_#W5/C#X[S\1/BTMKXF\->)_%.D^*OB!)=>)=$T'Q9I7PY&HZKHG
M@71M3O/6?^%6?#W_`*%/2O\`OW+_`/':/^%6?#W_`*%/2O\`OW+_`/':`._H
MK@/^%6?#W_H4]*_[]R__`!VC_A5GP]_Z%/2O^_<O_P`=H`[^BN`_X59\/?\`
MH4]*_P"_<O\`\=H_X59\/?\`H4]*_P"_<O\`\=H`[^BN`_X59\/?^A3TK_OW
M+_\`':/^%6?#W_H4]*_[]R__`!V@#OZ*X#_A5GP]_P"A3TK_`+]R_P#QVC_A
M5GP]_P"A3TK_`+]R_P#QV@#OZ_*;XH?#GXDZI^V;^P#\8?#?PZ\6>,_AS\,?
M%?\`P4"\)?$GQ!X5O-!A;P+>?%[Q]X&TCP1J^NVFJ>)-!U2Z\.R77AK7+G7)
M=#M]:E@TO2[R.ZTVZ6ZM[*^_1K_A5GP]_P"A3TK_`+]R_P#QVN(^'WPV\#7F
MA7\UUX9TV>5/''Q-M4=TD++;6/Q(\5V-G"")!A+>TMH((QU"1*"2<D@'L\EI
M.^IVE^NJWT-I;6&I6D^B1QZ8=,U"XOKC2YK;5;R:73I=9CO]'CT^\M-.CL-7
ML=,EM]<U5M7T[5+N'1+G1Z7B349])\/:]JMIIVMZQ<Z9HNJ:A;Z3X;ATZX\0
MZI/96,]U#INA6^L7-GI4VM7SQ+:Z7#J=U:Z?+?36Z7MS!;-)*G.?\*L^'O\`
MT*>E?]^Y?_CM'_"K/A[_`-"GI7_?N7_X[0!\B_\`!+KX2_$?X%?L!?LQ?"7X
MN>%;OP1\1_!?@"?3_%?A._OM'U*]T+4+KQ-KVJ1V-W>Z!J6KZ/-.ME?VLDHL
M=2NHXFD,+2>;'(B>D?&3]DKP?\1?AM\0O!O@75[KX-^(_$WP7^)OPO\``_C#
MP3I>DV4WPT\6?$#P#K7P_P!-^,NDVME:Z;?ZE\2/!&CZU>6GAC6;[6Q/I>EW
M^OZ9IDFG)XFUV>]]R_X59\/?^A3TK_OW+_\`':/^%6?#W_H4]*_[]R__`!V@
M#Q_]ESX&>)?@7HGQ7M/$7BF#58?B5\:_%?Q5\->!M%:5O`WP5\-Z]H'A+0K7
MX6?#MKBQTJ=O"\6H>&-3\>WCR:1I*R>,O'GBM[>PAM&MVD^GZX#_`(59\/?^
MA3TK_OW+_P#':/\`A5GP]_Z%/2O^_<O_`,=H`[^BN`_X59\/?^A3TK_OW+_\
M=H_X59\/?^A3TK_OW+_\=H`[^BN`_P"%6?#W_H4]*_[]R_\`QVC_`(59\/?^
MA3TK_OW+_P#':`._HK@/^%6?#W_H4]*_[]R__':/^%6?#W_H4]*_[]R__':`
M._HK@/\`A5GP]_Z%/2O^_<O_`,=H_P"%6?#W_H4]*_[]R_\`QV@#OZ\Y\3-<
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MH%?B(?$OB#P_X`TQ8?!FD^%['PI87]Q=^,IOL7_A5GP]_P"A3TK_`+]R_P#Q
MVC_A5GP]_P"A3TK_`+]R_P#QV@#RGQA^SW:-XN\/?$_X>>)?B#X:\0_#GP?<
MZ)X%^#^A_%OQE\-_V<-<U"V'B.[TD>/?AMX0M=0\.7L5UJ/B`PZKK7_"*ZOJ
M4=A8:08;&[DT6Q@KYL\:?L;>/_\`A5'P"U[X=ZAH8_:L^"?Q6\%?&B+Q-XT^
M+OQ8N_ACJ'C;6M6U.']IR:'3UT76K&U@^.G@;QY\8_"CG2_ASH<.A7?Q%&NZ
M?8V;:#9Z=-]T_P#"K/A[_P!"GI7_`'[E_P#CM'_"K/A[_P!"GI7_`'[E_P#C
MM`'P_?\`[*GCG4_VB_VF/C9XJ^$?[.'Q-TOXR>"?@7X5\%Z-XS\:^(X=9\-7
M/P=LOB&\U_=:N?@7K\VCMK&K^-+"ZL9_#L[WVCOHB:C#<27S6RVM77/V,_'W
MQ;\1_!SQ_P#'&7X12?'GX&?'32_B-X!_:F^%]IK7A?XN:9\+-+^)L?C;5O@4
MUA-H8DNO`7Q*\$3:Q\&?B%X?O_'5YX5O/"NMMXI3PW>>,])TG4(/NK_A5GP]
M_P"A3TK_`+]R_P#QVC_A5GP]_P"A3TK_`+]R_P#QV@#OZ*^8_A4/`?Q3\`:S
MXRL?A?IMAJ.C>._C9\/'\/G4Q=)>Z]\%?BUX]^$.H/::Q-;Z>@T_Q!K/@.YU
M'3)[NQM9+6PU&V6]@CFAF6LO]GK5/AG\>/AS_P`)S;>#/A_;2VGC#Q]X&U/_
M`(07QS9?$WP;/K?P\\9:UX+UN?PUXUT^RT&36=+?5-$NA#)JWAKPUK$,B2P7
MVAVICCDG`/K"BN`_X59\/?\`H4]*_P"_<O\`\=H_X59\/?\`H4]*_P"_<O\`
M\=H`[^BN`_X59\/?^A3TK_OW+_\`':/^%6?#W_H4]*_[]R__`!V@#OZ*X#_A
M5GP]_P"A3TK_`+]R_P#QVC_A5GP]_P"A3TK_`+]R_P#QV@#OZ*X#_A5GP]_Z
M%/2O^_<O_P`=H_X59\/?^A3TK_OW+_\`':`._HK@/^%6?#W_`*%/2O\`OW+_
M`/':/^%6?#W_`*%/2O\`OW+_`/':`._HK@/^%6?#W_H4]*_[]R__`!VC_A5G
MP]_Z%/2O^_<O_P`=H`[^OSN_;?\`^0Y\/_\`L%:[_P"E>GU]I?\`"K/A[_T*
M>E?]^Y?_`([7P?\`MA^&M!\,:QX'BT'2[;3([S3=:DN5M5D43/%=6*QL_+Y*
M*[`=.">M`'&_$K6_%&G_`+0?_!.;PSI$WQBUGPUXZ_9V^/<GC#X?_#+XI:OX
M&L_$=QX#\(_`N_\`".L:E82?$?X>^'9KKP]<^*->CBO?[035+A-6CM[@7MG9
MVRV%+]F?]L[X@Z[JOQV^!0\.S_$#X^?"#6OC;XZU'X0>/_&T'AOQM\'?AWIN
MN>%;OX1_!?XE?$+3_#?BWP[XR^)_B#POXRTWQ+HWB/P_=>)_",7@75O"3ZM\
M4O',\\7C_P`6?1%A\+_A!\0&^`7Q3\7>#/C/=_$/X3_"IO"/@CQ'X3\4?&_P
MCIVD:1XUT/PRGB];32O`GB_P_P"&-8/B#_A']&$FLZCI6H:B]IIUC':WL5M&
MB#7MO@1^SA8ZZ/%EA\&?B)8>,9?^%@KJ7C>P3XKV/CKQ';_%.;PQ+X\L/&/C
M:TU^'Q5XUTS7?^$(\$P_V3XMU?6M-TRS\%>#K'1[73[+PMH,&G@'SL__``5`
MTK48M>\:>%OA1;ZC\%]&_9(_8L_;%MO&OB#X@:CX9\:ZU\/_`-N74?V@O"OP
MI\+6/PYC^&NN65GX[L_'GP4T;1-:L]<\=Z3X=M-"\=3>([OQ)8W7A27P]KGI
M'QY_;NU3X`6?[3]CXD^#L&L>-OV<O@C\-_VA[/1=%^(<Q\,_$3X:_$?QI\0?
M`=M#9^+KSP#;77ACQMH6N_#/Q"=6\/:KX7NM*GL=1\,W6D>)]2^V:_'X8[G4
M/V??V8]5UWXHZ]J?P)\9W[?&;X&^!_V:_B-X=O-,^)=Q\/M<^!WPUE\<S>`O
MAY:?"^76&^&_AO2O"LWQ,\?R:1=^%O"NB:Q;OXLUD_VDQNVQ9\<?`W]GSXE>
M`/'?PT\<_"[XP>)/#/Q-\,>'/!7CVZO]:^.(\:^*/"'A#4M9UCPUX9U/XFV_
MBZ#XDOH6C:KXC\1:A9:7%XLBLTN_$.OSM$[ZUJ9N@#O/@=\>-8^*/CS]H?X8
M^+?!6E>"O&?[/GQ#\,^$-33P]XQO?'/A[Q'H?C;X9^#_`(G^%/$=EK&I>"_`
M5]8:A-IOBJ72M<\/3:)<Q:1JFD3-9:]K=E=V]T/I*OF#P!X*^%'PQ\<_%'XD
M>#O`7Q?M/&7QFOO"^I?$C5=8N_B[XLA\0ZAX,\,V'@WPY>1:1XN\0Z[HFA7&
MG^&=+T_27D\.:;I#:A#:12ZD;RY!G/L'_"PK3_H5O'__`(16N?\`R/0!W]%<
M!_PL*T_Z%;Q__P"$5KG_`,CT?\+"M/\`H5O'_P#X16N?_(]`'?T5P'_"PK3_
M`*%;Q_\`^$5KG_R/1_PL*T_Z%;Q__P"$5KG_`,CT`=_17`?\+"M/^A6\?_\`
MA%:Y_P#(]'_"PK3_`*%;Q_\`^$5KG_R/0!W]%<!_PL*T_P"A6\?_`/A%:Y_\
MCT?\+"M/^A6\?_\`A%:Y_P#(]`'?T5P'_"PK3_H5O'__`(16N?\`R/1_PL*T
M_P"A6\?_`/A%:Y_\CT`=_17`?\+"M/\`H5O'_P#X16N?_(]'_"PK3_H5O'__
M`(16N?\`R/0!W]?C!+J/QN\:_P#!17X@_"OP!\:?'7@;3?!G[$/Q(^*7P]\&
M6.N6=I\-+OXU>,_VJ?VH/AEIOB[Q_H%_X9\4VNOVNE6L/A^[BBN-)U&*TNM`
MTR^&F:BUI]BN/U@_X6%:?]"MX_\`_"*US_Y'K\W/`G@?XGZ+_P`%!M0_:7L/
M`]SK/P=\4?LZ>)O@)KU\B>)+7Q?X9\4Z#^U!\>/BS%?V_AI/"5[INNZ9>0>*
M_#_AZY0>)]*O]*U*35Y+FUD&E);WP!Q]O^RM_P`%2H_@[^R9X/\`^&WM`M/B
M-\*?BSJ%]\?/&UA:-=CXC?"6#5[3P3X>MO#Q\4_#[Q-J&M^,D^%=WX@^(&HV
MOQ<NO&_AJ;XPW-II^H0Z]IEEX7\6>"<7]J+X2_MO^!/`O_!3SXX^*?VLM?TC
MX3Z?\"/B%\5_V6-!^%'B"_\`#OQ`^&OB;X7_``^U[Q;IUOXJFN_"$?AQ-#M[
MW1TTJ+2_"#V:>)-$O+R3XBR^,_%2:9XJTS]7+?Q9H5KJ&H:M;>"O'$&HZM'9
M1:G=P^"-;26_&G+-'9-=%;=5FEMHIY((YW4SBW$5N7,,$$<?A?[;6E>-/BI^
MQY^T%\+OA=X1O=?\>?&_X'_%#X6>%=.UV#7_``[I>EZC\0/"U_X(EU+Q1?VG
MAOQ#J.CVVB0>(+C6DA70[N36AI;6-E)&ETE_"`?+$W[>GQ.^&OP[M;:/X.V'
MQ=U#X6?\$[OA/^VS\1?%&J_%V3P=XA\6>'+S3O$MOX\T;P_HI^&7B33[[X@B
M+P'KFM^'K;5_$>@>&_$FI7]II6K^(_!L#/JJ>@>)?^"@.NZ%XP^+$=G\$K'6
M/A7\%_C+^RQ\,/&7C>+XFZC9^,[C0?VK[#X5OX3\<>'/AE/\+6CU%_!VI_%S
MP\/&GA34_&VB:FF@6&M:GX<N_$&NP6?A*_\`.OA]^S)J\?Q;\*^)OBQX0O\`
MQ%\-M/\`V"_@[^R7XF\-:1<?%FVE\1:YX%U;Q/JOB_\`M_PM9^&M!\->+?A[
MXDM_%%SH7]E^)-5O5NK"UG:_T$0:S=6$'IGP]^"ALOVDOVIOC!\2_!6N:[X4
M^,?Q#^!GC[X>Z'II^*=Y%I=_\$_`'@KPUH=]XR\"3Z%H?@>XUO3/%G@G3?&_
MAK4=_B:YT;4H=,>WN(;W1+*^H`YSPW_P4+\>^*O'7AWP5IG[/OAB(^,?VV/V
MDOV%/#6IZA\<-1@67XH_`+X+_&'XYV/BK5[2V^"UZVF_#WQEX3^!WC6POK^U
MN-5\3>%=?G\/VMMX6\5V&H7FI:7]I?LR?'"R_:3_`&?OA#\>+#0)_"L/Q3\#
M:)XLF\,7&H+J\GAW4+^W"ZMHBZNEEIJZQ!I6J17EC;:O_9FF'4[:"*_.FZ>U
MP;.'YXT3]E3]EGPYKNA>)='^$WQQM-;\,_M$>-OVK]"O6\=_M)78L/C_`/$?
MP3XW^''C?Q^EM>?$.XM)F\1>!_B1XY\-W_ABY@F\&BP\2:A]G\.P3F&:+VSX
M+^&_A?\`L^?#/PK\'OA/\/OBAX>^'G@FRDTWPOH>IVOQ+\:W.E6$EU/>&S7Q
M!XZU7Q+XENK>.>XF-O%?:Q=):Q,MO;"&WCCA0`^D**X#_A85I_T*WC__`,(K
M7/\`Y'H_X6%:?]"MX_\`_"*US_Y'H`[^BN`_X6%:?]"MX_\`_"*US_Y'H_X6
M%:?]"MX__P#"*US_`.1Z`._HK@/^%A6G_0K>/_\`PBM<_P#D>C_A85I_T*WC
M_P#\(K7/_D>@#OZ*X#_A85I_T*WC_P#\(K7/_D>C_A85I_T*WC__`,(K7/\`
MY'H`[^O.?$UM'>>.?!-I*TZ176A^/;>5[6ZN;&Y6.>V\/Q.UO>V4MO>6<ZJQ
M,-U:3P75O(%E@FCE1'6?_A85I_T*WC__`,(K7/\`Y'K@?$7C&QU#QCX167P]
MX^B@;1?&UI,D/AOQ%IVI.E];Z)$TFGS6:V^H12PJK$WEC-#<6+M#-'/%*8G`
M!^5'[+OQW^)VIC]@CX#ZQXW^(.I:=^T7X\_X*.>,_B5\2/$7C;Q/XC\8:QI/
M[+/Q>U+PCX`^$&E^,?$.LW^O>&X=;TSQ/HNN%_#=Y9:H_AWX0Z]:VT]L=>\1
M:A<^Y?M0>'?&GPE^//[$]AX=^)/Q_P#&'A/X[?MS^)/#>O?#71/C/XITO4D\
M`P_\$V/VPO&%U\/++5-1\?>$4N_"$/Q4^`?@CXRV<WB3Q3+KMGXF3Q9I^DZH
M=$OX?#,_NFE?LR?LOZ+\+O#'P=T[X0?&&+P7X'^(.N_%;P)/-XE^/MYX\\`_
M$7Q-J'B+4_$'BWP#\6KWQM<?%?P1JVKS^+_%UM?2>%?&ND13Z3XL\3Z$T1T7
MQ!J^GWFQJ7P&^`&L:S\(_$FK_#[X]ZIXC^!OCVX^)_PW\1:AXZ_:-O=?T_QY
M=?#WQ?\`":7Q'XCUJX\?2:G\0;P?#7Q_XS\$0P_$.Z\565MX<\2:KIMM;107
M&``8/P.^.T/PU\7?\,]?M)_%;1=,^-GQ&^(GQ#\5?L__``L\3ZO9:S\4T^`6
MI^*/$<?PUTKQ9K?A^35=!\1Z]I]OX9\3P0:I%K>J:@OA[3](L/$FN>(/%=AK
MFO:IXSH/[4?Q-TW]L;P;XAUS5/$.I_LE_M,ZEX@^`'P^L]1^'?C'0M`^%WQ-
M^&3:]K'PI^).G?$"[\+6?A#Q3X5_:S%O\5=,M-?C\4:AI^H#3?V6=)\&))?>
M+]?-Y^@?B'Q-HWB?0=:\-ZGX;^*L&G:_I6H:-?SZ#I/CGPKK<-GJ5K+9W,FD
M>)_"]SH_B3P]J:0S.UCK6@:MIFLZ9<B.]TR_M+R"&>/Q;QG\(/@7\0/@IX8_
M9Z\4?#CXR7'PI\&3_#*[\,:1I.M?&_PQXAT:]^#7B+P]XM^&-_:_$3POXLT?
MXD'4/!WB;PGX;US3+^7Q;+>MJ6BV%S>3W4D()`/E'6/$'C27]KG]N_PC'H7[
M2_Q3\->$_A;^R_X@\(^%/AG\=?$WA&R\&:U\1M.^,UMXPOM%LV^+'AC5-,&H
M#P_HVKS6W@SPWXGO+2+09&\,^&[[7)K;1M5Y&?XL?&#X1_'GPGX+_:$\0?%8
M?#+Q?^TQX#\-?L]?M??#+QFGC+X#^-[/4[S3/AGI?[*W[3/@#2+N._\`A%\2
MM=\=_;?"NE>.)?#.K^#?B#\4+GP[:7GQ.\-^(M9G^%<_V@OP4^!\7CKXD?$N
MS\'_`+1FE^.?BWI7A31/B!XAT3XE?M,Z'=:UI?@>RURP\)6MM!H_Q%L;+P__
M`&%;^)-<^PS^&[72+@7&HSWDDLEX(YXW^#?@E^SYX!TRUT'PU\*/BI#X9L?'
M8^)MEX2U>\^,GBCP99^/(_$UMXVM/$MIX-\4>)M9\+VU]I?C:SM/&VBI!I"6
MNA^,[6W\6:/;V/B&&/45`/6?"OP6?P%X+/@GP1\2/'&@P77Q%^*7Q(U;Q!)9
M^`=6\0ZAJGQ>\8^/?B)XJL8_[2\$S^'K*QA\=>/KWQ!HQB\///9KI>F:3=27
M^DM?VEYWG@WP%X?\#+XBET>!GU7QEX@_X2WQIKD\-A;ZEXL\5?V!H/A=_$.K
MQ:39:7I*ZE+H'A?P_IDATW3-/M6@TNW;[,)FFEEJ?\+"M/\`H5O'_P#X16N?
M_(]'_"PK3_H5O'__`(16N?\`R/0!W]%<!_PL*T_Z%;Q__P"$5KG_`,CT?\+"
MM/\`H5O'_P#X16N?_(]`'?T5P'_"PK3_`*%;Q_\`^$5KG_R/1_PL*T_Z%;Q_
M_P"$5KG_`,CT`=_17`?\+"M/^A6\?_\`A%:Y_P#(]'_"PK3_`*%;Q_\`^$5K
MG_R/0!W]%<!_PL*T_P"A6\?_`/A%:Y_\CT?\+"M/^A6\?_\`A%:Y_P#(]`'?
MT5P'_"PK3_H5O'__`(16N?\`R/1_PL*T_P"A6\?_`/A%:Y_\CT`=_17`?\+"
MM/\`H5O'_P#X16N?_(]'_"PK3_H5O'__`(16N?\`R/0!W]?G=^V__P`ASX?_
M`/8*UW_TKT^OM+_A85I_T*WC_P#\(K7/_D>O@_\`;$UR+7]8\#R0Z7K6G"VT
MW6D*Z]HUYI$DIDNK!MULE['&9T7;B1H]P1BH;!89`/HJP_:"^$/PB^&WP_M/
MB'XO7P_+I_PP^%&JZHPT+Q+J]MH]AXU:V\&^#;C6KW0M&U.ST9?%WBVSNO#7
MAA-4GM)?$&NP2:7I*7=XI@KWCP=XY\,>/M.O=4\*ZA+?6^F:O?\`A_5(;O3-
M6T34])US2S&+_2=6T;7;'3=8TO4+430226M_8V\WDSP3JC0S1._YQ_MT?9HO
M^"=^B*D!EU74]2_8P@M;>RLY;S5M3A\/_';X-^*;^&UM+.&;4+^/0_#VE^)/
M$E['!%,FEZ+IVNZS<+!86=_<Q>G_`!R\4^.;CXW6?A$ZGXW\'?`KQM^S'\1/
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M[0_@OQ!^T[XDTRS_`&@+GX!6/_!2[X:6FOZ_J7PB_:#\<:]X)_8X\>_\$W_@
M9K^H>)_A%X5TN#0?BAK?P]TK]N"^N$\=6WPMU(7/PV\.:O\`$O4C9Z7X=T:7
M3B`?N317\^WQ0\9?'C1M-U_P[_PTA^T-XA/A_P#X)J?M4_%#P7KUQX=\2?`G
MQ/K/QQ\+?%O3M1_9LNM3\$LC>,3\0(O"!@TS1_!?C;4+WQ+\5_#VD3W?Q#\&
MZJVM^*=!?VOP?\</V@_B9^T;I?A7QAXR^*OPR,WC#]F+XF_!%_`'[//Q2\=?
M##XQ_`+6_@[\+Y_CMX<\4?$;3-4B^"'@W4;;XQZA\</#GC:'XCVQ^(/PX\.V
MOPQ\3^$9KK4=6\.:7<@'[/4444`%%%%`!1110`4444`%%%%`!1110`5^5]U^
MU9\</#/[5WC+]G?X=?#?P+XS\&?#_P#9P^+W[57BB&^OO&-O\2_&&KWGQ^_:
M'\"^'/AYX`C\/:1XATZ.ZU#Q%X*\.-+/>^']7O9K34]3@TZQNM0%A`_ZH5^0
M?PVBU'1/^"M>OZWJ7A_Q9#X<\;_L6ZYX$\->+8?!_BB]\&7OC+P[^VM^TQXT
MUGPQ<^,K'2+GPOI&M6/A?RM7>PUG5M/N)8+O3X[=);G4M/AN0"GI/[<_[=4W
MPI_9'\6ZK^P)XIA\<?%WXKZO\.OCKX/(\56%]\*=,T34K;X;MXUUO34TG6E\
M"^#=:^*NKV.M67B<^(/BC%9_!G1[SQW9Z7XETK5+_6?!&S\5?VU_VP_!B_\`
M!16\LOV6M/\`"?A3]D/X6:Q\5/@W\3/B:OCFP^''QOTSP3I+>*_%&EZ/KVFZ
M=#)XAO\`5/".F>(6,EA;>&[?P)XLCT31`_Q*T.[U#Q=IGZWU\4?\%!)]3/[`
M7[:-E)HFJZCK?B#]FWX_^#?#OA_P9I7B3QYK>NZUXT\$^*O!W@73M,T70=`F
MU^]U7Q%J.M:%%<Z?9:3=6VB7FH7$+ZC=:1ILFMR`'TE\'_&MW\2OA+\+OB+?
MV5OIM]X^^'7@GQK>:=:222VMA=^*O#.F:[<65M+-^^DM[6:_>"&27]X\<:L_
MS$UZ+7X`>+=9^-UI/=?!;PI\3/C7X!\?>%?^"0/P1^(GP*^''A&]U'0;NQ_:
MNTN^^)7A_P`.K+X<72EB\2Z[>:GX6\/Z)KGPW\>C5_"NNZ/8ZU_PD7A>XT[1
M;^]TCTC6/%W[1/BC]H#]J;PWX6^*_P`0G^,/PC_:2_8''PW^'.BZ[JO_``K&
MR\">./"GP$U;]IS0K[PU'IB:/XG^'%WX1\0_$;5/$6J>);;6/$'@&*?2/$?A
MB_\`#/BN]T2XU,`_;>BOY_/`'Q-^+_B'XK?#^R\5?&KXT3^'?%G_``5@_;'^
M`/C6-_&6O^'=,M_V.I/V8?VE_%OPIN+:31$T2W\,^%KKXT^"/@;H7PZ^,NCO
MINO1:OKEGX5\%^.;:Z\;7-KJ?Z>_\$_/'_CKXF_L9?L[^+_BAJFJ:S\2;OX<
MZ1I_CK4=>M'L/$EWXET0S:-?W/B>QE@M)K;Q'=BQBO-;6:SLY)M0N)[H6L$=
MPD8`/L:BBB@`HHHH`****`"BBB@`K@-<_P"2A>`?^P5XW_\`17AVN_KRWQM;
M:E>>*O"]IHVH)I.KW7A?XCVVE:K);+>QZ9J4]AH<5CJ$ED[(EVEG=-%<M;.Z
M+.L9B9U#DT`5M5^._P`']$NVM=6^(7AS3XD\7:/\/)=8N;MH_#,'Q%\0>*-.
M\%:'\.KGQ:8CX7MOB#JWB[6-+\.:?X&N-7C\576L:A:6,.D//.B'UNOQ"^&=
M_P#'#X3?\$M/@%\"M%\.Z_H/[8_P>T3]GGX.?$SX?:YX$?QQK'Q!\;:#\1O`
M'P\^/OQ>T>PU+2YI?B/X.\3_`-K>+?C]8?&7PI>R65K?7%AXK\4^(+:[T[Q;
MH)P_A9\;/VC/%.H>*Q9>*OVD?"&A^/\`]E'X#^,='U+XU_!#XG^)=:\%_M`:
MC^T?XK\'_$#PMX_TKPWX=^'^E^']8B\-ZYX2\+?&[PW\"9_!^B?#GPU;ZEXE
M^'.KW%UX37XBZB`?NS7CMQ^T#\%+.XT6"[^)?A2T3Q/X@_X1+PEJ%UJ2V^B>
M,_%BC4FN/"W@G7YE30_&?B6P71M9DU;0?"^H:MJVD1Z/JTFJ6EHFF7K0?(_A
MNQ_:%^.7_!//X^^#=)BU[X4_M%^-O!?[87PZ^''B37?B%JWCK2M.\<:UKWQ7
M\._"WXA>`/B5JFA>%_%>N_"!;Z^\.ZW\(_$?B#PSHOB)OAO;>&KF>#4`EMK>
MJ[O[-/Q8^%6N?`+X%?"[5_AE\0_!7B/X<>`_A%I7B7X3^,?A!XV\'/\`!G7_
M`(8:9H9?_A(M:UG0M*\`Z/H7@'4_"UQ?Z1XKTWQ3=^$?%^FZ'!>?#?5O&=GJ
M^@QZP`?8_P`./B/X'^+O@;PS\2_AKXDT_P`7^!/&6F1ZSX7\3Z49FTW6]*ED
MDBBO[%KB*"62VE>)_*D:)1(H#IN1E8]M7\P_P;\?_%CX-_LQ_!+PSX#^('Q0
M\,W_`(J_X)'_`+>7BG7M$DO]7NIO!O[2OP<\:?L^6W[+^E>%O"FK6=UI7@'X
MC:MI/C7]H*UT?PUI.@Z?XB^*</A"_OM3L_$^I^`FU"Q^R-4\1?M'V?@/XUZ/
MX0\5?&F;Q-JG[#7PR^-?[&GC,ZYXJ\9Q>./VOM0T7XSWWQ/\):K-J"W.B:MJ
M$7BG3_@DS_`?QC%)X)L_!6J:YJ7@C0]-TNS\??\`"(`'[845^#_QB^*WQSTK
MQ[^TKJA^+?Q'TG6/AU^V]_P2_P#"_@[1O#'B+4X_!.@_"7XK^._V7/!/[94>
MAZ''80:7XQ^'^@>"/%WQTU'Q/K?BW3_$=K\,[GP_JGC&2Y\-:YX1N-0L?(+S
M]H[]I#3;/XZ^#?"VN?M0:IXG_9]^/0'PMU%O"_Q'\?\`AOQ9\(4_X*`:OX>U
M323K&B>&];U[XHZWX5_9]TZ"S\8ZO\6O%.JZ99_";Q#\.-=\*Z3XL\6>)O$W
MC7P^`?T;0W=I<R7<-O=6]Q-I]PEI?Q031RRV5V]I:WZ6MW'&[/;7#V-[97JP
M3!)6M+RUN`IAN(G>S7XE^"[WXM?";XB_M%?8=#^,4/@[QO\`\%4;.X^/>OWQ
M^*^H:AH7[+OC7]EWPXO@[QY\/-4U4W]O9>#[?XTV_P`-O"OCSQ#X!N;9?AS\
M*8_%TNL7_A?1OA]!-X=T/B%\>_C%\!?#GPKU3XX>+OB5<?!G4/VV/VAO!6FK
MX8\!_%OQ!\6/B'^S?!\.OBOJOP7&K^,OACX?O]>T"/PKXWT^P31=?ULZ/JGQ
M7^'WAOP=XBU/QQKNIZCKP\=`'[245^)_P=\7>._$WQ1_X)\>#=6_:*^*?Q=\
M)ZG^PG^U%XT^+VN^!M<\9^$[7XF_M&_"7XX_L93>!)-=_MBP\)>*].\5:TD7
M[4F@6O@3Q)'X,A\1>'_"?Q%T!_`V@Z!X9\0>'M'^;?$?[2/[2.G_``@^-/B.
MU\=_M->#O#*?LQ_\$G/B#X6\5^/_``-XQT?Q]I_Q@^)/[6OQD^%?[6FBZKJ7
MB;X=Z-H$7Q)U#P-H_P`'[?XD?#3X>^$?"W@SPMK>K2VW@+P%I<-YJMYJH!^_
MGQ!^+?PW^%4O@>#XB>+])\*3?$GQWX?^&/@6+4WG5_$_CWQ5.]MX>\,:8L$,
MQ?4M4F1U@63RX5".\LT:*7'HU?@1^TKI'Q"8>"?#FI>,/'GBCX.6W_!6[]D#
MQ1\`O$^N:YK'BOQ?I?P;M/!'PZU[XM:W8^-M7AU+7]5^%G@_XIZKXZDTGQ]X
MFU35CX=CN[[2H/$-OX5T?P>L'I'P[\4?'B+0/"7Q3\-^)_B]\3K?]G;]O?\`
M:`^`6K?#6X\=^,K^[^)W[-/Q6^*?B/X7_!WQ%XB;4M5<>/KGX/ZGXN^%WC70
M?B?XMDUV\O/@SX6\::E<:IXC\27EKXB4`_13Q7X_U+2?VQ/@9\-%\7)9Z!XU
M_9S_`&GO%=]X*EN-)0:YXF\!?$;]E"P\,:Y!%-!_;4MYHNA^./'MLD=G=K8R
M6>I7\]W:3264%Q:^6:M\4?&#_MD?!B#P'XIU'XD?`KXC^#?%GAKQ@GP_\;>!
M_&FB?#WQRO@J3XF_#K7?'G@>P\&1Z_X*^'7B+PEX<U\:+\7K3XEZN?$/C[QQ
MX%\!ZGX2AT37?"6L1?9_A705\+>&M"\.#4M6UG^Q-)L=-;5]>U75-;UG4Y+2
MW2&74-3U;6[[4]5OKR[D5IY[B^U"[G9Y"K3.%!K4LK&STVVCL["VAM+6'>8X
M($6.-6EEDFFD(49:6>:22>>5RTD\\DDTK-+([L`6Z***`"BBB@`K\[OVW_\`
MD.?#_P#[!6N_^E>GU^B-?G=^V_\`\ASX?_\`8*UW_P!*]/H`^F_AE8?$A_AO
M\/GL?%?@BVLG\$>%&L[>[^'VO7MU!:MH-@;>&YO(?B;80W=Q%"42:YBL;*.>
M16E2TME<0IV_]G?%+_H<O`'_`(;7Q%_\]>OE)OV@?'?@+QU^QW\!/"WPS\(^
M*K;XX_`SQIXJB\8>(/BCK'@Z?PU>?!SPW\,Y[[2I/#>G?"GQK'JUKK=IX[LG
MM=57Q#ILMG<6-U!-I,T3Q7)\G^*7_!2*/X=?!']L7QA'\,-/USXQ?LE?L>:_
M^VM=>!])\6>+=4^$?CWX/7\_[1^H_![5O#OQYB^%-II$S_%'P/\`LZZMXICM
MXO"TJ:+J^MR>"5O-4O\`PQXCU6Q`/T%_L[XI?]#EX`_\-KXB_P#GKT?V=\4O
M^AR\`?\`AM?$7_SUZYFP_:&^!VJV/BS4-*^*G@G5;?P-XLT7P'XJ32M<M-2O
M-*\;>)I-)A\*>$FT^Q>?4+OQ'XNN-=T6U\(:-86MW?\`BR\U;3K/P[!J=S>0
M129>H_M1_LYZ1I7A'6M2^-GPULK'Q]+XRM?!`G\5Z2M_XLO_`(=#51X_TKP_
MI'V@ZMJNM>";G0M8TWQ9HEG8RZMX?UK3KK0]5L[36(C8T`=U_9WQ2_Z'+P!_
MX;7Q%_\`/7H_L[XI?]#EX`_\-KXB_P#GKUS]]\?_`():=X2\/>/KGXI^!QX&
M\5>$[;Q_H/C*W\0:?>>%KWX>W5M8W</Q#?7[.:?2K+X>BWU32GF\=7]W:^$[
M4ZMI4=SK$,FIV*7'&^$?CMJGB3]K/X[?LU7?A33K#3/A'\`_V7_CAHOC6T\0
MW&H7GBF#]HCQU^U9X&O-$U+P_+H5A;^'Y/"=[^S++<VMS::YX@37+3Q3'++_
M`&5-8M:2`'J7]G?%+_H<O`'_`(;7Q%_\]>C^SOBE_P!#EX`_\-KXB_\`GKUW
M]%`'`?V=\4O^AR\`?^&U\1?_`#UZ/[.^*7_0Y>`/_#:^(O\`YZ]=_10!P']G
M?%+_`*'+P!_X;7Q%_P#/7H_L[XI?]#EX`_\`#:^(O_GKUW]%`'`?V=\4O^AR
M\`?^&U\1?_/7H_L[XI?]#EX`_P##:^(O_GKUW]%`'`?V=\4O^AR\`?\`AM?$
M7_SUZ/[.^*7_`$.7@#_PVOB+_P">O7?T4`<!_9WQ2_Z'+P!_X;7Q%_\`/7H_
ML[XI?]#EX`_\-KXB_P#GKUW]%`'`?V=\4O\`H<O`'_AM?$7_`,]>N(^'UA\2
M'T&_-GXK\$00CQO\35=+GX?:]=R-=)\2/%:7TRRQ?$VR5+>YO5N+BTMC"\EE
M:RPV<UW?S0/?7/NU?!'QT_:BU']E_P``?"JX\/\`PKU+XP^+_CI^UWXJ_9]\
M%^$-/\6Z+X)7_A)_&'BGXU>*;+4M1\0Z_;76G6FFP6_@:\M9M\6\S7MNX<)'
M)D`^N/[.^*7_`$.7@#_PVOB+_P">O5BTL/B0EU;/?>*_!%S9)<0M>6]I\/M>
MLKJ>U613<0VUY-\3;^&TN)80Z0W,MC>QP2,LKVERJ&%_S;\1?\%5?"6BM^W3
M9V7[/_QDUO6/V)I+&"]TZSM]("?$J?7;^'P?X2&@W$=Q<RRQ^*OB=8>-O">F
M)X)L_B5J$6G^`]<NK[3K;QO+9_#:2_K'_!5KX/:'XF_8\T[5O`'CW0O!W[8'
MPXU;XLZ!\1O%$WAWP_X5\$?#[3K";61XL\7ZG<ZG-HWA[0+7PO$OC[7+[QSK
M7@22Q\"W=G-I%MXC\<0ZSX!T<`^O'^`0@^.NN?M%:7JV@6GQ-UOP)I_PLEU>
M]L_BMJ%E_P`*XT7Q!J_B70?#L_A$?'"S^';W6FZOKFIWS^(+'P3IFL75W?7D
MC7$4,_V9*_@K]G^Z^'OQ"^+'Q3\)ZYX8L?&_QPU7P[K?Q,U.^TKXM:_8:_JG
MA/PY9>$O#UU9>&_$/Q[U3PQX7_L[PWIMAI*P^$=&T*WN+6T@^UQ3R1B2O/?V
M=_VQY_CC\#OCC\7-5^"OCKPCXC^`'Q+^/'PI\9_"3P]>:?\`%'QIK'B_X`W-
MU8^)-(\"'PQ#;6_C#4O$.H64NG>$].T]%N-7U"6TM(RLMPJK#X+_`&U+37O%
M7Q.\*^+/@_\`$/P#J'@GPKH_C'PMI6LV%_!XL\>Z;XK^.GQO^!'@+2T\,:[H
MOAJ3PQXG^(^M?!N#Q-X$TK5=0GL==\*>.]"U=M8M+33==GL0#ZA_L[XI?]#E
MX`_\-KXB_P#GKT?V=\4O^AR\`?\`AM?$7_SUZZW1YM5N-(TJXUZPLM*UR?3;
M&;6=+TS4YM:TW3=5EMHGU&PT_6;C3-%GU:RL[QIK>TU.?1M)FOX(TNI-,L'E
M:UBTJ`.`_L[XI?\`0Y>`/_#:^(O_`)Z]']G?%+_H<O`'_AM?$7_SUZ[^B@#@
M/[.^*7_0Y>`/_#:^(O\`YZ]']G?%+_H<O`'_`(;7Q%_\]>N_HH`X#^SOBE_T
M.7@#_P`-KXB_^>O1_9WQ2_Z'+P!_X;7Q%_\`/7KOZ*`.`_L[XI?]#EX`_P##
M:^(O_GKT?V=\4O\`H<O`'_AM?$7_`,]>N_HH`X#^SOBE_P!#EX`_\-KXB_\`
MGKUQ&L6'Q('CKP2LOBOP0]VVF>,3:SQ_#[7H[>&-8]"^TK<6K?$V66Y>4&$0
M/'=VBVY20O'=>:HA]VKSOQ'/#;>//`UQ<2QP6\&C>.YIYYG6.*&&*#P_)+++
M(Y58XXT5G>1B%1`68A030!+_`&=\4O\`H<O`'_AM?$7_`,]>C^SOBE_T.7@#
M_P`-KXB_^>O7@'PW_:3\<_&OX.>`?V@_@[\(M)\5_";XHMX*\6>`KG5OB+?^
M'/''B3X(^+_$FCQ0?%NS\))\.-9L$^W?#74+GXL>$O!-SXIAU[Q%H?\`8GA_
M4Y?"WBG6+O3-$]DT;X\?!OQ$_B&+0OB3X2U:7PM9Z-J6L16.K07$J:7XDUK5
M_#'AO5]/CC)?6]'\2>*_#_B'PAX>U?0UU'3=<\8>'O$'A/2KJ[\1:'JNF6@!
MM_V=\4O^AR\`?^&U\1?_`#UZ/[.^*7_0Y>`/_#:^(O\`YZ]9FI?&OX6Z3\*O
M&GQNN_&>D?\`"K?AWHWQ%UWQKXN@>:YL?#EC\([GQ#8_$R/4X8(GOK74O`VI
M>$_$ND>)M'DM1JNDZSH>IZ1=V<6HV<]LGENA?&GXR>*O`?PH^)?A[X#Z;-X:
M^)]WX"U"?1M1^)]Y:>/_``1X(^(:0R:;XB\3>&]/^&NL:))J_AN'5-#G\<^'
M=&\7:E9:#;R>(+NP\2Z[:>'TN-5`/9?[.^*7_0Y>`/\`PVOB+_YZ]']G?%+_
M`*'+P!_X;7Q%_P#/7KY0_9E_;Y^#/QQ^`OA3XM^.O&WPN^$WB>Y^#<_QP^)'
M@;4/B1I=Y:?#'P/8:E<Z?KNNZMXFUJT\+K<>&O"\\=K;^(/$MYI.C0:5+J&E
MR:U8Z*=8TRWG]YLOVG?V>]1TG^W[#XP^`[S04N;:UO-;M]>M)=(TC[=<BQTZ
M]\0:FC&R\.:/JNHM!I>D:[KT^G:-JVJWFGZ7IM_=:AJ5A;7(!VW]G?%+_H<O
M`'_AM?$7_P`]>C^SOBE_T.7@#_PVOB+_`.>O7#ZY^U%^SAX:\3ZGX+\0?'3X
M4Z-XKT/Q;X>\!:]H.H^.O#MKJ/A_QMXMTZUU7PMX4\002Z@IT+Q!XBL-0TN?
M1-*U8V=YJ9UG0X;.*:?6])BO$T_]J#]GC5;'P]J>F?&;X?:CIOBC53H>CW]G
MXCL+FT;5QX\?X5#3]2N(9&AT*YD^*BK\+8(]=;3?/^)DUI\/X3)XOO+31I@#
MN?[.^*7_`$.7@#_PVOB+_P">O7B_Q4_9L7XS:UX&\3^.M:T#_A*_AK)K[^!?
M&'@NW^-'PM\9>&X/%<&FV_BG3+'Q=\+_`-H/P=XD.A>)8=%T9?$'AZYU2?0M
M:;2-+DU+3KF33K-X=SP%^U)\)_B#??&VTTR]U[2H?@1\8/\`A1WBJ_\`$OA3
MQ-X=M=9\?CPYX4US^R/!8UC2+.?QA=3WGBRT\/Z;8^'H=1U#6M3CMI]&M;_2
M]?\`#-_K/?1_&;X5W'AO0_%UGX[\.ZGX?\3:SJOAOPY>:1?+K$VO>)=`.N_\
M)%X:T?3=+%WJFH^(_#(\*^*G\4:!:64VK^&H_"OB>77;/3X_#NLM9`#-*\-?
M$71=/M=+T_Q?X&2TM(RD?VGP!XNU"[E9W>6:YO=1U'XOW6H:C?74[RW-[J%_
M=7-]?74LUW>7$]Q-)*WG?QG^`EY^T#X"O/AE\5M;\*Z[X+U#6?"WB"[TO2-%
M^*W@>ZFU;P7XETKQ?X9N3KO@+X\>&/$*1Z7XET32=6%I'JJ65U<6,"7UO<P!
MHFTH?VL/V8KMOAXNG?M!?!S6/^%N>&AXT^%IT+XB>%=>7XB>#?\`A*?"O@=O
M%W@I]'U.^3Q)X7B\7>./"/A^?Q#I+7>D6^IZ_I]O/>1F4E9IOVIOV;[7PYK'
MC"^^.'PQTSPIH-KX#U'4O$>K^,-%TC1$TCXJ7TNF?"W7[34M3NK2TU3PY\3=
M3MKO3?AQXDTN6\T+QWJ-E?6/A34-7N[&[AA`.YBTGXH0Q1PIXS\"%(HTC4R_
M#KQ//*510H,D\_Q:DFFD(&7EED>:1B7D=G8L>;U;X>^.-;\1>&_$^H>-?#KZ
MAX5@UB#2K*VT#XF:?X8G.M2Z///=:_X+T_XXVO@[Q;J6G3Z%83^&M6\5Z%K6
MI^$)VU&;PI=Z++K.LO?_`#I\=/V[?`/PX\,?!SQM\-M0^'7Q7\&>/?VM_AG^
MRO\`$+Q%;_$>#2+?X5ZEXXU7[%J^J:A!:Z%KD-YKGANW>QO;GPMKNH>#W;2]
M7T[7%U.6RGLX=1]^\.?M,_`7QAJ?P[T;PI\4/#/B74?BP/B`/AW!H,UUJR>*
M)OA1?SZ3\3K*SN;&UGM8-3^'VKVTVC>,M*OYK34O#FM)_8^K6MKJ3):L`;<N
MI^,(/$5AX0G^*'PFA\6ZKHNK>)-,\+R^"=4C\1:CX=T"^T72]=U^PT1_B\NI
MWFBZ+J?B3P[IVK:K;VLECIU]K^BVEY/#<:K8QSXT?C74)O'4_P`+XOC;\#9?
MB7:Z&/$]S\.X_#LS^.K?PT9[>V'B&?PDOQE.OPZ&;FZM;<:M)IZV!GN;>+[1
MYDT:MR\FD:IXW_:&^`OQO\+64NI?#33_`-G_`./_`(1O-<F(TF[BU'XK^,_V
M:?%W@ZY70M:_L_7)-.NM,^$'B5+N==/$UK<7^@$6\UI>WEUIW+:G\,OB!\1_
MC]\`?CO`GB#X61_"V#QMI7CGPCX@U/1O%GAOXD^`_B)\.M0LSIFC:!!=W)\"
M_$?PO\4++P1K*?$6UMM'UJ]^'NBZWX%U6'5+3QD]AX(`/H3^SOBE_P!#EX`_
M\-KXB_\`GKT?V=\4O^AR\`?^&U\1?_/7KOZ*`.`_L[XI?]#EX`_\-KXB_P#G
MKT?V=\4O^AR\`?\`AM?$7_SUZ[^B@#@/[.^*7_0Y>`/_``VOB+_YZ]?!_P"V
M'!XFM]8\#CQ+J^A:M*VF:R;5]"\.:CX?CA075CYJW$=_XH\3M<L[%#&\<MH(
MU5E:.4L&3]+Z_.[]M_\`Y#GP_P#^P5KO_I7I]`%'Q9^SMXS^*WQ!_8E^+=IX
M1^#_`(U\"?!+X&?$+1M8\,?$O7=5M;W6]>^+OA?X6V>GW6FZ;%\,?'&C0VWA
MRV\"R2R7]U=K>WDFM/;06=I'8FXO_#OB[^P!\</'_@+]N;PCX4?X#>!-._:W
M_P"";GAO_@G_`.!O!.EZUXS@\(_`G1_A==_MA^&OAE?6&H6_P^%YXMT&;P'^
MU@FK:Y!_8?AFYT+7_A\OA#1K+5=#\3P^*?"OG/\`P35_X)R?L/\`Q*_X)S?L
M!?$7Q[^S=\/?%GCKQ_\`L4?LK>-?&GBG6H-5N]8\2^+/%7P+\":[XC\0:M=O
MJ@>ZU/6=8O[S4;^X8;I[NYEE;EC7VO\`\.K_`/@GG_T:=\*O_!?J?_RTH`XG
MQ7^S!^TKJ_QR^,'Q@T'4?@WHVG?$S5OV.=3G\(W7BKQA?W-_IO[/=QX]N/'/
MAP>*X?AG97_@:^UFZ\<66H>$/'WABPU'7H'\&V]A=:7I$7B>YNO#_,?"_P#8
MB^-7PM\0_LW7EOJ_PG\1:7\#OVM?^"B7[1>J2)K7B_PO/K&A_MH_$;]HWX@>
M%/#>CZ2W@_Q8ECJ'@QOCXNDZW)>:[<V\T/ADW%A<W;ZIY=GZ[_PZO_X)Y_\`
M1IWPJ_\`!?J?_P`M*/\`AU?_`,$\_P#HT[X5?^"_4_\`Y:4`?/WP,_X)\?&+
MX7_#&+P7K7C3X<ZK=>-?V';?]BWXH:0]YXI\0>$=,C\(>*OC+X@^'WQ0\%17
MWA[1)=7>:R^._CC1OB%X#U;3?#B^([73_!:VGC>PB\.20ZG]0_`O]F/Q7\&?
MVF?B'\1+?4M&U/X3ZM^QS^QI^R[X+?4?%&NZU\3FNOV4?%O[4/B&7Q)XQBO?
M"UKI-U_PE]G^TDMD]Y;^)[_4(KWP3)J=W!<'Q6UOX=Y__AU?_P`$\_\`HT[X
M5?\`@OU/_P"6E'_#J_\`X)Y_]&G?"K_P7ZG_`/+2@#[_`**^`/\`AU?_`,$\
M_P#HT[X5?^"_4_\`Y:4?\.K_`/@GG_T:=\*O_!?J?_RTH`^_Z*^`/^'5_P#P
M3S_Z-.^%7_@OU/\`^6E'_#J__@GG_P!&G?"K_P`%^I__`"TH`^_Z*^`/^'5_
M_!//_HT[X5?^"_4__EI1_P`.K_\`@GG_`-&G?"K_`,%^I_\`RTH`^_Z*^`/^
M'5__``3S_P"C3OA5_P""_4__`):4?\.K_P#@GG_T:=\*O_!?J?\`\M*`/O\`
MHKX`_P"'5_\`P3S_`.C3OA5_X+]3_P#EI1_PZO\`^">?_1IWPJ_\%^I__+2@
M#[_HKX`_X=7_`/!//_HT[X5?^"_4_P#Y:4?\.K_^">?_`$:=\*O_``7ZG_\`
M+2@#[_K\8/\`@H%>>$=`C_X)Q^-/%UUX;T2R\*_\%;[&>3Q9XCFTS3;7PYI]
MY8_M7IJ4SZ]J;P0Z/972P6RW\C75O#<"&W6X9A''CZ@_X=7_`/!//_HT[X5?
M^"_4_P#Y:5\0_L$_\$W/V%_B1\"/'>L^/?V9_AOXMU33_P!MC_@I3X,LKW7;
M/4K^>V\*_#3_`(*,?M5?#CP#H,3S:DP73?"7@3PMX=\*Z);@8LM&T:PM$.R%
M:`/W/N3>I/8FSM+*>.:Y\K59KB]FLY[73EM+V1)[&.'3[T:E=+J'V.W%C<SZ
M7`EI>7M^NH&>SBT_4+BJJ*J(JHB*%55`5550`JJH``4`8`&````,5\!?\.K_
M`/@GG_T:=\*O_!?J?_RTH_X=7_\`!//_`*-.^%7_`(+]3_\`EI0!\^_\$VM+
MTGXN_`?_`(*!Z-H7CK6M'T?XH?\`!07_`(*#:1IOQ'^%'BV&U\0Z)9>+?'^H
MZ5;^,?AGXRM8=0M-/US2H;R/6O"?B*TM;JWM=6@L]62VG(9)/M7X]_LZZW\>
M-#^,6D2>.IOAWJ?BCX)^//A-\(/&7A2VDG\3_##Q1\0?`GBKPE=_&P7$KZ<]
MSXZ\)#Q?J&G^`+6WN8_^$7TE_%LMIKWF?$S7=/T?R>'_`()4_P#!.VWC$5O^
MR3\)8(E)*QPZ9J,48))+$(FI*H)8DG`Y))/-2_\`#J__`()Y_P#1IWPJ_P#!
M?J?_`,M*`/8/V7/@9XE^!>B?%>T\1>*8-5A^)7QK\5_%7PUX&T5I6\#?!7PW
MKV@>$M"M?A9\.VN+'2IV\+Q:AX8U/Q[>/)I&DK)XR\>>*WM["&T:W:3Z?KX`
M_P"'5_\`P3S_`.C3OA5_X+]3_P#EI1_PZO\`^">?_1IWPJ_\%^I__+2@#[_H
MKX`_X=7_`/!//_HT[X5?^"_4_P#Y:4?\.K_^">?_`$:=\*O_``7ZG_\`+2@#
M[_HKX`_X=7_\$\_^C3OA5_X+]3_^6E'_``ZO_P"">?\`T:=\*O\`P7ZG_P#+
M2@#[_HKX`_X=7_\`!//_`*-.^%7_`(+]3_\`EI1_PZO_`.">?_1IWPJ_\%^I
M_P#RTH`^_P"BO@#_`(=7_P#!//\`Z-.^%7_@OU/_`.6E'_#J_P#X)Y_]&G?"
MK_P7ZG_\M*`/O^O,?&&EZ?K?B_PEHVK6<&H:5J_ASXA:9J=A=()+:^T^_LM!
MM;VSN8SQ)!<VTLD$R'AXW93P:^3O^'5__!//_HT[X5?^"_4__EI7Q1\8/^"<
MG[#^C_MQ?L5^!]+_`&;OA[8^$?&GPW_:]U+Q7X>MX-5CTO7[_P`(Z?\``R3P
MQ=ZG;#5-MQ-HCZYJ[:>[<P'4;HK_`*PT`>^ZC_P3T\0:E^Q%X#_X)^:UJWPY
M\;?"/X1:E\%=`^%GQ%\;:5/JOBW1_A'\!_B3X%\1_#KPQXA^'TV@7/A_7?&.
MA?#/PG_PJG4/&=CXST*'Q2D7_"5W.AZ,VNZIX<M>9\"_L#?&JRO;O4OBG?\`
MP$^(4NN?LN?"']G'QQID*>.?#V@>+KOX6_'75?B)K/CW0=,T72M-A^$$OCCP
MWXFUS5/!WAGX>"WTW]GGX@:?X?;P/<^*--M+?5--^@/^'5__``3S_P"C3OA5
M_P""_4__`):4?\.K_P#@GG_T:=\*O_!?J?\`\M*`.W\$_LI-=_LD_$G]D_X[
M>--=^*GA+XJ:)\??`&OW>J:S>:YXDM/A%\;-6\;6]IX#O_'NNVG_``D7C_6_
M"?@/Q='X4NOB;XSM;CQ?XVO["3Q1XK:^UK4+Z>XO_`[P;^U1\._`O@?X5>.M
M9^#?BK3OACX9\/\`AJU^+>AWGBO1_%?Q8L/"6G1Z9ID?B#X77OA:_P##OPKU
M;Q!;6.G'Q5X@T7XB?$RR6636I?#OA+1OMVF+H7G/_#J__@GG_P!&G?"K_P`%
M^I__`"TH_P"'5_\`P3S_`.C3OA5_X+]3_P#EI0!\>Z?_`,$ZOVD;#X2?!?X<
M#5_@B]W\-O\`@G#^W1^Q'K-^OCGQY'9:CXL_:T\3_L[:WX<\=:?!_P`*E:5M
M`\'6WP`$6KV%WY.IWTWC2=;%DC\/^9X@^AO$/[#?C_Q3X9^-GA35/%WA-="_
M:D_81^'?[&OQ8TJXN=:UNW^&^H_#[PY\9_"T7Q`^&CW>B6</C'2M<TOXY^(&
MU/P3K^G^!H5U/POH^J0:PDGB#78(>\_X=7_\$\_^C3OA5_X+]3_^6E'_``ZO
M_P"">?\`T:=\*O\`P7ZG_P#+2@#Q;XC_`+#WQM\1:M^T&_AG4/AB=(^)7[6/
M_!-_]H+P3)XF\?>.)M:A\-?L*_$S]F?QWK?A_P`7W7_"MM7E'B+X@67[/D^G
M:?JUM?:]'87OBI+[5)+XZ9,NI>0ZY_P3G_:BUYOVE=`N_&OP,'@?XP?&1/C)
MX"M%U+QO#K7A+6M._;%U3]IV>U\2W6G^!M._X2NU\=Z!<^'/!#V>KW6JZ9\(
M-<\'W?C3P7I_B6Z^(?B:QL_=/C!_P3\_X)X?"7PMHGBB7]C7X6:[!JWQ3^"7
MPREM(_[2TZ6U?XT?&/P+\'K/64D:XO4N5T#4/'5GK5SI["V-_9V-S;17EM/)
M$]>I_P##J_\`X)Y_]&G?"K_P7ZG_`/+2@#C7_8M^*6G^._%/CK0O&_A&*\TC
M]OFQ_;>^'%K<7'B&UL?$]OXA_9U'[.OQ(^%'Q)L[;39UT:T7PWKGC35/!?BC
M29O&*6_B63P9XCU+PPC^&;C2=6^</VFOA+X\_9UUSX&^)OA/I^DWOQ0\6?MA
M_M(?M*:G\1/$?A'XOZK\+?A/-\4?AGXG\%:IX.3Q?\.?!/Q/B\#KXML?%?A[
M3((O&WPPU;PU\4/&5EXK\564'@CQE-H;V/V#_P`.K_\`@GG_`-&G?"K_`,%^
MI_\`RTH_X=7_`/!//_HT[X5?^"_4_P#Y:4`<!\#OV9?BOHGC_P#8Q^)-CX2^
M$WPD\)_L^_L9_M1_LQWG@W0/%OQ#\5W>FZG\:/B3^R]XE\%>+_#5IXT^&?@S
M6-=TFQTO]E72]3U^Q\<W7ACQ7=W_`,3;^"_>2\\)2WOBWXB_:%_91^-WP4^`
M_P`7OB1X_P!;^&WBCQ/XU^`W_!*_]G2?2/`I\5O'?^-?V0OVR_B5X[U[QU8:
M3-X=L;;1_!_C7PO\<KKQ1-X*\+Z/9Z5\'M%\&ZIH&DVVN>&-'B\0G]'/^'5_
M_!//_HT[X5?^"_4__EI1_P`.K_\`@GG_`-&G?"K_`,%^I_\`RTH`\Q^+O[$O
MQ%\?^);#XE>#]1^'4'B/QA^WA^S3^V-X_P!,U/Q;XGB\-V'A[]GGX<?#OX;Z
M=X5\):CIO@743XE\0>*-)\!1:K<>)]2T+PLD`U"QT29=3L/#VG7LN59_LK>,
M=%TZS\&^(/%&F>%?C1J7[>/Q7_;`^"/C'X>6'C7QM:>&/`OCWXDRQ_&/PWXB
MUB]\)^#]#\.ZEK/P*^,'Q"^'4D.IZS!#?:EXAA\4>%UUC6/#J6%M['_PZO\`
M^">?_1IWPJ_\%^I__+2C_AU?_P`$\_\`HT[X5?\`@OU/_P"6E`'WQ;6UO9VU
MO9VD$5K:VD$-M;6T$:Q06]O!&L4,$,2`)'%%&BQQQH`J(JJH``J>O@#_`(=7
M_P#!//\`Z-.^%7_@OU/_`.6E'_#J_P#X)Y_]&G?"K_P7ZG_\M*`/O^BO@#_A
MU?\`\$\_^C3OA5_X+]3_`/EI1_PZO_X)Y_\`1IWPJ_\`!?J?_P`M*`/O^BO@
M#_AU?_P3S_Z-.^%7_@OU/_Y:4?\`#J__`()Y_P#1IWPJ_P#!?J?_`,M*`/O^
MOSN_;?\`^0Y\/_\`L%:[_P"E>GUI?\.K_P#@GG_T:=\*O_!?J?\`\M*_A<_X
M.]_@M\,OV0OB]^Q-I'[,7AA/@?IGC?X<?&/4O%MC\/-5US0;?Q#?Z/XG\#VV
MEW>J)!J9%S-8V]]>0VSMS&EQ*HX:@#^H_P"'%GKW@_\`X(=?L"_%_P`)?$3X
MI^$_%=I^Q)_P2;\$Z7!X2^)/C+PEH.E:;K>I_L_Z!XKOK?1/#.L:38W>M>+O
M#?CC4/#FMZIJL>HW"Z1I^DP:4=,EM[B:Z_4G5OBA)\'_`!YXG^`WPOT;Q-\7
M?B'!\*?%O[2G]@?$GXKZ[%'IOAD:_I_A/2/!^B>.?$^D>.M;N'\3>)K7Q%)H
M=AJLMQI?AE;2[@O-6TC1KGP_81_DA^QM\>/@;\6O^"3_`.P!\!OC#^RU^WUX
MX\):%^QY^Q0^H3_#7]G[]IW0_#_B#7?AE\)OACK'A[7/#_Q`^$]QX9O_`!'X
M8C\2Z!IOB+1+JQUJ;P_KT5MI>I-!>VWV<C[<\5_M*_`#QKXB\->+_$7['7_!
M0RY\7>$?"'B;P!HGBJP_94_:?T+Q.O@?QD^@S^*O">J^(-!33-6\1>']>O?"
MWAS5-1TKQ#>:I9SZUHFF:VT0U>TAO5`+?PZ_;X\5_$GXB?&;Q?X.\+^']?\`
MV?=._P""='[#7[:WP<T[Q#XHTKX9>-=0N?VI];_;`,6E^,-4\7V<'A7PU_:N
MF_!7PC9:@^L>*(K'P:+1[RWCUV^UN^T_3^:_:$_:K\3?$/X4>/H_#-OXM^$7
MCG]F[_@JM_P3%_9K\57GAGQ=XNTR+Q5I'Q?_`&E/^"=GC7Q5:;[K0/A[K][X
M/\;?!#]K"3P!XP\(^+/#*:=>W#^(;?R=8TK^R-8N>;\;?$3]D'X@W'B2X\1_
ML)?M^1?\);\(O`OP)UZV\+_LK?M3^!--N_A;\+?$OB/QE\+/#L&D^!I/#FF:
M9>?"WQ3XN\4:[\,O%&E6=EXN^'FH^(-5N/!NO:*UY-G'U;Q3^Q]KFC^--#U3
M]BW_`(*8W5E\1?C5\&/VBO'$W_"E_P!N*#5_$OQK_9[M_A5;?"#X@ZGX@M_$
M\.O2ZQX13X'?"*4PIJ2:;X@N_A[X9OO%%AK=]IZ7#`'W)^T[^UT_[-E_;O=?
M#M/%_ARS/PAF\4ZK:>-M/L=<TNQ^+?QMT'X,6D^F>#M/T;Q)K4XT2YUF3Q#/
MJ?B\^!/!^MI9GP[X?\6ZAX@CU:TT;B8/VZ-1\27?B;4/AK\#/%/CCX?>%/%G
M[5WP[U[QY+J.M^&=.\,>._V4-6^(/A+Q%;>*Y=4\!R>'(_"_C'Q_\*_&7@_P
M[K?@GQ9X]\0VES<>$=1UKP796>M:W_PBGSA\6OB=^RA\</$NM>+OB5^Q/_P4
M4UC7_$O@[P1X!\276D?LW?M>>"[?Q%X6^&?CW4_B?\-K'Q!I?@C4/#FDZW=_
M#SQ_K>N^*O`FMZG8W6N^#]4U_P`02>'=3TZ/7=6BO,6'Q?\`L?6GC3XI^/=.
M_8F_X*2:/K?QH77I_B-IN@_`?]M30?`^M:_XI\/OX4\4^/;#X9Z-K]C\-_"O
MQ5\3^')9]&\1?%WPCX4T'XH:[875[!JOBZ[6]N_.`/<OV??^"@7CO]H+X:_"
MGQ9X?^`7A:P\;_&7]BWX??MQ^#_AT/C?J-V;?X9_$?PAX)U7P_X8\0>*KSX+
MZ-86/CG4/&&O^*_"^GVNFV&L^'O[(\(V?BG7_$/ARY\40>&=+^=T_;Q\0Z/\
M5?VF?VL_`.C>)_B5^RU9?\$M_P#@G+^W'J/@'Q=\1O$OA35_`GPV^(?BC_@H
MIXI^(_CGX;_#B?PUXWT&X^*&K?"7X:>")-?\#07_`(`MO%>H>`='TV\\4#5?
ML]PW1^#/'O[(7P]\(?!OP-X,_8?_`."B.@Z#^S_\)+OX"_":6U_9O_:^E\2>
M&?@O?6GANRN/AA<^-;O4;CQIXH\%_9_!WA(0Z%XNU_7K*UF\,:!<VL<-SI%C
M-!UEW\<OV7+SQ)=^*G_87_;JMM2U+X;>`O@[J]CIO[''[1.D>%M=^%?PMUKQ
M=X@^'7@#Q!X'TJPLO!?B#PMX,U3Q_P"-Y?#^D:SH%_:Z=:^+/$.FPQKIFJWE
MI*`>QV/[8T,/[57QC_9C\/\`PZ>\^+%KXSM]/\+?\)%\7_$H\&^,;'1?V<_!
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MCII'Q>_95U+]G?X1?LK_`+;FA/<^(_A%?V4GBO\`93_::T>T@TGX>?%SP5\3
M-8DN/%&D>!_%GBV[\1Z['X4N;5M=N/.UB[UO5Y?$.IZS+J"SS70!ZU^TA^TS
M\1/$GPS\7:%+I6L?!+XM?L^?\%,_^"8'P9\42_#GXG>(M<\->+_`WQP_;&_8
MFEU!].\6VWAOX<7VO^%/B#\&OCCK?@+X@>!/%'A6WM[34_\`A)-*GMM>T0>'
M/%&L9?QZ_P""CWQ#T'X/?M/S>`/AIX?\*_%'X9_LL^&?VB?AYK.J>-[7QYX3
MO-'\:?$?QU\,@U_J'A_PS+X3U#7?#,OA"/Q!9#P?K_Q'\":Y<ZE%ITOB5H--
MO!?,\9?&']F3XC^#)/!'C3]B_P#X*,7>D7_Q7^%_QVUEM-_9W_:_T;Q!K'Q=
M^#7B#P+XL^&7C#7?'>@W>A^-O$UUX(\0_#+X>7>B6^O:S=:7Y'@?PM97.E/I
M^C6-C;^<:2/V%M%\)ZSX%L?V"?\`@H@?"&N?`YOV:[OP_?\`[/O[:&K:?:?`
MJ+5;[6=&^&F@1:MKU\WA;P]X-O\`4;QOAROAEM(O?AG:S?V?\/KOPUIL<5K&
M`?>?B?\`;#U73?B=XG^$_@WX,>)?B;XL^&'B7X`>'?C'9^$;S7FB\(1?&R;3
M;O6O$6A:U?\`@6U\(:]H7PL\&ZM:_$+Q%_PE'BGX>ZUX@\+V&N6GA/1M4\7V
M>F>%]:]`^*?[0FN^%?B!K?PA^%GPU_X6[\6M!^"]W\<I?`TOC;2OAY-K7AI?
M%@\(Z-H7AK7_`!!IEYX=N?%/B/4K'Q#!IT?B#4O#/AG3KO3-.C\3^*-`L-<@
MU2U^`]4^)'[*&L?%KPW\<[S]C#_@I*OQ2\-^'O"_A63Q+8?`/]L[2(O&^@>!
MM1U#6/!&G_&+P_I.M67ACXZKX,UC5M3UCPC<?&C1?'MWX9U:_N]3T2>QOIY)
MVUOC!\8_V8?CMXK\$>._B-^QG_P4;N/&GP]L]:T?PWXJ\'?LX_M>?"S7Y/"_
MB6ZTB^\3>`_$^J?"V_\`!EYX[^&GB:]\/Z)>>)/ACXYE\1?#[7[G2K&?6/#5
MY+;QLH!].:W^V_H.F7%SKUAX)N-;^%6C?M>^"_V,/$_C2T\0,GB'2OB7X^\6
M>"_A9H.N67@@^'Y(]5\&P_&;X@^%_`.L:@WBG3]1L=/FU'QO;:7J'AZQC:[\
M@^$W_!1;Q-\3=1^#>F7'P*T+0+CXH?\`!0W]M'_@GSJ[0_&'4-9A\+^)OV1_
M`O[6WC.S^)&G,_PBTA_$VA?$=_V3]8TNYT&YB\,:AX*3QCIE_'?>,#I5U8W7
M.V?[0?[-=AXL\0>-+/\`8B_;SMM:\5>-]!^)?B.VB_8]_:,7PQK/Q'\,:%HO
MAKP_X_O_``.++_A"I_&NE:+X:\,VMIXI;P__`&XDGAGPU?-?-?\`A_1[JR\^
M'C+]CR+QE:>/;3]A_P#X*,:9XETWXU^(_P!HS1Y=&_9Y_;'T31]`^-OC/P/X
M\^'/C7XB>&_"VD:O9>%?#>N>-_"/Q/\`']CXV70M%T^P\87_`(IU3Q%XDL]4
M\2/%J\0!T(_X*:_$+Q#\$(_B!IGP0\)>#/$GQ(_X)]?M6?ML?!9-0^*.J^.+
M&*Y_98U+X4^'?&/A'XBZ;;?#7P:=/MI]4^.7P[U3PS?^']<UF;Q)I\7B:QU6
MT\&7.GV5QJ/Z=?!37_$WBOX/?"[Q/XS6Q'BOQ%\/_".M^(&TVZ^V64^J:IH5
MC?75U!.-&\/)_I<DYNI(8-&L+>UFFDM;:)H(8Y9/R'\-7W[$GA.T^'^G:1^P
MM_P4=ETKX7_!+XN?LY>"]%UWX#_MK^*]#L?@G\=]0\*:K\6?`&J:)XI\0ZSI
M/BG3/&=_X%\&3WMYXKL];UBQ_P"$7T*+2-2TZ'3;6./Z<\"_MK?#'X<>#O#/
M@+PI^RM_P44@\,^$-&L?#^@P:W^R=^TGXOU6WTG3(%M;&VO/$WC"SUWQ-K#V
MUM''`EWK.L:A>M%'&CW#)&H`!^E=?S1_!3P]IWC3]IK_`()^>$_$2ZO=^&X_
MVX/^#CCQXVEV/B#6]$TZ;Q=\.?\`@IA\1M>\#ZMJ$&B:KILFI7/A_5Y)=0TN
M*\2[LHG^U)/$4N6AN/U=_P"'A?A'_HUK]O\`_P#$*_C?_P#,[7XM?LT_%B[\
M0>*?@!\??"WPE_:X@/[.W[;'_!:23Q%H`_8?^.WCK3_%OA+]J#_@HM\9M7U/
M2],\1^&Y=*MO"_C[P-HOA^;1=7TW4[/6UT'QQ)J.@:]IT5WX<U"QN`#[SO\`
M_@E-\0=>_9I^,'[.]G_P4!^-`\2^*_VAXOC18?$ZS767UOX?Z@L"?$FU\$7?
MARV^)<=OJ$TWQC\0R?%B\\4ZU??\)YJ6CW7A2VN=9E\4^'O#'Q'L?J"Z_8)E
MUK]J:[^/>O\`[0'Q)\3?"G6/V<Y/V?-;_9YUC4?$M_H_B#3KSP]+X9U#Q/J?
MQ'D\<-XLNI-6TRYN+W4/#WD_V#=^*YV^(<L+_$4)XM&]X?\`V[OAU?:LUI<?
MLV_MP^$X-8GENM5U[5OV'OVAI-.-S#IJ6\5QJJ>&?`6O:W>3SVVGV&D030Z3
M?2(B6,-PUOI]NT]MSFO?\%"=.?0]:3PQ^S#^W3:^)7TG44\.W.O?L0?'R_T.
MWUQK.<:3/K5CI^DZ=?WFDPW_`-GDU&UL=0L;RXLQ-#:WEK,\<Z@'*_\`!&1K
M^Y_X)E_LG:GJVN>(_$>K:QX$U/4-0U?Q3X@UCQ+J<TQ\7^(K2&(7VM7E[<16
MEI9VEK;6UI#)'"JPM<.LE[<7EU<>OV_[5?C;QSX!\7_$OX4_"O2]7^&>G^&?
MVIX=!^(^L?$&RT_['\1_V</'VL?#BT\/>*O`DF@#78=&^(&J^%/'6M:'K'AF
M\\476DZ;X36S\7Z1X=O]=M4M?C;]B+X]^'OV1OV5/@C^SEJ?P(_;U\>ZE\)O
M"4OAR]\7V'["'QW\-6.N7-UK.I:U<75KH-Q9ZY+86Z2Z@;:".?5;V8QP"4RQ
MF=X4=I7C;]D30M=^+&OZ'^Q7_P`%)M%D^-C>,[GQ]H.D?`C]M33?`;ZU\1WO
MIOB'XO\`!GPVLM>@^'OPM^('CZYU75KWQM\1?A=X8\&^._%=_J^KW^O>(M0O
M-5U">Y`,OX.?M@_$KX5_"S2_''C/P#>_$7X@>*O^"6&D_MVZ_JNM?M._$;5_
M#?BW6?@_X6\&#7]`T[P5XB^&>J>&O@QJGC]OB%<ZOK&I_#K3KS0YK[2].L[_
M`,-7QMH-8C^P/B+^TEJ&E65W\:H-!\7ZEX0^`_[(U_\`M+>.?AIX0U&ZFU#Q
M5XF^)FF7;_#CPW!<6<-K'X@@\,>'/`/Q=DUNTU>P_L^SNM?\$^+TT:;4--TU
M]/\`D74O$G[&NK^"/`7PZU#]B#_@I#/X1^&OP:\7?L\^%]/'P&_;4@O9/@AX
MYTG1-$\3_##Q7KUOK\7B#X@^$=0TWPWH$,.E^/\`5?$T>ERZ1I]YI!L+VVCN
M%=\6OC'\,?$7[-_QN^!7PH_9:_;U\%S_`!A\%1^#]0U+7_V2/VMM7BGL+7P)
MX9^%\5C<:]I>JZ3X\T19?ASX4T[PQ::UX8\3V&HZ)?L_C)+;5]?EU5=:`/IC
MQA^W7XP\)>'/B5XG7X)>'/$.C>!OVL/V.?V7M`U[0/C%>7GA+XB-^UQ\0_V?
M?AG%X\\+^)F^$\=K/:?#/Q+^T+H%KK^APVUXNI3^&_$EFFNZ5>0VL-QJZ?\`
MMK>,]/\`C#\,O@Q\0/@MX7T#7OB7^T#KG[--CJW@KXVVOQ,T&P^(?A[]C?QK
M^UW?:E>WFE?#O2&T3PO):?#7QUX`M-*\=1^"/C$\MGX;\>W/P@M/!7B_2[]/
MS_\`AQK7P8N?AE?>!/C/^RO_`,%7=8TC4OB)\'?BO'X&USQ%_P`%1OVE;7PQ
M\1_@+X\L_B7\./%WAGXR_&O6M&^*]HMGXYT/PAXIN/!EG_9'@;^V?!?AZ^N]
M#U:^BN[ZZ];'C']CZ/QZ?B7;?L2_\%(;#Q>OQIU;]HJSN=+^`?[:&DZ-I'QL
M\0_#/Q;\'?$OQ%\/>$=-URT\(>&]=\4?#CQYXO\`#GBK^P-"TVR\3CQ!J&K:
M]9ZCKKIJ:`%U_P#@K+XIM/@IJWQPU+]FK0[3P]I/[#/Q#_;YETR'X[7MWJ9^
M%/P3UI]/^,/AAMOP3B@3QY8:;<:5J?PWLHWGT'QS-<W^G>)=?^&IT^"[U+]G
MZ_!27P_^P1/X#E^&4_["/_!2R;P+<?LZ?$']DNY\/2_"/]O.2"Y_9[^*FH'4
M_'_PYN;I_&;:A<6OB*[VB;Q!+>/XLLK2*WTW2]?LM.MH+6/[?T[]OSP5I>G6
M.EVO[+W_``4,EMM.LK6PMY=1_8\^/^L:A)!9P);PR7VKZQH]]JNJWKQQJUUJ
M.J7MYJ%].7N;VYN+F665P#]#**^`/^'A?A'_`*-:_;__`/$*_C?_`/,[1_P\
M+\(_]&M?M_\`_B%?QO\`_F=H`^_Z*^`/^'A?A'_HUK]O_P#\0K^-_P#\SM'_
M``\+\(_]&M?M_P#_`(A7\;__`)G:`/O^OSY^/EM'>?\`!0/]@RTE:=(KKX1_
MMRV\KVMU<V-RL<^D?L\Q.UO>V4UO>6<ZJQ,-U:3P7-O(%E@FCE1'6?\`X>%^
M$?\`HUK]O_\`\0K^-_\`\SM?#_QD_;J\+7_[=7[$?B1/V;_VW[:'P]\-?VQ+
M2;2K[]D7XPV?B'5&UW3O@0L4^@:'/H2W^M6FF_V:[:Y<V,<D6D)=Z<UXT8O[
M?>`>G_#?6O'VH?\`!(WX_P#C6]^(?Q>O?BCHOA3]N[7-%\<7/Q0^(UQ\1M+\
M3?"SXE?'30?A_%IOBB3Q&_B:S7PU:^"O#.F6>@VU['IMP=.:.^TZ[N+_`%)K
MQGQ4^*OQ4^#WQUGT3XT7_P`6=)_9N\7_`+1?P)T7X`_M9?![XAZIXR^&OP^T
MZWU;X5?#;7/V5OVL/`JZS+XL\(ZG\0_B9I/C3PS%\>-5L/'FBZAKOQ/T^U\9
M_$'X9ZMHVFZ"W96W[1W[/ED;^*Q_8X_X*&V.DZIXJUGQOJ7A6R_97_:AM/`M
M_P"*O$GBB;QOXCUF[^']N(_!-Q<^(O&=S?>+=?230&M]:\2ZGJ^N:G#=:GK&
MIW-WDCXY_LV?;_$U_)^QO_P49ND\8_$.T^*_B+1[W]FO]K:_\*7_`,1-.U'P
M]K&F^*E\&7MU/X2L=1TO6_"?AS7M+73M$M+73-?TBSURQM[?5D:\8`Y_]DJZ
M_:2\=>%?"VM^"=;^+-Y<^$O^"D/[>W@3XE?$#XI?%(>./`'B#]F+X.?MN?M?
M?"71OA]:>&/$OQ!\2^+3KOA_P;X2^'7@WP3K.F>$/#FN6OB'PIINL^(/$VJ>
M%_\`A(H/%?VI\9/VA?'7@;QQ>^"HO".F?"OP;!9:=<?\-*_&.UU[6OA`C7UO
M'<7,UG8_#P3Z79V^CW3#P]JJ?''XJ?LXRW&MW$$_@_\`X372U2YN?F3X+?M*
M_`7]GOPOJ_@SX4_LC?\`!1[1O#FN^//B-\3M4L=>_9H_:P^(,TWCGXN>//$G
MQ0^)&O0ZE\1)O%>JV4GBWX@^+_$WBS4[&QO;;2QJ^MW\]K96ZR[!Z_\`\/"_
M"/\`T:U^W_\`^(5_&_\`^9V@#S:R_:DU:W\2_$?QM\0M2\7>*/@;\"_VA/@I
M^S&OB+P%?V/AV77?'OQ-T7X%:O:?''Q1H&AS:3J7B+X;S>-OCQX;\#P^%-)U
MK4=#TWP/IDGC^ZT+XHVOB5KKP5N_"SXF>.D\8_\`!2Z#Q!\?=(\"Z'\#OVX_
M`OA7P%XH^,<.F:_X"\&>"?$G[`?["7Q1U'P1J5O>>(/`DT/A?4/B1\7O&^OZ
M9;Z9XR\-ZA9:_K\$5KJ,VF+)H=[Q*_M&?LXQZS?:Y;?L1_MWV$VJ:[X6\4ZO
MI.E_L;_M#Z3X1UGQ;X'ET";PAXOUKP+IVG6O@O6/%WAM_"?A(:-XJU/0+O7[
M&+PEX4@@U)8?#.B1V#/`_P"T5^SO\.O%_P`5_'GA?]C7_@H5'XI^-OQ-T[XR
M?$;4=>_95_:@\8PZG\3-(^'7A?X2:;XMT32O&"Z]H_@>]M/AIX*\)^"HK;P+
M8>&M._L'0--LVLF6!6(!](^&M8U_]K'POJW@WXB?#WQS\.M$\(^.OA)\0/#G
MQ6\*2Q6'@SXB:[\+_B/X<^*/A>3PAIOQ8\(^'_B5#!9>*/!'A[4_$*ZM\*I?
M`6J:+J-K8>!OBKX[#ZQ=:;]IU\`?\/"_"/\`T:U^W_\`^(5_&_\`^9VC_AX7
MX1_Z-:_;_P#_`!"OXW__`#.T`??]%?`'_#POPC_T:U^W_P#^(5_&_P#^9VC_
M`(>%^$?^C6OV_P#_`,0K^-__`,SM`'W_`$5\`?\`#POPC_T:U^W_`/\`B%?Q
MO_\`F=H_X>%^$?\`HUK]O_\`\0K^-_\`\SM`'W_17P!_P\+\(_\`1K7[?_\`
MXA7\;_\`YG:/^'A?A'_HUK]O_P#\0K^-_P#\SM`'W_17P!_P\+\(_P#1K7[?
M_P#XA7\;_P#YG:/^'A?A'_HUK]O_`/\`$*_C?_\`,[0!]_T5\`?\/"_"/_1K
M7[?_`/XA7\;_`/YG:/\`AX7X1_Z-:_;_`/\`Q"OXW_\`S.T`??\`17P!_P`/
M"_"/_1K7[?\`_P"(5_&__P"9VC_AX7X1_P"C6OV__P#Q"OXW_P#S.T`??]?Y
MUW_!\+_R6_\`X)^_]DJ^.O\`ZEWP]K^U+_AX7X1_Z-:_;_\`_$*_C?\`_,[7
M\'/_``>)_'K2OCO\8?V'K[2_AI\=/AJOASX:_&:TFM_CE\'O&?PAOM6;4/%'
M@69)_#UIXQL+";6[2U%LT=_<V*R1V<TUO%.RM/&"`?W+?\$R/'_@WP1_P2T_
MX)AQ>*?$%CI-SJW_``3^_9$ETVPD,USJ=]::5^SI\,'UK4K;2[**YU"72/#]
MO>6U[XDUE;8Z5X<TZ5=2UR\T^P#7(_0SP?XO\*_$'PEX6\>^!?$>B^,/!'C?
MPYHGB_P=XN\-ZE::SX=\4^%?$NF6NL^'O$>@:QI\L]AJNBZWI%[9ZGI6I64\
MUI?6-U!=6TLD,J.?P*_9R^']KXV_8,_X(H7_`(2^+?Q4_9E^/OA'_@F3\,=8
M^$_[3'A;P;_PFWP@\/://\#/V1++QW\%/V@]!\0Z3<_#?Q!X,^,UY+X'UW1_
M"?B3Q)X!\8:SK'PD;4?A=XTT3Q-X?EN5]6TOP1^V-XQ\!>#_``4+3QW\`?$G
M[3'[#5_\-M+7X:>)/BOI?PJ_9(_:3_9VUE+?X;>/?"V@OK4&O?#CPG\</A]X
MO77[CP?X@N;/4H(?@SX=^&GBZ6Y\3^)_$5QJP!^X5>%?%K]IKX"_`FXUBU^+
MWQ/\-^`KCP_\'OB+\?\`68M<>\1M/^#7PEU/P?HWQ(^(4_V:TN`-`\'ZGX_\
M&V>L2H6N8I?$.GF.WE1Y'C^"=+^)?QM^(NN^"_$/Q&T+XX?`'X>_'_\`9$\0
M_$[2+?0[KQQ=>(OA?^TO;_\`"!:5:_#O5H+9=8M='\6Z/X8QXD^&7P\&GQ^&
MOBQXBU7XD66K^$_'6L>'K`G\[?VY+K]HCQ?^S=X+;]I3PW;6W[4_B[_@W3_X
M*T^`_B]X5\&::;ZU_P"&F_C7X<_X)_)X=^&>BV.A"_L9/&_Q$\3>!/B-:>#/
M!N@W%^_B34?!GB^T\%+K.G^';JXB5UW7]?\`#K[P/Z?:*_$#1?C9\=O&_C+X
MV3>)_BE\8?AIXM^&.O\`[8EPGA7PY\!_B1-\(?B#^SGJ^G_$&^_9`^(_A?X]
MZU>WGP'?S_!$/PA\2Z?K?P\TR7XD7OQ47QQ\-];L[ZTA\2WUEZ5^P7\2_B;J
M/Q4\!>%O&GC_`,>^,K+Q]_P3J_91^+OC1/'^LZOKCV'[2,E_XUT+XK0:<-3V
MV?@SQ+<:&/"K^._AUHUOI-MI]UIVE^(KKPWIVMZQK^K:\77=?U_PZ^\#](=!
M^-GPQ\4>._B+\,O#_B==5\??"6RT?4/B/X5MM(UXZMX3L_$<%Y=>&I]2A?2T
M4KXGM-.U"[\,K:O<2>([2PO;K15OK>TN)(^A^'GQ"\'?%?P5X=^(OP]URW\3
M^"?%NGIJWAKQ%9P7MO8ZWI4LDD=OJ>GB_MK6>?3KP1F>POEA^RZA:/#>V4L]
MG<03R?#?[5WA'XN>#?C7\/OB[\!]#\0:CJGQ[\'W7[''Q?OO#-LMQ<>`;'6K
MK7/%OP(_:2UI64F70_V=_$VI_%'3;^SA99+ZW^-;S2-LTB&2'R^PU']HG2=8
MO_!?@;3_`!1X+\=?"']M[X.?#GP#\-DM];C^$WB#_@G^7^%>B>*-8TR"XM'\
M-:UHVC_!#4/'OBYO'3S/XD\-_M%>&X?A>/$\%HVD^"M3+KNOZ_X=?>!^E?P_
M^)O@+XJ:?KNK?#WQ/IOBO3?#/C'Q5\/]<O=+:9X-.\9>"=5FT/Q9X?F>:&'=
M?:%K%O<:=?B(20QW<$L2RNT;8[ROYTOA?XD^)'A'XO?%F^T?4?C)8_"SQUJ?
M_!:31]0MO`<7Q1OM%U#XV:I^T9^S-X[_`&5-=M=.\$P71T7Q-K/PX3]HW6?A
M[X]L(-,&O>&EUU(]?O[*VTF*#RVS^-_[74'[+_@77?$WQ-_:/T'XT^"/^"/G
M[$'Q6U/PYK]IXN\,^+4_;5L?$\NF?%=/&7A/5=!T[7?%'C_6I8=/@\>_#[Q=
M9ZQ8>(M)UNSU+4/#=WI^K:-J#%UW7]?\.OO`_I_HK^=KQ-\>_P!H+3?VD?VE
M_@9-\3_CMX:_9>/Q.^)G@GX,_';P+\*?CE^TUXO\'>.?&W[+O[!'Q"^%MX;W
MX6W5UXUNO"8^+WCC]L:'X::MXB/B[X*:EXR\(>(_@GXETR#_`(0SP/X5/]`7
M@\:T/"/A8>([JYO_`!"/#FAC7KZ]TRQT2\O-9&F6HU2[N]&TN^U33-(N;B^\
M^:?3-.U/4;&PE=[2TO[NWBCN)"Z[K^O^'7W@='1111==U_7_``Z^\`HHHHNN
MZ_K_`(=?>`4444[KN`5^?_\`P33/_&.OQ&_[/^_X*Q''?_E*;^V1V_SS7Z`5
M_/[^P)\/=1^,/Q'_`&DO#$OQK^.'PZTWX>?M`_M->.M,T/X6_$[4_"^EWS:O
M_P`%OO\`@L'=>+]/U7PS<1ZMX>:P^(4'PU\&^&_&>MV6BV/BW4O#&APZ#8>)
M],A2-X2Z[@?T`^_/0\#K^`YR??GVX)K(T37]&\1Z7'K.B:A;ZAISS:A:-<0E
MD-M?:1?W6E:QIM]!,L=QI^J:+JUC?:1K6E7T5OJ.CZM8WNF:E;6M]9W,$7YF
M_M2_`#5O@S^RI\=OB9IG[5O[65UXB^%'[.G[5FO:-=ZY\<+O2[36_%7BKP[J
M_B_P7J.L2>&-+\+WJ:I\+_$&FZ7HGPE70M0T?[!HL\VAZ]#XLFU"2X?ZU_;+
M\->(O&'[(7[4WA3P=:^([SQ=XB_9W^-.D>$K'P;?:SIOBN^\4ZA\.O$D'AZS
M\.WGAZYLM;BUJ\UF2S@T\:9=17<UW+'#&S&4JRNNZ_K_`(=?>!]'6MU;7UM;
M7ME<07EG=P175I=VLT=Q:W5M<1K+!<6\\3/%/!/$Z2PS1,T<D;*Z,58$SU^*
M-[XP_:`C^$WC_P`(_#D_%WPG=:'_`,$\O@]XV_86U>WL/';3>+_VH]*T7XW#
MQUX1\6VWBRR6?Q1XDM=<TWX&02?"CXJ17^BZC\.[R\\0^%K5M-M_'5_X8_7/
M4_$_ASPQH?AK5_BGK?@CPKJ2"S)O-8UG3],T>V\4RZ/<0ZE%X=U'Q!+9RLWV
M>XU:VMI%,=_+I4MRLR".6Y0EUW7]?\.OO`XZV_:3_9WO['3]3T[X[_!S4].U
M:V\*WVEWVF?$SP9J-GJ-CXXN!:^"]1L[BQUFXCN=.\57&(_#^H0F2SU;:[V,
MTZ12,G2^&/C%\(_&VN-X8\&?%/X<>+O$BV>O:BWA[PQXW\,Z_KBZ?X5UJR\-
M>)[YM)TK5+N_%GX<\1ZCI^@:]=&W$&CZU?V6E:@]O?74$$GR9^R!^SG\'+[]
MEC]F"^\??!;X3ZU\1M+^!'[,>F^,M:U;PG\/_%^M_P#"=?`KP%H^B^&_MOBN
MRAUNVUG4OA;XE@UM?!^I6>LZE!X9U-KV_P##5Y;3W$ES)97X.:)\-/VH_@EX
MB^&&@:%\-?@W\-O@Q^U/#\6-=M+3P_!HFO\`COXR^.?V8M3TK3?$VM7^IQZ]
M=?$'Q7J'@#5_B%XK\;:C'J>NZY>Z-')XHUB\U'QDUU<.Z[@?>-8'BKQ1HG@K
MPYK7BWQ+=R:?X>\.Z=<ZOK>H1V.H:E_9^EV49FO;^6TTNUO;YK6RMUDNKR:*
MVD2TM(IKNX,=M!-*GQ5^WC\1?%?A_P#9Z^&'C/X:>+?&G@/5M;_:P_8'LKB]
MTO3K[P]XDE^%7C#]L7X$Z7\=+'Q#H/B/1/[7TC0[+]GW4_B=K?Q`M]9TG3KC
MPMX5T;Q!K'B(:9I^AZL8OR]O_C'\9M%TVVTG5OB1\4]7T;3?V^O^"@?[,VMZ
M;XLUKQ5XAMY?V0+3]DK]L#X@?!J^\20ZH;J;Q+:M\<_"WP,\(^`?C7XF.L^*
MM8GOM"^'FG>--1/C"[TW62Z[@?T#^!/'GA+XE^"_#GQ$\#ZQ'KO@KQ?H]KXB
M\,^(8[6^LK+7-`U"/[1INNZ>NI6ME<3Z/JMF8]1TC4Q!]BU;2KBTU73I[K3K
MRUNIM+PQXDT/QEX:\/>+_#.H1:MX;\5:'I/B3P_JL,<T4.IZ'KEA;ZII.H11
MW,4%Q'%>6%U;W,:3PPS(L@66*.0,@_+?X7_$G1M5_8/_`&2?V9_"U[J>K?%?
MXL?LX?`7X,^(]&\*V]W>:]\*-`O_`(=^!O"GQC\5>-;BUVQ_#W6_ASX2O_$=
M]ING^*)=.U:Z\9:;9:/;Z9<R0:H+'@_B/\?I]-_;!\2_`?5_C-XV^&EOX1_:
M4^`-YX.N-/\``GQP\,?"G2O@&?@9\+]2\5_`O5];\.^$HOA/K^I>,OB'JNM:
MUIOQ)NO%=A:^'K7Q<_@_7-:TIOA=:>$?&A==P/VAHK\2O`/CWQM>6GB#Q3XM
M^(G[4'BB^UG_`(*%_'KX!K=>$=9\;ZAX1\*_`@^)OB%XI^%6I^,O"G@C1;S4
MM&^'&H1^"_#7A/P1\3/ASHFC>-/$FN^,_"7@N7XFZ+X`\3ZYK.C_`"%XW^/G
M[8%Y^S-=>(;SXC_'S0_C?X/_`.".O[2?Q2TKPW;Z3XF\%Z_J/[;'PA\4Z)'\
M%AJG@\:'INL>)/B+XGU#1KV'_A7.J0:E;?$[26U6SN?#6OZ#?WT5P77<#^G*
MBO@_]E'QQX@U3XZ_MJ>`KCQEXA\9?#[PO\2/A-XH^$.H^)=9U#Q(TGAKXB_`
M3X=^(_%Q\*>(]1DG_M3P:_Q#;Q)?V6GZ5<3:#X3U75-5\-Z'!HNBV>EZ!I7W
MA2NNZ_K_`(=?>`5^?/Q\N8[/_@H'^P9=RK.\5K\(_P!N6XE2UM;F^N6C@TC]
MGF5UM[*RAN+R\G95(AM;2">YN)"L4$,DKHC?H-7Y\_'RZMK'_@H'^P9>WMQ!
M9V=G\(_VY;J[N[J:.WM;6VM](_9YEGN+B>5DB@@@B1Y9II76..-6=V55)#NN
M_P#7]-`?87PL^+7PU^-_@RQ^(GPE\::#X_\`!.HZCXAT>U\1^'+U;VP;6?"7
MB'5/"?BG1YR`DUIJWASQ/HFK^']<TR\B@OM+U?3;W3[VWAN;>6-8_AC\7OAK
M\9]$U/Q-\*O%^E^._#.D>*/%7@JZ\2^'C<WGAV;Q1X'\1:GX1\8Z1I>N^0FE
M:Y/X8\5:)K/AK7)=%N]0MM-U[2=2TBYGCU"RN;>/\6/V:O#_`,6?@_HFEK\$
M'U^]^%?[<#>+M`\73Z-I0#?LL_M,^'M9U6V\1_'2]FN%C3P[X:^('[.&B:CX
MFOK7Q%#IV@#XQ_!KX=VMFUWXC_:,O;F?RKX+^-_&7P;^"GPS^%W@EOB%\,_V
M9]?_`&HO^"R?A;Q-XQ^$7P<^,OQ7\4_"_P`8^+_^"A/Q1\9?L3WTGA/X*W%E
M\2-$^&WQ`^#OBCX@>*/!GC-X[[P+KNJ7/P@MM1AU33_&>ASR*Z[K^O\`AU]X
M']!/Q!^)O@+X5:5H>M_$3Q1IOA/2O$OCOX?_``RT*_U1IE@U+Q[\5?&6B_#[
MX>>%[<PPS'^TO%GC3Q%HGAS2ED5(7U'4K9)IHD8R+W=?@5^T/XF^-OBOPDGP
MR^,&E_'?Q?X]^&W[8G_!&SQW\+-2\.?!_P"(UEI7Q:^!?A3]I7]@/Q]\>?B[
MXM\'?#G0_$/@;3?&_ACXNZ9^T)?_`!(\$C5-2O?A;X7\'^`+JT@T[2-;L;[Q
M)[/I_P`8_C7??MG_``2AT^7]HG3OAAX@^/?[;/P?^.>C>._!7CF#POHOAKP'
MX3U^^^"VMC4=,\+Z5\+_``5X,UV\\&V'BCX0^,-`NKSQ3XE\`>(]+UGQW\0+
MK7_%6K>%]"=UW`_4OP]\5_A]XK\5:GX+\.^)+?5O$.DV>IWUU;VMGJ1L)8-"
M\3:AX+\1#3-=DLDT'6[GPQXNTN^\,^*K+1M3O[WPOKD*Z9K]OIUW/;Q2^AU^
M"_[#^H>+M#\"?`7P!JU]\5O#WP#\;6__``4#N/''C71_%'Q)F\1^'/VAE_:S
MTS7?@9I'B/6);J^\2^`X_%WPA\0?$'Q9X$M+F2#PC\4]:U+3AK=CK/B'7?`-
MMXL]E_9>U_\`:1\=?M$?!OPQ^T[X]\?:=XPT/]@#]F_XG^/O!/AS5KWP1X*?
M]IB3QEX[LOB1_;^B^&;?2M+OO$-[X7D\/7/C7X:W]UJ7AO3%U&RO['0H[2U\
M.:K;%UW`_0K5/VF_@7H7B7QYX3UWQ_9Z%JWPLM-,U+XG2ZWI'B/1]!^'6D:U
M:ZC>Z'KOCGQ7J.C6OA7PGX>URTT?5+C1/$&O:S8:+K$.GWCZ;?W2V\FWW9'1
MU5T971U5XW1@RNC`$.K`D,I!!#`D$$$$YK\F=+\(7GQ9_;?_`."B?PWA\>VW
MA#PC\3_@1^S'\/=8O+'PU!J/BK6(+;PY\?-$\=Q?#GQ'K>H3>$HM=\(VOBG3
MK;Q$E]X-\>0>'KS6=(&LZ99RW=O#<^)?"K4/BA\/]6\1V7AKQ/\`&7Q!\%OA
M=^W^?V:/$]G#XK\8ZA#\,?V'A^S[X37P1K_A/1-+51-X>\/_`+0VB>#/"WB+
MXQVUK<:[X4^&>K?&;4K[QO8:9X?US4-&+KN!^YLUW:6TEI#<75O;S:A</:6$
M4\T<4M[=I:75^]K:1R.KW-PEC97MZT$(>5;2SNK@J(;>5TLU^+,GA[XXWWQY
M_8G\1_%5OBMXB\`>`_VY?VO]%^'?B?3Y_B/)<R?!K5_@S\4;+X&:I\6['PF+
M>WU.SAUQ-3\#>$/B!X[TZ[C\4?#]?#U_XE\2:U=?$;7]2\4WO!7CS]N'7_"7
M[*WC?P=;>*I?VA]0\!?'W1OVV/@EX^M=6MOA;H/Q/\._!7QS>^#Y])FUS3;>
MP\#VEC^U)I'PX\)?":X\):KX?T_XM?L_^/O$7Q!>V\>Z9HNF^,-`+KN!^S%<
M)XZ^)O@+X9IX4?QYXGTWPRGCGQOX:^''A(ZBTP.N^./&-^NF>&?#EBL$,S-?
MZO?NMM;&01P+(09IHE.ZORL\+_'3XK>(?@"/BQ\*&_:VUSQ#-K?[$VB_M$?#
MOXK_``=^(/A?Q#\*+&V^*>@:7^V'JGPPT+QE\/M#\9^)?',WPRU?Q#)X\T#X
M7WGB;P?X6MO!MKXB^#-KIOC'58;3Q9SGQSNOB:+>SL/$NL:KXH^#>C?\%3_V
M)M:_9O\`$&MW&HZ[K\_P9LK#X$^,_B5JMSXENTN-3\3?#[PC\3KSXGS:9X\\
M0:AJ,UEH=K>V5]K4WAS0=#OIRZ[@?KWXL^(W@GP++'#XM\0VFB22>&_%_C`"
MZ2Z=8_"_@*SL;_QAKL[V]O-';:;H%MJFFM?7-PT2"2_LK>(RW-S#$]#XF_%'
MPI\)?A-\0OC3XMDU!/`WPR^'7BSXH^)YK"PFNM53PKX+\-7_`(LUJ2RTJ7[/
M<7&H+I&FW+VUA(8)I;D);/Y4C';^1G_!0OX&?&7XR?&GQ>O@CX9ZCXCT!/V>
M_!'P5CU[_AM3]J_X&6,T_P"UU\:;+X;^([J'X=?"+P5XC\"ZGIGP[TSX<67B
M+X@VEQ=Q0:WX=UC2M8\76&O+H&AZ9!]Q?M_K]@_X)U_MIQ7QBM98/V,OVB;2
M59=5N]66.[?X)>+[1+<:UJJ0:AJTCW#K;1:A?Q1:AJ<CI-<1+=7#1TKKNOZ_
MX=?>!S7AC_@I'^SCXA\;_LZ?#748/BCX'\?_`+4?@37_`(B_"GP=XV^&^N:5
MXAO_``UHVO6>B:?-=Z98G5+F67Q/:W%UXKTDZ"FNV>D^"=+OO%/C>[\(Z7)I
MDNH\9)_P5I_8O7X$?$G]HQ/&OB1_AM\*_BO-\&/%NH7'A'4-,_L_QL/%.L>&
M=/MK[4M8DTWPQX>BU1-(;7H[;Q?XA\-ZUI&DZOX6LO%&DZ!XJ\7>&/#>K>_?
MLU_#3X<Z]\$/V3OB'K?@'P9J_C_PA\!OA!_PBOCC4_#&B7WB_P`-Y^%AT<KH
M7B2YLI=9TE?[*\7^+--*6-Y`OV+Q-K]KM\G5]02X]#A_9N^`$7A+Q!X#F^"G
MPDO?!/BKQ)!XM\1^$+OX8>`SX6UOQ!8Z?I6C:3JVK>'+?P[;Z)J>IZ)H&@^'
M]`TG5K^PN=6MM'T#1[1[Z;[!$X=UW_K^FOO`\Y^%7[:'P6^,OQV\7?L]^"&\
M83^-/"7PK\'_`!F?5-6\*WNB^%M>\!^-+H:587VAZCJ$D.I?VMI/B"+4?"WB
MKPYK>CZ+K_ACQ-H>MZ+J^G6UYITJ'ZR'<<<'H.P[9]SUZ#&<<XW'\N]`M+33
M_P#@LIXPL+&VM[*QLO\`@EU\([2SL[2".VM+2TMOVI_C'#;VUM;PJD,%O;PH
MD4,,2)'%&BQQJJJ`/TW@TW3K6\OM0MK"RM[_`%,6O]I7T%K!%>:A]BB:"S^W
M74<:SW?V2`F&V^T22>1$3'%L0X)==P+I_7MVSWQ^..:^:/@7XZU?Q/\`%3]L
MGPIJ_BHZ\GPQ_:(\*>&?#>CS2Z6;KP?X4U[]E']FGXA1:.(+"WMKM=/O?%WC
M#QEK=E/JWVF\FEU.]ABO)+.TMX+7Z!UJQ74+2WA.E:5K!BU;0;Y;76)3#:P'
M3];T^^.JP2+IVJ$ZIHBVYUC18A;1+<ZQ8V-LVHZ2DS:K9:]*Z[K^O^'7W@%?
MYUW_``?"_P#);_\`@G[_`-DJ^.O_`*EWP]K_`$4:_P`Z[_@^%_Y+?_P3]_[)
M5\=?_4N^'M.Z[_U_30']&'_!._4_^"A6A_L!?L.:)X0_:#_8VTOPAI'['W[,
MVF>$]*\2?L3_`!L\3>)M*\+V/P6\$6OA_3?$?B?3/^"@W@_2O$VOV&DQVEMK
M/B'2_!_A'3M9U&.XU.Q\,:!:W,6DVGV-_P`)/_P4K_Z.2_8>_P#$#/CU_P#3
M)J_F[^.NC2WG@+_@W.O=&^$?A/XU>(+OX$:=;-\-/%5UH^C:7\2[71/V4/A;
MJVF>!]6UW6=`\1Z7#;W6H371T2/7]*NM"MM;OUEO)=,M[F\U6V\?^,EWI?C/
M_@B;XZ\>VDUL^O>(_P!OFX\2Q?!;4[&ZTQ_V2;KQ-\;-+@U/]ENQCU.Q&JZ#
MHO@VSMDEG2#P_HMO>V'B,W<'AV*RN(89O\[.)N,_&^MFN'Q&4>)V!RS+LQXC
MHY:L#/AC+,5/`8?%9KC\!3E&O/WJWLX8%5/WTJ*G*4H<\7%2E]90P^6*FU5P
M,ISA2<^?V\USM4Z<W[J5DVY6=N9I*[WT_JD_X2C_`(*5?]'(_L/#V/[!GQZS
M^/\`QLF'\ABC_A)_^"E0QC]I']A[!Z8_8,^/0X[]/^"DQQ[9ZU^$_C'PEK>A
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M[J6`RJKRJ.7SE.554E!5ZFLI4X5.VD;.TI6T;>]D?K(?$W_!2H\']I']A_'O
M^P9\>\#_`'B/^"DHSSU&!T.,]D_X2?\`X*5=_P!I']AX_P#=AOQZ_P#IDIK\
M@OBY\&O@;XM_X++>*?"GQ4\'>#I_AA!_P1TUCQ'KMUKNG::EIX>U'3?VG9O#
M=Q\0X-:NHA<:#XR\/>#EFL[+QY;WEKXCT?3[<?9=6M8[=2OT=_P2*^,'Q7UW
M_@EY\$OBW^U#J>N2Z_HGA/X@ZIJ/BSQ1)?ZCXDU?X;^$O%7BI?#/B#5Q-"VI
MWL__``B.F6T&GS.+Z]US2;'3=7%Q=S:KYK_%>+?CK])3@?PTX>X]X<\3\CSJ
MKG57AFFLLK<,Y10Q+?$=+'5J+PZC3K>VI8=8"2J5&H-NI3]U:I=&`RO)L3C*
MN&K8&K!4_:VFJU1I>R<(M/6*3DY_<M>B/N[_`(2;_@I3V_:0_8>XZ?\`&!GQ
MZ_\`IDHH/B?_`(*4_P#1R'[#QZ?\V&_'G\?^<DOI[>G)Q7Y-_LC_`+2GQE\/
M_M]?M*?"GXMKXV5?VJ_AQI/[2/[.7@KXB^"_'?PSB\*^-?AYH7_"*>.?@5IS
M^.O"GA>+Q)K6C>$K+P7-K?BOPG;ZCX7O++PC=:K:ZK>WDU^R3_\`!+[P%X%_
M:B_8*N_BE^U#;P:]^T;\2O'OQFTG]H/X@>)V@TSXI>!O&VG?$_7O#WAWPKIW
MB#48AJ_P_@\.>$+'P,VA>![!K/P[8+?1VG]@SV6KWEC=Y9MXW?2CX6X;Q'$_
M$'B3D*RY4^$HX58#AK*:U6OB>(\'6KUTXNG32P^58G!XK`XNO%SBL3348I*7
M-$IY;D=:LJ-/!SYVZU^:M-1C&C."6S;O.,HR@GJXROZ?JZ?$_P#P4J(Y_:1_
M8>(]#^P7\>C^G_#R4TI\3_\`!2H_\W(_L/?3_A@SX]<_^=):_,']@G1]%_:&
M^)7_``4;\4?M9:'I'BGXQ>!OVN/B#\,-.T;QTZ:A<?"/]G30O#FF2?"FV\`O
M>F)O`OA_5DO_`!GJ4?BWPJ=%N/%5[IK>([G4;G4;1+Z+Y.^*GP%T/1O^"N/P
M6^$?PY^#/P_^-_P^T;_@F/\`LW>&M>L_B?8:!XJE3X;V/[<O@GX8^,_BPMI?
M^"O$.D>-?B)I_P`'VO-/O]:N/^$4OXO"ESKNN:=XG@ET2P\.ZQ]QPMXQ>..<
M<7Y_P=C?%O`4LPR+A?!<2.OAN$LFJX'%0Q.%H8FI3H8F=2G&<*4:]!1JI<LV
MY2M%13ES8C+\KI4*.(C@9.%6LZ2BZ]13CRM)-JS>MGHMEI;M^]W_``E/_!2G
MO^TC^P]TSS^P9\>N.F?^<DO?G@>AZX-+_P`)/_P4J_Z.1_8?_P#$#?CUC\?^
M-DN?R(K^8;X*_LB7_P`>/CM_P4U^"/[+5AX(\%1^%/CE^QR?A1^U--XA%IXL
M^!GA;P+I=GK>IZK\+;W0]`OO$7B37O'>A^&+NSDDT_7/#7AWQ#-?S:YK.NNS
MVDMS][?M;_LU?`W1/^"JO_!);18/A1X#U+1_BMXK_P""F_C7XIVVM>$="UE/
MB)X@UKX0V/Q#@N_'3:CIDP\5KH/BWQ#JE_X4AUX:A'X:7[/!HQM%MXROJ8SQ
MC\4,+Q!'AI^-^`EF_P#JMFW$]7+J7!^3SQ>'PN4\,0XB?MHNI&$88BTL+1E&
MK*7[NK6G3BE"G,AEN!E1]O\`V7*,/;4Z,9RQ%1*4JE>-)6M?6*]YZ6U2C)ZV
M_8(^)O\`@I1@?\9(_L/X'3/[!WQYXYYSC_@I*,^WW?QI?^$H_P""E7_1R/[#
MW_B!GQZ_^F35^2'_``4E^*?C3]E[PO\`L]ZC^SZGQ#'PY_X)_P#B;X.>,?B)
MX0\*^!O'WB72?&7P\BTZ+P!JW@76?B%H/A74/!WA'4O!/P6U'4_$&N6_C;Q-
MH%OJ6A_$#1-3M;>]OHM/CKH_VR/@+X\^.7Q?NOVO?V+=>T]?VF?@1\!?V;OC
M'\";Z&[N(/"7QF\'^,?$?[29\;?#3Q/;V\]I9:KIWQ5\#:5X>T_2=1U,+<P7
M&DZ+I<>K^'].U"_U:S^%X<\;_I$YM1R3.<;XJY1EG#>?_P!HX7"XW%<*952K
M8/,L-5P\,#1S"G**A0PV+HXK`U9XJG6K1HQKSM"JZ3YMZF6913]K3C@9SK4G
M3<HQKSDITW;GE!Z-R3C-*+2;:O=71^I?_"3?\%*<$?\`#2'[#P'H/V#/CSC\
M1_P\E[]>HQ_M4O\`PD__``4J'3]I']A['_9AGQZ_^F2C^5?SX^$/BQ=?&;Q7
M_P`$H-+U'X>7OPD_9)_:K_:)_;W\9_&[P#?Z=:Z'I^N?$KPG\4/BC=?`;X._
M%J"PL;&TU.UTCQ+::;H6F^$M:#Z+XO\`LBZ=+HMQ!X=MK>R^B/\`@N7\$_A%
MX!_X)D?MN^+?ASX5\->&_%M[X=_9<L;G2/#-AI.EV.@CPY^TAX9M]%UK1="T
MNU@7PSK&M:9XV\3:-JNKV*6SZWHMK;:?*SPV$XE]3%>,_P!(#)^/>`>!,X\4
M\!'&<=YB\%AL3@N$\FQ='`1AGE3)I+%R52G&.(B\)6K^Q3:<?90]I:JYT\X9
M?E-7#8O$T\!)PPL%)J6(J1<VZ4*EXZ.Z]Y+;O=:)/]AAXF_X*5G_`)N0_8=X
MZ`?L&?'K(S@<_P#&R;OSTQZ<X)H/B?\`X*4*"?\`AI']AU<=S^P9\>A]<_\`
M&R7^9&/>OG7X$_L[_#?6/A[\1O"7Q+^"WPV^%GC+XJ:IKMA\5_A'\,X=+L/!
MU]\/OAU\<_BC8?"2^\G1_"7@==8TGQ+X'73M/C\6:AX2\.:MXVT"VB%S96=U
MIURMG^>G[#7[-'P)\9_MT?\`!5/1O$/PG\!S:9\.?VA/V;=8^'EO!X0T"T3P
M6VCZ!KGB";3?"_EZ8J:%H>N7>C6]KXGT;25M+#Q!I5Q=Z=J<,]O=R*WS&2?2
M;\8\RXC\1<@Q/BC["OP&L-*4O]3<CE0QOMLPRW+.:%:%9QY'B<8W"I%5(U*-
M.$U:564*>]3)<NC2P=:.`YHXNZ5\1533]FZFJ<4[V5I*\;-VULF_V4_X2C_@
MI5CG]I']A\'G_FPSX]$8]\?\%)2?UX]#7C/P.^&/[>WP`\+:_P"%/!O[2_[&
MFH6_B+XK?'[XO:CJOB+]A'XRW6M_\)#^T7^T!\4?VD?&>C1WVF?\%#]&0>%]
M#\>?%WQ58^#=/N+>:]TSPTFFVFJZGK>L1ZEKVJ?S._\`!-SX0:%X^_8P^.%[
M\0K'P7\#_".F>/OVF[/P=^V;;III^)'PQ^,>K:]\"_`/PTT^\UN;PWIVM^%O
M"&E:=X\\426^FZ;XWN(/%5AKWBE[>R\*ZOX5TG7)/UC_`&,/`.IWWC[Q-^Q%
M^V;^SA\._#7Q1\(_`KP/XJ'C?X*76D7?[._[3/P?\(_%OPU-I'C#Q#X,_L^T
MDT'QQJ/C;PU8VGBW3=:T>TF^(&E?\)`=4TRPT&T\.Z9;_HG&7BMX\\.8/,<;
M@?%G+\=1R;&TJ>9X>?"N1T<:L%[6E3JXW"T95)1Q2HQJPE4HT:OM*;;]K&%-
M2JG+A\!E5:4(2R^<'5BW3E[:HXN=DU"3M[MW=*35GIK=I+]7+S6O^"CNHV\M
MGJ'[0W["M]:3[/.M+S]@7XZ75M+Y<BRQ^;!/_P`%(GBDV21I(FY3MD17&&52
M+7_"3_\`!2KG/[2/[#W'3_C`SX]>W_624^_]W_'^?7X#?LQ?!#QC9_\`!8B#
M4QX;^!^M>"OVQ/'NA?"3XW^'/#VE:9KGP$;5O#Y\,Z!=^&M1TZSM+[0/!&F7
M.ORQZYH6C7>F64>B3:A<:?+I.I6UEJUC]G?L`:E\4_A-\?M)_9>_:<_9Y\`?
M#GXU>%/V>]9N_`WQM_9WU"PE^"G[0/POTOQ;X+TK5/%GBGPE96-GJ7A#XC0Z
MW8:3,VKZW8Z5_;\VJ:ZITO1[>?PQ877RWB-XY>/W#?"N=Y]PQXK91FV/R+)<
M-G6+RC%\,Y'@\;+"XC*:&:.IAH3G*.*AAX581Q$*$IUJ5/GKRHJG&[VPF5Y5
M6KT:-?`5*<:M5THU(UZDX\RJ*F^:RM%NSM>RO97O9'Z>_P#"4?\`!2K_`*.1
M_8>_\0-^/7_TR6D_X2C_`(*5?]'(_L/?^(&?'K_Z9-7N1]<9]L^N`<]N@'KT
MI:_S%K_M7?I54JLZ?]L9-^[E*-O[`RIZQ:MJ\)UM=]+W2\_M%P)D=DW2J:K_
M`)^3O>RZ<VAX;_PE'_!2G_HY']A\>_\`PP;\>C^@_P""DF?7U_3E/^$G_P""
ME7_1R/[#W_B!GQZ_^F35[B<`9QT[9]<`\=.@'Y4ZL_\`BK#]*JROG&3VTT_U
M?RK2ZB]%]3>FB;OU5NH_]1,CT_=5/_!D^EO[W;;;\[>&_P#"4?\`!2G_`*.1
M_8?'O_PP;\>C^@_X*29]?7].4_X2?_@I5_T<C^P]_P"(&?'K_P"F35[D?7!/
MMGUP#QTZ`?E2T?\`%6'Z55E?.,GMII_J_E6EU%Z+ZF]-$W?JK=0_U$R/3]U4
M_P#!D^EO[W;;;\[>&_\`"4?\%*?^CD?V'Q[_`/#!OQZ/Z#_@I)GU]?TY\2TS
MX/\`[:NA_$CQ7\5M&_:`_9)TKQ7XYU>W\0^,K+3_`-EO]LNT\`>)O$=KH&@>
M%HO$FL_":#_@JPGPIO\`Q$?#_A;P[I<VOS^"SK%Q;Z+IIN+V:6UCD7[=.`,D
M?AGUP#QTZ`?E^-.H_P"*L'TJDE?.,GZ*W]@95;:+=O\`9'IHF_3S#_43(]/W
M53_P9/I;^]VVV_.WAO\`PE'_``4I_P"CD?V'Q[_\,&_'H_H/^"DF?7U_3E/^
M$G_X*5?]'(_L/?\`B!GQZ_\`IDU>XG`&2/PSZX!XZ=`/R_&G4?\`%6#Z522O
MG&3]%;^P,JMM%NW^R/31-^GF'^HF1NW[JIK_`-/9]+?WMK;;?G;PW_A*/^"E
M/_1R/[#_`!G_`)L-^/7/T_XV2^QZ9SQ]2G_"4?\`!2K_`*.1_8>_\0,^/7_T
MR:O<CZX)]LG/.`>.G0#V.*6C_BK#]*E)7SC)^G_,@RO1OEV7U/71+\$'^HF1
MZ?NJG_@R?2W][MMM^=O#3XG_`."E.<']I#]A_'0C_A@WX]'I[_\`#R3`]N/S
MKXV^+>K?\%"9OVS_`-CG5+WX_P#['-QXBL?`?[5-CX;U.S_8K^-=EH.F6VIZ
M5\'IM>AUOP]-_P`%`+^_\076HQ:;IZZ+=Z?XI\,1:$UIJ#7]AXD_M*V31_TX
MYX(!.#TSC/Y]<CC.?<=Z^1/BWC_AL#]CSU_X1;]IW'T_X1OX;Y_I7ZKX4?M,
M/I+<89SF."S7.<K]EA<@SO,:7L\CRRG+VV`RVOBJ7,UA$^5SHP4EU5]C@Q_!
MF38>E"<*4XN56E!_O)O2<X1:UEK?FZ7ZGI?_``E'_!2G_HY#]A_/_9AWQYYZ
M=O\`AY+VY[__`%S_`(2?_@I7_P!')?L/?^(&?'K_`.F35[E^'Z^N`>.G``^M
M+7YEBOVKGTIZ.(KTX9QD[C3JRA&^094[*,HI?\PC;T7GMO<[8\"Y'*$6Z=6[
MC%MJI4L[)/\`FVOTV:V/#?\`A*/^"E/_`$<C^P^/?_A@WX]']!_P4DSZ^OZ<
MI_PD_P#P4J_Z.1_8>_\`$#/CU_\`3)J]R/K@GVSZX!XZ=`/RI:Y_^*L'TJ4E
M?.,GMHK/(,J[1>G^Q[6U>F_34K_43(]/W53_`,&3Z6_O=MMOSMX;_P`)1_P4
MI_Z.1_8?'O\`\,&_'H_H/^"DF?7U_3E/^$G_`."E7_1R/[#W_B!GQZ_^F35[
MD?7!/MGUP#QTZ`?E2T?\58?I565\XR>VFG^K^5:747HOJ;TT3=^JMU#_`%$R
M/3]U4_\`!D^EO[W;;;\[>&_\)1_P4I_Z.1_8?'O_`,,&_'H_H/\`@I)GU]?T
MY3_A)_\`@I5_T<C^P]_X@9\>O_IDU>Y'UP3[9]<`\=.@'Y4M'_%6'Z55E?.,
MGMII_J_E6EU%Z+ZF]-$W?JK=0_U$R/3]U4_\&3Z6_O=MMOSMX;_PE'_!2G_H
MY']A\>__``P;\>C^@_X*29]?7].4_P"$G_X*5?\`1R/[#W_B!GQZ_P#IDU>Y
M'UP3[9]<`\=.@'Y4M'_%6'Z55E?.,GMII_J_E6EU%Z+ZF]-$W?JK=0_U$R/3
M]U4_\&3Z6_O=MMOSMX;_`,)1_P`%*O\`HY']AX?]V&_'L_H/^"DN:3_A)_\`
M@I5_T<C^P]_X@9\>O_IDU>Y'UP3[9/?`(QR.@'KTI:/^*L/TJK*^<9/;33_5
M_*M+J+T7U-Z:)N_56ZB_U$R+_GW/S_>STV_O>?6U_P`O##XH_P""E7_1R/[#
M_P#X@9\>OY?\/)?TS^>*PO%'_#PCQOX9\1^"_&'QV_8*\3>$O%VA:OX7\4^&
M];_8`^.>HZ+X@\.Z_I]QI6MZ)K&GW7_!2.2VO]+U;3+NZL-0LKB-X+JTN)8)
MD>.1E/T>?7&?;/K@'CIT`[XX_&EH7[6'Z5-K_P!L9/I;_FG\J:O[O_4)MHN^
MUNNK_P!1,C=OW537_I[/I;^]M;;;\[?+?P_T3]O+X4^#]$^'_P`-_C3^P-X+
M\$>&H;BVT#POX?\`V`OCO8:/I%M=7MSJ-Q;Z=9Q_\%)?*M89+V\NKGRHU6-'
MF?:H4A1[1KGC7]M^X\'>!++PQ\9OV6-(^(6G_P#"3_\`"S?$^O?LG_%KQ%X+
M\7&ZU6&7P8/`G@33_P!M;PKK?PZ_L#0A<:?XG_X2#XC?%+_A+M6EAU?2?^$)
MM+>30KGNST/&?:EJ)?M7?I43E"3SK*4Z<^:*CD6613;@X/G4<*E4BE)VC.\>
M9*:7/",D?ZB9'K^ZJ:JW\6?>+_F[KUZ7LV?(ND^!OVUM"^)OBOXTZ1\4?^">
MFG?%OQSH6B^&/%_Q'MO^">?QM3QEXA\-^'0O]A^']2U\?\%(#J,VBZ6R++::
M7YXLDG`N/)\\>8?1_P#A*/\`@I5V_:1_8>_\0-^/1_\`@DHKW(^N"?;/K@'C
MIT`_*EJU^U@^E5I_PLY/?1)/(,JO]G;_`&/9?+7U#_43(]/W53_P;4Z6_O\`
M;:]OSMX;_P`)1_P4J_Z.1_8?_P#$#?CU_P#3)?K_`)ZI_P`)1_P4J_Z.1_8>
M_P#$#/CU_P#3)J]R/K@GVSZX!XZ=`/RI:/\`BK!]*I6OG&4=$U_J_E3UM'9?
M5-4K=_ON'^HF1Z?NJG_@R?2W][MMM^=O#/\`A)_^"E."/^&D?V'F;`/_`"8;
M\>2!DXRP_P"'DOL1C(/Y8/\`$Q_P=@:3^T?XV^+O['+?M`_$GX+^/+_3?AS\
M5QX9G^#/P-\=?!*TTVRN_$WA#^T8=?L_&_[1/[0LWB&ZN+BVMY+&[TZ_\+Q6
M,*3PW%EJ4EQ'/:_WM5_$I_P=@?\`)8OV._\`LFGQ2_\`4I\+U_;'T%_IY>.O
MCMXO4N$.-LRR^OE$LHS7&.&'RG`X2?ML'E]6O2:J4,/2FTIPC=<S33U36_SO
M$G"V599@/K&&IS4U4A%-U)NZ<H)[R?1O779]C]KOV/M.^+7C/]D3]AGQ#XF_
MX)Z?`7XIWO@#]EW]GZW^&/Q'\9?%_P"'U_XIL]#@^%/A$:9KFCKXB^#>IZQX
M&OM8MEAU2ZT?3M9G?2[FX>U;4=0:$WDOO_B'X9^*/%LWBBY\5?\`!*G]E?Q/
M/XVUI/$GC&?Q!\1?@[K,_BWQ%!)+-%KOB:74O@9=/K^M0S2RRQ:IJK7=_')+
M(XN`TCFN]_8@^)VA>&_V,?\`@GYX$AM-4\1^-O%?[%GP)\0Z3X5\/1Z<^IIX
M8\,_!SX;VVN>)=2N-8U+1M)TO1;'4M<T'2%NM1U.VDO]5UFRL=.BNY%N_LOV
M'X<^(.E:];ZO+J6G:MX'N=&\72^"[C3?&CZ+IUY<ZP;.PO[$Z=+I^LZKINHV
MNKV6J6-UI$EO>O->Q2G%LC!E'\\>/_C7XF\'^*'&-'+.&G5P6!SS&K`5/[2S
M6CB*N'AF52I2K8?"T,PHWHQQ<)3YZ-+DA72<K2>OJ91E>"Q&"H<U>TW3@Y1<
M*;C&7LZ::E*4&[N/=W<5Y'P"WPZ\>+X5\6>#-,_X)B_L\>'O#GCB.Q_X2FP\
M)_&KX=>$&U6YTB"[M]"U2>]\,?!S3+Z'7?#2ZC>S^%]?M)XM:\,WEP][H5[8
M78$R\7^RI\.?VP?V5?#VN>!]`_9YM/&G@F_U2[UO3(O&W[2'PVOO'5OJFI7,
MUSJ>H>*?B-HOP0\.ZU\0KMXWATZQU/Q?;7^M6.BV&G:2VJW5II]JL/ZP7&K:
M9931VUWJ5A:7$LME!#!<WEO!-+-J,EQ#I\,<4LB/)+?2VEW#91J&>ZDM;E(5
MD:"4+R&C_%#P!X@\8>-/`FC^+=&OO%/P[@TNX\::1!>V[3Z`NKV\MY:IJ`$N
M8I(;-8+F]1E'V*.^L!<F-[J-6_`L5]([Q.SC*<URO'^'"QN65XX?$YC1Q']N
M5+TZ4H4:$YSEC74ITU/$1IQ2E"G*52$;-RC;U8Y)@H5*<X8YPDG[CM23U47)
M).#3;MUO:W36WP?XK\#^.O'?BN3QSXU_X)>?LS>,O&LUM'I\OC+Q9\3_`(2^
M(/%4MC%(6BLI?$&K?!&^U>2TCD=W2W:[:)'D=T0.Y)](\0>*?VDO%GAYO"/B
MC]@WX6^)O"SQVD4GACQ!^T'X)UCPZT6GR0R6$<FCZC\*+K36BLG@A:T1K7;;
M/#&UN$>)2OV@==T/^S+?6CK>D?V+>+:M:ZO_`&C9?V7=)?2)%9&WU`S?9)UO
M))8XK8QRN+B61$A+LZJ>=TOXD^!M:\=^*/AKI/B?1K_QUX+TG0M<\4>&[34;
M6?4]&T_Q++J,>EO?6D4KS07$J:?]JFM9HTN+:RU+1;RX2.VUO39+GPZ_CUQO
MF6!HU,1X;O$8#A6C1J474Q/$;HY30H5:5&A.+>8VH0HU:E.G3E=*%2I"*?-)
M)Z?V5A:<WRXWEGB96E:-&]1R4').U.[;2?GIJET^*M6T_P",.O\`B7P7XPUW
M_@F_\!-;\6_#>"*U^'?BG6/C/\,]4\1>`;6(H8;;P7KM[\&9]3\+P0>5%Y<.
M@W>GQ1B.,*J[$`LP_P#"[K?QA=>/X/\`@G7\$;?QY?3Q7=[XX@^-OPZC\77M
MU"B117-YXD3X/1ZS<7$4<:)%-+>R2HBHBLJJ!7WLNIZ8^I2:0FHV+:O%9QZA
M+I:WD#:C%822F".]DL1(;E+.28-"ERT0A:4&-7+Y`;9ZMI>HO,FG:IIM]);P
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M4ELHWDD9;:2\:!2\A$0=PU?:GQ7^,OAGX4_#2_\`BE=6]YXL\.V.J^&])9O"
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MGGPEXV\2_&OX;ZUXN\+FYB6*Z/AWQ'J?P>NM8T7[1"J1SG3;ZU,L2*DN]%`K
M[AF\:>#K::ZM[KQ9X9MI['4;32+V"?7M+AFLM7U`3&PTNZCDNDD@U&_6"X:S
MLI52YN5@F:"*01N1R?COXP^`/AMHFN^+O&'B30='\%>%-(\0:EXI\476OZ/'
M:Z+?Z#=Z#8Q^'I+%[U=0O-<U2XUY+:QLK.VFF&I1V>DSQQZEKFBV]YSY;XW>
M(7$W$L,VPGAPL9Q%F6"J8&./EB^(/K>+P53"JA4PL:KS).=&KA)^P=)74Z4E
M3LXOE=2RS"4:#ISQO+0A4C)PM1<8SC*#OI3=GS:W3T:O>^WR'<V?QCO-)\;Z
M%=?\$W_@/<Z'\2IOM'Q%T:Y^,_PUFTGX@7(C"";QMIDGP;:U\53!`(A/KMO?
MN4(0.J#"KX)L?C%\-KJ*]^'O_!-_X#>`;VWTFW\/P7G@CXT?#/PM<P:%:233
MVFBQ7&A?!K3I(M(M9;FYDMM.BD%G#+<3210*\DN?K#1/C3X4UOXG^+?AC#OL
MKSPQX'^$/CVQ\1W>I:$_AWQCH_QHU3XH:1X4_P"$5GLM5O+B[F^V_"CQ%!)%
M?6MC-=2>1/IL%Y8R0WT]WX@?%71_AWXG^$OAO7-/OVM_BWXS\0^"=-U]+G2;
M?1/#^I>'OA;\0?BU-+X@DOM0M[^.VOO#OPV\11VLNGV%[;PW,*_VI/I\36S7
M7UN,\2_&*EC7P/B?#:/M)Y3'/WE<\QSSV4\!A\LI9HL2H_VIR7I9=2IUE&[G
M&,(04>9)'+'`Y>J:Q,<=:#J>R=3DIWYG4C3M_#;UFVG>RW^7R[KVJ_M`^*/#
M]WX0\3?\$_\`X0>(_"E_JE[K=[X8U[X]>`=5\/7FM:EJUWKVHZO=:)J/PCN=
M-N-4O=<O[W6KS4)K5[RZU:\N]2N)I+VXFGDY37_#OQ.\4^"W^''B?_@F9^SO
MXD^'LEY#?2>`M?\`BY\*]7\%2WT'D-#?/X7O_@M=:&UW"]K:M#<MIYFBDMK=
MED5HHF3[)\0?%O0_#WQ/^%_PMGTW5+O4/BQHWCC6_#^O6C:9)H$-MX!L-&U#
M5XKN1M034C<W$.O:<UB;?3IK&6.61WO8V14;T*QU?2M6M&U'2]5TW4M.22XC
M:^L+VUO;))+-WCND>ZMI9(%>UECD2=6D!ADC=9`K(0/E\9XW>(G#M/)<QK>'
M<:#=5YIE->ECL_J5</B(8B5!XFG)9I*="LJ]"<%)\LVXJ25FF^BGEN"KN<8X
MQ.R5.K>-'5-0?*[PUT?5M+KIJO@GX>P_&?X4OJTGPO\`^"<WP+^&DGB"+38M
M>D^'_P`:OAMX0;6XM&6]71X]8?P_\'=+.H)I2ZEJ"Z='>-,EBM_>BV6+[7.'
MK^'[#XP>$M5\6ZYX5_X)O?`7PSK7CVVEM?'6L:!\9?AGHNK>-+6=!'-;>+M1
MTWX.6]WXCMY8OW<EOK$]Y%(A*LA0,M??<FNZ-'HTGB(:MIDFAI9-J`UA=0LE
MTI[%$+BZ34Y+B.P%JP`*W,ERML`0S2JOS#A/@W\5-%^-?PZT7XE:!IVJ:1I6
MN7_B>QM=.UG[`-5MW\,>*]=\)W8N_P"S+S4+`-->:%<3H+6_NH5CF54N)<,Q
MX\3X]<<4\OSOC'&<`86C0KULNR[.,;7Q^=TZV*=E6R^A74LS4JU.FL#S4O==
M.FZ%/9J!I'*L+STL/'&-N*E4I14*?NZTXU'%J&C?-;HW=WW9^>]G\#[K27AF
MTG_@D1^QW836^IPZU;O8^,?@A8R0:U;S)<P:K#+;?`16AU2*YCCGBOXQ]LBG
M1)DF61`U=%\!?BC\8;K0O$GBGX/?\$]/A#X"M+CQS\1?A_XC;PO\<O`7A.XU
M;Q'\&/B3XU^$_B+^T!HWP>TR34K&S\4^%?$@T2[NR_G:=.EY;K`+V6*OTV&#
MD@YSC]*^4?V1;JUL/@SXWOKVYMK*PL_VH?V[KJ\O+J9+:TM;>W_;7_:%DN+B
MYN)RD,,$42/)-+*ZQQ(K,[*JDC]=RGQSS7CWP5XKXSQW#O\`:F;Y-Q-D.4X7
M!2S'.:M&I0S+"YE7Q$IQ^ORJRES9?AWS<ZMRZ]SS:F5PPV9X;#QK\E.K1J5'
M+DIIIPE12^Q9V4Y>NFO1^)Z'H'Q3\,'Q./#G_!-+]GKP]_PG,T=SXT_L/XN_
M"W2CXQN(+F&]BG\4_P!G_!FU_M^:*\@AN8Y=6^V,EQ#',&\V)67=\'W7QV^'
MUWJ5[X$_X)Y_!;P/>ZTD$6KWWA#XY?#SPU>:K%;/(]M%J5QHOPBL)[U+>266
M2%+J25(WE=D`9W+?1DO[0?@"[U>/0/"`USXAZT_AWQ/XNALO!MA;3P7WA?PC
M?Z)I6MZWHNJZ]J&@Z)XFL8-6U_3-(MI/"^I:S+>ZHUU9VD<LVG7Z6M'PO^TQ
M\*?&VGKXC\&:M=>)/`HU[P-X5G^(6EPVH\*6GB;XD6'A+4?"&BR->7UIKEQ=
M:A%X]\%6]Q/I^AWNG:5?^);73]8O[&^TW7K?1_A*WB!XJYOEN)QN+\*7BL#C
M,-0HXN5;$\0R6(PZ<<-AZ-1O,N:I&3I*A2A=J4H>SBFXM+KC@\#"<8O,$I0E
M>+A&DE&3Y&Y+W-'9MNVEM[71Y^?BW^V`"2/V._"W/K^T]X<'YX^&Q`VCH>_X
M\A^+?[8`(/\`PQWX4R#W_:>\.``'W_X5LW7&.>/>O8_CA\9O#/P%^'.O_$CQ
M5;WFH6.A6R3QZ/I=SI$&LZH[S11LFFPZQJ&FPW)M(I#?7ZVTL]W!IMO=7<-I
M<&$0-ZA)J.GQW\&E/?V2:I<VTU[;::]S`M_<6=L\45S=06;2"XEMK>6>&*:X
MCC:**2:)'=6D0'\FK9M2IY9ALZGX&\/3PF*Q6*PM.<9YY.I*OA(X>>(C*G',
MW*"BJ])\\HQC+FM%NTK=T8-U/91S6JIQ496?LDDI-*+OR?W7I_=5TCY-_P"%
MM_M@_P#1GGA;_P`2=\.?_.VI/^%M_MA<_P#&'?A7V_XR>\.<_7_BVO'X9KZP
MM-6TJ_GU"VL-3T^]N=*N!::K;VEY;7,^FW9C$JVNH102O)9W!B/F""Y6.4QD
M.%VD&JX\1>'VB@G_`+=T<P7-];Z7;3#4[(Q3ZG>11SVNG02B?9+?W,$T4UO:
M1LUQ-%+')'&R2*Q\I\68*+C?P'R?WN7E_=Y_:35MO^%+5W3VO=^C-%AY/19K
M4;36B=):>YJOW?1?DNSM\K_\+;_;"_Z,[\*?^)/^'?\`YVE'_"V_VP<_\F=^
M%=OK_P`-/>',_P#?/_"M<?\`CU?6?]HZ>-0&DF^LAJAM#?KIOVJ#^T&L1-]G
M:]%F9/M)M!.5A:Y\KR1,?*\POQ3;/4]-U(2MIVHV&H+`[1S-97EO=K%)%/<6
MLB2FWDD$<L=W:75K(CX:.YM;B%E$L$B+QXKCS)<'2=?%>!^0T:,(J4JM19]&
M$8MI*3D\RM9N+M?2][[:U'"5)/DCFM63LO=7LFV[0;O[GEY/X=G>WR?_`,+;
M_;!Y_P",._"OM_QD]X<Y^O\`Q;;C]::?BW^V",[?V.O"F.V?VG_#@_/'PT./
MUK[`)P0/7/Z4BOD?4D8Y['W]/_U>E>"O&'@CXO\`B$7"E]+OV^=:VY=6O[4_
MNO5_?N;++L3;_D88BVGV:7]V^O)_==O1;:V^0?\`A;?[8//_`!AWX5]O^,GO
M#G/U_P"+:\?K0?BW^V"`VW]COPK[9_:>\.`'_>(^&IQ^`-?7Y."!ZY_2D5\C
MZDC'/8^_I_\`J]*:\8>"'K_Q"+A3H_X^<].777-/[K!9=B4DO[0Q"6FT:7]W
M;]W_`'7;_#'SM\@_\+;_`&P>?^,._"OM_P`9/>'.?K_Q;7C]:/\`A;?[8(SM
M_8[\*^W_`!D]X<&?7./AJ<?AFOK\G!`]<_I0&!Z'KD=^<?X4/QAX'5FO"/A5
M[7_?9UM:+;_Y&?5Q=K^>W467XE*W]HXBVC?NTO[O_3OR=O2/G;Y`/Q;_`&P!
MG_C#OPJ`.F?VGO#@'X_\6UPOZU\E?%;XK?M:R?M:_LG3S_LG>%;75+7PK^TB
M-&T<_M(:'/#K<5SH?PUCU:YN=63X;I#I#Z/$MH]O;26MX=7^VR(DEDM@[7'Z
MYG(![C\C^@_7C%?'7QDE>']KO]D&>.WFO)8?!W[4<D=K;M;I<73Q^&OAJXMK
M=[RXM;1)9W`BB:YNK>W$A4W$\,2LX_</`?Q%X8X@XKQV79?X9<-8+$UN'<^C
M3G1KYM^\?]D8K]U)U,RFE&:33>BU=TXW3\G-L'7IT*<Y8ZM.*JT;IJGI:I35
M[<BV:MWMIHR?_A;?[86/^3._"N[T_P"&G_#F/S_X5IG_`,=IW_"V_P!K_P#Z
M,]\+_P#B3GAO_P"=Q7I?P&_:#\"?M">!]5\<^#X->T*V\/\`B7Q#X1\4:!XP
ML]-TKQ%X7USP^T4LT&M1:9JFMZ.(-2T:]TGQ+I-[I^M:C97OA_6=.O1<Q232
MV]O%\$/VAO`WQY^&T?Q:\,V^N^&O`UYXJ\7^%-'U3QRFA:#+K=[X*\=:]\.M
M5N[2QM]>U.YL;2X\5>'-2LM.M_$$6D:U<*(&ETBWFGCC7GS[*,TRB&>X_%^`
M_#_U7),SH9?C\1&KG%2/UC'0K5L)&#AFCC55>EAJU2%6C>$HQ<E+EE%RTH5(
MU)48+-:UZD.:-U3VINFI+6&C3<59M.Z2>IYNWQ:_;`(Q_P`,>>%S]?VGO#@S
M^7PVX]>_]:#\6_VPN<?L=^%?;/[3WAP?G_Q;0X(^A^@KVSXK_%K0/A'I?AG4
MM;M;O4CXH^(OPM^'-G8Z?>:1#?VMW\5/B;X0^%FDZY-::GJ=A<W6BZ3XB\;:
M$-7.D0ZE?0PWD,@LF@,T\'H7]LZ0+R\TXZKIHO\`3[./4-0L3?VOVRPL)=_E
M7M[;>;Y]K9R^5+Y=S/&D+F*0)(^TD>$ZE>&39;G_`/Q`3(GEV:8[$9?@ZS>>
M/VF+PD<+4Q%+D_M1R3IQQ-&3<HI6J)IWN:Z.K.DLUJJ=-1G)6I:1E91:_=JZ
M?*_3E6B/E$_%O]L'M^QWX5/KG]I[PX/_`'FIS^E'_"V_VP>?^,._"OM_QD]X
M<Y^O_%M>/UKTWX:?'[P7\5H-0\0>%;O3;OX?PZAJNBZ=X_C\4>&9-*O=?T3Q
M?JG@V[T*[TW^TTUG3[[5+_3!JOA:86=YI_B#P_?Z=>K>V6H74.DM[)/?Z=:W
M-K9WE_96]Y>/Y=I:SW4,-S=L5=L6\$DB2SMMB<A8ED;"2'&%8CDSG,Z>1XEX
M3,?`K(*=:FDJ_++/)_5Y<T82A7<<T:HSA).,H3<91:UC?=T(NM'GAFM;EO[K
M:I)-+V=G&]/5:7NK[+I<^3O^%M?M@<_\8=>%<]O^,G?#?.>N?^+:\?\`CV?:
M@_%O]L')_P",._"W7@?\-/>&\#IG/_%ML@^GWL]\=NOU7]I;0M)\6?&7PDWP
MZ^)5[)\"/#F@^+/'>KV$7P];2!X<\1:1K^N:;J6BQW'Q!M=:U-6TWPWK,TEE
M_8T&I1&WCMULGGGBC?V31?'7@WQ#HFG^(])\3:/>:+J?AZT\565^;Z&!6\.W
MNG6&JVVL3PW1@N+.S?3M2T^[>6[AMQ!#>VS7`B,R*?2SJ%;(\'A,?B_`CAZ>
M%Q='"XBE5P]3.L1'V>*H4,51YY4LTFHRE2J0E*,FI)RE&2C*+0J-JLG&.:UN
M:+<=523]V48/XH6]UIZ^2=[;?-G_``MO]L'G_C#OPK[9_:>\-@\^N/AH0,>@
M!S[4O_"V_P!L`Y_XP]\+$^G_``T[X;X^I/PV&,_CR>U?0&O_`!2^'OA?7/A_
MX;UWQ=H.GZW\4=3N])\!:=/JEDESXEN[/1[K6[B33(FG5[JT2SMHX3>PK);G
M4-1T;31+]LUC3X9^Q@O["ZN[RQM;ZRN+[36A74;*"Z@FN[%[F+S;=+VWCD::
MU>>("6%;A(FFB821[E.ZOGL5Q#A\)2PU;$^`N3TJ>,I.OAI2IY^O;485'3E4
MIMYE:4%5I5(.4=.>$XWNFEK"CSMI9M4<H-1DDZ.CM3Y4_<[->=K-^7R;_P`+
M;_;`_P"C._"O'3_C)WPYZ?\`9-?Y9IW_``MO]L#_`*,\\+\=/^,G?#G_`,[?
MC]:^KK;4]-O!>O::A8W,>FW,]GJ#VUY;SK97=NJ/<VMZT4C"TN;99%>:"<QR
MQ(P9U4,,^;_$'XO^&_`&F_#_`%BX@N_$6F?$;XD>!OAKHFH>'[G2[NQMM2\>
MZM%I&EZK>7,M_$)M)BED8R2:8FI7#/Y*);K$[W$.V2YWAL_QU'+LO\#>'Y8B
MJU&$:D\[I)MQA*,>:IFD8J4K)0CS)SE)1CS2DDYK4)48>TGF=6RM=KV3M%<F
MME"^FE[+HMGMXO\`\+;_`&PL'_C#OPIGL/\`AI[PY@YZY/\`PK3C\CGVH/Q;
M_;"SQ^QWX5(]3^T_X<!_(?#0C]:]*^*_[0OP[^$.I#2?%.L:5#?)X$\=^/[J
MSN-=TBQO(-(\"VNDRRVD5G?74-S=:IKUSK=I9:#8Q1^=?O%?RVZ2QV-SCZ*\
M)Z1+XK,!@G@M7ELH+K`DCO"$G1698GAD$=S%&SA)+B.01MOC9"RRJ:^WX<X>
MS3B;-,CRC+O`;AR6)XAK5J&5*I4SJ$,54PTH0K*$GFMI>SEI)WT;L]SDJU(4
M:=6I+-:RC047425)N*;A;3V?VKZ;:*_:WQ8?BW^V"",?L>>%2!V/[3OAL#]/
MAJV?S&/PH_X6W^V#_P!&=^%?;_C)[PY_\[;C]:]CF_:8_91MIOB';W7[1/@J
MSD^%/Q2T+X*^/$N[+6[-=$^*GB+Q3J/@W3?`\<D]K'%K6LQ:_I.K0:RF@MJE
MOX<T_2M1U[Q%<:5H-C=ZI'V\/Q2_9[O?&6L_#^V_:%^%LOBO0/!&D_$G6+$>
M)-(6SLO!&M:/X@\26&OG7'U1=!EMV\+>%=:\7WMO;ZG+?:7X-MK?Q?J=K9>&
MM2TO5+S^C)?0Z\:804U]'#AF22C)?[9F]W?V;6V;>C[)/OOY"XAR^[7]L5U9
MIQTA:_N=?9Z?=:\3YE/Q;_;`[?L>>%C]?VG?#@_E\-F[?X>]+_PMO]K_`/Z,
M]\+_`/B3GAO_`.=Q7MFD_M#_`+,&MR?"*'2OC_X0O)/CMXRUKX=_"N%-.UM9
MO%/CS0+73M1U/P?Y<EJKZ%XC32M7TO6;32?$JZ/>ZKH>H6>MZ5#>Z1<1WA^J
MS\);_D_VDA)SDFRSGGO_`*6,Y'\ZC_B3SQJ23G]&_AJ*ZMXS-DW9P3_YFO1Q
M:=EIKO=W:XBR]._]LUNFO+#;W?\`IV^VFNMM#\Y?^%L_M@'=G]CSPMSC'_&3
MWAP9QZ_\6T^4_@WT%'_"V_VPO^C.O"GM_P`9/^'/<?\`1-./I_D_HI+\+;^%
M&8ZBIV`D`6C*<C)!)-TPZ\\#MNZ]?C;PIHV@VWQH\=ZAI7@;QMX6U&UL-5T7
MQ%X@O=(N-*\)^/M177[:X_M>:_NM1EF\3:CIACGLO".H-I\(TOP_<:SI\-W_
M`&7<Z186GYOQ]X3YGX1Y=B,R\2?!3AK(*$L-5JY?4]MFU6&(Q%)0?L9R><)P
M4K-)KGES67*TVX]V#Q\<PJ1A@\RK5&I1OI33BGRZI>SUMIN]DM3S8?%O]L`!
M@O['7A7MMS^T_P"'!GGG</\`A6W'KP6Z8X'(_CG_`.#G7QA\9_$WQ9_93D^*
MGP<TCX4W-I\/OB5'HEKH_P`3;#XE_P!LVDOB3PVUU<W4]IX8\+IH\EI,D44=
MNRWYNEF:02P^28V_O7K^)/\`X.P0#\8OV.\C_FFGQ2_]2GPO7ZY^S>X_X<XA
M\?*."RS@7(^'ZT,DSV:Q>7U,PE5E&&5XB].7UK&5X.,DM;13UT=E8\_C#!UZ
M>6.=3%5:J]I233Y5KSTUI:*?GNU?9+8_>W]C?X<^._"_PJ_X)T_M*>#/"NI_
M$K2)O^":GP-^`_C?P3HNN^&]#\2Z-9W'@?X:_$+PMXW\.)XSUOPWX6UJ'^TM
M/U/PWXITN\\2Z)J,=MJ.AZKI?]K1Z??6%?6/CCP?\4/&GQ*G\3>(?AI=Z[\,
M_%/P'^(WPK?X?GQ+X/.M^&=;U[6M`O3JWB);GQ!9Z$L7C;1[6XTJ\F\(Z[XD
MN]"70=&\PSC4+F33/E[]@W]ES7=3_8C_`&/=9_X:K_:NTI-;_9;_`&?-9CT#
M1?'/@*R\/^'X=4^$OA&]CT'P_:2?#"XN[;0M(2<:?I-O?ZAJ%]!86]O'=:A>
MW"O<2_6G_#*.LCK^UM^UWV'/Q"\!<XQ_U2T<G'.,9R:W\?..>'<'XO\`$=3'
M<4\*8+,<HS7-<'2>.PF;2Q<*-7&5:D(U98?#5*+J4*DI3A.F^:5W3JNI2;ID
MY5A*KP%)1H5IQJPI2?)*FHM\L&G'FDI.ZW3TNM+,^)/'W[*OQP?PY\9-*3X9
MR_$GXB7G[%_[%'PH\*_%:+6/AE:3>,OCU\$?$_QBO/B7XPT[4?$OC#2?%6BW
ML^G^-_!<L/B37M-T6ZU*/0[RP@EE73-*AO\`Z(\6?##XKS>(/VN=8@^#UWXN
MTOXS:[^S3XG\,Z)>>)_!UH]_I?A#3_`'ASXAZ)/"GQ"\/PKXU\*6.D:[K^BZ
M7JVL6/P_\5WNGZ?HNI>*KO2-4O[9O4S^RCK)S_QEI^UV,_\`50O`?Z?\6O/_
M`-?O1_PRCK(R3^UM^UWCW^(7@+`_\Q:!VKY3._'WAW/L51Q>.XG\/.:-#`T*
ML*.79WAZ6(IX*EE-*G&5.AA:<(*<<JHN2HJFDZM7V?(O8JETT<JKTH.,,/C+
M-MQO.DW!SNV[N3O_`!'H^9V47N]?F7PS\)?V@O"VKPZKXI^#'B#XJ_#K5_BC
M^V78>*OABWC7X4VOBYO!O[1/B+P;XD\"_$71H+SQIX?\`//HFGZ7XX\&>+M&
MB\6^&]<T^W^)/B*^\-6&LV_GQ7WTW\$OA?XO^'GQL^+&NW_A'^Q_!?C?X4_L
M[:/X9N[#Q):>(+'1=3^&&@>,=`UWPE?W&J:G'XOU"\L!JNFR:?K=QI5W8ZQ8
M.+F[U6+4S=642#]E#63_`,W:?M=CZ_$/P)_3X7FE_P"&4=8Y_P",M?VN_P#P
MX/@/_P"==Q^%?-<4>*W"7$^38W)ZW%G`F#IX_#U\-BJ^$P.>TJU:%?,,-F+E
M/EPGLZE2-:ERPJSA*?LING.4E"E[+2A@<30J1FL-BYVE!Q4I4FDXPA#3W[V<
M9-V3M=1>EW?Q76?A3\7M0_:3\)^.KCX.:A-X"\.?%OXZ:OXICTOQ1\/]3T;Q
MYX)\<_`>/P1X<U<V/BSQM#K]SJVNZQH.@Z)XE\,7MOX:\*:4+31'L-$N[:SU
M7Q3/\E7'P3^*'P7_`&=M#F\4?"S5OAU:>'/^"7-M\"?B;J^D^,_@_HLNH_M#
MZ0G@32-!T[4=6L?'<\6N/K=_I>L:=:^([O[5I]W8^)(-,O\`4+";4[V&R_1_
M_AE'6>?^,M/VNN?^J@^`_P!/^+7<?ABJ.I?L?W>KZ??:7JG[57[6.H:;J-M<
M66H:??>._A]=V=[9W,;P7%I=VMS\*9;:YMIX7DCG@GCDBEC=HY%9&93]?PMX
M\\'Y!E.#R2KGO`6*RJC_`&7"M?!9]*K5654\72H+VE3#-[8V;:<K1=.DJ?(H
MR4L*V5XFK5E-4L7&;YVFI44E[3V3>TE>_+9='=MWO=?+7BOX;_$?XC_"O]J`
M:%\!?B7H'QI^+7Q(_9J\<:UX7\1/\`/#-AJ&@^!O$'@""*;PW>>$/VA_BGX6
MCCM/#WPPU_4M4AUWQ];ZY<:IKNGBVTG^S;V*[/JW[-GP<^,.A_$+3M1^-GA?
MQK=^*/AQXQ^/VJ>'_BVWC'X80^`/&GA#XU>+K_Q1%#;^$O"4LOQ&7Q2()?#6
MGZSX7\>PW/A+PM>>%)KKP7XPU6S72-.KMO"7[#FE^`M'C\/^"OVDOVG_``EH
M4,DTT.C^&_%/PPT'2H)K@J]Q+#IND?"2RLHY)W56F=8%:0HI<L0*Z4_LI:PN
M6;]K;]KH#@C_`(N%X#XQU_YI=R#W&*X.+?&K@K/LGSS(<%Q+P1EV"S6I)X.O
M##<11Q>64Y82C@52PU1TJK5*6#A*A.C6E6A.G4G&7,E3Y'A<NQ-&K2J3HXJ<
MH).4>:A:;YHRO)76O,U*ZLU)*SU9Q/QV_9P\>>-O$_QH'@2>TTG2/C!\./!'
MBF#76U5(-0\*_M&?`'7I=9^%&M6UK<)(/L?B>X;P-%KEU:Q>3;Z3\,+FUFFL
M+_6[2ZN?$_VM/V>?C=\7VTJ[\)_"LS^(_$O['O[27@OQCJ\/B7P#:Z?IWQ.^
M)OQ._9J^)WA'X?SZEJGB33_$&MVNFK\*?B#X<T;6XM*NO#FFW>J^'WN]3TW3
M]6UJ_P!)^H_^&4]8YQ^UK^UT2-H`'Q!\!8./3/PN`Z#GU[\Y-'_#*&L?]':_
MM=_^'#\"?_.NKRN"_&O)>#:V25H\<\"X^>2Y?CL!0]OEV<P52GF&5PRFI4J>
MQP5&]6.#C0C"<>7WJ%.I-3E*LZFF*RV>(]I&.%QE-59TYRY9TGK&I&JN6\Y6
MO)MK7[5M%:WS7^TK\%?BS\5/%G[3WBKPW\"=8O\`5?&7[-/[+O@KX1:OJNN?
M!Z#4M.^(_P`-/BW\?O''BZVL+FY^(4EUX<N='TOXJ^%&_MK?:6>HW6CZS#I=
M_?)::7-JWUA^T!\.M5^(^M?LPZX/`@\8:'\-OCE?>/O'?A&_/A&>>/P]J_[.
M7[0/PO@DDLO$.L6OAW5I])\7?$SPS/>6EMJ=S(MM;W>HZ:;^:TBBGPQ^RCK/
M(_X:U_:[/3_FH?@3(_\`,7<9XSZ]L<4']E+61DG]K7]KH<]OB%X#_3'PNX_#
MZUZ>;>/V59KGN69_3XXX$PF.RS+L7E<)T\#G<G5PN-R3"Y'4C553"3C+EPV'
M52#7*E6G4;BZ?)3C%'*JD*4Z3PV*G"<X5&G.E=.%6-72TTM9-IW6JM?5GQ;\
M8?V3OVAY/"OP;\'?"CPZD!\):'^V),]U:>(O"MAX?\&Z%\:OB9IGCSX??!IQ
MJ&NZ?J[Z;'\/[.?X/W>I^'=#U71]!@>TO8'FTN%I(_H_XE_!OXL>*/&7C;XF
M^!=`G\,:?KMK^RI/KGPEUBZ\&6]]\2+GX*_&G7_''CFWN]0TG7-;\,:;J6K_
M``[OM&\&Z3>WFL10>(3I=OX>\236/AS3=/OXO0C^RCK))_XRU_:[[<#XA>`?
M_G6Y^N?PIW_#*.L<_P#&6O[79^OQ!\!__.NX_"N#%^-N18I82=?C7@"KB*$I
MRQ-6>5YLXXSVN94LT<:M%8)4:<5B(1BHT*=&/)>+5Y.00RNK&3Y<+C%%M<JY
MZ?N^Y"FFGS\S?++=W=[/KIYO=_"GXR>&?B7=_%+P[X5U#7?`&L?M,Q_%?4_@
M787O@*S\20:)>_LSV_PMOO$-E>ZMXLT_P0=6C^+"2>/-4\-GQ9%:7D1?Q=:7
MI\8M-IE[[#^QM\//%GPL_9Y\'^`O&OAAO"'B#0];^(]Q/H"ZAH6J06>G^(?B
M7XO\3Z*EM=^'=3U72GA&BZU8*8(;@/;3+-;&)1"&DQ?^&4=9_P"CM/VN_P#P
MX7@3M_W2[_\`7WI?^&4]7`)_X:U_:Z(<\#_A87@/C!/`V_"_WY(X;J,`XKXS
MQ$XXX2\0^$8\*XSCO@G`P=;`5JV-P6!SBC7K++Z-6AAH32P3I/DAB9J3]DIN
MR][1I]F#PM?!UXUX87$S=Y)0E*E**YW3<K/GYM6EI>RTTU/KD`#H*^`_@1\(
M?"WQ:^#UX/$-QJME?>$/VP?V[M>\.7]A/97=K8:LW[:?[1-B]W?^&/$-CKO@
MGQ&\-K-/%9#Q-X8UF71Y9I;_`$.33=4"7T??3?LG:W,CQ#]KO]L&!G!430_$
M+X?F1>.J>;\*I8\C@KNC89Z].?F#]D']EK7;SX4^*II/VK/VKK,P_M+?MH:7
M]ET[QUX!L[2<Z'^V'\=M$?69XO\`A6$C-K?B1M/;Q#XGN5=+.\\2:KJUW8V.
MEV$]MIEK]%X;\-\-\+>`/&]3)/$?*>5<9\+U99O'#X_V%"?]GY_36'J4YX-5
M9JM"<TX^QG"<4XR=FT8XRK5KYMA?:X2H_P#9JR5*\%*7OX=W34FE9I6=]_,^
ML_&_PX^*%W?Z-XOTN:QU#XR^'M`\4>!_!7Q)\,QZ7X1\.0>&O&4GA:YU>T^*
MOA3Q+=>+Y]0TNTUOP[HWB6VM_",&J:G>7^@/::9)X*M]9OA=_-_PG_8BO_@K
M\#?%/[*'AH:IJGP]UCXV_#SXA^'?B`^J:3:R:;X'\/Z[\)_$.OZ)K5K]OAUV
MV\5VY^'6MZ/H3:'HNIZ++'J?AJZDU#3%_M:TT;Z!_P"&4M8))'[6O[76>.GQ
M"\!C&.F,?"[C_/O2']E#61P?VM_VO&W<_P#)0O`0Z8Q_J_A:,8QG''7G(K@R
MGQ+IY?E*RI>*G#>*PE.I1Q%.G5P6<NC"OAZ\L12J0HK+U2BJ<ZV(4:<8JE'Z
MQ6M!2FY#J8652ISO`5XO:ZG2NU*,8M-\_5)7=[NV]['B_P"V%\)/C9\1;7]H
M?PSX6^'<WQ,T;XM_!WX7>%_AW>V>M?#_`$:U\`>)_`OC3Q5XA\36'B*/QEXI
MT#4EAU\ZKX>UO2-<\.V6LO/>Z5'IVL6VFQZ)I-_=7X/A5\4+C]H?QAK?Q(\(
M^,=7\`1_&OPG\??AI\2=-\<_"[0/!?@FQT7X4:)X)U7PMX^TH7"_%E-7\/6V
MG^*M+L]*\-MXE^&OBVS\2KJ.MW?AN=M8O#ZQ_P`,H:Q_T=O^UZ"<8'_"PO`?
M\(`R?^+7$`]3QU).>@H?]E#62IS^UM^UXF?XD^(7@+C(QGGX6'ID<#&&]J^M
MR;QDX5P&$H9?6XCX$Q%)82IA*LX8#/X59NNL%3K8F*CA8PAB:E/"0IS:7LYP
MG452G*,[+"KEU>4G)4<6G=22YZ+V=TG[]W%.3=N]G%JQ\.?`?P]XH^(7PX^&
M>I^(?@!\2$U.W_8[^(7P>^#_`(BU.+]G'4/#OCG1O'WA_P`'^(8+SQ'XI\,_
MM&>.?$VO^(9X?!5J+'QOXG^'WPBTBXU#Q?XUN=?T3PYK?C2#PW:[\G[,GQ:T
MWPC\&_"EU\'O$>K?#WQ/^R#:?`WXU?#SX>>*_@AX5UWP]\518^%[/7O&?B/5
M_%%]<:5J6F^,['1;#3M4\>_#?7-2^)FAGP=X;U33K'4KB"RMK+Z,\)?L"^%_
M`EYK.H>"_P!H']I'PE?>([C[5K]YX:U[X3:!<ZW=K)(XN=7GTCX-V5QJ5QOF
ME;SKZ2>02232A\NV>X'[*&LY/_&6_P"UV?4'XA>`L#/T^%F1Z\&OJ,_^D)P3
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M\(^(-?@UC4--U[3[]/#VEZM>'_#*6LG_`)NV_:Z.?^J@^`N<?]TM_/&,_P`6
M:7_AE+6.?^,M?VNO?_BX7@/@?^&MX^HQ7Y#QIXA\'\8Y'F615N,^!,#A\RRS
M"9;.5'`9W4GAXX;%+%RKX6=;!U98:IB*\JE2O3H^SP\I5:CC1BVFO1PF"KX:
MM2J+#8N<J<W4NYTTGS*$;2M+WE%6Y;WE\.K3/KJD``X%?(W_``RCK//_`!EI
M^UUSU_XN#X#_`$_XM=Q^&*/^&4=9Y_XRT_:ZY_ZJ#X#_`$_XM=Q^&*_EY^$_
MAL_^;L</6;O_`+OF^OP_]2[U\E?S9[JQ^+?_`#+J_3[5/KR]ZGFK>J]']=4@
M`'`KY&_X91UGG_C+3]KKGK_Q<'P'^G_%KN/PQ1_PRCK//_&6G[77/_50?`?Z
M?\6NX_#%+_B$OAO_`-'8X>Z?\P^<?W?^I=Y/[_-@L?BW_P`RZOT^U3Z\O>IY
MJWJO1_75)SCH,^F>/SQ_2OD;_AE'6>?^,M/VNN>O_%P?`?Z?\6NX_#%'_#*.
ML\_\9:?M=<]?^+@^`_T_XM=Q^&*%X3>&]U_QMCAZZ:_YALXUMR_]2[79_?KU
M$L?BW_S+ZU_=^U2V]V_V^M]/\2['USSQP/?D\?3CG\<5\;_&2=X/VOOV0)HK
M>:\FA\&?M3316=N]NES=O#X9^&;+;6S7<]K9K+,S)%&;N[M[82.IGN((@95N
MG]E/61N+?M;?M=`''_-0?`0QCTQ\+>,]\8Z=*^2/BO\`LN:[!^UK^R=IP_:H
M_:GN4U;PK^T?*-7N_'/@:36]&DTO1?AQ*MMH5VOPR6WM;/68KF6'7(;NROI+
MM;'3VM9M/:WF:X_=?`3P_P"!LAXLQ>88#Q'R7,JU'(,]_<4:&:*2@\IQ*G-\
M^!IMQ@KMV=[7>G3R<UQ6)KX>"E@ZM)2JT=92IZ?O*3::4GJVK6>^BU.B\"?L
MN?%71-,\/7.G>$IO!\7QB\*ZM\'_`-JGPOJ7B/PD)[CP;HWBOQ!XM\+>/]"E
M\.ZGKNG:AXIOO!&L^,?@J\T>MV^K0Q>._!VM3_8M+^';2-SUI\&OVA[+2/!!
MO?@]X]N_!K?%7_@H5;_$CX:>'_&7[/\`%XVN/"'[57[1'B7XJ?#/Q[X?;Q;X
MIUKX<WRZ%X&U'4_!GBO3SXL\*^-M&@\?ZTOANXU6TMM2L=7^MQ^RAK.T+_PU
MM^UV>/O'XA>`PQ]\CX6@9[<`#\.:7_AE'6.?^,M?VN__``X/@/\`^==Q^%?O
M>$\?<HRO"8G*<1Q1P'C,+/$X:=:..P&?5:DW@Z&/P>&IU*DL.YM4</F$J5.?
M-[:C'#X=TJL)0;EYG]FSG*$E1Q49)-1<)4DO>=*3E\5M91NUM)MW5F?-7BGX
M$_&C3M!N_`%A\)]2\;:98?&C_@G[\3?AUXIA\>>!=6G\'^`?V=?%W[-UQ\1/
MAOJ6I>./$7A7Q)/KVB'X8_%7QCH6K:?I4VD>+7^).H^=>:1K-]J.GW.[:_![
MXUG]J+X-?$J'X6:CX=\(>`_C)^UQJWC2;3/%?@>[TO7/#7Q0\/W>E?#KQCIO
MV[QM?>,]6N?$Z:3X<OO%VB:O%HMOX4UUH-*\,^%(O#FC0:H?>/\`AE'6.?\`
MC+7]KOG_`*J#X#]^?^27<?AFC_AE'6?^CM?VNO\`PX/@/_YUM35^D%D%;)L'
ME53B/@!T\-6Q=6CB8Y=GM.7M<=@,-E^(JM0PD:4ZLZ6'ISG.4)2G7YJE1R<W
M<_LFNJSFJ.+?-&":<Z3;4*D9)?&]+R=K-)*RO='@7[/GP;^,_@W2/@W'\1OA
M5>:EX7T#PQ^U;X'\9_#B[UCX8:K?:;=_%_XT:9\0O"GC9"OC.Z\-:]HFK>";
M;5O!^N6(UR+7M&N=3D@@T>^TG5-4N8]?]GG]FWQ]\/\`XQ_#G4?B7X3M_%UG
MX%_8[^#GPJF^)U_-X0U2.X^*W@7Q1XCU6[DL(;G5I?&,UQH^BZGIND:?XPO-
M"M;W4?L$DMQ>+*[33>R_\,H:Q_T=K^UW_P"'#\"?_.NI#^RCK`Y/[6W[70'7
M_DH7@,`]N/\`BUN<>V?\*^:SCQCR+-,LSO*GQGP/AJ.=X=4J\J67YY"M3?UR
MIC(585'A'4E.,\1*DG5G4C*E&"FI2BI'11RZK3G2FL-B9.D]%STK-N$(6:4V
MNG,K6=]M['&Z;\`KWQC^T]^TMXG^)/@+QQ#\-/B-X/\`@_X8\/:G:?$V70_"
M?C&U\':3XVTWQ=IGB?P?X'^)5IJ&L:5J`U^RMK6U\9^%+BUO-/GU2SN8+6WN
M;NVO/)_"7[./Q#\)>*O%7C?0_@YI6DOIO[<5_P#%:#1(;GX;V.K>/?@#K7PS
MLO"2:-H.H:=KDUAIW_"._$.WT+XJVOA#Q5J'ABRNM3\%:9<PF+6FLI(/HS_A
ME'6?^CM/VNO_``X/@/\`^==2?\,H:UDG_AK;]KO_`'?^%@^`MOU_Y)9D?0''
MM7-EWBWE>6_683X]X.KX;$Y)@LEAAL5@<]K8>C2PF%PV$EB*%.M@YPCB*].A
M"4ZB5J=1\^'5%QIN%3P%2IRKZKB5*-9U6U*C=N4E)IM23<5*32C;6UG>[/)-
M`_9]^*/A+XF?!/QI;Z/+JGA7PO\`M+_M)^/IO"5CJOAZWOOAM\/OC/X*\4:)
MX>M;.&]UJSTF\TNR\27\OB'6=+\.ZE>W>EGQ1):Z-I>JQ6-R8>?T3]G#XZZI
MX7_9RLIDC^'OQ;^"O@CXW^"/&WQ;MO$=C<V'Q"?QA\-O%?@_2M:M(M#NY=<U
M2/Q9\3]5\(_'*X'BK1=+U'PYJ7AG4H-O]KWV=4]\_P"&4=8Y_P",M?VN_P#P
MX/@/_P"==Q^%(/V4=8//_#6O[79SCI\0O`0X'O\`\*MX]_QZ5I'QER2-*A"7
M''`=2=*C.@ZU?*,RKU:M"K'&QK4W.OEM1Q=6GF->-1PY7*4:55WK4U4(CE]7
M5_5<4DY1:BJD$HV]E:UJB5HN*Y6W>S:2LSQ?1OAA\7-8^$FFS0_`67X9_$_0
ME_94LOB/I6J>-O`NKV_QNT?X!^.-/UOQ#X=\-3^'_%OB#P]I^CWF@QZU:^'_
M`!!XRC\*>(?%7]I:;X9\8Z7I&@:9#=6L_C[X'?%:;5=4\0^&/!VJ7VC^*OVV
M_@!\>K;P%'JO@33[GP7X3\#>&_AQ8?$?7+N6\\66FC-JWB?Q#X8U[7)=&T+5
MM5:]NI_[8=1J^N:SM]B_X91UG_H[3]KKM_S4'P'V_P"Z7?GZ]\TG_#*6L'_F
M[7]KK\/B%X#_`*?"ZM*'C%PY0Q-6I@^+>`Z$*U5U706!S^K:"67*G056KAJF
M)]A0^H4?8Q]MS4XRG%2Y)**'EU?ECS8?%RLDN;FHI;^])VDE=\\F]+-I-K9G
MF'[3W[+OQ$^-GQ%UC7M"UOP]I6@R^!/`/@*R-]\/OA_XEOI[#Q;\2FC^+]XF
MI^(94U:RO/"_@C1M!UW2)D*7%V+N\T7P]<V]_+>A_P!2OA+-!I-PFG74\+7`
MLK&"-U@CM8YVLXY(YF@MH1]GMPW$@M(B$B0,L2M'"S)\"']E'6#N/_#6O[70
M[G_BX7@,`8YZ#X7`#CKC&?K3U_9)\07,AA@_:S_;"DD<$[;7Q]X#D?:F,L%'
MPHDP!\N24VY(4Y)Q7O>%_BC@,J\0^",[PO%W#>:OAK&U*V#RG+\NSA5L0J\*
M$*T(WR]\TI.FZFMOWE2I)_$9XS`3J87$4IT*U/VT8J524J?+!1::;M4V5[;/
M1*VAR/[*W[/OP2_:B^`_[<7PJ^/7PP;XO^`;W_@JG^V]JLOA%-9N-$\O4H_B
MIK.FV6OK>6GB;PI,EQH$&K76HZ;/%J;7FF:K#8ZYHUN->TO2KNU_2O\`X92_
M9I3XT^(/VBE^&>EV_P`9O%OPROO@[XB\;QZOX@BO]1^&NH6OABS?PC)9Q:S_
M`&1;6%G;^$=)32I-/L+>ZT:677KG2;FTN?%'B2?5OQ?7]FCX1_L?>-=,\%2?
MMV_ML_"WQ5^UC\4?%WBOPYX/D^)VE7UKX[^)NL:WIEWXYUW1-'C^#VIZ7HMU
M>ZQXTT6X\3ZDJ:5IN+[3IK^=+6SC>WT'U;X$W_A:[\>3?\%,_P!H_5?#5EXX
ML?ADVL/\6OA_?.WB_4?&.H^"-+TNRM8_A!)J=_9:GXBTK6#IFN:?:3^'K_1-
M)UGQ;::G-X4TS4-;MO\`8'%_3+Q4L-0J9/P)G^+IU(T(8>O7R3-:=*K.7+3D
MHNG@JW,_;TZE)<LI)RIM+:1^?+AV*ERU,52CNI)58-JW*US7E%VL_P`5Y'O7
M[4/P`^!?[*WAC_@E]\&OV?/`VF_#7X8Z'_P5*^$NKZ9X2TK4=;U*QL+W7OA?
M^T5J>L3PS^(-5UC41]NU&XFNY8S>-`LTTC11QEV!_:&?5["".262:*.-$9Y&
M=U541`2SEB0JJJ@LS'Y0`23@<?S8_%'X#?LR>._'7@FP^(/[>G[3WB#Q=\$;
M,_M*^#]%T_XN>&-1MM+72?!>I^(+'QS:Z?X:^%4^F>)==L?AY=:SXIT#1HUU
M7Q#)X*U'4/$VDZ//X?U&:_F^D/AA\![#XT>`/#'Q3^%G[:?[7GC?X>^-M-&L
M>%/%6C>-_!+Z9K>FF>>V%W9/-\';:8Q?:+>:$^9$C!XF!48Y\7-/IHY[A\LH
M8BGP+F5&K.DUB*V+R?.:>%IUZDZCP\:-58"7M54H4O:WE&FW)3C&,HPE)W3X
M<I.HU]:A)722C4I\VG)=OWM-79;[^:/V0G\4>&7N+BZ_MFQ=Y+:.U"&]M&CC
M2*2:5GB&0V^8RJLQ9W1EMX-J(RN7^=->6P.JW7]F2O+`\A)>21Y@\S$^:R2R
M,TDJDX.^5Y&=]S*[(58_&3?LB^)4C:9OVL/VQ1$K&-Y#X[\!JBNK>6R._P#P
MJA55PXV,N0=S8(R:\_TCX)0ZQXRU;P+'^U9^V[8Z[IUKJ&H6[:SKOAW2-+US
M3](OK'3=:OO#>L7WP@AT[6H-(U+4].L;][6=G22^L[F".>PN[:]E_P`\OI8>
M+>(^D'PS3X;XBQ>3<.++IRS"6+J9?G5/$4\/'E4V[Y?I32^)I))?<?7Y!@(9
M37]O2A5J\[45'GIM-WA;7GU;^;WVU9][5_$M_P`'7S*/C%^QYN(_Y)I\4<9_
M[&GPO7]5_P#PRCK//_&6G[77/_50?`?'T_XM;Q^&*_CD_P"#G;X1ZI\,_BU^
MRG;S_&#XM_%#^V?A]\2KE)_BOKV@:]<:*MKXD\-Q&VT)]`\*^%A;6MV9?.O$
MO$OY))HH3%+"J-&WQ?[.+@/A'A_QZP^+R7CC*L^Q3R/.Z;PF#HX^G4C&658F
M,YOZQA*,;15V[2D[K;4Z.+L97KY:X2PU2@O:4W>3C)-\]-W5I.RU2Z;H_IS_
M`&0_&GC?1_A-_P`$B_`NC>++[3/!?Q$_8=\*:CXN\.Q:3X8NH-2O?AW\"/@O
MJ.AR1:EJ6@WVN6`NG\2WD.K1V&JV\<T-O9"U2RN([FYN_NSXA_M$>`/AJ_C=
M]=CUR^TWX7Z;X2UGXF:SH5KIFH6'@#1_&5[>6^F:GXAAEU>VU9K>SLK&XU_6
MHM'TK5;S2_#ODZQ<6IMKF$O^3W[)'Q]_9-UG]G;_`()Q^.Y/VZOV5/`OC/X#
M_L=?#;P5=^!/%7Q.^&5[?V'B+Q;\&?AQH/C;2?&>GS?%;PSK6DZOX<N/"UCI
MRZ#)%I>HZ+K%IJL.L?;)98[#3_?6\>?L%ZG)\5I_$_[??[..O_\`#0&@V_A[
MXZ63?'/X+V^E^-=,TR[UV/2+?1+23QEJ%SX--OX.UX?#>]6UO-1%]X-TO3)8
MA9>+X'\5R?1^/GT>(\:>+.=YSFO"&>U<!0Q>+5593E59U<PJUL\JU:E256%.
M,*LE@:DG"I.IO&E"_+%I895G$L/@*-*GB*7,XPY?:5%[J5*"22=Y*\ULE?=]
M[_=UK\=_"%_XR\3^#M/TWQ+J%QX*U;4=#\6ZM8V>F7>G^']5T[PD/&@M=5TR
M#5I/&%HFI:*6.A7\OA@:?K]VC0:-=WJ`2R6OA!\:?"_QNT2W\2^#K#5_^$=O
MO#WA_P`2:+K]W/X;OM(UO3_$5QKEHD%C>>&O$7B"%-7TBY\.WL'B+1-1_L_5
M]"N9[.VO[*&XFDAA^+-3^+G[!NK?$Z#XL7?[>/[.<?C+2M)^(.C>'M<TWX\_
M!'2O$&F:3\0;5;:7P]J.O6/B:"_\3^$_"<D=OK'@K0=;-S_8'B3[1JJWEQ;Q
MZ18:/T/PN^/'[`GPN\4^/O&FF_MH?LLWGB/XD6OA"V\6W]O\;/@1X=M]?O?!
MJ^(5L_%^O:3X=\0Z?H]_\0=?7Q'=IXR\66UAIRZ[;:;X;L4TO3K70[.W;\$S
M?Z)V"_L+,99?P-QC'-%ALO>`3RW$R?UAXN*QT'913B\+[\*SM[.4?8>PJ<WU
MF'J4N(:CK4U/%89T^9\R<UJK1Y7W^+1JSO\`%S+8^G[G]H7P+::WH>ER6NO?
MV3XB^)^K_!C2/&7D:1%X5NOB;HEOK_VWPGYL^MQ:Y%<OJWAC7/"UKJ4VA)H5
MQXIL1HJZF+B[LOM'+_"O]JSP)\6]5\#:9I?ACQUX;3XDZ;\3;_P-J?BVV\)V
MUGK\_P`(?%EOX.\=Z/;V^B>+]=U>UU73-3NUNK<:EI5I8ZEI<%Q>6%_<M`\2
M_,]G\5O^"?-GJ4H_X;9_9EO?#-O\9]4_:$T/PCJ/[0'P?NK30_BSK5SK6K:C
MJ5M?Q^,K:\F\,2>+-=U#QY!X?/DW5OXPO+J[&O-HD\6@V_"?#/QG^Q1\-]4^
M!M_'_P`%"?V5M8A^!TGQL;2;:;XL?"&RFU^/XY^(#XD\3IJMU%\4KB*V?3=1
MV+HCV-E&J6ZF.]@U!V,J^X_HI9'2R',:%+@#B^OF,\+4C@:]?`XR-7FEA,7/
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ME?M4^,H=0\0Z'IGQU^`'A\^##>_"+P=\&3J][J>O_%VP%WHFF^%OAIX,OKNY
MT.TNO%-MXC_M/6/#^A7\-[9Z7H?W/!7T:N&,#P=1R_B7PXS[-L?A\/5Q%+ER
MK%T<7/&XO^QH5J-:M"-%U(86E#,98:+JJ"JI2:M4<9<F)SJO/$.I0QM*G"34
M6O:1DH1@Y-.*=[<UZ?-I>R=MKK[<^(/QKTWP>?`KWVA?$"(^+_C#<?"OP[;:
M#;^`KD^)?$=KIWBB6"VOO[<U_P#T#PQK,GAW5A:7\<^CZW'?:9:_;O[,TNZ9
M[SR/X>_MW_!WX@>`]'^)IT'XA^#O`GB;X!?$;]I3PYXC\7Z3X9@BUSX6_".]
M\,V/Q`U"TTOP]XO\2:Y:ZCX=?QCX7F>RU73-/BU2TUBUN-%NM2B$WE^4?$7X
MZ_L4^,]$^"VD:7^WW^RWHLWP7\<^'OB%IVJZO\:OA%XFOO$?B#PWH&LZ!:2^
M(&7XC:$9UU*/Q!JVH:_+"8[[4M0ECNHKVSVW`N_EK^TOV1/A'\"_"W@_X8?M
M[_LK^,]8^"G[)'[07[-_PWT+4OC9\!?#^H^+++XQ#P3JZ7&H^(=;\?:SX6T[
M7]/UGX7^`X=)N-4\.77AF6*/78-?TZ6VUF&[T'TN!OHH<!9SDRP?%G`O$^7Y
MG*LZ6'G1P>)P\84E_:E2+J5_J]6*E*K_`&93]I.%;EHSJVBW%<AB<^Q5*HIX
M?%4915G)2G%M_P`'975U;G:7NW:3>S/U[\"_%O2_'/C+Q]X#A\+^+?#?B+X<
M0>%+GQ%!XD3PR;?RO&FG7.J:$^GW/A[Q-X@2]$UM9W8N7(MU@GMY(7D,H"-Z
MQD<\].OXU^1_[(?[4/[.7P_T;7AXY_;@^`5[9:LFEK:Z7\1?BE^QQH7CFPO-
M)@_LZTDFUOX%_%_QAX?UC0X-$BL=*TNRUC4;J[T6RTVPTS1ETS1;.&R?[*/[
M<W[$G(/[8G[+`[X/[0?PE'O_`-#?GGMZU_&?B_\`1)\3<!QABL+P7P'GF)R6
MC2P\*-;#83%XBE5G"C1A5J\\Z,)?O*BE.W*E!MJ-XV;^BP'$&"J8>,L3BJ<:
MMW=2E%-*5K)/FZ7MNWKY'U/17RS_`,-S?L3?]'A_LL_^)!?"7_YKJ/\`AN;]
MB;_H\/\`99_\2"^$O_S75^4KZ*GCW_T;WB3I_P`R_$]>7^YYK[CN_MS*O^@R
MCT^TGOR]O\2OVU/J:BOEG_AN;]B;_H\/]EG_`,2"^$O_`,UU'_#<W[$W_1X?
M[+/_`(D%\)?_`)KJ/^)5/'M_\V]XDZ:_V?BNO+_<\U;7I]Q_;F5?]!E'_P`"
M7E_FOQ/J:BOEG_AN;]B;_H\/]EG_`,2"^$O_`,UU'_#<W[$W_1X?[+/_`(D%
M\)?_`)KJ%]%7Q[T_XU[Q&MK?\)^)_N_W.EU]WW/^W,K_`.@RCT^TNMO/^\OQ
M/J7'(]@?Z#^M?`OP+^,'A?X4_""Z_M^UU6[O_%_[8'[=GA[PU8V$%G:6FH:Q
M%^VG^T1>-::AXI\17^A>"?#DDMM!/-9'Q/XFT:36)89+#0XM3U,+8OZA+^W=
M^P]!&TLO[9/[*D**#N>;]H;X11HH!S\TC>+P`.F<\=_2OE;]DK]M7]BAO@_X
MSTOQ!^U9^R[:KJ?[2W[;EZ^D:_\`'+X30'4_#7BC]L?X^:UH&J'3]0\5*;S0
M/%OA?5=*\0Z#?&&73=?\-ZSIVLZ?+=:9J5I<3_V9X4>`?B+E'@'QGE/$_A[Q
M#C:F*XRX8Q=/*(X>O1Q&)I8;`9[3E4BG"4G2I5*]%U>1<TXRLIPDU)?/8[,\
M)5S/#5*.*I1MAZUY\RDH\TL/9-WW]UV3T3LU=*Q]0_%_XD_%WP1I'PDUF[B\
M+>%Y?&?[0WP;^'VHZ!I4LGBUQX2\;^(;?1M:M;[7]4TS2(?[3F$LKJVDZ-`N
MFM'$MIJNHH&N)-'XEW'QX\/?%;X6:QX7\<^'+[P1XI^(6F>"=7^$TW@RS1IO
M"DGA[7M9\2>,)?'T^K#6$\1Z#;Z-=:S96MI8V7A^>VCM_#\VFZAJ-PFK7OS?
MXZ^+O[`?B/2/!^B^$_VU/V5?`6F^#_BSX+^+=KIEO\=_AGJ^@C6?`VKC6M+T
MK2M!N/B;IVD>&-$O+_,VK6?ARVTZ*[=Y)8E@NI'N#2U3]H+]GO4?C$/B3#_P
M53_9XTOPN+K3;6/X;6OC_P#9@N=/M?"EI>6=[JOA:Q\5:GKM_P")]-C\4362
M/XBUK3[NUU>\86/E7,$>B>'X])]W(?`'/IY5AUAN`*F75Z<<Z6)I9OP[B*DJ
MV$Q='!0PN%A..&QU2%:G/ZQ*E652-:E%.4,33J.+,*N;TO:OFQ7M(MT4O9U5
MI)-.4G[T$TERWC:S>DDT?0'Q7^.NOZ!?_M*KX8NXK9/V8_@=H?Q8OK&?2X9H
M?&'B'5]*^(_BG_A'-2N;Q3/!H<6@?#^QMEN=#>SOQ>^)KN9[YI-'CLY?`/%?
M[9'Q$O\`]G;P?^T+\)M*E\6_\+D^(/Q?^'?PW\`S>'G:Y@B\/:9\98?AQKEM
M:VMO+XAU'Q)JVH_"K2[K5?#]U--8W[^*KO1[.STJ6PM[UNB\2_'7]A#Q;9^)
M;?7/VYOV:KI_B-\/K'X6_%BZ7XY?`RWF\>>#-.D\42P6CBU\1P6V@:B\/C+Q
M1I+:EIEOD:%KVHVT<,6KV^@:[HMO1/CQ_P`$_M"U;P_+:?MF?LN#PWX.\=>,
MOB;X/\)K\>/@M#8^'_''C^/Q>OB758[R'Q.+JYL5?QYXON=#TF0Q1:1=>)M5
M:2:_MK3PQ9^&_<RCP8RK+<NP\\1X+9]C,SPM2C4?-E6*EAZ_L<LC2JTY)U-8
M5LS_`'VL4U2;T<;45E4S2K4J6CF-)4Y+E3<XJ4;U(V>SNXTU;=KTT9Z-X5^.
MOB:+0S9>/+^W\/21?$3QX]MXXU"ULWGU'X,:'\2=5\.?#GQ`VA:?IEO!+XK^
M+UM8C2_!%CIFDBS\0Z+I_B'Q]HUO);Z?;:+=_7UC?6.IV%CJNEWMGJ>FZC:6
M]_INHZ?<0WEA?6-Y"EQ:7EC>6SR6]W:75O)'/:W%O))#<0R12Q.Z,K'\[O$'
MQL_8#U_1M.27]MO]F>+QAIOQ!TKXK1^.C\??@Q<ZI>>.](MKRPT^_P!3LY_%
M1L[_`$>PT>_GT#2]`D(M=)T"&QL;"6"6Q@N1Z/\`#S]K']@KX:^`?`_PV\,?
MMB?LR?\`".?#SPCX9\#Z!_:7[1GPCN]1.A^%-%LM!THW]VOBN!;J\-C86PN+
M@0Q":<R2>4F=H_#O%?Z-O$O$645\TX7\..)LJSF681J0RFADE6&%^KU_:RQ'
M[_FE42H..%IT*:@XRA*HVJ3IMU_5P>=4:52%&OBZ-2FZ?\1U5SQE'DC%I6UY
MKR;;MMO9VC]KT5\L_P##<W[$V<?\-A_LLY/_`%<'\)?_`)KJ/^&Y_P!B7.W_
M`(;$_99W>G_#0?PES^7_``EV:_FO_B53QZ_Z-[Q)_P"&_$[>[_<Z7[]$>O\`
MVYE6G^V4=?[RZV_S_,^IJ*^6?^&YOV)LX_X;#_99SZ?\-!?"7/Y?\)=1_P`-
MS?L39Q_PV'^RSGT_X:"^$N?R_P"$NI?\2J^/6G_&O>(^C_Y%^)V?)K\'FON6
MW1_VYE6G^V4=?[Z\O/\`O+[GV/J:BOEG_AN;]B;_`*/#_99_\2"^$O\`\UU'
M_#<W[$W_`$>'^RS_`.)!?"7_`.:ZA?14\>M/^->\2=/^9?B?[O\`<\U]PO[<
MRK_H,H_^!+R_S7XGU-17RS_PW-^Q-_T>'^RS_P")!?"7_P":ZC_AN;]B;_H\
M/]EG_P`2"^$O_P`UU"^BIX]:?\:]XDZ?\R_$_P!W^YYK[@_MS*O^@RC_`.!+
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MVM9W=]+L\G-LWR^MAHPI8JBVJM+527,_WE.4I)7LK)ZV>^C6]_3_`-E_]K77
M]4\`?%33_CW=RZE\0/A-H>K?$^TU6QTK2=)N?B9\'-4U?Q1;>%]:T+2-/_L[
M3KOQ)I/B#PSK_P`,M8L=+LK*W?7-'T&]:.*3Q9:1-8^"G[5VI^'/@W;>(_VC
M_$$&M?%75OB+^UKI4_ACPDO@[1M)M=%_9J^/OC;X4:U#X,DUZZ\'QZIIVFVF
ME^$[2VM]5UK5O&>OZEKD$]M;7,?V\:?YEH/C;_@G[9Z7\&8]?_;H_9DUK6O@
MGK?B/5/#NM:?\>_A7X=M_$.F:]K%OXO3PQXRTFS^)%U%KFAZ;\0M(\%^.[6W
MBN;'=KG@/PV24A&K+JO,Z;XF_8QTF/PCJVC?\%-/@-X2\?\`@GXB?'WQMH?C
MCP3\8OV?K&:;1?VG_B=>?%KXR>`O$'AOQAXF\=>&=;\.:MXON+/4?#<ESIT6
MI^&[GP[X6NQ>:C<:=>'5?Z^?@#PEG^19W0S7PZS3+<VSK'Y9CZDZ&18A1PU;
M!8'-*6+I8>K2P\'A\+C\?+!UZE'#0C"G3J0I4U;#H^?6:5J%>E[/&4YTZ<9Q
MUJWYE*='D<DW:4HP4DG*][-];GU!\6?VH([WP%X#\5_!FY\23VNH?'']BOPU
MX@\21:/X;?1;#PY^T1\7_@GIVH^$?$UEXHE.OV>J:Q\*OBOIVI>9H&B_VGH5
MWXC\,3'5K%VO$3UI?VF?`P^+/ASX-W>@^-]/\4>,]3^)&C^$+G5=&TS3M*\3
MZC\*[%-2\4IIB7NN0:ZNG/;+>?V'XBOM"M/#&OOI]Z-,UJ<1(TOQ%XJ\6_L'
M>(M1U^6U_P""COP>T'2?&'CGX"_%+Q;I$'[07[.6KRZW\3OV=M>^$^K^"O&Y
MU3Q%+JMY::IJMA\'/!.D^+;5/,T[6UT33[V.SL91JD6L36OC7]@VU^*WA#XM
M'_@HC\#+[5_`'Q)^,OQ&\+:3JGQX_9VO-.MI/C?I%_IWB?P_JU_!?VGB37=+
MTF2\@M/"KWNO-=:!X3TS1_"6FR16.F6MW%R5_HU<"2X-RC*:/`7$$L;EV9YG
MCIU:F35XXNM3Q>59?]7P]?%TZ*GB*.&S&A5A2C*,8M3G5Y:?M)(I9SBOK$Y_
M6Z2C4C3@FJD7%.-3WFHMZ.4&F]WLKV1[?\`OVE/$GQ#T+1_&.OZ/X]O_`!#X
MUM/C?JNB?"#1+/X77%O;^%/A1\8)/!4OB71M3.M:/J;W.EVVL>%O#.HV>O\`
MB"2?7M:N;N^\/:.UG;27E>N^#/VH?`OQ'\8>#O"G@'0/&7BQ/&_PJ\%_&O2?
M%&G0>%+7PU:_#CQSJ-_I6EZWJ4FM>+-+UJ*ZLK_3;JVU70K?0[S7[5T98-,N
MFANO(^*OA7XV_8:^%=O\/+[1_P#@H+^S0_B_X=6/Q5\.6'B:'XP_!*U37_`_
MQC\;67Q&\4>'/$VD77CG4X[RYTOQC9V^M^$M6TZ\TIM'DMK:VOM/UFPN?$-G
MX@ZCX8_%#]@/X3?$+0_%/@_]MG]E:T\/^&?@5X3^`NC>#W^-GP?,L/AKPEKF
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MAG6I+_6+'5TL-*O_`"7P=^T?^QCX3^,WQ9^+3_MY_LF:@GQ7L/!&G:EX;/QD
M^$UH='M?A]8ZUI_AXZ?K"_$^X:6:>+7[^76FO=-E6]N/LS:?#I$43PR^=V7Q
M`_83@N/$FJW/[?7[,C>(;W]HN;]ISPAK>F_&SX0:?-X/^(-UX1'@.]TZ>UE^
M(>HP>(/"FJ^#)+_PUJNG7`L;^ZTS7-?^R:M97USI=YH^M#P%P&>4/[-S[PJS
MG!TL-D&`C@L=@\GQ%*H\WCEV!H58U51H4G.DL1"M4JU)NI*3<JD%.<IJL+-I
M4INI2QU.;E6?/&=5-*E*?,G&[LGRN*2M:W;I].M^UAINJ^/_`((^"?"/@_5]
M3'Q(^*?QB^%OCAM1NM!L]7^&_B'X-^&]>U#7]*U&PCU][.YNVOM/L=76_P!-
MU+5K"[\(K)?Z/'JUWK.B1/UEK^U3\+)+_P"'Z:C_`,)!H'AOXK>'_&OB7X;^
M.];T^QA\'^+=(\`:%/XLUVXM;VRU2_U71S-X+M;[QEHZ>)M'T/\`MCPYINI7
MM@TTMG-;+\JK\2_^">EIXF\!^-M)_;>_9OT;Q7X.^*_C_P",&HZO9_'_`."$
MB>*_$?Q1\/ZEX9\8VFIV-]X@O+:VTZZT2^LM+TE[0)J.E:?HVG1G4;F]-UJ-
MUD:+XP_X)N6'A;P'\/M;_;3_`&<?%?P[^%-CXVT7X;>$]6_:*^#L8\/:#X\\
M'^(_A]>:5J&L6GBR+5=9@\/^`/%WBCP)X0>.XTQM.\+:NT.L+K^N6-CXA@XJ
MWT6.$L;1P4:GA_Q?A71PE3#N&&R[%RJRQ%268SIU\15J0C"<J%1Y=3?)"G&I
MA^=\D:J=[6>8BG*3^N4)N4HR3<XVM:DG%)=&N=J]W>SNU9GVO9_M$>$Y]/N]
M3O\`PWXYT&U$'PAGT"36M'TNWMO&;?'+7'\,_#RT\+:C:ZW=:7>:CJ&O!=-U
MC3M1O]+O/#3W%I>Z]!I^F75O>2>4?%+]HN],/@^W\"W>J^$/$NA?M:_!3X'?
M%3PIX@TSPY<ZK:V'CVY\-ZO=Z;<"&?Q)8&SU_P`'^*]$UC1M?\/ZL6$5XR17
MT5]9WMM:_/&C^/OV'4^&=G\,?%7_``4H^$WCRU\+:G\.=2^%^OZ[\?\`]FFT
MUSX:R?"37M-\0_#VZTPZ"FF:7XAUO3K[1M-M]>UWQ9IFLWGB33()=-ODAMK_
M`%*.\O\`C#XF?L*>*)X]9B_;K_93TSQ;J/QP^&WQX\7:^OQ?^#MU'XA\4?"G
M1_#FB>%=$@L$^(=E-IGA>UL/"^FP-9/J6IZD5>_E35A=WUS=N\G^B]PYP[FO
MUB/`7%685L/B(QHRGEE;$9;4HTHY=%U:M'$X:,ZD,1'^T)3HRI<U*:PT(2DH
MS<E4SRM5ARK$T(*4?>]]1FGKHN5M*WN>]JG[S=FSVS]I_P#:`^)?PM\27ND>
M"/`?C?6[72_@;\6/'$^J:%/\'&TE_%-K/X,T/P#?:C!XX\?:'XB71-%U?6-4
M_M6QT[2!JFLZ@^E6VAZ;XIMH-7MK/]%?A.T\M_:Q7JW*RS:3%/=07R6/VU+I
M/LH(O#IKSZ<+I&FG6X&GSR633%VM7DMQ"P_(WXF^-_\`@EY\7_&-_P"-O'G[
M1W[%7B77-0MOA+9B[U[XJ?`/6[RTM/A9X^U/QRMM:WNJ^(KFXCM_%T6I'POX
MH@258M1\.6EMIUPDULGV>OKSP3^W_P#L$>$I@TW[7/[+,4%K:06>FV^G?M`?
M!V&WM+2!3&+>.W/C6U@B@CBBMXX8EC*0I$$C"*!G]/\`"3PEED_B9X5XO">'
MV-R?"Y+F&+K\0YGC<AQ.&I5*514:E.-:O.OB85VI*K3I\M##J*2;34K0XL?F
M$:F#Q\)8R%656G!4:<:R;BTHWY4E%KHVKOMZW_VC],?_`(>A_P#!,,-<(+>3
MX:?\%`&BBAM45T>/P9\!S*)KB0SI-%)&\"QHD$$D312.991<!8/6)_\`@EU^
MPS=?!_QS\!KOX#Z/=?"KXE?$67XN>-?"DGB/QG'%K?Q*E\,6OA/_`(3.6_MO
M$4&IVVM1Z=9V^I17%G>6ZIXO#^/`G_";S2^(9/GCXE?M>_\`!+GXI?%'X*_&
M7Q1^UM\#[?XA_L^7?BRX^&NO>&OVM/A[X82QMO'@\+CQGHVMZ?HGQ.M-.\3:
M#XDM_!^@V>JZ1KUM>6D]A!<6@C2#4+Q)_=O^'I/[`VTC_AKS]FDYY/\`QD'\
M&-W8C!'CX<'C@$?Q9'7/^W]'BOP[HT*,(8>C#V<(+]W@I1490ESQ44J2LE.<
MIQ;5TY-[MGYK]7Q;=^9W;NFY)WORJ^_HK6U:]3WZW_9'_9YLOV@8/VI[;X;:
M9;_'NV^'L/PGMOB)'J6O"]@^'<$RW$7A2/2%U7_A'%TU+A%G7.C_`&D3@2B?
MS!N'R)_P1ILH9/\`@F#^QTXAC?=\.+\.6.PA#XU\5@LH\M][#`^4E0><L#C.
MMXC_`."FO[#FO:3KFA1_M=_LX6-AK6EZCI#ZMI'[4WPN\.^(+&'4K&2RFOM)
MU73?%;7FBZO:>>\NF:G87JWEE=16][;313QKY?'?!O\`;5_X)C_LU?!7X=_!
M/X(_M7_LO:;X$^'>C1>'_#?AG4/VH?`>LZCI6G/-=ZC<F]\1>(O&>JZCJUR=
M1O)WFEN;ZX=Y)W:&06\2QIQ?Z\^&F(P6/;RSVBP2@ITJN52;JQI7C!8=5:*]
MKRJ<[*FGRJ3^=O"XV,H\T[<S334UI?EUDT_1N[Z*]]3]!OB[!J]I\,?'M_X4
M31;7Q59>$/%5QX;E\3)>OX>CUVTTF_?1YM=72B-3;13?1VTNI+IV;X6!E^R;
MI_+5OC_1]!\9VWC#6M>U[Q%X3U/1;FUN+#0=,TGP-J.BZ_IME)?0W=I#K'BC
M4/''B*WUE;6".6-UTSPWX9M[VZN3>7,+>1:V\'*^(?\`@IC^QUKFGR:?8?MA
M_LIZ4MRD\%S=#]HCX2WMXD$UO-$K6#-XK@M[6\BF>*5)[F&_B"QM$UHQD62/
MS[_AN?\`8D;C_AL3]E@GK@?M"?"4X_\`+NS^-?X]_M!<MS_Q(Q654O"#@#-*
MZJX&>"S6O1X><(^RE.E->RG[#FI3;C9U*?+.S<%)1G)2_0>$:E'!1F\QQ<(O
MG4J<755[I):J^J5]M>]M+GU.,@X)SGIQCIUK^)7_`(.P/^2Q?L=_]DT^*7_J
M4^%Z_K#_`.&Z?V(_^CQOV5__`!(3X2?_`#75_&Q_P=!_M"_`OXN_%O\`9/N_
MA#\8OA;\6;30?A[\3++7;CX8>/?"OQ`@T*[N_$GAF>SM=:F\(ZIK,>EW%Y"D
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ML/#>I:1I>I#]A+4,7FN:'?:_8&`_L]?L[%X6L+#7_#-P)789CE&I^5&0S-;S
M9%=GXS^.OQE^%.E_M`6^D^+?",%_^S_\`?V8OC/XC\+^&_"^C7>@:K\:OBS\
M4?V@;'X]>&M0U>X^WWDF@^(=:\$2:C-#I%SINKZ-J6I0)IFIZ:UAJECJL^/O
M@KQCQCX@\?9KPMQUCL%C:.9XC,:F!KX_$8?#TL-7SJ>6JE2Y9R4G&M/#->[!
M*-2;:7(G*,JS+#X;"8.%;"1G#DA#G4%*3?LZ<[R;]'=:ZV>MVU^KE]K&EZ=)
M8PZCJ>G:?-JEY'INEQ7U[;6DFHZA*CR16%@EQ+&UY>21QRR):VXDN'CBE=4*
M1N1?K\LOBU\3;GXB?$CX-WE_JRZ&/AK_`,%&=*^$H\&31Z,DEMIND?"[QM=V
M/B/4KF>PC\0QWOBU[J+7M),6I0:#<>'-5T>W&DWM_;+K<_KW@K]H#XD^+Y?@
MUXNM[.YBM?B)^T=\:/@+XZ^%ESIVC1ZI\.]+\!GXUR:%XE>^AD&IV7BG2K3X
M5^'M0\7VFJ:EK&AZKIWBN^N?#^GVK'PZMQ_/F.^C_P"*L,NR>O0\0,;&K7PC
MKYLL3FE:A#"SOCJL(4'*K>O&>$P$JL)1TG*481YFTY>M'-<O<ZJG@XI*:5)Q
MIJ3=E23Z.S4II6Z*S=M4ON[I@'D_0\CJ>![>G0<]^5K\P_V8_BQ\0=1\+?L^
M_#OQ!X^UM]7^,FL?MA^(=6\>ZEIOAJY\01ZU\,?B[<V>@^"]*@ET.+0+:ZU[
M3-8\0^,95OM$U*=;#P9KUAI":=I2VT6C:5O^T#\9Q\-_@C\9_&.JOX-\'>._
M"FJ^&OC1:V&EZ"D/P@GO/$L&B^#_`-IG2WUGPUKEW_PKZ^FTN9=7TCQ+J&H:
M%I6@^.M&\57-RF@>$_$NL0>=_P`0&\6X9Q++5XDM4ZF(J4<!.>;XM3S"-.IB
MJ,71HTW4J0G5JX&I2ITJL85'.5*/+:HF[69Y>Z49+!-M1BY+V<?<=J;]Z3]W
M123;C=63U=FC](+6^L[U)WLKRTNTMKJ>RN'M9X+D6][:R-#<V<SPNXAN[:5&
MBN+:4K-!*#'*BNA46J_(SPS\>OV@=5\6^,O`J?$^UL[3P]X8_P""A&IQ:_8?
M#_P7%K%YK7[+?Q8_9[\,^!-3N5?39=!5]?L?B;KB^)X8]%5-1ADOY+'[!J<N
ME:KH?Z4_![QC?_$;X1_"KX@ZK:VUEJ?COX;^!_&6I6=GYHL[+4/%'AC2M;N[
M6T2>2686L%Q?20VXFEDE,2)YLCOEC\CXQ>%_B_X3Y'@N(\9QKC,3@<PJ.-*E
MALUQ52O12Q&*PL'5BW3OSSP&(Y6EI&*<U'FC%[Y=C,NQTYT(X:,9PU]ZG!72
MC3;L_)3C?RO:^K/2J***_F)>(GB!=/\`UFSVZM9_7L7I\/\`T\]/2[[Z>U]3
MPO\`T#TO+W%MT"BBD`(ZG/X8H?B)Q_)\T^)L];;2N\=BVWK%K_EYY+>V]NM@
M^IX7_GQ2_P#`5Y?Y+[D+1114_P#$0N/E;_C),\TM_P`QN*_NV_Y>>2^_[G]4
MPO\`SXI?^`+I;_)?<%%%%'_$0N/O^BDSOI_S&8K^[_T\]/O?R/JF%_Y\4O\`
MP!=+?Y+[@HHHH_XB%Q\O^:DSSI_S&8K^[_?]/O?R/JF%_P"?%+_P!=+?Y+[@
MKY3_`&-XDC^$GB]8U15_X:K_`&[9N,*-T_[<'[0\\A```W/)(S$\%V=B<G@_
M584C`STSD8Z_X8K\_?@Q_P`+>'P/U5OA,=%<K^V'^W$OC2"=;./QB_A1_P!M
MS]H+[7-\.;K7F/@N/Q=;NH-I;>-[-_#UY"\OGW=C-!$9_P"V_"7-N+>*/HZ<
M=86MQ7C,#B9\<<*4Z698['UJ2HP_LWB"52'MG-N*J.G&*BVDYJ*;3U/FL?'#
MX?.,(XT(U%]6K7C"*;ERSH6=GHW:[?E?0^_IKB&W57GFBA5Y88$::1(EDGN)
M5A@A5G*AI;B:1(8HP2TLKI&BLS!3$][9QW<-@]W;)?7$,]S;V3SQ+=W%O;/$
MES-#;,XFEA@>>%)I8T:.%Y8ED92ZJWYZ_'BVT63PQ\`[NUA^(,GB*S_;(_9O
M&MW'Q-BUYO$EMJ-UXYM8;];*;40/#D6G31&>&0?#9AX&EQ+'I1:WW`\Q+=>/
MV\,_M-:A*+9OC/:?MU_#;3/!']J!!>P>#$\<?!:U^&]G;$*+R#PO=?##5M=E
MO8]/"VL^EZQX[NY/,FO_`!'+,95X1<1YAD='-7XH9W1E4QE3`2I5J]:G%5(U
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M^>&H_%+4?ACI'P<UC5_$5E\/M/\`VE_$WQ0^(_CCQ2IT_7O&>F7^I>%UU_X6
MZ):^&M<MK^?4M-T/PG!X7\&>)+[3]!>#2!X;T"PENM%CUP:@]N;XH?&O2]9_
M9VT7QY\1]+\#/XA_8^^+7QW^,^H6/AKPOXLLM-\>_"+Q!^S)/K]K9:AIMK=6
ME[X/%G\6/&.C^7X<A-Y=:-IUM>:;JESJSVVJ0^9@_`KQ4XBQ=660<?XJ&"AA
MZ]>,\?FN(I5:T<!@\5BL;4I4H5)3E3IO+Z].#:4GST.>,'6BBY9I@**A[?"1
M]I[L6H4TTE.5)05]K^\KVTNFUHM?T%I`<DCTQ^M?D_8_M4_&F>U\::79^+M'
MO[OP[\1_^";]GIOB&]\,>'Y;K5?#?[6OQ6\"^`/B);?V/HUW'8:7I']GZY<>
M(O"<5U/>>*=)TO4K6+6=7GOY89=,[#X0?M`?&+6/&_@G1/$OBX:[I1_;A_:.
M_9&U.*Y\-^&["XU_PG\./A)\;OBQX4\=ZQ=:-I6G"W\:V]W\-]#\-7)T"'0O
M"U_I=Y?S2^&_[3G@O;7LG]&?QTCPWCN(Z7'RJ8?!T<UQ"I/-\7&K5HY1D]+.
M<3.,96M?"SA&G&3C.59\BCHVHCG>5NLJ,L(U*4J<?X4;1=2HJ4+[-KF6N]K:
M/O\`IC112#IR2?PQ^F,U_%-?CWC_``]:I0EQ)G?/2J2INV-Q6K@TG_R\TLTO
M6Y])'"X5I-4*5FDU[D=M&NGDON%HHHK'_B(7'W_129WT_P"8S%?W?^GGI][^
M3^J87_GQ2_\``%TM_DON"BBBC_B(7'R_YJ3/.G_,9BO[O]_T^]_(^J87_GQ2
M_P#`%TM_DON$.<<#)KXU^,DEM:?M?_L?:C>3P6L-EX+_`&IWGO;F2.WM[6U3
MPW\,)[J>>XF9(K>&-8$EFDD98XT3?(P5=P^R<'CN1WZ=?;O[]..G-?('Q<Q_
MPV'^QUZ_\(I^U!CZ?\([\-,_TK^C/HU\5\7YYQQB<NS#B'.)8>OP_GT&ZN,Q
M,HTY?V3B53J)3G92A*TXMV<9135F>-G%##T<-"4:-+F56D](I7M5IWO;NM+6
MV[GTK'X^\#S:--XDA\9^$Y?#MO=?8;C7XO$FD/HT-ZRQ.MI-JBWAL8KPK/`R
MV[W"R[9XV"XD3=>'B?PV3`!XBT(F\TV#6;-5U;3R;K2+EXXX-6M2)U^T:9<2
MSPQP:A%YEK*\T2QRNS*K?GE\-O#UU9?\$Y?B=X'N["&W\0-H?[5_@6/0&6`3
M_P#"8:I\4/BSX>T+PY%!$TB/JU[KM]IFFZ3;1%I;N\N[%;,M]H@+<K\4+/Q3
MX(^*FI_$[0$\._'G]GCQ3^U)\*(_BIX*O;9[+XU_L[?&W0O$GPV^''A7QC\,
M]8ABOQXN\'2W]GX2D\2_#R]L;+Q':>&-6NKCP;J=YHWB+4-)A_H'AGP7QG%/
M$.:91+Q7S?+L1A\ZS/`T88G&U:4<1#!UL#&$HREB?9TJE=8BK.FJTX4W*BJ,
M*M2I42/-KYE'#TJ519?3FI4J<Y<L;\K:3=[1NU'E2LE=7O9+4_2[0/&G@_Q6
M\\?A?Q;X8\2R6RK)=1>']>TO67@1V*H\ZZ?=W#0J[JP1W"J[`A6)!-=/7Y>_
M`OX9?$7XD^`VO=+G\&^";;X4_ML?MU>.?`7B2&_UK5_$NOZA8_M<?M+Z1I_A
M+Q#IEMHOA^+PCX%U2]U5+?Q5!HGB?Q-<^*/"%A%I4-MH-SJ8NM)]!\>FY/PL
M^*'_``U/=?'/2=4'PQ^)AUR]^%DFLW'PUL-"7PIXJ_M_4/AG)\.K:.U:YMM$
M$EUX5C_:#MI/%*:XFEIIR2W"HS_/<4>#V893XA8O@S`>+^;XJ669M5RO&T:=
M?$2QZG3Q+H4ZF'PL<7)8A5(0]K5C3JR]BG).4K1<]*.80G@XXF6`IQ52G&<&
MTE#:%U*32Y7K976KULME]U1Z_H4NG7NL1ZWI,FDZ:UZNH:DFI63Z=8-II<:D
M+V]2<VUJ=/:&1;X3RQFT9)%N/+*D"QI>JZ9K=A;ZKHVIV.KZ7>*[6>HZ7>6]
M_8W*12O!(UM>VDLUO.J3Q2Q.8I&$<L3QMAT91^57PA\%_%/X@7'QJ^#/Q[\2
M:=\._C#J_@7X#C0/'?PZ\,?##Q%\'_B=\(]#L?B!-X`O;KP%XNT+Q;X5_P"$
MWNM<L_'^G_%GPE+;V<&IZ/X4\//\.-6B\":-!<V7J7PHU#QU=_"_0U^'WAK5
M_#_Q@TF3Q?X9O;+X;:7+X:_9:U<>%?&FL^%_#WC)-*\9F^\&Z5X$^(.GZ1I?
MCR:U^#;7_P`2XM!\2,@NKZ7;<R;<5^#.=\/8+&U*/BUC9XS"XW+Z2C7S"I2H
MK#XS!4\73Q4ZOUEQ6';YH.2O*#=-8BG0G5C%1A\RHU7&^`CRRC*4HQAK>,XP
M:6GQ:+3KJTWRN_V/=7GQ*MOB%HUM#/X3U'P!J8U"/4-/AT'6++Q-X;@M=(N)
MK#5)O%DWBN;1M:.HZQ##9CP];>#=-NX++4)KZ/5+J+0[M[WTNO,?#?PV\.P:
MAI7C_P`4^!OAD?C))I=K'XC\=>&O"-C:ZA+JDFEQZ;J*:3K^HVUQXJ.E_9?,
MTZU^WZH]U-I:Q07`CB)MU].P<C^6.N>G^>]?S%XG^)7$'US*LOR/BS-L4\KR
MZE@L=BL/[3!TJ^+HS<9RBZ&)JK%1^&,,7-4JE:*4JE.,KRE[F"P=%0J5)X:G
M'VLW.,7:34&HVT:7*[IW5VH[)M:(HHI,CGVZ_P`Z_+/^(A\?:?\`&29[I;_F
M-Q7]W9^TTO:/3J^QV_5,+H_84NZ]Q?UV%HHHH_XB)Q^]?]9L\>UG]=Q>OPV?
M\3RC]_W/ZIA?^?%+_P``7E_DON"BBBA>(G'\;/\`UESW1II_7<5I\/\`?ZZ?
M>_DOJ>%_Z!Z7_@""BBBJ7B/XA/;B?/WMI]?QC_EM_P`O?./W^8?4\)_T#TO_
M``!!1110O$;Q!2=N)\^7-O;'8KWMEK^\UU2];W[!]3PO_/BE_P"`(****E^(
MG'[M?B7/7MOC<4_Y;;U/3[V/ZIA?^?%+_P`!7]=%]P5_$;_P=C01S?&+]CG?
M&K[?AI\4\;@#MSXH\*YQG'7`_*O[;P,$XX!P3V`P?UW$X_R:_B7_`.#L#_DL
M7['?_9-/BE_ZE/A>O]*/V7W%W%.;_2#I8;-<XS/&X;_5_/9JGBL37J4FXY3B
M'!\LYM732:OLTGZ?'\9X>A2RISITHQDZM-/E45;WZ=[K[M;]7H?T1?LY?`[]
MLWPM^SC^R_X*\6_L`_LV_$C6_A'^SS\(OAGIOCO7/VD_#4VI:A8>%/A]X?T*
M:^L(=6_9ZU:_T"SUJ2Q?4FT6/5;J.V:[:"6XN9$>>7UM/@W^TY$FIQ1_\$P?
MV4(X=<MX[36HH_VA/`BQZO:0ZBVK06NJ(/V:@NH6\.J.^I107:2PIJ!:\55N
M/WE?L%\.M6T72?A5\-Y]7U33-+B7X=>$[MI-1OK:QC6U@T30[6:X9[J:-1!#
M<W]C;R2EO+CGO;2)F#W$*OZ!=:II%E=Z;87NI:=9ZAK$EQ#I%C=7EM;WFJRV
MD)N;N+3K::2.>^EMK=6N+A+9)&AA!EE"Q@M7^].=_1"\-\^S7,,XQM/%_7,R
MKSQ&)E3Q5>G&<ZE7VSM&$XI1C5ES)6LG=[V9^5T^(,=2IPI0<.2GRI:)NR2C
M>[6_*O*Y^,#>"/VQ9-<M/$I_X)V?LZ/XCL(--M;#Q`W[3GA9M;LK;1D>/2K:
MUU8_L[_;[>#2D>2/3H8;A([".1X[58U8BMVWL/VZ;35K[7[3]@SX(VFO:K''
M%J6MVW[66BP:OJ$<*0PPI?:E%^S\MY>)#%;011)<32+'#;P1H`L,:+^G?@[X
MW?"#Q]XA^+/A7PA\0/"NNZ_\#/%B^!_BQIECK.GS7/@?Q*?!OA7Q[)IVNI'.
M38FW\,^,]!N[N:?9#:W$]U87#QWMA>P0><?&6RU#Q)\0/V-?%7A&SO?$7A[0
M/C]KWB/Q+KOAJ*?5],L?!.N_LN?M%^#+#5M1OM,6XA?P_>>//&'@&T,H>6U%
MU=V&KS*MCI5UJ%C\U6^@OX0XA)XC!XNK+EA'W\;B6K14;*WM=5%<UE;IIIOL
MN)<R7+[T4D[KW4K[7=K6N[?\'8_/IO#/[:;VMS8O_P`$^?@`UC>:_<>*KNR/
M[4OALVEWXGNR[7?B.YMS^ST8IM>N'=C<ZQ*CZC<,6,MRQ9BQK7AC]M+Q'!J-
MMK__``3W^`&OP:MHL/AO5+?6_P!J7PWJ5OJGAVVNFOK?P_J45[^SS<1WFB07
MLLMY!I=R)K".Z=[A+=)G+G]6+_XQ?"+3;^\TFZ^)OP[BUJPN[G3KK0YO'/A.
MVU>/5+6:2VETF2RN]8MY+?44NT>S>UNOL[Q7(:&?RF5]ORYX3_;X\!>*/"7A
M[QK<_!_XU^%="\5_M%_%[]E+P]-XDB^#P?4?CC\'/B[\6/@7J_A-_P"P/C'K
M]OIMMXJ^)OP<\4^'/!7B'6+G3_#^ISW_`(9;5=2T0:W&L,T_H*^#]*O3Q,,#
MBX5Z<HSC4CC<5SJ2E":DFZKU4DY)[WNT](W7^LV9--.<;6VY8Z[+72[6GY]#
MX:T[X+?M,:5(;C3?^"7W[)VFS&UU2Q^T:?\`M`^`K28V>N0+;:U9A[?]FF)_
MLFL6RBWU6WW^3J$*K%=I-&H4>C:-;_MX>'=+L-"\._L)?!70-#TN`6VF:/HO
M[6VCZ7I6G6REF2WLM/L?@!:V=I`K.["*"&--S,VT,Q-?4_[-W[=/A3]JKX6?
MLV?%[X3_``1^.=[X4_:5\)VOQ#TV/6(_@KI^K?"?X;ZI;&7P]X\^,%I!\:KZ
M#1M(\4W27.F>&M'\&W?COQGJU]INMM#X6%AX?UV^T[T.Z_:J\)7/@OQK\2?`
MW@'XE_%3X=^`?$_BWPEK7C/P!9^"+K2[O5/AYXNG\#?$N70;3Q)XZ\,Z[K^F
M_#SQ-IGB?3?$6I:5H]U:2S^#_$J>'Y-<EM+2._6<?03\&N(J$,+G.7XC,<,G
M&2HXK%XFK24D[WY75233G-I^<MKN]4^)\RHS4Z<HPE=7:24G?D3^6BWMHV?%
M/]I_\%"/^C*?A5_XF+8__.&XH_M/_@H1_P!&4_"G_P`3%L?U_P"+#\?CUK]:
M[S4=)TYX(]0O]/L9+ID2V2\O(+5[AYKRST^-(%GD1I6EU#4M/L46,.SWFH65
MLH,UW`DE9M>\.K#K5RVMZ,+?PV\T?B*<ZG9B'09+>TCU">/6I3/LTMX+">*]
MF2^:!H[2:.Y<+#(KM\I_Q3;^C=_T2&&Z?\O<1_=_Z?>OW/?[6_\`KCG7_/\`
M[?AR_GRZ_P"*7<_)W^T_^"A'_1E/PJ_\3%LO_G#4?VG_`,%"/^C*?A5_XF+9
M?_.&K]8KK7O#UE9+J5YK>C6FG.)RNH76IV<%DPMBZW16ZEG2`BW9'$^)#Y11
MQ)M*G$]]JFD:6U@FJ:EIVG/JM]%IFEI?WUO:-J.IW"220:=8+<2QF\OIXX9I
M(K2W$EQ(D<C)&RHQ"_XIM_1NNO\`C#\+;2UZN(NG[KU_>NZT;\^5[_:?^N.<
MV_CNZMT5G;EW_P#`7?OS/:Y^2W]I_P#!0C_HRGX5?^)BV/\`\X;BC^T_^"A'
M_1E/PI_\3%L?U_XL/Q^/6OUHN]6T6PGBM;[5-,L[J>:PMH;:[O[6VGFN-5EN
M8-,@BAFE222;49K.]AL(D4O>2VMU';K(\$H11JFCG49-(74]..K0Q6\\VEB]
MMCJ,<-XEX]I-)9"7[2D5TFGZ@]O(T02=;&\:(LMM.4:_9M_1NT_XQ##=/^7N
M(_N[_OGY]]GO]I?ZXYU_S_[?AR_GRZ_XI=S\EO[3_P""A'_1E/PJ_P#$Q;'_
M`.<-Q1_:?_!0C_HRGX4_^)BV/Z_\6'X_'K7W'X!_:8\,^,_CAX_^`&J>%==\
M#^./AY\)?@#\6K^?Q!K'@B^T#7]/_:#\3?M$>$?#WA[PMJ/AKQ5KDNIZ_P"'
M-:_9H^(-OXCM;FST\!6TZXT@ZG:/<W$&SX9_:$\(>(/C!\>O@]>Z1K'A2^_9
M\\/_``J\2^*?%?BBZ\-V7A36=(^+-EXROM&O]#O;37[ZZ@L],3P7J=OJ\GB2
MST"XBNG006DUGY=Y,?\`%-OZ-W_1(8;I_P`O<1_=_P"GWK]SW^T?ZXYU_P`_
M^WX<N_KRZ_XI=SX#_M/_`(*$?]&4_"G_`,3%L?U_XL/Q^/6E_M/_`(*$'_FR
MGX4_^)BV/Z_\6'X_&OTA^-WQJ^&_[//PD\<_&WXI:Y;:#X!^'_AS4/$NMZ@T
MUKY]Q;V5L\T&FZ3'<W5K!?ZUK$XBT[1;`7,1O]1NK:V65!*9%N>`/B)!XRM1
M_:FEV7A;4[R^UT>&[(^,/!OBBV\<^%]'FM(XOB!X*O/#&N:C/J/@_4DU&S\J
M76-.T#7K"Y=K?5]!L$EL+B_%^S:^C=I_QA^&2T7\3$=.6_\`R^UZWUZ.VC7,
M?ZXYU;_>'?3IVY=__`==.LN^GYHOJ/\`P4)V@Q_L3_"IV`.Q7_;&LHP3T()'
MP&?\RIQCIW'D'P/\"_\`!1CX2^#-<\+:I^Q_\'];N-6^+O[07Q,CO[/]KRVM
M(H;3XU?'KXD_&2PT5H)?@5</)-X<L?'EMX>NKWSECU*YTN;4H[>SBNTLK?\`
M<M-3TI[]M+34=/?4U2:1M-6\MFOU2UCL);F1K02&X"V\6KZ5).QCQ%'J6GO(
M56]MC)2F\1^&K<79N-?T2`6%M/>7QGU:QA^Q6EM?7&F7%U=^9./LUO;ZE:76
MGSSS;(HKZVN+5V6>&2-?J\%]!#P.RWAG'\)X+(*=+)LRQ^#S'%X2%2HHSQ6!
MI5Z5"HI<[FN2.*K)I-;JWGS/B?,Y5X8B5:4JM.#A&32^&3@Y1T233Y$GUM:[
MW/Q^\1:'^V[XPALK?Q9^P#\"/%$&FWT.IZ=!XC_:K\/ZW#I^IVS;[?4;*+4_
MV>[I+2_@;!BN[<1W$;#,<J\$W9;?]O"XU6WUV?\`82^"TVMV=N]I9ZQ+^UOI
M,FJVEI)YV^TM]0?X`&[AMI/M$V^"*9(G$TNY#YC9_7+4/$GAO2)+V/5M>T32
MY--T:Z\2:C'J.K6%D^G>'['S!>Z[>I<W$36NC6GE2?:]4N!'8V^U_-G38V/E
MO0_VV_@;XM\1_LXV/@G5AXP\$_M._"KX@_&+P%\7=%U;PL_PXT_PC\/-"\`^
M(M17Q'?W'B"'7-.U?4M)^)'AZ]L+8:#+8VT$6IC6=2TN\MK:SO>:/T"?!-8>
MGA%E598:E?DHK%XKDIN;I\ZBO:]XJ[3^RKWLD:/BG,KI\\>9M-OE2;>BLN^S
MMIUL?#K>&OVU9/%,/CB3_@GU\`7\:V]L]C!XQ?\`:G\.MXI@LI8&M9+2+Q`W
M[/+:O';26S-;O`EV(GMV:%HV1B*EB\/_`+;%O<:E=P?\$_/@'!<ZW!>6VLW$
M'[57A^&XUBVU)VEU*WU2=/V>A)?P:A*6>^ANVECNW)>X61LL?V,O-5TC3YM-
MM[[4=.L[C6[MK'1X+R^MK6?5;T6L]Z;/3(IY4>_NA9VUU=FWM5EF%M;SW!3R
MHI''BGQU_:$\(?`23X5VWB+2]8UR]^+/QA^&OP=T:QT"Y\."\TC4/B;XKT_P
M?IWBK6;'6==TG4)O"FE:OJMA;ZQ=:#9ZYJ-O-?6,?]G>3/)<V]R^@9X+UJ=.
MC5RRM*G1@J5*$L7B>2G3BTU&-ZMDDY3:MIO9=Y7%&91=_:*[:;]V-VVTM=-G
M9VT72Y^.GQY^`W[>'QUO/`M[JG['?P?MT\#/KB6^@:]^TI\,?B#X,U>V\1/H
M`OIM3\)_$']E?Q+8P^(=,M=`%MX3\4:/-I6J:#%JNNVLO]J:3K.HZ7<]_P"&
M/A?^U[X2C\-/I'_!.G]G6UU#P?I.IZ)X:U:+]I[P?!JFAZ7K5S?7FM:9HMU8
M?LV6*:#I.J76IW\ESHVAP:9HP2ZFMX--@M=MNO[8:]K-EX=TF]UB\V-%;1@0
M6IO-*T^;4K^=UM].TBRNM<U#2=)34=7U"6WTW35U#4]/M9;^ZMXIKN!)#*GD
M?P`^/_@C]H/]GK]G[]H[0XKKPEX2_:-^$_PH^+7@C1O&5SI.G^(K33OC#X)T
M7QUX:\-ZI'9ZA?:;)XG@TW7(+.]L=)U'4X'O[>Z2PNKV!%GD]^'T,/"ZGEV$
MRRG0Q='"8)5(X>E2Q-:G&FJM_:).,E)J2G-2NV[2:ZF3XAQSFYMQYI-7?+&[
MY>6W3=<J]#\JIOA5^U5/I\6DS?\`!,W]EN?28!IGDZ5-^T9X*DTZ(Z+?ZCJ>
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MJKM.G^[GHTXJS;13XDQ]U*\+JS4N17NN5ZZ=&KJ^J>NBN?FC_:G_``4(_P"C
M*?A5]?\`AL6Q_+_D@_MGIVZTHU/_`(*$'I^Q1\*03U_XS%L1^>/@-BOTE^$'
MQ<\)?&/X;_"[XC:'(NE1?%;X9^`_BEHWA?5[S3E\3Z=H/Q!\-0>)]'AU.PL[
MRZ47,5I)=V\\MK)<64ESIVH"UN9XK620>J[%_NY_R?\`']?K7PDOV;WT<*E2
M4ZG".&E*4N:4I5<1S-OE=V_;:[.]ENG:_7J7&.<JW[_16TMT7+_\C^,N^GY"
M_P!I_P#!0C_HRGX5?^)BV/\`\X;BC^T_^"A'_1E/PI_\3%L?U_XL/Q^/6OU[
MV)_='Z^_^)_,T;$_NC]??_$_F:7_`!3;^C=?_DD,-T_Y>XC^[_T^]?N>_P!H
M_P!<<Z_Y_P#;\.7\^77_`!2[GY"?VG_P4(_Z,I^%/_B8MC^O_%A^/QZT?VG_
M`,%"/^C*?A3_`.)BV/Z_\6'X_'K7Z][$_NC]??\`Q/YFC8G]T?K[_P")_,TE
M^S;^C=?_`)(_#=/^7F(_NK_G\]N_D[7MJ?ZXYU_S_P"WX<OE_=U_Q2[GY"C4
MO^"A)Y_X8I^%/_B8MC_\X;V/Y5\^>//!_P#P41U[]H3X`?$)/V0/A#91?#OP
MW\;+`Z%)^UU:RRZY_P`)OI_@2Q%S'J"_`V./3AHHT8R-"UE>G4?MZ@2V'V5C
M<_OX$4CE0.O^<CKU/7U-<!KBJ/B#X"ST.E>-N"#VB\/=>_6OH,A_9_\`@'PU
MBIXS)^&Z>#Q%3#5\+4J4ZM=2]EB:/L*JNZC?\.<O)M6E=.SQJ\5YM6A&%2MS
MI2BU=+>,HN[TZ<OEKOJ?E*VC_MPMK`\1/^P)\"F\0;ED&N-^U=H+:NKI$ENK
MC4S^S\;T2+;QI`L@GW&&-(\[%"BFOAC]M)=5FUT?\$]OV?QKEQ+<7%QK0_:D
M\-?VK<3W<;174T]^/V>3=RRW,3-'<2O.SS(S),TB.PK]I`J$LN!QCCTR/SY]
M\]_>C8"0<<<Y![YZ=\C'Z@X(].B'T#O!>C76(HY97IUE:7M88K$1FG>,F^95
M-^973U>E[=&GQ1F;BXNHFK6U2=_AOK;5-*VG_#?B]X4\._ML>!K*?3/!G_!/
MSX!>#].NKJ:^NK'PK^U/X=\/65Q?7#L\]]/::3^SS:02W<[NSS7$D;S2,S%W
M=BS-TS:C_P`%"'!4_L4?"A@P*G=^V)8L"K?>5@WP&(92.&!/S#@\\U^OFQ/0
M<^_7_'O1Y:?W17)6^@!X&8C,9YM7R6I/,:D_:5,9+%XIXB<W:\Y3]M=WUNVW
M>S>O5KBK-%2C252*A'11Y4DE:-K*R[=MWWV_$JY\!?M?7FCGP]>?\$X_V;KK
MP_\`;[?5O["N/VF/"<^C_P!JV@D^R:D--E_9T:Q^WVWF.+:\\@7$(=MDJ[F-
M=S'J/_!0=`J)^Q-\)DC0*B(G[8=@JHB@`*JCX#*H10``H`P``H`%?K[M7T_G
M2;!SE>G0YSU_E_GK6V-^@1X)YA16'QN4U\304G)4JN+Q+@FU"+E;VU[R44G=
MWM!7O97(<59E!J4:D5)))M1C=I):7279Z+H]MC\A1J?_``4()Q_PQ3\*O_$Q
M;+_YPWM2_P!I_P#!0C_HRGX4\_\`5XMC_P#.'XZ=^M?KUL3^Z/\`.?\`$_G1
ML7^Z/\Y_Q/YU\_\`\4W?HWRUEPCAF]+WJXA_R-IOVU^COUTZWUV7&.=*W[_:
MW3MR_P#R/EO+OI^0G]I_\%"/^C*?A5_XF+8__.&XH_M/_@H1_P!&4_"G_P`3
M%L?U_P"+#\?CUK]>O+7C\<^_7_$_7)I/+7CI[\=>O^)_,^M3_P`4V_HW7_Y)
M##:-/^+B/[NMO;>3Z='O]H_UQSK3]_V_]MWZ?9UMWE;<_(;^T_\`@H1_T93\
M*O\`Q,6Q_P#G#<4?VG_P4(_Z,I^%/_B8MC^O_%A^/QZU^O>Q/[H_7W_Q/YFC
M8G]T?K[_`.)_,T+]FW]&ZZ_XQ##75G_%Q&GP_P#3Y^??9[_:/]<<Z_Y__P!>
M[W3_`)>O>7<_(3^T_P#@H1_T93\*O_$Q;'_YPW%']I_\%"/^C*?A3_XF+8_K
M_P`6'X_'K7Z][$_NC]??_$_F:-B?W1^OO_B?S-"_9M_1NT_XQ##='_%Q']WI
M[9]GWO9[_:/]<<Z_Y_\`;\.7?UY=?\4NY^0G]I_\%"/^C*?A5_XF+8__`#AN
M*/[3_P""A'_1E/PI_P#$Q;']?^+#\?CUK]>]B?W1^OO_`(G\S1L3^Z/U]_\`
M$_F:%^S;^C<O^:0PW3_E[B/[N_[Y]GWV>_VC_7'.O^?_`&_#EW]>77_%+N?D
M)_:?_!0C_HRGX5?^)BV/_P`X;BC^T_\`@H1_T93\*?\`Q,6Q_7_BP_'X]:_7
MO8G]T?K[_P")_,T;$_NC]??_`!/YFA?LV_HW77_&(8:ZL_XN(T^'_I\_/OL]
M_M"XQSI?\O\`M\[<N_KRZ^LNY^0G]I_\%"/^C*?A5_XF+8__`#AN*/[3_P""
MA'_1E/PI_P#$Q;']?^+#\?CUK]>]B?W1^OO_`(G\S1L3^Z/U]_\`$_F:/^*;
M?T;O^B0PW3_E[B/[O_3[U^Y[_:/]<<Z_Y_\`;\.7R_NZ_P"*7<_(3^T_^"A)
MX'[%/PJS_P!GBV7_`,X:OYQ/^"Y7_!.[_@HM^W3X^_9_\0I\&O@I\'U^'WA#
MQOHOV2]_:'D\<OKIUK6M#OC<K-8_"SPR--^PBS$+PR1WIN#,'2:,1%6_NUV@
M'ID']./US^E?GA^V[C^V_A_MZ?V5KO\`Z6:?_6OTOPM^ACX/>$/$4.*."\CH
MY5FT</7PRKP=2HG2Q-+V-6+C4E--.$YJZ2=]==WQXWB/,,?1]AB:SG3YHR;E
MY<K5VEU<>G=7O<\%^-G[.WBWXL_%O]G/QY9?L[Q_%GP'H_\`P2Z_;(^">O\`
MB2YE^#4EG_PL[XSZ[^Q/XH^#7@^72O'_`(VT'Q#>O<V7P7^*CP:TFBS>%O#%
M[K=D+W6]/_M[4IK7SG1_V2_VNO&'[.7Q?^$WCW0=9TKQ]\:/V*?V2/AY\+_B
M3JOC/P!K&N?LR_M!?![X?:GX=UB_\0W&F^+-7N+N?X;?&4:9^T1X.\8_#V]\
M=+XAUK5M=MFCTS5M&TT:_P#JY\,O!EU=?#?X?7*^./&]HMSX(\*3K:6E_HZ6
MML)M!L)!;VR2Z%-(EO"&\N%9)99%C50\CL"Q[?\`X06[_P"B@>/_`/P9:'_\
MSU?UV>"?E#\6?V>?VHK#Q;^V-XH\"?#'7O&>D>,/^"B/[,W[7V@>$O#7Q4\)
M?#VZ^/OP8\"?L>?LD?`+QQ\-]`\32^-_#NH>#?B?X3^(OP/U_P"(GAVR\>2^
M"?`^OWGA;P):_P#"P=/BU[5+_P`-?H-^RE\.M$^'/PRU&'0/@UXT^`5MXW\?
M^./BAJ'PQ^(GQ)C^)_C;1_$WQ"UF3Q%XOU'Q+J^E_$GXN^#=(U7Q'XKNM9\0
MW7AWX>_$7Q-X.M7U/^T;6[AU?5=9M+?UC_A!;O\`Z*!X_P#_``9:'_\`,]7E
M?Q5\4>'/@UI-OX@\:^-_C8-`(O+G5];\.>'+WQ;I?A31-,2"35O%'B^[\.>"
MM2C\.^&])CN8)]2U34/+CM++[9JCI_9.DZU?:<`?.?BS_@GSK'B'XC>)OB3#
M^V?^TCI":YXUUGQQ%X!T;X'?\$OK_P`/Z8FI:[<Z\GA#2M?\9?\`!/;Q!\3;
MS1K(3C1;'6/%?Q,UOQW<6445[KGCK4O$#W7B"?*_8M_9\UGP)\+?&'B#XT_`
MGQU9?$W0?VROV^/C]\/?!?B7X@>#/&42:=\=?VQ/VE/BU\+_`!;X$T'3/C!X
MF^$?A+Q?J/PB^+FFZ?<WMQ=^%-<T74]<\4:=J%W;O>ZK>7WWK_P@MW_T4#Q_
M_P"#+0__`)GJ/^$%N_\`HH'C_P#\&6A__,]0!^'G_!+OX!?MF?\`!/3]F+]D
MKX>:O^SO\4/B%I_C+P%X"\&?M.?!Z/XG_L]:GXL_9L^+/@?P!IWA*7XQ^!?&
M7B#XYV?A7QS\'?&FF>&?#'AWQ#\+O#OBO5/$'A+4]-@\9^!='CM-4\0>$KG[
M:_8R\`_'3]DGX6P_LI7WP5\1^.=(\"_$#XPW7PX^/6E^./AI'\-O$?@#XA_%
MKQ9\2O!MSX\L-?\`'MO\:-`\:>'])\;?\(YXXL]*^&GC33M0UGPU>ZWH7B'4
MK;7;6VL_NG_A!;O_`**!X_\`_!EH?_S/4?\`""W?_10/'_\`X,M#_P#F>H`_
M/_\`:Q_9F\>?&S]L+X3^,/#?PVL_^$>TG]@S]NOX,#X]:E'\-[_3_A;\</B[
M\2/V-/&7[/>K-H>K>(XOB1?WGA.\^"/Q'\2Z7K?ACPCJMGX4UFYTMX=3L+O6
M[V>S^=?@O^RI\1[O]GYM*\<?LJ_'CX#?M(:!\)?V:?V?O%7Q.^'W[6?@;QC>
M>*+CX/\`Q=\*^,/#WQ=_9[C\6?%#QS\/KWP?\*?$L_C'XT0:;\?OA=\-_&'B
M:WEU/X4W7P\\4:%XPUO3[S]BO^$%N_\`HH'C_P#\&6A__,]1_P`(+=_]%`\?
M_P#@RT/_`.9Z@#\99OA1XCTGX[_\$X_"/[1/P+^'/Q#\=CP1_P`%,+'Q;X;\
M%^#_`(;VNA>*=%UWXA?#?6]&\<:KX5\4^*9?!6@:]\1O#^I:3X^^)7@O0O%6
MM^&_#GQ$\8>)]%\+76JZ!I]I>OVGA/\`8Q_:#\$?#&W^#7C32K?XX^#O$'_!
M+SP/^R5912^*M#6Q^%?QK\!R_$Q_$-S-=>*KW2-;O/"?Q-TGQY\,_#\?C7PU
M!JOB:V/[/'A[5?$.CB^N-%NX?TXU3X#>#]<\4>'_`!QK5WJ6K^-?"<%[:^%?
M&&J:9X+U#Q3X9MM34+J5OX?\07?A&;5M&@U!0%OHM.N[:.Z4`3JX%==_P@MW
M_P!%`\?_`/@RT/\`^9Z@#\0/VAOV,?VB-:U7]L6ZTGX):K\:OB!XH_X)Z?\`
M!/+X.?"SXYMJWP'T77/B1^TY^SA\3_VL_$7Q'\;Z?<^+?B1H'B7P;XDM--^+
M?POUNU\7>(K+PW%<3Z5?:?H6JW;^'M+BN_M3PW\&_C1:?M=ZC\8%\"ZW+\'_
M`!5/\3-5\:^`?BIJGPH\6W'A'Q6_@/PYX,\.>-/V<_%V@>(I/&6A0_&#0=`T
MGPY\6_@U\2)+[X;P7^EVWBCPOK/A:[T,_P#"=_=?_""W?_10/'__`(,M#_\`
MF>H_X06[_P"B@>/_`/P9:'_\SU`'\^?P8_X)R?'K4/@;\2_ASX_^!5C\/?&G
MQ$_X)D?LP_LK?"GQKJ^L_!KQ%??LW_M"?!7XP?M[>)E^(]M<^%_&?B>XTE_`
M#_M$_!KXF^`]:^'3:]<WFI^$+VR<Z+K&C:=!=?0/[0'P+_:OD_;A\;?M!^#/
MV?OB/\2O@QHWB_\`9PU/6/`W@SXS_"OX8^+OC;X>\'_!/]JOX9^(+KX>:C>_
M&?P4(?$'PT\8?&7P-XML_"WQ;UWX6>%_%NDVNO7-EXD3Q#H.@6=_^Q?_``@M
MW_T4#Q__`.#+0_\`YGJ/^$%N_P#HH'C_`/\`!EH?_P`SU`'P#^T+^SEXEM_^
M"77CC]F3]GGX&^(K36I_A#'X&^&7P+'Q.T7Q+KWABPN-9MKG2/"FH_$?XL?$
M:/0KB;PSI#);:CYWQ%U?1-+:SET3PCJ^MZ)8Z--<\]XS_9O_`&@OB#J/Q_T6
M_P!)O='U'XA_MG_LF?M1?!3XS2:]X-:\^%'P]^&4?[,$?CKX<:C866O7>OZ1
MXT\.:;\*/C/X:@TKPQ8>*/AUX]T;XF1VFJ^)WL?&_P`0K/3_`-'_`/A!;O\`
MZ*!X_P#_``9:'_\`,]1_P@MW_P!%`\?_`/@RT/\`^9Z@#XU_9%^`^H^`?VA_
M^"A'Q-\6?`:Q^'7_``MO]K'0_B-\&O&MY!\*;W5?$_PXO/V,?V/OA%XQO-*N
M/`_B?Q-XA\,0:M\7O@AX\U/6M%\46_AJ_P!:^T:1XDN+"\N-2N&L_P`W_!G[
M#_Q@LAX._M?]C3[-:1^(_P#@N(OB?3KC4OV9;D2>#_VM?VLO%OQT_91T?48;
M3XJW5GJ6F^(?#&J:`FGZ1'+>6OP^\1:>MOXEA\,VUE;:DW[U?\(+=_\`10/'
M_P#X,M#_`/F>H_X06[_Z*!X__P#!EH?_`,SU`'XQ?\$__P!E_P#:`\&:A\(=
M&_:[_9L^*6J_$CX7^+=+^-'@?]I>]_:8T#4?!GA.]UC]G+3O@_K/@/Q9\/O!
M7QRO=;USXC^%=+U'Q+\)(]+3X>>.?@SXH\&6/A[XAS_$./Q3I^F>'=,N?`3]
ME7XS^&O`G_!(KX?_`!A_9=U'Q5I'[('[#7CC]G[X\Z?J>N?L_>*O#5O\0-)^
M"_P`^'FBKH^G:K\49!XGT7QOK'PN\3/X9U*'3,V6FWVDS>,[;PC-=7MM8?LC
M_P`(+=_]%`\?_P#@RT/_`.9ZC_A!;O\`Z*!X_P#_``9:'_\`,]0!^('P:_8]
M_;`E_8YD^"?Q<\!:D_C3XD?\$AOV5/V4=*GUOQ_\/M0U']GO]J[X&_#KXK^&
M/&NN^(M<\/\`C35_,T_6?B%XQ^'GQ.\*_%3X3ZQXU\3_`&_P1+>7^GZ-K/A?
MP6NH>O\`Q,_9]_:DU3QW=^'=9^&.M?&6UT__`(*!_L@?M/\`A+X[1>)?@_I6
ME6WP>^&'AKX+^&/&OAN[\.^(?''A_P`9^'O'7A+4O!GQ)UD:%X=\)WWA+Q!H
MOB]-7T7Q(_B?Q-XE\+Z9^L'_``@MW_T4#Q__`.#+0_\`YGJ/^$%N_P#HH'C_
M`/\`!EH?_P`SU`'SQ\>?#'Q9/[07[.WQ$\.>`=0^,7P=T+P3\??AM\4?AEI.
MK^!+"_TOQ5\5;GX-S_#OXU'3_B1XF\)>'-:TOP%X:\"?%OX<Z_9Z;JMSXQ31
M/C=?R>']#URR.NV#_ECX"_8W_:!\/_L[_L+?!OXX_LP>/OCK\--,_P""7?PP
M_89^//P8\`_M&>$_AAJ_P=^+'ACPQX%\/>,O%VK:YI7QH^'VD>*OA?X_L]#&
MG:_XK^&'C3Q5\3/"(\`^#=;\)^`?$.I7SIH7[J_\(+=_]%`\?_\`@RT/_P"9
MZC_A!;O_`**!X_\`_!EH?_S/4`?F?=?!/X_^"_&W[8+Z;\";SXB^'?C'^WQ^
MRQ^T#X2UZP\;_#JXU&T^&W@C]DS]C#X,Z_XR\)V/Q!\?Z&=0^*WPJ^*O[-VL
M^)+72?BE':>'[[0Y-%\7Z;)\2-?MY/`%]\YZ?^RO^TWH/PR_8QT*?]G7Q9XA
M\4_`_P`3_P#!133O$]S:>.?@+/>^'_!/QG\+?M!^'/@U;:=JVM_%G1S>:)XG
MC\:_#V*UTC27,GAVQLXT\2Z3X>_L:.VA_;S_`(06[_Z*!X__`/!EH?\`\SU'
M_""W?_10/'__`(,M#_\`F>H`_)O]D7]FG]I7X<>-OV6=<UWX=Z[X6\*>$?!'
MPJ\*_'#P%\6O$?P=\<Z%X3\8^!?V%O#WPF/QV_9R\1_#[Q7XA\:^"?'5_P"+
MM/T[]G?XA?#;5+W7?A;XT\#:7KWQ;T(>&/$[1WGC_P#8W0M1O-7T?3M3U#0=
M6\+WM]:17%UX>UV;0[C6-'FD7+V&HS^&=9\0Z!+=VY^6632-<U2Q9N8+V9?F
MKEO^$%N_^B@>/_\`P9:'_P#,]1_P@MW_`-%`\?\`_@RT/_YGJ`._HK@/^$%N
M_P#HH'C_`/\`!EH?_P`SU'_""W?_`$4#Q_\`^#+0_P#YGJ`._HK@/^$%N_\`
MHH'C_P#\&6A__,]1_P`(+=_]%`\?_P#@RT/_`.9Z@#OZX#7/^2A>`?\`L%>-
M_P#T5X=H_P"$%N_^B@>/_P#P9:'_`/,]7$:SX,ND\=>";<^./&\C3Z;XQ87$
ME_HYN+<0QZ$2ENRZ$L:I/Y@$XDCD+"./88\-N`/=J*X#_A!;O_HH'C__`,&6
MA_\`S/4?\(+=_P#10/'_`/X,M#_^9Z@#OZ*X#_A!;O\`Z*!X_P#_``9:'_\`
M,]1_P@MW_P!%`\?_`/@RT/\`^9Z@#OZ*X#_A!;O_`**!X_\`_!EH?_S/4?\`
M""W?_10/'_\`X,M#_P#F>H`[^BN`_P"$%N_^B@>/_P#P9:'_`/,]1_P@MW_T
M4#Q__P"#+0__`)GJ`._HK@/^$%N_^B@>/_\`P9:'_P#,]1_P@MW_`-%`\?\`
M_@RT/_YGJ`._HK@/^$%N_P#HH'C_`/\`!EH?_P`SU'_""W?_`$4#Q_\`^#+0
M_P#YGJ`._HK@/^$%N_\`HH'C_P#\&6A__,]1_P`(+=_]%`\?_P#@RT/_`.9Z
M@#OZ*X#_`(06[_Z*!X__`/!EH?\`\SU'_""W?_10/'__`(,M#_\`F>H`[^BN
M`_X06[_Z*!X__P#!EH?_`,SU'_""W?\`T4#Q_P#^#+0__F>H`[^BN`_X06[_
M`.B@>/\`_P`&6A__`#/4?\(+=_\`10/'_P#X,M#_`/F>H`[^OSN_;?\`^0Y\
M/_\`L%:[_P"E>GU]I?\`""W?_10/'_\`X,M#_P#F>KX0_;#T-]'UCP.D^N:W
MKIGTS66637I[.XDMPEU8@I;FRT^P"I(6W2"19"65=I4`@@'H6L_M:>&_@=8?
M!SX77GPP^+'Q"\7>(?V1?'O[16BVWP]MOAR]G?>!_P!GJ?X$>%?B9IXOO'7Q
M)\"P6GB;3KCX[^`M2TRRU`VFEZSILVIQ6.LR:S9Q:1=;FO\`[>/P'T3P%XB^
M*EM-XJ\1?#/P-\-OA5\8?B7XYT#2=.ET?X9_#'XOZ5+XE\.>,O%UKJFM:5KI
MT_2/!<+^//%UGX=T?Q!K/ASP<T.L7>F,MS;PR^3ZQ\+?A]\2=>^"_P`5+C]H
M#P3X.UKP/^QK\9/V7QX6O6\/:B(]*_:2/P%U[QYKFI23^+M(O8/$?AW6OV>/
MAS#X?L6@BM+*V;QI9ZQ;ZI<ZYI%UX7Y?PE^Q[^S#X<^'7BGX5W_QW\/Z]X&^
M*_[.WPD_9H^/7ARXU[P-;Z3\6/!'P:\'ZA\-]"UN2%KZ[NO"_C'QA\,[Z/X=
M?$O4]-O;K3M>\*Z=I0\-Z/X,U[3K#7;8`]/TS]O/PIH7B[]K/1_C)H</PU\.
M?L]_M:_#[]EKP=XFU'Q%X0M-.^(.L_$/]F[]G/X\:/-/?ZQXKT^QT/4?*^-V
MH7ER^LOHFB67A/1[*2749/$2:KI5MW'A7XL:Q^UY\/(/%?[/7C#PIX'T'1?B
M+XT\!^/K'XO?""\^*$NJWO@?74TQSX1O_`_QQ\'^"[G3+SR(O$?AOQIINM?%
M#P;XDT?5=%NX[-FM]2TY_$/B/^RS^SYX^U7XY^(M._:DU7P!XI^,'[0GPE_:
MO\/>*/"/C+X12:Q\'?VA/@_\(/A3\"M%\:^!O^$D\.Z_IVJZ/K_PS^#7A/PQ
MXM\$>.K#Q5X:UK3=7\=VKVL47BB,:1]<?#/Q/X,\#^$[31/%?[26G?%KQ*99
M+O6_'?C/Q1\--+U;6;V6.*(>1H/@:P\*>#O#VF6EO;V]I8Z5H'A_3X=D37^J
M2ZMX@O\`5];U,`\#\4?\%`/`7A_QYXB^&\WP]\3OJ>B>+M6\$2ZS:_'K]@?3
MXWO]-UFXT%]3MO#OBG]L#2O'-DC7$)NH=%\1>!M-\66P*V.K^$[/6$N-'C\H
M_91_;#\?6UG^UGX/_::U@^*?$7P,^(W[0?C'X3^)])T#1=(UWXJ_LU^#OV@/
MC!\%?"%B^CZ':Z)X>U3XN^$_&OPEUOP#XCT[P[IVG6^IV^N_"77Y[2QU/XB)
M8Q?9-_9_LJW]]>ZQ-#^SK/K][=W.IRZS?VGPXOKZ?5[F9[J35+VY=X[V\NI+
MV0W=S.UY'=7$S.[7*2N9:^8=&_9Q^`@O?A5XA\7_`!^\)^(?&/PB^,_QV^+V
MBZYHVM^&?"EEXEM/CY\3-4^.OB3X:>.-(B\3:N^M>`=%^.__``@GQ2T&RT_4
M]$U(:K\'OAC9:IJ.HP6/BJ7Q<`>9?LT?MR^)/"_PY\7ZS^V?X\\*K\6_$/[5
M/[4?PH\'>`O#FI?#;P;X.T#2_@;XDUR-_!_A'Q9XZO\`X;6.O6OAS2K;3M"F
M\6^._$\.L>+M9NM,U.+3M"@U2YTS3-W]HO\`;SBU_P#98A^+?[,%]X[L-:N;
MO]C;Q3>ZW?>#?"MC=^!O"O[1WQA^'6C)X4^(G@[XEYUG1O%5]X#\0:I%KN@6
M7AJ]\1^$+C4=+O+B7396AFK+A_9"^&ELUAXET7]M8^`_BWX;_:(^-O[0_@GX
ML?#E_A#9:MH-W^T?<ZA/\9OA?JGA;XAI\3O!7BWX7>)?MEC+I>F:UH3^)=`U
M/PUX6UN#Q3=ZMHT5W)T/Q._9*^`WQ)N?'VW]KWQ1X9T_XOV'P'E^,%OI_C#X
M(ZO?>/\`QQ^SKXJ\.^(_`GQ0GU/Q)X.U<Z%XSU*S\-:7X<\7P:):6G@_5M&T
M?PW#IOA70QHTZ:H`?5FJ?M7>!M%^-_A[X!:KX4^(VF^,_&FJ^.-#\!7NJ:'H
MND:'X]U?X?\`P]TWXEZY%X4_M;Q)8^(+[1YM!N]3L-+\:7/A^S\`WOB3PKXF
M\/\`_"51ZC8VT5]\C?L?_MI^+OCAX2\'?$WQ9I?Q0O\`QO\`%CPY^TEXE\)?
MLU>&=/\`@E+I5MX#^`_[1,_PXG\<^'_$UWK.@:R^KZ;8>*_AYX(URQ\9?$*.
M+Q1KL]WK?A'PA9V-EJNH#LXOV>/@[;?&S0?CC'^UI?:AKWA+XT?$GXV^%M!\
M1^)OA-K6AV.L?$_X/:K\(]:\*ZE?KI-AXQU;P7I5GJ:ZCX7TD^*K.Y\-6-G;
M>%M&U"ST2WLH[/E_V?\`]E/X)?L]Z=\%KCPS^T]H-YXZ^!^B?';P)H?C62^\
M!6I\5_"[]HCXE:-\7?'?@SQUX>;5[S3-5O-&^(.A:7X@^'_B;1V\/WGAB32[
M+3[RSUW1]3\;Z;XS`/??AQ^W'\,OC+XY^'/@WX0^#/B=\1;'XF?`WX6_M'Z+
MXZTBP\#Z)X0TSX/_`!:U;Q#HF@^)=?B\;>/O"OC*QO\`2-2\-7]KXG\(VWA"
M^\9:;+)%#;Z!?S0:E%8=Q#^TYHL_Q1^.7P?C^&OQ-_X3;X'Z1\&/$4]G)_PK
M6"W^)7AOX\:OXI\.>!/$7PWFN/B3%+)H[>)_`_C3PSJMUX\M_`1MM:\+:S;V
M<>H0V\=Q-X?\%O@9^S]\!/BCX:\;?#WXT>![#PAX._9A^'/[*_AOX?3:SX6E
M2T\&?#+Q!K_B?1/$-YXE3Q!'=7_BN_U3Q/K+:]>2:;%9ZC#+;2?8X=22[U&^
M]@UW0_@!KOQV\"_M`R?%7PS8>,/!/P_\9?#>6PT[QWX6@T#Q?H'BG7/"WB+3
M#XRL7N97UFZ\!:OX=U"^\!3F:&3PY<^,?&$EHP77;Y)@#C(_^"@'[/.I?%NT
M^"_A35M3\=^,[KXK_$#X'/;^#9_".KG2OBI\-?!GB/QAXC\,^)-'?Q9:^+/"
M>G^;X3U_P59^.O%'AO1_AP_Q$MM/\'7?C"SU/Q'X876OG+Q1_P`%-O#VH_!3
MP#\?O`?PK^/NEZ?\6?V-/C%^UM\`]!\86'P+M/!WQ4\&>$/@?\,OC7::IXR.
MD?$GQ-X]\)7>AV/C[2-$M]*2\\+S7M^OC<RZ?XDTZV\%ZS>>H_#3X%?"GX*?
M%#XL^./A#^US?^$?`'Q:^(7COXWZM^SW<^)/A%K/PCL?CS\2HI;GQQ\0K6^;
M1;#XOIHOBWQ9-+\1/$OPYL_BKIWA74?'=[K.KVT6G6>M7^E2>$W7[$'P??X$
M?LT_`.Q_:V\+6GA[]F;]CGXD?L4>'=;GMO!=YK?B7X:_$GX7>#?@U>^)-;"^
M,K6P@\<:/X'\`>&I=,O+"TAT&3Q6=9UB_P##]WI&H6?AK2@#N?`_[;GA3X5>
M);2Q_:+^)_Q;M/$GQ'^$GP!^)^A>%?B1IW[-/A;X9^%V^+NM:[X%T[0O!7B[
MP7)H&IMJ.K^(_!WBOQ5JH^*'C'4;#1?"D-F+?5+?48Y].D]6\)_\%'O@1XYT
M3PW>^%="^)6J>*?&&L?M$^'?"7PV;2/"6F^-_&.O_LQ:CIMG\1='^'YU?QM8
M>$/B?>:M8:QI?BKX<'X9>+?&-M\2/!-S/XQ\)7&I>'])UN_TSP/XA?L7_"#X
MF>*?"'CG6/VP;'PKXY^''PJ^"'P_^&7C;X<3_#G1?$O@/Q/^S]XR\2>,O`WQ
M+TE?%NK>//#6IZQJI\8^*/"7CSPSXE\-:WX,\5^!]>U/0/[$TR2Z?4*];^+7
M[/WP=^/'PLMOA1\9OVKYOB;I%[X?\6Z7XKUKQ3K/P5M]?OO$_B.Y\'7'A[XL
M>!I_"7AWPII_P?\`BW\'1X3E'P3\8_#C3M%'@S4/$FN^*-6TSQ5XSFM_$MN`
M>]_M-?M!:]\"+[]G73=`\!77CBX^.O[17A#X(W,EOJ.D61\,V&M>%O&OC+4-
M:CMM6UC1(]2OI-.\#WFEZ?;?;[:WM;B__M6[>Z73XM&U?YJ_9H_;)\07OC.^
M^%_QHM_'/B#4?B#^W)^U]^S7\'/B=_8OPTTWP8+SX*CXK?$3PM\+]5M?#^L:
M%XN?7(_@W\(O'>MV?BC_`(5Y?Z#J#^$M0LM?\86_B*]TNPU#Z%^.F@?!;XY1
M?"J2^^..A>$-9^#OQC\*?&KPAK/ASQ=X!N)U\1^&=+\1^'9=/U&R\01:SIUY
MI>K>&O%WB+3)D-JEQ:7-U::G;3"6P6&;YN\._LU_##0/%GPK\4_\-1^!KQ_A
M;^VQ\;?VWK*R,'A6!-5\;?'CX9?&[X2^*_!=S.OCF1K;PCI?A3]H;XD7'AZ6
M.*76[?78?!M]J6I:K9:'K&E>*`#MM*_X*A?LG:UIUSXATOQ3J&I>"XO@/\0?
MVD+?QWHTOA/Q'X4;X6?#>Y\,'6]2\07?AGQ;K-_\--5OM"\8:'XQT/0OB]IO
MP]U+4/"2>)M5>&V?P!\0K7PKZAXH_;8^#_@?0O"6L^-1J/A&;XAZQXCTWX<:
M9XF\2_"?0H?B%I_AOP?9^-IO%?@[QKJ?Q+M?A?K'A'5-'U+2HM%UI/'D:7^I
MZI;:?Y,4L5Z;3PGX$_LX?#C]GGX?W/P=\"?MW?$6?X-^'=)A\,_`[X<Z_P",
M?@!J-C\!?!L&LV&I:?X,\+:[%\/K3Q-XW\,^%=(L1X%\":/\6M6\>Z?X<\`R
M+X=N[;7/LEC>6W.R?L=?LX:%HW@.7X._M,)^SW\0?AI\8/BC\8?!'C/X1:U\
M'H-!\+S?&^Q_L[XN?#/0/A3X\T7QW\.-,^#_`(R1+76Y/!J:)+=Z;XWTW3O'
MEGKP\4#4=0U(`^HO$/[97PST/]G'X/?M0VWAKXEZ_P##OXV^)_V:/"?A32K#
MPO9:)X[TS5?VK/B=\/?@_P##)/%OA'QQKGA*\\/R67CWXG^%-'\::;/+-KOA
MIIM0DDTF[_LV[5."\/?\%$_@+K_Q!\,_"M[7Q9I/Q!UGXM0_`KQ+X2FN_AMK
M_B#X8_%:3P6/&-QX9^(&B>!OB-XMU>#3--EDM_!VI_$#PI8^+/AC9^-;NWT>
M3QI]F=]136^.W@CX9?&OX.^"/A)/^TCX=TZ3P9\6/V;OB_)XVUW7O!_BGQ)X
MD\2?LR?&[X=_M">$/[;BM]8\,Z4J>)_B-\+O"_\`PF0TJRTZUE\,W/B'0_#%
MEX8GO=(U30.,^'GP,^$7PG^.?Q.^*GPY_:^\3^&/AW\9/B)=?&;XB?LY0>-_
M@Y>_"W4_C!J.G:-IVM^,]$UW4/"MU\6O"=AXKFT/3M?\9>"_#WQ%L?"OB+Q/
M!-?2Z=;:9K?BS1?$@!T3?\%!/A'<_!#_`(:,T#P=\3O%OP@FG^#4&E>+_#%O
M\.=2L-9?XS_%&?X06EM9N_Q)MDM-=^''C!;6W^+W@O6GTGQ[X$34K&SN_"]U
MK@O-&M/-OCS^V-KTUU=:'\(D\:^"/$OP2_X*3_LP_L??%^QU_1?AS?6GQ!TK
MXK>&O@+\6-6A\(W,NJ>+4C\+^*/A;^T'X-33==NI_`OC32/$<&KV=U8Z/%I\
M=W?YQ_9$_9AN_!GQP\/ZI\?=,E\3_'WPW\"]/\?^/M'\0?##PWJ6N>._V>-;
MU'Q1X%^.^O>&=+LT\$:Y\<]?\2WFFWOQ0\;S^'+>S^(.E>#O`?AB^T&RT#PE
MIEDK-4_9;^$E]JGC?Q`O[7%K?:[\2/VP/@%^VCXPN?$=W\*+ZPD^)?[/WPI^
M!OPFT'1M"L/#2>#I-)\*>)]'^`'@BZ\36=Y?:Q?"8ZA'H-_HKW4MS(`=/\(_
M^"B&A^*_V>/@-\8/B'\,_%?ASQW^T5H'Q"\0?##X1>'+_P`":AK_`([N?!&F
MW/B@>!_A[J&N^/=$T3Q;X_U+PVIA\.^$)-5T7QIXSO-`\6Z]I/@W3_#&AZI=
M:5[G^VW\=/%?[.7[.?BSXI^"?#LOB7Q+9^)_A9X0TZUC.D;=/;XF_%7P9\-I
M-<>+6]5TBRN9-'B\6->V%K)<317&JQV$=];G2VOYH/F"Y_9"_9RU#]FG2?V3
M-:_:1L/%7P8T?PAX]\!6/A[Q=?\`P7UM[+0O%NJZ3?>%?$&EW8T*SN=,^*7P
M:ATZXN?A)\2;>4ZIX>\4ZG<>)M3LM<\BSTJ#Z$_:.\)_";]H'X(7/P1'Q[\)
M>#]/N=;^&.LMXD/B7P]XKUL?\*L\>>%?B'HT+R:QXCB-Y/J6M^#M(MM:U#49
MKV[NM,GU14:+4[RWU2R`*'AK]J3P9X$L['2/&_B3XI>-+"X_:)L/V>=7^*_B
MG0?A;;:5X.^+_P`2M6TK_A!OA-XF/PUET*TE&E>)_&OA'X'V'BGP]X0UG1[C
MQW<:;I.O^*+[49=3UYO1/@1^TWH7Q^T?Q+XH\/\`PY^)7A#P5X3\8_'3X>ZS
MXT\>_P#"N--T2+QU^SM\=/B'^S_\3/#<5KH/Q&\2^(I7L?&'PR\2ZMIVN_V$
MOA/4/#'V*Y'B"'6GN]!LO$;#X$?LW0ZAXLBU'XQ>$M4\$^./VB/`W[6FO_#M
M_$O@Z+P]:?'_`,":KX(\7:=XB\,74FH76MZ'X4O?BA\/?#7QBOO"MQJ6K7[?
M$FUN+Z#Q1#X:U+5O"VH=A^SQX,^$GP-^&'C7X5ZO\</AS\1M`\;_`!;_`&C/
MBYJ1U"]\+Z*HU']J#XV_$GX^_$CPY-:1^)]5M[SP[;>-OBKXJT[PU#-MOK+P
MDNE:3K%[KNHVEUK=^`>2S?\`!57]FZZ\*Z[XW\':+\1OB7X4\/\`@7X/?%74
M/$'P_7X7ZQHMO\*OC!XT@\%IX^U/6;WXHZ7I'A>R^&9O=/\`%?Q;\*>,[[PW
M\2?"'@B_B\20^"-6MK?4([+Z8^*?[5?PO^"US;VOQ*EN/"1UOXB?\*O\#7?B
M#7_AUX=TGXA>*8/ACJ7Q8U)/#FM^(_'6CZ/I5AI/AS1-<L+VZ\=W_@XR^(])
MET;3H;^2^T:74_G_`."7P`^"/PI^"^O_`+.7C/\`:KUG]H'X$W/PUO?@?X0^
M&_Q?\9_"";3_``9\#[S0CX7_`.%=SZOX(\,^#?$7Q`:'PN+;PK%XP^)6K>+/
M%P\/:=:0KJJZQJ'BS6_%"^/O@/\`!_QE\,/V>?"FD?M=>(/!7Q6_9BUK3O%G
MPT_:,TOQM\)-?^)U]XND\#>)/AYXZU?Q[IOC'P_X@\`>-++XK^'/&/BH>/\`
M0;[PC;Z7-JFK6^N^&H_#>MZ!X<U#20""P_X*3^!/%EQX3TOX4?L]_M-_&+Q-
MXT_9R/[3^A>$?!OA_P"#_A[Q%/\`#VR\=V'PY\1Z5-;_`!9^-7PULHO&WA;Q
M1?&VU'PX+]QK5M:7-UX*OO%:/8B\^LO@M\<O#?QX\(^!O'W@K0_$D7@SXB?"
M#X9?&7PUXCU5_"IL+C0OBII=WK>A:!*NB>*=;NU\3Z;I$%MJ&N1Q6T_AZ*#5
M=-_LKQ%J\DMREK\LV_@'P%X#^/,'[5B?M!#XN^+?!?[,?B7X&1>!+C7_`(31
M^+?B3:W?BZS^*MYJ:>(M1\7?#_P/IWQ"\2^-='@T[1;9E\`?"K0]*U!-!CTW
MPOH]I;:OI/KG[.ME\#/@7\.'\&^&?'?A;1M+U3QK\0_'T/A[6/B'X2U*;PG'
M\0_&VN>,+/P18'3M6N-(T[0?`NF:M8^#?#NA:)=7FB:!H6A:?H^D7]_I]E;W
MMP`<Y^RU\0/B3XU^-G_!0+PMXW\>ZMXK\.?`C]JWPC\'_ACI-]HG@K2X]"\&
MZY^Q9^R%^T3>1W%YX9\+:%J>LZFOC?X^>,=/@O\`5[Z\*>&K#P[9-"^HV>H:
MMJN%^S7\:?B;^U_^SM<?M'^`?$L/@"7QEXB^,MI\&?!-]H.EZGX8CT/X=?$C
MQO\`#GP)=_%4ZCI:^,-1O_&4OA&W\4^-=.\*Z_X+;PY9:X/!NBW4NH>'I_&G
MB+*\,_#G2?!WB3]J#Q!X7_:X^'FBR?M7?%_3_C!XWN[/3?#B^(_"&K:;\"O@
MI^SI:Z=\.-:;XCM8Z-&GPY^`_@VX74=?T'Q1?P^,+[Q!K]L\%E<Z7HFD=AX9
M\`?!GX>^$_&7PU^%W[0.B_#WX8^./$?Q"\5W7AG1O%G@R?5/!&K_`!2\1:OX
MR\<+\*/$MW=O/X-TW7_&7B/Q-XE?3]6L/%T?AZ\UZZL_`+^#-)L=%T_2P#Y#
M^%7[5'Q9_:%TG_@F7\7/"?Q9\=^!O`O_``4&TSQE\0];\"+X0^$KW7PU\,R_
MLS>)?B]X7\$^'-6\0?#/6-3O[KPSXATBSL]2\6:Q<:M#XN5+[4=.M--T?4M-
ML+#].;.PUO2]=^#^F>)=>_X2GQ'IW@WQ#8>(/$XTRTT4>(];L]+\*V^JZ]_8
MU@38Z3_:]_'<:A_9ED3:6'VC[+;DPQ)7S#JGP?\`@1:^+?V/]1^&WQ?^%OPR
M\`?L8V^HZ5\-/A?HT_AN]T*7PUJ7POU'X-)X9EOY?%UK=:;I.@_#_4I+3PNM
MC")]/UJVLM1U6;7M/BET2?VZZ\?>!X_B5H>K3?%SPGJNDSV_B5[6U?Q!X/BT
M[PK$VD^%K,:?%?64D-S<#5K^ROM5$FM7=W<_:+FXM;%XK&UAMX@#Z,HK@/\`
MA:_PM_Z*5X`_\++P[_\`+&C_`(6O\+?^BE>`/_"R\.__`"QH`[^BN`_X6O\`
M"W_HI7@#_P`++P[_`/+&C_A:_P`+?^BE>`/_``LO#O\`\L:`._HK@/\`A:_P
MM_Z*5X`_\++P[_\`+&C_`(6O\+?^BE>`/_"R\.__`"QH`[^BN`_X6O\`"W_H
MI7@#_P`++P[_`/+&C_A:_P`+?^BE>`/_``LO#O\`\L:`._HK@/\`A:_PM_Z*
M5X`_\++P[_\`+&C_`(6O\+?^BE>`/_"R\.__`"QH`[^BN`_X6O\`"W_HI7@#
M_P`++P[_`/+&C_A:_P`+?^BE>`/_``LO#O\`\L:`._HK@/\`A:_PM_Z*5X`_
M\++P[_\`+&C_`(6O\+?^BE>`/_"R\.__`"QH`[^BN`_X6O\`"W_HI7@#_P`+
M+P[_`/+&C_A:_P`+?^BE>`/_``LO#O\`\L:`._HK@/\`A:_PM_Z*5X`_\++P
M[_\`+&C_`(6O\+?^BE>`/_"R\.__`"QH`[^BN`_X6O\`"W_HI7@#_P`++P[_
M`/+&C_A:_P`+?^BE>`/_``LO#O\`\L:`._K\[OVW_P#D.?#_`/[!6N_^E>GU
M]I?\+7^%O_12O`'_`(67AW_Y8U\'_MA^*/#/B?6/`\OAKQ'H7B"*TTS68[J3
M0M7T[5H[9Y;JQ:)+A[">X6%I%1VC60J756*@A3@`^\/A/_R2WX:_]B!X-_\`
M4=TVN_K\HOBQ\7OC;X8\=_L]_"#X<_$>+P#X5\6_\$U/VM_C]?7MCX,\+^(?
M$UG\1OV:O$O[#6C^`[K3[_Q9::UI":+J&G?'SQ9IOB32+S0+Q;[3US876EZR
M=-UO1O,I?V^?COXQ^`7QV^+W@_0=-TCXC?`;]C[]D_\`:C\*?!^#2[+4+7X_
MZC\;?AAK/Q,UGPOI\NI/+XABT#QUX@T/6?@-\+;GP_?:3J^C_$GPWK>IZI=>
M,8'M_#,`!^U5?,W[4_Q0^(WP8\`:7\3/!%EI6H^'/#'B[PS/\6H+_P`$:QXS
MN=-^%MSK>G6WC7Q7`^A^/_"&J>&['P=X<DU7Q%K&OZ9X9^*^IV-I9+-!\-]9
MM8[^>T_-O5_VHOB%\`/B5^WAJ>L_$.34/#5W_P`%4_V<_P!GO2-7^*&N^%_#
M7P_^!GPY^*?["'["OC*?63K\7@F];P_H]]\0_'=S\/M"U'7+/7]#M?%GCCP]
M?ZSI^IZS=:[J&M?HO^SU!K7Q`\)OK_QBUOX(?&3Q;X-^(GQ$TSP)\0OAXFG>
M*XM+\%WFL6U]X>TR^\2'PQX=TQ?B!IVB+HVB>/[[P5HN@>'M6UC0H+R+2-*N
M%ETC30#ZBEEB@BDGGECAAAC>66:5UCBBBC4O)))(Y5$CC12[NQ"JJEF(`)K-
MT/7]"\3Z9;ZUX:UK2?$.C79F%IJ^AZE9ZMIET;:>2VN!;W]A-<6DQ@N89K>8
M12N8IXI(GVR(RK^:WBRW_;C/Q3\3-X?@_:R/@0_$#66T1M&^)7_!.&U\(GPD
M?$=R=-;2M,\4?LYZI\2[;PW_`&-Y)L;#Q%XDU'QS#IGE6^K:Y=Z^MQ?R?*7[
M//BWQ)^RKXK^,7@7P5Y::'^W/^TS^W%J_P``TNH#>Z!X'_:^\._MK_%?X:>-
M]%%@&1'\,>*/A1-X6_:";P?HD22QZ9\`/VGO&]P9+C6)FB`/W2TSQ'X>UN[U
M?3]&U[1=7OM`NQ8:]9:9JEC?W>BWQ\S%EJ]M:SRS:;=GRI<6UXD,Q\N3Y/D;
M$NLZ[HGARP?5?$6L:5H.F1SVEM)J6LZA9Z78)<7]U%96,#WE]-!;K->7EQ!:
M6L32"2XNIHK>%7EE1&_GX_9J^*K_`+*'A_3/V>/!OB31/!?ASXN_\%"?^"C7
M@:;XS_%CQYI^D73^+O`7B7Q-XET+2=5\>>+?"7CW3-:^+7Q,N8=;\8S7OB;P
M]JEWXL3P3XP4E-1OXKJ"]^U-\?O''Q;_`&9/BKX!^+OC;X86_C3X&7/_``3%
M\5>)M0^&T=E-\,_C+JGQ1^.OPGUSQ'\9?A_)XRAN/%=I\'=7\0V&K^'/A=>Z
M=J%C/9ZOX0\4/J7B'QC8R0VEN`?T'5@V?BGPQJ&N:GX8L/$>@WWB71;6TOM9
M\/6>KZ?<ZYI-E?RW,%C>:GI,-Q)J%A:WL]E>0VEQ=6\45Q+:7,<+N\$H3\V)
M/VK_`!O?_M??#GX7>&_B+H'B/X9_$OXY?M!_`B^AT_P_H>CW/@W4?A'^SQ8_
M$6>/0'OGUW7O$/C#PKX_TG4]+\0>)];ELO!FI6GB>#1M+^']S_95EXIU'Y*_
MX)R?$WQYK/@K]F+X9:GXXUBT\6?&SX7?\%#/BR/C]XD\/_#[6_%TWBGX<?MI
MZ'I1^'.A:I?>&([;4=(U-?B+K_Q)\>:!JT,^LZF=+TV[\+ZSH^FZ+K(TX`_?
MJBOR4_92_:8_:0_:3^*WP.M?'.KV7PDT?Q-^P3^S?^U=XN^'/AGPEHER=0\?
M_$3QI\0?#?B_09==\5IXAUVR^'^MZ9H6G:MH.GV3Z/XQT7?I:WVOM-%K-AJ?
MNVJ_$/XJ^'_VNO'GP`\0?$K6;;0?C;\,/`OQ/_9CNK30OA];WWA?_A7_`(ND
M\,?M2^%M-FN_!EY'K<WA71M>^$_C73M0\:/XCENHOB+=:+865HWAU+S4P#[U
MK/GU?2K;4K#1KG4]/M]7U6"_NM+TJ>]MH=2U*VTHV@U2XT^QDE6ZO(---_8_
M;YK>*2.S^VVGVAH_M,._\I_@Y^UU\:?CY\=/'_@[2?&?P2^$Y^$?[8?QX_9Q
M\;_!/QQXA74/B]K/PX\$^#/$X^&GC_PI\/[7PI;^(4\4^.;NW\#_`!^\/:S?
M^,Y_`FK?`;6?$.G7'AZVU6*T\7Z-\5^(/VIOVGO&?[$?[+?Q(\4?&(2Z[^V)
M_P`$D?VB?VHO&5WH/@3P1X;U+P)\0]$_8\^!'Q"M;/X;ZS9Z3->:/X>?Q9XS
M\3:O>0:F-7U@W%_;QV6M6%GI&CVFG@']!N@>/_`?BS4]8T7PMXV\(^)=8\.R
M"'Q!I/A_Q)HVLZGH<KL46+6;#3KRYNM,D9U91'>Q0,64J`2"!U]?@#XC_:Q\
M<_LG_$;X-_#^SU+P%'X$^(O[/G["LWB_XI>-M+\&>`[CPGJ_Q;^(?Q`^%O\`
MPE_Q)^)&C>$9=-?2H]+\$^!OA)X!N=9\*7>F:!K7B;PZVJ6VLEIVG]E^)?[5
MG[3'P8^"4GCWQE\1_A'\4O#_`(4O/VH-8^(GQ(_9EG\.^-_%OP^^#W@S7_"#
M?#CXS^(?`'B[2-!T;XN>'O@#X;\5QV7[7FE?"+_A&/$T^KW.@Z[\,_#2,VL>
M`80#]F:R=)UW1->BNY]"UC2M9@T_4;W1[^72=0L]1BLM6TV7R-1TN[DLYIDM
MM1T^<&&^L9F2YM)08YX4?`KX:_;KUKQ?I.L?L267AGX@>)_`>E^*OVW?AQX9
M\;GPZ?#J0>(?"P^&GQ?\41:1KK^(=!UR(Z9%XF\+>'=36.(6JR7ME:B=I@L2
M+\5?LS_$3QY\(OBMX#T'PWXAM_\`A7O[1'_!7W_@H?\`L^^*_A\?#_A^#1]/
MT[3OA?\`MB?M+Z;XXTW5X[!O$\?C"R\6_L\Z=X:%O#K5KX2N?"OBS64O/#$_
MB&ST_7T`/W0HK\5_V=/VV?CQ^T9\&O!WQQ\'?%?]E&RU/QW^SGXZU;Q)\"?%
M'Q#<>+_A-^TU#X@\#Z5X?\`^(1H_P_CU/X::+\,?%>L>+O@M\:QX^F^(MU:>
M.9_A_JNCF%8-7T#QC>M/V]?'=U#\$_"&M:E=_!_7OBQ\<?VAO@QXVU7]H6\^
M''PUUWX,_$GX/_#VU\0Z5\%9_&'ASPW\2O@WXR\6^*99-6\=>!?%WA[2]:\.
M^/\`X?>';M+.+2==GNK'2`#]FJ*_.3XW_&[X]?#W]C#]GCXEP>//A7=_&#Q=
M\<?^"=GPM^(_CCX;Z%=^(OA-XKL?VCOVNOV>?V??BOK_`,+[3Q3.E];^&==\
M/_%'Q!XA\`:CJ$VJ36-LVD2+=ZJFS4YO&/@=^UA\;/B1\</''PEF^,7P5TG6
M?V</VN'_`&??B1\/OB;K6DZ)\8OBA\*8_AKH]_HGQ!M/AQX:\!65W!X\^)>M
M:_:?$SP%XH\+Z[H?PMG\"V>H^&;OP7]MTK5_$UF`?L%65JNNZ)H2V#ZWK&E:
M.FJZI8Z'ICZKJ%IIZZCK>J3"WTS1[`W<T(O-4U&X(@L=/MS)=W<Q$5O#(YQ7
MXI:I^VI^T/'\$_CAJVIZ]=>$/C3\'%_8=\4WUKIFA?#OQK\)?&?PS^/OQSU'
MPIJ'QQ^#/Q$T[29X?%?[/_Q?\$Z;XLMO#FG>+](\,_%OX5:E\-=?D\57+V]Y
MI7B#6LCXX?%;Q+\5?%_Q>\">)O%]EXDM?V=_^"WO["?PN^%UY!8>$XM=\'>"
MO%GP5_8E^--UI;S:7I,$%_/I'Q'^,?Q.TS2]4UJQO=5?2[.#0=;O=9FT:[FE
M`/W9HK\#OAU^TI\?_A1_P36^`/Q=A\=^*OBEK5_\&/BU\6/C?KT8^&&M_'OP
M=HNDO:OK7QL\.>`-<T+P]X=^+'@'X1Z[K$WBGXO?#R"XTCXG:Y9^(-/_`.$"
M\0W]]IEI\/?$WZP_M`_%<>#?`?P_U#PWXUL_"FK_`!1^*7PH\!^#KNX\/0:Q
MJ'B:7QGK]G=7GAOP_!KEYIFC:#X@UGPA9Z])8>(O%%OJFF^&A;S:E<>%_$E]
M;6GA[4`#Z0HK\C=9_;#^-$W_``1W_:0_;'T76_"EM\<O@_\`L[?MH>.?#OB"
M+1K/7/#%_P"*?V9KSXQZ=X6U;4-$#:?IM\OB:#X:Z7?ZS%:P:;I4EWJMY<:;
MI-CIQM=+BX/XD_M6_M(_#/XY?M&^#4^)=IXB\-?!3]J[_@E?X)\/V.I^!O!U
MI)K7@G_@H3^T#\-_@+\1O"'B&]TW2[:[DT;X;6WC+5O&'PNU#2)=(\81:M:Z
M1IWCOQ7XXTNVU"+5`#]GM+U?2M<LUU'1=3T_5]/>>]M4OM+O;;4+-[G3;VXT
MW4;=;JTEF@:>PU&TNK"]A#F2UO;:XM9UCGADC4@U?2KG4K_1K;4]/N-7TJ"P
MNM4TJ"]MIM2TVVU4W8TNXU"QCE:ZLX-2-A??8)KB*..\^Q7?V=I/LTVS^<T_
MM\_M9P?`?]JCXHQ_$3PM8W?[-O[`_P"TE^V#HND:%\-/"=C:>,?B!\!OVE?V
MO?"EEX7\3RZA#K2V_@3QMX3^!?AW1/%5OH%MI'BQ)-0U+6="\7:3K3M?2_6W
MQE_:A^/_`(?_`&V;_P"!OA;QGX<\/^"M6^.7[&WPW^U6_@/0K_Q38>$?C7\'
MOVMO%OBV.TUG5)+V"XUFVU_X0>'-0T'4-7TS5-/TT2WML=%N+6YO(KL`_8RB
MOYPOB3^WE^USX-_9Z^'OQ2L?BE%>^)/&/P1_;JU/5(E^'_P]CTC2/$?[%?QM
M\)>#-"^(-O:MX7N[A#XW\&_\)5=_%C3+V^E\,P/=VNJ>!['X?0:%<)J7U1\2
M_P!K;XXZ)\;OCE\.?"/Q/T)]+\(_M[_L+?`O2(KOPOX1UG5/#_PT_:,\'?#B
M\\?Z);O96VG;[RWUOQ/K,^AZSK]OK.IZ>84L9[BZ2!@`#]E:*_(']EO]J?X\
M>+?B_P#`GPE\0/&UMXQT+XB^.?\`@JM\%M:M9?"OA?0I3<_L!_MF:Q\!/AC\
M2([KP_I6GSKXO\<>"M"OYOB7IL#6W@F[U>^TZ\\'>%?!L>E7L.N]MXK_`&L/
MC)+H/QJ\?^#+./\`M[X%?M[?"C]E>[^!%UI6DSOXI^'WC[XF?L_?#^YUW5M2
M9!XDTSQCXE\&_&&Z^-7PVUJSU?2?"UMX>O\`P;8^)?#NK:=#K6LWH!^E4GBG
MPQ#XAMO",OB/08O%=[87>JV?AB35]/3Q#=Z78/;1WVI6VBM<#4I["SDO;-+N
M\BMGM[=[NV6:1&GB#[U?F;^QS::C+XV_X*"^.?$-_K_Q1UWP5^VW\3H/!FEZ
MO8>#+K5='.E?L\?`?3K;3?!VHP>'M)U'2K_4=`:V\(1QR:NE@^E6]I!/$DD^
MI7E[X#JO[;O[0[_L_P#PQ^-7A+4-`UE/CO\`\$OOVB_VQM1:;PQI\^D_`7XT
M?!KP!\$/%.CZ!IMO&^E7VJ>"-0U[XJ^)/!VN^%?'-UK?C;3M?\*Z6W]M)#!X
MJL8@#]L**_"3Q+_P4#^-OP-^)_Q1\)?$#Q-H_C;P38_LD?\`!-7]IB\\::OX
M=\.^&?\`A2UO^UM^UMXZ_9G_`&@O$LG]BV^FZ???"GX/>`?"Z?'2QC\72ZKK
MFB?V!XNMO$'B[7?#]YI]KH7N'Q._:P^(/@SQ_P##+X'Z)^T5\#=9MOC3;?M9
M7_@?]HG7-7\*>!=`T#Q5\*[3X&Z_\*O@=X@U9-#^(7@'Q;\1;[PG\6O'/C?4
M4T+PQX7E\4^!_@[JLUE:>'=3M-<N[L`_6NBOC;QS\7_%NB?"?]EL:M\2?`>@
M_$_X]>)OAUX)EU?X?Z.=9\,>.O%>I?"?Q=\4/&=E\(=5\=W":5X7T-M#\">+
M?'&D>*OB#I?B>:#X>>&M6TZQ\(>)OB#JWAK2+K\O_AQ^W-^U1\:]>_9PT&W^
M)GAWP):?%3_@DI^T;^USXJU#P=X#\*:QJ2?&_P""7Q@_9W\%:%J^D7?BRVU_
M2K?PYKMA\0M>&M>'IM#GM)-.O[B+2WTS5!H^NZ(`?T$T5^"WQC_;N_:4M?@[
M\7OC=X6\6>'_``C;?#+_`((U>"_^"DVE>"],\':'J=KK'Q9M]!^*7C;6/`6N
MZYXEBUR^?X9>*+?P'9^&M4MM(M](\766G7DU[X?\6:/JT8O)/7?CI^UA\:?A
MEXQ_:4L(OB5;Z-I?PR_;]_X)6?"KP1;ZUH'@6&*Y^#O[6OQB_9<^'WQG\,W5
MQ>>'H;C5-*FT3XG_`!1N="\2PW$?B?P_J>@).GB2:U\/ZG9S`'[$3316\4L\
M\L<$$$;S33S.L<4,,:EY999'*I''&BL[N[!44%F(`S7/:!XS\'>*F">%_%?A
MKQ(YT+P[XH":!KNEZPQ\,^+HKZ?PGXB"Z==7).A>)X-,U*;P[JX']GZW%I][
M)IMQ<I:3M'^5/@K]LKQYXI_;;_9\^"">,?!GQ+^"7[1GA'_@I;-JDA\+:9H2
M:9??LB?'_P"$?PT\$V/A?3%O-3UT:?::3X]\7_#;XB:KXWUG6+?XH>-/!VH>
M-/!GA?X;^%9+#0]5_+G]BCQGX^^#7PB^#/QU^'OB.?PYH?PA_P""(O\`P;H?
M$WX_:7IWA[PSJLGC7]GO1M9_X*#:;\<FN;G6=#U>_P!.U#P7\+3JGQ!LM1T(
MVNNW\7@*+PK;WMG%JT=_IP!_6#17#>!;J^?P[I]_KGB"ZU:Z\4W^K:]HXU6+
M1+&\L]&UR\O==T#PS!!HVFZ5!<'PYX<EM-/DEDCU#4IA87-W?ZKJ<GF7TG<T
M`%%%%`!1110`4444`%%%%`!1110`5^=W[;__`"'/A_\`]@K7?_2O3Z_1&OSN
M_;?_`.0Y\/\`_L%:[_Z5Z?0!ZWX8^'VB^+_"?PX\1>)OV??A9XWUJR^$VD^#
M=-\5^*5\,:IK[>"];T"RCU7P^E[JOA#4-0LM`U^%V?5_#R7KZ;=^;)%>17/+
M-WVE^#+?0XO#$&B?L_?#'1X?!.G_`-D^#(=+NO#>GQ>$=*\V*?\`LSPQ':>#
MH4T#3_/@@F^Q:4+2V\V&*3R]\:,O<_"?_DEOPU_[$#P;_P"H[IM=_0!X7J?A
M)-;D\73:S\`_AKJ\OQ`TFQT'QY+J=]X>OY/&^AZ7#=6^F:-XNDNO!\K>)-)T
MZWOKV"QT[63>V=I#>745O#&EQ,K[7ARV\0>#M#TOPQX1^$7A#PMX:T.TCT_1
M?#OASQ'IFB:%H]A#_J;+2](TSPM:Z?I]I$"?+MK2WAA3<=J#->M44`>>2ZOX
M^GBD@G^'NC30S1O%-#+XT@DBEBD4I)%+&_AQD>.1"5=&!5E)5@02*XCPUX*M
M?!NEQ:'X0_9\^&'A31;?6M5\1P:/X;N?#6AZ7#XAURSO=.UK7H=/TOP;:VD>
MLZQI^I:C8ZIJB0K?:A9W][:W<\T%U.DGO5%`'S#%\%_`L'AK7/!D/[*/P+A\
M'^)]8B\0^)?"D6E^!X_#7B'7X+D7L&N:YH2>`QI>K:Q#>`7<6IW]K<7L=R!.
MDXE`>NB\1>!K'Q?JFCZYXL_9Y^%OBC6O#UC-I>@:OXBG\,ZWJFAZ;/<V=[/I
M^CZAJ7@RYN],L9[S3M/NYK2RFAMY+FPLYWC,MK`Z>^44`?/]QX!TRZUO4/$U
MU^SI\*;GQ'JNI0ZSJGB"XD\+S:WJ6KVWAR_\'V^JZAJLG@MK^\U*#PCJFI^%
MH;ZXN);J+PYJ-_HB2KIEY<6LE#1?A;X9\-^&[#P=X<_9C^#>@>$-+UN7Q-IG
MA718/!^E>&].\23Q2PS>(+'0['P/!IEGK<T,TT,NJV]K'?R132QO.R2.#]'T
M4`>(Q>&I8?&<_P`1X?@5\.X?B'=:-%X=N?'D>IZ#'XSN/#\$GG6^A7'BA/"(
MUR;1H9@)8M,DOFLHY!O2`-S7227OC26]MM2E^&GA^74;*WN[2SOY/%]H][:6
MNH26DM_;6UTWAHSP6][)I]A)=PQ2)'<R65H\RNUM"4]*HH`\(O\`P=#JGB/4
M_&&I_L__``RU'Q;K7AB?P3K'BF_O/#EYXCU;P9=LS7/A'4];N/!TFIW_`(8N
M6=VGT"ZNI=*F9V,EHQ8D\;=_`CX;:AI'A[P_?_LB?`"]T'PEH>I^&/"NB7>A
M>`;G2/#/AK6F=]9\/>']-F\`/9:-H>K/+(^IZ1IT-M87[R.UU;REF-?5-%`'
MS&GP;\$1"[$?[*GP-C%_X1'@"^":;X(07G@-69QX)N]O@0"Y\(AW=QX;FWZ,
M&=B++))/1+X*M5M?"UB/V?/A@MCX&LVT[P39K<^&Q:^#]/:73)FL?"UN/!PA
M\/V;3:+H\K6NDI:0&72=,D*%["U,7O5%`'D7B.RUSQAI\>D^+?@]X,\4:5#J
M.F:O%IGB+Q!I6N:?%JVB7]OJFBZI'9:GX5N;9-1TC4[6UU+3+U8UN;"_MH+N
MTEBN(8Y%X*S^#O@K3[[2M3L/V5O@?8ZGH7BV_P#'^AZA::?X)MK[1O'>JHL>
MJ>-=*NX/`B3Z=XMU&-5CO_$EI)#K%XBJEQ>R@`5]-44`>`1>`M-AOO&.IP_L
M[?"J+4OB&]G)\0-0BE\,1WWCJ33RS6#^,;M/!@G\3/8L[-9MK<E\;8LS0F,G
MG/.@Z1X_\#3>#=3_`&>_AIKOP]AUS6+"3P3K\OAG4/"G]J^%O%.HV5S<#PS>
M^#[K1BT/B'3+K4+*Y^R"3SC'?KY5RY*_1]<!\-?^1=U'_L?_`(L?^K2\94`<
M=XP\+M\0M&L_#GC[X#_#GQQX>T_4M,UFPT'QAJ.@>)M&L=7T63S='U6STO6O
M"%[8VVI:3+^\TR^A@2ZL)/GM98FYJ6;P[<7'C.T^(T_P-^'T_P`0K#19_#EA
MX\FU30I/&=EX>NIOM-SH-IXG?PBVMVVC7%S^_GTN&^2QFG_>R0,_S5[710!X
M38^#H=+\-:KX+TSX`?#/3O!VO:?+I.N>$[&\\.6?AK6=+GT\:3/INJZ#;^#H
M]+U'3YM+`TR6SO+6:WET\"S>(V_[JL*?X3^$[JPL=+NOV7O@M<:9IFK>']>T
MW3KBT\&RV&GZYX3T?3O#WA76;*SD\#-;VFK>&M`TC2=#\/ZC!''>:-H^EZ=I
MFG36UE96T$7TG10!\]1_#O1X84MHOV;_`(2Q6Z:QK?B%((SX52!-?\2WEMJ7
MB/7$B7P4$76/$&H6=I?:WJ847NJWEK;W5]///#$Z]+XITW5_'&C3>'?&OP:\
M$^,/#]S<6%W<:#XIUW2/$&C3W>EWL&I:;<S:9JWA2\LI;C3M1M;6_L9W@:2T
MO;:"ZMVCGACD'L%%`'@VH>"[;5O"&M_#[5?V??AAJ?@+Q+<:K>>(_!&H77AN
M]\(>(+O7=6FU_7+K6_#5SX-DT;5;C6==N+C6M5GO[*>74=6GFU&\:6\E>9N4
MN_@?\/K^34IK[]DKX"WLNL_\(M_;$EWH_@2YDU7_`(0<VQ\%'4GF\!.U]_PA
MYL[0^%OM1E_X1\VML=)^R&"+;]244`?)<'[//PHM;/5M/M?V./V=;;3]>T6X
M\-Z[8P>&OAW#9ZSX>N]4?7+O0=6MH_AZL.HZ+=:U+)J]QI=XDUC/J<CZA)`U
MV[3'1?X(_#^37+/Q,_[)GP&D\2:?<>'[NP\0/I'@1M;L;KPE9/IWA:YL]5/@
M(ZA;7'AK3Y9+#P_-#<))HUE(]KIS6T#M&WU'10!\P67P5\!Z:FD1Z=^RA\"K
M"/0(_$D.A)8Z7X'M4T2'QDKIXOBTA8/`<:Z=%XK21U\21V8@375=UU1;H,<R
M?\*=\%?V=IFC_P##*WP/_LG1+_P_JNC:5_9_@G^SM(U/PG9QZ=X5U+3+'_A!
M/LUA?^&M/ABL?#]Y:Q17&C6<26NFRVT"*@^FZ*`/FW1OA1X5\.ZII.N>'_V7
M_@OH6M:#J_B7Q!H>KZ-:^#=,U31=>\9R12^,-;TG4++P-!=Z=J_BN6"&3Q+J
M5G-#>:[)#$^J3731H5[!M+U5O$@\9-\&/`[>+Q:)IX\5MKFCGQ(+"(3+%9#7
M#X4.J?9(UGF5+877DH)Y@J`2/N]BHH`\-\*>%3X$N_$FH>!_@-\-_!M_XRU5
MM>\7WOA34/#_`(>N_%6N,)`VL^)+G2/!]G-KNJMYLH;4=4>ZO")9?WWSL#B:
MGHFEN=5\#ZE^S[\-KO3_`(I1Z]>>*]&GG\-7.B>,?)DANM9?Q?8S>$#::]+?
M3:H9YSJUO?&\FFN))V+LS/\`1M<!KG_)0O`/_8*\;_\`HKP[0!Y;IGPI\*Z)
MJMWKNB_LP_!C2-;O_"=OX"OM9TRU\':?JM]X&M+465KX+N]0M/`\5W<^$[:R
M`M+?P[-,^CPVH^SQV:Q?)4\_PR\/W7@G1?AI<_LT?!^X^''ARZL+[P]\/YX_
M",W@G0;W2KI[[2[S1?"DG@EM"TNZTV]DDO+"XL;"":SNG>XMWCF9G/T510!X
M[XFTO5?&FG6^C^,?@QX'\6:3::EIFLVFE^)M<T?7=.MM8T6ZCO\`1M5M[+5/
M"EW;0ZEI-]#%>:9?QQ+=6%U%'<VLL4R*XX.3X+^!9K^+59?V4?@7+JD&B:[X
M9AU*32_`[W\/AOQ1=7E_XF\/Q7C>`S<1Z)XBOM1U"\UW2DD%AJ]W?7MQJ%O<
M374[O]/44`?*TOP)^'$]G<Z=-^R+\`)M.O?"5KX!O+"70_`,EG=^!;&X2[L?
M!5S:OX`,$_A*SNHTN;7PY*CZ/;W")-#9I(JL.DN/AWH]Y?V.JW?[.'PENM4T
MS0=!\*Z;J5P?"LU_I_ACPKK=CXF\+^'+&\D\%-<VF@^&_$>F:;X@T#2+>6/3
M]'UO3['5=/M[>_M+>XC^A:*`/G9OAIH#W]]JK_LT_"!]4U/4?$^L:EJ3)X2:
M_P!0U?QMI4>@^,]4OKP^"3<7>H^+M#BBT;Q/?3R276OZ5%'IVJRW=FBPCAQ\
M`M&T-K$?#+X$_"SX/I)9VOA?Q<_PWTCX9Z#>^-OAA::9K5HOPJU34H_AJU]I
MO@XW^J6VKQ1:%-IU_87.FQQ:9=V,5Y?>=]@T4`>874WBV^O-+U&^^%WAJ\U#
M1+BYNM%OKKQ58W%YI%S>65QIMW<:7=3>&7GT^XNM.NKJPN9K1XI)[*YN+65F
M@FDC;0_MSXA?]"#I7_A;Q?\`S.UW]%`'`?VY\0O^A!TK_P`+>+_YG:/[<^(7
M_0@Z5_X6\7_S.UW]%`'`?VY\0O\`H0=*_P#"WB_^9VC^W/B%_P!"#I7_`(6\
M7_S.UW]%`'`?VY\0O^A!TK_PMXO_`)G:/[<^(7_0@Z5_X6\7_P`SM=_10!P'
M]N?$+_H0=*_\+>+_`.9VC^W/B%_T(.E?^%O%_P#,[7?T4`<!_;GQ"_Z$'2O_
M``MXO_F=H_MSXA?]"#I7_A;Q?_,[7?T4`<!_;GQ"_P"A!TK_`,+>+_YG:^$/
MVP[W7KS6/`[:[H5KHDD>FZR+=+;65U@7"-=6)D=W6PL/(,;!0%*R;PQ.5VX/
MZ75^=W[;_P#R'/A__P!@K7?_`$KT^@#Z:^&7CFUM/AO\/K1O#?C>=K7P1X4M
MVGM/".L7-K,T&@V$1EMKF*W,5Q;RE2\,\9,<L;+(A*L#7<?\+"M/^A6\?_\`
MA%:Y_P#(]'PG_P"26_#7_L0/!O\`ZCNFUW]`'`?\+"M/^A6\?_\`A%:Y_P#(
M]'_"PK3_`*%;Q_\`^$5KG_R/7?T4`<!_PL*T_P"A6\?_`/A%:Y_\CT?\+"M/
M^A6\?_\`A%:Y_P#(]=_10!P'_"PK3_H5O'__`(16N?\`R/1_PL*T_P"A6\?_
M`/A%:Y_\CUW]%`'`?\+"M/\`H5O'_P#X16N?_(]'_"PK3_H5O'__`(16N?\`
MR/7?T4`<!_PL*T_Z%;Q__P"$5KG_`,CT?\+"M/\`H5O'_P#X16N?_(]=_10!
MP'_"PK3_`*%;Q_\`^$5KG_R/1_PL*T_Z%;Q__P"$5KG_`,CUW]%`'`?\+"M/
M^A6\?_\`A%:Y_P#(]'_"PK3_`*%;Q_\`^$5KG_R/7?T4`<!_PL*T_P"A6\?_
M`/A%:Y_\CT?\+"M/^A6\?_\`A%:Y_P#(]=_10!P'_"PK3_H5O'__`(16N?\`
MR/7$?#[QU:VN@W\3>'/&\Q;QO\3+C?;>$=8GB`O/B1XKNUB:2.`JMQ`LX@NX
M"?,MKN.:UE`EB=1[M7`?#7_D7=1_['_XL?\`JTO&5`!_PL*T_P"A6\?_`/A%
M:Y_\CT?\+"M/^A6\?_\`A%:Y_P#(]=_10!P'_"PK3_H5O'__`(16N?\`R/1_
MPL*T_P"A6\?_`/A%:Y_\CUW]%`'`?\+"M/\`H5O'_P#X16N?_(]'_"PK3_H5
MO'__`(16N?\`R/7?T4`<!_PL*T_Z%;Q__P"$5KG_`,CT?\+"M/\`H5O'_P#X
M16N?_(]=_10!P'_"PK3_`*%;Q_\`^$5KG_R/1_PL*T_Z%;Q__P"$5KG_`,CU
MW]%`'`?\+"M/^A6\?_\`A%:Y_P#(]'_"PK3_`*%;Q_\`^$5KG_R/7?T4`<!_
MPL*T_P"A6\?_`/A%:Y_\CT?\+"M/^A6\?_\`A%:Y_P#(]=_10!P'_"PK3_H5
MO'__`(16N?\`R/7$:SXZM9/'7@FY'AOQNJV^F^,$,4GA'6$N)3/'H05[:W:`
M23I%Y;>>Z`B$/'OQYB9]VK@-<_Y*%X!_[!7C?_T5X=H`/^%A6G_0K>/_`/PB
MM<_^1Z/^%A6G_0K>/_\`PBM<_P#D>N_HH`X#_A85I_T*WC__`,(K7/\`Y'H_
MX6%:?]"MX_\`_"*US_Y'KOZ*`.`_X6%:?]"MX_\`_"*US_Y'H_X6%:?]"MX_
M_P#"*US_`.1Z[^B@#@/^%A6G_0K>/_\`PBM<_P#D>C_A85I_T*WC_P#\(K7/
M_D>N_HH`X#_A85I_T*WC_P#\(K7/_D>C_A85I_T*WC__`,(K7/\`Y'KOZ*`.
M`_X6%:?]"MX__P#"*US_`.1Z/^%A6G_0K>/_`/PBM<_^1Z[^B@#@/^%A6G_0
MK>/_`/PBM<_^1Z/^%A6G_0K>/_\`PBM<_P#D>N_HH`X#_A85I_T*WC__`,(K
M7/\`Y'H_X6%:?]"MX_\`_"*US_Y'KOZ*`.`_X6%:?]"MX_\`_"*US_Y'H_X6
M%:?]"MX__P#"*US_`.1Z[^B@#@/^%A6G_0K>/_\`PBM<_P#D>C_A85I_T*WC
M_P#\(K7/_D>N_HH`X#_A85I_T*WC_P#\(K7/_D>O@_\`;$UR+7]8\#R0Z7K6
MG"VTW6D*Z]HUYI$DIDNK!MULE['&9T7;B1H]P1BH;!89_2^OSN_;?_Y#GP__
M`.P5KO\`Z5Z?0!]$?#;XQ?"W2_AUX!TW4?'GAJSO]/\`!?A:POK2XU*&.>UO
M+30["WN;:9"<I+#.CQ2(>5=2IYKM?^%X?"'_`**)X5_\&D'^-7O^%4_"[_HF
MW@'_`,([P[_\KJ/^%4_"[_HFW@'_`,([P[_\KJ`*/_"\/A#_`-%$\*_^#2#_
M`!H_X7A\(?\`HHGA7_P:0?XU>_X53\+O^B;>`?\`PCO#O_RNH_X53\+O^B;>
M`?\`PCO#O_RNH`H_\+P^$/\`T43PK_X-(/\`&C_A>'PA_P"BB>%?_!I!_C5[
M_A5/PN_Z)MX!_P#".\.__*ZC_A5/PN_Z)MX!_P#".\.__*Z@"C_PO#X0_P#1
M1/"O_@T@_P`:/^%X?"'_`**)X5_\&D'^-7O^%4_"[_HFW@'_`,([P[_\KJ/^
M%4_"[_HFW@'_`,([P[_\KJ`*/_"\/A#_`-%$\*_^#2#_`!H_X7A\(?\`HHGA
M7_P:0?XU>_X53\+O^B;>`?\`PCO#O_RNH_X53\+O^B;>`?\`PCO#O_RNH`H_
M\+P^$/\`T43PK_X-(/\`&C_A>'PA_P"BB>%?_!I!_C5[_A5/PN_Z)MX!_P#"
M.\.__*ZC_A5/PN_Z)MX!_P#".\.__*Z@"C_PO#X0_P#11/"O_@T@_P`:/^%X
M?"'_`**)X5_\&D'^-7O^%4_"[_HFW@'_`,([P[_\KJ/^%4_"[_HFW@'_`,([
MP[_\KJ`*/_"\/A#_`-%$\*_^#2#_`!H_X7A\(?\`HHGA7_P:0?XU>_X53\+O
M^B;>`?\`PCO#O_RNH_X53\+O^B;>`?\`PCO#O_RNH`H_\+P^$/\`T43PK_X-
M(/\`&C_A>'PA_P"BB>%?_!I!_C5[_A5/PN_Z)MX!_P#".\.__*ZC_A5/PN_Z
M)MX!_P#".\.__*Z@"C_PO#X0_P#11/"O_@T@_P`:XKP#\8OA;I^AWUO?>//#
M5K-)XT^)-\D4VI0H[6>J?$7Q3J6G7(!.?*O+"[MKNW?[LD$\;CAA7H?_``JG
MX7?]$V\`_P#A'>'?_E=1_P`*I^%W_1-O`/\`X1WAW_Y74`4?^%X?"'_HHGA7
M_P`&D'^-'_"\/A#_`-%$\*_^#2#_`!J]_P`*I^%W_1-O`/\`X1WAW_Y74?\`
M"J?A=_T3;P#_`.$=X=_^5U`%'_A>'PA_Z*)X5_\`!I!_C1_PO#X0_P#11/"O
M_@T@_P`:O?\`"J?A=_T3;P#_`.$=X=_^5U'_``JGX7?]$V\`_P#A'>'?_E=0
M!1_X7A\(?^BB>%?_``:0?XT?\+P^$/\`T43PK_X-(/\`&KW_``JGX7?]$V\`
M_P#A'>'?_E=1_P`*I^%W_1-O`/\`X1WAW_Y74`4?^%X?"'_HHGA7_P`&D'^-
M'_"\/A#_`-%$\*_^#2#_`!J]_P`*I^%W_1-O`/\`X1WAW_Y74?\`"J?A=_T3
M;P#_`.$=X=_^5U`%'_A>'PA_Z*)X5_\`!I!_C1_PO#X0_P#11/"O_@T@_P`:
MO?\`"J?A=_T3;P#_`.$=X=_^5U'_``JGX7?]$V\`_P#A'>'?_E=0!1_X7A\(
M?^BB>%?_``:0?XT?\+P^$/\`T43PK_X-(/\`&KW_``JGX7?]$V\`_P#A'>'?
M_E=1_P`*I^%W_1-O`/\`X1WAW_Y74`4?^%X?"'_HHGA7_P`&D'^-'_"\/A#_
M`-%$\*_^#2#_`!J]_P`*I^%W_1-O`/\`X1WAW_Y74?\`"J?A=_T3;P#_`.$=
MX=_^5U`%'_A>'PA_Z*)X5_\`!I!_C7%:O\8OA;-XW\%W\7CSPU)9V.F^+HKR
MY34H3#;R7D>ABU25\X1K@P3"($_-Y3X^Z:]#_P"%4_"[_HFW@'_PCO#O_P`K
MJ/\`A5/PN_Z)MX!_\([P[_\`*Z@"C_PO#X0_]%$\*_\`@T@_QH_X7A\(?^BB
M>%?_``:0?XU>_P"%4_"[_HFW@'_PCO#O_P`KJ/\`A5/PN_Z)MX!_\([P[_\`
M*Z@"C_PO#X0_]%$\*_\`@T@_QH_X7A\(?^BB>%?_``:0?XU>_P"%4_"[_HFW
M@'_PCO#O_P`KJ/\`A5/PN_Z)MX!_\([P[_\`*Z@"C_PO#X0_]%$\*_\`@T@_
MQH_X7A\(?^BB>%?_``:0?XU>_P"%4_"[_HFW@'_PCO#O_P`KJ/\`A5/PN_Z)
MMX!_\([P[_\`*Z@"C_PO#X0_]%$\*_\`@T@_QH_X7A\(?^BB>%?_``:0?XU>
M_P"%4_"[_HFW@'_PCO#O_P`KJ/\`A5/PN_Z)MX!_\([P[_\`*Z@"C_PO#X0_
M]%$\*_\`@T@_QH_X7A\(?^BB>%?_``:0?XU>_P"%4_"[_HFW@'_PCO#O_P`K
MJ/\`A5/PN_Z)MX!_\([P[_\`*Z@"C_PO#X0_]%$\*_\`@T@_QH_X7A\(?^BB
M>%?_``:0?XU>_P"%4_"[_HFW@'_PCO#O_P`KJ/\`A5/PN_Z)MX!_\([P[_\`
M*Z@"C_PO#X0_]%$\*_\`@T@_QH_X7A\(?^BB>%?_``:0?XU>_P"%4_"[_HFW
M@'_PCO#O_P`KJ/\`A5/PN_Z)MX!_\([P[_\`*Z@"C_PO#X0_]%$\*_\`@T@_
MQH_X7A\(?^BB>%?_``:0?XU>_P"%4_"[_HFW@'_PCO#O_P`KJ/\`A5/PN_Z)
MMX!_\([P[_\`*Z@"C_PO#X0_]%$\*_\`@T@_QH_X7A\(?^BB>%?_``:0?XU>
M_P"%4_"[_HFW@'_PCO#O_P`KJ/\`A5/PN_Z)MX!_\([P[_\`*Z@"C_PO#X0_
M]%$\*_\`@T@_QH_X7A\(?^BB>%?_``:0?XU>_P"%4_"[_HFW@'_PCO#O_P`K
MJ/\`A5/PN_Z)MX!_\([P[_\`*Z@"C_PO#X0_]%$\*_\`@T@_QKX;_:Z\9^$_
M&6K^"IO"VOZ7K\5CINL17DFFW,=RMM)/<V+Q)*4^XTBQNR@\D*?2OO+_`(53
M\+O^B;>`?_".\.__`"NH_P"%4_"[_HFW@'_PCO#O_P`KJ`.^HKE_''C3PS\-
M_!?B_P"(GC75$T/P;X"\+^(/&GBW6I+:]O4T?PSX6TF[US7M4>STVVO-0NTT
M_2K&[NVMK"TNKV<0F*UMIYWCB9(O&_A&Y\%)\1K'7],U3P-+X8_X3.U\4:-.
M-9TF_P#"ITO^VH]<TRXTH7G]J6%QI6V^M)=.6Y-Y`T;6JS-(@8`ZFBO!;#]J
M#X`WW[/7@O\`:M?XH^&]'_9\^(?P]\!_%'P=\3/%;WO@S2M:\%_$_2-'UOX>
MWR:=XML]$U^SU7Q?9>(-$AT3PKJ.D6?BR[U?5++P^NAC7ITTT^6?#/\`X*`_
MLM?%3QQH'PWTGQ=\0?`WC3QG,EO\/-%^/G[/?[17[,+?%BZ.G:OK+6GP9O\`
M]I#X4?"K2_C+>0Z'H6K:_=6?PMOO%US:>'[-]>NHH=(DAO9`#[-HKX4^-O\`
MP4=_9@_9Y^*FD_!?XI1_M+V/Q"\2:X/#'@RP\'?L*_MR_%;0/B)XC7P1=?$F
M[T'X7^._A1^SGXV\!?%'6-)\#Z=K'B+7].^'OB;Q-=^';+P]XG378M.N?#'B
M"#3;'C/_`(*)?LU>!_&]Y\-[^R_:?\2^.=*\'>!/'GB'PW\+/V#OVZOC3?\`
MA#P]\3-/O]4\$CQR?A!^SCXYM_`FOZS9:5J;MX.\8SZ'XPTN;3K^TUG0M/O+
M2X@C`/N.BN3\">--'^(O@[P[XY\/V?BW3]$\4:9!JVFV/COP#XZ^%OC"UM;D
M$QQ>(OAY\3?#?A'Q_P"#]37:?/T7Q9X9T36;;@75A"64'K*`"BO,?`OQD^&_
MQ+\6_&'P+X)\1_VUXJ^`7CK2/AI\6M+_`+'U[3?^$3\;:[\./`WQ<TK1?MVK
MZ78:=KOVKX>_$GP5X@_M+PU>:SI,']M?V3<W\.MZ=JVFV%SX??%7P%\4_P#A
M-_\`A`]>_MW_`(5Q\0O$OPJ\9_\`$KUG2_[&\>^$/L1\1:#_`,3G3M._M'^S
MO[1L_P#B::5]NT:[\[_0=1N?+E\L`]"HKSOPG\6_AGXZ\9_$_P"'?@_QOX>\
M1^./@MK/AWP[\5_"^E7\=UK'@'6_%WA32_'/AG3/$EHAWV%WK?A'6]*U_3T?
M(GL+V*0$,)$3YQ^+'_!0#]FSX-_%W7_@1XFE^/?BOXK^$_!G@_XA>+/"OP._
M8Z_;#_:5;PIX.^(%_P"+-,\%:UXHUK]G7X$?%+P[X=C\3WW@7QA!I%GK6KV.
MH79\.:I(EIY=LSD`^TJ*^9?$O[9/[,GA'X!:/^U)KWQ>\.6WP!U[7O`7A?3_
M`(EVEMK>K:+_`&_\2_B3H'P=\)Z7J%KH^E7^L:/<2?$KQ-I/A/Q"=8TVPC\$
MWYU&;QL_A^PT/7;O3OH[4-1L=)T^^U;4[J"PTW3+.YU#4+Z[D6&VLK&RA>ZN
M[JXE<A(K>W@CDFFD8A4C1F8@`T`7**\)\(_M.?`+QO\`LZ>'OVM]&^*7A>R_
M9N\3_#+3_C+IOQ?\7W%Q\/O"5M\,=3T6/Q#;>,/$,WCVV\-7GA'3(M'E6]U!
M/%=GHMYI*B2'5;6RN(9H4\7\&?\`!17]DOQOXKT7PC:^-/B%X0N/%6L+X?\`
M!'BGXP?LZ_M)?`?X6?$?6Y=232=.TKX6_&?XV?"3X?\`PB^*-[KVH36T'A:W
M^'OC?Q+)XL%]ITWAH:M;ZC8RW`!]O45YWJ_Q:^&V@?$_P3\%]:\8Z)I?Q2^)
M'A3QUXW\!^"[ZX:WUCQ9X8^&E]X-T_Q[J>AK)&MO??\`",7/C[PB=3LHK@Z@
MEKK"7\5I+8VFH7-HOB/XJ^`O"7CWX;_#'Q!KW]G^./BY_P`)A_PKS0_[+UJ[
M_P"$@_X0'1H/$'BW_B966G7.D:3_`&3I%S!=G^W-0TW[=O\`L^F_;+I7A4`]
M#HKY&UO]N'X`Z3\.?!OQ8TU?CK\1O`?C[7/&WAWP[JWP/_9)_:S_`&@KX:M\
M._$FI>$/%D?B#PW\#?@E\0O$_@VUL?$FCZII5AJGC'1M!TOQ!-8W,OAR]U:W
MC,U><'_@I_\`L9O\%_A?\?;+QM\5-9^'OQH^,OB[]GOX86GAO]E;]K'Q/\4/
M%WQF\!?\+'_X33P#8_`GP]\$=4^.5MJ_A9OA%\2HM<EU+X=66GZ?/X.UB"XO
M4GBCCE`/T`HKXJ@_X*`_LZ?\*U^)?Q<UFQ_:8\#>!?A,/!B^+;[XJ?L-?MO?
M"+6KVY^(/B-?"/A+3?A]X,^*'[/'A'QI\7=9U+Q)-9Z1/HGPF\/>-M7TB[U3
M11K5EIR:WI#WJ_#W_@H/^RS\1?'>A?#&/Q/\3OAAX^\77UII/@?PM^TK^S7^
MTS^R3JGQ%UF^L]=U&#0_AG'^U'\(/@_'\2M>73_#&O7]UH?@23Q#JUC9:;/=
MWMG;P&*20`^U**BGG@M8)KFYFBM[:WBDGN+B>1(8(((4,DLTTLA6.***-6>2
M1V5$169F"@FOD3X+?MZ_LI?M">)AX0^$OQ/N_$7B"^\&:C\2?"-EJ?PY^*G@
MN'XJ_#329])M=1^)GP*U+QUX(\-:7\?_`(;6MWKVAVC_`!`^"=[X^\'M=ZSI
M5K'K3SZC9QS`'V!17S-'^V)^SC+^S%-^V.GQ&_XQWM_"5SXSG\;/X1\=QZO#
MIEG?2:1<Z5)\-Y/#"_%%/',7B"-_"I^&C>"Q\1F\8@>#D\*MXH9=(//?%S]N
MO]EWX$^+M+\$_%3X@:YX7U:]T70_$>MZDOPI^,.N^"?AEH/B>\;3_#&K?';X
MD>&O`.L?#S]GFP\1W\<]EX?G^.OBCX=QZU=6EY!IANY;.Z6$`^NJ*^$OC3_P
M4@_9=_9^^*.C_!OXG#]I6U\>^*-:3PWX)M/!?["_[<GQ8\._$?Q"?`UU\2KC
M1/A9X]^$_P"SIXV\`?%/5M+\"Z?K'B37-/\`AYXG\377A^R\/^)EUR+3[GPQ
MX@@TV?QQ_P`%%_V8O`'Q#D^$VJ)^TEXD^)-G\-_A[\6M<\%?"K]AO]M_XVZ_
MX/\``GQ5D\30_#_4_B!8_!O]G?QV_P`.]3\1W/@SQ9:0>%?')\/>+;*]\.:U
M9:EH=E=Z=<PQ@'W-17S?_P`-:?`JV@_9YDU_Q%XJ\"WO[5/C35?AU\#?#WQ0
M^$OQ?^%'C+Q1XWT;P?XU\>7OAO7/`WQ*\!^%?&/PXU)O"GP^\5:I8)\3="\'
M)JS6FG:?I,E[J?B+PW9:MW'QU^.7PJ_9H^#_`,1/CY\</%UMX#^$GPH\,:AX
MQ\?>+[K3M:UB+0O#VF(K75VNC^'--UCQ#J]RS/'!9Z5H>DZGJ^I7<T%EIUA=
MW<\,#@'K%%(CI*B21NLD<BJ\<B,'1XW`9'1E)5T92&1E)#`Y!((-?)OQ9_;?
M_9S^#?C.^^&_B'7_`(B>-OB/HUGIFI>)/AY^S]\`/V@_VI_'O@W3-;AFGT;4
M_'G@S]F;X6_%OQ+X!TS5X8&?2M2\9:9H=EJ"RVOV2>8WMF)P#ZSHKQ[X,?'_
M`.#?[0OA>_\`&'P<\?Z+XWT71]7N_#OB)+,7NFZ[X1\26$<4U]X9\;>%-<M-
M+\5>"/$UG;W%O=77AWQ;HVC:U;VEU:W<MBEM=6\LGS5J_P#P4W_8LT6[U"2Z
M^)_BRZ\$:+<:M:^(/CMH?P&_:'\3?LK>%Y-`DOHM?;Q;^UWX<^%.J_LO^$[?
M0I=.NHM;N_$?Q<TNUTF7[/'J$UL][9+<`'WM17A/QG_:4^#_`,`_ASHOQ7^(
M.N>([OP5XGUWPGX9\*7'PO\`AM\3?CMX@\7Z[X[F2'PAIW@_P-\#O!_Q%\=>
M+)->,B2V,OAWPWJ=NUJ?MDDT=H#././A+^W;^S)\9O'UA\)_#OB_QKX+^*^L
MV&MZMX;^%?Q_^!OQZ_9:^)OC#1_#4&E7/B'6O`WP^_:8^&?PE\8>.M$T*#6]
M,DUC6?"&C:WIFG"X87=U$UO=+"`?7M%?&/Q0_;Z_9V^$GQ3\2_!;7X/VB?%O
MQ(\&Z'X4\1>+M#^!W[%O[9W[25CX8TGQQ%JL_A*7Q!XH_9X^`7Q0\)Z/=:]#
MH>KS6&EZAKEOJDD.GW,KV21IN/U%X$\::/\`$7P=X=\<^'[/Q;I^B>*-,@U;
M3;'QWX!\=?"WQA:VMR"8XO$7P\^)OAOPCX_\'ZFNT^?HOBSPSHFLVW`NK"$L
MH(!UE%>"?%?]I[X&?`_4M?TGXJ>.X_"%SX6^!/Q6_:8\2W%WX?\`%=]I'A_X
M(?!*X\,6WQ+\<:UKVCZ%J&AZ;%H,WB_0S::!>:C#XI\30MJMQX4T/7+?P[XB
METKV[3=0M-7TZPU6PD>6QU.RM=0LI9(+BUDDM+V".YMI'MKN*"ZMW>&5&:"Y
MAAN(6)CFBCD5D`!=HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@#Y4_;M_Y,?_;)_P"S5/VAO_51>+Z_)/X9ZF/^":'[/G@CX7>*=:U/_A@W
M]I+X*6-C\$?%7B*_N=1TW]D?]H#Q[\+H[_\`X4)XB\17[2W&D_`CXV>*;G4K
MSX%ZGX@OGTWX??%#67^"%I?67A[Q9\(O#FE_NO\`%GX;Z%\8_A7\3/A#XGNM
M5L?#7Q4^'_C+X;^(;[09[.UURST+QQX<U+PQJUUHUSJ%CJEA;ZK;V&J7$VG3
MWVF:E9PWB0R7-C=PJ]O+R_B/]G_X5^./@#??LR_$+PS:?$+X/:S\,8?A%XC\
M,^,(;748_$O@V+P]#X9>WU@P6UG`U_/801S_`&^PMK"2TU)8]0TQ;&X@MFA`
M/PL_8EW>);'_`(-TO`7Q"@BNOA#9?\$DU^+_`(`TS4K"VN]`U?\`:S^'GP,_
M8KT+X>WL\EU#)'_PEW@KX)>/OC_XD\#60E290WBGQ196MQ?>$+;4]`_4/_@J
M/HGP[U?_`()\_M;:A\2[R;1=+\$?!+QQ\3/"_B[3;..\\5^`?BG\-]%NO&?P
MB\?_``]0V]U<Q_$SP;\2]%\+:]\/'TZ"35'\7V>D6UA'-<SI#+Z+9?L4_`JS
M_9J^!G[++:;XEG\!_LV>"/A?X,^"?BJ+Q1J6C?%;X>W'P=\%6?@'P'XX\,_$
M3PT^B:UHGCW3_#UFUI?Z[HYL(-:M=1UK1]6TZ\\.:WJNBW?G.E?L#:/K7B/P
MKK7[1/[3'[3O[8.B?#SQ5X;\<_#CX<?'W5?@=H_PQ\(>,_!]W<:AX6\4:EX-
M_9V^!/P#L?BWK/AK4VTW7?#-S\?7^+0\+^+?#WASQUX;CTGQSH]MXD4`^=OV
MJKSQ%J/[2'_!"W4/&%O]D\6WW[4'Q/O/%-KL$?V;Q'<_\$T_VMYM;M_+``C\
MC4WNH]@`"[=H`Q6/I_AG]K37_P#@I)^WI)^S9\;/V=OA/IMM\,/V*4\56GQP
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M>33%E@1P`>NVOP,\;:]X_P#V>OB_\2/CQ\09O'WP5\%?$3PWXM\$_!NZU;X2
M_LQ_&W7?B7IWABRU#Q7\0/@7KWB3XJZS?7'@:?PTU]\)+;4_BMKMYX%G\0>)
M#/K/B!]3,L7TG7S=:?L\ZK_PGW[/OQ&U_P#:._:1\4ZU\!O!'Q#\&ZCHUWXP
M\&>%O`/Q^O?B)8^%K*?QY^T%\-?AK\/?`O@'Q=XX\''PNU[\/+KPKX<\#^'_
M``??>)?%4VG^'"FIQ1V?TC0!^%OP"\5?MDZ#^VO_`,%<;7]G+X#?LR_%7PC+
M^V=\()]9USXV?M:_%/X`>([#Q&?^">'[%,<VE:9X6\"_L5?M+:9J^B1Z9'IE
MW'X@NO&.B7TM_=WVG-X:AM].M]5U3LOV2_V@;W]G7]E7_@HK^T?^T?X9\/>%
M-5^%?[7G[5_CSX@>"/A9XOU_XJZ.VKZ/:>$YK3P;\/\`Q;K7PY^&'B/QMJ7B
M741IOA_PU)=?#/POJ&J:[JUII\>B(\D;3?I7\*/V?/!GP=^(?[27Q+\,ZGXG
MOM=_:C^*_AWXQ?$"TUV]TJZTG1_$_AGX*?"GX#V%CX.@T_1=,O-/T*;PA\'_
M``UJ-Y::U?\`B'4)/$E]KMY#J=OIESI^CZ9XEXC_`&`/@UXLTN;PYKWB'XBZ
MEX/U7]LFT_;=\6>#;K4/!T_ASQO\3M'U&R\2^&O!_B>&?P/)J$WPN\+^/M#\
M(?$;2-"TK4=)\23>*_!GAZ+7/%^L>%VUSPWK0!^%W['Q_:*_8S_:(_9__:B_
M:1_9/_:`^`FJ?MH7VO\`PG_X*2?&'XG>)_V0-0^%'B/]H/X[?$Y?&/[(OB+1
M;CX1_M0?$_XMV.@?!7QIXGUK]D+X:1^-?A7X/@?X;?$WPF_C74-%U_PM8:3?
M>R?M)_M8_'#]CS_@J1^VO\3_`(9?`;X9?%[P!J'[,G_!,7P;\8O&GQ,^/'C?
MX+Z%\"-.\6?%7]N/P_X.^)?B2#P'^S9^T9K>O_#2+Q!J;V'Q'\06FEZ3+\.+
M*;2/$VI6FH>#W\7>(O!'[U_M#_`;P/\`M.?!#XG?`+XD?VU#X,^*?A34?"VK
M:GX6U-=$\6^'9[@)<:-XO\&:X;>[_L'QMX,URVTSQ7X-U[[)=-HGBC1M)U5;
M:=K01-YSX>_8Z^%^D_%CXV_&#Q!J/BOXD:]^T+\!/@I^SK\5=#^(<GA36?"'
MB3P+\#V^+S:1>7.AV'A/2#-KWC0?&SQDGQ`-Y=W7A_5HH])AT;P]X>BM[]-3
M`/RZ_:&_8U\'Z3^RM^S]^Q]^T#JOA;XG+^VM_P`%0]*^)OQ;T?0=`MM`^'?B
MGQ'XZ^+7Q1_;L\?_``^\.>'EB>?4?`=CI/PRUS1TE\1R:CK?BK2=+O/$/BZX
MNM0U34@/??!?Q1\3_%[]GCX0?LD>-[F[UOXQZO\`&CQ;^R+^T-<:E::/)=:O
M\/?V9+^[NOC3\1O%&D6&K2VEEX<_:1^#7A_P8NF0V\CW6G_\-2>`[B\\/VUJ
M=0TZQ^H?A]^PM\-_`/AW]DOPQ-X^^,OC[3?V*/'WC'QW\"9OB+XNT/Q%J^G)
MXD^%7Q6^!_A[PEXLUR'PIINK^-?#?PQ^%'Q@\2>#/`-[X@O;OQNUKIWA[5O'
M'C'QKXBLKW6=2Z?P9^QM\(/`?[6GQB_;,T)/$8^+'QM\">#O`OBK3;G4=,?P
M/IO_``BMMIFFZGXP\-:%!H]M?Z?X[^(?A[PE\*_"OQ'\17NMZFWB3PS\%/A%
MI$=KI]OX.A-V`?BO^SCIW@34/V:?^".'[.WBT2/\`_`?[9G[1G[/.M^%M7TQ
MM7\,>+/B9^Q(_P"U?X1^`'@_Q]+KUC=.NG:;\1/@C9_$7PU)?2PKJ7Q.\`?#
MZ&&ZO+NXL8+O][?VB?"GPK\<_`7XR>%/CC#I,OP>UGX:>,[?XER:XT,6F6'@
MR+0+ZYU[6)[J:2)=.DT/3X)M9M-6CGMKG2+VQM]4M;JUNK2&XB\AM/V$/V>3
M\$?BA^SSXA\/:YXP^%WQ8^-OQ9_:#UC3-<\17UAK?A?XG?%_XS:Y\?\`5?$/
MPW\7>$3X7\5?#W5?!OQ7U^[\7_"_Q+X7UC3O&GP]UBUTK4_#WB>VU72K'4(>
M$_X=_P!IXG8Z#\=?VK_VMOVF?@]%>)=6GP`^,?B3X(V'POFM[34XM3TG1/&6
MH_!KX#_"/XL_&7PWIC6UE:S^'?CO\4/BCHOBFSM%3QW9^*Y[O4Y[X`_#VW^#
MGQ+_`&UO%7_!`V7XW^,_''P[_:FM_P#@E7^TC\<O#/QEMS>:9\1/AU^TCH-I
M_P`$[-0T/XDZWI&_3XM4O-4EU;5+#XI>`->MDT/QCX:\5>-?`OB+2XM-UN\M
MH?O#P;^T]JOQR_;>_84^''Q;\,0_##]JKX":S^UQX,_:!^%0DE?3X-2N/@GH
MESX7^*OPUOKDE_%?P1^+^B+%XM^''BFW>:2UBGU3P+XI72OB%X,\8>'])_5+
MQ1^S9X&\5_M'_!?]I^^U'Q1:^._@3\+OC;\)/!^B:=>Z-!X+OO#/QXUCX0:U
MXNNM?TV?0KG6;C5]+N?@KX5A\,3Z7K^D6%C:W^OQZGINL276G2Z5#XQ_9:^#
MGC?]H?X._M4ZOX7C@^.7P.\/^//!O@[QOIQM;6_N_`_Q'TDZ;XE\%^)&:UG?
M6/#OVN.R\0Z1;F6VN]&UZP$^GWD%EJ>OV&L`'Y/_``H^-WC+X(?\$AO#\WPF
M:%_C]\7?C!\=?V>_V;[2?3]0U6!_CK\:_P!K_P",O@CP)KFH:?I;1WT_ASX?
MRZA??$[QM/#-;)IG@7P3XFU>ZN[2ST^XN8J_[;'P"US]G_PI_P`$0_V=?V:/
M%?A+P/KOPL_;E\+^`_`7C;XL^!_%'QC\/)<^'_V"_P!LV#5_$WCGP?HOQ3^$
M?BKQMJWBA8M8U+5;F+XJ>'-0N/$VL/KU]J.H>7<Z=J'UMXH_X)>>#=1T7]F'
M2?A_^TW^T_\`!:Y_9*\=_';XE_"[6_`<7[+OBJ^NO&_Q_O\`Q?-XF\1>*--^
M.G[,?QB\*WFI^&-&^(7C[PGX#O=$\.>'[O0_#GC'78KZ?6-5GM]6M>V^*O[!
M&I?&?P+\`M!\<?ME_M777Q._9M^.MS^T#\-OVC-/TG]CO3OBU'XMN/AW\2OA
M9'HVN>'(/V23^S[JWA6T\&?%;Q386]I_PHRVUMK@:9J%UK]U>6DDMP`>%?M?
M>'/VIO#_`.R!\4?^&EOC)\`/BU]K^,'[&7_"%?\`"C/V:OB+^SQ_PC_V?]K?
MX2?\)'_PE'_"??M8?M0?\)A_:OG:#_8G]D_\(/\`\(__`&;J_P!O_P"$F_MN
MS_X1_P!O_P""K6@^`-9_X)Q_MFZG\1KR#1-,^'W[/GQ-^+?AOQ@;:&XU;X>?
M$CX2^%M3^(?PO^(WA1WM+Z>T\:>!OB!X<\.>)/"-WIUM+J<>O:?8I8))<R)&
M^QKW[$'BKQ]\&OBE\&/B_P#MO?M:_&'3_B+??#/5]!\:>+M!_8K\.>-?A!KO
MPL\<V7Q#T;6OAO\`\*E_8[^&O@S4;K6/$FC>')O$%K\6O!GQ2TF6T\/6%IH^
MF:+'>Z^=8SH/V`O^$HU_PGJ?[1W[7/[6/[7/ASP/XJT+QSX:^&/QFO?V</`W
MPM'B_P`-3R7N@:QXN\'?LJ?LW_LW6OQ4M]%U86'B#2?#7Q<G\>^#],\2:)H?
MB+3_``]::SID%\`#ZP\,:?=?$7X+>'M+^).GN][XZ^%^DZ?X_P!*83V#M=>)
M_"EO;>*M/8+Y%S9.9KZ^MF51#/;$X'ER)Q^?G[/%QXR_9<^,OP)_8F^//AG3
M/B?H6G?#;QKHG[$?[72Z5H$?B6\\)_#W1]$'B'X!?%C3YI6U?PW\8=*^&NG:
M5JD/C?P9$G@OXU>$O`^LZQKFG^#_`!5X??1=8_2GQUX%\,?$SP3XO^'7CC1X
MM>\&>//#6N^#_%FAS7%W:1:OX<\2Z9=:/K6G/=Z=<V>H69O-.O+B`7>GW=K?
M6K.)[*ZM[F**9/DOX-?L-Z!\*/B+X2^)?B[]H#]I7]HO6?A=X<\3>#_@?IOQ
M]\8>`M:T/X+>&?%J:?9ZW;>&+?X=_#/X:ZAXX\33Z%I5AX6B^*/QSU+XM_%^
M#PR=6TB+X@B'Q3XN.O`'P;>_L?7\G_!3.R^#G_"9:1%^Q3>3WG_!3>Z_9TC\
M,JXO_P!KVP\91^![B6_U2ZN[G1V^$D_Q$UFP_:I/A.TT&UUF3]IW3H?'KZ^E
ME'/I.H>Z?M9>"O'7[+OC+X\?MH^$?#>G?';]G#XC_#6Q/[=G[*NM^&K/Q!XB
MU[P=\,/!NJ:#<?&?X'RW"S6GB#Q1I?PR4>'OB7\"O%FEZQH7Q<\)>&M$C\&Z
MEX/\96&H6OQ`_0.3X.^&)/CI;?M`&^UX>,K7X3WWP>CTP76G_P#",GPQ?^,-
M.\:S7SV9TLZJ==75=.@MX[I=:73QI[RQ-I;W+)=Q_,?Q3_X)^^!/B;XS^*.O
M6GQL_:,^&7@;]H&2*7]I7X(?#3QGX,T_X6_'Z>/PEHG@&:X\5S^*OAUXN^)_
MP\NM5\#^'-$\)>)+S]GSXE_!B[\7:%IMO:>*Y]:(:1@#P?\`;(U?0_$'[5O_
M``1'U[PS+!/X;UO]K;XP:OX>FM8#:VTVAZE_P3?_`&O;S29;>V,<1MX)+":W
M>&`Q1F*-EC,<97:/'_\`A'?VHO$'_!83]NH?LT_&+X!_"62T_8P_X)Y'QDWQ
MR_9L^(G[1":\D_Q`_;H_X1]/#$?@']JW]F!O"3Z88M9.L/JLGC8:Z+_2ELD\
M.G2+MM;_`%!^(_[,'PX^)?C[]E?X@:C<>(?#]]^Q_P#$'Q%\1OA5H7A6XT73
MO#%UJ?B/X(_$;X!SZ-XIT^\T+4KJZ\.:=X*^)NN76DV/A_4/#EW;:]8:'<3:
MA<Z5;7ND:AXA\2/V$+WQ5^TA\0/VH?A=^V#^U/\`LS_$+XI_#/X4_"GX@Z7\
M&]*_9%\2>$O$OAOX+ZO\2];\!74NG?M'?LH?'W5M)UC3[OXM>-%O;GP_KND6
MFIP7EFEW82OI]M(H!\3_`+='PN^*'QU^.?[$/[._B/7_`(>>+OVF?`O[/W[9
MW[7WP_\`B9X=^&NL^"?AAX;_`&C/@)<_L[^"?@AX^TWX;:]\4OB%XKT#3['Q
MQ\;;&.?2/^%O:KJ-QHT7B&Q/BNT35XTCH?MNZ]HW_!4/]BG7OA!X&@O=.\/?
M$[_@G_\`%_\`:<\<Z'KVG&'5_!WBWQ?\)?&7@7]G+P#X\\'ZI':ZU9:[I7QI
MD\;^.C83+I=_H_CC]F.33[JZMKA3!+^L'@7]GVS\*^-_!WQ/\4?$OXC?%SXG
M>$/@_JWP7/COX@V_PQT[5O$>@Z]XPT?QKK>NZYI/PK^&GPT\(VOB74]2\.^'
M[2Y;PMX;\->'/[/T:R6+PW%??:+^XY'X$?L9_!S]G>X_:+F\!_\`"77D/[37
MQ1\6_%+QS8>*O$3:[IOAVZ\9K<W&K>"/AS9-9VL/@[X:P^(-8\8>,=-\'6RW
M-I8^+?'WC;5XYB=<>"$`])^`7BS_`(3O]GKX*^.M,:*X'C+X,_#CQ9ISR,S0
MS_\`"1>"-&UBT:1B(G,4GVR,LQ$;%&)(0Y`^-O\`@D'IRI_P3\^`?BW7!YWQ
M@^)^DZW\3/VFM3O+O^T/$.H_M2^+?$>JWO[0=MXHO'N[Z9-7\+?$]?$7@B'0
M7NFM/!>B^&-)\#Z+;:=H'AO2M,L_LK]G7X'^%OV9?@!\$?V<O`VJ^)M<\$_`
M/X2_#SX->#M7\9WNF:CXMU'PK\,_">D^#/#MUXDO]$T;P_I%YK4FD:-9G4;C
M2]!T>PEN?->TTRR@*6\?@OB[]B#2V\8^+O'GP!_:)_:*_8\U_P"(VMR^)OB5
M:_L^W?P2UOP7XZ\3W0<ZGXKU#X8?M)_`_P#:%^&'AWQCKT@M9_$_C/P#X-\'
M^+/%5QI]I+XDUK5F-U]J`/(O^"JVFZ?X(_8G_:+\8^&-)T+P>?B1K7[/OA']
MI;XCZ1);>"?$A_9HU?XV?#;X=_M">*O$'C_2-2\,:];_`/"OOV9_$7Q1N],\
M13^(X+SP;I5M<W^CW$#6B02?H]H/AWPUX>\-:1X5\-:+HVD>$=(T:ST30_#^
MCV%G9Z!I^@6=G%9V&E:=IUK&EC!I<%BD=M;6D$2VJ6RK&B>7@5X1\(?V4_A;
M\)/#OQ)T::7Q;\6=7^-,C2?&GQQ\;_$<WQ)\7?%:/^Q)/#,&E^*WU2WA\.V_
MA6P\-RS:#IG@3POX=\.>`]*TRYOH=-\,VK:EJ4EWX2?^"?$-CI2_#WPG^V3^
MVYX"_9\_L^\T4_L[>$?B=\-8/#%MX>O$NX3X<\/?''6/@WK7[9O@31+"VN+>
MQ\/VGP[_`&H?"3^%--TO3=-\+2Z-IT=Q:W0!\"_#=-`TWX,^!O!WP]U!=2^"
M/PY_X+:CP#\")8-7GUK2M+\`>'OC#J2Z]X-\-W4]Y?)9^#_AK\7;GXH?#/P;
MHEC*FD^'/"O@_1_#^CVUKI6F6<$?VY_P5ATW0H?V/]3^(4D\&E_$GX0_%_\`
M9Z^(/P#\0I?RZ1K.F_'.#XY_#_P_\/M#T/5+5X[Y7^)>IZ^WPHUW1[60#Q7X
M6\<ZYX5NHYK369XS[E\5OV./A[X]^!_PT^!/P]\4^-?V:/#GP9\6_#OQG\)M
M>^`UC\+XM>\`ZO\`#"\-YX:CTG3/B_\`#3XN_#[4;%G>5=6@\2^!M=DU+SY[
MJ69=1E>\/)^#OV(+>#QYX.^(OQX_:;_:6_:\UGX;:Q#XG^&6D?'NX^`?A[P-
MX$\76L-S;V'C/3_AY^S/\`OV=_!'B3QAI$=[>GP]XE^(.@^,M7\,7%RUYX;N
MM)O8;6YMP#Y(T_PS^UIK_P#P4D_;TD_9L^-G[.WPGTVV^&'[%*>*K3XX?LN_
M$K]H2]UF^D\.?&UM,N/#^H>`OVOOV8X/#-K:0"[CO[/4M,\6S:C-/;3V]_I2
M6LEO>?KCX(M/&UAX0\.67Q(\0>%O%GCVUTFSA\6^)?!'@_5OA]X0UO74B`U#
M4?#G@C7O'/Q,UGPMI-S/NDL]%U/X@^,+RQB(AGU_474SM\<?$']B'7O$?QV^
M(_[0'PM_;._:L_9K\3?%KPW\-_#7C_PW\']$_8Y\2^$-<@^%5KXDLO".IK;_
M`+17[(_QY\2Z7J<%KXJUB*^_L?Q/8:;>B6%Y-,66!''V/X(\/:MX3\(>'/#6
MO>.?%/Q,UG1-)L].U/X@^-[3P38>+_&%Y;1".?7_`!'9?#?P?\/O`5KJVHN#
M/>0^$O!'A;0DE8C3]%L8-L(`/XX?^"@GQ4/CGX^?MO>%/$O[6O\`P5"D^''B
M?X;?LT_LC^'?"8_X)O22:9JFJ?M:_M/_`!$\(?&[X%1ZW<_\$KGNY/AE8?#[
M4?A(WP,F7Q5+\5_COK-W=Z5X0^)?QMU&\T#18/ZU/V:WN)_@EX#O+GXF_'#X
MP-J-CJ&I0_$#]I'X4Z/\#_C5K%IJ&LZC=V=MXY^%&A_`O]FNU\$W>B6LL.A:
M=I-S\$_`^K-HNFZ;=ZU:ZIJUS>:YJ?`W_P"QY\.M5\?>.?B%J?B?X@W^J>/?
MVBOA%^TIJ>F7.H>%FT33O%/P2^&?@OX:^!O"&BP+X06_MO`%NW@?3_'M]I]U
MJ5]XFF\?:EK6H6WBNST"ZMO#=E]8T`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!3D.#R>O`_,?RR!],=_O-
MJI>Z?8ZE#';ZA:P7D$5YI^H10W,:RQI?:1J%KJNF72HV0)[#4K.SO;60#=!<
MV\,J%60$`&G13-X]#^G^-&\>A_3_`!__`%=\&@!]%,WCT/Z?XT;QZ']/\:`/
MSP^*G[5GQP\,_MH>(?V=_AU\-_`OC/P9\/\`]C&?]JKQ1#?7_C&W^)GC#6+W
MQ9\5O`OASX>>`(_#VD>(=.CNM0\1>"O#AEGO?#^K7LUIJ>IP:=8W6H"P@;PS
M2/VY?V[IOA1^R/XOU3]@+Q7%XV^+GQ8U7X<?';PCM\5V-Y\)]-T;4H/AO_PF
MFN:='I.MQ^!/!NN?%75K/6K'Q,WB'XHQ6GP9T:^\=66E>)M+U34-9\$>C,NH
MZ)_P6-O]:U+P]XNB\.>-O^"=W@3P)X;\60^#_%%[X,O?&7AW]H/XS>--:\,W
M/C*QTFY\+:1K5CX7\K5WL-9U?3YY8+O3X[=)KG4M/@N?T\WCT/Z?XT`?DI\5
M?VV/VP_!B_\`!16\LOV6=.\*>%/V0_A9K'Q5^#?Q,^)J>.;#X;_&_3/!.DGQ
M7XHTO1]>TW3H9/$-_JGA'2_$+&2PMO#5OX$\6)HNAA_B5H=YJ'B[3/TI^#_C
M6[^)7PE^%WQ%O[*WTV^\??#KP3XUO-.M)));6PN_%7AG3-=N+*VEF_?26]K-
M?O!#)+^\>.-6?YB:^>/^"B=S(O[!'[9UC::9K^MZIXA_9A^-_@_0=$\,>'-=
M\6>(-;\3^-OAUXA\(>%]&TGP_P"&=.U;6]1O-6\1:WIFGQK:6$R6_P!I-W>/
M;6-O<W4/KG[-.GZCHO[./P`T;6=.O])U?2/@G\*M,U;2M3M)[#4M+U*P\"Z!
M:WVGZC8W217-E?65U%+;7=I<Q17%O/%)#+&LB,H`/<**9O'H?T_QHWCT/Z?X
MT`/HIF\>A_3_`!HWC&<-W['MUQZ_AF@!]1N3TQQZ^O\`A2[QZ']/\::SY!`'
MY_Y/YT`,HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
,*`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g30330image7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image7.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`#@!
M30,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/Z\O^"3_P#RBS_X)J?]F`_L;_\`K.OPYK[^K\(_^"9?[*'QX\1_
M\$W?^"?7B'1_^"FG[;W@+2-=_8A_90UG2_`OA/P%_P`$W;SPKX+T[5/@/X"O
MK'PGX:O/'7_!/KQIXVNO#_ARVGBT?1KGQCXQ\6>*I].L[:7Q#XEUW5VN]4NO
MM[_AC?\`:*_Z2P?M_?\`AN?^"6?_`-+4H`^_J^`?^"3_`/RBS_X)J?\`9@/[
M&_\`ZSK\.:/^&-_VBO\`I+!^W]_X;G_@EG_]+4KXA_X)E_LH?'CQ'_P3=_X)
M]>(='_X*:?MO>`M(UW]B']E#6=+\"^$_`7_!-V\\*^"].U3X#^`KZQ\)^&KS
MQU_P3Z\:>-KKP_X<MIXM'T:Y\8^,?%GBJ?3K.VE\0^)==U=KO5+H`_=RBO@'
M_AC?]HK_`*2P?M_?^&Y_X)9__2U*/^&-_P!HK_I+!^W]_P"&Y_X)9_\`TM2@
M#[^HKX!_X8W_`&BO^DL'[?W_`(;G_@EG_P#2U*/^&-_VBO\`I+!^W]_X;G_@
MEG_]+4H`^_J*^`?^&-_VBO\`I+!^W]_X;G_@EG_]+4H_X8W_`&BO^DL'[?W_
M`(;G_@EG_P#2U*`/OZBO@'_AC?\`:*_Z2P?M_?\`AN?^"6?_`-+4H_X8W_:*
M_P"DL'[?W_AN?^"6?_TM2@#[^HKX!_X8W_:*_P"DL'[?W_AN?^"6?_TM2C_A
MC?\`:*_Z2P?M_?\`AN?^"6?_`-+4H`[']O/]K&]_8N_9[U+XX:?X'TGX@7-C
MXM\'^&/[#UW5OBQH^CV]OXGU9+&\UO4KCX&_`+]I[XK36FB68N+^:V\'_!'Q
MI=NL1DOH])T>+4=;T[Y5^'O_``5#\3ZEX@\?:G\;?V9]6_9X^#?PTU[X9Z#X
M^\?>.->^,$FK_#NZ^(7@9-3NX?&VJ7?[,V@_LO:SJ7A/XHZOX1^$6NZ-\"OV
MMOCIJ.EZGXAEU_Q)#X:M=-73=0]<\0?L'_&7Q9:V]CXH_P""H7[<WB*RM+V'
M4K:SUOX3_P#!*C5+6#4+>.:&&\CM[W_@F?-"MQ%#<W$22A-XCGE0';(X/EVC
M_P#!**;P_/XMN-%_;W_:RTY_'NFZ=H_C5;;X#_\`!)=8/%6EZ3!I]MIECKMJ
M?^"9#6VI6]C!I.EQVT=U#((AIUD5PUK"4`-9/^"D_B2QU?2E\7_L\+X#\/7]
MKX/LIY/$_P`4KI/&2>./$/Q"\(>#/$?@33?#.E_"[4_#FIZY\.M*\60>*/%%
ME)X^T_6M1MH73P9H7BG2-*\:^(O!>Y!_P4+\5^&=2^%5G\6?V=WT>'X[2>&?
M%OPK3X/_`!0'QOUG_A2OB'PWJ7B"]\9_$#1[;X>>"5T3Q]X1CL8[K7_AI\.]
M0^+>DZ[H,EW?_"_XD_$;7M-N?"M<M?\`_!*Z^U7QC-\0M4_;Z_:OU'QW<K;+
M<>,+[X!?\$D;OQ'.++Q'%XOL_.UB?_@F))?2&T\4PIX@MB\Q,&K&2]B*SS2N
M\?@W_@E/<?#O4+O5O`?[>G[5?@[5+[Q1'XUN]0\-?L_?\$C]&O)O%D%GK^GV
MVOM<V'_!,."5=2M++Q7XHM[*=&4V2>)=?-H(6UG46N0#Z!_94_;1M_VI/&?C
MS3=&\'^&]!\!Z38R:S\+_&5I\2'\5:G\7_"]CXDU#PGJGCS0-$L_`^G>%E\"
M+KFGR6&G:MH/Q%\8:OO:SNO$_A[PEI7B/P-J7B_[FK\L/!/_``3(\2_#7Q'X
MG\7_``\_X*&?M>>!O%/C5HW\7>(?"7P)_P""2OA[6/$C1RM.K:U?Z5_P3&M;
MG4&,S>:[7,DAED2)Y"[0Q%/4?^&-_P!HK_I+!^W]_P"&Y_X)9_\`TM2@#[^H
MKX!_X8W_`&BO^DL'[?W_`(;G_@EG_P#2U*/^&-_VBO\`I+!^W]_X;G_@EG_]
M+4H`^_J*^`?^&-_VBO\`I+!^W]_X;G_@EG_]+4H_X8W_`&BO^DL'[?W_`(;G
M_@EG_P#2U*`/OZBO@'_AC?\`:*_Z2P?M_?\`AN?^"6?_`-+4H_X8W_:*_P"D
ML'[?W_AN?^"6?_TM2@#[^HKX!_X8W_:*_P"DL'[?W_AN?^"6?_TM2C_AC?\`
M:*_Z2P?M_?\`AN?^"6?_`-+4H`^_J*^`?^&-_P!HK_I+!^W]_P"&Y_X)9_\`
MTM2C_AC?]HK_`*2P?M_?^&Y_X)9__2U*`#_@D_\`\HL_^":G_9@/[&__`*SK
M\.:^_J_"/_@F7^RA\>/$?_!-W_@GUXAT?_@II^V]X"TC7?V(?V4-9TOP+X3\
M!?\`!-V\\*^"].U3X#^`KZQ\)^&KSQU_P3Z\:>-KKP_X<MIXM'T:Y\8^,?%G
MBJ?3K.VE\0^)==U=KO5+K[>_X8W_`&BO^DL'[?W_`(;G_@EG_P#2U*`/OZBO
M@'_AC?\`:*_Z2P?M_?\`AN?^"6?_`-+4H_X8W_:*_P"DL'[?W_AN?^"6?_TM
M2@`_8W_Y.*_X*P?]G_?#G_UUG_P34K[^K\(_V4/V4/CQJGQX_P""FEC8_P#!
M33]M[PY<^'/VWO`6C:QK&C>`O^";L^H^/=1G_P"";G_!/KQ#%XL\61>(?^"?
M6NZ19^(+/2-=TOP+;6W@72_!?A5O"O@OPU>7?AJZ\;77C'QCXL^WO^&-_P!H
MK_I+!^W]_P"&Y_X)9_\`TM2@#[^HKX!_X8W_`&BO^DL'[?W_`(;G_@EG_P#2
MU*/^&-_VBO\`I+!^W]_X;G_@EG_]+4H`^_J*^`?^&-_VBO\`I+!^W]_X;G_@
MEG_]+4H_X8W_`&BO^DL'[?W_`(;G_@EG_P#2U*`/OZO@'X<_\I3/VR/^S`?^
M":G_`*T5_P`%8*/^&-_VBO\`I+!^W]_X;G_@EG_]+4KR#]D_X:>-/A7_`,%(
MOVU_#WCK]H3XO_M*:O>?L0_\$W]9M_'7QJT7X!:%XJTG3KCX\?\`!4NQA\)Z
M?9_LZ?`_X!>"9/#]C<Z=>:Q:W.J>#M2\5/J.NZK%?>);S2(=#TO1@#YT^&7[
M).K_`+;/_!"7_@F]\!]'USPCX<DU3]CO]@+Q1=:MXX^'GPR^+/ARVM_"'P'^
M'NMPB^^&WQF^'7Q7^%_C%)=2M["-]*\8^!=9L4@::_L38ZU9:9?VU'X#?\$M
MOC9\"1\;/$OPM\1>&/AK\9-?\6^#]:^%?Q-U[7?`OQ/NTT72-,\6?#B2P^*G
MC[2?V=?AE^U!\;M7T;X1>/O$<=OJ?[1G[0OQRLF^(EAH'B3P?I/@&S@DLDVO
M^"9?_!,O_@F[X]_X)N_\$^O'7CK_`()]?L0^-/&WC3]B']E#Q9XQ\8^+/V4/
M@/XC\5>+/%7B/X#^`M8\0^)?$OB'6/`5YJ^N^(-=U>\N]4UG6=4O+K4=4U&Z
MN;Z^N9[F>65OJ:/_`()T_P#!'>7XDW/P?C_X)^_\$ZV^)UGX)L_B/<^"A^Q]
M^SO_`&Y#X&O]<O/#5IXF:W_X5ML.F3:]876EB59"Z74062-%EA:0`^\OA;X7
ME\">#M+^']OH%AX?\+_#^TTSP1X`AL_$EYXENM0\">&=#TK2]`U/6Y[W0]%E
MTW7)DM[BVO\`2UDUQ$^R17QUZ\EOY8+3Y%_X)/\`_*+/_@FI_P!F`_L;_P#K
M.OPYH_X=/_\`!+/_`*1J?L`_^(;_`+.O_P`[FOB'_@F7_P`$R_\`@F[X]_X)
MN_\`!/KQUXZ_X)]?L0^-/&WC3]B']E#Q9XQ\8^+/V4/@/XC\5>+/%7B/X#^`
MM8\0^)?$OB'6/`5YJ^N^(-=U>\N]4UG6=4O+K4=4U&ZN;Z^N9[F>65@#]W**
M^`?^'3__``2S_P"D:G[`/_B&_P"SK_\`.YH_X=/_`/!+/_I&I^P#_P"(;_LZ
M_P#SN:`/OZBO@'_AT_\`\$L_^D:G[`/_`(AO^SK_`/.YH_X=/_\`!+/_`*1J
M?L`_^(;_`+.O_P`[F@#[^HKX!_X=/_\`!+/_`*1J?L`_^(;_`+.O_P`[FC_A
MT_\`\$L_^D:G[`/_`(AO^SK_`/.YH`^_J*^`?^'3_P#P2S_Z1J?L`_\`B&_[
M.O\`\[FC_AT__P`$L_\`I&I^P#_XAO\`LZ__`#N:`/OZBO@'_AT__P`$L_\`
MI&I^P#_XAO\`LZ__`#N:\M^,_P"P5_P1B_9Y^'FJ?%?XS?L"?\$\_`GP]T76
M/!F@:GXFU']B[X$7EI:ZS\0O&WAWX<^#-/:VTCX5ZCJ$D^O^-O%GAWP]:>39
MR(EYJD$ER\%JLUQ$`?%W[6OP&_;^\2^'?CM#^S@/VMO#'Q&\<?M,>&[WQ_XL
MU']I3QUJ_P`-O$/[,UO^UM\,KZQT?]G?X<:3^U_\*]=^%FN:3^SZOBRX\767
MP'\6?LE>)_&7@S3?&GA#4/B5!\2/$G@+7;#OO`/P9_;"T/PYJ7AGQCX:_;*\
M6_#"X\1_!B3XKG2?VH/&G@KXU>/_``DGP1^(7P\U[0/@9>^)/VU?C%XZ^%7A
M_P`%>/+'X,?$[Q+?Z!^TM\//C/XMT[4?$=AXQ^(GQN^+7A3Q]XK^/=_XM_"[
M_@WU^"3_``_C\;?L3_L*:A)\4Y_AG#X"3X8?\$X_#/QQ;7XOC+K^C^$_A3J2
M+\$_V>/B"=.T'X@^+?$?AOPGX4\1:L+#0=8\5>)?#?ANTU)];U_1[&]]0MOV
M3?\`@A=>06\]K^Q'_P`$Z+A[KX9^'/C)!8Q?L5?!)]8D^&/BWQ*?!WA[QC_8
M:_"0ZRNEZAXF']C@/8+=VMUC[;;6T1$A`/C#QE^SQ_P57N?BE^TY\1?AYKO[
M1OA?P)XM^,G[%FF_L\_#KQ'^T7=>(/'/A[X(>#/$?_!/W4OVB[7Q;<3?M0^(
M/@9H6E7/A^V_:PMGN_!WPQ7X]>-];T3XD6WC'XT^//#7B[X7:%KW9V?[!_\`
MP4%^#?AWX1:SX+_:3_:%^,7Q@2[_`&?9/$E[J7[1W[05A\'/`V@0?ML_L;^(
M?BQX1N?A;\<OVL/C[?>.X[3]GS3_`-J/Q%XU\;?$7QK\6O'_`(GMO%/C/X=_
M#G5O#OPZLO@3\"O`7T7\7_V7?^"&GP&\::?X"^*G[`/[$/AO7+_PC<>.I;ZV
M_P""<_@WQ-X,T+PS'=ZEIUE=^,?B/X3^`.N_#SP+>^(M4TC5-(\%Z'XT\4:#
MKWCK6+"YTCP9IFNZE$UJ.+'P7_X(0CX7ZM\6YO\`@G%^S99^'=%D^'T5]X8U
M#_@D/XGTWXSM-\5O&VK?#SX<0Z=^SO?_`+)MM\?M9F\8^*=#U.#0X='^&E]+
M=Z-#%XK"+X4O++6[@`@T'X3_`/!0>T^*'[,4WPBN?VB_AMX5T_XL2ZU^V3?_
M`+27QQ\._&W0/B)XHTO]E[]HVSCUWP/H]U\4_'%YX5_9_P#%7QN@^#ND>)?`
MWPDT3X3Z3;W?BKP?XR^'?P@\$WOA3Q_J6E_K'^SC;?%.T^"7P^M_C992:;\5
M(])N?^$TTV3Q+%XR_L[5'U;4)$L(O%L4%J/$EM9636MM::W):6=QJ5K%#=75
ME9W,LMM%^;>N_LL_\$,O#6C>+M7U?]@G]A2&X\!Z=\)M1\8^$;7_`()[>`-3
M^)_AYOCI+#!\)]&U'X1:7\";WXI1>+?&5S/'9V/@E?![^,+.]\RRU;0]/NX9
M84W/A/\`L8?\$7_C=XH^(/A/X<_\$V/V1=1O?ACJ,>D>*-;U_P#X)DZ%X#\`
MW&KFXN[.\TKP9\3_`!]^SMX8^&_Q*U/0[ZQN].\5:?\`#CQ7XKN_".I0G3?%
M$.D7S);L`?KK17P#_P`.G_\`@EG_`-(U/V`?_$-_V=?_`)W-'_#I_P#X)9_]
M(U/V`?\`Q#?]G7_YW-`'W]17P#_PZ?\`^"6?_2-3]@'_`,0W_9U_^=S1_P`.
MG_\`@EG_`-(U/V`?_$-_V=?_`)W-`'W]17P#_P`.G_\`@EG_`-(U/V`?_$-_
MV=?_`)W-'_#I_P#X)9_](U/V`?\`Q#?]G7_YW-`'W]17P#_PZ?\`^"6?_2-3
M]@'_`,0W_9U_^=S1_P`.G_\`@EG_`-(U/V`?_$-_V=?_`)W-`'W]17P#_P`.
MG_\`@EG_`-(U/V`?_$-_V=?_`)W-'_#I_P#X)9_](U/V`?\`Q#?]G7_YW-`!
M_P`$G_\`E%G_`,$U/^S`?V-__6=?AS7F?QH\!_M%I^UAJ7Q&^%N@_M$W6I66
MJ?L_/X;UZ'XWZN/V61\&/#OB&/6?VD_`^N_L]:E\;]'\!:G\6?'_`(+L_$G@
M_P"'GCL?!B_\7:'\0?$W@'7)_'&G^"-`\1K9_B%^R3^QE\(_'?[-/[+_`(7^
M#'_!.W_@F/\`%7XC6?\`P1>_8`_:#%K\;/V,_@KK/C+XM?'_`/:`T7Q3X2U?
MQKX[^-&K1V,]IIF@K\/CXX\4MJ7ASQ9XD\;7][K@_M'^UKRS$GW9J'_!.W0;
MB^^),FB?\$-_^"4^GZ>W[.7@3Q-\)K?Q!\!_V6IYT_:/EM]`N_B)\-?'#:1X
M>G4^';5_%>H:5X=\2Z1*VDW%W\+?$<]SJ4=CXF\)W>M`$GQP_9Y_X*A>-/@-
M\0EU/6?BC_PTCX:\'?M@>./@EKW[/_[6GC[P+X2C\3?'[]E+XLWWPV^$WBC2
MK#QK\'O"GC_5?@K^U?IOA+3_`(7ZM\1?`VK^%OA[X*U_X=6F@>(I(]-^(WB"
M[_6;]A_P/\0/AQ^S-\//!OQ1U+Q;K'C?29_&+:OJ7CFZ^+-YXGNDU#QQXCU/
M33J$_P`<?VL?VW_B@RPZ9>6=O9CQ-^TQ\00ME#;KHMOX.\/C2O!/AW\R?V:O
M^"?G['_BWX__`!?^%_Q^_P""8'_!,GPQ/H/[-'['?QSTKP'X5_8G_9XEU3X9
M^*/C?X@_:B\%?$;X?^(/&T&A^(M'^(2Z5K/[/VG:MIFO:+9Z-86;:]J6BV[^
M(+/3[/Q%J/W2_P#P2>_X):H4Q_P32_8"<,VUF7]CC]G/$8V.V]]_P[5BI95C
M`C$C[Y$)01AW0`/V-_\`DXK_`(*P?]G_`'PY_P#76?\`P34K[1\?/XVC\"^,
MW^&MOX>O/B*GA7Q"W@*U\6W][I7A6Y\9C2;L^&(/$NIZ;I>MZAI^@RZU]B35
M[RQT;5;RVL#<2VVGWDR);R?BA^RA_P`$R_\`@F[XC^/'_!331_$/_!/K]B'7
M=(\!?MO>`O"?@72]9_90^`^J:=X+\*WG_!-S_@GUXZN_#7A.QOO`4]MX<\/W
M7C;QIXQ\8W.C:/%9Z=/XJ\6>)?$,MLVKZ[JEY=?;W_#I_P#X)9_](U/V`?\`
MQ#?]G7_YW-`'QQX=_P""3?CK4?B/^SSKGQH^.%O\4--_9*C^,6L_!OQJG@OX
M?)X^U[Q/\3/$'P6\?0IXOU;XG^`OC+X\\"6H\?\`A?XE3:]K7P'^*OPR\0:S
MX.U+P_X#U"\OO`EYK7A!?'?A=_P0RC^$E_\`L:7WA+XC:=8O^SEI]MXD\276
MF>`?V<_`WB%/BEKT7@M=>U#X8>)_A'^S)\-=8^&GA;P]K'@;P[KNNV/PMNOA
M?KO[3VA1^,_A]^U!X@^(^A_%#QI<:C]<?%+]B;_@C-\&_&/PX\$^/O\`@G+^
MPCI&I_%2V\9R^$[\?L3?L]3Z"UWX*B\//=:5K.LK\.Q::#?Z[<^)])TCPJ^K
M-:Z=KWB.[L?#%M?KXBUGP_I>K_&W[0FE?\$8/V<?#EEX]\6?\$:OV;-7^%FJ
M_!OX2?&;2?BW;_LR_P#!+_X=_#BZT[XT?$+PG\.?"7A+4M?^/GQ?^#DG@[Q/
M:ZCXPT[6=>U3Q]9>%/AQIVAVU\(?']YKWV#0K\`^FO"7[`OQM\):1=>(/A/X
M=_9Z_9F^+W@;3O#&H>%?$7@76?%7COP[\>/CCI:/X2\5_M&_'JQN_!7@;6;[
MQMXN^$.J>-?`<VJZ]JWQ&^(.K/X^O)O&GCO78O`_A>XO_G+4?^"/5YHWQX^)
MOC6?X%?`#]HKX7>)OB#\)M2E\"_'<?`75;/XH_#CX:?`SPA\-M.T/XE^(-5_
M8R\2_'7Q/XBLO&NA+X[-E\3_`(^_%7X9G5=%T_7-`\"^'O%$]KJ^E=]J_P`-
MO^"$^AZ3/J5__P`$UOV1'OK7]F_PW^U+<>%M*_X)^?`GQ#XP/PU\1ZII.EC3
M]+\.>'?A[JM_XG\?:2=>T._O_`WA)->UR_TO6]#OO#$/B&/7=%&H?1/PA_8<
M_P"",GQUOOBK9_#'_@GI_P`$_P#Q+#\'?'WA_P"''BS5K3]C/]G5M$N?$'BC
MX)_"']H'19O#NJ1_#R2VUW1[OX;?''P#?C5+-O(74;S4=,/^D:;.2`?H%^S_
M`.`O$_PP^#O@7P)XRUFWUSQ'X?TRY@OI[+4-4U?3-*BN]4O]1T[PGHNLZY!:
MZWK7A_P1I=Y9>#?#^M:U9V.KZQHN@V&I:I86-]=3VD/S'\.?^4IG[9'_`&8#
M_P`$U/\`UHK_`(*P4?\`#I__`()9_P#2-3]@'_Q#?]G7_P"=S7D'[)_[/?P"
M_9K_`."D7[:_@7]G3X'_``@^`7@G5OV(?^";_BS5/!WP5^&G@OX5^%=2\57W
MQX_X*EZ/?>)=0\/>!=%T+2+SQ!>:1H6AZ7=:S<6<FHW&G:-I5C-<O;:=9Q0@
M'@'_``3+_P""FG_!-WP%_P`$W?\`@GUX%\=?\%!?V(?!?C;P7^Q#^RAX3\8^
M#O%G[5_P'\.>*O"?BKPY\!_`6C^(?#7B7P]K'CVSU?0O$&A:O9W>EZSHVJ6=
MKJ.EZC:W-C?6T%S!+$O:0?M2_P#!&VV_:)'[4L'_``5)_8_C^+\NN:G+J.JG
M]N_]GN;1=3\`ZE\.[3P&?A!)X6NO'\_AW3OA_;ZAHWA?XBJVAZ;I7C"Z^(7A
MC3M6O_%=UIM[KFCZM]5?\$G_`/E%G_P34_[,!_8W_P#6=?AS7'-X'_:TLO\`
M@IV_Q%TV[\97O[*>L?"+2O".OZ-J'BGQ%'X`TO4+70?$VJIXIT'1+OX[ZGX,
M_P"$MB\;6WA[P]>:%HW[+?ASQGJ^D^([[Q7J_P"T;<^'?"-A\*M9`.Q_X>P?
M\$L_^DE?[`/_`(F1^SK_`//&KXA_X)E_\%-/^";O@+_@F[_P3Z\"^.O^"@O[
M$/@OQMX+_8A_90\)^,?!WBS]J_X#^'/%7A/Q5X<^`_@+1_$/AKQ+X>UCQ[9Z
MOH7B#0M7L[O2]9T;5+.UU'2]1M;FQOK:"Y@EB7]W*_`+X%V4VN_\$V/^#>#P
M=+KOC'1=`\:Z/^PIH_BR#P5XZ\9_#Z_U_1M(_P""<7Q6\;6.BZEKG@37?#FN
MSZ*/%/A/PYK-UI#:E_9VHW.CV::C;75O&86`/O\`_P"'L'_!+/\`Z25_L`_^
M)D?LZ_\`SQJ/^'L'_!+/_I)7^P#_`.)D?LZ__/&KD_"'[#G[17AO_A4?]I?M
M_P#Q;\3?\*R_:+\7_&_5O[1\&6,?_"Q?"7CK^R_[<^"WBS;XOE\WP?I?]J?%
M3_A"KZ/?=>%_^$N\%[K35?\`A6O_`!5WFMS\!OB=\`/CQ^PO<^./VGOB[\==
M2\;_`+=?QSTS39_$FL:YX9TS1_A3XW_8._:^^(EU\+M?\,:1XHN_#/C^RTCX
MA_#;PQXF\/:[XETI[KPXFBZ+8>&K+17M]:OO$(![M_P]@_X)9_\`22O]@'_Q
M,C]G7_YXU'_#V#_@EG_TDK_8!_\`$R/V=?\`YXU?H)L7T_4_XT;5';^O\Z`/
MS[_X>P?\$L_^DE?[`/\`XF1^SK_\\:C_`(>P?\$L_P#I)7^P#_XF1^SK_P#/
M&K[[OC*EE=O;-%'<K;3M;/+;S7427`B<PM+:VSQ7-S&LFTO;V\D<TR@QQ.LC
M*P_FA^,?Q1_X+':-X<U7QCIWCOQ?X5\+_$O_`(*9_M'_``?\(6FE^'_"MCXO
M^'7[*'PHU#]N[3OAQXHO7M_^"6/[35]\%O`/CF3X1?LZQZ#XR\9?"W]MJ_\`
MC)_PEWAOQ!H?Q.^"6C_%RST_PD`?K'_P]@_X)9_])*_V`?\`Q,C]G7_YXU'_
M``]@_P""6?\`TDK_`&`?_$R/V=?_`)XU?`'Q5^/G_!1Z'QW^RU\-O&&J?%WX
M.?!OQYIO[2WB+XW_`+5G[.O[//ACQGXS\-6.C?%'X8VG[.O@VX\%?$7X3_M$
MZ+X(\>1>%KWQ[X?\=SZA\)==\-_$;1AIOQ&\$S^#KV;6?"7P\Y6+]JK_`(*\
MV_A;_@H!XLTSX.ZOXLN/A#\-/B-'^S1X#U3X!ZGX5\8^/?$4W[)?[-'C#X)_
M$GP>FH2:19^+;H?&?Q9\3KCXO?!;43?ZVMU?>)?`?AC6=&\7?!:3X<>-@#]*
M?^'L'_!+/_I)7^P#_P")D?LZ_P#SQJ^:OVN_VO?^"/7[9?P&\1?L^?$?_@J-
M^Q9X=\)>)/%WP@\9W>K>"?VTOV7K/Q%!JGP7^,G@'XW>&(+:XUWQ;X@TP6&H
M>*/AUHVG:]%+I<EQ<:!=ZG;:?=:9J,MKJ=GZA\%/BW^T9K'QA\0:;XLO?C_K
M6L:AX`\:WOQ!^'&O?!GPOX2^`OP`\:>&KF^/A?2OA3XYD^#GA3QG\3CXIBNM
M(LX-8NOC7\;M+\<+'/K_`(6T/P7IVE>([2S_`"T\-?''_@L'HO@7]GO_`(61
MXQ^,.G^.YO!OQ_\`%7Q&TF7PUX"UF_U_Q!8^%/@5J'P@\+ZYJW@;_@D;>^$/
M&5SJ-]XD\:^(M!^'GA=/V3)]&TG7&\!^//V@_&7C3X=^(KZW`/:O%VK_`/!"
MOQ3\2K/XF6W_``5'_9/\+WUIXR_9_P#'J^&_#_[=/[+G_"))XC_9W_:!^#_[
M2'AR73=$U?Q%JT7AW3?&/Q`^#6BS?$+1_#+Z-IVN/XF\<^(;"#1O&GBB_P#$
M[5)=7_X(CP6EC>Z!_P`%:_V9?#OCS3]`L_!T/Q"M?V\/V8]4U%_`FF_#G1/`
M^G>!'\*>(/%.K?#R#PO;^(?"GA#XLS0Z;X2L-5O_`(D^&K.^OM6G\/7VM>'=
M3]$\5_M/_MR>(?CU\5G^#*_%WQ!X+\6?!_P3X'_9X\#7?PQ;PUH^G?%SQ?X>
M\&IXF^+^N>#?B/\`L5>$S<:3\,M3F^(/B34M:^(?_!03X;^%=1/AB+P#9_`3
M5;O6=`\6ZES/[0_[37_!0"^\/ZS>_#I?VAOAAX_\2_#+]GR#5?`^B_"'1K'X
M??L^^/=(^.GPY\$_M"S)\7/$'[#7[6-YXLG\6VVO>-;+P;\0M`\"_'_PC??#
M[PKK?B+3O@1X%D\.V/Q1\<@&_P#&+XK_`/!%#X]>-?#?Q6^*?_!3_P#8=\2_
M&+PI\%;_`.!^B?$^?]JK]B__`(2+3/#GB;1?'FA_$#4]&BFO[C3O#NK^/K;Q
MY<7&M-X=M=*L[:]\-^%)M,M;2/2YH;WP27P__P`$/G^$VJ_`J#_@J=_P3VT_
MX-ZYH7PFTS5_A#IGQ%_X)CV'P>U'5/@W\:O$'QL\,>(+WX16WA-/AQ=3:IK?
MBG7-+\8Z-<>&I?#OBJ._G\1:II4GC*67Q#)^B'Q2\0_MC>&%T7XD>`OB1\9?
M%6D+^RO\%+GQ3\.+;X=_#7Q?X7T[Q%KGQ:\!Z)\=/C=X<-E^RKX`^-?C_P".
M/@+X):CX_P#B'X-^#]M8^"?#?Q`\4^'='\.Q_L]^&KO7!X>LN/\`$?BG]NGQ
ME^S-XQ\._L__`!(^+GB'QM_PTE\/OA]\%/V@/BQX(^''[.OQ7^(/PB.@>#-0
M^)'BWQ_:ZY^Q7\:?AYX*LK+QRWQ$\(:7\0U_85TW2-?\.:1H\^@>"8K&^TOX
MN^(@#YAL/$/_``13T3P[XHT_PY_P5M_9.\/>)_B!X8UWP7\2/%FG_M@_L6RZ
M;XX\(ZEK?A&\T#PQ??"/49K[X%^'M"^'OA/P/X<^%_P^M/!/PS\,3>'/AW9'
M2HKJ;599-;/K_P"S+^T%_P`$8?V6?'WQB^(O@C_@II^P%K/BCXVZG;:KXV\5
M>(?VD?V(X_B5XANK2\O[VU;QO\8?#U[H?Q4^*"Z>^I74&BK\2?%OBA="M)9+
M?25M$D?/+?M"?'7_`(*1:[:^!]#_`&?S\7=%UOPE\0?!NC?&G6C\*=%\%V%G
M:Z4_[7-W\1;A=3\??LB_'?3OB3X3TO1?#GP!\17_`(=^#^@Z)X@^(VC+I&@_
M"[XQ>#O$?CZ+5-:[V/QU_P`%./`.J>-=-\,WFM?M`>'+[XB?%6[U7Q?\;;;P
MI\(O$_PM\!Z7^T=I'@#P;:?`KP7\'/V+M6T3XT1M\+],U?Q'I_A[XI>+/"VM
M74&KW6OW?Q7UO3Y])/A<`^NO^'L'_!+/_I)7^P#_`.)D?LZ__/&H_P"'L'_!
M+/\`Z25_L`_^)D?LZ_\`SQJ_)?\`X)W_`!K_`."NOQ0\4?LLZ]^T-XI^)P\'
M^)/#G@?Q'^T)!XP\*^#]*TGPIXL\>^$M-U;5/AQK_@"+_@EU^S3X]\.WNF:I
MH>O^'M-\,>'OC1K&E_`?Q/X@TF\\?_M)_M4Z7KECX:\$_H#\=?A!XI_:(_;<
M_:`^%.A_'#XM?!>]3_@G]\`X/!_BOP!XT\76MOX&O?B/^T!^TSH_Q$\3:5X"
MM?$^E>!-6\9^(?"7@S2/#VG^*/$NBZQ?^&VLM,U+3!OTY;6X`/9_^'L'_!+/
M_I)7^P#_`.)D?LZ__/&H_P"'L'_!+/\`Z25_L`_^)D?LZ_\`SQJP]0_8K_:*
MU>^^).H7W[?'Q8M9_B/^SEX$^##IX?\`!MAHL'@[X@^"K?P^;GXY^"(SXMOF
MT/Q%XLU.7XDWGB+03)<P7%IXR\.:?#K,3^`DOO$J?LM^"_%?PP_;&_:*^'7B
MOXI>-OBOJMK^QC_P3[\5^+?$OBK6M??2_$7Q-U#Q[^W=X!\8>._#_@?4?$&O
M:!\.F\7Z'\+_``1;ZGH7A-H+2Y7P[IMWK%SKFO\`]H:]J(!N_P##V#_@EG_T
MDK_8!_\`$R/V=?\`YXU'_#V#_@EG_P!)*_V`?_$R/V=?_GC5^@N!Z#\A1@>@
M_(4`?GU_P]@_X)9_])*_V`?_`!,C]G7_`.>-1_P]@_X)9_\`22O]@'_Q,C]G
M7_YXU?H+@>@_(48'H/R%`'Y]?\/8/^"6?_22O]@'_P`3(_9U_P#GC4?\/8/^
M"6?_`$DK_8!_\3(_9U_^>-7W[=,8H@R132,9[:/;;B(R!9;F*)Y&$S(GDQ([
M2W)!,JVZ2M`KSB-"M`'\M_\`P2__`&UOV*/A9X`_8@^(WBS]O_\`X)S^&?#T
MO_!(/]@+]FWXD^#_`!M^VQ\)O!OQL^&?Q7^!WA/QCXBUC1=3^&6IR2V,B-=?
M$P>'=?M=>\:>$O$GA+6_#NIVEUX<U&1]D'[+_P##V3_@EE_TDJ_8"_\`$R/V
M=?\`YXU?EE^PM-^U7\2/V:/V2/@Y^SU^T%<_"35/#?\`P0@_X)H^*_AUI>M:
M#X4UOX:V'Q&^+.B^.O!OBGXB^+;*Y\%ZUXTUC6/#G@WX=:1)X.TG1O$^@:.V
MMV4<6KQR6FH7MS%^ENH?#G_@IOJ-]\2;NV^._P"SSX=A\4?LY>!/#G@.QLO"
M^O:S#\.OVD]%M_#\_C;QJCZAX2M/^$C\`>+-0UKQ_9VMKJ$4.J:5IWA7X=7:
MZ1+<:[XALO#H!\]>!/\`@H5_P3WT?]KS]HGXY^(_^"EW_!-2/P%X_P#@7^RM
M\'/AY#I?[='P*U7QC?7'P3\5_M1>-_&?B'QIHMQJ'AW0_"D=_J?[0MAHOAS3
MM"\3>-SJ-IX:OM<U&Z\/2:E;^'K/Z8B_X*M_\$N8TB23_@IQ^P5<F-I6:2;]
ML;]FI'G$C.R+*+;QY;Q[8%8)%Y21$JB-.9I-TC3_`+,6L_M`Z;^U'\=/A?\`
M'?XI+X^U32?V3/V&_BKJ.@Z-8Z/:?#SP3\4_B+XN_;(\`?%.'X7O!X6\.>)Y
M/!WB%?@=X,U-%\8S:CJ4FKQ:GJEI#X?LM53PYIGZ#DXY-`'X-_LH?\%-/^";
MOASX\?\`!336/$/_``4%_8AT+2/'O[;W@+Q9X%U36?VK_@/I>G>-/"MG_P`$
MW/\`@GUX%N_$OA.^OO'L%MXC\/VOC;P7XQ\'7.LZ/+>:=!XJ\)^)?#TMRNKZ
M%JEG:_;W_#V#_@EG_P!)*_V`?_$R/V=?_GC4O[''_)Q7_!6'_L__`.'/_KK/
M_@FI5?XX:7^U)\0KS]K_`$+X6VOQ.^%B:I^S;H7PF^"7C4>(_`B0)\7M>UCX
MHPZK\7OAGIUOXLU]-+OO"6@^)O!FIOK'C+0O#NIW&HZ#8Z>FD:LND)$`#S3X
MA_M[_P#!&/XLSQ2_$C]OO_@G?XQ@3P3\0?AS-I>M_MD_L_76B7_@OXI0:!:^
M.]"U713\35TO5;37K7PSH]O*=0M;B6VB@E6RDMS<W!DX/Q#^U9_P0S\6>'?"
MWA'Q)^W7_P`$^-<\,>#?"'@/P%H6A:G^V_\`!2]TV/PE\--<TGQ%X0T74;:X
M^+4B:W;6.IZ)I[W;:S]OFU>WCDM-6DO;>>:-^-U'6_\`@KUH'BOXJ^+]7\'Z
MCKWAC6_A3X%TKP%X.^#L/P)UCQ=H'QD^&$'QT\.:K>P:?\7OBQX8^'4WPW_:
M%\3VGPV^(NJWCZEH_C/PCX*\5>%_!.HZCX9U+1O$OB/P7WGA+Q#_`,%3K?PA
M:ZM\2]%U8WNN_$_XNCQ1HWPU\+_L]:GX\\!?"KPY\7_CCX8^"1^&EMXF\=Z9
MX'U[7/'_`,-]+^`?CKQY/X[U?6;C2](\3>,K72]+\,>*-/71=-`.-OOCU_P0
M5U/4;/7]2_;B_8`O_%UKK>GZ[<>/;S]NWX0W'Q$UNXTOX=VGPLL=.\4>/I/C
M"?%OBOPW!X.T[2H!X4\1:QJ?AI]<T70_%LFE/XKT;3-9M?9?AM^WM_P1A^#^
MH_%75?AG^WO_`,$Z_!U[\;?B???&?XHMH_[8W[/L,'BSXGZIX0\&^!=5\87=
MH_Q-DM+35-4\-?#_`,*6FI?V;!96U_=Z;+K%U!+K&I:I?WGS7^S#X@_X+37^
MJ?!#P3\=/AK:>`_"2:1X"TCXL^.]0\?_``6\8^(-$\,:9H/@X2>([&.PT;Q;
M>>)_C/XFU"'Q-9_%+0M0U_5O!7AFZU#4;OP?XU\5#P)X=UK]H#YJ6T_X.#]%
M_9Q^"_P]\.>"M*\1?&3PSX:_82UWQ3XB^(/Q<^'UIINN:YX:\5_LQ>,?VBM%
M^(?CS0-6O_&VH:UJ_BFV^.OA/XNRZ#J&N^$=7^!EOK^A?#OPAK'B*3P9K7Q#
M`/UZ_P"'L'_!+/\`Z25_L`_^)D?LZ_\`SQJ\@_9/_:$^`7[2G_!2+]M?QU^S
MI\</A!\??!.D_L0_\$W_``GJGC'X*_$OP7\5/"NF^*K'X\?\%2]8OO#6H>(?
M`NM:[I%GX@L](UW0]4NM&N+R/4;?3M9TJ^FMDMM1LY9O?_V.;C]H^_U3XY:E
M\?-/^+VGZ5=>*?!2_#,?&.S^"6D:Y<Z9#X"T@^+Y='T#X%>/?'?AC2=!M/&,
MNI:/:G4I-"UG49M+GU%]/UBPN+'QGXHY_P"'/_*4S]LC_LP'_@FI_P"M%?\`
M!6"@#Y!_X)[_`+$G[46B?L#?L/Z-XB_X*'_M_?`[Q!I'[('[-.F:[\%?^%4_
M\$[M(_X4_K%A\&/!5KJ?PN_LKXH_\$\?%'Q-TS_A7][%/X3_`+/^(OB7Q%X[
MLO[)^S>+M=U?Q!%J&H7'U]_PQO\`M%?])8/V_O\`PW/_``2S_P#I:E%%`!_P
MQO\`M%?])8/V_O\`PW/_``2S_P#I:E?`?[%G_!-7XT^*OV&O^";'_"T_V\_V
M_OA-XR^!O[/W[,OCSPU\'?\`A7?[`OAC_AG_`.*.E?LTQ?#B_P#!/]B>/?V`
M=:^(K?\`"O=!\;^,OA]_PCGQ@\0>-/$=ICS?&%[K'C+3%UR,HH`^_/\`AC?]
MHK_I+!^W]_X;G_@EG_\`2U*XGQ7_`,$\OBOXWU[X9^)O%'_!4C]O[4];^#WC
M>_\`B-\.;W_A"?\`@F19?\([XRU/X<?$#X27VL_9M/\`^"<5I::OY_P]^*7C
MOP__`&?KMOJ>E1?V[_:L-C'K>F:-J6GE%`';?\,;_M%?])8/V_O_``W/_!+/
M_P"EJ4?\,;_M%?\`26#]O[_PW/\`P2S_`/I:E%%`!_PQO^T5_P!)8/V_O_#<
M_P#!+/\`^EJ4?\,;_M%?])8/V_O_``W/_!+/_P"EJ444`'_#&_[17_26#]O[
M_P`-S_P2S_\`I:E'_#&_[17_`$E@_;^_\-S_`,$L_P#Z6I110`?\,;_M%?\`
M26#]O[_PW/\`P2S_`/I:E'_#&_[17_26#]O[_P`-S_P2S_\`I:E%%`!_PQO^
MT5_TE@_;^_\`#<_\$L__`*6I1_PQO^T5_P!)8/V_O_#<_P#!+/\`^EJ444`'
M_#&_[17_`$E@_;^_\-S_`,$L_P#Z6I1_PQO^T5_TE@_;^_\`#<_\$L__`*6I
M110`?\,;_M%?])8/V_O_``W/_!+/_P"EJ4?\,;_M%?\`26#]O[_PW/\`P2S_
M`/I:E%%`!_PQO^T5_P!)8/V_O_#<_P#!+/\`^EJ5P5K_`,$Z?BC9?%#7/C/;
M?\%1?V_HOB5XD\`^%?AAK7B3_A"_^"9;_;?`W@GQ#XR\5^&-#_L>3_@G(^@6
MW]F:_P#$#Q=?_P!IVFE0:Q>_VO\`9=0U"[LK#3+:R**`.]_X8W_:*_Z2P?M_
M?^&Y_P""6?\`]+4KB;#_`()Y?%?3/B/XK^+=C_P5(_;^@^(7C?P1\/\`X<^*
M/$'_``A/_!,B7^T_!OPMU[XF>)O`FC?V5-_P3BDT2R_L+6_C#\1KW^T-/TVT
MU74_^$B^S:S?:A::1H5OIA10!VW_``QO^T5_TE@_;^_\-S_P2S_^EJ4?\,;_
M`+17_26#]O[_`,-S_P`$L_\`Z6I110`?\,;_`+17_26#]O[_`,-S_P`$L_\`
MZ6I1_P`,;_M%?])8/V_O_#<_\$L__I:E%%`!_P`,;_M%?])8/V_O_#<_\$L_
M_I:E'_#&_P"T5_TE@_;^_P##<_\`!+/_`.EJ444`?F3_`,$]_P#@F-^UIX:^
M#/[%/Q@O/^"D/[8GP"U.Y_X)P?LB_!/XG?`6Z_9W_8DM_B'\.KWX=^`Y_$>A
M_"W3?$/Q0_90UVZ\'>'/A/K_`(^\4>&IO#/Q$^&GC/XRSW5O=0>._BYK-];V
M\&F?IM_PQO\`M%?])8/V_O\`PW/_``2S_P#I:E%%`'C'A?\`X)R?M+Z+\=_B
M]\:-2_X*W?MFWLGQ%\!_!GX<:'%HWP0_X)Q:/XOTKPI\(M0^+'B*UTOQIXBU
M/]B;Q-X*\80GQ;\9/&VL>&;KPG\*_A;K&BV.L7FC>+=6^(L=OX;O/#?L_P#P
MQO\`M%?])8/V_O\`PW/_``2S_P#I:E%%`'R#^S3^Q)^U%8?&?_@H1=:G_P`%
M#_V_OA_9:W^U_P""M3\.^+/^%4_\$[K+_A>.CQ?L#?L/Z-/\4?M/B[_@GCJ_
MA_5_[)\0:1KOP5_M#X7:?X7\"1?\*?\`[*U#0KCXFZ9\1?$OB+Z^_P"&-_VB
MO^DL'[?W_AN?^"6?_P!+4HHH`/\`AC?]HK_I+!^W]_X;G_@EG_\`2U*/^&-_
MVBO^DL'[?W_AN?\`@EG_`/2U***`#_AC?]HK_I+!^W]_X;G_`()9_P#TM2C_
M`(8W_:*_Z2P?M_?^&Y_X)9__`$M2BB@`_P"&-_VBO^DL'[?W_AN?^"6?_P!+
M4KR#]D_X:>-/A7_P4B_;7\/>.OVA/B_^TIJ]Y^Q#_P`$W]9M_'7QJT7X!:%X
MJTG3KCX\?\%2[&'PGI]G^SI\#_@%X)D\/V-SIUYK%K<ZIX.U+Q4^HZ[JL5]X
,EO-(AT/2]&**`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g30330image9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30330image9.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`)$!
MX`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/Z\O^'3_P#P2S_Z1J?L`_\`B&_[.O\`\[FC_AT__P`$L_\`I&I^
MP#_XAO\`LZ__`#N:YW_@H=\%]'^+J?LYW?C']AX_M_\`PZ\!_%+Q3KWC/X(+
MHG[+?B9K1-6^$OCKPOX?\:+X>_:W^*GPA^&6H'1->UBSMA-9>)KGQ1IYU+[7
MINF36Z7L]O\`GQH/[('[:7P[^,?PL^.^E?!B]\37WP!^$/B[QK\,?`UG\8/`
M]_=VNJ-\5+?2?!O[)":YXK\>>'X?$GB;0_V/_B/\2/@KH7Q1\8ZG9_#.W\:^
M$=+\7:OKLD5SH\T@!^E/_#I__@EG_P!(U/V`?_$-_P!G7_YW-'_#I_\`X)9_
M](U/V`?_`!#?]G7_`.=S7Y,^(?\`@FA\0M,^*G[.]SXR_9Z^*'Q>L_A]\7OC
M1\49?B'\*_"'_!-'QWI6G_%KXX:_^RW\6_'/Q8\>6_[=5UXH^)'@'P[XG^,.
ME_&;6M9UW]E%-$^.NCW.BZK)X7NK6VF^'5UJ/H_QT_8A_:4U#X1_!WX:W_P$
MN_VFO!WPU_9M\!>#M#TO7OB7\,O&'CS0/'UG>>`=9M/#WQ!T#X\^-/#OA+XZ
MZ1\-_B%X3MM1N?$%W\:?`7C"7X87EYXL^'OQ+L?VCOA'\.]>^)P!^C__``Z?
M_P""6?\`TC4_8!_\0W_9U_\`G<T?\.G_`/@EG_TC4_8!_P#$-_V=?_G<U\2>
M,/V4/&\_BW6?$W[0_P"P)#^W5X#U_7]=N/AO\)H_&OP'\42?`+XEZCKVL:IK
M/QPD3]I3XM>"/#=_#XWT._\`"GANU^*_AC5-7_:-^&;?#RY?0_">N6OQ(UV;
M2N;\1?L/_MI?\*%\3^#(+6W\>^+?%'[7_P#P39^(GB3PMXK^/&KQ:%=^`?V6
M=5_X)Y^._%OC;PI\3]0M-<\71:UX<U']G[XL_#;6]:U?PWHGQ#^)\,&D_%";
M3+O7=*T#1_%X!]__`/#I_P#X)9_](U/V`?\`Q#?]G7_YW-'_``Z?_P""6?\`
MTC4_8!_\0W_9U_\`G<UXK\"/@Y^TO\.OV!O''P3^#?PMF_9A^*?B#QAXC\"?
M"-_&-U\(]1U7X/\`@[QUJ^BZ!J7[0'B?P;\%/B3K?P3N/$_@*QU'Q?\`$S3O
M`GPB\0>$-&^+WB'0M$U[6_!_PB\6?$[QMH/A#X1\<?\`!.?]LR35_P!B_P``
MZW\/OV</C7X%_9+M?C%\(S\;V^%FE+\4O!OP<\<^-_V=/$OPA\7?L5Z'\5?V
MFM9U_P"!'Q8^#6@:;KGPN3QA\0OBMX^U^W^'_P`&-;\4VTWCCQ=X@\%^%?'(
M!^K'_#I__@EG_P!(U/V`?_$-_P!G7_YW-'_#I_\`X)9_](U/V`?_`!#?]G7_
M`.=S7Y@^!OV`?B3H'[''_!87X8>#?V:/BWX,^/'[5W[/'[3'@?PU<>._"_\`
MP2^\"^"_C?\`$#X@>&/VB]/\"0?#?XF?LJ'1/CKXGTR_U3Q[I0N_$7[?7BR7
MQ'HD'B/3+RUU73+Z?XCSK^@G[/\`^SK\<_AAXZ_9YCUNUU#5OAUX6/[1/BO7
M9?$WCVV\4>)?AEXJ^)NJ3SKX.TR:]OM1OM8^'6NRS+XB\':=9:WKO_"N+B]U
MSP3IT'A[X<:=\/\`PIX3`.Z_X=/_`/!+/_I&I^P#_P"(;_LZ_P#SN:/^'3__
M``2S_P"D:G[`/_B&_P"SK_\`.YKY(\*?LC?M0>&OA]XDMK'P[=->^*_V@OV6
MM0\3?#_6/B/HTNAO\-OA=\2/@YXWU/XC>#K&/7=6\+Z/XR\)W7AOQ;::]I\$
MOAG5OB)X5N-FHW7B;5/`_P`+M%/#Z-^QSXPNO`_Q!\$^%_V$-8^`G[26I?#B
MU\+?%?\`;RT'XG_LZW&O?M&^,V\8^!KVY\?Z-J:>+/'GQ!^.^L276D:I\0].
M?]MGX6>#]/\`AK>V4.C>%-`\6P:A<Z3<@'W?_P`.G_\`@EG_`-(U/V`?_$-_
MV=?_`)W-'_#I_P#X)9_](U/V`?\`Q#?]G7_YW-?CC\1/^"9_QWD_:U\4>/OB
M;\+/VB_VPM-M_P!I[Q5\2OAE\>IM'_X)$77BOQ#)JO[,7_!,KP7X>\;_`!FN
M?C7\+O#EU\#?#6B>,O@%\3?AG;^,_P!B'X'^`_VBM#\*_":Q\8VNE>(?%NK>
M%?&/CG]G_P#@G7\+O%7P;_9V7X?^)?@UJGP(L]&\>^+_`/A#O`.O7WPME\1Q
M>$;B6QDL];\2:/\``OQGXW^"/AW6M<U8ZS?7D'PLO?#WA_Q4'C^)&L?#_P"'
M/C?QQXL\$:"`9W_#I_\`X)9_](U/V`?_`!#?]G7_`.=S7Q#^U?\`\$R_^";O
MASX\?\$R]'\/_P#!/G]B'0=(\>_MO>/?"?CK2]&_90^`VEZ=XT\*V?\`P3<_
MX*"^.K/PUXLL;'P#!;>(_#]KXV\%^#O&-MHVL17FG0>*O"?AKQ#%;+J^A:7>
M6O[N5^87_!1GXE^'?@_\3_\`@EW\1?%FF_$#5_#_`(=_;^\9_P!H:?\`"[X3
M_%/XY>.[C^UO^"9?_!1O0K7^POA=\%?!OQ`^)OB?R;S4[:?4_P#A&O".K_V)
MH\6H>(M9^P>'](U74[(`[_\`X=/_`/!+/_I&I^P#_P"(;_LZ_P#SN:/^'3__
M``2S_P"D:G[`/_B&_P"SK_\`.YH_X>5_LZ_]$Y_;^_\`%3__``5,_P#H-Z/^
M'E?[.O\`T3G]O[_Q4_\`\%3/_H-Z`#_AT_\`\$L_^D:G[`/_`(AO^SK_`/.Y
MH_X=/_\`!+/_`*1J?L`_^(;_`+.O_P`[FC_AY7^SK_T3G]O[_P`5/_\`!4S_
M`.@WH_X>5_LZ_P#1.?V_O_%3_P#P5,_^@WH`^(?^"@O_``3+_P"";O@OX#^`
MM8\'?\$^?V(?">KWG[;W_!,OPG>:IX:_90^`VA:C=>%?'O\`P4C_`&4/`OCK
MPU<WVE^`;6YG\/\`C3P3XC\0>#O%FC2RMIWB/PKKVL^'M8MKS2-4OK.?[>_X
M=/\`_!+/_I&I^P#_`.(;_LZ__.YKXA_X*"_\%!O@-XL^`_@+2]+\!?MO6MS:
M_MO?\$R_$LLOB7_@F7_P4B\%Z<VG>"_^"D?[*'C'6+:VUCQC^RAH6D7GB"\T
MC0;ZS\)^$[.^G\5>/?%4^C>!?`NC>(_&WB/P_P"'M4^WO^'E?[.O_1.?V_O_
M`!4__P`%3/\`Z#>@#P[XI?L3?\$9O@WXQ^''@GQ]_P`$Y?V$=(U/XJ6WC.7P
MG?C]B;]GJ?06N_!47AY[K2M9UE?AVMIH-_KMSXGTG2/"KZLUKIVO>([NQ\+V
MU^OB+6?#^EZOX)-\.?\`@@E;^%/BSXTG_P""?7[#T6A?!3P#\'?B3X_E;]AC
M]GMKFP\-?&W2M$UOPO\`V?;1^`7?6=6TC2_$WARY\7:-IGVG4-!?7]%LVANK
M[5;"VN/IKXA_M@_L3?%F>*7XD?`K]NSQC`G@GX@_#F;2];_X)0?\%5+K1-0\
M%_%*#0+7QWH6JZ(?V/ETO5;37K7PSH]O+_:%K<2VT4$JV3VYN;@R?/6CZU_P
M2T\/Z5X<TG1/V6OV]-,'AG5]-UB#6+/_`()C?\%?H/%6O#1_B[X$^.&DZ'XX
M\8I^RP/%7Q!\(:=\0/AEX$DM/!7C;6-?\*0^$O#EE\.ET?\`X5\]UX8G`/$/
MB3JW_!`/X=_M-_#S]D^+_@FW^Q!XM^)GQ$^*UU\(;+4[7]F+_@G[\./`5AXC
MTZT_9[O-2?3O%WQ^\2_!NT^*EU:C]ICX>65IX&^`D'Q<^+7B/6--\?Z'X2^'
M7B#6?`7B&PM?U&_X=/\`_!+/_I&I^P#_`.(;_LZ__.YKXA\,:U_P3+\!_$;X
M:_%?X=_`?_@I1\./&GPH\(^(O`7A:^\!_P#!/+_@LUX7L+CP=XR\;>$OB+XU
M\/\`BG1=,_9DBT?QA:>-/&/@7PEK7BN;Q-9:G?:[-H=K#?7<MLT\,WV]_P`/
M*_V=?^B<_M_?^*G_`/@J9_\`0;T`?$/CW_@F7_P3=LO^"D7[*'@6T_X)]?L0
MVO@GQ'^Q#_P4%\6>(?!UM^RA\!X/"NN^*O!7QX_X)EZ/X.\3:SX>B\!+I&J>
M(/">D>/?'6E^&M9OK.?4="T[QIXLL=+N;6V\1ZQ%>?;W_#I__@EG_P!(U/V`
M?_$-_P!G7_YW-?$/CW_@H+\![K_@I%^RAXQB\!?MO+I&A?L0_P#!07PU?6EU
M_P`$R_\`@I%9^*I]1\6?'C_@F7JFEW6C>!;O]E"#QMXC\/VMMX+UB+Q+XL\/
M>'M4\*^"]1O/">C^,=9T+5_'O@6Q\1_;W_#RO]G7_HG/[?W_`(J?_P""IG_T
M&]`'R+XS_9@_X)%>`/C=)\(_%/\`P2&_96TWPE::K\)/".K?M%2?L=?L/?\`
M"D=$^)?QX\3V'@OX0_"[4[=K]/C8OBKQUXMUKP[X:T?5;3X,7?P_77O$N@Z-
M?>-K34]02U7Y[^*47_!#WX:^`-5^+&G?\$B_V</BE\,/"5]^U'8?$CQM\.?V
M*OV%Q9_#-_V4_A;KOQM\47'BC0/'^O>`O&NIV7Q(^$OA^Y^(7P=NO`?ACQG%
MXK\*ZAX<U?5SX8M/%/AV34_J[QK\??V%/B#\0K[XE>*/A=_P4RO=;U)?#4]]
MH]K_`,$ZO^"QFE>![O6_!45Y'X*\677@'2_V6[/P?>>,/!L]XNK>%/$=WHT^
MI>'O$>FZ!XITJ:T\2>&O#^K:;YMKVJ?\$J]=\"^+/ADO[)?[<'AOX?>./`&O
M?#/Q-X.\"_\`!+'_`(*V^`O#VH>%?$_PD\>_`KQ#C3/!_P"R=HMK;>(M:^%7
MQ'\1^$M2\8VL</BV\LX?#MQ/K<E]X3\-W6E@'JO[+/[%W_!(']K7X&>#/C[\
M/_\`@F-^P#IOA/QO+XEBTRS_`.&??^"?GQ8\IO"_BK6_"-\?^$]_9FUKX\_!
M76O,U'0KJ79X0^*?B632]_\`9'B*/1/$]CK.@:7]"?\`#I__`()9_P#2-3]@
M'_Q#?]G7_P"=S7)>!OV^?V9_`/AG3_"NG>$?^"E>O6FG->/'JOCG_@F;_P`%
M;?'7B>Y-[>W%^XU#Q-XI_9'U/6K]8'N6M[-+F\DCL[**WL[=8[>"-%ZW_AY7
M^SK_`-$Y_;^_\5/_`/!4S_Z#>@#XA_X)E_\`!,O_`()N^/?^";O_``3Z\=>.
MO^"?7[$/C3QMXU_8A_90\6>,?&/BS]E#X#^(_%7BSQ5XC^`_@+6/$/B;Q+XA
MUCP%>:OKOB#7=7O;O5-9UG5+RZU'5-1NKF^OKF>YGEE;[>_X=/\`_!+/_I&I
M^P#_`.(;_LZ__.YH_P""3_\`RBS_`.":G_9@/[&__K.OPYK[^H`^`?\`AT__
M`,$L_P#I&I^P#_XAO^SK_P#.YH_X=/\`_!+/_I&I^P#_`.(;_LZ__.YK[^HH
M`^`?^'3_`/P2S_Z1J?L`_P#B&_[.O_SN:/\`AT__`,$L_P#I&I^P#_XAO^SK
M_P#.YK[^HH`^`?\`AT__`,$L_P#I&I^P#_XAO^SK_P#.YH_X=/\`_!+/_I&K
M^P#@?]6<?L[<?^8YK[^K\L/^"E'Q/^/7PLUG]D5O@M\5KSP`GQ2_:E^%OP=\
M2:5-X=\,Z[X?U>Q\77]U.ESJPO=+7Q-]FAETM+6]L-#\4Z`-2TVZN[1I8II8
MKRVY,;BXX+#SQ,J52K&#@G"E[/GE[2<::M[2<(Z.:;O):)_/W^&,@K<3YUA<
MEH8S!X"KBH8FI'%8]XB.%IK"86MBYJ;PM#$UDY4Z$XPY:,DYN*DXIMKU'_AU
M!_P2SY_XUJ_L`^__`!AQ^SK^O_%N:/\`AT__`,$L_P#I&K^P#_XAQ^SK_P#.
MYKY%EU;]J;1/^"A<W[)EA^UE\0M0^'_CS]FRT^,NI>(/$/A+X5W_`(V\.:A:
M^-]3\*WUGX#NM.\#:-X4T&XU$Z8I6XU+PAKNG65C?7R0:0=4ATK5[#DM,_:\
M^/W[/W[-W[?ESXO^(DOQ:\9_LX_'JT^&/PI\:^,=-T.VOETSQ]>>!]*\*2>*
MX])M?#^E:J_A>;Q<-6U6XF%DE\\%U;K);:=]BM;;RI<0T*;J*OAL50A1GBZ=
M2I-49QC4PE!XFHDJ=:4FI4(N47:SE:#:D]/NX>$6:XN.!659UDF:8K,L+P]C
ML)A,/_:5*K4PO$>:T\DPM2I/%Y?AZ-*5#-*D</B(.JY*FO;Q4J:YG]S_`/#I
M_P#X)9_](U?V`?\`Q#C]G7_YW->"?M-?L%?\$OOV>/@KXZ^,=O\`\$FOV'/B
M';^`M%OO$6K:!H'[)?[*NDWD>BZ5:7&H:KJD]YXC\%:?;)8Z;8VLMQ=)8IJ>
MKR#:FGZ3?2%E7OO#-M^V%X8^-'PC\16,WQ3UOX-W6A>)[']H2U^,>O\`P,D#
MWIT>"]\)>.?AY9_#C6=7OM)O8-96_3Q!X<M19:%-HUU:P:7I7VJWCG@^+=:^
M(WQ9_;'_`."<W[6/[3_B#XH^)?#&EZ_X?^.9^'/PX\.6VAVWA;0OA7X(M]:T
M6+PQXFT^\TO4KSQ)XB\76&FZPOB7Q#<ZHMQ;W&IVLWA2'PZNGVL<<XS.FJ->
ME1P^*I8MT,55H*<(1;CAZ%&K*M!U+TYQB\12II2T=7FBURQE(OAWPW5;,,IS
M#&YGDF8<.+..'L!FM2ABL55C3KYUFN.P5+*\5#!1CC,/7K4,JQV+<H.')@?8
M5XU/;5H47]7?`'_@GG_P2T^.?P0^%7QB7_@EW^P'X8_X6=X!\*>.1H+_`+(W
M[.FK/HH\3Z+9:R-,;4A\+--74&LA>?9C>#3[(7'EF46L&_RU]4O/^"5G_!*O
M3+6>]O\`_@F[_P`$^[>TM89[FZN[G]CO]G*VM[:VMT,L\]Q,_P`.5BA@@A5Y
M9I9&5$C5G8A02/B#2?'_`,2_`?[.G_!+6\B^.^F?"+]G:\^"]I;?&CP;X1>Z
MU']I3XY>)'^$/AFW^#WP^^`7A?2/!'C#Q3XGOX_&4[:IXRL/!QTC5T\-17-W
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MF'X`>*M9^'^BZ7KEYH_A_P`??&;X<1_L\6-EX#\#>,K:SD\1:1KD'Q!U]-.T
M,K!XCBTCQ%);Z%<?ILG_``2?_P""6SJ&_P"':W[`(SGY3^QK^SKC()!'_).0
M<`@X[XP&R0<_E7\)OV@?&'['G_!(_P#8IUOPE\1/%^I_$?\`:A/[/G[.OP?/
MBC3?`FJ>"O@QXD^(EUK!U#QC86,'A?1KRYTWP_X8LM=U"VM?%^H>-8[OQ#8^
M&;6\MI-)GUMY?K#]K'XO?&/_`()]_&']CGQY#\8?BA\9O@;\>?C9I'[,_P`9
MOAW\2KCP9K.IVWB3X@6-S/X"^*7@/6=#\$^'M0\/ZGH5]IFO7/BKPU:2?\(K
MXBTQ+33-(T3P_=K%J%O]#C^''6QRPF`IX?#J6)SC"X)RGB93S%Y5)U:DFZO/
M"G4<)+#4^7V=*K6IM.,')R?B1=DKMO2$F[K3GT6GNMJ]V]/=35KI7/J@?\$G
MO^"6@Z_\$U?V`3SW_8W_`&=1QVZ?#GTZGC)R0`,`>??$O_@GG_P1T^#O@O6_
MB%\3/^"?_P#P3G\%^#O#MN;G5]?U[]D7]G*RL;5681P0H\GPY$EU=WMPT=II
MUA:1SW^H7DT%G96L]W-%`WQ]\+]&_;V_:)_::_;Q^#VD_P#!0GQY\.?#'[-O
MQF^"NG^!=6M_@Y\%=>\0:EIOB;PII?CG5M`UV&V\*>&]`?1+;0I]1TBT73=.
MLK_5M>N[#6_$]UJNEZ-)X9U;OO\`@JUK&AZE\2OV6O"7Q,C\$ZQ\#/#VL>,/
MBA\0_`OB;X]?`KX-W_CWQ#I&E1Z-\/;2UA^,7CWP:-8\/:+JFH:Q=>)4ACO=
M)O[:[BTJZWRR&-/EN),#5R*%*E2Q.%Q^-Q$,(XT,/'%N-!X^EA*V'E7E4H4>
M:/L\6IS]BYN,:51-QERQ?UG!628/B3/\+E^8XIX'+E2QF+QN(C5P].L\-E^$
MKXRK0PLL5.G0^MXKV"PN$562I_6*U.51>S4C\Y?&WQ0_X):Z#)>ZIHG_``0B
M_96'@F]\+W_BCX>^)?B+^R;^SG\-Y?B58Z=XO\&>$9[KPOI$WP1\223:3+-X
MWTJ_MM5^W2^:CI9O9Q7,DHMON/\`9@^#/_!'G]H3Q+JWPM\5_P#!*7]C7X`?
M'K0%2XU#X,?%K]BG]F_0_$VK:=Y322Z[X,EE^',2^+=`B>*XBDO;.WM;J-;9
M[V;3X=,GLKZ[_)6+X&?'[]L&U^+_`(ZUC]H3X+'Q+X(\+>()?$,]K^TQ^S?\
M3+*\M]8\??#3Q!9_$S1M$\&?&CQ%X7^&GBG4_"_PMT_0?$'@'Q#KGP\^#2:Q
MH/A^Z\)^(=#TW5O$-KH&GX5\=>-]5L/!WB36OB9\'-7^,OP@^/FF?$3X!^(F
M_;<_8?\`$D?A[P/J/B6\UOXD>'_'/BK3OC?<>,?&WB+XOZGJ^K>+/&?FP'PQ
M8:^J:7X'T3PSX8U/4].?FS+A[-LFRY9O+.\-FGLW3>*RZG3H0E&F^64O8^QB
MJKJ<LK0O.I'3DJ^\^=?K5/`>&'$\Y\-Y=D$.&\Q_>TJ6>K.\QK^SQ*C"."EB
MEF.)GE]?"5*B:S&5##X.JHU)8C">S5*."K?THK_P2=_X):CD_P#!-?\`8"?C
MO^QM^SH/Q^7X<#_)IW_#I_\`X)9_](U/V`?_`!#?]G7_`.=S7WU"288BWWC'
M&3]2HS^M25"=TGW5S^?FK-K>S:OZ'P#_`,.G_P#@EG_TC4_8!_\`$-_V=?\`
MYW-'_#I__@EG_P!(U/V`?_$-_P!G7_YW-??U%,1\`_\`#I__`()9_P#2-3]@
M'_Q#?]G7_P"=S1_PZ?\`^"6?_2-3]@'_`,0W_9U_^=S7W]10!\`_\.G_`/@E
MG_TC4_8!_P#$-_V=?_G<U\0_\%-/^"9?_!-WP%_P3=_X*"^.O`O_``3Z_8A\
M%^-O!7[$/[5_BSP=XQ\)_LH?`?PYXJ\)^*O#GP'\>ZQX>\3>&O$.C^`K/5]"
M\0:%J]E::IHVLZ7>6NHZ7J-K;7UC<P7,$4J_NY7P#_P5@_Y19_\`!2O_`+,!
M_;(_]9U^(U`';_M=6_Q/>Z_9S;X;?'SXF?`^/5/VA/!?A+QG!\._#WP,U^+Q
M[X4\06^I7-]X?\0M\:/@W\6I]+M5;15CM[_P--X/UR./4+_?JTL@T^2P_)OQ
MI^W'\5=`\#?$+QSX._;A/C#]IJ'X3?'?Q3\<?V#[OX=_`2Z?]AJ[\'?L_P#Q
M/\>V6H7>F^'?A[#\9/AM)\+/&WAGPK87/C;]I_X@?%3X8?'UY73X:Z7:Z=\0
M?!'V#]+OV_/C-^U;\)?#GP5TW]C_`,"Z;X_^)?Q+^+%[X2U;1[WX8>"_BU>V
M_A'2OA=\0_'&H:AI'A?XA?MM_L">$H[N+4_"ND07&IW_`,=GGM=.N+R/3_!F
MOW5PD^F_"?PU_P""JWQ1UGX3_M@_$6XA\)_&K6/A#XRUCX0_##PK\,?V1_VN
MOA_/HO[1M_XWUWPIX)^`7B&T&H_'WQW^U%)9Z#+X3^*'Q&^*/[+7P\EM?#OP
MV'B#Q#8?#R_#Z7#0!XA^U1_P44\9ZW\;/C1XE_91_P""@_P)U_X1:%^R%\3_
M`(@_!WX7?!W]J+]C+Q3\1_BUXS\,?!?X]WM[XT^!/P)\6?L9?&;Q5^TA=>"O
MB'X'1[[5=+_;.^%GP\\)Z[\/?$%KXV\`>*M$\'>-/"GC?T_PE^WE^U[<_!7X
M1:C\)?`?QZ_:'U_2OB?J_P`3?CI#\0/#7[(7_#2/PT_9,\#:JOAGQ1X*_:7\
M&_#+XE_!3X2>`OVA/$7C72_B;HVC>&?@AX>\<?$CPS8?"V\T+5O@CJ_CF+Q!
M;6?UOX?_`&P_C9^TO;?#JV_9PU_X)?`'4F_9Z\._M!?%&?\`:L^%7Q,\57[:
MC/XQ^('PU^(_P)T+P!I?Q7_9]\2>`_&'P'^(/PQ\1>'?V@_&?C#4?$5Q\']5
MUSP#H6J_"G6=0\43S:-\R_$__@H7^V#\#O&-GJ'BSQ!^QS\2?AOXT_:VTSX"
M^$8/!7@#XH^#M*\*^"?%_P#P3K^.7[:_A_QEXE^/VI?'SQYH'B_PUX8\1^'?
MAEX=\5?%/3_@KX%T34_AAX?^(OQ#M_`?ANZ\7:%HGP[`/5/'O[9_[0VC^'=(
MUSP5=:5XXMO'O[0G[35K\#]8\+?#N_\`$.D>-OA]\+O@[^TEK_A7X3^+H=*^
MW2ZGXAN/&'@+P!XJ\*ZUX4O_``3XG^(_A*]F\*Z593:GX+\8^)_&'SE\8?VO
MM2\.?L]_$7Q#^S__`,%@O!/QJOHOB!\#-)\:_%[XC:_^QW\$/!/[-6K>,/&&
MIZ?XF\%:_P#M$:%^QQ\8_@I\$[;6[*T328?A3\?_`-G?XV?'[PG>16RZKXE@
M_M^TU;3OL;6/VJ_VMOA#X[A^$?C&/]F?]IGQ]J&H?!GQ58M\#=)\9?!.>V^'
M7Q$\8>(="\0^%=6\(>-_BI\<8--^(4^@:%=ZS\"_%6L?$+1?!/QGUK1O$>@^
M(=.^#^BZ7>>-++C/B7_P5:L/A_J7PY?2_",WQ$\)>(?VAO&^C_$GQ=X&^&WQ
MN\6:%\(/V3?!FH:=X7U7XU_$/6_`7@SQWH7PROM#\2^)])UO6=9^-NI?"CX>
M-X#\!?&NYBUJV\7>![7PKJP!C_L=?MD^+?$OQ8U#P!XL_:T^"_[0%Q?^`/V<
M;V*Q7XJ_">]\*Z$?&%EX+\,7?B3PY\1_AY^SA\"/$'BGQ?\`&'5=6U3QK\(5
MUWX.:)\(?VQ-"U3P_P#$3]F76O@MX/L/&?PN\)?M57YK?''_`(*"P_LU?L/_
M`!^_:]^(?P[\5>/;_P"$7BO]M30/#?@7X4?#OXO^*;/Q)-^S7\1_V@]`\"V7
MCOQ!\.O`GQAF^#'A7Q+X:^#%A;_$'X]?$+2=,^$'@+7-7DUC7KW0;"_T;0)?
MT*\)^)=.\:>%?#7C'1[;7[/2/%F@:-XETNT\6>$_%7@+Q5:Z=KNG6VJ6-MXE
M\"^.M&\.>-O!?B""UNHHM9\)^,?#VA>*O#FHK<Z/XAT;2]7L[NQ@`-^BBB@`
MHHHH`****`"O@']LC_DXK_@D_P#]G_?$;_UUG_P4KK[^K\PO^"C/C+Q%\/\`
MXG_\$N_%WA/X3_$#XY>(-(_;^\9_V?\`"[X7:E\+-(\=^)_M_P#P3+_X*-Z9
M=?V%J'QJ^)?P?^&5O_8EG>W/B+4_^$E^(OAWSM'TC4(-&_M;Q!+I6A:F`?./
MQF_X*&?M,?#U/V@9O`>H_L^?%OQ%IGQ)^)/PR^%'P1\"?"SQ'K/QI^#\GP^^
M*FE?#/2?&7QDT_4OVJ_"^@_&'2_B7>:OI=GX5T>.[_9)L+'Q?XD\&>'KCQQJ
MFDZ[J'BKP_V'A/\`X*0?&KQ+;6GAJS^%7AC5/&-S^SEXDU2'QI;:1XGB^&`_
M;$?X?:W\9OAU\`/%=[X:\1?$#PYX"U'7/@]INA>*_&OA'_A:OC+Q!X1U_P`<
M^'/!_A[Q+X](37M1^CHOVL_CM!/=W,'_``2-_;OAN;^6">^N(O'?_!*N.>]F
MM6+VLUW*G_!2=9+F6V=B\$DS.\+$M&5))JPO[7W[0";MG_!);]O==\YNGV_$
M#_@E>NZZ8_-<MC_@I2-T[8&9C^\)'+'B@#Y$^'G_``5&^.OQ1^(/@/2/"7[-
MT?\`PC'B[4O`_CG2])UR/Q)X;\8^.?V<?VB-!^(7CS]F;QQX1U'Q&^D:!H/Q
M-UOP#\$_C$GC3X6^+;.)[+Q]H6D>'-0U[P7H&IV7B_4OU%_9D^,\G[07P8\-
M_%IM*ET2+Q+KGQ#L['3KG2=>T"^BTKPG\2?%W@W1YM4T#Q1:V'B/0=8O=*\/
M6=]K&AZY8V.IZ/JES=Z=>65I/;/;Q_.R_M?_`+02>5M_X),?M\+Y"HL&WX@_
M\$L%\E8XY(HUBQ_P4I'EJD4LL:!,!8Y9$7"NRF5?VQOVB%&%_P""3O[?B@EF
M(7XB_P#!+(#<S%F;`_X*5=68EF/4L222220!?^"E?_)NOPY_[/\`O^"3_P#Z
M],_8WK[^K\(_^"@O[5_QYUWX#^`K'5/^"9?[;W@NV@_;>_X)EZS%K'B7Q]_P
M3=NM.O-1\.?\%(_V4/$.C^$[:+P=_P`%!O%FKKX@\>ZOI=CX%\)W-YI=KX5L
M_%7B/1KSQUXE\%^"8/$'C'0?M[_ALC]HK_I$_P#M_?\`AQO^"6?_`-,KH`RO
M!O[8_P`1/$GQF\/_``<U?X;6?AX^-?CU^TW\,?!/Q`MK37_$'@_5O!_P)TKX
M@"'5=2FMI;"#P]X_LO$OA32K/7/`^LZK:1>+/#&JKXH\!ZO<M9^,='^'_P`*
M>!O^"D/[87@WXT^&_#'Q\T?X0^-?A/I7[/6O?%3XA^-OA-^S_P")?AK9Z[XU
MBUWX^IX?^'_P[U3Q5^VG\8/&K_$W6=+^&O@S3/!_P5TSX'?$FZ^)5Q=^.O%5
MI\5O!4&A1^#H?OQ?VP_VA4`"_P#!)K]OI0LDDH"_$/\`X)9*!+*TC2R`+_P4
MJ&))&ED:1Q\SM)(6)+MF$_M=?'TE"?\`@DG^WH3$T3QD^/\`_@E<3&\#2O"Z
M'_AY1\K0O/.\3+@QM-*R$&1R0#Y`\:?\%3OCGX#_`&>/B;\8-4_9L@U#Q7\$
M/V1_C]\1OC)\/;:'QYIGB_P+^TI\)I;FW\`^%[GP#J&AOXPG^"'Q?B31_$<7
MB>XAT_Q[X#\&>./AYXK\0>%KKP[J_C76?AO^X]?GW_PU]^T%OED_X=+_`+?'
MF3C;,_\`PL'_`()8;YAM5-LK?\/*=T@V(B8<D;45<84`3?\`#9'[17_2)_\`
M;^_\.-_P2S_^F5T`'Q&_Y2F?L;_]F`_\%*__`%HK_@D_7TC^T%\5]:^#GPXD
M\4>%O"6F^.O&FM>+?A_\.O`?A37O%<_@/PQK'CGXG^-]!\`>$X?%OCBS\+^.
M-0\(^$H-;\0V=YXF\0:5X(\:ZWI^C6]Y)H/@_P`4ZT;#0=0_)#Q[^U?\>)_^
M"D7[*'B&7_@F7^V]9ZOI?[$/_!071K'P+<^/?^";K>*O$>G:[\>/^"9=]JGB
MS1KRT_X*"W7@F#P_X*N?#FCZ/XEMO$/C'0?%5UJ/CWPG+X.\,^+-(L_'6J>"
M_K;QI^TC\6?B/X7U?P3X_P#^"._[<'C3PAK\$=MK7AGQ/XQ_X)3:UHFIPP7,
M-[;"\TW4/^"DMQ:S/:7MM;7UG*T?FV=]:VU[:O%=6\,L8!B_!K_@I?H/Q!^.
M6G_"KXC_``RC^!_A/QGX?TJ#X2_$CQAX_BGM?B9\6H-*^&FI>,OA3H5E+X1T
M?PMJU]I[?$^SC\&ZAX(^('CO6O$=IX+^(&K>,_!_PNTVS\&S^.MC0O\`@IM\
M%8-?^'/ACXJ'3_A3=^+M,^(E[XH\8ZIJGB34_@SX+U3PG\5/%?PF\$^#3\9I
M/`6C>";WQ_\`&/5O!'B_Q#\-_`^OW?@WQ+K_`(2\)>*-5TW3=0FTVTLM3Y+P
M9\4=>^'/B6[\9>`/^"(G[6W@GQ9?^'=+\(W?B/PIJ7_!)+P_K4_A;1;'1M,T
MKP\^HZ7_`,%&[6Z_L>RTSPWX:TZ'3UD6V^P>&O#=F\;V^@:1'9EC\4=?TWQA
MHOQ!T_\`X(B_M<V7CGPW#K=OX>\76NJ_\$E(/$6AQ>)-4U_6M=72=7C_`."C
MBWNGG5=5\6>*[Z\>UFB>6?Q3XF;<!X@U<7@!UWPR_P""@.J?$CQEIOA*+X.Z
M9I:ZQXE^!>KV&I+\3-2U"-O@3^T=?_M`>&?AIXYN%'PNLK.W^+=KXT_9W\5Z
M9X_^!_\`:4EAX/T#4]$\11_%?6[R\M_#MQ^D]?E5X7^*6O\`@A]9D\'?\$1O
MVN?"K^(O'LWQ2UYO#VJ_\$E-';6/B3<22SS>.]2.G_\`!1RW^U^*Y9[BYGDU
MV??J+W%U<SFX,US.\GJ__#9'[17_`$B?_;^_\.-_P2S_`/IE=`!_P2?_`.46
M?_!-3_LP']C?_P!9U^'-??U?SA_\$XO^"FD7P\_8V_X)R?LQ3?L>?'[Q%\7S
M_P`$^OV4]<\'>#]*_:)_X)4Z!XQ^)OP\TCX%^%=+M?BSX%^%OQ&_X*0>!?C/
M-\.?$$?A[5-3TG5?$OPU\,ZK;65K=6_B+1-!UG3M6TK3_JKX;?\`!97P/\9I
M]+MO@_\`LF_&KXK7.N:7XMUS18/AM^UW_P`$8_'4^L:+X!;2T\=ZQI<7A?\`
MX*J:I)J&E^"FUS15\6ZA:+-:>'&UC2QK$UF=0M!,`?LE17XT:9_P6=\`:W>?
M#[3]%_93^,NKW_Q:\0>+?"7PJL=+_:__`.",&H7GQ,\5>`+NVL?'?AGX?6UI
M_P`%599O&?B#P3?7UG9^+M&\.)J6H^&[N[MK?6;:RFGB1\M/^"W'PF>[>P3]
MFKXHO?1_$/0?A$]DG[9W_!%5KI/BOXI@O+GPQ\,'MA_P59,R_$+Q';:??W&@
M^"B@\2:O#8WDNGZ;<QVT[(`?M717Y+V?_!5H:EXJU?P+I_[#?[2E_P"-_#_@
MC2OB;KW@VS_:9_X(]77BK1/AOKD*7.B?$'5_#T'_``5(?5]-\$:Q;R1SZ5XK
MO;.'0=0AD26TOYD96/KEI^VY\=]0N-4M+#_@EA^WA>W6AW\>EZU;6GQ2_P""
M5=S<:/J<VF:=K46G:K##_P`%+WDT^_ET;6-)U:.TNUAN'TS5-.OUC-I>VTLH
M!^AE?D!_P4X\6?`EO&'[-.B?%;]J#PI\`-7^$_Q8\)?M&^'])U_X3^,/B//X
MPO/`FH7-MI-L]UX<\2>'X-(T=[N?4+748S]IU"Y;R7MI+6.%_M'T#_PV1^T5
M_P!(G_V_O_#C?\$L_P#Z977F/CGXN>*OB;?6FI_$3_@B?^U]XZU&PMC9V-_X
MNU;_`())>([NSM'E:9[6UN=9_P""C-Y-;VS3.TK01/'"9&:0H78L>#,L-5Q>
M%G0I.BISE3?[]5I4_<J1GJJ%6A4NN6Z<:D=4KIK0^IX,SK`</Y_A<TS&.93P
M]"EBH-95/+:>-YL1AJN&?LY9KE^9X%)PJSC/VF#J2Y')TW":C./QS?\`[6G[
M%ES^VEH?[8`_;J^',,ND?!>#X)S>`6^`OQ4D%WH*^);OQ9J&JQ>)U\1I]DU>
M?5;^YBLQ)X?NK.SL!!;W%O>SH]Y-Y8_Q<_X)\>*?#'[7O@;XM?MV>"?%?A']
MK/Q?#X[U:U\*_`[XF>"]9\$^(]-.AMH%SI&K:KJGCJTU*'2IO#6CZ@(KW1HA
M>7UI-+OBM)VLX?N'^T='(P?^""_[2+<][+_@CT>,Y`Y_X*&G@8`]\4HU+1!Q
M_P`.%/VC?J=/_P""/)_7_AX82/PKR(Y+7J*7UGZA452I6JU%&&/2E/$4/J]:
MZGC9)QG1;IN#7+%?"D_>/U&'B;PQA%0>60XXPL\+A,KP&%J_7N$%5HX3)LRA
MG&6PIUJ7"<*L9X7,J<<5"M&:K3FE&K4G!<I\=?L_?MF?L]^#+_P9HO[0G_!2
MCP/\8/AO\'V_XMCX>TOX+^/O#FNZY-9>']3\+:#K'Q/URXT+5)M<G\/:+J5Q
M-8Z9;Q,MQXD33_%.I:Q?ZII%DS_/>D?%_P#92^%GPE^/'[,WP;_X*)?".W_9
MQ^,&C^/SH^B_$'X+_&'6O'_@/4/&VBSZ1=Z!HWB;1DT;1&\,NS6TUQJ=_P"'
M-1U6'S+M[33QJ,LFIS_J1_:&@]_^"!W[1!YSSI?_``1V/Z?\/"\?Y'H*/M_A
M_&#_`,$"_P!H0CT.C_\`!',_GG_@H4<UV4\BP7)2A7=6HZ4:T(U8U\5[=4J\
M(4ZM'VL\1*;I3A"$>5RM%TX2C:23.>7BM@*>*QN)PF$S.C''U\MQ>)P:PW"<
M,OGC<JQ%3%X''K`4.&Z.%AC:.)K8BH\33I0J5HXC$4:KG1JRIO\`+RY^-W[+
M'@[Q=^Q3\2OA3_P4W^#>F>/?V4/AIKWP-OW\??LU?%OQ!X,\1?"WQ)H^AZ3=
MWNF>&]*U+2M4L/&6F+HIF2\C\5V4.ORR645U>Z7IFFW6F:UWGPH_:F_9)^%'
MA7]LWP;#_P`%2OAEK>E?M3?$'XI_$72+[Q)^RY\1;S4/"?BGXP^&O"OA_P`5
MZWXCC\/:AX,L_$7]GQ:#/#X8\/Z$O@_3K!KR[U#6KKQ!+>6>GZ'^@9NO#1Z_
M\$!OV@#]=$_X(XG^?_!0FFF?PL>O_!`+X]M_O:!_P1N8?B#_`,%"/\^M?>X3
M.X8;`X3+N6I+#X*A1PU!NC@:E>-'#UWB*4'B:^%JUY*G5G.2YJDG9N+;CI+\
MSS7,,ES7,,7F=:AFLL7CL37Q>)DZ^`I0EB,1/VE6<:.%P-"C34YN3<*5.,;[
M))H_-^X^,/\`P2]\5_\`!/\`\'_L)?%O_@H3X&\4?\*LT[PK+\'_`(T>$/@+
M\5?`_BWP!XR\":A?7GA#QJNAZC=^.[2_U6PM;S^Q+Z"SU'0_[4\/7>MV236$
MNL17MAW3?MY?L4?&OQ1\`M;_`&T_V]?V>/B'I7[,_C^W^*W@C0?A;\"/CGX/
MA\>_%?0='O-%\&_$KX@3^((O$5MI7_",0ZKJ.NV?@3PMIZ:;)XKDM-5G\23Z
M):+X;/W&6\(MRW_!O[\=V(]?#O\`P1M.>W?_`(*#GI]::5\&$8/_``;[_'(\
MYY\,?\$:2<^N?^'@O?OZ]\UZ4>(\ODY.O#-YSGB,7BO:4Z^64YT:V/A&GC9X
M>7]F-T/K$4E.%/EA>*G",9I2/"J+`.WL:>)2M%)5*L)Z1MRI\L8)V=_FNQY)
M_P`$]?V@/V8_$O[8_P"TEJOPM_;G^%/Q[\;?M;Z[H_Q$O?A3X5_9U^*WPXU3
M0)/AAX'/AF!]$\7^*OB!XATF\LH?#]I!>ZQ;:CI,=U>:A#.^G36D<T5G']5?
M\%$_@=\7_%T'P8_:*_9U\/:9XQ^-/[-?BC7M8L?`VK#2VL?B#\//&VCQZ/\`
M$;PBJ:NCV$NIW=E8Z;<:2UP6N+9K:[?28GUU]-!Y;P9XT_X5QK\'BOX>?\$)
MOVFO`?BBU@N;:V\1^#(/^"0'AC7K>VO(F@O+>#5M$_X*(6-_%!=P,T-U#'<+
M'<1,8Y5="17M1_;&_:((VG_@D]^W\1Z'XC?\$LSVQG)_X*5YSCOUKYCB6KA,
MZK.>'>.HQ=#"4XU,34PDL13J8*-*&&G3EA<)AJ/[F%"A&'/1E)\C=252^OI<
M,Y[B>&,XPF<82CAL3/#.O3J8/%TYSPF-P>+P]3"XS!XF$:D)RHXK"UJV'J\D
MX24*CE"49I2C_(9\9_#GP?\`M7B$_"3XK?$9X(O"GCG4/'?@WQ7X:U[P+\1_
MA3XH?XV?`&_U#7?B+?WKW</BKXUZCJY\3IXC\<Z#=1Z.MCX7\,Z)HGAGPE::
M.F@6_P"F'[-_[.-A^T;XHTOX0_L[:]XO\?\`[,%K\<-&^+?[3OQZ\4^%CX'\
M&_$'7/!.JWMSX?\`"7PN\,ZM:?VNWB/QM81Z+J_QLU"QCL/#NI^.;.R\3:)H
M?A'2ULM+\0?KKXF^+GBKQIJ5SK'B[_@BA^U_XFU6\LTTZ[U+7M7_`."2>KWU
MUIR3V]TMA<7=_P#\%&KBXFLEN;2TN5M9)&A6XMK>98Q)!$R]WHW[5GQQ\/:?
M:Z3H7_!(O]N_1],LH4MK+3M,\=_\$K+&QM+>($1P6UI;?\%)XH+>&,'"Q0QH
MBC@`8%>;C,9Q#FF!I97FF94:N7T6G*%##RI5L1&+@U"I*56<81GRI5$N9M74
M913N?I]7Q'X5R^G+'\-<+8_!<0RC55+%YEFF%QN#PM6O24?K2HT,LP=;$XK!
M5.:>75)U:,*53V=;$4\34IJ_Z((NQ$3^ZJK_`-\@#^E.KX!_X;(_:*_Z1/\`
M[?W_`(<;_@EG_P#3*Z/^&R/VBO\`I$_^W]_X<;_@EG_],KK38_%F[MM[MM_>
M??U%?`/_``V1^T5_TB?_`&_O_#C?\$L__IE='_#9'[17_2)_]O[_`,.-_P`$
ML_\`Z970(^_J*^`?^&R/VBO^D3_[?W_AQO\`@EG_`/3*Z/\`ALC]HK_I$_\`
MM_?^'&_X)9__`$RN@#[^KX!_X*P?\HL_^"E?_9@/[9'_`*SK\1J/^&R/VBO^
MD3_[?W_AQO\`@EG_`/3*Z^(?^"FG[5_QX\1_\$W?^"@OA[6/^"9?[;W@+2-=
M_8A_:OT;5/'7BSQ[_P`$W;SPKX*T[5/@/X]L;[Q9XEL_`O\`P4%\:>-KKP_X
M<MIY=8UFV\'>#O%GBJ?3K.YB\/>&=>U=K32[H`_6S]H;XJ?#+X"?##7OCQ\4
M=%U+6M(^%$$FN:5;^%_!EUX\^(4^O:S&WA+3M$^&OAK2K2[U_5O&_B^37_\`
MA#]&TG0$74=:DUQM(+?9;VX!^<M<^*_[%GPZ\?\`C36+'X3>$I/B)\'?@OX#
M_:!T[QCX3^$/A2*^UKX=>+I/BSX6\/W_`,+?B/)9:7I6LZOHUIXE^)%KK&C:
M?XFL=0\.>'_BW=75U%#HWQ/GEU;?_;3TG]ACQ/;?!OPG^WCXZ^`%CX"U;X@W
M#^`/@[^TMXO^%.E?"[XV_$>70;WPUHVD:AX!^*KKI7Q:UCPNGBF75?"OA..'
M4X-,\6W>@^+!H\_B30O">I:3XOIWP!_80\6_#F7X7Z3^T-H&O^&?%OPY^`/B
MGX=/X;^-'PN@U/P;\%O%WC_XFZ)^RSJGPFO/"=E8HGPK\9V_Q)\0_L^?"/5[
MN#Q'H'Q7\!:99_#L:AXVU:Y\57?B$`3XE^*?V0?C=8WVO_%C_@G[=?&OX'?#
M[4/'_P`6O!?QY\=_L]_L^_$CX5:O\0?"^G>)]0\8^)O`FA^)/%6K?%OPWXBU
M)/`5S;V/QB\5_"GP/\/O&4MQX6DT/XGZQ9:UI%W-]%P^+?V<_&WQUMOA-??!
MW1=2^(4%M=?&&U\2:W\/O`MYIUOK;?";2?AE<>(H=9FN;O6X?&4WP;^*-U\*
M7U>/35NY/A_J?B7P,^I_\(M>2V&H?(?A[]E[_@GW^T1\:F\$Z?\`'_X5?M&Z
MI^RE/XY/A[]G*Q\1?LT?$+QI^R9)\4K/_A'O$>B:1XJ\+^$)_P!IOX4>%[][
M:YCM?">K_$:QL+BYBM-%U#^U/#?A?PGX;\.M^#WPB_9MUSXAWEW\)/\`@J;\
M0OB5\>?A%\8)/"OQ:\1:%\7?V'?B+\1#++8>%?`\/[+'Q3\%V7[/VK>$_`.B
M0P_".WTI-)\*^`OAQ\=+O7[/Q?JNH?$2^\5:AKFI,`=/H'QC_8@_9_\`"/QS
MT;]F7]D+1[^Z^#'[27PT\`ZG\(/V;OA!^SW\,=0^)7QF^)/C32_AIH/Q"^'D
MGC#Q=\&_A=JL6B?%>_\`B!\*_$?Q#\6>-/"5]H_Q$^$'QD\.13W5SX:@?6?6
M%_:+_9%\+?LY_M)_M;Q>`?#VBV/@3X)?$+XK_M1^!](\*?#*X^.$?A/X50_&
M#Q)XH\)?$S0_#FMWVF>)=737-(^,]KX=CU'Q;JW@KQ3X@OO&.I^%_%&J:5KN
MI:[>>$^,/^"17_!-?QGX1\:?`6]^'OA#1K'7OA_\-+K]IOP_X4NO!/A?QW^T
M%H6C_%+2/B+X!^+'[5&NZ1H5MXZ\?^+=<\<_!KX@1V'Q=\1:E8>(-9N=?^-[
MZ=KYU^6?4O#VLGC3_@G3??L5_%GX6>(?V_?@/XJ_9!L_A[9_L>_$3Q5<?&S]
MC[PQ\-OANVI>%=4\':OX%U'Q+\-_"O@GX=^$_'/C?P[KL%CJW@CQ!;'2_L]G
MIT/AOP7HEK=ZM!JP!RE[H'_!.7Q3\0_#OPZ\+_!;Q7^SMXG_`&D/@VO[:WQ.
M^+?[-'B3Q1^PIXKD\/>"H-7TWP_I_P"U#\5_V8/BI\#?C=KFNW,?C7XG7VF^
M!O%]SXR\%V>K>!/'VJ^*'T;Q+X8\/2W?T!X,_;+^'=K\!O@!J'[/_P`'OVH_
MVAK[QUX,U*T\!?!ZS?37_:'T_P`,?""[TWP%XZU+XU^+OVP?C'\,[?0_%?@;
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M>/O$.M>)`#W/Q3_P5'_9/\#^+_"?PM\:^)=0\&?'?QSXO_9A\&^$OV;O&=]X
M$\(?M%^(;O\`:C^(WA'X::#K6A_!CQ/XXTCQSK/A?X7:KXJN]>^,NNZ1I-]:
M^&/!_@KQSXB\/_\`"76NB0+J'U'>_M'?".T7XM^5X@U#4I_@5\6_`'P.^*EE
MI7A;Q5?7WACXF?$SPQ\&?&OA'P]#:1Z,)?$POO"'[0/PGU^;4O"*Z]IEK!XE
METV:[77M$U_2-,^%H++_`()Z?$7X6^%Y[7]N7P3X^\&?$KXI?LJ_%/PO\46_
M:E^#_C>Z^)WCC]AO]IG]GG4_"#:1X\O9]9LO&,6M?M`Q_!CX9?%BUTN>\N6\
M1_%70/A[X8G\">(_&'@FVM_-/V8OV*_A!^R=#^UCX?C^(/\`P35^$WB6?QI^
MR=^T[\<K?]DS]E"Y_9-M_AMX/^"WB2#Q1I.K?&OP=XE_;/\`CI9^%_AOXR\(
M?!CQ)!\-;O2X_A!\.O!GB>#XZ?%R70?B+XL\:?$B[N`#[*_X>(?LIBPCOV\8
M>-XDDTOP1J[Q77P2^-NGO:6GQ&TGQIK?@QM2FU+X>V=II"ZUI_P]\73I<ZK<
MV5A8QZ/<3ZG>65MMG.9^TY_P4/\`@7^RQX*_9Y^(/C&R\3>)O"7[2_BOPWX8
M^'NI>']:^$GA*18_%6A0^)-+U:XTWXW?%/X1:GXDN;C29X9M/^'7PTLO'OQJ
M\27+/IW@_P"&'B/4;>XM8?KWQ2]IXMT?QSX`T;Q)H=EXKG\)7-I<12K%KESX
M:3Q;I^LZ;X>US6_#5KJ^DZE-I=U=6&HRVD#ZAHPUM=(U*TL=4MY+>>XMOD[X
MH?L/Z/\`%KX*_!;X,ZS\:OBMX$LOA/\`#\?#+7=<^%>G?"6SE^*G@75_AK#\
M,/'O@KQ9IOQ9^&?QFM]%\+^._#Z2K?3^"IO#GC[0FD0^'/B!ID\<EU,`>1>!
M_P#@K-^S5XV_:"\8?LZ_V5XH\/>)?!GQW\1_L[ZCKU[X^_9A\56\7CGPPGQ;
M-[J?B3X9_"[]H?X@_M$_"?P/>/\`!GQ.ND>,?CE\$OA;I.I6NH^&M9MW.@:K
M+JUG<TG_`(*@^`-=\2>.H-&_9P_:?U/X6?"3QW\3?`7QJ_:"MM/^`'_"K?@]
M=?"C]HGXX?LU>*O$OC+0I?V@XOCC?^"X?%WP#\8>+I/$G@;X.>,;30_AKJ&B
M>*_&"^&7@\5:9X8ZFR_8\^&7P:U-/&GQ"_:0^+FM_!7P]\:_'OQ5\)?!7XJ#
M]G:#X(_#WQC^T6?C+X"\4:!9:YHGP&\*_%K7?"WBG5/VF_%UI:Z7\4/B[XX:
MVU"Y\.VR:FFFV=W9:A\=>&OV9/V!_#-OKND>#?\`@H_XTL?@I\6IM:UGXM_`
M*#X]_LO>+/!?[0-O\:/C#\>?V@=3TWQYXR\3?"7Q-^TI?67Q'\1?%3XH:-<Z
M3X&^-GA2X\<>#--?PSJ<>N2-XEN-<`/V1\9?%'P)\/\`Q%\)_"?B[7?[(\0?
M''Q_J7PN^%VG_P!F:Q?_`/"4>.](^%GQ+^-6H:%]KTO3[VRT7[/\,O@_\1?$
MW]I^([G2-'E_X1W^QH-0E\0:OH6E:G\@?MD?\G%?\$G_`/L_[XC?^NL_^"E=
M<A\?_P!ASPU^U)^U#^RK^U[8:/\`L)^*=-^!U_\`#3QYX/\`&?Q1_8\\1_&;
M]H*\CT#4_'.JV=S\,OVF/"W[57PKT#0/"2^'?B/?^(OA+X<\9?!GXP>#_AM\
M9QIW[06G:3XC\9Z-X-C\*Y__``49TWXIZO\`$_\`X)=Z?\%?&7P_^'_Q-N/V
M_O&?_"->+OBC\-/$7Q@\":1Y/_!,O_@HW/K/]N_#KPG\6/@;X@\1?;_#\6JZ
M9IG]G_%'PQ_9.L7NGZ[=?VW9Z9<^'=7`/B3X/_!#_@J1X0^)_BS5M*\3_$B_
M\-WG@;]O3Q#J_AWXJ?$3X@?\(IXM^)7BCXA_LTVG[,O@BT\3?$G]L+]JW5/#
M,T7@"'X]:QX!\??`OX;_`+./PN\"ZK86UIXB^"NG6VKC3M:^N?V=O!O[6>C?
M'+P5JWQ-\$_&^\UV35?BE;?&?XG^.?VD;O5O@3?_``KENO%NK_`W2_A1\#O#
M/Q%O_`$'CO2;+Q!X.\)>,;VY^`7P_P#'$FH^$O$FJ>(?B_XWTS3M`U3XH^P_
M\*Y_X*F?]'D?L`_^*U/VBO\`Z;!1_P`*Y_X*F?\`1Y'[`/\`XK4_:*_^FP4`
M?(/Q5^"O_!2[XU>)?%GA.[\7W7PI^''QE^/?ACXE>%/$OA;XH_$O^T/@%\-O
MAU8^-?#-UX#\;6GP3^-'[+'Q)-G\4?#MC\&_&,/@WX9?&'6M!T_XJ1_%+4/'
MFL^+O".L6_@#4_DWQ-^PM_P5AA\!:;<Z3^TW\8?%/BKQ;_P44^/OB_QEHNJ?
M&7XZZ!J&D_LA>`X_VZ4^".IZQJ_@G]N#P-I=Q>?$BV?]E>?P!\+_`-GL_LT?
M#30]8U?P!8_M,?"7XE:?X1^+>LZE^N'_``KG_@J9_P!'D?L`_P#BM3]HK_Z;
M!1_PKG_@J9_T>1^P#_XK4_:*_P#IL%`'(?MWZCJFI_LF_"J76=%\5Z'J-C_P
M4'_X);Z#/#XU'AE?$6K)X9_X*S_LD^'+;Q=<IX0UC6]"CL?'-KI<'C/0XX;N
MUU"/0M>TV/7="\,Z\NI^'-*_2VOPC_X*"^`?^"D5K\!_`4OC']J_]B'7=(;]
MM[_@F7;6=CX:_P""?/QY\)ZC!XJO/^"D?[*%GX%UFYU35/\`@IIXTMKKP_X<
M\;3^'_$/BSPU%H]GJ/C3PKI>L^#M'\6>`M7UZQ\=>'/M[_A7/_!4S_H\C]@'
M_P`5J?M%?_38*`/.O@;\5_VUOB%XL?P;\6?"7BOP%X5\6?&C_@HIX2\/?%?P
MMX$T71;WP?\`#3X5_M%?%3X7?LUW.O:1X]T?7[>T\8ZI\.O#7@_XF_"_QO=>
M%M>^&?Q?\*:VFJ:OI%]]FM6\6?"/[+7QU_X*O:5X<\$_$#XT6'QG^*+:A^Q/
M\$M>'@3Q]\-?AWX%N_&O[8OQ'^`7PS\8:_\`#;4?!GP^_9,^'FN?".YT#XW_
M`!330=>^(GBSXTR>`_!WP_\``GC+PEXB^#,'C/P;XC^)=]^F?_"N?^"IG_1Y
M'[`/_BM3]HK_`.FP4?\`"N?^"IG_`$>1^P#_`.*U/VBO_IL%`'S(/VB?^"BN
ME^`_$%U<_!OQ'K7C3X<_L]:)X?\`'OA[_A76D6OB?5_CW%\2?B!X/_X6]\/9
M-%UC6OA_XN\,ZOX4\/\`A#XD>+?A7X<\2:_<:=X.\91W/@S4IO%7A.;P-XY_
M9FO@'_A7/_!4S_H\C]@'_P`5J?M%?_38*/\`A7/_``5,_P"CR/V`?_%:G[17
M_P!-@H`/B-_RE,_8W_[,!_X*5_\`K17_``2?KU[]KWQ-XZ\*_!N>^\"^)/B%
MX%DU#Q?X+T#Q7\1OA+\.[+XL?$WX;>"=>\06FF:_XW\$_#[4_`/Q6TO7]6T8
M7%J)Y-7^&'C_`$;0M(N-2\2ZUX;N-)T:]O+/\P_'O@+_`(*1+_P4B_90L[O]
MJ_\`8AG\;3_L0_\`!06Y\/>(;;_@GU\>+7PKI?A6U^/'_!,N+QCHVL^#I?\`
M@II>:OKWB#7=7O/`M]X:\36/CKPYIWA/3O#GBS2]4\)^-;GQIH^L>`OM[_A7
M/_!4S_H\C]@'_P`5J?M%?_38*`/FC]C[]H']OWQ)\;&T;]H#X6_$W7?#GB7X
M>^$7\1:+9_#[P=\,O"?P"\4V&C_#*VU#Q!>:GXRTGPG<Z[_PL6]\1^.?$UKX
M2\`_%O\`:DO-.L_"FHZ;KJ?!W7-#MO!_C/<\!_M._MK>'OC!\$_A;XA_9^^*
M'QI\'7'PBU,^-/'EK::#X$\?:U\19_$?C-K;QKXZM=>^%?PV_9^T3X?^'_"O
M@;3=#GA\'_&+PC\3]0^)GQ)\/I:_`'5/AQ<+XXT+WO\`X5S_`,%3/^CR/V`?
M_%:G[17_`--@H_X5S_P5,_Z/(_8!_P#%:G[17_TV"@#YQ_9@^+W[<'Q`L?@%
MJ_Q2?XO^'M1O/BQ\+U^/GA3Q%\'_``AX>M?#GBGQ=^SG\8M;^/WP!M]0/PIT
MB?6_@7\!?C'9_#JU^&WQO\'WPU#QAJD5OI.I?&GXF:+-J]KJW[&5\`_\*Y_X
M*F?]'D?L`_\`BM3]HK_Z;!1_PKG_`(*F?]'D?L`_^*U/VBO_`*;!0!\%_L%?
MLA^-?B_^P7_P3^U\?$?P3HOPK\>_\$_/^"5&H>*?#E_\,+CQ+\0+7Q+^S-\.
M]#^)_A"[\*>*]0\:0>$])L]8\2:KH$>KR:CX!UK5;72=+U>UT6]T_5-8L-=T
M#TKX8?\`!*7QQX0\">%_AQKO[0EK<^']+^$M[\)O%VIII_QQ^*7BWXD^'H/!
MVOZ%X7\-^,M>_:=_:*^.Z7/PX\->+?$$WCKP[\.=+L-(T/P)'_PF/@+X<MX3
M\%?&CXN:;XE^JO\`@D__`,HL_P#@FI_V8#^QO_ZSK\.:^_J`/RY^('[`/Q'^
M-WQ=^%7QS^,7QO\`#,'C3X5KJD%KX:^#'@SXJ?"?X9>,K34-;^%FIVT7Q7\)
MVG[0&L#XO+X;N?AW)XI\#67CRZU#1_!OC9/!6IVFF:A;^#[V+Q3RG[*7_!*'
MPE^R]\#M$^&]G\3]>\9?$"/XV?$/XL>)?B-K=U\0M0T.;2/&OQG^+OQ8T[P)
MX`^%WBGXH>+/"'PAT?2(?B?;Z=K\?PTB\,Z3\0/%.AWOQ'\4Z%/XJ\1WTT'Z
MXT4`?B];_P#!)W7I_@/I'[+GB+XT^!?$WP0\,3?&?Q9HL>O?`]O$7Q'UCQ[\
M=_AI\1/A]XVT[QSXM\5?$;7]%UOX5V8^,7Q,3P]X4T;PAX<\0:?X'/PR^&*^
M+5\+?#O4U\>?HE\`OV>8O@-K?QHO++QQKOBW1?B?X[T'Q3X;TCQ##%->_#SP
M]X>^&_@SX?:7X%M]?,TFH>)M)TF'PF9=&U+7%?7+;2[JUTG4M0UB73QJ=S]'
MT4`%%?)W[<W_`":C\8_^P)H__J5Z!7F__!13XP?$[X?_``-@^&WP!\(_$;QY
M^T/^T;X@C^#OPPT'X1W7@+3OB-X>T;4K"[U?XQ?%WPQK7Q9U;P]\(M!UOX._
M!_3/&7C7P7=_%GQ-X8^'WB/XK6GPW^&VK:[;:EX^T:VO`#[YHK^=?Q#XTNK[
M_@FA^TG^PU^T)\-?BM\'M6\*7/P?_9;\*^`OCQXV^&>N?%SQ5^RI^UE\:/"_
M[/O[/>NZUXP^#7QK^.WA[6=;;3O$&O?!.]\31?$W4O$FO>+?AI?>*M>M]%OO
M$<5I'P'[9GC?XN_'?]@+]H/]A/PIXZ\2ZE^TK^Q_\&OVA]=^/GB;3]8TJ/QM
MK=Q^R;X`C\:_LB:IXEOO#8\)Z1H'BK]K+7-4_9]^.TNA3>'K;PKKGA+3/BEX
M(U#P]_PC-V;D@'],]%?@1KO[/T'[1W[:'[0OQ4M?^"=?_!.3]KFUAO\`]FF\
MMOBQ^UUXX/AOXL?#R"[^!?@+Q'#HGPZT]OV%/VFVOM"TV/4%\2Z7,WQ)\"F3
MQ)?7\!T?3RAUZ\Y_X=_L6>)_C+\=_B_\3O"/[,G[%WPVUC1_^"A'B/QQ-^WO
MIWBWQ)'^W)>>'_A)^TMX:\7^,/AFGAGPS^SCX3N4\/>._"/A/7/@L\NK?M=Z
M_P"%IO`NN%_%?PV\4^'YM0^'-P`?T+T5^>/[)WQ(\(_![]BCQS\5O'NI?V1X
M+^'7Q8_;K\9>)]06)KB:#1O#W[7/[0>IWHL[2,^=?:A-#;FWT[3K</=:E?RV
M]C:1R7-Q%&WQ5^Q)\6OVHOAC^T1JNN?M6?LW_M/_``3\/?MQ7FO>,?$FL_&/
MQC^SGXV^'/@G]IK0+'4;[X=_"_X1Z1\#/C]\:_'GA_PUKG[+_A72OA[//\0?
M"GPVT_4O&'[/WAR\M='/Q)^,>LZ5(`?O'17X6?LM?!7]C36?&<W[/OC;X'?`
M[]H?PG^UW\"?$G[1?A7XS7?@7_A)O#G[6?PD\'?%KX8ZTUY^V;\)_&^G:AH^
MM?M&?#+Q5XU^$K>'_B5\3M,U[7O%4ECKUSX4'PRU3PSXL^'.D?37_!(?X+_"
M'X._\$^_V>I?@[\)?AA\+KKQ_P##/PQXR\;-\/O`OACP,OC?QI/I$5@_BGQE
M)X6TG3I/$7B">SL[.RN->U9;_5GLK6WMS</%!%&H!^G-%?A]^SE\#/V,_CW^
MR=X?_:@_;<\)_!W6?VK='\!_;?VO/CCX_P!:TNU^+G[+'Q[BTD1?&CX=>"?B
MY<^([_QM^S)H?PH\6MK/A/P5H'PY\:>$M.TWPQIFD:CILNI+J\FL:LO[;7C_
M`.('QB\$?L_?LC_LWZ-^UA\?X]5^'/@'X_?'?Q[\%=?^`_PZ_:9\*?"[3M+U
M1_V9/%OBE_VAOC9^R+I/A+Q;\7OC]X.LO&VJ64^C:E!XH\-?!#XQ?#KQ'\,+
M/2O$MV^D@'[@56O;VSTVSN]1U&[MK#3["VGO;Z^O9XK6SLK.UB>>ZN[NZG>.
M"VMK:"-YIYYG2*&)'DD=44D?@+^T+KGB?]M_X6?\$W[/XC?L??L[_&;XSVG[
M2WQ'\'?'K]DC]L7Q%INA_";PI\:_AU^R9^T/:?$'3/$.N:+\%/VJ]%N6T'5;
M<>,_AIJVB?#WQ?H/BO0=3\*>(=`\40Z)K6G^(W]Q\5?!7Q#\(OV/M#_8TO-/
M^'_PS\0_ML?'6Z^#?A_X-_`CQ-XP_P"%7_`7X/?$2ROO%WQT^&_P-\4V7A#X
M;^)+'PUX`_9V\"_%_6?"_B33O`OPGTK3_&VK6?\`8?ASP-976BZ/;@'[!:1J
M^D^(-)TS7M!U/3M;T/6].LM7T;6=(O;;4M)UC2=2MHKW3M3TS4;*6:SO].O[
M.:&[LKVTFEMKJVEBG@EDBD1SH5^,GQ+_`&./V1-/_;O\?_$RP_98_9RLOB18
M?L2^*OB+9?$*V^"/PTA\=6GQ"M?&E_X>M?'EOXNC\,KX@B\:0:!&FAQ>*DU$
M:[%I"+IJWXL\0U\4:+^RS??M(?%G2TTO]BW]A7]HG4]+_P"";?\`P3GT;3OC
M3^U3XOU/P[\4/V>;[6]&_:+%IXH^!]CHG[*/QOUG5=4TVXAC\5JFD?%[X$ZG
M_P`)#X>T.&P\3:;=2Q>)]"`/Z<J*Y3P)X?U#PCX'\&^%=7\0ZAXMU7PSX4\.
M^']3\5ZL2=5\3:AHND6>FWOB#4RTDI.H:U<VTNI7A,LI-S<R9D<Y8]70`444
M4`%?`/\`P5@_Y19_\%*_^S`?VR/_`%G7XC5]_5\`_P#!6#_E%G_P4K_[,!_;
M(_\`6=?B-0!],?&+X=ZW\0I/A,^BW6EVH\!_&;P;\1-7_M2>[A-SHGAZTUR"
M]M=-%I97OG:I*^IP&U@NC9VCJDQEOH"J"3\F/"O_``3,_:%L/B+\-?$&M_$#
MX26?A;2OCO\`%C3/B!#X=U#QLWB4_L>>$[CPAXR_8JT#P-=R^%],MT^,/PJ^
M+7P<^'/C;7-.\4SZCX.\(GXB?&B#PAXB\2(?#\%_^@W[77PEO/BA=?LYS6&J
M_'73#X9_:$\%WFNCX*?&KX]?"&&Y\'W5OJ4NOI\1(/@CX\\$P>+?!BW&FZ0+
MRQ\?1ZUX<L_,DA-O#'JM]'>?C!\4/#?_``5.3X%?"-O$-K\5/VF;O4_@U\-M
M2L?@E\%_$?[5_P"P'\4EN++XE^`=0\2>"?C[^UAX=^/?Q4\43_%:?PHMVFH?
M$#1?"GP6N-0CTKQ5I>J^%(M$\77=MH0!^G'P&_9K_:%\/>-_V>--^*'@K]E3
MX=_#/]D#PWK^@?#'Q9^SUK?CJX\;_%^'7_`FH?#R;1?$GP[\2_"_PAH?P`^&
M<EI?P^//$/PWT+XI_'__`(2WXD>&_A[K<OBO1$\#*-?X9OV'OCO\.=.O/BAX
M&\>V'[0/QUT[XZ:SX^\!?#GX[?$3P]\'_@CX!^&&M?'3QW\4;SX;^#/'WP7_
M`&3?$7Q&LUN[+Q7IFI7FJ_%'PA\</$8\0Z&NAZ;XLTS0+NZU&X_-+XA>'/VH
M;C6?'%]=_&G]M6P\3K^REX=M/!'AS0/V=?\`@MOXOL)X;_X(V#ZYKVD_$?X3
M?';X'_`]?'7A'5;S7[*^\)?$;X":=^W)X^\4>&I[S0/&_@7XG^,O`4OA#ZWU
M+X0?M$_$/]CG]CWX??!CQ)\:/BCXA;XU?%"]\8>,_'GQ@_X*T_\`!-77[?08
MO"OQTET?7OB-J7QI\9_M2_MS+HWA?Q;/X7'ASX;_`!R\<ZY\,_BG?6/ALZ1>
M>&/`UYX+TG3P#O+S_@G1^T5XV\9?%?X_^//COI4'Q=_:B\%?$?X:?'/X$S-X
M;^(G[*W@3X=:OX:L[/X5>$/A_JG_``HSX5_'?XM:7X)O_A]\.-$\;:3\2O&'
MA;P7XZTGXA?M/^)_"'@GX1Z]\8-2TR?I/C)^S/\`M@_'3P4+SQ9\$/V0O!OC
MCPEXR^%T'A;PY\"?VP_VJ_V?O$OC?X?_``_T7XE::S:Q^VA\&_V=_!7QN^#>
MGV=Y\0A?>#O@WX!^&/B_2M%M[3Q9HVK_`!=\0:-\1M4L=&Y_Q5XY_:R\2_L^
M_%?]DKX,V/QK\1_M97GQ?\4?##6_C5\4O"_[0W[.7PS\-?"WQ5X@\=>*-4^*
MG@3]JC4O@=\0_!\=Q?\`PG\+ZCX3^%FN_`O3OC7<?"/XN>._A4FO^%;+3;&[
MA@XCQAXJ^+/B\^!M1_;&\,_\%$O"7Q%L/AKX*\,^`=)_8%M_VD8_AE-^T[X/
M\1^,?"/Q2UW4;SX+:-X?T;5],\5>,]#T?Q1\.];_`&W](T[]C#6?@MK/@/5M
M9LK66]^)\*@'UC\6/@[^U6NK?"/5/A)\)/V8_B)8M^R[XD_9]^+GA/\`:0_:
M:^-VL:7X:N/$UW\/+M[NT\0WG[-?Q5\7?M3:+:IX<US3_$4WQ0U7X+>*_B/"
MMM?Z]KNE:IXEU6YT7Y$^'W_!-W]HOX=:AXOT".+X?_$;1]%7X6Z]X$^(/QB_
M;6_:X^(7@GXO:]\*+[X)7]CHGQ=_X)]ZE\-D_9=^%6K>([SX;:IK;_'SX8^,
M/&/Q&\+^-;;0/%W_``C?BR'7/%_ARXZ?X&Z1\98/VA/V_P#6=9^(7[3.I^*+
MSP7\;K?P%\.?%_P<_P""CNA^'/#D$6LV:_#[5OAE\:/'_P`=?$/_``3K\::Q
M>Z=#I<OA_P`/?LF?`3P#\1-,BU*:"[\3ZL^B>.KGQ#\?^*K3XBZE^SYJVE?L
M]>*O^"I7@SX5W:?L_2_&?Q=^T%\.?^"PWQ0^*'A[XMCQ+I">+/\`A4/@B3XF
M?!K_`(*5>*_`EWX:@O$^*^G_``.^)'AOX+Z?=2^%]0T+4WQ\5M)OP#ZW^+__
M``3Q_:!_:U^-GPA^+OQ\\(?LF_"?2+/PS\=_#7QD\#_!'QA\1_&?B#44\;?%
MC_@G_P"./AYKJ_%C7?@]\*+CXM>,;+3?V/=?-]XHU[X?_"M_`\%Y\-_!.AZ7
MXSM=!O\`QLEO4?\`@FI^T%\7H_'^I_&?XS>$/`'C+]JK1O@7HO[9'B[X%6FC
M>(]8\0Z'^SOXY_:'\;?#SP;\.+7XV_![Q5X"U3PS=Q^.OA%X(\;V'Q.^'.N^
M%O%_P]TWXN>%+OP';6?C&P:VP_@#;:K9>+_@M9_$W6_^"G_B3XXVNN_"BW^&
M_B+P9X8_;:\$?LSZ[\"8;/P7&=7^)?@W]HSQ?\0/AEX4M=1\+KJ=Y\=O#G[<
MOCOQG^WWHOB";QYIW@3Q3K_CNV\!ZI<_$_P1T+_@I9J/_!/[4_A1XHUS]NG3
M?CS^UU^R?\/)=)^)'BB?XTP_$_\`9>^)_P`!?V'/A5!\2Y[WQ7XDEN?%'PO\
M:_'CXH:;:Z+H-FLVE^)M?^,M_P#$KQ6-+O/%5]XLUFQ`/V6_9C^"/[5?P"^(
MWA_PSXG;X6?%OX-P?!;P!\)=:^.'B+XQ^+=/_:$F7X'ZU\9=-^&FKZO\)=._
M9TB^'?C?7_&G@/Q)\.+GXF>)8OC#\/8-,\;S>.KC0?"6LZ58:+_;?Z)U^'/Q
M$^('_!1&U^(7[4/QAUGX;>,='_9H^(7PC^*'PN^"OA'X:>(?BSXU^/\`X!\5
M_`;P_P")-?\`"/Q,G_9_\'?!D7'A.;XPZ[H_QUFTCQKX(^)WC7QO\4="\7_L
MB^`I_A[X8\5^&H[;6?U.O_B_#XN_9U\6?&;X;'QQX49OAQX[\2^$IOB3^R_^
MT)>>-]#U7P]IFN+8W^O_`+)-]HWPK_:4\:SVNJZ6+VV^$>A:9X0^(GQ-L%M-
M(\"WUO>>)=!U9P#\QOV,OV#?VC_@K)^V%??$7P[X'\/S?M"_M7_L??'WPAI<
MO_!0S]LW]N!M,\(_`_3?V?/#/Q!\->*O%W[4WP;\):ZOC,V'P2UGQ)X;\=V5
MGK&O?$*Q\:>"O@EXWU/PK\.?V>OA;JJ?J?XL^#/@"Y\&^(M+\)_#'X96VOOX
M?\GPJ+GPUHNB:?9^(-"T#7=(\#3R:GIOA[5+W18?#HUW4;+2]4T[2M0O?#FG
M:KJW]CV,GVJ>SN?R._8U_:;_`&P_B;\`_BYJ7[2WQ2\4:/XYTG]KSP)X)\$Z
MKK7_``3@_:2_8#UO1OA/\1_^"@/BCX>_#Z_T_4OVI-4\1>!?C%HGQ'^!$OP^
MN/"'A+PGX:7Q]\#_``MK&C>!_P!HKQ-\4/BWXAE\=:K]T>*/@]^T=X*\"ZOX
MCUK]N[Q[=67@OPMHNM:[=7WPF^`VAV^IZ9X'\+^,YO'4E_JL/@Z.71'\;W-_
MH6I3:U;W$;^#[?PJ%T\7$VI7.H6X!]2?!7P?J?PX^#?PE^'FN3V-UK7@/X9^
M`_!FL7.E2W$^EW&J>%_"VE:'J%QILUY:V-W-837=C-)9RW5E9W,ENT;SVMO(
M6A3Y)_;(Q_PT5_P2?QT_X;^^(W_KK/\`X*5U]4?L_>)=;\:?`7X)>,?$U\VJ
M>)/%GPB^&WB7Q!J;06MJVHZWKO@W1=4U:^:VL8+:RMVN[^ZN+@P6=M;VL)D\
MNW@BB5(U^%/^"BWPX\-_&3XG_P#!+WX>>*[_`.(>B^'O$/\`P4"\<)J%_P##
M'XK?%/X%>/8/[#_X)H?\%'M7MGT'XH?!7QE\/_B;X8CN;[2+=+U_#7B[21K^
MA3WN@ZN+_P`/:SJFF7H!\_\`[2?[`W[:?Q*;XZ+\.OC?X8MO"WQ6^-Q^-=A\
M._$_CKQS9V5GK/VG0?@G<:')X@@\*^(TTOX=W7[-$%UX_A^&NC:!#I2?M%^'
MM-NI]6%MXIU3QMH4O@;_`()>^(_@3;?"3P+\+O#'[/GQ&TSX;:WX6USX;_'3
MXI^`?@UX&^(/[,S)K.J:K\3-(^#/PE_9^_9G^%GPET2'QK<>(_$>LS>*/A5:
M?`_Q9XXU._?2?BY>>*)+[5/&]Q]>_P##M3]G7_HHW[?W_BV#_@J9_P#1D4?\
M.U/V=?\`HHW[?W_BV#_@J9_]&10!XI^V#^Q3^TM^TIXQ^/>KZ3\5?!6A?#[X
MF_`3QS^RGH_PLU*SO=:TR]^%GCOX9:CJ>K?$+5Y->TK6_!-G\0[CXY:GIVEW
M?AW7?AK\1/#US\*O!EE]HUB=_%6O>#HOFGQK_P`$,O`U]=>+O^$2\<0QVVD_
MLJZ-^S5\))-<^%'[(L82R\1>*?CCJ_Q-NO&&E:'^R3IFG:/X.M+3XO3/X1^`
MWPY'A;]EO4IK/2[7Q;\!-1@\,>'FL_T!_P"':G[.O_11OV_O_%L'_!4S_P"C
M(H_X=J?LZ_\`11OV_O\`Q;!_P5,_^C(H`^2?BK\#/$G[,7_!/KX`?L^:K9Z-
M-HOPP_;C_P""3^GZ/XITOQ%:W7_"4:IK/_!6_P#9?\0>*+JR\!:-\/O`'@OX
M0>#H-0U*"7X?_"GX<Z=:_#;X9>$[^P^%OPZ\,^#_``'X"\,Z2_U%^VC^R_X[
M^.OB#1M9T+X=?`GXUV%GX5M-&\*^&?VA+MAX>^"'Q*TOQ-)XDTGX\>!=%N?A
MI\3=*U7QK(HT[1)]9@M/"GC?P79Z%8:IX#\3B[O]6T^?XU_X*"_\$^?@-X3^
M`_@+5-+\>_MO75S=?MO?\$R_#4L7B7_@II_P4B\::<NG>-/^"D?[*'@[6+FV
MT?QC^U?KND6?B"STC7KZ\\)^++.Q@\5>`O%4&C>.O`NL^'/&WASP_P"(=+^W
MO^':G[.O_11OV_O_`!;!_P`%3/\`Z,B@#QWXB_\`!/CQSXG_`&G_`!#^V#H7
MQ%T2P^/7AW]EOP%\"/@SXD_X1/X>6FG:;XTAL/B]HWB_Q]XQUV3X9:K\?XO"
MVCR_$BU\7Z1\'_"/[06E?#+QOJVFP)X[\,ZAKFE:'XHT^_X#_8=^+G@OPK\`
MO"6L^/M$\=G]G;Q#\1M`T/Q'/K/BSP^?B)\&W\/7OC;X!>'O'?AJZ_X2M;S5
MO@A\<+3P#;^%[W5_$GBG7+/PY\.K7Q9)XKU/6/&WCCP[JOJ?_#M3]G7_`**-
M^W]_XM@_X*F?_1D4?\.U/V=?^BC?M_?^+8/^"IG_`-&10!^6_P`4?^"1G[5_
MQ!^'WPJ^%WC/XV:'\6_A9\&?A)I?P+\/?#GQ?>_#KQG;^*_"'A_XC_L]_$OP
MGXZ\76_[2?[-O[1OPTUSXG>&U\(_$KX8O+X^^&?Q,T/6O`_A[X<>)+E;;Q[J
MNHZEX9]HU7_@E'X_\5_#CX8?"+XC:Q\+OC-\'O#^L?$C7O%/PK^.-C#\0]*M
M-6\9?M=_"?XS6R>'/M7@N/P>?!L_PR\#ZM8R?#>W\!Z!X2\#>*[DZ%\-K30_
MAWJ-MX>\.?<'_#M3]G7_`**-^W]_XM@_X*F?_1D4?\.U/V=?^BC?M_?^+8/^
M"IG_`-&10`WXAHD7_!4G]C6.)%CCC_X)_?\`!2E(XT4*B(G[1'_!)Y41%4!5
M55`554!5````Q7L'[7OP?UCXX_!NX\":9X+^'OQ2L)O%_@O5_%OP>^+6I2Z5
M\,OB_P""=)\06ESXI^'WC6[7PEX]M7TG4]+\[4K?3M7\%^(]"UK5M*TW1=;M
M+/3-0N=7TW\P_'O_``3Z^`]K_P`%(OV4/!T7CW]MYM(UW]B'_@H+XEOKNZ_X
M*:?\%(KSQ5!J/A/X\?\`!,O2]+M=&\=7?[5\_C;PYX?NK;QIK$OB7PGX>\0Z
M7X5\::C9^$]8\8Z-KNK^`O`M]X<^WO\`AVI^SK_T4;]O[_Q;!_P5,_\`HR*`
M/FC]C[]@G]I_]G?XV-\0=:^*GPRN++4_A[X1\%_%CQ->6'B3XF>+/C9;>$]'
M^&6B^%;"SFU>/P)XG\#?\(=H_A7QKI%WXC^)WQ`_:0U;7[SQ/IVO>#[7X7:?
M+XQ\(>)-OP'^QS^V5\./C!\$]2^&WQC^%_P[^#/PN^$6I_#-?`-UX4T;QWX!
M\/Z3JGB/QGXAU1?`OPVL_`_P]\9:+\0-4OQ\*=-@^(%M^T%8?#S3/AGX8U_P
M)+\!=2\1SZ%\0K'WS_AVI^SK_P!%&_;^_P#%L'_!4S_Z,BC_`(=J?LZ_]%&_
M;^_\6P?\%3/_`*,B@#YQ_9@_X)^_%OX66/P"?XEO\(-5\3_!3XL?"_QCK/B?
MP[)>W-U\2/%_@O\`9S^,7P:^+O[5MQ#=>#-);PG\=/VI->^)5MK/Q)\.V4^K
M&#2[.XM]8^)GC"YNKEI?V,KX!_X=J?LZ_P#11OV_O_%L'_!4S_Z,BC_AVI^S
MK_T4;]O[_P`6P?\`!4S_`.C(H`/^"3__`"BS_P"":G_9@/[&_P#ZSK\.:^_J
M_"/_`()E_P#!/KX#^-/^";O_``3Z\8ZQX]_;>L]7\6?L0_LH>)=4M/"?_!33
M_@I%X"\*VNHZ[\!_`6J7UKX:\"^!?VK_``YX)\%^'X+FZEBT;PGX.\/:%X5\
M.:<MMH_A[1M+TBSM+&#[>_X=J?LZ_P#11OV_O_%L'_!4S_Z,B@#[^HKX!_X=
MJ?LZ_P#11OV_O_%L'_!4S_Z,BC_AVI^SK_T4;]O[_P`6P?\`!4S_`.C(H`^_
MJ*^`?^':G[.O_11OV_O_`!;!_P`%3/\`Z,BC_AVI^SK_`-%&_;^_\6P?\%3/
M_HR*`/M7QOX&\$_$SPAXC^'WQ(\'^%OB#X"\8:3>:!XM\$>-_#^D^*_"'BG0
MM1B,&H:+XC\-:]:7^C:WI-]`S0WFG:G975G<Q,8YX70D5X_\'?V0?V3/V=[R
M#4/V?_V7OV=O@9?VT/B>WMK[X._!/X:_#*\MX/&Q\%MXS@@N?!7AK1)HH?%S
M_#CX>-XGCC=4U\^`O!9U5;L^%M#^P^%?\.U/V=?^BC?M_?\`BV#_`(*F?_1D
M4?\`#M3]G7_HHW[?W_BV#_@J9_\`1D4`?8'BOX4_"[QW?6VJ>./AMX!\9:G9
M3>%;FSU'Q7X.\.^(;ZTN/`OC/2?B/X)GMKO5].O+B";P=\0]!T/QYX6EBD23
MP]XST;2?%&D-9ZYIUG?0SM\,_AN^K^./$#_#[P0^O?$W1=+\-_$G6V\*:"VK
M_$'P[H=EJ>FZ+H/CC4C8&\\6:+I&G:WK-AI>EZ]/?V.GV6KZG:VD$,%_=QS?
M''_#M3]G7_HHW[?W_BV#_@J9_P#1D4?\.U/V=?\`HHW[?W_BV#_@J9_]&10!
MZ=\0/V"_V&?BSXRTWXB_%/\`8P_9/^)?Q!T;3_#^DZ1XZ^('[.OP@\9>,M*T
MKPG%'!X6TS3?$_B+P=J6MV.G^&888H?#]E:WT5MHT44<>G1VR(H'TQHOAWP_
MX;BU"#P[H6CZ##JVL:KXBU2'1=,LM+BU+Q!KMW)J&MZ[J$=C!`E[K&L7\TM]
MJNIW`DO=0NY9+F[GEF=G/PS_`,.U/V=?^BC?M_?^+8/^"IG_`-&11_P[4_9U
M_P"BC?M_?^+8/^"IG_T9%`'JFB_L)?L0>&_'GB7XI^'?V-OV5-!^)WC34KK6
M?&/Q&T7]GGX1Z7X\\6:O?^*].\>7VJ^)?%]CX0@\0:[J5YXXT?2/&=W?:KJ-
MU=7'BO2].\132OJ]C;7D7T;X@\+>&?%D&G6GBGP[H7B6UTC7=#\4Z3;:_I&G
MZS!I?B;PSJ5OK/AOQ%IT.HV]S'9:[X?U>TM=5T35[98M0TG4K:WOK"XM[J&.
M5?A[_AVI^SK_`-%&_;^_\6P?\%3/_HR*/^':G[.O_11OV_O_`!;!_P`%3/\`
MZ,B@#ZK\!_`OX)?"SQ'XZ\8_#'X._"SX<>+OBCJX\0?$SQ3X#^'OA+PAXC^(
MNO*"JZWXZUSP_I&G:GXNU=5+*-2\076H7H!($V"<=MX8\+>&?!/A_2/"7@SP
M[H7A'PKX?L8=,T'PSX8TC3]`\/Z)IML-MOI^D:+I5O::=IMC`ORPVEE;0P1+
MPD:BOA[_`(=J?LZ_]%&_;^_\6P?\%3/_`*,BC_AVI^SK_P!%&_;^_P#%L'_!
M4S_Z,B@#Z`\:?LH?LM?$?XF:#\:OB'^S7\`?'GQD\*I#'X7^+7C/X.?#OQ1\
M3?#<=M$T%NF@^/-<\.7WBG1T@@=X85T_5;=8HF:-`J,0?9;'PYX>TS6-<\0Z
M;H.BZ=K_`(G_`+,_X237+'2[&TUCQ#_8MJ]CH_\`;FIV\$=[JW]DV4DEGIGV
M^>X^P6KO;VOE1.R'X:_X=J?LZ_\`11OV_O\`Q;!_P5,_^C(H_P"':G[.O_11
MOV_O_%L'_!4S_P"C(H`^O[7X4?"VQ\2WOC2R^&O@"S\8:EXPD^(>H^++7P=X
M=M_$M_X_E\`V/PIE\<WNNPZ<FJ77C"3X7:9IOPVD\33W4FM/X!T^Q\'->GP]
M:6^G1V-6^''@[7?'O@WXFZMI,EYXT^'VB^,=`\'ZF^JZREIHVG>/7\.-XJ9-
M!AU"/P]>:GJ$?A31K6WUS4=*N];T?3QJNFZ+J&G6'B'Q#;:I\<?\.U/V=?\`
MHHW[?W_BV#_@J9_]&11_P[4_9U_Z*-^W]_XM@_X*F?\`T9%`'V[=^$/"=_J]
MSX@OO#'AV]UZ]\.S>$;S6[O1=-N=7N_"=S=/>W'ABZU*:V>]G\/3WKO=S:)+
M,^FRW3M</;-*Q<U?#W@/P/X1N9+WPIX-\*>&+R;P[X7\(S7?A[P[I&BW,OA3
MP/'J<7@OPQ)/IMG;ROX>\(Q:WK47A?16<Z;H$>KZFFE6UHM_="7XL_X=J?LZ
M_P#11OV_O_%L'_!4S_Z,BC_AVI^SK_T4;]O[_P`6P?\`!4S_`.C(H`^_J*^`
M?^':G[.O_11OV_O_`!;!_P`%3/\`Z,BC_AVI^SK_`-%&_;^_\6P?\%3/_HR*
M`/OZBO@'_AVI^SK_`-%&_;^_\6P?\%3/_HR*/^':G[.O_11OV_O_`!;!_P`%
M3/\`Z,B@#[^KX!_X*P?\HL_^"E?_`&8#^V1_ZSK\1J/^':G[.O\`T4;]O[_Q
M;!_P5,_^C(KXA_X*:?\`!/KX#^"_^";O_!07QCH_CW]MZ\U?PG^Q#^U?XETN
MT\6?\%-/^"D7CWPK=:CH7P'\>ZI8VOB7P+XZ_:O\1^"?&GA^>YM8HM9\)^,?
M#VN^%?$>G-=:/XAT;5-(O+NQG`/W<HK\S=?_`&??BCX5\4^"O!7B/_@L1^W3
MHOBGXC/XDB\#:-J'@#_@EI;W7B>?PAHK^(_$MOI3/_P32\B>YTC0(KC6;JV,
MJ3_V9:7U['');V-Y)!X/>ZOH5MX$3XDZ?_P6[_;K\6>$KCX#WW[3VG7/PZ^#
M/_!.3XGZSKWP#TV[M+*\^)_A?PE\._\`@EEXH\7>*O#R7%];"/\`X1S0]4U"
MYB:6YMK*:VM[B6(`_:JBOY^-6^/_`(%T+4-.TO5?^"O/_!8&SO-7UGPAX9TM
M6_X)M_!*6#4?%?C3X1R?'FQ\&V5Y!_P1+EL[GQKX=^#EKJGQ$^)G@R&=_%'P
M?\->'_%5[\6-)\%GPGXECTKV_1VTOQ!93ZAH?_!<+]M?5K6W\,_'WQB[6'PV
M_P""9-S++X9_9>^(EY\)OCQK%I;1?\$PFNKZV^'OQ#T[4/#-\ME#/-J]U8W=
MSX;BUG3K>:\0`_9BBOSXL_V0_P!H'4+2UO[/_@K+^W[/:7MM!=VLR_#C_@EJ
MJS6US$LT$JJ__!--7421NK@.JL,X90<BK/\`PQO^T5_TE@_;^_\`#<_\$L__
M`*6I0!]_45\`_P##&_[17_26#]O[_P`-S_P2S_\`I:E'_#&_[17_`$E@_;^_
M\-S_`,$L_P#Z6I0!]_45\`_\,;_M%?\`26#]O[_PW/\`P2S_`/I:E'_#&_[1
M7_26#]O[_P`-S_P2S_\`I:E`'W]17P#_`,,;_M%?])8/V_O_``W/_!+/_P"E
MJ4?\,;_M%?\`26#]O[_PW/\`P2S_`/I:E`'W]17P#_PQO^T5_P!)8/V_O_#<
M_P#!+/\`^EJ4?\,;_M%?])8/V_O_``W/_!+/_P"EJ4`??U?`/[9'_)Q7_!)_
M_L_[XC?^NL_^"E='_#&_[17_`$E@_;^_\-S_`,$L_P#Z6I7Q#^U?^RA\>=+^
M/'_!,NQOO^"FG[;WB.Y\1_MO>/=&T?6-9\`_\$W8-1\!:C!_P3<_X*"^(9?%
MGA.+P_\`\$^=!TB\\07FD:%JG@6YMO'6E^-/"J^%?&GB6\L_#5KXVM?!WC'P
MF`0_MW>"O^"ANI>'_P!I:T_9M\(?M&W'QW\4^!OVB=$^$'QF\$?M#Z9X<^"N
M@>'=;^&NMV_P*\(>&_@=>_%/1O#VG?$"37KVW\/W_P`8-3\`Z%\1/`GQ7AT/
MQX?'U[\'DU270O7+/X:?M\^&_P!D+]GSX6?!74=1?XN^&_&_B_XD_$CQO\8/
M&_Q9\.WNLZ!X!\::YXR\'?"/4=7^,O[3/_!07XS!_BSXDU+PAH6IOXF^.?Q,
MT";X1^'OB!X>BU#X56>O^"/#OAKZ(_X8W_:*_P"DL'[?W_AN?^"6?_TM2C_A
MC?\`:*_Z2P?M_?\`AN?^"6?_`-+4H`_,23]B/_@IQ\1ET/7M0_:5^+OPP/QG
M_P""EO[0WQ%\>>$[SXH?'^[;X)?L=:*/V\+WX!VGB";X<_M[>$$UBPUPWO[)
MNF^$_AQ^S1J7P%\$^'#=^"G_`&A/@W\<1X*^*4_B3[D_8-^%G[77P0\??'J3
M]I'6/B=\3M-^,WQV\8ZO\/KP^._$WC3PE\-?`$WB+XU^)=#UKQ3!\8/VD_B=
M>^$;VZT[3/"G@J/P=^S?X*^'GPETG2]?^$;:?\)K*_?XF>(?"7J__#&_[17_
M`$E@_;^_\-S_`,$L_P#Z6I1_PQO^T5_TE@_;^_\`#<_\$L__`*6I0`?\%*_^
M3=?AS_V?]_P2?_\`7IG[&]??U?A'_P`%!?V4/CSH7P'\!7VJ?\%-/VWO&EM/
M^V]_P3+T:+1_$O@'_@F[:Z=9ZCXC_P""D?[*'A[1_%EM+X._X)\^$]7;Q!X"
MU?5+'QUX3MKS5+KPK>>*O#FC6?CKPUXT\$S^(/!VO?;W_#&_[17_`$E@_;^_
M\-S_`,$L_P#Z6I0!]_45\`_\,;_M%?\`26#]O[_PW/\`P2S_`/I:E'_#&_[1
M7_26#]O[_P`-S_P2S_\`I:E`'W]17P#_`,,;_M%?])8/V_O_``W/_!+/_P"E
MJ4?\,;_M%?\`26#]O[_PW/\`P2S_`/I:E`!\1O\`E*9^QO\`]F`_\%*__6BO
M^"3]??U?A'X]_90^/$'_``4B_90\/2_\%-/VWKS5]4_8A_X*"ZS8^.KGP%_P
M3=7Q5X<T[0OCQ_P3+L=4\)Z-9VG_``3ZM?!,_A_QK<^(]'UCQ+<^(?!VO>*K
M74?`7A.+P=XF\)Z1>>.M+\:?;W_#&_[17_26#]O[_P`-S_P2S_\`I:E`'W]1
M7P#_`,,;_M%?])8/V_O_``W/_!+/_P"EJ4?\,;_M%?\`26#]O[_PW/\`P2S_
M`/I:E`'W]17P#_PQO^T5_P!)8/V_O_#<_P#!+/\`^EJ4?\,;_M%?])8/V_O_
M``W/_!+/_P"EJ4`?E9^P5\&_VSM4^$/[`O[0OPV\;>*(_@C\)_\`@B%_P3CL
M?A3\%AXV\<6/@[XU?M(:A\*OCB_C[0;W0=*^//A?X5>&[*TT2Z_9S;X@>-OB
M[^SS\7->O/#]SH$'P0\8?#O7/"OCE-?]AU+]F7_@I-XY\?\`[*7AOXG_`!*\
M?V_@KX%Z[\3_``I\<_B+\,/CM\6_"FI_'/P5X[\3?!W6_!GBWPM!\,/CU^S]
MH]_XG\+>&=;\7?#7Q1K'QU^$/C23PWIWA'XE^,_@[X3T?QM=?#OQ#K_WE_P2
M?_Y19_\`!-3_`+,!_8W_`/6=?AS7W]0!^0WP;^$?[>G@7]EG_@GYX?M?$_C:
M;XW_``U_8TU*3]I[2OC%\7+OXCCXC_M+ZG\./A')K/@SXH?%'7/$?Q!\47&H
MZC\1KOXI3>%_B3X-U+Q5I?P[U33]/ETNTUKX:PGP)XCX?X!^%/V[/`>N?#OQ
MM\7O!G[2_CCXQ^%[KQMJ_P`>-9TWXX^#=3^`/Q3^!6G>`O'EY\(_A!\*?@=X
MD^.,W@32OVA[;7O$7PL\/^+/'\?@KX0W_B?X@?#GXF>*O%'QMNOACK7@[PMX
MX_;&B@`HHHH`****`"BBH;G[0+><V@@:[$,OV87+.MN;CRV\D3M$KR+"9-@E
M:-&<(6**S``@$U%?F)^RC^UU\7-6UC_@H[H/[5_B'X.ZA8?L(_&J'PC_`,+#
M^#_PR\:_"K1]9^&K?LR_"C]HC4=;\0>#O&GQE^.-[#KN@0_$'5-'N+G3O&,6
MGZI:Z+;WT>DZ;+=26T/CFI?MH?MQ?#_]F.W_`."BWQ9\`?`C1/V6$\&Z7\:/
M&O[+VD>$_B++^U%\*/V;]9ET_79_BAKOQSD^)EW\./&'Q)\!_"V\?X@?$'X#
M:/\`L^:%:P7EGK?@SPQ\9O$.HZ/8:EXE`/V>HK\P=,_:'_:^_:>^)'QSC_8[
MF_9P\#?!/]GCQ_'\*#XY^/?@GXD?$[5?VDOBCH7A_0_$_P`1=`\`)\._BK\*
M[+X,_#WPF_B32O`$/Q<UNV^-6IZEX\L?&HC^$*Z1X1L;CQ=RW@C]N[X__M2^
M%?V>=%_9;^"5KX'^(?Q23]H'3_C_`/$GXU>%O''C_P"!?[('C+]F+QTOP9^*
M7PV\1OX$U#X??\+?^*NI?&A[O1_A?X"M?B-\)K?Q]\._"?CCXE?\);H>GZ1I
MNFZR`?K/17P+^S1^T?\`&+5?VBOCG^QI^TK9_#;4_C1\&OAQ\(_CAH/Q2^"^
M@^)_!WPT^*_P;^,NL_$;P?H>JO\`#CQGXR^(_B;X6>._#7COX2^.=#\1>#KG
MXD_$?2;S0V\*>*-&\93S:UJ_ASPS]]4`%%%%`!1110`4444`%%%%`!1110`5
M\`_\%8/^46?_``4K_P"S`?VR/_6=?B-7W]7P#_P5@_Y19_\`!2O_`+,!_;(_
M]9U^(U`'H_[2W[&WPU_:IUWP1K/Q$\1>/M*7P#X4^(GA?0['P3K.E^'G@D^)
MFN_"V_U_Q-;ZZ-#N_%>C^)HO"_PXU?X;V5[X?U_2+-_`OQ6^)=AJ=AJ.J7WA
MK5_#'AUA_P`$N/@#I;:_>:;XH^*ECKFIZ3XO\#:%JUCXETW3[;P5\%_%OP^\
M6_#\?`OP]X3TW0[+P/<?#CP\OCKQ5XO\.#Q#X9UOQ9IWC/5!J@\3R66GZ5IE
MC^E%%`'X\?%W_@B5^Q_\<OC/>_&?XDZ>FOZS=_%'0_C')!<_"O\`9XN=8U#Q
MMX2_9ZUO]GOP.GBCXA:C\'+_`.)'C3PEX#L]9C^)OA#P+XJ\4ZIX3TOXHZ%X
M>UJ72[O1=/F\/W?H&C?\$E_V>]%E^(.L1>-_C1<^-_'WC;]H#Q2/&LOC*PLK
MGPSX=_:3\<_M!?$3XA_"[1_"FC:%I?P_U'X?V_BK]J3XW:EX6A\6>$_$?B?0
M;GQ9#=1^)KB\TC3[B+]1Z*`.+^'?A;5/!'@GPYX2UGQCK/C_`%'0=/&G2^+O
M$&G>'-)UC6(H9I39M>V'A+1]`\/026=DUOI\?]G:19B6"TCGN1/>27-S-VE%
M%`&+K/B7PYX<.F+XAU_1=";6KZYTO1AK.JV.EG5M2L]%U?Q+>:=IBWT\!O[Z
MU\.^']?U^YM+7S;B#1=$U?598TL=-O9X>8C^+7PJF;4EA^)OP^E?1;+3-3UA
M8_&?AQVTG3M:M=$OM&U#4@NI$V%EJUEXF\-WFF75T(H+^U\0Z)<6LDL.JV#7
M'C_[7O[-S_M4?"*W^%T'CO4OAK<+\0OAMXGNO%>CZ:FI:H_@_1/&&EGXK^"[
M#-]IEQI%U\5_@U=_$3X2Q>*]/OH=5\%-XY'B_2X[V_T.WT^Z^$]$_P""/?P]
MT1;EHOC'\48I;#Q'X@USP='X5\<_%/X3:'IVDI\2?!^K?"SP+X]\&?!WXG>`
MO!7QL\"_!_X)?#3X8?`7PMX7^+WA[Q?HDWASP19:K/IL<U_J5C<`'V/X9_X*
M)_\`!/SQI)X3A\'?MT_L<>+)O'OCBV^&7@:+PS^TY\%->D\:?$F]?1EL_A]X
M332_&]T_B/QQ=MXB\/K;>$]'6\UZ=M=T816#G4[(3]7XN_;7_8T^'X^(Y\>?
MM;_LR>"1\'=>T;PM\73XN^/7PK\-CX6>)_$8SX>\.?$<ZSXKLAX'U[7ASHVD
M>)O[+U#5.MC;SU^9WP1_X(\^(_@AJW["6HZ9^T9>:VO[&_PYF^&NIKHX^.?P
M9?XDV%Y\/O\`@GYX'N-2OV^"?[1/@F35=',O[#<^IWOPC^*L_P`5O@WXL7XD
MV5KXW\%^(I/`>G76J>T_%;_@EQX?\;6GB?Q#X;^)7C+1?BMXI_:/\6?'&Y\8
MR_%K]J7PU;:'X;\3:QXTU%OAO\-O^%2?M%?#7Q+\#+6X7Q)HUUXQUCX#>)/A
MF/B9K/AM=0^(.F>(?[6U**4`_5NTN[6_M;:^L;FWO;&]MX;NSO+2:.YM;NUN
M8UFM[FVN(6>&>WGA=)8)HG>.6-U=&96#&Q5#2;6;3]+TVQN)OM-Q9:?9VD]Q
MYM]/]HFM[>.&6;SM4O=4U.;S71G\W4=1U"^DW;[N^N[@R3R7Z`"BBB@`KX!_
M;(_Y.*_X)/\`_9_WQ&_]=9_\%*Z^_J_,+_@HSIOQ3U?XG_\`!+O3_@KXR^'_
M`,/_`(FW'[?WC/\`X1KQ=\4?AIXB^,'@32/)_P""9?\`P4;GUG^W?AUX3^+'
MP-\0>(OM_A^+5=,TS^S_`(H^&/[)UB]T_7;K^V[/3+GP[JX!\X:K_P`$O_C9
M/\0OVJM<\,_%/PCX'LOVR/BYJFO^/_&WAS3-&T/QEX#^&-EXT\2^-++1(H_`
M/P_^'?C?XT>*?%Y\.?";PJNO_%GXTZKJWPC\'Z]\4?#_`,,M:TGPY#I/AC7O
MK/X\?`G]L3XN^#/V<Y-%^*/P[\&_$;X%66G_`!9\4R6?_"5IX<^,/[0W@JUT
M6R\,^%KJXT\V-QX0^#?C.VD\?V?C*YOM)\?7VDV7B_2WT_P?K>I^%[:^N=O_
M`(5S_P`%3/\`H\C]@'_Q6I^T5_\`38*/^%<_\%3/^CR/V`?_`!6I^T5_]-@H
M`^`4_P""&/P^\4:C+>_$#QK>VQ\>_M1?&+]I+XK2>"/!G[,FCZK9:GX@\4_%
M34?AW%\.?%D7[*UEXUT;QRFD?$B8ZM^TC+X@A_;(\"ZE::.WPH_:7\)KX2\+
M/IGV!_P3J_8P^('[$?A_Q1X0U@^"/%4/Q-\2W/COQEXJ\.7'A7P5#HNKW&EQ
M7RZ19^`?`7P7\!Z1XWUQ_%.J^*+?Q!\7_&^LZE\5_'.B0^%]1^('BWQ?J^G0
M6^F=]_PKG_@J9_T>1^P#_P"*U/VBO_IL%'_"N?\`@J9_T>1^P#_XK4_:*_\`
MIL%`!_P4K_Y-U^'/_9_W_!)__P!>F?L;U]_5^47QP_9/_P""D7Q]\%Z+X%\8
M_MK_`+$.FZ3H7Q?_`&>_C5:7'AK_`()O_'BRU&3Q5^S7\??AI^T7X%T^YFU3
M_@J7K-L_A_5?&WPK\/:7XLM([.'4;[PK>:S8Z/JN@ZO<6.N:=Z__`,*Y_P""
MIG_1Y'[`/_BM3]HK_P"FP4`??U%?`/\`PKG_`(*F?]'D?L`_^*U/VBO_`*;!
M1_PKG_@J9_T>1^P#_P"*U/VBO_IL%`'W]17P#_PKG_@J9_T>1^P#_P"*U/VB
MO_IL%'_"N?\`@J9_T>1^P#_XK4_:*_\`IL%`!\1O^4IG[&__`&8#_P`%*_\`
MUHK_`()/U]_5^46M?LG_`/!2+7?CY\-/VB[O]M?]B&/QO\*_A!\</@KX>TNV
M_P"";_QX3PK>>%?C[XT_9[\=>,=0UFQE_P""I<VKW'B'3=6_9K\"V_AJ[L=<
MT_3K+3M5\60ZII6LW-]H]YH7K_\`PKG_`(*F?]'D?L`_^*U/VBO_`*;!0!]_
M45\`_P#"N?\`@J9_T>1^P#_XK4_:*_\`IL%'_"N?^"IG_1Y'[`/_`(K4_:*_
M^FP4`??U%?`/_"N?^"IG_1Y'[`/_`(K4_:*_^FP4?\*Y_P""IG_1Y'[`/_BM
M3]HK_P"FP4`'_!)__E%G_P`$U/\`LP']C?\`]9U^'-??U?`/_!)__E%G_P`$
MU/\`LP']C?\`]9U^'-??U`!1110`4444`%%%%`!1110!_/EH'PC\0_M`:5_P
M<Q?`?PBRIXK^-GC_`,5_"/PP[Q"=4\0_$C_@E?\`L\^#=%9H3/;"95U+6;4M
M$;BW$@!0S1`[U[']IO\`:3^&OQH_X(0?$B^^&^HZ?KGBG]H[]C3Q!^R7\-OA
MG:"&W\:W?[3WQ;^%]U\![/\`9^?PB\W]IZ-\5/"/Q/UNX\)^+O!VH1P:AX(U
M#P_KDWB5=.TW0M3O;;]K_#W@'P+X1UGQIXB\*>"O"7ACQ!\2-=M/%'Q#UWP]
MX<T?1=9\>^)K#0-(\*6'B+QIJ>FV5M>^*==LO"^@:'X;M-7UR>^U"VT#1=(T
M>&X33M-L[:'SK3_V8/V:M(^,6H?M$:5^SQ\#=+_:`U:RGTW5?CGI_P`)?`-E
M\8M3TZZ6%;JPU#XFVWA^+QK>V5PMM;K/:W.MR03"WA$D;"*/:`?FE_P2IOO"
MG[-/@_\`;6_9@^*?B_PQX4^)?P`_:U_:)^.7CZTU^YM/"P7X-_M(^+;[]H'P
M%\7H7U:]0:E\-9M.\8ZUX'7X@*T6AMXH^&_C'P_</9:GX;U&RMO//V,_VEM!
M_95_8/UWXX^,?"?B;Q'XJ_;$_;>_;7^+W[)/P#\*6<:?%K]H1?VE_P!J?XQ?
M%'X$^&_`OAS59+)K)O&WPZU72?B+J>N^('TS0/AS\,[J^\=_$2^\-Z!H&NW-
MA^N7Q7_9D_9M^/&M>#_$?QQ_9[^!_P`9O$/P]OX=5\`Z]\5_A/X"^(FM>!]4
MM[N*_M]2\'ZIXOT#6+[PU?P7T$-[#>:+/97$5W#%<)(LR(XQ/C;^Q]^R5^TQ
M<^&[W]H_]ES]G3]H"]\&V=]I_A"[^-OP2^&GQ6N?"MAJDEI+J=CX;G\=^&=>
MET.SU&6PL9;ZVTQ[6"[DLK1[A)&MX2@!XA^Q+^R_\1?A;?\`Q9_:1_:8\0:+
MXP_;#_:CO?#.K?%NY\+O+<?#_P"$/@?P;;:G%\+?V9_@]<WEM:ZG>?#7X16W
MB#Q!+<>*-6AM]9^)/Q"\3>-OB)J5EHUOX@TKPOX<^^J^</@A^QQ^R'^S-JVN
M:]^S?^RM^SA^S[KGB;3K?2/$FL_!#X'?#'X4:MX@TJTN?MEKIFN:CX#\+Z!>
M:KIUM>?Z7;V5_-<6T-S^_CC67YZ^CZ`"BBB@`HHHH`****`"BBB@`HHHH`*^
M`?\`@K!_RBS_`."E?_9@/[9'_K.OQ&K[^KX!_P""L'_*+/\`X*5_]F`_MD?^
MLZ_$:@#QSXK^`;CX#W7A.Q^./_!=7]IOX,WOCV?6;7P+9_%>X_X(^_#NZ\:7
M/ARSM]0\0V_A.W\7_P#!/#1Y?$<^A6%W:WVLPZ.EY)I=G<V]S?+!#-&[7O%W
MPNUKX?\`A>/QQX\_X+B_M4^"?!4N@ZEXJB\7^+D_X)"^&_"\GAC1],NM:U?Q
M''X@UG_@G99:2^@Z5HUC>ZMJ6L+=G3['3+.ZO[JXBM;>65-O_@H3_P`$W-(_
M;YF,^K?%SQA\,7L?V,?VZ?V6=#7PCK/Q(T*$>(_VR+'X":?IWC_QG;_#OXH_
M#>#XG^!OAS!\&+^36O@+\08_$'P\^)M]XETC4]932=2\$:-=S>*>*/\`@D5%
M=Z?\$[7PQ\8-$-C\(?"DEFW@+Q]\.=:\2?#34?B!>S2ZEK_Q(\+VGA?XF>`_
M'GPY\0^)->73?%$L_AKQYL\-?$+1=.^*GA6#3/'%WXKO?%8![AHOP!^(GB1-
M*D\._P#!9_\`;)U^/7KU--T.31="_P""2VJ)K.H2^%X/&\5AI36/_!..X74;
MV3P7=6WB^.ULS-._A>X@U]8SI,J7;=K_`,,;_M%?])8/V_O_``W/_!+/_P"E
MJ5PGP*_X)QGX2_&'P9\??%'QX^)7Q,^*FC^*I?$/C"ZU/Q=\5=+^&/BN.Z_9
MF\._`2]N-'_9Z_X6OJOP"\`>+[G6?#X\83^/_"WPXM_&=WI-[<^$;[7+FUN=
M0O\`4/TYH`^`?^&-_P!HK_I+!^W]_P"&Y_X)9_\`TM2C_AC?]HK_`*2P?M_?
M^&Y_X)9__2U*^_J*`/@'_AC?]HK_`*2P?M_?^&Y_X)9__2U*/^&-_P!HK_I+
M!^W]_P"&Y_X)9_\`TM2OOZOC+7_V\?@AX;F\8P:CX&_;-N7\"^,8O`NM-H'_
M``3C_P""AGBN&^UN9_$R)>^#KCPO^R]K%O\`$3P<I\):J9?B)\/Y?$_P_@6[
M\,O/XGC3QKX-;7@#CO\`AC?]HK_I+!^W]_X;G_@EG_\`2U*/^&-_VBO^DL'[
M?W_AN?\`@EG_`/2U*^_J*`/@'_AC?]HK_I+!^W]_X;G_`()9_P#TM2C_`(8W
M_:*_Z2P?M_?^&Y_X)9__`$M2OOZB@#X!_P"&-_VBO^DL'[?W_AN?^"6?_P!+
M4H_X8W_:*_Z2P?M_?^&Y_P""6?\`]+4K[^HH`^`?^&-_VBO^DL'[?W_AN?\`
M@EG_`/2U*^8/B[\`OBM\*_VL_P#@E=XA\=?MN?M/_M*:1>?MO?%#1K?P+\:_
M"?[&&A>%=*U&X_X)B?\`!1:^A\66%Y^SI^R)\`O&TGB"QMM.O-'M;;5/&.I>
M%GTW7=5EOO#5YJT.AZIHW[.U\`_MD?\`)Q7_``2?_P"S_OB-_P"NL_\`@I70
M!Z7XA_:]\)^'-2^(-S<?#+XQ:G\,/AF_BG2?$WQPT#P_X4USX?-XZ\&Q2C7/
MAQHWA_3_`!M-\9];\41:G#)X9MM3T[X33^`[SQBO_"(6WC23Q(1IAY;2?V\O
MA5:^+/`GPX^+?@[XG?L\?%/Q_P".[_P'8?#GXMV'@6]U319T\"^./B-X>\3^
M)?%WPC^('Q4^%>E^"_&_A;X?>(CX6\01_$&[C_X25+7P'XA@\/\`CR=_#4'I
M&N_LD_!'Q-XE\7>(=;T?Q=>V?CM-;D\6>!%^)_Q,M/A1K.K>)-&F\/Z]XEN/
MA38^+;;X?Q^*-5TN>0W>O6_AZ&_.L$^*HY(_%C/KK<7?_L#_`+,6OZ)?Z)XV
M\'^*/B6NK0WD&KZU\4/BG\4?B+XKU47$_A:XT^2_\6>+O&&K>(I9O#$G@S07
M\&2KJ2-X2G35K[0/L.I>)/$EYJP!Y;HG_!53]CC7O"/BOQI9>-=?AT;PGX.^
M%/CF;^T/"NH:?<ZYH/QG^(_BSX5^!SX:6[:*WU;4F\5^#[X>*-(2YBU'P-H^
MHZ%K/C*WT.PU6"4<+\(O^"P/[*_Q>M?%EW8:?XY\.)X:T_X[:E:?;-:^!?CV
M#7U_9[TWP1J_C/0;G4_@;\;/BUHOPO\`B-JMCX]T>?PK\&?CUJ?PD^,^H1VF
ML2ZE\/M&AL5EG]JU'_@FO^QEJVE>+-'U'X12W4'C'4_CGJE_>MX^^)$>N:1)
M^T;9Z[9_%6Q\&>((?%L>M^`M%OU\0WUUX4T3P9?Z%I7PVU"UT+4/AQ:>%+SP
MSX<FTOJ++]A#]FJ'P3K7PXUGPAKWC7P-KG@'Q=\+)O#/Q`\?>.?&^FZ=\.?&
MM[X3U+6/!V@1^(]?U"30-'M=2\$>&]2\/)I$EI<^&-2L&O\`P_<:==W-S-*`
M>/\`P(_X*9_#7X[:]'I$'P,_:+^&6G[_`(]17/BGXDZ3\&FT.&;]G3XW^*?V
M=_'\6GVGPY^-?Q%\5>+'C^*O@?Q;H9/@;PUXH3PK96/AO7/B8_@+1_BI\&[S
MXB?I%7QWH_[!W[-GAR\\/WOAOP[XX\.R>$_%/Q=\>>%HM$^,?Q?TZU\.>/?C
MIXY^+GQ#^)OCG0[:W\<+#I7BSQ!X@^//Q?@36K%8+O3?#GCK4?"FFO:^&]/T
M+2])^Q*`"BBB@`HHHH`****`"BBB@`HHHH`^`?\`@D__`,HL_P#@FI_V8#^Q
MO_ZSK\.:^_J_FJ_X)_?MK?M=_#+]A[_@GU\)++]GC]C748+']@?]B+5O#.M^
M)?VR_P!KK0KFY\#>./AQX"^'GPHU7X@S>#?^"4/Q.^&7PV\:^/M4B1(OAW+\
M6_$MY:7-MK[Z1K7B?PYX=U#Q2?HGX'_\%0_VM_VC?&>F>`?A'^R+^S=KGB34
M-+\1:I=CQ!\=O^"GOP[T#PG_`,(IXS^(/P]US1OB1XQ^)'_!##PCX/\`A7XN
MM_&GPL\>^'K7P/\`$K7?"GC+5K[P_(=(T*_@O]*FO@#]S**_'[XE_MQ?MZ?!
M[XH^&/AA\2_V4O\`@G[X*3Q#\!/VA/VD;[XC^*/^"GGQE\.?"KP1\,?V9O$_
MP!\+?$O4O'OC#7_^"7VF#PU)%-^T7X-U?3;R;3Y_#Z:#H?C*_P!?UW0'TS2K
M?7.F\'?MC_MI?$3PMH7CCX?_``E_X)2>.O!7BBUT^^\,^,/!W_!73XK^)_"W
MB*RU;Q):>#M+O-"\0:)_P2XOM)U>UU+Q=?V/A73[C3[NXBO/$E[::';/+J=Q
M#:N`?JW17Y07O[9O[9NF^-O!?PUU'X5?\$H+#XC?$E=>;X=^`+W_`(*[_%6U
M\;>/E\+:BVD>)V\%^%9_^"74>N^*5\.:O&^F:\=#L+\:1J*-9:@;>Y4Q5I?%
M']K/]N7X'V/A?4_C3\%/^"67P@TWQOXPTCX>>"]0^*/_``5I^+_@"Q\7^/\`
M7X;VXT+P-X7N_%G_``2TTBWU_P`8:W!INHSZ1X9TF2[UK4H;"]DL[*9+6=HP
M#]3:*_)3X3?MN_M>_'RTU"_^!7PX_P""2GQIL=)U+Q%HVJ7OPF_X+`_$[XC6
MFFZOX/C\,S>+=*U"X\'_`/!+W68;/4O"T/C7P;+XCL;AX[G1(_%OAF34X[5=
M>THW<?A/]N/]KCQ[XWUSX9^!?A[_`,$D/&GQ(\,3>'K?Q+\/O"?_``6$^)GB
M/QOX>G\7:'>>)_"<&N>%-'_X)?7FO:3-XG\-:??^(?#T=_I]N^M:'8WFK::M
MS86TUP@!^M]%?D_X\_;._;,^%EQHMI\3OA7_`,$G_AS=>)/B'I7PC\.VWCS_
M`(*\?%3PA<:_\5]=TRQUK0_ACHL/B#_@EUI\FJ_$+6='U/3=6TKP78K/XDU'
M3-1L;^STV:UN[>62Q\'OVQ/VUOVA]"UKQ1\`/A%_P2F^.7AGPWXDO?!GB+Q%
M\'O^"N7Q9^)FA:#XPTRST_4=1\*:UJ_@K_@EQK>GZ7XEL-/U;2KZ]T*^N(-3
MM;/4]/NI[6."]MGD`/U8HKX!_P"%C?\`!4S_`*,W_8!_\65_M%?_`$I^C_A8
MW_!4S_HS?]@'_P`65_M%?_2GZ`/OZBO@'_A8W_!4S_HS?]@'_P`65_M%?_2G
MZ/\`A8W_``5,_P"C-_V`?_%E?[17_P!*?H`^_J*^`?\`A8W_``5,_P"C-_V`
M?_%E?[17_P!*?H_X6-_P5,_Z,W_8!_\`%E?[17_TI^@#[^HKX!_X6-_P5,_Z
M,W_8!_\`%E?[17_TI^C_`(6-_P`%3/\`HS?]@'_Q97^T5_\`2GZ`/OZBO@'_
M`(6-_P`%3/\`HS?]@'_Q97^T5_\`2GZ/^%C?\%3/^C-_V`?_`!97^T5_]*?H
M`^_J*^`?^%C?\%3/^C-_V`?_`!97^T5_]*?H_P"%C?\`!4S_`*,W_8!_\65_
MM%?_`$I^@#[^HK\HO@?^UA_P4B^/O@O6O'7@[]BC]B'3=)T+XO\`[0GP5N[?
MQ+_P4@^/%EJ,GBK]FOX^_$O]G3QUJ%M#I?\`P2TUFV?P_JOC;X5^(=4\)W<E
MY#J-]X5O-&OM8TK0=7N+[0].^=I/^"L?[4*W^H:1:_LF_LY:SK.G_%BY^"R:
M)X9^-7_!4OQ5KFM>-;*;XBVU[?\`A'1?#?\`P0HU;5?&_P`-+.Z^$?Q*M+OX
MV>#K37/@Q:WG@[6+2?Q]'<0QQ2@'[S45^6/@#]J[]O[XI-IL?@+]F/\`X)[>
M(IM5^'?@OXKVMO;_`/!1[]IZTNH_`/Q$GUVU\&:[J-KJ7_!)"SN-';7;KPOX
MCM;?2=6BL=<@NM"U>VO--MIM/NHXO4/^%C?\%3/^C-_V`?\`Q97^T5_]*?H`
M^_J^`?\`@K!_RBS_`."E?_9@/[9'_K.OQ&H_X6-_P5,_Z,W_`&`?_%E?[17_
M`-*?KXA_X*:>/?\`@I%>?\$W?^"@MGXZ_90_8A\.>";K]B']J^V\8^(?"?\`
MP4%^/'C3Q5H7A6?X#^/8O$.L^&O!VL?\$R_`6D>+/$&EZ0UW?:-X9U3QUX*T
M[7M1@MM+OO%GARVNI=8LP#]W**^`?^&-_P!HK_I+!^W]_P"&Y_X)9_\`TM2C
M_AC?]HK_`*2P?M_?^&Y_X)9__2U*`/OZBO@'_AC?]HK_`*2P?M_?^&Y_X)9_
M_2U*/^&-_P!HK_I+!^W]_P"&Y_X)9_\`TM2@#[^HKX!_X8W_`&BO^DL'[?W_
M`(;G_@EG_P#2U*/^&-_VBO\`I+!^W]_X;G_@EG_]+4H`^_J*^`?^&-_VBO\`
MI+!^W]_X;G_@EG_]+4H_X8W_`&BO^DL'[?W_`(;G_@EG_P#2U*`/OZBO@'_A
MC?\`:*_Z2P?M_?\`AN?^"6?_`-+4H_X8W_:*_P"DL'[?W_AN?^"6?_TM2@#[
M^HKX!_X8W_:*_P"DL'[?W_AN?^"6?_TM2C_AC?\`:*_Z2P?M_?\`AN?^"6?_
M`-+4H`^_J*^`?^&-_P!HK_I+!^W]_P"&Y_X)9_\`TM2C_AC?]HK_`*2P?M_?
M^&Y_X)9__2U*`/OZO@']LC_DXK_@D_\`]G_?$;_UUG_P4KH_X8W_`&BO^DL'
M[?W_`(;G_@EG_P#2U*^8/B[\`OBM\*_VL_\`@E=XA\=?MN?M/_M*:1>?MO?%
M#1K?P+\:_"?[&&A>%=*U&X_X)B?\%%KZ'Q987G[.G[(GP"\;2>(+&VTZ\T>U
MMM4\8ZEX6?3==U66^\-7FK0Z'JFC`'[.T444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`'XD?L$?L@^&?CE^P#_`,$L_B5XE^(OQ#TAO"__``3K_85T
M[2?"OAP>![#1!+X=^&_P8^(PGO\`4YO!MSXRU;3]7UGPMH/]K>%M4\47GA(W
M.C:-KVFZ'IWB73+?5Z@_8>^%?[!_B3]L#Q_=_!3]HJQ_:&_:E_8(\#^%/V6_
MC?/XS^#7PK?XH>"HS<?%VXTF(_&#4/@GX<\<"\U^Z\5^+;;Q[JOPD\>OX;\7
M^)/#4R>.VO/$<WB*/4^S_9;^+OC+X"_\$$_V3/C#\./AOX\^,'Q%\`_\$M/V
M8=;^'OPP^&7@S7?B#XX\<>/%_9D^'UKX-\/Z'X0\-:=JVM:N;WQ)<Z8NHFTT
M^YCT_25O]4O52QLKF6/\:O\`@G!^PM_P5A_X)L?M>_LA?%+]H+X>?LS_`!"^
M$?QCT'QS^R]^T9XF_9`/[1'Q`^-5[KGQC\8_$/\`:6\-?M"?M=0^,?`__".7
MLOA3XZ:WKOA35?B-X0D\/^$/`F@_$>^TV_\`LG@ZPT>2S`/V_P#VR_AAJ/QJ
M_;:^!_PFT?7K+POJWQ#_`."8W_!4WPII?B+4M)GU[3M%U+5_CS_P2EMK+4;_
M`$6UU31+G5+*UN7BDNK&WU?39[B!9(X;VWD99%C^(O\`P2[T[XZ>);CQ]\9_
MBC#)XP\4>*/B5XM^(&G_``P\&R>"O`6L:MXE^''P;\&?#.^TO0=4\3>*-;MO
M$?P<\8_L]?!;XV>%_'&H^)M1\6I\6/`NGZOHVI>&="2R\/:?[/\`$;_E*9^Q
MO_V8#_P4K_\`6BO^"3]??U`'Y=^!/^"?7Q#^%5OIGACX>?M&OI_@O7O$'P+\
M>?%W4M=\!7FN?%#Q9X^^"7PM^'WPPGG\.^)W\=VWA+P_X'^(Z?#C1_''B#P3
M?>`=9B\/_$W6_'7C[P_JW]M^+Y/[)^S_`!S\+/%'Q,^'_P`+]!\8>*M`B\9>
M#_'GP/\`B1XLUSPUX7U'3?#/B'Q%\+?&'ACQGXBMO#OAO5/%.MZKX9T7Q-J&
MB7MOHMMJ7BGQ3?>';.\M8[[4?$4]I+<W?NM%`'X1_`3_`((P:E\)?A+^S_\`
M#S6_VD_%&L:_\`?A3+\!].\:V>L_'SQ%<>(/A#XU\*_"#X>_'/PII5A\7_VA
M_B?/\(-'^)W@7X600>&O`7P<U7P=\(?@[XPC\*>-/`OP[2\\*_8=5]2^#?\`
MP28T/]GO1/@CXB^&_P`2)O$GQ[^!^I^#K/P[\3/C-J'QA^)GAN#X>Z#\)-%^
M%7B;P=X7^&^K?&1?#?PSN?B-_P`(QX0\9?$G7_AG'X3O/B=XL\$>"]7^)4?B
M[4?#6CWUE^Q5%`'YP?"K]@?6_ACXQU3QI+\>?$7C.]^(/Q;\*?'[XLZ=XC\,
M:.NF:G\8="U_Q;JNKZWX$;3)K+5O#?A[6M&\66W@BPT+Q5JOCV\\,>"?A]\-
M/#.D:VNC^&([*7K?^"<'['&N_L(?LM>`?V;M=^)FH_%B3X?Z%X.\-6/BZ_\`
M$_QQUV*]L/!WP[\&^`X9-*T'XV?&GXU)\,='O6\*/J=C\+/A-J'@SX-^#%OG
MLO!?@311-?SWWWE10`5\P?LY_M(ZS^T3%KVLI^S?\=?A!X$M,R^"?B-\5M4_
M9VN/#7Q8L5U;5=);4O!&D?"/]H#XL?$#2+55TQ-2,/Q2\$_#?4#8:G8*MBVI
M)J6GZ?\`3]?F]\&O^"97[-?@#X=Z'87'PPT/X6_%R_UNU\8?%GXJ?LE^-_B9
M^RQX[^+_`(ML-4\2ZE:W7Q7^*7[.FO?!/XC_`!FT/SO%&IW]YX8^*NI^(_#.
MH:Q=2:K?Z%=:A!:WL8!NQ_\`!1GX66S^+-7\2_"KX]^#OAG8:?XON_A5\8]<
M\*>"K[P)^TE>>!M0DTG7M!^"6E>$OB)XF^*#^(+G4XS;^$=-^*OPY^%C?$:U
MW:Y\.9/%?AN&?6(D_P"&_P")M+&BQ_LD?M72_M$#5+NWF_9"6#]FM/CM#X8L
MM)@UVX^)!\13?M*1?LUS_#Q=,O-/"Z]9_M!W,\FOZC:>!8].;X@M)X4B^?=:
M_8D_:C\=^$_!'P7\5:M\`?#OPV_92U>[\<?LJ_$70_$GQ%\4>./B%X^T*'5=
M.^$LGQO^&5YX#\'Z#\-O#_@KPWK&H>'O&4'@WXJ?%RY^)%W=CQ1IR?#I[2'P
M\^]XZ^%'_!2'7-,\;_$7PUX(_9+T#XT_'"?X=?#GXI>%="_:V^.?A#0O`O[/
MOPFB\?:AHVF?"WX^6O[%WB3Q/J7Q2\=>)_B;XQN=:\6W?P%\#_\`"O?#6I1Z
M3X4NM;\4:;H_CO30#[@\,_M/?#?QI)\!K;PG!XFUS4OV@_#VI^,_#6BPZ7:Z
M?KOA+P/H6B+J/B#QG\1-&UK4M,U'PUH.A:[>>'_A_J9@M]4U./Q[XK\/Z)!I
MMQ!+J.H:;]$U^-.H_L$?%/Q9\4_@_P".-3^"O[(WP_N?"=W^SGJFB?$WPC\3
M?B3XB^,G['GA;X#ZSX*U;7?V;OV9-;@^`GPSNOB#\&OB]%X0U.Q\5:GXA\4?
M`W3KBU^(7BW3_B+\(OC#X56U\)R_LM0`4444`%%%%`!1110!\`_\$U/^3=?B
M-_V?]_P5@_\`7IG[9%>)Z]_P1I_9'U*6_GTO0M'L&UW]H[5OVJ_%EGXA^#W[
M/'Q,T?QC\:M;MOBEI]]XS\3:+\3?A%XKT_5-<@TOXF_9-#U:6(7_`(<N?"FC
MZUH<UCKNJ^+=2\1>V?\`!-3_`)-U^(W_`&?]_P`%8/\`UZ9^V17W]0!\W_##
M]F;PG\&=>\3:U\-_%'C/0;;QS\8?%7Q>\<Z'=76A>(--\1?\)1X=UG3A\.;>
M?Q!H.I:QX1^&OASQ3K,GQ#\+>'O`^I^&IM(\3QW%FNH3^%M9U_P]JGXS_MU?
MMVZ_\"/C=^VM;6O_``4:T_X+?%GX)^!?A5>_LB?L,ZKIG[).O:9^TS\1?&_P
MQ_M+0?"E[\/O&'PXM?VJ_'\'Q#^*=YIO@W[=\+_CS\.M,\-O=)>7.KZ1INEZ
MO*_]%%?DE\1;#XZ^"/V@_P!L[3;?]@+XG?M4?#+]IO3O@O:>&_$FF^._V1=(
M^"\J^'_A?!X'\1:1\6-,^+O[1'@OXM:=HNF:NGVO5[CPG\&/'UU-HJ/=>&[#
M7-56#37`/U7\/W>J7^A:)?:WI@T76KW2=-O-7T9;F.]72=4N;.&;4-,%Y#F&
M\%A=O-:BYB_=SB+S4&UQ7PO_`,%8/^46?_!2O_LP']LC_P!9U^(U>T_L:?!S
MQU^SS^R7^S9\"/B=X^F^*7Q$^#_P0^&GPX\:_$.>;4KE_%_B;P?X2TK0]8UM
M;K6)[C5[R"[O;*4VUYJLSZE=VPBN;X)=2RHOBW_!6#_E%G_P4K_[,!_;(_\`
M6=?B-0!]_5^2_P"WS^T#I?PK^.7PH\'^*_\`@HS!^P+H.L?!CXI>-O"UI=0_
MLMW]O\</B5X9\8_#?3-#\(3>&/CY\*OB!\0/B+%:6&N7L+_#O]G_`%_P)\1O
M$PUHV.EZU'K,^@W5C^M%%`'X*V_[9OQ@U;6?">O>._VGY?@/^U=J.N?">T\.
M_P#!*^Y^'?PJU"Y\?:'XK@\`2:_%<66M^"M5_:4\6RZDFO:]<M\;_A?\4=`^
M#GP8#+!\2_#FJR^`?&4=Y^G_`.TY\1/BMX"U[]F&R^$ZZ7?WOCW]H#6/"WB_
MPQJEI:2?\)OX*T/]F;]HWXI7OA'2M4NY[5?#7B'4]=^''AZ;P_XA^U0VEGJ]
MG:6^M_:/#EWK-I<?5=%`'\Y/AO\`;F\>^,M$\4Z]\>O^"A6K_L-6ME\8?VN(
M?V;[77_@9\'M+UC]IC2?!O[>7[67PR^%'@6[\/\`QE^$FKZW\3QX<^$?P]^$
M/@.']GSX"V?PW_:Q\11D>,]<\<W>L_$CPUJZ?H_^PMK'[0GBKQC^T?XA^/7Q
M=^*6O7D7B3X4+I7P%\::%\!+'PQ^SU?_`!`^`?PL^-WBSX?>%M=^%_P4^'7C
M_P`2P>#?%?Q0UGX?Z9J7Q-\;_$'5I?"7A+PX^I:CJ7BIO$7BKQ%^B]%`'X-?
M$']M+Q]H7QG_`&H?A_=?MB1^#/ACX?\`C#X2\-_$_P"+J^#/@P\/_!/?X6WF
ME_$[39=?U+3/&/P_TS6/A_XA\1>-O!_@#PU!K_[5O@WXU_"+6?"_QA\'?M9?
M#KQYK_P-?Q!\,_"79^,?VP_CAI/PD^$FA?L5^//&'_!2WQ/??$N?Q[XE^,_A
M#P)\`()=9_94^%VO>%KKXA2W7BJ'QE^SG^SS\0M=^(&K:O'\)?"/Q'^`.BNU
MS:WOC/7_`(??!WQ[XJ^"_C*RO/VRHH`_G>_:K_X*7Z?K7PTMM+^`O_!07]FG
MX4>.)_VO[31=<\3>*OVE?V8?@6G@G]F_Q?\`L^?%#XJ_"N[\:>-_B[^S-^V/
MH/PS\.?$2_T/PC<>!_%GBK]G#Q+JGQ#N+S3/">A^(]&/B5?$.G_HM^V1\8+G
MX8_LC>`/'>I_M56'[-6E:YXU_9P\/^.OVJ-+\2_`&_TSPKX5\<>,_"6C^*?%
MFG>-_C=\)]7^`LEAXBM-1FMK3Q9KGPDT_0;BWU>/4=$\-^';B?3K?3_T+HH`
M_F;\;_MW_M&6/Q`_9R\)?#+]I'XS?%_X7^(O%GQM\(_#+]JCP-X(_8KM/V?_
M`-HZ#1-=_97L_AG\4/VM/'WC#P-HNB>&O@K!XS^*WQ+_`&?%\<?L?K\-;KXP
M?$3P]I%W\-M'DN?&7@K2)?I7QI^WY^T+IMS^T_\`$?Q1X<\8?!C]F#0]*\-_
M'/\`96^,^J>&O@Y>>'?B;\%_V8?%_A[Q?^U+:VM[IOCWXJ^--3T'XY_!C1O%
MGC#PW=^/_A!\%/&6A_"FZ\1ZU\+[W5-:T.W\?^'?W/HH`_G.\/?MV?M:7FM^
M,O"FI_$O4;/Q%X%M?AQ\8_$%EJ7PR\#6DEO\*OVZ/$WPM\?_`+,?A>*\@\%/
MH#GX-:%X<_:>_9_N);36-5\3>(CX(@\9>-M2UG7;K2-=KW[7_P!L+]I/1]=^
M"'P]^(GBS2_AK;^(/AK\,#^T?^T%H?A#PWHGPW^%VA^*]'\?Z_#^TYX13XFV
MVO:3I.D^/]:\+^!_A"?#7B75/B+X4^"?Q!^)=S_PDX\?^&O`L_B_Q-^V=(Z)
M*CQR(LD<BLDD;J'1XW!5T=6!5D92596!#`X(()%`'PS^PA\:]:^,7@GXG6>I
M>(_BU\1]-^%WQ7UOX:^'/C/\5[/]EJ2Y^+NF:!I>CQWGBOP_XI_8^\;>(O@U
MXPTYM=;5HKJ]L?!GP;\1>'KYI?!7BWX6>'O$WAG5GN<C]LC_`).*_P""3_\`
MV?\`?$;_`-=9_P#!2NOO>UM;6QMXK2RMH+2U@01P6UK#';V\*+DA(H8D2.-`
M22%15`R>,FO@C]LC_DXK_@D__P!G_?$;_P!=9_\`!2N@#[^HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`/PC_P""9?CW_@I%9_\`!-W_`()]6?@7
M]E#]B'Q'X)M?V(?V4+;P=XA\6?\`!07X\>"_%6N^%8/@/X"B\/:SXE\':/\`
M\$R_'ND>$_$&J:0MI?:SX9TOQUXUT[0=1GN=+L?%GB.VM8M8O/M[_A8W_!4S
M_HS?]@'_`,65_M%?_2GZ_/#]F?\`9:^*7QY_X)Z_\$E/$OPGN_`WP^\3Z+_P
M2Q^%/PZLOV@]6OI-6^)'P0F^*7['7A#P[9>*_A%X(O?!.KV#>-=.\13>&?$&
MG^*-.\>^`GA3P_<Z1XLT_P`=:'=V&DZ?[]KG[$/Q[\2?#G1OA_\`!_P+^S!^
MP/#8>/=*^,_B:;X':YXP^)6F_$;XO_#V"Y\0^!M3\6Z/8^`_@";FSUSXO:U#
M\1_&/C*[U#4O'GBV7X;>&+7X@GQAIOBO7/#6D@&EXC\)?\%3/$'[4WP;_:6_
MX9@_8!M/^%2_`#]I7X&?\(5_P\0_:*N/^$@_X:'^(O[)_C[_`(2C_A(_^'6T
M/]E?\(?_`,,O_P!D_P!B?V#J7_"0?\)Q]O\`[7T3_A&?L?B#W_\`X6-_P5,_
MZ,W_`&`?_%E?[17_`-*?KXS^+/[!'[07QO\`&GP5OOB%X*^%<OAOX-_M._&?
MX^:=)8^-OA;XQU&[N?BW\0-)\?:1-867Q]_8\^-FF^!]0\`FUU#1H/%7PV@\
M&?&2V>[34_AO\6OAY+)J,>H_8=W^RWXLU*_^,G]H>&/!]SHWQ]^'FG>'?B!I
MU]X]U'4K;6]<@_9VNOA-?R?$VPG^'26GQMCO+V+1M`;6?$O]B7AT'3;77'L'
M>S@\+@`L_P#"QO\`@J9_T9O^P#_XLK_:*_\`I3]>0?$O]K#_`(*1?"OQI^SW
MX%\0_L4?L0WFK?M*?%_6O@KX%N-&_P""D'QXN-.TKQ5H7P"^.'[1=WJ'BR:^
M_P""6FG7-CX?D\$_`+QCI=M=Z/9Z]J+^*M2\-6,FE0Z1>ZIKFC?I;\/-!O?"
MO@#P-X7U)[>34?#?@[PSH-_):/)+:/>Z/HMEI]T]K)+%!+);M/;R-"\D,,C1
ME6>*-B4'QC^V1_R<5_P2?_[/^^(W_KK/_@I70`?\+&_X*F?]&;_L`_\`BRO]
MHK_Z4_1_PL;_`(*F?]&;_L`_^+*_VBO_`*4_7QYXQ_X)E?'_`%KQ7\2]=LOC
MU:ZAX6\9:W^T-HUG\.-7U'Q)#X;7X0ZSI'Q6\??LJ^$EMXH[W3-%\0?!7]H?
MXQ>-M5O_`!3H^E07NM?#*Z\->&-9'B.Y\#^&;BP\U^''_!+#XI?#;X9>#?!C
M_#K]GCXJ_#[PUX.\8>'+O]E_XJV7P0T?X.ZAX[\0^)-)\5>"/CQ?^%O@S^QI
M\./@%JOC?X)>(M'UFZ\#^'+7]G;PMINL6GQ3\8>+/%>NZO\`%K0[?QAXJ`/T
M-_X6-_P5,_Z,W_8!_P#%E?[17_TI^C_A8W_!4S_HS?\`8!_\65_M%?\`TI^O
M@/Q[_P`$DOC!\7+"+2_CC\4_!_QS\`W?Q2T?QMJ?[-?Q%\*?";Q#^S9I=SI?
M[.7@3X90^.O"^GZU^SY?_&:;QK9^,?#6K6VG:5XQ^+WB7P;8>%;]-4LM`M_$
MC12Z=^VWPQT/6O#OAR_TK6M.BTDQ>-/B!/HFGV_C&^\:VUOX1N_&VO77@P6M
M]?>&_"QT"T?PM+I$EKX"L=/O-(^'5N\7@?2/$'B;3=`MM?U$`^1?^%C?\%3/
M^C-_V`?_`!97^T5_]*?H_P"%C?\`!4S_`*,W_8!_\65_M%?_`$I^OOZB@#X!
M_P"%C?\`!4S_`*,W_8!_\65_M%?_`$I^C_A8W_!4S_HS?]@'_P`65_M%?_2G
MZ^_J\6^)NA?M%:KXJ^'=W\&_BG\%O`?@G3-6\[XL^'OB;\`_'/Q:\5>-=#_M
M'2)?[.^'?C'PM^TE\%=(^%^K?V1!K]C_`&SXE\"_%ZS_`+1U+2-4_L'[-H=[
MH_B``^:O^%C?\%3/^C-_V`?_`!97^T5_]*?H_P"%C?\`!4S_`*,W_8!_\65_
MM%?_`$I^OIKX)Z'^T'H/AS5+7]HWXG_!OXJ^+I=;EGT;7/@G\"?&WP!\.6'A
MPV%C'#I6I^%O'7[1?[2NI:OK4>IQZG=R^(+3QCHEA+87=CIR>&H;C3KC5-4]
MDH`^`?\`A8W_``5,_P"C-_V`?_%E?[17_P!*?H_X6-_P5,_Z,W_8!_\`%E?[
M17_TI^OOZB@#X!_X6-_P5,_Z,W_8!_\`%E?[17_TI^O(/CA^UA_P4B^`7@O1
M?'7C']BC]B'4M)UWXO\`[/?P5M+?PU_P4@^/%[J,?BK]I3X^_#3]G3P+J%S#
MJG_!+31K9/#^E>-OBIX>U3Q9=QWDVHV/A6SUF^T?2M>U>WL=#U']7:^`/^"E
MNX_LZ?#H*0&_X;]_X)0;2REE#'_@J9^QQ@LH92P!P2-REAP&'4`'C_AK]L[]
MLSQGH^L^(O!_PJ_X)/\`BOP_X=U*;2/$&N>&O^"N_P`5==T?0M5M_%E_X"GT
MK6=3TO\`X)=75EIFHP>.=+U/P7-97L\%S'XLTZ_\./$NL6=Q9Q_/FI?\%@O$
M6CZ7X?UO5OB)_P`$'=+T7Q;9WVH^%=7U'_@N]?66E^)M/TS5;W0M2OO#]_<_
M\$W8K36;/3];T[4-&OKG3I;F"TU6PO=.N'CO+6>&/O?^'1,FO/?W_C;]H#Q1
M%=Z1/\)8OA/X3^$VJ_&SX+_"'X<^'/A?\3](^(8\$ZI\+?!GQZA\/?%_X>W3
MZ5<KX+\`?&A/'_A7X.#Q!=^%_ACI^A?#W0/#/A.P\^\*?\$<_'VA^,M3\4ZA
M^TQX@OX-;_92\%_LQWVGWGQ._;E\6Q>7X&U?]J'6;'Q9KUE\1OVU?&.@_%RS
MO9_VCS!HG@CXX:+\1?"_P@'A1[_X*VO@>_UVXDM0#NOV7-4_X*'_``*\+7'P
M:TWX+_\`!-+Q_P")/B+\4/VN/VM/#EI8_P#!33XX:5KFJ^`OVE?VLOB7^T/=
M7VB>&X/^"86OW^N>$/A]?_'WP_\`#VX^(%A*=&U^\31M:DM?#LWBFR\/6FKX
MA_X*-?M"^$=$^(7B7Q9I?_!&CPQX<^$?BZP^'_Q6U_Q#_P`%H_&^BZ)\,?'F
MJY.E^"?B%JNI?\$R;:P\%^+M2`)L/#?B2?3=9O,$V]E)7Z&^,/@'_P`);^T]
M\(_VB7\526%O\,/V=?VG_@'-X1M],D%WK?\`PT=\0?V3O'`\56WB>/5(&T:3
MP>G[,<NF+IBZ-?R:Q+XUBU"/5-'/APVNM_`LO_!*V_\`&>H_LWV/Q6^.VH'P
M/^RAX-7X2_"NP_9\B^+7[*WCW7/A<MK8P+)\0?B;\%?CIX=\1CXC6P\&_#B#
M2_$OPS/PVT/18/\`A<]IIWA>+PW\;M4\*>&@#URP_:"_X**:KXNUKX?Z7^S5
M_P`$UM2\>>&_#WAOQ=XB\$V'_!4SXY7GB[0/"GC*[\06'A#Q/K7ANW_X)52:
MSI7A[Q7?^$O%5EX;UJ^LH--UR[\,^(;;2[FZFT;4DMNJ_P"%C?\`!4S_`*,W
M_8!_\65_M%?_`$I^OJ/3OA>UA\<?$?QA&M>;#KOPD\"?"^/P^]G(TULW@SQ?
M\0O%#ZU+K,M](UR=07QQ'9"S>Q62%]-DNI+Z<W8AA];H`^`?^%C?\%3/^C-_
MV`?_`!97^T5_]*?KXA_X*:>/?^"D5Y_P3=_X*"V?CK]E#]B'PYX)NOV(?VK[
M;QCXA\)_\%!?CQXT\5:%X5G^`_CV+Q#K/AKP=K'_``3+\!:1XL\0:7I#7=]H
MWAG5/'7@K3M>U&"VTN^\6>'+:ZEUBS_=RO@'_@K!_P`HL_\`@I7_`-F`_MD?
M^LZ_$:@#_$-HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
HB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
